<SEC-DOCUMENT>0000950170-25-033510.txt : 20250305
<SEC-HEADER>0000950170-25-033510.hdr.sgml : 20250305
<ACCEPTANCE-DATETIME>20250305160344
ACCESSION NUMBER:		0000950170-25-033510
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		94
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250305
DATE AS OF CHANGE:		20250305

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FATE THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001434316
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				651311552
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36076
		FILM NUMBER:		25710824

	BUSINESS ADDRESS:	
		STREET 1:		12278 SCRIPPS SUMMIT DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92131
		BUSINESS PHONE:		858.875.1803

	MAIL ADDRESS:	
		STREET 1:		12278 SCRIPPS SUMMIT DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92131
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>fate-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-05T12:23:07.5152+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:fate="http://www.fatetherapeutics.com/20241231" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_aab7885e-9564-4d4e-8a32-4335881564a1" name="dei:EntityCentralIndexKey" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2">0001434316</ix:nonNumeric><ix:nonFraction id="F_c9ca9aea-e8bc-4cae-92f6-da083b3a525f" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" contextRef="C_232568ed-817b-44c3-b6de-570d4f2c0eb0" unitRef="U_USD" decimals="INF" scale="3" format="ixt:num-dot-decimal">0</ix:nonFraction><ix:nonNumeric id="F_3b4d5183-26bd-4ae8-90cd-1552e3260e2f" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" contextRef="C_c3192fe5-8746-48bc-b8dc-2864fac0be36" format="ixt:fixed-true">true</ix:nonNumeric><ix:nonFraction id="F_f6ca1fb2-0d37-4e86-ad77-62d2e37595bb" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" contextRef="C_a289a3e2-7277-4925-8f75-b1b8d86807d3" unitRef="U_USD" decimals="INF" scale="3" format="ixt:num-dot-decimal">0</ix:nonFraction><ix:nonNumeric id="F_0c353b9f-246c-41c7-8d40-c96c7ea72723" name="dei:AmendmentFlag" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2">false</ix:nonNumeric><ix:nonFraction id="F_9b4227fd-6f0b-4b1c-ad07-559350ccc031" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" contextRef="C_8f7a9881-7e2f-4fbb-add2-b72bdff2cc59" unitRef="U_USD" decimals="INF" scale="3" format="ixt:num-dot-decimal">0</ix:nonFraction><ix:nonNumeric id="F_afe3f5ce-a539-4e46-b9af-82534af2ee03" name="dei:DocumentFiscalPeriodFocus" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2">FY</ix:nonNumeric><ix:nonFraction id="F_89c55976-9468-4820-a52b-dae8d981199b" name="us-gaap:CommitmentsAndContingencies" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_4871b3f6-bcbf-43c8-836c-b69e9e915c2f" name="us-gaap:CommitmentsAndContingencies" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_21f3a184-e10d-4206-ab0b-30c744f8de9d" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2">http://fasb.org/us-gaap/2024#LicenseMember</ix:nonNumeric><ix:nonNumeric id="F_55fe3d11-ab15-4251-b6ea-70a768289f34" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1">http://fasb.org/us-gaap/2024#LicenseMember</ix:nonNumeric><ix:nonNumeric id="F_36b18d82-10b0-4496-9bd3-0d13c236998e" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_3afaeabf-cfe2-4152-bbed-2e1495b5dbec" format="ixt-sec:durwordsen">two years</ix:nonNumeric><ix:nonNumeric id="F_ac600eed-1df0-477d-b544-b5ccb3c5dacc" name="fate:ShortTermInvestmentMaturityPeriodRangeStart" contextRef="C_2575346e-5767-4842-b149-16db06beaf77">P3M</ix:nonNumeric><ix:nonNumeric id="F_2f454c57-baac-4705-a580-50decd7c868a" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2">http://fasb.org/us-gaap/2024#LicenseMember</ix:nonNumeric><ix:nonNumeric id="F_ec6c8190-36ba-401a-8dbc-a9e6f704f525" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1">http://fasb.org/us-gaap/2024#LicenseMember</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="fate-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="C_805cb483-0110-4ded-9a01-7cfc77c9ed1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_805f2b9e-0637-4e41-afb0-b23379a1c6bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8073b9ee-958a-4e70-8014-118578a7c26b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EmployeeRetentionCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_821efd00-9226-4b6b-acf3-b68a5fe00775"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">fate:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_82ed1266-1238-4e4a-9fcf-ef99a6cc8c97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_83226ba1-7f86-458e-b153-94d4da5af37e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8515b700-bba4-47e5-8cd3-b446bc59b1e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_85e19190-1f38-4b84-928d-1b10e8632e63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8647c356-eb54-4cef-883d-ccfb6f2c7d27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_87a8873b-2dbd-48eb-a3c4-71b7b6ecb603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a02d4d5-85f9-464c-8c77-3930bc912652"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8a618607-b312-44dc-9409-e35bb5b9ee3c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8ab196d3-69ab-4d26-b22d-9350aa81b0a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8b609e2a-1e60-4b1e-b0db-d6a181ac993b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b7007bc-3d95-44d8-90bb-9b611207cb91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fate:November2016PlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8bb72297-578c-44bb-bcc6-356a01b01bc6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8cb1a266-41ae-44a5-9398-af9a30767436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">fate:RedmileGroupLimitedLiabilityCompanyAndAffiliatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d696b36-8d44-4c55-9a08-7819757a59b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fate:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e179833-9ef6-4071-837e-b071b6572377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fate:StockPriceAppreciationMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f2c86db-20b2-4603-88f9-51afe5ae61e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:AmendedMSKLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8f7a9881-7e2f-4fbb-add2-b72bdff2cc59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_914c3fc5-d128-4c00-a001-75c4add6174a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EmployeeRetentionCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_926e58f0-2ed3-4a7a-845d-34981bf5a884"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_92ae6775-3137-46d3-9d0f-95226e202633"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_94e46ef6-c33c-4951-8ea1-9765cebbe9a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_977cdbf8-9aef-4f82-a0e6-e955360ee9d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_979e1e1b-585d-4deb-90b9-0ebe66970591"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97e27d0f-6140-4723-b214-d402e6450492"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98c3e645-6b5a-4fbd-a7b5-c0bf4a509495"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_99d86bdb-f819-4ada-9573-3db9972228f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a61a4db-53f2-4f25-957f-9ca42291c122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9ba83a55-9961-4e4b-8d65-f9275f3c0342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c256c41-e766-4081-83ce-a706df7de970"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9ddb50f7-7408-40d0-a949-d5236775a322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:StockOptionAndIncentivePlan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-09</xbrli:startDate><xbrli:endDate>2022-06-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9f433503-cde7-4c8a-84a1-6742576e7a9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fate:ScientificEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a289a3e2-7277-4925-8f75-b1b8d86807d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a31bca4a-3e98-45a1-a466-8da5458c6984"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a3ff6b11-0c22-4b27-8dc1-b44fdb3a724c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a53d5f30-4ead-4f12-abb3-1d519e3a22c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fate:JohnsonJohnsonInnovationJJDCIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="fate:StockPurchaseAgreementAxis">fate:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a5e8db20-c26c-4eec-81dc-6ac0d0db25ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a641074c-59aa-4f3c-8a89-4a805c5db02a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6afb152-c99a-4b4f-8ec2-a459b2a92d61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a95850c5-78b7-4a48-b9d3-80bfd15bcd46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fate:ScientificEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac2d1d69-5e84-41e7-b540-c202f61299ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_acf53715-2f34-438d-9496-5f75227814aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ad67a626-7c86-4e93-88d6-33d3a62a1c24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ae9121c7-17e3-4b53-8ea5-3c6e73560888"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_afe59ea1-745d-4337-875d-4dbe66b0f606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1694544-d57a-4079-9403-45d7021d8147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fate:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:StockOptionAndIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b18b95bd-40a9-49db-97ef-2faba14a93a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1dc2798-8465-41bc-83d9-cb6a02fcf5c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fate:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:StockOptionAndIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b28e1793-9bb2-4e61-9e28-a2fa970d72c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b3047a8d-c14c-4b39-8c15-7c44dd30c23c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b416aca9-c7b0-442c-b1c2-2934711580f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b434e138-ff00-4c3d-bbe3-be9b301a7015"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fate:CandidateTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b44c450a-2dc3-4462-8d2c-f77c56795b1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="fate:StockPurchaseAgreementAxis">fate:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fate:JohnsonJohnsonInnovationJJDCIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-02</xbrli:startDate><xbrli:endDate>2020-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b524e977-baf9-4884-add0-8ccda59b00ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fate:CandidateOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b5de5eaf-450a-48f0-8a17-e88454281754"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b7a41695-3727-4f36-8184-049efe051469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b831d8dc-5480-4f60-b15f-b532465e4ca2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b8f2b2d3-e3a5-40c0-8565-7b6bedfecd7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b943fa46-6631-448b-b8ef-ffce3d36d5be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bbc6feb5-7fbe-40df-a81f-6062a8a5fbb8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc041da4-e745-4f8b-9d20-f7e54aa2e7d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fate:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc446b6b-8934-40b7-bcdd-742d1f50b677"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc45b335-2d95-4276-ad2c-dab6f6cd2b27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bceaaf53-4594-42b0-af63-0c188d7eaf41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_be1fc325-ff5d-4b35-952c-3aa39e4cfadc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fate:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf1abdb0-874a-4c56-9fa4-d32731526c6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fate:OnoLetterAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bfbd6f4d-b000-45b5-9a79-42c6794f12c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bff210f5-02f8-4782-9744-563ff4baaf6c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c138b804-b864-4563-8180-753f77d0e77a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c1b46ce1-8237-43cf-86cd-6a985c5ce0ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fate:CandidateTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-01</xbrli:startDate><xbrli:endDate>2024-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c2029f3a-6dfd-4668-a724-7134c2e52a11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c243b78d-2e22-425b-8d5a-ec8cc2edf72d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c3192fe5-8746-48bc-b8dc-2864fac0be36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c351f635-f8e4-4ef1-98df-8b05b6facf67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3abcd74-97fc-43ce-9d4c-92aeb8a7a7d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c4256f0f-bf1b-4d25-ba9b-95785d196f09"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fate:CandidateOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-13</xbrli:startDate><xbrli:endDate>2018-09-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c52c4c88-5230-4895-b325-46e4cd2518ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c5d2707d-a24c-478b-b6da-97a0477550df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fate:StockPriceAppreciationMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c61bcb64-4368-4879-8eae-3bea4e1f47f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EmployeeRetentionCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8f88322-9cd7-4ec4-92f5-a0a2e5bc4363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fate:PerformanceBasedRestrictedStockUnitsPrsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ca3bbae4-b7ef-4100-8179-d51130791abc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fate:CandidateTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cacd56f9-2988-4b00-88a4-4b37683a2fc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_caf5635b-36dc-4bb5-83b2-d3bfaff93dac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:AmendedMSKLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cbf96da0-08c5-44ae-8e97-d5dc42fe1fcc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cc863354-869b-4206-b33e-59e639b10e95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cc8f53ba-0de4-45e3-a08a-c8528a309add"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd31cee6-b14e-476a-ac84-63e70036233f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce45b517-0884-46c2-a4a4-3f9f7359e4f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cebe70a2-446f-4a43-a422-52cd427ada3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cec4892c-e35c-4232-846a-7628de00f77e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MunicipalNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ced1b62f-5a61-4b35-bc5e-24a1d2c9771c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fate:CandidateTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-14</xbrli:startDate><xbrli:endDate>2018-09-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d0dc00f7-c9cf-41d7-89f0-cc4fe78c6101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:StockOptionAndIncentivePlan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d0df7940-8ed7-4acc-bf9b-0fb78b52dd30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d21f4f6f-8713-4aa6-8283-c3de33b87b2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d2920029-80c7-4108-9176-bd4bda38a66b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">fate:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d2feccdf-3708-47ad-92f7-48fa021ea96b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fate:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d7619f35-5038-4477-8ad7-9f872ef12d50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fate:FtEightOneNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d7661ece-b1bb-47ae-89fd-c9e5fb4fce03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d8f9c7ba-407a-4a32-8e3a-a7d43910792c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da752dee-4bbf-4d64-b7ab-bbf88b372ec6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MunicipalNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dad32687-8050-4e65-8354-068f686b84df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">fate:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_db4ca2c8-7dec-42f6-9326-27fb5b437f80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fate:ScientificEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc572fae-d1e3-4dc6-9902-fa5e71563255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:AmendedMSKLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fate:MilestoneThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df4185ff-6291-44b2-b42f-fe0d6dd2b4c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2008-12-25</xbrli:startDate><xbrli:endDate>2009-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e07453e5-70e2-4589-84ee-63184d1649d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e07a21dc-a40b-48ca-81a4-731bcea56eb4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e122feae-e127-43e8-a5fa-96cea5382fa8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e243220b-bcd5-4012-8eef-5b2d39ca5281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e2c30eb4-cb8a-4c56-94e1-15d379546979"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fate:CandidateOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e3dc601c-f824-4b78-bf0e-07dae896ef9c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:AmendedMSKLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fate:MilestoneOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e5f0eeec-87ae-44d4-9289-b8c650cd8dd3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e5ff0703-7a69-43d6-9e8c-8654aebbd5ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e741f2c7-90d6-40a1-ab1f-b596c102b3bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e9fc8192-6581-4017-a8d5-9e3b97aa8020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fate:StockPriceAppreciationMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea581251-e0f9-4e1a-ba72-0e031fd4585d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">fate:RedmileGroupLimitedLiabilityCompanyAndAffiliatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb400e71-8a95-42b3-aaea-dc66ceacad22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb50e59a-b806-4c03-9930-ed4b25c0c2ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ebe17901-fd0e-4988-91ae-8f5cdea8a285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_edad96f6-a6a9-4612-9c79-acc88724dfb5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f1dea256-3b9e-495e-a654-b31799d22af3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-30</xbrli:startDate><xbrli:endDate>2025-01-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f1f2b64c-9a2c-4bc4-9f3e-aaf2c1023a51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f255de04-23de-47b2-bf4a-1d7b7bf4d379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f28a10a2-8fc0-44c9-a166-60bb7e722119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:AmendedMSKLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fate:MilestoneTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f2e41800-cc41-4b94-a30a-fb6e56d72a7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f482e228-69f4-4567-8679-ff6ec159f4e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f5465cc9-eacc-41b4-9cfc-f0dad102ddfb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-13</xbrli:startDate><xbrli:endDate>2018-09-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f6acdf54-a780-4f0d-a5a2-e9a7888f459a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fate:CandidateThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f776f2a9-7c7a-491a-991b-ad0fcec60954"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f98f7f9d-7ad9-48be-9ec2-e497587e292e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f9d2101e-3c01-4cba-a24b-48c0f0b161d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fate:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_faac2f19-7ee6-46a4-9641-0352d10ce9d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fb2cf769-bd37-47d3-ab4b-f93d4365d73d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fba769b4-c31e-4914-8c9d-294bd6abcddd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fbf420d5-255c-421e-9863-8fd4aeac0e96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fc28b484-986a-4aa3-ac45-ec88d93742f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:AmendedMSKLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fcdf4845-34e5-4331-ba78-17eade1d2dde"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fd5563c2-aea8-4a6a-8a5b-e1869c4151d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fd6d1a6c-963f-4a77-8037-388fc2ef3404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fate:StockPriceAppreciationMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe5fbe72-2c15-4c48-9e0f-6faab2b2ebf8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe855db0-cbd1-4634-932c-99540e86df56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe916e0a-bfad-43cf-8d7e-6d37daaba7da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_febf2ab8-3d7f-42f3-8e8f-9f2795618370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:StockOptionAndIncentivePlan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-09</xbrli:startDate><xbrli:endDate>2022-06-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fece1b4a-7679-43ae-91f1-803e3e834572"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff4ddbec-d136-4b09-a4a0-5e321b435ca7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:AmendedMskccLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_00cbef97-1aad-4784-a3ca-62ddc68740ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0284ad68-4270-4896-8d67-06f5f506fa6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:AmendedMSKLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fate:MilestoneOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02925833-8677-4697-ab8d-c844642a03e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fate:November2016PlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0519f681-f046-4690-9e46-0dd9cba066f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0792edb8-8c75-4ac5-9ff2-3638bf624ca6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fate:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:StockOptionAndIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_07bf6ed7-be95-444c-ba21-1cca631dcf34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0929cf2c-6047-4152-8767-1d831d5874a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MunicipalNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_094d60cc-9d76-4080-b9c2-2f03fda72660"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ad23255-7a2a-4f76-96d1-4206f5e0c875"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:StockOptionAndIncentivePlan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fate:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-09</xbrli:startDate><xbrli:endDate>2022-06-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0c2bd9af-d58c-4b2f-a7bf-36d6102fcb98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fate:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:StockOptionAndIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d302d4d-cf60-4de8-bf11-2d38492826e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d4321be-2b98-4d77-827f-dd1e376a2681"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EmployeeRetentionCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d79e020-c388-40bd-a1ab-ccdba8d6c0f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:AmendedMskccLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10f659e3-4c5b-460d-bada-3a35f1b947ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_126fd19f-3eec-4444-a458-398859e1ae58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">fate:RedmileGroupLimitedLiabilityCompanyAndAffiliatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_13e7d164-655d-47b3-8816-15b789699d5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_14a6993c-8757-45a1-9ffd-ead3d146845f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fate:CandidateOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1cb3ab28-0ea4-4691-8f06-03acbacd707e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1cf4be6b-4800-4f2a-bcb7-d38f5709c7aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1de58b0e-3458-4fdb-9110-32fd64de36b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e42a653-35ec-4959-8224-d96563396f11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="fate:StockPurchaseAgreementAxis">fate:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fate:JohnsonJohnsonInnovationJJDCIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1eb4c942-f4c7-47f9-994f-95d18338c9fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1f598670-03c3-4c12-a086-312e2fe99e74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fate:November2016PlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1fd96e00-b6bb-46df-a4e7-fd1bd210a4a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_208fb1ba-72a9-4ce5-8560-933151337e0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_228a9429-468e-442d-a38d-9b5441b82b3c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fate:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_22baae92-8d72-48bd-bc26-99cb822ac436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_232568ed-817b-44c3-b6de-570d4f2c0eb0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2341069e-9c1e-4801-a758-1b22a7e72c60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-02-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_235e1198-6534-41bd-9a50-81f2b487638e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_253be32e-0a0d-4574-b01a-92170bea60d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2575346e-5767-4842-b149-16db06beaf77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_26715720-1a7f-4abb-8779-318e83f66b8b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fate:FtEightOneNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28eaa775-35eb-4f9b-a403-7245d490401e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fate:CandidateOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2a171456-ff92-4460-82a4-d71189a47904"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2c762660-e17f-4068-960c-6e97d50571ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e15e9a9-cf48-44bc-a273-b652fd1f9dd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e7da839-7541-4872-8420-d82b12974e64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fate:PrepaidExpensesAndOtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e9f4ffe-10e2-4108-a3d9-3d3ffddd7ad0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:AmendedMSKLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fate:MilestoneThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_306e095e-df5e-46ff-bb9b-07308bdff1ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_309808ad-31af-4b1f-8e61-083557c2542c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_31099ea4-f12e-4b2c-9160-b411e31dd257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3121bc29-a859-42c3-8c2f-1cc407771269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_35de3dab-1655-4fae-8a01-0f3d2ee62306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_36c7dc1f-1f68-4486-a90a-7021092d1f27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3993554b-9513-4d91-b34e-db9cda665ac3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fate:CommercialOptionExerciseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3aa72a78-bcb4-4041-8da5-aa19c436d13a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3afaeabf-cfe2-4152-bbed-2e1495b5dbec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fate:ScientificEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b620cbc-79bd-4c67-b41b-219dae13d7b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3baffb0b-73df-44c6-85eb-9c15e2247168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c6a67d5-eeb4-4acd-987b-91a972c863ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ef185b6-d2e3-41eb-af64-8722d09aa801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41031951-bbc6-4651-8f90-88528e8885ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41a96d2d-db51-45dc-a3d4-a00f6dd5f281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:AmendedMSKLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_439addc5-9548-4d3a-bc32-ad8b68c23597"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fate:CandidateTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_453cb5ab-24d8-4b66-961f-9f4dd63a05ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_473eb942-1f90-41e1-b4de-c3380615c958"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fate:JanssenAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:JanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_47a8c41d-7932-412e-a1cf-a28cc3a2ebb4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-14</xbrli:startDate><xbrli:endDate>2018-09-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_47e3c4a5-6a9e-488c-9ae1-4d92329efada"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a27cfd3-c4bb-4733-abe8-a5141e381e3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fate:JohnsonJohnsonInnovationJJDCIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="fate:StockPurchaseAgreementAxis">fate:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a42522d-d9fd-49e6-a443-91460120f25e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4bd1be9a-9ef2-4939-bc4f-c8ced0fd9412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fate:CandidateTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-07</xbrli:startDate><xbrli:endDate>2022-11-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4c6c4dd6-4ab5-46a0-bc89-10dab775b034"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4cba0539-2744-4997-a638-c19edef83006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4cd86a5a-2ced-41c7-9f0e-9f68de9fef11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fate:SublicenseConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fate:OnoLetterAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d2a294e-b4ae-4f93-abc5-44f79d16ce96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4dd02f91-14ae-4ec9-ba06-e9a1c6c69591"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fate:FTFiveOneSixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e4a3db2-068c-46c3-9e45-17fdfb12f653"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fate:CandidateTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-13</xbrli:startDate><xbrli:endDate>2018-09-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4e67b46a-884c-4f90-a95b-2ef3d7aea6aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:StockOptionAndIncentivePlan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4f0fc4a6-d283-49a9-971d-0333511e8d5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4fb1c409-95ec-4aa9-9296-606146c23c7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_50b6586c-23fc-4c7e-870d-e60fbf83a55e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5445f2d2-5e33-4281-9239-4322ce42c9cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fate:PrepaidExpensesAndOtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_54bb083b-1c65-43f0-903c-ff27e3c8a59d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fate:PerformanceBasedRestrictedStockUnitsPrsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5617f7c9-ae5a-4956-8221-b18d672649e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fate:UpfrontFeeAndEquityPremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5773cffb-0793-4d07-bf3f-34a1272bc4c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5928b276-cfe4-4ddc-bcb9-ba1063ef39c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:AmendedMskccLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_59f16426-b465-46ba-aa94-5befab44d9d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MunicipalNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c738271-04b6-46a1-bc09-e0d54f7b433b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fate:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5cc2f3d5-6422-4ca7-ba47-f826548fe079"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5e663327-b86d-4b6c-a039-7b7d8ac711f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60fe76db-e159-48de-b30e-daed5bf713f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fate:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fate:OnoLetterAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6199ef4e-6533-4919-aa08-7b8879357aa9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62a2a941-1986-48b3-9796-58a5b98fe1ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_643af01a-b028-4eee-8c3b-c5192d3e319a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">fate:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6558896f-2704-4857-9934-3ac8fb755e52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:AmendedMskccLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_681d2241-9055-4fd4-b908-7ff2e5469107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fate:FtEightOneNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_687fd488-edfe-4a2c-989f-8d86d4b11852"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_68edd7f5-9eba-4cf2-9c06-c892f1e0d26b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_69c1fc96-8425-49fc-a5df-640ad6ae407c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fate:CandidateOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ada6b38-7f9b-45ef-acbb-49e492518216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6bd370ac-1bca-4909-9d77-e3887063a36a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6c678e63-62cc-45c4-9884-6caff102c094"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fate:CandidateThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6c749fc7-3fa7-4811-a7f5-999fcbd298ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6e421e14-6d5d-4504-b9b2-ead06e38f45f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:StockOptionAndIncentivePlan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f3f91dc-9183-4b96-83ab-8d0a1cf21e83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6fcf025e-eabb-4c7b-9b3c-cc45fd082e86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_705e67ff-045b-436e-92bc-cce8ba8f5edd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:AmendedMskccLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7261e0f3-a26f-46dd-86c9-8888bb0227e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7272a2e8-f365-434c-8a2e-ca7e7c674867"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">fate:RedmileGroupLimitedLiabilityCompanyAndAffiliatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7388956d-1347-4f5e-b3bd-7ff47628173c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_77ef949f-bbd0-4757-abd9-d2cf6948dfea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_780d7cf9-0c20-4ef0-a014-ce112efe3de2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">fate:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_79fca80f-8b40-4c0b-9152-12e26417ea73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7bc2c0be-3669-4b09-a396-9031cd164016"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:AmendedMSKLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fate:MilestoneTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d04432b-9ec3-45bd-848d-144b3dd8b270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7d5efccd-12ae-4328-a434-fc9ca1b3827d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7df46466-a06c-4ab1-909b-db1961aa969c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7fc491c3-db47-4e1f-9c36-5199ecfed9ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>fate:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_6ec5b87e-3b57-47e9-bcc1-09fda434533f" fromRefs="F_09e675d8-070d-4377-b897-566ff7993c23 F_9b365eab-0f43-4cb0-abaf-bc342af9c6ec"/></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:16pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4fe890a3-f2b3-461a-b39b-a4d47c09defb" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Mark One)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:5.56%;box-sizing:content-box;"/>
    <td style="width:94.44%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_974870f4-ff2a-4e0e-9843-cfd39db6fa23" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_189bf727-0f06-4244-9cbb-9384578a7093" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9db64099-e67e-47b4-b886-59fe13cf978c" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7221bdd9-72bb-4b46-b6e4-7a99e64310d2" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:5.56%;box-sizing:content-box;"/>
    <td style="width:94.44%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:2pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:2pt;text-indent:0;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_4ebac6df-19f9-4817-9d01-7d149775c427" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the transition period from                to                .</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission file number </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_54ff033e-e124-4ea4-984e-a9151190e55a" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-36076</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:20pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a8aef33a-9d65-4593-9790-96c33e7dbef7" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:20pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FATE THERAPEUTICS, INC.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49%;box-sizing:content-box;"/>
    <td style="width:2%;box-sizing:content-box;"/>
    <td style="width:49%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_ce7e5b7e-e858-45f8-9309-633c0abfe8f3" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_b5d9504d-f2c6-46c9-8369-e843a0151007" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">65-1311552</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="text-indent:-10pt;padding-left:10pt;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_00b8925c-077a-437b-ab18-2096d3f15fc5" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12278 Scripps Summit Drive</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_4a638a18-81e6-49cc-a05e-d60599eb73f1" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">San Diego</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_62c994ba-39cb-4a66-bee3-7b7610ebb50f" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_d4207395-b717-4d96-afbc-6cf7d8cb5449" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">92131</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_da5500a6-45f6-4cf2-9c70-03d52bc73b36" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">858</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_06c7a3fa-fe0c-443d-aed1-41a88873c524" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">875-1800</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Registrant&#8217;s telephone number, including area code)</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.333%;box-sizing:content-box;"/>
    <td style="width:33.333%;box-sizing:content-box;"/>
    <td style="width:33.333%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.05in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.05in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading symbol(s)</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:10pt;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_62e3728e-1970-447f-9dce-614b2e94ecba" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock, $0.001 par value</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.05in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.05in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_0c0a5860-908d-47b0-b80c-51b137bf13c7" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">FATE</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_5f3d2d59-3fff-4c0f-8aa0-4dd1b85e2207" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">NASDAQ Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: None</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  &#9744;    or    </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9328bc3e-b4e6-428e-b31d-8576204be76a" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  &#9746;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.  Yes  &#9744;    or    </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_de5a4362-f1c8-41b9-a00d-098d15d4bd8d" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  &#9746;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8a86c880-460f-418f-a0b3-4660deeaebd6" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  &#9746;    or    No  &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_09ccca1f-244b-471d-914a-e9d820d277b4" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  &#9746;    No  &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:24.88%;box-sizing:content-box;"/>
    <td style="width:1.74%;box-sizing:content-box;"/>
    <td style="width:45.06%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:24.9%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.42%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10.8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:3.6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_be77403d-cb4b-4b56-b5b1-a9cde15f6004" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_f65035d0-b284-483a-960a-f654fa9cdeb4" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:EntitySmallBusiness" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_c3bc6b1d-fa09-4355-be96-ff4401193b61" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_20bad9c7-6c6c-4956-ac6f-85af7a108856" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_faa54fec-31d3-4cb2-a917-d5df221ea549" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  &#9744;    No </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1c98e526-d6ba-4762-a0ef-30bab2ea1317" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate market value of the common stock held by non-affiliates of the registrant was approximatel</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">y $</span><span style="font-size:7.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_687b6aea-9470-4ae2-af99-0c733010c49f" contextRef="C_c138b804-b864-4563-8180-753f77d0e77a" name="dei:EntityPublicFloat" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">369,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s of June 30, 2024 based upon the closing sale price on The Nasdaq Global Market reported for such date. Shares of common stock held by each executive officer and director and certain holders of more than 10% of the outstanding shares of the registrant&#8217;s common stock have been excluded in that such persons may be deemed to be affiliates. Shares of common stock held by other persons, including certain other holders of more than 10% of the outstanding shares of common stock, have not been excluded in that such persons are not deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The number of outstanding shares of the registrant&#8217;s common stock, par value $0.001 per share, as of February 25, 2025 w</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as </span><span style="font-size:7.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bbd4716-51ec-435c-b567-f913ed332db3" contextRef="C_2341069e-9c1e-4801-a758-1b22a7e72c60" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">114,597,425</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c89ad169-5c16-4825-913d-69f301930ea8" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Portions of the registrant&#8217;s definitive proxy statement to be filed with the Securities and Exchange Commission, or SEC, on or before the date 120 days after the conclusion of the registrant&#8217;s fiscal year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pursuant to Regulation 14A, in connection with the registrant&#8217;s 2025 Annual Meeting of Stockholders are incorporated by reference into Part III of this annual report on Form 10-K.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="toc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FATE THER</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">APEUTICS, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual Report on Form 10-K</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the Fiscal Year Ended December 31, 2024</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TABLE OF CONTENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.007%;box-sizing:content-box;"/>
    <td style="width:1.003%;box-sizing:content-box;"/>
    <td style="width:83.785%;box-sizing:content-box;"/>
    <td style="width:1.003%;box-sizing:content-box;"/>
    <td style="width:6.201%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#risk_factor_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">RISK FACTOR SUMMARY</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#forwardlooking_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">FORWARD-LOOKING STATEMENTS</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="5" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_i"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART I</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Business</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Properties</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART II</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of <br/>Equity Securities</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_selected_financial_data"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 8.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_or_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item9c"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART III</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 10.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 11.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 12.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 13.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships_related_pa"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 14.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART IV</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 15.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits and Financial Statement Schedules</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">132</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">132</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">SIGNATURES</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="risk_factor_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RISK FACTO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">R SUMMARY</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading &#8220;Risk Factors&#8221; and should be carefully considered, together with other information in this Annual Report on Form 10-K and our other filings with the Securities and Exchange Commission (SEC) before making investment decisions regarding our common stock.</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates and programs represent novel therapeutic approaches to treating disease, and our product candidates may cause undesirable side effects or have other properties that could delay or halt their preclinical or clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. If we fail to complete the preclinical or clinical development of, or to obtain regulatory approval for, our product candidates on a timely basis or at all, our business would be significantly harmed.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development of our product candidates will require substantial additional funding, which, if available, may cause dilution to our stockholders, and without which we will be unable to complete development of, or obtain regulatory approval for, our product candidates. Additionally, we may not be able to secure adequate funding on acceptable terms or on a timely basis.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our proprietary induced pluripotent stem cell (iPSC) product platform enables the production of next-generation product candidates, and we have multiple iPSC-derived cell product candidates currently undergoing clinical development. We may elect to deprioritize or discontinue the clinical development of one or more of our product candidates for any number of reasons, including due to our prioritization of product candidates, data or results from our ongoing clinical trials, and the competitive therapeutic landscape for which our product candidates are being developed. In addition, one or more of our product candidates undergoing clinical development may have therapeutic potential in more than one disease area, and we may elect to prioritize clinical development in one disease area over another disease area. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use iPSC technology and gene-editing technology in the creation of our product candidates. If we are unable to use these technologies in the creation of our product candidates, our business would be significantly harmed.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may face delays in initiating, conducting or completing our clinical trials, including difficulties recruiting appropriate clinical trial investigators, enrolling patients in our clinical trials, or manufacturing adequate clinical supplies, and we may not be able to initiate, conduct or complete our clinical trials at all.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face significant competition in an environment of rapid technological change from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Initial, interim and preliminary data from our preclinical studies or clinical trials may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data. Furthermore, results from our ongoing or future clinical trials involving our product candidates may differ materially from initial, interim and preliminary data as well as previous study results.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The manufacture and distribution of our product candidates is complex and subject to a multitude of risks. Additionally, the U.S. Food and Drug Administration (FDA) or other regulatory authorities may impose additional requirements on our manufacturing operations. These risks and requirements could substantially limit our supply of our product candidates and increase our costs, and the development and commercialization of our product candidates could be significantly delayed or restricted. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have limited experience manufacturing our product candidates on a clinical scale, and no experience manufacturing on a commercial scale. Any failure to manufacture sufficient quantities of our product candidates consistently and at acceptable quality and costs may result in delays to our clinical development plans and impair our ability to obtain approval for, or commercialize, our product candidates and would materially and adversely affect our business.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We depend on third-party suppliers, including sole source suppliers, for certain aspects in the production of our product candidates, the loss of which suppliers could adversely impact our ability to conduct our clinical trials.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may face challenges recruiting and retaining key personnel due to labor market changes, availability of qualified candidates, and competition for employees from other companies. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may face cost fluctuations and inflationary pressures, including increases in prices of materials and costs of labor, which may adversely impact our operating performance, expenses, cash utilization and results.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We depend on strategic partnerships and collaboration arrangements for the development and commercialization of certain of our product candidates in certain indications or geographic territories, and if these arrangements are </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unsuccessful or are terminated, this could result in delays and other obstacles in the development, manufacture or commercialization of any of our product candidates and materially harm our results of operations.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have a limited operating history, have incurred significant losses since our inception, and anticipate that we will continue to incur significant losses for the foreseeable future.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to protect our intellectual property or obtain and maintain patent protection for our technology and product candidates, other companies could develop products based on our technologies and discoveries, which may reduce demand for, or limit the commercial potential of, our products and harm our business.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to comply with our obligations under our license agreements, we could lose rights to our product candidates or key technologies.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be successful in obtaining or maintaining necessary rights to product components and processes for development or manufacture of our product candidates which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have experience marketing any product candidates and do not have a sales force or distribution capabilities, and if our products are approved, we may be unable to commercialize them successfully.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The commercial success of our product candidates will depend upon the degree of market acceptance by physicians, patients, third-party payers and others in the medical community and may require additional evidence to support the anticipated benefits, comparative risks, and costs.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Security breaches, loss of data and other disruptions could compromise sensitive information related to our business.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and may be able to exercise significant control over our company.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our stock price is subject to fluctuation based on a variety of factors.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently qualify as a &#8220;smaller reporting company&#8221; and a &#8220;non-accelerated filer,&#8221; and any decision on our part to comply with only certain reduced reporting and disclosure requirements applicable to such companies could make our stock less attractive to investors.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Global economic and market conditions, any continued and prolonged public health emergency similar to the COVID-19 pandemic, global geopolitical tensions, including wars and other armed conflicts, or significant political, trade, or regulatory developments in the jurisdictions in which we may develop or commercialize our product candidates or conduct our operations, could adversely impact various aspects of our business, results of operations and financial condition, and could cause disruptions to our supply chain and the development and manufacture of our product candidates.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The summary risk factors described above should be read together with the text of the full risk factors below, in the section titled &#8220;Risk Factors&#8221;, and the other information set forth in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes, as well as in other documents that we file with the SEC. The risks summarized above or described in full below are not the only risks that we face. Additional risks and uncertainties not precisely known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, results of operations and future growth prospects.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="forwardlooking_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORWARD&#8211;LOOKIN</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">G STATEMENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties, as well as assumptions that, even if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this Annual Report on Form 10-K are forward-looking statements. In some cases, you can identify forward-looking statements by words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or the negative of these words or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our plans to research, develop and commercialize our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the initiation, timing, progress, size, duration, costs and results of our clinical trials and preclinical studies for our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability and timing to advance our product candidates in, and to successfully initiate, conduct, enroll and complete, clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the therapeutic differentiation and potential of our product candidates, and the disease indications for which we intend to develop our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and likelihood of, and our ability to obtain and maintain, regulatory clearance of our Investigational New Drug (IND) applications for and regulatory approval of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential of our technology platform, including our iPSC product platform, and our ability to leverage our platform in our research, development and commercialization activities for our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to manufacture our product candidates for clinical development and, if approved, for commercialization, and the timing and costs of such manufacture;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to source clinical and, if approved, commercial materials and supplies used to manufacture our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the performance of third parties in connection with the development of our product candidates, including third parties conducting our clinical trials as well as third-party suppliers;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to attract, successfully partner with, and retain strategic collaborators with development, regulatory and commercialization expertise;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential benefits of strategic collaboration agreements and our ability, and the ability of our collaborators, to successfully develop product candidates under the respective collaborations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain funding for our operations, including funding necessary to initiate and complete clinical trials of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to develop sales and marketing capabilities, whether alone or with actual or potential collaborators, to commercialize our product candidates, if approved;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to successfully commercialize our product candidates, if approved;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size and growth of the potential markets for our product candidates and our ability to serve those markets;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory developments and approval pathways in the United States and foreign countries for our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential scope and value of our intellectual property rights; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability, and the ability of our licensors, to obtain, maintain, defend and enforce intellectual property rights protecting our product candidates, and our ability to develop and commercialize our product candidates without infringing the proprietary rights of third parties;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to recruit and retain key personnel;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the accuracy of our projections and estimates regarding our expenses, capital requirements, cash utilization, revenues and need for additional financing;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to compete with rapidly evolving therapeutic technologies and respond to other developments relating to our competitors and our industry; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other risks and uncertainties, including those described under Part I, Item 1A. Risk Factors of this Annual Report on Form 10-K.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any forward-looking statements in this Annual Report on Form 10-K reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under Part I, Item 1A. Risk Factors and elsewhere in this Annual Report on Form 10-K. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K also contains estimates, projections and other information concerning our industry, our business, and the markets for certain diseases, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">In this Annual Report on Form 10-K, unless the context requires otherwise, &#8220;Fate Therapeutics,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; means Fate Therapeutics, Inc. and its subsidiaries.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART I</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 1. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Business</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of off-the-shelf cellular immunotherapies to patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have pioneered a therapeutic approach that we generally refer to as cell programming: we create and engineer human induced pluripotent stem cells (iPSCs) to incorporate novel synthetic controls of cell function; we generate a clonal master iPSC line for use as a renewable source of cell manufacture; and we direct the fate of the clonal master iPSC line to produce our cell therapy product candidate. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, we believe our proprietary clonal master iPSC lines can be used to mass produce multiplexed-engineered, cellular immunotherapies which have off-the-shelf availability, can be administered alone or in combination with standard-of-care therapies, and can reach significant numbers of patients.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Utilizing our iPSC product platform, we are developing off-the-shelf, multiplexed-engineered T-cell and natural killer (NK) cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. We have a pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted T-cell and NK cell product candidates currently under development:</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.378%;box-sizing:content-box;"/>
    <td style="width:28.854%;box-sizing:content-box;"/>
    <td style="width:12.378%;box-sizing:content-box;"/>
    <td style="width:12.378%;box-sizing:content-box;"/>
    <td style="width:11.998%;box-sizing:content-box;"/>
    <td style="width:12.737%;box-sizing:content-box;"/>
    <td style="width:9.278%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:7.2pt;background-color:#7f7f7f;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="border-top:0.5pt solid #000000;padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Program</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Indication</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cell Type</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">CAR Target(s)</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"># of Synthetic Controls</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Development Stage</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Partner</span></p></td>
   </tr>
   <tr style="height:7.2pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="7" style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Autoimmune Diseases</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FT819</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Systemic Lupus Erythematosus</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CAR T</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CD19</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Phase 1</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FT819</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Antibody-Associated Vasculitis, Idiopathic Inflammatory Myositis, and Systemic Sclerosis</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CAR T</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CD19</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Phase 1</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FT522</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">B Cell-mediated Autoimmunity in combination with rituximab</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CAR NK</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CD19; 41BB</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Phase 1</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FT829</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Autoimmunity</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CAR T</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Not disclosed</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Not disclosed</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preclinical</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:7.2pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="7" style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Oncology &#8211; Solid Tumors</span></p></td>
   </tr>
   <tr style="height:7.2pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FT825</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Solid Tumors</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CAR T</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">HER2</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Phase 1</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ono</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:7.2pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Undisclosed</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Solid Tumors</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CAR T</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Not disclosed</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Not disclosed</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preclinical</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ono</span></p></td>
   </tr>
   <tr style="height:7.2pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FT836</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Solid Tumors</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CAR T</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MICA/B</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Not disclosed</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preclinical</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Approach</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The use of human cells as therapeutic entities has disease-transforming potential across a broad spectrum of severe, life-threatening diseases. One particular form of cell therapy, CAR T-cell therapy, has emerged as a revolutionary and potentially curative treatment for patients with certain hematologic malignancies. In fact, multiple CAR T-cell therapies have now been approved by the United States Food and Drug Administration (FDA) for the treatment of relapsed / refractory B-cell malignancies and relapsed / refractory multiple myeloma. Additionally, several groups have demonstrated use of CAR T-cell therapy for the treatment of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">autoimmune diseases including systemic lupus erythematosus, idiopathic inflammatory myositis, systemic sclerosis, and myasthenia gravis.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cell therapies approved for commercialization, as well as those undergoing clinical development, today most often rely on the use of autologous, or a patient&#8217;s own, cells and are generally only available for patient treatment at a limited number of specialized medical centers. Sourcing, engineering, expanding and delivering cells patient-by-patient is logistically complex and expensive, resource intensive, and challenging to manufacture. Significant hurdles remain to ensure that autologous cell therapies can be consistently manufactured and reliably delivered at the scale necessary to support broad patient access.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe iPSCs, which possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body, can be used to overcome key limitations inherent to the manufacture, development and commercialization of today&#8217;s cell therapies. We have established a proprietary iPSC product platform and have amassed significant internal expertise in the production of off-the-shelf, multiplexed-engineered, T-cell and NK cell product candidates for therapeutic use. Our proprietary iPSC product platform includes: generating, engineering, isolating and characterizing single-cell iPSC clones; creating, qualifying, and cryopreserving clonal master iPSC lines; differentiating clonal master cell iPSC lines to produce T cells and NK cells at scale; and cryopreserving and storing these T cells and NK cells under conditions that support multi-year stability. Our cell product candidates</span><span style="color:#000000;white-space:pre-wrap;text-decoration:line-through;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">can be mass produced at significant scale in a cost-effective manner, are well-defined and uniform in composition, and can be stored in inventory and delivered off-the-shelf to maximize patient reach. Our proprietary iPSC product platform is supported by an intellectual property portfolio of over 550 issued patents and 550 pending patent applications.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We operate our own fully-integrated Good Manufacturing Practice (GMP) facility for manufacture of our iPSC-derived CAR T-cell and CAR NK cell product candidates that is intended to support all phases of clinical development as well as initial commercialization. We believe our therapeutic approach is highly differentiated and has the potential to overcome numerous challenges associated with today&#8217;s cell therapies, address significant unmet need, and deliver transformative medical benefit for patients.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Strategy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our mission is to bring off-the-shelf cellular immunotherapies with disease-transforming potential initially to patients with cancer and autoimmune diseases. The key pillars of our strategy include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Establish therapeutic differentiation with FT819 for the treatment of Systemic Lupus Erythematosus (SLE).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Autoimmune diseases affect organs throughout the body and are often characterized by the presence of auto-antibodies, which are produced by aberrant B cells and can attack healthy cells and tissues. The chronic and debilitating nature of these diseases results in substantial medical expenses and a low quality of life, creating a significant burden for patients, their families and the health care system. Current treatment options for SLE, which include corticosteroids, immunosuppressive medications, and biologics, often require chronic administration and have life-threatening side effects, with a majority of patients not adequately responding to today&#8217;s approved therapies.</span></div></div>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe FT819, our off-the-shelf, iPSC-derived, CD19-targeted CAR T-cell product candidate, has the potential to eliminate disease-causing B cells, enable reconstitution of a healthy immune cell compartment, and induce complete and durable responses in B cell-mediated autoimmune diseases. We base this on a ground-breaking academic clinical study published in Nature Medicine in September 2022, where intense conditioning chemotherapy, consisting of treatment of multiple days of cyclophosphamide (Cy) and fludarabine (Flu), coupled with an investigational autologous CD19-targeted CAR T-cell therapy were administered to five patients with SLE. Rapid B-cell depletion and elimination of auto-antibody production enabled all patients to achieve clinical remission. Recovery of a na&#239;ve B-cell compartment occurred several months after treatment, enabling an &#8220;immune reset&#8221; marked by restoration of a normal functioning immune system for the five patients.</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently conducting a multi-center, Phase 1 clinical trial of FT819 for the treatment of moderate-to-severe SLE. In contrast to treatment with autologous CAR T-cell therapy, patients enrolled in our Phase 1 clinical study are not required to undergo apheresis, may be administered a less intense, Flu-free conditioning regimen, and are administered drug product that is available on-demand. In addition, our Phase 1 clinical trial includes the opportunity for patients, in the absence of conditioning chemotherapy, to receive FT819 as an add-on to current maintenance therapy. We believe our therapeutic approach with FT819 is highly differentiated and may offer a more convenient and favorable experience for patients, including treatment in the outpatient setting. We intend to expand clinical investigation of FT819 to countries outside of the United States in 2025.</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expand the clinical footprint of our iPSC product platform within the field of autoimmunity, including initiating clinical investigation in additional B cell-mediated autoimmune diseases. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The prevalence of autoimmune diseases is both widespread and growing, with over 80 known autoimmune diseases affecting up to 8% of the U.S. population. Since the targeting and deep depletion of B cells may be a key mechanism of action to enable an immune reset and durable </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical remissions across autoimmune diseases, we plan to expand our clinical investigation of FT819 within the field of autoimmunity. In December 2024, we reached agreement with the FDA to allow for the clinical investigation of additional B cell-mediated autoimmune diseases under our current Phase 1 clinical trial of FT819. In February 2025, we submitted an amended clinical protocol to the FDA which included three additional diseases: anti-neutrophilic cytoplasmic antibody-associated vasculitis (AAV), idiopathic inflammatory myositis (IMM), and systemic sclerosis (SSc). We have completed a first dose-escalation cohort, and have also initiated a dose-expansion cohort, for FT819 at 360 million cells in SLE. We plan to initiate dose-expansion cohorts in one or more of AAV, IMM, and SSc in 2025 at that same cell dose. We believe the independent assessment of multiple B cell-mediated autoimmune diseases under one Phase 1 basket study enables the most cost-effective and efficient pathway for broad clinical development.</span></div></div>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, our investigational new drug (IND) application was allowed by the FDA to initiate clinical development of FT522, our off-the-shelf, CD19-targeted CAR NK cell product candidate, for the treatment of certain B cell-mediated autoimmune diseases.</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe there is a significant opportunity to combine, in the absence of conditioning chemotherapy, FT522 with rituximab to drive deeper B-cell depletion, and achieve higher rates of clinical remissions, for the treatment of autoimmune diseases. FT522 incorporates a proprietary high-affinity, non-cleavable CD16 (hnCD16) Fc receptor, which receptor has two unique features designed to synergize with monoclonal antibody therapy and augment antibody-dependent cellular cytotoxicity (ADCC): a high-affinity homozygous 158V variant to promote binding to the Fc domain of IgG antibodies, and a modification to block its cleavage and down-regulation upon receptor activation. In addition, FT522 is our first product candidate that incorporates our novel Alloimmune Defense Receptor (ADR) technology, which is designed to reduce or eliminate the need for administration of intense conditioning chemotherapy to patients receiving cellular immunotherapy. These attributes may create therapeutic differentiation for FT522 by enabling a more favorable safety profile, treatment in the community setting, and a broader commercial opportunity. We are currently evaluating opportunities and timelines for the clinical development of FT522 in autoimmune diseases.</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Design and develop off-the-shelf, multiplexed-engineered CAR T-cell immunotherapies that incorporate multiple novel mechanisms of action for the treatment of solid tumors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> While autologous CAR T-cell therapies have emerged as highly effective treatments for patients with relapsed / refractory hematologic malignancies, adoption of FDA-approved CAR T-cell therapy has been relatively modest to date due to complex logistics, high cost, and toxicities that necessitate administration only in specialized centers with intensive care units, as compared to more accessible outpatient infusion centers and community hospitals. In addition, successful development of autologous CAR T-cell therapies for the treatment of solid tumors has been hampered by on-target, off-tumor toxicities, inefficient CAR T-cell trafficking to the tumor, and modest efficacy. Today, there are no FDA-approved CAR T-cell therapies for the treatment of solid tumors. </span></div></div>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently advancing CAR T-cell product candidates that incorporate multiple novel synthetic controls selectively designed to overcome key mechanisms that limit CAR T-cell safety and efficacy in treating solid tumors. For example, our most advanced CAR T-cell product candidate for the treatment of solid tumors is FT825, which is currently undergoing Phase 1 clinical investigation in collaboration with Ono Pharmaceutical. FT825 incorporates seven novel synthetic controls of cell function including a novel binding domain targeting human epidermal growth factor receptor 2 (HER2), which is uniquely derived from a cancer-specific monoclonal antibody and has been shown in preclinical studies to overcome on-target, off-tumor toxicities by preferentially recognizing tumor-associated variants of HER2. FT825 also incorporates a novel synthetic CXCR2 receptor to promote effector cell trafficking to the tumor site, a novel synthetic TGF&#946; receptor to resist immunosuppressive signals in the tumor microenvironment, and our proprietary hnCD16 Fc receptor to support targeting of additional cancer antigen when combined with therapeutic antibodies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we are conducting IND-enabling activities for FT836, a CAR T-cell product candidate targeting major histocompatibility complex (MHC) proteins A (MICA) and B (MICB). While expression of MICA/B cell-surface proteins is detectable across many types of cancer cells with limited expression on healthy tissue, proteolytic cleavage and shedding of MICA/B is a common mechanism of tumor escape. We have designed FT836 to uniquely target a specific domain of MICA/B that is resistant to shedding as a potential pan-tumor targeting strategy. We believe there is significant opportunity to develop off-the-shelf CAR T-cell therapies that incorporate multiple therapeutic mechanisms of action, and can be combined with standard-of-care treatment regimens to significantly improve patient outcomes in the treatment of solid tumors.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Discover and incorporate novel synthetic controls of cell function into our iPSC product platform that significantly improve the patient experience, expand patient reach, and enhance therapeutic differentiation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Conditioning chemotherapy is one of the most significant barriers that limit patient reach and disease application of cellular immunotherapy. Conditioning chemotherapy often results in severe blood cell deficiencies and related toxicities, requiring administration in large tertiary care facilities. We are exploring the integration of novel synthetic controls of cell function </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">into our iPSC product platform that may enable our off-the-shelf, iPSC-derived cell product candidates to be administered without intense conditioning chemotherapy and in the community setting on an outpatient basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, FT522 is our first iPSC-derived cell product candidate to incorporate our novel alloimmune defense receptor (ADR) technology, which is designed to reduce or eliminate the need for administration of intense conditioning chemotherapy to patients receiving cellular immunotherapy. FT522 incorporates a synthetic ADR receptor that targets the cell surface receptor 4-1BB (CD137), a member of the tumor necrosis factor receptor superfamily that is upregulated on activated CD4+, CD8+, and regulatory T-cells as well as activated NK cells of the host immune system. The ADR receptor is designed to (a) selectively recognize and destroy alloreactive host immune cells, (b) maintain other components of the host immune system to preserve hematopoietic cell function, and (c) activate the product candidate to enhance its potency and persistence. Published preclinical studies have shown that ADR-armed allogeneic cells are protected from both T- and NK-cell mediated rejection (Mo et al. Nature Biotechnology, 39, 56&#8211;63 (2021)), providing proof-of-concept that ADR-armed allogeneic cells can persist and function in immunocompetent patients.</span></p>
  <p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to our ADR technology, we have also begun to incorporate the knock-out of CD58 (CD58KO) into our iPSC product platform, which we collectively refer to as our Sword &amp; Shield technology, to both target and evade host alloreactive immune cells. In preclinical studies, we have shown that iPSC-derived Sword &amp; Shield CAR T cells demonstrated functional persistence and durable anti-tumor activity, indicating the potential of Sword &amp; Shield CAR T cells to thrive without administration of conditioning chemotherapy. We believe that the use of a more tolerable treatment paradigm for cellular immunotherapies may significantly improve the patient experience, expand patient reach, and enhance therapeutic differentiation.</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Selectively share our proprietary iPSC product platform with strategic partners. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The research, development and commercialization of cell therapies for the treatment of human diseases is rapidly expanding. We believe we are well positioned to form partnerships with third parties seeking to develop and commercialize iPSC-derived cell therapies for the treatment of human diseases. For example, we are collaborating with Ono Pharmaceutical to research and develop off-the-shelf, multiplexed-engineered, iPSC-derived CAR T-cell and CAR NK cell product candidates for the treatment of solid tumors. We will continue to seek partnerships with companies and institutions for the research, development and commercialization of iPSC-derived cell therapies for the treatment of human diseases.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Off-the-shelf, Multiplexed-engineered, iPSC-derived Cellular Immunotherapy Pipeline</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FT819: CAR T-cell Program</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FT819 is our first iPSC-derived CAR T-cell product candidate and, to our knowledge, is the first-ever iPSC-derived CAR T-cell product candidate to undergo clinical investigation in the world. FT819 incorporates two novel synthetic controls of cell function: a novel 1XX CAR construct inserted directly into the T-cell receptor (TCR) alpha chain (TRAC) locus that targets CD19; and the complete disruption of TCR expression for the prevention of graft-versus-host disease (GvHD), a potentially life-threatening complication associated with donor-derived T-cell therapy. Together, these features of FT819 are designed to induce antigen-specific cytotoxicity, enhance CAR activity through TRAC-regulated expression, and mitigate risk of GvHD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Published preclinical data has shown that directing a CD19-specific CAR to the TRAC locus resulted in uniform CAR expression in human peripheral blood T cells, enhanced T-cell potency, and delayed effector T-cell differentiation and exhaustion (Eyquem et al. Nature. 543, 113&#8211;117, 2017), and that CAR T-cells utilizing a novel 1XX CAR signaling domain exhibited enhanced antitumor activity, persistence and long-term cytotoxicity as well as a decrease in T-cell exhaustion (Feucht et al. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nature Medicine</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. 25, 82&#8211;88, 2019). In preclinical studies, we have shown that iPSC-derived TCR-CAR+ CAR T cells targeting CD19:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">displayed antigen-specific anti-tumor potency </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including cytokine release and targeted cellular cytotoxicity, comparable to peripheral blood CD19-specific CAR T cells;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">did not respond or proliferate against HLA-mismatched (CD19-) peripheral blood mononuclear cells as targets in a mixed lymphocyte reaction, indicating the risk of GvHD is alleviated;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">controlled tumor progression </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> comparable to peripheral blood CD19-specific CAR T cells in a preclinical mouse model of acute lymphoblastic leukemia; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">enhanced tumor clearance and durable control of leukemia </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as compared to primary CAR19 T cells, in a xenograft mouse model of disseminated lymphoblastic leukemia.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">B-cell Lymphoma</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have successfully completed the dose-escalation stage of a multi-center, Phase 1 clinical trial to assess the safety, pharmacokinetics, and activity of FT819 in patients with relapsed / refractory B-cell malignancies (BCM), including B-cell lymphoma (BCL) (NCT04629729). 43 heavily pre-treated patients (B-cell lymphoma, n=25; chronic lymphocytic leukemia, n=12; and acute lymphocytic leukemia, n=6) were treated with conditioning chemotherapy and a single dose of FT819 across five dose levels ranging from 90 million cells to 1 billion cells. The safety and tolerability profile of FT819 was favorable, with no dose-limiting toxicities (DLTs), no events of any grade of immune effector-cell associated neurotoxicity syndrome (ICANS) or GvHD, and low incidence (14%) of only low-grade cytokine release syndrome (CRS). There were no study discontinuations or deaths related to FT819. Clinical responses were observed across all three histologies. In 17 patients with aggressive large BCL, 12 (71%) of whom had previously been treated with autologous CD19-targeted CAR T-cell therapy, the overall response and complete response rates were 47% and 24%, respectively. With the completion of the dose-escalation stage of the Phase 1 study in relapsed / refractory BCM, we elected to focus further clinical development of FT819 exclusively in autoimmunity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">B Cell-mediated Autoimmune Diseases</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe the clinical and translational data from the Phase 1 study in relapsed / refractory BCM demonstrated proof-of-concept for the treatment of patients with autoimmune diseases, where multiple mechanisms implicated in generating an immune reset in patients with B cell-mediated autoimmune diseases were observed:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Blood samples taken from 23 patients treated for relapsed / refractory BCL showed rapid and deep CD19+ B-cell depletion, with sustained suppression of B cells, in the periphery during the initial 30-day period following administration of conditioning chemotherapy and FT819;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patient case studies demonstrating secondary and tertiary tissue trafficking, infiltration, and activity of FT819, with complete elimination of CD19+ cells in tissue;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patient case studies of plasma cell depletion and B-cell reconstitution showing recovery of na&#239;ve and immature phenotypes, with little to no recovery of activated memory B cells or plasmablasts; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patient case studies demonstrating the capacity of FT819 to induce rapid, deep, and sustained B-cell depletion without the use of fludarabine as a conditioning agent.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span><img src="img143810944_0.jpg" alt="img143810944_0.jpg" style="width:633px;height:192px;"/></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently conducting a multi-center, Phase 1 clinical trial to evaluate the safety, pharmacokinetics, and anti-B cell activity of FT819 in patients with moderate to severe SLE, including those with active lupus nephritis (LN) or active extrarenal lupus (NCT06308978). The Phase 1 autoimmunity study allows for the administration of conditioning chemotherapy consisting of cyclophosphamide (Cy) and fludarabine (Flu) as well as two alternative, Flu-free conditioning regimens (single-agent Cy or single-agent bendamustine). In February 2024, we were awarded $7.9 million from the California Institute for Regenerative Medicine (CIRM) to support the clinical investigation of FT819 for the treatment of moderate to severe SLE.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">First Patient Case Study</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In April 2024, we announced that the first patient, a 27-year-old African American-Asian woman with refractory disease despite having been treated with multiple standard-of-care therapies, had been treated in the Phase 1 autoimmunity study. The patient presented with active LN and severe disease, which was marked by renal BILAG A (British Isles Lupus Assessment Group) disease activity score based on biopsy, SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index) score of 20, FACIT-Fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue) score of 33 (range 0-52, where a score of 52 indicates no fatigue), and PGA (Physician Global Assessment) score of 2.5 (where a score of 3 indicates most severe activity). Following administration of a Flu-free conditioning regimen and a single dose of FT819 at 360 million cells, the patient was discharged from the hospital without notable adverse events (AEs) after a protocol-required three-day stay. Rapid elimination of CD19+ B cells in the periphery was observed following treatment. B-cell recovery occurred by 3-month follow-up, where the B-cell</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compartment was predominantly comprised of na&#239;ve, non-class switched B cells with near-complete elimination of switched memory B cells, indicative of an immune reset. The patient reported that her debilitating fatigue had entirely resolved without further treatment, and treatment with methylprednisolone was discontinued at 3-month follow-up. The patient achieved DORIS (definition of remission in SLE) clinical remission, including with resolution of arthritis and substantial reduction in proteinuria, as of 6-month follow-up. As of a data cutoff date of December 4, 2024, the patient had experienced no Grade &#8805;3 AEs, no serious adverse events (SAEs), and no events of any grade of CRS, ICANS, or GvHD, and continued on-study in DORIS clinical remission and free of all immunosuppressive therapy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img143810944_1.jpg" alt="img143810944_1.jpg" style="width:570px;height:473px;"/><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Additional Treated Patients</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In December 2024, we announced that two additional patients, each of whom presented with active LN despite having been treated with multiple standard-of-care therapies, were administered a Flu-free conditioning regimen and a single dose of FT819 at 360 million cells. In both patients, FT819 was detected in the peripheral blood and rapid, deep, and sustained elimination of CD19+ B cells in the periphery was observed during the first month of treatment. As of a data cutoff date of December 4, 2024, both patients remain on-study, and there have been no DLTs and no events of any grade of CRS, ICANS, or GvHD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Enrollment in the multi-center, Phase 1 study of FT819 for the treatment of moderate-to-severe SLE is currently ongoing. Based on clinical observations from the first three treated patients, we have initiated dose expansion in up to 10 patients at the first dose level of 360 million cells and are also initiating dose escalation at 900 million cells. In addition, we have opened a second study arm for the treatment of moderate-to-severe SLE, which is designed to assess the safety, pharmacokinetics, and anti-B cell activity of a single dose of FT819 as an add-on to maintenance therapy without administration of any conditioning chemotherapy. In December 2024, we announced that the first patient had been treated in this second study arm at a starting cell dose of 360 million cells.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FT825: CAR T-cell Program</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FT825 is our first iPSC-derived CAR T-cell product candidate for the treatment of solid tumors being developed in collaboration with Ono Pharmaceutical. The use of autologous CAR T-cell therapies for the treatment of solid tumors has been hampered by tumor-associated antigen heterogeneity, inefficient CAR T-cell trafficking to the tumor, immunosuppression inherent to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the tumor microenvironment, and differentiating tumor-associated antigen expression between tumor and normal tissue. To date there are no FDA-approved CAR T-cell therapies for the treatment of solid tumors. FT825 is specifically designed to overcome these challenges in treating solid tumors, and incorporates seven novel synthetic controls of cell function: a 1XX CAR construct inserted directly into the TRAC locus that is armed with a novel human epidermal growth factor receptor 2 (HER2) binding domain designed to preferentially target tumor cells; a novel high-affinity 158V, non-cleavable CD16 (hnCD16) Fc receptor that has been modified to prevent its down-regulation and to enhance antibody-dependent cellular cytotoxicity (ADCC); a synthetic IL-7/IL-7 receptor fusion (IL-7RF), a potent cytokine complex that is intended to promote T-cell stemness; a synthetic CXCR2 receptor to promote cell trafficking; a synthetic TGF&#946; receptor to redirect immunosuppressive signals in the tumor microenvironment; the complete elimination of CD38 expression to promote persistence and function in high oxidative stress environments; and the complete disruption of TCR expression for the prevention of GvHD.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While HER2-directed therapies, such as trastuzumab (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Herceptin</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) and trastuzumab deruxtecan (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Enhertu</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), are effective in treating HER2-positive cancers, widespread HER2 expression in normal epithelial tissue can lead to significant on-target, off-tumor toxicities. In preclinical studies of FT825 presented at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting, the product candidate&#8217;s novel HER2 binding domain exhibited robust, dose-dependent cytolytic activity </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">against both HER2-high and HER2-low cell lines from multiple tumor types, and showed a highly selective and differentiated targeting profile </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">against HER2-expressing cancer cell lines versus healthy tissue in comparison to other HER2-directed agents such as trastuzumab (see figure below). We believe the cancer selectivity of the product candidate&#8217;s novel HER2 binding domain is attributable to its derivation from a cancer-specific monoclonal antibody H</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CasMab-2 (Kaneko et al., 2024), which has been shown to differentially and preferentially recognize both locally misfolded HER2 and p95 truncation variants of HER2. FT825 also exhibited enhanced trafficking and resistance to TGF&#946;-induced suppression </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(see figure below). In addition to its CAR-mediated anti-tumor activity against HER2, co-activation of the product candidate&#8217;s hnCD16 Fc receptor through combination with monoclonal antibody therapy showed enhanced anti-tumor activity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img143810944_2.jpg" alt="img143810944_2.jpg" style="width:681px;height:192px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img143810944_3.jpg" alt="img143810944_3.jpg" style="width:562px;height:192px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2024, we announced the initiation of enrollment of a multi-center, Phase 1 clinical trial of FT825 for the treatment of advanced solid tumors (NCT06241456) alongside our collaborator Ono Pharmaceutical (see &#8220;Our Partnership with Ono Pharmaceutical&#8221;). The Phase 1 study is designed to assess the safety, tolerability, and pharmacokinetics, as well as anti-tumor activity by overall response rate, duration of response and disease control rate, of a single dose of FT825 as monotherapy and in combination with monoclonal antibody therapy.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the 2024 SITC 39th Annual Meeting, we presented initial clinical data from three heavily pre-treated patients, all of whom were previously treated with at least five prior lines of therapy including HER2-targeted therapy. Each patient was administered a conditioning chemotherapy regimen and a single dose of FT825 at the first dose level of 100 million cells. As of a data cutoff date of October 25, 2024, FT825 demonstrated a favorable safety profile with no DLTs and no events of any grade of CRS, ICANS, or GvHD. In addition, at Day 8 following treatment, peak CAR T-cell expansion was observed and phenotyping of FT825 sourced from the patients&#8217; peripheral blood was indicative of an activated state (as evidenced by high levels of Granzyme B expression and maintenance of CAR expression) with no evidence of exhaustion (as evidenced by low levels of PD-1 and TIM3 expression).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img143810944_4.jpg" alt="img143810944_4.jpg" style="width:557px;height:153px;"/></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Enrollment in the multi-center, Phase 1 study of FT825 for the treatment of advanced solid tumors is currently ongoing at the second dose level of 300 million cells as monotherapy and at the first dose level of 100 million cells in combination with epidermal growth factor receptor (EGFR)-targeted monoclonal antibody therapy.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FT522: CAR NK Cell Program</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FT522 is our first iPSC-derived CAR NK cell product candidate that incorporates our novel Alloimmune Defense Receptor (ADR) technology, which is designed to reduce or eliminate the need for administration of intense conditioning chemotherapy to patients receiving cellular immunotherapy. While approved autologous CAR T-cell therapies have demonstrated compelling efficacy in treating patients with relapsed / refractory hematologic malignancies, several key challenges limit its adoption and patient reach including the need to co-administer conditioning chemotherapy to patients. Conditioning chemotherapy induces toxicities, necessitates treatment at specialized medical centers with intensive care units, and prevents effective combination with standard-of-care treatment regimens widely used in the community setting. Its use has also been associated with treatment-emergent secondary malignancies, such as myelodysplastic syndrome.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FT522 incorporates a novel synthetic ADR targeting the cell surface receptor 4-1BB (CD137), a member of the tumor necrosis factor receptor superfamily that is upregulated on activated CD4+, CD8+, and regulatory T cells, as well as activated NK cells, of the host immune system. Four additional synthetic controls of cell function incorporated into FT522 include: a proprietary CAR that targets CD19; a novel high-affinity 158V, non-cleavable CD16 (hnCD16) Fc receptor that has been modified to prevent its down-regulation and to enhance ADCC in combination with a monoclonal antibody; an IL-15/IL-15 receptor fusion (IL-15RF), a potent cytokine complex that is intended to augment NK cell activity; and the complete elimination of CD38 expression to promote persistence and function in high oxidative stress environments. These features of FT522 are designed to reduce or eliminate the need for administration of intense conditioning chemotherapy to patients, enable dual-antigen targeting of antigens expressed on B cells through combination with monoclonal antibody therapy, and extend the functional persistence of FT522.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In preclinical studies, we showed that ADR-armed CAR NK cells selectively targeted and eliminated alloreactive immune cells in an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> co-culture assay with allogeneic peripheral blood mononuclear cells (see figure below); targeted and eliminated activated T-regulatory cells, overcoming a major suppressive mechanism associated with poor anti-tumor activity; and were potentiated through 4-1BB engagement, promoting NK cell expansion and persistence. In addition, in a disseminated Nalm6 leukemia model comprised of alloreactive T cells and CD19+ tumor cells resistant to T-cell killing (MHC class 1-null), ADR-armed, CD19-targeted, iPSC-derived CAR NK cells exhibited uncompromised effector function </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> compared to ADR-null, CD19-targeted, iPSC-derived CAR NK cells, suggesting that ADR-armed NK cells functionally persist, proliferate, and kill tumor cells while resisting rejection by alloreactive T cells. These preclinical data suggest that FT522 has the potential to robustly deplete CD19+ B cells, evade host immune cell rejection, and drive clinical responses without administration of intense conditioning chemotherapy to patients.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img143810944_5.jpg" alt="img143810944_5.jpg" style="width:550px;height:249px;"/></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">B-cell Lymphoma</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are completing a multi-center, Phase 1 clinical trial of FT522 to assess its safety, pharmacokinetics, and activity in patients with relapsed / refractory BCL (NCT05950334). The Phase 1 study includes two regimens: Regimen A, or the &#8220;conditioning&#8221; arm, which consists of three days of conditioning chemotherapy; one dose of rituximab; and three doses of FT522; and Regimen B, or the &#8220;no conditioning&#8221; arm, which consists of one dose of rituximab and three doses of FT522 without conditioning chemotherapy. At the 2024 American College of Rheumatology (ACR) Convergence meeting, we presented initial clinical and translational data from the Phase 1 study of FT522 in relapsed / refractory BCL. As of a data cutoff date of November 8, 2024:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regimen A &#8220;Conditioning&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. At the first dose level of 300 million cells per dose (A-DL1; n=6), all three patients with indolent lymphoma achieved a complete response (CR) and one patient with mantle cell lymphoma achieved a partial response (PR), while two patients with diffuse large B-cell lymphoma (DLBCL) did not respond to treatment (1 stable disease (SD); 1 progressive disease). At the second dose level of 900 million cells per dose (A-DL2; n=3), two of three patients with DLBCL achieved an overall response (1 CR; 1 PR; 1 SD). The potential for FT522 dose-dependent activity was supported by pharmacokinetics (PK), which showed a greater than 20-fold increase in median cumulative PK between the two dose levels (&gt;80,000 copies*day/&#181;gDNA for A-DL2 and &lt;4,000 copies*day/&#181;gDNA for A-DL1). </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regimen B &#8220;No Conditioning&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. At the first dose level of 300 million cells per dose (B-DL1; n=3), live FT522 cells were detected in the patients&#8217; peripheral blood through Day 15 (one week post-infusion of the third dose), demonstrating the ability of FT522 to persist in the presence of an unmatched, fully-intact immune system. Notably, in all three patients, each dose of FT522 maintained functional activity as evidenced by a similar percent reduction in circulating CD19+ B cells in the patients&#8217; peripheral blood with each infused dose. These first-of-kind translational data support the potential of live FT522 cells to functionally persist and deplete pathogenic CD19+ B cells without administration of conditioning chemotherapy to patients. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img143810944_6.jpg" alt="img143810944_6.jpg" style="width:465px;height:249px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tolerability</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. There have been no DLTs, and no events of CRS, ICANS, or GvHD.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Enrollment in the multi-center, Phase 1 study of FT522 for the treatment of relapsed / refractory BCL has been completed in Regimen A at the second dose level of 900 million cells per dose and we are planning to complete enrollment in Regimen B at the second dose level of 900 million cells per dose. We intend to analyze the data from both Regimen A and Regimen B at 900 million cells per dose for safety and activity to assess whether to pursue any further clinical development of FT522.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">B Cell-mediated Autoimmune Diseases</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In a preclinical </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> re-challenge assay using peripheral blood mononuclear cells (PBMCs) from unmatched SLE donors, FT522 uniquely drove rapid and deep CD19+ B cell depletion, eliminated alloreactive T cells and maintained functional persistence, indicating that FT522 has the potential to function effectively in the presence of an unmatched host immune system. In addition, in a preclinical </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> biodistribution study, FT522 showed dose-dependent trafficking, infiltration, and residency in secondary and tertiary tissues without cytokine support at human dose equivalency levels of 250 million cells per dose and 1 billion cells per dose (based on 20 gram mouse and 65 kilogram human allometric conversion).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently, the FDA allowed our Investigational New Drug (IND) application to assess the safety, pharmacokinetics, and activity of FT522 across a basket of B cell-mediated autoimmune diseases including anti-neutrophilic cytoplasmic AAV, IMM, SSc, and SLE. The Phase 1 clinical protocol permits treatment of patients with up to four weekly doses of FT522, without administration of conditioning chemotherapy, as an add-on to rituximab induction therapy (Regimen A) and as an add-on to maintenance therapy in combination with rituximab (Regimen B). We are currently evaluating opportunities and timelines for the clinical development of FT522.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical Programs</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FT836 CAR T-cell Program</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. FT836 is our a multiplexed-engineered CAR T-cell product candidate targeting MHC proteins MICA and MICB. The expression of MICA/B cell-surface proteins is induced by cellular stress or malignant transformation, and is detectable across many types of cancer cells with limited expression on healthy tissue. MICA/B targeting is emerging as a novel cancer-specific strategy to attack a wide range of solid tumors, however, proteolytic cleavage and shedding of MICA/B at the membrane-proximal &#945;3 domain is a common mechanism of tumor escape. FT836 is designed to uniquely target and bind the &#945;3 domain, which has been shown to stabilize MICA/B expression and induce robust cytolytic killing of tumor cells.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The novel suite of synthetic controls incorporated into FT836 is intended to address critical challenges that have limited CAR T-cell safety and efficacy in treating solid tumors including on-target, off-tumor toxicity, effector cell suppression in the tumor microenvironment, tumor heterogeneity, and limited functional persistence. At the 2024 SITC 39</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Annual Meeting, we presented preclinical data showing that FT836 exerted potent and durable anti-tumor activity </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">across a broad array of solid tumors (see figure below). In addition, treatment of tumor cells with chemotherapy or radiation therapy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> elicited an increase in MICA/B expression and further enhanced the cytolytic activity of FT836, indicating the potential for combination with standard-of-care regimens used for the treatment of solid tumors.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img143810944_7.jpg" alt="img143810944_7.jpg" style="width:571px;height:173px;"/></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FT836 is also our first product candidate to incorporate our novel </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sword &amp; Shield</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> technology, which utilizes our ADR technology alongside CD58KO, to both target and evade host alloreactive immune cells. In preclinical studies presented at SITC, iPSC-derived </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sword &amp; Shield</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> CAR T cells demonstrated functional persistence and durable anti-tumor activity </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that was uniquely maintained upon supraphysiological challenge with alloreactive T cells, indicating the potential of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sword &amp; Shield</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> CAR T cells to thrive without administration of conditioning chemotherapy to deplete host immune cells.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img143810944_8.jpg" alt="img143810944_8.jpg" style="width:423px;height:115px;"/></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2025, we were awarded $4 million from CIRM to support the clinical translation of FT836 for the treatment of multiple solid tumor indications. We plan to submit an IND application to the FDA in 2025 to initiate Phase 1 clinical investigation of FT836 for the treatment of advanced solid tumors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FT829 CAR T-cell Program</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We are applying our iPSC product platform to preclinically develop next-generation CAR T-cell therapies with the potential to target multiple aberrant cell types while evading recognition by alloreactive immune cells. FT829 is our first multi-antigen CAR T-cell product candidate that is designed to express two unique CARs: a first CAR targeting CD19+ B cells, and a second CAR targeting additional disease-causing cells. At the 2024 American Society of Hematology (ASH) Annual Meeting, we demonstrated that iPSC-derived CAR T cells targeting CD19 and the cell surface glycoprotein CD38 specifically eliminated a variety of malignant cell types, including CD19+ lymphoma and CD38+ multiple myeloma cell lines, in several </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cytotoxicity assays and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> models. In addition, dual CAR T cells showed enhanced elimination of CD19+CD38+ cells </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> compared to single CAR controls. In a preclinical proof-of-concept study in autoimmunity, using unmatched PBMCs sourced from a patient with SLE, dual CAR T cells showed robust eradication </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of aberrant CD19+ B cells, CD38+ plasma cells, and CD38+ activated T cells. We plan to finalize the product configuration, and complete IND-enabling activities, in 2025 to support initial clinical investigation of FT829 for the treatment of autoimmune disease.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Partnership with Ono Pharmaceutical</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. (Ono) entered into in September 2018 and amended in June 2022 and August 2024 (the Ono Agreement), we are conducting research and preclinical development of iPSC-derived CAR T-cell and CAR NK cell product candidates for the treatment of solid tumors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2022, we announced that Ono had exercised its preclinical option to FT825 / ONO-8250, an off-the-shelf, multiplexed-engineered, iPSC-derived CAR T-cell product candidate targeting HER2-expressing solid tumors (also referred to as Candidate 2 below), and that we exercised our preclinical option to co-develop and co-commercialize FT825 / ONO-8250 in the United States and Europe under a joint arrangement with Ono. As a result, we received an option exercise fee of $12.5 million from Ono. In January 2024, we announced the initiation of enrollment of a Phase 1 clinical trial of FT825 / ONO-8250 for the treatment of advanced solid tumors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The companies are also currently conducting preclinical development of a second iPSC-derived CAR-targeted effector cell product candidate for the treatment of solid tumors (referred to as Candidate 3 below) under the Ono Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the original Ono Agreement entered into in September 2018, we and Ono intended to research and preclinically develop two iPSC-derived CAR T-cell product candidates, one of which was designated to target an antigen expressed on certain lymphoblastic leukemias (Candidate 1) and the second of which was designated to target an antigen expressed on certain solid tumors (Candidate 2) (each a Candidate and, collectively, the Candidates). We granted to Ono, during a specified period of time, a preclinical option to obtain an exclusive license under certain intellectual property rights to develop and commercialize: (a) Candidate 1 in Asia, where we retained rights for development and commercialization in all other territories of the world; and (b) Candidate 2 in all territories of the world, where we retained rights to co-develop and co-commercialize Candidate 2 in the United States and Europe under a joint arrangement with Ono under which we are eligible to share at least 50% of the profits and losses. We maintained worldwide rights of manufacture for each Candidate. For each Candidate, the preclinical option expired upon the earliest of: (a) the achievement of the pre-defined preclinical milestone under the joint development plan; (b) termination by Ono of research and development activities for the Candidate; and (c) the date that is the later of (i) four years after the effective date, and (ii) completion of all applicable activities contemplated under the joint development plan. Ono paid us an upfront, non-refundable and non-creditable payment of $10.0 million in connection with entering into the Ono Agreement. Additionally, as consideration for our conduct of research and preclinical development under a joint development plan, Ono agreed to pay us annual research and development fees set forth in the annual budget included in the joint development plan, which fees were estimated to be $20.0 million in aggregate over the course of the joint development plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2020, we entered into a letter agreement with Ono pursuant to which Ono delivered to us proprietary antigen binding domains targeting an antigen expressed on certain solid tumors for incorporation into Candidate 2 and paid us a milestone fee</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of $10.0 million for further research and preclinical development of Candidate 2. In addition, Ono terminated all further research and preclinical development with respect to Candidate 1, and we retained all rights to research, develop and commercialize Candidate 1 throughout the world without any obligation to Ono.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2022, we entered into an amendment with Ono to the Ono Agreement (the 2022 Ono Amendment). Pursuant to the 2022 Ono Amendment, the companies agreed to designate an additional antigen expressed on certain solid tumors for research and preclinical development, and Ono agreed to contribute to us proprietary antigen binding domains targeting such additional solid tumor antigen (Candidate 3). In addition, for both Candidate 2 and Candidate 3, the companies expanded the scope of the collaboration to include the research and preclinical development of iPSC-derived CAR NK cell product candidates (in addition to iPSC-derived CAR T-cell product candidates) targeting the designated solid tumor antigens. Similar to Candidate 2, we granted to Ono, during a specified period of time, a preclinical option (Candidate 3 Development Option) to obtain an exclusive license under certain intellectual property rights, subject to payment of an option exercise fee to us by Ono, to further develop and commercialize Candidate 3 in all territories of the world, where we retained rights to co-develop and co-commercialize Candidate 3 in the United States and Europe under a joint arrangement with Ono under which we are eligible to share at least 50% of the profits and losses. We maintained worldwide rights of manufacture for Candidate 3. Ono agreed to pay us annual research and development fees set forth in the annual budget included in the joint development plan for Candidate 3.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2022, Ono exercised its option to obtain a license to develop and commercialize Candidate 2 (the Candidate 2 Development Option). We exercised our option (the CDCC Option) to co-develop and co-commercialize Candidate 2 in the United States and Europe. As a result, we received an option exercise payment of $12.5 million. We and Ono are proceeding under a joint development plan for the ongoing development of Candidate 2.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 30, 2023, we entered into an amendment with Ono to the Ono Agreement (the 2023 Ono Amendment). Under the 2023 Ono Amendment, aggregate estimated research and preclinical development fees payable by Ono to us for Candidate 3 have been increased by approximately $1.4 million, for a total estimated $30.7 million in aggregate research and preclinical development fees over the course of the joint research plan.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2024, we entered into an amendment with Ono to the Ono Agreement (the 2024 Ono Amendment and collectively with the 2023 Ono Amendment and 2022 Ono Amendment, the Ono Amendments). Under the 2024 Ono Amendment, the preclinical option period for Candidate 3 has been extended through June 2025 and the aggregate estimated research and preclinical development fees payable by Ono to us for Candidate 3 have been increased by approximately $7.3 million, for a total estimated $38.0 million in aggregate research and preclinical development fees over the course of the joint research plan. We will continue to receive committed funding under the joint research plan from Ono during the preclinical option period. The Candidate 3 Development Option expires upon the earlier of: (a) June 30, 2025 or (b) the achievement of the pre-defined preclinical milestone under the joint research plan for Candidate 3. Subject to payment of an extension fee by Ono, Ono may choose to defer its decision to exercise the Candidate 3 Development Option until no later than June 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Ono Agreement (as amended by the Ono Amendments), for Candidate 2 and for Candidate 3 (subject to exercise by Ono of its Candidate 3 Development Option), we are eligible to receive additional payments upon the achievement of certain clinical, regulatory and commercial milestones (the Ono Milestones) with respect to each Candidate in an amount up to $843.0 million in aggregate, with the applicable milestone payments for the United States and Europe subject to reduction by 50% if we elect to co-develop and co-commercialize the Candidate in the United States and Europe as described above. In addition, in those territories where Ono has exclusive rights of commercialization, we are eligible to receive tiered royalties (Royalties) ranging from the mid-single digits to the low-double digits based on annual net sales by Ono for each Candidate in such territories, with the Royalties subject to certain reductions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Ono Agreement will terminate with respect to a Candidate if Ono does not exercise its development option for a Candidate within the option period, or in its entirety if Ono does not exercise any of its development options for the Candidates within their respective option periods. In addition, either party may terminate the Ono Agreement in the event of breach, insolvency or patent challenges by the other party; provided, that Ono may terminate the Ono Agreement in its sole discretion (x) on a Candidate-by-Candidate basis at any time after the second anniversary of the effective date of the Ono Agreement or (y) on a Candidate-by-Candidate or country-by-country basis at any time after the expiration of the development option period, subject to certain limitations. The Ono Agreement will expire on a Candidate-by-Candidate and country-by-country basis upon the expiration of the applicable royalty term, or in its entirety upon the expiration of all applicable payment obligations under the agreement.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Intellectual Property</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We seek to protect our product candidates and our cell programming technology through a variety of methods, including seeking and maintaining patents intended to cover our products and compositions, their methods of use and processes for their manufacture, our platform technologies and any other inventions that are commercially important to the development of our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We seek to obtain domestic and international patent protection and, in addition to filing and prosecuting patent applications in the United States, we typically file counterpart patent applications in additional countries where we believe such foreign filing is likely to be beneficial, including Europe, Japan, Canada, Australia and China. We continually assess and refine our intellectual property strategy in order to best fortify our position, and file additional patent applications when our intellectual property strategy warrants such filings. We also rely on know-how, continuing technological innovation and in-licensing opportunities to develop and maintain our proprietary position. We have entered into exclusive license agreements with various academic and research institutions to obtain the rights to use certain patents for the development and commercialization of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 28, 2025, our intellectual property portfolio is composed of over 450 issued patents and 150 patent applications that we license from academic and research institutions, and over 450 issued patents or pending patent applications that we own. These patents and patent applications generally provide us with the rights to develop our product candidates in the United States and worldwide. This portfolio covers compositions of programmed cellular immunotherapies, our cell programming approach for enhancing the therapeutic function of cells </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and our platform for industrial-scale iPSC generation and engineering. We believe that we have a significant intellectual property position and substantial know-how relating to the programming of hematopoietic and immune cells and to the derivation, genetic engineering, and differentiation of iPSCs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot be sure that patents will be granted with respect to any of our owned or licensed pending patent applications or with respect to any patent applications we may own or license in the future, nor can we be sure that any of our existing patents or any patents we may own or license in the future will be useful in protecting our technology. Please see &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property&#8221; for additional information on the risks associated with our intellectual property strategy and portfolio.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual Property Relating to iPSC Technology and Platform</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 28, 2025, we own over 30 patent families directed to programming the fate of somatic cells </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including patent applications pending in the U.S. and internationally related to our platform for industrial-scale iPSC generation and applications related to differentiation of iPSCs into specialized cells with therapeutic potential. These patent applications cover our proprietary small molecule-enhanced iPSC platform, including novel reprogramming factors and methods of reprogramming to obtain iPSCs. Our intellectual property portfolio also includes gene editing compositions and methods of genetic engineering, as well as methods of directing the fate of cells to obtain homogenous cell populations in the hematopoietic lineage, including CD34</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cells, T-cells and NK cells. Our proprietary intellectual property enables highly-efficient iPSC derivation, selection, engineering, and clonal expansion while maintaining genomic stability. Any U.S. patents issued from these patent applications are expected to have statutory expiration dates ranging from 2031 to 2044.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we have licensed from the Whitehead Institute for Biomedical Research a portfolio of four patent families, including issued patents and pending applications broadly applicable to the reprogramming of somatic cells. Our license is exclusive in commercial fields, including for drug discovery and therapeutic purposes. This portfolio covers compositions used in the reprogramming of mammalian somatic cells to a pluripotent state. The earliest filed patent family in the portfolio expired in November 2024, and the remaining issued patents and any U.S. patents that may issue from these pending patent applications are expected to have statutory expiration dates ranging from 2028 to 2029.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have exclusive licenses from The Scripps Research Institute to a portfolio of seven patent families relating to compositions and methods for reprogramming mammalian somatic cells, which covers non-genetic and viral-free reprogramming mechanisms, including the use of various small molecule classes and compounds and the introduction of cell-penetrating proteins to reprogram mammalian somatic cells. This portfolio includes issued U.S. patents (including U.S. Patents 8,044,201 and 8,691,573) that provide composition of matter protection for a class of small molecules, including thiazovivin, that is critical for inducing the generation, and maintaining the pluripotency, of iPSCs, and compositions and methods of using the small molecule. Any issued U.S. patents and any U.S. patents that may issue from patent applications pending in this portfolio are expected to have statutory expiration dates ranging from 2026 to 2031.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have exclusively licensed from the J. David Gladstone Institutes (Gladstone) intellectual property covering the generation of iPSCs using CRISPR-mediated gene activation. This approach for inducing pluripotency uses CRISPR to directly target a specific location of the genome and activate endogenous gene expression, and does not rely on established methods of cellular reprogramming that require the transduction of multiple transcription factors. Any U.S. patents that may issue from patent applications pending in the U.S. and internationally in this portfolio are expected to have a statutory expiration date in 2038.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have exclusive rights to four families of patent applications from the University of Minnesota. As of February 28, 2025, this portfolio includes over 75 issued patents or pending patent applications in the United States and foreign jurisdictions directed to compositions of NK cells, including adaptive memory NK cells and genetically-engineered NK cells, and therapeutic strategies for the treatment of cancer using these NK cells. These applications also describe compositions and methods of enhancing effector cell cytotoxicity by genetically engineering the CD16 Fc receptor in immune cells, including iPSC-derived NK and T cells. The portfolio also includes applications describing methods of increasing NK cell tumor specificity and cytotoxicity by incorporating CARs on NK</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cells. Any U.S. patents that may issue from patent applications pending in this portfolio are expected to have statutory expiration dates between 2035 and 2038.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have exclusively licensed from MSKCC intellectual property covering the production and composition of iPSC-derived T-cells and their use in cellular immunotherapy, and have a license from MSKCC to two patent families covering novel CAR constructs as well as off-the-shelf CAR T-cells, including the use of CRISPR and other innovative technologies for their production. Collectively, this portfolio covers compositions of CAR constructs, compositions of T-cells and NK cells derived from pluripotent cells which are engineered with CARs, methods of engineering pluripotent cell lines, methods of deriving CAR T-cells from CAR expressing pluripotent stem cells, and methods of using CRISPR for producing off-the-shelf T-cell immunotherapies. Any U.S. patents that may issue from patent applications pending in this portfolio are expected to have statutory expiration dates between 2034 and 2038.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  In addition, we have licensed exclusive rights from the Max Delbruck Center for Molecular Medicine to intellectual property directed to novel humanized antibody fragments, antigen-binding domains and CAR constructs that </span><span style="color:#222222;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">uniquely target and specifically bind BCMA. Under the license agreement, we are granted an exclusive license for use in allogeneic engineered pluripotent stem cells. Any patents issuing from </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patent applications pending in the U.S. and internationally in this portfolio are expected to have statutory expiration dates between 2033 and 2037.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have also licensed exclusive rights from the Dana-Farber Cancer Institute (DFCI) to certain intellectual property covering novel antibody fragments that uniquely and specifically bind the alpha-3 domain of MICA/B. We are granted exclusive worldwide rights for use in iPSC-derived cellular therapeutics for the treatment of human disease under the license agreement. Any patents that may issue from patent applications pending in this portfolio are expected to have statutory expiration dates in 2038.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we have licensed exclusive rights from BCM to intellectual property covering the composition and use of a novel ADR that selectively targets activated T-cells to protect engineered allogeneic cell products expressing the ADR from elimination in the host immune system. Under the license agreement with BCM, we are granted exclusive worldwide rights to use ADR in the field of iPSC-derived cell products, including T-cells and NK cells derived from iPSCs engineered with ADRs. As of February 28, 2025, the portfolio includes three issued patents and 14 pending applications broadly applicable to making and using ADR-expressing effector cells, including T-cells and NK cells differentiated from iPSCs engineered with ADRs. We expect U.S. patents related to this technology to have statutory expiration dates starting in 2039.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual Property Relating to CRISPR Engineering</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2019, we entered into a license agreement with Inscripta, Inc. Under the license agreement, we obtained a royalty-free, irrevocable license to a patent portfolio covering the composition, production and use of MAD7, a novel gene-editing CRISPR endonuclease from the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Eubacterium rectale</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> genome. The intellectual property includes issued patents and pending applications broadly applicable to MAD7 and the editing of mammalian cells. Our license covers the making and using of MAD7 for editing iPSCs, making master engineered iPSC lines and using master engineered iPSC lines to manufacture human therapeutic products. We expect U.S. patents related to this work to have statutory expiration dates starting in 2037.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual Property Relating to the Programming of Hematopoietic Cells</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 28, 2025, we own 17 families of U.S. and foreign patents and pending patent applications covering our cell programming technology and compositions of programmed cellular immunotherapies. This portfolio includes over 150 issued patents or pending patent applications relating to methods of programming the biological properties and therapeutic function of cells </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and the resulting therapeutic compositions of hematopoietic and immune cells. Patents and patent applications in this portfolio include claims covering (i) therapeutic compositions of hematopoietic and immune cells, including T-cells, NK cells, and CD34</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cells, that have been programmed </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with one or more agents to optimize their therapeutic function for application in oncology and immune diseases and (ii) methods of programming cells including by the activation or inhibition of therapeutically-relevant genes and cell-surface proteins, such as those involved in the homing, proliferation and survival of hematopoietic cells or those involved in the persistence, proliferation and reactivity of immune cells. Any U.S. patents within this portfolio that have issued or may yet issue from pending patent applications will have statutory expiration dates between 2032 and 2044.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Material Technology License Agreements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The University of Minnesota</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2016, we entered into a license agreement with the Regents of the University of Minnesota for rights relating to compositions and methods relating to NK cells, to modifications of cytotoxic receptors naturally expressed on NK cells including the CD16 Fc receptor, and to CARs for expression on NK cells. Under our agreement with the University of Minnesota, we acquired an exclusive royalty-bearing, sublicensable, worldwide license to make, use and sell licensed products in all fields for commercial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">purposes. The licensed patent rights are described in more detail above under &#8220;Intellectual Property Relating to the Programming of Hematopoietic Cells.&#8221; The University of Minnesota retains the right to practice the patent rights for research, teaching and educational purposes, including in corporate-sponsored research subject to certain limitations during the initial three years of the license agreement. The University of Minnesota also retains the right to license other academic and non-profit research institutes to practice the patent rights for research, teaching and educational purposes, but not for corporate-sponsored research. Our license is also subject to pre-existing rights of the U.S. government.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the license agreement, we are required to pay the University of Minnesota an annual license maintenance fee during the term of the agreement, and are also required to make payments of up to $4.6 million for development, regulatory and commercial milestones achieved with respect to each of the first three licensed products. If commercial sales of a licensed product commence, we will also be required to pay royalties at percentage rates in the low-single digits on net sales of licensed products. Our royalty payments are subject to reduction for any third-party payments required to be made until a minimum royalty percentage has been reached. In the event that we sublicense the patent rights, the University of Minnesota is also entitled to receive a percentage of the sublicensing income received by us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the license agreement with the University of Minnesota, we are obligated to use commercially reasonable efforts to develop and make commercially available licensed products. In particular, we are required to conduct activities toward specific development milestones of licensed products on an annual basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The license agreement will continue until the abandonment of all patent rights or expiration of the last to expire licensed patent. The University of Minnesota may terminate the agreement if we default in the performance of any of our obligations and fail to cure the default within a specified grace period. The University of Minnesota may also terminate the agreement if we cease to carry out our business or become bankrupt or insolvent. We may terminate the agreement for any reason upon prior written notice to the University of Minnesota and payment of all amounts due to the University of Minnesota through the date of termination.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Memorial Sloan-Kettering Cancer Center (MSKCC)</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2018, we entered into an amended and restated license agreement with MSKCC. The agreement amends and restates the exclusive license agreement we entered into with MSKCC in August 2016, under which we obtained rights relating to compositions and methods covering iPSC-derived cellular immunotherapy, including T-cells and NK cells derived from iPSCs engineered with CARs. Pursuant to the amended and restated license agreement, we continue to hold exclusive rights to the foregoing patents and patent applications, and obtained additional licenses to certain patents and patent applications relating to compositions and methods covering novel CAR constructs as well as off-the-shelf CAR T-cells, including the use of CRISPR and other innovative technologies for their production.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under our amended and restated agreement with MSKCC, we have royalty-bearing worldwide licenses to make, use and sell licensed products in all fields for human therapeutic uses. The licensed patent rights are described in more detail above under &#8220;Intellectual Property Relating to iPSC Technology.&#8221; For those patent families where our rights are exclusive, MSKCC retains the right to practice the patent rights for research, teaching and non-clinical research purposes, and to license other academic and non-profit research institutes to practice the patent rights for research, teaching and non-clinical research purposes. Our licenses are also subject to pre-existing rights of the U.S. government.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the amended and restated agreement, we are required to pay MSKCC an annual license maintenance fee during the term of the agreement, and are also required to make payments of up to $12.5 million for development, regulatory and commercial milestones achieved with respect to each licensed products. If commercial sales of a licensed product commence, we will also be required to pay royalties at percentage rates up to the high-single digits on net sales of licensed products. Our royalty payments are subject to reduction for any third-party payments required to be made until a minimum royalty percentage has been reached. In the event that we sublicense the patent rights, MSKCC is also entitled to receive a percentage of the sublicensing income received by us. Additionally, in the event a licensed product achieves a specified clinical milestone, MSKCC is then eligible to receive additional milestone payments, where the amount of such payments owed to MSKCC are contingent upon certain increases in the price of our common stock following the date of achievement of such clinical milestone.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the amended and restated agreement with MSKCC, we are obligated to use commercially reasonable efforts to develop and make commercially available licensed products. In particular, we are required to conduct activities and commit a minimum amount of funding toward specific development milestones of licensed products on an annual basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The agreement will continue until the abandonment of all patent rights or expiration of the last to expire licensed patent. MSKCC may terminate the agreement if we default in the performance of any of our obligations and fail to cure the default within a specified grace period, if we cease to carry out our business or become bankrupt or insolvent, or if we institute a proceeding to challenge the patent rights. We may terminate the agreement for any reason upon prior written notice to MSKCC.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Max Delbruck Center</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2018, we entered into a license agreement with Max Delbruck Center for Molecular Medicine for rights relating to novel humanized antibody fragments, antigen-binding domains and CAR constructs that </span><span style="color:#222222;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">uniquely target and specifically bind BCMA. Under our license agreement with MDC, we acquired</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> an exclusive royalty-bearing, sublicensable, worldwide license to make, use and sell products covered by the licensed patent rights, and to perform licensed processes, in each case, using cells derived from allogeneic engineered stem cells.</span><span style="color:#222222;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> MDC </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">retains a non-exclusive right to use the technology for its own internal research, teaching, and educational purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the license agreement, we are required to pay to MDC an annual license maintenance fee during the term of the agreement. We also are required to make product development, regulatory and sales milestones payments to MDC of up to $11 million per product. If commercial sales of a licensed product commence, we will pay MDC royalties at percentage rates ranging in the low single digits on net sales of licensed products in countries where such product is protected by patent rights. Our obligation to pay royalties continues on a country-by-country basis until the expiration of all licensed patent rights covering licensed products in such country, and our royalty payments will be reduced by other payments we are required to make to third parties in certain circumstances until a minimum royalty percentage has been reached. In the event that we sublicense the patent rights, MDC is also entitled to receive a percentage of the sublicensing income received by us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the license with MDC, we are obligated to use commercially reasonable efforts to develop and obtain approval of a licensed product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The agreement will expire concurrently with patent rights on a country-by-country basis. We may terminate the agreement by providing prior written notice to MDC, and MDC has the right to terminate the agreement if we materially breach the agreement and fail to cure such breach within a specified grace period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Whitehead Institute for Biomedical Research</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2009, we entered into a license agreement with the Whitehead Institute for Biomedical Research, as amended in October 2009 and September 2010, for rights relating to compositions and methods for reprogramming somatic cells to a less differentiated or pluripotent state. Under our agreement with the Whitehead Institute, we acquired an exclusive royalty-bearing, sublicensable, worldwide license to make, use and sell licensed products in all fields for commercial purposes, excluding the sale or distribution of reagents for basic research use. The licensed patent rights are described in more detail above under &#8220;Intellectual Property Relating to iPSC Technology.&#8221; The Whitehead Institute retains the right to practice the patent rights for research, teaching and educational purposes, including in corporate-sponsored research under limited circumstances and in some cases only after obtaining our consent. The Whitehead Institute also retains the right to license other academic and non-profit research institutes to practice the patent rights for research, teaching and educational purposes, but not for corporate-sponsored research. Our license is also subject to pre-existing rights of the U.S. government.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the license agreement, we are required to pay the Whitehead Institute an annual license maintenance fee during the term of the agreement, and are also required to make payments of up to $2.3 million for development and regulatory milestones achieved with respect to licensed products. If commercial sales of a licensed product commence, we will also be required to pay royalties at percentage rates in the low-single digits on net sales of licensed products. Our royalty payments are subject to reduction for any third-party payments required to be made until a minimum royalty percentage has been reached. In the event that we sublicense the patent rights, the Whitehead Institute is also entitled to receive a percentage of the sublicensing income received by us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the license agreement with the Whitehead Institute, we are obligated to use commercially reasonable efforts to develop and commercialize licensed products, and to make licensed products or processes reasonably available to the public. In particular, we are required to commit a minimum amount of funding toward the development of a licensed product on an annual basis or conduct activities toward specific development milestones.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The agreement will continue until the abandonment of all patent rights or expiration of the last to expire licensed patent. The Whitehead Institute may terminate the agreement if we default in the performance of any of our obligations and fail to cure the default within a specified grace period, or if we institute a proceeding to challenge the patent rights. The Whitehead Institute may also terminate the agreement if we cease to carry out our business or become bankrupt or insolvent. We may terminate the agreement for any reason upon prior written notice to the Whitehead Institute and payment of all amounts due to the Whitehead Institute through the date of termination.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The Scripps Research Institute</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into various license agreements with The Scripps Research Institute (TSRI) for rights relating to compositions and methods for reprogramming somatic cells, including the use of various small molecule classes and compounds in the reprogramming and maintenance of iPSCs. Under our agreements with TSRI (the TSRI License Agreements), we acquired exclusive royalty-bearing, sublicensable, worldwide licenses to make, use and sell products covered by the licensed patent rights, and to perform licensed processes, in each case, in all fields. The licensed patent rights are described in more detail above under &#8220;Intellectual Property Relating to iPSC Technology.&#8221; TSRI retains a non-exclusive right to practice and use the patent rights for non-commercial educational and research purposes, and to license other academic and non-profit research institutions to practice the patent rights for internal basic research and education purposes. Under certain of our TSRI License Agreements, other third parties maintain a right to practice the patent rights for their internal use only. Our license is also subject to pre-existing rights of the U.S. government.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the TSRI License Agreements, we are required to pay to TSRI annual minimum fees during the term of each agreement. Additionally, upon the achievement of specific regulatory and commercial milestones, we are required to make payments to TSRI of up to approximately $1.8 million under each of the TSRI License Agreements. We will also be required to pay TSRI royalties at percentage rates ranging in the low- to mid-single digits on net sales of licensed products. In the event that we sublicense the patent rights, TSRI is also entitled to receive a percentage of the sublicensing income received by us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the TSRI License Agreements, we are obligated to use commercially reasonable efforts to meet the development benchmarks set out in development plans under each of the TSRI License Agreements, or otherwise expend a minimum specified amount per year for product development. TSRI has the right to terminate any TSRI License Agreement if we fail to perform our obligations under the applicable agreement, including failure to meet any development benchmark or to use commercially reasonable efforts and due diligence to develop a licensed product, or if we otherwise breach the agreement, challenge the licensed patent rights, are convicted of a felony involving the development or commercialization of a licensed product or process, or become insolvent. We may terminate any of our TSRI License Agreements by providing ninety days&#8217; written notice to TSRI. Each TSRI License Agreement otherwise terminates upon the termination of royalty obligations under such agreement.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Dana-Farber Cancer Institute (DFCI)</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2020, we entered into a license agreement with the DFCI for rights relating to novel antibody fragments that uniquely and specifically bind the alpha-3 domain of MICA/B. Under our license agreement with DFCI, we acquired an exclusive royalty-bearing, sublicensable, worldwide license to make, use and sell products covered by the licensed patent rights in the field of iPSC-derived cellular therapeutics for the treatment of human disease, and a non-exclusive royalty-bearing, sublicensable, worldwide license to make, use and sell products covered by the licensed patent rights in the field of cellular therapeutics for the treatment of human disease. DFCI retains the right to practice and to license to other academic, government and non-profit institutes to practice the patent rights for research, teaching and education purposes, as well as to license third parties to practice the patents rights to make or sell research reagents or other research tools solely for use in research. Our licenses are also subject to pre-existing rights of the U.S. government.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the license agreement, we are required to make minimum annual payments to DFCI throughout the term of the agreement. We also are required to make development, commercialization and sales milestones payments to DFCI of up to $25 million per licensed product. If commercial sales of a licensed product commence, we will pay DFCI royalties at percentage rates ranging in the low single digits on net sales of licensed products in countries where such product is protected by licensed patent rights. Our obligation to pay royalties continues on a country-by-country basis until the expiration of all licensed patent rights covering licensed products in such country, and our royalty payments will be reduced by other payments we are required to make to third parties in certain circumstances until a minimum royalty percentage has been reached. In the event that we sublicense the patent rights, DFCI is also entitled to receive a percentage of the sublicensing income received by us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under our agreement with DFCI, we are obligated to use reasonable efforts to develop and bring one or more licensed products to the marketplace through a program of development, production and distribution, including by meeting certain diligence benchmarks with respect to exclusively licensed products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The agreement will continue until the expiration of the last to expire licensed patent. DFCI may terminate the agreement for cause, including if we default in the performance of any of our obligations and fail to cure the default within a specified grace period, if an officer of ours (or of an affiliate or sublicensee) is convicted of a felony related to the manufacture, use, sale or important or a licensed product, if we cease to carry out our business or become bankrupt or insolvent, and if we institute a proceeding to challenge the patent rights. DFCI may also terminate our exclusive license if we fail to materially comply with our diligence obligations. We may terminate the agreement for any reason in its entirety or on a product-by-product or country-by-country basis upon prior written notice to DFCI and payment of all amounts due to DFCI through the date of termination.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Baylor College of Medicine (BCM)</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2020, we entered into a license agreement with BCM for rights pertaining to a novel ADR that selectively targets activated T-cells to protect engineered allogeneic effector cells expressing the ADR from elimination in the host immune system.  Under our agreement, we obtained an exclusive royalty-bearing, sublicensable, worldwide license to make, use and sell products covered by the licensed patent rights in the field of iPSC-derived cell products, including T-cells and NK cells derived from iPSCs engineered with ADRs. BCM retains the right to practice and license to other academic, government and research institutes for non-commercial research purposes. Our licenses are also subject to pre-existing rights of the U.S. government.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the license agreement, we are obligated to make a minimum annual royalty payment to BCM starting in 2024.  We are also required to make development and regulatory milestone payments to BCM for the first three (3) distinct licensed products, where the milestone payments total up to $7 million for the first licensed product, and are reduced by fifty percent (50%) for each of the second and third licensed products. If commercial sales of a licensed product commence, we will pay BCM a low single-digit percentage royalty on net sales of licensed products in countries where the product is protected by licensed patent rights. Our obligation to pay royalties continues on a country-by-country basis until the expiration of all licensed patent rights in that country, with possible reductions for payments that we are required to make to third parties. In the event that we sublicense the patent rights, BCM is entitled to receive a percentage of our sublicensing income.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the license agreement, we are obligated to use reasonable efforts to develop and introduce licensed products to the commercial market including by meeting certain diligence timelines. These timelines are extendable by us for one year upon a one-time payment, subject to BCM&#8217;s discretion for further extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The license agreement remains in effect until the expiration of the last to expire licensed patent. BCM has the right to terminate the agreement if we materially default in the performance of any terms and fail to correct the default within a specified grace period after BCM&#8217;s written notice. Termination by BCM is also possible if we are subject to insolvency or similar proceedings, assignment of all or substantially all of our assets for the benefit of creditors, or the appointment of a trustee, in each case that are not dismissed, stayed or suspended within thirty (30) days following such events. We retain the right to terminate the agreement for any cause, upon prior written notice to BCM and payment of all amounts due to BCM under the agreement.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Off-the-shelf, Multiplexed-engineered, iPSC-derived Cellular Immunotherapies</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The manufacture of our off-the-shelf, multiplexed-engineered, iPSC-derived CAR T-cell and CAR NK cell product candidates involves a three-stage process:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The first stage is intended to generate a clonal master iPSC line and generally consists of the following steps: (i) obtain appropriately-consented healthy human donor cells, such as fibroblasts or hematopoietic cells, and conduct transfusion transmissible disease testing on the donor cells; (ii) induction of pluripotency in the donor cells using a proprietary transgene integration-free and footprint-free method of reprogramming; (iii) genetic engineering of iPSCs; and (iv) isolation and selection of a single iPSC, followed by clonal expansion of the single iPSC to produce a clonal master iPSC line for cell product manufacture. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The second stage is intended to derive the cell product population of interest and generally consists of the following steps: (i) expansion and differentiation of the clonal master iPSC line to produce CD34</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> definitive hematopoietic progenitor cells; and (ii) further expansion and differentiation of these progenitor cells to produce the cell product population of interest.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The third stage is intended to derive the final cell product and generally consists of the following steps: (i) washing the cell product population; (ii) formulating the cell product population in an infusion media for intravenous administration of the final cell product; and (iii) cryopreserving individual aliquots of the final cell product and storing these aliquots in single-dose infusion bags.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of our manufacturing process, we endeavor to utilize current Good Manufacturing Process (cGMP) grade materials and reagents, if commercially available; however, certain critical materials and reagents are currently qualified for research use only. Additionally, we obtain key components required for the manufacture of our iPSC-derived cell product candidates from third-party manufacturers and suppliers, which include, in some instances, sole source manufacturers and suppliers. We do not currently have long-term commitments or supply agreements in place to obtain certain key components used in the manufacture of our iPSC-derived cell product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently operate a cGMP-compliant manufacturing facility for the production of our iPSC-derived cell product candidates for use in research, preclinical development, and clinical development. Our manufacturing facility is located in San Diego, California, and is custom designed for the production of off-the-shelf cell product candidates using clonal master iPSC lines as the starting cell</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">source. The state-of-the-art facility has been commissioned and qualified, and we have been issued drug manufacturing licenses for the facility by the State of California, Department of Health Services, Food and Drug Branch. We believe we are positioned to support manufacturing and production of our product candidates for all phases of clinical development as well as initial commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also contract with third parties, including medical center cell therapy facilities and contract manufacturing organizations (CMOs), for the conduct of some of the activities required to manufacture our iPSC-derived cell product candidates for use in clinical investigation. We expect that we will continue to contract with third parties, including medical center cell therapy facilities and CMOs, for the conduct of certain of the activities required to manufacture our iPSC-derived cell product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketing, Market Access and Sales</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently intend to commercialize any products that we may successfully develop. We currently have no experience in marketing, market access or selling therapeutic products. We may need to further evaluate and generate evidence beyond what is generated in our clinical programs that would satisfy the needs of payers and healthcare technology assessment (HTA) bodies. To market any of our products independently would also require us to develop a sales force with technical expertise along with establishing commercial infrastructure and capabilities. Our commercial strategy for marketing our product candidates also may include the use of strategic partners, distributors, a contract sales force or the establishment of our own commercial infrastructure. We plan to further evaluate these alternatives as we approach approval for the first of our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government Regulation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, the FDA regulates biological products under the Federal Food, Drug, and Cosmetic Act (the FDCA) and the Public Health Service Act (the PHS Act) and related regulations. Biological products are also subject to other federal, state, local, and foreign statutes and regulations. The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of biological products. These agencies and other federal, state, local, and foreign entities regulate research and development activities and the testing, manufacture, quality control, safety, effectiveness, packaging, labeling, storage, distribution, record keeping, reporting, approval or licensing, advertising and promotion, and import and export of our products. Failure to comply with the applicable U.S. regulatory requirements at any time during the product development process or after approval may subject an applicant to administrative or judicial sanctions. FDA sanctions include refusal to approve pending applications, withdrawal of an approval or suspension or revocation of a license, clinical hold, warning or untitled letters, voluntary or mandatory product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties. As we have seen in recent years, different laws and regulations on the same topic may not always have the same requirements, and even when requirements overlap, the rules are not always consistently implemented, interpreted, and enforced from jurisdiction to jurisdiction. In addition, government regulation may delay or prevent marketing of product candidates for a considerable period of time and impose costly procedures upon our activities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketing Approval</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process required by the FDA before biological products may be marketed in the United States generally involves the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">completion of nonclinical laboratory and animal tests according to good laboratory practices (GLPs) and applicable requirements for the humane use of laboratory animals or other applicable regulations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission to the FDA of an IND application which must become effective before human clinical trials may begin;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval of the protocol and related documentation by an independent institutional review board (IRB), or ethics committee at each clinical trial site before each trial may be initiated;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">performance of adequate and well-controlled human clinical trials according to the FDA&#8217;s regulations commonly referred to as good clinical practices (GCPs) and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product for its intended use or uses;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission to the FDA of a Biologics License Application (BLA) for marketing approval that includes substantive evidence of safety, purity, and potency from results of nonclinical testing and clinical trials;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of an FDA pre-approval inspection of manufacturing facilities where the product is produced to assess compliance with the FDA&#8217;s cGMPs to assure that the facilities, methods and controls are adequate, and, if applicable, current good tissue practices (cGTPs) for the use of human cellular and tissue products to prevent the introduction, transmission or spread of communicable diseases;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential FDA audit of the nonclinical study sites and clinical trial sites that generated the data in support of the BLA; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">review of the product candidate by an FDA advisory committee where appropriate, if applicable;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment of user fees for FDA review of the BLA (unless fee waiver applies); and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA review and approval, or licensure, of the BLA which must occur before a biological product can be marketed or sold.</span></div></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Biological Products and Drug Development Process</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before testing any biological product candidate in humans, nonclinical tests, including laboratory evaluations and animal studies to assess the potential safety and activity of the product candidate, are conducted. The conduct of the nonclinical tests must comply with federal regulations and requirements including GLPs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to commencing the first clinical trial, the trial sponsor must submit the results of the nonclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of an initial IND application. Some nonclinical testing may continue even after the IND application is submitted. The IND application automatically becomes effective 30 days after receipt by the FDA unless the FDA, within the 30-day time period, raises concerns or questions about the conduct of the clinical trial and places the trial on a clinical hold. In such case, the sponsor of the IND application must resolve any outstanding concerns with the FDA before the clinical trial may begin. The FDA also may impose a clinical hold on ongoing clinical trials due to safety concerns or non-compliance. If a clinical hold is imposed, a trial may not recommence without FDA authorization and then only under terms authorized by the FDA. A clinical hold may either be a full clinical hold or a partial clinical hold that would limit a trial, for example, to certain doses or for a certain length of time or to a certain number of subjects. Further, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial before it commences at that site. An IRB is charged with protecting the welfare and rights of study subjects and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. Some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board or committee. This group provides authorization as to whether or not a trial may move forward at designated check points based on access that only the group maintains to available data from the trial and may recommend halting the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials involve the administration of the product candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety, including rules that assure a clinical trial will be stopped if certain adverse events occur. Each protocol and any amendments to the protocol must be submitted to the FDA and to the IRB. Information about certain clinical studies must be submitted with specific timeframes to the National Institutes of Health for public dissemination at www.clinicaltrials.gov.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 1&#8212;The investigational product is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. These trials may also provide early evidence on effectiveness.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 2&#8212;These trials are conducted in a limited number of patients in the target population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 3&#8212;Phase 3 trials are undertaken to provide statistically significant evidence of clinical efficacy and to further evaluate dosage, potency, and safety in an expanded patient population at multiple clinical trial sites. They are performed after preliminary evidence suggesting effectiveness of the product has been obtained, and are intended to establish the </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">overall benefit-risk relationship of the investigational product, and to provide an adequate basis for product approval and physician labeling.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 4&#8212;In some cases, the FDA may condition approval of a BLA for a product candidate on the sponsor&#8217;s agreement to conduct additional clinical studies to further assess the candidate&#8217;s safety and effectiveness after approval. Such post-approval trials are typically referred to as Phase 4 clinical trials. The FDA has statutory authority to require post-market clinical trials to address safety issues. A sponsor may also voluntarily conduct additional clinical studies after approval to gain more information about their product. All of these trials must be conducted in accordance with GCP requirements in order for the data to be considered reliable for regulatory purposes.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Within 15 calendar days after the sponsor determines that the information qualifies for reporting, written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events; any findings from other studies, tests in laboratory animals or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> testing that suggest a significant risk for human subjects; or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory authorities, a data safety monitoring board or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the participants are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the trial is not being conducted in accordance with the IRB&#8217;s requirements or if the investigated product has been associated with unexpected serious harm to patients, and the trial may not recommence without the IRB&#8217;s authorization.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Typically, if a product is intended to treat a chronic disease, safety and efficacy data must be gathered over an extended period of time, which can range from six months to three years or more.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concurrently with clinical trials, companies usually complete additional animal studies and must also develop additional information about the physical characteristics of the investigational product and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents with the use of biological products, the PHS Act emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency, and purity of the final biological product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A drug being studied in clinical trials may be made available to individual patients in certain circumstances. Pursuant to the 21st Century Cures Act (the Cures Act), as amended, the manufacturer of an investigational drug for a serious disease or condition is required to make available, such as by posting on its website, its policy on evaluating and responding to requests for individual patient access to such investigational drug. This requirement applies on the earlier of the first initiation of a Phase 2 or Phase 3 trial of the investigational drug, or as applicable, 15 days after the drug receives a designation as a breakthrough therapy, fast track product, or RMAT. Further, the Right to Try Act of 2017 among other things, provides a federal framework for certain patients to request access to certain IND products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. We review each individual request for access through the Cures Act, the Right to Try Act and similar state laws, and may or may not provide access depending upon the facts of each request.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Review and Approval Processes</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to obtain approval to market a biological product in the United States, a BLA must be submitted to the FDA that provides data establishing to the FDA&#8217;s satisfaction the safety, purity and potency of the investigational product for the proposed indication. A BLA includes all data available from nonclinical studies and clinical trials, together with detailed information relating to the product&#8217;s manufacture and composition, and proposed labeling.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Prescription Drug User Fee Act (PDUFA), as amended, each BLA must be accompanied by a user fee. PDUFA also imposes an annual prescription drug product program fee for biologics and drugs. The FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business having fewer than 500 employees. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has 60 days from its receipt of a BLA to determine whether the application will be accepted for filing based on the agency&#8217;s threshold determination that the application is sufficiently complete to permit substantive review. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. After the BLA submission is accepted for filing, the FDA reviews the BLA to determine, among other things, whether the proposed product is safe and effective for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with cGMPs to assure and preserve the product&#8217;s identity, safety, strength, quality, potency, and purity, and for a biological product, whether it meets the biological product standards. The FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee, typically comprised of clinicians and other experts, for evaluation and a recommendation as to whether the application should be approved and, if so, under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before approving a BLA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. For a human cellular or tissue product, the FDA also will not approve the product if the manufacturer is not in compliance with cGTPs. FDA regulations also require tissue establishments to register and list their human cells, tissues, and cellular and tissue based products (HCT/Ps) with the FDA and, when applicable, to evaluate donors through screening and testing. Additionally, before approving a BLA, the FDA may inspect clinical sites to assure that the clinical trials were conducted in compliance with IND study requirements and GCPs. If the FDA determines the manufacturing process or manufacturing facilities are not acceptable, it typically will outline the deficiencies and often will require the facility to take corrective action and provide documentation evidencing the implementation of such corrective action, which may delay further review of the application. If the FDA finds that a clinical site did not conduct the clinical trial in accordance with GCPs, the FDA may determine the data generated by the site should be excluded from the primary efficacy analyses provided in the BLA, and request additional testing or data. Additionally, the FDA ultimately may still decide that the application does not satisfy the regulatory criteria for approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA also has authority to require a Risk Evaluation and Mitigation Strategy (REMS) from manufacturers to ensure that the benefits of a biological product outweigh its risks. A sponsor may also voluntarily propose a REMS as part of the BLA submission. The need for a REMS is determined as part of the review of the BLA. Based on statutory standards, elements of a REMS may include &#8220;dear doctor letters,&#8221; a medication guide, more elaborate targeted educational programs, and in some cases restrictions on distribution. These elements are negotiated as part of the BLA approval, and in some cases may delay the approval date. Once adopted, REMS are subject to periodic assessment and modification.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After the FDA completes its initial review of a BLA, it will communicate to the sponsor that the biological product will either be approved, or it will issue a complete response letter to communicate that the BLA will not be approved in its current form. The complete response letter usually describes all of the specific deficiencies in the BLA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the BLA to address all of the deficiencies identified in the letter, or withdraw the application, or request a hearing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One of the performance goals of the FDA under PDUFA is to review 90% of standard BLAs in 10 months of the 60-day filing date and 90% of priority BLAs in six months of the 60-day filing date, whereupon a review decision is to be made. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs and its review goals are subject to change from time to time. The review process and the PDUFA goal data may be extended in certain circumstances, such as by three months if a major amendment is submitted at any time during the review cycle.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if a product candidate receives regulatory approval, the approval may be limited to specific disease states, patient populations and dosages, or the indications for use may otherwise be limited. Further, the FDA may require that certain contraindications, warnings, or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a risk management plan, or otherwise limit the scope of any approval. In addition, the FDA may require Phase 4 post-marketing clinical trials and testing and surveillance programs to monitor the safety of approved products that have been commercialized. Further, even after regulatory approval is obtained, later discovery of previously unknown problems with a product may result in the imposition of new restrictions on the product or complete withdrawal of the product from the market.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Post-Approval Requirements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Products manufactured or distributed pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things, requirements relating to monitoring, record-keeping, advertising and promotion, reporting of adverse experiences, and limitations on industry-sponsored scientific and educational activities. Further, if there are any modifications to the drug or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">biologic, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new BLA or a BLA supplement, which may require the development of additional data or preclinical studies and clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA regulations require that approved products be manufactured in specific approved facilities and in accordance with cGMP regulations which require, among other things, quality control and quality assurance, the maintenance of records and documentation, and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved drugs or biologics, and those supplying products, ingredients, and components of them, are required to register their establishments with the FDA and certain state agencies, and are subject to periodic announced and unannounced inspections by the FDA and certain state agencies for compliance with cGMP requirements and other regulatory requirements. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. The discovery of violative conditions, including failure to conform to cGMP regulations, could result in enforcement actions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA does not regulate behavior of physicians in their choice of treatments and physicians may legally prescribe available products for uses that are not described in the product&#8217;s labeling and that differ from those approved by the FDA. However, the FDA does restrict an applicant&#8217;s communications on the subject of off-label use of their products. The FDA and other agencies actively enforce the laws prohibiting the marketing and promotion of off-label uses, and a company that is found to have improperly marketed or promoted off-label use may be subject to significant liability, including criminal and civil penalties under the FDCA and False Claims Act, exclusion from participation in federal healthcare programs, and mandatory compliance programs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA also may require post-marketing testing, known as Phase 4 testing, and surveillance to monitor the effects of an approved product. Discovery of previously unknown problems with a product or the failure to comply with applicable FDA requirements can have negative consequences, including adverse publicity, restrictions on a product, and judicial or administrative enforcement.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expedited Development and Review Programs</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA is authorized to designate certain products for expedited review if they demonstrate the potential to address an unmet medical need in the treatment of a serious or life-threatening disease or condition for which there is no effective treatment. These programs are referred to as fast track designation, priority review, accelerated approval, breakthrough therapy designation, and regenerative advanced therapy designation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fast Track Designation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The FDA may grant &#8220;fast track&#8221; status to product candidates that are intended to treat serious or life-threatening diseases or conditions and demonstrate the potential to address an unmet medical need for the condition. Fast track is a process designed to facilitate the development and expedite the review of such product candidates by providing, among other things, more frequent meetings with the FDA to discuss the product candidate&#8217;s development plan and rolling review, which allows submission of individually completed sections of an BLA for FDA review before the entire submission is completed. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a product candidate may request the FDA to designate the product as a fast track product at any time during clinical development. Fast track status does not ensure that a product will be developed more quickly or receive FDA approval. In addition, the fast track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process, or if the designated drug development program is no longer being pursued.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Priority Review.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The FDA may give a priority review designation to a product candidate if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or to provide a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. Priority review is intended to reduce the time it takes for the FDA to review a BLA, with the goal to take action on the application within six months from when the application is filed, compared to ten months for a standard review. The FDA will attempt to direct additional resources to the evaluation of an application for a biological product or drug designated for priority review in an effort to facilitate the review.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accelerated Approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Additionally, a product may be eligible for accelerated approval. Drug or biological products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval, which means that they may be approved on the basis of adequate and well-controlled clinical trials establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a biological product or drug receiving accelerated approval perform adequate and well-controlled</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">post-marketing clinical trials with due diligence and, under the Food and Drug Omnibus Reform Act of 2022 (FDORA), the FDA is now permitted to require, as appropriate, that such trials be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. In addition, the FDA currently requires, unless otherwise informed by the agency, pre-approval of promotional materials for products being considered for accelerated approval. Under FDORA, the FDA has increased authority for expedited procedures to withdraw approval of a drug or indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Breakthrough Therapy Designation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation if preliminary clinical evidence indicates that it may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. If so designated, the FDA will expedite the development and review of the product candidate&#8217;s marketing application, including by meeting with, and providing advice to, the sponsor throughout the product candidate&#8217;s development, and taking steps to facilitate an efficient review of the development program and to ensure that the design of the clinical trials is as efficient as practicable.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RMAT Designation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As part of the Cures Act, Congress amended the FDCA to create an accelerated approval program for regenerative advanced therapies. To qualify for this program, and be granted regenerative advanced medicine therapy (RMAT) designation, a product must be a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or a combination of such products, and not a product solely regulated as a human cell and tissue product. This program is intended to facilitate efficient development and expedite review of regenerative advanced therapies, which are intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition and preliminary clinical evidence must indicate that the product candidate has the potential to address an unmet need for such disease or condition. A BLA for a product candidate that has received RMAT designation may be eligible for priority review or accelerated approval through (1) surrogate or intermediate endpoints reasonably likely to predict long-term clinical benefit or (2) reliance upon data obtained from a meaningful number of sites. Benefits of such designation also include early interactions with FDA to discuss any potential surrogate or intermediate endpoint to be used to support accelerated approval. A designated RMAT product candidate that is granted accelerated approval and is subject to post approval requirements may fulfill such requirements through the submission of clinical evidence, clinical studies, patient registries, or other sources of real world evidence, such as electronic health records; the collection of larger confirmatory data sets; or post approval monitoring of all patients treated with such therapy prior to its approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Designated Platform Technology Status.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Under FDORA, a platform technology incorporated within or utilized by a drug or biological product is eligible for designation as a designated platform technology if (1) the platform technology is incorporated in, or utilized by, a drug approved under a BLA or NDA; (2) preliminary evidence submitted by the sponsor of the approved or licensed drug, or a sponsor that has been granted a right of reference to data submitted in the application for such drug, demonstrates that the platform technology has the potential to be incorporated in, or utilized by, more than one drug without an adverse effect on quality, manufacturing, or safety; and (3) data or information submitted by the applicable person indicates that incorporation or utilization of the platform technology has a reasonable likelihood to bring significant efficiencies to the drug development or manufacturing process and to the review process. A sponsor may request the FDA to designate a platform technology as a designated platform technology concurrently with, or at any time after, submission of an IND application for a drug that incorporates or utilizes the platform technology that is the subject of the request. If so designated, the FDA may expedite the development and review of any subsequent original BLA for a drug that uses or incorporates the platform technology. Designated platform technology status does not ensure that a drug will be developed more quickly or receive FDA approval. In addition, the FDA may revoke a designation if the FDA determines that a designated platform technology no longer meets the criteria for such designation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RTOR. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may review applications for oncology products under Real-Time Oncology Review (RTOR) established by the FDA&#8217;s Oncology Center of Excellence. RTOR, which allows an applicant to pre-submit components of the application to allow the FDA to review clinical data before the complete filing is submitted, aims to explore a more efficient review process to ensure that safe and effective treatments are available to patients as early as possible, while maintaining and improving review quality. Products considered for review under RTOR must, among other things, be likely to demonstrate substantial improvements on a clinically relevant endpoint(s) over available therapy, and must have easily interpreted endpoints. In addition, no aspect of the application should be likely to require a longer review time, such as, for example, a requirement for a REMS. To determine eligibility for RTOR, the FDA requires top-line efficacy and safety results from an applicant&#8217;s pivotal clinical trial(s), as well as completion of database lock for the clinical trial(s). The FDA will generally make a decision regarding acceptance into RTOR within twenty (20) business days of receipt of the request from the applicant. If an applicant is not accepted into RTOR, the applicant will follow routine application submission procedures.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fast Track designation, priority review, accelerated approval, breakthrough therapy designation, RMAT designation, designated platform technology status, and RTOR do not change the standards for approval but may expedite the development or approval process. Moreover, even if a product candidate or platform technology qualifies for one or more of these programs, the FDA may later decide that the product candidate or platform technology no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Patent Term Restoration and Marketing Exclusivity</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under certain circumstances, U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. Patent term restoration can compensate for time lost during product development and the regulatory review process by returning up to five years of patent life for a patent that covers a new product or its use. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The period of patent term restoration is generally one-half the time between the effective date of an IND application (falling after issuance of the patent) and the submission date of a BLA, plus the time between the submission date of the BLA and the approval of that application, provided the sponsor acted with diligence. Only one patent applicable to an approved product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The application for patent term extension is subject to approval by the U.S. Patent and Trademark Office in consultation with the FDA. A patent term extension is only available when the FDA approves a biological product or drug for the first time.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With the Hatch-Waxman Amendments, Congress authorized the FDA to approve generic drugs that are the same as drugs previously approved by the FDA under the NDA provisions of the FDCA. To obtain approval of a generic drug, an applicant must submit to the agency an abbreviated new drug application (ANDA) which relies on the preclinical and clinical testing previously conducted for a drug approved under an NDA, known as the reference listed drug (RLD). For the ANDA to be approved, the FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration, the dosage form, and the strength of the drug. The FDA must also determine that the generic drug is bioequivalent to the innovator drug.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An abbreviated approval pathway for biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed reference biological product was created by the Biologics Price Competition and Innovation Act of 2009, which was part of the Patient Protection and Affordable Care Act of 2010 (ACA). This amendment to the PHS Act attempts to minimize duplicative testing. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical trial or trials. Interchangeability requires that a biological product is biosimilar to the reference biological product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the product and the reference product may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reference biological product is granted twelve years of exclusivity from the time of first licensure of the reference product. The first biological product submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against other biologics submitting under the abbreviated approval pathway for the lesser of (i) one year after the first commercial marketing, (ii) 18 months after approval if there is no legal challenge, (iii) 18 months after the resolution in the applicant&#8217;s favor of a lawsuit challenging the biologic&#8217;s patents if an application has been submitted, or (iv) 42 months after the application has been approved if a lawsuit is ongoing within the 42-month period.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A biological product or drug can obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods for all formulations, dosage forms, and indications of the active moiety or the biological period and, for drugs, patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or, for drugs, patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study provided that at the time pediatric exclusivity is granted there is not less than nine months of term remaining.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan Drug Designation and Exclusivity</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to biological products and drugs intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making a biological product or drug in the United States for this type of disease or condition will be recovered from sales of the product. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the identity of the applicant, the name of the therapeutic agent and its designated orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a biological product or drug that receives orphan drug designation is the first such product approved by FDA for the orphan indication, it receives orphan product exclusivity, which for seven years prohibits the FDA from approving another application to market the same product for the same indication. Orphan product exclusivity will not bar approval of another product under certain circumstances, including if the new product is shown to be clinically superior to the approved product on the basis of greater efficacy or safety or a demonstration that the new product otherwise makes a major contribution to patient care. More than one product may also be approved by the FDA for the same orphan indication or disease as long as the products are different. If a biological product or drug designated as an orphan product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan product exclusivity. Orphan drug status in the European Union has similar, but not identical, benefits.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pediatric Research Equity Act</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Pediatric Research Equity Act (PREA), as amended, a BLA or supplement must contain data to assess the safety and effectiveness of the biological product or drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The intent of the PREA is to compel sponsors whose products have pediatric applicability to study those products in pediatric populations. The FDCA requires manufacturers of biological products and drugs that include a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration to submit a pediatric study plan to the FDA as part of the IND application. The plan must be submitted not later than 60 days after the end-of-Phase 2 meeting with the FDA; or if there is no such meeting, before the initiation of any Phase 3 trials or a combined Phase 2 and Phase 3 trial; or if no such trial will be conducted, no later than 210 days before submitting a marketing application or supplement. The FDA may grant deferrals for submission of data or full or partial waivers. Generally, the PREA does not apply to any biological product or drug for an indication for which orphan designation has been granted.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Coverage and Reimbursement</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of our products, when and if approved, will depend, in part, on the extent to which our products will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. In the United States, no uniform policy of coverage and reimbursement for drug or biological products exists. Accordingly, decisions regarding the extent of coverage and amount of reimbursement to be provided for any of our products will be made on a payor-by-payor basis. Additionally, coverage determinations often require generating additional evidence related, for example, to the relative costs and benefits of new therapies versus standard of care &#8211; which goes beyond the data able to be generated within our clinical programs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of their cost.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, for example, principal decisions about reimbursement for new products are typically made by the Centers for Medicare &amp; Medicaid Services (CMS), which decides whether and to what extent a new product will be covered and reimbursed under Medicare. Private third-party payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. However, one third-party payor&#8217;s determination to provide coverage for a product candidate does not assure that other payors will also provide coverage for the product candidate. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. As a result, coverage determination is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. Further, coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including price-controls, restrictions on reimbursement and requirements for substitution of biosimilars for branded prescription drugs. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Increasingly, third-party payors are also requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly lower.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Healthcare Reform and Other Regulatory Changes</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been, and likely will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system directed at broadening the availability of healthcare, improving the quality of healthcare, and containing or lowering the cost of healthcare.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, in 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, each as amended, collectively known as the ACA was enacted in the United States. The ACA includes measures that have significantly changed, and are expected to continue to significantly change, the way healthcare is financed by both governmental and private insurers. The ACA contained a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement adjustments and changes to fraud and abuse laws. Among the provisions of the ACA of greatest importance to the pharmaceutical industry are that the ACA:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subjects biological products to potential competition by biosimilars;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">made several changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers&#8217; rebate liability; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">extended a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted include the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year. Subsequent legislation extended the 2% reduction which remains in effect through 2031.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which further reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 13, 2017, CMS published a final rule that gives states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On&#8239;May 23, 2019, CMS published a final rule to allow Medicare Advantage Plans the option of using step therapy for Part B drugs beginning January 1, 2020.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminated the statutory Medicaid drug rebate cap, previously set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, effective January 1, 2024. Due to the Statutory Pay-As-You-Go Act of 2010, estimated budget deficit increases resulting from the American Rescue Plan Act of 2021, and subsequent legislation, Medicare payments to providers were further reduced starting on January 1, 2025; however, legislation has been introduced in the U.S. Congress that would, if enacted, reverse these payment reductions. These laws and regulations may result in additional reductions in Medicare and other healthcare funding available for healthcare providers and may otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Inflation Reduction Act of 2022 (IRA) includes several provisions that may impact our business to varying degrees, including provisions that reduce the out-of-pocket spending&#8239;cap for Medicare Part D beneficiaries from $7,050&#8239;to $2,000 starting in 2025, thereby effectively eliminating the coverage gap; impose new manufacturer financial liability on certain drugs under Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D price caps for certain high-cost drugs and biologics without generic or biosimilar competition;&#8239;require companies to pay rebates to Medicare for certain drug prices that increase faster than inflation;&#8239;and delay until January 1, 2032&#8239;the implementation of the HHS rebate rule that would have limited the fees that pharmacy benefit managers can charge. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one orphan designation and for which the only approved indication is for that disease or condition.&#8239; If a product receives multiple orphan designations or has multiple approved indications, it may not qualify for the orphan drug exemption. The implementation of the IRA is currently subject to ongoing litigation challenging the constitutionality of the IRA&#8217;s Medicare drug price negotiation program. The effects of the IRA on our business and the healthcare industry in general is not yet known. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The costs of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. To date, there have been several recent U.S. congressional inquiries, as well as proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. At a federal level, President Trump reversed some of President Biden's executive orders including rescinding Executive Order 14087 entitled "Lowering Prescription Drug Costs for Americans." President Trump may issue new executive orders designed to impact drug pricing. A number of these and other proposed measures may require authorization through additional legislation to become effective. Congress and the Trump administration have indicated that they will continue to seek new legislative measures to control drug costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our drugs or put pressure on our drug pricing, which could negatively affect our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Healthcare Laws and Compliance Requirements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business that may constrain the financial arrangements and relationships through which we research, as well as sell, market and distribute any products for which we obtain marketing authorization. Arrangements with third-party payors and customers can expose pharmaceutical manufactures to broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act (FCA) which may constrain the business or financial arrangements and relationships through which companies research, sell, market and distribute pharmaceutical products. In addition, transparency laws and patient privacy laws can apply to the activities of pharmaceutical manufactures. The applicable federal, state and foreign healthcare laws and regulations that can affect a pharmaceutical company&#8217;s operations include without limitation:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under the Medicare and Medicaid programs, or other federal healthcare programs. A person or entity can be found guilty of violating the statute without actual knowledge of the statute or specific intent to violate it. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA or federal civil monetary penalties. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but such exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The federal civil and criminal false claims laws, including the FCA, and civil monetary penalty laws, which prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false, fictitious or fraudulent claim for payment to, or approval by, the federal government or knowingly making, using or causing to be made or used a false record or statement, including providing inaccurate billing or coding information to customers or promoting a product off-label, material to a false or fraudulent claim to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the federal government. In addition, manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which created federal criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH), and their respective implementing regulations, which impose, among other things, specified requirements relating to the privacy, security and transmission of individually identifiable health information held by covered entities and their business associates as well as their covered subcontractors. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The federal legislation commonly referred to as the Physician Payments Sunshine Act, created under the ACA, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to CMS, information related to payments or other transfers of value made to physicians, other licensed care professionals and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Analogous state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including, but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state and local laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state laws that require the reporting of information related to drug pricing; state and local laws requiring the registration of pharmaceutical sales representatives; and state laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div></div>
  <p style="text-indent:5%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations with respect to certain laws. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect our business in an adverse way. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall or discontinuation of our products; or (iv) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. Ensuring our business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#8217;s attention from the business.</span></p>
  <p style="text-indent:5%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The failure to comply with any of these laws or regulatory requirements subjects companies to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, possible exclusion from participation in federal and state funded healthcare programs, contractual damages and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Any action for violation of these laws, even if successfully defended, could cause a pharmaceutical company to incur significant legal expenses and divert management&#8217;s attention from the operation of the business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulations Governing Data Collection and the Use, Processing and Cross-Border Transfer of Personal Information</span></p>
  <p style="text-indent:5%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also may be or may become subject to various state and foreign laws governing the privacy and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:5%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, the California Consumer Privacy Act (CCPA), created individual privacy rights for California consumers (as defined in the law) and requires compliance with privacy and security obligations for entities handling personal data of consumers or households. The CCPA requires covered companies to provide certain disclosures to consumers about its data collection, use and sharing practices, and to provide affected California residents with ways to opt out of certain sales or transfers of personal information. The California Privacy Rights Act (CPRA) amended the CCPA and expands consumer privacy rights in California, including by expanding consumers&#8217; rights with respect to certain sensitive personal information and by establishing a state agency vested with the authority to enforce the CCPA. The CPRA also applies to personal information collected about employees, applicants and retirees, as well as that which is collected in a business-to-business capacity. While there is currently an exception in the CCPA for protected health information that is subject to HIPAA, the CCPA may nevertheless impact our business activities. Numerous other U.S. states, including Virginia, Colorado, Connecticut, Utah, and more than a dozen other states, have passed or enacted legislation similar to the CCPA, but contain key differences in the scope, application, and enforcement which may complicate compliance efforts. Moreover, some states have advanced privacy laws focused on protecting consumer health information, such as Washington&#8217;s My Health My Data Act, and this remains a rapidly changing legislative and regulatory environment.</span></p>
  <p style="text-indent:5%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In Europe, the EU General Data Protection Regulation (EU GDPR), as well as other national data protection legislation in force in relevant European Economic Area (EEA) Member States, and the UK equivalent of the same (UK GDPR) (collectively referred to as the GDPR in this Annual Report), regulates the collection and processing of personal data in the EEA and the United Kingdom (UK). The GDPR covers any business, regardless of its location, that provides goods or services to individuals in the EU/UK or monitors their behavior in the EEA/UK, and, thus, could incorporate any activities we undertake in EEA/UK. The GDPR imposes strict requirements on controllers and processors of personal data, including special protections for &#8220;sensitive information,&#8221; which includes health and genetic information, obtaining consent of the individuals to whom the personal data relates, having legal bases for processing personal data, providing transparency information to individuals, implementing safeguards to protect the security and confidentiality of personal data, having data processing agreements with third parties who process personal data, responding to individuals&#8217; requests to exercise their data protection rights, reporting personal data breaches to the competent national data protection authority and affected individuals, appointing data protection officers, ensuring certain accountability measures are in place and record keeping. Failure to comply with the requirements of the GDPR and the related national data protection laws of the EEA Member States and the UK, which may deviate slightly from the GDPR, may result in warning letters, mandatory audits and financial penalties, including fines of up to 4% of global revenues, or &#8364;20,000,000, (&#163;17.5 million for the UK GDPR), whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR.</span></p>
  <p style="text-indent:5%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The UK&#8217;s data protection regime is independent from but currently still aligned to the EU&#8217;s data protection regime. However, the UK has announced plans to reform the country&#8217;s data protection legal framework in its Data Reform Bill, which will introduce significant changes from the EU GDPR. This may lead to additional compliance costs and could increase our overall risk exposure as we may no longer be able to take a unified approach across the EEA and the UK, and we will need to amend our processes and procedures to align with the new framework.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:5%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The GDPR also impose restrictions in relation to the international transfer of personal data from the EEA and UK to other countries in respect of which the European Commission or the UK government has not issued a so-called &#8220;adequacy decision&#8221; or &#8220; adequacy regulation&#8221;, including the US in certain circumstances, unless the parties to the transfer have implemented specific safeguards to protect the transferred personal data, such as the European Commission&#8217;s Standard Contractual Clauses for transfers outside of the EEA (SCCs)  and a similar transfer mechanism for transfers of personal data outside of the UK, the International Data Transfer Agreement or Addendum (IDTA). Where relying on the SCCs or IDTA for data transfers, exporters are also required to carry out transfer impact assessments to assess the risk of the data transfer on a case-by-case basis, including an analysis of the laws in the destination country. Although the UK is regarded as a third country under the EU&#8217;s GDPR, the European Commission (EC) has issued a decision recognizing the UK as providing adequate protection under the EU GDPR and, therefore, transfers of personal data originating in the EEA to the UK remain unrestricted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:5%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2023, the European Commission adopted its adequacy decision for the EU-U.S. Data Privacy Framework (Framework), the successor of the EU-U.S. Privacy Shield framework, which the Court of Justice of the European Union invalidated in 2020. On the basis of the new adequacy decision, personal data can flow safely from the EU to U.S. companies participating in the Framework, without having to put in place additional data protection safeguards. However, the Framework&#8217;s validity has already been challenged in court.</span></p>
  <p style="text-indent:5%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Implementing mechanisms to endeavor to ensure compliance with the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial condition, results of operations, and prospects. In addition to the foregoing, a breach of the CCPA, GDPR or other applicable privacy and data protection laws and regulations could result in regulatory investigations, reputational damage, and orders to cease/change our use of data, enforcement notices, or potential civil claims including class action-type litigation.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:5%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, the U.S. Department of Justice issued regulations implementing Executive Order (&#8220;EO&#8221;) 14117, &#8220;Preventing Access to Americans&#8217; Bulk Sensitive Personal Data and United Stated Government-Related Data by Countries of Concern,&#8221; which are expected to become effective in April 2025. These regulations prohibit transactions involving access to bulk sensitive data by countries of concern, such as China (including Hong Kong). In the life sciences sector, the regulations prohibit investment agreements, employment agreements, vendor agreements, and other transactions involving human genomic data and biospecimens, except where necessary for specified exempt activities. Tracking and complying with these regulations may require significant time and expense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Regulations</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances. We may incur significant costs to comply with such laws and regulations now or in the future.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biotechnology and pharmaceutical industries are characterized by rapid innovation, intense and dynamic competition and a strong emphasis on proprietary products. While we believe that our proprietary iPSC product platform, scientific knowledge and experience in the field of cellular immunotherapy provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions, as well as standard-of-care treatments, new products undergoing development and combinations of existing and new therapies. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies, including antibody-based therapies such as bi-specific antibodies, and combinations thereof, that may become available in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cellular immunotherapies for the treatment of cancer and autoimmune diseases have recently been an area of significant research and development by academic institutions and biopharmaceutical companies. Several autologous CAR T-cell therapies have been approved by the FDA for the treatment of relapsed / refractory hematologic malignancies including Kymriah (Novartis AG), Yescarta (Kite Pharma), and Breyanzi (Bristol-Myers Squibb Company) for aggressive large B-cell lymphoma (LBCL) and Abecma (Bristol-Myers Squibb Company) and Carvykti (Janssen Biotech) for multiple myeloma.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are developing our iPSC-derived CAR T-cell and CAR NK cell product candidates for the treatment of cancer and autoimmune diseases. While we believe our proprietary iPSC product platform and our off-the-shelf, multiplexed-engineered, iPSC-derived cell product candidates are highly differentiated, a number of clinical-stage companies are currently focused on the development of cellular immunotherapies for the treatment of cancer and autoimmune diseases. These competitive companies include, among others, Allogene Therapeutics, Inc., Arcellx, Inc., Artiva Biotherapeutics, Inc., AstraZeneca plc, Autolus Therapeutics plc, Bristol-Myers Squibb Company, Cabaletta Bio, Inc., CARGO Therapeutics, Inc., Caribou Biosciences, Inc., Cartesian Therapeutics, Inc., Cellectis SA, Century Therapeutics, Inc., CRISPR Therapeutics AG, ImmunityBio, Inc., Janssen Biotech (Johnson &amp; Johnson), Kyverna Therapeutics, Inc., Legend Biotech Corporation, Lyell Immunopharma, Inc., Kite Pharma (Gilead Sciences, Inc.), Nkarta, Inc., Novartis AG, Sana Biotechnology, Inc. and Takeda Pharmaceutical Company Limited. Preclinical-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We compete against our competitors in recruiting and retaining qualified scientific and management personnel and establishing clinical study sites and subject enrollment for clinical studies, as well as in acquiring technologies complementary to, or necessary for, our programs. Many of our competitors, either alone or with their collaboration partners, have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of treatments and commercializing those treatments. Accordingly, our competitors may be more successful than us in obtaining approval for treatments and achieving widespread market acceptance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We anticipate that we will face intense and increasing competition as new products enter the market and advanced technologies become available. We expect any treatments that we develop and commercialize to compete on the basis of, among other things, efficacy, safety, convenience of administration and delivery, price, the level of generic competition and the availability of reimbursement from government and other third-party payers. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insurance</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain product liability insurance for our clinical trials. We intend to expand our insurance coverage to include the sale of commercial products if marketing approval is obtained for products in development. However, insurance coverage is becoming increasingly expensive, and we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. In addition, we may not be able to obtain commercially reasonable product liability insurance for any products approved for marketing.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human Capital</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success as a company depends upon the innovation, drive, and dedication of our employees, and we seek to attract, incentivize, and reward creative and performance-driven employees. We believe our commitment to our human capital resources is an important component of our business that enables us to deliver superior performance in our industry.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We focus on identifying, recruiting, developing and retaining a team of highly talented and motivated employees. As of December 31, 2024, we employed 181 employees, all of whom are full-time employees, including 54 in research and development, 93 in clinical development, manufacturing and regulatory affairs and 34 in general and administrative. We have never had a work stoppage, and none of our employees is represented by a labor organization or under any collective bargaining arrangements. We believe that our relationship with our employees is good, and we provide all employees with the opportunity to share their opinions in open dialogues with our human resources department and senior management.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inclusion and Belonging</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that an equitable, diverse, and inclusive workforce is a necessary foundation for innovation and dedication of our employees. Accordingly, we strive to promote inclusion and equal opportunity across the organization. We are committed to actively seeking out highly qualified women and minority candidates, as well as candidates with diverse backgrounds, skills and experiences. As of December 31, 2024, women made up 56% of our workforce and represented 54% of leadership positions at the director-level and above.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, as of December 31, 2024, ethnic or racial minorities made up 56% of all of our employees, with 32% Asian, 13% Hispanic, 6% Black, 1% Native Hawaiian or other Pacific Islander, 1% American Indian or Native Alaskan, and 3% of two or more races. Ethnic or racial minorities made up 46% of our director-level and above employees, with 38% Asian, 3% Hispanic, 3% Black, and 3% of two or more races. The age breakdown of our employee workforce consisted of 48% of employees between the ages of 23 &#8211; 39 years old, 46% of employees between the ages of 40 &#8211; 54 years old, and 6% of employees 55 and older.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Health and Safety</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The success of our business is fundamentally connected to the well-being, health and safety of our employees, and we are committed to providing a safe, healthy and secure workplace for our employees. We have an environmental, health and safety program and several cross-functional committees to support our environmental, health and safety program. We routinely train and educate our employees on workplace safety and security and maintain various compliance programs to support this commitment. We continue to monitor and adjust our safety training and protocols as needed to ensure the safety and wellbeing of our workforce.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation and Benefits</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We offer competitive pay, with performance-based bonuses and equity awards. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. We have a comprehensive benefits program offering flexibility for our employees&#8217; individual needs and requirements. Our benefits program includes a choice of medical plans, vision and dental coverage, flexible spending accounts for health and dependent day care needs, and income protection through life, AD&amp;D, short term and long term disability coverage, sick leave, paid family leave, and generous paid time off. We offer a 401(k) retirement plan with company matching a percentage of employee contributions, an employee assistance program, and onsite fitness centers at no cost to our employees.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee Development and Engagement</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are focused on attracting and retaining a team of highly talented and motivated employees. We invest in and develop all levels of employees by engaging in ongoing career pathing and professional development conversations throughout an employee&#8217;s tenure. In addition, we provide targeted leadership development programs for frontline leaders through executive leadership programs and offer a number of professional, management and leadership development training programs to help our employees develop cross-functional skills and tools to grow their careers.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employees are incentivized for key contributions through awards programs that recognize their commitment and dedication by demonstrating our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fate Pathways to Success</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We focus on identifying, recruiting, developing and retaining a team of highly talented and motivated employees. We believe that our relationship with our employees is good. We believe our commitment to our human capital resources is an important component of our business that enables us to deliver superior performance in our industry. We provide all employees with the opportunity to share their opinions in open dialogues with our human resources department and senior management. We provide all employees a wide range of professional development experiences, both formal and informal. The safety and wellbeing of our employees is a paramount value for us. Further, the health and wellness of our employees are critical to our success. We provide our employees with access to a variety of flexible and convenient health and wellness programs. Such programs are designed to support employees&#8217; physical and mental health by providing tools and resources to help them improve or maintain their health status and encourage engagement in healthy behaviors. Additionally, we provide competitive compensation and benefits. In addition to salaries, these programs can include annual bonuses, stock-based compensation awards, a 401(k) plan with employee matching opportunities, healthcare and insurance benefits, health savings and flexible spending accounts, paid time off, family leave, and family care resources.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Environmental Sustainability</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize the importance of the environment to a healthy, sustainable future for our business, our patients, and communities. Our headquarters located in San Diego, California was designed to be energy efficient through the use of LED lighting, energy efficient air handling units, a fully integrated building management system, and other tools. Our facilities are also outfitted with smart building solutions, such as occupancy sensors and air conditioning units reducing airflow based on occupancy. Water-saving bathroom faucets and toilets are installed throughout the building to help reduce water consumption. We recently implemented a lab recycling program diverting 50% of lab generated waste from landfills and designed to lower our environmental footprint. The exterior of our building is made up of draught tolerant landscaping to reduce the volume of water needed to maintain plant life around the building. Employees are also provided free access to electric vehicle charging stations. Our commitment to environmental sustainability is ongoing and we continue to be mindful of how we can minimize our environmental footprint as a company.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were incorporated in Delaware in 2007, and are headquartered in San Diego, California. Our principal executive office is located at 12278 Scripps Summit Drive, San Diego, California 92131, and our telephone number is (858) 875-1800. Our website address is www.fatetherapeutics.com. We do not incorporate the information on or accessible through our website into this Annual Report on Form 10-K, and you should not consider any information on, or that can be accessed through, our website a part of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We own various U.S. federal trademark registrations and applications, and unregistered trademarks, including Fate Therapeutics</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, our corporate logo. All other trademarks or trade names referred to in this document are the property of their respective owners. Solely for convenience, the trademarks and trade names in this document are referred to without the symbols</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and &#153;, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Available Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We post our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits, and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, on the Investors section of our public website (www.fatetherapeutics.com) as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. In addition, you can read our SEC filings over the Internet at the SEC&#8217;s website at www.sec.gov. You can access these filings on our website or from the SEC free of charge. The contents of these websites are not incorporated into this Annual Report on Form 10-K. Further, our references to the URLs for these websites are intended to be inactive textual references only.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1A.  R</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">isk Factors</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You should carefully consider the following risk factors, as well as the other information in this Annual Report on Form 10-K, and in our other public filings. The occurrence of any of these risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described in our public filings when evaluating our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to the Discovery, Development and Regulation of Our Product Candidates</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to complete the preclinical or clinical development of, or to obtain regulatory approval for, our product candidates, our business would be significantly harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of our product candidates are currently in research or early clinical development. We have not completed clinical development of or obtained regulatory approval for any of our product candidates. Only a small percentage of research and development programs ultimately result in commercially successful products, and we cannot assure you that any of our product candidates will demonstrate the safety, purity and potency, or efficacy profiles necessary to support further preclinical study, clinical development or regulatory approval. In addition, we have historically focused on the development of cell therapies for cancer. We have limited prior experience in developing treatments for autoimmune diseases, and there are no cell therapies approved in the United States to treat autoimmune diseases.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may experience delays in, or cancel our ongoing and planned clinical development activities or research and development activities for any of our product candidates for a variety of reasons, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulties in optimizing the right dose and dosing schedule for our product candidates, which might result in a determination that a product candidate is ineffective, causes harmful side effects, or otherwise presents unacceptable safety risks during clinical trials or has an unfavorable toxicity profile in preclinical studies or early clinical trials to support initiating or continuing clinical investigation;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulties in manufacturing or distributing a product candidate, including the inability to manufacture and distribute a product candidate in a sufficient quantity, suitable form, or in a cost-effective manner, or under protocols and processes and with materials and facilities acceptable to the U.S. Food and Drug Administration (FDA) or comparable foreign regulatory authorities for the conduct of clinical trials or for marketing approval;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our prioritization of certain of our product candidates for advancement or the emergence of competing product candidates developed by others, including a decision to cease research and development of any existing product candidate due to the potential obsolescence of our product candidate by a competing product or product candidate or our determination that another of our existing or future product candidates has greater potential for clinical development, regulatory approval, or commercialization, including potentially greater therapeutic benefit, a more favorable safety or efficacy profile, a more consistent or more cost effective manufacturing process, or a more favorable commercial profile, including greater market acceptance or commercial potential, or more advantageous intellectual property position;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">challenges and delays in trial execution which may result from our testing of multiple product candidates in the same indication in different clinical trials, as well as competition from biotechnology and pharmaceutical companies, universities, and other research institutions for patients, qualified investigators and clinical trial sites;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the proprietary rights of third parties, which may preclude us from developing, manufacturing or commercializing a product candidate;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">determining that a product candidate may be uneconomical to develop, manufacture, or commercialize, or may fail to achieve market acceptance or an adequate pricing and reimbursement profile;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our inability to secure or maintain relationships with strategic partners that may be necessary for advancement of a product candidate into or through clinical development, regulatory approval and commercialization in any particular indication(s) or geographic territory(ies); and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulty establishing predictive preclinical models for demonstration of safety and efficacy of a product candidate in one or more potential therapeutic areas for clinical development.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, in January 2023, we announced the discontinuation of our FT516, FT596, FT538, and FT536 NK cell programs to focus our resources on advancing our most innovative and differentiated programs. We also announced the termination of the Collaboration and Option Agreement we entered into with Janssen Biotech, Inc. (Janssen) on April 20, 2020 (the Janssen Agreement),</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which termination took effect on April 3, 2023. As a result of the termination, we discontinued the development of two product candidates that had been expected to enter the clinic in 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we will only be able to obtain regulatory approval to market a product candidate if we can demonstrate, to the satisfaction of the FDA or comparable foreign regulatory authorities, in well-designed and conducted clinical trials that such product candidate is manufactured in accordance with applicable regulatory requirements, is safe, pure and potent, or effective, and otherwise meets the appropriate standards required for approval for a particular indication. Our ability to obtain regulatory approval of our product candidates depends on, among other things, completion of additional preclinical studies, process development and manufacturing activities, and clinical trials, whether our clinical trials demonstrate statistically significant efficacy with safety profiles that do not potentially outweigh the therapeutic benefit, and whether regulatory agencies agree that the data from our clinical trials and our manufacturing operations are sufficient to support approval. In addition, the approval by the FDA of new products in the same indications that we are studying may change the standard of care, and this may result in the FDA or other regulatory agencies requesting that we conduct additional studies to show that our product candidate is superior to the new standard of care. Securing regulatory approval also requires the submission of information about product manufacturing operations to, and inspection of manufacturing facilities by, the relevant regulatory authority. The results of our current and future clinical trials may not meet the FDA&#8217;s or other regulatory agencies&#8217; requirements to approve a product candidate for marketing, and the regulatory agencies may otherwise determine that our manufacturing operations are insufficient to support approval. We may need to conduct preclinical studies and clinical trials that we currently do not anticipate, including as a result of changes in the standard of care. If we fail to complete preclinical or clinical development of, or obtain regulatory approval for, our product candidates, we will not be able to generate any revenues from product sales and our ability to receive milestone or other payments under any collaboration agreements may be impaired, which will harm our business, prospects, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may face delays in initiating, conducting or completing our clinical trials, and we may not be able to initiate, conduct or complete them at all.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are heavily dependent on our ability to complete the clinical development of, and obtain regulatory approval for, our product candidates. We have not completed the clinical trials necessary to support an application for approval to market any of our product candidates. We, or any investigators who initiate or conduct clinical trials of our product candidates, may experience delays in our current or future clinical trials, and we do not know whether we or our investigators will be able to initiate, enroll patients in, or complete, clinical trials of our product candidates on time, if at all. Current and future clinical trials of our product candidates may be delayed, unsuccessful or terminated, or not initiated at all, as a result of many factors, including factors related to:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulties in identifying eligible patients for participation in clinical trials of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulties enrolling a sufficient number of suitable patients to conduct clinical trials of our product candidates, including difficulties resulting from patients enrolling in studies of therapeutic product candidates sponsored by us or our competitors and difficulties resulting from patient availability as a result of any measures taken by governmental authorities, hospitals, or clinical trial sites in response to any future public health crises or other serious disasters or similar events;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulties determining suitable doses and schedules of our novel cell product candidates for evaluation in clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulties in obtaining agreement from regulatory authorities on study endpoints and/or study duration, achieving study endpoints, the amount and sufficiency of data demonstrating efficacy and safety, and completing data analysis in clinical trials for any of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in filing an Investigational New Drug (IND) application or IND amendment with the FDA to initiate or amend clinical trials of our current product candidates and any other product candidates that we may identify;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulties in obtaining agreement with regulatory authorities on the preclinical safety and efficacy data, the manufacturing requirements, and the clinical trial design and parameters necessary for an IND application to go into effect to initiate and conduct clinical trials for any of our current product candidates and any other product candidates that we may develop;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the occurrence of unexpected safety issues or adverse events in any ongoing or future clinical trials of our product candidates, including in trials of our product candidates conducted by investigator-sponsors;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">securing and maintaining the support of clinical investigators and investigational sites, including investigators and sites who may conduct clinical trials under an investigator-sponsored IND with our financial support, and obtaining institutional review board (IRB) approval at each site for the conduct of our clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reaching agreement on acceptable terms with third-party service providers and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different service providers and clinical trial sites;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to manufacture certain of our product candidates consistently, and at acceptable quality levels and costs, in accordance with our protocol-specified manufacturing requirements and applicable regulatory requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure or delays in obtaining sufficient quantities of suitable raw materials, components, and equipment necessary for the conduct of our clinical trials or the manufacture of any product candidate, including any inability to obtain materials as a result of supply chain issues related to any future public health crises or other serious disasters or ongoing or emerging global geopolitical tensions, including wars and other armed conflicts, or other factors;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure or delays by us or by our clinical sites to obtain sufficient quantities of components and supplies necessary for the conduct of our clinical trials, including any inability to obtain agents such as cyclophosphamide or fludarabine which may be required to condition patients for treatment with our product candidates, or certain monoclonal antibodies which are intended for administration to patients in combination with many of our product candidates in certain of our clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">challenges in distributing our product candidates to clinical trial sites, or failure to establish effective protocols for the supply and transport of our product candidates;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of conducting clinical trials or manufacturing of our product candidates being greater than we anticipate, including due to rising inflation rates, or the timelines for these activities being longer than we anticipate;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our failure, or the failure of investigators, third-party service providers, or clinical trial sites, to ensure the proper and timely conduct of and analysis of data from clinical trials of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to reach agreement on clinical trial design and parameters with regulatory authorities, investigators, and IRBs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imposition of a temporary or permanent clinical hold by data monitoring committees or regulatory agencies for a number of reasons, including after review of an IND submission or amendment, a new safety finding that presents unreasonable risk to clinical trial participants, a negative finding from an inspection of our clinical trial operations or trial sites, developments in trials conducted by us or our competitors that raise concerns about the safety risk to patients of novel therapeutics derived from pluripotent or genome edited therapies and/or negative public perception of the same, or if the FDA finds that the investigational protocol or plan is clearly deficient to meet its stated objectives;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the serious, life-threatening diseases of the patients in our oncology clinical trials, who may die or suffer adverse medical events during the course of the trials for reasons that may not be related to our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure of patients to complete clinical trials or adhere to study protocols due to safety issues, side effects, disruptions in study conduct, or other reasons;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval of competitive agents or changes in the standard of care or treatment landscape on which a clinical development plan was based, which may require new or additional trials, or render our product candidates or clinical trial designs obsolete;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trials of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon product development programs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">governmental or regulatory delays, including any delays due to limitations on the availability of governmental and regulatory agency personnel to review regulatory filings, conduct site inspections or engage in discussions with us as a result of the change in administration following the 2024 U.S. presidential election, any future public health crisis or other serious disaster or similar events, failure to obtain regulatory approval, or uncertainty or changes in U.S. or foreign regulatory requirements, policy or guidelines; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limitations on clinical trial conduct at our clinical trial sites resulting from prioritization of hospital and other medical resources toward other efforts, such as any future public health crisis or other serious disaster or similar events, policies and procedures implemented at clinical sites with respect to the conduct of clinical trials including those relating to site initiation, study monitoring, and data collection and analysis, and other precautionary measures taken in treating patients or in practicing medicine in response to various public health concerns.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If there are delays in initiating or conducting any clinical trials of our product candidates or any of these clinical trials are terminated before completion, the commercial prospects of our product candidates will be harmed. In addition, any delays in initiating, conducting or completing our clinical trials or adjustments to certain of our study protocols and procedures, including as a result of any shortage of materials or agents necessary to conduct our studies or as a result of any future public health crisis or other public health concerns or other factors, will increase our costs, slow down our product candidate development and regulatory approval process, and jeopardize our ability to gain regulatory approval, commence product sales and generate revenues. Furthermore, many of the factors that cause, or lead to, a delay in the initiation, conduct or completion of clinical trials may also ultimately lead to the denial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of regulatory approval of our product candidates. Any of these occurrences would significantly harm our business, prospects, financial condition, results of operations, and market price of shares of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The manufacture and distribution of our cell product candidates, particularly our induced pluripotent stem cell (iPSC)-derived cell product candidates, is complex and subject to a multitude of risks. These risks could substantially increase our costs and limit the clinical and commercial supply of our product candidates, and the development and commercialization of our product candidates could be substantially delayed or restricted if the FDA or other regulatory authorities impose additional requirements on our manufacturing operations or if we are required to change our manufacturing operations to comply with regulatory requirements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The manufacture and supply of our cell product candidates involves novel processes that are more complex than those required for most small molecule drugs and other cellular immunotherapies, and accordingly present significant challenges and are subject to multiple risks. For our iPSC-derived product candidates, these complex processes include reprogramming human fibroblasts to obtain iPSCs, in some cases genetically engineering these iPSCs, and differentiating the iPSCs to obtain the desired cell product candidate. As a result of the complexities in manufacturing biologics and distributing cell therapies, the cost to manufacture and distribute biologics and cell therapies in general, and our cell product candidates in particular, is generally higher than for traditional small molecule chemical compounds. In addition, our cost of goods development is at an early stage. The actual cost to manufacture and process our product candidates could be greater than we expect and could materially and adversely affect the commercial viability of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have limited experience in the manufacture of cell-based therapies. We are still developing optimized and reproducible manufacturing processes for clinical and commercial-scale manufacturing of our product candidates, and none of our manufacturing processes have been validated for commercial production of our product candidates. We may face multiple challenges as we scale our manufacturing for large-scale clinical trials or commercial-scale including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, compliance with good manufacturing practices, lot consistency and timely availability of raw materials. In addition, we are continuing to optimize our protocols for the supply and transport of our product candidates for distribution to clinical trial sites. Although we are working to develop reproducible and commercially viable manufacturing processes for our product candidates, and effective protocols for the supply and transport of our product candidates, doing so is a difficult and uncertain task.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may make changes or be required by the FDA or other regulatory authorities to make changes to our manufacturing processes, including materials and equipment used in manufacturing our product candidates, as we continue to develop and refine the manufacturing and distribution processes for our product candidates for advanced clinical trials and commercialization, and we cannot be sure that even minor changes in these processes, materials, and equipment will not cause our product candidates to perform differently and affect the results of our ongoing and planned clinical trials or the performance of the product once commercialized. In some circumstances, changes in our manufacturing operations, including to our protocols, processes, materials or facilities used, may require us to perform additional preclinical or comparability studies, or to collect additional clinical data from patients prior to undertaking additional clinical studies or filing for regulatory approval for a product candidate. These requirements may lead to delays in our clinical development and commercialization plans for our product candidates, and may increase our development costs substantially.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The manufacturing processes for any products that we may develop are subject to FDA and foreign regulatory authority approval requirements, and we and any contract manufacturing organizations (CMOs) or other third-party manufacturers that we may engage for manufacturing our product candidates will need to meet all applicable FDA and foreign regulatory authority requirements on an ongoing basis. Our existing product candidates are currently manufactured by us and our current manufacturing operations, including protocols, processes, materials, and facilities, may not support regulatory approval of our existing product candidates. We may be required to identify alternative protocols, processes, materials or facilities for the manufacture of any of these product candidates in compliance with applicable regulatory requirements. In addition, we may be required to make changes to our protocols for the supply and transport of our product candidates to enable effective distribution of our product candidates. Any modifications to our manufacturing and supply protocols, processes, materials or facilities, and any delays in, or inability to, establish acceptable manufacturing and supply operations for our product candidates could require us to incur additional development costs or result in delays to our clinical development. If we or any CMOs or other third-party manufacturers that we may engage for manufacturing our product candidates are unable to reliably produce products to specifications acceptable to the FDA or other regulatory authorities, we may not obtain or maintain the regulatory approvals we need to commercialize such products. Even if we obtain regulatory approval for any of our product candidates, there is no assurance that either we or any CMOs or other third-party manufacturers that we may engage for manufacturing our product candidates will be able to manufacture the approved product to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities and on the requisite timelines to meet the requirements for the potential launch of the product, or to meet potential future demand. Additionally, changes in regulatory requirements may require us or any third-party manufacturers that we may engage for manufacturing our product candidates to perform additional studies or to modify protocols, processes, materials or facilities for the manufacture of our product candidates or any components thereof. Any of these challenges could delay initiation or completion of clinical trials, require bridging clinical trials or the repetition of one or more</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trials, increase clinical trial costs, delay approval of our product candidates, impair commercialization efforts, increase our cost of goods, and have an adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A disruption to our manufacturing operations, or the inability by us or our third-party suppliers or manufacturers to manufacture sufficient quantities of our product candidates at acceptable quality levels or costs, or at all, would materially and adversely affect our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Developing manufacturing processes to support clinical studies and commercialization requirements is a difficult and uncertain task, and there are risks associated with scaling to the level required for clinical trials or commercialization, including, among others, cost overruns, potential problems with process scale-out, process reproducibility, stability and purity issues, lot consistency, and timely availability of acceptable reagents and raw materials. If we are unable to scale to the level required for the conduct of clinical trials or commercialization, we may not be able to produce our product candidates in a sufficient quantity to conduct our ongoing and planned clinical trials, or to meet demand if any product candidates are approved for commercialization. We have not yet caused any of our product candidates to be manufactured or processed on a commercial scale and may not be able to do so for any of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are substantially dependent on our own internal manufacturing facilities in San Diego, California for the production of our product candidates, and we rely, and expect to continue to rely, on third parties for the manufacture of certain components to manufacture our product candidates for use in conducting clinical trials. The facilities used to manufacture our product candidates, including our own facilities, must be evaluated by the FDA or other foreign regulatory agencies pursuant to inspections that will be conducted after we submit an application to the FDA or other foreign regulatory agencies. If the FDA or a comparable foreign regulatory authority finds deficiencies with or does not approve these facilities for the manufacture of our product candidates or if it later finds deficiencies or withdraws any such approval in the future, we may not be able to locate additional or replacement facilities to produce such product candidates or materials in a timely manner and on commercially reasonable terms, or at all. This would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we rely on our own manufacturing facilities to produce our product candidates and on third parties for the manufacture of certain components, we are required to transfer certain manufacturing process know-how and certain intermediates to third parties, including larger-scale facilities operated by a CMO or by us, to facilitate manufacture of our product candidates for clinical trials and commercialization. Transferring manufacturing testing and processes and know-how is complex and involves review and incorporation of both documented and undocumented processes that may have evolved over time. In addition, transferring production to different facilities may require utilization of new or different processes to meet the specific requirements of a given facility. We and any CMOs or third parties that we engage to manufacture our product candidates will need to conduct significant development work to transfer these processes and manufacture each of our product candidates for clinical trials and commercialization. In addition, we may be required to demonstrate the comparability of material generated by any CMO or third parties that we engage for manufacturing our product candidates with material previously produced and used in testing. Any inability to manufacture comparable drug product by us or any CMOs or third parties that we engage to manufacture our product candidates could delay the continued development of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to relying on third parties for the manufacture of certain components for the manufacture of our product candidates, we manufacture our product candidates ourselves, and intend to manufacture some or all of the clinical supply of our iPSC-derived NK-cell and T-cell product candidates for our ongoing and planned clinical trials. To do so, we will need to scale up our own manufacturing operations, as we do not currently have the infrastructure or capability internally to manufacture sufficient quantities of each of our product candidates to support the conduct of each of our clinical trials or commercialization of each of our product candidates, if approved. Accordingly, we will be required to make significant investments to maintain and expand our existing Good Manufacturing Practice (GMP) manufacturing capabilities and facilities, establish additional GMP manufacturing facilities, conduct GMP production, and process and scale up development and technology transfer activities for the manufacture of our product candidates, and our efforts to scale our own manufacturing operations may not succeed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we are successful in developing manufacturing capabilities sufficient for clinical and commercial supply, problems with our manufacturing operations or those of the third-party manufacturers upon which we rely, including difficulties with production costs and yields, quality control, stability of the product, quality assurance testing, operator error, shortages of qualified personnel, shortages of materials and supplies, facility shutdowns, global pandemics or other public health concerns, global geopolitical tensions, including wars and other armed conflicts, natural disasters (including due to the effects of climate change) or other reasons, as well as compliance with strictly enforced federal, state and foreign regulations, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims or insufficient supplies of our product candidates for our ongoing and planned clinical trials or eventual commercialization. Further, delays in regulatory inspections, commissioning and receiving regulatory approvals for our manufacturing capabilities or facilities, including any new facilities could delay our development plans,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">including the initiation and conduct of our ongoing and planned clinical trials. In addition, we and our third-party manufacturers may have limited manufacturing capacity for certain product candidates or components used in manufacturing our product candidates, and we may fail to locate suitable additional or replacement manufacturing capacity, including for the manufacture of our product candidates in compliance with current GMP (cGMP) or current Good Tissue Practice (cGTP), on a reasonable basis or at all. Any such failure could be the basis for the FDA or other regulatory authorities to issue a warning letter, withdraw approvals for product candidates previously granted to us, or take other regulatory or legal action, including recall or seizure of outside supplies of the product candidate, total or partial suspension of production, suspension of ongoing clinical trials, refusal to approve pending applications or supplemental applications, detention of product, refusal to permit the import or export of products, injunction or imposing civil and criminal penalties.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, certain of the components currently used in manufacturing our product candidates are research-grade only, and we may encounter problems obtaining or achieving adequate quantities and quality of clinical grade materials that meet FDA, European Medicines Agency, or other standards or specifications applicable in the United States or in other countries with consistent and acceptable production yields and costs. In addition, if contaminants are discovered in our supply of product candidates or in our manufacturing facilities or those of our third-party suppliers and manufacturers, such manufacturing facilities may be closed for an extended period of time to investigate and remedy the contamination. Any such events could delay or prevent our ability to obtain regulatory approval for or commercialize our product candidates, which would adversely affect our business, prospects, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Because our approach to the development of product candidates is based on novel and unproven technologies, it is subject to a substantial degree of technological uncertainty and we may not succeed in developing any of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of our current product candidates are based on our novel iPSC platform, and some of our product candidates utilize novel genome editing technologies. To date, no iPSC-derived therapeutic product candidates have been approved in the United States or worldwide, and there have been only a limited number of regulatory approvals of genome edited therapeutics, and similarly a limited number of clinical trials involving the use of a therapeutic product candidate manufactured using a master iPSC line or genome edited cells. The development of such complex cell therapies is a relatively new and emerging field, and the scientific research that forms the basis of our efforts to discover and develop iPSC-derived and genome edited cellular immunotherapies is ongoing; this is particularly true in relation to the development of cell therapies for the treatment of autoimmune diseases where there is limited clinical data available and where we have limited prior experience. We may determine to incorporate information learned from this research into the design of our ongoing Phase 1 clinical trials of our iPSC product candidates, as well as our planned future clinical trials, which could delay or impair our clinical development activities. We may ultimately discover that our product candidates do not possess certain properties required for therapeutic effectiveness or protection from toxicity in our target patient populations, or they may exhibit undesirable side effects as more patient data become available. In addition, our product candidates may demonstrate different chemical and pharmacological properties in patients than they do in laboratory studies. It may take many years before we develop a full understanding of the pharmacological properties of our product candidates, and we may never know precisely how they function in vivo. As with any new biologic or product developed using novel technologies, our product candidates have an unknown immunogenicity profile. As a result, our cellular immunotherapy product candidates may trigger immune responses that inhibit their therapeutic effects or cause adverse side effects. In addition, one or more of our product candidates may:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be found ineffective or cause harmful side effects during preclinical studies or clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fail to receive necessary regulatory approvals on a timely basis or at all; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be precluded from commercialization by proprietary rights of third parties; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be difficult to manufacture on a large scale; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be uneconomical to commercialize or fail to achieve market acceptance. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any such problems that affect one of our product candidates may have an unfavorable impact on all of our product candidates. As a result, we may never succeed in developing a marketable product and we may never become profitable, which would have an adverse effect on our business, prospects, financial condition, results of operations, and market price of shares of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We anticipate that our current product candidates and any future product candidates may be used in combination with third-party drugs or biologics, some of which may still be in development, and we have limited or no control over the supply, regulatory status, or regulatory approval of such drugs or biologics.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of our product candidates are being developed for use in combination with one or more other cancer therapies, such as monoclonal antibodies, and other current or future product candidates may be used in combination with other biologics or drugs, both</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approved and unapproved, such as fludarabine. Our ability to develop and ultimately commercialize our current product candidates and any future product candidates used in combination with another drug or biologic will depend on our ability, or the ability of third-party clinical trial sites on which we rely, to access such drugs or biologics on commercially reasonable terms for the clinical trials and their availability for use with the commercialized product, if approved. We cannot be certain that we, or third-party clinical trial sites on which we rely, will be able to secure a steady supply of such drugs or biologics on commercially reasonable terms or at all.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any failure by us, or by third-party clinical trial sites on which we rely, to secure a steady supply of such drugs or biologics may delay our development timelines, increase our costs and jeopardize our ability to develop our current product candidates and any future product candidates as commercially viable therapies. If any of these occur, our business, financial condition, results of operations, stock price and prospects may be materially harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, the development of product candidates for use in combination with another product or product candidate may present challenges that are not faced for single agent product candidates. For example, the FDA or comparable foreign regulatory authorities may require us to use more complex clinical trial designs in order to evaluate the contribution of each product and product candidate to any observed effects. It is possible that the results of such trials could show that any positive previous trial results are attributable to the combination therapy and not our current product candidates or any of our future product candidates. Moreover, following product approval, the FDA or comparable foreign regulatory authorities may require that products used in conjunction with each other be cross labeled for combined use. To the extent that we do not have rights to the other product, this may require us to work with a third party to satisfy such a requirement. Moreover, developments related to the other product may impact our clinical trials for the combination as well as our commercial prospects should we receive marketing approval. Such developments may include changes to the other product&#8217;s safety or efficacy profile, changes to the availability of the approved product, quality, manufacturing and supply issues, and changes to the standard of care.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that any collaborator or supplier cannot continue to supply their products on commercially reasonable terms, we would need to identify alternatives for accessing such products. Additionally, should the supply of products from any collaborator or supplier be interrupted, delayed or otherwise be unavailable, our clinical trials may be delayed. In the event we are unable to source an alternative supply or are unable to do so on commercially reasonable terms, our business, financial condition, results of operations, stock price and prospects may be materially harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, to the extent a third-party clinical trial site on which we rely sources a combination therapy itself and does not submit the costs of such therapy to government programs or patients&#8217; insurance, the costs of such therapy may be passed on to us, which could harm our business, financial condition, results of operations, stock price and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we encounter difficulties enrolling patients in our clinical trials, including as a result of challenges in identifying and recruiting eligible patients to participate in our trials or competition for patients, our clinical development activities could be delayed or otherwise adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are required to identify and enroll a sufficient number of patients with the disease under investigation for each of our ongoing and planned clinical trials of our product candidates, and we may not be able to identify and enroll a sufficient number of patients, or those with required or desired characteristics and who meet certain criteria, in a timely manner. In addition, we will be competing with other clinical trials of product candidates being developed by our competitors in the same therapeutic areas, and potential patients who might be eligible for enrollment in one of our clinical trials may instead choose to enroll in a trial being conducted by one of our competitors. We may also face an unwillingness of sites to participate in our clinical trials. A number of cell therapy companies have recently commenced clinical trials for the treatment of autoimmune diseases, which has increased competition for investigators and for patients for our ongoing and any future clinical trials that we may initiate for the treatment of autoimmune diseases.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability, and the ability of investigators, to enroll patients in our ongoing and planned clinical trials of our product candidates is affected by factors including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to identify clinical trial sites and recruit clinical trial investigators with the appropriate capabilities, competencies and experience;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to open clinical trial sites;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to identify, solicit and recruit a sufficient number of patients;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">severity of the disease under investigation;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the design of the clinical trial and whether the FDA agrees to the design and implementation of the trial;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the relatively small size and nature of the patient populations for certain of our clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eligibility criteria for the clinical trials in question;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinicians&#8217; and patients&#8217; perceptions as to the potential risks and benefits of the product candidate under study, including any perceived risks associated with our iPSC-derived product candidates, which we believe are the first ever iPSC-derived cell therapies cleared by the FDA for clinical investigation in the United States, or with our chimeric antigen receptor (CAR) T-cell therapies broadly following FDA&#8217;s investigation into reports of T-cell malignancies for B-cell maturation antigen (BCMA)- and CD19-directed autologous CAR T cell therapies, and perceived risks associated with the novel use of cell therapies for the treatment of autoimmune diseases, where there are no FDA-approved cell therapies and limited clinical precedent;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changing medical practice patterns or guidelines related to the indications we are investigating;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of competing therapies and clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">efforts to facilitate timely enrollment in clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of time and resources at the limited number of institutions at which our clinical trials are or will be conducted, including any constraints on resources, or policies and procedures implemented, at hospitals and clinical trial sites as a result of any natural disaster or public health crisis;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of cells suitable for the manufacture of our clinical product candidates from eligible and qualified donors for certain of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of components and agents necessary to enroll and treat prospective patients in our clinical trials, including agents which may be required to condition patients or monoclonal antibodies which are intended for administration to patients in combination with our product candidates, in certain of our clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to monitor patients adequately during and after treatment, including through remote monitoring if required as a result of precautionary changes implemented at clinical trial sites as a result of any public health crisis; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the proximity and availability of clinical trial sites for prospective patients.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, development of certain of our product candidates as treatment for autoimmune diseases represents a novel approach, and no cell therapies have been approved for commercial use for the treatment of autoimmune diseases. As a consequence, use of cell therapies such as our product candidates for the treatment of autoimmune diseases may not gain the acceptance of the public or medical community. Our ability to enroll patients in our clinical trials for treatment of autoimmune diseases will depend upon the treatment practices of physicians who specialize in the treatment of autoimmune diseases targeted by our product candidates, and enrollment in our clinical trials may be impaired if physicians are reluctant to enroll patients into our clinical trials in lieu of, or in addition to, using existing treatments with which they are more familiar and for which more clinical data may be available. In addition, patient populations targeted for autoimmune diseases by our product candidates are typically not at risk of near-term death, even if they may suffer life-threatening symptoms, so these patients will need to deem the potential benefits of our cell therapy product candidates to be worth the risk of unknown potential adverse side effects. Furthermore, autoimmune disease patients and their physicians may choose to use conventional therapies, such as corticosteroids or systemic immunosuppressive medications, rather than participate in our clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, certain of our clinical trial sites at times have delayed or paused patient enrollment in clinical trials as a result of the COVID-19 pandemic and supply chain shortages, and may do so again in the future for a variety of reasons. The extent and duration of such delays and disruptions, and the overall impact on the timing and conduct of our clinical trials, are uncertain. If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay or terminate ongoing or planned clinical trials, either of which would have an adverse effect on our business, prospects, financial condition, results of operations, and market price of shares of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The clinical development of our product candidates could be substantially delayed if we are required to conduct unanticipated studies, including preclinical studies or clinical trials, or if the FDA imposes other requirements or restrictions including on the manufacture, of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may require us to generate additional preclinical, product, manufacturing, or clinical data as a condition to continuing our current clinical trials, or initiating and conducting any future clinical trials of our current product candidates or other cell product candidates that we may identify. Additionally, the FDA may in the future have comments, or impose requirements, on the conduct of our clinical trials or the initiation of clinical trials or any of our other iPSC-derived cell product candidates, including the protocols,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">processes, materials and facilities we use to manufacture our product candidates and potential future product candidates in support of clinical trials. Any requirements to generate additional data, or redesign or modify our protocols, processes, materials or facilities, or other additional comments, requirements or impositions by the FDA, may cause delays in the initiation or conduct of the current or future clinical trials for our product candidates and subsequent development activities for our product candidates, and could require us to incur additional development or manufacturing costs and resources, seek funding for these increased costs or resources or delay our timeline for, or cease, our preclinical or clinical development activities for our product candidates, or could create uncertainty and additional complexity in our ability to obtain regulatory approval for our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, if the results of our clinical trials are inconclusive, or if there are safety concerns or adverse events associated with our existing product candidates or any other product candidates we may identify, we may:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be delayed in obtaining, or unable to obtain, regulatory approval for such product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be required to amend the protocols for our clinical trials, perform additional nonclinical studies or clinical trials to support approval or be subject to additional post-marketing testing requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings or contraindications; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the event a product candidate is approved, have regulatory authorities withdraw their approval of the product or impose restrictions on its use.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if our current and planned clinical trials are successful, we will need to conduct additional clinical trials, which may include registrational trials, trials in additional patient populations or under different treatment conditions, and trials using different manufacturing protocols, processes, materials or facilities or under different manufacturing conditions, before we are able to seek approvals for our product candidates from the FDA and regulatory authorities outside the United States to market and sell these product candidates. In addition, changes in regulatory policies or the administration as a result of the 2024 U.S. presidential election may result in delays in the regulatory review and approval process and cause uncertainty regarding approval pathways. If we fail to meet the requirements to support continued clinical development, our clinical development activities for any of our product candidates are delayed or suspended, or we fail to obtain or maintain regulatory approvals with an acceptable scope, our business, prospects, financial condition and results of operations will be harmed.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are pursuing multiple programs and product candidates in our novel cell therapy development pipeline using an approach that is designed to enable rapid incorporation of new product features. If we elect to incorporate these new features into next-generation product candidates, this may render our existing product candidates obsolete, and we may devote our limited resources in pursuit of a particular program for which there is a greater potential for success and fail to capitalize on development opportunities or product candidates including those which may be more advanced in development.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We focus on the development of programmed cellular immunotherapies for patients with cancer and autoimmune diseases, including off-the-shelf NK- and T-cell product candidates derived from clonal master engineered iPSC lines. Because our iPSC product platform is designed to enable rapid incorporation of novel functional product features in an evolving clinical setting, we may elect to incorporate these discoveries into next-generation product candidates that render our existing product candidates, including product candidates under clinical development, obsolete. Additionally, because we have limited financial and personnel resources, we may elect or be required to abandon or delay the pursuit of opportunities with existing or future product candidates, including those that may be more advanced in development than those we ultimately elect to pursue. For example, in January 2023, we announced the discontinuation of our FT516, FT596, FT538, and FT536 NK cell programs to focus our resources on advancing our most innovative and differentiated programs. We have also expanded our research and development efforts into areas outside of our initial focus in oncology, such as autoimmune diseases, where we have limited or no experience. Due to these factors, our spending on current and future research and development programs and product candidates and the scientific innovation arising from these expenditures, may not yield commercially viable product candidates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences following any potential marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the conduct of clinical trials, patients may report changes in their health, including illnesses, injuries and discomforts, to their doctor. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. Regulatory authorities may draw different conclusions and may require us to pause our clinical trials or require additional testing to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">confirm these determinations, if they occur. Drug-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, it is possible that as we test our product candidates in larger, longer and more extensive clinical trials, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were not observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, may be reported by subjects or patients. Many times, drug-related side effects are only detectable after investigational products are tested in large-scale pivotal trials or, in some cases, after they are made available to patients on a commercial scale after approval. Furthermore, because certain autoimmune diseases we seek to treat may be less serious than the later stage cancers traditionally being treated with cell therapies or other immunotherapy products, we believe the FDA and other regulatory authorities will apply a different benefit-risk threshold such that any potential harmful side effects may outweigh the benefits of our product candidates and require us to cease clinical trials or result in denial of regulatory approval of our product candidates in autoimmune disease indications. Tolerance for adverse events in the autoimmune disease patient populations being pursued with cell-based therapies, such as in SLE patients in our FT819 clinical trial, is expected to be lower than it is in oncology, and the risks of negative impacts from these toxicities may therefore be greater for our autoimmune programs than for our oncology programs or the oncology programs of others. If any of our product candidates cause undesirable side effects or have unfavorable benefit-risk profiles, this may cause us or regulatory authorities to interrupt, delay, or halt clinical trials, and the development of the product candidate may fail or be delayed. If the product candidate receives regulatory approval, such undesirable side effects could result in a more restrictive label than anticipated or in the regulatory approval being revoked. Any such delay or failure as a result of undesirable side effects would harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Certain of our product candidates are being developed for the treatment of patient populations with significant comorbidities, particularly in the case of oncology patients, that may result in deaths or serious adverse events or unacceptable side effects and require us to abandon or limit our clinical development activities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patients treated with our current product candidates, particularly in our clinical trials in oncology indications, may also receive chemotherapy, radiation, and/or other high dose or myeloablative treatments in the course of treatment of their disease, and may therefore experience side effects or adverse events, including death, that are unrelated to our product candidates. While these side effects or adverse events may be unrelated to our product candidates, they may still affect the success of our clinical studies. In particular, the oncology diseases we are studying have complex comorbidities and the patients enrolled in those studies are often critically ill. The inclusion of critically ill patients in our clinical studies may result in deaths or other adverse medical events due to underlying disease or to other therapies or medications that such patients may receive. Any of these events could prevent us from advancing our product candidates through clinical development, and from obtaining regulatory approval, and would impair our ability to commercialize our product candidates. Any inability to advance our existing product candidates or any other product candidate through clinical development would have a material adverse effect on our business, and the value of our common stock would decline.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Because our product candidates are based on novel technologies, it is difficult to predict the regulatory approval process and the time, the cost and our ability to successfully initiate, conduct and complete clinical development, and obtain the necessary regulatory and reimbursement approvals, required for commercialization of our product candidates, if approved.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cell programming technology and platform for generating cell therapy products using iPSCs represent novel therapeutic approaches, and to our knowledge there are currently no iPSC-derived cell products approved anywhere in the world for commercial sale. As such, it is difficult to accurately predict the type and scope of challenges we may incur during development of our product candidates, and we face uncertainties associated with the preclinical and clinical development, manufacture and regulatory requirements for the initiation and conduct of clinical trials, regulatory approval, and reimbursement required for successful commercialization of these product candidates. In addition, because our iPSC-derived cell product candidates are all in the early clinical or preclinical stage, we are currently assessing safety in humans and have not yet been able to assess the long-term effects of treatment. Animal models and assays may not accurately predict the safety and efficacy of our product candidates in our target patient populations, and appropriate models and assays may not exist for demonstrating the safety and purity of our product candidates, as required by the FDA and other regulatory authorities for ongoing clinical development and regulatory approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preclinical and clinical development, manufacture, and regulatory requirements for approval of novel product candidates such as ours can be more expensive and take longer than for other more well-known or extensively studied pharmaceutical or biopharmaceutical product candidates due to a lack of prior experiences on the side of both developers and regulatory agencies. Additionally, due to the uncertainties associated with the preclinical and clinical development, manufacture, and regulatory requirements for approval of our product candidates, we may be required to modify or change our preclinical and clinical development plans or our manufacturing activities and plans, or be required to meet stricter regulatory requirements for approval. Any such</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">modifications or changes could delay or prevent our ability to develop, manufacture, obtain regulatory approval or commercialize our product candidates, which would adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cellular immunotherapies, and iPSC-derived cell therapies in particular, represent relatively new therapeutic areas, and the FDA has cautioned consumers about potential safety risks associated with cell therapies. For example, in November 2023, the FDA announced that it would be conducting an investigation into reports of T-cell malignancies following BCMA-directed or CD19-directed autologous CAR T-cell immunotherapies following reports of T-cell lymphoma in patients receiving these therapies. In January 2024, the FDA determined that new safety information related to T-cell malignancies should be included in the labeling with boxed warning language on these malignancies for all BCMA- and CD19-directed genetically modified autologous T-cell immunotherapies. To date, there are relatively few approved cell therapies as treatments for cancer, and no cell-based therapies have been approved for commercial use for the treatment of an autoimmune disease. Currently, all approved CAR T-cell immunotherapies are in oncology indications, and there can be no assurance that the FDA will find the risks of treatment with cell therapy acceptable in other indications, such as autoimmune diseases. The development of any cell therapy may be placed on hold by the FDA upon the detection of any unexpected safety event to evaluate the potential relevance of such novel technology to the occurrence of such safety event, highlighting the technical and regulatory risk of working with new technology. As a result, the regulatory approval process for product candidates such as ours is uncertain and may be more expensive and take longer than the approval process for cell therapy product candidates based on other, better known or more extensively studied technologies and therapeutic approaches.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory requirements in the United States and in other countries governing the development of cell therapy products and therapeutic products created with gene editing technology have changed frequently and the FDA or other regulatory bodies may change the requirements, or identify different regulatory pathways, for approval for any of our product candidates. For example, as regulatory expectations regarding cell therapy products and products created with gene editing technology continue to evolve, the FDA could require additional testing or new testing of products created with gene editing technology, including our product candidates, and any such additional FDA requirements for approval for any of our product candidates may adversely impact or slow development of our product candidates. The FDA previously established the Office of Tissues and Advanced Therapies (OTAT) within the Center for Biologics Evaluation and Research (CBER) to consolidate the review of cell therapy and related products, and to advise CBER on its review. In September 2022, the FDA announced retitling of OTAT to the Office of Therapeutic Products (OTP) and elevation of OTP to a &#8220;Super Office&#8221; to meet its growing cell and gene therapy workload and new commitments under the Prescription Drug User Fee Act agreement for fiscal years 2023-2027. It is possible that over time new or different divisions may be established or be granted the responsibility for regulating cell and/or gene therapy products, including iPSC-derived cell products made with gene editing technology, such as ours. The regulatory review divisions and committees, and any new guidelines they promulgate, may lengthen the regulatory review process, require us to perform additional studies or clinical trials, and delay or prevent development, approval, and commercialization of our product candidates. As a result, we may be required to change our regulatory strategy or to modify our applications for regulatory approval, which could delay and impair our ability to complete the preclinical and clinical development and manufacture of, and obtain regulatory approval for, our product candidates. Changes in regulatory authorities and advisory groups, or any new requirements or guidelines they promulgate, may lengthen the regulatory review process, require us to perform additional studies, increase our development and manufacturing costs, lead to changes in regulatory pathways, positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will be required to consult with the FDA and other regulatory authorities, and our product candidates will likely be reviewed by an FDA advisory committee. We also must comply with applicable requirements, and if we fail to do so, we may be required to delay or discontinue development of our product candidates. Delays or unexpected costs in obtaining, or the failure to obtain, the regulatory approval necessary to bring a potential product to market could impair our ability to generate sufficient product revenues to maintain our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preliminary data and interim results we disclose may change as more patient data becomes available or as we make changes to our protocols or manufacturing processes, and such interim results and results from earlier studies may not be predictive of the final results, or of later studies or future clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may from time to time disclose results from preclinical testing or preliminary data or interim results from clinical studies of our product candidates. Such results from preclinical testing, process development and manufacturing activities, and clinical studies, including interim clinical trial results as of specified data cutoff dates and results of earlier clinical studies with similar product candidates, are not necessarily predictive of future results, including later clinical trial results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The results of our current and future clinical trials may differ from results achieved in earlier preclinical and clinical studies for a variety of reasons, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not demonstrate the potency and efficacy benefits observed in previous studies;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our efforts to improve, standardize and automate the manufacture and supply of our product candidates and any resulting deviations in the manufacture of our product candidates, may adversely affect the safety, purity, potency, stability, or efficacy of such product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">differences in study design, including differences in conditioning regimens, eligibility criteria, and patient populations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advancements in the standard of care may affect our ability to demonstrate efficacy or achieve study endpoints in our current or future clinical trials; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">safety issues or adverse events in patients who enroll in our current or future clinical trials.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, some of the data from clinical trials of our product candidates performed to date were generated from open-label studies, and these studies are being conducted at a limited number of clinical sites on a limited number of patients. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which treatment regimen patients have received and may interpret the information of the treated group more favorably given this knowledge. Accordingly, the preliminary data from our Phase 1 clinical trials of certain of our product candidates may not be predictive of future clinical trial results for these or other product candidates when studied in a controlled environment or larger patient populations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we also publish interim, &#8220;top-line,&#8221; or preliminary data from our clinical studies based on a preliminary analysis of then-available data. Preliminary or interim data from clinical trials that we are conducting are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues, the duration of treatment increases and more patient data become available. For example, although we have, from time to time, reported positive interim clinical data for certain of our clinical programs, we may encounter dose-limiting toxicities or unacceptable side effects for these product candidates as dose escalation and expansion progresses in our clinical trials and additional patient data become available. Our preliminary or interim results and related conclusions also are subject to change following a more comprehensive review of the data related to the particular study or trial. Preliminary or &#8220;top-line&#8221; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Material adverse changes between preliminary, &#8220;top-line,&#8221; or interim data and final data could significantly harm our business prospects, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Results of clinical testing of any of our existing or future product candidates may fail to show the necessary safety and efficacy required for regulatory approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before obtaining marketing approval from regulatory authorities for the sale of any of our product candidates, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy in humans of any such product candidates. Clinical testing is expensive, difficult to design and implement, can take many years to complete, and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Our product candidates have a limited history of being evaluated in human clinical trials. Any of our product candidates may fail to show the desired safety and efficacy in later stages of clinical development despite having successfully advanced through initial clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is a high failure rate for drugs and biologics proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in later stage clinical trials even after achieving promising results in earlier stage clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit, or prevent regulatory approval. In addition, regulatory delays or rejections may be encountered as a result of many factors, including changes in regulatory policy during the period of product development.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our product candidates are ultimately not approved for any reason, our business, prospects, results of operations and financial condition would be adversely affected. In addition, the standard of care may change with the approval of new products for the same indications that we are studying.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any product candidate for which we obtain marketing approval, along with the manufacturing protocols, processes, materials and facilities, qualification testing, post-approval clinical data, labeling and promotional activities for such product, will be subject to continual and additional requirements of the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information, reports, registration and listing requirements, requirements relating to cGMP, applicable product tracking and tracing requirements, quality control, quality assurance and corresponding maintenance of records and documents, and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product. Additionally, under the Food and Drug Omnibus Reform Act of 2022 (FDORA), sponsors of approved drugs and biologics must provide 6 months&#8217; notice to the FDA of any changes in marketing status, such as the withdrawal of a drug, and failure to do so could result in the FDA placing the product on a list of discontinued products, which would revoke the product&#8217;s ability to be marketed. The FDA closely regulates the post-approval marketing and promotion of pharmaceutical and biological products to ensure such products are marketed only for the approved indications and in accordance with the provisions of the approved labeling. Later discovery of previously unknown problems with our product candidates, manufacturing operations, or failure to comply with regulatory requirements, may lead to various adverse conditions, including significant delays in bringing our product candidates to market and/or being precluded from manufacturing or selling our product candidates, any of which could significantly harm our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may seek regenerative medicine advanced therapy (RMAT) designation for certain of our product candidates, but such designation may not actually lead to a faster development or regulatory review or approval process and we may be unable to obtain or maintain the benefits associated with such designation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek RMAT designation from the FDA for certain of our product candidates. A product candidate is eligible for RMAT designation if: (1) it is a cell therapy, therapeutic tissue engineering product, human cell or tissue product, or a combination product using any such therapies or products; (2) it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3) there is preliminary clinical evidence that indicates that the product candidate has the potential to address unmet medical needs for such disease or condition. This program is intended to facilitate efficient development and expedite review of RMATs. A Biologics License Application (BLA) for a product candidate with RMAT designation may be eligible for priority review or accelerated approval through (1) surrogate or intermediate endpoints reasonably likely to predict long-term clinical benefit or (2) reliance upon data obtained from a meaningful number of sites. Benefits of such designation also include early interactions with the FDA to discuss any potential surrogate or intermediate endpoint to be used to support accelerated approval. A product candidate that has RMAT designation and is subsequently granted accelerated approval and is subject to post-approval requirements may fulfill such requirements through the submission of clinical evidence, clinical studies, patient registries, or other sources of real-world evidence, such as electronic health records; the collection of larger confirmatory data sets; or post-approval monitoring of all patients treated with such therapy prior to its approval. RMAT designation is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for RMAT designation, the FDA may disagree and instead determine not to grant such designation. In any event, the receipt of RMAT designation for a product candidate may not result in a faster development process, review or approval compared to product candidates considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualifies for RMAT designation, the FDA may later decide that the product candidate no longer meets the conditions for qualification.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may rely on orphan drug status to develop and commercialize certain of our product candidates, but orphan drug designations may not confer marketing exclusivity or other expected commercial benefits and we may not be able to obtain orphan drug designations for our other product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may rely on orphan drug exclusivity for product candidates that we may develop. Orphan drug status confers seven years of marketing exclusivity in the United States under the Federal Food Drug, and Cosmetic Act, and up to ten years of marketing exclusivity in Europe for a particular product in a specified indication, subject to certain conditions. However, we may be unable to obtain orphan drug designations for any of our product candidates that we are currently developing or may pursue. Even if we do obtain orphan drug designations and are the first to obtain marketing approval of our product candidates for the applicable indications, we will not be able to rely on these designations to exclude other companies from manufacturing or selling biological products using the same principal molecular structural features for the same indication beyond these time-frames. Furthermore, any marketing exclusivity in Europe can be reduced from ten years to six years if the initial designation criteria have significantly changed since the market authorization of the orphan product.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For any product candidate for which we may be granted orphan drug designation in a particular indication, it is possible that another company also holding orphan drug designation for the same product candidate will receive marketing approval for the same</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">indication before we do. If that were to happen, our applications for that indication may not be approved until the competing company&#8217;s period of exclusivity expires. Even if we are the first to obtain marketing authorization for an orphan drug indication in the United States, there are circumstances under which a competing product may be approved for the same indication during the seven-year period of marketing exclusivity, such as if the later product is shown to be clinically superior to our orphan product, or if the later product is deemed a different product than ours. Further, the seven-year marketing exclusivity would not prevent competitors from obtaining approval of the same product candidate as ours for indications other than those in which we have been granted orphan drug designation, or for the use of other types of products in the same indications as our orphan product.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may seek designation for our cell programming technology as a designated platform technology, but we might not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek designation for our cell programming technology as designated platform technology. Under FDORA, a platform technology incorporated within or utilized by a drug or biological product is eligible for designation as a designated platform technology if (1) the platform technology is incorporated in, or utilized by, a drug approved under a BLA or New Drug Application (NDA); (2) preliminary evidence submitted by the sponsor of the approved or licensed drug, or a sponsor that has been granted a right of reference to data submitted in the application for such drug, demonstrates that the platform technology has the potential to be incorporated in, or utilized by, more than one drug without an adverse effect on quality, manufacturing, or safety; and (3) data or information submitted by the applicable person indicates that incorporation or utilization of the platform technology has a reasonable likelihood to bring significant efficiencies to the drug development or manufacturing process and to the review process. A sponsor may request the FDA to designate a platform technology as a designated platform technology concurrently with, or at any time after, submission of an IND application for a drug that incorporates or utilizes the platform technology that is the subject of the request. If so designated, the FDA may expedite the development and review of any subsequent original BLA or NDA for a drug that uses or incorporates the platform technology. Even if we believe our cell programming technology meets the criteria for such designation, the FDA may disagree and instead determine not to grant such designation. In addition, the receipt of such designation for a platform technology does not ensure that a drug will be developed more quickly or lead to a faster FDA review or approval process and does not assure ultimate FDA approval of a drug. Moreover, the FDA may revoke a designation if the FDA determines that a designated platform technology no longer meets the criteria for such designation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may seek approval of one or more of our product candidate into real-time oncology review (RTOR). This program may not lead to a faster regulatory review or approval process and does not increase the likelihood that our product candidate(s) will receive marketing approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Participation in RTOR is voluntary. Our acceptance into RTOR does not guarantee or influence approval of our application, which is subject to the same statutory and regulatory requirements for approval as applications that are not included in RTOR. Although early approvals have occurred with applications selected for RTOR, this may not be the case for our application even if it is selected for RTOR. If at any time the FDA determines our participation in RTOR, if selected, is no longer appropriate, the FDA may rescind our acceptance and instruct us to follow routine submission procedures for marketing approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to certain regulations, including federal and state healthcare fraud and abuse laws, physician payment transparency laws, anti-bribery and anti-corruption laws and health information privacy and security laws. Any actual or perceived failure to comply with these regulations could have a material adverse effect on our business and financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations may be subject to various federal and state healthcare laws, including, without limitation, fraud and abuse laws, false claims laws, data privacy and security laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers. These laws may impact, among other things, our proposed sales, marketing and education programs. Additionally, we may be subject to state and foreign equivalents of such healthcare laws and regulations, some of which may be broader in scope and may apply regardless of the payor, as well as patient privacy regulation by both the federal government and the states in which we conduct our business. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge and may not comply under one or more of such laws, regulations, and guidance. Law enforcement authorities are increasingly focused on enforcing fraud and abuse laws, and it is possible that some of our practices may be challenged under these laws. Efforts to ensure that our current and future business arrangements with third parties, and our business generally, will comply with applicable healthcare laws and regulations will involve substantial costs. If our operations, including our arrangements with physicians and other healthcare providers are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, the curtailment or restructuring of our operations, exclusion from participation in federal and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">state healthcare programs (such as Medicare and Medicaid), and imprisonment, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business and our financial results. For more information, please see &#8220;Business&#8212;Government Regulation&#8212;Other Healthcare Laws and Compliance Requirements.&#8221;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The scope and enforcement of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the European Union. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of European Union Member States, such as the UK Bribery Act 2010. Infringement of these laws could result in substantial fines and individual imprisonment.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments made to physicians in certain European Union Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual European Union Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the European Union Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or individual imprisonment.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A variety of risks associated with conducting research and clinical trials abroad and marketing our product candidates internationally could materially adversely affect our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We plan to develop and potentially commercialize our product candidates worldwide. Accordingly, we expect that we will be subject to additional risks related to operating in foreign countries, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">differing regulatory requirements in foreign countries;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increased difficulties in managing the logistics and transportation of storing and shipping product candidates produced in the United States and shipping the product candidate to the patient abroad;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">import and export requirements and restrictions;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with data privacy regulations in foreign countries;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign taxes, including withholding of payroll taxes;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulties staffing and managing foreign operations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">workforce uncertainty in countries where labor unrest is more common than in the United States; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">differing payor reimbursement regimes, governmental payors or patient self-pay systems, and price controls;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential liability under the U.S. Foreign Corrupt Practices Act or comparable foreign regulations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business interruptions resulting from ongoing and emerging geopolitical tensions, including wars, armed conflicts or acts of terrorism.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These and other risks associated with our potential international operations may materially adversely affect our ability to attain or maintain profitable operations, which could have a material adverse effect on our business and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may decide to conduct clinical trials for our product candidates outside the United States, and the FDA may not accept data from trials conducted in such locations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have only conducted clinical trials in the United States. However, we may in the future choose to conduct one or more of our clinical trials or include sites in current or future clinical trials outside the United States.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although the FDA may accept data from sites or clinical trials outside the United States, acceptance of these data is subject to conditions imposed by the FDA. The FDA will generally not consider the data from a foreign clinical trial not conducted under an IND unless (i) the trial was well-designed and well-conducted in accordance with Good Clinical Practice (GCP) requirements, including requirements for the design, conduct, performance, monitoring, auditing, recording, analysis, and reporting of clinical trials in a way that provides assurance that the data and reported results are credible and accurate and that the rights, safety, and well-being of trial subjects are protected, and (ii) the FDA is able to validate the data from the trial through an onsite inspection, if necessary. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such as inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering must be met. Many foreign regulatory authorities have similar approval requirements. In addition, while these clinical trials or trial sites are subject to the applicable local laws where the trials are conducted, FDA acceptance of the data will depend on its determination that the trials or trial sites also complied with all applicable U.S. laws and regulations. There can be no assurance that the FDA will accept data from trials conducted outside the United States. If the FDA does not accept the data from any trial or trial site outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and would delay or halt our development of the applicable product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, the U.S. Supreme Court overruled the Chevron doctrine, which gives deference to regulatory agencies&#8217; statutory interpretations in litigation against federal government agencies, such as the FDA, where the law is ambiguous. This decision may result in more lawsuits against the FDA to challenge longstanding decisions and policies of the FDA, which could undermine the FDA&#8217;s authority, lead to uncertainties in the industry, and disrupt the FDA&#8217;s normal operations, any of which could delay the FDA&#8217;s review of our regulatory submissions. We cannot predict the full impact of this decision, future judicial challenges brought against the FDA, or the nature or extent of government regulation that may arise from future legislation or administrative action. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Financial Condition</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ongoing and planned operations, including the development of our product candidates, will require substantial additional funding, without which we will be unable to complete preclinical or clinical development of, or obtain regulatory approval for, or commercialization of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently advancing multiple product candidates through clinical development, and conducting preclinical research and development activities in other programs. Drug development is expensive, and we expect our research and development expenses to remain significant in connection with our ongoing activities, particularly as we advance our current product candidates in clinical trials and seek to initiate clinical development for additional product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, our cash, cash equivalents, and investments were $306.7 million. We intend to use our cash, cash equivalents, investments primarily to fund the advancement and clinical development of our current product candidates and our ongoing preclinical, discovery and research programs, and for working capital and general corporate purposes. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic and licensing arrangements or a combination of these approaches. In any event, we will require additional capital to obtain regulatory approval for, and to commercialize our existing product candidates and any other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product candidates we may identify and develop. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations. Our future capital requirements will depend on many factors, including, but not limited to:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the progress, results, size, timing and costs of our ongoing and planned clinical trials, and any additional clinical trials we may initiate, conduct or support for our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the progress, results, size, timing and costs of our preclinical, process development and manufacturing studies, and activities necessary to initiate and conduct clinical trials for our product candidates and to establish and maintain manufacturing capabilities necessary to support such trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continued progress in our research and development programs, including preclinical studies, process development, manufacturing and other research activities that may be necessary in order for an IND application to go into effect for a prospective clinical development candidate, as well as potential future clinical trials of any additional product candidates we may identify for development;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we are required to pay milestone or other payments under our existing in-license agreements and any in-license agreements that we may enter into in the future, and the timing of such payments, including payments owed to Memorial Sloan Kettering Cancer Center (MSKCC) in connection with the stock price appreciation milestones;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability and the ability of our investigators to initiate and conduct, and the progress, results, size, timing and costs of, clinical trials of our product candidates that will be necessary to support any application for regulatory approval;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to manufacture, or enter into arrangements with third parties for the manufacture of our existing product candidates, as well as potential future clinical development candidates, both for clinical development and commercialization, and the timing and costs associated with such manufacture;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, or other costs we may incur, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of manufacturing, distribution, and commercialization activities and arrangements, including the manufacturing of our product candidates, establishment of effective protocols for the supply and transport of our product candidates, and the establishment of a sales and marketing organization either internally or in partnership with a third party; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and maintain strategic arrangements and alliances with third-party collaborators including our existing collaborations with Ono Pharmaceutical Co., Ltd. (Ono), the University of Minnesota, and MSKCC, to advance the research, development and commercialization of therapeutic products.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible securities would dilute all of our stockholders. The incurrence of indebtedness would result in increased fixed payment and interest obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at a different stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. In addition, while the overall impacts of the ongoing and emerging geopolitical tensions, including wars and other armed conflicts, on the global economy remain unknown and difficult to predict, these events caused significant disruptions and created uncertainties in the global financial markets, and the economic impacts of these and other similar global events could materially and adversely affect our ability to raise capital through equity or debt financings in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we cannot raise additional capital or obtain adequate funds, we may be required to curtail significantly our research and clinical programs or may not be able to continue our research or clinical development of our product candidates. Our failure to raise additional capital, or obtain adequate funds, will have a material adverse effect on our business, prospects, financial condition, results of operations, and market price of shares of our common stock.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have a limited operating history, have incurred significant losses since our inception, and anticipate that we will continue to incur significant losses for the foreseeable future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biopharmaceutical company formed in 2007 with a limited operating history. We have not yet obtained regulatory approval for any of our product candidates or generated any revenues from therapeutic product sales. Since inception, we have incurred significant net losses in each year and, as of December 31, 2024, we had an accumulated deficit of $1.4 billion. We expect to continue to incur losses for the foreseeable future as we continue to fund our ongoing and planned clinical trials of our product candidates and our other ongoing and planned research and development activities. We also expect to incur significant operating and capital expenditures as we continue our research and development of, and seek regulatory approval for, our product candidates, in-license or acquire new product candidates for development, implement additional infrastructure and internal systems, and hire additional scientific, clinical, and administrative personnel. We anticipate that our net losses for the next several years could be significant as we conduct our planned operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the numerous risks and uncertainties associated with pharmaceutical, biological, and cell therapy product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. In addition, our expenses could increase if we are required by the FDA, or comparable foreign regulatory authorities, to perform studies or trials in addition to those currently expected, or if there are any delays in completing our clinical trials, preclinical studies, process development, manufacturing activities, or the research and development of any of our product candidates. The amount of our future net losses will depend, in part, on the rate of increase in our expenses, our ability to generate revenues and our ability to raise additional capital. These net losses have had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have broad discretion over the use of our cash, cash equivalents, and investments and may not use them effectively.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management has broad discretion to use our cash, cash equivalents, investments and any additional funds that we may raise to fund our operations and could spend these funds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline or delay the development of our product candidates. We may invest our cash and cash equivalents in a manner that does not produce income or that loses value.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Reliance on Third Parties</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are, and expect to continue to be, dependent on third parties to conduct some or all aspects of manufacturing of our product candidates for use in clinical trials and for commercial sale, if approved. Our business could be harmed if those third parties fail to perform satisfactorily.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we currently manufacture clinical supplies of our iPSC-derived cell product candidates at our cGMP facilities located in San Diego, California, we also rely on third parties to manufacture certain components required for the manufacture of our product candidates, and we may rely on third parties to conduct some or all aspects of manufacturing of our product candidates for use in conducting later stage clinical trials and for commercial sale upon approval of any of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reliance on third parties for manufacture of our product candidates and components utilized in manufacturing our product candidates entails certain risks, including reliance on the third party for regulatory compliance and quality assurance, the possibility that the third-party manufacturer does not maintain the financial, personnel or other resources to meet its obligations, the possibility that the third party fails to manufacture such components, or our product candidates or any products we may eventually commercialize, in accordance with our specifications, misappropriation of our proprietary information, including our trade secrets and know-how, and the possibility of termination of our manufacturing relationship by the third party, based on its own business priorities, at a time that is costly or damaging to us. In addition, the FDA and other regulatory authorities require that our product candidates and any products that we may eventually commercialize be manufactured according to cGMP, cGTP and similar jurisdictional standards. These requirements include, among other things, quality control, quality assurance and the maintenance of records and documentation. The FDA or similar foreign regulatory agencies may also implement new standards at any time, or change their interpretations and enforcement of existing standards for manufacture, packaging or testing of products. We have little control over our manufacturers&#8217; compliance with these regulations and standards.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some cases, the technical skills required to manufacture our product candidates may be unique or proprietary to a particular CMO, and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier if needed, or we may be unable to transfer such skills at all. In addition, if we are required to change contract manufacturers for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">study, that any new manufacturing process will produce our product candidate according to the specifications previously submitted to the FDA or another regulatory authority. The delays associated with the verification of a new CMO could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. In addition, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies produced by different manufacturers, which could require the conduct of additional clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, we depend in some instances on third party suppliers, including sole source suppliers, for the provision of reagents, materials, devices and equipment that are used by us and our third-party contract manufacturers in the production of our product candidates, including certain of our iPSC-derived cell therapy product candidates. Any disruption to or loss of supply from any of these suppliers could delay our clinical development and commercialization efforts, which would adversely affect our business, prospects, results of operations and financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We depend on strategic partnerships and collaboration arrangements for the development and commercialization of certain of our product candidates in certain indications or geographic territories, and if these arrangements are terminated or are unsuccessful, this could result in delays and other obstacles in the development, manufacture or commercialization of any of our product candidates and materially harm our results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our strategy for fully developing and commercializing our product candidates is dependent upon maintaining our current arrangements and establishing new arrangements with research collaborators, corporate collaborators and other third parties. We currently have a corporate collaboration agreement with Ono; our collaboration with Janssen terminated effective April 2023. Our collaboration agreement with Ono provides for, among other things, research funding and significant future payments should certain development, regulatory and commercial milestones be achieved. Under our arrangement with Ono and any future corporate arrangements that we may form, our corporate collaborators may be responsible for:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">electing to advance product candidates through preclinical and into clinical development;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conducting clinical development and obtaining required regulatory approvals for product candidates; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">commercializing any resulting products.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result, we may not be able to conduct such corporate collaborations in the manner or on the time schedule we currently contemplate, which may negatively impact our business operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our lack of control over the research funding for, and the development and commercialization of, certain of our product candidates being developed under the collaboration and option agreement we entered into with Ono on September 14, 2018 (as amended to date, the Ono Agreement) and any other product candidates that we may develop under a future arrangement could cause delays or other difficulties in the development and commercialization of any of our product candidates, which may prevent completion of research and development activities and intended regulatory filings in a timely fashion, if at all. Because we expect to continue to rely on our current collaborator and to enter into new collaborations in the future, the development and commercialization of any of our product candidates could be substantially delayed, and our ability to receive future funding could be substantially impaired, if one or more of our current or future collaborators:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shifts its priorities and resources away from our collaborations due to a change in business strategies, or a merger, acquisition, sale or downsizing of its company or business unit;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ceases development in therapeutic areas which are the subject of our collaboration;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fails to select a product candidate for advancement into preclinical development, clinical development, or subsequent clinical development into a marketed product; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes the success criteria for a particular product candidate, thereby delaying or ceasing development of such product candidate;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significantly delays the initiation or conduct of certain activities which could delay our receipt of milestone payments tied to such activities, thereby impacting our ability to fund our own activities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">develops a product candidate that competes, either directly or indirectly, with our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">does not obtain the requisite regulatory approval of a product candidate;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">does not successfully commercialize a product candidate; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">encounters regulatory, resource or quality issues and is unable to meet demand requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exercises its rights under the agreement to terminate the collaboration, as Janssen did in January 2023, or otherwise withdraws support for, or otherwise impairs or delays development under the collaboration;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disagrees on the research, development or commercialization of a product candidate resulting in a delay in milestones, royalty payments or termination of such product candidate; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">uses our proprietary information or intellectual property in such a way as to jeopardize our rights in such property.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the termination of the Ono Agreement or any future strategic partnership or collaboration arrangement that we enter into may prevent us from receiving any milestone, royalty payment, sharing of profits, and other benefits under such agreement. Furthermore, disagreements with these parties could require or result in litigation or arbitration, which would be time-consuming and expensive. Any of these events could have a material adverse effect on our ability to develop and commercialize any of our product candidates and may adversely impact our business, prospects, financial condition, and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cell-based therapies depend on the availability of reagents and specialized materials and equipment which in each case are required to be acceptable to the FDA and foreign regulatory agencies, and such reagents, materials, and equipment may not be available to us on acceptable terms or at all. We rely on third-party suppliers for various components, materials and equipment required for the conduct of our clinical trials and the manufacture of our product candidates and do not have supply arrangements for certain of these components.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development and manufacturing of our product candidates requires many reagents and other specialty materials and equipment, some of which are manufactured or supplied by small companies with limited resources and experience to support commercial biologics production. To date, we and our CMOs have purchased equipment, materials and disposables used for the manufacture of our existing product candidates from third-party suppliers. Some of these suppliers may not have the capacity to support commercial products manufactured under cGMP by biopharmaceutical firms or may otherwise be ill-equipped to support our needs. Reagents and other key materials from these suppliers may have inconsistent attributes and introduce variability into our manufactured product candidates, which may contribute to variable patient outcomes and possible adverse events. We rely on the general commercial availability of materials and equipment required for the manufacture of our product candidates, and do not have supply contracts with many of these suppliers and may not be able to obtain supply contracts with them on acceptable terms or at all. Even if we are able to enter into such contracts, we may be limited to a sole third-party for the supply of certain required components and equipment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the clinical development of our product candidates depends on the availability of certain materials and agents used in our clinical trials. For example, we intend to develop certain of our product candidates as a combination therapy with other cancer therapies, such as monoclonal antibodies, requiring availability and use of these monoclonal antibodies in certain of our clinical trial protocols. Additionally, in October 2024, the FDA reported a shortage of certain intravenous solutions which are required for the conduct of our clinical trials. We cannot predict the extent and duration of this shortage of these intravenous solutions, although any failure or delays by us or by our clinical sites to obtain sufficient quantities of materials and agents required under our protocols, or other components and agents necessary for the conduct of our clinical trials, may delay our ability to enroll and treat patients in, or complete, our current or future clinical trials of our product candidates on time, if at all.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of any public health crises, the business and operations of our suppliers and other third parties which produce agents and materials used in our clinical trials or manufacturing of our product candidates may be disrupted or delayed, and we in turn may experience disruptions or delays in our supply chain. A delay or inability to continue to source product or materials from any of these suppliers or third parties, which could be due to the impacts of any public health crises, natural disasters (including due to the effects of climate change), ongoing and emerging global geopolitical tensions, including wars and other armed conflicts, regulatory actions or requirements affecting the supplier, adverse financial or other strategic developments experienced by a supplier, labor disputes or shortages, unexpected demands, or quality issues, could adversely affect our ability to manufacture our product candidates and our ability to conduct clinical trials, which could significantly harm our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are required to change suppliers, or modify the components, equipment, materials or disposables used for the manufacture of our product candidates, we may be required to change our manufacturing operations or clinical trial protocols or to provide additional data to regulatory authorities in order to use any alternative components, equipment, materials or disposables, any of which could set back, delay, or increase the costs required to complete our clinical development and commercialization of our product candidates. Additionally, any such change or modification may adversely affect the safety, efficacy, stability, or potency of our product candidates, and could adversely affect our clinical development of our product candidates and harm our business.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We currently rely on third parties to conduct certain research and development activities and clinical trials of our product candidates. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to timely develop, manufacture, obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely upon third parties, including medical institutions, clinical investigators, and clinical research organizations (CROs) for the conduct of certain research and preclinical development activities, process development and manufacturing activities, and for the conduct, management, and supervision of clinical trials of our product candidates. We do not have direct control over the activities of these third parties, and may have limited influence over their actual performance. Our reliance on these third parties and CROs does not relieve us of our responsibilities to ensure that our clinical studies are conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are responsible for complying, and we are responsible for ensuring that our third-party service providers and CROs comply, with applicable GCP for conducting activities for all of our product candidates in clinical development, including conducting our clinical trials, and recording and reporting data from these trials. Regulatory authorities enforce these regulations through periodic inspections of trial sponsors, principal investigators and trial sites. We cannot assure that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with applicable GCP requirements. In addition, our registrational clinical trials must be conducted with product produced under applicable regulatory requirements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If these third parties and CROs do not successfully carry out their contractual duties or obligations, meet expected deadlines or successfully complete activities as planned, or if the quality or accuracy of the research, preclinical development, process development, manufacturing, or clinical data they obtain is compromised due to the failure to adhere to applicable regulatory and manufacturing requirements or for other reasons, our research, preclinical development, process development and manufacturing activities, and clinical trials, and the development of our product candidates, may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. Further, if our agreements with third parties or CROs are terminated for any reason, the development of our product candidates may be delayed or impaired, and we may be unable to advance our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed or impaired.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If conflicts arise between us and our collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability to implement our strategies.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If conflicts arise between our corporate or academic collaborators or strategic partners and us, the other party may act in a manner adverse to us and could limit our ability to implement our strategies. Some of our academic collaborators and strategic partners are conducting multiple product development efforts within each area that is the subject of the collaboration with us. Our collaborators or strategic partners, however, may develop, either alone or with others, products in related fields that are competitive with the products or potential products that are the subject of these collaborations. Competing products, either developed by the collaborators or strategic partners or to which the collaborators or strategic partners have rights, may result in the withdrawal of our collaborators&#8217; or partners&#8217; support for our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some of our collaborators or strategic partners could also become our competitors in the future. Our collaborators or strategic partners could develop competing products, preclude us from entering into collaborations with their competitors, fail to obtain timely regulatory approvals, terminate their agreements with us prematurely, or fail to devote sufficient resources to the development and commercialization of our product candidates. Any of these developments could harm our product development efforts.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may also rely on certain third-party vendors located in China or who are owned by or are associated with certain Chinese companies to assist in non-clinical or clinical trials or provide laboratory services. It is unknown how current or future geopolitical relationships with China or specific Chinese-owned or associated vendors may affect our ability to complete our non-clinical or clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently, and may in the future, do business with one or more companies located in China, or that are owned or operated by Chinese companies to provide non-clinical or clinical trial support services. The process of changing these vendors could have an adverse impact on our current clinical development programs if they were no longer permitted to provide services or products due to geopolitical pressures, including legislative activities or executive orders aimed at prohibiting certain Chinese or Chinese-owned biotechnology companies from engaging in biotechnology or biopharmaceutical research activities. We could experience delays in finding suitable replacement service providers located outside China or not otherwise owned by or associated with Chinese companies, which could have a material adverse effect on our development activities and our business. We are unable to predict whether or when proposed legislative or executive actions would be effective, and whether such changes would materially and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adversely affect our liquidity, access to capital and our ability to conduct business. Any failure on our part to comply with changing government regulations and policies could result in the loss of our ability to manufacture and develop our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Intellectual Property</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to protect our intellectual property, or obtain and maintain patent protection for our technology and product candidates, other companies could develop products based on our discoveries, which may reduce demand for our products and harm our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success will depend in part on our ability to obtain and maintain intellectual property protection for our product candidates, the operations used to manufacture them and the methods for using them, and also for our cell programming technology in order to prevent third parties from making, using, selling, offering to sell or importing our product candidates or otherwise exploiting our cell programming approach. The scope of patent protection in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. One aspect of the determination of patentability of our inventions depends on the scope and content of the &#8220;prior art,&#8221; information that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention. There may be prior art of which we are not aware that may affect the patentability of our patent claims or, if issued, affect the validity or enforceability of a patent claim. Further, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates or their intended uses, and as a result the impact of such third-party intellectual property rights upon the patentability of our own patents and patent applications, as well as the impact of such third-party intellectual property upon our freedom to operate, is highly uncertain. Because patent applications in the United States and most other countries are confidential for typically a period of 18 months after filing, or may not be published at all, we cannot be certain that we were the first to file any patent application related to our product candidates. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are uncertain. We own and have exclusive licenses to patent portfolios for our product candidates and cell programming technology, although we cannot be certain that our existing patents and patent applications provide adequate protection or that any additional patents will issue to us with claims that provide adequate protection of our other product candidates. Further, we cannot predict the breadth of claims that may be enforced in our patents if we attempt to enforce them or if they are challenged in court or in other proceedings. If we are unable to secure and maintain protection for our product candidates and cell programming technology, or if any patents we obtain or license are deemed invalid and unenforceable, our ability to commercialize or license our technology could be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Others have filed, and in the future are likely to file, patent applications covering products and technologies that are similar, identical or competitive to ours or important to our business. Since patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that any patent application owned by a third party will not have priority over patent applications filed or in-licensed by us, or that we or our licensors will not be involved in interference, opposition, reexamination, review, reissue, post grant review or invalidity proceedings before U.S. or non-U.S. patent offices. The scope, validity or enforceability of our patents or the patents of our licensors may be challenged in such proceedings in either the courts or patent offices in the United States and abroad, and our business may be harmed if the coverage of our patents or the patents of our licensors is narrowed, or if a patent of ours or our licensors is judged invalid or unenforceable, in any such proceedings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, our intellectual property rights may be subject to a reservation of rights by one or more third parties. For example, the research resulting in certain of the patent rights and technology that we own or have licensed was funded in part by the U.S. government. As a result, the government has certain rights, including march-in rights, to such patent rights and technology. When new technologies are developed with government funding, the government generally obtains certain rights in any resulting patents, including a non-exclusive license authorizing the government to use the invention or to have others use the invention on its behalf. These rights may permit the government to disclose our information to third parties and to exercise march-in rights to use or allow third parties to use our technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Any exercise by the government of such rights or by any third party of its reserved rights could harm our competitive position, business, financial condition, results of operations, and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We depend on our licensors to prosecute and maintain patents and patent applications that are material to our business. Any failure by our licensors to effectively protect these intellectual property rights could adversely affect our business and operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain rights to our key technologies and product candidates, including intellectual property relating to our iPSC technology, are licensed from third parties. As a licensee of third-party intellectual property, we rely on our licensors to file and prosecute patent</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applications and maintain patents, and otherwise protect the licensed intellectual property under some of our license agreements. We have not had and do not have primary control over these activities for certain of our licensed patents, patent applications and other intellectual property rights, and we cannot be certain that such activities will result in valid and enforceable patents and other intellectual property rights. Additionally, our licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents and we cannot be certain that our licensors will allocate sufficient resources or prioritize enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with our obligations under our license agreements, we could lose rights to our product candidates or key technologies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have obtained rights to develop, market and sell some of our product candidates through intellectual property license agreements with third parties. These license agreements impose various diligence, milestone payment, royalty and other obligations on us. In particular, under our Amended MSKCC License with MSKCC, in the event a licensed product achieves a specified clinical milestone, MSKCC is eligible to receive from us certain milestone payments totaling up to $75.0 million based on the price of our common stock, where the amount of such payments owed to MSKCC is contingent upon certain increases in the price of our common stock following the date of achievement of such clinical milestone. If we fail to comply with our obligations under our license agreements, including any payment obligations, we could lose some or all of our rights to develop, market and sell products covered by these licenses, and our ability to form collaborations or partnerships may be impaired. In addition, disputes may arise under our license agreements with third parties, which could prevent or impair our ability to maintain our current licensing arrangements on acceptable terms and to develop and commercialize the affected product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are and may become involved in litigation or other proceedings from time to time relating to the enforcement or defense of patent and other intellectual property rights, which could cause us to divert our resources and could put our intellectual property at risk.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To prevent infringement or unauthorized use of our intellectual property, we have in the past, and may in the future, need to file infringement claims. For example, in May 2022, we filed a patent infringement lawsuit in the Southern District of California against Shoreline Biosciences, Inc. (see </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8220;Item 3. Legal Proceedings&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for a more detailed description of this matter). When we pursue litigation to stop another party from using the inventions claimed in any patents we own or control, that party has the right to ask the court to rule that such patents are invalid or should not be enforced against that third party. In addition to patent infringement lawsuits, we may decide to file interferences, oppositions, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex parte</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reexaminations, post-grant review, or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">review proceedings before the U.S. Patent and Trademark Office (the USPTO) and corresponding foreign patent offices. Litigation and other proceedings relating to intellectual property are unpredictable and expensive and may consume time and resources and divert the attention of managerial and scientific personnel. Such litigations and proceedings could substantially increase our operating losses and reduce the resources available for research, development, and other activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings or may be required to divert such resources from our ongoing and planned research and development activities. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing or misappropriating or successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There also is a risk that a court or patent office in such proceeding will decide that our patents or the patents of our licensors are not valid or are not enforceable, and that we do not have the right to stop the other party from using the inventions. Additionally, even if the validity of such patents is upheld, the court may refuse to stop the other party on the ground that such other party&#8217;s activities do not infringe our rights to such patents. If we are not successful in enforcing or defending our intellectual property, our competitors could develop and market products based on our discoveries and technologies, which may reduce the commercial viability of, and demand for, our product candidates and any future products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We or our strategic partners may infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us from commercializing, or increase the costs of commercializing, our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success will depend, in part, on our ability to operate without infringing the proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex parte </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reexaminations, post-grant review, and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">review proceedings before the USPTO and corresponding foreign patent offices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights or misappropriation of other intellectual property rights of third parties.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot be certain that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our products are not covered by a third-party patent or intellectual property rights or may incorrectly predict whether a third-party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot guarantee that the manufacture, use or marketing of our existing product candidates or any other product candidates that we develop, or the use of our cell programming technology, will not infringe third-party patents. There may be third-party patents or patent applications with claims to materials, cell compositions, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Our competitors may have filed, and may in the future file, patent applications covering products and technologies similar to ours. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties asserting their patent or other intellectual property rights against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates or force us to cease some of our business operations. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business, cause development delays, and may impact our reputation. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties, or redesign our infringing products, which may be impossible on a cost-effective basis or require substantial time and monetary expenditure. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in obtaining or maintaining necessary rights to product components and processes for development or manufacture of our product candidates which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We own or license from third parties certain intellectual property rights necessary to develop and manufacture our product candidates. The growth of our business will likely depend in part on our ability to acquire or in-license additional proprietary rights, including to advance our research or allow commercialization of our product candidates. In that event, we may be required to expend considerable time and resources to develop or license replacement technology. For example, our programs may involve additional technologies or product candidates that may require the use of additional proprietary rights held by third parties. Furthermore, other pharmaceutical or biotechnology companies and academic institutions may also have filed or may be planning to file patent applications potentially relevant to our business. From time to time, in order to avoid infringing these third-party patents, we may be required to license technology from additional third parties to further develop or commercialize our product candidates. We may be unable to acquire or in-license any relevant third-party intellectual property rights, including any such intellectual property rights required to manufacture, use or sell our product candidates, that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, and as a result we may be unable to develop or commercialize the affected product candidates, which would harm our business. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights, and may need to seek to develop alternative approaches or technology that do not infringe on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license under such intellectual property rights, any such license may be non-exclusive, which may allow our competitors&#8217; access to the same technologies licensed to us.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business and financial condition could suffer.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. In addition, it may be more costly for us to secure and maintain the necessary patent protection to block third parties from using our technology than to negotiate out-licenses or similar agreements with these parties to provide them with limited rights to use our technology. There can be no assurance that we will be able to successfully complete any such negotiations and ultimately acquire or maintain, on commercially viable terms, the rights to the intellectual property required for the successful development and commercialization of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may be able to make product candidates that are similar to ours but that are not covered by the claims of the patents that we own or have exclusively licensed;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that our pending patent applications will not lead to issued patents;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issued patents that we own or have exclusively licensed may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we cannot predict the scope of protection of any patent issuing based on our patent applications, including whether the patent applications that we own or in-license will result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the claims of any patent issuing based on our patent applications may not provide protection against competitors or any competitive advantages, or may be challenged by third parties;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if enforced, a court may not hold that our patents are valid, enforceable and infringed;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we have initiated, and may from time to time initiate, litigation or administrative proceedings to enforce and/or defend our patent rights which will be costly whether we win or lose;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may fail to adequately protect and police our trademarks and trade secrets; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patents of others may have an adverse effect on our business, including if others obtain patents claiming subject matter similar to or improving that covered by our patents and patent applications.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Should any of these events occur, they could significantly harm our business, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed alleged trade secrets.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In conducting our business operations, we have obtained confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers or other parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we could lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be subject to claims that former employees, collaborators, or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. If we fail in defending any such claims, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. We may also be subject to monetary damages, and any of these outcomes could have a material adverse impact on our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Proprietary information and invention assignment agreements with our employees and third parties may not prevent unauthorized disclosure of our trade secrets and other proprietary information.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the protection afforded by patents, we also rely upon unpatented trade secrets and improvements, proprietary know-how, and continuing technological innovation to develop and maintain our competitive position, which we seek to protect, in part, through confidentiality agreements with our collaborators, employees and consultants. We also have invention or patent assignment agreements with our employees and some, but not all, of our collaborators and consultants. Because we expect to rely on third parties in the development and manufacture of our product candidates, we must, at times, share trade secrets with them, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trade secrets, however, may be difficult to protect, and any disclosure, either intentional or unintentional, by our employees or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Although we use reasonable efforts to protect our trade secrets, our employees or former employees, consultants, outside scientific advisors, contractors, and collaborators might intentionally or inadvertently disclose our trade secret information to competitors. In addition, competitors may otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third-party, we would have no right to prevent them from using that technology or information to compete with us. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, or misappropriation of our intellectual property by third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results, and financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filing, prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">their own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with any products that we may develop and commercialize, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology and pharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in the patent law in the United States could diminish the value of patents in general, thereby impairing our ability to protect our product candidates and technology.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As is the case with other biotechnology companies, our success is heavily dependent on intellectual property rights, particularly patents. Obtaining and enforcing patents in the biotechnology industry involve both technological and legal complexity, and therefore obtaining and enforcing biotechnology patents is costly, time-consuming and inherently uncertain. In addition, the United States has recently enacted and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The term of our patents may not be sufficient to effectively protect our market position and products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Even if we obtain patents covering our product candidates, once the patent life has expired for a product, we may be open to competition from other products. If the lives of our patents are not sufficient to effectively protect our products and business, our business and results of operations will be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to the Commercialization of Our Product Candidates</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We do not have experience marketing any product candidates and do not have a sales force or distribution capabilities, and if our products are approved, we may be unable to commercialize them successfully.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have no experience in marketing and selling therapeutic products, including obtaining and maintaining adequate pricing and reimbursements. If any of our product candidates are approved for marketing, we intend to establish marketing and sales capabilities internally or we may selectively seek to enter into partnerships with other entities to utilize their marketing and distribution capabilities. If we are unable to develop adequate marketing and sales capabilities on our own or effectively partner with third parties, our ability to generate product revenues will suffer.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The commercial success of our product candidates will depend upon the degree of market acceptance by physicians, patients, third-party payers and others in the medical community.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The commercial success of our products, if approved for marketing, will depend in part on the medical community, patients and third-party payers accepting our product candidates as effective and safe. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. For example, in November 2023, the FDA announced that it would be conducting an investigation into reports of T-cell malignancies following BCMA-directed or CD19-directed autologous CAR T-cell immunotherapies following reports of T-cell lymphoma in patients receiving these therapies. In January 2024, the FDA determined that new safety information related to T-cell malignancies should be included in the labeling with boxed warning language on these malignancies for all BCMA- and CD19-directed genetically modified autologous T-cell immunotherapies. FDA&#8217;s investigation into CAR T-cell therapies and other similar actions could result in increased government</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulation, unfavorable public perception and publicity, stricter labeling requirements for those product candidates that are approved, and a decrease in demand for any such product candidates. The degree of market acceptance of our products, if approved for marketing, will depend on a number of factors, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the safety and efficacy of the products, and advantages over alternative treatments;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the labeling of any approved product;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence and severity of any side effects, including any limitations or warnings contained in a product&#8217;s approved labeling;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the clinical indications for which any product candidate is approved;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the emergence, and timing of market introduction, of competitive products;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effectiveness of our marketing strategy; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining and maintaining adequate pricing and reimbursement; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sufficient third-party insurance coverage or governmental reimbursement, which may depend on our ability to provide compelling evidence that a product meaningfully improves health outcomes to support such insurance coverage or reimbursement.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patient populations targeted by our autoimmune product candidates are also typically not at risk of near-term death, even if they may suffer life-threatening symptoms, so those patients will need to deem the benefits of cell therapy to be worth the risk of unknown potential adverse side effects. Our success in this space will depend upon physicians who specialize in the treatment of autoimmune diseases targeted by our product candidates prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments with which they are more familiar and for which greater clinical data may be available.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if a potential product displays a favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance of the product will not be known until after it is launched. Any failure to achieve market acceptance for our product candidates will harm our business, results and financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We expect to face uncertainty regarding the pricing of our existing product candidates and any other product candidates that we may develop. If pricing policies for our product candidates are unfavorable, our commercial success will be impaired.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to the novel nature of our cellular immunotherapy product candidates, we face significant uncertainty as to the pricing of any such products for which we may receive marketing approval. While we anticipate that pricing for any cellular immunotherapy product candidates that we develop will be relatively high due to their anticipated use in the prevention or treatment of life-threatening diseases where therapeutic options are limited, the biopharmaceutical industry has recently experienced significant pricing pressures. In particular, drug pricing and other healthcare costs continue to be subject to intense political and societal pressures, which we anticipate will continue and escalate on a global basis. These pressures may result in harm to our business and reputation, cause our stock price to decline or experience periods of volatility and adversely affect results of operations and our ability to raise funds.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates could limit our product revenues.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to commercialize any of our product candidates successfully will depend in part on the availability of coverage and reimbursement for these products from third-party payors, including government health administration authorities, private health insurers, and other managed care organizations. The availability and extent of reimbursement by governmental and private payors is essential for most patients who generally rely on third-party payors to reimburse all or part of the costs of their care, including treatments such as cellular immunotherapy. Because our product candidates represent new approaches to the treatment of cancer and autoimmune diseases, there is significant uncertainty as to the insurance coverage and reimbursement status of any product candidates for which we may receive regulatory approval. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare &amp; Medicaid Services (CMS), an agency within the U.S. Department of Health and Human Services. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare, and private payors tend to follow CMS determinations to a substantial degree. If reimbursement or insurance coverage is not available for our product candidates, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be sufficient to allow us to establish or maintain pricing to generate income. Factors payors consider in determining reimbursement are based on whether the product is: (i) a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">covered benefit under its health plan; (ii) safe, effective and medically necessary; (iii) appropriate for the specific patient; (iv) cost-effective; and (v) neither experimental nor investigational. For more information, please see &#8220;Business&#8212;Government Regulation&#8212;Coverage and Reimbursement.&#8221;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, reimbursement agencies in foreign jurisdictions may be more conservative than those in the United States. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits. Moreover, increasing efforts by governmental and third-party payors, in the United States and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. Failure to obtain or maintain adequate reimbursement for any products for which we receive marketing approval will adversely affect our ability to achieve commercial success, and could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products, and our overall financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If the market opportunities for our product candidates are restricted or smaller than we believe they are, our revenues may be adversely affected and our business may suffer. Because the target patient populations of our product candidates may be small and variable, we must be able to successfully identify patients and capture a significant market share to achieve and maintain profitability.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We focus our research and development on product candidates for rare diseases, including cancer and autoimmune diseases. The FDA often approves new therapies initially for use in patients with relapsed or refractory disease. We expect to initially seek approval of our product candidates in these settings. Subsequently, for those products that prove to be sufficiently beneficial, if any, we would expect to seek approval in earlier lines of treatment. There is no guarantee that our product candidates, even if approved, would be approved for earlier lines of therapy, and, prior to any such approvals, we will have to conduct additional clinical trials, including potentially comparative trials against approved therapies. Certain of our product candidates also target similar patient populations as autologous cell therapy product candidates, including approved autologous CAR T products. Our therapies may not be as safe and effective as approved autologous CAR T therapies and as a result, such product candidates may only be approved for patients who are ineligible for autologous CAR T therapy.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our projections of the number of people who have or will have the diseases we may be targeting, as well as the subset of patients with these cancers in a position to receive second or later lines of therapy and who have the potential to benefit from treatment with our product candidates, may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients in the United States, Europe and elsewhere may turn out to be lower than expected, or the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates, all of which would adversely affect our results of operations and our business. Additionally, because our target patient populations may be small and variable, we may never achieve profitability without capturing a significant market share or obtaining regulatory approval for additional indications for our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Healthcare legislative or regulatory reform measures may have a negative impact on our business and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect our ability to profitably sell any product candidates for which we obtain marketing approval. Payors, whether domestic or foreign, or governmental or private, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our products profitably. Additional changes that may affect our business include those governing enrollment in federal healthcare programs, reimbursement changes, rules regarding prescription drug benefits under the health insurance exchanges and fraud and abuse and enforcement. Continued implementation of the Affordable Care Act (ACA) and the passage of additional laws and regulations may result in the expansion of new programs such as Medicare payment for performance initiatives, and may impact existing government healthcare programs, such as by improving the physician quality reporting system and feedback program. For more information regarding the risks related to recently enacted and future legislation please see &#8220;Business &#8211; Government Regulation &#8211; Healthcare Reform and Other Regulatory Changes.&#8221;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There has been increasing legislative and enforcement interest in the United States with respect to drug pricing practices.&#8239; Specifically, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, and review the relationship between pricing and manufacturer patient programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The continuing efforts of the government, insurance companies, managed care organizations and other payers of healthcare services to contain or reduce costs of healthcare may adversely affect:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the demand for any of our product candidates, if approved;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to set a price that we believe is fair for any of our product candidates, if approved;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to generate revenues and achieve or maintain profitability;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the level of taxes that we are required to pay; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of capital.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare drugs and services, which could result in reduced demand for our drug candidates or additional pricing pressures. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain drug access and marketing cost disclosure and transparency measures, and designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our drugs or put pressure on our drug pricing, which could negatively affect our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the U.S. Supreme Court&#8217;s 2024 decision in Loper Bright Enterprises v. Raimondo overruled the Chevron doctrine, which for 40 years required federal courts to defer to permissible agency interpretations of statutes that are silent or ambiguous on a particular topic. In Loper Bright, the Supreme Court held that the U.S. Administrative Procedure Act requires courts to exercise their independent judgment when deciding whether an agency has acted within its statutory authority, and that courts may not defer to an agency interpretation solely because a statute is ambiguous. This landmark Supreme Court decision may invite more companies and other stakeholders to bring lawsuits against the FDA to challenge longstanding decisions and policies of the FDA, which could undermine the FDA&#8217;s authority, lead to uncertainties in the industry, and disrupt the FDA&#8217;s normal operations, any of which could delay the FDA&#8217;s review of our regulatory submissions. We cannot predict the full impact of this decision, future judicial challenges brought against the FDA, or the nature or extent of government regulation that may arise from future legislation or administrative action. Any such challenges, if successful, could have an impact on our business, and any such impact could be material. In addition to potential changes to regulations and agency guidance as a result of legal challenges, these decisions may result in increased regulatory uncertainty and delays in and other impacts to the agency rulemaking process, any of which could adversely impact our business and operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Business and Industry</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The success of our existing product candidates is substantially dependent on developments within the field of cellular immunotherapy, and specifically developments relating to the use of pluripotent or genome edited cells for the manufacture of cellular therapeutics, the majority of which are beyond our control.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates are designed and are being developed as therapeutic entities for use as cellular immunotherapies, and all of our current product candidates are based on our novel iPSC product platform. Additionally, some of our product candidates utilize novel genome editing technologies. To date, there is limited clinical trial experience testing iPSC-derived therapeutic product candidates using genome edited cells. The fields of cellular and genome edited therapies are evolving, and as more therapeutic product candidates derived from pluripotent and genome edited cells are reviewed by regulatory authorities, regulatory authorities may impose additional requirements for approval that were not previously anticipated. There have also been several significant adverse events from gene therapy treatments in the past, including reported cases of leukemia and death. Additionally, in November 2023, the FDA announced that it would be conducting an investigation into reports of T-cell malignancies following BCMA-directed or CD19-directed autologous CAR T-cell immunotherapies following reports of T-cell lymphoma in patients receiving these therapies. In January 2024, the FDA determined that new safety information related to T-cell malignancies should be included in the labeling with boxed warning language on these malignancies for all BCMA- and CD19-directed genetically modified autologous T-cell immunotherapies. There can be no assurance that any product candidates developed from or related to our iPSC product platform or any of our research programs will not cause severe or undesirable side effects or result in significant delays or unanticipated costs, or that such development problems can be solved. Any adverse developments in the fields of cellular immunotherapy or genome edited</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">therapy, such as FDA&#8217;s investigation into CAR T-cell therapies and other similar actions, could negatively affect our ability to develop and commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face intense competition in an environment of rapid technological and scientific progress from other biotechnology and pharmaceutical companies that are commercializing, have developed or may develop product candidates for the treatment of the diseases that we may target, including companies developing novel therapies and platform technologies. If these companies develop product candidates or platform technologies more rapidly than we do, if their commercialized products or product candidates are more effective, more cost effective, or have fewer side effects, or if they compete in various other aspects of our business, our ability to develop and successfully commercialize product candidates and to execute on our business plans will be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biotechnology and pharmaceutical industries are intensely competitive and characterized by rapid and significant innovation, particularly in the areas of immune-oncology and the development and commercialization of cell therapies. We compete with a variety of large pharmaceutical companies, multinational biopharmaceutical companies, other biopharmaceutical companies and specialized biotechnology companies, as well as technology and/or therapeutics being developed at universities and other research institutions. Many of our competitors have greater financial and other resources, such as larger research and development staff, more experienced manufacturing organizations and facilities and greater sales and marketing organizations. Third parties are commercializing, have developed, are developing or may develop product candidates, platform technologies and processes that compete with ours. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community, as well as novel treatments that are currently in preclinical or clinical development or may otherwise enter the market. We believe that a significant number of product candidates are currently under development, including various cellular immunotherapies as well as multifunctional targeted antibodies, such as bi-specific and tri-specific T-cell engagers, which may become commercially available in the future for the treatment of indications, including a variety of cancers, for which we are developing or may try to develop our product candidates. Additionally, several companies with experience and knowledge in the development of CAR T-cell therapies for oncology indications have now commenced the development of cell therapies for the treatment of autoimmune diseases where B cells may play a role in initiating or maintaining disease affected populations, and the product candidates these companies develop may be competitive with product candidates that we are developing for autoimmune diseases. Should one or more of these competing product candidates or other competing product candidates of which we are not aware receive regulatory approval or otherwise achieve clinical or commercial success, our regulatory strategy could be impaired, our ability to obtain regulatory approval could be delayed or prevented, or the market for our products may be reduced or eliminated, thereby harming or preventing our commercial success.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the relative safety and efficacy of our product candidates, the actual or perceived quality of patient life while undergoing treatment with our product candidates, the ease with which our product candidates can be administered, the timing and scope of regulatory approvals for these product candidates, the availability and cost of manufacturing, marketing and sales capabilities, pricing, reimbursement coverage and patent positions, and the relative prioritization of our product candidates by physicians and healthcare providers among available therapies. Competing products and product candidates could present superior treatment alternatives, including by being more effective, safer, less expensive or marketed and sold more effectively than any products we may develop. Competitive products and product candidates may also make any product we develop obsolete or noncompetitive before we recover the expense of developing and commercializing such product. We could also face competition from other companies for collaboration partners, employees, advisors and service providers, which could negatively impact our ability to execute our business plans.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Our competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive or more commercially viable than any products that we may develop. Furthermore, currently approved products could be discovered to have application for treatment of our targeted disease indications or similar indications, which could give such products significant regulatory and market timing advantages over our product candidates. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours and may obtain orphan product exclusivity from the FDA for indications that we are targeting, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, products or technologies developed by our competitors may render our product candidates uneconomical or obsolete and we may not be successful in marketing those product candidates, once approved, against competitors.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to compete effectively with other biotechnology and pharmaceutical companies depends on our ability to distinguish our company and our product candidates from our competitors and their product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some of our competitors may have, and new competitors or alliances may emerge that have, greater name and brand recognition, greater market share, a larger customer base, more widely adopted proprietary technologies, greater marketing expertise, larger sales forces, and/or significantly greater resources than we do and may be able to offer solutions competitive with ours at a more attractive price. Further, our current or potential competitors may be acquired by third parties with greater available resources. As a result, our competitors may be able to respond more quickly and effectively than we can to new or changing opportunities, technologies, standards or customer requirements and may have the ability to initiate or withstand substantial price competition. In addition, our competitors may in the future establish cooperative relationships with vendors of complementary products, technologies or services to increase the availability of their solutions in the marketplace. Our competitors could also be better positioned to serve certain segments of our market, which could create additional price pressure. In light of these factors, even if any products that we may develop are more effective than those of our competitors, current or potential customers may accept competitive products in lieu of purchasing our products. If we are unable to successfully compete, our business, financial condition, and results of operations could be materially and adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The loss of any member of our senior management team or our inability to attract and retain key personnel and consultants could adversely affect our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are highly dependent upon the efforts of our senior management team and other key personnel. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, initiation or completion of our preclinical studies and clinical trials or the commercialization of our product candidates. Although we have executed offer letters with each member of our senior management team, these agreements are terminable at will without notice and, therefore, we may not be able to retain their services as expected. Our former Chief Financial Officer resigned in June 2024. Our former Chief Executive Officer (CEO) retired on December 31, 2024, transitioning to an advisory role, and our former President of Research and Development assumed the role of CEO effective January 1, 2025. Management transitions may create uncertainty and involve a diversion of resources and management attention, be disruptive to our daily operations or impact public or market perception, any of which could negatively impact our ability to operate effectively or execute our strategies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to retain or attract qualified management, finance, scientific and clinical personnel and consultants due to the intense competition for a limited number of qualified personnel and consultants among biotechnology, pharmaceutical and other businesses. We may also experience difficulties in attracting or retaining personnel with sufficient experience and skills in the complex and emerging field of cellular therapeutic development and manufacture to support our ongoing and planned clinical development activities. We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants. There can be no assurance that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. We may also be subject to penalties or other liabilities if we misclassify employees as consultants. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all. Further, some of the qualified personnel that we hire and recruit are not U.S. citizens; changes to U.S. immigration policies, particularly to H-1B and other visa programs, could restrain the flow of technical and professional talent into the United States and may inhibit our ability to hire qualified personnel.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options and restricted stock unit (RSU) awards that vest over time. The value to employees of stock options and RSU awards that vest over time has been significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. A significant number of our employee options remain underwater and may not provide the intended incentive for employees to remain at our company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of the biotechnology and pharmaceutical companies that we compete against for qualified personnel have greater financial and other resources and different risk profiles than we do. We may be required to provide compensation in excess of historical levels in order to recruit and retain personnel in the current market. If we are not able to retain and attract necessary personnel and consultants to perform the requisite operational roles and accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we engage in an acquisition, reorganization or business combination, we will incur a variety of risks that could adversely affect our business operations or our stockholders.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we have considered, and we will consider in the future, strategic business initiatives intended to further the expansion and development of our business. These initiatives may include acquiring businesses, technologies or products or entering into business combinations with other companies. If we pursue such a strategy, we could, among other things:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issue equity securities that would dilute our current stockholders&#8217; percentage ownership;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incur substantial debt that may place strains on our operations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">spend substantial operational, financial and management resources to integrate new businesses, technologies and products;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">assume substantial actual or contingent liabilities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reprioritize our development programs and even cease development and commercialization of our product candidates; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">merge with, or otherwise enter into a business combination with, another company in which our stockholders would receive cash or shares of the other company on terms that certain of our stockholders may not deem desirable.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we intend to evaluate and consider acquisitions, reorganizations and business combinations in the future, we have no agreements or understandings with respect to any acquisition, reorganization or business combination at this time.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face potential product liability exposure far in excess of our limited insurance coverage.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The use of our product candidates in clinical trials, and the sale of any products for which we obtain marketing approval, exposes us to the risk of product liability claims. Product liability claims might be brought against us by participants in clinical trials, hospitals, medical centers, healthcare providers, pharmaceutical companies, and consumers, or by others selling, manufacturing or otherwise coming into contact with our product candidates. We carry product liability insurance and we believe our product liability insurance coverage is sufficient in light of our current clinical programs. In addition, if and when we obtain marketing approval for product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain insurance coverage for any approved products on commercially reasonable terms or in sufficient amounts to protect us against losses due to liability.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. In addition, under some of our agreements with clinical trial sites, we are required to indemnify the sites and their personnel against product liability and other claims. A successful product liability claim, or a series of claims, brought against us or any third parties whom we are required to indemnify could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patients with the diseases targeted by our product candidates are often already in severe and advanced stages of disease and have both known and unknown significant pre-existing and potentially life-threatening health risks. During the course of treatment, patients may suffer adverse events, including death, for a variety of reasons. Such events, whether or not resulting from our product candidates, could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively affect or end our opportunity to receive or maintain regulatory approval to market our products, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which we do not believe that an adverse event is related to our products, the investigation into the circumstance may be time-consuming or inconclusive. These investigations may interrupt our development and commercialization efforts, delay our regulatory approval process, or impact and limit the type of regulatory approvals our product candidates receive or maintain. As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition or results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our insurance policies are expensive and protect us from only some risks, which leaves us exposed to significant uninsured liabilities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not carry insurance for all categories of risk to which our business is or may be exposed. Some of the policies we maintain include general liability, product liability, property, employee benefits liability, employment practices, workers&#8217; compensation, cybersecurity, directors&#8217; and officers&#8217; insurance, and umbrella. We do not know, however, if we will be able to maintain insurance coverage at a reasonable cost or in sufficient amounts or scope to protect us against losses. Even if we obtain insurance, a claim could exceed the amount of our insurance coverage or it may be excluded from coverage under the terms of the policy. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our cash position and results of operations.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees or third party service providers may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk of employee or third party service provider fraud or other misconduct. Misconduct by employees or third party service providers could include intentional failures to comply with the regulations of the FDA or foreign regulators, to provide accurate information to the FDA or foreign regulators, to comply with healthcare fraud and abuse laws and regulations in the United States and abroad, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. Employee or third party service provider misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. If any actions alleging such conduct are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant effect on our business, including the imposition of significant fines or other sanctions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face risks of potential liability related to the privacy of personal information, including health information we utilize in the development of our products, as well as information we obtain from clinical trials sponsored by us from research institutions and directly from individuals.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and our partners and vendors may be subject to various federal, state, and foreign data protection laws and regulations (i.e., laws and regulations that address privacy and data security). In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators, including the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) and privacy and security requirements under HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH). Depending on the facts and circumstances, we could be subject to civil, criminal, and administrative penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. There is no certainty that all of our employees, agents, suppliers, manufacturers, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Even when HIPAA does not apply, failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute a violation of the Federal Trade Commission Act. In addition, certain of the materials we use as starting material in our iPSC-derived product candidates are derived from human sources, which potentially contain sensitive identifiable personal information regarding the donor. In addition, in conducting our clinical trials, we may maintain sensitive identifiable personal information, including health information, that we receive throughout the clinical trial process, in the course of our research collaborations, and directly from individuals (or their healthcare providers) who enroll in our clinical trials. As such, we may become subject to further obligations under HIPAA. Our collection of personal information generally (e.g., of employees currently and/or of patients in the future) may subject us to state data privacy laws governing the processing of personal information and requiring notification of affected individuals and state regulators in the event of a breach of such personal information. These state laws include the California Consumer Privacy Act, as amended by the California Privacy Rights Act (the CCPA), which establishes data privacy rights for residents of the State of California, with corresponding obligations on businesses related to transparency, deletion rights, and opt-out of the selling or sharing of personal information, and grants a private right of action for individuals in the event of certain security breaches. Similar laws relating to data privacy and security have passed in numerous other states, which may have potentially conflicting requirements that would make compliance challenging, require us to expend significant resources to come into compliance, and restrict our ability to process certain personal information. Moreover, some states have advanced privacy laws focused on protecting consumer health information, such as Washington&#8217;s My Health My Data Act, and this remains a rapidly changing legislative and regulatory environment.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain state laws may be more stringent or broader in scope than the CCPA, or offer greater individual rights, with respect to confidential, sensitive and personal information than federal, international or other state laws, and such laws may differ from each other, which may complicate compliance efforts.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An increasing number of foreign data protection laws, regulations and industry standards may also apply to personal information we obtain from individuals outside of the United States. For example, the European Union&#8217;s General Data Protection Regulation (EU GDPR) and the United Kingdom&#8217;s General Data Protection Regulation (UK GDPR) impose strict requirements for processing the personal data of individuals within the EEA and UK, including health-related data, and on the transfer of personal data out of the European Economic Area (EEA) and United Kingdom (UK) to non-adequate territories such as the United States; any inability to transfer personal data from the EEA and UK to the United States in compliance with data protection laws may impede our ability to conduct trials and may adversely affect our business and financial position. Failure to comply with the requirements of the EU GDPR</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may result in potential fines for companies of up to the greater of &#8364;20 million (&#163;17.5 million for the UK GDPR) or 4% of annual global revenue and other administrative penalties. In addition, under the EU GDPR and UK GDPR, companies may face private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to protect their interests. Although the EU GDPR and the UK GDPR currently impose substantially similar obligations, it is possible that over time the UK GDPR could become less aligned with the EU GDPR, particularly with the introduction of the new Data Reform Bill into the UK legislative process. In addition, EEA Member States have adopted national laws to supplement the EU GDPR, which may partially deviate from the EU GDPR, and the competent authorities in the EEA Member States may interpret EU GDPR obligations slightly differently from country to country, such that we do not expect to operate in a uniform legal landscape in the EEA and UK with respect to data protection regulations. The potential of the respective provisions and enforcement of the EU GDPR and UK GDPR further diverging in the future creates additional regulatory challenges and uncertainties for us. The lack of clarity on future UK laws and regulations and their interaction with EU laws and regulations could add legal risk, uncertainty, complexity and compliance cost to the handling of European personal data and our privacy and data security compliance, and could require us to amend our processes and procedures to implement different compliance measures for the UK and the EEA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, the U.S. Department of Justice issued regulations implementing Executive Order (&#8220;EO&#8221;) 14117, &#8220;Preventing Access to Americans&#8217; Bulk Sensitive Personal Data and United Stated Government-Related Data by Countries of Concern,&#8221; which are expected to become effective in April 2025. These regulations prohibit transactions involving access to bulk sensitive data by countries of concern, such as China (including Hong Kong). In the life sciences sector, the regulations prohibit investment agreements, employment agreements, vendor agreements, and other transactions involving human genomic data and biospecimens, except where necessary for specified exempt activities. Tracking and complying with these regulations may require significant time and expense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are likely to be required to expend significant capital and other resources to ensure ongoing compliance with applicable data privacy and security laws. Claims that we have violated individuals&#8217; privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend, and could result in adverse publicity that could harm our business. Moreover, even if we take all necessary action to comply with legal and regulatory requirements, we could be subject to a data breach or other unauthorized access of personal information, which could subject us to fines and penalties, as well as litigation and reputational damage. If we fail to keep apprised of and comply with applicable international, federal, state, or local regulatory requirements, we could be subject to a range of regulatory actions that could affect our or any collaborators&#8217; ability to seek to commercialize our clinical candidates. Any threatened or actual government enforcement action or litigation could also generate adverse publicity, damage our reputation, result in liabilities, fines and loss of business, and require that we devote substantial resources that could otherwise be used in other aspects of our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We make public statements about our use and disclosure of personal information through our privacy policy information provided on our internet platform and press statements. Although we endeavor to comply with our public statements and documentation, we may at times fail to do so or be alleged to have failed to do so. Moreover, despite our efforts, we may not be successful in achieving compliance if our employees or contractual partners fail to comply with our published policies, certifications and documentation. The publication of our privacy policy and other statements that provide promises and assurances about data privacy and security can subject us to potential government or legal action if they are found to be deceptive, unfair or misrepresentative of our actual practices. Any failure, real or perceived, by us to comply with our posted privacy policies or with any legal or regulatory requirements, standards, certifications or orders or other privacy or consumer protection-related laws and regulations applicable to us could cause our prospective customers to reduce their use of our products and could materially and adversely affect our business, financial condition and results of operations. In many jurisdictions, enforcement actions and consequences for non-compliance can be significant and are rising. In addition, from time to time, concerns may be expressed about whether our products or processes compromise the privacy of customers and others. Concerns about our practices with regard to the collection, use, retention, security, disclosure, transfer and other processing of personal information or other privacy-related matters, even if unfounded, could damage our reputation and materially and adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many statutory requirements, both in the United States and abroad, include obligations for companies to notify individuals of security breaches involving certain personal information, which could result from breaches experienced by us or our third-party service providers. For example, laws in all 50 U.S. states and the District of Columbia require businesses to provide notice to consumers whose personal information has been disclosed as a result of a data breach. These laws are not consistent, and compliance in the event of a widespread data breach is difficult and may be costly. We also may be contractually required to notify customers or other counterparties of a security breach. Although we may have contractual protections with our third-party service providers, contractors and consultants, any actual or perceived security breach could harm our reputation and brand, expose us to potential liability or require us to expend significant resources on data security and in responding to any such actual or perceived breach or security incident. Any contractual protections we may have from our third-party service providers, contractors or consultants may not</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be sufficient to adequately protect us from any such liabilities and losses, and we may be unable to enforce any such contractual protections.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the possibility of fines, lawsuits, regulatory investigations, public censure, other claims and penalties, and significant costs for remediation and damage to our reputation, we could be materially and adversely affected if legislation or regulations are expanded in a manner that requires changes in our data processing practices and policies or if governing jurisdictions interpret or implement their legislation or regulations in ways that negatively impact our business. Complying with these various laws could cause us to incur substantial costs or require us to change our business practices and compliance procedures in a manner adverse to our business. Any inability to adequately address data privacy or security-related concerns, even if unfounded, or to comply with applicable laws, regulations, standards and other obligations relating to data privacy and security, could result in additional cost and liability to us, harm our reputation and brand, damage our relationships with contract partners and the physician and patient community and have a material and adverse impact on our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The increasing use of artificial intelligence-based software (including machine learning) may result in reputational harm or liability or could otherwise adversely affect our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The use of artificial intelligence-based software is increasingly being used in the biopharmaceutical and global healthcare industries. As with many developing technologies, artificial intelligence-based software presents risks and challenges that could affect its further development, adoption, and use, and therefore our business. For example, algorithms may be flawed; data sets may be insufficient, of poor quality, or contain biased information; and inappropriate or controversial data practices by data scientists, engineers, and end-users could impair results. If the analyses that artificial intelligence (AI) applications assist in producing are deficient or inaccurate, we could be subjected to competitive harm, potential legal liability, and reputational harm. Furthermore, use of AI-based software may lead to the inadvertent release of confidential information which may impact our ability to realize the benefit of our intellectual property rights.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A growing number of legislators and regulators are adopting laws and regulations and have focused enforcement efforts on the adoption of AI, and use of such technologies in compliance with ethical standards and societal expectations. For example, the EU&#8217;s Artificial Intelligence Act (&#8220;AI Act&#8221;) imposes significant obligations on providers and deployers of AI systems, and encourages providers and deployers of AI systems to account for EU ethical principles in their development and use of these systems. Likewise, in the United States, several states, including Colorado and California, passed laws to regulate various uses of AI, including to make consequential decisions. In addition, various federal regulators have issued guidance and focused enforcement efforts on the use of AI in regulated sectors. The FDA, for example, issued guidance on the use of AI in medical devices, requiring detailed risk management and review processes to obtain approvals. If we develop or use AI systems governed by these laws or regulations, we will need to apply significant resources to design, develop, test and maintain such systems in accordance with applicable law and regulation, with the potential for significant enforcement or litigation in the event of any perceived non-compliance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our vendors may in turn incorporate AI tools into their offerings, and the providers of these AI tools may not meet existing or rapidly evolving regulatory or industry standards, including with respect to privacy and data security. Further, bad actors around the world use increasingly sophisticated methods, including the use of AI, to engage in illegal activities involving the theft and misuse of personal information, confidential information and intellectual property. Any of these effects could damage our reputation, result in the loss of valuable property and information, cause us to breach applicable laws and regulations, and adversely impact our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our internal computer systems, or those used by our third-party research institution collaborators, CROs or other contractors or consultants, may fail or suffer security breaches.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors, vendors, and consultants may be vulnerable to damage from cybersecurity risks, including attempts to gain unauthorized access to and to harm sensitive or confidential information and networks, insider threats, and ransomware. These vulnerabilities may be heightened as a result of flexible work arrangements, including hybrid or remote work policies implemented by us and our third-party contractors, that were first adopted in response to the COVID-19 pandemic and have continued by many businesses in an effort to attract and retain talent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Like other companies in our industry, we, and our third party vendors, have from time to time experienced, and will continue to experience in the future, cyberattacks on our information technology systems, including malware and computer virus attacks, despite our best efforts to prevent them. Although such incidents have been immaterial to our business to date, investigations into and remedial efforts in connection with any security incidents, even those with immaterial impact, can be costly and time-consuming, and any future incidents could be material, or cause significant disruption, to our business. Our technologies, systems, networks, or other proprietary information, and those of our vendors, suppliers and other business partners, may become the target of cyberattacks or data</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">breaches that could result in the unauthorized release, gathering, monitoring, misuse, loss, or destruction of proprietary and other information, or could otherwise lead to the disruption of our business operations. For example, the loss of clinical trial data from completed, ongoing or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for research and development, the manufacture and supply of drug product and drug substance and to conduct clinical trials. We depend on these third parties to implement adequate controls and safeguards to protect against and report cybersecurity incidents. If they fail to do so, we may suffer financial and other harm, including to our information, operations, performance, and reputation. To the extent that any cybersecurity incident or data breach were to result in a loss of, or damage to, our data or systems, or inappropriate disclosure of confidential or proprietary information, we may have an obligation to provide legal notifications and disclosures, and we could incur liability and the further development and commercialization of our product candidates could be delayed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are increasingly dependent on information technology systems and infrastructure, including mobile technologies, to operate our business. Cybersecurity threats, both on premises and in the cloud, are evolving and could occur and result in information theft, data corruption, operational disruption, damage to our reputation, or financial loss. Such threats include, but are not limited to: malicious software, destructive malware, ransomware attacks, denial-of-service attacks, business email compromises, viruses, wrongful intrusions, social engineering (including phishing attacks), attempts to gain unauthorized access to systems or data, data breaches, the unauthorized release of confidential, personal or otherwise protected information, data corruption, the breakdown or damage or interruption of networks or systems from, among other things, natural disasters, terrorism, war, telecommunication and electrical failures, and  harm to individuals. In addition, we could be impacted by cybersecurity threats or other disruptions or vulnerabilities found in products or services we use that are provided to us by third-parties. The risk of a security breach or disruption, particularly through cyberattacks or cyber intrusion, including by computer hackers, cyber criminals, hacktivists, foreign governments, and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. The techniques used by criminal elements to attack computer systems are sophisticated, change frequently and may originate from less regulated and remote areas of the world. As a result, we may not be able to address these techniques proactively or implement adequate preventative measures. These events, if not prevented or effectively mitigated, could damage our reputation, require remedial actions and lead to loss of business, regulatory actions, potential liability and other financial losses.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain data breaches must also be reported to affected individuals and various government and/or regulatory agencies, and in some cases to the media, under provisions of HIPAA, as amended by HITECH, other U.S. federal and state law, and requirements of non-U.S. jurisdictions, including the European Union Data Protection Directive, and financial penalties may also apply.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our privacy and data security obligations. Further, although we maintain cyber liability insurance, this insurance may not provide adequate coverage against potential liabilities related to any experienced cybersecurity incident or data breach. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and defending a suit, regardless of its merit, could be costly and divert management&#8217;s attention.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inadequate funding for the FDA, the Securities Exchange Commission (SEC), the National Institutes of Health (NIH) and other government agencies, including from government shut downs, or other disruptions to these agencies&#8217; operations, could hinder their ability to hire, retain or deploy personnel, and substantial leadership, personnel, and policy changes or otherwise, could prevent new products from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result of these factors. Disruptions at the FDA and other agencies, including substantial leadership, personnel and policy changes, may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. Currently, federal agencies in the U.S. are operating</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under a continuing resolution that is set to expire on March 14, 2025. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Additionally, disruptions at the NIH or changes to the NIH&#8217;s budget may negatively impact our operations and ongoing clinical trials. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to the Ownership of Our Common Stock</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our stock price has been and may continue to be volatile or may decline regardless of our operating performance.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The market price of shares of our common stock has fluctuated in the past and could be subject to wide fluctuations in the future as a result of many risks listed in this section, and other risks beyond our control, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of the initiation of, and progress in, our current and planned clinical trials and preclinical studies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the results of our clinical trials and preclinical studies, and the results of clinical trials and preclinical studies by others for product candidates or indications similar to ours;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments related to the FDA or to regulations applicable to cellular immunotherapies generally or our product candidates in particular including, but not limited to, regulatory pathways and clinical trial requirements for approvals;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments, such as our announcement in January 2023 of the termination of our collaboration with Janssen;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments related to proprietary rights including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additions or departures of key management or scientific personnel;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actual or anticipated changes in our research and development activities and our business prospects, including in relation to our competitors;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments of technological innovations or new therapeutic products by us or others in the field of immunotherapy;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements or expectations of additional equity or debt financing efforts;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales of our common stock by us or by our insiders or our other stockholders;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">comments by securities analysts;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fluctuations in our operating results (including changes related to stock-based compensation from performance-based awards);</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acts of war or periods of widespread civil unrest, including the increasingly volatile global economic conditions resulting from the ongoing global geopolitical tensions, including wars and other armed conflicts; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general economic and market conditions, including inflationary pressures and stock market volatility.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These and other market and industry factors, including the effects of any future public health crises or other public health concerns, wars or other armed conflicts, changes in the regulatory landscape and governmental agency personnel in the United States or similar events resulting from the change in the U.S. presidential administration, and global economic conditions, may cause the market price and demand for our common stock to fluctuate substantially regardless of our actual operating performance, which may limit or prevent investors from readily selling their shares of common stock and may otherwise negatively affect the liquidity of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in our stock price may also trigger financial obligations under our licensing arrangements. For example, pursuant to the terms of the Amended MSKCC License, MSKCC is eligible to receive from us certain milestone payments totaling up to $75.0 million based on the price of our common stock, where the amount of such payments owed to MSKCC is contingent upon certain increases in the price of our common stock following the date of achievement of a specified clinical milestone. In July 2021, we achieved the specified clinical milestone for a licensed product under the Amended MSKCC License and our ten-trading day trailing average common stock price exceeded the first, pre-specified threshold. Accordingly, MSKCC received the first milestone payment of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$20.0 million in November 2021; however, uncertainty of the price of our common stock results in an inability to ascertain the precise timing of any remaining future milestone payments in advance.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, a decrease in our stock price may cause our common stock to no longer satisfy the continued listing standards of Nasdaq. If we are not able to maintain the requirements for listing on Nasdaq, our common stock could be delisted, which could have a materially adverse effect on our ability to raise additional funds as well as the price and liquidity of our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and may be able to exercise significant control over our company.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 25, 2025, our executive officers, directors and entities affiliated with our five percent stockholders beneficially own, in the aggregate, shares representing approximately 42.9% of our outstanding voting stock. If, in accordance with the CoD (as such term is defined in Note 9 of the notes to the consolidated financial statements herewith) relating to the Class A Convertible Preferred Stock, Redmile (as such term is defined in Note 9 of the notes to the consolidated financial statements herewith) elects to remove certain limitations on the percentage of our outstanding common stock that it may own such that the 2,755,086 shares of Class A Convertible Preferred Stock currently held by Redmile become fully convertible at Redmile&#8217;s option into 13,775,430 shares of common stock, the beneficial ownership of our executive officers, directors and entities affiliated with our five percent stockholders would increase to 46.7%. Although we are not aware of any voting arrangements in place among these stockholders, if these stockholders were to choose to act together, as a result of their stock ownership, they would be able to influence our management and affairs and control all matters submitted to our stockholders for approval, including the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of ownership may have the effect of delaying or preventing a change in control of our company that our other stockholders may believe are in their best interests, or adversely affecting the liquidity, volatility, and market price of our common stock. For example, if any of our directors, executive officers or other entities affiliated with our five percent stockholders elect to sell, transfer or otherwise dispose of a significant amount of shares of our common stock, this could result in a decrease in our stock price. Furthermore, any transferees or successors of all or a significant portion of our existing stockholders&#8217; ownership in us will be able to exert a similar amount of control over us through their ownership position.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may sell additional equity or debt securities or enter into other arrangements to fund our operations, which may result in dilution to our stockholders and impose restrictions or limitations on our business. Issuances of common stock or rights to purchase common stock under our equity incentive plans could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that significant additional capital will be needed in the future to continue our planned operations, and we may seek additional funding through a combination of equity offerings, debt financings, state or government grants, strategic alliances, licensing and collaboration arrangements, or other third-party business arrangements. These financing activities may have an adverse effect on our stockholders&#8217; rights, the market price of our common stock and on our operations and may require us to relinquish rights to some of our technologies, intellectual property or product candidates, issue additional equity or debt securities, or otherwise agree to terms unfavorable to us. Further, in November 2023, we filed a registration statement on Form S-3 pursuant to which we were initially eligible to issue and sell up to $300.0 million in common stock, preferred stock, debt securities, warrants and/or units, in one or more series or classes, including up to $100.0 million in shares of common stock that may be issued in sales deemed to be an &#8220;at the market offering&#8221; as defined by the Securities Act of 1933, as amended (the Securities Act). In March 2024, we issued and sold 14,545,454 shares of our common stock at a purchase price of $5.50 per share in an underwritten offering pursuant to the shelf registration statement for aggregate gross proceeds of approximately $80.0 million. Accordingly, we are currently eligible to issue an aggregate of approximately $220.0 million under the shelf registration statement (including the $100.0 million issuable in &#8220;at the market offerings&#8221;). Any sale or issuance of securities pursuant to a registration statement or otherwise may result in dilution to our stockholders and may cause the market price of our stock to decline, and new investors could gain rights superior to our existing stockholders. In addition, any debt financings that we may enter into in the future may subject us to unfavorable repayment terms, including increased interest rates, impose restrictive covenants or otherwise adversely affect the holdings or the rights of our stockholders, and any additional equity financings will be dilutive to our stockholders. Furthermore, additional equity or debt financing might not be available to us on reasonable terms, if at all.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to our 2022 Stock Option and Incentive Plan (as amended and restated, the &#8220;2022 Plan&#8221;) we are authorized to grant stock options and other equity-based awards to our employees, officers, directors and consultants. The 2022 Plan authorizes the issuance of up to 17.5 million shares. We also make equity grants to new employees joining our company pursuant to an inducement plan, and our board of directors may elect to increase the number of shares available for future grants under the inducement plan without stockholder approval. If our board of directors elects in the future to increase the number of shares available for future grant</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and, in the case of the 2022 Plan, if our stockholders approve of any such future increase, our stockholders may experience additional dilution, and our stock price may fall.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A significant portion of our total outstanding shares may be sold into the market in the near future, which could cause the market price of our common stock to drop significantly.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. A significant portion of our outstanding shares of common stock are held by a small number of stockholders, including our directors, officers and significant stockholders. Sales by our stockholders of a substantial number of shares, or the expectation that such sales may occur, could significantly reduce the market price of our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, we registered all of the 5,250,000 shares of common stock issued by us in our August 2016 private placement transaction for resale on a Form S-3, which was declared effective by the SEC in September 2016. We also registered all of the 6,766,915 shares of common stock issued by us and all 14,097,745 shares of common stock issuable upon the conversion of an aggregate of 2,819,549 shares of Class A Convertible Preferred Stock issued by us in our November 2016 private placement transaction for resale on a Form S-3, which was declared effective by the SEC in January 2017. Additionally, we have registered the shares of common stock issued to Johnson &amp; Johnson Innovation &#8211; JJDC, Inc. under the stock purchase agreement entered into in June 2020 in connection with the Janssen Agreement pursuant to a registration statement on Form S-3. Moreover, we registered all of the 5,380,117 shares of common stock issued by us and all of the 257,310 prefunded warrants to purchase common stock in our public offering in January 2021. We registered all of the 14,545,454 shares of common stock issued by us in our underwritten offering in March 2024. In addition, we registered for resale all of the 3,636,364 shares of common stock issuable upon exercise of the pre-funded warrants sold in the concurrent private placement in March 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have also registered or intend to register all shares of our common stock subject to options, restricted stock units or other equity awards issued or reserved for future issuance under our equity incentive plans. As a result, these shares will be available for sale in the public market subject to vesting arrangements and exercise of options, and restrictions under applicable securities laws. In addition, certain of our executive officers, directors, employees and affiliates have established and may in the future establish programmed selling plans under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the Exchange Act), for the purpose of effecting sales of our common stock. If any of these events cause a large number of our shares to be sold in the public market, the sales could reduce the trading price of our common stock and impede our ability to raise future capital.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Provisions of Delaware law or our charter documents could delay or prevent an acquisition of our company, and could make it more difficult for you to change management.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions of Delaware law, our amended and restated certificate of incorporation, and our amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions may also prevent or delay attempts by stockholders to replace or remove our current management or members of our board of directors. These provisions include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a classified board of directors with limitations on the removal of directors;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advance notice requirements for stockholder proposals and nominations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability of stockholders to act by written consent or to call special meetings;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability of our board of directors to make, alter or repeal our amended and restated bylaws; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the authority of our board of directors to issue preferred stock with such terms as our board of directors may determine.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us. Any provision of our amended and restated certificate of incorporation or amended and restated bylaws or Delaware law that has the effect of delaying or discouraging a potential acquisition proposal or tender offer could limit the opportunity for our stockholders to achieve liquidity for their shares of our common stock, even if the acquisition proposal or tender offer is at a premium over the then-current market price for our common stock, and could also affect the price that some investors are willing to pay for our common stock.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our amended and restated bylaws designate the Court of Chancery of the State of Delaware and the U.S. federal district courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to litigate disputes with us in a different judicial forum.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to our amended and restated bylaws, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i) any derivative action or proceeding brought on our behalf; (ii) any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, or employees to us or our stockholders; (iii) any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware, our amended and restated certificate of incorporation or our amended and restated bylaws; or (iv) any action asserting a claim governed by the internal affairs doctrine. This exclusive forum provision will not apply to any causes of action arising under the Securities Act. Unless we consent in writing to the selection of an alternate forum, the U.S. federal district courts shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. The forum selection clause in our amended and restated bylaws may limit our stockholders&#8217; ability to litigate disputes with us in a different judicial forum. While the Delaware courts have determined that these types of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we may incur significant additional costs associated with resolving the dispute in other jurisdictions, and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A sustained decline in our stock price may result in an impairment indication which could have an adverse impact on our results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any significant change in market conditions, including a sustained decline in our stock price, that indicate a reduction in carrying value may give rise to indicators of impairment in the period that the change becomes known. For example, as of December 31, 2024, we identified an indicator of impairment of our long-lived assets due to a sustained decline in the trading price of our common stock over the preceding year, resulting in the our market capitalization being below its net asset value. As a result of the fair value analysis, we recorded a $13.4 million impairment charge against property and equipment and a $1.3 million impairment charge against the right-of-use asset in the statement of operations during the year ended December 31, 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We currently qualify as a &#8220;smaller reporting company&#8221; and a &#8220;non-accelerated filer,&#8221; and any decision on our part to comply only with certain reduced reporting and disclosure requirements applicable to such companies could make our common shares less attractive to investors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of our public float (the market value of our common shares held by non-affiliates) as of June 30, 2024, we qualify as a &#8220;smaller reporting company,&#8221; as defined under the Exchange Act. In addition, we are a &#8220;non-accelerated filer&#8221; as defined under the Exchange Act. For as long as we continue to be a smaller reporting company or a non-accelerated filer, we may choose to take advantage of exemptions from various reporting requirements applicable to other public companies that are not smaller reporting companies or non-accelerated filers, as applicable, including, but not limited to, an exemption from the requirement that our independent registered public accounting firm attest to the design and operating effectiveness of our internal controls over financial reporting under Section 404(b) of the Sarbanes-Oxley Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we choose to rely on any of these reporting and disclosure exemptions, the information we provide stockholders will be different than the information that is available with respect to many other public companies. Moreover, if some investors find our common stock less attractive as a result of any choices to reduce future disclosure or have an independent review and attestation of our internal control over financial reporting, there may be a less active trading market for our common stock and the market price of our common stock may be more volatile.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to use our net operating loss carryforwards and certain other tax benefits may be limited and, as a result, our future tax liability may increase.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had federal and state net operating loss carryforwards of $689.2 million and $644.2 million, respectively, some of which begin to expire in various amounts in 2027 and 2028, respectively. As of December 31, 2024, we also had federal and California research and development tax credit carryforwards of $45.6 million and $37.8 million, respectively. The federal research and development tax credit carryforwards will begin to expire in 2035 unless previously utilized, while the California carryforwards will carry forward indefinitely. These net operating loss and tax credit carryforwards could expire unused and be unavailable to offset future income tax liabilities. In addition, in general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its pre-change net operating losses (NOLs) or tax credits, or NOLs or credits, to offset future taxable income or taxes. Generally, a change of more</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">than 50 percentage points in the ownership of a corporation&#8217;s stock, by value, over a three-year period constitutes an ownership change for U.S. federal income tax purposes. We have determined that we triggered an ownership change limitation in November 2009 and again in May 2015. We have determined that we do not believe there were any ownership changes from May 2015 through December 2024. We have not analyzed periods subsequent to December 2024. We may experience additional ownership changes as a result of shifts in our stock ownership in the future. Limits on our ability to use our pre-change NOLs or credits to offset U.S. federal taxable income could potentially result in increased future tax liability to us if we earn net taxable income in the future. The amount of NOLs generated in taxable periods beginning after December 31, 2024, that we are permitted to deduct in any taxable year is limited to 80% of our taxable income in such year, where taxable income is determined without regard to the NOL deduction itself. U.S. federal and certain state NOLs generated in taxable years beginning after December 31, 2017 are not subject to expiration.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Risk Factors</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are and could be further subject to securities class action litigation and other types of stockholder litigation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The stock market in general, and the Nasdaq Global Market and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. For example, in January 2023, a purported stockholder filed a lawsuit against us and certain of our officers captioned Hadian v. Fate Therapeutics, Inc. et al. in the U.S. District Court for the Southern District of California and two derivative actions were filed in the same court in June 2023 and June 2024, respectively (see </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8220;Item 3. Legal Proceedings&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for a more detailed description of this matter). We could also be subject to other types of litigation, which may involve claims of breach of fiduciary duties by our directors or officers for misuse/mismanagement of company assets/resources or conflicts of interest. Any such litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results, or financial condition. Additionally, the dramatic increase in the cost of directors&#8217; and officers&#8217; liability insurance may cause us to opt for lower overall policy limits or to forgo insurance that we may otherwise rely on to cover significant defense costs, settlements, and damages awarded to plaintiffs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business operations may subject us to disputes, claims and lawsuits, which may be costly and time-consuming and could materially and adversely impact our financial position and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may become involved in disputes, claims and lawsuits relating to our business operations. For example, we have in the past and we may, from time to time, face or initiate claims related to intellectual property matters, employment matters, or commercial disputes. Any dispute, claim or lawsuit may divert management&#8217;s attention away from our business, we may incur significant expenses in addressing or defending any dispute, claim or lawsuit, and we may be required to pay damage awards or settlements or become subject to equitable remedies that could adversely affect our operations and financial results. Litigation related to these disputes may be costly and time-consuming and could materially and adversely impact our financial position and results of operations if resolved against us. In addition, the uncertainty associated with litigation could lead to increased volatility in our stock price.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to invest in and expand our business and meet our financial obligations, to attract and retain third-party contractors and collaboration partners and to raise additional capital depends on our operating and financial performance, which, in turn, is subject to numerous factors, including the prevailing economic and political conditions and financial, business, regulatory and other factors beyond our control, such as the rate of unemployment, rate of inflation, the number of uninsured persons in the United States, political influences and inflationary pressures, and fluctuations in costs, particularly due to changes in labor costs and material costs. For example, an overall decrease in or loss of insurance coverage among individuals in the United States due to high levels of unemployment, underemployment or the repeal of certain provisions of the ACA may decrease the demand for healthcare services and pharmaceuticals. If fewer patients are seeking medical care because they do not have insurance coverage or are unable to obtain medical care for their conditions due to resource constraints on the healthcare system, we may experience difficulties in any eventual commercialization of our product candidates and our business, results of operations, financial condition and cash flows could be adversely affected. In addition, if we are unable to manage cost fluctuations and inflationary pressures, including prices of materials, costs of labor, it may adversely impact our operating performance, expenses and results.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets upon which pharmaceutical and biopharmaceutical companies such as us are dependent for sources of capital. In the past, global financial crises have caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">economic downturn, ongoing and emerging global geopolitical tensions, including wars or other armed conflicts, interest rate fluctuations, rising inflation rates or recession, could result in a variety of risks to our business, including a reduced ability to raise additional capital when needed on acceptable terms, if at all, and weakened demand for our product candidates. A weak or declining economy, and rising inflation could also strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which ongoing wars and other armed conflicts, current economic climate and financial market conditions could adversely impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Significant political, trade, regulatory developments, and other circumstances beyond our control, could have a material adverse effect on our financial condition or results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to expand our clinical operations to countries other than the U.S., and are developing products for regulatory approval and sale in countries throughout the world. Significant political, trade, or regulatory developments in the jurisdictions in which we may conduct clinical trials, develop, or sell our products, such as those stemming from the change in U.S. federal administration, are difficult to predict and may have a material adverse effect on us. Similarly, changes in U.S. federal policy that affect the geopolitical landscape could give rise to circumstances outside our control that could have negative impacts on our business operations. For example, on February 1, 2025, the U.S. imposed a 25% tariff on imports from Canada and Mexico, which were subsequently suspended for a period of one month, and a 10% additional tariff on imports from China. Historically, tariffs have led to increased trade and political tensions. In response to tariffs, other countries have implemented retaliatory tariffs on U.S. goods. Political tensions as a result of trade policies could reduce trade volume, investment, technological exchange and other economic activities between major international economies, resulting in a material adverse effect on global economic conditions and the stability of global financial markets. Any changes in political, trade, regulatory, and economic conditions, including U.S. trade policies, could have a material adverse effect on our financial condition or results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Volatility in capital markets and lower market prices for our securities may affect our ability to access new capital through sales of shares of our common stock or issuance of indebtedness, which may harm our liquidity, limit our ability to grow our business, pursue acquisitions or improve our operating infrastructure and restrict our ability to compete in our markets.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operations consume substantial amounts of cash, and we intend to continue to make significant investments to support our business growth, respond to business challenges or opportunities, develop new product candidates, retain or expand our current levels of personnel, improve our existing products, enhance our operating infrastructure, and potentially acquire complementary businesses and technologies. Our future capital requirements may be significantly different from our current estimates and will depend on many factors, including the need to:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">finance unanticipated working capital requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue the research and development or our existing product candidates and develop or enhance our technological infrastructure;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pursue acquisitions, in-licenses or other strategic relationships; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">respond to competitive pressures.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, we may need to pursue equity or debt financings to meet our capital needs. With uncertainty in the capital markets and other factors, such financing may not be available on terms favorable to us or at all. If we raise additional funds through further issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences, and privileges superior to those of holders of our common stock. Any debt financing secured by us in the future could involve additional restrictive covenants relating to our capital-raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. If we are unable to obtain adequate financing or financing on terms satisfactory to us, we could face significant limitations on our ability to invest in our operations and otherwise suffer harm to our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recent volatility in interest rates could affect our ability to obtain working capital through borrowings such as bank credit lines and public or private sales of debt securities, which may result in lower liquidity, reduced working capital and other adverse impacts on our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To meet our liquidity needs, we have previously relied, in part, on borrowed funds, and may do so again in the future. Continued volatility in interest rates will impact the cost of new indebtedness and could materially and adversely affect our results of operations, financial condition, liquidity and cash flows.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Increasing scrutiny and changing expectations from governments and third-parties relating to environmental, social and governance (ESG) policies and practices may cause us to incur additional costs, expose us to additional risks or impact our reputation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In recent years, there has been increasing public focus and scrutiny from certain investors, employees and other stakeholders concerning corporate responsibility, specifically related to ESG factors. In addition to the changing rules and regulations related to ESG matters imposed by governmental and self-regulatory organizations, a variety of third-party organizations, institutional investors and customers evaluate the performance of companies on ESG topics, and the results of these assessments are widely publicized. These changing rules, regulations and stakeholder expectations have resulted in, and are likely to continue to result in, increased general and administrative expenses and increased management time and attention spent complying with or meeting such regulations and expectations. Reduced access to or increased cost of capital may occur as financial institutions and investors increase expectations related to ESG matters. Third-party providers of ESG ratings and reports on companies have increased in number, resulting in varied and, in some cases, inconsistent standards and frameworks. Topics taken into account in such assessments include, among others, our efforts and impacts with respect to climate change and the role of our board of directors in supervising various sustainability issues.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Developing and acting on initiatives within the scope of ESG, and collecting, measuring and reporting ESG-related information and metrics can be costly, difficult and time consuming and is subject to evolving reporting standards. We may also communicate certain initiatives and goals, regarding environmental matters, diversity, social investments and other ESG-related matters, in our SEC filings or in other public disclosures. These initiatives and goals within the scope of ESG could be difficult and expensive to implement, the technologies needed to implement them may not be cost effective and may not advance at a sufficient pace, and we could be criticized for the accuracy, adequacy or completeness of the disclosure. Furthermore, statements about our ESG-related initiatives and goals, and progress against those goals, may be based on standards for measuring progress that are still developing, internal controls and processes that continue to evolve and assumptions that are subject to change in the future. In addition, we could be criticized for the scope or nature of such initiatives or goals, or for any revisions to these goals. If our ESG-related data, processes and reporting are incomplete or inaccurate, or if we fail to achieve progress with respect to our goals, including our previously announced commitments to reduce greenhouse gas emissions, within the scope of ESG on a timely basis, or at all, our reputation, business, financial performance and growth could be adversely affected. In addition, in recent years &#8220;anti-ESG&#8221; sentiment has gained momentum across the U.S., with several states and Congress having proposed or enacted &#8220;anti-ESG&#8221; policies, legislation, or initiatives or issued related legal opinions, and the President having recently issued an executive order opposing diversity equity and inclusion (&#8220;DEI&#8221;) initiatives in the private sector. Such anti-ESG and anti-DEI-related policies, legislation, initiatives, litigation, legal opinions, and scrutiny could result in the Company facing additional compliance obligations, becoming the subject of investigations and enforcement actions, or sustaining reputational harm.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our business practices do not meet evolving investor, government agency or other stakeholder expectations and standards with respect to ESG, then our reputation, our ability to attract or retain employees and the market price of our securities could be negatively impacted. New governmental regulations could result in new directives and new or more stringent forms of ESG oversight and disclosures which may lead to increased expenditures for sustainability initiatives, which in turn could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common stock to decline.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and its financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, on March 10, 2023, Silicon Valley Bank (SVB) was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (FDIC) as receiver. Similarly, on March 12, 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. In these cases borrowers under credit agreements, letters of credit and certain other financial instruments with SVB, Signature Bank or any other financial institution that is placed into receivership by the FDIC may be unable to access undrawn amounts thereunder. We currently use deposit accounts to fund our operations and other financial instruments such as cash-collateralized letters of credit associated with our facilities leases. Our excess cash is invested according to a restrictive investment policy within custodial accounts at various financial institutions. If any of the financial institutions that hold our deposit accounts were to be placed into receivership, we may be unable to access the funds in those accounts, which could result in liquidity constraints or failures. In addition, if any of our collaboration partners, suppliers or other parties with whom we conduct business are unable to access funds pursuant to such instruments or lending arrangements with such a financial institution, such parties&#8217; ability to pay their obligations to us or to enter into</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">new commercial arrangements requiring additional payments to us could be adversely affected. In this regard, counterparties to SVB credit agreements and arrangements, and third parties such as beneficiaries of letters of credit (among others), may experience direct impacts from the closure of SVB, or the sale of its assets, and uncertainty remains over liquidity concerns in the broader financial services industry. Similar impacts have occurred in the past, such as during the 2008-2010 financial crisis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inflation and rapid increases in interest rates have led to a decline in the trading value of previously issued government securities. Although the U.S. Department of Treasury, FDIC and Federal Reserve Board have announced a program to provide up to $25 billion of loans to financial institutions secured by certain of such government securities held by financial institutions to mitigate the risk of potential losses on the sale of such instruments, widespread demands for customer withdrawals or other liquidity needs of financial institutions for immediately liquidity may exceed the capacity of such program. Additionally, there is no guarantee that the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions, or that they would do so in a timely fashion.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we assess our banking and other business relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect us, the financial institutions with which we have credit agreements or arrangements directly, or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could involve financial institutions with which we have financial or business relationships but could also include factors involving financial markets or the financial services industry generally.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The results of events or concerns that involve one or more of these factors could include a variety of material and adverse impacts on our current and projected business operations and our financial condition and results of operations. These could include, but may not be limited to, the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial assets; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delayed or lost access to, or reductions in borrowings available under working capital sources and/or delays, inability or reductions in our ability to refund, roll over or extend the maturity of, or enter into new working capital resources.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our current and/or projected business operations and financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, any further deterioration in the macroeconomic economy or financial services industry could lead to losses or defaults by our collaboration partners, suppliers or other parties with whom we do business, which in turn, could have a material adverse effect on our current and/or projected business operations and results of operations and financial condition. Any bankruptcy or insolvency of a collaboration partner, supplier or other party with whom we do business, or the failure of any such party to make payments when due, or any breach or default by any such party, or the loss of any significant commercial relationships, could result in material losses to us and may have a material adverse impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Geopolitical risks associated with ongoing wars and armed conflicts could have an adverse impact on our business, financial condition and results of operations, including our clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are ongoing and emerging geopolitical tensions, including wars and other armed conflicts, and although the conflicts have had little direct impact on our business to date, the uncertainty and ripple effects created by these conflicts may have unknown indirect impacts. For instance, the ongoing conflicts have resulted in significant volatility in certain equity, debt and currency markets, material increases in certain commodity prices, and economic uncertainty. Global conflicts, including Russia&#8217;s invasion of Ukraine, conflicts in the Middle East, and heightened tensions in the Pacific region, have significantly elevated global geopolitical tensions and security concerns.  It is not possible to predict the broader or longer-term consequences of these conflicts, although a prolonged conflict may</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">result in adverse effects on microeconomic conditions including inflation; disruptions to our global technology infrastructure, including through cyberattack, ransom attack, or cybersecurity-intrusion; adverse changes in international trade policies and relations; disruptions in global supply chains; our exposure to foreign currency fluctuations; and constraints, volatility, or disruption in the capital markets, any of which could negatively impact our business, financial performance and financial condition. Economic sanctions imposed by the United States, Canada, EU, and other countries in response to the ongoing conflicts and the potential response to such sanctions may also have an adverse impact our business, including our clinical trials and supply chain, the financial markets and the global economy.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continue to monitor any adverse impact that the outbreak of war and the subsequent institution of sanctions by the United States and other countries may have on the global economy in general, on our business and operations and on the businesses and operations of our suppliers and third parties with whom we conduct business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We or the third parties upon whom we depend may be adversely affected by earthquakes, wildfires, power outages, or other natural disasters, including public health crises, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our facilities are located in San Diego, California, which is a seismically active region, and has also historically been subject to wildfires and electrical blackouts. Earthquakes, wildfires, power outages, or other natural disasters (including due to the effects of climate change or any public health crises) could severely disrupt our operations, or the operations of third parties upon whom we depend, and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our manufacturing facilities or those of our CMOs, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. For example, clinical supplies of our NK and T-cell therapeutic product candidates, as well as the working and master cell banks from which these product candidates are manufactured, are maintained in freezers at our manufacturing facility and at third-party biorepositories. If these materials are damaged at our facility or at the facilities of our third-party repositories, including as a result of a power outage or natural disaster, clinical supply of our product candidates may be impacted and our clinical trials may be delayed. Further, any measures taken by governmental authorities or businesses in response to any public health crisis, such as quarantines, stay-at-home orders or travel restrictions, could adversely affect our business, operations, financial condition, prospects or results of operations by restricting our ability to conduct our clinical trials and research and development activities, and limiting our and our third-party manufacturers&#8217; ability to manufacture product and forcing temporary closure of our facilities and facilities that we rely upon. The disaster recovery and business continuity plans we and our third-party biorepositories have in place currently may be limited and may not prove adequate for protecting and continuing our business in the event that our business is disrupted as a result of a public health crisis or other serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans which could have a material adverse effect on our business. Any insurance we maintain against such risks may not be adequate to cover losses in any particular case.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to maintain an effective system of disclosure controls and procedures and internal controls, our ability to produce accurate financial statements or comply with applicable regulations could be impaired.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a public company, we are required to comply with the Sarbanes-Oxley Act of 2002, as amended (the Sarbanes-Oxley Act), and the related rules and regulations of the SEC, expanded disclosure requirements, accelerated reporting requirements and more complex accounting rules. Company responsibilities required by the Sarbanes-Oxley Act include establishing and maintaining corporate oversight and adequate internal control over financial reporting and disclosure controls and procedures. Effective internal controls are necessary for us to produce reliable financial reports and are important to help prevent financial fraud.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot assure that we will not have material weaknesses or significant deficiencies in our internal control over financial reporting. If we are unable to successfully remediate any material weakness or significant deficiency in our internal control over financial reporting, or identify any material weaknesses or significant deficiencies that may exist, the accuracy and timing of our financial reporting may be adversely affected, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements, and our stock price may decline materially as a result.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with environmental, health, and safety laws and regulations, including regulations governing the handling, storage or disposal of hazardous materials, we could become subject to fines or penalties or incur costs that could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to numerous environmental, health, and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment, and disposal of hazardous materials and wastes. Our operations involve the use of hazardous materials, including chemicals, biological materials and infectious agents. Our operations also may produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We will not be able to eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from any use by us of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may incur substantial costs in order to comply with current or future environmental, health, and safety laws and regulations. These current or future laws and regulations may impair our research, development, or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in tax law may adversely affect us or our investors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service (IRS) and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. For example, the Tax Cuts and Jobs Act was enacted in 2017 and made significant changes to corporate taxation, including the reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, the limitation of the tax deduction for net interest expense to 30% of adjusted taxable income (except for certain small businesses), the limitation of the deduction for net operating losses to 80% of current year taxable income and the elimination of net operating loss carrybacks (though any such net operating losses may be carried forward indefinitely), and the modification or repeal of many business deductions and credits. In addition, under Section 174 of the Internal Revenue Code of 1986, as amended, in taxable years beginning after December 31, 2021, expenses that are incurred for research and development in the U.S. will be capitalized and amortized, which may have an adverse effect on our cash flow. It cannot be predicted whether, when, in what form, or with what effective dates, tax laws, regulations and rulings may be enacted, promulgated or issued, which could result in an increase in our or our stockholders&#8217; tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 1B. Unresolve</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d Staff Comments</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not Applicable.</span></p>
  <div><ix:nonNumeric id="F_02dbb3b3-1e31-4b08-9303-32d3d0e71595" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" escape="true" continuedAt="F_02dbb3b3-1e31-4b08-9303-32d3d0e71595_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 1C. Cybersecurity</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b81ddda9-7bc4-4dce-8b4b-1c285b50bc9a" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6e8f4496-6196-4b51-b30f-04ccb6a49c69" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">implemented</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and maintain a cybersecurity risk management program that includes processes for the identification, assessment, and mitigation of cybersecurity risks.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ef8f26d4-d948-4ebf-b2ca-b61519a10371" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conduct annual cybersecurity training for all of our employees and periodically </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_57cc5f09-5801-4ff8-8864-4b6a2d6e940c" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engage </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party consultants to conduct penetrating testing and vulnerability assessments. Additionally, we use automated tools designed to monitor, identify, and address cybersecurity risks. Further, we have a process to evaluate and review the cybersecurity practices of our key vendors prior to onboarding, including through a general security assessment and contractual requirements, as appropriate.</span></ix:nonNumeric></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face a number of cybersecurity risks in connection with our business. Although such risks have </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6c903752-7656-4550-b27d-f544d745ab4b" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not materially</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> affected us, including our business strategy, results of operations or financial condition, to date, we have, from time to time, experienced threats to and breaches of our data and systems, including malware and computer virus attacks. For more information about the cybersecurity risks we face, see the risk factors entitled &#8220;Our business could be negatively affected by cyberattacks or a deficiency in our cybersecurity system and infrastructure&#8221; and &#8220;Our internal computer systems, or those used by our third-party research institution collaborators, CROs or other contractors or consultants, may fail or suffer security breaches&#8221; in Item 1A- Risk Factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_02dbb3b3-1e31-4b08-9303-32d3d0e71595_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_48506c07-4c4e-4e1c-84c1-c1330fdab3da" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governance Related To Cybersecurity Risks</span></p><div><ix:nonNumeric id="F_c4c87428-256a-4adf-a2e6-b23eccb62a56" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0f071a69-7750-413c-a208-a8a73e64531b" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity process is overseen by our Information Technology department, which is managed by our Head of IT. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e59d3a6e-6022-4f66-b650-983ebd418718" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Head of IT role is currently held by an individual who has approximately two decades of professional IT management experience.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In addition, our Security Leadership Team (SLT), which is comprised of the Head of IT as well as leaders from our operations, finance, and legal departments, is responsible for documenting, reviewing, and assessing our cybersecurity processes, monitoring for cybersecurity incidents, and periodically reporting on cybersecurity risks and risk management to a committee of our executive team (Executive Committee). </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_58c6a48a-bcf2-4a5f-9bc6-b39b0788a060" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" escape="true" continuedAt="F_58c6a48a-bcf2-4a5f-9bc6-b39b0788a060_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Executive Committee, which is led by our </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_37cdeb37-814c-4d66-89f0-8b760b5ececa" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, undertakes reviews of our cybersecurity program and assesses any security incident updates from the SLT on a quarterly basis.</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_58c6a48a-bcf2-4a5f-9bc6-b39b0788a060_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></ix:continuation></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bb869a86-cf20-487f-ab00-4117118c898c" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Executive Committee meets with the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d633354a-5aae-43a6-955c-7a662389e2c6" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audit Committee</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of our Board of Directors on a quarterly basis to report on and discuss material updates to our cybersecurity program.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fcc9aaf2-1e38-4927-bdeb-0350138f3380" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee provides oversight of our cybersecurity program as part of its periodic review of enterprise risk management and provides regular reports to our Board of Directors regarding our cybersecurity processes, including updates on the status of ongoing cybersecurity projects, the results of cybersecurity risk assessments, and the emerging cybersecurity threat landscape.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Additionally, the Board of Directors reviews the enterprise risk management program on at least an annual basis.</span></p></ix:nonNumeric></div></ix:nonNumeric></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 2. Pr</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">operties</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Facilities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we occupied approximately 200,000 square feet of office, laboratory and Good Manufacturing Practice (GMP) manufacturing space at our corporate headquarters in San Diego, California under a non-cancelable operating lease through May 2036. We believe that this facility is adequate for our current needs. In addition, we have additional operating leases for office and laboratory space in San Diego, California.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 3. Legal</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Proceedings</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the reporting period, we pursued claims in two lawsuits that we filed in 2022 against Shoreline Biosciences, Inc. (Shoreline) and certain of its founders and officers (collectively, the Shoreline litigations). The first suit, filed on May 13, 2022, was pending in San Diego Superior Court against Shoreline and four of its founders, Drs. Dan S. Kaufman (Kaufman), Kleanthis G. Xanthopoulos, and Messrs. William Sandborn and Steven Holtzman. Our claims included actions for breach of contract, breach of implied covenant of good faith and fair dealing, fraud and deceit, tortious interference, restitution and unfair competition. On August 9, 2024, the court denied the defendants&#8217; motions for summary judgment preserving for trial all of Fate&#8217;s claims against the defendants, with the exception of defendants&#8217; motions with respect to certain theories under Fate&#8217;s tortious interference claim (which claim by Fate was otherwise preserved for trial). On September 19, 2024, the court denied defendants&#8217; motion for reconsideration of its summary judgment ruling. Trial began on October 21, 2024, with a jury selected on October 24, 2024. On October 28, 2024, the parties entered a settlement agreement resolving the litigation on terms agreeable to all parties, pursuant to which we filed a request for dismissal with prejudice of all claims on October 31, 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the second of the Shoreline litigations, also filed on May 13, 2022, we and Whitehead Institute for Biomedical Research (Whitehead) filed a lawsuit in the U.S. District Court for the Southern District of California against Shoreline and Kaufman seeking monetary damages for the defendants&#8217; infringement of U.S. Patent Nos. 8,071,369, 8,932,856, 8,951,797, 8,940,536, 9,169,490, 10,457,917, and 10,017,744. On June 7, 2023, we and Whitehead filed a motion to dismiss our patent infringement claims against Kaufman in his personal capacity; that motion was granted on June 9, 2023. On August 30, 2023, the court granted Shoreline&#8217;s motion for summary judgment and denied our motion for partial summary judgment as moot. Judgment in favor of Shoreline was entered on August 31, 2023. On September 27, 2023, we and Whitehead filed a Notice of Appeal with the Court of Appeals for the Federal Circuit challenging the trial court&#8217;s claim construction and grant of summary judgment in favor of the defendants; the defendants cross-appealed challenging the district court&#8217;s earlier denial of a motion to dismiss and partial motion for summary judgment on other grounds. The Federal Circuit docketed the case on October 5, 2023, and briefing was completed on June 26, 2024. On October 28, 2024, the parties entered a settlement agreement resolving the litigation on terms agreeable to all parties, pursuant to which the parties filed a joint notice of dismissal of the appeal and cross-appeal on October 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 20, 2023, a purported stockholder of the Company filed a securities class action lawsuit against the Company and certain of its officers captioned Hadian v. Fate Therapeutics, Inc. et al. in the U.S. District Court for the Southern District of California (the Securities Action). On May 4, 2023, the court appointed a different purported stockholder of the Company to serve as lead plaintiff in the Securities Action. On July 24, 2023, the lead plaintiff filed an amended complaint. The amended complaint alleged that the Company violated the federal securities laws by making allegedly false and/or misleading statements and/or omissions in its public disclosures dating back to August 2020 relating to our collaboration agreement with Janssen Biotech, Inc. (the Janssen Agreement), potential product candidates subject to the Janssen Agreement, and the termination of the Janssen Agreement. On September 22, 2023, we filed a motion to dismiss the amended complaint. On September 19, 2024, the court granted our motion to dismiss the amended</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">complaint, with leave for plaintiff to file a second amended complaint. On October 18, 2024, the lead plaintiff filed a second amended complaint alleging substantially similar facts and claims as in the prior amended complaint. We filed a motion to dismiss the second amended complaint on November 18, 2024, and briefing on the motion was completed on January 21, 2025. We intend to continue to vigorously defend against this action.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 2, 2023, a derivative complaint, captioned Guarino v. Wolchko, et al., was filed by a purported stockholder of the Company in the U.S. District Court for the Southern District of California (the Guarino Action). On June 12, 2024, an additional derivative complaint, captioned Horrobin v. Wolchko, et al., was filed by a purported stockholder of the Company in the same district (the Horrobin Action). On December 3, 2024, the court entered an order consolidating the Guarino Action and the Horrobin Action under the caption In re Fate Therapeutics, Inc. Derivative Litigation (the Derivative Action) and staying the Derivative Action pending the court&#8217;s decision on our motion to dismiss the second amended complaint in the Securities Action. The court&#8217;s ruling on the motion is pending. The Derivative Action names members of our board of directors and certain officers as defendants. The Company is also named as a nominal defendant. The plaintiffs in the Derivative Actions assert derivative claims arising out of substantially the same alleged facts and circumstances as the Securities Action. The Guarino complaint asserts claims for breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and violation of federal securities laws. The Horrobin complaint asserts substantially similar claims in addition to a claim of breach of fiduciary duty for insider trading. We intend to vigorously defend against the Derivative Action.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may be subject to various other legal proceedings and claims that arise in the ordinary course of our business activities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 4. Mine Saf</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ety Disclosures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> II</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 5. Market for Registrant&#8217;s Common Equity, Related Sto</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ckholder Matters and Issuer Purchases of Equity Securities</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ticker symbol is &#8220;FATE&#8221;, as traded and reported by The NASDAQ Global Market.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of Common Stock</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 25, 2025, there were approximately 17 stockholders of record of our common stock. The approximate number of holders is based upon the actual number of holders registered in our records at such date and excludes holders in &#8220;street name&#8221; or persons, partnerships, associations, corporations, or other entities identified in security positions listings maintained by depository trust companies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never declared or paid any dividends on our capital or common stock. We currently intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay dividends will be made at the discretion of our board of directors.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Authorized for Issuance under Equity Compensation Plans</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information about our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, we did not issue or sell any unregistered securities not previously disclosed in a Quarterly Report on Form 10-Q or in a Current Report on Form 8-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issuer Purchases of Equity Securities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We did not repurchase any securities during the year ended December 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_selected_financial_data"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 6. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reserved]</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 7. Management&#8217;s Discussion and Analysis of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Financial Condition and Results of Operations</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes included under Item 8 of this Annual Report on Form 10-K. The following discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those expressed or implied in any forward-looking statements as a result of various factors, including those set forth under the caption &#8220;Item 1A. Risk Factors.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of programmed cellular immunotherapies to patients.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To create better cell therapies, we have pioneered a therapeutic approach that we generally refer to as cell programming: we create and engineer human induced pluripotent stem cells (iPSCs) to incorporate novel synthetic controls of cell function; we generate a clonal master iPSC line for use as a renewable source of cell manufacture; and we direct the fate of the clonal master iPSC line to produce our cell therapy product candidates. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, we believe our proprietary clonal master iPSC lines can be used to mass produce multiplexed-engineered. cellular immunotherapies which have off-the-shelf availability, can be combined and administered alone or with standard-of-care therapies, and enable significant patient reach.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Utilizing our proprietary iPSC product platform, we are developing off-the-shelf, multiplexed-engineered T-cell and natural killer (NK) cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function, and intended to deliver multiple therapeutic mechanisms to patients. We have a pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted T-cell and NK cell product candidates currently under development. In addition, we have entered into research collaborations and license agreements with academic institutions to support the development of our iPSC product platform and our off-the-shelf product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have also entered into collaborations with pharmaceutical companies to research, develop and commercialize off-the-shelf, multiplexed-engineered, iPSC-derived CAR T-cell CAR NK cell product candidates for the treatment of cancer. In September 2018, we entered into a collaboration and option agreement (Ono Agreement) with Ono Pharmaceutical Co., Ltd. (Ono), under which we are currently researching and developing iPSC-derived CAR T-cell and CAR NK cell product candidates for the treatment of solid tumors. In April 2020, we entered into a collaboration and option agreement (Janssen Agreement) with Janssen Biotech, Inc. (Janssen), part of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, for the research, development and commercialization of iPSC-derived CAR T-cell and CAR NK cell product candidates for the treatment of cancer. On January 3, 2023, we received notice of termination of the Janssen Agreement from Janssen, which took effect on April 3, 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were incorporated in Delaware in 2007 and are headquartered in San Diego, California. Since our inception in 2007, we have devoted substantially all of our resources to our cell programming approach and the research and development of our product candidates, the creation, licensing and protection of related intellectual property, and the provision of general and administrative support for these activities. To date, we have funded our operations primarily through the public and private sale of common stock, the private placement of preferred stock and convertible notes, commercial bank debt and revenues from collaboration activities and grants.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never been profitable and have incurred net losses in each year since inception. Substantially all of our net losses resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect to continue to incur operating losses for at least the foreseeable future. Our net losses may fluctuate significantly from quarter to quarter and year to year. We expect our expenses will remain significant in connection with our ongoing and planned activities as we:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conduct our ongoing and planned preclinical studies and clinical trials of our product candidates, which may include higher clinical trial expenses associated with arrangements we may enter into with clinical research organizations (CROs) for the execution and management of certain clinical trials, including trials outside of the United States;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conduct Good Manufacturing Practice (GMP) production, including through the use of contract manufacturing organizations (CMOs) for the conduct of some or all of the activities required for manufacturing our iPSC-derived cell product candidates, process and scale-up development and technology transfer activities for the manufacture of our product candidates, including those undergoing clinical investigation and Investigational New Drug (IND) application-enabling preclinical development;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">procure laboratory equipment, materials and supplies for the manufacture of our product candidates and the conduct of our research activities;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conduct preclinical and clinical research to investigate the therapeutic activity of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue our research, development and manufacturing activities, including under our sponsored research and collaboration agreement with Ono;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintain, prosecute, protect, expand and enforce our intellectual property portfolio;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engage with regulatory authorities for the development of, and seek regulatory approvals for, our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue our business operations at our corporate headquarters, including maintaining internal GMP production capabilities; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue operating as a public company and support our operations.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not expect to generate any meaningful revenues from product sales, royalties, or sales milestones unless and until we successfully complete development and obtain regulatory approval for one or more of our product candidates, which we expect will take a number of years. If we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Accordingly, we will seek to fund our operations through public or private equity or debt financings, collaboration arrangements, or other sources. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements when needed would have a negative effect on our financial condition and ability to develop our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Operations Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conduct substantially all of our activities through Fate Therapeutics, Inc., a Delaware corporation, at our facilities headquartered in San Diego, California. Our results of operations include the operations of the Company and its subsidiaries. To date, the aggregate operations of our subsidiaries have not been significant, and all intercompany transactions and balances have been eliminated in consolidation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaboration Revenue</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have not generated any revenues from therapeutic product sales or royalties. Our revenues have been derived from collaboration agreements and government grants.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Agreement with Ono Pharmaceutical Co., Ltd.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 14, 2018, we entered into the Ono Agreement for the joint development and commercialization of two iPSC-derived CAR T-cell product candidates (Candidate 1 and Candidate 2). Pursuant to the terms of the Ono Agreement, we received an upfront, non-refundable and non-creditable payment of $10.0 million. Additionally, we are entitled to receive funding for the conduct of research and preclinical development under a joint research plan, which fees were estimated to be $20.0 million in aggregate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2020, we entered into a letter agreement with Ono (the Ono Letter Agreement) pursuant to which Ono delivered proprietary antigen binding domains targeting an antigen expressed on certain solid tumors for incorporation into Candidate 2 and paid the Company a milestone fee of $10.0 million for further research and preclinical development of Candidate 2. In addition, Ono terminated all further research and preclinical development with respect to Candidate 1, and we retained all rights to research, develop and commercialize Candidate 1 throughout the world without any obligation to Ono.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2022, we entered into an amendment with Ono to the Ono Agreement (the 2022 Ono Amendment). Pursuant to the 2022 Ono Amendment, the companies agreed to designate an additional antigen expressed on certain solid tumors for research and preclinical development, and Ono agreed to contribute proprietary antigen binding domains targeting such additional solid tumor antigen (Candidate 3). In addition, for both Candidate 2 and Candidate 3, the companies expanded the scope of the collaboration to include the research and preclinical development of iPSC-derived CAR NK cell product candidates (in addition to iPSC-derived CAR T-cell product candidates) targeting the designated solid tumor antigens. Similar to Candidate 2, we granted to Ono, during a specified period of time, a preclinical option (Candidate 3 Development Option) to obtain an exclusive license under certain intellectual property rights, subject to payment of an option exercise fee to us by Ono, to further develop and commercialize Candidate 3 in all territories of the world, where we retain rights to co-develop and co-commercialize Candidate 3 in the United States and Europe under a joint arrangement with Ono pursuant to which we are eligible to share at least 50% of the profits and losses. The Candidate 3 Development Option represents an option with no material right. Under the 2022 Ono Amendment, aggregate estimated research and preclinical development fees have been increased by approximately $9.3 million, for a total estimated $29.3 million in aggregate research and preclinical development fees over the course of the joint research plan.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2022, Ono exercised its option to obtain a license to develop and commercialize Candidate 2 (the Candidate 2 Development Option), and we exercised our option to co-develop and co-commercialize Candidate 2 in the United States and Europe. As a result, we received and recognized an option exercise fee of $12.5 million from Ono during the year ended December 31, 2022. We and Ono are proceeding under a joint development plan for the ongoing development of Candidate 2, and, as such, we have initiated clinical studies for Candidate 2. The costs of this joint development plan are accounted for in accordance with ASC 808, and cost sharing payments to us from Ono are recorded as contra-research and development expenses.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, we entered into an amendment with Ono to the Ono Agreement (the 2023 Ono Amendment). Under the 2023 Ono Amendment, aggregate estimated research and preclinical development fees payable to us by Ono for Candidate 3 have been increased by approximately $1.4 million, for a total estimated $30.7 million in aggregate research and preclinical development fees over the course of the joint research plan.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, following Ono&#8217;s exercise of the Candidate 2 Development Option and grant of the development and commercialization license, we achieved a $5.0 million clinical development milestone for Candidate 2. We determined that we had completed our performance obligation with respect to such milestone during the year ended December 31, 2024 and accordingly, recognized such amount as revenue during the period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2024, we entered into an amendment with Ono to the Ono Agreement (the 2024 Ono Amendment and collectively with the 2023 Ono Amendment and 2022 Ono Amendment, the Ono Amendments). Under the 2024 Ono Amendment, aggregate estimated research and preclinical development fees payable to us by Ono for Candidate 3 have been increased by approximately $7.3 million, for a total estimated $38.0 million in aggregate research and preclinical development fees over the course of the joint research plan. We will continue to receive committed funding from Ono through June 2025. The Candidate 3 Development Option expires upon the earlier of: (a) June 30, 2025 or (b) the achievement of the pre-defined preclinical milestone under the joint research plan for Candidate 3. Subject to payment of an extension fee by Ono, Ono may choose to defer its decision to exercise the Candidate 3 Development Option until no later than June 2026.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We account for the Ono Agreement, Ono Letter Agreement, and Ono Amendments (collectively, the Ono Arrangement) under ASC 808. We concluded that certain units of account, specifically the grant of a research license to certain intellectual property and the performance of research and preclinical development, within the Ono Arrangement represented a customer relationship and applied relevant guidance from ASC 606 to evaluate the appropriate accounting for those units of account. The initial transaction price under the Ono Arrangement was determined to be $48.0 million, consisting of the upfront, non-refundable and non-creditable payment of $10.0 million, the aggregate estimated research and preclinical development fees of $38.0 million. We also concluded that the Candidate 2 milestone fee of $10.0 million for further research and preclinical development of Candidate 2 represented a variable consideration that was previously constrained. We identified our promised goods and services under the Ono Arrangement to include our grant to Ono of a research license to certain of our intellectual property subject to certain conditions, our conduct of research and preclinical development services, and our participation in a joint steering committee. We determined that the promised goods and services should be accounted for as one combined performance obligation. We recognize revenue for the combined performance obligation over time as the research and preclinical development services are performed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024 and 2023, we recognized $13.6 million and $11.2 million, respectively, of collaboration revenue under the Ono Arrangement. During the years ended December 31, 2024 and 2023, we recognized $5.1 million and $8.0 million, respectively, of contra-research and development expense under the Ono Arrangement. As of December 31, 2024, aggregate deferred revenue related to the Ono Agreement, Ono Letter Agreement, and Ono Amendments was $0.4 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Agreement with Janssen Biotech, Inc.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 2, 2020 (the Janssen Agreement Effective Date), we entered into the Janssen Agreement. Additionally, on the Janssen Agreement Effective Date, we entered into a Stock Purchase Agreement (the Stock Purchase Agreement) with Johnson &amp; Johnson Innovation - JJDC, Inc. (JJDC). Under the terms of the Janssen Agreement and the Stock Purchase Agreement taken together, we received $100.0 million, of which $50.0 million was an upfront cash payment and $50.0 million was in the form of an equity investment by JJDC.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We determined the common stock purchase by JJDC represented a premium of $9.93 per share, or $16.0 million in aggregate (the Equity Premium), and the remaining $34.0 million was recorded as issuance of common stock in shareholders&#8217; equity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 3, 2023, we received notice of termination from Janssen of the Janssen Agreement. The termination took effect on April 3, 2023, and during the three months ending March 31, 2023, we performed wind-down activities, including discontinuing development of all collaboration product candidates under the Janssen Agreement. We were reimbursed for all wind-down activities associated with the termination of the Janssen Agreement during the second quarter of 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2023, we recognized $52.3 million of collaboration revenue under the Janssen Agreement, of which $41.2 million was deferred as of December 31, 2022.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist of costs associated with the research, preclinical development, process and scale-up development, manufacture and clinical development of our product candidates, the research and development of our cell programming technology including our iPSC product platform, and the performance of research and development activities under our collaboration agreements. These costs are expensed as incurred and include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">salaries and employee-related costs, including stock-based compensation;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs incurred under clinical trial agreements with investigative sites;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs to acquire, develop and manufacture preclinical study and clinical trial materials, including our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs associated with conducting our preclinical, process and scale-up development, manufacturing, clinical and regulatory activities, including fees paid to third-party professional consultants, service providers and suppliers;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs incurred for our research, development and manufacturing activities, including under our collaboration agreements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs for laboratory equipment, materials and supplies for the manufacture of our product candidates and the conduct of our research activities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs incurred to license and maintain intellectual property; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">facilities, depreciation and other expenses including allocated expenses for rent and maintenance of facilities.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We plan to continue to significantly invest in our current level of research and development activities for the foreseeable future as we continue the clinical and preclinical development and manufacture of our product candidates, research and develop our iPSC product platform, and perform our obligations under collaboration agreements including under our agreements with Ono, University of Minnesota and MSKCC. Our current planned research and development activities over the next twelve months consist primarily of the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conducting clinical trials of our product candidates, including through the engagement of CROs to manage various aspects of our clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conducting GMP production, including through the use of CMOs for the conduct of some or all of the activities required for manufacturing our iPSC-derived cell product candidates, process and scale-up development and technology transfer activities for the manufacture of our product candidates, including those undergoing clinical investigation and IND-enabling preclinical development;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">procuring laboratory equipment, materials and supplies for the manufacture of our product candidates and the conduct of our research activities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conducting preclinical and clinical research to investigate the therapeutic activity of our product candidates; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conducting research, development and manufacturing activities, including under our sponsored research and collaboration agreement with Ono.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to the inherently unpredictable nature of preclinical and clinical development and manufacture, and given our novel therapeutic approach and the current stage of development of our product candidates, we cannot determine and are unable to estimate with certainty the timelines we will require and the costs we will incur for the development and manufacture of our product candidates. Clinical and preclinical development and manufacturing timelines and costs, and the potential of development and manufacturing success, can differ materially from expectations. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development and manufacturing plans and capital requirements. We cannot predict the effects of the impact of global economic and market conditions, a continued and prolonged public health emergency such as the COVID-19 pandemic, and wars and other armed conflicts, such as the ongoing wars between Russia and Ukraine and in the Middle East, on our business and operations, and our expenditures may be increased by delays or disruptions due to these or other factors, including as a result of actions we take in the near term to ensure business continuity and protect against possible supply chain shortages.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist primarily of salaries and employee-related costs, including stock-based compensation, for our employees in executive, operational, finance and human resource functions; professional fees for accounting, legal and tax services; costs for obtaining, prosecuting, maintaining, and enforcing our intellectual property; and other costs and fees, including director and officer insurance premiums, to support our operations as a public company. We anticipate that our general and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">administrative expenses will remain significant in the future as we maintain our focus on innovation, and research and development activities, maintain compliance with exchange listing and SEC requirements, protect and enforce our intellectual property, and continue to operate as a public company.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income consists of proceeds from a settlement agreement and changes in the fair value of stock price appreciation milestones associated with the Amended and Restated Exclusive License Agreement dated May 15, 2018 (Amended MSKCC License) with MSKCC, interest income earned on cash, cash equivalents, and investments (including the amortization of discounts and premiums).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">California Institute for Regenerative Medicine Award</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FT819 CIRM Award</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2024, we were awarded $7.9 million from the California Institute for Regenerative Medicine (CIRM) to support the conduct of the Company&#8217;s Phase 1 study of FT819 in patients with systemic lupus erythematosus and, in April 2024, we executed an award agreement with CIRM (the FT819 CIRM Award). Pursuant to the terms of the FT819 CIRM Award, we are eligible to receive five disbursements in varying amounts from CIRM, with one disbursement receivable upon the execution of the award and four disbursements receivable based upon the completion of certain development milestones throughout the period of the award, which is estimated to be from April 1, 2024 to March 31, 2028 (the Award Period). Under the FT819 CIRM Award, we have certain obligations of co-funding and are required to provide CIRM progress and financial update reports throughout the Award Period.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the conclusion of the Award Period, we, in our sole discretion, have the option to treat the FT819 CIRM Award either as a loan or as a grant. If we do not elect to treat the FT819 CIRM Award as a loan within 10 years of the award date, the award will be considered a grant and we will be obligated to pay CIRM, on a quarterly basis, a low single-digit royalty on commercial sales of FT819 until such aggregate royalty payments equal nine times the total amount awarded to us under the FT819 CIRM Award.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since we may, at our election, repay some or all of the FT819 CIRM Award, we account for the award as a liability until the time of election. During the year ended December 31, 2024, we received two disbursements under the award in the aggregate amount of $5.1 million, which is recorded as a liability on the accompanying consolidated balance sheets. As of December 31, 2024, the entire balance is classified as non-current as we do not expect any amount to be payable within the next 12 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FT516 CIRM Award</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2018, we executed an award agreement with CIRM pursuant to which CIRM awarded us $4.0 million to advance our FT516 product candidate into a first-in-human clinical trial for the treatment of subjects with advanced solid tumors (the FT516 CIRM Award). Under the FT516 CIRM Award, we have certain obligations of co-funding and are required to provide CIRM with progress and financial update reports.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the terms of the FT516 CIRM Award, we, in our sole discretion, have the option to treat the FT516 CIRM Award either as a loan or as a grant. During the first quarter of 2023, we elected to treat the FT516 CIRM Award as a grant. As such, the liability associated with the FT516 CIRM Award was reversed and such amount was recorded as other income during the first quarter of 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee Retention Credit</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Coronavirus Aid, Relief and Economic Security (CARES) Act provides an employee retention credit (ERC), which is a refundable tax credit against certain employment taxes of up to $5,000 per employee for eligible employers. The tax credit is equal to 50% of qualified wages paid to employees during a quarter, capped at $10,000 of qualified wages per employee through December 31, 2020. Additional relief provisions were passed by the United States government, which extend and slightly expand the qualified wage caps on these credits through December 31, 2021. Based on these additional provisions, the tax credit is now equal to 70% of qualified wages paid to employees during a quarter, and the limit on qualified wages per employee has been increased to $10,000 of qualified wages per quarter. In connection with the CARES Act, we adopted a policy to recognize an ERC when it is reasonably assumed we will comply with the conditions and the grant will be received and include in other income in the statement of operations. The Company received a cash payment and recorded $5.1 million of other income during the year ended December 31, 2023. No such amount was received or recognized as other income during the year ended December 31, 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Policies and Significant Judgments and Estimates</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with United States generally accepted accounting principles. The preparation of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to the fair value of the stock price appreciation milestones for the Amended MSKCC License, contracts containing leases, accrued expenses, stock-based compensation, and the estimated total costs expected to be incurred under our collaboration agreements. We base our estimates on historical experience, known trends and events, financial models, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While our significant accounting policies are described in more detail in the notes to our financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe that the following critical accounting policies reflect the more significant procedures, estimates and assumptions used in the preparation of our consolidated financial statements.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaborative Arrangements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We analyze our collaboration arrangements to assess whether they are within the scope of ASC Topic 808, Collaborative Arrangements (ASC 808), to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, we assess whether aspects of the arrangement between us and our collaboration partner are within the scope of other accounting literature, including ASC Topic 606, Revenue from Contracts with Customers (ASC 606). If it is concluded that some or all aspects of the arrangement represent a transaction with a customer, we will account for those aspects of the arrangement within the scope of ASC 606.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC 808 provides guidance for the presentation and disclosure of transactions in collaborative arrangements, but it does not provide recognition or measurement guidance. Therefore, if we conclude a counterparty to a transaction is not a customer or otherwise not within the scope of ASC 606, we consider the guidance in other accounting literature as applicable or by analogy to account for such transaction. The classification of transactions under our arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration we are entitled to receive in exchange for such product or service. In doing so, we follow a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. We consider the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard. We apply the revenue recognition standard, including the use of any practical expedients, consistently to contracts with similar characteristics and in similar circumstances.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A performance obligation is defined as a promise to transfer a product or a service to a customer. If a promise to transfer a product or a service is not separately identifiable from other promises in the contract, such promises should be combined into a single performance obligation. We determined that the promised goods and services for our collaboration agreements should be accounted for as one combined performance obligation. We recognize revenue for the combined performance obligation over time as the research services are performed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transaction price is the amount of consideration we are entitled to receive in exchange for the transfer of control of a product or a service to a customer. To determine the transaction price, we consider the existence of any significant financing component, the effects of any variable elements, noncash considerations and consideration payable to the customer. For our collaboration agreements, we calculate the transaction price as an estimate of the total research and development plan reimbursement.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expense incremental costs of obtaining and fulfilling a contract as and when incurred if the expected amortization period of the asset that would be recognized is one year or less, or if the amount of the asset is immaterial. Otherwise, such costs are capitalized as contract assets if they are incremental to the contract and amortized to expense proportionate to revenue recognition of the underlying contract.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Price Appreciation Milestones</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We estimate the fair value of the stock price appreciation milestones under the Amended MSKCC License using a Monte Carlo simulation model, which relies on our current stock price at the end of each quarter as well as significant estimates and assumptions to determine the estimated liability associated with the contingent milestone payments. We account for the fair value of the stock price appreciation milestones in accordance with ASC 815, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Derivatives and Hedging</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with fair value marked to market. The assumptions used to calculate the fair value of the stock price appreciation milestones are subject to a significant amount of judgment including the assessment of achieving a specified clinical milestone, the expected volatility of our common stock, the risk-free interest rate and the estimated term, which is based in part on the last valid patent claim date. We achieved the specified clinical milestone in July 2021 and met the first milestone during fiscal 2021. Accordingly, we remitted a payment to MSKCC of $20.0 million during the year ended December 31, 2021. We remeasure the fair value of the remaining stock price appreciation milestones at each balance sheet date, with changes in fair value recorded in earnings as a non-operating income or expense.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  The long-lived asset evaluation is performed at the asset group level (i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities). Recoverability of these assets is measured by a comparison of the carrying amounts to the future undiscounted cash flows the assets are expected to generate from their use and eventual disposition. If the carrying amount is not recoverable, the carrying amount of such assets is reduced to fair value. During 2024, we identified an indicator of impairment of its long-lived assets due to a sustained decline in the trading price of the Company&#8217;s common stock over the preceding year, resulting in our market capitalization being below our net asset value. Although there have been no changes in the intended use of our long-lived assets. We utilized observed market lease rates for comparable properties to estimate the fair value of the right-of-use asset and leasehold improvements. We utilized trend factors applied to historical costs, estimates of economic depreciation, normal useful lives, and benchmark values for orderly liquidations of the assets in secondary markets to estimate the fair value of our property and equipment. As a result of the fair value analysis, we recorded a $13.4 million impairment charge against property and equipment and a $1.3 million impairment charge against the right-of-use asset in the statement of operations during the year ended December 31, 2024. No impairment was recorded during the year ended December 31, 2023.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the process of preparing our financial statements, we are required to estimate our accrued expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. Examples of accrued research and development expenses include amounts owed to clinical research organizations, to investigative sites in connection with clinical trials, to sponsored research organizations, to service providers in connection with preclinical development activities and to service providers related to product manufacturing, development and distribution of clinical supplies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We base our accrued expenses related to clinical trials on our estimates of the services performed and efforts expended pursuant to our contractual arrangements, including those with clinical research organizations. The financial terms of these agreements are sometimes subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our service providers will exceed the level of services performed and result in a prepayment of the clinical expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid accordingly.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we do not expect our estimates to be materially different from expenses actually incurred, if our estimates of the status and timing of services performed differs from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period. To date, there have been no material differences from our estimates to the amounts actually incurred.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense represents the grant date fair value of employee stock option and restricted stock unit grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. Performance-based stock units/awards represent a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, and to the extent achievement of one or any of the performance conditions is probable, we reassess the probability of the achievement of such corporate performance goals and any increase or decrease in share-based compensation expense resulting from an adjustment in the estimated shares to be released is treated as a cumulative catch-up in the period of adjustment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We estimate the fair value of stock option grants using the Black-Scholes option pricing model, with the exception of option grants with both performance-based milestones and market conditions, which are valued using a lattice-based model. These models require the use of highly subjective and complex assumptions which determine the fair value of stock-based awards, (a) the risk-free interest rate, (b) the expected volatility of our stock, (c) the expected term of the award and (d) the expected dividend yield. The expected volatility is based on the historical volatility of our common stock over the most recent period commensurate with the estimated expected term of our stock options which is derived from historical experience and anticipated future exercise behavior. The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon U.S. Treasury securities. See Note 9 of the notes to the consolidated financial statements for additional information.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of our restricted stock units, including performance-based restricted stock units, is based on the closing price of our common stock as reported on The NASDAQ Global Market on the date of grant.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a discussion of recently issued accounting pronouncements, please see Note 1 of the notes to the consolidated financial statements.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comparison of Years Ended December 31, 2024 and 2023</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the results of our operations for the years ended December 31, 2024 and 2023:</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.477%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.776%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.776%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.776%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended<br/>December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Increase/</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Decrease)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,631</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,533</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(49,902</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135,001</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">172,596</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(37,595</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,169</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,448</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(7,279</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,737</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,737</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,014</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,583</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5,569</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> During the year ended December 31, 2024, we recognized revenue of $13.6 million under our collaboration agreement with Ono. During the year ended December 31, 2023, we recognized revenue of $63.5 million under our collaboration agreements with Janssen and Ono. The decrease in revenue was attributable to the termination of our collaboration with Janssen in April 2023. The following table summarizes the revenue recognized with respect to each collaboration partner for the years ended December 31, 2024 and 2023:</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.071%;box-sizing:content-box;"/>
    <td style="width:2.06%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:18.404%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:2.06%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:18.404%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended<br/>December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Janssen Biotech, Inc.</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,312</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ono Pharmaceutical Co., Ltd.</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,631</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,221</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total collaboration revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,631</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,533</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">95</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Research and development expenses were $135.0 million for the year ended December 31, 2024, compared to $172.6 million for the year ended December 31, 2023. The decrease in research and development expenses was attributable primarily to the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$18.8 million decrease in third-party professional consultant and clinical trial related expense; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$16.1 million decrease in employee compensation and benefits expense, partially offset by a $1.7 million increase in employee-stock based compensation expense; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$6.2 million decrease in sublicense consideration owed to existing licensors. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and administrative expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> General and administrative expenses were $74.2 million for the year ended December 31, 2024, compared to $81.4 million for the year ended December 31, 2023. The decrease in general and administrative expenses was attributable primarily to the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$7.3 million decrease in employee compensation and benefits expense, which includes a $3.6 million decrease in employee stock-based compensation expense;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$1.7 million decrease in third-party professional consultant expense; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$4.7 million increase in patent and legal expense.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other income. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income was $24.0 million and $29.6 million for the years ended December 31, 2024 and 2023, respectively. During the year ended December 31, 2024, we recorded proceeds from a settlement agreement, and $0.8 million in other income attributable to the decrease in fair value of the stock price appreciation milestone under the Amended MSKCC License. Other income for the year ended December 31, 2024 also consisted of $17.3 million interest income earned on cash, cash equivalents, and investments (including the amortization of discounts and premiums). During the year ended December 31, 2023, we recorded $4.0 million in income attributable to the CIRM Award, $5.1 million in income attributable to the ERC, and $2.5 million in other income attributable to the decrease in fair value of the stock price appreciation milestone under the Amended MSKCC License. Other income for the year ended December 31, 2023 also consisted of $17.2 million of interest income earned on cash, cash equivalents, and investments (including the amortization of discounts and premiums).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred losses and negative cash flows from operations since inception. As of December 31, 2024, we had an accumulated deficit of $1.4 billion and anticipate that we will continue to incur net losses for the foreseeable future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth a summary of the net cash flow activity for each of the years ended December 31:</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.967%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.897%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.897%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(122,874</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(132,263</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by investing activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,218</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112,665</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99,892</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net decrease in cash, cash equivalents and restricted cash</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(10,764</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(19,513</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The net cash used in operating activities was $122.9 million for the year ended December 31, 2024 and primarily consisted of a net loss of $186.3 million adjusted for non-cash items including stock-based compensation of $41.5 million and depreciation and amortization of $19.0 million. Operating cash inflows were primarily from cash receipts under the Ono Arrangement - see section </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Agreement with Ono Pharmaceutical Co., Ltd. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">above and Note 2 of the consolidated financial statements for additional detail.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The net cash used in operating activities was $132.3 million for the year ended December 31, 2023 and primarily consisted of a net loss of $160.9 million adjusted for non-cash items including stock based compensation of $43.5 million, $41.5 million change in deferred revenue, and depreciation and amortization of $18.3 million. During the year ended  December 31, 2023, we experienced a termination of the Janssen agreement, restructuring activities and discontinuation of programs implemented in January 2023.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024 and 2023, investing activities provided cash of $12.2 million and $112.7 million, respectively. During the year ended December 31, 2024, we purchased $317.8 million of investments, which were partially offset by</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">96</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$330.7 million in maturities of investments. During the year ended December 31, 2023, we purchased $358.8 million of investments, which were partially offset by $477.6 million in maturities of investments. The remaining investing activities for the periods presented were primarily attributable to the purchase of property and equipment.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financing Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financing activities provided cash of $99.9 million for the year ended December 31, 2024, which primarily consisted of (i) the issuance of 14,545,454 shares of common stock at a purchase price of $5.50 per share in an underwritten public offering of common stock in March 2024, (ii) the issuance of pre-funded warrants to purchase an aggregate of 3,636,364 shares of common stock at a purchase price of $5.499 per pre-funded warrant, which represents the offering price per share of common stock in the underwritten public offering less the $0.001 exercise price per share of each pre-funded warrant, in a private placement concurrent with the underwritten public offering in March 2024, and (iii) the issuance of common stock from equity incentive plans pursuant to the exercise of employee stock options.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financing activities provided cash of $0.1 million for the year ended December 31, 2023, which consisted of $0.1 million received from the issuance of common stock from equity incentive plans pursuant to the exercise of employee stock options.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From our inception through December 31, 2024, we have funded our consolidated operations primarily through the public and private sale of common stock and pre-funded warrants, the private placement of preferred stock and convertible notes, commercial bank debt and revenues from collaboration activities and grants. As of December 31, 2024, we had aggregate cash, cash equivalents, and investments of $306.7 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Registration Statements on Form S-3</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the SEC declared effective a shelf registration statement on Form S-3 filed by us in November 2023 (File No. 333-275402). The shelf registration statement allows us to issue certain securities, including shares of our common stock, from time to time. The specific terms of any offering under the shelf registration statement would be established at the time of such offering. We are eligible to issue an aggregate of $300.0 million in securities under the shelf registration statement. Additionally, we entered into a sales agreement with Jefferies Group LLC (Jefferies) with respect to an at-the-market offering program, under which we may offer and sell, from time to time at our sole discretion, shares of our common stock having an aggregate offering price of up to $100.0 million (which is included in the $300.0 million registered under the shelf registration statement) through Jefferies as the sales agent.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, we entered into an underwriting agreement with BofA Securities, Inc., Jefferies, and Leerink Partners LLC with respect to an underwritten public offering, under which we sold 14,545,454 shares of our common stock at a purchase price of $5.50 per share pursuant to the shelf registration statement. To date, we have not sold any securities pursuant to the sales agreement with Jefferies and are eligible to issue an aggregate of approximately $220.0 million under the shelf registration statement (including the $100.0 million issuable pursuant to the sales agreement with Jefferies).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, concurrent with the underwritten public offering, we entered into a securities purchase agreement with a fund affiliated with Redmile Group, LLC under which we sold pre-funded warrants to purchase up to 3,636,364 shares of our common stock, at a purchase price of $5.499 per pre-funded warrant, in a private placement exempt from the registration requirements pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the Securities Act). Pursuant to the terms of the purchase agreement, we agreed to register for resale the shares of common stock issuable upon the exercise of the pre-funded warrants (Warrant Shares). On April 18, 2024, we filed a resale registration statement on Form S-3 (File No. 333-278792), registering the Warrant Shares. The resale registration statement on Form S-3 was declared effective on April 29, 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Capital Requirements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We anticipate that we will continue to incur losses for the foreseeable future, and we expect the losses to remain significant as we continue the research, manufacture and development of, and seek regulatory approvals for, our product candidates and conduct additional research, manufacturing and development activities pursuant to our collaboration agreement with Ono. Our product candidates have not yet achieved regulatory approval and we may not be successful in achieving commercialization of our product candidates.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">97</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also subject to all the risks and uncertainties incident in the research, manufacture and development of therapeutic products, and cell therapy product candidates in particular. For example, the FDA or other regulatory authorities may require us to generate additional data or conduct additional preclinical studies, manufacturing activities, or clinical trials, or may impose other requirements beyond those that we currently anticipate. Additionally, it is possible for a product candidate to show promising results in preclinical studies or in clinical trials, but fail to establish sufficient safety and efficacy data necessary to obtain regulatory approvals. As a result of these and other risks and uncertainties and the probability of success, the duration and the cost of our research, manufacturing and development activities required to advance a product candidate cannot be accurately estimated and are subject to considerable variation. We may encounter difficulties, complications, delays and other unknown factors and unforeseen expenses in the course of our research, manufacturing and development activities, any of which may significantly increase our capital requirements and could adversely affect our liquidity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will require additional capital for the research, manufacture and development of our product candidates and to perform our obligations under our collaboration agreements, and we may need to seek additional funds sooner than expected due to any changes in our business, operations, financial condition or prospects, including any impacts of inflation rates and global economic conditions, and wars or other armed conflicts. We expect to finance our capital requirements in the foreseeable future through the sale of public or private equity, debt securities, or through existing or future potential collaborations. However, additional capital may not be available to us on reasonable terms, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the research, manufacture or development of one or more of our product candidates. If we do raise additional funds through the issuance of additional equity or debt securities, it could result in dilution to our existing stockholders, increased fixed payment obligations and the existence of securities with rights that may be senior to those of our common stock. Additionally, if we incur indebtedness, we may become subject to financial or other covenants that could adversely restrict, impair or affect our ability to conduct our business, such as requiring us to relinquish rights to certain of our product candidates or technologies or limiting our ability to acquire, sell or license intellectual property rights or incur additional debt. Any of these events could significantly harm our business, operations, financial condition and prospects. In addition, the full impact of inflation rates, global political and economic instability, a continued and prolonged public health emergency such as the COVID-19 pandemic, and wars and other armed conflicts, on our business, operations, financial condition and prospects, and on the global economy, are currently unknown and difficult to predict, and these events could materially and adversely affect our ability to raise capital through equity or debt financings in the future.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">98</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our forecast of the period of time through which our existing cash, cash equivalents, and investments will be adequate to support our operations is a forward-looking statement and involves significant risks and uncertainties. We have based this forecast on assumptions that may prove to be wrong, and actual results could vary materially from our expectations, which may adversely affect our capital resources and liquidity. We could utilize our available capital resources sooner than we currently expect. The amount and timing of future funding requirements, both near- and long-term, will depend on many factors, including, but not limited to:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the initiation, timing, progress, size, duration, costs and results of our clinical trials and preclinical studies for our product candidates, including the timing and costs of manufacturing activities to support such clinical trials and preclinical studies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number and the nature of product candidates that we pursue;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the time to and cost of establishing and maintaining internal GMP production capabilities to support the clinical and potential commercial manufacture of our product candidates at our corporate headquarters;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of GMP production, process and scale-up development and technology transfer activities for the manufacture of our product candidates, including the cost of laboratory equipment, materials and supplies to support these activities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the time, cost and outcome of seeking and obtaining regulatory approvals;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we are required to pay milestone or other payments under our existing in-license agreements and any in-license agreements that we may enter into in the future, and the timing of such payments, including payments owed to MSKCC in connection with the stock price appreciation milestones;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which milestones are achieved under our collaboration agreement with Ono, and any other strategic partnership or collaboration agreements that we may enter into in the future, and the time to achievement of such milestones and our receipt of any associated milestone payments;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights, and the cost of enforcing any of our other contractual rights;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of our research and development activities, including our need and ability to hire additional employees and procure additional equipment, materials and supplies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the establishment and continuation of collaborations and strategic alliances;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and terms of future in-licensing and out-licensing transactions; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of establishing sales, marketing, manufacturing and distribution capabilities for, and the pricing and reimbursement of, any products for which we may receive regulatory approval.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we are closely monitoring inflation rates and global political and economic conditions, including the ongoing wars between Russia and Ukraine and in the Middle East, and evaluating adjustments to our business and operations, which may negatively impact our financial condition and prospects and our operating results. We will continue to assess our operating capital requirements and may make adjustments to our business and operations if circumstances warrant. If we cannot continue or expand our research, manufacturing and development operations, or otherwise capitalize on our business opportunities, because we lack sufficient capital, our business, operations, financial condition and prospects could be materially adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contractual Obligations and Commitments</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We lease certain office, laboratory, and manufacturing space under non-cancelable operating leases. In addition to rent, our leases are subject to certain fixed amenities fees. These leases are also subject to additional variable charges for common area maintenance, property taxes, property insurance and other variable costs. See Note 8 of the consolidated financial statements for additional detail.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total undiscounted aggregate future operating lease obligations under all of our operating leases as of December 31, 2024 are $133.7 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 15, 2018, we entered into the Amended MSKCC License with MSKCC. In the event a licensed product achieves a specified clinical milestone, MSKCC is then eligible to receive certain milestone payments totaling up to $75.0 million based on the price of our common stock, where the amount of such payments owed to MSKCC is contingent upon certain increases in the price of our common stock following the date of achievement of such clinical milestone. See Note 2 of the consolidated financial statements for additional detail.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have no material contractual obligations not fully recorded on our consolidated balance sheets or fully disclosed in the notes to the financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have obligations under various license agreements to make future payments to third parties that become due and payable on the achievement of certain development, regulatory and commercial milestones (such as the start of a clinical trial, filing for product approval with the FDA or other regulatory agencies, product approval by the FDA or other regulatory agencies, product launch or product sales) or on the sublicense of our rights to another party. We have not included these commitments on our balance sheet because the achievement and timing of these events is not fixed and determinable. Certain milestones are in advance of receipt of revenue from the sale of products and, therefore, we may require additional debt or equity capital to make such payments. These commitments include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under a license agreement with the Whitehead Institute for Biomedical Research, pursuant to which we license certain patents relating to our iPSC product platform, we are required to make annual maintenance payments and payments based upon development, regulatory and commercial milestones for any products covered by the in-licensed intellectual property. The maximum aggregate milestone payments we may be obligated to make per product are $2.3 million. We will also be required to pay a royalty on net sales of products covered by the in-licensed intellectual property in the low single digits. The royalty is subject to reduction for any third-party payments required to be made, with a minimum floor in the low single digits. We have the right to sublicense our rights under this agreement, and we will be required to pay a percentage of any sublicense income.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under license agreements with The Scripps Research Institute (TSRI), pursuant to which we license certain patents relating to our iPSC product platform, we are required to make annual maintenance payments and payments based upon development, regulatory and commercial milestones for any products covered by the in-licensed intellectual property. The maximum aggregate milestone payments we may be obligated to make are $1.8 million. We will also be required to pay a royalty on net sales of products covered by the in-licensed intellectual property in the low- to mid-single digits. The royalty is subject to reduction for any third-party payments required to be made, with a minimum floor in the low single digits. We have the right to sublicense our rights under these agreements, and we will be required to pay a percentage of any sublicense income.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under a license agreement with the Regents of the University of Minnesota, pursuant to which we license certain patents relating to compositions and uses of NK cells and to compositions of engineered receptors and immune cells expressing such receptors, we are required to make annual maintenance payments and payments based upon development, regulatory and commercial milestones for any products covered by the in-licensed intellectual property. The maximum aggregate milestone payments we may be obligated to make per product are $4.6 million. We will also be required to pay a royalty on net sales of products covered by the in-licensed intellectual property in the low single digits. The royalty is subject to reduction for any third-party payments required to be made, with a minimum floor in the low single digits. We have the right to sublicense our rights under this agreement, and we will be required to pay a percentage of any sublicense income.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under a license agreement with MSKCC, pursuant to which we license certain patents relating to compositions and uses of T-cells derived from iPSCs, CARs and genetic modifications using CRISPR, we are required to make annual maintenance payments and payments based upon development, regulatory and commercial milestones for any products covered by the in-licensed intellectual property. The maximum aggregate milestone payments we may be obligated to make per product are $12.5 million. We will also be required to pay a royalty on net sales of products covered by the in-licensed intellectual property up to the high-single digits. The royalty is subject to reduction for any third-party payments required to be made, with a minimum floor in the low- to mid-single digits. We have the right to sublicense our rights under this agreement, and we will be required to pay a percentage of any sublicense income. Additionally, in the event a licensed product achieves a specified clinical milestone, MSKCC is then eligible to receive additional milestone payments, where the amount of such payments owed to MSKCC are contingent upon certain increases in the price of our common stock following the date of achievement of such clinical milestone. See Note 2 of the notes to the consolidated financial statements for additional detail related to the stock price appreciation milestone payments.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under a license agreement with Dana Farber Cancer Institute, pursuant to which we license certain patent applications relating to novel antibody fragments that bind the alpha-3 domain of MICA/B, we are required to make annual maintenance payments and payments based upon development, regulatory and commercial milestones for any products covered by the in-licensed intellectual property. The maximum aggregate milestone payments we may be obligated to make per product are $25 million. We will also be required to pay a royalty on net sales of products covered by the in-licensed intellectual property in the low single digits. The royalty is subject to reduction for any third-party payments required to be made, with a minimum floor in the low single digits. We have the right to sublicense our rights under these agreements, and we will be required to pay a percentage of any sublicense income.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under a license agreement with Baylor College of Medicine, pursuant to which we license certain patents relating to the composition and use of a novel allo-immune defense receptor (ADR), we are required to make annual maintenance payments and payments based upon development, regulatory and commercial milestones for any products covered by the in-licensed intellectual property. The maximum aggregate milestone payments we may be obligated to make per product are $7.0 million. We will also be required to pay a royalty on net sales of products covered by the in-licensed intellectual property in the low single digits. The royalty is subject to reduction for any third-party payments required to be made, with a minimum floor in the low single digits. We have the right to sublicense our rights under this agreement, and we will be required to pay a percentage of any sublicense income.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under a license agreement with Max Delbruck Center for Molecular Medicine (MDC), pursuant to which we license certain patents relating to novel humanized antibody fragments, antigen-binding domains and CAR constructs that </span><span style="color:#222222;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">uniquely target and specifically bind B-cell Maturation Antigen, w</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e are required to make annual maintenance payments and payments based upon development, regulatory and commercial milestones for any products covered by the in-licensed intellectual property. The maximum aggregate milestone payments we may be obligated to make per product are $11.0 million. We will also be required to pay a royalty on net sales of products covered by the in-licensed intellectual property in the low single digits. The royalty is subject to reduction for any third-party payments required to be made, with a minimum floor in the low single digits. We have the right to sublicense our rights under this agreement, and we will be required to pay a percentage of any sublicense income.  </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We enter into contracts in the normal course of business, including with clinical sites, CROs, and other professional service providers for the conduct of clinical trials, contract manufacturers for the production of our product candidates, contract research service providers for preclinical research studies, professional consultants for expert advice and vendors for the sourcing of clinical and laboratory supplies and materials. These contracts generally provide for termination on notice, and therefore are cancelable contracts and not included in the table of contractual obligations and commitments.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inflation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inflation has increased during the periods covered by this Annual Report on Form 10-K, and may continue to increase or remain elevated for the near future. Inflationary factors, such as increases in the prices of material, interest rates and cost of labor may adversely affect our operating results. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, we may experience some effect in the near future, especially if inflation rates continue to rise.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 7A. Quantitative and Qualitat</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ive Disclosures about Market Risk</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable to smaller reporting companies.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">101</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statements_supplementar"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 8.  Financial Stateme</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nts and Supplementary Data</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="report_of_independent_auditors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Stockholders and the Board of Directors of Fate Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a523066f-ac40-48ab-91c9-51264d21dbd2" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:AuditorOpinionTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Fate Therapeutics, Inc. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(the Company) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Audit Matters</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the account or disclosure to which they relate.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">102</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:80%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;margin-right:0.04861111111111111in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued research and development expenses &#8211; clinical trials</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Description of the Matter</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:0.05in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Company recorded research and development expenses of $135.0 million for the year ended December 31, 2024. Research and development costs are expensed as incurred. Research and development costs include fees paid to contract research organizations, investigative sites and sponsored research organizations that conduct certain research and development activities on the Company&#8217;s behalf for clinical trials.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:0.05in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Auditing the Company&#8217;s research and development expenses and related accruals was challenging due to the complex nature of evaluating the completeness and accuracy of the expenses and accruals. Research and development expenses are recognized as the services are being performed by the vendors, which requires management to accurately reflect the cost of services performed by vendors, such as patient enrollment and treatment at several investigative sites.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:0.05in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">How We Addressed the Matter in Our Audit</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:0.05in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">To test the clinical trial expenses and related accruals, our audit procedures included, among others, confirming with a sample of vendors the progress of activities under research and development contracts at period end, testing a sample of invoices from vendors providing clinical services, testing a sample of cash disbursements after period end to assess the completeness of the expense recognition, and testing a sample of research and development expenses recorded during the period and evaluating the timing and amount of the expense recognition.</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:80%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;margin-right:0.04861111111111111in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of long-lived assets</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Description of the Matter</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:0.05in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">As discussed in Note 1 of the consolidated financial statements, the Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable. The long-lived asset evaluation is performed at the asset group level, i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. Recoverability of these assets is measured by a comparison of the carrying amounts to the future undiscounted cash flows the assets are expected to generate from the use and eventual disposition. If such review indicates that the carrying amount of the long-lived assets is not recoverable, the carrying amount of such assets is reduced to fair value. During the year ended December 31, 2024, the Company recorded an impairment of $14.7 million, consisting of $1.3 million related to right-of-use assets and $13.4 million related to property and equipment.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:0.05in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Auditing the valuation of the Company&#8217;s impairment of its long-lived assets was complex and required a high degree of auditor judgment when performing procedures due to the significant estimation uncertainty in determining the fair value of its property and equipment. Management used observed market lease rates for comparable properties to perform the impairment test for its leasehold improvements and the right-of-use lease assets.  To establish an estimate of fair value of the remaining property and equipment, primarily consisting of scientific equipment, management utilized trend factors applied to historical costs, estimates of economic depreciation, normal useful lives, and benchmark values for orderly liquidations of assets in secondary markets.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:0.05in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">How We Addressed the Matter in Our Audit</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:0.05in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Our audit procedures included, among others, evaluating the methodology and valuation models used and testing the key inputs and significant assumptions made by management. We evaluated the significant assumptions used by management related to the valuation of the leasehold improvements and right-of-use lease assets by obtaining observable lease rates for comparable properties and recalculating the impairment charge.  We evaluated the significant assumptions for the valuation of other property and equipment by testing a sample of observable market data and comparable executed transactions and listings for scientific equipment.</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Ernst &amp; Young, LLP</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have served as the Company's auditor since 2009.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">San Diego, California</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 5, 2025</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">103</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fate Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated B</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">alance Sheets</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except par value and share data)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.12%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.82%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.82%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cea0dfbd-d8ad-435b-88ad-1251f2c68d37" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,056</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_056b18f9-b07c-4257-9588-975e1e2a08c3" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,870</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33fb6c09-ac47-4233-affc-fd045da1360f" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,539</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85cb2596-050d-486e-9e56-effaa21ec5e1" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,826</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_872100f8-28fd-4334-b712-9b5f9dfca6c4" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">243,012</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_381c4661-c9e5-46bc-9928-0e31db7d3a4d" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">273,305</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8388298d-5e84-4796-b67f-7f4f63e911c9" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,302</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ff8d068-07f6-4809-bcf2-2930ad588a7d" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,539</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebeae2b0-b39b-4111-a79b-a0938d363341" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">291,909</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2a09f13-2bad-4b16-b7b6-8ee26b2ccd72" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">331,540</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term investments</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1ac3824-2930-4fef-bdca-2b608b244b47" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,657</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe3e951c-614f-4c46-976f-b449ae4ed35f" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">980</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d65782a-849e-4076-b01d-4e3193fcd7d1" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,384</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd0949e7-bec2-44bd-bf62-9bec906cb6c7" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,836</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c113b737-8c1e-4684-abfe-d8926ee296c2" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,508</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25bba73a-b1fe-4fa1-a6e5-6b15d1b17064" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,675</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b3fbecb-6741-414d-abd3-4ee721edd5ca" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,227</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce8f7bed-076b-42bc-acbc-e6b392ee0067" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,177</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3470a525-12ac-4c6f-9a2b-2ec68454d253" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acaeaeb0-b151-4643-b0d9-979ef0b8d5f1" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12858f5d-75ae-4106-ae49-7cdc1d6c65a9" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">440,694</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77ff0b83-bd7b-4249-a10f-c41acbb02aa6" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">506,217</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and Stockholders&#8217; Equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7589c90e-776a-42b1-a399-5cdbd22bcb34" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,365</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_512cae74-8513-4fb1-b8c0-b40be4b9c265" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,719</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d7d4e66-46fb-4634-bff7-923cfd681f07" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,348</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76debe4a-e949-42c9-8099-685a1bd908e2" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,514</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f419dce4-76a5-400d-a032-e177ca1e07e3" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">393</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_377b3efe-fd27-4db1-8b49-942dfe6b8e1c" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">685</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, current portion</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a2ea7bc-1e39-4116-801c-7205e89a25c1" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,416</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a7fbc11-7f21-4286-af8f-06d78442c509" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,176</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_376023cd-65ef-4b3a-9a8d-79f84fb16fb9" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,522</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d77429c-33ea-498c-8f26-8840cdb58b41" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,094</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CIRM award liability</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3827df8e-b569-48a7-bce2-74bfe8d0fb27" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="fate:CIRMAwardLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,070</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_432338c9-d764-4919-b058-50d06c2c149b" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="fate:CIRMAwardLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, net of current portion</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32ca65c6-183f-4355-83db-8c984a9744ba" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,849</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a00da818-0159-4b62-a448-be60488b6697" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,360</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock price appreciation milestones</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9d73ab6-511f-4935-b7c2-4682c4b7173f" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="fate:StockPriceAppreciationMilestonesLiabilitiesNonCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">527</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_093d4de8-08d1-4a2c-9585-716ee5edb19a" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="fate:StockPriceAppreciationMilestonesLiabilitiesNonCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,346</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_89c55976-9468-4820-a52b-dae8d981199b;"><span style="-sec-ix-hidden:F_4871b3f6-bcbf-43c8-836c-b69e9e915c2f;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies</span></span></span></span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders&#8217; equity:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54b7c8fe-9ef2-429f-8090-368205d895d4" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3"><ix:nonFraction id="F_fb70378f-3646-4cab-b9dc-790da42fed5a" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value; authorized shares&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a241fbd4-f186-4cbf-8af4-e5536074f26b" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7f36e0df-e6f3-421e-a809-20da3b45a3fe" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">; Class A Convertible  <br/>&#160;&#160;&#160;Preferred shares issued and outstanding&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_293fe793-df4a-4ea7-9612-14706cc23731" contextRef="C_306e095e-df5e-46ff-bb9b-07308bdff1ed" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3e7d91b4-78c2-4557-aac1-80d3b8e07388" contextRef="C_306e095e-df5e-46ff-bb9b-07308bdff1ed" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,755,086</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;at December 31, 2024 and <br/>&#160;&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e886c381-1fd0-4d8b-96bd-fcfc5acd4d9c" contextRef="C_41031951-bbc6-4651-8f90-88528e8885ab" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0d45029b-d84e-4e73-950a-99a6b38c688d" contextRef="C_41031951-bbc6-4651-8f90-88528e8885ab" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,761,108</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;at December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f418a529-c45b-4b05-bcc7-0c19f128df98" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27e1cb11-2254-42db-a386-8a1fd9d99829" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_406d9539-2ef6-4f6a-81b6-b2582e7b0862" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3"><ix:nonFraction id="F_e77a7d12-07f3-487e-92a3-b276c63ba7d0" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value; authorized shares&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33f5dd60-b53b-4565-ab58-c54793ef0523" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f8ab9687-01d2-4fe1-aea8-bd93ffac3f09" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">250,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">; issued and<br/>&#160;&#160;&#160;&#160;outstanding&#8212; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_725baf35-efe3-4699-a93a-5f7af8f90e29" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c602af93-1e34-4a66-a132-2e9edb2d48ba" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">113,928,279</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;at December 31, 2024 and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0e29ade-c042-4c7d-a953-ff063a82eea0" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_27027961-ba98-4fc5-be29-521de07ee590" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">98,627,076</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;at December 31, <br/>&#160;&#160;&#160;&#160;2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_808714d2-7d00-495a-ba04-892c36071660" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">114</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4402f7dd-268c-4684-9491-ec9e669c7aaf" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">99</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28163d61-184b-4609-b1a9-70cd246f0050" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,716,335</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6ff9b91-c986-42cc-bffd-0909d9e1bdfd" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,580,032</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fc51f31-25a1-4ad6-93dd-0a5521cf3d19" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">268</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_036517a7-3710-490f-8ef9-7d2c9c05d500" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2e06fd9-274d-4266-a536-607f93012e82" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,397,994</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7342c10d-f8f3-4e25-880c-68b8baeefbc8" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,211,732</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c576ac11-6935-4ddf-a489-d509f5b00dcd" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">318,726</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38d344fb-e78c-4fef-a258-9e7696b92438" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">368,417</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21401e2e-da78-4758-bcf0-99ace55c62fa" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">440,694</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90390461-c29d-4b00-8de1-edada2a9b87b" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">506,217</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See accompanying notes.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">104</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fate Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_operations_compr"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of Ope</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rations and Comprehensive Loss</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share and per share data)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_21f3a184-e10d-4206-ab0b-30c744f8de9d;"><span style="-sec-ix-hidden:F_55fe3d11-ab15-4251-b6ea-70a768289f34;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration revenue</span></span></span></span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_199a54a1-62ea-4e7c-b5c9-0710ef1747b5" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,631</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20718c9b-d4cf-4be7-aa09-d1952b842d99" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,533</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f3d3647-1468-4e0d-b7d4-dcc74fc1f815" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">135,001</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee6bdc3d-3567-492b-a59d-24df9dd6691c" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">172,596</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2efa5ef9-b4aa-4649-b0ff-36726a08b517" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,169</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d8fd1c5-4c9b-4f69-bcab-5824a1012cfe" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,448</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec923fc4-7bb8-4ef6-8563-d30a4e04ea99" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,737</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3fd522e-0cc0-4dbf-aba7-9e3adb9850d8" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_434dd900-b4c8-4594-868e-6044a589b9f2" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">223,907</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_789e6066-dd77-49d0-87e1-6ec68f370c71" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">254,044</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4f838e5-76ae-465f-8fa1-8ef67dac7276" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">210,276</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73b9a446-2575-475c-bd04-da487da27d1c" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">190,511</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13c4649e-4c08-4cbb-8656-c19d73e60805" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,288</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3d11b7c-a1ab-49f6-a7b8-cf70ab2518ca" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,186</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of stock price appreciation milestones</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f49d3691-1a47-48f8-93e4-53bd767903fa" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="fate:IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">819</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59a539c3-80fe-423d-be5d-b522ba9a415f" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="fate:IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,515</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0005e251-34b0-4dde-b3a7-aab50a64b64b" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:OtherNonoperatingIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,907</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74f4f7dc-9fdc-4d21-8031-752f20b16fb5" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:OtherNonoperatingIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,882</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91a8b4b4-df01-409c-ab18-c1fee9bd727b" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,014</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc354f15-0ca0-4d18-ad6c-2ef7fc0c3ab3" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,583</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac477b3f-2ea6-4929-b6b2-f2b031ab70f8" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">186,262</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab4ec2a6-7468-4c43-ba79-37781547940e" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">160,928</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive gain:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized gain on available-for-sale securities, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_963dc447-1d07-4cfd-8b89-526465f46e7b" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">253</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08a723e8-542a-4edb-aa61-405b4fbe2b5e" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,869</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c17c90e2-8b6b-4ee0-a588-c0d210c9628b" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">186,009</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a573a730-f032-414a-843c-f4de9868e447" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">159,059</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per common share, basic and diluted</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_325b8c4d-d4e3-4918-8cba-14e7500f86c9" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d8c39ceb-73cd-4c00-a83a-77343ec87450" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.64</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee7def0f-b0c5-4364-bd08-6c478ea18497" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_dfe7ff9b-1d85-4bd3-aa01-32dd5722e8d4" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.64</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted&#8211;average common shares used to compute basic and<br/>&#160;&#160;&#160;diluted net loss per share</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_134c460e-4229-410e-931a-8e024d954ab3" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f8088458-a8ed-418f-863c-a7ee4586bc0a" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">113,685,177</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30b9d36d-e6be-4717-99a2-f2fd0449f938" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_257c9a8d-ae14-4d4f-93e9-bdf1713b6b36" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">98,411,162</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See accompanying notes.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">105</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fate Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_convertible_pref"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of Convertible Prefer</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">red Stock and Stockholders&#8217; Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share data)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:28.686%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:4.261%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.401%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.261%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.821%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.821%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.821%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.821%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.101%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Convertible<br/>Preferred Stock</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional<br/>Paid-in</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated <br/>Other Comprehensive</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>Stockholders&#8217;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gain (Loss)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10521dd2-da3b-4cd2-b4c0-2221ea17300d" contextRef="C_cc8f53ba-0de4-45e3-a08a-c8528a309add" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,794,549</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e2db3a3-7bfc-4465-bb2c-11742bcc1b2d" contextRef="C_cc8f53ba-0de4-45e3-a08a-c8528a309add" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3aaefc2d-5ebc-4b47-98ff-fe1703d1e60c" contextRef="C_35de3dab-1655-4fae-8a01-0f3d2ee62306" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">97,294,917</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7df74479-1fd3-447c-bb83-36b0e524c817" contextRef="C_35de3dab-1655-4fae-8a01-0f3d2ee62306" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1b73ec5-090a-46f4-902d-2f3cbaa68fcb" contextRef="C_fcdf4845-34e5-4331-ba78-17eade1d2dde" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,536,497</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c4b6462-d6c5-4954-a948-9d588b7de3f1" contextRef="C_9ba83a55-9961-4e4b-8d65-f9275f3c0342" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,854</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_461b0e95-f71a-44ba-8f85-a5e85a591f31" contextRef="C_e741f2c7-90d6-40a1-ab1f-b596c102b3bf" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,050,804</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e84dab35-aeed-4233-a586-b1588a281972" contextRef="C_6199ef4e-6533-4919-aa08-7b8879357aa9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">483,939</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of stock options, net of issuance costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f1b2086-e300-442f-b13e-5718f279d290" contextRef="C_e243220b-bcd5-4012-8eef-5b2d39ca5281" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">93,787</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d38b4b41-240a-4b34-a940-59ff4221dc32" contextRef="C_4fb1c409-95ec-4aa9-9296-606146c23c7b" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1272b21-8f53-4455-8dbb-b4bc49aa9763" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon vesting of restricted stock units</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_817e15f8-22bb-4cb6-aecb-31c0cbd62d67" contextRef="C_e243220b-bcd5-4012-8eef-5b2d39ca5281" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,071,167</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af862436-bb5d-442f-9db5-a58032031231" contextRef="C_e243220b-bcd5-4012-8eef-5b2d39ca5281" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ab94845-b6e7-4617-9267-5929afbcdbd3" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Conversion of preferred shares to common stock</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_347bfe30-2a0c-4afe-b8f7-e90eef8c5664" contextRef="C_453cb5ab-24d8-4b66-961f-9f4dd63a05ad" name="fate:ConversionOfPreferredSharesToCommonStocksShares" unitRef="U_shares" decimals="0" sign="-" format="ixt:num-dot-decimal">33,441</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9bd8e56f-1222-47b2-bfa3-55cd075e0f51" contextRef="C_e243220b-bcd5-4012-8eef-5b2d39ca5281" name="fate:ConversionOfPreferredSharesToCommonStocksShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">167,205</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4dd000d8-d127-43cb-a77e-948a5c8a2bf5" contextRef="C_e243220b-bcd5-4012-8eef-5b2d39ca5281" name="fate:ConversionOfPreferenceShareToCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_426edce6-8294-44ea-bf7b-1c3d5a05d9bb" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="fate:ConversionOfPreferenceShareToCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock&#8211;based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13df00ef-553f-46e4-986e-d8f737ac3e83" contextRef="C_4fb1c409-95ec-4aa9-9296-606146c23c7b" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,459</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5c310de-71e4-4d6a-acff-8297f03db824" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,459</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized gain on investments, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4766bcd4-63de-4a82-8bed-312d71b2aa2a" contextRef="C_bbc6feb5-7fbe-40df-a81f-6062a8a5fbb8" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,869</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29f852ec-984a-4a81-8adb-d7f5ba589794" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,869</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1021e347-7b14-441b-a8e3-4914dad290ae" contextRef="C_eb400e71-8a95-42b3-aaea-dc66ceacad22" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">160,928</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cb70446-ac78-4d75-b561-b1cdb0fbb96f" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">160,928</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c916f00-2071-42fc-aa51-51125650ddb8" contextRef="C_7df46466-a06c-4ab1-909b-db1961aa969c" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,761,108</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea6bca76-a063-4d2e-a929-1a9d2c9e10b8" contextRef="C_7df46466-a06c-4ab1-909b-db1961aa969c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d70cf89-fa79-40d3-990b-de57d9779b51" contextRef="C_fe855db0-cbd1-4634-932c-99540e86df56" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">98,627,076</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83212770-06b0-4ecb-87d1-23e13fc07d9f" contextRef="C_fe855db0-cbd1-4634-932c-99540e86df56" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">99</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9a541f8-79dd-40bb-a132-2997e8cc328a" contextRef="C_f255de04-23de-47b2-bf4a-1d7b7bf4d379" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,580,032</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce04e3b3-c77f-4a5b-88d3-e51ba25e1d81" contextRef="C_77ef949f-bbd0-4757-abd9-d2cf6948dfea" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3c738c0-4fc2-43e3-ab87-be99e44ab314" contextRef="C_22baae92-8d72-48bd-bc26-99cb822ac436" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,211,732</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4123f55c-b1a6-4dfe-aacf-f2c20e8f8e49" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">368,417</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of stock options, net of issuance costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b4cbf11-0006-4886-a3d2-719283c04f94" contextRef="C_31099ea4-f12e-4b2c-9160-b411e31dd257" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">45,438</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92f20ef2-c307-456d-a5a5-529bf65fb99a" contextRef="C_00cbef97-1aad-4784-a3ca-62ddc68740ab" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">295</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebf04b13-1e69-4c30-a99d-ab11f7bbf88a" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">295</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon vesting of restricted stock units</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92834f17-4cc0-4392-aa75-356ce690c831" contextRef="C_31099ea4-f12e-4b2c-9160-b411e31dd257" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">680,201</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Conversion of preferred shares to common stock</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be6c86cc-1a35-44c2-b923-c2e209fc83ef" contextRef="C_805cb483-0110-4ded-9a01-7cfc77c9ed1a" name="fate:ConversionOfPreferredSharesToCommonStocksShares" unitRef="U_shares" decimals="0" sign="-" format="ixt:num-dot-decimal">6,022</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d767f1bb-db4c-469d-9c2f-21fd08da784f" contextRef="C_31099ea4-f12e-4b2c-9160-b411e31dd257" name="fate:ConversionOfPreferredSharesToCommonStocksShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">30,110</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock&#8211;based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2a26260-4b64-4786-a127-228061bee08a" contextRef="C_00cbef97-1aad-4784-a3ca-62ddc68740ab" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,496</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c39cb23-907a-49a8-a959-4404bf40659b" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,496</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Public offering of common stock and issuance of pre-funded warrants, net of offering costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5064c4fc-b538-4a3c-85d2-25ca890e13ef" contextRef="C_31099ea4-f12e-4b2c-9160-b411e31dd257" name="fate:CommonStockOfPublicOfferingAndIssuanceOfPreFundedWarrants" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">14,545,454</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6af51857-7475-4467-a25f-e730ed6d1747" contextRef="C_31099ea4-f12e-4b2c-9160-b411e31dd257" name="fate:PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bec71fd3-095d-42e7-a1ee-63f130bbf533" contextRef="C_00cbef97-1aad-4784-a3ca-62ddc68740ab" name="fate:PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,516</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_714289b1-686a-4bcc-b87a-8d5340e8cba9" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="fate:PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,531</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Private placement of pre-funded warrants</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_edb686fe-0e71-4f85-90dc-e8ad50de4d57" contextRef="C_00cbef97-1aad-4784-a3ca-62ddc68740ab" name="fate:PrivatePlacementOfPreFundedWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,996</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b50f455c-89a3-4603-a806-17fa222ff12d" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="fate:PrivatePlacementOfPreFundedWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,996</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized gain on investments, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d34647c-3597-4710-93c6-c5de6a205215" contextRef="C_7d04432b-9ec3-45bd-848d-144b3dd8b270" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">253</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c72ab05-0b26-4670-a3d2-909bdc0e6a72" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">253</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97df79b2-9394-48ca-ac4c-bdc5f0b26def" contextRef="C_d7661ece-b1bb-47ae-89fd-c9e5fb4fce03" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">186,262</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6dda60d-32f6-4742-91ea-580c368ecd8d" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">186,262</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99ea3921-aa21-405e-8308-e35a4f6f3287" contextRef="C_ad67a626-7c86-4e93-88d6-33d3a62a1c24" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,755,086</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57d519e7-60b9-4b06-9157-faf616a00759" contextRef="C_ad67a626-7c86-4e93-88d6-33d3a62a1c24" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a51925a-b51d-4b0c-ac20-b52c85ba2b74" contextRef="C_d8f9c7ba-407a-4a32-8e3a-a7d43910792c" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">113,928,279</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e4e427d-a4fe-4611-bbb7-938e5ac3f6d9" contextRef="C_d8f9c7ba-407a-4a32-8e3a-a7d43910792c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">114</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b33a3f5-82d3-419a-a8dc-8fc23d1eb3fd" contextRef="C_6f3f91dc-9183-4b96-83ab-8d0a1cf21e83" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,716,335</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a388aca-3536-4e13-8991-c25dcd8224a4" contextRef="C_a641074c-59aa-4f3c-8a89-4a805c5db02a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">268</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ad9cea7-09ba-48be-a93b-18f338918761" contextRef="C_8b609e2a-1e60-4b1e-b0db-d6a181ac993b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,397,994</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f84b9420-d1c6-48a2-b76d-e25bc1796711" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">318,726</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See accompanying notes</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">106</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fate Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statem</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ents of Cash Flows</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0b6a5c1-f07e-474f-add9-68295e9adad3" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">186,262</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0490291f-0a14-4f6a-a3b6-ba4a0efc2b63" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">160,928</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62a8a08c-32d0-49e7-aaaa-599bebaa6bd7" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,962</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95d4f0c2-9113-4fc3-9bb5-078a3e2ebcda" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,282</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock&#8211;based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbd81015-75eb-4cde-aa07-3fd0241a2944" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,496</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d3c6aa6-c4ea-4b1d-a3fb-c7695a2eb3ad" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,459</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accretion and amortization of premiums and discounts on investments, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58f9f36d-5a2d-4368-aebe-6c8ed45628d9" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,080</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1dc8d521-75fb-4f9a-918a-687193974842" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,398</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of collaboration contract costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddf01c27-dd56-42a5-914c-5c998da935fc" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:CapitalizedContractCostAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91400ca7-1bc9-46a4-be7c-bd459d37f3e9" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:CapitalizedContractCostAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,196</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48e65167-b277-40e7-a9e1-008d701cf801" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">892</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec2d8f4a-bf97-4267-a839-49d767da958c" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,541</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of stock price appreciation milestones</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13067de5-661f-4386-8eea-dd3e75d187b0" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="fate:IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">819</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d83effff-bbd2-409f-b37a-6ab614f0b770" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="fate:IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,515</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment of long-lived assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b2fbdff-7243-4a60-bc06-21315bb4149c" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,737</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c6269c9-cc6f-4b1c-bfa0-76aea91c6271" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss on disposal of property and equipment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f23f616-8410-497c-bf7c-9f1b3cabbd5f" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">942</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9be0bf8-40a4-4e6e-a321-fd8503f7dee4" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Grant income from FT516 CIRM award</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82bdde7f-88ef-49bd-866f-0708f9c3330a" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="fate:GrantIncomeFromCirmAward" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2910321b-864e-4801-9fab-7e91319e3dc4" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="fate:GrantIncomeFromCirmAward" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:15pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in assets and liabilities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3599681-9daf-473a-8c1c-6400bda1c547" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,113</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c208dad8-c243-44cf-8213-005bb6ec4574" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,654</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee6f411e-78d2-4dd3-acfb-51abaa29dabd" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,237</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f99a417-ef6b-406e-82f2-29eae0558218" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,876</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable and accrued expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_043d9ef6-550c-4e8f-8949-9373a95f25f3" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,661</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ae9c872-9a54-42f5-88d9-c25f468ce345" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">28,940</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets and lease liabilities, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_509e3cb6-b593-4a69-9559-aebf34788eba" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="fate:IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,421</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02226264-6009-4f8c-89a9-56166ee994d6" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="fate:IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,408</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:35pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_daf8e7bb-89f3-4875-9d35-26296f600552" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">122,874</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9cdc9c0d-2cd3-4718-9ed2-e1e8a3106ba5" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">132,263</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Investing activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afa36d65-67f5-4e92-a65a-2324e66cf257" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">730</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b780e27-86fb-48c3-bed0-23fb601b231d" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,153</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of investments</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8933da28-7a58-4e93-90db-d946cb17837b" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">317,750</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1cf6050-4021-4a44-bbf3-47527ea805c2" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">358,810</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maturities of investments</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7dfa016a-15a9-4816-bf2e-697d7f2ba305" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">330,698</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42b26c60-c7a6-4cb1-863d-39da7d146cfc" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">477,628</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:35pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by investing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98870a26-f2be-4dd8-a469-de5cdaad1ff1" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,218</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1e1a0a8-45ef-48ed-a3a7-0767b1559d45" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112,665</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financing activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock from equity incentive plans, net of issuance costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66341f13-d10e-43e1-9215-fb14fc36646e" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">295</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2925d5fb-349d-42ce-8d66-781d5e8b52e2" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from public offering of common stock, net of issuance costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5082482c-f315-4c6a-84cd-fe6372a4f8ee" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,531</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_555c5c32-bfb5-4f22-b001-20ead03e7fe7" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of pre-funded warrants, net of issuance costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d51dbbea-ce38-4554-a68e-453ed930840d" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,996</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6c5e64b-284c-4137-80c3-b72c694c5ae8" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from FT819 CIRM award</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25352d53-0db8-43dd-8646-9ce1be570d57" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="fate:ProceedsFromCIRMAward" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,070</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_631dea7d-028f-4ef7-a5cc-bcc1cc53e70a" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="fate:ProceedsFromCIRMAward" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:35pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4785044c-1259-4831-ac13-365e932d75c3" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">99,892</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd5b18cb-8f8a-4731-a47f-87f2e2ad785b" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net change in cash, cash equivalents and restricted cash</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c737042c-fe67-4b6f-a58e-96657f2ed7de" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,764</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f408aa6-f12e-4022-914d-3d95082478cf" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">19,513</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash at beginning of the year</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4fc7262d-f129-4853-894b-63fa7795722c" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,047</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecf9fb49-0b46-4555-a35b-a86b1e578d10" contextRef="C_6199ef4e-6533-4919-aa08-7b8879357aa9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,560</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash at end of the year</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec572674-1a7b-49cc-839b-7c93a301f9a1" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,283</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_826b4ad1-342a-4d47-9307-05e8c3019190" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,047</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental schedule of noncash investing and financing activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property and equipment in accounts payable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4150fe7c-bb27-4e73-93a4-8e1e16c656a8" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">140</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98396104-6b1e-49fb-a07b-03bd0ea5f193" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See accompanying notes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">107</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fate Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_consolidated_financial_statemen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Financial Statements</span></p>
  <div><ix:nonNumeric id="F_cdf8302a-0044-42f7-981b-5200b227c465" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_cdf8302a-0044-42f7-981b-5200b227c465_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Organization and Summary of Significant Accounting Policies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Organization</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fate Therapeutics, Inc. (the Company) was incorporated in the state of Delaware on April 27, 2007 and has its principal operations in San Diego, California. The Company is a clinical-stage biopharmaceutical company dedicated to bringing off-the-shelf, multiplexed-engineered, iPSC-derived cellular immunotherapies to patients.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company has devoted substantially all of its efforts to product development, raising capital and building infrastructure and has not generated any revenues from any sales of its therapeutic products. To date, the Company&#8217;s revenues have been derived from collaboration agreements and government grants.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_41d7cda7-22d3-4586-bf7b-4986ab6652ec" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The preparation of the Company&#8217;s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#8217;s consolidated financial statements relate to its stock appreciation milestone obligations, contracts containing leases, and accrued expenses. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f9918a61-6c69-425f-b5e1-9daa5b54294a" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements include the accounts of the Company and its subsidiaries. To date, the aggregate operations of these subsidiaries have not been significant and all intercompany transactions and balances have been eliminated in consolidation.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cb716ee8-0f8b-45f5-8e83-8e62a8997c97" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true" continuedAt="F_cb716ee8-0f8b-45f5-8e83-8e62a8997c97_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s financial instruments consist primarily of cash and cash equivalents, marketable securities, accounts receivable, stock price appreciation milestones, accounts payable, and accrued liabilities. The carrying amounts of accounts receivable, accounts payable and accrued liabilities are considered to be representative of their respective fair values because of the relatively short-term nature of those instruments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three- tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></p><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1: Observable inputs such as quoted prices in active markets;</span></p><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></p><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_cb716ee8-0f8b-45f5-8e83-8e62a8997c97_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><ix:nonNumeric id="F_24671eec-5380-469a-9cba-6a0538dd91a3" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true" continuedAt="F_24671eec-5380-469a-9cba-6a0538dd91a3_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash, Cash Equivalents and Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and cash equivalents include cash in readily available checking and savings accounts, money market accounts and money market funds. The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">108</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_cdf8302a-0044-42f7-981b-5200b227c465_1" continuedAt="F_cdf8302a-0044-42f7-981b-5200b227c465_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_24671eec-5380-469a-9cba-6a0538dd91a3_1" continuedAt="F_24671eec-5380-469a-9cba-6a0538dd91a3_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_acdcee18-1ac5-4ca1-8b57-2700a8ae939d" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"/>
          <td style="width:1.62%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.883000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.62%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.883000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_375352cd-4883-4edd-9775-a9bf38d00407" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,056</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32c035f6-c346-408c-a0a8-ecf0456e310d" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,870</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92901940-0d2e-4b87-b409-e89f1b9e440e" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,227</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd5406cc-71e8-4972-ad3f-198edcd77a7e" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,177</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7ea7f85-8095-4070-81b5-109716566eed" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,283</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_889bc29f-0d58-4169-82d3-e0a7fc935f51" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,047</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_24671eec-5380-469a-9cba-6a0538dd91a3_2"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024 and 2023, the restricted cash balance includes cash-collateralized irrevocable standby letters of credit for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04e8e001-752b-4191-b503-2cf6ff125264" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:LettersOfCreditOutstandingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mill</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">io</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">n and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab176181-d768-47b8-93c1-a49935289816" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:LettersOfCreditOutstandingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, associate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d with the Company&#8217;s facilities leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ebfaadfc-badf-4637-a994-46e11b0cca35" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:InvestmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments are accounted for as available-for-sale securities and are carried at fair value on the consolidated balance sheets. Upon initial recognition of the investment and at each reporting period, the Company evaluates whether any unrealized losses on investments are attributable to a credit loss or other factors. Any unrealized losses attributable to credit loss are recorded through an allowance for credit losses, limited to the amount by which the fair value is below amortized cost, with the offsetting amount recorded in other income or expense in the consolidated statement of operations and comprehensive loss. Unrealized losses not attributable to an expected credit loss and unrealized gains on investments are recorded in other comprehensive income (loss) on the consolidated statements of operations and comprehensive loss. Realized gains and losses, if any, on investments classified as available-for-sale securities are included in other income or expense.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amortized cost of investments classified as available-for-sale debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest income. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_10588eff-1fa1-4fac-bf67-b74a20036ace" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:ConcentrationRiskCreditRisk" escape="true" continuedAt="F_10588eff-1fa1-4fac-bf67-b74a20036ace_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_10588eff-1fa1-4fac-bf67-b74a20036ace_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments, which potentially subject the Company to a significant concentration of credit risk, consist primarily of cash, cash equivalents, and investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits and investments are held.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8a4a252a-9619-4bcb-b11c-c2df45751edc" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_36b18d82-10b0-4496-9bd3-0d13c236998e;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1b72d334-a768-4b11-9610-7e30695e21c7" contextRef="C_db4ca2c8-7dec-42f6-9326-27fb5b437f80" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) and generally consist of furniture and fixtures, computers, scientific and office equipment, and in-process costs related to facilities construction. Repairs and maintenance costs are charged to expense as incurred.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_18dd735e-d7a3-4e23-b624-de13bca2ea27" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true" continuedAt="F_18dd735e-d7a3-4e23-b624-de13bca2ea27_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The long-lived asset evaluation is performed at the asset group level (i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities). Recoverability of these assets is measured by a comparison of the carrying amounts to the future undiscounted cash flows the assets are expected to generate from their use and eventual disposition. If the carrying amount is not recoverable, the carrying amount of such assets is reduced to fair value. During 2024, the Company identified an indicator of impairment of its long-lived assets due to a sustained decline in the trading price of the Company&#8217;s common stock over the preceding year, resulting in the Company&#8217;s market capitalization being below its net asset value. The Company utilized observed market lease rates for comparable properties to estimate the fair value of the right-of-use asset and leasehold improvements. The Company utilized trend factors applied to historical costs, estimates of economic depreciation, normal useful lives, and benchmark values for orderly liquidations of the assets in secondary markets to estimate the fair value of the property and equipment. As a result of its fair value analysis, the Company recorde</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_889596c7-cd51-459d-8a79-40d82095205b" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million impairment charge on its property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">109</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_cdf8302a-0044-42f7-981b-5200b227c465_2" continuedAt="F_cdf8302a-0044-42f7-981b-5200b227c465_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_18dd735e-d7a3-4e23-b624-de13bca2ea27_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and equipment a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bb4780c-6fee-4f0a-8e6d-c4d27407d67a" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="fate:ImpairmentOfRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">illion impairment charge on its right-of-use asset in the statement of operations during the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4c1174b-65d0-4c01-bf95-bd74f92bae2d" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impairment was recorded during the year ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_862c0bea-c483-48a9-bfb8-c903019e5766" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:5.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines if a contract contains a lease at the inception of the contract. The Company currently has leases related to its facilities leased for office and laboratory space, which are classified as operating leases. These leases result in operating right-of-use (ROU) assets, current operating lease liabilities, and non-current operating lease liabilities in the Company&#8217;s consolidated balance sheets. The Company does not have any financing leases. Leases with a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f65fabd7-3665-498b-9e74-044fc728bb1d" contextRef="C_3c6a67d5-eeb4-4acd-987b-91a972c863ed" name="fate:ShortTermLeasesTermExcludedFromCalculationOfRightOfUseOfAssetsAndLeaseLiabilities" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12 months</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or less are considered short-term and ROU assets and lease obligations are not recognized. Payments associated with short-term leases are expensed on a straight-line basis over the lease term.</span></p><p style="text-indent:5.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lease liabilities represent an obligation to make lease payments arising from the lease and ROU assets represent the right to use the underlying asset identified in the lease for the lease term. Lease liabilities are measured at the present value of the lease payments not yet paid discounted using the discount rate for the lease established at the lease commencement date. To determine the present value, the implicit rate is used when readily determinable. For those leases where the implicit rate is not provided, the Company determines an incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. ROU assets are measured as the present value of the lease payments and also include any prepaid lease payments made and any other indirect costs incurred, and exclude any lease incentives received. Lease terms may include the impact of options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term. The Company aggregates all lease and non-lease components for each class of underlying assets into a single lease component.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4c134d80-4d89-48e7-81f4-773209937b6a" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:CollaborativeArrangementAccountingPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaborative Arrangements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC Topic 808, Collaborative Arrangements (ASC 808), to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, the Company assesses whether aspects of the arrangement between the Company and its collaboration partner are within the scope of other accounting literature, including ASC Topic 606, Revenue from Contracts with Customers (ASC 606). If it is concluded that some or all aspects of the arrangement represent a transaction with a customer, the Company will account for those aspects of the arrangement within the scope of ASC 606.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC 808 provides guidance for the presentation and disclosure of transactions in collaborative arrangements, but it does not provide recognition or measurement guidance. Therefore, if the Company concludes a counterparty to a transaction is not a customer or otherwise not within the scope of ASC 606, the Company considers the guidance in other accounting literature as applicable or by analogy to account for such transaction. The classification of transactions under the Company&#8217;s arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3e034a2d-2d1b-49be-b950-7742c66765f5" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. If the Company concludes that some or all aspects of the arrangement represent a transaction with a customer, the Company accounts for those aspects of the arrangement within the scope of ASC 606.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For arrangements attributable to ASC 606, the Company recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration the Company is entitled to receive in exchange for such product or service. In doing so, the Company follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_3a3dc854-00bd-4d02-989d-897972f4462e" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="fate:StockPriceAppreciationMilestonesPolicyTextBlock" escape="true" continuedAt="F_3a3dc854-00bd-4d02-989d-897972f4462e_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Price Appreciation Milestones</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company estimates the fair value of the stock price appreciation milestones associated with the Amended and Restated Exclusive License Agreement with Memorial Sloan Kettering Cancer Center (MSKCC) using a Monte Carlo simulation model, which relies on the Company&#8217;s current stock price as well as significant estimates and assumptions to determine the estimated liability associated with the contingent milestone payments. The Company accounts for the fair value of the stock price appreciation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">110</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_cdf8302a-0044-42f7-981b-5200b227c465_3" continuedAt="F_cdf8302a-0044-42f7-981b-5200b227c465_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_3a3dc854-00bd-4d02-989d-897972f4462e_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">milestones </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in accordance with ASC 815, Derivatives and Hedging, with fair value marked to market at each reporting date. The assumptions used to calculate the fair value of the stock price appreciation milestones are subject to a significant amount of judgment including the probability of achieving a specified clinical milestone, the expected volatility of the Company&#8217;s common stock, the risk-free interest rate, and the estimated term, which is based in part on the last valid patent claim date. The Company remeasures the fair value of the stock price appreciation milestones at each balance sheet date, with changes in fair value recorded in earnings as non-operating income or expense on the consolidated statements of operations and comprehensive loss.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c8b032ec-614d-4acf-936d-bbd2f3343f12" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense represents the cost of the grant date fair value of employee stock option and restricted stock unit grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. Performance-based stock units/awards represent a right to receive a certain number of shares of the Company&#8217;s common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, and to the extent achievement of one or any of the performance conditions is probable, the Company reassesses the probability of the achievement of such corporate performance goals and any increase or decrease in share-based compensation expense resulting from an adjustment in the estimated shares to be released is treated as a cumulative catch-up in the period of adjustment. For stock awards for which vesting is subject to both performance-based milestones and market conditions, expense is recorded over the derived service period after the point when the achievement of the performance-based milestone is probable or the performance condition has been achieved.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, with the exception of option grants for which vesting is subject to both performance-based milestones and market conditions, which are valued using a lattice-based model. The fair value of restricted stock units, including performance-based restricted stock units, is based on the closing price of the Company&#8217;s common stock as reported on The Nasdaq Global Market on the date of grant. The Company recognizes forfeitures for all awards as such forfeitures occur.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7b460596-6f8a-47a5-913a-fc4634446b13" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more- likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6ac1eeb4-43fe-4fbc-88d7-da80faccb06e" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">more than 50 percent</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_d8381bb6-9a7f-4eb9-92ce-9eabb3de3570" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="fate:EmployeeRetentionCreditPolicy" escape="true" continuedAt="F_d8381bb6-9a7f-4eb9-92ce-9eabb3de3570_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee Retention Credit</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CARES Act provides an employee retention credit (ERC), which is a refundable tax credit against certain employment taxes of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b04a5055-b9f1-4a0a-8060-c20d20602af3" contextRef="C_8073b9ee-958a-4e70-8014-118578a7c26b" name="fate:RefundableTaxCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per employee for eligible employers. The tax credit is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88b3eec9-048b-49f1-a107-80c9feee1698" contextRef="C_914c3fc5-d128-4c00-a001-75c4add6174a" name="fate:PercentageOfTaxCredit" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of qualified wages paid to employees during a quarter, capped at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0fd6de8-e705-42ae-b0f3-5fa4cc9c595f" contextRef="C_914c3fc5-d128-4c00-a001-75c4add6174a" name="us-gaap:PaymentsToEmployees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of qualified wages per employee through December 31, 2020. Additional relief provisions were passed by the United States government, which extend and slightly expand the qualified wage caps on these credits through December 31, 2021. Based on these additional provisions, the tax credit is now equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfb2633b-0dd0-453c-8743-5ba17e0b31c4" contextRef="C_c61bcb64-4368-4879-8eae-3bea4e1f47f9" name="fate:PercentageOfTaxCredit" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">70</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of qualified wages paid to employees during a quarter, and the limit on qualified wages per employee has been increased to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a92ab14f-784c-4622-ad1a-b1435bc51bab" contextRef="C_c61bcb64-4368-4879-8eae-3bea4e1f47f9" name="us-gaap:PaymentsToEmployees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of qualified wages per quarter. The Company qualifies for the tax credit under the CARES Act and expects to continue to receive additional tax credits under the additional relief provisions for qualified wages through December 31, 2021. In connection with the CARES Act, the Company adopted a policy to recognize the employee retention credit when received and include in other income in the statement of operations. T</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">he </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company received a cash</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">111</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_cdf8302a-0044-42f7-981b-5200b227c465_4" continuedAt="F_cdf8302a-0044-42f7-981b-5200b227c465_5"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_d8381bb6-9a7f-4eb9-92ce-9eabb3de3570_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_215e2fe0-57ce-409f-a70b-fef16849b4a2" contextRef="C_0d4321be-2b98-4d77-827f-dd1e376a2681" name="us-gaap:OtherIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of other income during the year ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No such amount was received or recorded during the year ended December 31, 2024.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a515dfdb-367b-4b5f-a3bc-89ea7335cf0d" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non&#8209;owner sources. Other comprehensive loss includes unrealized gains and losses on available-for-sale securities.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_7ff33053-5f45-49d4-8145-43fcbb78f780" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Loss Per Common Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. The Pre-Funded Warrants associated with the January 2021 public equity offering and the private placement concurrent with the March 2024 public equity offering (see Note 9) are considered outstanding shares in the basic earnings per share calculation given their nominal exercise price. Dilutive common stock equivalents comprise convertible preferred stock, warrants for the purchase of common stock, and common stock options and restricted stock units outstanding under the Company&#8217;s stock option plans. For all periods presented, there is no difference in the number of common shares used to calculate basic and diluted common shares outstanding due to the Company&#8217;s net loss position.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_be17614c-2814-4ecf-b9aa-00cd7d4cbfc9" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per share attributable to stockholders for the years ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024 and 2023 are calculated as follows (in thousands, except share and per share data):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"/>
          <td style="width:1.62%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.883000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.62%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.883000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d73149c7-0d75-4648-a978-1d3ae57fa137" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">186,262</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d2eadf8-e4e0-4a4c-a3cd-56c15b155337" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">160,928</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares used to compute net loss per share, basic and diluted</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b241fb8-52fd-4e31-a247-779aeafb9031" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">110,596,272</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac8575f0-90ec-444a-a425-cfa858c191dd" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">98,153,852</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average pre-funded warrants</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3535c001-3212-4aee-823a-1116361e7eee" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="fate:WeightedAveragePreFundedWarrants" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,088,905</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1e9ce1c-6340-46cb-b4ab-5361893ea98e" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="fate:WeightedAveragePreFundedWarrants" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">257,310</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding used to<br/>&#160;&#160;&#160;&#160;compute basic and diluted net loss per share</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ead170d-2d9e-45d9-9f0e-616db3ffe017" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_5cccd998-c21f-48b6-85c1-5cdc29e3f591" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">113,685,177</ix:nonFraction></ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d3cc42d-2666-4743-a887-1597651727d1" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_33a99673-a391-4995-a63c-bf87b52797fe" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">98,411,162</ix:nonFraction></ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic and diluted</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c65af818-2483-48c0-840a-a1f28e023089" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8bce824a-bb16-4ec7-9e1b-e54cdae9ba79" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.64</ix:nonFraction></ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19483d53-9809-4832-a1e1-7dfb47a8efd2" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_cc2bb94d-2f80-4c50-9de4-c9cce261aacf" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.64</ix:nonFraction></ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1b228c9b-8377-41b6-860a-98c23a56519d" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_1b228c9b-8377-41b6-860a-98c23a56519d_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Potentially dilutive securities that are not included in the calculation of diluted net loss per common share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.967%;box-sizing:content-box;"/>
          <td style="width:1.16%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:13.357%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.16%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:13.357%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock options</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0499f8ae-1100-4ff1-a0fd-ecb6c62cfc60" contextRef="C_83226ba1-7f86-458e-b153-94d4da5af37e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,722,674</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9333e94-6a86-4338-9c7f-4eebdd8ac065" contextRef="C_ce45b517-0884-46c2-a4a4-3f9f7359e4f1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,850,841</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05e8f48e-7f28-4aff-a0fb-eee268a9791c" contextRef="C_2c762660-e17f-4068-960c-6e97d50571ec" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,214,064</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7518b583-05ae-4053-85f0-751a4555aa9c" contextRef="C_1cf4be6b-4800-4f2a-bcb7-d38f5709c7aa" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,065,087</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series A convertible preferred stock (if converted)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6dd6fd1c-f30a-4834-82bc-a236b43ae477" contextRef="C_0519f681-f046-4690-9e46-0dd9cba066f1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,775,430</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a62b2379-e923-4193-9327-eeeeaa34fd67" contextRef="C_b8f2b2d3-e3a5-40c0-8565-7b6bedfecd7a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,805,540</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebb6617f-0dfd-4b55-ab79-3bac25913dd1" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">30,712,168</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67c0f04a-5239-4db7-b48b-fa0c9a490422" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">26,721,468</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><div><ix:continuation id="F_1b228c9b-8377-41b6-860a-98c23a56519d_1"></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e6b999c0-fcc7-41a7-98ea-9d33e3d52095" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="fate:LiquidityPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Going Concern Assessment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Substantial doubt about an entity&#8217;s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year from the financial statement issuance date. The Company determined that there are no conditions or events that raise substantial doubt about its ability to continue as a going concern for a period of at least twelve months from the date of issuance of these financial statements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_b10b001f-f29c-4adb-82d3-caa309a39f90" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true" continuedAt="F_b10b001f-f29c-4adb-82d3-caa309a39f90_1"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU No. 2023-07, which requires public entities to disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about a reportable segment&#8217;s profit or loss and assets that are currently required annually. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The ASU does not change how a public</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">112</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_cdf8302a-0044-42f7-981b-5200b227c465_5"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_b10b001f-f29c-4adb-82d3-caa309a39f90_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">entity identifies its operating segments, aggregates them or applies the quantitative thresholds to determine its reportable segments. The ASU is effective for fiscal years beginning after December 15, 2023, and for interim periods beginning after December 15, 2024, with early adoption permitted. The guidance should be applied retrospectively to all periods presented in the financial statements, unless it is impracticable. The segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The Company adopted ASU No. 2023-07 during the year ended December 31, 2024 and have included required disclosures in Note 11.</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This new standard will be effective for the annual periods beginning the year ended December 31, 2025. The new standard permits early adoption and can be applied prospectively or retrospectively. The Company does not expect the adoption of this guidance to have a material impact on its consolidated financial statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement: Reporting Comprehensive Income- Expense Disaggregation Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which requires detailed information about specified categories of expenses included in certain expense captions presented on the face of the income statement, as well as disclosures about selling expenses. This ASU is effective for fiscal years beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</span></p></ix:continuation></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_a1a92a81-7872-40f3-970f-b8a915ba36bb" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true" continuedAt="F_a1a92a81-7872-40f3-970f-b8a915ba36bb_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Collaboration and License Agreements</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ono Collaboration and Option Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 14, 2018, the Company entered into a Collaboration and Option Agreement (the Ono Agreement) with Ono Phar</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maceutical Co., Ltd. (Ono) for the joint development and commercialization of two off-the-shelf, iPSC-derived CAR T-cell product candidates (Candidate 1 and Candidate 2). Pursuant to the terms of the Ono Agreement, the Company received an upfront, non-refundable and non-creditable payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d870057-ac41-4be5-95f3-677f20af50b0" contextRef="C_f5465cc9-eacc-41b4-9cfc-f0dad102ddfb" name="fate:CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Additionally, the Company was entitled to receive funding for the conduct of research and preclinical development under a joint research plan, which fees were estimated to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9be82fb-639b-4c17-9947-425484ebe6bb" contextRef="C_f98f7f9d-7ad9-48be-9ec2-e497587e292e" name="fate:CollaborativeArrangementAggregatePaymentsReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in aggregate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2020, the Company entered into a letter agreement with Ono (the Ono Letter Agreement) pursuant to which Ono delivered proprietary antigen binding domains targeting an antigen expressed on certain solid tumors for incorporation into Candidate 2 and paid the Company a milestone fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b669c8f-b2c1-4988-9f4b-89fb1b942010" contextRef="C_bf1abdb0-874a-4c56-9fa4-d32731526c6f" name="fate:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for further research and preclinical development of Candidate 2. In addition, Ono terminated all further research and preclinical development with respect to Candidate 1, and the Company retained all rights to research, develop and commercialize Candidate 1 throughout the world without any obligation to Ono.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2022, the Company entered into an amendment with Ono to the Ono Agreement (the 2022 Ono Amendment). Pursuant to the 2022 Ono Amendment, the companies agreed to designate an additional antigen expressed on certain solid tumors for research and preclinical development, and Ono agreed to contribute proprietary antigen binding domains targeting such additional solid tumor antigen (Candidate 3). In addition, for both Candidate 2 and Candidate 3, Ono and the Company expanded the scope of the collaboration to include the research and preclinical development of iPSC-derived CAR NK cell product candidates (in addition to iPSC-derived CAR T-cell product candidates) targeting the designated solid tumor antigens. Similar to Candidate 2, the Company granted to Ono, during a specified period of time, a preclinical option (Candidate 3 Development Option) to obtain an exclusive license under certain intellectual property rights, subject to payment of an option exercise fee to the Company by Ono, to further develop and commercialize Candidate 3 in all territories of the world, where the Company retains rights to co-develop and co-commercialize Candidate 3 in the United States and Europe under a joint arrangement with Ono pursuant to which the Company is eligible to share at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdac4b2a-7b1b-432d-b8e9-fb6977b781ee" contextRef="C_b524e977-baf9-4884-add0-8ccda59b00ff" name="fate:ProfitLossSharingPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the profits and losses. The Candidate 3 Development Option represents an option with no material right. Under the 2022 Ono Amendment, aggregate estimated research and preclinical development fees have been increased by approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfb38631-838d-4798-9ed7-3af0ec5c29c4" contextRef="C_e2c30eb4-cb8a-4c56-94e1-15d379546979" name="fate:CollaborativeArrangementPotentialAdditionalMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, for a total estimated $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7dd2e5d9-aca5-435f-9c82-aeee244fe2fc" contextRef="C_69c1fc96-8425-49fc-a5df-640ad6ae407c" name="fate:CollaborativeArrangementPotentialAdditionalMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">29.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in aggregate research and preclinical development fees over the course of the joint research plan.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 2022, Ono exercised its option to obtain a license to develop and commercialize Candidate 2 (the Candidate 2 Development Option). The Company exercised its option (the CDCC Option) to co-develop and co-commercialize Candidate 2 in the United States and Europe. As a result, the Company received an Option Exercise Payment (as defined under the Ono Agreement) of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">113</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_a1a92a81-7872-40f3-970f-b8a915ba36bb_1" continuedAt="F_a1a92a81-7872-40f3-970f-b8a915ba36bb_2"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d028a311-6ca0-413f-ac67-ff81b17ba7e2" contextRef="C_4bd1be9a-9ef2-4939-bc4f-c8ced0fd9412" name="fate:OptionExercisePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company and Ono are proceeding under a joint development plan for the ongoing development of Candidate 2. At the inception of the Ono Agreement, the Company determined the Candidate 2 Development Option represented an option with no material right that is distinct and separable from the ongoing development of Candidate 2 being performed by the parties. As such, the option exercise was treated as a separate contract with a single performance obligation of granting and delivering Ono a license to further develop and commercialize Candidate 2. The Company has completed its performance obligation with respect to the Candidate 2 Development Option and accordingly, recognized the Option Exercise Payment as revenue for the year ended December 31, 2022. The costs of this joint development plan are accounted for in accordance with ASC 808, and cost sharing payments to the Company from Ono are recorded net into research and development expenses. In addition, in connection with the ongoing joint development of Candidate 2, the Company is eligible to receive additional payments upon the achievement of certain clinical, regulatory, and commercial milestones</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (as further described below).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Company entered into an amendment with Ono to the Ono Agreement (the 2023 Ono Amendment). Under the 2023 Ono Amendment, aggregate estimated research and preclinical development fees payable by Ono to the Company for Candidate 3 have been increased by approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68e16fa5-905a-4387-a19c-b8351511b534" contextRef="C_14a6993c-8757-45a1-9ffd-ead3d146845f" name="fate:CollaborativeArrangementPotentialAdditionalMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, for a total estimated $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52b04bf4-2a14-4eaa-8736-ce796843f3ed" contextRef="C_28eaa775-35eb-4f9b-a403-7245d490401e" name="fate:CollaborativeArrangementPotentialAdditionalMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">30.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in aggregate research and preclinical development fees over the course of the joint research plan.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, following Ono&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s exercise of the Candidate 2 Development Option and grant of the development and commercialization license, the Company achieved a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fcddaf3e-f5d4-4c4a-bee8-8abbe269fbaa" contextRef="C_c1b46ce1-8237-43cf-86cd-6a985c5ce0ca" name="fate:ClinicalDevelopmentMilestoneFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million clinical development milestone for Candidate 2 and the Company recognized such amount as revenue during the period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2024, the Company entered into an amendment with Ono to the Ono Agreement (the 2024 Ono Amendment and collectively with the 2023 Ono Amendment and 2022 Ono Amendment, the Ono Amendments). Under the 2024 Ono Amendment, aggregate estimated research and preclinical development fees payable by Ono to the Company for Candidate 3 have been increased by approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea0605d5-fba3-4288-8fb8-fab516a9ff1e" contextRef="C_6c678e63-62cc-45c4-9884-6caff102c094" name="fate:CollaborativeArrangementPotentialAdditionalMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, for a total estimated $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b22e83f5-229d-4cb9-8054-0f8d2440867b" contextRef="C_f6acdf54-a780-4f0d-a5a2-e9a7888f459a" name="fate:CollaborativeArrangementPotentialAdditionalMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">38.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in aggregate research and preclinical development fees over the course of the joint research plan. The Company will continue to receive committed funding under the joint research plan from Ono through June 2025. The Candidate 3 Development Option expires upon the earlier of: (a) June 30, 2025 or (b) the achievement of the pre-defined preclinical milestone under the joint research plan for Candidate 3. Subject to payment of an extension fee by Ono, Ono may choose to defer its decision to exercise the Candidate 3 Development Option until no later than June 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Ono Agreement (as amended by the Ono Amendments), for Candidate 2 and for Candidate 3 (subject to exercise by Ono of its Candidate 3 Development Option), the Company is eligible to receive additional payments upon the achievement of certain clinical, regulatory and commercial milestones (the Ono Milestones) with respect to each Candidate in an amount up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16277907-e8d3-439f-b76d-c2e5d657b30f" contextRef="C_4e4a3db2-068c-46c3-9e45-17fdfb12f653" name="fate:CollaborativeArrangementAggregateMilestonePaymentsReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">843.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in aggregate, with the applicable milestone payments for the United States and Europe subject to reduction by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5a4c971-57f9-44bf-b716-acf52889f64a" contextRef="C_c4256f0f-bf1b-4d25-ba9b-95785d196f09" name="fate:CollaborativeArrangementPercentageOfReductionOnMilestonePayments" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% if the Company elects to co-develop and co-commercialize the Candidate in the United States and Europe as described above. In addition, in those territories where Ono has exclusive rights of commercialization, the Company is eligible to receive tiered royalties (Royalties) ranging from the mid-single digits to the low-double digits based on annual net sales by Ono for each Candidate in such territories, with the Royalties subject to certain reductions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Ono Agreement will terminate with respect to a Candidate if Ono does not exercise its development option for a candidate within the option period, or in its entirety if Ono does not exercise any of its development options for the candidates within their respective option periods. In addition, either party may terminate the Ono Agreement in the event of breach, insolvency or patent challenges by the other party; provided, that Ono may terminate the Ono Agreement in its sole discretion (x) on a Candidate-by-Candidate basis at any time after the second anniversary of the effective date of the Ono Agreement or (y) on a Candidate-by-Candidate or country-by-country basis at any time after the expiration of the development option period, subject to certain limitations. The Ono Agreement will expire on a Candidate-by-Candidate and country-by-country basis upon the expiration of the applicable royalty term, or in its entirety upon the expiration of all applicable payment obligations under the agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determined that the Ono Agreement, Ono Letter Agreement, and Ono Amendments (collectively, the Ono Arrangement) were within the scope of ASC 808 and applicable to such guidance. The Company concluded that certain units of account, specifically the grant of a research license to certain intellectual property and the performance of research and preclinical development, within the Ono Arrangement represented a customer relationship and applied relevant guidance from ASC 606 to evaluate the appropriate accounting for those units of account. In accordance with this guidance, the Company identified its promised goods and services, including its grant of a research license to Ono to certain of its intellectual property subject to certain conditions, its conduct of research and preclinical development services, and its participation in a joint steering committee. The Company determined that its grant of a research license to Ono to certain of its intellectual property was not distinct from its conduct of research and preclinical development services and participation in a joint steering committee. Accordingly, the Company determined that the research license, the research and preclinical development services, and the participation in a joint steering committee during the development option period, should be accounted for as one combined performance obligation, and that the combined performance obligation is transferred over the expected term of the conduct of the research and preclinical development services. The Company also determined that, subject to the guidance of ASC 606, the license to develop and commercialize Candidate 2 upon exercise of the Candidate 2 Development Option was distinct and separable from the development and commercialization activities, which are accounted for under ASC 808.  The termination of the Ono Agreement with respect to Candidate 1 did not impact this assessment.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">114</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_a1a92a81-7872-40f3-970f-b8a915ba36bb_2" continuedAt="F_a1a92a81-7872-40f3-970f-b8a915ba36bb_3"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with ASC 606, the Company determined that the initial transaction price for research and preclinical development under the Ono Arrangement equaled $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a8a5f32-7989-4ced-a412-67441e5d27d7" contextRef="C_47a8c41d-7932-412e-a1cf-a28cc3a2ebb4" name="fate:TransactionPriceOfAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">48.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, consisting of the upfront, non-refundable and non-creditable payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb31dfcc-2625-4122-94ae-fe11bd65d9b9" contextRef="C_f98f7f9d-7ad9-48be-9ec2-e497587e292e" name="fate:UpfrontNonRefundableNonCreditablePaymentReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and the aggregate estimated research and preclinical development fees of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_773967ba-53c0-47c4-8420-6aca600cdc27" contextRef="C_f98f7f9d-7ad9-48be-9ec2-e497587e292e" name="fate:CollaborativeArrangementPotentialAdditionalMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">38.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company also concluded that the milestone fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50c4ad60-c217-4c29-892b-bd3096aa524f" contextRef="C_b434e138-ff00-4c3d-bbe3-be9b301a7015" name="fate:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million paid by Ono to the Company for further research and preclinical development of Candidate 2 represented a variable consideration that was previously constrained. Both the upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a45a094a-d1df-4749-9c59-8770e7f5bf3e" contextRef="C_f5465cc9-eacc-41b4-9cfc-f0dad102ddfb" name="fate:CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and the Candidate 2 milestone fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7dde2251-c7ac-4199-ad1c-9ed375e02c06" contextRef="C_ced1b62f-5a61-4b35-bc5e-24a1d2c9771c" name="fate:MilestonePaymentUnderDeferredRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million were recorded as deferred revenue and were recognized as revenue over time in conjunction with the Company&#8217;s conduct of research and preclinical development services based on actual costs incurred as a percentage of the estimated total costs expected to be incurred over the expected term of conduct of the research and preclinical development services. The Company recorded the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d1637da-b6a7-4acf-b8b9-325582e27a8a" contextRef="C_ced1b62f-5a61-4b35-bc5e-24a1d2c9771c" name="fate:CollaborativeArrangementAnnualPaymentsReceivableRecordedUnderDeferredRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million prepayment of the first-year research and preclinical development fees as deferred revenue, and such fees were recognized as revenue as the research and preclinical development services were delivered.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9336a7a5-5669-49f5-92a8-8c086a72731a" contextRef="C_c2029f3a-6dfd-4668-a724-7134c2e52a11" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4baf354-e79a-4368-95a8-3cf7340a89e4" contextRef="C_5773cffb-0793-4d07-bf3f-34a1272bc4c5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under the Ono Arrangement during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, respectively. Such revenue consisted of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_232f5dc3-7945-4e38-b00d-d94a1dd0e80e" contextRef="C_f9d2101e-3c01-4cba-a24b-48c0f0b161d9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million associated with research and preclinical development services, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f4fbf40-acff-4c7a-9fb3-852f9000c09e" contextRef="C_60fe76db-e159-48de-b30e-daed5bf713f6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million associated with the achievement of a clinical development milestone for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024. During the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, such revenue comprised $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_157f3d0e-b4ca-4162-abb3-880c1e4944c4" contextRef="C_5773cffb-0793-4d07-bf3f-34a1272bc4c5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million associated with research and preclinical development services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized contra-research and development expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90dec9db-a2b2-41d8-ad89-7138b0907354" contextRef="C_ca3bbae4-b7ef-4100-8179-d51130791abc" name="fate:ContraResearchAndDevelopmentExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million associated with the joint development of Candidate 2 under the Ono Arrangement for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024. During the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recognized contra-research and development expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b746ee4a-a011-4397-be8f-545bf8088a28" contextRef="C_439addc5-9548-4d3a-bc32-ad8b68c23597" name="fate:ContraResearchAndDevelopmentExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a direct result of the Company&#8217;s entry into the Ono Arrangement, the Company incurred an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52370a52-e833-4dfc-9648-f8b2706570f6" contextRef="C_4cd86a5a-2ced-41c7-9f0e-9f68de9fef11" name="fate:CorrespondingAssetForSublicenseConsiderationPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in sublicense consideration to existing licensors. The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c0c9236-12df-4364-8380-613bbdeb91aa" contextRef="C_c2029f3a-6dfd-4668-a724-7134c2e52a11" name="fate:AmortizationOfSubLicenseConsideration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of such expense during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company recognized </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5e4f7ba-b74e-4bf2-9837-44de2112e050" contextRef="C_5773cffb-0793-4d07-bf3f-34a1272bc4c5" name="fate:AmortizationOfSubLicenseConsideration" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> such expense during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Janssen Collaboration and Option Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 2, 2020 (the Janssen Agreement Effective Date), the Company entered into a Collaboration and Option Agreement (the Janssen Agreement) with Janssen Biotech, Inc. (Janssen), part of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson. Additionally, on the Janssen Agreement Effective Date, the Company entered into a Stock Purchase Agreement (the Stock Purchase Agreement) with Johnson &amp; Johnson Innovation - JJDC, Inc. (JJDC). On January 3, 2023, the Company received notice of termination from Janssen of the Janssen Agreement. The termination took effect on April 3, 2023, and during the three months ended March 31, 2023, the Company performed wind-down activities including discontinuing development of all collaboration product candidates under the Janssen Agreement. The Company was reimbursed for all wind-down activities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Janssen Agreement and the Stock Purchase Agreement taken together, the Company received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb2a41aa-3182-4282-acd2-e0cddc87efcf" contextRef="C_b44c450a-2dc3-4462-8d2c-f77c56795b1f" name="fate:CompanyReceivedPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec77b66d-3595-4f3e-982d-64d0fba1be3f" contextRef="C_b44c450a-2dc3-4462-8d2c-f77c56795b1f" name="fate:UpfrontCashPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was an upfront cash payment and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69bcb902-b5a4-4d41-a97b-7b5d23b92fa3" contextRef="C_4a27cfd3-c4bb-4733-abe8-a5141e381e3f" name="us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was in the form of an equity investment by JJDC. The Company determined the common stock purchase by JJDC represented a premium of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b5085b3-6383-446f-a535-e5774d162598" contextRef="C_b44c450a-2dc3-4462-8d2c-f77c56795b1f" name="fate:EquityPremiumOnSharePricePerShareUnderAgreement" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.93</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, or $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99c86f51-8c0d-45b3-911b-0f5f558b7dbe" contextRef="C_b44c450a-2dc3-4462-8d2c-f77c56795b1f" name="fate:AggregateEquityPremiumOnSharesIssuedUnderAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">16.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in aggregate (the Equity Premium), and the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_180cfd8b-a46f-44b2-b52f-f738e69b3a3b" contextRef="C_b44c450a-2dc3-4462-8d2c-f77c56795b1f" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">34.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was recorded as issuance of common stock in shareholders&#8217; equity. In addition, under the Stock Purchase Agreement, the Company exercised the right to require JJDC to purchase an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5334dd00-fdaf-45a9-84c0-152595daba8b" contextRef="C_b44c450a-2dc3-4462-8d2c-f77c56795b1f" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in shares in a private placement at the same price per share as paid by investors in a public offering. In June 2020, JJDC purchased </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e54204b-cbc3-44ef-b443-a0de644bb7ee" contextRef="C_1e42a653-35ec-4959-8224-d96563396f11" name="fate:StockIssuedDuringPeriodSharesForPrivatePlacement" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of the Company&#8217;s common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ee76e3f-c5b8-49f7-9c13-79cc9281da70" contextRef="C_a53d5f30-4ead-4f12-abb3-1d519e3a22c5" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">28.31</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. Additionally, the Company received full funding for the conduct of all research, preclinical development and Investigational New Drug Application (IND)-enabling activities performed by the Company under the Janssen Agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c564d8dc-dd6d-48db-a943-f18beb7e9c11" contextRef="C_a6afb152-c99a-4b4f-8ec2-a459b2a92d61" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">52.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under the Janssen Agreement for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3d2fe73-3b9f-42bd-9df6-7f4b458742ab" contextRef="C_3aa72a78-bcb4-4041-8da5-aa19c436d13a" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">41.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was deferred as of December 31, 2022. Such revenue consisted of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1484ee6-084d-48cb-8a59-1718133f4d3f" contextRef="C_c3abcd74-97fc-43ce-9d4c-92aeb8a7a7d9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million associated with research and development services, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ace6f79c-9b05-4e13-a6d6-687361bc431e" contextRef="C_5617f7c9-ae5a-4956-8221-b18d672649e5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">31.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million associated with the upfront fee and Equity Premium, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa241997-8fe3-4cfa-89ef-6c10b69ffea8" contextRef="C_3993554b-9513-4d91-b34e-db9cda665ac3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million associated with a commercial option exercise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Janssen Agreement, the Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5905b783-906e-4a41-aebe-da411c7f38ea" contextRef="C_b5de5eaf-450a-48f0-8a17-e88454281754" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in sublicense fees to certain of its existing licensors. The $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db51980b-cb75-4ed0-ba1d-3075490be49c" contextRef="C_473eb942-1f90-41e1-b4de-c3380615c958" name="fate:SublicenseConsiderationRepresentsAnAssetUnderAscOtherAssetsAndDeferredCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in sublicense consideration represents an asset under ASC 340, and was amortized to research and development expense ratably with the Company&#8217;s revenue recognition under the Janssen Agreement. During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1b96d29-8591-4f02-847a-d439629d5f2c" contextRef="C_a6afb152-c99a-4b4f-8ec2-a459b2a92d61" name="fate:AmortizationOfSubLicenseConsideration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of such expense. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, there was no remaining balance on the Janssen Agreement.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Memorial Sloan Kettering Cancer Center License Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 15, 2018, the Company entered into an Amended and Restated Exclusive License Agreement (the Amended MSKCC License) with MSKCC. The Amended MSKCC License amends and restates the Exclusive License Agreement entered into between the Company and MSKCC on August 19, 2016 (the Original MSKCC License), pursuant to which the Company entered into an exclusive license agreement with MSKCC for rights relating to compositions and methods covering iPSC-derived cellular immunotherapy, including T-cells and NK-cells derived from iPSCs engineered with CARs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">115</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_a1a92a81-7872-40f3-970f-b8a915ba36bb_3" continuedAt="F_a1a92a81-7872-40f3-970f-b8a915ba36bb_4"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Amended MSKCC License, MSKCC granted to the Company additional licenses to certain patents and patent applications relating to new CAR constructs and off-the-shelf CAR T-cells, including the use of clustered regularly interspaced short palindromic repeat (CRISPR) and other innovative technologies for their production, in each case to research, develop, and commercialize licensed products in the field of all human therapeutic uses worldwide. The Company has the right to grant sublicenses to certain licensed rights in accordance with the terms of the Amended MSKCC License, in which case it is obligated to pay MSKCC a percentage of certain sublicense income received by the Company.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is obligated to pay to MSKCC an annual license maintenance fee during the term of the agreement, and milestone payments upon the achievement of specified clinical, regulatory and commercial milestones for licensed products as well as royalty payments on net sales of licensed products.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event a licensed product achieves a specified clinical milestone, MSKCC is then eligible to receive certain milestone payments totaling up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8cb1db9-afbc-40e7-bb20-aed8b46d5125" contextRef="C_0d79e020-c388-40bd-a1ab-ccdba8d6c0f6" name="fate:EnterpriseValueMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million based on the price of the Company&#8217;s common stock, where the amount of such payments owed to MSKCC is contingent upon certain increases in the price of the Company&#8217;s common stock following the date of achievement of such clinical milestone. These payments are based on common stock price multiples, with the numerator being the fair value of the ten-trading day trailing average closing price of the Company&#8217;s common stock and the denominator being the ten-trading day trailing average closing price of the Company&#8217;s common stock as of the effective date of the Amended MSKCC License, adjusted for any stock splits, cash dividends, stock dividends, other distributions, combinations, recapitalizations, or similar events. Under the terms of the Amended MSKCC License, upon a change of control of the Company, in certain circumstances, the Company may be required to pay a portion of these payments to MSKCC based on the price of the Company&#8217;s common stock in connection with such change of control.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bc5adeaf-b1e1-4d3d-9d5a-f41dbcd7342e" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="fate:CommonStockMultiplesAndTheEnterpriseValueMilestonePaymentsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> following table summarizes the common stock multiples and the stock price appreciation milestone payments under the terms of the agreement:</span></p><p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.44%;box-sizing:content-box;"/>
        <td style="width:1.28%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.9%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.28%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.9%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.28%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.92%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock multiple</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_a0a78c0c-4ba7-461f-925b-48d836450f14" contextRef="C_e3dc601c-f824-4b78-bf0e-07dae896ef9c" name="fate:CommonStockMultiple1"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0x</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_dee9e57f-ee00-4238-8f93-596059ba6646" contextRef="C_f28a10a2-8fc0-44c9-a166-60bb7e722119" name="fate:CommonStockMultiple1"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0x</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_415a8cb6-86fb-40fb-9102-4ab55db52e29" contextRef="C_2e9f4ffe-10e2-4108-a3d9-3d3ffddd7ad0" name="fate:CommonStockMultiple1"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.0x</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ten-trading day trailing average common stock price</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0f62a0c-0bdd-416c-bb92-3fae6ef162ce" contextRef="C_0284ad68-4270-4896-8d67-06f5f506fa6e" name="fate:TrailingStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">50.18</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5993db9e-69bd-4a37-8ddc-fac762abad6e" contextRef="C_7bc2c0be-3669-4b09-a396-9031cd164016" name="fate:TrailingStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">100.36</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a829a54-51a8-411b-b075-064e051b1e53" contextRef="C_dc572fae-d1e3-4dc6-9902-fa5e71563255" name="fate:TrailingStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">150.54</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock price appreciation milestone payment (in millions)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_739b8fab-67a3-416f-8a2c-d50d97e3e154" contextRef="C_0284ad68-4270-4896-8d67-06f5f506fa6e" name="fate:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31a75d61-a314-4c6d-b901-6ea726c236be" contextRef="C_7bc2c0be-3669-4b09-a396-9031cd164016" name="fate:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">30.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82cb6d6c-6498-4032-8a6a-39da66d1e428" contextRef="C_dc572fae-d1e3-4dc6-9902-fa5e71563255" name="fate:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:5.147%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2021, the Company achieved the specified clinical milestone for a licensed product under the Amended MSKCC License and the Company&#8217;s ten-trading day trailing average common stock price exceeded the first, pre-specified threshold. As a result, the Company remitted the first milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec64161f-ca4d-49ef-a7ba-9c4b38c0697e" contextRef="C_6558896f-2704-4857-9934-3ac8fb755e52" name="fate:StockPriceAppreciationMilestonePayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to MSKCC during the year ended December 31, 2021.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To determine the estimated fair value of the remaining stock price appreciation milestones, the Company uses a Monte Carlo simulation methodology which models future Company common stock prices based on the current stock price and several key variables. The following variables were incorporated in the calculation of the estimated fair value of the stock price appreciation milestones as of December 31, 2024:</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f63510bb-f3b7-492f-9662-e9994705aae5" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="fate:ScheduleOfMilestonePaymentsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:5.147%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.34%;box-sizing:content-box;"/>
        <td style="width:1.64%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.42%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.64%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.96%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35ecd59e-48b3-4bb8-ae45-510cd0f383fe" contextRef="C_8f2c86db-20b2-4603-88f9-51afe5ae61e0" name="fate:FairValueAssumptionsRiskFreeInterestRate1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.8</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54a24f73-d122-4a80-b769-a6b7bced505b" contextRef="C_41a96d2d-db51-45dc-a3d4-a00f6dd5f281" name="fate:FairValueAssumptionsRiskFreeInterestRate1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c03dbc89-e89e-4f9b-bfea-18eee66174a4" contextRef="C_8f2c86db-20b2-4603-88f9-51afe5ae61e0" name="fate:FairValueAssumptionsExpectedVolatilityRate1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">85.3</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_615da8fe-532b-490a-8e3f-ba80e6d4510a" contextRef="C_41a96d2d-db51-45dc-a3d4-a00f6dd5f281" name="fate:FairValueAssumptionsExpectedVolatilityRate1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">84.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Estimated term (in years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_6a48b2da-31ae-439f-988d-9f52b3d86c9f" contextRef="C_8f2c86db-20b2-4603-88f9-51afe5ae61e0" name="fate:FairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.0</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_9d29a709-924d-42df-9a57-83bad6ee4360" contextRef="C_41a96d2d-db51-45dc-a3d4-a00f6dd5f281" name="fate:FairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.0</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Closing stock price as of measurement date</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1dfdf8b2-1f6a-4e9c-bdba-603cea67f7a1" contextRef="C_caf5635b-36dc-4bb5-83b2-d3bfaff93dac" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.65</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23c0919c-d7b0-4553-a1ce-1fd81023fda1" contextRef="C_fc28b484-986a-4aa3-ac45-ec88d93742f0" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.74</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The key inputs to the Monte Carlo simulation to determine the fair value of the stock price appreciation milestones include the Company&#8217;s stock price as of the measurement date; the estimated term which is based in part on the last valid patent claim date; the expected volatility of the Company&#8217;s common stock, estimated using the Company&#8217;s historical common stock volatility as of the remeasurement date; and the risk-free rate based on the U.S. Treasury yield for the estimated term determined. Fair value measurements are highly sensitive to changes in these inputs and significant changes could result in a significantly higher or lower fair value and resulting expense or gain.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">116</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a1a92a81-7872-40f3-970f-b8a915ba36bb_4"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At each balance sheet date, the Company remeasures the fair value of the stock price appreciation milestones, with changes in fair value recognized as a component of other income (expense) in the consolidated statements of operations and comprehensive loss. Amounts are included in current or non-current liabilities based on the estimated timeline associated with the individual potential payments. During the years ended December 31, 2024 and 2023, the Company recorded </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b5d55bb-d762-4de4-a3c4-5657938c6d12" contextRef="C_705e67ff-045b-436e-92bc-cce8ba8f5edd" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e8c8c3d-fe8c-4131-a3cd-9df2861612ab" contextRef="C_ff4ddbec-d136-4b09-a4a0-5e321b435ca7" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of income, respectively, associated with the change in fair value of the stock price appreciation milestones. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, the Company recorded a liability of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78822599-0d23-431c-bacd-95540f362c7f" contextRef="C_0d79e020-c388-40bd-a1ab-ccdba8d6c0f6" name="fate:EnterpriseValueMilestonesLiabilityAtFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_859e8989-88c7-4bd3-8172-7e21bec61f33" contextRef="C_5928b276-cfe4-4ddc-bcb9-ba1063ef39c7" name="fate:EnterpriseValueMilestonesLiabilityAtFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, associated with the stock price appreciation milestones for the Amended MSKCC License.</span></p></ix:continuation></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_db8ac0e7-60e4-4dd9-8954-5c98a9eaa407" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="fate:AwardAgreementForResearchAndDevelopmentDisclosureTextBlock" escape="true"><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.	California Institute for Regenerative Medicine Award</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FT819 CIRM Award</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2024, the Company was awarded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98bf3f2c-d83e-4f0c-95a9-ba7163b104f5" contextRef="C_d7619f35-5038-4477-8ad7-9f872ef12d50" name="fate:GrantAward" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from the California Institute for Regenerative Medicine (CIRM) to support the conduct of the Company&#8217;s Phase 1 study of FT819 in patients with systemic lupus erythematosus and, in April 2024, the Company executed an award agreement with CIRM (the FT819 CIRM Award). Pursuant to the terms of the FT819 CIRM Award, the Company is eligible to receive five disbursements in varying amounts from CIRM, with one disbursement receivable upon the execution of the award and four disbursements receivable based upon the completion of certain development milestones throughout the period of the award, which is estimated to be from April 1, 2024 to March 31, 2028 (the Award Period). Under the FT819 CIRM Award, the Company has certain obligations of co-funding and is required to provide CIRM progress and financial update reports throughout the Award Period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the conclusion of the Award Period, the Company, in its sole discretion, has the option to treat the FT819 CIRM Award either as a loan or as a grant. If the Company does not elect to treat the FT819 CIRM Award as a loan within 10 years of the award date, the award will be considered a grant and the Company will be obligated to pay CIRM, on a quarterly basis, a low single-digit royalty on commercial sales of FT819 until such aggregate royalty payments equal nine times the total amount awarded to the Company under the FT819 CIRM Award.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the Company may, at its election, repay some or all of the FT819 CIRM Award, the Company accounts for the award as a liability until the time of election. During the year ended December 31, 2024, the Company received two disbursements under the FT819 CIRM Award in the aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3751e96-e6a2-4f32-94e0-708a9e73f96e" contextRef="C_681d2241-9055-4fd4-b908-7ff2e5469107" name="fate:FirstDisbursementAmountUnderTheAward" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which amount is recorded as a liability on the accompanying consolidated balance sheets. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the entire balance is classified as non-current as the Company does </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc1842ca-6574-404d-a909-ac2d77bd8711" contextRef="C_26715720-1a7f-4abb-8779-318e83f66b8b" name="fate:FirstDisbursementAmountUnderTheAwardPayableForNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t expect any amount to be payable within the next 12 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FT516 CIRM Award</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2018, the Company executed an award agreement with CIRM pursuant to which CIRM awarded the Company $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d360d8ff-8129-4b8a-9846-b5bc6710bb78" contextRef="C_4dd02f91-14ae-4ec9-ba06-e9a1c6c69591" name="fate:AwardForFirstInHumanClinicalTrial" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to advance the Company&#8217;s FT516 product candidate into a first-in-human clinical trial for the treatment of subjects with advanced solid tumors (the FT516 CIRM Award). Under the FT516 CIRM Award, the Company has certain obligations of co-funding and is required to provide CIRM progress and financial update reports.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the terms of the FT516 CIRM Award, the Company, in its sole discretion, has the option to treat the FT516 CIRM Award either as a loan or as a grant. During the first quarter of 2023, the Company elected to treat the FT516 CIRM Award as a grant. As such, the liability associated with the FT516 CIRM Award was derecognized and such amount was recorded as other income during the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_06ae2ecd-43a0-4357-b849-82d98578d04b" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true" continuedAt="F_06ae2ecd-43a0-4357-b849-82d98578d04b_1"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Investments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company invests portions of excess cash in United States treasuries, commercial paper, non-U.S. government securities, municipal securities, and corporate debt securities with maturities ranging from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_ac600eed-1df0-477d-b544-b5ccb3c5dacc;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dabad995-b5e1-41b2-963a-a3e31361c21c" contextRef="C_2575346e-5767-4842-b149-16db06beaf77" name="fate:ShortTermInvestmentMaturityPeriodRangeEnd" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> thirty-six months</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the purchase date. These investments are accounted for as available-for-sale securities and are classified as short-term and long-term investments in the accompanying consolidated balance sheets based on each security&#8217;s contractual maturity date.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">117</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_06ae2ecd-43a0-4357-b849-82d98578d04b_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0cb24d95-8288-4513-88c2-29fa34ec7b95" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s investments accounted for as available-for-sale securities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.8%;box-sizing:content-box;"/>
        <td style="width:1.08%;box-sizing:content-box;"/>
        <td style="width:9.96%;box-sizing:content-box;"/>
        <td style="width:1.08%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:7.960000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.08%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:7.960000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.08%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:7.960000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.08%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:7.960000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Maturity<br/>(in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Classified as current assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market fund</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b0ca5ac8-e518-486a-ba34-06f388e572d7" contextRef="C_cc863354-869b-4206-b33e-59e639b10e95" name="fate:InvestmentMaturityDateRange"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89796295-0975-489d-b874-358b612eb15d" contextRef="C_f482e228-69f4-4567-8679-ff6ec159f4e8" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,491</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_016496e7-1505-409c-a841-e6a506ab83c6" contextRef="C_f482e228-69f4-4567-8679-ff6ec159f4e8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07d70390-405a-4122-9c6c-a1cccb050b38" contextRef="C_f482e228-69f4-4567-8679-ff6ec159f4e8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbaf9b18-d6ce-4500-81a7-9de96e8c14b3" contextRef="C_f482e228-69f4-4567-8679-ff6ec159f4e8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,491</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_0661649c-60b6-4bb4-86cd-3b22ed1fcb74" contextRef="C_97e27d0f-6140-4723-b214-d402e6450492" name="fate:InvestmentMaturityDateRange"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2cce6430-e152-4588-aa48-8b907d0c48d5" contextRef="C_d0df7940-8ed7-4acc-bf9b-0fb78b52dd30" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,206</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_081a7d31-0d96-4dc7-b2a1-a7b71c99ddc1" contextRef="C_d0df7940-8ed7-4acc-bf9b-0fb78b52dd30" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d21abf1-761f-4359-be0b-5949bc996e04" contextRef="C_d0df7940-8ed7-4acc-bf9b-0fb78b52dd30" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee495096-a4a0-4536-badb-60fb25abfc33" contextRef="C_d0df7940-8ed7-4acc-bf9b-0fb78b52dd30" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,291</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-US government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_273b6298-a2cf-49d3-b0d4-06280540f07f" contextRef="C_8a02d4d5-85f9-464c-8c77-3930bc912652" name="fate:InvestmentMaturityDateRange"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17e5e32e-1ae8-45a2-804b-ec055aaab8d4" contextRef="C_926e58f0-2ed3-4a7a-845d-34981bf5a884" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,994</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ccfa1f6e-e522-4cdb-9833-ac6017e9c354" contextRef="C_926e58f0-2ed3-4a7a-845d-34981bf5a884" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_930da7bf-33fd-484c-be75-82b1dedfa378" contextRef="C_926e58f0-2ed3-4a7a-845d-34981bf5a884" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81ad61e8-1df1-46b8-8175-845b96a827a3" contextRef="C_926e58f0-2ed3-4a7a-845d-34981bf5a884" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,995</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Municipal securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_4d43c462-38cd-43ec-904d-1ddf78a0bbe2" contextRef="C_687fd488-edfe-4a2c-989f-8d86d4b11852" name="fate:InvestmentMaturityDateRange"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfa00851-7a9e-452f-badc-0e6c4610370d" contextRef="C_fe916e0a-bfad-43cf-8d7e-6d37daaba7da" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,490</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e5489bc-8c9a-4c24-b1af-75dd0f220a78" contextRef="C_fe916e0a-bfad-43cf-8d7e-6d37daaba7da" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c11a9a9-e74a-44e5-925b-60b061ad7fca" contextRef="C_fe916e0a-bfad-43cf-8d7e-6d37daaba7da" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a829d01-71ed-43a6-bb54-22cbc61b6798" contextRef="C_fe916e0a-bfad-43cf-8d7e-6d37daaba7da" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,492</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_507f8709-2357-4733-8479-7b8eb35b820c" contextRef="C_fe5fbe72-2c15-4c48-9e0f-6faab2b2ebf8" name="fate:InvestmentMaturityDateRange"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be71c3b1-a716-4fd5-b9b8-8c9746cd082e" contextRef="C_bff210f5-02f8-4782-9744-563ff4baaf6c" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">170,169</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b8244ed-c206-4b14-ae52-7971d698153e" contextRef="C_bff210f5-02f8-4782-9744-563ff4baaf6c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf2fba95-33a5-4ab6-bd93-4be0585b765c" contextRef="C_bff210f5-02f8-4782-9744-563ff4baaf6c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">228</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71b29265-f5c5-4e32-89c9-b3bacea4e93a" contextRef="C_bff210f5-02f8-4782-9744-563ff4baaf6c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">170,327</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_5e065386-3e42-49ae-ba9e-41ac78401eb6" contextRef="C_edad96f6-a6a9-4612-9c79-acc88724dfb5" name="fate:InvestmentMaturityDateRange"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_978d61f7-9576-4232-aaeb-2d705fd6f235" contextRef="C_ebe17901-fd0e-4988-91ae-8f5cdea8a285" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,903</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d871b29-784c-4834-b1e8-e56b1ceb0430" contextRef="C_ebe17901-fd0e-4988-91ae-8f5cdea8a285" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3bec3210-2f9f-47d8-a18c-cf483258d025" contextRef="C_ebe17901-fd0e-4988-91ae-8f5cdea8a285" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f336b700-095f-46b8-8478-6ecbf1cf1ecc" contextRef="C_ebe17901-fd0e-4988-91ae-8f5cdea8a285" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,907</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f1244e3-dfa5-45ee-a5c9-7847c990e2f2" contextRef="C_208fb1ba-72a9-4ce5-8560-933151337e0d" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">272,253</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfdfa803-ce18-47ad-83ae-63dd7d079a3d" contextRef="C_208fb1ba-72a9-4ce5-8560-933151337e0d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fe67304-f0f6-4ef3-9e4a-cc007866dcf3" contextRef="C_208fb1ba-72a9-4ce5-8560-933151337e0d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">336</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a598a460-3bf0-486c-8cb5-12327348d706" contextRef="C_208fb1ba-72a9-4ce5-8560-933151337e0d" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">272,503</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Classified as non-current assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_61ee2389-dc7c-453f-8eea-d8a5f914ae39" contextRef="C_8515b700-bba4-47e5-8cd3-b446bc59b1e5" name="fate:InvestmentMaturityDateRange"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Greater than</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;1</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37611322-3085-4a8d-a11e-28d9241953da" contextRef="C_6bd370ac-1bca-4909-9d77-e3887063a36a" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,752</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d62e9c1-c64a-4dca-8162-54462b817b10" contextRef="C_6bd370ac-1bca-4909-9d77-e3887063a36a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c6c8301-3ca6-4b47-ad18-10a2307e26e8" contextRef="C_6bd370ac-1bca-4909-9d77-e3887063a36a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72ca06af-8f9b-4279-9f42-2520752090f3" contextRef="C_6bd370ac-1bca-4909-9d77-e3887063a36a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,745</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_0ac94c7b-6815-45e4-8e66-d9d90868e18b" contextRef="C_3b620cbc-79bd-4c67-b41b-219dae13d7b0" name="fate:InvestmentMaturityDateRange"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Greater than 1</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4db99b2e-c4fa-40e8-9738-6d99b50c0d31" contextRef="C_c351f635-f8e4-4ef1-98df-8b05b6facf67" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,887</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f42f582c-c785-4604-b44e-fe8befaafcc8" contextRef="C_c351f635-f8e4-4ef1-98df-8b05b6facf67" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a8b8315-43e6-4dff-85fd-d25004c22d0c" contextRef="C_c351f635-f8e4-4ef1-98df-8b05b6facf67" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81cd0a16-bb28-4aa3-b06a-a18d2269446d" contextRef="C_c351f635-f8e4-4ef1-98df-8b05b6facf67" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,912</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total long-term investments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5fdc936-1c02-4bbd-935f-75f23872978a" contextRef="C_1fd96e00-b6bb-46df-a4e7-fd1bd210a4a8" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,639</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be9ee334-f80a-4cf8-8b44-5dec410c5b7c" contextRef="C_1fd96e00-b6bb-46df-a4e7-fd1bd210a4a8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd336a49-18a6-49e0-aad1-ea7ecad6ac80" contextRef="C_1fd96e00-b6bb-46df-a4e7-fd1bd210a4a8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_883aebfe-4611-4994-b72c-bb5647474a81" contextRef="C_1fd96e00-b6bb-46df-a4e7-fd1bd210a4a8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,657</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Classified as current assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market fund</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_8704a9a6-3523-4018-9d32-e9eea6057c04" contextRef="C_99d86bdb-f819-4ada-9573-3db9972228f5" name="fate:InvestmentMaturityDateRange"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e2ea447-4266-40f3-b7b7-c9877fa339a6" contextRef="C_6c749fc7-3fa7-4811-a7f5-999fcbd298ba" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,273</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0dfbde2a-ffde-434e-ba9e-335599e1c4ba" contextRef="C_6c749fc7-3fa7-4811-a7f5-999fcbd298ba" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c69d064-1af0-43b2-88e5-5d973d12e95f" contextRef="C_6c749fc7-3fa7-4811-a7f5-999fcbd298ba" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00e1295b-0ae6-4a25-8ced-fd51e0ca75d2" contextRef="C_6c749fc7-3fa7-4811-a7f5-999fcbd298ba" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,273</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_78b1cc24-5639-4907-b98c-e97af3598bbf" contextRef="C_1cb3ab28-0ea4-4691-8f06-03acbacd707e" name="fate:InvestmentMaturityDateRange"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d816e9b7-bf95-49c2-a730-5690f8e48dae" contextRef="C_3121bc29-a859-42c3-8c2f-1cc407771269" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,811</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f910f4a9-272c-4e37-8008-d8822d7cc264" contextRef="C_3121bc29-a859-42c3-8c2f-1cc407771269" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb803049-872b-411c-8077-c8fcdcc32cc7" contextRef="C_3121bc29-a859-42c3-8c2f-1cc407771269" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_836e6707-ca4e-4293-b808-db71560880f5" contextRef="C_3121bc29-a859-42c3-8c2f-1cc407771269" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,804</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-US government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_1ae4ddbe-7757-416d-a626-d2acda4bd608" contextRef="C_50b6586c-23fc-4c7e-870d-e60fbf83a55e" name="fate:InvestmentMaturityDateRange"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_167a5d3b-59b3-4ce5-9c3a-ca436576240e" contextRef="C_07bf6ed7-be95-444c-ba21-1cca631dcf34" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">999</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99c660a6-c555-4901-bbef-75f065b368a6" contextRef="C_07bf6ed7-be95-444c-ba21-1cca631dcf34" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb1beb61-1d02-47cd-9e5d-8c1e00251090" contextRef="C_07bf6ed7-be95-444c-ba21-1cca631dcf34" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ddcc6a8-bec2-488b-b07c-0fc33bcdba0d" contextRef="C_07bf6ed7-be95-444c-ba21-1cca631dcf34" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">999</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Municipal securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e1dcd3dd-a36a-4467-9666-d67dafc9aa4a" contextRef="C_b3047a8d-c14c-4b39-8c15-7c44dd30c23c" name="fate:InvestmentMaturityDateRange"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67862f30-a3f7-4a72-8618-8a6d41e60ec6" contextRef="C_62a2a941-1986-48b3-9796-58a5b98fe1ff" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8ffb9ff-e35a-4a98-9936-0b1886258668" contextRef="C_62a2a941-1986-48b3-9796-58a5b98fe1ff" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6da69c14-f355-448f-81f7-8d2327700253" contextRef="C_62a2a941-1986-48b3-9796-58a5b98fe1ff" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_675b32fd-7880-4918-8b6a-64c0d454398f" contextRef="C_62a2a941-1986-48b3-9796-58a5b98fe1ff" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,997</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_9d11d8d5-306f-4af8-a7e1-204019c52b43" contextRef="C_2e15e9a9-cf48-44bc-a273-b652fd1f9dd4" name="fate:InvestmentMaturityDateRange"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27861f09-526b-4bd5-b376-3d0350b3522e" contextRef="C_8a618607-b312-44dc-9409-e35bb5b9ee3c" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,144</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0fc0e52-aaa4-447d-b360-2149e58bef0b" contextRef="C_8a618607-b312-44dc-9409-e35bb5b9ee3c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bee0701b-2f00-42d2-a459-3653ab1ebea3" contextRef="C_8a618607-b312-44dc-9409-e35bb5b9ee3c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c35fc4d0-cc12-430a-b47a-08705fa427e7" contextRef="C_8a618607-b312-44dc-9409-e35bb5b9ee3c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,107</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_4551165d-f5eb-4ebf-bdd5-677ada5e6133" contextRef="C_8bb72297-578c-44bb-bcc6-356a01b01bc6" name="fate:InvestmentMaturityDateRange"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d80f2e84-62cd-4d78-ab0f-e788900869ff" contextRef="C_cd31cee6-b14e-476a-ac84-63e70036233f" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">137,339</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d43de351-207a-4752-b118-233ed2280e62" contextRef="C_cd31cee6-b14e-476a-ac84-63e70036233f" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac7673bc-c1f3-4278-ac9a-ac61b7c60082" contextRef="C_cd31cee6-b14e-476a-ac84-63e70036233f" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a338e49-e701-4482-aa70-8602c55da285" contextRef="C_cd31cee6-b14e-476a-ac84-63e70036233f" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">137,398</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b539fa49-8798-4998-874e-8c742d0a0776" contextRef="C_10f659e3-4c5b-460d-bada-3a35f1b947ba" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">308,566</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec9c4774-017c-418d-a411-5b6a5a2fb8cd" contextRef="C_10f659e3-4c5b-460d-bada-3a35f1b947ba" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a95846af-f71a-4302-a741-d19b0ece2cbe" contextRef="C_10f659e3-4c5b-460d-bada-3a35f1b947ba" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">162</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a680ef09-ed05-4378-9896-cac9d54bbacf" contextRef="C_10f659e3-4c5b-460d-bada-3a35f1b947ba" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">308,578</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Classified as non-current assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a123f651-07d0-49f1-885f-e064a41a4207" contextRef="C_e5ff0703-7a69-43d6-9e8c-8654aebbd5ed" name="fate:InvestmentMaturityDateRange"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Greater than 1</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc2c6e2a-cd30-4bab-add0-fa195c0e911b" contextRef="C_0d302d4d-cf60-4de8-bf11-2d38492826e0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">977</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a10e00e4-e35d-4e88-a6f4-3baceb28e3d9" contextRef="C_0d302d4d-cf60-4de8-bf11-2d38492826e0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40dfb46b-e842-4792-a56b-43403fa9e35a" contextRef="C_0d302d4d-cf60-4de8-bf11-2d38492826e0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b299878e-2ecc-4a99-86db-0747ba85400a" contextRef="C_0d302d4d-cf60-4de8-bf11-2d38492826e0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">980</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total long-term investments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4df20994-7d5e-4a27-8bf6-eefe1ea7d254" contextRef="C_bfbd6f4d-b000-45b5-9a79-42c6794f12c6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">977</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffed2d8e-fbbf-439e-82ae-151191aec0f4" contextRef="C_bfbd6f4d-b000-45b5-9a79-42c6794f12c6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb537324-320d-4548-8b15-aedada2cb767" contextRef="C_bfbd6f4d-b000-45b5-9a79-42c6794f12c6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ddfe12b-5876-4a2c-b012-616c37e4dc00" contextRef="C_bfbd6f4d-b000-45b5-9a79-42c6794f12c6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">980</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1aa452c-9234-4b9f-aeee-2d1a90ee76d7" contextRef="C_5445f2d2-5e33-4281-9239-4322ce42c9cf" name="us-gaap:InterestReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_310c76d0-76c6-49bc-bff2-a83d149bba4b" contextRef="C_2e7da839-7541-4872-8420-d82b12974e64" name="us-gaap:InterestReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, of accrued interest on investments recorded in prepaid expenses and other assets on the consolidated balance sheets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews its investment holdings at the end of each reporting period and evaluates any unrealized losses using the expected credit loss model to determine if the unrealized loss is a result of a credit loss or other factors. The Company also evaluates its investment holdings for impairment using a variety of factors including the Company&#8217;s intent to sell the underlying securities prior to maturity and whether it is more likely than not that the Company would be required to sell the securities before the recovery of their amortized basis. During the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddba17f3-40df-4972-a809-ee986cca9a44" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e91f9730-9da0-41b2-adac-9e131e83e8c5" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize any impairment or realized gains or losses on sales of investments, and the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac2d7467-d3f5-4dc5-8213-7504c09cacb1" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:FinancingReceivableNonaccrualNoAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_63ea366e-6573-4342-b7f4-1368b0aa5521" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:FinancingReceivableNonaccrualNoAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t record an allowance for, or recognize, any expected credit losses.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">118</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_0d8abd03-757d-4617-84cf-be64112d69de" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:FairValueDisclosuresTextBlock" escape="true" continuedAt="F_0d8abd03-757d-4617-84cf-be64112d69de_1"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Fair Value Measurements</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_deb613be-49d0-4eb1-95e6-44963390af2b" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables presents the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.184000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.184000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.184000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.184000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements at<br/>Reporting Date Using</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market fund</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f268726-3ca2-42ad-bf4f-450c5a9d19df" contextRef="C_3ef185b6-d2e3-41eb-af64-8722d09aa801" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,491</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e39601a-c858-4a86-915b-bd222a943025" contextRef="C_a5e8db20-c26c-4eec-81dc-6ac0d0db25ea" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,491</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8af5a82-6ba6-4a17-8267-90178e3282ce" contextRef="C_cebe70a2-446f-4a43-a422-52cd427ada3b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,036</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ff37acc-3cb2-4d51-9b8d-afe7cefd6645" contextRef="C_805f2b9e-0637-4e41-afb0-b23379a1c6bf" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,036</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-US government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86e46869-3132-412a-bf9c-150294f2a5f8" contextRef="C_94e46ef6-c33c-4951-8ea1-9765cebbe9a1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,995</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3107f192-8680-470d-925a-4d98ce2fce58" contextRef="C_094d60cc-9d76-4080-b9c2-2f03fda72660" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,995</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Municipal securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b4c1453-1a69-4a84-b529-3099ec2e4593" contextRef="C_cec4892c-e35c-4232-846a-7628de00f77e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,492</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1bfc072-c57f-48c7-ba59-080260f00e48" contextRef="C_59f16426-b465-46ba-aa94-5befab44d9d3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,492</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1e99741-104c-47ca-9d7b-ae2c252146e7" contextRef="C_f2e41800-cc41-4b94-a30a-fb6e56d72a7f" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">188,239</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b2c9c54-347c-4da8-b2af-e516cb69ac7c" contextRef="C_1de58b0e-3458-4fdb-9110-32fd64de36b8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">188,239</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c754115b-2203-46f3-b165-886d755564b5" contextRef="C_6fcf025e-eabb-4c7b-9b3c-cc45fd082e86" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,907</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_397eb1fc-29db-4761-ac48-6c49114800f7" contextRef="C_3baffb0b-73df-44c6-85eb-9c15e2247168" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,907</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets measured at fair value on a recurring basis</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7cebe46-c013-459e-8de9-37ec1c5b5b8b" contextRef="C_b416aca9-c7b0-442c-b1c2-2934711580f1" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">300,160</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_416bc7c1-f637-425b-b631-c0df501823b2" contextRef="C_7d5efccd-12ae-4328-a434-fc9ca1b3827d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,527</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ade6c14d-a2c8-49ab-8cad-b80fb997667c" contextRef="C_cacd56f9-2988-4b00-88a4-4b37683a2fc4" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">220,633</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock price appreciation milestones</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4f93854-e896-45f1-8717-931ae82ed90e" contextRef="C_fd6d1a6c-963f-4a77-8037-388fc2ef3404" name="fate:StockPriceAppreciationMilestones" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">527</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8aeadbcc-0bf1-48c7-b110-38a345e50420" contextRef="C_e9fc8192-6581-4017-a8d5-9e3b97aa8020" name="fate:StockPriceAppreciationMilestones" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">527</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total financial liabilities measured at fair value on a recurring basis</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85a11d8b-0707-4d54-814c-a57948414aa3" contextRef="C_b416aca9-c7b0-442c-b1c2-2934711580f1" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">527</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_808fa75e-e3c8-4324-92c5-f55db177cd30" contextRef="C_ac2d1d69-5e84-41e7-b540-c202f61299ca" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">527</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2023:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market fund</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01adf47f-f527-4046-aa6b-e03b5f5085d7" contextRef="C_a3ff6b11-0c22-4b27-8dc1-b44fdb3a724c" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,273</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a9402d0-8a7c-4ee9-9f1f-b72f8a64d7a0" contextRef="C_d21f4f6f-8713-4aa6-8283-c3de33b87b2f" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,273</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e334d99-b811-401c-b280-6680a274c7f1" contextRef="C_fd5563c2-aea8-4a6a-8a5b-e1869c4151d7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,804</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e0eb268-d7c8-499b-8c03-ad6d0765e897" contextRef="C_977cdbf8-9aef-4f82-a0e6-e955360ee9d1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,804</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-US government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c037bd77-4e10-4d48-8d74-fe2e2d84288b" contextRef="C_7388956d-1347-4f5e-b3bd-7ff47628173c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">999</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_000152d6-a5d2-46e5-b1ee-052828a1f2fa" contextRef="C_9c256c41-e766-4081-83ce-a706df7de970" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">999</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Municipal securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22d07414-ae63-4882-ad0a-61d1a04120a2" contextRef="C_da752dee-4bbf-4d64-b7ab-bbf88b372ec6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,997</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_034f3a38-05d9-4b73-be6c-151c528918b3" contextRef="C_0929cf2c-6047-4152-8767-1d831d5874a9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,997</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_928db028-707a-4e86-833b-56cbcd2a663e" contextRef="C_82ed1266-1238-4e4a-9fcf-ef99a6cc8c97" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,087</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3daf85c2-1557-4aa0-899c-3b7077038fe0" contextRef="C_1eb4c942-f4c7-47f9-994f-95d18338c9fc" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,087</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59a822f6-5987-41f5-87af-fd44c9c9d72a" contextRef="C_fba769b4-c31e-4914-8c9d-294bd6abcddd" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">137,398</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c124ed4b-f8e3-4a13-80f5-69009b3d003b" contextRef="C_8647c356-eb54-4cef-883d-ccfb6f2c7d27" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">137,398</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets measured at fair value on a recurring basis</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb39c15f-dfe9-4991-9507-bb99b94eb196" contextRef="C_b28e1793-9bb2-4e61-9e28-a2fa970d72c7" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">309,558</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf84b0ca-6e76-4e14-9f63-e29bc7c5586f" contextRef="C_87a8873b-2dbd-48eb-a3c4-71b7b6ecb603" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118,077</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee4aa8aa-ad5f-4af3-953e-99edbf8bc23d" contextRef="C_fb2cf769-bd37-47d3-ab4b-f93d4365d73d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">191,481</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6894410e-911b-43e9-800d-37318a750ecc" contextRef="C_c52c4c88-5230-4895-b325-46e4cd2518ab" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock price appreciation milestones</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77e81504-5457-43c3-8598-c68ad47cffc3" contextRef="C_8e179833-9ef6-4071-837e-b071b6572377" name="fate:StockPriceAppreciationMilestones" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,346</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de8bad5d-aa1f-46ca-8b7b-d3d1d7ffd64c" contextRef="C_c5d2707d-a24c-478b-b6da-97a0477550df" name="fate:StockPriceAppreciationMilestones" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,346</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total financial liabilities measured at fair value on a recurring basis</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d981912-82a2-4a67-8011-fc0ed380b463" contextRef="C_b28e1793-9bb2-4e61-9e28-a2fa970d72c7" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,346</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1af442db-5556-4ff8-90a4-b12606ad29f4" contextRef="C_c52c4c88-5230-4895-b325-46e4cd2518ab" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,346</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1 assets consisted of money market funds and U.S. Treasury securities measured at fair value based on quoted prices in active markets as provided by the Company&#8217;s investment managers.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2 assets consisted of corporate debt securities, commercial paper, municipal securities, and non-U.S. government securities measured at fair value using standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers. The Company validates the quoted market prices provided by its investment managers by comparing the investment managers&#8217; assessment of the fair values of the Company&#8217;s investment portfolio balance against the fair values of the Company&#8217;s investment portfolio balance obtained from an independent source.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no Level 3 assets held by the Company as of December 31, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3 liabilities consisted of stock price appreciation milestones associated with the Amended MSKCC License as described in detail in Note 2.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">119</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_0d8abd03-757d-4617-84cf-be64112d69de_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b39cbc43-c6a6-4493-954c-1bef40115d07" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true"><p style="text-indent:5.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the changes in fair value of the Company&#8217;s Level 3 stock price appreciation milestones liability (in thousands):</span></p><p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"/>
        <td style="width:1.94%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.823%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b464f4bc-1079-497b-b242-e91966f79a43" contextRef="C_fbf420d5-255c-421e-9863-8fd4aeac0e96" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,861</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in fair value of stock price appreciation milestones liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86987487-c83d-4b0d-8ffb-ab52960c7221" contextRef="C_c243b78d-2e22-425b-8d5a-ec8cc2edf72d" name="fate:IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,515</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc24223b-6245-4db4-99b5-53c92b55f080" contextRef="C_cbf96da0-08c5-44ae-8e97-d5dc42fe1fcc" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,346</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in fair value of stock price appreciation milestones liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bfbea23-46d9-4b5f-9c85-f66997c71142" contextRef="C_68edd7f5-9eba-4cf2-9c06-c892f1e0d26b" name="fate:IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">819</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26f2817b-a0e5-472b-8a16-384e4c8f0ef4" contextRef="C_4d2a294e-b4ae-4f93-abc5-44f79d16ce96" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">527</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:5.2%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_790b7152-7ca8-4269-891b-9a62fc876e84" contextRef="C_85e19190-1f38-4b84-928d-1b10e8632e63" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_06b823ca-284a-4e5a-9c87-eb69c4e5db66" contextRef="C_85e19190-1f38-4b84-928d-1b10e8632e63" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">None</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d2e3acb-f043-4316-ba5f-6285c38a68c2" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="fate:Fairvalueassetslevel1Tolevel2Transfersamounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_cb2f47cb-e456-4840-a3b7-d54eb3d232f4" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="fate:Fairvalueassetslevel2Tolevel1Transfersamounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e0528753-2430-48b4-88c7-a30bca84d4b1" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="fate:Fairvalueliabilitieslevel1Tolevel2Transfersamounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_3c5d001f-72e9-4e2f-a133-6b03b680ba43" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="fate:Fairvalueliabilitieslevel2Tolevel1Transfersamounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> transfers between levels have occurred during the periods presented.</span></p></ix:continuation></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_484e35db-1dfd-4e16-9c99-a68062fe24c4" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Property and Equipment</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_157e9ec7-f0dc-4972-aaa6-5e672641216e" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aafcaf3a-a7a4-4e97-b711-6b2791fde491" contextRef="C_a31bca4a-3e98-45a1-a466-8da5458c6984" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">508</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75698cea-6952-4e86-99dd-02dccfa3d4b2" contextRef="C_309808ad-31af-4b1f-8e61-083557c2542c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,309</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer and office equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33c76b76-7d74-4b6c-be48-c1154fb08cd6" contextRef="C_be1fc325-ff5d-4b35-952c-3aa39e4cfadc" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,444</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be647e7f-2609-474c-a1b3-ebb9da0ab287" contextRef="C_bc041da4-e745-4f8b-9d20-f7e54aa2e7d6" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,132</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Software</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_041599c2-3c0c-4864-b7a6-eca68970f6a5" contextRef="C_98c3e645-6b5a-4fbd-a7b5-c0bf4a509495" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,188</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8ef2624-a92b-4809-96bf-1cafe125ea2a" contextRef="C_faac2f19-7ee6-46a4-9641-0352d10ce9d7" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,130</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements&#8212;building</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc2b9fdb-32cf-493d-a96a-1b57975ec970" contextRef="C_4a42522d-d9fd-49e6-a443-91460120f25e" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,485</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_defbf3d8-8b5c-4c8d-a743-adc0c2fe550c" contextRef="C_f1f2b64c-9a2c-4bc4-9f3e-aaf2c1023a51" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,038</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Scientific equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b1e6df3-8e68-4414-b1c5-edc172dd3aa2" contextRef="C_a95850c5-78b7-4a48-b9d3-80bfd15bcd46" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,895</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92412d6e-14c3-4693-8cd7-1af19a652e9d" contextRef="C_9f433503-cde7-4c8a-84a1-6742576e7a9b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78,853</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, gross</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_537712b4-31e6-4804-947e-f500413a346d" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">99,520</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0a7a54a-2702-4311-ba70-772d3c9e7cc1" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">144,462</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1df8a995-9e47-4c16-ba6c-a2abebce4f72" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,136</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_479eadef-d77f-4fd1-bcc0-feaf5e074af1" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,626</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69640f5d-5597-415c-839d-a28b13220986" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,384</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b47d0a77-78a3-4590-8b64-f2a1ba9e63bf" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,836</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:5.2%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized an impairment charge of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4dd3c870-12c4-42b7-985f-609d39524307" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of long-lived asset impairment described in Note 1 above for the year ended December 31, 2024, which was calculated as the difference between the fair value of the assets and its carrying value. The cost basis for these assets was updated to fair value. The fair value was based on a cost approach which utilized Level 3 non-recurring fair value inputs and assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:5.2%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation expense related to property and equipment was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3104209e-e998-43b4-891d-b85f4ae15cf2" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">19.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc5a6543-02fe-411e-9c07-3166d0566bd9" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">18.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_86b0edb8-7e74-413f-a416-c3b719441e3c" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Accrued Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued Expenses</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_bb04031e-fb31-4ed5-ac86-461c097ab9b2" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true" continuedAt="F_bb04031e-fb31-4ed5-ac86-461c097ab9b2_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Current accrued expenses consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued payroll and other employee benefits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d491b735-a7a5-4f58-87c6-c5c8df7c931d" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:AccruedSalariesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,710</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_577816d5-a47d-4333-a4d4-5cb6fb36f339" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:AccruedSalariesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,563</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued clinical trial related costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a720d835-4a23-4cdd-ac02-001a1bcfa48e" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="fate:AccruedClinicalTrialRelatedCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,279</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48123a4d-a9b4-4422-ac56-fa311e0a6d9f" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="fate:AccruedClinicalTrialRelatedCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,833</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11eaa7e8-51d4-4435-b5fe-3f369e43bf36" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,359</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7647c9a5-b299-4455-86a9-384d156f0652" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,118</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current accrued expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07e117bc-7d9a-4529-8d10-518b69b0b488" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,348</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6a34d55-35a7-4da5-8c6d-a66d559f07f5" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,514</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <div><ix:continuation id="F_bb04031e-fb31-4ed5-ac86-461c097ab9b2_1"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_948e0487-94d3-4c75-995a-0ffb0d584845" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true" continuedAt="F_948e0487-94d3-4c75-995a-0ffb0d584845_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has lease agreements for office, laboratory and manufacturing spaces that are classified as operating leases on the consolidated balance sheets.</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7fa3ffd2-d2ee-4b6f-9999-1dfff3fe5653" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> These leases have terms varying from one to approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5b8141b5-1ea2-4a89-8986-92e919ec3625" contextRef="C_92ae6775-3137-46d3-9d0f-95226e202633" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sixteen years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with renewal options of up to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dc0e11bd-08cc-4401-a1a8-707a0be0c927" contextRef="C_979e1e1b-585d-4deb-90b9-0ebe66970591" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as well as early termination options. Extension and termination options are included in the total lease term when the Company is reasonably certain to exercise them. The leases are subject to additional variable charges, including common area</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">120</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_948e0487-94d3-4c75-995a-0ffb0d584845_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintenance, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">property taxes, property insurance and other variable costs. Given the variable nature of such costs, they are recognized as expense as incurred. Additionally, some of the Company&#8217;s leases are subject to certain fixed fees which the Company has determined to be non-lease components. The Company has elected to combine and account for lease and non-lease components as a single-lease component for purposes of determining the total future lease payments.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, the Company exercised its right of early termination for its Torrey Pines operating lease, which consists of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_588e423c-eb0d-4021-9c0e-82bbf1f52f4c" contextRef="C_2a171456-ff92-4460-82a4-d71189a47904" name="us-gaap:NetRentableArea" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">72,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office, laboratory, and Good Manufacturing Practice (GMP) space. In connection with such exercise, the Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebd6514c-3c3d-4b86-89a6-6ecfd7b43e5b" contextRef="C_2a171456-ff92-4460-82a4-d71189a47904" name="us-gaap:TenantImprovements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to its landlord. Termination of the lease, which previously extended through December 31, 2028, will now take effect on October 31, 2025. The Company accounted for this transaction as a modification to the lease agreement, which reduced the ROU asset and corresponding lease liability balances as of December 31, 2024 in connection with such transaction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, future undiscounted minimum contractual payments under the Company&#8217;s operating leases were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07a9279e-e7c9-4332-bd56-2b462a7e86ab" contextRef="C_47e3c4a5-6a9e-488c-9ae1-4d92329efada" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">133.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million, which will be paid over a remaining weighted-average lease term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f98ffc9a-ba55-46b4-9a56-cd532a5d2254" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.6</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. The weighted-average discount rate for the operating lease liabilities was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bc1c92d-bfab-4f85-9b83-5cbbc0064d1e" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">8.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, which was the Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s incremental borrowing rate at lease commencement, as the discount rates implicit in the leases could not be readily determined.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cd9b30b9-335e-49ba-a2a5-b2ef68f52ad5" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of lease expense for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.474%;box-sizing:content-box;"/>
        <td style="width:1.66%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.102%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.66%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.102%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Straight-line lease expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7dfc6e08-688f-437f-8143-a8d537e477bd" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:StraightLineRentAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,737</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09461f77-30cc-4d63-9ca7-b32b510410c0" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:StraightLineRentAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,159</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc1524a2-24e9-46e9-8d86-4fb397ddf913" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,733</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f408f5d2-0e54-4108-bf54-f3023d008cb9" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,250</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_112e5060-647d-47ef-bc8c-750d14661c36" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,470</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e7fb761-b376-4607-811b-e66cfde60053" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,409</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ec891862-61df-4484-b630-1873ef3bdf47" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future undiscounted minimum payments under the Company&#8217;s operating leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 are as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"/>
        <td style="width:1.94%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.823%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating<br/>Lease Payments</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Years Ending December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ac3e488-ea5c-4611-a051-6d704b4add66" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,361</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11de6103-a64f-4f0c-b1f4-042ccfce67c2" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,050</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c06c9f4-08dd-4017-bcde-c6eeb7d3c293" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,382</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55e06a78-5a07-4938-9e98-9c8305e0dc5b" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,293</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c4c0b66-3b3d-4bfe-88c8-c1d794af6f67" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,602</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a87a414-434b-4b2c-b32a-837c34bd003f" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,976</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24b6d42f-01cb-4e4a-a292-9b2112459e56" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133,664</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5840108-a094-42cf-8275-c090a4e4ccc5" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,399</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86351c64-a57c-49da-bcf5-993f8b280126" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,265</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As described in Note 1 above, the Company incurre</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6306e5f3-dda7-44d0-a396-dc130905544b" contextRef="C_4cba0539-2744-4997-a638-c19edef83006" name="fate:ImpairmentOfRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mill</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ion impairment charge against its right-of-use asset during the year ended Decem</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ber 31, 2024. The Company applied a discounted cash flow method to estimate the fair value of the right-of-use asset, which represents Level 3 non-recurring fair value measurements. The estimated fair value of the was determined by discounting the estimated rental rates using market participant assumptions. The Company&#8217;s estimates and assumptions used to determine the estimated fair value of the asset group is subject to risks, uncertainties, and changes in circumstances that may result in adjustments and material changes to the estimated fair values in future periods.</span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_90a8e417-e64b-4c75-a879-d49ea4d6a6c1" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="F_90a8e417-e64b-4c75-a879-d49ea4d6a6c1_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Convertible Preferred Stock and Stockholders&#8217; Equity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Convertible Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2016, the Company completed a private placement of stock in which investors, including investors affiliated with the directors and officers of the Company, purchased convertible preferred stock and common stock of the Company (the November 2016 Placement). The Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_022b79eb-9a2a-4a07-9dbd-e34c6178b1c3" contextRef="C_02925833-8677-4697-ab8d-c844642a03e7" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,819,549</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A Convertible Preferred Stock, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ada62dfe-c302-4d35-a0bc-5296827255f3" contextRef="C_02925833-8677-4697-ab8d-c844642a03e7" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> par value per share (the Class A Preferred), at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9479f34-beff-45e9-99f0-cda7d14f9897" contextRef="C_02925833-8677-4697-ab8d-c844642a03e7" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.30</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">share, each of which is convertible into five shares of common stock upon certain conditions defined in the Certificate of Designation of Preferences, Rights and Limitations of the Class A Preferred filed with the Delaware Secretary of State</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">121</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_90a8e417-e64b-4c75-a879-d49ea4d6a6c1_1" continuedAt="F_90a8e417-e64b-4c75-a879-d49ea4d6a6c1_2"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 22, 2016 (the CoD). </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_279ec3e9-6372-4e01-a687-2ddd365e5c3b" contextRef="C_ea581251-e0f9-4e1a-ba72-0e031fd4585d" name="us-gaap:ConvertiblePreferredStockTermsOfConversion"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Class A Preferred were purchased exclusively by entities affiliated with Redmile Group, LLC (collectively, Redmile). The terms of the CoD prohibited Redmile from converting the Class A Preferred into shares of the Company&#8217;s common stock if, as a result of conversion, Redmile, together with its affiliates, would own more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e059d750-e932-491c-b806-6777025adbac" contextRef="C_126fd19f-3eec-4444-a458-398859e1ae58" name="fate:PercentageOfCommonStockOwnershipUponPreferredStockConversion" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">9.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company&#8217;s common stock then issued and outstanding (the Redmile Percentage Limitation), which percentage could change at Redmile&#8217;s election upon 61 days&#8217; notice to the Company to (i) any other number less than or equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc3d19e3-8787-4da2-a290-ff643da434a6" contextRef="C_126fd19f-3eec-4444-a458-398859e1ae58" name="fate:PercentageOfCommonStockOwnershipForPreferredStockConversionChangeUponNotice" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">19.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% or (ii) subject to approval of the Company&#8217;s stockholders to the extent required in accordance with the NASDAQ Global Market rules, any number in excess of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6daa836-89c7-44f6-aaaa-0f03135c6f0c" contextRef="C_7272a2e8-f365-434c-8a2e-ca7e7c674867" name="fate:PercentageOfCommonStockOwnershipUponPreferredStockConversion" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">19.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. On May 2, 2017, the Company&#8217;s stockholders approved the issuance of up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a73bfb22-e609-4417-8450-58a356f5de05" contextRef="C_36c7dc1f-1f68-4486-a90a-7021092d1f27" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">14,097,745</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock upon the conversion of the outstanding shares of Class A Preferred. As a result, Redmile has the right to increase the Redmile Percentage Limitation to any percentage in excess of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d92592d3-5789-430e-afd4-b1034826fd5e" contextRef="C_8cb1a266-41ae-44a5-9398-af9a30767436" name="fate:PercentageOfCommonStockOwnershipUponPreferredStockConversion" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">19.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% at its election.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company also issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8093ced1-43f6-45e2-9e2d-c881094fe059" contextRef="C_1f598670-03c3-4c12-a086-312e2fe99e74" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">7,236,837</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cae5c03-4440-41e7-95d1-c12bcb30445a" contextRef="C_8b7007bc-3d95-44d8-90bb-9b611207cb91" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.66</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share as part of the November 2016 Placement. In </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 2023, the Company filed with the office of the Secretary of State of the State of Delaware a Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitations of Class A Convertible Preferred Stock which amends the definition of Beneficial Ownership Limitation to be </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04be4f4f-8f83-4ff1-a002-48b62a6cefb1" contextRef="C_bceaaf53-4594-42b0-af63-0c188d7eaf41" name="fate:PercentageOfCommonStockOwnershipUponPreferredStockConversion" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">14.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the number of shares of the Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s common stock outstanding immediately after giving effect to the issuance of shares of common stock pursuant to a Notice of Conversion. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6f59369-5637-4df8-a3f9-47d3617f90e4" contextRef="C_79fca80f-8b40-4c0b-9152-12e26417ea73" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">33,441</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A Preferred were converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aaa0dd29-e5ac-4591-86df-73e3ef8e13b9" contextRef="C_7261e0f3-a26f-46dd-86c9-8888bb0227e9" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">167,205</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock. In December 202</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cc100bd-d613-4409-b92b-3eaf64fca108" contextRef="C_b943fa46-6631-448b-b8ef-ffce3d36d5be" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,022</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Class A Preferred were converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1ff4737-b0be-4ef8-81e0-38e2c3ede53e" contextRef="C_31099ea4-f12e-4b2c-9160-b411e31dd257" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">30,110</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Class A Preferred are non-voting shares and are convertible into five shares of the Company&#8217;s common stock at a conversion price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf70b179-0c8f-4f3e-a1f2-6b229ca11eda" contextRef="C_02925833-8677-4697-ab8d-c844642a03e7" name="fate:PreferredStockConversionPrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.66</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which was the fair value of the Company&#8217;s common stock on the date of issuance. Holders of the Class A Preferred have the same dividend rights as holders of the Company&#8217;s common stock. Additionally, the liquidation preferences of the Class A Preferred are </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">pari passu</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> among holders of the Company&#8217;s common stock and holders of the Class A Preferred, pro rata based on the number of shares held by each such holder (treated for this purpose as if the Class A Preferred had been converted to common stock).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Option and Incentive Plans and Inducement Equity Plan</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2022 Stock Option and Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 9, 2022, the Company adopted the 2022 Stock Option and Incentive Plan (the 2022 Plan). The 2022 Plan initially authorized </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_377848fb-03e0-4d38-ad91-951eaf81e02f" contextRef="C_9ddb50f7-7408-40d0-a949-d5236775a322" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares, and in June 2024, stockholders approved an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fccb4fb-5257-4b88-815c-b99931e87fe9" contextRef="C_4e67b46a-884c-4f90-a95b-2ef3d7aea6aa" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="6" decimals="-6" format="ixt:num-dot-decimal">8,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, of common stock for issuance and allows for the grant of stock options, stock appreciation rights, restricted stock awards, performance-based awards, and other awards to individuals who are then employees, officers, directors or consultants of the Company. The shares of common stock underlying any awards from the 2022 Plan and a previously existing equity plan from 2013 or 2007 that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without any issuance of common stock, expire or are otherwise terminated (other than by exercise) are added back to the shares of common stock available for issuance under the 2022 Plan.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recipients of stock options under the 2022 Plan shall be eligible to purchase shares of the Company&#8217;s common stock at an exercise price equal to no less than the estimated fair value of such stock on the date of grant. Under the 2022 Plan, stock options generally vest </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5f75518-adaf-4171-9472-fd22e5840dbd" contextRef="C_0ad23255-7a2a-4f76-96d1-4206f5e0c875" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% on the first anniversary of the original vesting date, with the balance vesting monthly over the remaining </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e78daa6f-0e2e-4c03-8261-95d588ca14bf" contextRef="C_0ad23255-7a2a-4f76-96d1-4206f5e0c875" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or vest monthly over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4969a46d-eb63-400d-adac-16bab069eba8" contextRef="C_0ad23255-7a2a-4f76-96d1-4206f5e0c875" name="fate:ShareBasedCompensationArrangementByShareBasedPaymentAwardMonthlyAwardVestingPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, unless they contain specific performance and/or market-based vesting provisions. The maximum term of stock options granted under the 2022 Plan is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_02a50ca1-b165-4302-b833-cc3847488623" contextRef="C_0ad23255-7a2a-4f76-96d1-4206f5e0c875" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under the 2022 Plan, restricted stock units generally vest annually over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3da56a36-1492-4d73-bc54-87bad9e6b1c6" contextRef="C_febf2ab8-3d7f-42f3-8e8f-9f2795618370" name="fate:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnuallyAwardVestingPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Performance-based stock units/awards vest upon the achievement of certain pre-defined company-specific performance-based clinical achievement criteria.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inducement Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 10, 2016, the Company&#8217;s board of directors approved the Fate Therapeutics, Inc. Inducement Equity Plan (the Inducement Plan), the purpose of which is to enable the Company to grant equity awards to induce highly-qualified prospective officers and employees who are not employed by the Company to accept employment with the Company. Under the Inducement Plan, the Company may grant non-qualified stock options and restricted stock units. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55908229-e514-4d60-a393-ab1544a58597" contextRef="C_253be32e-0a0d-4574-b01a-92170bea60d8" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">500,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were initially reserved for issuance under the Inducement Plan. In January 2021, March 2020, and January 2019, an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b81e4232-cfdf-4345-bddd-fbe0fedc772e" contextRef="C_acf53715-2f34-438d-9496-5f75227814aa" name="fate:CommonStockCapitalAdditionalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">300,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec1cf42a-214e-4484-97d3-8c2fae30cb72" contextRef="C_b18b95bd-40a9-49db-97ef-2faba14a93a6" name="fate:CommonStockCapitalAdditionalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">470,822</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4b52162-cfa3-4a3a-b300-4a3cdc9e8dbf" contextRef="C_afe59ea1-745d-4337-875d-4dbe66b0f606" name="fate:CommonStockCapitalAdditionalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">200,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively, of common stock were reserved for issuance under the Inducement Plan. The shares of common stock underlying any awards from the Inducement Plan that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without any issuance of common stock, expire or are otherwise terminated (other than by exercise) under the Inducement Plan will be added back to the shares of common stock available for issuance under the Inducement Plan.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">122</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_90a8e417-e64b-4c75-a879-d49ea4d6a6c1_2" continuedAt="F_90a8e417-e64b-4c75-a879-d49ea4d6a6c1_3"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-Funded Warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2021, in conjunction with a public offering, the Company issued Pre-Funded Warrants, in lieu of common stock to certain investors, to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6384487-f947-454d-a529-18e8e7748c79" contextRef="C_821efd00-9226-4b6b-acf3-b68a5fe00775" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">257,310</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock (the 2021 Pre-Funded Warrants). The purchase price for the 2021 Pre-Funded Warrants was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0eaf41de-e300-4f5e-abb9-c3ffb7badb0b" contextRef="C_643af01a-b028-4eee-8c3b-c5192d3e319a" name="fate:PurchasePriceOfPrefundedWarrants" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">85.499</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per pre-funded warrant, which equals the per share public offering price for the shares of common stock less the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50a97554-40a2-47a2-b221-62eb28e11a8e" contextRef="C_821efd00-9226-4b6b-acf3-b68a5fe00775" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> exercise price for each such pre-funded warrant. Given that the 2021 Pre-Funded Warrants are indexed to the Company&#8217;s own shares of common stock (and otherwise meet the requirements to be classified in equity), the Company recorded the consideration received from the issuance of the warrants as additional paid-in capital on the Company&#8217;s consolidated balance sheets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, in conjunction with a public offering, the Company issued in a private placement, in lieu of common stock to certain investors, pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c111aa5-10cb-4868-b864-a69223a7b562" contextRef="C_780d7cf9-0c20-4ef0-a014-ce112efe3de2" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,636,364</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock (2024 Pre-Funded Warrants, and collectively with the 2021 Pre-Funded Warrants, the Pre-Funded Warrants). The purchase price for the 2024 Pre-Funded Warrants was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d388a94-0aee-427d-bc7a-a22799a90657" contextRef="C_dad32687-8050-4e65-8354-068f686b84df" name="fate:PurchasePriceOfPrefundedWarrants" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">5.499</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per pre-funded warrant, which equals the per share public offering price for the shares of common stock issued in the March 2024 public offering, less the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5bd514a-a811-4d66-9e40-08e766e13b0b" contextRef="C_780d7cf9-0c20-4ef0-a014-ce112efe3de2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> exercise price for each such pre-funded warrant. Given that the 2024 Pre-Funded Warrants are indexed to the Company&#8217;s own shares of common stock (and otherwise meet the requirements to be classified in equity), the Company recorded the consideration received from the issuance of the warrants as additional paid-in capital on the Company&#8217;s unaudited condensed consolidated balance sheets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e3b31658-d751-4b7c-b9ac-3c274816bf73" contextRef="C_643af01a-b028-4eee-8c3b-c5192d3e319a" name="fate:WarrantsExerciseTermsDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Pre-Funded Warrants are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0a0391a-4fa3-4a82-8f9c-6e4ab9fe7619" contextRef="C_821efd00-9226-4b6b-acf3-b68a5fe00775" name="fate:MaximumPercentageOfCommonStockOwnershipTogetherWithAffiliatesAllowableAfterExerciseOfPrefundedWarrants" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">9.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the number of shares of the Company&#8217;s common stock outstanding immediately after giving effect to such exercise. A holder of Pre-Funded Warrants may increase or decrease this percentage not in excess of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b6333f4-69cc-49aa-ae7b-a231e44215a1" contextRef="C_821efd00-9226-4b6b-acf3-b68a5fe00775" name="fate:MaximumPercentageOfCommonStockOwnershipAfterChangeUponNotice" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">19.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% by providing at least 61 days&#8217; prior notice to the Company.</span></ix:nonNumeric></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, there w</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ere </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72b7eb1f-19c0-458a-98d6-a92e3cca6d50" contextRef="C_d2920029-80c7-4108-9176-bd4bda38a66b" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,893,674</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Pre-Fu</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nded Warrants outstanding.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Options and Restricted Stock Unit Awards</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Options.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_42c862d9-3a55-43d8-9d4c-1b77fb049ef9" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" escape="true" continuedAt="F_42c862d9-3a55-43d8-9d4c-1b77fb049ef9_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes stock option activity and related information under all equity plans for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span></ix:nonNumeric></span></p><div style="font-size:8pt;font-family:Times New Roman;"><ix:continuation id="F_42c862d9-3a55-43d8-9d4c-1b77fb049ef9_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.41%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.902%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.08%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.142%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.902%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.08%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.482%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price Per Share</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic Value<br/>(in 000s)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c20c1ca5-1cbc-4f3c-b246-f4ab2bfda977" contextRef="C_d2feccdf-3708-47ad-92f7-48fa021ea96b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,850,841</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_accff89f-45f8-4b96-86c1-a37e8e64d023" contextRef="C_d2feccdf-3708-47ad-92f7-48fa021ea96b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">13.71</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b338d061-ba5b-41d6-8ab4-f8e3ec978b66" contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,210,625</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e15a2241-3143-41ac-9600-ad5c81609e57" contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.46</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_707f4793-f90a-4dac-baa0-3722fd1327cf" contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">45,438</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7abd2d18-19d3-48ee-99f0-d6b1e3d87805" contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.57</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e113eadb-25f8-4dca-a85b-51cc9e780c1f" contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,293,354</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe4b0148-8a85-48bd-936f-1cd973335221" contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.40</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc795042-02f2-4c69-a87d-3ad6a3fabd93" contextRef="C_5c738271-04b6-46a1-bc09-e0d54f7b433b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,722,674</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_839fb2f3-d250-4b74-baa9-fbe76731a304" contextRef="C_5c738271-04b6-46a1-bc09-e0d54f7b433b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.99</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><ix:nonNumeric id="F_dbf2d1dc-cfde-472c-bf02-3893829cfa90" contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.83</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a7a13a5-c52d-423f-9daa-fb05f6e6158c" contextRef="C_5c738271-04b6-46a1-bc09-e0d54f7b433b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options vested and expected to vest at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0c46494-915c-4c99-a71f-b2bbdd6469af" contextRef="C_5c738271-04b6-46a1-bc09-e0d54f7b433b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">10,722,674</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a70dbb5-be8e-4255-b789-ee8856c85249" contextRef="C_5c738271-04b6-46a1-bc09-e0d54f7b433b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.99</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><ix:nonNumeric id="F_809ab1a8-28bf-498c-a7d1-8ab776d224a0" contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.83</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2698d3f-061e-48fd-9cb5-6553999ba34c" contextRef="C_5c738271-04b6-46a1-bc09-e0d54f7b433b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercisable at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a22c4041-181f-4f73-b4c1-ca6adfa3693e" contextRef="C_5c738271-04b6-46a1-bc09-e0d54f7b433b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">7,328,404</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58ac7038-fd3c-4173-8542-dcd4b6481347" contextRef="C_5c738271-04b6-46a1-bc09-e0d54f7b433b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.91</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><ix:nonNumeric id="F_3a810de8-0cb0-4fdb-812b-d0e98797e234" contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.91</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd2c6621-17f2-4853-97d0-371bfc91776e" contextRef="C_5c738271-04b6-46a1-bc09-e0d54f7b433b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024 and 2023, the weighted average grant date fair value of stock options granted per share was equal to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34007827-b267-427a-98be-104160ba31c4" contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.89</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60b747c9-6fbe-4e88-b24b-f0d493ce06dc" contextRef="C_8d696b36-8d44-4c55-9a08-7819757a59b4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.83</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023, the unrecognized compensation cost related to outstanding options was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_508cbcbe-c72d-4532-9555-75bda3f5ef1f" contextRef="C_b1694544-d57a-4079-9403-45d7021d8147" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27445156-32ca-4f99-9df2-5838e4ef54d0" contextRef="C_0792edb8-8c75-4ac5-9ff2-3638bf624ca6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">23.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, which was expected to be recognized as expense over approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_37376a3a-afbb-4bf3-a5cd-d74de5284ff9" contextRef="C_b1dc2798-8465-41bc-83d9-cb6a02fcf5c5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.6</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_79ca7e18-e21e-4d3c-8a6c-89bf00fe6a8c" contextRef="C_0c2bd9af-d58c-4b2f-a7bf-36d6102fcb98" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.9</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total intrinsic value, which is the amount by which the exercise price was exceeded by the price of the Company&#8217;s common stock on the date of exercise, of stock options exercised during the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32278971-a1ba-4344-98a6-e0ddfa541c48" contextRef="C_8d696b36-8d44-4c55-9a08-7819757a59b4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. As of December 31, 2024, all outstanding options had an exercise price above the Company's common stock price and therefore </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a921306-0f34-49ef-a2d9-7565434de695" contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> intrinsic value. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total cash received upon the exercise of stock options was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7aabf5a-0163-4b38-85d8-740bd44fb244" contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">123</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_90a8e417-e64b-4c75-a879-d49ea4d6a6c1_3" continuedAt="F_90a8e417-e64b-4c75-a879-d49ea4d6a6c1_4"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_a5724135-beef-4e00-8ec2-c43f43b10fc3" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" escape="true" continuedAt="F_a5724135-beef-4e00-8ec2-c43f43b10fc3_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes restricted stock unit activity and related information under all equity plans for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a5724135-beef-4e00-8ec2-c43f43b10fc3_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.41%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.902%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.08%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.142%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.902%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.08%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.482%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Restricted Stock Units</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value Per Share</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Vesting<br/>Period</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic Value<br/>(in 000s)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa9cfa40-d200-4cb4-9b74-c377ecd9ef80" contextRef="C_e07453e5-70e2-4589-84ee-63184d1649d3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,065,087</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a13c06de-5ace-4b3c-bc8e-933e11b6c569" contextRef="C_e07453e5-70e2-4589-84ee-63184d1649d3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">37.96</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d95db063-5596-4633-b970-b0b2cb0922a2" contextRef="C_13e7d164-655d-47b3-8816-15b789699d5d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,451,874</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1676fb0-b54c-46ba-bc0f-010f4c81614b" contextRef="C_13e7d164-655d-47b3-8816-15b789699d5d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.69</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b8ed1c8-5e36-4dfd-94eb-a356daa3e5cb" contextRef="C_13e7d164-655d-47b3-8816-15b789699d5d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">680,201</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dec01be6-ef46-49b3-a212-f33846027f42" contextRef="C_13e7d164-655d-47b3-8816-15b789699d5d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">33.68</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7680c28f-050d-419e-be1b-0baf1b8d4960" contextRef="C_13e7d164-655d-47b3-8816-15b789699d5d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">622,696</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db73423e-50f0-4fe4-8a66-e467a11a5352" contextRef="C_13e7d164-655d-47b3-8816-15b789699d5d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">35.78</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d0b1cb0-6458-4feb-bc51-bc42e320fb5f" contextRef="C_5e663327-b86d-4b6c-a039-7b7d8ac711f3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,214,064</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22ee9ad8-c241-424a-8348-a7f9823fc6bc" contextRef="C_5e663327-b86d-4b6c-a039-7b7d8ac711f3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.50</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><ix:nonNumeric id="F_6baf3ea6-a30b-42e7-bbe1-0e27572420ca" contextRef="C_13e7d164-655d-47b3-8816-15b789699d5d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.01</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a522b4ad-47e5-45b1-8368-da873e9c6548" contextRef="C_5e663327-b86d-4b6c-a039-7b7d8ac711f3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,253</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units expected to vest at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72f440d4-44c8-4137-aea4-127ca73262d8" contextRef="C_5e663327-b86d-4b6c-a039-7b7d8ac711f3" name="fate:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,151,457</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23633ff6-64da-4c48-8aa6-d0ebea9cadc0" contextRef="C_5e663327-b86d-4b6c-a039-7b7d8ac711f3" name="fate:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.78</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><ix:nonNumeric id="F_79f591e3-0107-4ea3-ba46-5719d53979f7" contextRef="C_13e7d164-655d-47b3-8816-15b789699d5d" name="fate:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.92</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2cd90981-ec37-48d1-ad81-f4710cc6bae1" contextRef="C_5e663327-b86d-4b6c-a039-7b7d8ac711f3" name="fate:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,500</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023, the unrecognized compensation cost related to outstanding restricted stock units (excluding those with unachieved performance-based conditions) was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d95d24f-ade5-4978-8244-4ecaf0e3b6e6" contextRef="C_5e663327-b86d-4b6c-a039-7b7d8ac711f3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">31.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3bf5771e-6eed-42e7-86c0-4efb2d24d778" contextRef="C_e07453e5-70e2-4589-84ee-63184d1649d3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">38.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, which was expected to be recognized as expense over approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0b5b820e-dd90-497e-ac14-b8749e9c3db7" contextRef="C_13e7d164-655d-47b3-8816-15b789699d5d" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.7</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">years and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ed274875-4530-4115-b344-fcaad915f4e7" contextRef="C_ae9121c7-17e3-4b53-8ea5-3c6e73560888" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.0</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2021, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b45feac9-c907-4627-ad17-d73564527d80" contextRef="C_54bb083b-1c65-43f0-903c-ff27e3c8a59d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,997,377</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> performance-based restricted stock units (PRSUs) were granted, none of which have vested. During the year ended December 31, 2024, the Company granted </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12c47d59-65aa-4a06-95b7-90247fe9ce49" contextRef="C_c8f88322-9cd7-4ec4-92f5-a0a2e5bc4363" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">300,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> performance-based restricted stock units with a total grant date fair value of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57af6182-a375-44eb-bf13-0bfd1a87457a" contextRef="C_c8f88322-9cd7-4ec4-92f5-a0a2e5bc4363" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, none of which have vested. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bafa1d3-c47b-46f1-9194-466473c36337" contextRef="C_5e663327-b86d-4b6c-a039-7b7d8ac711f3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,062,607</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a842c688-7cf2-424e-9791-85753c0eee23" contextRef="C_e07453e5-70e2-4589-84ee-63184d1649d3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,020,617</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> PRSUs outstanding at December 31, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-Based Compensation Expense</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_419ff781-41d9-43fd-bf6c-81fc46b93796" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The allocation of stock-based compensation for all stock awards is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fb0ab7e-1ab2-4c26-8112-6410c5b7c2ba" contextRef="C_e07a21dc-a40b-48ca-81a4-731bcea56eb4" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,520</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5611911f-39e1-4616-9614-b1217af6c542" contextRef="C_8ab196d3-69ab-4d26-b22d-9350aa81b0a8" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,849</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4e29880-8b79-4889-8bd7-584aa887a1ad" contextRef="C_e5f0eeec-87ae-44d4-9289-b8c650cd8dd3" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,976</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_529a70c0-880a-4496-bef3-7cdb7a18db53" contextRef="C_b7a41695-3727-4f36-8184-049efe051469" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,610</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_baaaedc5-b8e0-488d-97eb-d4ff92f3a11f" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,496</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_635114e8-1d8d-42f6-8c70-5c702b8fd180" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,459</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Option Grants Valuation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_1a65d281-abd0-40cf-9643-ff875e96f6de" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true" continuedAt="F_1a65d281-abd0-40cf-9643-ff875e96f6de_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee and nonemployee stock option grants were as follows:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_1a65d281-abd0-40cf-9643-ff875e96f6de_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.343%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.343%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk&#8211;free interest rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_168fe627-6dfa-4245-8c1f-f52b85825267" contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.9</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e98032e4-8291-4669-84c3-646e6fa4f2ca" contextRef="C_8d696b36-8d44-4c55-9a08-7819757a59b4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.8</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0ccdd4e-b96c-4a41-9001-bef72dbc787b" contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">87.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25c76ec4-7c30-4280-9184-cb2c567f6380" contextRef="C_8d696b36-8d44-4c55-9a08-7819757a59b4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">89.3</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_175c91eb-692f-4369-b418-683d97239acb" contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.4</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_91275898-7127-43be-b327-feee5f485c96" contextRef="C_8d696b36-8d44-4c55-9a08-7819757a59b4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.5</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19c97ba6-90fb-4d96-9a5a-6c41ad94808d" contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2185b019-316f-497e-b491-d1f52b841ae3" contextRef="C_8d696b36-8d44-4c55-9a08-7819757a59b4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk-free interest rate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company bases the risk-free interest rate assumption on observed interest rates appropriate for the expected term of the stock option grants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected dividend yield.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected volatility.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company based the expected volatility on the historical volatility of its common stock over the most recent period commensurate with the estimated expected term of the Company&#8217;s stock options, as the Company determined there was sufficient operating history and company-specific historical volatility to estimate the expected volatility.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">124</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_90a8e417-e64b-4c75-a879-d49ea4d6a6c1_4"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The expected term represents the period of time that options are expected to be outstanding. The Company estimated the expected term using historical experience and anticipated future exercise behavior.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock Reserved for Future Issuance</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_62c42cce-3697-45fc-a436-e46f30fee853" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="fate:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common stock reserved for future issuance is as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.357%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.357%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible preferred stock (if converted)</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ccecff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ccecff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1335002-ef90-4fd0-949a-29c9d6d85d54" contextRef="C_f776f2a9-7c7a-491a-991b-ad0fcec60954" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">13,775,430</ix:nonFraction></span></p></td>
        <td style="background-color:#ccecff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ccecff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ccecff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5b2ca37-815c-40ae-b98b-075dca4cd963" contextRef="C_4f0fc4a6-d283-49a9-971d-0333511e8d5e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,805,540</ix:nonFraction></span></p></td>
        <td style="background-color:#ccecff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock options</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d1a87b5-ff3d-4698-aeeb-bd102bc35d84" contextRef="C_4c6c4dd6-4ab5-46a0-bc89-10dab775b034" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">10,722,674</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_576a1349-34ba-45d6-84e3-782db27d42cd" contextRef="C_bc45b335-2d95-4276-ad2c-dab6f6cd2b27" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,850,841</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf67eb77-c86f-430c-b555-db3af7b2022d" contextRef="C_5e663327-b86d-4b6c-a039-7b7d8ac711f3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,214,064</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_418cb805-1cba-418c-baed-358ccf84524d" contextRef="C_e07453e5-70e2-4589-84ee-63184d1649d3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,065,087</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Awards available under the 2022 Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54d2e9ed-dcc3-4474-8762-9d2b9fd76154" contextRef="C_d0dc00f7-c9cf-41d7-89f0-cc4fe78c6101" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">11,656,109</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70820944-a5b8-404e-a399-f9b344afd650" contextRef="C_6e421e14-6d5d-4504-b9b2-ead06e38f45f" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,633,496</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Awards available under the Inducement Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60cc8c1d-43b2-4406-9108-d9d4c588eb67" contextRef="C_bc446b6b-8934-40b7-bcdd-742d1f50b677" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">920,688</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3122030c-fba4-47bc-9d56-24a0ad4e9dbd" contextRef="C_9a61a4db-53f2-4f25-957f-9ca42291c122" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">689,750</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_317641ef-84d2-4b86-8dd0-49ff846378e8" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">43,288,965</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb213d98-ff36-43f2-ae47-5b200200b9e0" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">36,044,714</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_1b193051-df74-4650-80c7-338244a1f411" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_1b193051-df74-4650-80c7-338244a1f411_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Income Taxes</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0980a0ab-94f7-4c95-b2bd-abe3ac758828" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is a reconciliation of the Company&#8217;s expected federal income tax provision (benefit) to the actual income tax provision (in thousands):</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax computed at federal statutory rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f45c0713-f974-47b2-8900-b05c97bbfb29" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39,115</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12da07ec-e313-47da-a3d8-2d75218c9415" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">33,794</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State tax, net of federal tax benefit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac19dbe2-eed8-4e63-9308-d5f5b4087a69" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,429</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_096cba59-4dd5-4ccb-afaa-bd064b1bb226" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,851</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-deductible compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_325c844b-d1ed-49e3-8254-cc6fff11eb49" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="fate:IncomeTaxReconciliationNondeductibleCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de699c77-ffbf-4d7e-8d6e-38d2a14264fa" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="fate:IncomeTaxReconciliationNondeductibleCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_788e1282-2258-45ca-95e1-4796f10388a8" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="fate:IncomeTaxReconciliationPermanentTaxDifferences" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_778c29ff-40bd-4dd9-bf61-31d14401008f" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="fate:IncomeTaxReconciliationPermanentTaxDifferences" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,305</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_832b388b-6341-4f14-86fd-30fb7c77e3c5" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,560</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a440c28d-249c-4b76-8bfb-8331ef38fcaf" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,801</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R&amp;D tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e378b58-d19e-4d60-b171-768452d886ea" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,672</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da5073be-c51b-49cb-803d-5512100a18a0" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,773</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reserve for uncertain tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3422ea9-ab6c-4f2e-be1b-8f002488b730" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="fate:IncomeTaxReconciliationReserveForUncertainTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,612</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2114a3aa-0ebb-492f-b656-cec36151af09" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="fate:IncomeTaxReconciliationReserveForUncertainTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,254</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_791b98c1-8e9e-4fe3-b4f6-9f72127c1cae" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">135</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_139636b5-a8dd-4872-8154-cd822c8d4350" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,928</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8fb9e9b-06fb-4827-8fcf-37ef752885ad" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,122</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_675f8deb-10e6-4b40-b136-10edcad9d10a" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,715</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64e11b3e-360e-4145-9fbf-ed496c14159b" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a7d28bf-6d51-489f-a292-b3b31bbf73f8" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_242ac8b3-921f-4942-8ca7-fb3ab1b8a7b6" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant components of the Company&#8217;s deferred tax assets are summarized as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized R&amp;D expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5e702db-819c-4b57-93af-bcd925d36db3" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="fate:DeferredTaxAssetsCapitalizedRdExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">127,559</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a706b936-7452-4e9d-9c60-e0361dd3ee8b" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="fate:DeferredTaxAssetsCapitalizedRdExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">134,209</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating losses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18b8ffe1-7d71-40b0-abf2-f36b32811611" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">147,019</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02d21aab-075b-418a-9e25-00bfe78b48f2" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112,810</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R&amp;D tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03cf3248-8fec-4cb7-9399-4002bdaa1f32" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,126</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3faeed9-09f5-4dfd-b0b3-e55c923c7d79" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,492</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible asset amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2af5cd52-b048-4787-ad08-c6f7805ba1a2" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,692</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d0407a9-21bb-4d28-b9bd-ce96fdf26eb9" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,220</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_591efa6e-6496-412d-ac87-9fdb98da2313" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,147</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce02fbb3-2eca-464d-9c80-0c43ee1b395c" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">144</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33921a84-dee2-48e2-bbb5-d7295b9c5c47" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,836</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_511739b4-480a-489b-95d1-453949442520" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,322</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4f9c411-4b66-4fd2-9974-8d7eb7d4fdef" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="fate:DeferredTaxAssetsLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,925</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53c152e1-4aae-4dbc-9f91-314976bbf3d6" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="fate:DeferredTaxAssetsLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,761</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cc8ff8f-51b3-43ff-bef5-423e2efe1801" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">788</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e632b85c-f83c-4d0c-a306-a6ef1a926149" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">672</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0b52635-c6d7-4842-8c88-83183d9a4ed5" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">374,092</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7572555f-1aa1-403a-9c72-f3c48e309656" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">342,630</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d56017e2-00e9-40a3-8d01-0d62aa011764" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="fate:DeferredTaxLiabilitiesDepreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,212</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1f33e8f-fda3-4680-ba27-106ad3fe4d82" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="fate:DeferredTaxLiabilitiesDepreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,639</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14caade0-9237-4127-839a-6444f8227655" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="fate:DeferredTaxLiabilitiesRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,796</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_887f04bb-f920-4ca4-935e-e903f1301f71" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="fate:DeferredTaxLiabilitiesRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,029</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24576641-3cbf-4b76-8bc0-10092a82c523" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,008</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9237b7de-2370-454b-aa7b-c7a12d4adf96" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,668</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net of deferred tax assets and liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97afa3c4-8bb8-4605-995d-43b369bbb338" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">362,084</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f519f8a-6c66-4187-8667-8fb1909cdbae" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">323,962</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_271a23c3-0b46-435c-96d6-6b840f0cbf6b" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">362,084</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cdc8604-dce1-4b35-a29a-cd334fae35f9" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">323,962</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc6d04c4-c3cc-4d5a-9686-4288f6897498" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_862c9642-cfa5-47fe-8138-1cf5d9a1f2e9" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:86.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">125</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_1b193051-df74-4650-80c7-338244a1f411_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A valuation allowance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9db93f24-ec42-4c96-9871-19c55a1cb055" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">362.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_322bc58d-5269-4c24-a890-7f68eea16960" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">324.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, respectively, has been established to offset the deferred tax assets, as realization of such assets is uncertain.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024, the Company had federal and state net operating loss (NOL) carryforwards of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15eb3006-6182-41e4-bf20-31c2c42e8858" contextRef="C_fece1b4a-7679-43ae-91f1-803e3e834572" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">689.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f12a53d9-484f-44ad-be5c-73bef8bd81de" contextRef="C_6ada6b38-7f9b-45ef-acbb-49e492518216" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">644.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, which may be available to offset future taxable income. The federal and California NOL carryforwards begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dee7ce50-ba53-4445-9f28-ecb4c10c4593" contextRef="C_b831d8dc-5480-4f60-b15f-b532465e4ca2" name="fate:OperatingLossCarryforwardsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2027</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_de3e78fa-f539-4698-b4c5-20ecac366651" contextRef="C_5cc2f3d5-6422-4ca7-ba47-f826548fe079" name="fate:OperatingLossCarryforwardsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2028</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, unless previously utilized. At </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had federal and California research and development (R&amp;D) credit carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1da7584-942e-421d-ace2-3d1b0bac0dd7" contextRef="C_e122feae-e127-43e8-a5fa-96cea5382fa8" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">45.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bca3f51-acca-435f-87fa-81af3a0a5bbf" contextRef="C_6ada6b38-7f9b-45ef-acbb-49e492518216" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">37.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The federal R&amp;D tax credit carryforwards will begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c54b7f59-bf9b-4959-a580-cf9b8d37c275" contextRef="C_eb50e59a-b806-4c03-9930-ed4b25c0c2ce" name="fate:TaxCreditCarryforwardBeginningExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2035</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> unless previously utilized. The California R&amp;D credit carryforwards will carry forward indefinitely.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, (the Code), substantial changes in the Company&#8217;s ownership may limit the amount of net operating loss and research and development credit carryforwards that could be used annually in the future to offset taxable income. The tax benefits related to future utilization of federal and state net operating loss carryforwards, credit carryforwards, and other deferred tax assets may be limited or lost if cumulative changes in ownership exceeds </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e48c2d49-5d5f-4b52-9eec-488ef611859b" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="fate:CumulativeChangeInOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% within any </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1719cfca-cfed-4b80-89ee-ca4dd860af6c" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="fate:PeriodForCumulativeChangeInOwnership" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period. The Company completed a study to assess whether an ownership change, as defined by Section 382 of the Code, had occurred from the Company&#8217;s formation through December 31, 2015. Based upon this study, the Company determined that several ownership changes had occurred. Accordingly, the Company reduced its deferred tax assets related to the federal NOL carryforwards and the federal R&amp;D credit carryforwards that are anticipated to expire unused as a result of these ownership changes. These tax attributes were excluded from deferred tax assets with a corresponding reduction of the valuation allowance with no net effect on income tax expense or the effective tax rate. The Company updated the study December 31, 2024 and concluded there were no ownership changes during 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Future ownership changes may further limit the Company&#8217;s ability to utilize its remaining tax attributes.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company files income tax returns in the United States, various state jurisdictions, and the Netherlands with varying statutes of limitations. The Company currently has no years under examination by any jurisdiction; however, the Company is subject to income tax examination by federal and state tax authorities for years beginning in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_90f2d18a-da8a-47e8-ae74-919153df00ba" contextRef="C_b831d8dc-5480-4f60-b15f-b532465e4ca2" name="us-gaap:IncomeTaxExaminationYearUnderExamination"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2021</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7ea583c4-873b-4a3a-9a0e-b0257da81476" contextRef="C_235e1198-6534-41bd-9a50-81f2b487638e" name="us-gaap:IncomeTaxExaminationYearUnderExamination"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2020</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. However, to the extent allowed by law, the taxing authorities may have the right to examine prior periods where NOLs and tax credits were generated and carried forward, and make adjustments up to the amount of the carryforwards.</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_aee5e994-a7e9-4706-8ee5-6399b8a78c0b" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The change in the Company&#8217;s unrecognized tax benefits is summarized as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.92%;box-sizing:content-box;"/>
        <td style="width:1.6%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.64%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.6%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.64%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.6%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beginning unrecognized tax benefits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7956458-7d9c-4f03-b666-fde558481164" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,680</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d14d1c2f-0af4-4824-8fb4-6e85a646a7aa" contextRef="C_6199ef4e-6533-4919-aa08-7b8879357aa9" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,767</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase related to current year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_306f22e8-2291-403d-b522-d4e7d70b5157" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,345</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b66a408-4f60-4fbb-a302-5f814b608386" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,724</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase related to prior year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cad7831-fdb5-469e-88dd-5bd3b8f98da2" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">687</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4c09a29-d6d8-4c66-8843-c542d703b245" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Decrease related to prior year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fd1ca62-52d5-4205-a2d3-324c5d8e17ee" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">207</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_527a2ed9-6a7e-4453-8604-8f33ec16db32" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,901</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ending unrecognized tax benefits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83b67c3e-fc0e-4924-acdf-021dae715ae1" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,505</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d11fe421-76bc-48cd-8817-f086dd5762ca" contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,680</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company does </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa317ecb-f4f6-4444-b46b-f3a8acc9156f" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="fate:UnrecognizedTaxBenefitsResultingInNetOperatingLossAndTaxCreditCarryforward" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t anticipate that the amount of unrecognized tax benefits as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> will significantly change within the next twelve months. Due to the valuation allowance recorded against the Company&#8217;s deferred tax assets, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0308d48d-8cd3-46c6-a981-1e474aaff428" contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ne of the total unrecognized tax benefits as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> would reduce the effective tax rate if recognized. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. The Company has not recognized interest or penalties related to income tax matters in its consolidated statements of operations and comprehensive loss since inception.</span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_fe1cff8f-5d21-4000-8479-2012323eaaba" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true" continuedAt="F_fe1cff8f-5d21-4000-8479-2012323eaaba_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Segment Reporting</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1633fcd5-5ad6-4a1e-8675-fc764ea085ac" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment relating to its operations. The segment derives its current revenues from research and development collaborations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0c8d46ba-7b96-4017-8e46-a6b4b89866b5" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s Chief Operating Decision Maker (the CODM), its Chief Executive Officer, manages the Company&#8217;s operations on an integrated basis for the purposes of allocating resources. When evaluating the Company&#8217;s financial performance, the CODM reviews total revenues, total expenses and expenses by certain categories and makes decisions using this information.</span></ix:nonNumeric></span></p><div><ix:nonNumeric id="F_2588e50f-0337-462b-a6c2-90bcbde4bb60" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" escape="true" continuedAt="F_2588e50f-0337-462b-a6c2-90bcbde4bb60_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">126</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_fe1cff8f-5d21-4000-8479-2012323eaaba_1"><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:continuation id="F_2588e50f-0337-462b-a6c2-90bcbde4bb60_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_2f454c57-baac-4705-a580-50decd7c868a;"><span style="-sec-ix-hidden:F_ec6c8190-36ba-401a-8dbc-a9e6f704f525;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration revenue</span></span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1e1870d-0307-414c-a652-ad26c70a4a16" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,631</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2430e201-4380-41d9-b89c-8180170bc4eb" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,533</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5616850-5fa9-4429-9dd1-fe82a561caf5" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="fate:PersonnelCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,684</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2638df7d-c1e5-40c1-96be-aac1fe512479" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="fate:PersonnelCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,454</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical programs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c810798-7e58-46f2-858d-b90168bf40d1" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="fate:ClinicalProgramsExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,818</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cbe910d-4901-4749-830f-d46ad97eee56" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="fate:ClinicalProgramsExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,289</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research activities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c50688dd-ed68-410a-834a-94a632dd7097" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="fate:ResearchActivitiesExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,692</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55bf494a-2363-4aef-bca4-189800929d0d" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="fate:ResearchActivitiesExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,768</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Facilities costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f51b31bf-b7ed-4525-9575-a63993b9c14b" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="fate:FacilitiesCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,648</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd397846-2598-423a-a638-0ecaab6a7d9e" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="fate:FacilitiesCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,005</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment expenses (1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b365eab-0f43-4cb0-abaf-bc342af9c6ec" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="fate:OtherSegmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,065</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09e675d8-070d-4377-b897-566ff7993c23" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="fate:OtherSegmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,528</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_686dae30-7163-4f6c-a400-ac2f4e8ae811" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">223,907</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb693143-269d-49e6-bdc0-f32a8eaee239" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">254,044</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ed95370-21e2-4047-87fa-c6b9d67c3ba6" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">210,276</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae565115-5a61-4011-8ad9-2ed29c3f6fc5" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">190,511</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense):</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d576340-6a07-4aa5-9fb8-fe4b87d6f19d" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,288</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8596f12f-b52a-472a-aaeb-9102c3a7a55e" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,186</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of stock price appreciation milestones</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8056bc2d-c0d8-418c-9624-85ef8a154a7b" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="fate:IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">819</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca891d05-8f63-4a0e-9bc0-828abc11c7db" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="fate:IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,515</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53405b32-abe8-4bf0-ac5d-945152b89b92" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:OtherNonoperatingIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,907</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a7da979-efb9-4b57-9942-1b6090c76e83" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:OtherNonoperatingIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,882</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dce53816-8b8a-4dba-abf1-275e5b4c64bc" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,014</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a34b3ff0-55af-4ff2-99da-219965ed8928" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,583</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5af7607b-06b7-4389-8c37-c59a7986fe69" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">186,262</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af8dd702-2e0e-4048-a564-6cf5839481b9" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">160,928</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><ix:footnote id="FNT_6ec5b87e-3b57-47e9-bcc1-09fda434533f" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other segment expenses include stock compensation expense, depreciation, legal fees, general &amp; administrative expenses, and corporate expenses.</span></ix:footnote></p></ix:continuation></div></ix:continuation></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_72d49ecf-d3fb-4f5d-a1a4-51e6ac961c1a" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Employee Benefits</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective January 1, 2009, the Company adopted a defined contribution 401(k) plan for employees who are at least </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_23dbb662-f198-4a6b-992b-575a576aa447" contextRef="C_df4185ff-6291-44b2-b42f-fe0d6dd2b4c5" name="fate:DefinedContributionPlanMinimumAgeOfEmployee" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years of age. Employees are eligible to participate in the plan beginning on the first day of the calendar quarter following date of hire. Under the terms of the plan, employees may make voluntary contributions as a percent of compensation. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b22853d6-70b0-4612-9bd9-1d8b3ad2c1f6" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="fate:PercentageOfDiscretionaryContributionsDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company makes discretionary contributions to the 401(k) Plan equal to 100 percent of each employee&#8217;s pretax contributions up to 20 percent of the IRS Standard Limit.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s total contributions to the 401(k) Plan </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7ba7e16-79e4-48cb-9729-51a74a19a2c4" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mill</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ion and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b44b77c0-f5fc-4349-b602-e3f559d0e804" contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_82e35e26-ef9e-46bb-a1a5-07cd83d40f9f" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="F_82e35e26-ef9e-46bb-a1a5-07cd83d40f9f_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License Agreements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into exclusive license agreements with certain academic institutions and universities pursuant to which the Company acquired certain intellectual property. Pursuant to each agreement, as consideration for an exclusive license to the intellectual property, the Company paid a license fee, reimbursed the institution for historical patent costs and, in certain instances, issued the institution shares of restricted common stock. Additionally, under each agreement, the institution is generally eligible to receive future consideration including, but not limited to, annual maintenance fees, royalties, milestone payments and sublicensing fees. Each of the license agreements is generally cancelable by the Company, given appropriate prior written notice. Minimum annual payments to maintain these cancelable licenses total an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6b031ed-24da-46fa-b3c5-d9bf74143112" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="fate:MinimumAnnualPaymentsToMaintainLicenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million. See Note 2 for additional information on certain licenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Litigation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the reporting period, the Company pursued claims in two lawsuits that were filed in 2022 against Shoreline Biosciences, Inc. (Shoreline) and certain of its founders and officers (collectively, the Shoreline litigations). The first suit, filed on May 13, 2022, was pending in San Diego Superior Court against Shoreline and four of its founders, Drs. Dan S. Kaufman (Kaufman), Kleanthis G. Xanthopoulos, and Messrs. William Sandborn and Steven Holtzman. The Company's claims included actions for breach of contract, breach of implied covenant of good faith and fair dealing, fraud and deceit, tortious interference, restitution and unfair competition. On August 9, 2024, the court denied the defendants&#8217; motions for summary judgment preserving for trial all of the Company&#8217;s claims against the defendants, with the exception of defendants&#8217; motions with respect to certain theories under the Company&#8217;s tortious interference claim (which claim by Fate was otherwise preserved for trial). On September 19, 2024, the court denied defendants&#8217; motion for reconsideration of its summary judgment ruling. Trial began on October 21, 2024, with a jury selected on October 24, 2024. On October 28, 2024, the parties entered a settlement agreement resolving the litigation on terms agreeable to all parties, pursuant to which the Company filed a request for dismissal with prejudice of all claims on October 31, 2024.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">127</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_82e35e26-ef9e-46bb-a1a5-07cd83d40f9f_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the second of the Shoreline litigations, also filed on May 13, 2022, the Company and Whitehead Institute for Biomedical Research (Whitehead) filed a lawsuit in the U.S. District Court for the Southern District of California against Shoreline and Kaufman seeking monetary damages for the defendants&#8217; infringement of U.S. Patent Nos. 8,071,369, 8,932,856, 8,951,797, 8,940,536, 9,169,490, 10,457,917, and 10,017,744. On June 7, 2023, the Company and Whitehead filed a motion to dismiss our patent infringement claims against Kaufman in his personal capacity; that motion was granted on June 9, 2023. On August 30, 2023, the court granted Shoreline&#8217;s motion for summary judgment and denied the Company&#8217;s motion for partial summary judgment as moot. Judgment in favor of Shoreline was entered on August 31, 2023. On September 27, 2023, the Company and Whitehead filed a Notice of Appeal with the Court of Appeals for the Federal Circuit challenging the trial court&#8217;s claim construction and grant of summary judgment in favor of the defendants; the defendants cross-appealed challenging the district court&#8217;s earlier denial of a motion to dismiss and partial motion for summary judgment on other grounds. The Federal Circuit docketed the case on October 5, 2023, and briefing was completed on June 26, 2024. On October 28, 2024, the parties entered a settlement agreement resolving the litigation on terms agreeable to all parties, pursuant to which the parties filed a joint notice of dismissal of the appeal and cross-appeal on October 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 20, 2023, a purported stockholder of the Company filed a securities class action lawsuit against the Company and certain of its officers captioned Hadian v. Fate Therapeutics, Inc. et al. in the U.S. District Court for the Southern District of California (the Securities Action). On May 4, 2023, the court appointed a different purported stockholder of the Company to serve as lead plaintiff in the Securities Action. On July 24, 2023, the lead plaintiff filed an amended complaint. The amended complaint alleged that the Company violated the federal securities laws by making allegedly false and/or misleading statements and/or omissions in its public disclosures dating back to August 2020 relating to the Company&#8217;s collaboration agreement with Janssen Biotech, Inc. (the Janssen Agreement), potential product candidates subject to the Janssen Agreement, and the termination of the Janssen Agreement. On September 22, 2023, the Company filed a motion to dismiss the amended complaint. On September 19, 2024, the court granted the Company&#8217;s motion to dismiss the amended complaint, with leave for plaintiff to file a second amended complaint. On October 18, 2024, the lead plaintiff filed a second amended complaint alleging substantially similar facts and claims as in the prior amended complaint. The Company filed a motion to dismiss the second amended complaint on November 18, 2024, and briefing on the motion was completed on January 21, 2025. The Company intends to continue to vigorously defend against this action.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 2, 2023, a derivative complaint, captioned Guarino v. Wolchko, et al., was filed by a purported stockholder of the Company in the U.S. District Court for the Southern District of California (the Guarino Action). On June 12, 2024, an additional derivative complaint, captioned Horrobin v. Wolchko, et al., was filed by a purported stockholder of the Company in the same district (the Horrobin Action). On December 3, 2024, the court entered an order consolidating the Guarino Action and the Horrobin Action under the caption In re Fate Therapeutics, Inc. Derivative Litigation (the Derivative Action) and staying the Derivative Action pending the court&#8217;s decision on our motion to dismiss the second amended complaint in the Securities Action. The court&#8217;s ruling on the motion is pending. The Derivative Action names members of the Company&#8217;s board of directors and certain officers as defendants. The Company is also named as a nominal defendant. The plaintiffs in the Derivative Actions assert derivative claims arising out of substantially the same alleged facts and circumstances as the Securities Action. The Guarino complaint asserts claims for breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and violation of federal securities laws. The Horrobin complaint asserts substantially similar claims in addition to a claim of breach of fiduciary duty for insider trading. The Company intends to vigorously defend against the Derivative Action.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company may be subject to various other legal proceedings and claims that arise in the ordinary course of business activities.</span></p></ix:continuation></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8ccde67a-0914-44ba-a594-e890c7084e96" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14. Subsequent Events</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">California Institute for Regenerative Medicine Award</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 30, 2025, the Company received approval from CIRM for funding of a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17d8684f-47fb-4ef5-a013-33b360073bb0" contextRef="C_f1dea256-3b9e-495e-a654-b31799d22af3" name="fate:GrantAward" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million grant to support the conduct of pre-clinical and IND-enabling activities for FT836.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employment Agreement with Chief Executive Officer</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 3, 2025, the Company entered into an Employment Agreement (the &#8220;Employment Agreement&#8221;) with Bahram Valamehr (&#8220;Valamehr&#8221;). Pursuant to the Employment Agreement, Dr. Valamehr will have the customary powers and responsibilities of a chief executive officer of a corporation of the size and type of the Company.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">128</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 9.  Changes in and Disagreements with Acco</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">untants on Accounting and Financial Disclosure</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 9A.  Control</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s and Procedures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We are responsible for maintaining disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Disclosure controls and procedures are controls and other procedures designed to ensure that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including the individual serving as our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on our management&#8217;s evaluation (with the participation of the individual who serves as our principal executive officer and principal financial officer) of our disclosure controls and procedures as required by Rules 13a-15 and 15d-15 under the Exchange Act, the individual serving as our principal executive officer and principal financial officer has concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2024, the end of the period covered by this report.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management&#8217;s Report on Internal Control Over Financial Reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company&#8217;s management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act). Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including the individual serving as our principal executive officer and principal financial officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. Management conducted an assessment of the effectiveness of the Company&#8217;s internal control over financial reporting based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control&#8212;Integrated Framework (2013 Framework). Based on this assessment, our management concluded that, as of December 31, 2024, our internal control over financial reporting was effective based on those criteria.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K does not include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. Our auditors will not be required to opine on the effectiveness of our internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002 as the Company is classified as a smaller reporting company.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in Internal Control Over Financial Reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> There were no changes in our internal control over financial reporting during the quarter ended December 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">129</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_or_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 9B.  Othe</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">r Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a) 8-K Events.</span></p>
  <p style="margin-left:2.947%;text-indent:3.847%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 3, 2025, the Company entered into an employment agreement with Bahram Valamehr, Ph.D., pursuant to which Dr. Valamehr serves as the Company&#8217;s President and Chief Executive Officer (the &#8220;Employment Agreement&#8221;). The Employment Agreement sets forth Dr. Valamehr&#8217;s then-current annual base salary, an option grant and his eligibility to participate in our incentive bonus and benefit plans generally. Pursuant to the Employment Agreement, Dr. Valamehr is eligible to receive an annual incentive compensation at a target percentage of 60% his annual base salary, as determined by the Board of Directors or the Compensation Committee from time to time. Dr. Valamehr&#8217;s employment is at-will. In the event that Dr. Valamehr&#8217;s employment is terminated by the Company without &#8220;Cause&#8221; (other than due to death or disability) or by Dr. Valamehr for &#8220;Good Reason&#8221; (as such terms are defined in the Employment Agreement), in each case outside of the &#8220;Sale Event Period&#8221; (as defined below), subject to his execution of a nonrevocable separation agreement and release, Dr. Valamehr will be entitled to (i) a lump sum cash payment equal to the sum of (A) twelve (12) months of Dr. Valamehr&#8217;s then-current base salary and (B) his annual target incentive compensation for the year of termination, and (ii) payment of the premiums for Dr. Valamehr&#8217;s and his family&#8217;s participation in the Company&#8217;s group health care plans, subject to Dr. Valamehr&#8217;s copayment amount, for up to twelve (12) months after such termination.</span></p>
  <p style="margin-left:2.947%;text-indent:3.847%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Employment Agreement, in the event that Dr. Valamehr&#8217;s employment is terminated by the Company without Cause (other than due to death or disability) or by Dr. Valamehr for Good Reason, in each case within the period beginning three months prior to and ending eighteen (18) months following a &#8220;Sale Event&#8221; (as defined in the 2022 Plan) (the &#8220;Sale Event Period&#8221;), subject to his execution of a nonrevocable separation agreement and release, Dr. Valamehr is entitled to (i) a lump sum cash payment equal to the sum of (A) eighteen (18) months of Dr. Valamehr&#8217;s then-current base salary (or base salary in effect immediately prior to the Sale Event, if higher) and (B) one and a half (1.5) times his annual target incentive compensation for the year of termination; (ii) full acceleration of vesting of all outstanding equity awards; provided, however, that for any equity awards that include a performance-based vesting condition, no acceleration of vesting will be provided unless the applicable performance-based vesting condition has been satisfied as of the date of Dr. Valamehr&#8217;s termination, provided further that, in determining whether achievement of a specified stock price has been satisfied, such price is satisfied to the extent that the consideration payable per share of common stock of the Company upon a Sale Event exceeds such stock price; and (iii) payment of the premiums for Dr. Valamehr&#8217;s and his family&#8217;s participation in the Company&#8217;s group health care plans, subject to Dr. Valamehr&#8217;s copayment amount, up to eighteen (18) months after such termination.</span></p>
  <p style="margin-left:2.947%;text-indent:3.847%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The payments and benefits provided to Dr. Valamehr under the Employment Agreements in connection with a change of control may not be eligible for federal income tax deduction for the Company pursuant to Section 280G of the Code. These payments and benefits may also be subject to an excise tax under Section 4999 of the Code. If the payments or benefits payable to Dr. Valamehr in connection with a change of control would be subject to the excise tax imposed under Section 4999 of the Code, then those payments or benefits will be reduced if such reduction would result in a higher net after-tax benefit to him.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b) Rule 10b5-1 Trading Plans</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:2.947%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, none of the Company&#8217;s directors or officers </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_42226c14-472f-4797-9822-5e01534c2c82" contextRef="C_7fc491c3-db47-4e1f-9c36-5199ecfed9ff" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_44afc77e-a5fb-4727-865c-4460ed9753ea" contextRef="C_7fc491c3-db47-4e1f-9c36-5199ecfed9ff" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, materially </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c2c5cb77-e66a-4444-b149-e096c883ccf0" contextRef="C_7fc491c3-db47-4e1f-9c36-5199ecfed9ff" name="fate:Rule10B51ArrModifiedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_1c9083bb-727a-4458-a9c5-b4340c6e1743" contextRef="C_7fc491c3-db47-4e1f-9c36-5199ecfed9ff" name="fate:NonRule10B51ArrModifiedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">modified</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8af7c83b-27bf-42a1-8012-a2bb482e2493" contextRef="C_7fc491c3-db47-4e1f-9c36-5199ecfed9ff" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_2e01c90e-99e9-44be-9090-12b88993971d" contextRef="C_7fc491c3-db47-4e1f-9c36-5199ecfed9ff" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terminated</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> any contract, instruction, or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any non-Rule 10b5-1 trading arrangement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item9c"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">130</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> III</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 10.  Directors, Executive Of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ficers and Corporate Governance</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as set forth below, the information required by this item is contained in our definitive proxy statement (the Proxy Statement), to be filed with the SEC in connection with the Annual Meeting of Stockholders within 120 days after the conclusion of our fiscal year ended December 31, 2024 and is incorporated in this Annual Report on Form 10-K by reference.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A current copy of the code is posted on the Corporate Governance section of our website, which is located at www.fatetherapeutics.com. If we make any substantive amendments to, or grant any waivers from, the code of business conduct and ethics for our principal executive officer, principal financial officer, principal accounting officer, controller or persons performing similar functions, or any officer or director, we will disclose the nature of such amendment or waiver on our website or in a current report on Form 8-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 11.  Execut</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ive Compensation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item is contained in the Proxy Statement and is incorporated in this Annual Report on Form 10-K by reference, except as to information disclosed in the Proxy Statement pursuant to Item 402(v) of Regulation S-K relating to pay versus performance.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 12.  Security Ownership of Certain Beneficial O</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">wners and Management and Related Stockholder Matters</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item is contained in the Proxy Statement and is incorporated in this Annual Report on Form 10-K by reference.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13_certain_relationships_related_pa"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 13.  Certain Relationships and Related P</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">arty Transactions, and Director Independence</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item is contained in the Proxy Statement and is incorporated in this Annual Report on Form 10-K by reference.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14_principal_accounting_fees_servic"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 14.  Principal Acco</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unting Fees and Services</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our independent public accounting firm is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ae4592fb-2220-4424-aede-170cde3b0d74" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ernst &amp; Young, LLP</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_71de0d36-8423-4bb8-be7a-9da603de4b32" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">San Diego, CA</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, PCAOB Auditor ID </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_421b4107-5499-4dce-ac93-e43cd12cd69f" contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2" name="dei:AuditorFirmId"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item is contained in the Proxy Statement and is incorporated in this Annual Report on Form 10-K by reference.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">131</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IV</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 15.  Exhibits and Fin</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ancial Statement Schedules</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following documents are filed as part of this report:</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Index list to Financial Statements:</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:94%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_of_independent_auditors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID: 42)</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_operations_compr"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_convertible_pref"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial_statemen"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financial Statement Schedules</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All other schedules are omitted because they are not required or the required information is included in the financial statements or notes thereto.</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exhibits</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The exhibits listed in the accompanying Exhibit Index are filed or incorporated by reference as part of this report.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 16.  Form</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 10-K Summary</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">132</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT INDEX</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10%;box-sizing:content-box;"/>
    <td style="width:55%;box-sizing:content-box;"/>
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:10%;box-sizing:content-box;"/>
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:15%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporated by</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Reference</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit Title</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File No.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000119312513351036/d590580dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Certificate of Incorporation of the Registrant</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-190608</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 29, 2013</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000119312521184402/d191657dex31.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect</span></a></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 7, 2021</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000119312516778378/d301639dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Designation of Preferences, Rights and Limitations of Class A Convertible Preferred Stock</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 29, 2016</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.4</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000156459021008086/fate-ex33_493.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Bylaws of the Registrant, as currently in effect</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 24, 2021</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000095017023013471/fate-ex3_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitation of Class A Convertible Preferred Stock of the Registrant</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 19, 2023</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.6</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000119312524158374/d764437dex31.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect</span></a></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 10, 2024</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000119312513351036/d590580dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Specimen Common Stock Certificate</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-190608</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 29, 2013</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000119312521005180/d95890dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Pre-Funded Warrant</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 8, 2021</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000119312524072871/d799248dex41.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Pre-Funded Warrant</span></a></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 21, 2024</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000095017023061080/fate-ex4_3.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of Securities</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 8, 2023</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000156459021008086/fate-ex102_726.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated 2013 Stock Option and Incentive Plan and forms of agreements thereunder</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 24, 2021</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000110465915000991/a15-1355_1ex10d2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Unrestricted Stock Award Agreement under the 2013 Stock Option and Incentive Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 7, 2015</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000156459018004394/fate-ex105_89.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Employment Agreement by and between the Registrant and Scott Wolchko, dated January 14, 2018</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 5, 2018</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000110465915000991/a15-1355_1ex10d1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Senior Executive Incentive Bonus Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 7, 2015</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="fate-ex10_5.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Non-Employee Director Compensation Policy</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Filed herewith</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6#</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000156459021008086/fate-ex108_663.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Fate Therapeutics, Inc. Amended and Restated Inducement Equity Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 24, 2021</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000156459021008086/fate-ex109_727.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Forms of Stock Option Agreement under the Registrant's Inducement Equity Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 24, 2021</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8#</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000156459021008086/fate-ex1010_728.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Forms of Restricted Stock Unit Award Agreement under the Registrant's Inducement Equity Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 24, 2021</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000119312513333316/d552384dex1014.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Lease Agreement by and between the Registrant and ARE-3535/3565 General Atomics Court, LLC, dated December 3, 2009</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-190608</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 13, 2013</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000119312513333316/d552384dex1015.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First Amendment to Lease Agreement by and between the Registrant and ARE-3535/3565 General Atomics Court, LLC, dated October 1, 2011</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-190608</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 13, 2013</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">133</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10%;box-sizing:content-box;"/>
    <td style="width:55%;box-sizing:content-box;"/>
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:10%;box-sizing:content-box;"/>
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:15%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000119312513383888/d552384dex1025.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Second Amendment to Lease Agreement by and between the Registrant and ARE-3535/3565 General Atomics Court, dated September 26, 2013</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-190608</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.25</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 30, 2013</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000156459016013981/fate-ex1015_610.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Third Amendment to Lease Agreement by and between the Registrant and ARE-3535/3565 General Atomics Court, dated September 2, 2014</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 3, 2016</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000156459016013981/fate-ex1016_611.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Fourth Amendment to Lease Agreement by and between the Registrant and ARE-3535/3565 General Atomics Court, dated March 2, 2015</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 3, 2016</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000156459016023312/fate-ex102_105.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Fifth Amendment to Lease Agreement by and between the Registrant and ARE-3535/3565 General Atomics Court, dated June 1, 2016</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 8, 2016</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000156459021008086/fate-ex1019_494.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Whitehead Institute for Biomedical Research Exclusive Patent License Agreement between the Registrant and the Whitehead Institute for Biomedical Research, dated as of February 24, 2009</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 24, 2021</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000156459021008086/fate-ex1020_495.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License Agreement between the Registrant and The Scripps Research Institute, dated as of July 13, 2009</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 24, 2021</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000156459021008086/fate-ex1021_496.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License Agreement between the Registrant and The Scripps Research Institute, dated as of May 25, 2010</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 24, 2021</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.18&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000156459021008086/fate-ex1022_497.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License Agreement between the Registrant and The Scripps Research Institute, dated as of August 24, 2010</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.22</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 24, 2021</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000156459018004394/fate-ex1032_90.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Severance and Change in Control Policy</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.32</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 5, 2018</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000156459019006258/fate-ex1033_244.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Offer Letter by and between the Registrant and Cindy R. Tahl, dated October 23, 2009</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.33</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 5, 2019</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">134</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10%;box-sizing:content-box;"/>
    <td style="width:55%;box-sizing:content-box;"/>
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:10%;box-sizing:content-box;"/>
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:15%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000156459018019456/fate-ex101_80.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Sixth Amendment to the Lease Agreement by and between the Registrant and ARE-3535/3565 General Atomics Court, dated May 31, 2018</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 6, 2018</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.22</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000156459018019456/fate-ex102_223.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Exclusive License Agreement by and between the Registrant and Memorial Sloan Kettering Cancer Center, dated May 15, 2018</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 6, 2018</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.23&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000156459018026214/fate-ex101_83.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exclusive License Agreement by and between the Registrant and The David Gladstone Institutes, dated September 11, 2018</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 1, 2018</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.24&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000119312519032261/d699031dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Collaboration and Option Agreement by and between the Registrant and Ono Pharmaceutical Co., Ltd., dated September 14, 2018</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q/A</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 8, 2019</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.25#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000156459019006258/fate-ex1038_245.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Offer Letter by and between the Registrant and Bahram Valamehr, dated November 23, 2009</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.38</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 5, 2019</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.26&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000156459020008141/fate-ex1034_359.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Lease Agreement by and between the Registrant and Scripps Summit Investments LLC, dated January 7, 2020</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.34</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 2, 2020</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.27&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000156459021008086/fate-ex1039_662.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Letter Agreement, dated December 4, 2020, by and between the Registrant and Ono Pharmaceutical Co., Ltd.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.39</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 24, 2021</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.28&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000156459021008086/fate-ex1040_664.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Patent License Agreement by and between the Registrant and Max-Delbr&#252;ck-Centrum f&#252;r Molekulare Medizin in der Helmholtz-Gemeinschaft, dated August 30, 2019</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.40</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 24, 2021</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.29</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000119312523273593/d541003dex12.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Open Market Sale Agreement</span><span style="color:#0000ff;top:-4.6899999999999995pt;white-space:pre-wrap;text-decoration:underline solid;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">SM</span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">, dated November 8, 2023, by and between the Registrant and Jefferies LLC</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-275402</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 8, 2023</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.30&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000095017022002293/fate-ex10_40.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License Agreement, dated April 9, 2020, by and between the Registrant and Dana-Farber Cancer Institute, Inc.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.40</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 28, 2022</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.31#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000119312522171100/d231890dex991.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2022 Stock Option and Incentive Plan and form agreements thereunder</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-8</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-265502</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 9, 2022</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.32&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000095017022014236/fate-ex10_2.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment 01 to Collaboration and Option Agreement, dated June 28, 2022, by and between the Registrant and Ono Pharmaceutical Co. Ltd.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 3, 2022</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.33</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000095017022022488/fate-ex10_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Letter Agreement, dated November 7, 2022, by and between the Registrant and Ono Pharmaceutical Co., Ltd.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 7, 2022</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.34</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000095017024020158/fate-ex10_41.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment 03 to Collaboration and Option Agreement, dated November 30, 2023, by and between the Registrant and Ono Pharmaceutical Co. Ltd.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.41</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2024</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.35&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000095017024020158/fate-ex10_42.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exclusive License Agreement, dated April 17, 2020, by and between the Registrant and Baylor College of Medicine</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.42</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2024</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.36</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000119312524072871/d799248dex101.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Securities Purchase Agreement, dated March 19, 2024, between the Registrant and RedCo II Master Fund, L.P.</span></a></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 21, 2024</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.37#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000119312524157554/d839723dex101.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated 2022 Stock Option and Incentive Plan and form agreements thereunder</span></a></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 7, 2024</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.38</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000119312524211130/d703760dex101.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Form of Indemnification Agreement</span></a></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 30, 2024</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.39&#134;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000095017024125317/fate-ex10_2.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No.4 to Collaboration and Option Agreement by and between the Registrant and Ono Pharmaceutical Co., Ltd, dated August 28, 2024</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 12, 2024</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">135</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10%;box-sizing:content-box;"/>
    <td style="width:55%;box-sizing:content-box;"/>
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:10%;box-sizing:content-box;"/>
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:15%;box-sizing:content-box;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.40#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000119312525002153/d900848dex101.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Strategic Advisory Services Agreement between the Registrant and J. Scott Wolchko, dated as of December 31, 2024</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 6, 2025</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.41#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="fate-ex10_41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement by and between the Registrant and Bahram Valamehr, dated March 3, 2025</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Filed herewith</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000095017024020158/fate-ex14_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended Code of Business Conduct and Ethics</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2024</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="fate-ex19_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Insider Trading Policy</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Filed herewith</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000095017023005067/fate-ex21_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Subsidiaries of the Registrant</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="fate-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Filed herewith</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Power of Attorney (included on signature page to this Annual Report)</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Filed herewith</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="fate-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rules 13a-14 and 15-d-14 promulgated pursuant to the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Filed herewith</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="fate-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Filed herewith</span></p></td>
   </tr>
   <tr style="height:4.3pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1434316/000095017024020158/fate-ex97_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Compensation Recovery Policy</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-36076</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2024</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Filed herewith</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema with Embedded Linkbases Document</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Filed herewith</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:28.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:12pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File </span><span style="color:#212529;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(formatted as inline XBRL and contained in Exhibit 101).</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#252525;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Filed herewith</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:86.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#134; Certain provisions of this Exhibit have been omitted as confidential information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"># Indicates a management contract or any compensatory plan, contract or arrangement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">136</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNAT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">URES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55%;box-sizing:content-box;"/>
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:40%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fate Therapeutics, Inc.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 5, 2025</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.5pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bahram Valamehr</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bahram Valamehr, Ph.D., MBA</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">President, Chief Executive Officer and Director</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Bahram Valamehr as his or her attorney-in-fact, with the power of substitution, for him or her in any and all capacities, to sign any amendments to this report, and to file the same, with exhibits thereto and other documents in connection therewith with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorney-in-fact, or his or her substitute or substitutes may do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:40%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:43%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">SIGNATURE</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TITLE</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">DATE</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bahram Valamehr</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President, Chief Executive Officer and Director</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 5, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bahram Valamehr, Ph.D., MBA</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">William H. Rastetter</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chairman of the Board and Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 5, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">William H. Rastetter, Ph.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">John D. Mendlein</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vice Chairman of the Board and Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 5, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">John D. Mendlein, Ph.D., J.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shefali Agarwal</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 5, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shefali Agarwal, M.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Timothy P. Coughlin</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 5, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Timothy P. Coughlin</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Robert S. Epstein</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 5, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Robert S. Epstein</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Karin Jooss</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 5, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Karin Jooss, Ph.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael Lee</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 5, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael Lee</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Neelufar Mozaffarian</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 5, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Neelufar Mozaffarian, M.D., Ph.D., FACR</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.05pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Yuan Xu</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 5, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Yuan Xu, Ph.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">137</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>2
<FILENAME>fate-ex10_5.htm
<DESCRIPTION>EX-10.5
<TEXT>
<html>
 <head>
  <title>EX-10.5</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FATE THERAPEUTICS, INC.<br><br>AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The purpose of this Amended and Restated Non-Employee Director Compensation Policy (the &#x201c;Policy&#x201d;) of Fate Therapeutics, Inc., a Delaware corporation (the &#x201c;Company&#x201d;), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company.  In furtherance of this purpose, effective as of the date of approval by the Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;) of this Policy (the &#x201c;Effective Date&#x201d;), all non-employee directors shall be paid compensation for services provided to the Company as set forth below:</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Retainers</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual Retainer for Board Membership</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:  $40,000 for general availability and participation in meetings and conference calls of the Board.  No additional compensation for attending individual Board meetings.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Annual Retainers for Committee Membership and Service as Chairperson</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board Chairperson:	$35,000</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audit Committee Chairperson:	$20,000</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audit Committee member:	$10,000</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation Committee Chairperson:	$15,000</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation Committee member:	$7,500</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nominating and Corporate Governance Committee Chairperson:	$10,000</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nominating and Corporate Governance Committee member:	$5,000</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Science &amp; Technology Committee Chairperson:	$12,000</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Science &amp; Technology Committee member:	$6,000</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No additional compensation for attending individual committee meetings.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All cash retainers will be paid quarterly, in arrears, or upon the earlier resignation or removal of the non-employee director.  Cash retainers owing to non-employee directors shall be annualized, meaning that with respect to non-employee directors who join the Board during the calendar year, such amounts shall be pro-rated based on the number of calendar days served by such director.</font></p>
  <div class="page-border-spacing">
   <hr style="border-top: 2px solid black; width: 192px; margin-left:0px"><p style="text-indent:-4.167%;padding-left:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 	This policy shall supersede any prior arrangements between the Company and the directors.</font></p><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Retainers</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Value</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Policy, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Value</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means with respect to (i) any award of stock options, the grant date fair value of the option award (i.e., Black-Scholes Value) determined in accordance with the reasonable assumptions and methodologies employed by the Company for calculating the fair value of options under ASC 718; and (ii) any award of restricted stock and restricted stock units, the product of (A) the average closing market price on The NASDAQ Global Market (or such other market on which the Company&#x2019;s common stock, par value $0.001 per share (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is then principally listed) of one share of Common Stock over the trailing ten (10) trading day period ending on the grant date, and (B) the aggregate number of shares pursuant to such award.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Initial Equity Grant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: One-time equity grants to each new non-employee director upon his or her election to the Board after the Effective Date of </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an option to purchase 110,000 shares of Common Stock, with a an exercise price per share equal to the closing price of a share of Common Stock on the date of grant and a term of ten years. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Such initial option grant shall vest in equal monthly installments during the 36 months following the grant date, subject to the director&#x2019;s continued service on the Board.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On the date of each Annual Meeting of Stockholders</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:  Annual equity grants to each non-employee director serving on the Board immediately following the Company&#x2019;s annual meeting of stockholders of an </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">option to purchase 55,000 shares of Common Stock, with an exercise price per share equal to the closing price of a share of Common Stock on the date of grant and a term of ten years</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Such annual option grant shall vest on the earlier of the one-year anniversary of the grant date and the Company&#x2019;s next annual meeting of stockholders, subject to the director&#x2019;s continued service on the Board.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sale Event Acceleration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In the event of a Sale Event (as defined in the Company&#x2019;s 2022 Stock Option and Incentive Plan, as amended and restated from time to time), the equity retainer awards granted to Outside Directors pursuant to this Policy shall become 100% vested and exercisable.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The form of option agreement will give directors up to one year following cessation of service as a director to exercise the options (to the extent vested at the date of such cessation), provided that the director has not been removed for cause. All of the foregoing option grants will have an exercise price equal to the fair market value of a share of Common Stock on the date of grant.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expenses</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company shall reimburse all reasonable out-of-pocket expenses incurred by non-employee directors in attending Board and committee meetings.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amended and Restated Non-Employee Director Compensation Policy adopted by the Board of Directors on September 9, 2019.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amended and Restated Non-Employee Director Compensation Policy adopted by the Board of Directors on December 17, 2020.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amended and Restated Non-Employee Director Compensation Policy adopted by the Board of Directors on April 2, 2021.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amended and Restated Non-Employee Director Compensation Policy adopted by the Board of Directors on April 4, 2023.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amended and Restated Non-Employee Director Compensation Policy adopted by the Board of Directors on January 16, 2025.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.41
<SEQUENCE>3
<FILENAME>fate-ex10_41.htm
<DESCRIPTION>EX-10.41
<TEXT>
<html>
 <head>
  <title>EX-10.41</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.19in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EMPLOYMENT AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Employment Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is made by and between Fate Therapeutics, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and Bahram (Bob) Valamehr (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), effective on this date of March 3, 2025 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The Company and Executive are individually referred to as a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and collectively referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  WHEREAS, Executive was appointed as Company&#x2019;s President and Chief Executive Officer (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CEO</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) on January 1, 2025, and Executive was appointed as a member of the Company&#x2019;s Board of Directors (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) effective that same date;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:6.992%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, Company desires to continue employing Executive as the Company&#x2019;s President and CEO;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:1.107%;text-indent:6.741%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;text-indent:6.741%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, Company and Executive desire to set forth in writing Executive&#x2019;s new and continued terms and conditions of employment as of the Effective Date above.</font></p>
  <p style="margin-left:1.067%;text-indent:6.739%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.067%;text-indent:6.739%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW, THEREFORE, in consideration of the foregoing and of the mutual promises contained herein, the Parties hereto, intending to be legally bound, hereby agree as follows.</font></p>
  <p style="margin-left:1.067%;text-indent:6.739%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term of Employment</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  The Company and Executive desire that their employment relationship be governed by this Agreement, commencing as of the Effective Date and continuing in effect until terminated by either Party in accordance with this Agreement.  Executive&#x2019;s employment with the Company will be &#x201c;at-will,&#x201d; meaning that Executive&#x2019;s employment may be terminated by the Company or Executive at any time and for any reason subject to the terms of this Agreement.   </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Duties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Executive will continue serving as the President and CEO of the Company and will have such powers and duties as may from time to time be prescribed by the Board.  Executive shall continue to serve as a member of the Board.   Executive shall devote Executive&#x2019;s full working time and efforts to the business and affairs of the Company and not engage in any other business activities without prior written approval by the Board, which approval shall not be unreasonably withheld.  Notwithstanding the foregoing, Executive may engage in religious, charitable or other community activities as long as such services and activities do not interfere with Executive&#x2019;s performance of Executive&#x2019;s duties to the Company.  Upon the ending of Executive&#x2019;s employment, unless otherwise agreed to by the Company and Executive, Executive shall immediately resign from the Board as well as from any other Company positions to which Executive was elected or appointed in connection with Executive&#x2019;s position as President and CEO.   Executive will be treated as an exempt employee.  Executive&#x2019;s primary work location shall be San Diego, California, and Executive&#x2019;s role may require reasonable travel as necessary to perform the duties and responsibilities of Executive&#x2019;s position.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation and Related Matters</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  In consideration of the services to be rendered by Executive under this Agreement, Executive shall be compensated as follows:</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Base Salary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Executive&#x2019;s initial annual base salary is $600,000, which is subject to review and redetermination by the Board or the Compensation </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.19in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Committee of the Board (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) from time to time.  The annual base salary in effect at any given time is referred to herein as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Base Salary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d; The Base Salary will be payable in a manner that is consistent with the Company&#x2019;s usual payroll practices for senior executives.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Incentive Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Executive is eligible to receive annual incentive compensation, to be paid on an annual basis, as determined by the Board or the Compensation Committee from time to time in accordance with the Company&#x2019;s Amended and Restated Senior Executive Incentive Bonus Plan, as amended from time to time, or any subsequent plan in effect from time to time. Executive&#x2019;s initial target annual incentive compensation shall be 60% of Executive&#x2019;s Base Salary.  Any such incentive compensation shall be paid no later than March 15 of the year following the year to which such compensation relates.  Executive must be employed by the Company on the date such incentive compensation is paid in order to earn or receive any annual incentive compensation. </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Executive shall be entitled to participate in or receive benefits under any employee benefit plan or arrangement currently maintained or which may, in the future, be made available by the Company generally to its executives and key management employees, subject to and on a basis consistent with the terms, conditions and overall administration of such plan or arrangement. </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification and D&amp;O Insurance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  During Executive&#x2019;s employment and for the period of time following termination of Executive for any reason during which time Executive could be subject to any claim based on his position in the Company, Executive will receive the maximum indemnification protection from the Company as permitted by the Company&#x2019;s by-laws and shall be covered, with respect to matters arising during Executive&#x2019;s employment with or service as a director of the Company, under the Company&#x2019;s directors&#x2019; and officers&#x2019; insurance policy in amounts at least equal to that which is provided to any other director or officer of the Company. </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reimbursement of Business Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company shall reimburse Executive for expenses reasonably and necessarily incurred by Executive in connection with the Company&#x2019;s business.  Expense reimbursement shall be subject to such policies the Company may adopt from time to time, including with respect to pre-approval.   </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If Executive&#x2019;s employment with the Company is terminated for any reason, the Company shall pay or provide to Executive (or to Executive&#x2019;s authorized representative or estate) any earned but unpaid Base Salary through the date of such termination, earned but unpaid bonus for the calendar year prior to the year of such termination, unpaid expense </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.19in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.692662720527998%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reimbursements, accrued but unused vacation, and vested benefits Executive may have under any employee benefit plan of the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), in addition to any other payments that may be required under this Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Withholding</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  All compensation, benefits and other amounts payable or provided hereunder to, or for the benefit of, Executive shall be subject to all applicable taxes and other withholdings under federal, state, and local law.  Nothing herein shall be construed to require any compensation arrangement in any way that is most tax-favorable to Executive.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain Definitions.   </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.8457544394060026%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means: (i) conduct by Executive constituting a material act of misconduct in connection with the performance of Executive&#x2019;s duties, including, without limitation, misappropriation of funds or property of the Company or any of its subsidiaries or affiliates other than the occasional, customary and de minimis use of Company property for personal purposes; (ii) the commission by Executive of (A) any felony; or (B) a misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) any conduct by Executive that would reasonably be expected to result in material injury or reputational harm to the Company or any of its subsidiaries and affiliates if Executive were retained in Executive&#x2019;s position; (iv) continued material and substantial non-performance by Executive of Executive&#x2019;s material responsibilities hereunder (other than by reason of Executive&#x2019;s physical or mental illness, incapacity or disability) which has continued for more than 30 days following written notice of such non-performance from the Board; (v) a material and substantial breach by Executive of any of Executive&#x2019;s confidentiality, noncompetition, nonsolicitation or other similar restrictive covenant obligations to the Company; (vi) a material and substantial violation by Executive of any of the Company&#x2019;s written employment policies; or (vii) failure to cooperate with a bona fide internal investigation by or on behalf of the Board or an authorized committee thereof or an investigation by regulatory or law enforcement authorities, after being instructed by the Company to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigation.</font></div></div>
  <p style="margin-left:16.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.8457544394060026%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the inability of Executive to perform Executive&#x2019;s duties under this Agreement, whether with or without reasonable accommodation, because Executive has become permanently disabled within the meaning of any policy of disability income insurance covering employees of the Company then in force.  In the event the Company has no policy of disability income insurance covering employees of the Company in force when Executive becomes disabled, the term &#x201c;Disability&#x201d; shall mean the inability of Executive to perform Executive&#x2019;s duties under this Agreement, whether with or without reasonable accommodation, by reason of any incapacity, physical or mental, </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.19in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.8457544394060026%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which the Board, based upon medical advice or an opinion provided by a licensed physician acceptable to the Board, determines to have incapacitated Executive from satisfactorily performing all of Executive&#x2019;s usual services for the Company, with or without reasonable accommodation, for a period of at least one hundred twenty (120) days during any twelve (12) month period (whether or not consecutive).  Based upon such medical advice or opinion, the determination of the Board shall be final and binding and the date such determination is made shall be the date of such Disability for purposes of this Agreement.  Nothing in this Section shall be construed to waive Executive&#x2019;s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. &#167;2601 et seq. and the Americans with Disabilities Act, 42 U.S.C. &#167;12101 et seq.</font></div></div>
  <p style="margin-left:16.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.8457544394060026%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means that Executive has complied with the Good Reason Process (defined below) following the occurrence of any of the following events: (i) a material diminution in Executive&#x2019;s responsibilities, authorities, powers, functions or duties; (ii) a material reduction in Executive&#x2019;s then-current Base Salary or target annual incentive compensation, except for across-the-board reductions based on the Company&#x2019;s financial performance similarly affecting all or substantially all senior management employees of the Company; or (iii) the relocation of Executive&#x2019;s principal place of business to a place that is more than twenty-five (25) miles from Executive&#x2019;s current location of employment as of the Effective Date (not including intermittent business trips).  Notwithstanding the above, none of the following shall be considered Good Reason: (x) the mere occurrence of a Sale Event; (y) any change in the identity of the surviving corporation in the event of a Sale Event; or (z) any change in the status of the surviving corporation after a Sale Event as a public or private company. </font></div></div>
  <p style="margin-left:16.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.8457544394060026%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Good Reason Process</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Good Reason Process</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means that (i) Executive reasonably determines in good faith that a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; condition has occurred; (ii) Executive notifies the Company in writing of the occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii) Executive cooperates in good faith with the Company&#x2019;s efforts, for a period of 30 days following such notice (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cure Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exist; and (v) Executive terminates Executive&#x2019;s employment within 30 days after the end of the Cure Period.  If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.8457544394060026%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">e.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sale Event Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sale Event Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the period beginning on the date three (3) months prior to, and ending on the date twelve (12) months after, the consummation of a Sale Event (as defined in the Company&#x2019;s 2022 Stock Option and Incentive Plan, as may be amended from time to time (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;)).</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.8457544394060026%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">f.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Terminating Event</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  A &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Terminating Event</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means termination of Executive&#x2019;s </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.19in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.8457544394060026%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">employment by the Company without Cause or by Executive for Good Reason.  A Terminating Event does not include: (i) the ending of Executive&#x2019;s employment due to Executive&#x2019;s death or Disability, (ii) Executive&#x2019;s resignation for any reason other than for Good Reason, or (iii) the Company&#x2019;s termination of Executive&#x2019;s employment for Cause.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Severance and Accelerated Vesting if a Terminating Event Occurs within the Sale Event Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  In the event a Terminating Event occurs within the Sale Event Period, subject to Executive signing and complying with a separation agreement and general release agreement that is timely provided in good faith by the Company and which, among other things, requires a reaffirmation of Executive&#x2019;s restrictive-covenant and confidentiality obligations to Company  (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Separation Agreement and Release</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and the Separation Agreement and Release becoming irrevocable pursuant to its terms, all within 60 days after the Date of Termination (defined below), the following shall occur:</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.8457544394060026%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company shall pay to Executive a lump sum in cash in an amount equal to the sum of (i) eighteen (18) months of Executive&#x2019;s then-current Base Salary in effect immediately prior to the Terminating Event (or Executive&#x2019;s Base Salary in effect immediately prior to the Sale Event, if higher) and (ii) an amount representing 1.5 times Executive&#x2019;s target annual incentive compensation for the year in which the termination occurs;</font></div></div>
  <p style="margin-left:16.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.8457544394060026%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if Executive was participating in the Company&#x2019;s group health plan immediately prior to the Date of Termination and properly elects COBRA health continuation, then subject to Executive&#x2019;s copayment of monthly premium amounts at the active employees&#x2019; rate, the Company shall pay to the group health plan provider or the COBRA provider, on a monthly basis, the remainder of the premiums for Executive&#x2019;s and Executive&#x2019;s family&#x2019;s participation in the Company&#x2019;s group health plans until the earliest of (i) eighteen (18) months, (ii) the date Executive becomes eligible for group health plan benefits under any other employer&#x2019;s group health plan, and (ii) the cessation of Executive&#x2019;s health continuation rights under COBRA; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that if the Company determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (as applicable) without potentially violating applicable law (including, without limitation, the Patient Protection and Affordable Care Act or the Health Care and Education Reconciliation Act of 2010, and the guidance and regulations issued thereunder), then the Company shall, in lieu thereof, convert such payments to payroll payments directly to Executive for the time period specified above, and such payments to Executive shall be subject to tax-related deductions and withholdings and paid on the Company&#x2019;s regular payroll dates; and</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.8457544394060026%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">notwithstanding anything to the contrary in any applicable option agreement, restricted stock unit award or other stock-based award agreement, including those under the Plan (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), all (i) time-based vesting provisions of Executive&#x2019;s then outstanding Equity Awards shall immediately accelerate and (ii) the Company&#x2019;s repurchase rights with respect to all such </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.19in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.8457544394060026%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">outstanding time-based Equity Awards shall immediately lapse, in each case, in full such that as of the later of (A) Date of Termination (or date of the Sale Event, if later) and (B) the effective date of the Separation Agreement and Release (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accelerated Vesting Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, that</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> if such termination occurs following the Sale Event, then any termination or forfeiture of the unvested shares subject to such Equity Awards that would otherwise occur on the Date of Termination will be delayed until the effective date of the Separation Agreement and Release and will only occur if the vesting pursuant to this Section does not occur due to the absence of the Separation Agreement and Release becoming fully effective within the time period set forth herein; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided further</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that if such termination occurs prior to the Sale Event, then any termination or forfeiture of the unvested shares subject to such Equity Awards that would otherwise occur on the Date of Termination will be delayed until three (3) months following such termination and will only occur if either the Separation Agreement and Release does not become fully effective within the time period set forth herein or a Sale Event does not occur during those three (3) months. Notwithstanding the foregoing, no additional vesting of the shares subject to the Equity Awards shall occur during the period between the Date of Termination and the Accelerated Vesting Date.  For the avoidance of doubt, for any Equity Awards that include both a performance-based vesting condition (which may include the achievement of a specified stock price or market capitalization) and a time-based vesting condition or any Equity Awards that vest solely upon the achievement of a performance-based vesting condition, no acceleration of vesting shall be provided unless such performance-based vesting condition has been satisfied as of the Date of Termination (or date of the Sale Event, if later) and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, further</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that in determining whether the achievement of a specified stock price as reported on the NASDAQ Stock Market has been satisfied, such price shall be deemed satisfied to the extent that the consideration payable per share of Common Stock of the Company in connection with such Sale Event, as determined in good faith by the Board or the Compensation Committee, exceeds such stock price.</font></div></div>
  <p style="margin-left:16.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:8.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amounts payable under Section 6(a) and (b) shall be paid or, with respect to Section 6(b), commence to be paid within 60</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">days after the Date of Termination;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payments, to the extent they qualify as &#x201c;non-qualified deferred compensation&#x201d; within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;)  shall be paid or commence to be paid in the second calendar year by the last day of such 60-day period; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided further</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination.  The payments pursuant to this Section 6 are intended to be exempt under the &#x201c;short term deferral&#x201d; and &#x201c;separation pay&#x201d; exceptions under Treasury Regulation Sections 1.409A-1(b)(4) and 1.409A-1(b)(9)(iii), respectively, to the maximum extent permitted by Section 409A of the Code, and this Agreement shall be interpreted and administered in a manner consistent with such intent.  Each payment pursuant to this Agreement is intended to constitute a separate and distinct payment for purposes of Treasury Regulation Section 1.409A-2(b)(2).</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Severance if a Terminating Event Occurs Outside the Sale Event Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  In the </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.19in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">event a Terminating Event occurs at any time other than during the Sale Event Period, subject to Executive signing and complying with the Separation Agreement and Release and the Separation Agreement and Release becoming irrevocable pursuant to its terms, all within 60 days after the Date of Termination, the following shall occur:</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.8457544394060026%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company shall pay to Executive cash in an amount equal to the sum of (i) twelve (12) months of Executive&#x2019;s then-current Base Salary in effect immediately prior to the Terminating Event, and (ii) Executive&#x2019;s target annual incentive compensation for the year in which the termination occurs (with the payments for both (i) and (ii) to be paid in approximately equal installments over the course of twelve months on the Company&#x2019;s regular payroll dates, commencing on the first payroll date that occurs after the Separation Agreement and Release becomes fully effective); and</font></div></div>
  <p style="margin-left:16.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.8457544394060026%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if Executive was participating in the Company&#x2019;s group health plan immediately prior to the Date of Termination and properly elects COBRA health continuation, then subject to Executive&#x2019;s copayment of monthly premium amounts at the active employees&#x2019; rate, the Company shall pay to the group health plan provider or the COBRA provider, on a monthly basis, the remainder of the premiums for Executive&#x2019;s and Executive&#x2019;s family&#x2019;s participation in the Company&#x2019;s group health plans until the earliest of (i) twelve (12) months, (ii) the date Executive becomes eligible for group health plan benefits under any other employer&#x2019;s group health plan, and (ii) the cessation of Executive&#x2019;s health continuation rights under COBRA; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that if the Company determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (as applicable) without potentially violating applicable law (including, without limitation, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patient Protection and Affordable Care Act or the Health Care and Education Reconciliation Act of 2010, and the guidance and regulations issued thereunder), then the Company shall, in lieu thereof, convert such payments to payroll payments directly to Executive for the time period specified above, and such payments to Executive shall be subject to tax-related deductions and withholdings and paid on the Company&#x2019;s regular payroll dates.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:8.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amounts payable under Section 7(a) and (b) shall commence to be paid within 60</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">days after the Date of Termination; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payments, to the extent they qualify as &#x201c;non-qualified deferred compensation&#x201d; within the meaning of Section 409A of the Code, shall commence to be paid in the second calendar year by the last day of such 60-day period; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided further</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination.  The payments pursuant to this Section 7 are intended to be exempt under the &#x201c;short term deferral&#x201d; and &#x201c;separation pay&#x201d; exceptions under Treasury Regulation Sections 1.409A-1(b)(4) and 1.409A-1(b)(9)(iii), respectively, to the maximum extent permitted by Section 409A of the Code, and this Agreement shall be interpreted and administered in a manner consistent with such intent.  Each payment pursuant to this Agreement is intended to constitute a separate and distinct payment for purposes of Treasury Regulation Section 1.409A-2(b)(2).</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.19in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Restrictive Covenants.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Contemporaneous with the execution of this Agreement, Executive agrees to enter into and abide by the Proprietary Information and Inventions Agreement (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PIIA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Limitation. </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.8457544394060026%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any compensation, payment or distribution by the Company to or for the benefit of Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Code and the applicable regulations thereunder (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Aggregate Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which Executive becomes subject to the excise tax imposed by Section 4999 of the Code; provided that such reduction shall only occur if it would result in Executive receiving a higher After Tax Amount (as defined below) than Executive would receive if the Aggregate Payments were not subject to such reduction.  In such event, the Aggregate Payments shall be reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section 280G of the Code:  </font></div></div>
  <p style="margin-left:16.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:21.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.0467873615352183%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">i.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) cash payments not subject to Section 409A of the Code; (ii) cash payments subject to Section 409A of the Code; (iii) equity-based payments and acceleration; and (iv) non-cash forms of benefits; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. &#167;1.280G-1, Q&amp;A-24(b) or (c) shall be reduced before any amounts that are subject to calculation under Treas. Reg. &#167;1.280G-1, Q&amp;A-24(b) or (c).</font></div></div>
  <p style="margin-left:23.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.8457544394060026%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Section 9, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After Tax Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the amount of the Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on Executive as a result of Executive&#x2019;s receipt of the Aggregate Payments.  For purposes of determining the After Tax Amount, Executive shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes.</font></div></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.8457544394060026%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to Section 9 shall be made by a nationally recognized accounting firm selected by the Company  (provided such firm may not be the same firm </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.19in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.8457544394060026%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engaged as the accountant or auditor for the individual, entity or group effecting the change in control event triggering the implication of Section 280G)  (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounting Firm</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), which shall provide detailed supporting calculations both to the Company and Executive within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or Executive.  Any determination by the Accounting Firm shall be binding upon the Company and Executive.</font></div></div>
  <p style="margin-left:16.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 409A. </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.8457544394060026%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anything in this Agreement to the contrary notwithstanding, if at the time of Executive&#x2019;s &#x201c;separation from service&#x201d; within the meaning of Section 409A of the Code (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Separation from Service</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), the Company determines that Executive is a &#x201c;specified employee&#x201d; within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that Executive becomes entitled to under this Agreement on account of Executive&#x2019;s Separation from Service would be considered deferred compensation subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (i) six months and one day after Executive&#x2019;s Separation from Service, or (ii)  Executive&#x2019;s death.</font></div></div>
  <p style="margin-left:16.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.8457544394060026%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Parties intend that this Agreement will be administered as exempt from Section 409A of the Code and if not so exempt, this Agreement shall be administered in accordance with Section 409A of the Code.  To the extent that any provision of this Agreement is ambiguous as to its exemption from of compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder are exempt from, or comply with, as applicable, Section 409A of the Code.  The Parties agree that this Agreement may be amended, as reasonably requested by either Party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either Party.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.8457544394060026%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by Executive during the time periods set forth in this Agreement.  All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred.  The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year. Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.8457544394060026%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that any payment or benefit described in this Agreement constitutes </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.19in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.8457544394060026%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;non-qualified deferred compensation&#x201d; under Section 409A of the Code, and to the extent that such payment or benefit is payable upon Executive&#x2019;s termination of employment, then such payments or benefits shall be payable only upon Executive&#x2019;s Separation from Service.  The determination of whether and when a Separation from Service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h).</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.8457544394060026%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">e.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company makes no representation or warranty and shall have no liability to Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notice and Date of Termination.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.8457544394060026%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notice of Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.   Executive&#x2019;s employment with the Company may be terminated by the Company or Executive at any time and for any reason.  Any termination of Executive&#x2019;s employment (other than by reason of death) shall be communicated by written Notice of Termination from one Party hereto to the other Party hereto in accordance with this section. For purposes of this Agreement, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notice of Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon.</font></div></div>
  <p style="margin-left:16.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.8457544394060026%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date of Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date of Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean: (i) if Executive&#x2019;s employment is terminated by Executive&#x2019;s death, the date of Executive&#x2019;s death; (ii) if Executive&#x2019;s employment is terminated on account of Executive&#x2019;s Disability or by the Company for Cause or without Cause, the date on which Notice of Termination is given or the date otherwise specified by the Company in the Notice of Termination; (iii) if Executive&#x2019;s employment is terminated by Executive for any reason except for Good Reason, 30 days after the date on which a Notice of Termination is given, and (iv) if Executive&#x2019;s employment is terminated by Executive with Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period.  Notwithstanding the foregoing, in the event that Executive gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Governing Law and Jurisdiction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement shall be governed by, interpreted, and construed in accordance with the laws of the State of California without regard to conflicts of law principles.  The Parties consent to the jurisdiction of the state and federal courts in the State of California. Accordingly, with respect to any such court action, Executive submits to the personal jurisdiction of such courts.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">13.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Integration</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  This Agreement and Executive&#x2019;s Amended and Restated Director and Officer Indemnification Agreement (dated January 1, 2025), PIIA, and any existing equity award agreements entered into prior to the date of this Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Award Agreements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.19in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">contain the entire understanding with regard to the Company&#x2019;s employment of Executive, and supersedes any prior offers, arrangements, communications, and agreements between the Parties concerning such subject matter, whether written or oral.  For the avoidance of doubt, this Agreement supersedes all previous Company offer letters and/or any severance policies, arrangements or agreements previously provided to Executive, including the offer letter entered into by and between the Company and the Executive, dated November 20, 2009, and the Company&#x2019;s Severance and Change in Control Policy; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, this Agreement shall not supersede any Equity Award Agreements unless amended pursuant to this Agreement.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">14.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  The provisions of this Agreement shall be deemed severable, and the invalidity of any portion of this Agreement shall not affect the validity of the remainder of this Agreement.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">15.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendment and Waiver</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No amendment, alteration or modification of any of the provisions of this Agreement shall be valid unless in a writing that expressly refers to the provision of this Agreement that is being amended and that is signed by Executive and an authorized officer of Company (which shall not be Executive).  No waiver by either Party of any breach of any provision of this Agreement shall be effective unless such a waiver is in a writing that expressly refers to the provision of this Agreement being waived and that is signed by the Party against whom it is sought to be enforced.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">16.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Notices.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight currier service of by registered or certified mail, postage prepaid, return receipt requested, to Executive at the last home or e-mail address Executive has filed in writing with the Company, or to Company at its main office, attention of the Board of Directors. </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">17.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Headings</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Section headings and numbers have been inserted in this Agreement for convenience of reference only and in no way define or limit the scope or content of this Agreement or in any way affect the interpretation of its provisions.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">18.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assignment and Transfer by the Company; Successors</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company shall have the right to assign and/or transfer this Agreement to any entity or person, including without limitation the Company&#x2019;s parents, subsidiaries and other affiliates.  Executive expressly consents to such assignment and/or transfer.  This Agreement shall inure to the benefit of and be enforceable by the Company&#x2019;s successors and assigns.  </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">19.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document. </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">20.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Survival</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  The Parties&#x2019; respective rights and obligations under this Agreement shall survive any termination of Executive&#x2019;s employment to the extent necessary to preserve the intended rights and obligations.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.19in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Parties have executed this Agreement as follows:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FATE THERAPEUTICS, INC.				EXECUTIVE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Cindy Tahl	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">						</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Bahram Valamehr	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Cindy Tahl							Bahram (Bob) Valamehr</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Chief Legal &amp; Compliance Officer</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3/3/2025                                       </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 			Date: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3/3/2025                               </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>4
<FILENAME>fate-ex19_1.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html>
 <head>
  <title>EX-19.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FATE THERAPEUTICS, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insider Trading POLICY</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:18pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fate Therapeutics, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) has adopted the following policy and procedures for securities trading by Company directors and employees (our &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insider Trading Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Our Insider Trading Policy is intended to prevent the misuse of material nonpublic information, insider trading in securities, and the severe consequences associated with violations of insider trading laws.  It is your obligation to review, understand, and comply with this Insider Trading Policy and applicable laws.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our Board of Directors has approved this Insider Trading Policy, and we have appointed Cindy Tahl, as the as its insider trading compliance officer (with their designees, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) to administer the policy and to be available to answer your questions. Please contact the Insider Trading Compliance Officer at 858-875-1826 or compliance@fatetherapeutics.com if you have any questions regarding the policy.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:18pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART I.  OVERVIEW</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Who Must Comply?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Insider Trading Policy applies to all of our employees and members of our Board of Directors, including anyone employed by or acting as a director of any of the Company&#x2019;s subsidiaries, as well as any other individuals whom the Compliance Officer may designate as Insiders (defined below) because they have access to material nonpublic information about the Company.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, all of our directors, executive officers (as defined by Section 16 of the Securities Exchange Act of 1934, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;)) and other designated employees must comply with the Trading Procedures included in Part II of this Insider Trading Policy (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trading Procedures</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); we will refer to these individuals in this policy as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insiders</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d; The Trading Procedures provide rules for when Insiders can trade in our securities and explain the process for mandatory pre-clearance of proposed trades. You will be notified if you are considered to be an Insider who is required to comply with the Trading Procedures.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Insider Trading Policy and, for Insiders, the Trading Procedures also apply to the following persons (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Affiliated Persons</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;):</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">your &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Family Members</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; (&#x201c;Family Members&#x201d; are (a) your spouse or domestic partner, children, stepchildren, grandchildren, parents, stepparents, grandparents, siblings and in-laws who reside in the same household as you, (b) your children or your spouse&#x2019;s children who do not reside in the same household as you but are financially dependent on you, (c) any of your other family members who do not reside in your household but whose transactions are directed by you, and (d) any other individual over whose account you have control and to whose financial support you materially contribute. (Materially contributing to financial support would include, for example, paying an individual&#x2019;s rent but not just a phone bill.).);</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all trusts, family partnerships and other types of entities formed for your benefit or for the benefit of a member of your family and over which you have the ability to influence or direct investment decisions concerning securities; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all persons who execute trades on your behalf; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all investment funds, trusts, retirement plans, partnerships, corporations and other types of entities over which you have the ability to influence or direct investment decisions concerning securities; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that the Trading Procedures do not apply to any such entity that engages in the investment of securities in the ordinary course of its business (e.g., an investment fund or partnership) if the entity has established its own insider trading controls and procedures in compliance with </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable securities laws and it (or an affiliated entity) has represented to the Company that its affiliated entities:  (a) engage in the investment of securities in the ordinary course of their respective businesses; (b) have established insider trading controls and procedures in compliance with securities laws; and (c) are aware the securities laws prohibit any person or entity who has material nonpublic information concerning the Company from purchasing or selling securities of the Company or from communicating such information to any other person under circumstances in which it is reasonably foreseeable that such person is likely to purchase or sell securities.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You are responsible for ensuring compliance with this Insider Trading Policy, including the Trading Procedures contained herein, by all of your Affiliated Persons.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">B.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">What is Prohibited by this Insider Trading Policy?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You and your Affiliated Persons are prohibited from engaging in insider trading and from trading in securities in violation of this Insider Trading Policy. &#x201c;Insider trading&#x201d; is (1) trading (buying or selling) the securities of a company whether for your account or for the account of another, while in the possession of material nonpublic information (see definition below) about that company or (2) disclosing material nonpublic information about a company to others who may trade on the basis of that information. Insider trading can result in criminal prosecution, jail time, significant fines and public embarrassment for you and the Company.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prohibition on Trading in Company Securities</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When you are in possession of material nonpublic information about the Company, whether positive or negative, you are prohibited from trading (whether for your account of for the account of another) in the Company&#x2019;s securities, which include common stock, options to purchase common stock, any other type of securities that the Company may issue (such as preferred stock, convertible debentures, warrants and exchange-traded options), and any derivative securities that provide the economic equivalent of ownership of any of the Company&#x2019;s securities or an opportunity, direct or indirect, to profit from any change in the value of the Company&#x2019;s securities, except for trades made pursuant to plans approved by the Compliance Officer in accordance with this policy that are intended to comply with Rule 10b5-1 under the Exchange Act.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading prohibitions in this Insider Trading Policy do </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">apply to: (1) an exercise of an employee stock option when payment of the exercise price is made in cash or (2) the withholding by the Company of shares of stock upon vesting of restricted stock or upon settlement of restricted stock units to satisfy applicable tax withholding requirements if (a) such withholding is required by the applicable plan or award agreement or (b) the election to exercise such tax withholding right was made by the Insider in compliance with the Trading Procedures.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading prohibitions in this Insider Trading Policy </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">do</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> apply, however, to the use of outstanding Company securities to pay part or all of the exercise price of a stock option, any sale of stock as part of a broker-assisted cashless exercise of an option, and any other market sale for the purpose of generating the cash needed to pay the exercise price of an option.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prohibition on Tipping</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Providing material nonpublic information about the Company to another person who may trade or advise others to trade on the basis of that information is known as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tipping</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and is illegal.  You are prohibited from providing material nonpublic information about the Company to a friend, relative, or anyone else who might buy or sell a security or other financial instrument on the basis of that information, whether or not you intend to or actually do realize a profit (or any other benefit) from such tipping.  Additionally, you are prohibited from recommending to any person that such person engage in or refrain from engaging in any transaction involving the Company&#x2019;s securities, or otherwise give trading advice concerning the Company&#x2019;s securities, if you are in possession of material nonpublic information about the Company.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prohibition on Trading in Securities of Other Companies</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This policy&#x2019;s prohibitions against insider trading and tipping also apply to trading in securities of other companies, including the Company&#x2019;s suppliers, collaboration partners and other business entities with which we are working (such as when negotiating an acquisition, license investment or other transaction that could be material to the other company).  Whenever, during the course of your service to or employment by the Company, you become aware of material nonpublic information about another company, including any confidential information that is reasonably likely to affect the market price of that company&#x2019;s securities (for example, discussions of licensing a product or acquiring that other company), neither you nor your Affiliated Persons may trade in any securities of that company, give trading advice about that company, tip or disclose that information, pass it on to others, or engage in any other action to take advantage of that information.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If your work regularly involves handling or discussing confidential information of one of our suppliers, collaboration partners or other entities with whom we conduct business, you should consult with the Compliance Officer before trading in any of that company&#x2019;s securities.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Duration of Trading Prohibitions</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These trading prohibitions continue whenever and for as long as you know or are in possession of material nonpublic information.  Remember, anyone scrutinizing your transactions will be doing so after the fact, with the benefit of hindsight.  As a practical matter, before engaging in any transaction, you should carefully consider even the appearance of improper insider trading and how enforcement authorities and others might view the transaction in hindsight.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Insider Trading Policy applies to you and your Affiliated Persons so long as you are associated with the Company. If you leave the Company for any reason, this Insider Trading Policy, including, if applicable, the Trading Procedures described in Part III, will continue to apply to you and your Affiliated Persons until the later of: (1) the first trading day following the public release of earnings for the fiscal quarter in which you leave the Company or (2) the first trading day after any material nonpublic information known to you has become public or is no longer material.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">C.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">What is Material Nonpublic Information?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Insider Trading Policy prohibits you from trading in a company&#x2019;s securities if you are in possession of information about the company that is both &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">material</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">nonpublic</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d;  If you have a question whether certain information you are aware of is material or has been made public, you should consult with the Compliance Officer.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Material&#x201d; Information</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information about our Company or any other company is &#x201c;material&#x201d; if it could reasonably be expected to affect the investment decisions of a stockholder or potential investor or if disclosure of the information could reasonably be expected to significantly alter the total mix of information in the marketplace about us or any other company.  We speak mostly in this Insider Trading Policy about determining whether information about us is material and nonpublic, but the same analysis applies to information about other companies that would preclude you from trading in their securities.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In simple terms, material information is any type of information that could reasonably be expected to affect the market price of our securities.  Both positive and negative information may be material.  While it is not possible to identify all information that would be deemed &#x201c;material,&#x201d; the following items are examples of the types of information that could be material:</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">program developments, regulatory or clinical status or updates, including preclinical and clinical data and communications with regulatory authorities;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">projections of future earnings or losses, or other earnings guidance;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">quarterly financial results that are known but have not been publicly disclosed;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential restatements of the Company&#x2019;s financial statements, changes in auditors or auditor notification that the Company may no longer rely on an auditor&#x2019;s audit report;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pending or proposed collaborations, strategic partnerships, licensing transactions, corporate mergers, acquisitions, tender offers, joint ventures or dispositions of significant assets or financing transactions;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in senior management or members of our Board of Directors;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant actual or threatened litigation or governmental investigations or major developments in such matters;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cybersecurity risks and incidents, including the discovery of significant vulnerabilities or breaches;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant developments regarding collaborations, licenses, product candidates, research and development programs, products, customers, suppliers, orders, contracts or financing sources (e.g., the acquisition or loss of a contract);</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in dividend policy, declarations of stock splits, or proposed securities offerings or other financings; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential defaults under our credit agreements or indentures or potential material liquidity issues; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">bankruptcies or receiverships.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The above items will not always be material. For example, some new product developments or contracts may clearly be material while others may not be. No &#x201c;bright-line&#x201d; standard or list of items can adequately address the range of situations that may arise; information and events should be carefully considered in terms of their materiality to the Company.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Nonpublic&#x201d; Information</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material information is &#x201c;nonpublic&#x201d; if it has not been disseminated in a manner making it available to investors generally.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To demonstrate that information is public, one must be able to point to some fact that establishes that the information has become publicly available, such as the filing of a report with the SEC, the distribution of a press release, publishing the information on our website or posting on social media if those are regular ways we communicate with investors, or by other means that are reasonably designed to provide broad public access.  Before a person with material nonpublic information can trade, the market must have adequate time to absorb the information that has been disclosed.  For the purposes of this Insider Trading Policy, information will be considered public after the completion of one full day of trading following our public release of the information.  For that purpose, a full day of trading means an entire calendar day in which a session of regular trading hours on the Nasdaq Stock Market between 9:30 a.m. and 4:00 p.m. Eastern Time (or such earlier close time as has been set by exchange rules) has occurred.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, if the Company publicly discloses material nonpublic information of which you are aware before trading begins on a Tuesday, the first time you can buy or sell Company securities is the opening of the market on Wednesday.  However, if the Company publicly discloses material information after trading begins on a Tuesday, the first time that you can buy or sell Company securities is the opening of the market on Thursday.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">E.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">What are the Penalties for Insider Trading and Noncompliance with this Insider Trading Policy?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Both the U.S. Securities and Exchange Commission (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and the national securities exchanges, through the Financial Industry Regulatory Authority (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FINRA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), investigate and are very effective at detecting insider trading.  The U.S. government pursues insider trading violations vigorously, successfully prosecuting, for example, trading by employees in foreign accounts, trading by family members and friends of insiders, and trading involving only a small number of shares.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The penalties for violating rules against insider trading can be severe and include:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">forfeiting any profit gained or loss avoided by the trading;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment of the loss suffered by the persons who, contemporaneously with the purchase or sale of securities that are subject of a violation, have purchased or sold securities of the same class;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment of criminal penalties of up to $5,000,000; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment of civil penalties of up to three times the profit made or loss avoided; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imprisonment for up to 20 years.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company and/or the supervisors of the person engaged in insider trading may also be required to pay civil penalties or fines of $2 million or more, up to three times the profit made or loss avoided, as well as criminal penalties of up to $25,000,000, and could under some circumstances be subject to private lawsuits.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Violation of this Insider Trading Policy or any federal or state insider trading laws may subject you to disciplinary action by the Company, including termination of your employment or other relationship with the Company.  The Company reserves the right to determine, in its own discretion and on the basis of the information available to it, whether this Insider Trading Policy has been violated.  The Company may determine that specific conduct violates this Insider Trading Policy whether or not it also violates the law.  It is not necessary for the Company to await the filing or conclusion of a civil or criminal action against an alleged violator before taking disciplinary action.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">E.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">How Do You Report a Violation of this Insider Trading Policy?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you have a question about this Insider Trading Policy, including whether certain information you are aware of is material or has been made public, you should consult with the Compliance Officer.  In addition, if you violate this Insider Trading Policy or any federal or state laws governing insider trading or know of any such violation by any director or employee of the Company, you should report the violation immediately to the Compliance Officer.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART II.  TRADING PROCEDURES</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Special Trading Restrictions Applicable to Insiders</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to needing to comply with the restrictions on trading in our securities set forth above, Insiders and their Affiliated Persons are subject to the following special trading restrictions:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Special Closed Trading Periods</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Compliance Officer may designate, from time to time, a &#x201c;Special Closed Window&#x201d; or &#x201c;Trading Blackout Period&#x201d;. During any such Special Closed Window or Trading Blackout Period, designated Insiders (which could be all Insiders or a subset of them) may not trade in the Company&#x2019;s securities. The Compliance Officer may also impose a Special Closed Window or Trading Blackout Period on Insiders or a subset of them to prohibit trading in the securities of other companies, including specified peers or competitors of the Company. The imposition of a Special Closed Window or Trading Blackout Period will not be announced to the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company generally, should not be communicated to any other person, and may itself be considered under this Insider Trading Policy to be material nonpublic information about the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Prohibited Transactions</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Short Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> You may not at any time sell any securities of the Company that are not owned by you at the time of the sale (a &#x201c;short sale&#x201d;).  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Purchases or Sales of Derivative Securities or Hedging Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  You may not buy or sell puts, calls, other derivative securities of the Company or any derivative securities that provide the economic equivalent of ownership of any of the Company&#x2019;s securities or an opportunity, direct or indirect, to profit from any change in the value of our securities or engage in any other hedging transaction with respect to our securities.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Company Securities Subject to Margin Calls</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  You may not use the Company&#x2019;s securities as collateral in a margin account.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Pledges</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  You may not pledge Company securities as collateral for a loan (or modify an existing pledge).</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">3.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Gifts and Other Distributions in Kind</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Insider may donate or make any other transfer of Company securities without consideration when the Insider is not permitted to trade unless the donee agrees not to sell the shares until the Insider is permitted to sell. In addition to charitable donations or gifts to family members, friends, trusts or others, this prohibition applies to distributions to limited partners by limited partnerships that are subject to this Insider Trading Policy.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">B. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pre-Clearance Procedures</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Insider may trade in our securities, even during an open trading window, unless the trade has been approved by the Compliance Officer in accordance with the procedures described below.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In reviewing trading requests, the Compliance Officer may consult with our other officers and/or outside legal counsel and will seek approval of their own trades from the Chief Executive Officer.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Procedures.  </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Insider may trade in our securities unless:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Insider has notified the Compliance Officer of the amount and nature of the proposed trade(s) using the Stock Transaction Request form attached to this Insider Trading Policy.  To provide adequate time for the preparation of any required reports under Section 16 of the Exchange Act, a Stock Transaction Request form should, if practicable, be received by the Compliance Officer at least two (2) business days before the intended trade date;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Insider has certified to the Compliance Officer in writing before the proposed trade(s) that the Insider does not possess material nonpublic information concerning the Company;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Insider is an executive officer or director, the Insider has informed the Compliance Officer, using the Stock Transaction Request form, whether, to the Insider&#x2019;s best knowledge, (a) the Insider has (or is deemed to have) engaged in any opposite way transactions within the previous six months that were not exempt from Section 16(b) of the Exchange Act and (b) if the transaction involves a sale by an &#x201c;affiliate&#x201d; of the Company or of &#x201c;restricted securities&#x201d; (as such terms are defined under Rule 144 under the Securities Act of 1933, as amended (&#x201c;Rule 144&#x201d;)), whether the transaction meets all of the applicable conditions of Rule 144; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Compliance Officer has approved the trade(s) and has certified their approval in writing (which may be by email). </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Compliance Officer does not assume responsibility for, and approval by the Compliance Officer does not protect the Insider from, the consequences of prohibited insider trading.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Information.  </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insiders shall provide to the Compliance Officer any documentation the Compliance Officer reasonably requires in furtherance of the foregoing procedures.  Any failure to provide such information will be grounds for the Compliance Officer to deny approval of the trade request.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notification of Brokers of Insider Status</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insiders who are required to file reports under Section 16 of the Exchange Act shall inform their broker-dealers that (a) the Insider is subject to Section 16; (b) the broker shall confirm that any trade by the Insider or any of their affiliates has been precleared by the Company; and (c) the broker is to provide transaction information to the Insider and/or Compliance Officer on the day of a trade.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Obligation to Approve Trades.  </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foregoing approval procedures do not in any way obligate the Compliance Officer to approve any trade.  The Compliance Officer has sole discretion to reject any trading request.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, an event may occur that is material to the Company and is known only by a limited number of directors and employees.  The Compliance Officer may decline an Insider&#x2019;s request to preclear a proposed trade based on the existence of a material nonpublic development &#x2013; even if the Insider is not aware of that material nonpublic development.  If any Insider engages in a trade before a material nonpublic development is disclosed to the public or resolved, the Insider and the Company might be exposed to a charge of insider trading that could be costly and difficult to refute even if the Insider was unaware of the development.  So long as the event remains material and nonpublic, the Compliance Officer may decide not to approve any transactions in the Company&#x2019;s securities.  The Compliance Officer will subsequently notify the Insider once the material nonpublic development is disclosed to the public or resolved.  If an Insider requests preclearance of a trade during the pendency of such an event, the Compliance Officer may reject the trading request without disclosing the reason.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Completion of Trades.  </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After receiving written clearance to engage in a trade signed by the Compliance Officer, an Insider must complete the proposed trade within two (2) business days or make a new trading request.  Even if an Insider has received clearance, the Insider may not engage in a trade if (i) such clearance has been rescinded by the Compliance Officer, (ii) the Insider has otherwise received notice that the trading window has closed or (iii) the Insider has or acquires material nonpublic information.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Post-Trade Reporting.  </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The details of any transactions in our securities (including transactions effected pursuant to a Rule 10b5-1 Plan) by an Insider (or an Affiliated Person) who is required to file reports under Section 16 of the Exchange Act must be reported to the Compliance Officer by the Insider or their brokerage firm on the same day on which a trade order is placed or such a transaction otherwise is entered into.  The report shall include the date of the transaction, quantity of shares, the price and the name of the broker-dealer that effected the transaction.  This reporting requirement may be satisfied by providing (or having the Insider&#x2019;s broker provide) a trade order confirmation to the Compliance Officer if the Compliance Officer receives such information by the required date.  Compliance by directors and executive officers with this provision is imperative given the requirement of Section 16 of the Exchange Act that these persons generally report changes in ownership of Company securities within two (2) business days.  The sanctions for noncompliance with this reporting deadline include mandatory disclosure in the Company&#x2019;s proxy statement for the next annual meeting of stockholders, as well as possible civil or criminal sanctions for chronic or egregious violators.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">C.	Exemptions</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-Approved Rule 10b5-1 Plan.  </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transactions made pursuant to an approved Rule 10b5-1 Plan (as defined below) will not be subject to our trading windows or pre-clearance procedures, and Insiders are not required to complete a Stock Transaction Request form for such transactions.  Rule 10b5-1 of the Exchange Act provides an affirmative defense from insider trading liability under the federal securities laws for trading plans, arrangements or instructions that meet specified requirements.  A trading plan, arrangement or instruction that meets the requirements of the SEC&#x2019;s Rule 10b5-1 (a &#x201c;Rule 10b5-1 Plan&#x201d;) enables Insiders to trade in Company securities outside of our trading windows, even when in possession of material nonpublic information.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has adopted a separate Rule 10b5-1 Trading Plan Policy that sets forth the requirements for putting in place a Rule 10b5-1 Plan with respect to Company securities.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee Equity and Retirement Plans.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exercise of Stock Options</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading prohibitions and restrictions set forth in the Trading Procedures do not apply to the exercise for cash of an option to purchase securities of the Company.  However, the exercise is subject to the current reporting requirements of Section 16 of the Exchange Act and, therefore, Insiders must comply with the post-trade reporting requirement described in Section C above for any such transaction.  In addition, the securities acquired upon the exercise of an option to purchase Company securities are subject to all of the requirements of this Insider Trading Policy, including the Trading Procedures.  Moreover, the Trading Procedures apply to the use of outstanding Company securities to pay part or all of the exercise price of an option, any net option exercise, any exercise of a stock appreciation right, share withholding and any sale of stock as part of a broker-assisted cashless exercise of an option or any other market sale for the purpose of generating the cash needed to pay the exercise price of an option.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tax Withholding on Restricted Stock/Units</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading prohibitions and restrictions set forth in the Trading Procedures do not apply to the withholding by the Company of shares of stock upon vesting of restricted stock or upon settlement of restricted stock units to satisfy tax withholding requirements if (a) withholding is required by the applicable plan or award agreement or (b) the election to exercise the tax withholding right was made by the Insider in compliance with the Trading Procedures.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee Stock Purchase Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading prohibitions and restrictions set forth in the Trading Procedures do not apply to periodic wage withholding contributions by the Company or its employees that are used to purchase Company stock pursuant to the employees&#x2019; advance instructions under the Company&#x2019;s employee stock purchase plan, if any.  However, an Insider may not: (a) elect to participate in the plan or alter their instructions regarding the level of withholding or purchase by the Insider of Company securities under the plan; or (b) make cash contributions to the plan (other than through periodic wage withholding) without complying with the Trading Procedures.  Any sale of securities acquired under the plan is subject to the prohibitions and restrictions of the Trading Procedures.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">D.	Waivers</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A waiver of any provision of this Insider Trading Policy or the Trading Procedures may be authorized in writing by the Compliance Officer (or by the Chief Executive Officer if such waiver pertains to the Compliance Officer). All waivers shall be reported to the Board of Directors.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART III.  ACKNOWLEDGEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will deliver a copy of this Insider Trading Policy to all current employees and directors and to future employees and directors at the start of their employment or relationship with the Company.  Each of these individuals must acknowledge that they have received a copy and agree to comply with the terms of this Insider Trading Policy, and, if applicable, the Trading Procedures contained herein.  The attached acknowledgment must be completed and submitted to the Company within ten days of receipt.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At our request, directors and employees will be required to re-acknowledge and agree to comply with the Insider Trading Policy (including any amendments or modifications).  For that purpose, an individual will be deemed to have acknowledged and agreed to comply with the Insider Trading Policy, as amended from time to time, when copies of those items have been delivered by regular or electronic mail (or other delivery option used by the Company) to the Compliance Officer.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Questions regarding this Insider Trading Policy are encouraged and may be directed to the Compliance Officer.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ADOPTED: </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 5, 2023</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EFFECTIVE:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 5, 2023</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT A</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">STOCK TRANSACTION REQUEST</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fate Therapeutics, Inc.&#x2019;s</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Insider Trading Policy, I hereby notify </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fate Therapeutics, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#x201c;Company&#x201d;) of my intent to trade the securities of the Company as indicated below:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:18.61%;box-sizing:content-box;"></td>
    <td style="width:1.001%;box-sizing:content-box;"></td>
    <td style="width:7.961%;box-sizing:content-box;"></td>
    <td style="width:1.001%;box-sizing:content-box;"></td>
    <td style="width:15.144%;box-sizing:content-box;"></td>
    <td style="width:56.284%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="6" style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:2.9pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">REQUESTER INFORMATION</font></p><p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Insider&#x2019;s Name:	 _________________________________________</font></p><p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="6" style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:2.9pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">INTENT TO PURCHASE</font></p><p style="text-indent:-27.119%;padding-left:21.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of shares:		__________________________</font></p><p style="text-indent:-27.119%;padding-left:21.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intended trade date:		__________________________</font></p></td>
   </tr>
   <tr style="height:10.95pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:2.9pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Means of acquiring shares:</font></p></td>
    <td colspan="2" style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:2.9pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&uml;</font></p></td>
    <td colspan="2" style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:2.9pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquisition through employee benefit plan (please specify):</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:2.9pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:2.9pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">___________________________________________________________</font></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:2.9pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10.9pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:2.9pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:2.9pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&uml;</font></p></td>
    <td colspan="2" style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:2.9pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchase through a broker on the open market</font></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:2.9pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10.9pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:2.9pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:2.9pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&uml;</font></p></td>
    <td colspan="2" style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:2.9pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other (please specify): ________________________________________</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="6" style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:2.9pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">INTENT TO SELL</font></p><p style="text-indent:-27.119%;padding-left:21.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of shares:		__________________________</font></p><p style="text-indent:-27.119%;padding-left:21.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intended trade date:		__________________________</font></p></td>
   </tr>
   <tr style="height:10.95pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:2.9pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Means of selling shares:</font></p></td>
    <td colspan="2" style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:2.9pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&uml;</font></p></td>
    <td colspan="3" style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:2.9pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sale through employee benefit plan (please specify):</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:2.9pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:2.9pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">___________________________________________________________</font></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:2.9pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10.9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:2.9pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:2.9pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&uml;</font></p></td>
    <td colspan="3" style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:2.9pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sale through a broker on the open market</font></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:2.9pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10.9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:2.9pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:2.9pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&uml;</font></p></td>
    <td colspan="3" style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:2.9pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other (please specify): ________________________________________</font></p></td>
   </tr>
   <tr style="height:10.9pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="6" style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:2.9pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">INTENT TO GIFT</font></p><p style="text-indent:-27.119%;padding-left:21.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of shares:	__________________________</font></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intended trade date:              __________________________</font></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intended recipient:                __________________________</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="5" style="padding-top:0in;border-right:0.5pt solid;text-indent:115.2pt;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="text-indent:-27.119%;padding-left:21.333%;font-size:10pt;margin-top:3.5pt;font-family:Times New Roman;margin-bottom:2.9pt;border-bottom:1pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">SECTION 16</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:115.2pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="text-indent:-27.119%;padding-left:21.333%;font-size:10pt;margin-top:3.5pt;font-family:Times New Roman;margin-bottom:2.9pt;border-bottom:1pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">RULE 144 (Not applicable if transaction requested involves a purchase)</font></p></td>
   </tr>
   <tr style="height:160.65pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="5" style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&uml; </font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">I am not subject to Section 16.</font></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&uml; </font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">To the best of my knowledge, I have not (and am not deemed to have) engaged in an opposite way transaction within the previous 6 months that was not exempt from Section 16(b) of the Exchange Act.</font></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&uml; </font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">None of the above.</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&uml; </font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">I am not an &#x201c;affiliate&#x201d; of the Company and the transaction requested above does not involve the sale of &#x201c;restricted securities&#x201d; (as those terms are defined in Rule 144 under the Securities Act of 1933, as amended).</font></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&uml; </font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">To the best of my knowledge, the transaction requested above will meet all of the applicable conditions of Rule 144.</font></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&uml; </font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The transaction requested will be made pursuant to an effective registration statement covering such transaction.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&uml; </font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">None of the above.</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <table style="border-spacing:0;table-layout:auto;width:88.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:2.947%;box-sizing:content-box;"></td>
    <td style="width:40.747%;box-sizing:content-box;"></td>
    <td style="width:1.811%;box-sizing:content-box;"></td>
    <td style="width:6.684%;box-sizing:content-box;"></td>
    <td style="width:2.284%;box-sizing:content-box;"></td>
    <td style="width:37.779%;box-sizing:content-box;"></td>
    <td style="width:4.8%;box-sizing:content-box;"></td>
    <td style="width:1.905%;box-sizing:content-box;"></td>
    <td style="width:1.042%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="8" style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">CERTIFICATION</font></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">I hereby certify that I am not (1) in possession of any material nonpublic information concerning the Company, as defined in the Company&#x2019;s Insider Trading Policy and (2) purchasing any securities of the Company on margin in contravention of the Company&#x2019;s Trading Procedures.  I understand that, if I trade while possessing such information or in violation of such trading restrictions, I may be subject to severe civil and/or criminal penalties and may be subject to discipline by the Company including termination of my employment.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:16.6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="border-top:0.5pt solid;padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Insider&#x2019;s Signature</font></p></td>
    <td colspan="2" style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="border-top:0.5pt solid;padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date</font></p></td>
    <td colspan="2" style="border-top:0.5pt solid #ffffff03;padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.55pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="9" style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">APPROVAL</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.55pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Signature of Compliance Officer (or designee)</font></p></td>
    <td colspan="2" style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="border-top:0.5pt solid;padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date</font></p></td>
    <td colspan="3" style="border-top:0.5pt solid #ffffff03;padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">*NOTE: Multiple lots must be listed on separate forms or broken out.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT B</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACKNOWLEDGEMENT</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I hereby acknowledge that I have read, that I understand, and that I agree to comply with the Insider Trading Policy of Fate Therapeutics, Inc. (the &#x201c;Company&#x201d;).  I further acknowledge and agree that I am responsible for ensuring compliance with the Insider Trading Policy and the Trading Procedures by all of my &#x201c;Affiliated Persons.&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I also understand and agree that I will be subject to sanctions, including termination of employment, that may be imposed by the Company, in its sole discretion, for violation of the Insider Trading Policy, and that the Company may give stop-transfer and other instructions to the Company&#x2019;s transfer agent or any brokerage firm managing the Company&#x2019;s equity incentive plan(s) against the transfer of any Company securities that the Company considers to be in contravention of the Insider Trading Policy.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This acknowledgement constitutes consent for the Company to impose sanctions for violation of the Insider Trading Policy, including the Trading Procedures, and to issue any stop-transfer orders to the Company&#x2019;s transfer agent that the Company, in its sole discretion, deems appropriate to ensure compliance.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date: _______________________			Signature: 	__________________________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Name:	 	__________________________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Title:		__________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br> </font><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Send signed Acknowledgement to:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[Name]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[Title]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fate Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12278 Scripps Summit Drive</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">San Diego, CA 92131</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>fate-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We consent to the incorporation by reference in the following Registration Statements:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statements (Form S-3 Nos. 333-213590, 333-215460, 333-219987, 333-275402 and 333-278792) of Fate Therapeutics, Inc., and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statements (Form S-8 Nos. 333-191576, 333-194625, 333-202690, 333-209392, 333-211484, 333-215880, 333-219989, 333-223521, 333-230152, 333-236835, 333-253459, 333-263102, 333-265502 and 333-280097) pertaining to the 2007 Equity Incentive Plan, the 2013 Stock Option and Incentive Plan, the 2013 Employee Stock Purchase Plan, the Inducement Equity Plan and the 2022 Stock Option and Incentive Plan of Fate Therapeutics, Inc.;</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of our report dated March 5, 2025, with respect to the consolidated financial statements of Fate Therapeutics, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2024.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Ernst &amp; Young LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">San Diego, California</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 5, 2025</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>fate-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PURSUANT TO RULE 13a-14(a) AND 15d-14(a) OF THE SECURITIES EXCHANGE ACT,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Bahram Valamehr, certify that:</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. I have reviewed this Annual Report on Form 10-K of Fate Therapeutics, Inc.;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">c. Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d. Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:60%;box-sizing:content-box;"></td>
    <td style="width:40%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 5, 2025</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">BAHRAM VALAMEHR</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bahram Valamehr</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Executive and Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>fate-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Bahram Valamehr, Principal Executive Officer and Principal Financial Officer of Fate Therapeutics, Inc. (the &#x201c;Registrant&#x201d;), do hereby certify in accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, based upon my knowledge:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">this Annual Report on Form 10-K of the Registrant, to which this certification is attached as an exhibit (the &#x201c;Report&#x201d;), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:60%;box-sizing:content-box;"></td>
    <td style="width:40%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 5, 2025</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bahram valamehr</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bahram Valamehr</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Executive and Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img143810944_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img143810944_0.jpg
M_]C_X  02D9)1@ ! @$ D "0  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $@ [8# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2_TZ:"_MKF#0-,U%9);65'6":16=4=F'Y?>-=6\(?\$.O^"CW@GPW\%?C/\
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M6FF6FN2LUM#=V*HDUOX._P#!PE^U=8:/\6O''QX^'G[/GC'P+)^PM\3?VN?
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MCZI8:63IL%X+:.V%O\::E_P2<_X*5?&#X_\ [7_QN^,O[%'B+2H/VB]3\#>
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MGC_@K=^WI#\4_P#@GKXO_:^^%_[,'AK]FS_@J)I_Q UCX,>#OA3J7C^3XY?
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MFU#5Y_"'A_2?">G:=<#5+:X&JW'B&YM6OHK+0].O+<1_UP5_+U\"?V,OVM?
MOQ*_X)VSWG_!+OP?X1\'?\$^=-U_X>_!+46_X*+:#XNL/!'A7XF6,?AGX@>/
M_$O@Z+X.Z:WQ$\=VFA7.HZGI]Q'?Z(9M3EG5(E$\2P_U"TW[.-/V<.:7)7K<
ME6=O:3PRIX>C1]JU\56I.C6Q=2R4:<\6Z$+PI18+GE4]I*T5.A3YZ4?@IXAU
ML35JJFG=JG3IUJ&%@W)NI'"JM*,9U9)E%%%9EA1110 4444 %%%% !1110 4
M444 %%%% !1110 5X/\ M2_%_3_V?_V:_CY\<-3O(K"S^$WP?^(GQ :ZG94B
MCG\+>%-4U>R5F?Y09;VUMX5+<;Y%!XKWBOS0_P""O'@+5OB_^P1\;/@CIGPX
M_:&^)MM\:['2OAIX@T3]E_3O >J_%JQ\,ZWJ=O<ZWJVF6/Q(USP]X7FTM+/3
MVT[6?M.HK.+/4F-O%(^0.?%QJSPV(IT7:M4HU(4G>W+.<'&,FVUI%M2>J;2L
MM;&^&E3AB*$ZRO2A6ISJI:N5.,U*<4K/644TKIJ[UTN?PV? CXL_'SXG_"3]
ME/PU^SA^T-_P6)UW_@L;\;]<T#XMZ+X3\>^)O$OA#]CQOAU=^/I]8\2>-$L/
M'UM:6GC;X-:-X FM(M0U30-0U+3[V<W7F0FP66U/[U_M ?\ !RGXC^&/Q=^-
MB_#7X5?L_P#C[]GS]E+X^>#?V;OC!)XH^.B>%/VGOBYXRN]=L?"OQ(\7_L\?
M!>WTNZ&L^"/ .O7$T/V_59IAK<5O-<(VF0(YBT?C1J'CGXJZK^P/XH\-?\$J
M/^"J/P=\<?\ !.[Q'X;O/@UXS\$:%^S->:MK_@/2?#&G^#_$7PF\91ZK\5?)
MG\&>.="TG3[;6X[)HY+:2%I;2!O,*CYDT+X#_%?P-^TIXQ^,OPJ_8=_X+(?"
MOX.?$?\ :(?]JGQ_^RWX6\!?L57'ACQ!\8KRZ74-=:T^+>M^,-3^*6@_#SQ3
MJ:?;?$?P\TW4UT>^5Y;5'B5XIK?N4H?6(05HX.&-Q<U&46X>R57*HX67+%NK
M3PU3 0S"E5H1G4K_ %^,:TI*E4I5*7$HS=&4YW>*EA,/&3BTI.M*GF$L5'GE
M>G.M3QDL%.C6E"%%8.52E&/M(U(3_4[_ (>P_MN_M!_&;X[G_@GI^Q#X'_:.
M_9C_ &5?C3X9^!?Q6\8^+OC"?A]\5/B=XRN'TJ7XBGX(^&[K2F\-KIWPQL-8
MMKC4KGQ;JZ2:S+%/%:6]LR,J^2_'[_@N/^U%H]U^VM\:_P!F']D/X;_$O]BC
M_@G1X]M?AK^T;\2?B1\6M2\%_$SQ_P",-(?2#\4-)^"/AK3M"U+0Y/\ A746
MM6D<MUXEOWCUZZ:-+*. 7"*OPWX9^$'Q[^'W[0/C/XD?"G]E#_@NA\(?V??B
M)^TC/^UMXW_9!^&$O[+W@[P3XA^-U_);W>M37/Q6TCXFV_Q1B^&WB'4;:&[U
M[X:0ZHNB:I$ILKIG01W,7GGQ/_9-^('Q'\<?'33K/]B7_@M3X#_9#_:B^.=M
M^T;^T5^Q%X3T']DB+X:_$OXGK>Z9J6L%/B)<_$5_B)X8\&>*M0T?3;KQ+X1T
M>]6SOQ:00&7;!92VF$%+DPJ349O#Q=1UO?\ 98]QRM59XA4ERUL IK-W0H4%
M[>2>#]I.FIU(4.B7*IXAV<H+$6@J?N.K@5+'N$*/.W[+'2BLM5>K6:HQ<L7[
M)5/9TI5?TU_:/_X+D?M"Z;\:/VAOAS^QY^RW\,?BGX!_9R_8.\"_ML_$KXN_
M&'XLZI\.M)\$:?XT\)M\0[/P7KNB:=X>U.?4/$&H^#IM/7P_HVFZA#?:AK%S
M.US-::;9R3OY+\?/^#ASXT>"?"_["S^%/V>_@G\'M<_:]_9-T7]IF;Q]^UY\
M3O&?P^^!">(M8E\G3_@3X'\?>&O"&HVUUXXUN.%]5L]5\67.@Z1I6DZEHTNK
M)&;EYAX#XS^#WBKQ?X3_ ."DWAB+_@FE_P %:/#5S_P4M3X=:+X]U_1/"7[+
M O?A!\//A?H.E>%_#/PT^&EI-\6/LUUX9C\.:8=&G?6V-PUI<85 T.9>%_:1
M^!7[17QRTN^\ ^"_V7?^"V'P8^ GBKX)_#_X!_$#]G-_ W[&7QI^$NI>"OAY
MX6M/!FGZE\-= ^+'C_6;?X'^+M8T"SC37-?^'<6G7=SJ;-K$,T-RL21DVFI>
MRC*/-4P]6$:DHIP56.=5:^&G57M/W>%EB<GPZK1HUI5:F J5%0K8>O4BRFTF
MO:\LK4ZM*4H*34I0>34Z>)A2;IIU,1['-Z[HSJTHTX8NG#VM*K3A*/VK\?/^
M"C'_  4>\9_M_?\ !*W]GGP5X'^%/P/\#?$GX.7'[9W[5'AS1OC/HOCLZM\-
M_!%M?Q^/= N?B%X9\/ZC8O\ #S18K636?!EWX:FW?$^^N;73-9FTNQLIE;\_
MC_P44_;V\??"_P#8FO/V(M$N_!6K?\%5O^"B'QQUR'5?BS^T3XF\?>*)?AO\
M%/'T5I>^#_ Q\0>#G'PD^$'C3PKX7U2^UJ]\*6MQ<^%X9AI/AXW3ZM-=)VNI
M?L[^/=(^*_PR^)'P6_8#_P""Q7P3TCX;_L':I_P3TB\#Z?X7_9/\>6^L?!6\
MT_5[>UU!/$GBWXG/JGA_Q,FK:G%XCU>[T:*V?5]4T^&."YTNPN;NT?8T/X(_
M$7P)K/\ P3"UWX4_\$^O^"N_P[O_ /@F#X6U[P/X(%OX'_9'\0V?Q@\+>-#I
MS_$&/QCI^L_$N>Q\+>(?&QM+^WU'Q'X<AFO+*RUJ\33UBO;>TOTUI>SCB:<G
M>-%9E4G-.+DY82><XC$KVB4ISGAH8#+,BIK"^TE)/%XUSI8ETYTZF51U'0DD
MDZOU"G&%FDHXJGE%/#NUXQC]8GF&99M5>):Y>7"810GAH3C.G^COQ-_X+I^(
M_ 7P#_X*L?M!:=\#O".N>#_V _VA/"G[+WP;9/&VM!?V@?BU>:IX=\+^,=/N
M[F/0670[#P_XIUTV=E)I2:K/?V5OYTJ02,RK\D>/?^"OG[;'PG_X*(_M=^.O
MCOX7\%^&/V'_ /@G1^QIX-\<?&GX1> /'7]H:WKOQ7^/_A[0=3^&(^WW/AJU
MNM9^(.H^-7/P_L_">KW5GX=\%Z!/>^*+N:ZU:54?X8G_ &$O']^VL^#]4_9(
M_P""W][^SOJ'[:W_  W%;?LT)X7_ &-[;P!)\1[OQ,GB?7-$\7:\/B WC#QU
MINIS0VVG6=[K.J*FB6< N[/29=6GGOG^BO&/P0\6_$;XF_\ !1SQ-X]_X)P?
M\%=/$?PJ_P""F'AWPQ:?&+X(OX7_ &4;2R\&^-O!<>B)X-^(?@;XACXE3^+5
MOO!DFB)<^%?#M]G0;*XO)O[2@U5+>V"<T?:JA3J77UG^SYPY&HRA#&K)</AY
M5)1UIRGB,QQ.8U:+<JU##RPN";C2C.5>EN_9NI*"5L.\="3:;]I+!2SEUHPA
M/EA4@L/EF%PL*K4:56L\9C%&57V:H5?H+X,_\'*&JZ-J_P 3!^UU\)_@'I_A
MW3/V,-<_;-^']_\ LH?'F+XWS:9!H][:V2_L^_%R:73+&R\+?&&[DU+38QY#
M1Z?;W,[13V(4K(OE'QB_;?\ ^"G'[3?[6_\ P2&_96^.7P;T;]D"P_:>^-7A
MK]KN.^^ 'QN\1>(-9UC]GGX:>&[_ ,6ZY\'_ (R6SZ/HMSI^M(;G0'\5165Q
M<>&]7BU,:4+:&YLKE3Y=X;^ 'QCU/X _M$_L_P#[17[%_P#P67_:3T'X_?"+
MP[\$[34]8^'?[$/PMM_A1X2\&7-G?>$]9\'>&?ASXNT[2]5\?6-]IFF3:UXQ
M\1S7E]XGM[1K'5DE2>2X'7_LN?#O]HWX$?M7?"?]LGXP?LB_\%HOVO?BY\$_
M@+J_[//PXMOBWX,_8^\,^$?"W@W4VAMX[S1=(\$_$>QDM=5M]'BDTV\O;J6^
MU+7KBZGU;6M4NKH11Q]5-THXS#U)1O0P]6AB(WE*T_J];-,90IU(.,Y/$*K'
M(\-6=Y4*E*CB)NI+VM=SYJBJRPM:"=JU>E6H3LDG"5>CEN%JU*<[J,:'LY9Q
MB*225:%:I02A!4Z/L_JC_@XV_:A/@3XD_P#!-W]F*?XP_M'_  =\!_%_XT^,
MOB-^T%X@_9.C\87?QO?X+_#;PPMM+I_AG3O FGZOXCO$U;7==$$[P:3J$&GF
MU35)[66.Q8#\^OV6/^"@'Q]_8:\6?M(?$3X.6'[>_P"U#^R1\<_'/P!_9A_X
M)Z_#+_@H)KFK^&_B3\5_VQ_',EY=>,M3\.:SXL\/V7BGPM\&?#NAV6H7'B34
MKKP\K7<AT6VCC_M!99+;]&_$/Q=^+7BK_@H+\/O^"AVO_P#!*?\ X*E:AX\^
M%O[/GBC]G_P)\,9-#_9K'@'0;+QEXC77?$7C>"^/Q6;7G\27]LK:,UOYB626
M<C2[V;$0H?\ !0+XG_%?_@H%\-OA]X2\2_\ !*[_ (*K?!;XA?!;XL^%?CI\
M"_C=\+]/_9PN/&?PM^*G@X74>D:_9:5X@^*EUH>OZ?-:WUW::IH>J1"UOHGB
M8R(\"AN?#WH1C.?/.=;&59XN%)PC)82KBJ.$J0BZB=.K4CE&&6)P:;IQH8^N
MJDY.I3D=%9QJSE"/)&%'"4X8:<U*2>*IX>IBX3ERVG3IRS3$/#8M\M65; T)
M0IQ4:D;=3XL_X+F_M _LU^ _^"C?@[]L7]FCX5>&?VK/V#_A5\'_ (N:)X<^
M$OQ/USQ-\'OC'H?QVU72?#_@71[7Q!JV@P>*/#GB&TU[6+6PU6PDT[4&O82]
MYIRHL;1GOOAM_P %B_VH?A_\?_&'P3_;W_97^%GP)>3_ ()_>-OV^_A_?_##
MXOZC\0WT[PK\,]*%[XT\!_$V;5/#^B1Z7X@AFCN4M;O2[5K.)XTM%.HO,+E/
MP*_:E_9,_:H^)'P4\9?#6S_8(_X*J_&3XV_MD?M4_ 3XC?MN?M3?&#P_^S[X
M>^('B_X._!.>]O=,^'GPRT'X9^,KGP9\/;;1M]G+X4TV>#3] M]0LX[JZNF2
MVTZPM?K#2/V=/B3KFG_M4ZC^T7^P[_P6B_:B^+O[3W[.=Y^R0GQO\>Z!^R/X
M5\5_"#]GY@'L/!OP^T+P;\1+#PW)?27D5GJ'BK7M2MFNO&5Q;2C4XXVU'4I[
MLDJKH5I)T_K$:.(H148M4:E9937GAZE!3E&7M%F6-P-.I5K^QH3CEN+J1IQC
M5C1JD/9*M0C)3]A*MAZLVVO:PHO,<+#$0J\J<.1X+!YA4A2IRJ5X/,<)"4FZ
M<JE']4? W_!:KXG:_P" _P#@D=JWB;]GSP9X>\=_\%)+?XL?$7QUX6C\<Z[-
M9_!/X!_"CPGJOCW4_'UE>7'AZ"XU_4+[PC9VE_!:ZE;Z7IRSW#PF[*A)#^8W
M[*'_  58_:(_9N_8,^&_QYUCQI\$_&?Q*_;Z_::_:L^.6D>(OVUOVD-6\&>%
M?@]\#-%\77FA?#G2O"_@71-.\5?%#Q)HFN6GA]K;PUI_@_1+;P[I$[7;ZC>Q
MR/Y->4> _P!D7XS:!JWASQ5\0OV6O^"W7QB\8^ /V*?B1^P[\)]6\4>"?V,M
M$T;X/?#WX@>&6\%0^)?AUX7\.?$2PLM,\0^&O",MQHT7]H3ZC=>(WG.H>(=9
MN;B*%$77OV,O%\6K? [5OA'^PY_P6<^!5Q\)/V*8_P!@[Q)=^#O!/[%_B+6/
MB7\%T;4;RXO(]4\;>.-=7X8^,-8U?5;R_P!>\0^!;6UU.^@9;*VOK(O=75S=
M:RJ8J6';2K2KPHI_\N\)/$8JO2P\U)/KE>1>UK0;JP>9X]TUB(8=T5G2UAAH
MUW=THTJE:VOM,5"C0HU*T'%PC9QS3-O8TIQ5.7]EX-5'1EB?:GT!\3?^"S?_
M  4,_;)^$O\ P2$'[(GPQ\ ?!'Q9^WM\?O'6C^.5N/B/<2W>O:+^S7XXN?\
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M7PHO%^%_PO\ '6B>/XO!MCX ^'/CS0_!][?^,=6T#3X?%WC/6(+S7[NUB6.
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MW['/BW6_"_C.W\0-KVFZ%%^TUJ7CR]^.R?##1-1E5X?!EIKEO:#2;==+B$(
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M_AS^SOI'QN\8>"-4\;0^)/#OA_X>>+O@3':OINJ6'Q@T35X;2'XC:C;W&H^
MUT73QH.H:-J.NK?18SFX4J<^7GJ5,/@ZO(KI0J8F#JU*4FE-WIPBX6BIU74E
M",*4\1*.$GK&,9UZU/FY:=+$8JDJCM[].A-TX5()N*?M)KFNW&FH7DZBHQ>(
M7]1R_$3P WB/0/!Z>-_"3^+/%6AW/B?PQX9C\1:1)KWB'PW9K;O=^(-$TA+M
MK_5-$MTN[5IM5LH)K",7$):<>:F<?P7\9/A)\2->\6^%_A_\3/ GC;Q)X"O5
MT[QKH7A7Q5HNO:MX5OGDEB6UUZPTR]N;G3)C/;W%OMNXXL7-O<6QQ/!+&GXA
M>!/ M[X4_:6_X)8ZIJ/[''Q7^''C#PC^R9XO^$?QP\4^!OASXF\:>&/A:OC#
MX7?#+PI\-_A[KWQI"W,IL/#-WX>U^.\$M]>#PS=K]JURX-U<"]E=_P $ZOV7
MO'_PU_:ZT35?#</C-?@#^S[^S;\3/@;;>,?B!^S;+^SKXT\=^(_&OQB\/>+M
M!T'Q+?WVOZAJ/QRU3PAIWAO6=2U+XG6^A>'- DN=;MY[6VN=8\0ZS..CDC]9
ME14KTHO'Q5=6<7+"/%\E^5R253V.%I:^XZN,7+4_=TXXC",Y/#>VM:I_L3]B
M])6Q*PRG:]KNFZN)J:>_&EAKRIM2J3H?NOX7\>>#?&UUXMLO"7B/2_$%SX#\
M4W7@CQA'I=P+G_A'O%UCIVF:M?>'=1=!Y<6JV6GZSI=S=VJNSVPO8HYMDN^-
M>MK^>#X ?#[XS?$?5/@#X(TWQ)\;/#GAOPG^VY_P4MUG]L9OA)XMO?!2ZYXZ
MT?Q_K_BSX/Z#\3_$&G20ZE'H/B1-4\)WVC6:7%K'K.G-IEO+,='G>*;Q+X?1
M?\%%OB%J'QNL;#P_^V3\'O"'Q#U7]DB\N=-O?$7Q*U'Q9\.O$]W^UA_8_P"T
M%IW@WXA_$664W4UC\#42Y\8:S\.]*TKX?KH+1WF@6DLENET^5.]1X2"24\51
MPM3FD^6E!XBA3J^TE-IN.'<G549VE**^KJI%/$4V])VI_692=X8>OB:5HZU)
MJABJV'Y8POK6484YR@W!33K.FVJ,T?U&45_(9^U=X]_:F^%&L3_LW^)_B[^T
MMX-^'G@"]_:_\;Z7\2I_B9X]B^(_PZ^ 'A_XP?"O3_A=\>]?U+PI]J\;?&;0
MO"OA:X^(7AKPIHWBF^BL=7M[]I;N_:_TNW:3] OV>+7]L/Q)^WWJ/B;QC\3O
MC-I7PSB^)7C#4? FF-X!^*OB;X,_%#]DF^^&VF_\*@@?Q7)KR?!_PKKKWUS!
MXCU76KK0(?B;_P )Q%JND:O)/'J.:JBE65&46HPK4G6BYZ2IQYH04:L-7"MS
M2J.5./._9X;%NFZE7#5J,9J-T_:*46Y4YNFXJ_OM)2YZ;:2E3E!P49RY'&I6
MP\:L:<,11JS_ 'QKS;4_C)\)=&^(FB_"/5_B9X$TSXI>([&34M!^'=_XJT6U
M\9ZQ81)-(UUIWAR:]35KN$Q6]S*C0VK^;%;7,D8=+>9D^-(_A1^V,O[8#>/'
M\:ZH?V=3XIEO1X:/QUA:P&@MH!M4M_\ A5W_  H)90@U8B8:;_PM<[7'VW^T
MV'^@G\[_ -L']DSXD^-?VR-5L/@%)X[F\4_%O]H#]F[XX^-O%?B?]G"XF\/_
M  FMO@SX>MK2Y\2> OVM;W7M/LM'T*[T30K?1)/AAIN@>(-<F\3ZUJ=II]SI
M^F:SK2"%)WP]XNU::C.*UJ4TYTHR<HI-QC"G4J5I3Y9)*A*,E",Y5:6C2MB%
MS*]*#E&3TIS=IM*,G9.4IQA34;Q;=52CSSC&C5_=KP9\9?A)\1O$'B[PGX ^
M)G@3QKXG\ 7JZ=XW\/\ A;Q5HFNZQX3OGDEA6UU_3M-O;FZTN;SX)[<I=Q1%
M;FWN+9L3P2QIZ57\_/\ P3=^#7C[1OC3^S+=3_LZ^/O@5??LV_L>?%3X)?M+
M>*O%_@9?!NF_$_XN^*_B;X UC1++P]XA4!?BW:^?X7\7?$4^-;274M-M[?Q3
M:.VH)JFNW=HODEW^SK^W?X@TVV\0ZG\4/V[[+7_&GPN_X*'>*/&6D:9\4M>T
MK3-,^(OP[^*.LW7[$^@:%I=F\2^%H)]!-K<>&=&T>2*W\=Z=)#;^+?[4LE^S
M&YVA&D[\ZE1Q=6<H:IK"UL1"#IQOS2^MT:,,1AXNS:K4X\TDXU)$(NI.<%:#
M5?"T8JH^6SQ-&E4G[23T2PM2I.C7E%2M*E)N$9<U.'] NO?'SX*^%]8N/#_B
M'XI>"-'URTU'5](NM)O_ !!I\%_:ZIH'@Z?XA:UI]Q;--YL%YIG@:VG\67EO
M*JRPZ#$^I,OV9=]=-X)^)/@#XDVEQ?\ @'QCX=\86=I!HES=7'A[5+34XK:#
MQ)H.G>*- DN&M9)/(76/#FKZ7K>G^:%-SIE_:7<0:&>-F_GH\4_"C]LSXG>-
M4\0_$+X7_$S7)8?$GC+5+26X\-V5K;6#>,?^"8=SX/UY[2.S$ 6WU7XV:A>^
M%669IC'XIF;3(6C@" 9NA^#OVM_!/A#P5X<^)_A/]K'P]^S5I_COX(Z+\4=)
M_9_T[7=.^,\7A'0?V!OAQHOAJP\.-X",/CV?P#I/[0EAJ>E?$&3P[<2ZG;:_
M:6EK?2G0(M04*2=.MC*,W%_5J>7RIS@_W=66*E&-91D[\WL93B^6*O%*7/)-
M*XDITL)5CS+ZPL9*=.27M*:H*,J2<4U:51-I\S7O)<JM>W]+]0-=6R7$=F]Q
M MW-%+/#:M-&MQ+#"T:S31P%A+)%$TL2RR*I2-I(PY!=0?YI-*^&O_!3'6O
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M"E+5+EJ5,+'%PA)R:2;A.G#F^!59J#DN6;A_9'17\8FN?MA_ML^%OCS^VEX
M\$_$#QYXFM?CE\</C;IL_P"S3=_!_P"(MQXJ\#_"76OV!]/\=3?M#?"CXS3P
M@^&_#'P^^)FFZ?H&D^%M)<Z9_;FJW%HT,OB*_MY$I^ O^"IW_!0OX?\ C[]F
M?X&_#^76]4\-Z!^S;\*O 7CW0/C9^S_XNO;ZP\=W?[$+?%/3/B[J_B#0X=<^
M+WC#1;OXE65EIFL>)Y8]"T34=2.J>$K/P_J6OPSWU.5HTI56]8T\NFX)7;GC
ML+7Q$H)WY9*A.E3PWM(.4)5JWLZCH5*->G3<?>E%)KEG];DIMV7)AJ].C&35
MFXRJQG.LJ<U&7LJ7M*:JTZU"=3^T>BOXT/@1_P %#?\ @H%\?=5_8@U+XI?'
M7Q;X*T7PY_P43\(_"[XX>./"/P)TZ/X/_$GPIX\_9_UOQ;X?\%)XS\'LFC^(
M] 3QO9S^& NH>&_"NJ^$O$>O:'9>,!=^(-"AFE^C/^"B_P"S/^VG^UG_ ,%0
MOBE\./V<=4\8^#K?0OV,_@#K'@7XRZC^T)\;O@KX$^ 'Q!U+XR_$1-3^)'AC
MP=\/=%U/PK\<?%T6CZ7#%JO@;Q#<Z=;O9V^G1ZA<FSN3$].G.,J,6D_:XJKA
MGRN[BJ>58?-O:7ER0]ZEB84E&I4I1C43E4J0IM3:A*,XXB2ER^PPM'$MS4N6
M7MLVJ93[/W%.;Y*E*5>3ITZLY4FHTZ<ZKY%_5'17\L7BO_@IE^W[X%^/OQM\
M%'4-(UN_^&NN_M:> M4_9VU#X!Z[IVJ_#;X._ ']GW5O''PI_;?UKXQRL--U
MW0?C!XYTC3-_AVY?_A%;ZT\60>'O#B+K6CZA(OE?[/G_  6(_;3U&P^$WCGQ
MQXZ\,?%W]GO6_B1^P5>_&S]H+P_^S5XM\%>'_A-9_M$?#?XA:I\<O@7+IUG:
MZG)J<GPV\3:+X#N(OB'9P7=S8GQ=::=J,@34;&..:7+6Y73DG"7U%QG*\(6S
M&<H8:3E))*'+%RK5&_9T9J6%G-8Z,\+%S4Z:DIP:G%8IR@G&4D\'%.O&*C)J
M<U)J,(0<IU(6Q,(O!N.)?]>-%?Q6V/\ P49_;EL1XB_:A\0W_P 4_!7C7XL?
MLG?LV>$M%U)/@IK=S\+O!'B3Q3^V7\=_"+>+=3\$^.&TSP/X O+CX=:-X=B\
M1>,/$5GJDFE6UQIMS?>'=2^U6%N?.D_;E_X**?&CPGKWQ!^-'CSQW8:MX[_8
M2^"FN^'?V=]"^$7COPCH/B;XF>&?V_O^%9?$3QEX4N-"@TS7M+\467@?1-+\
M8>*H[%K..[\/ZU:6BZ?#X61%+IQ]HZ$4U&5:OB</*,E).G4PT,?5DK)-N]+!
M1E*ZCR2Q-*+O%2F*4E%2DO>BOJG(XV?.L76P-",DK_#&>,D^:[BX8>HW*$I0
MB_[EZ*_DG^(__!5;_@I%X:\1_M+GP;INF^)?&OA'PS^W(VH_LQ1_LW^+O[9_
M9%TC]GR&%?V</BQX@\?;7D^+=G\?)#9R#1&66QUY-?MY/!0@31=45?V'_P""
M:GQO_:P^)'B']K?X:_M6ZQ9>,M6^"?Q,^%]EX ^(6G_"BZ^$=KXE\+?$[X&>
M!/B?J&DQZ(9KK3M33P7XE\1:MX;BUBQN[FZFAMHX-8D_M*&840BYP5164982
MAC(W:?-#$572A33@YQ=5<LI32DX0490=3VT94T2?))Q>LHXFKA)))^[4HPYY
MR:DHRC3=N6#E&,YIQJ*'L9PJ2_5&BBBI&%%%% !1110 4444 %%%% !17\WG
M_!8?X,_M,?M$_ML?LB_!_P"!'ASQ9XITW6?V:?VJM5U&W3]H;XS?LT?#OPOX
MSM-2^&6G>"_B!X@\>?"+1]9GUCQ'X2NM4GO=!\&:G!"NNV[:@L5Q"L3R+Y+J
M'[9G_!23]F#X]?#+]DW7/'=G\6O'GP:D_8W^"EE\.-3^ _B_Q'KG[<GA_P"(
M'@"*3]H?]J^Q^,-FOVGPKIGP?\0Q:D;RQLD6WBC\+7L?B^&36/$FEQM-*2J1
M@Y>Y*K75"E%VM-?6L1A)33NI6IU:-.511A-1HUU6<O98;&SPU58NDYVM.%+#
M?6*TEO#]QA\1&%E>-YTZ\E#FG"4JE&5-0YJV&5?^IVBOXC1_P4G_ ."D_P 8
MOA=XVTSQM\>=9^'NJ?"K]KW]BS5/&OQD^$/[/4D_PL\+_"#QW\<-=\(>/_"N
MH:[90V'B9-*TJST[0]8\7_#OX@^$+3QWI>A+(GB/7KK2]8V)^B/[;W[8/[=G
M@W]J?]GGQKIFC_$_]F'X?Z)\&?V_X]#^$FO:%X7^+7A3]I3XE_##X;:+XB^#
MNL7=]\.+W7X]%NO&HDN9?!?A?Q(VGZ]IW]GZL(+&6XU&<1DI*%#ZQ)VI\V(\
MVX8? 8?'2E%*[E.;Q'U:G02]M4Q%*JJ<)TX3G$46ZSHKXTH>G-/$5*"3>T81
MC3]O.M/EI0I2A[2<)SA"?],-%?R*'_@I)_P5H^&?QF_90^&GCVY\.^/-3^)/
MPN_9<^+DND6_[.L7@K3/CM%^T%JNH:C\7? 6D3#6K[Q-X9UC]G'PM#!IMB_A
MNVEU#4->C&H_$*UTS3-4LH(OEZ__ ."HG_!2+X_Q?$"T3XQ^,?A5\)/"?QX_
M8O\ B!;?%*P_9R/AOQ1X,^''C/\ :?UOX:_%?X<?$#1O#JZI::?H7A+0K#0-
M:\:^&]:UGQ#XQM+"7[/XEU6WT[66MH='!JK"DW'FEC:N!EKI3JT,32PU:4GL
MX0<YU(S3<9PH57&5^13RE-1I5:SORT\)2QB34N:I3KT*E>A&$4G-U*BC"'L^
M7VD)UJ?-!)5'#^XRBOX_O$G_  4(_P""P;:;XP\<^'O'6@6WAVV^%W[;OQG\
M/^&F_8\U6_N(]-_9(_:CTKX5> O D.J/=1W=[=_&_P !ZU_;-WJ4]F=2BL=/
MCU+P=IY9[N^J_JO_  5M_P""G\GQ,_;9L].^'.F:1<_"/X1_M5^)O#OP0U+X
M0W-SK/PL@^$G@WPOK'P'^)-AJ5G+=^+OB,GQ;UK5IXM3T/7].L]'U*PO(5\#
MM)<Z/J8,7]V[33^HULP<&K36'HJI>Z?_ "\G*E5C"FFY1<'*K[*FXS>\:<I3
MA!6_>8RA@82YER.O7=*SNKOV<(UZ4I5+6ESJ%+VM7]V?UY45_)E<?M4_\%)'
M_:[_ &4?AS\:/C_K'ASX<^$/VZOA-X.\=^./"W[.^H^"O"'Q.\'_ !V_8ML?
MC/HGPY\865LVH6']EZ%\2;_4?AIH&LF\;;XAU#3]0UVY76]%M[9?G_\ X+LZ
M[\:;+]O?XKQ^%?B9XG^']EH?[ _@7Q'\%O.\7_M>>&8[SXS6WQ'^(TTT7P-T
MS]G72-5\&^+?C->6ECI%C!HWQ2C_ .$<D>;1(]2SIDM^ 5&Z?L.975:M.E:'
MOS2AE5/-5)12493J4JL*,*7/&3JM7:C*#E-&*KPJ3C+E4<+0Q,.>T5.-?-I9
M2DW=NG&%2$Z\YRCI1B_=YE)1_M-HK^?C]J7]O+]M#X;?!3X%V]O\*/B+^R)X
M,\3^+_@9X.^(_P"VY\9_"O@OXYOX)\(>*OA%JGBOQ+XQUWX+^"=3OM6T+Q)!
MX[TS2/A]XBN/'6CZ7H>GZWKER]O$LDED8/C;Q!_P4[_X*$^+/VH?"/P2T&TB
MU;X=>*_AK\-+#1[1_@)XC^%-_P#M!^ /B%\!_&/BKXC?M->$G\3ZA=?$WX;Z
MIX1\6Z=:6_AOP=#9W/A[2'M3I7BJ[75-6TK:ZUZ4J\5:;HXF6%5FDIU8T(UT
M^LJ<91G"*]K&%2_M9JFZ6%Q=2A-%JK&C*5Z:JX:&*=XMN%.57V34=HUIQ:DW
M[*4X*U.G*I&MB,-3K?UH45_-)_P1>U_]H36!\6S\5]5^->I"/_@G1_P3\O\
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M_BHEK8Z;-J5UINK?V5/>:3&GF_BS]M#]N#XLZGXG\<^*/'WQ@CTKXH?L:?\
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M5*%.@\,XOFMAJS@ZV*I^][:IR_"X\Y567M5-*\.>A0H<\7[\/959557B]/\
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MQO?7YL;&RLVO+DRW!MK2V@,AC@B5=2OFO_A3WQF_Z.A\:?\ A!?#O_Y3T?\
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M4]\9O^CH?&G_ (07P[_^4]'_  I[XS?]'0^-/_""^'?_ ,IZ/8TO^@NC_P"
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MX9MXXI])U"YCUG4O$5^NK?V[:"Q_>_LG_P *T\#?]"_;_P#@3?\ _P ET?\
M"M/ W_0OV_\ X$W_ /\ )=;0J.#;48/FK0K24HJ2<H5752<7IRMM0DK7=.,8
MIJS;Q<$U9N6E&=%/F?-&,Z<:;E&6ZFN7GC*^DY2E;X4NZHKR/Q/X*\'Z1IIE
MM/"%]?W-U(;*$Z/'=ZA<V4MQ%(L5_):R7T:26]JX62;+$  94@D5PGA[3(-/
MG\#/+X?UC1]=A\36\-QJ][;R:?'K%C>:?K@:);>&_NH$VB* 3V<ZAU\N.=>&
M!K,L^EZ*\TU3X>:*E]JOBJ&X\3/K!L-6,<,/BK5[6V+W<,CE(+<WB6=LZN-M
MI*4"V6XF(QINKQ6SO+-+#PL)M0^)374=CI$WB4?;/&NJMJ4FJ:<+N*'2-2L[
MY;*2:.6*:*XN$+0++)#$#E@  ?FU\:O^"=G[;FJ_&C]L/XL_L]?M$^%/A?XE
M_:(U7PM+\/\ Q]=>*_B$/$_PN\-Z5H_@^PU?P]I6@PZ'JF@6$M[?^&I[[[7:
M375C=6]Y-:S:;!/<S7:-M/V)/^"B?@KXZ?"+XB6W[6OC/QS+XW\<Z=H?[1-_
M'KZCPOHGP9TKQWXG\?WMAX9T#7EL5T.]DT2V\(_#SPO_ ,(OI-_J4=SK?C'4
M=7N$L9H+B+]E=/\ !.@ZE96NH6^J>-E@NX8[B);CQ9XHMYU610P2:":_26*1
M?NO&ZAE8$&N&^$_A.#7OA[X9U;5M?\:WNHWMK=/=74_C/Q&99G34KV)6<KJ"
MJ2(XT084850.U31BJ"PRAJL(Z*H\_OI0HTY452DI73IU:4YPKQLG64I2FW-N
M0JJ5;VW/?]^ZTJG*W!^TK-3=5.-G[2G4C&I1;;5*48J$5"*B?E_\;/V+?VTO
M#7Q$^/'Q<_9X\?>%S\1/BG\3?#NH^!_B/;:QXMC^)6C>"?%7C+P=;>)_A[X\
MTKQ1XF3X6Q_";X8>!M/\3W/AH^&M#O\ QE>:O/HEUIUK9WEMJ<>L<[\5O^"?
MO_!2GQ3?:SK/@/\ ;JD\->*-(U/XBV7@WQCJ7B/QK=:OJO@OQGK7@.ZTW39]
M)BT.3PW\.=0TS0O"3:7=S>&]-\1BXU)KC6;>>!]>U"WM_P!IO^%>:/\ ]!7Q
MA_X67B3_ .6-'_"O-'_Z"OC#_P ++Q)_\L:J%Z<(0BW:%.5*+>ZIRIPI<B?1
M*,97:LYRJU9U.><^8N4G*<JC47*4E.5XIIS7/[S33NVYK1MJ')35-0C!(U_!
MFF:[HO@_PKHWBC7#XG\2Z3X<T33?$/B1K>.U;Q!K=CIMM;:KK1MH4CBMSJE]
M%/>F&.-$B\_8JJ  .EKRO7O!^BZ1IEQ=G5?&HD($%NT7BCQ3>^7<S@QV\DMO
M#J!D>!)2K3;1Q&#DCK7 >$)C+_PAM^FJ>,/[73Q:FEZRNIW?BFTTS4+2ZT7Q
M%,GDZ;KL[1W-L[6D$@?RR\=Q '&W"LU2DY2E)V3E)R=DHJ[=W:*LDM=$DDEH
MM#.,5&,8J[48J*NW)V2LKR=VWIJVVV]7J?2=%>.^)/A_I>BZ7XO\3Z5<^+)=
M;?PYJXB2+Q?J]N Z+-J$;VGG7RVMG/%.H$5SA6CMQ]G#>3A*\WCN=*A?13+J
M?Q+EMK6PM+?7X$N?'=[>WVI3Z9:7T=WIMW!>K;RV:(TXNKB/?&TS*B9.,R4?
MEK^UK_P2G_:H^/7[<>L?M-?#_P#:V;X?_"C5!X U27X-R:M\08;67Q7\._ '
MB/P7HFK20Z1>QZ-%:.WBK5KW4=-B@-KJTJ6%S?Q275E"Z=9X'_X)R_MB6WP^
M_:;T#XL_M,:-\3_$OQ7TWX#Z3X1?5O$'Q(3PGJ>A?!OQ?<>)-;\%^)]*T]M'
MO/ ?@SXE>'9(?A]XDLOA_=3ZE)IGV[7+J_O[R^EL3^O4_@719-*GOK;5_&@6
M33Y;J!F\8^)XY &MFEC8QR:@'C< J2KJ&1N&4$$5SWPY\&6>L?#WP)JVHZ[X
MUN]0U/P;X9U"_NI?&GB0RW-[>Z+97-U<2E=14&2:>621R% W,< # $TXJE3J
M4X:0J-RDG[WOMQ?/:5US6BHM-.,H>Y.,HZ"DN>HJLK\R@J?NRE#]VGS<GN.+
M7O>\I1:G&5Y1G%ZGY/:%^R#_ ,%%K'Q)K/A3PG\;[#X4_!OP#8? V;P5\.?"
MGBSQ/HO@/Q#J\M]+JOQN\*^#O&$]UXW^+^@?#[0K32O"]IX1D\49U34M4U+Q
MSI#06GAK5+22P][_ &)_V0_VT/V>OC7XWU_XS?M70_%CX$ZGX:UNV\$_"JU3
M69(?#GB'7_%[^)9+N0:[92SK+IWVC5B-;BUR>ZU1-972[C3;:RT>SE?]&/\
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M.ZM2HDEADB?A@J,=Q4,9*/8J^>_C?_R-_P"S1_V7I?\ U4'Q<KZ$KY[^-_\
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MKOB*":2VDF?6H+HO/=QSJWD.@_\ !9/PM926EK\0?@K\0(==UK5M9NK'PKX
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M(OC_ %WQE8:)!IT2I!#+I<&L"UNWMHXX+BZ2:XC0"2O?J^3OV//C7\0_CO\
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MV\/^2S^$O^R;M_ZD=W7Z!_LU?\FY_ '_ +(I\*__ %!=!K\_/V\/^2S^$O\
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M &'/ O\ Z8;^OUPK\C_^"6?W_C__ -ASP+_Z8;^OUPK]\X'_ .28R[_%CO\
MU88H_P BOI3_ /)]>-?^O7"O_K&\/A1117UA_/@4444 %%%% 'RK^U]\2_@-
MX,^%=WX)^//[2?\ PROI7QG-[\.?"_Q3T_XFZ?\ !_Q9IGB&]L9;T-X'^(>J
M@Z?X<\4V]G;3W.GWLYR@CD\M7;Y:\&_8?_8@^!7P"\7>-OC[\/\ ]IG]H7]K
MCQS\3_!OAKP'=_%GX_?M%M^T'=V7@+PUJ>HZ[I'AGPEJMG;V>CZ=H[ZOJMYJ
MUP88KFXN;N9I!=)$S1-]0?M4_$+X(?"/X ?$[XJ_M%Z%IGB3X0?#[PU=>(?%
M^CZGX0M/'8U*T1XK*VTS3_"EY:WD6MZMJ]_>6NDZ7IWD_P"F7U]!;L\:2,Z_
MFQ_P3-^.W_!-?XG_ +0'[37AK]BG]G#4_P!G[Q_H5I8_\)KJJ_"M/A1X'^,7
MAGP_XIU?PKJ/BGX>Z3HNIR>&-5T[P?\ $6VU[P5XAU"+0=#U2#7[2:U9;RS$
M<JE&SK54K>V]A*:<+.HJ$83BTX2MH^>NIU*<U)4933IRA&;DZMU1IMW5)U8P
M:E=0E6]I3E'WH]FL.XTYQDO;1A)3C*4%'] O$/[#W[(GBOXT+^T7XB_9X^%N
MK_'1=6\.:Z?BK=^&;1O&LNL>$($MO"VH7.M($N;JX\/VT:0:2URTHL81Y4 1
M"RFIIW["'[&^DV/Q6TS3OV;?A+::;\;X);3XIV$7A.Q%GXMLYM6D\0/8W%LR
MM#IUC_PD,LGB)+'14TVTC\0$:['"FJHEXOUG1222CRI)12G%12M%1J**J1MM
M:HH04U:TU&*E?E5B[<N=M\]X/FO[UZ3;I/FWO3<I.#O>#DW&UV><?#+X3_#?
MX'^ -+^&OPD\&:%X \"^'H;XZ1X:\.6:V6GVLM]<W&H7]V_+SW>H:C?W-Q?:
MCJ-Y-<7]_>SS75Y<S3R/(?RC_P"#??G_ ()8? S/_0^_M*_^M*_%BOV>G_U$
MW_7*3_T!J_&'_@WW_P"45_P+_P"Q]_:5_P#6E?BQ5-N3;DVV]VVVWZMZDI**
M2BDDMDDDEZ):'[1T444AA1110 4444 %%%% !1110 4444 %%%% 'SU^TE_R
M*GP^_P"R_P#[/O\ ZMWPE7N^I:;I^L6-QINJ6=O?Z?=H([FSNHEFMYT5UD"2
MQ."KJ'16PP(RH/:O"/VDO^14^'W_ &7_ /9]_P#5N^$J^A:WG_NU'_K[7_\
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M$47V3ZS_ &>OV8_VK_!'QYTKQC\8_$7Q ^*'A6']G_QEX3A/BOXQV^KV%O\
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MM?96C+V5"-&37N+$*2E[>47S6I4XNI2KT>2HJ\8T*JC.K.JJ7,6'_!67X*?
M3X9:_+^WW\0O!WPG\?\ @[]H/XP?LVWFN>"O"/Q"U3P7\0?$/PJM]$UIO%?A
MG1-/LO&.M>&;/6?"?BGP]J5UHNMZM?'3=5EO["WU6^AACEKC?^#>'5+#7?\
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M?B!%-%%-$_AG4 \4T:2Q.-@(#QR*R, 0" RG! (Y ->H@         8  X
M'  '05FHU?:RDZB=%PBHTN1)QFFW*?M+W::LN5JRM=6=^;)1K>WE-U8N@Z<8
MQH^S2E&HI-RJ.KS7:E%J/(XV5KIIWYEHHHK0U"N$;_DIL/\ V(EQ_P"I!:UW
M=<(W_)38?^Q$N/\ U(+6@#NZ^>_C?_R-_P"S1_V7I?\ U4'Q<KZ$KY[^-_\
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M6(BHX.I)W;J+!1BDE4D>AT445WGIA1110 4444 %%%% !1110 4444 %%%%
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M0/%GC+Q'=>%/"G@+X5)XL\+:_I,VIZ==^(=+\+OJ]K>:=-8PIJ2:9'IR_?\
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M<9>S52YOD=*+3;K).+C%N*3>(7ORMRQ?^SRM%OFDI1<%)*HZ?[R_LU?\FY_
M'_LBGPK_ /4%T&OS\_;P_P"2S^$O^R;M_P"I'=U^@O[-H4?L[? ,(V]!\%OA
M8%?:5WJ/ VA!6VGE=PP=IY&<'D5^?7[>'_)9_"7_ &3=O_4CNZ_,/%__ )(R
MM_V,LL_]2$?C7CS_ ,F^K_\ 8XR;_P!3(GQK1117\KG\2G[+_L:?\FY?#W_K
MEKG_ *D6JU]0U\O?L:?\FY?#W_KEKG_J1:K7U#7]J<&_\DCPO_V3^3_^J_#G
M^B? /_)#<&_]DMD'_JJPH4445](?6GX4?\%I?^/O]E[_ +"OQ6_],7AROQ.K
M]L?^"TO_ !]_LO?]A7XK?^F+PY7XG5_L!]&/_DQ/ '_7GB3_ -;/B,^"SG_D
M9XOUH_\ J-1"OZ&?^"-?_)M7Q"_[+[X\_P#33X6K^>:OZ&?^"-?_ ";5\0O^
MR^^//_33X6KP_I;?\F1S;_LI.&?_ $_C#3(O^1G3_P"O%?\ ]QGZWT445_DV
M?<A7YL?\%0/^2*> ?^RP^&O_ $R^)*_2>OS8_P""H'_)%/ /_98?#7_IE\25
M\WQ?_P DUG'_ &"_^Y:9^T?1V_Y/9X<_]E!3_P#47%'XO4445_/9_L@?JQ_P
M2S^_\?\ _L.>!?\ TPW]?KA7Y'_\$L_O_'__ +#G@7_TPW]?KA7[YP/_ ,DQ
MEW^+'?\ JPQ1_D5]*?\ Y/KQK_UZX5_]8WA\****^L/Y\"BBB@ HHHH \ _:
ME^#GPD_:&^ /Q-^!7QROQIOPQ^+/AZ3P3XCO(_$%OX7O[<ZI<VYTJXT76[EA
M%9:]9ZQ!87NB.4GSJ=M;*;6Y4M!)\=_L&_L<?#'X)?$?XM_&%?VP_B-^VY\=
M+_0M ^!7B?XC_$GQG\.?$&K?#7P%X$U34-;T3X21:%\,='T+1O#]U8ZOJ=WJ
M>MS:U9-XCU6]$,UZ\?E,LG@O_!;7]D+X\_M=> _V:-'^#WP!\*_M1^'/AS\7
M/&?B_P")OP.\:_%S3O@[X=\1VNJ?!SQQX-\!^);C7]3WVU[??#[QWXAT?QEI
M-B+>>9=0TJ"X@\B:-+B+YS_X(@_L%_M5?LD?%3QOXE^./[+WP[_9>\,3_L@?
MLX_ W4K?X?\ QE\,?%,_'3XU?"G7/&MWXV^//BV#PY:V4FG^*?&-EXCMOM]Y
MK:ZCJ]RR&.YUF^*CRWA5SU,3.35&4+TH2E_R]IK!U:RJ0Y^6,7S5*V E[+FJ
MS^N*,92I+%TX/$<T:5",7[2,K5903MR2>+ITI4YJ#<I>[2HXU*JE33PT6XJI
M]7J/^DFBOC[XB_M?:-\/_P!K3]G[]DUOAG\1-7U;X[6/Q!OA\4$TB33?A?X1
M?P+X)U3QK'H<_B&^B$7B3Q5KEGI5R(] T$S2Z/9+_:6LW%K'-9V]U\&_#[_@
MLQH'Q.T'XO\ BKP;\#]/\0:)X.^).F_!SX3Z?HGQ^^'NK>//BU\2/$WQBE^#
M/@JPUCP%;::-6^%7AGQ-KEGJ>KKXL\03:M9V6C:;<$VES?M%9NH^]*,8WE*<
M9RA&*<G+DK1P[BDDVZCK3A2IT_XE6<DJ49W$_=4I2<8QBX*3E**4>>$ZJE)M
MJT53A.<YNT:<(N51Q2N?M=/_ *B;_KE)_P"@-7XP_P#!OO\ \HK_ (%_]C[^
MTK_ZTK\6*^TO@K^VI\.?B)\.]>\0?%RZ\)_LY^-_!GQ1^(7P1\?>!OB%\2?"
M:6FD?$GX<3P+KUAX;\77D^A6'C'1+G2-1T;Q'I6KV=A933:/J]K)>Z;8W"30
MI\4?\&^$\-S_ ,$J?@+<VTT5Q;7/CC]I&XM[B"1)8+B";]I+XKRPSPRQEDEA
MFC99(I$9DD1E=25();37*]&I0A4BTU*,J=6$:E.<91;4HSA*,XR3:<6FA7UD
MM4X3G3DFFI1G3G*G4A)-)J4)QE&2:34DT]C]J****0PHHHH **** "BBB@ H
MHHH **** "BBB@#YZ_:2_P"14^'W_9?_ -GW_P!6[X2KZ%KYZ_:2_P"14^'W
M_9?_ -GW_P!6[X2KZ%K>?^[4?^OM?_TF@9Q_BU/\-/\ ]O//=4LOB ^K7<L6
ML^$1X2:PU!)=/U#2+^2_WNC^0T]Y'?);&UCC)6[4P$RH&*[,FOYC_%?_  7H
MMO"^L:I\/?A#\/OB7XX'P^_M_P"'VN>(?!_P]\0^,O ^FZUX<O;O1%O;6XT?
M2"J7=G?VC_:],ENG6"PA9 ?/V.?ZJ;R3RK2ZEW2)Y5M/)OAA^T3+LB=MT4&U
MO/D7&4AVMYC )M.[%?S:>#_V+_VZOA/\&_&WA3P7I_A;Q%X2U3Q?XI^)G@/X
M@_!77=&\(?&B\TWQ[XHUCQC<Z1XF\#^.]('A?6-4T_\ MC['/);>)-*N+OR8
MXHH6<,:^ARS/,#POPIQ=Q%A_"^/C1QA@*O#>'X9\-ZOBED7@_1S/ X_&XNCQ
M)G,N+N).&^)<KK5L@PT,!6HY L+A\?FD<56JX*K7G@IX.OX.<//JV:\+9;E>
M895P_E.:9Q+"<3<89ODV?<383A/*_JE>K2S.?#'"_P#QD6=PJXV&'P=6EE$:
M^*PM.N\6L+B*=*<5\26G_!S-8>"+_2[;XCZ5XDT:;3+B\T_4=&UWP)XJTN[U
M5'D*6UZ!>:/YS7,4CK+#''<K#);JZ3JK*D=<AX+_ .#CGQ]J7A#P_P"$?@M\
M OC7\0/$$1O+:TO]%^'J#02R7>I3B=([WRSJ%O=->)$/W\;K]GANY(8 LD,W
MU?X]^#?[5_Q5^%Y^$VM_L-?$GXU?&74,0Z'\3?CGX.^$?PY\!>%&G,<-KJ7B
M+Q%H?BCQ ;^32I)4O)SHUI->70BD10B+(RYG[('_  13_;$A^%GAW5O&G[<-
MQ\.+_5H-1DE\/?"3P-X8DT+12]]/%%%:'7M,N9;S^SWCD_?,]LUR\,94)"Y6
MOZW\(>(?HM\4>&U+CGQ>\$>(_ WC[Z_F^54O#+B[QGX?\0<+FGU*>"GAN(\O
MQ_A1X?XO.L-P[BG6Q,,*N*<KX6S/'.F_JV$JX:E[<_$.+L]^D52XAXGX9\.,
MA\->+<!D>*PF'RSQ)S;,/$3@WA;B:CB*=>56OEG#7%' N6<88>K@73H?6J&*
MP?U*4L3&GA,WQ-2EB?8?&^M_\%?O^"S^LZ%J]YX<_9*^(]C"'NGTSQ%/#HD%
M[$IFF=?[3\/6^F7EM;VZ1"U:(0QF2$_:HY9)HY8O*QOV-?\ @OC^V=\4OC(/
M@?\ %Z+4[;QW!)I%J='BT7PWI5HU[;W(AU./4=3AC,L U!VB6UMXHK>26YC^
MS":U@GN%'[76W_!$'Q-XC067Q<_X*%?M7>.=!F21-1T#0M6\/?#^ROU,6Q89
M;CPSI-O?&TE9F-Q +@.4"I%/&"^[ZQ_9;_X) ?L2_LGSV^K^!OAAIGB'Q9!+
M)>-XR\;0KXC\3W.I7$@DN+^ZUG43<7UQ(VU#;I+.RV3AY+0Q/(QKV>)/%/Z)
M<>!.)<LPOA%D-7CC%/#+A7,^!Y<:+*<LC"I3>(K9UF/'^-IXO'5*M.%2#PF6
M<,Y72C*JJM/&1]FZ=3V?#C+OI#?VAB:_BMF_AK_9OLE]2P7!6$XB6+]LZDG)
MXO$YOB9TO90I<D(>RIRG4J*4Y.G&T']F? 7Q!X]\3>$K+6/&<UO=R7\;W!N$
MLWTZ2.X;RS):?8I9KB1%MI#)"6\TH=N03D =YXQ97O? ;*<@^-+3!P1TTC6A
MT(!ZCN*Z^RTZRTZ/R;*WCMX@7*QQ*%13(5,FU1P-[*'?U?+=ZY+QG_Q_>!/^
MQTM/_31K-?P?BZT,1B*M:G2A0A4FY0I4XJ,81OI%*-HJRLGRI)O5);'[O%-1
M2;;:23;U;?>Y3UAOB#/J&I6?]F^#)O"$VF:I&\]Y?ZI'J3L]O(EM%<0"W:S6
MVD5BM[(9<H@8QJP/'\L7Q$_X.4?A;\+O$#_!OP+IK^*]:\%W6I^"M:OM(\(:
M[>Z/H6H^%-2N='N[62:W$T]PX_LYT@OK>UELCN$(MS(XGC_K5U29;?3=1G=H
MD2"QNYG>>,RPHL=O([--$"#)$H4F2,$%T!4'FOY)_A3_ ,$]_P!J+]E/PG\4
M-2T']EKP-\;['XC>-/&?Q,\)_%WX8S>"]8^)^C:?XTUK5/%-C:ZM\,_B)#IE
MEJDUC#>_93#HFO\ G2#RHXH/M$BY_6_"Z?AME^1>(O$/''"'$'B5GV193DM7
M@3PRX:XWX(\.<RXOS#&YG4PV;R7%WB'*GPS@Z61X%T<QJ9?4J?VEFD.>CE=#
M&8FFL'7^&XXS3B_+H\/4>$LJRW&RS7/\-EF=9MG-?/(Y3PIE%>C7G4XBS+!\
M+Y#Q3Q3F>$P]>E1PU3!<.\/9MF3EBH5EAEAJ6(K4I/!/_!T'\'?%E\$U/2M2
M\(W>FQV_VG1=>T&]M/M*1WEC!J=W=3M K1(MO-<26:J(E,A4SO#Y15_U<_8G
M_P""D?PU^-_PM\-3^%+G2;BVM[B_T9XFN?L<]MJD%[>7LD%PTTDL8L9;2>V=
M;X8)FN(XUBP'*?SJ?M(_L(_'']NWX?>'OA=HO_!/KXC^%OCSJ^HM-J?[0OCG
MX=:#\"/ OABPN!Y]MJ&OZ)I>O:[?ZK<Q1>9;RI8PQQS7S(K>0B3%OV+_ ."3
M'_!(+1?V:?@1\.KWXG7UCXP\8Q'6-3U0&2YNK.XN+Y$TI;++RDC3X(89 ,7$
M\L!B0V\A)^3]4X\RCZ/6*\+^$^.,AR7C7PQXXX@Q&=T,V\&.,L^X'XSXEX6H
MY96P^'P>98CB7P_SG,,DQ65Y[56*K91#'4\ISN.#4,1C\LPRJP@^3A#.^,,R
MQ_$>7<093@*,,@SJKE."XCR>?$/^K7%V%IT:%:.><-T^,.&N#>+:>6S=:6&<
M<_X4R3%+%8?$1HT*V&5+%UOWCT7Q7=:_I<&J6J-!%)#$JND4E]$[SR$"Z$<4
M<;M9)M3R;F-V^T6\HG\I5&\==%=W$I;<OEHH38P7+32_*?+(+;$+$NC1[BRE
M00XY ++1M/L;.*QMK6.VMHH+2W6WMFEB@CBL8TBMHXE\PE$BCC2, -\ZJ!)N
MK26-4:1AG,C!FR21D*J\#L"%!('4Y/>OY.JRIN4O9PY8\S<4]6E[MKOKL[WN
MM=$KL_15LK[]2.%Y&WK)]]2"3@#A\D *"?E7&%)8LP&6 -<AXP_X_O G_8[6
MW_J.^)*[:N(\8 _;_ ASQ_PFML-N!P?^$>\2'=GKTXQT[UB!R7C.7Q[+HOC>
MWU72?!;^%3X5UKRIY-5U*.\FF\F8;+R&6T%M#;?8]TC2"8N+E0BCRR''2:7X
MGTW2/#&C27C^5!:>'M-:9R5C+-%IUFSI;"9HEG"B6/<ZN$RP 8YK1^(#Q)X&
M\7O-+9P1+X<U@O+?VYNK.-?L,^6N+<,IFC']P,"3CZ5_,1_P49_9@_;_ /'/
M[0_P/\0^#/BG\:-!_93U[PA;:1\1Q\ O#MUX@U_P;<PZ9&]C-J=M!IUU?_V'
MK%H1'J]YI=C/)8W4=I(R30O(\/W_ (;\&Y=QSQ#/)LTXMR7@S"TLJS?-9YKG
ME+-,31JQR?+L3F=3+L!@LEP.99GF.<YA3PL\)D^5X+!UL7FF95L-E^$IU,5B
M:%.?@\39['AK(\RSR>69KF]/+<-4Q53+\DP<LPS3$QII-T\'@X2A*O6E]F//
M"*UE4G"G&4X_T_S^(=&O["_BM;^"25K6^@6,.N]YH[1I)HHQD^:T"NGFF(NB
M%U&X[AG"^$DF_P"%GPS9!E3X!\([B<JR$>'M.X*$9SG((XQC/.17\?D_A[_@
MH%\'M1T;QI^S#\0?VQOC=?Q_$2&TU[X'_%;P.FI7OBGPK=J8=1\:6/CO1;*S
MTWPRFD1N-4:P\3W,%I?6D?V*_M"I41_UL?L[-XEF^!/PB/BNPAL-8N/AMX'D
MOK&&Y\Y;)Y?#.E/-;R3JS%KB.1Y$<1,T(*8C=%(5>?B/A;)LNR#A?BOASBS#
M<39!Q7#,_J<<3P[QCP/Q-EV(R?$TL+CL+GO!/B%P]PKQ;E5JE:F\%CZV42R;
M-J:JRRK,\;+"XR&&G(L]GG$LSP^(RC,,FQ^3XV. QV$QM?)LQHJM/"8;&TYX
M#/.&<VS_ (9SK#3PV+HR>*R3.\QP]"NZV Q52AF&$Q>%H>W @YP0<'!P<X(Z
M@^A'I2T@4+G  R23@8R3U)]2>Y/)I:^(/H K@?$YD'BSP 8E5Y1=>)C&CL55
MY!X=NBBLP!*JS84M@[02<'&*[ZN$\1_\CC\//^OWQ'_ZC]S0!YYX]U;QC<>%
M/$(\4>$]-TK2;+4_#<UGJ%KXL,DDT$>LV,MQ=S6\5G"P^R21IBRDE*7J/EBH
M5E&U+\=_AIY^J6EKXO\ #MW?:0+Q[FR&K6<,SPV<Y@FN(V>8_P"C0R@Q33F,
MIO1Q'O\ E!Q?VH])U;7O@-\1=#\/RZ1#XAUC1X],\/S:W&\MA#K=[?6MOIDS
M1QRPNTL5W)'+"JR+O=!&2%<D?QP:9_P2\_:+\#^)?BAXL_;7^&?[4OQ.^,5Q
MK>N:UX.^+OP/\:>)->^%FJ:)<7D]S]A/A;X:W$GB/PL8K>-[BYTQ/#FHHCM
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M?_DF,N_Q8[_U88H_R*^E/_R?7C7_ *]<*_\ K&\/A1117UA_/@4444 %%%%
M'R_^V7X\^+GPS_9N^*'C;X''X31_$?0_#]S<:)<_&SQO=?#SP!9!HWCN;R_\
M4VFFZJUGJ5M$_F:'!<6JV=]JPM+.[N;6"9YT^4/^".7QN_:;^/O[#/PB\>?M
M6:K\*=?^)ESX8\/17&O_  W\>'QOK>KJVBV<]W=_%6*#3+#2_"GQ(:]EE_MO
MPQH\NH6-@/*VW0D=X8_%?^"Y'PR^$OQ%^!WP,N_BI^TY^S=^SP/ 7QULO&/A
M+0_VPM _X37]F3XV:]%X0\2:/+X!^*G@%/$'AJ?Q;!IVFZM=^+/#EK#J3&P\
M0Z+8WSVEQ'&QC^=O^"&?[,O[''P&\<_$VX_90_;B^#W[2S6_[/WP8^'OC_P#
M\$+#0M"T.+Q/X>\0>,M<UOXT>-],T36-2CU#Q3XGU;Q!-X.\-:E/!;WFF^ _
M#6CZ'?WFJW5N;A%A5S2QW/=KFI4X+^)[.-'#2Q#K)1^!5*E58::E[T+PK24J
M4HRIO$:1PG)O%5*D_L*HZU>&']FW+2?LH4G7A)>[)\]&+C44E/\ :_XM?L_/
M\3_CC^R_\9%\5'1!^SEKWQ7UMM"72A>OXJ/Q,^&&K?#E84U%KV :.VBMJ?\
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M3X??]E__ &??_5N^$J^A:^>OVDO^14^'W_9?_P!GW_U;OA*OH6MY_P"[4?\
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MURXLK+P-IOC231K[QI::_::E87GAN_\ #D&HVVMVMW#+9-(&P/T._:0_92^
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MR'-\'FKPL82Q#P=3VL:*J75/VDDN6+G:7+%N\E&32:39](T445^3'T(4444
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MQ1_PM'XZ?]&P:]_X=?X7?_+BO1^K5/YL/_X587_Y=Y_GV9\;[6/:K_X)K?\
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M8?";PMX\\/\ B7Q#XE\;?%+Q=XP\4>/?"5_K&GQ>-=<NXOB/8P>'9=3U)_\
MA&-3\ ^%]:A:\<7-K5#1/^"*OP6T7PPGAEOB%JVLE+#Q=IXU_7? _A34?$7E
M>+!\+M#++J;E)(CH?PZ^'6H_#_0HH%AM=,TWQEJ=[9V]O/8VL$A3LU^\;C*,
M-=-*E2$;2<;.;IPK2M.'-SNE&\)\[:DG+22LKQDT[IW=*,Y-VGS<GM)48)1D
MX656<N:/LXPM4_5S0_C%\)?$VL^-/#OASXG?#_7M?^' +?$#1M(\8>']1U/P
M2HB>9G\5V-IJ$MQH$<<<4K2R:I':I$89ED97AD5>4M_VG/V;[S3?#FLV?Q^^
M#-YI'B_Q+<^#/"FJVGQ-\&7.G>)/%MD81>>&M#O8-9DMM4UNU-S:BXTVREFN
MX?M=IYD2_:[?S?RZTW_@E7XY^%/A+]L[7_A_\;KGXA?&/]I[X.ZY\#_#VI^*
MM(E\.V7@_P ->+_&/B+5-9\0W]R_B'Q#:ZCXCMM*\77<]RFC:3X8T34KCPYI
MD<&CV<]Y<W!YWQ)_P13B\87GA"]\0?M(WEM';>)=(\5>/=!\)?"K3?!O@S6=
M3\-:IX".@+X'\(>'O&%AI7@Z&7PE\.]!\%^(8=:'C>TUBR275H[*QU4QRQ*G
MK[/G3BG3H.I:S<:DJU15XI*3;4:$*=2#2:<ZR@W>G,':T^5^\I55!232E%4J
M+I2;2=E*M4JPEM)0H.7(O:P:_2OPK^W#^RGXRLK_ %K1?C?\/1X6T_7;WPI/
MXQU7Q5H.A^%6\7V'C+7_  '<^$H=6U?4;)9?$0\1^&=:MH=.6+?=V]E+>6CS
MVZ.Z;OQ!_;!_9=^%T?B ^-OCW\*M)O/"FN>$_#?B71U\;^'K[7]!UWQQXIL/
M!7A;3-7T&PU"XU;3;K5_$^IV6DP1WEI!LN)AYQC168?E5XA_X(:>"_%C^!M0
M\1_&<:MJOAF]GT[6[:3X<?V7X7USP3J%C-::S90Z!X9\<>'VM_&6IW-_XAU1
M_%FIZAK5DMUXO\2Q3^'+N"ZA$7O5A_P2?\":+XD^%_BC2_B##<7_ ,/?'5IX
MXU:#6?AQX<O[;QW?7/QJNOC%XG/B247L=Y<WFI3Q>&O#VC7MQ/>/X<LO">F3
MVZ7+2RP(X6<J*GI"56$*TUJX4W[/GJ\MMDI3T@ZDE)<JC-14ZBFVHUI4XW<8
M.5&#:]^=Y*-/FVN[1;E+V<7%MWC+]W'](]6^,OPBT'Q9=> ]<^*/P\T;QO8Z
M$GB>^\(:IXR\.Z?XELO#<D\5JFO7>B7>HQ:C;:.]Q/#$NHS6Z6A>6,"7YUSY
M]J/[6?[.^E_%&W^#=[\6/!4'Q"OO!5UX\TG0W\1:.AUS1+'6=?T&^@T*YDOD
MM]8UJQU+PMX@BOM%T^2?4+%-*NY;R&!(F(^!?'W_  2.\&?$7]H/]H3XY:G\
M6=0B3X_V6OV=[:_\(O+JGBOPG#XW\#^'?A?XXL/#WB74_%USX:M[!O ?A^[T
MOP<5\!)J'A74O$6I:H][JLEE80+/J_\ P2+\#:QX1L/#<WQ:U2#4](T3X1>$
M='\4V_@#PTFKZ9X-^#/P^\;>#?#NB6K_ &W?#/K&O>-[[XA^*M2MYX'USQ8E
MQ/<6X2_G983DX4Y-<LFJ?M8)IM.I&NI\LM(_[-/ZO+[7UB'M>7V,N6)?NWFK
MNR<^25M'R>PE&\;W_?Q^LP6J]A-4>;VL7.2^O?#W[=_[+_B?1/B?K.D_$[0W
MF^#6HZ=IOQ+\.W-_IEGXI\*-JD>D26U]J.AW6H17(T?9K5MG6(R^FRO!>Q6M
MS<2VKQG:\"_MK_LM?$32O#6O>'?C=\.TT'QP?#:> =9UGQ=X=T.S\?3^*K.R
MO-)L_!R:IJEM>:W?E-2TV&ZT^"U%[:W.I:?!) 'O+?S/SA'_  1=TN[L]3TS
M6/VA;NXTZTNO&TG@M=)^#_A#0KZSM/'>LR>)]1M_'VHP:M<7'Q&FTK7=/\')
MX=N-2^P1Z1HGA&'38+4S:K=7L/2K_P $=O 9\/>,XM8^(TOB#7?%7AOPYH"G
M3? OA[PG:Z)I^A>+? ?BO5-'\%307.I7'@Q/%5K\+? ?A&75[!IK[1M'TJ:Z
M@%W<7;Q)2:2O)._)!NU])QC)U%HI-JHU!0Y5*5'FG=8BT;S9N22:LYS5]_=;
M@H2][D7N)S<E)P55J*YJ"YIGZD:+\>?@?XCB\8S^'_C'\+=;@^':Z@_C^;2O
M'_A6_A\$1Z5/<6VIR^+I;7594\.0V%Q9W<%W-K#6<5O+:7,<KJUO,$YZR_:E
M_9GU)-:EL/VA/@G>1>'-!MO%/B"6W^*/@F6+1/#=Y<I96NO:K*NMF.PTB>[E
M@MH]0NFBM6GN;6(2[[JV$OY5?LM?\$S?B;+\%?VA/!/[3E]X-\+ZC\9]#^!_
MP6TS3? VA>&+^]L/V<_@2UK(GA+Q=J.BPZ;I7B;6_B7+=^*H?%&O.#>R6VO2
M7\T$-ZSZ?%R7QA_X(Y^/M>^/7_"Z_ 'QST2[NO$7QAC\03Z)XT^&UCJ?A+P)
M\.U\8^%OB;%I-SX-;Q3'X9\=0:5K/PW\'_#_ $SP_I>B^!K>Y\(7,VH:O?7F
MKZ?'/(--5*<+WC4A&]1)?NZDN50YXN:2B_:TW47/^X='%0G4DE1JU#1PJ26D
MJ=1I4Y<R=2G'6;A)0=VG3JPIR<4ZWM,-4C37-5IT_P!9?%?[8/[-7@C1+_Q7
MXJ^,OP]T;P79^$-+\;6WC>\\8^&4\)Z]I&M6WB&^TJW\,ZS_ &N8/$6KZA8>
M%M:OK'2])%S=7UK:F2S6X.Y5]$NOC3\+=)^&.A_&/Q5XV\/>!/AQX@T7P_K]
MCXI^(&JV'@K3(;'Q3:6MYH::A<^([C3X=/O;Z*\MTBL+J2.Z-P_V<1&8%*_(
M;4_^"*NC_8;^W\/_ +0]_;WGB[PCXE^''Q O?%/P?\&^,;>\\!>-]$TBS\8V
MG@31+W5+32/A_P")=0U>'Q;=Z1XAL;;4%\.Z1X]UK1;+3I%M+:\E^T_CM^R)
MX^^._P +/@MX<D^*GA;X?^/_ (.^*-3UW2]6B^%VF?$;X>SV.H>%?%G@"RM+
MGX=>*M8L["]U?PYX2\2PS^']:NKYTT[Q/IQU&.P:UNVM8LYRG&G-QASU>>BH
M14ERQA*I459RE)0=10IRHRA)*DY<E6+I)\LI.-I3@I/DARUG.33NY*G2=&T5
MS.'/45:,XWJ*"E2E[27O1A[3\//VNOV;/BAH%IXB\+?&7X?FUN_!VH?$46.L
M>*=$T+7+7X>Z;J5[ID_CO4-$U2^MM3T_P?++82W5KXCO+>'2;G3I;748[HVE
MU!*_7:9^T)\!=;OO VEZ/\:_A1JFI_$ZR.H_#C3=/^(7A.\U#QY8 WJM>^$+
M&WU:2Z\16JOINHQ-/I,5U&LUA>PEA+:SI'^+<_\ P0*^%(LO'^EVOQ>U)[/7
M_#'A?3_!MU?^%M7?6-!U_0M+^'FDZDOB*YTOXAZ3I>O> M<L/AW!IDW@S0]%
M\(7D&D>(]:L/^$FF-OI\T75_";_@DSX\^''Q)U3Q'8_$?P/9>%/ >J_"[Q%\
M+](_X5]!?:IXK\?_  VT_P 3>-K#Q?K'BK4/$.K>*O ?@Z[^-OQ*\8:[XC^'
M>DZIK-SXHTS1-'6Z\2VK:A>JVON\T=VKQ<_[M/GJ*I:5ESU(P=%0BH)U9<TN
M6%-S>&6O+)I>_P M104FDG-1H^R4FN;EA.3K.<WI345%<\HP>(_=FBJFGI>Q
MV%E'J4\%SJ,=I;)J%S:PM;VUQ>K"BW4]O;N\KP02SB22*%I9&BC949W*EC;H
M:LVKIV=KK9^:O9V^0D[I.S5U>SW7D[75_F%%%%(84444 %%%% 'XZ^,?^">_
M[2</_!22;]NWX2_'GX0^']&UBW\.^'/$O@_QM\+?&/B7QGJ'PYB\-Z)X=\4>
M +7Q;I?Q&T/1[?07N-';Q;X2MI/#<T>A>,-0O=6NUU%9GA;X1_;,L->U3_@H
M)X[\4^&/B9^U+HOA[PY\:?V,?!/Q&^+OA>RT34?@1\%M/U'4?"VJ/^S]XC\.
M:KXTM?$=[IGQ*U74/"OB.[^)7PP\)VFL>!-4\87VD>+K_P 1>'=4N[&V_IXK
M^:;]J/PG\-=4_P""AOB>[U[]E/P1XJ_:%;]HO]D6^^$*WOPD^-FO-\5?@UIF
MF:6/BA\5M=^*WAK5X?@[X7UKX9W#W%WI&H>,4LV\'VOP_AMM3T[6/^$DL)4*
M#<<9ED$TH4<3!QTO)*IB,/&<4M/:0<95:E2ES1YH2Q-6HJF'>.I5BNN?!YG/
M7VE7"RBW=*+<*%2,).SYH37)2A"K"$FIQHQAR8A86I2_5W]N?]CKQ3^UA=_L
MZ:EX3^(&C^!K[X%_&*S^)TO]N:-J>LP7Z6E@\=O/HRZ7JNEOIWB?3[V&W33=
M3N6NK:'3;_6H3 )KB*1?B;]NW]A;5]-_8\_X**^-8OV@/BW\,+KXB:1\6/VD
M/$&F_ WQ.WAJR\4:S;?LX:?X0\2^ _&\WBW3_%UUK/P[U_5?"USJ0T'27T!K
M2QU'[#;W$(C)/[II(DJ))$Z21R*KQR(P='1@&5T=25964@JRD@@@@D&OCG_@
MHE_R8/\ MH_]FM_';_U6GB2B/N1G&.TY3E+O>I]7<TGORR>$P[:VO2CV0Y2<
ME&]FHQBEHOL.JX-]W'V]51?15))?$[^Z? IMWP1^#C;57=\*_AZVU00JY\(Z
M0=J@DD*,X ))P!R:]4KRGX$?\D/^#7_9*?AW_P"HAH]>K4""BBB@ HK\./@W
M^U'^T-JO[56@>"M2U_Q7XV\'W/C+X@Z=J/AVWB\.VS"QTJ#Q0UC:+%<Z=I\@
MCT\V-E.DYU.%G$*Q.[M(=_Z\#XL^';8E=?TOQ?X593@MKWA75UM1S@%M2TN#
M5-+1<9;<]\JA02Q %?/Y/Q)@,YH5Z])5L+&ABIX67UN,::E.%.E4<H5(RG2<
M6JL4ESJ5T[Q2LW^O^(_@KQ;X;YGE.5XZIEV>U\WR+#9_07#U:MC:E'"XG%XW
M!PI8C!U:&'Q].M&I@:LFUA9473G3<:KESQAZ?17+:1XX\&Z_C^Q?%.@:FQQ^
M[L]6LIIADX :!9O.0YXPT8.>,5U ((!!!!Y!!R"/4$=:]Z$X5(J5.<9Q>TH2
M4HOT<6T?D^(PN*PE1TL7AJ^%JK>EB*-2C47K"I&,E\T+1115& 5YYI8_X13Q
M5<Z"WR:'XIEN]7\/G@1V>M*#<:YHRX&$2[7=K5C'\JECJ<:+^Z&?0ZYWQ3H9
MU_2)K2&;[+J-O+#J.C7P^]8:Q8OYUA=#@Y191Y5PF")K66>%@5D(/)BZ4Y1A
M7HJ^(PTG4I1O;VL;6JX=MZ6KT[QBW[L*RI56G[-(X<=1J2A3Q&'CS8K"2=:C
M%-)UHM<M?"MMI<N)I7A%R?)"NJ%>2;HI%#Q_X0LO'?@WQ%X5O8K1SJ^DW]K8
MW%W#YRZ;JDMK-'INK0[<30W6F7CQ7EM<6SQW,,L0>"1) &'Y6?\ !-3]D;]H
MW]G#QS\5M4^+^J7(\.ZMIZZ+91WOBU/%=YXRUJ'6GOH_%\\D;,\2V^G-):17
MNI*FLW@O&AN_,^SN]?K'X7UW_A(-'@O9(3:7\4DUAJ]@Q^?3]7L7,&H6;\DX
MCG4M"Q_UMO)#,/ED%=#7Z)PWXEY[D?!'%G!>6QRZOD''4,JJ9B\;A)5\7A7E
MM9XFC5RVHZL(82K6YE3Q3JT*SM3IRIJC7I0JQ2HX;&SP>80E-\D'4HRBW!3A
M6BG:I%KFNE]E\KBW*,END4445\,=X4444 %%%% !1110 5\H?MF_LC>$_P!M
MOX)ZI\!?'?Q-^-OPP\&>(-3L+SQ+?? GQ^_PY\3^)-*LA/Y_A+6]:CTS5'O/
M".KF9?[;T7R(X]26W@BFE$2NC_5]%3*$9KEDE*-XNSV;C)2C==4I)-IZ/9II
MM%1E*#YHMQE9I-:-<R<79]'9NS6JW3329^-_[3/[-7CC]EC_ ()L^)/@+^SI
MJ?Q%^,=KI_B[X?V+KXVN?@C?>.O#7PEO/'/A.#QCI_PX;QIX<\'?"'3M=\-^
M&;*]G^'\WB;2)AIOB:YBU;SKW58[1EWO^"56D_&#3Y?VK;KXE^"_BGH&@7OQ
M9\*0^!O$W[0NI?!'Q%^T;XK?3? &EV?C&T^+GBWX'N=*\17/A3Q /[+\,3>+
M8U\9:?H4T>G:D\UK!9,/H?\ X*.?!W7?C;^RQXH\->%-"\3^)?%OAOQ=\./B
M9X4T+PKI7A;Q-=:EXD^&OC?1?&&CP:KX(\::WX;\,_$#PZ+W2HI-<\$ZEX@T
M5M=L4DBT_4;;5([)Z^8_^"7^F?%;3O%_[1GC#XH?"+XT>'/&OQZ\96'Q1^)_
MCSQS\&?"?[-GPRD\8:)X?T7P-I6@?#7X16?Q.^)GB_4=3O\ 1=*.L>-OB%KU
M_"?$NKHDDDTQBMD6Z,I3K8V51N4YTI+FJ.[DD\ME3Y)*SLUA\5S.I=*I%J,Z
ME7%J%)55&%+"1@E&$9I.-/1*3>,4G.-W=KVF'45&UX--TX0PKJU/I_\ X* _
MLZ?%']I[X/\ A+X=_"F]\%:5J]A\8/AUXQUW6/&7B_X@^#9M*\*>%M8_M+7+
MOP7J7P^L=3G/CUH$6V\,R>(].U#PU87$\NHWEG-=6MF4_)KX[?L'_M<_!/\
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M9_\ 3^,-,B_Y&=/_ *\5_P#W&?K?1117^39]R%?FQ_P5 _Y(IX!_[+#X:_\
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M?"?_ -16PK^6?XO_ /)(?BQ_V3+QY_ZB^J5_4Q_P2C_Y1J_L-_\ 9LWPG_\
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MI_/1I%I_P5PUI=<\:Q1^)/!7C:V;X:7\'AJS\+^!++P]\4?&Z^(_!/@[4/\
MA.+K49=4FT;P!H_@GP1XZ\0ZY;>'VTNYFF^(F@%;LOIT8KQR/Q9_P61U;X+^
M(8OB _Q^DU#X@/\ $(Z7_P *F^"?@W0_B3X2^*]OX"LT\.>#KBV\7^(;VUT;
M]GK5/&VJZDS>,S!!<Q6WA:*UTC4I['6X;R?^GJBB24U4C.*<:BY9):6BY0;4
M-^5VA&*T:BHP2CR*<*BA>$HR3;<&G&^NL8M1<NKU=W:SES3YFY.$J?\ -?\
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M/]8?RK#Q?H3S][:XOHK&Z!SMVM:WQMK@-NXVF,-GM7YU_P##R_QQ_P!(S?\
M@I)_X9;P+_\ /4K'U3_@H=K6MKLUG_@EE_P4.U9<;0-2^ OPZO<#&/E-S\3I
M"N,\%2".H(-+DQ<?AKTJB72K1<9OUJ4ZB@OE0?H)8GA^M_&RO,,'.6\\!F5.
MKAX;:QP>.P=6O-7O92S-.VG,]S]'-4O+7PCKZ^*3<00^%?$J16OB.[,T:V.F
M:I;1E-+\03W!/DP6EU;H=)U.X=TB5X],FD=5CE8[N@>/O WBJZEL?#'C#PSX
MAO8(/M4UIHNN:;J=S%;;UC^T20V5S-(D'F,J>:RA-[*N[) /XN_$C]JL^+/
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MJY^I5%?EK_P\7^,G_2+;_@H)_P"$Q\#O_GV4?\/%_C)_TBV_X*"?^$Q\#O\
MY]E>Z?2GSE_P6E_X^_V7O^PK\5O_ $Q>'*_$ZOT9_P""@_Q7_:L_:LF^#,GP
M]_X)C_MMZ?\ \*]OO&]SK7_"3:=\%],$T7B/3-)L[!; 6WQ8U'SGCFL)FN/,
M:()&T>T,<U^6WQ-L/VMO@U\/_%_Q4^)O_!/C]JSPG\/_  'HEWXD\7>)+N/X
M57-MHVB6"AKR_FM[+XA3W<T<"L'=((9)-H+!< U_IQX >+_AGPSX/\&9%G_&
M>2Y5F^7TL^CC,OQ>(=/$8=XGBK/,9052'(TO:X7$X>O#5WIU82ZGQN:8#&5L
MPQ-6EAZDZ<W2Y9Q2:?+0I1=M>DDT_1]CL*_H9_X(U_\ )M7Q"_[+[X\_]-/A
M:OYZ+/X8?MSZA:6E_9_\$W/VLY[.^M;>\M9@?A$HEMKJ%)X)-C_$973?%(C%
M'574G:P# BOU8_8"_:!_:<_9:^$'BCP%X_\ ^"8?[<E_K.M_%#Q/XSMIO#>D
M_!74K!=*UFRT6VM(I9KCXN:?)'>QOILYGB$<B!7B*OG<*\CZ2OBQX<\6^$V8
MY)PWQ?D^<9M6S[(,32P."Q#J8B=##5<3*O54.5>Y2C.#F[Z<R\[7D^!Q=#'P
MJUJ%2G35&K%RDK*\N2RWZV9_1=17Y:_\/%_C)_TBV_X*"?\ A,? [_Y]E'_#
MQ?XR?](MO^"@G_A,? [_ .?97^;Q]>?J57YL?\%0/^2*> ?^RP^&O_3+XDKG
M/^'B_P 9/^D6W_!03_PF/@=_\^RODC]LC]I_]I']H/X=>&?"?@W_ ()@_MUV
M>IZ-X^T?Q1<R:YHWP3L+1M.L-.U>UN(XI(?C!>O)=/)?PF)-B+M60LQ.T5X7
M$V&KXS(<SPV&I2K5ZV'Y*5*"O*<O:0?+%=79,_5/!#.LJX=\6.!L[SO'4,MR
MK+LZAB,=CL3+DH8:BL/B(.K5E9\L%*<4W9[H^.**\OU:Z_;#T'2=4UW6/^";
M7[8-AI&B:;?ZOJM]+;_!]H[/3=,M9;V^NG2/XG/(ZP6L$LI2-&D?;M168@'G
M?AWXV_:B^+/@/P?\3OAW_P $Z_VOO$W@/Q_X=TGQ;X/\0VUE\);:WUOPYKMG
M%J&D:K!!>?$N"ZB@O[*>&YA2XACE\J1"R*3BOQ/_ %6XA_Z%&,_\%KR_O>:/
M]1O^(^>#G_1P^'.G_,6^NW_+OS/W*_X)9_?^/_\ V'/ O_IAOZ_7"OYT/V+_
M -H']IW]G<_%$^-?^"8?[<EX?&FI>&KS2O[!TGX*WXBBT?3+JRNUO!/\7;/R
MI'EFC:'89 R!LX.*^[[#_@H?\8;R_P!/LI?^"8'[?EA%>W]E92W]WX9^"*V>
MGQ7=S%;R7]XT7QIEE6SLDD:ZNFBBEE$$4ABBD?:C?LO"6$Q.!X?P&&Q=&=#$
M4WBW.E45IP53&XFI#F73FA*,U_=DF?YG_2'XAR7BGQ?XKSWA[,<-FV48VGPZ
ML)F&$G[3#UWA>%LEP>(5.=E?V.*P]:A/16J4IKH?J!13(V+HCE&C+HK&-\;T
M+ $H^"1N7.&P2,@X)'-/KZ0_%0HHHH **** "BBB@ I"0 22  "22<  <DDG
M@ #J:6OS=_X*I:G-IG[+NF#5-5U30OA9J?Q\_9ZT3]H+6=+U'4M'_L_]G_6/
MBKX<L?BA)JVLZ/-;ZEI/AJXT:9;+Q1J%M<VRP>'[K4OM-Q%9M<.$WK3C[J=2
MM1HJ4Y<L(NO6A14ZDDI.-.#FIU)*,G&$9-1;5F^DY-2:A2JU7&$>:<E1I3JN
M%.-X\]2:@XTX\RYIN,;J]S]')F5K>5E(96A=E92"K*4)!!'!!'((X(Y%?C%_
MP;[_ /**_P"!?_8^_M*_^M*_%BO'_@%XR_;IT/X#>-K+_@FK\/\ ]G'XV?"#
M2OVQOVDO#7PQG_:0^+_Q*\->$],_9_TNZT(^#HOA#XE\,Z#XTO?%/@ZU\>3^
M/-(T2:YNGTNVT+3[.UT2ZFL(X&@\&_8<^$'_  7\_8@_9I\$_LW>%/V;O^":
MWC/1O!FL_$+68/$GB']I3XW:?JU]-\0?B'XH^(5Y%<V>F?">6QB73[SQ//IU
MJT,A,MG:6\DP%PTI:Y))4VN:U2C0KI3CR3BJ]"G74)QN^6<%44)J[2DFDVM2
M4]:D?=;IUJ]%RA+FA-T*TZ+G3E9<U.;ASTY67-"4797/Z?*_(W_@O)_RB'_;
MH_[)+8_^IWX0KRO_ (6K_P '#_\ T:-_P2[_ /$H/C]_\Z2OF+]L[X9?\%_/
MVT_V7OC)^RUXN_9O_P"":G@GPY\9O"\7A?5/%?A[]I/XXZEK.AV\6LZ7K(N[
M"PU'X31V5U,9=+C@\NXD1 DK/DE K?:^&>=Y=PUXD>'W$>;U9T,IX?XWX3SO
M-*].C4Q%2CEV59]@,=C:T*%&,ZU:=/#4*LXT:4)U:CBH4X2G))\^-I3KX/%T
M::3J5L-7I03:2<ZE*<(IMV23DU=O1;L_/K1_^0+H?_8#T7_TUVE:%=%:?\$V
M_P#@N?:6EG:+\(_^"=[K9V=I9JY^/OQC!=+2WCMD=A_PK# 9UB#,!P"2!P!4
M_P#P[C_X+H?]$A_X)W?^']^,?_SL*_T7G]*/P:E.37$&8V<FU_QCN=[-W_Z
MO/\ K6W\#R\ _$YRDUDN$LVVO^%K*.K_ .PSS_/LSEJ*\9T'X#_\%A/$?[5?
MQ#_8[T_X-_L(#XL?#/X.^!_CAXBNY_C?\5D\)R^#OB!X@UGPUH=MINH)X DU
M*;7(=2T'4#J-I<:5:VD%J+>:&^N&N$C'T?\ \.X_^"Z'_1(?^"=W_A_?C'_\
M["I_XFB\&_\ HH,QZ?\ -/9UY?\ 4'Y]>VMM;3_Q +Q.?_,EPG_AZRA?GC#Q
M/XO_ /)(?BQ_V3+QY_ZB^J5_4Q_P2C_Y1J_L-_\ 9LWPG_\ 45L*_FV\5?\
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M:POH)7C5HF8QR.K?7_ZK\.]/$S@_YY3XDI=-[< MV]$WH]-K\_MJW_0'B/\
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M^3MU\*6TGI_U4BNM7U6S[:_"?ZP\==?#RK_XE'#_ )=\5YO[GH?K1JO_  =
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M.L2S?L._\$HF8DDD_&7XU$DGJ23\/,DGN30N#OHQJU_&OCUW2T7A.U:]NO\
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MFH>&-(U;X8Z=IFI:Y:V1DFTZRO[VWM;FX5(9IHD<RI^6'T!^QM%%% !1110
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MK:P&C:Q#>6UPD$4MP);E!-7V8B)$B1QJJ1QJJ(B *B(@"JJJ,!550 H
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MBBB@ HHHH **** "C SG'/(SWP<9'XX&?H*** "BBB@ HHHH **** "BBB@
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MP%KXTWQ'IX!]LWO[46B>(OV6?C+^T-X*T[Q'X&G^&/@7XOZQ<:/\?/AC\2/
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M5/"TK>&/ GC/Q) ;'0=:U)(S=++#<O;16S-*OHI_X*2?L^-\.-:^(EMX=_:
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M0\0>#_CP?AUJW]J^'M=N-6M(O"7BKP5XR^%?@_Q)I6H76B^*=.U."VOM%O\
M2$@O3=Q 'M_[._[57PG_ &FX/&J?#T^,M%\1_#G4]#TWQUX!^)?@;Q-\-?B'
MX6'BO0;;Q3X.U35_!OBZPTW6K?0O&/AR[CUCPOK0MWT_5[6.\CMY_M>G:A;6
MOTA7QS^R[^RSXB^!WBSXQ?%;XF_%F/XS?&;XW0?"W0_%OBW2O <7PO\ "UKX
M.^"_AG4O#?P]T+1? \?BOQQ)9WT)\0^*=;\2ZW-XGNO[<UG7YFL].T33+&PT
MR#[&H **** "BBB@ HHHH ^(_P!HSX[?&72OC9\&/V8OV=-.^'%M\3OBEX9^
M('Q+\3?$3XN:9XC\3>!?AI\,_AT^A:9<7(\#>$?$W@CQ!XX\5>+_ !3XGT;0
M=#TR#QMX5T[1[&#7/$&J:C=FPL=$U;$\0?MA^(OV;_A!8>*/VROAMXETOQW9
MZK\28=:7]G'P%X\^,_A74OA_\,5EU#4_CP;#PO9^)M7^&GPYO?#3Z7K>H:3X
M_P!5?6_"M]JL7AR6_P!?NHDO[GM_VC/V8/$?Q6^(?P@^.?PA^+"?!+X]?!>W
M\:>'M \7ZGX%A^)_@KQ/\//B/::9#XS\ ^/OA^_BGP/=:WIEQJ6@>&O$N@:G
MI'C+PYK'AWQ%H-O<0W=WIE]K&DZC\6_M"?\ !)[Q'^TIX"\"^%_BE^UEXJ\>
M:]IJ_M"2_$75?B3\.XO'/@WQ'JO[0=AHEA-KWPV^%[^/M%\-_";5/@]:Z)_9
MWP.CN)_B!H_@S2-8\06^J:1XFU/6;W6I #Z_T']O[]F_Q7\6-'^$7A+6O&GB
MS4=5TOP%J-UXW\-?#;QOK7PH\+3_ !2\ 1?%/X<Z+XW^)%CHLOAGP;K/C/X>
M76F^*]#MO$-Y807&FZOI2R74-W?0VITOV?/VZ/V>OVF_%=[X/^%VM>+&U1_"
M]QX_\&7/B_P#XN\#Z/\ %OX96NOMX9F^*7P=U?Q1I6FV7Q)^'0UE[&W7Q5X;
MDN[!X-9T#4%8Z=KFEW5U\>V__!* -\2/V>/&6J?'33;C3O@/X&^!W@5M4T'X
M)Z/X*^./B?PW\%?!5WX-;X??\+T\)^.-+U*/X,_$);W4-4\9?#SQGX3^(NKB
M37?$>F:#XZT?2;[3+31.G_8,_P""6'@7]A7QM+XF\-^)O /B73]#^'EU\*?
M$FD? /PCX%^)$/@R;Q)%K5M-\4_BS'KWB?Q'\2/%-MIFG:%H,^H:!:?#+POJ
MZZ8^M:QX+OM<N(+VQ .X^+?_  4[^"/@#0/VF;KP=X2^+GQ2U_\ 9K\'?%O6
MM47PY\+O'Z_#WQ=XS^#&C:?JWCCX9:#\5H/#.I>$O^$O\.G5K"/Q#I[2RWFF
M6L>K7]O9:E%HU]''TW@+_@I#^SQXN\$Z=XFUR7QKX(UU?%7[+7PY\6>"M=\"
M>+TUSPC\3?VO=!\&:[\(?!]Y&VB0/=C4HO'>@)J&M00+IND1W7GZQ)IPCF2+
MPGX@?\$K(?B9\=?C#\7/$7QKTW2=,^*_@CXV>"]0M/A_\%]$^'?Q)U^P^,O@
M.W\!1Z-\9?B/X5\8V/A[XU^"_A_:))J_@_1M>^%NC>*_[9L/#%[K7C[5)] >
M75.6'_!)WQF_BC0-4N?VK$?PU>>-_P!B'XK_ !8\,6_P)TR";QY\4/V']*\&
M^'?"&I^&M<F^)-W+\/\ P=XW\/> ?#$/B?P@^G^+[ZTU>SGU32?%<%I?76CR
M@%WQS_P5^^%&B?M#_"7P3X9TOQ/?_ +7M _:,UCXA_&35/A-\3$T;5+7X(ZU
MX/\ !K>(_@AXHMK:/P]\1?!>A^-O$-]IOQ%\0Z39:S8:+I=M;:W!=Q:3]HU
M?I?X7^//PO\ %TOQH_LCQ%LL/V?O%5YX,^*>NZG97ND^'O#^OZ9X*\/?$+5[
M>/7-0AM].U.VT7PIXJT/4=7U#3I[FQTY[MK2YG2[MKJ&'\K6_P""847PET_P
M_?\ B;XK^/OC;^SG^SU\(_VLOAE\*?V7_ OP@T"/XE:G\-OVI;26V\3^#]2^
M(%SX\C?Q_P"*/"VGR#0/ .HQ:-X&MQHN^'Q%;ZKK#CQ!'].?L1?L>ZM\,O\
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MX3FL;;Q7\2_$VA>!])UC4M!\ >'+O4]-L=2\1WMNEM]OOK:PLTN[R3R!X?\
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MH'P2T;P-\<O%VC?"'X.3_":/P1JOQQ\*^-[%K_X-^,FFD\0^*/ASXV\!>/\
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M?C2^^*EQJOB/Q%#\>?CK\/\ P9\/_@9\%OC5XJ^(VG> ?@E8>&=5\8:Q\0?
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M'POX8\1^+=!M["\TS4(-2TWQAXE@UT:J;]'@ /S4D_X*?^+_ (U?&_X=^*/
M/CCXC^ ?@UXY\#_L+0M\/_"VG_#;6KK1_BKX]_X*(^(_V<OBG9'Q5XE\.WMK
MXK^'?B>ST/\ X1B]\8>&KM%\0_#=X/%_PZ&C:_J5G=1?2GA?_@LWX8B\&:K\
M6/C#^SSXN^%'P@N/@3^U1\>_A_XMM_'_ (6\=ZWXQ\-_LB?$O2/AG\2=-U/P
MEI=CI<G@Z^U?4?$&C:GX-GU#6+^TU.PN+L:F^BRV,@?ZM7_@F?\ LR2:SX2\
M2ZHOQ4\2>)_".E_!+3H/$WBKXL^,_$WB#7;CX!?':[_:0\$:WXHU;6M0O+O6
MM:NOBS?WFM>)+B:2.UU739_^$=CL[+0H+:PAGM?^"9_[)47A'P1X"U#P9KWB
M#P;X#^%W[1?P<TKP[XA\7ZYJ6GZAX"_:F\8:5XZ^+NEZ\KW$<NJW&H>(M&T^
MYT'49)8[[PU'"(M)G@X90"#]A']OOPG^V[;_ !3T[3?#>A^&/&'PANO A\4V
MG@GXH>&?C=\/[G2_B5X>NO$'A>;0?BKX,L['P[J^N6)TO7="\:^&8K5+[PCK
M^CRVL\U]97NG:C=_#6H?\%QM T?X.? KXH>(_@#I/@?5_P!H[PS\1_B;\+/"
M'Q'_ &D/AQX&MM1^$7PL@L+?Q%K^J>,=9T5=$M?'^O>)=2M?#OP^^%FF1:UJ
MGBF25;Z\UKP_"L\4'ZM_L[?LT>%?V;]*\26&@>/?C1\2=0\57FBS:GXF^-WQ
M2\1_$[Q!#I_AO1;?0/#N@:1-K$L>G:)HFD:?!(R6^DZ9:76IW]Y>ZGKMYJNH
M3_:4^?[_ /X)E_LX_P#"K/@=\+?"&J_&7X6I^SMX4\5^ ?A?\0_A=\5_$7A#
MXKZ7X!\><^-/!>H>.K8SZAJ_A_Q)-%87=Y#>Q27=GJ&DZ7J6CWFF:A9I<D \
M(T/_ (*X:'XM\=7TOA+]G?QYJ'[.WAKQ#^R-X?\ '/Q]UCQ7X<\-7GA>7]M/
MPYX,U;X2W*_"/4K4^+=231-6^(7A'2/B5;F^L+KPK:ZF^KV$7B 65W81>8Z_
M_P %KM*\-_#CX;>/?$/P!T?P5+\<?'?[0?AKX*V'Q-_:2^&OP\T3Q5X8_9@U
M_6O"OQ4\6>)?&.MZ0VC^#-1O?$MCHNB_#?P4R:[K?C:[\3Z<\\OAZTM=1N;;
MV;X?_P#!,'P_:?M8_';XV_$3Q%XEO_A9KOCG]ESQ7\'_ (2:%\4?&]QX2U9O
MV:?A-X;\+>#=2^.OA?5[<KXV\1>"OB!H%MXQ\(ZA?^)-?EU"^TO1-6\43W]W
M8I9K[5J/_!-?]G9_AM\+/AUX5U3XP?#2X^"GB3XN>)/AC\2OAO\ %+7_  Q\
M6?"DGQWUO7]>^+6C6?C91=W,_AWQG?>(;DW^D7MK<PVW]GZ%<::UE?Z'IMY;
M@'B7@G_@K-X'^)'QI_9\^&_A/X4:II_@_P#:#^'WP=^(/ACQ?\3/B%X0^$GC
M/5-+^,VB>*-:TN[^'/PJ\<IIM_\ &#1O!'_"-C2_B7<^!_$]SXB\+:M?1VT'
MA+5HUMY[SY[\,?\ !?3X'>+_  =\6?'7AKX7W?BK1O"7P=\;?';X9Z7X+^*O
M@;Q9XO\ ''@3P+X_TCP)?67Q*\.:=$I_9]\=:XOB/P_XI\*^#_'%_J,^L>'=
M0G:2_LM6TV^TN+]!M<_X)X_ GQ%XL^'.OZKXA^-]]X:^&TGPSU"R^$NK?&?Q
MMXD^$WB;Q+\'@Y^'7C3QEX5\57^NW&L^+_#]RNFZB^M0ZM82ZWJNAZ-JGB&/
M5K^T:XFXJW_X)8_LR0^#OB3\,Y=7^.5Y\*/B%X6UKP1IWPEN_C3XS;X:_"OP
MCXC\:Q>/];T#X2>$8;J#3?"5I>>(K>T-O/.FK:AHVDV5MH'A^]TG14:Q< ^8
M?%O_  4R_:+;XU_ _P"$.D_LUZ1X,\5:9^V5-^SU^U#X+N_B?H?CV^MO"VK?
MLD^*?VF?!5S\)O$&DZ)H]KXD\2:YH-BM_+926%F]IK7A>3P"RRW'C+3_ !'H
MWUS^P9^WKIG[<.F>/M0M/ &E?#V?P6/"MY_8UM\6O!WQ \365IXK&OHOA_XE
M>#=,M]$\<?!_XG^%KSP[>:?XT^'_ (V\+VZZ5>3VT&D>(O$$D.J+IO8>+?V!
M/V??&/Q$U_XJ:A!X[T[QMXE^/?@?]HW5=7T#QYKFBRO\0? OP5U+]GFSMK0V
M<BOIWA;7?A'K.L>%?$^@Z?);1:JNI7&II/:ZLEM>V_0_L_?L9_"W]G;QAXF^
M(6@>(_BM\0O'?B3P=X9^&D?C+XS?$35_B7XG\._"WP9JNO:YX6^&GA[7-:1=
M1A\):-K/B;6]5BCU.XU76+N_OY;K4]8OI@K  _$3]F[]JS]JB_\ 'OP'^(WC
M/XJ?M36_AKXA_M]?';X">/?$_P 9M"_9^E_8K\0?#32OC-\?_AUX&\ ?"6'X
M=:/#\== ^*$MQX.^'GA7PCXB\;P:9X5E\4:;XHB\1:O>Q:MI"ZA^R'QM_:[\
M7^ _CSI?[/'P;_9]\1?M ^/]/^%MG\<OB99:5XZ\*_#[_A#OA9J?C.Z\#Z+=
M>')O%\0TSQSXYUW5M&\42:5X-?5?"]J]IX=G>]\36,E]91R\7X"_X)C_   \
M ^+/#6MP^,?CWXJ\'>"?B_XK^/7@CX)^./BYK'B+X)^$?BWXN\7>*O'M[XRT
M;P/+:0%KS3?&?C;Q/XE\/V6I:IJ.E:-K&IF]M+!9K2Q:U];^/'[%OPG^/_CW
M1/B9KVO_ !7\ ^-M/\&WGPTU_P 0?!SXE:_\,=4^(/PLO]9B\07/PS\>:CX<
MDAU'5O"0U=;J]LX[&[TK6M+EU76#I.LV/]IW?F 'Y7?'K_@M3X,U;3OVL/A1
M\(K>'PKXO\)?#O\ ;!\(?"+XF:;X\\%^*_'^F?&_]G#X7^*/$]_JOC3X#)IN
MI:[\.OA]<ZGX8\2V_@3X@>,IK_1/$^M>'++3=0T+3X?$FEM-]7_L%_M1^.O%
M?PU_;.^)'Q]\<W_B7P_\"_B3X;GM+Z32-(@G\.^ K']B3]F;XQ^*K6TM=!TS
M3FU$R^*/%_C?Q(!<K=7K7.L2V%O-'806%G:^HZC_ ,$R_P!FW4=0^*J?VA\9
MM.\"?%_2/BQ8^(_@SH_QC\9Z3\'--USXX>&I_"GQ0\<>'O UC>PVEGXQ\3Z;
M?:M<R7U]<:GIFFZYK>K^(=(TBPUJ\-\GO7PA_90^"_P3\._%?PEX.T&_NO#G
MQLUJSUSXB:1XHUB]\2V>MW%G\)? 7P2^QB'4FD6WTNZ^'_PX\-:;?:?$!;W=
MVFHZA*IN-1N"P!\=1?\ !1?XIQ?#SX:>*]:_8W\4Z'XH_:5\5_#'PW^R/X1N
MOC%X'N;/XO+\3?"GB7XBQ_\ "<^)++2IY/@SK?@KX;^$->\6^.=&U/0/%=G8
MF&TT;0M=\1:A<R"VSM(_X*O>#]6\*>*O$'_"DO'5AJO@+]E#X^_M(>-_#%]K
M_A]-0T'Q1^S=\5+_ .#OQ'^#B74*S6>I:D/%^DZE)H'C2U;^P=7T1+/4Q:V[
M7IM;?TFQ_P""7O[/MCX0A\(+XW_:+NT\-7OP^NO@YX@U+XY>+-1\2?LYVWPL
M.I0^!=+^ M[>&:S\"V>BZ/K.K>%Y[B33]7UC7?"FHW/A[Q%JFK:8R0)G^-/^
M"3_[)WC/P7X-\"*/BYX0T7PU\,OB?\'/$MSX#^+/BGPQKOQ@^&_QK\36WC?X
MM^&OC)KMK-)J?C>/X@>.(;KQCKVI27%AK U_5]:N--U#3[;4I[4@'E4/_!5G
M5+WXH1>$]-_9?\13_#MOCI\%OV9IOB?=?%3PK:2I\;?V@/@7X/\ C5\-M#A\
M$)HEUJL_A5AXZ\/>%/%/BYM1A.@WETVK6FBZU8V]U'!\^_LT?\%B/B9K/PP_
M8PB_:$^"7A+3OB5^T=X2@\4>(/$\/Q@\%_##P3JMOJ_QOG^$6E:=\%5\?16.
M@?%+X@Z/%+8^)O'7PJL_&NB^*_#GA^6QO=,'B6ZUJPL3^E%G_P $^?V;[&?[
M3;Z1XN$O_#1/P7_:CRWC/66'_"VO@'\./!GPK^'=_M,FW^P[7PCX"\/6^K>'
MP!I^LWT5WJ%XC7%Y,Q\Q;_@E7^S4?"'A'X:KXF^/T?PG\+L;2_\ A%_PNKQ3
M-\,/'/ABU^(MQ\4/#_@GQQX-NC/I6J^%_"7B:\O8O#L.GQ:1J\.B73Z)J.L:
ME8PVD=L <=^W;^V^_P"QO\8M#\3:BGQ+\6^%?"W[(?[1?QKU;X2>%'^']AX5
M\<W?P_\ &?P;T33I=1USQ!ILOBS3?%EDWC"6T\-_V7JMIX7>SU'69/$5I<W,
M6DRV_OOP'_:S\8_&2#]J+PAXB^"C?"[XY?LOZY8>'/$GP[N/B/H?C/PYK-[X
ML^%>A_%;P#=Z;\1-(T:QL([;6M'\0V6GZVD^AF3PWJUMJ$,BZE;PPW-SO?M)
M?L,_ #]JZ^DU'XOZ5XGOKB3X/>/O@6?^$?\ %NK>'(Q\/_B5KG@SQ%XHM%CT
MZ1%74YM2\!>'6L=6'^EV$$-U!;L$O)@?6? OP$^'7P[^(OQU^*/ARQU)?%?[
M1FO>$/$?Q/?4-6N]1TW4-2\$>!-(^'&A?V5IEPS6VC6R>%]$L;>\MK-5BO;M
M9KV8&:9R0#^>;X(?\%;OVOK'3OAU\>_C7\&XO'/P^U+_ ()X?L__ +17QK\%
M_#SQUX*T+0_A])XT_:1^,/PVUSXN^"X=5T";7O%6O:_X5T7PS?\ _"II?$%K
M:Z18:'?VT?B2?6I(SJ/Z(>$/^"N_P:\:?MA1_LL:1X=LKBROOC+XJ_9WTSQ9
M:?$CPQJ/Q#;XM>#O"3>+=6N-<^ =C;3>-_#/P@G6QUWPYI?Q<U;4(],NO%.D
M#3Y]%L['5-,U.X]/\/?\$J_V4?#GPY\3_"R&W^)^I^$_%/P+TC]FVYBUKXF:
M_?ZAI?P9\-_$_P 6_%GPMX-T+4<Q7&F6WA?Q)XTUBQT.\C+ZA;>&X].T26ZG
MM[")Z]7\*_L,?!KP1\;;KXV>%-<^+N@2WOC'5?B9>?"C2/BGXITSX'7OQ5UW
MPQ#X0UOXFZA\-+"YMM,U/Q7JVAP[;Y=2GN_#TVJS7'B,: OB*5M5H ^?_P!H
MO_@I9=_L_P#QG^+W@!OV<O%WC3X9?LX^#_@U\1/V@?C/8>//"FCV?@KP/\9]
M>O= TO4/#'@B^MYM>\=ZUX:?2M5UKQ)H<%UH:0^'[-;K3]3O]2NH-(;Q;4?^
M"W'P4M/BY\8?AU8^!?[?T;X;3_M+^&M"U/0?B=X/U3X@^)/'W[+G@+Q)X[\:
M67BKX.VD$WBCX6_#CQ6G@GQAX>^'GQ7\3WMQI&OZ]INE6]YI&D0>)-)GD]A\
M;?\ !-S2OC-^VM\;_P!H#XP>(]>N_A#\0O /[.?ABR^%OA'X@>(]$T+XB3_!
MK5_%WB*]T7XZ^"8]+CT/Q9X3M-?U30]4\-6MOK'G7)_MRPUR.72KP6,GK=__
M ,$X?V>[_P 3_%G61JWQET[PM\9(/B]/XJ^$&C?%[Q?H_P &K7Q3\>?#-]X4
M^+'CW1/ &GW=OI]GXP\7:?JVMWL]S=S7^D:=K^N:KXCT?1M/UNY%]& ?"4G_
M  5!^)'AKQI<^.]>^"'Q2U+4OB+\%?V)M1^&G[+^F?$3X1ZAX8MM6_:S^*?Q
M1\)^ ?%;?$,^&M%UK2?%&HQZ3H\7Q+TW6+_6?#/AG0].M;SPRFI:C%J/]H\[
M\0?^"G7[04OQY^$C?#SX)ZO=W7P]\$_M^^'?VH?V69OB9X"TVTM/B%^S(/V?
MO$<'B/2_BY>^%+Y?$&FZ?X)\?G4_!8TJR\/1>);CQQ;6.OV6F2:5=3Z=]-?M
M6_\ !+KP?\6?"O@'3_A!J>L>#?$NBZI^Q?X&\0>(KOXA^*M$U73_ (%_LC_$
M#6/&'AT>"-6TO3]6GTKXIZ5_PD6JWNB>)9+9%U+6(M.&MW!LK9HY/?O#'_!.
M?]F[PO/H.IQVWC[6_$VD^$OVB?"FJ^,?$?CS6-4\5>.9?VJ#X1/QI\6^/-5/
MD_\ "1^-?$<?@7PO;6.ORP0/H%CI5MIVBV]E80PVT8!\?2_\%O/@%<_&'X;?
M#O1/"4EUX<\9:-^RU?>(=7UOXA>%/#OQ.T.__:ZT#0_$WPYM_"'P*ECOO&/Q
M1T7PEHOBSPGJ'Q:\2^'+ZUL?!-IJM[+:P^(&T/48DN>)/^"N>J>'?@.WQ]U+
M]G/PYX7\*Z]\4OBC\-?AJOQ-_:G^$GPU7QN?@U<^/-,\9WC2ZW83WUKK^LZU
MX"O--^&W@?PWI/C77O%Z:A9W^JGPE:"1Q]/^&O\ @FI^SMX)\3^ ?$7@76?C
M5X%L_!7A+X%>#]8\(>#?C!XM\-^#_BQ8_LV:19:#\&=1^,.EZ5<6UUXXUOPG
MI.EZ3IUQ?SZC9#Q/IVDZ=I?BV#7=*MEL37\1_P#!,?\ 9H\0>"/A5X$MI_BO
MX4T_X.^*OC+XE\):SX-^)^OZ!XHEL_VA+S7+OXS^#-:UZ#S+O4?!7CX:_>6F
MJ:0OV>YL[2"P31M1TR6RBF !Y[^Q/^UMXH_:A^/G[3NOV6NZROP6N/V<OV$/
MC/\ !CP7KFFZ197O@>+X]?#7XI>+O$ZWD]I8QZE<ZCJ<VDZ$=2@U._U""SGT
MS9IL=I%+<)+^85U_P5%_:JT7_@G1)+\0=#\4_#KX_?$#X$?%#XG?L\_M'R:O
M\.O$4OQ/?X0_'7PUX2\?C6_A[9>&8-,^'6L:=X7\;^%9_"]EJ.G^(+#Q/X?O
M+K4'NM+UC3Y[1_W;_9O_ &+O@;^RG_;'_"HM/\467]M_"SX(?!J\_P"$B\6:
MMXF*^ _V>/#GB#PG\,-/@?599G2\TK0O$NI6FHZHS27VM,+6?49IY[=9#\Q:
M'_P1[_9 T?P)XF^&5W+\:O%/@76? OB#X;>&/#OC#XQ^*O$%I\)?!WC/QU8?
M$CQWI/PBENY!=^"CXZ\7:3HM_P"*;V"XN[Z]M=%TG2+>XL](LHK$ %+4?^"J
MO@CPY\0O$O\ PF/PB\7^'OV;=*^(O[0WP6T+]HY->T?58]>^+_[+_@GQ5XZ^
M*?AZ[^&%M;1^(M#\+2:?\.OB9I/@SQJ^JZA!XDU_P>ME<:/HUKK^CW\W.V/_
M  59N;/PEJ4OCO\ 9B\8>#/BKXET']G7Q;^S]\+E^(GA77X_C5X:_:K\97'@
M+X037/C6ST^UTKX=:W;^(K.\/Q*T+7+#4F\$Z/%'JEC?>*O.6V'TE%_P3G_9
MB_X6]XE^+>HZ!XHUZ'Q+KOQ+\9O\)=>\7:IJ?P.T7XC?&;PM=>"?BS\3?#WP
MTF(TG3?'7Q#\*ZKXCT;Q'JQEGMY8?%_BVZLK"RU#Q!J%Y+R>A_\ !+O]F#2/
M /C7P#?2?%GQ8OBW2?AGX=T;QIXO^*?B36_B+\*_"_P1URX\4?!'PS\(/&+O
M!J/@+1OA'XHN[KQ'X*BT\2W46JW,LNM7>M0%;=0#QS]EC]LGXRCX$_\ !2GX
MZ_M'>%M8&J_LM?M)?M 6FG?".RUOPKK%WX5\!_"CX(_"_P <P_#SPQXQT?1O
M#^G>);*^O[_7M2\.>)=<L8=2O+?Q#:G5UL?*^P67-R?\%:O$^G6NB^&/$G[(
M'BSP]\<OB#J/[,=U\(?A/<_%_P $7=AXQ\!_M;:EXH\/?"OQAXB\?66DRZ=X
M(N]*\4^#=?T/XC^&6T;Q!=^%S;V]_I-_XIM+RW9OI.\_8(\)_#_]D;]L#]GO
MX):SXFU/Q5^U3H_QJ\0>(_%_QI\<Z_XRO_$7Q?\ BU\,K/P#?^*/%'B&2VN]
M1L].U!M&T:YU.UT335MK$B]ET?2X%DBM$Y?X)?\ !,#X'_#[P7\*T\<ZE\1_
MB%\3_ >M?L[>-)/'/BKXG>(_%&J:?KG[-VGSO\-? 7A[5K^&PN4^#O@S7M7\
M2:AH?@ZXLXUOY=:O;_79+W4+J250#YB\!_\ !3;QAX8T'XC^'M+^%_Q/_:/^
M*_A;XE_MP?$7Q[X/UWQG\+?!UU\*?@#^S!\5[?P5XUA\)^(M$\,Z?HGCVW\.
M>(-?T?P7\'O#M[IVG^+O'FFV]SJ_BWQ+I%Q:S33_ &]^SG^VXW[3_P :OB7X
M$^&_PEU-/A+\,_"GPM\07OQJUWQ?I>G2:[J/QC^&'A3XK^"M%T7X<)I=QK>U
M/#WB6:U\1:EJ>K:>FD:IIR6UM::I'>F:TYOQ;_P2\_9?\5Z?J-G$WQ5\(7FO
M>-?CYXL\4>(/ OQ.U_PUXC\6:'^T_P"(U\6?'7X4^(]8M3)<7_PD\?Z];Z;J
M%[X-7R5TNXT;2IM!O]*GMC+)]/?"']FWX2_ KQ/\3/%/PRT&?P[=?%9_AY_P
MDNF1:A<S:!9VWPM\ Z3\-/!>G^&]'D8VF@:?IGA+1-.LGM;)52ZGA:[GW3R.
MQ /RA^%'_!4G]H6]\.^*/#_BC]F/3OB;\=9/C?\ MLP^$/A_X ^*'A[PWI$/
M[.G[(WC2Q\-^)?%6L^*]<TBXL#XUM-1\2^$_!GA_PZMI&?'VM7=YKAOO"FD6
MEP(?H_\ :<_;C\?Z1\ ?V&OC[^RGX2T3QOX:_:O_ &D?V2_!MS#\0K[_ (1'
M4+/X2_M :K9FZ5+*6WOVL?%]Q97UKI*MNNH_#M_+/J$D&KP6;6T_9>+?^"87
M[.'BI=;EMM:^-/@O5-9^(_Q?^(L'B#P!\5M<\+>(/#T?[0-KIT/QP^'OAK5+
M.)Y]*^%_Q0OM(TO7_%'@]?.A/B73[+7M*N],U&U@FC][^(?[(_P5^(?P>^&'
MP+.BZIX(\ ?!3Q1\'/%_PEM/ASK-UX3U'X?ZQ\!M;T76_AJ?#NH6XGD@L](;
M0K32[JRN4NH=3T6:^T^]65+N5Z /S+US_@M3I?A_X5?"OXD:Y\ ]#\%77Q_\
M3_&+3_@=H_Q3_:3^''PVT+Q1X2^ L^K:5\0_%'BWQUK>B2Z%X&U.^\2:?9:!
M\._!IC\0ZQXTN-:L+F:;P_;Q:@;/OO'_ /P6.^%7A.\_9GU;1? ,.K_#_P#:
M-\/?L[^)+*Z\2_%CP)X&^,>C:?\ M*>-]-\!>$9-&_9YO?[5^(?BNU\):SJU
MG)\1=6N!X7T31K-I9?#^I>*F@F2/Z5U'_@F_^ST_PR^$7PU\*:G\7/AE+\"-
M3^(NH?"GXD_#7XG:YX8^+/A*#XMWVM7_ ,2-%M/&X6\NKG0?%LNN7*ZAIE]:
MW4</V32;C3FLK[2K&[AY[QM_P2U_9>\=>(K;Q!J%S\9=,0:#\ =&US0M&^,G
MC6#1?&EW^R]XGB\6_ KQ5XZ^W7VHZOXL\7> M725K76M7U>X?5H;JX'B"#59
MC#/" ?"_@7_@KG^T)H'@O79/B?\ LL:9X\\<6WB3_@H)XNMXO /Q<\,^'="T
MCX'_ +#WQ*\.^'O$]UJ=SK&B7<MWXN3P_P"*H;72;2T@\GQ9K.AM<2/X=L];
MC.F>G:S_ ,%HO"'@WP;XHUGXE? Z\^&?BN23]EF_^%'A[QE\7O!&E>&/&7A'
M]L"Q\9ZI\*?%/Q"^)4]BGAKX-0Z3IGP]\7WWQ&LM73Q(?"\6GV4>FW?B2XU2
MVA'UNG_!-7]F8:SXWUB6W^(EROCG0OVIO#%SI$_Q!UIM#\/:#^V3+X9N_CQI
MGA+3D\M-#@\1:IX4T[6=,:-YI?#^JW&IW6ER0B_EC!KW_!-/]F'7K:_/V#Q]
MHVO2>#OV9_"'AWQGH'C[6M-\9> 6_9%3Q='\#_%?@+6P97\/>,_#\7CCQ'!J
MVN)#<?\ "3VM\;+7[6^LP;=@#XON?^"U5KK/@^V\5?"S]F'7/B8OAW]G;]H_
M]H_XP-8?&/P9I/AWP/X4_92^)$'PW^*]KX*\62:+?Z=\8(=4NFF\0_"KQ%X6
M@LO#WQ!\.?8;]K[P^;UH[7ZS_8O_ &KOB[^T;\>?VTO"GB[P=X9T3X2_!_QE
M\'[7X):]I>M1W7B/6/"_Q'^#GA?XBNGB[2EMD:UU.0:[!JJ2^>JV4>H?V T-
MQ/I,VI7G4_\ #N;]GBZTO7['Q#>?%KQGJ7BW]FWXS_LL>+O%GC7XL>+O$_B_
MQ1\,_C_X@3Q3\4+K5M>U2\FN#XMUG6T^U:=KMBEDGAR!O[.\/6&F:;'!9Q>R
M_!S]EOX8? CQQ\1/'?P\E\6V-[\4-"^&.B>*]#U'Q->:KX7EF^$WA&W\">&?
M$-AHUTC+8>)KSPK8:7I7B+5H9R^MQ:3ITMS$)[<R. ?1M%%% !1110 4444
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MQ%T'P#XVUJU;2OC9X\\2>(=1TY/A'X*\,6&DZAX\TZ\CO]0N/"6UH!E?'O\
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MWXWT;P3I;VL%IJFO_#73X?"VM1->2V#6KS7FF6>F:HXOE /E#1/^"U7P\F^
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M_./C_P#\$@_AQK/[/7Q*^%_P#U?Q+9^+?&<7P/\  7A*^^*?Q-\6:KI?P<^
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M]6\.>&[R;P9XW\*^'_'KZC?6>H^*O#-W;76A:5I=[INJ7._>_P#!)#]D2\\
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MY%\6?L(?LF^.?&?C?X@>+/@[HVM>+/B-\3?@K\8_&6IW.K^)UCUCXC?L]?\
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M]JOQ%>>*/CE\.]3\5:GJ_P /)?A/XGBTSXC?$WP1H_CCX<_VQ<>)-.\)>/\
M0/ OC#PWHGCK2O#OBBYF\4^$X_%>GZM+X4\3,->\/2Z=J:K<@ ^/H?\ @I]X
MYTWXS>(M'\9? ?PMHG[/NA?MC_&G]C!?B-I7Q5U37?B;=>-/A#\ _%GQ_?QN
M?AA_PK>PT2'P=JNB>#-7\.SVP^(<OB"QUE[2YMM-U/3IO.''_LE?M;_M)_M&
M?MX_"'5/'WAC3OA;\!_C#_P39\7?M$_"WX=^%_BG=^/M/UFUU_X\_!NT\'>*
M/B+I-YX*\'Q^&_BOHW@O7Y+34+/0YO%/ANUT_P 52Z?I_BC4KNVU".U_1>U_
M8S_9MM-0LM4B^&\,E]8?M#>(/VJX)[KQ'XNO=_QZ\5> ]6^&?B'QY=17FO3P
MWSZKX(UW5M#NO#]Y'/X6:.]ENUT1=0$=TG,_ K]@;]E?]FSXBR?%;X/?#O4_
M#?C9/A_JOPET>_U'XC?$WQ=IOA'X4:OXKTOQQ/\ #'P)X;\8^,->\-^!? %G
MXKTBTUK1?"7A+2='T70+F2^31;.PM]2OX;D _-']IO\ X*:>-8?"_P"WO\*_
M$O@+4O@3JWP:^%'[0VH^!FT#XO:W\./VGM9C^$?]DG3O'W@BV\9?!.Z^&UWX
M<^(?AS6+3QUX%\9_"OQ?\:9?#.A7FF_\)_X7T+4'U"ST[UGP]_P5+\7V_P 4
MGTGQI\#= T?X#6_[3?QR_9+M_B)I_P 4]3\0_%*Y\<? OX">(/CO?>+[[X;G
MX;:5H">$O$&D>$]8\.(8/B!+KUKKLEC=MI$VE3RW,'UKXH_X)O?L?>-M0\=W
MOC#X::WXHM/B%HWQ,T+4_#6O?%7XN:IX)\-V7QFV'XM3?#+P/>>.9?"?PDU7
MXC.LDGB[6OACH_A/5M8>ZOS<7I&H7HG[9?V)OV;K*>UU+1_AQI]EK6E?&WQS
M^TGHE[>ZOXLU>RLOCG\0_ 6K_#3Q1XXO-'NO$:V>KV^J^#]<U'1KSPI>'_A%
MWMKF5[;2[2],=Y& ?C[\:O\ @I'^TI\0_A]\.=%C^&MA^SU-\8_#O[&/[3?P
MH^(7PY^,UQXQUN_^#/QI_:K^&O@&#X?^.])N_A_X4;P[XOU;P9KIF\:VNCWW
MB3PQ%::TVC:5X@U6>*]FMOH+X!?\%EO!7Q@^*>M:1K?PVOO#WP8:V^/%]I/Q
M%\,Z?\8O&WB#P-IWP$\63^&+R^^.FBP?!32O!'A1?B;%9WFL_#:R^'/Q(^*V
MI7"PC0]?M-)ULS6T%3]F#_@DA9>$OB'XM\;?M)6/PNUS1Q\/?A3\-? 7P_\
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M@/X6?%J[\,^*O'^GW>N7OA#6O&^C>%OAG;P^#]>3Q/XZT.YDTR&\^2?VG_\
M@D-:_%6Y^''PP^#UC\(OAO\ LZ^'OAU\(/A)J1N/$?[05C\4/#OP]^%/Q*M/
M'47AR32M ^(1^&O[0M@;2U^S_#^'X]:7?R_"3Q)<WGBSP_=ZI>7/V:+]/?CS
M^RE\%OVDQI3?%/2/%T]QI.B>)/"BWW@CXH_$_P"%>HZKX+\9)8Q^+_ GB:_^
M&'B_PC=^*_ GBD:7IIU_P=XDEU3P[JCV%I)<Z<[Q!J /RKT/_@H1\5](^,GQ
M"^%WP:\!0_&?Q/\ $_\ :=^.^D>%K[XT_M#)IOPS\$^%?A!^S'\+_C7=P^"M
M7\!_!_QC?6G@W7++6Y;'PUH6GVOBR,:_?7>OR>*Y]$U,+IVUJ/\ P5]\8^(?
MAA:?&;X/_LV:1XL\">$/V?OV1_CK\;K;QA\77\%^*O#(_;#\27&@^"?"OP]L
M+;P!XBTKQO/X/M-*UO7_ !AJNM:OX,@FLHM.L- MM2U6ZN+6S_13PY^PS^RM
MX0\8Z9X\\+_"32]!\2Z+KOC/Q'H]QI6L^*+/3M)U3Q_\,O#_ ,'/%)TS08=;
M30;"PO/AKX6T#PK9Z1:Z;%I.C6>FPW&C65A?M+=R?GC^TK_P207XGZK\,/AS
M\'H/A+\,_P!G?PGX%_9^^&%U(=?^/EC\5O#7P\^ 7Q+M_'^D^%3I>C>/Y?AE
M\?K.6&RATSP/<_'/2;S4/A-?:AXBUS0;O6KK6Y880#YA\'?\%<O'7[/_ (,'
M@;Q-HUU\=_B=K/Q+_P""@OQ9>X\<^(?B-%J,WP=^#/[9'Q&^$_@CX2?#2'X:
M_!_XM:CK_P 2+ZVL(_#7P_T3Q18^"O ]CI?A^TAUSQS837MG$WZ6_%?_ (*:
M?"[P]X=\+Z)\*- UCQK^T!X^\=_ KX7^%O@_X_T;QS\*++0/&WQ]O])MO#L7
MQ)\;:IX'U;3-"TSPM8ZC=:GXQ3PQ:^,=>M'TJYT?3M%O]5EA@KU#7_\ @G)^
MR-K^EV&E?\*^\3>&X[#5/C!J#:CX!^,'QD^'/B'5;+X_>,[OXA?&7PGXB\3>
M!?'WA[Q#XE^'WQ!\9WL_B#7?AWKVIZAX)-]Y36>A6D<$,:>__%?X ?"/XV?"
M_P#X4Y\1?"$&K> (9/#-UI&F:;J6L^%]2\+ZKX)U"PU;P7X@\&>)O"VHZ-XF
M\&>)O!^JZ5INI>&/$GA?5]*UO0[ZRM[C3[Z!T)(!^(OP)_X*%_M1^&KKX]?#
M#5?AOH?QC_:&L/V@_P!OCXGZGX0\5_&J_P!"^'?PY^ '[,>M> ='OO WPY^(
M)^&^J:AX@U"\UOQIHFC_  ST76?"/A738[;4+[4?&&J^%[>R99/I?PM_P5:3
MQ+\>_AOX(U'X3:?\.O@Y\4_ OP]\<>!O&_Q2\7^(O!_CKX@Z)\1O@UJOQ=TS
MQ!\+](E^'=Y\(?'6GZ9<Z3>_#O5/"%I\;K+XK_\ "5Z=JM[8> KS0+>SOK_Z
M+N/^"8G[%MQX-MO W_"K_$%MI</B[XC^-KS6-/\ B_\ &;3O'/B#6OC':V]G
M\7K?Q9\1;'Q_!X\\6>'?BI!:6H^(?A+Q%XBU+PMXNEMX;C6]'N[B*.5>_D_8
M2_9=?XD:#\3A\.[R'5/#.J>&O$.B^#K;QW\0K;X-V?BOP9X4'@7PEXU'P)@\
M51_!J7QMX;\&I;^&]%\73>!I/$&GZ59:?;V^H(;"T:$ ^1?^">G_  5,7]NS
MQM_8$'P?NO"GAGQ5\)E^-_P[\8:!<?$;Q#I-AX2N?$EKI&G^"/BSJWBOX3?#
MSPOX9^+EUHVL:#XFC\/^ _$?Q*\,SV4VM6]EXLNGT)YKSYO_ &4(/CK\<OVL
M/VK-3\9P_MJ>*O G@3]O#X]_#C0/B5X6_;)L_!'P+\">"_!JZ-_8/@F7X 6/
MQ$T3Q'J5CH3WC6<KP>"=3349[^*[%W<P6[O!^LGP,_8V_9^_9Q\1:MXF^$GA
M;Q%H=]J.CS>&=.L=9^)?Q-\:^&O!'A&?7KWQ/)X+^%_A'QMXO\0^%_A7X+.N
M7TU\GA/X>:1X:T"(Q6-M%8)::=I]O;>I?#'X,_#;X.'XA'X<>&T\.'XJ?$[Q
M7\8_'FS4M7U'^WOB/XX:R?Q1XC?^UK^_^P/JC:?9EM.TS[%I-MY(%G86X>3<
M ?B5HVB:M\%/C%_P50\8ZA^UW^U#I7AK]C?X5^"/&'PIO/BW\=/BS\8?AO\
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M4?L8?'WQ)XP_:N\0_#1?V O'?Q6\8?$7]G#5K6R\:S?M;:3X=T3Q3X%\4_M
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MOIO#_A"R2PAB6[L_#&FZ3;:C<(+W4(KF\_?T =31110 4444 %%%% !1110
J4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img143810944_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img143810944_1.jpg
M_]C_X  02D9)1@ ! @$ D "0  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" +" U,# 2(  A$! Q$!_\0
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M#4DTWQ[K6AV=V=.U231K@7$$>F12>=?QO9.D"?Z0.G_X(V>+_P!I/XI?L_\
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M!OC[XG\1V/AKXT:EXH2WDDU35-0TR6:ZAM/#US"T>DZ-<F:$68@C+,SW6_\
M5,XS#AC,\UPN5XGC#@>IP!B,UPE?AWARAE->5;*LGRG*L5B</3QV.I1R2ODN
M-S7$QP^4YI'$9M&MC\=BZN-Q>(I87#+$2_*LHR[BC*\IQ6:X7@_CJEQ_A\JQ
M='B'B*OFU)4<USC-\TP>%Q$\!@:TL\HYU@LJPKKYMEKPV4RHX#!X*EA,+AZN
M*Q#HQ[GX6_\ !4CQ&U[^UMX:^,7P[\#:IXB_98^%=I\6KO6OV?\ QV?B+X)\
M7Z1>I&B:%IVKRV5L\.M6MW,D%X61HH!'<%HR8@&Q?V-_^"F/[1'[2WCCPA-K
M/[-W@=/@MXRT[4-4O/'?PW^+N@>+==^&%E;1M)!<_$CPK)<0:QI<)<);W'^@
M0N&D66$2*K+7D_PC_P""9G[6W@#1/VQ=7\+?$'X5? KXJ_&CQEX4\0?#C5?A
M9IT\O@2U\)Z&TMQJ/PUU?P[?VTD]GX6U)'739$/VF69?-GN R3,@U_V1_P#@
MF?\ 'WPQ^U7#^TE\;K/X#_!^STWP1XB\*:IX%_9HL]4T32?B?J?B/3[K3;OQ
M%XNL6$&EVKLEY+?RVMO P-[%:B%4C1S4YC@/!2CEO&=7"UN&*F*CEN!_LF:Q
MN>8BO',(<-X">)IY3EM''X:FOKV>8C%.CC(XW-J&!KX6I0Q^ IX)1=2LLQ_C
M;5S+@NEBZ7$\,)+,<7_:L'@LDH47E\^),;&A4S?,J^!KSDL%DF'P\:^$E@LJ
MKXVAB85\OQM7&-^RXGQU_P %SM8T_6_%_CSX??!OP%X@_9L\ >/$\&:SXAU[
MXP^&-"^+OB2TAU%=-O\ Q+X3^&$EX=;N],CD9KFU/V&X26 )OF4&1T_?_2]?
M'BOP3IWBGPT&QXD\+6FOZ +I41\:QI,>HZ4+A2Q16_TF#S5+% =P+$#-?@5\
M%O\ @F7^UY\#/%5M\*_"\W[(/B'X 67Q&U+Q5;_$KXB?">S\9_%U_!VJ:G+J
M=YX,EM=2M'B:YD21[2WU(W96RF?S(&%LH0?MI\>/A)=_%WX&>/\ X/\ AWQ;
MJOPUOO%?@Z\\-:%XN\+NUAJ'A6Z-LL6FWVG"U:)H8K.2*%3# T9%L&BC*_+7
MQ/B5A_#.&-X8P/!DLKPN">(G'&YW@\=FF:U)Y14> IX7%9YEV)@G2S2DUCL7
MB</@ZE*I.-26&EA*"I8>=7[?PSQ/B=/!<3X_C59IBL<L/"6#R3%X'*\JIPS>
MFL=4Q.%R/,<-*U7+*B>"PF'Q&+IU*494XXF&+KNKB(TOY4/#&G^.O$6N^,?#
M_P"T+^UI^TK^R]_P4DN/B/?WWPZ?XI^)/$'A?]F'Q+)_;<0T'1M&>QL;_0KC
M2+RU<Q";:M@I,%LEM<1O)M_0_P#:;^+G[=&M_MI_L2?LI>'_ !!\//MC^&-(
M^+GQ(L_"_BSQ%I.C^/F\)VZ#Q>OC6^M- BU'2_#C207-[X>TW3!<1ZNSJ;^.
MV5EB3+\7?L!_\%)/VA_ GPZ_9E_:2^)G[/\ J/P3\!:_X7N+WXNZ3I.IZI\9
M_$.A>$+E9;&*VN+^$/IFKWEM&MM-?BY1YY"DUZSA7#?6.L_L=_'_ $3_ (**
M:3^TUX1D\ ^(_A5<_!'2/@C"_B'6M6L?&/PUTNUTK[%JNNZ)901-::]J>HW$
M4<K)<2QQ%)I=VV14:OU7.N+>$JV/I8O$YIP3F.-P7#?&^)R_+:4*.-R/ 9C6
MP& R[(J.3Y@\NRFO@L-BHSQ>/PO#>-J8[$934P<U0QRQF,H4X?E&2<(\78?
M5<)0ROC?+\#CN).",-F&8U)UL%GN.RZECL=F.?5<XR_^T,WP^.Q6$G'"8#%<
M28*G@,+FU/%1=; _5<)6J2K:9_P4OUN^\%?\% OBK)X"\/1?#3]C[6KKP;X(
MU@ZQ>K<_$?QGIL$UKJ5A>H8C#8VL.O+!8(UF\LS1W,3E0S8'(^*/^"F/QPFT
M3]F'X9_"3]G?2_B5^UM^T!\++/XQZ]\-5\2R:-X0^&O@J]B-Q;W>MZ]=J+@3
M7$10JMR+6..-DE9W,\<8^+F_X)8_\%"V_9]\>_LN-\4/@M#\(?&'Q^?XC>(&
MT^'4(?&7Q TK6/$$&K:OJ'B/7);<FVALUT^RN;?0HPTUU?>6LD_V>##?:_QS
M_8A_:M\'_M;>#OVH?V+?%_PKTBZG^#.B? _Q?X:^*5G?76FZ+H'AZUM;/3=4
MT1+2-WN3%!9V<@M4:&5[FWD$Q>"X8#YVME'@WA,?*A0Q_"68U*DLXQ642KYG
MG=/)VLHX;R7!Y+A.(<50]EB,,L]S:OF^=XNGAK6Q.%H9=#%4:<JE%?18?./&
M;&8%5\1E_%V74J4<FPN;*CEF2SSARS?B3.<;G6,X=PM=UL/B/[#RFAD^186I
MBO\ F'Q5?,986K*,*\_SKF_;R^/^M_M&?M0_M?W7P\\1>'I/V,O@EX5\#>(?
MV?==\9ZK'X*MOB!KWB^/P_XTU&X72I&T[5'L],O;S5-(U"XLVG,$,+AT5%<_
MKQ=?MZ^*/%O[17[+W[/'P<\!Z'XMUKXL?"?1?C?\:-:O-4O$L?A)X!UO2K+4
M-/*_98R+O5M0DN3#96]TT7F1W-A, RS/M_.O4O@EI_["_P"PQ^W(G[<7Q;\$
MM\8?VQ-8\>3:?J6GS2WMSXXU>'0;L^&M*T.T:WCGDU2:>YFN3IL06+3H/) D
M/DYKZV_X(R?LO^)?A;\ H?CY\7H;JY^-7QXT3PQ(\VK1R#4_#7PJ\+:1;:1\
M//"RK.!):(^E6T>K7-N%3 N;*%UW6U=_'%'P^GPWF/$]+*L#7PG#]6/!?!JP
MLLSCEG$56KPWE=/ZS@\16JTZN,RWAO.?]9,UE7E.>(K8JI@,+CZLXXCV:X>!
MJWB)3XERSA>KFV/I8KB&A+C3C.6,CECS/AVE1XDS.H\-BJ%&E.&#S+B3*/\
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MFZ/LU"YMK66>\L--D29HMABBE8P[F&\#MKY1@J'!V5Y35X'S'-J>3Y)DOU7
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M9OXF\07UK$SZE=33M;O+%<1RR7-REVGVBWMTA0?M[\#]1^'WC?X%^ [OX?\
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MWP;TVZM;37=:\2:5>V4>K^-O$%Q!#<7UK;S73.D,WVB:(F..(I;QLI\(L/\
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MD,:2R-,L4D7EOYA^S/\ \%=/'?Q0^/OP:^%'Q:^#WPZ\)>'?VBK>_;X8ZO\
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MCU6TNDM+K9\AG@"2%/E+$<5VL44<,<<,,:10Q(D4442+''%'&H5(XT4!41%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9W]E<;-'O=-M]<==,(!]]45\9_"3]O3]GCXW6WARX^'VM>(M3;Q9X@\'>'=
MM;CPU>V=UJ,WCCP=>^.=$U.!)6*-H/\ 8>EZO]LUD2&RM[[2KRR$DDHA\[[,
MH **** "BBB@ HHHH *_GK_X.A?%'Q(\+?\ !'_XXS?#V^UK2[/6O&WPC\-?
M$K4M FN8+^U^%>N>.]+LO&:2RVJF:/2[VS>*QUF3B--,N;GSB(B]?T*5Q?Q%
M^'7@7XN>!?%?PR^)OA71?&_@#QSH=_X;\7>$O$5E%J.BZ_H>IP-;WNG:A9S
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M<Z+>7T<4JL^6M\3GZP_X7[\"?^BU?"7_ ,./X._^7-?R<?\ !*/_ (-3[/\
M81_;-N_VD_CM\</"'QY\$^"]+\1:;\*OA_9^$KRWCUJX\3:7+I$NJ_$JUUI)
M--G.D65W=/9Z9IXO+2XU,6]Y,R+;Q)7]4'_#)_[,7_1OOP<_\-UX5_\ E70!
M_*S_ ,%XO^#DWXN_\$[/VE/AA\ OV3O!?PC^(NGGPCH_Q%^(/CKQ)JL?BO2?
M$%EJU_=6]OX.\.GPQK 326B@L9SJFJW3->QW,L*V<!B1W?\ I,_92_;J^"W[
M2?[-?P.^/FH^-_AU\.]0^+OPT\*>.[[P1K?Q'\(?VGX8O-?TN"\NM)N"VKH[
M"VG>18'D2.5[<Q/-''*717?%+_@FY^P/\:V\*O\ %+]D/X!^,9/!6LQ^(/#$
MVH_#K0(9]+U6';Y<XFT^ULY;N%=JG[#?O=6!.2;8DDGU=?V3OV7T54C_ &>?
M@O#'&JQQ0P?#7PA!!%&@"I'#!#I*0PQ(H"I'$B(B@!5 &* ,KXH_MD_LK?!K
MX=^,?BI\0_V@/A-H?@GP'H-_XD\2ZJOCSPUJ$EIIFG0F68V]AI^I7-]?74I"
MPVMG:6\US=7$D4$,;.X%?*/[$?\ P64_X)Z?\% -'\9:K\ ?CSH45SX"O[>R
M\2>'?B6UK\-_$EM!>F9=/U>UTSQ'>P#4-&OWMYTM[ZRGG"21&.ZCMW>-7[/]
MKW_@E]^R3^UY^S;\6/V<=?\ A=X*^'VG_%#PX=&C\<>!/!7AG3/%OA+4[>Z@
MU#2=?T6ZBL8";G3M0M8)7M9)4@O;?SK28JDQ=?S(_P""/O\ P;A?L]_\$Q[W
MXJ^,_B)XKTS]J/XE_$FRA\+6FH>+? ^EVOA3PGX(LM3BU6&STKP_J,NL"37M
M4O+6RN-5U=Y(VA2V6PLP;=Y9) #][_\ A?OP)_Z+5\)?_#C^#O\ Y<U^;GQS
M_P""[/\ P3&_9V_:;\)_LG?$K]HS1;;XG>*I-%@EU/0;1_$GP^\)77B)XTT2
MS\9^.=)FN-'T.YOO.@<H&NELHYXWU%[,%MOWX/V4/V8@<_\ #/OP<XY_Y)UX
M5_\ E77\V7[:'_!J!^S9^UC^WA!^U=I'Q>U;X3?##Q9K6D>)/BU\#O#7A'36
MM]7U?1DM%GB\&ZQ'=VMOX>T[Q2+18]8@DTZ;^S \TVEK))+MC /Z=/\ A?OP
M)_Z+5\)?_#C^#NXR/^8SW'/TKR+X[?MY?L>?LV?"WQ1\9/C!^T5\*?#7@+PA
M:QW&K:E;^,=$UV]>6XD$%EI^FZ-H5YJ&K:GJ6H7+);65G9VDLDLSC=LB621.
MJT[]D#]EG2M-T[2K/]GOX/I9:5I]EIEDDGP_\,SR)9Z?:Q6=JDD\VFO-,Z6\
M,:--,[RRD%Y'9V9C^;'_  5@_P"")_P$_P""CW[*UW\#?!-EX,_9Y\?Z-XIT
MWQQX&^('A7P1I%M:1ZUIT%Q9S:1XIL])MK.\U'P_JEE=213K#*UQ9W$<%W:Q
MM(C(X!^B7[(G[9W[-G[=?PCLOC?^R[\3]%^*'P_NK^XT>[O]-%Q::CH>N6:Q
MO=Z'X@T>^BM]1TC5+=)8W:"Z@5)HW66VEGA/F5]15^)__!#O_@C_ *=_P1__
M &>?'WPRN_BG+\6_B'\7/&]EXW\?^([*QN-'\*VDVC:6^BZ%I/AC2;MY+N*"
MVLI;B6_U"[,=SJ%S.@:&**T@!_;"@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BN'\<>-&\&Q^'&BT'4?$,_B+Q3I'AI;32Y;5;BQBU.21)]:
MGCN98VET[2T3SK[[.))DB8,$QDUW% 'Q3^U;\!'^*GQ!_95\?Z)X(T?7_%/P
MB^.&EZY)XKNHK4:QX.\&7^E:E:^)+G2[JX(EBCNY1IJ7D-K^_GCC5 =F\'\N
M=._8Y_:5T?5M-\12_!^TOX/V>==TJ2X\-PZUIK0?M(6\'[0'CWXE3:MH?FR!
M'O(?#7B33M55?$^ WB.2\TQ0! LK?T.44 ?FA\*/@?\ M.?#?]ECX?:'X:^+
M5E\&?$WAG3?B9XM\5^'KKP7X;^("F7Q)XC\0>+M!T-KS5DEBL6T"SOH+*^73
M%$$DWGQQ K'&Q^L_V6?B#XG^*_[.7P6^)'C26QG\6^,_AYX;UWQ)/IEJ+'3[
MC6;RPC;4+BSLP2+2WN+@/-';J2L*N(U^517JGCC_ )$OQ?\ ]BOX@_\ 33=U
M\[?L)_\ )G7[.'_9*/"W_I$* /K&BBB@!DDB1(\LKI'%&C2222,$2-$!9W=V
M(545069F("@$D@"OGWX7_M9_LR?&SQGXE^'?PC^//PK^(_CGP>UP/$?A;PAX
MTT36]:TY;.<VMY/]CLKN62[M+2Z4VUU>6(N;2VN/W,\R2D*?F7_@JS\2=+\(
M?L5_&3P!8>+=5T3XM_'?PGK'PA^!GAGPE'>7WQ ^(/Q*\5VC6>E^$O"&E:63
MJTLFI1--;ZUK%LL=MX:T6>\UJ^NK:&U#G^<O]EW]A;]K7XD?&3]E/1OAE^S%
M\1O^">WBO]GJ6WU;XE_M%Z[X)\*V5OX8TFS\*C2-=^'?@TV\]M;_ !M7XB:J
M7CO7N+K4-'M[6XEUS4)TNTW4TDTVW9K96>NOZ?UUL']J=>)?'/\ :2^ O[,_
MANQ\7?'[XL^!_A-X>U34!I6E:AXSURUTK^U=1V"1[/2K1V:^U.>&(B:Y6QMK
MC[+ 1-<F*(AZ^,9?V,/VT;PA;_\ X*??%=8E)9!H_P #?A9I,V\]/-G-U>^9
M$!D>5Y:Y)#;^,5^0_P"W=^PK^U_\.OVA/AK^T%XJC^+O_!3+X?6GPRUCX=6M
MA!X)\%7OC[X%>*KS7?[5EUWP[\-K0'3->T;QOINS1M9\16UG-K.CM;QPW,D>
MENI DFTF[)]=[ ?U%^"_&W@_XC^%=#\<> /$^A>,_!WB6PAU3P_XG\,ZI9ZU
MH>L:?.#Y=UI^I6$T]K<Q$AD<QR$QRI)#*$EC=%Z"[N[:PM;F^O9XK6SLK>:[
MN[F=UCAM[:WC::>>:1B%CBAB1Y)'8A512Q( K^>#_@G'_P $O?CEH/P-\3:G
M\7OCG^U/^R7;?$GXL>,OB-X1_9<^"?Q6\/\ AOPS\)?!7B)-)&EZ-J,4/AKQ
M#%IOBG5+BSO]<U_2=&OTTC2;K4EM(+6&ZCNQ7V[K7_!(W]G+QAINK:9\1OB?
M^UC\2X=;TK4=(U.3QC^TAXZDDN;75;.>RNV>/0I-"M/-:*XF9?\ 1C")'):%
MD 2D]WU \S\"_P#!<7]D?QU\8M!^'EOX:^,^A?#7QKXX'PT^'O[3'B+P.FG?
M KQKXXDU*71;+2].\0-J;ZM9:;K.LP2Z3H&OZIHUIIFJ7RK&)((Y%EK]EJ_F
M"\"?\$0/VE[/Q'\._@;\0/CA\)]5_8T^%7CCPSXCT[7-#T7Q%;?'WQUX*\">
M(1XD\%?#G7[&XLU\'Z!/:7$5KIVN^+],U.\O;^PM_M$%L+V:3']/M.7+IRMO
M17OWZK^OO>X!1112 **** "BBB@ HKYO^'/[2>A?$CXX?%[X'6'@/XH:%JGP
M@M/#=UJ/BSQ/X'US1/!?B'_A(5OBL7AS7[VUBL=1: V1:(PRL+V!WGMLQP2$
M?2% 'Y@_"[]ECXP^"?VA/B!KOA"[\0?!KX6^++/XNZEXMU*U^+>H?$;_ (6%
MX^^(-]I4GACQKX<\ >(+&;1?AYJ7A**SDN#&\=[;R,GV"*%[2ZGSZ+\"T^+?
M@#]J[XD?!GQK\=_&OQH\)0? +X;_ !%T@>.="\&:;J&@^(]7\>?$/P[JSV5]
MX4T31GNK/4--T+2R]M>QR);SP,\ 7S9&;[YKXLT/_E(3\1_^S2/A-_ZMCXM4
M ?3/Q,^)WP^^#7@7Q+\3?BIXPT+P%X \':9/K'B;Q9XEOHM.T?1].MES)/<W
M$IY9CB.&WA66YN9G2"VAEFD2-O"/V9/VY?V4OVQ1XFC_ &<?C+X=^)%_X-^R
M/XGT2VM=;T+Q%HUIJ#2+INI77A[Q1I>BZR=(U$1[K+5H;*73IBZ1?:5G)B'A
MG_!57]E/XE?M??LI7/P\^$9\/:AX_P#"'Q*^'7Q<T'P7XQO?[/\ !_Q*G^'&
MN#6G^'WB6^97M[*Q\1)F*"\O4?3[348;.>^0VZ2,GY;_ /!*/X,_&?QS^WM\
M9OCU\4_A[:_L]ZE^S'\/-1_9H\5?"^Y\3:#XF\=^,?%7Q!N/"?Q"L];UW4O"
M<USH-S\/-$T738SX+N1=7$NH:A>7LMJ((;.Y5G96;O9K96>OSV5@/Z;****0
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &=K&H-I.
MD:IJJV=UJ+:9IU]J"Z?8Q^;>WS6=M+<BSLXO^6MU<F/R;>/^.9T7O7YG_L_?
M\%%M>^.OQB\*_#Q/V=/%_AGPCXGN]6\-?\)W-J>JWITGQOX?\,:WXO\ $>G:
MCH]QX,TFW@\.>&K"PT7P[K/B:;6H%7QUXEL?#>GZ??\ V>>]/WG\9]*U/6OA
M9XZT[2-;A\-ZA+X>OI8=>N-3UG1H-(2T07=Q?RZIX>!UJR2WMX)9&FTT&Y4
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M]E<:;JUA9:IIUY'Y5W8:C:P7ME=1;@WEW%K<QRP3Q[E5MDL;+N4'&0*_'OX
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MEV\JP0J\=\D<D6Z1=TP4 9P*_J1'P<U#2MK>$/BI\1M!,;9BM-3U=/%FD0H
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M4OCKXB3Q)K_CC5(Y&>6UT6.ST]/T/HHI %%%% !1110 4444 %%%% !1110
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M ,2=8=O^$GU+X>:-I'C.WEVBYL?&OA:-O#/BNQO40D17EOK>E7BW$6=R.2K
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MZ;G]<K3E.7+5H1]R=:$I5I-<L:EG4M)H]Q;]C/X4-;Z?*-8^(Z>)]/U[5_$
M\?Q>-+J/QQ<W.O:+:>'=6M)]82U%O%I]YH=A8Z:T%A864L4%I$\$\5P99I.U
M\!?LQ_!GX<VUY8Z#X3@N]-O_  7X>^'][I?B%E\0Z9=>%_#,UY=:=8W-CJL=
MQ;W+2W=]<7FH37"2O?73+//ND4-7Q>/VX_CXF@7&O7GP,\ 6,:_ W2/VAEMY
M_B5?&6Q\#:KK=WI&GZ/J/_%/(O\ PE6O"T:72;:$K:Q3,;6X>5U+#TUOVT->
MEU>T\26OP^TR/X,1_%3PW\%]6\0WOB&2+QF?&FM:797FJW.E>'$LF@N-&\,W
MM]%8W?VBYBO+Z*&ZOK=(HH3'58C+>+I0E1K8F=2DW)2A#-,+4@YTI4ZL**]E
MB&G/GJJ6&H1U;=2="')SR)H9APM&<:M+#QIU$H6G/+<3":A4C.G*L_:4%+V?
MLZ3CB*ST45"-:5W%'NVL?LL_"75?&ECXUMK#6?#4T#>&'U/PWX0UF?PQX.\2
MR^"[E[OPE)XB\/:2EO;WIT"=LV*6\EG$\:1PWD=U"BQCEI/V*O@;-<^('GL/
M$D^G:U:>*[/3O#TWB.Z?P]X+7QU=)>>,9O!&F>4$T&Z\0RQ[;VX#W+Q0O+!8
MFTBD=#X99?MU^+-&T/P?XX^)'POT;PWX)^)_A_XEZQ\,VTCQ3<ZQXD\07WA+
M4M-L/!&ASZ9)I-K#%JGQ(&IV\VDVMM+<-:B1!*T@$ICQOVK/BK\9[C4/V<?
MNA:3\4-%\0^)_#7C'XE_%_PK\"=5\.MXRTK1_#_A^U.FZ9#K/BO[#81Z2?$M
MV]A>76U;FXF@$5M"_*F\/E_%$<3A\)5S&>#A4CBJ<*\LPA.C&.6T\1+$Q4Z5
M6=Y8?ZO/#2:E[DJE+#RG&G5BG-?'<-O#U\53P$<5.G+#5)4%@9PK2EF-3#QP
M[<*M*-HU_;PQ*C9\RA4Q"@ZE.37V!J_[,OPFUI/%$=]HMW-%XNL_AEIFLVQU
M&=+:;2/A%<-=^"M%CC108=)M;AY&O[5#_P 3!9'6=R" /&/A5^P]X,\-0R:O
M\2=7UCQSXIO_ !7\1O&NHV2ZYJ:>!8/%'Q%N-6MM1\1:3X>F2*2TUR+PWJ?]
MA17S3E8(O/FM8(IIFE/'?"#]L;PIX5_9?\,^*_B9X]'CKXE67PLUSXBW&E6M
MG<QZ]KVBV6KZY;:1:WEY%IEKH@UN-+"#0M8NE-O;MJ]I>7,<+0%'DUO&O[67
MQ:^%FAV=O\1OA/X:MO&_B_Q;X0\*>!-/\)^*K_Q9IB7GBC1[O6]0C\76>EZ3
M/XDTV;PO963O=+::7*-9BGMKG3_+@=V6(X7BNC+%Y?1Q%9*6+EA5*>(6'GBG
M@X+"5)X/ZRZ6(GAH8=T?;SI145AXT75M&DE&GB>&*T<+CZN'I-K"PQ+4:#KP
MPRQ<_K=.&+>'56A#$2KJHZ,:LG+VTJWL]:K<O3K']BWX*Z<_A(6<?BZ"U\*Z
M1X:T*>PB\37$5IXPTOP7>RWWA"U\;+#!'/KB^&Y)I(M-=9[.0VK&VO'NXB5-
MV_\ V/\ X27>G76G6LWC+16/CSQ3\1=&U+1O$CVNJ^%-?\<1W$?C&'PS>RVE
MPUAI/B0W=S+J6G3K>(TTQEMWMWCA,?Q)X]_; ^)OC3PUIGBKPI->?#S4-/\
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M2#13:.LHU&2W.0NZOB?]F_3/@_\ "GXF?"+P5K_P9^-OPM\?>*_"U]I_PO\
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M>/+NXMOA9I^L:QI_B&]E^$T2VB-X.OSKFE:=J4%[')>RV\]I$L6(=T3?:=%
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MNO1^*-(M7D2[626;3?$$2ZO:WLKO>)>%I#.P8J>B\-_L^?"#PCXYN?B/X?\
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M-=?!WP9=-:7(5;FT:XTR*9K6Y52RK<VQ<PSJK,JRHX!( ) /KFBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ^!OV[_"MQXUL/@=X;U_P(GQ8^#%[
M\4IY?CC\*K#2=(\1>*O&W@Z#P=XB.F0:+X:U*6"Y\0:7I'BA]'U?QAIVDRK>
MMX:M;Z9TFM89XGZ/]A'P)XN^'/PC\0>&-7\(7/@#P';_ !-\=W7P2\%:SIEG
MI'BWPU\)+[6[BY\,:9XML+)YEM]4A$EP;:&ZN;K4H-*:PAU"XDN(VQ\__P#!
M6#Q[X/\ A9\*OA=\2/$7@+7_ !9K?@;X@ZQXH\&>(-(\>:K\-+'P5J^B_#_Q
M5?ZC=:KXNT;2]9O8I?$F@P:GX8T+1VL)+37-<U*RLKV6"W+R#Z'_ &&_B5IW
MQ,^%?B2_TF+Q1<:;X?\ B5XO\,6?B37_ !7=>-].\7P:7=QA/$'A7Q/>:?ID
MVHZ%.L@M]@M%BL[^WO+6*6=(Q(0#[&%Y9F[:P%U;&^2!;I[(3Q&[2U=S$MRU
ML'\Y8&E!C68H(RX*!BP(KXUT/_E(3\1_^S2/A-_ZMCXM5Y/X4^$OBWP5_P %
M!?VF/B9X)\/ZU?7'Q%_9K\%266N^.-9\2#X?:EX[T7Q'=6^E>'+?4(;75+;P
M]86=EY;W]IX?TJ>\2"::^FMKR<H*E^!MY\;KS]O/XKM\<?#WPI\/:VG[*/PA
M&D1?"CQ;XO\ %NFW-BWQ4^+37#ZM=>+_  AX.N;6]CG/EP0V-C<6\EN!)).L
MN5(!^DU%%% !7\LG[9O[5O[26K?\%)/B!XO_ &4;GX:?#O5?V,OAQ+\$/%MQ
M\3-$U7Q,OQNN/B*FE_$R\\.ZK8Z7<VDOA+PAH$F@Z>='\31,=1N=2NK][>=;
M.&6(_P!3=?FK^U1_P2?_ &1?VN_B='\7_B/I7Q"\+^.K[2+'PYXWU/X4_$'5
M_A]%\4O#.F,QT[P]\2;;2TDC\0V%E')/;6US%_9^KQ6=S/:+J8MV6-7&R?O)
MM:Z)V \+_9Y_X+7? 3XP_!7X=_$?Q'\+OV@=!\2^)= BD\3Z-X6^"_C?QGX9
MTWQ-832Z9XAM?#GBO2[&6Q\0:"FKV=W_ &/JUN[+>:>;>9OG9JS?VFO^"V'P
M7^#WP+^(/Q"\!_"WXZ:_XXT;3(+7P;I7COX,^._!/@BX\4:S>0:5HC^,?%M_
M9P6GAWPQ;WUU%<:UJDTT?D6<;I&ZRR1L/V"\ > O!OPL\$^%/AO\//#FF>$?
M O@?0=,\,>$_#&C0"VTO0]"T>UCL].TZSBRS"*WMXD4R2O)/,^Z:>66:221F
M_$'X?^"OBMX(\5?#;XC>&M*\8^!/&^AW_AOQ9X7URV%WI.N:)JD#6]]I]] 2
MI:&>)R-R,DL3A989(Y41U0'X!?L9_P#!0;]M.W_:X^#O[/\ ^U5X@^%GQ=\,
M_M,VOCB'PKJ_PW\%2^!]7^%'C#P/X2U'QO=644*SS1^+_AKJ&DZ9?:=!XBOU
M?5[?4AI,DMX\-\\;?T6U^,5E_P $-?V1/ 1;QE\"M=^,?PF^/?A>1;KX*?'1
MOB5XC\;>)?@FT*2)'X?\)Z-XEO9M"O? >I0N--\3>%=8MKM]>T7?ITFK6K&.
MYC]U^!?[9/CKP=\1]'_95_;KT+0_A=^T!J32V?PP^*6AB>U^ _[4=G: 8U+X
M::U?[%\-^/V@V7&O_"3798=>T^=I9M#_ +6TDP3TW9MM)I:63U:T5]?77Y]@
M/THHHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5+_3['5;*ZTW4[.U
MU'3KZ"6UO;&^MXKJSN[:92DUO<VTZ/#/#*A*R1R(R.I(8$52T#P]H/A72++0
M/#.C:7X?T/3HC#I^D:-8VVFZ;91%F<QVME9QPV\"%V9RL<:@LQ8Y))K8HH *
M*** "OB?_@G6,?L;_!8'J-+\1#_R\?$-?6/C/P9X9^(7A?6?!?C+2HM<\,>(
M;3[#K.DS3W=M%>VOFQS^4\]C/:W<0$L,;AH+B)P4'S8)!^/_ /@FKI6G:%^Q
M#\ ]#T>T2PTC1O#FL:7I=C$\TD5EI]EXLU^"UM8Y+B6:X=((45%>>:65@,R2
M.Q+$ ^YZ*** "BBB@ HHHH **** "LK7-&T_Q%I&HZ'JL"W&GZG:RVEU$P',
M<JX#H2#MEB<++"X&8Y41UY45JT4I14HN,DI1DG&46KIIJS33T::T:>Z-*56I
M0JTZU&<J5:C4A5I5(2<9TZE.2G"<)*SC*$DI1DG=-)H\F^'NO:CIUS/\-_&%
MTTOBC0(#)H^IW'RGQCX6B98K'6X')Q-J-FA2QU^ $RQ7B+>-F*]4IZS7(^+_
M  ?9>++.W#7$VEZUI<_V[P_XALE3^T=$U%5*K/ 6PLUO,I,-]82G[/?6S-#*
M =DD?S)\7OVO_"7[+7ANQU/]I6QUO0H[O5(M#TOQ+X/\/ZEXFT'Q-<O&\D<]
MM'8H]SI%RT:%KG3=0"21.&>!I+=HS7FU<90RJC.>85X4,%1CS1QU>?+1ITTT
ME#%59.U.<;J,:E1J-9<OO>U<HO[7 <-YGQ_F>%PW!V58C-.)<SK*E5X6RN@Z
MV88O'34IU,1D6 HQY\7AJ_+.O5P6$A.METO:VHK 0IU8?9-%?,W[-'[6WP:_
M:TT;Q1KWP<U'7M1T_P 'ZI9:/K;:]X=U#P[-%>W]M+=VRP0Z@JO<QM##(6EC
M!56 4\FOIFNK"8S"X_#4L9@L11Q>%KIRHXC#U(U:-6,92A)PJ0;C)*<91;3=
MI1:W1X'$7#F?\(YSCN'>*,GS'(,^RR=.EF.49MA*V!S#!5*U"EB:4,3A:\85
M:,JF'KT:T%.*<J56$U[LDV5\L_MC?MG?L[?L&?!#7OVA/VG/'EMX"^&^A7EE
MI2W9M9]2U?7-?U0R#2_#OAW1[16NM6UK4/)F:WM8MD:10S7%S/!;Q22K]35^
M+O\ P5:_X(G?LW_\%._@MXK\&ZA+<?"3XPZIXLTCQYH?QBT9M4U>YM_$FCV=
MUIIM=;\.WFJC1[_1-6TR\ELK^*VM;6\@:.VN[.=)H&2;I/%/M[]B']O#]F3_
M (*'?!:T^/'[+7CY/&W@B34[G0M7MKRQFT;Q-X4\0VBI)/H/BG0;HFXTK4A!
M)#=1+OGM;JUGBN+2ZGC8LNC^VS^U=I?[%GP UOX^:Q\/?%WQ1L=#\5_#WPQ)
MX,\"?9G\5ZBWC[QMH?@R.YTBVN@8[Z;2WUH:G)IZ%9[V"TEM[=TFD1A^;7_!
M)/\ X(/_ +.'_!,3X46FBW]_-\;?C7<^-O\ A/\ 6OBMJ8U;0;>SUFVM$T[2
M-/\ #?AVRU<6%OI>DV,9VR:C#=75Y=7$\UP0HBC3]5_VE/@)8_M&_#_1O 6H
M>(KWPQ#H_P 4/A/\3(]2L+2"]FFNOA7\0- \>VNE/#<LL8MM8GT%--NY02\-
MO<R21JSJ%(!X=)_P4.^ \/B:]TD7.K:IH=WX!^$?COP#KGAFRNO$M]\2D^+R
M^,9]*T/POX9TNUDU5]4T:P\%ZI?:XMR8DT^-7AO/LMS%Y,GH/CC]KWX=:-\+
M_AG\1OA[%<?%:X^-WB71_!GP>\.:%.-+N/%WB?6))T^QWU[J4&/#EGHJ6=]-
MXBN]0M'FTI+.9'LY9@(Z^5=._P""76C> /CQ\4/V@_@O\:?%'@'Q1XN\7>'/
M&/P^\+:AX?TKQ/X$^$]S#IOBZV\?>']!T2[N+<W7A7X@ZOXRU3Q5<:2TMHOA
M_72ITAEM&: ^Y+^PWX;TCX%?"CX5>$O'FNZ%XT^"GC.'XF^ ?BM/IFGZGJ-O
M\0VU34-6UC5M6\-S21:5J.B>()=5U*SU/P[YT5N-/N(X(;A6MTD8 SOBK^VI
MXM^"?P<\8^/?B'^S;X]B^(OA_P =Z?X$\(_"CP[KNCZY<_%ZXO;6/69]9^&O
MB..VACU33-)\+V_B'7]6COM'L;VUC\,ZI:)!/(8)7Y'QA_P4+M8/&>H^'/AG
M\/\ P_XVT72/V:?#/[3USXI\0_%30O -AJG@[Q/>ZQ;6FD>'TU/2;X7^JQ1Z
M)>233RS6]DDQAMY'C:0-6O<_L&WOQ*^)GA?XF?M+?&[Q9\;?^$3O/$>NZ!X!
M_LZ'P;X"\+^)=9T73O#.FZEX7TW0[U;NP_L7P\OB.RE>>[GFUJZ\3WM]>F)H
M8H3X;X=_X(W_  (M;3XB>'?&/B36O&W@W7?AF?A)\+=(U&TC@U3X,>#=-\>:
M]X_\'6?AG78KLW6H-X,U+68+;2TU-)+>YM-*M8;Z&:"6>!P#["US]KS14^&O
M[/?B_P %^!?$7B[QA^T_)I%K\*/AY)/;Z%>SW%[X8N?&6M77B+6+J*XM='T;
MPIX9L-3UC5M32VO!/:V:G3X+C[5":R-5_;;\&_#31X%_:%\&^+?@_P"-FU+Q
M7%)X.@LKGX@-<^$_!B64^O?%'2M3\+6<AN/AK86FI6,MYK]_8:9/:SRSV0L)
MY+660[OBS]F?Q+XI^'WP(LY/BQ=6/QJ_9[O;#5O!GQ>MO">D+#J.IQ>';WP;
MKR:YX)BEAT9M+\8^$[^]TC6M/L9K>.T>Z:[TPQ-!#%7B/B_]@_XC>,[S6/&.
MJ_M2^+9_BEXU\+?$+X;>.?$MWX+T"^\-CX4?$B#2K:_\$>!?!\MVEKX/_P"$
M=33#<Z%K45[>7ESJE_J.HZI',]T(80#6^)'_  4[_9E\#:1\4[G1]3\2>.=8
M^&6B^+KL:?H7AK65TCQ;XB\(>$;?QQ>>"_#7BN:Q.AWWB&Y\-7=OJEO EPT?
MD.T3R+>+]E.SX4_X*-_L^^(O#T&HW9\::=XCAMOA]8:OX0M_!VN:IJMMX\^(
M?@'0/B1IGPZTEK6T$?B#Q1:^%?$%MJ][!IVZ"UTZ&XN[N:V$3(."/_!,KP!'
M\.9_A7:^/O$D'A!_B5X_^($%M)9VES<P1^.?AS9?#]M&>9Y5\]=.6R35Q>L$
MFN;F1X&5(L&M/PU^P!?^$O#]C=Z%\9;^T^*GAWXM>&?C#X2\;2^$],N]'TKQ
M!H/P%\._L]WVFWOA22[2UU+2=?\ !VASW%T'N8;FRU'4FFM9"+2(. >_? O]
MK+X??M"^._'OA/X>0W>H:-X*\,_#[Q/;^+79H+76[;Q]I$FJQ6/]E7-M;ZEI
M&I:*T3V6JV.HI'=072LDD,1&*^IJ^+_V6OV-=#_9A\3?$/Q5IWCG6_&>K?$W
M3O"G_"57.L:?96)O/$VAVUPFM>)(8K)VBM/^$BOKJ2].E0@VNEJ%MK:22,;J
M^T* "BBB@#XF_:X^)WB32==^$/P*\,W7PQT63X]7/CS3->\1_%S3?[>\(6GA
MGPIX3N-6U'1G\/'5-'BU6]\0W%Q8V&VYO#;P:=_:+_9Y)S!)%Q?_  3M\,_L
MYR_!GPS\5?A!\-_A?\/O&GQ%\/"Y\=6?@*^@U1H+BTU>^AO;"QNIKZ_U.S\,
M/K,5UJ.G:6TL5M!)=;G22<&5OM#QW\+?AU\3X--M_B#X,\/^+XM&N9;S21KF
MG0WKZ;<SQ>1//8RNOFVTDT!\J8PNGFQ_(^Y>*R_A_P#!+X2?"J>ZN?AO\/?"
MW@F:]M4LKD^'-+ATQ);1)FN%MS#;A85B$[M+M2-09&+'))- 'J! 8%6 *L""
M",@@C!!'<$<$5YCI/P2^#F@Q:]!HGPK^'ND0>*;-M.\2P:=X/T"SAU^P>5IV
MLM8BM["./4;5IW>8P72RQF9FDV[R6KT^L[5]8TGP_IMYK.NZII^BZ1IT)N+_
M %35;RWT_3K*!2 9KN]NY(K>WB!95WRR(NY@,Y(! .?\5V=IIW@#Q+8:?;6]
MC8V7A#6K6SL[2&.WMK2VM]&N8H+>V@A5(H888U6.**-52-%55   KY__ &$_
M^3.OV</^R4>%O_2(5] >++RSU'P!XFO]/NK:^L;SPCK=S:7EG/%<VMU;S:/=
M/#/;W$+/#/#*C*\<L;LCJ0RL00:^?_V$_P#DSK]G#_LE'A;_ -(A0!]8T444
M %%%% !1110 4444 %%%% !1110 4444 %%%% 'XA?M@?M!^-/"OQO\ C9::
MU\1/%/AS1_A"?V9+GX:_":'P)<>)/ OQ=T#Q[XMO(?C$?%-L?"FMKXA^QZ#;
M"%);2_MIO#*Q+>Q1I-()#^O'PM\;?#SQYX1LM6^&%[IUYX4M9)-+M1I6EW>C
MV%I-9;5GL[>PO+#39(4@9MH"6J1G^$GFNZGT^PNI%EN;*TN)44HDL]M#-(J'
M(*J\B,RJ03E00#DY%26]K;6<?DVEO!:Q;BWE6\,<$>YCEFV1*J[F/).,D]30
M!/7Q9H?_ "D)^(__ &:1\)O_ %;'Q:KVCP9^T1\'?B#\2_&WPB\(^-=-UCQ]
M\/D+^)-$@6=3$L,T%MJ/V"[DB2TU4Z+>7=G8ZV-/FN/[+O;NVMKORY)E%>+Z
M'_RD)^(__9I'PF_]6Q\6J /M.BBB@ HHHH **** "O'?CM\ OA+^TK\.=8^%
M7QG\':=XS\':P8;C[+>"2#4=&U:S8RZ7XC\-:Q:M%J?ASQ-HMSMO-&U_1[JT
MU/3KI%EM[A?F5O8J* /YAOB7^UW_ ,%#/V3_ (Z>,_V$OA/\1/A+\8])^#?A
M+P9\0]&^/?[1&@^)=;^)LW@_QV=4B\'?"/Q=IWA36] M?%>K::ND2I>?%@^1
M=W&F&&/4["XUGS+L_LO_ ,$\_P!KN^_;5_9LT7XN^(/!]OX#\=:3XJ\9_#+X
ME>&--OI-4\/V/Q ^'.OW?AGQ--X6U68+-J'AK4+VS.H:-+<9NX;2Y2TNWDN;
M>65^3_:__P""9'[-W[9_C+PU\2?'UY\4_AW\3?#>B3^%#\1?@?\ $"^^&WBW
MQ#X+N;E+N7P=XIO[*TOH=<T&.Y5[FQBN;47>GW$LDEG=Q*S1M]6? +X"?"S]
MF/X3>#_@E\&/#$'A+X>^"+![+1]+CFFN[J>:YN);W4]7U?4KIY+S5M<UK4KB
MZU/6-5O))+F^O[J>>1AN"J]+*R=];N^C[670#V*BBBD 4444 %%%% !1110
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M^O:;\)O"NAVPT5M%D_LZ9(;KXDRSRIJ-K?17<9ECMY(HRJ/$')Q]W:?_ ,%
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MP-M]D>*-%)\T2%AMKZ#HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^T%X.T[3;W=\.K'XCZ$3KOA1_P"U7L-;EM])%O=^)H=,?P]'J5B]\C2_?5%
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M+M;K2CXH\ M\1([+P]HDDHUGQ<]AHX2"ZN-+M$@-XS(C;(W<>C_##]L[X?\
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M,-XMU#Q-X7@AT)7L+V!M/^VS:;;?9E>OZ/PB!F<*H=@ S!0&8+G:&;&2%R<
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M7V6H:AHL,^HZ:_[-WBCPMXIO8[ORKJ..[G\<:AX?NGD=!%'I']HA(UN4MQO
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M"PM;'5-?T70M2\1^%X;6XLQ97D,NY7 /UJHHHH **** "BBB@ HHHH ****
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M35^A% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5@]O<&'8Q%;Q5_P3AL/B!X!C\ ?$/X_?$[QIIOA&\\#W7P975K;2DT[X8_\
M"NM635O"D\^CVCP0>--7LS%!I]SK.KSVEU=:7!%:;8OGD?G(/^"4WPGTS4+C
M6_#_ (\\3:1K=QX/L/"SL^B:!J&@236[6TU_J<_ANXB2RD_M6[BGN9[2*6W>
M![IGM[U+B-+B@#])_!/C+0/B%X3T#QMX7N+B[\/^)=-@U72KB[L+[2[J2TN
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M)X*\=66IV-SXHT70=8@F6V\8II]Y;3V/EK<V,DD$TL,J$ 'SE\(O^"7/P4^
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MM4 %?%,?_*1B[_[,IT[_ -7IJE?:U?%,?_*1B[_[,IT[_P!7IJE 'VM1110
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M/PSK>L>)?#O@[PUHGB#Q P?6M:TO1K"RU+4VSN)O+RW@2:;<WS.&?#MAG#,
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MW-XJ_LWJVF6FMZ5J>C7Z&2QU;3[W3+V,':7M+^VEM;A >Q:&5U![$YK\Y/\
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M&=2GM8U\+V\O]M637ET\MGFZB B,!F8B-AG]/J^(?VN_^1__ &-?^SFO#?\
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M;C[9#I7B&QEMM0T?4XBB1W4$L4EQ;^>B)#?V<B7,2K%.H !\D?L>_MJK\5?
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M +*>[X:_MW_\%!_@I*\<.G^-M2^#?[57A:SB4I"?^%C^%]0^'WC>:,-C,_\
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M.52%3WW*K3Q:INA65J<DO:UHQI?79>V@ZLI8M3HJI5P]3!_D/<_#O]I3Q/\
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MC%!9Z/?W-J+>ZU#3;:&*"SO9IX(XHE01J ?25?%W[+'_ "5K]NG_ +.AT_\
M]9]^"-?2GA?XH_#OQMXH\?>"O"/C'0?$7BOX6ZCI.C_$30=)OHKS4/!VJZYI
M[:MI.G:]#$3]AO;[35-[#;2-YWV<K(Z*&7/S7^RQ_P E:_;I_P"SH=/_ /6?
M?@C0!]HU^9O_  4_BD\+?#O]GGX^6Y:.;]G7]KCX$^.[ZX4^6MMX6\6^)3\(
M_&<]Q,/FBL[?PU\0K^ZN>=A%NID&$!'Z95\J_MR?"N3XU_L??M)_#&UMVN-5
M\4_!SQU;^'D0[9(_%-CH-YJGA:XB;@K);>(;'3;A&4A@T8VD-@@ ^IXI(YHX
MYHG62*5$DC=3E7C=0R.I[JRD$'N#3Z^=/V1/BI'\;_V7?@#\68Y(Y&\>?"?P
M3K]TT0(0:A<Z':)J288 JT6H17,;K@;71E' %?1= !1110 4444 %?FG^T/\
M,OBAXP_:?\!>*]!\">,-7T70IO NEO>)K[P^"IO"]EK-[XB\1>(K"[L=7L[O
MP9XZT.\VZ>(+K2]7MO&6E26VG,D$:O(/T@O]0L-*M)K_ %.^L]-L;9=]Q>W]
MS#9VD"9 WS7-P\<,2Y(&YW49(&<FLBS\8^$=1U"UTG3_ !5X;OM5OK#^U++3
M+/7-,NM0O-,)P-1M;*"Z>YN+ GC[7%&]OG_EI7J95C\1EE:KBJ&'C6<L/7P[
M<U5Y(1JQ7/.]*4&I1BK.\K*,G)<LU"I#S<SP5#,*5/#5Z\J*CB*-=*#I*4Y4
MY-PC:I&5TY;)+WI)1DI0<H2_GR\=Z=XLD\1?\(K\7;?Q+?:3HD^BCXLZ7#XA
MM;_Q=H_C'XP_$@^++27P3X:NO$&F3ZQ?R>&[33]&OWT>SU_3+/3+BZMEMHY5
MDBKZJN/V;_C5HB:;\2/"7@[7M-^*FL^*?VF/&NNO;>+;L6>DZ)<^&?$7@WX0
M_"^VT8:K_8,>B:I"WAK6[."QL((=,N+$N7AD#%OU!!^$VO:W?>)P_P /=9\1
M>#-]OJ>OK)X<U#6/"ODHTCPZAJ8::\T0PQAW9+J:V,2!F(5036V?'7@@:)!X
MF/C+PJ/#=R76V\0'Q#I T2X:(.9%@U7[9]@E,8CD+B.X8H(WW8V-CZK$\8XV
M<,/3PV6QHJ*J0Q5*:KRH5I8K#RC4HJE&4;4ZTYO$J$FW*-+"0Y6L/.IB/F</
MPI@Z<Z\\1F+J\SIRPU6+H1K48X6O"5.LZLHRO5I0BL.YI+E=7$SYDZ\*=#\G
M-+_9&^)=AJ6JW6F^%M4T[Q+KOCG]GCP)<>.+CQ%?/>2?"GX8^!8=3\1ZQK+Q
M:H9;ZTU'Q]"MO=6WEFZO QP@@#O)%;?"7XTVG@7Q>]E\%_B5;?&6XT/Q!H7Q
M,^)LWQ#DE7QVGC7Q]"=?E\(^&TUA[37'T?PB9-5\+RVRZ(--^RVNBI,)WE)_
M7"7QAX2@N-%M)O%'AV&[\2QB7PY:RZWID=QK\3()!+HL+W0DU6,QD2![%9U*
M$.#M(->8)^TC\$[F.]GTSXA>'=9L]'\8ZGX$\0W^DZC:WECX9\2:+I\VJ:M:
M^(+D3)'IL%A9P227%Y(6M5*E%D9D<)A#B;.\1J\MCB53EA9RM3QUK8>"H1A5
ME3KQYZ%:%'DEAZC=&56E&<:?M*=GO/AW)Z'NK'RP[G'$02<\%>^(G[>4Z4:E
M&3A6ISK<\:\$JL:56493=.I<_-KX<_LR_%W6I]'T#Q_X/\76_P ))?C5XX^)
M4W@VXUV;P](GA_P?\--&\/>!-%U&UT?Q5JEQ;0>._$5WK6J7VDQZK- +RV6>
M^B@=C'7)W7[,'QIM?#>@7E]\+M;\2_$+PM^QUXQ\'>!M9O->&IW&@^/O%GQ$
MEU#4O"3ZA=:IB*?1O \HTK0)[X3PZC;[[:YN9)545^P_@_XH?#KQ_P"&=.\9
M>#/&WAKQ%X7U;2K?7+#6M-U>SELIM(NI9(+?4&9I4>WMI)XI;</<I#MN(I8&
M"S1NBY.F?&[X0:QJ/C?2M.^)7@NXOOAM=Z=8^/(3X@TZ!/"MUJT*SZ;#K-Q<
M3Q6UJ;R-E\EFF*-(PA+";Y*O_6O/E6JO^SHKZO*G[>C&CC8*E.-2K0DJ\8U8
MRA+$?6XX/$\_++$15"E-N=FX?#.2^RIKZ_-^WC+V%65;"3=6+IT*T71E.G)3
MC1^J2Q6'5.\:#E6J02A=+\[?@UX&\0^+OVC_ !G\,M$O]4B_9V^$VK?"WXFZ
ME);ZQ>.UU\4M.^'NE>$],^%$TT%V%L[3PJ- @\6>*]$M'^P-JITF*:$"YN$?
M)U_X*_M+W7[3WBSQXMKXKU&ZL_B3XE\7>#]<@N+2Q\*1_#:P\$:C8>#?!*:X
MWB*-PFI:I<6EMK7AT^&7D_M"!M2DU!8<2M^ENN>,_A9\*?#5_KU_JOA+POHD
MUCK?B\1VESHVG/X@6UL)-9U;4-*M8YK;^W=0N;6$W#R6HGGNB8V:1MRM7GOC
MG]I[P'X'\,?"_P 1MH/C[Q7=?&*2)/ /A+P;X976/&&KHVE+K=S.^DSZA806
MMOIVFO'<:A)/?*(!)&JB1F J:.=YO6Q+JX+*XU:>)P$<IA&M1<_:.EAXSQF(
ME5_=IUZRP]2MBIN24:4(PG+V=%,JIDV5T<.J>,S*=.>'QSS.<J-6,.15:_)A
M*$:;C4:HT?;4Z.&CR\TZDY3A'GK-+\[M#_9I^-GB#PSX(\&ZIX4\8>'?#$OA
M3X!?#[Q+ /$9T>\TRQO?B1J?Q0^/^KQ)I&I0X\R]L+;P^E[#,-0O[358VA<P
M/,M:O_#+_P 4?"/V/Q;X!\#^)='\66WQL^./BO1/L_C76;UO"?PVT[PIXFT/
MX=^#=/LM2UVZL9]-\>ZU=:/KMS!=1W#6%R9I7DA6-53]2/A9\3_"?QB\!Z%\
M1?!5S=W'AW7X[PVW]H6DFGZC:7.FW]UI6IZ?J-E*2]I?Z;J5E=V-Y"7=4GMW
M"22)M=MFW\<>"KS2]4UNT\8>%KK1=$EEAUK5[?Q!I,^EZ1-"0)H=4U"*[:TL
M)8BRB6.[EB>,L-X&145>*\ZA6Q%">"I4^6O5ABL)R8I15>K"6&K4Z]/VUW4J
M5(Q<HSUE5IN-G"I5A.J?#.43I4*T,75J*5"E/#8GGPSE[&E.&(I5*%1TM(0@
MY*,HZ1IU%*_/"G.'Y)+^R9\7+VP:_OM \7'QGH6I_LU>!? &N2>/=51_"NB>
M'I%\0?%CQU;Q6^L)93I<:S>W5E<R7]K>7U[;0>0L30%,\GXA^!?[3OC/Q=\1
MO$W_  @7BK3=8UGP9^TK)XCM+[4((= \1ZUXDLY?#7PU\$Z%JH\4M+K6AR:-
M);ZY:W$FBZ5:Z?JEH(1<%WDW?JSXV_:!^&'@.[T"TUG7?M0\2>$_&'CC3;W1
M4BU733X6\$:1_;.LZQ+J%O/]E%H]N4M].DBDE%[>RQV\9&[>.RLOB+X.N/!W
MAKQU?ZY8>&_#OBS2]%U;2+KQ5>6?AYFB\06,&H:;:SC4;F&.'498+A UEYKS
M"4/& Q4UM'BG/:2IXB>6T)*OS4\/.I0Q+C*,J<<-5I44ZVL:D\*ZLX02:Q<)
MUHM3<U+)\-9+5E.A3S&M&5%QJ5X4ZV&4DXU/K-*K5?L;\T(XE4HSDVGAIQHM
M.*AR_C[J'[+/QBL_%OP[T/P-X;\;>&/ &E>$_@9I_P ,['3RD-E\+VT)K74?
MBC<Z[J5SXHLY_#^MWFM17C7D46EZ['K>F7?V2PBC&57T?X;? ;XDZW\?/A%X
MA\?_  K\7VOB+P5\4_B]\1_BK\7==\4K>>%O%%Q<VVO:7\--&\*: FKS1/I5
MMI]_H=SIWEZ1;1Z)+I,J2.MY,S2?JK<^*/#-EJNFZ%>>(M"M-;UF)IM'T:YU
M?3X-5U6%,EYM-T^6X2[OHD ):2UAE1<')&*SKKX@> [&XU"TO?&WA&SNM)@>
MZU6VNO$FC6]QIEM'(L4EQJ$,MZDEE!'*Z1O-<K%&DCJC,&8 X5.+<WKTI4G@
MJ3E4PE:A&M"&*5=PQ%"KA*M652G5BZ_M%4=6HJOM*=7&PCB:D95%8WI\+Y50
MJQJ_6JBC3Q-&LZ,YX9T8SH5:6*I4HTYTY*A[/V:I4W1]G4IX*<L-"4:;N?FE
MXF_97\3^./BE\0O$&I^ =4TK3_B_^U/X1NO&VMZ=XGU#3+V]^ WPS\$I%;P7
MDFG:Q!/'IOBOQ=:(RV5F8;A8+RXE=8U?8O%>'/@C\>/#7B*#5-&^&WB^V^(_
M@O5/C)K?B[QY<^,[B;PS\0O#&K:+K&D_#OX>>";2ZUBXB>P=;S2'AAO+"&7P
MZ^ESW%Q>BZF0M^M=UXS\'V,VEV][XL\-6<^N1VLNB0W6NZ7;S:Q%>EA92:7'
M-=(^H1W95A:O:+,MP581%\'%C_A*?#!UN;PT/$>@GQ';VG]H7&@?VOI_]MP6
M&,_;9M*^T?;HK3'/VEX%AQSOQ6<.*LUC25*>$IU:*PL*,:=18QP]C1PZP3<D
MJZYX?5O949QE>ES4,+-QYZ,>;27#.6.I[6&)J4ZSQ,JSG3>%4_:UJZQB4+T7
MR3>(52K"4?WO+7Q$(RY*KM^.U]^Q)XQTOPEXPT_2?!_B?4M9TW]FSX5^%] N
M+CXA^)R_B;X[:YK-Y)XW^(4TC^),1ZOX BGAN["5BMI/!YMLL,RA /H#]H[X
M,>./$OQ-^#?B6S^'NH>/IOAA\!_BKI_ACQ+#?*9;/XO:UX=L]#T-M6B>^MUM
MDFC6>]@U0PRQO=23V\TJ+LK[4N?C?\'K/Q3X>\%3_$WP0/%?BM-6D\/:%'XC
MTR>_U1=#@ANM5\B."XE539V\\4KK,\32(6,*R>7($Z"/XB_#Z8H(O'?@V4RZ
MDFC1B/Q/HCF35Y%WQZ4@6^)?4I$(9+%<W3*=RQ$<U53B3/95\/BL1A9SG"EC
M'2=2&,CSTL=A89?B)1G[12=.?L*S?LY*#J3K4W[D(0IS3X?R6-&OAL/BHQC*
MIA%54*F$ER5,'B7CJ"E#V;2J1]M22YTY*G&C->].<ZGY&WO[(OQE\!^"O$/A
MKX0Z=XH\)V2_!'X&^'?% TOQ)<ZE=_$/Q#-XMCU_XQW5CIVHZQ':P>(K#2[:
M_P!+MX[&?1[;4;77)K*&97*2+]Q_L7_#KQK\//AYXJA\90:[I2^(?'^O:[X:
M\-:\(K>?P_X==+6SLHH-)BU?7AH46IO:3:N^COJUT]I/>R[O*+^4OU-'XF\-
MRZQ>>'HO$&B2:_I]JM]?Z''JM@^L6-DX!2\O-,6X-[;6K@@K<30)"P((<YKC
M?$GQH^$GA'PKKOCCQ%\2/!>F^$O#,MK!X@\0/XATVXT[1[B^EBAL[>_FM+BX
M^SW%S)-&(8'432*WF*AC#,.?&Y_F^;X6> JX2-66*Q&'K2JTZ%:IBZ]25.C2
MI)SDZE2HZTZ<94_B=ZDJ5&U*2@ML'D>595B88VEBI4HX;#UZ,:52O2AAJ5.,
MZM6J^1*$*:HQJ25396C&I6O4BYOTVBJ>GZA8ZM86>J:9>6VH:=J%M#>6-]9S
M)<6MW:7,:RP7%O/$S1RPS1LKQR(Q5E8$'!JY7RS33::::;335FFM&FGJFGHT
M]CZ5--)IIII--.Z:>J::T::V84444AA1110 4444 %%%% !1110 4444 %%%
M% !7X$_MDIXD3]H+XRZU=6VH_P#"6^%_^%52? NZ\/Z/X:U7X#VVLZ^TMEI<
M?[6^JZJTUOH,.J^)X(;>T'B2.*V&@QQ7.B8F,CG]]J_+WXN?!_\ 9M\>^*OC
M-IS_ +56A>"_"?[0#Z7H_P ?OAA:^)?AY=)XMN=$LCX=N+6PU'5O-UKPK?:Q
MI:IHNMI"UY(JP12Z3'I-^KW#@'Z;:<;EM/L3>?9Q>&RMC=?8SFU%R8$\_P"R
MD\FW\W=Y!/6/::^7;+]B+]F*Q\)>+? 47POTZ3P7XVU3^W=>\-7&HZS-IDFO
M#6G\1+KMDCZAYVFZTNMR-J*ZK8SP7PGV_O\ RU5!]1Z?;6MG86-I8X%E:V=M
M;68#F4?98(4BM\2,6,@\I4PY8E_O$DG-6Z / =!_9:_9\\+^-_"WQ&\/?"CP
MIH_C+P5X8T[P=X7UJQLY89-(T#2+6YL-*MK>V$QLFNM/L;Z_L[;5)K>35$MK
MZ\A-ZR3N#\,?M>>'[CQ5\>?CUH=LAEGD_P""=5WJ%O%@L/M&C_&_4-9C<+SR
MKZ<CG R=@]!C]9:^!_%>B#Q+^W9XS\.,0%\0?L#W6B,2< #5?C%KM@23V $_
M)[4 ?7/PH\0-XL^%OPV\4O*)W\2^ ?!^OO,#N$KZQX>T[4'DW9.=[7!8G/4\
MUW]?*'[#FLR:S^RE\&DF+F;PUX?U'X?2^9GS _PS\2:W\/#OR Q)'A@'<1EU
M(?)# GZOH **** "BBB@ HHHH *^+O&$T_[4'Q&O_A7I,TG_  H;X9ZO;CXQ
M:Q;2-'#\1_&MA+'=VGPGTZYC8&X\/Z+,D-Y\09H6,=Q.L'AIBK-=D=K\<_'W
MB74M7TOX!?"6]-M\3O'6GO>Z_P")8 )H?A-\.&F:TU7QM?X#+%KFI$3Z/X$L
M)MC7VM^?J0$EIHEU')[/\//A_P"&/A=X.T/P-X/L%T_0]!LTMH%+&6ZO+AB9
M+S5-2NGS+?:KJ=TTM[J-].S375W-+*[<@  [&&&*WBB@@BC@@@C2&&&%%CBA
MBC4)'%%&@5(XXT4(B(H5% 50  *DHHH **** "BBB@ HHHH _EF_X*K?\&QW
MP_\ ^"G_ .UYXE_:QUW]J;QI\+=3\2^$/!WA:;P?I?@C0]=TZS/@_25TB"[M
M]0N[ZVN7%[$B330R(?+E+"-PG%?O?^P_^R[I?[%/[)?P'_94T7Q7J/CG2_@=
MX!TWP+9^+=6L;;3=1UZ+3Y;B8W]U8V;/:VLDCW#+Y4+,JJJ\DDU]544 %%%%
M !1110 4444 %%%% !1110!R_C?PGIWCSP7XN\#:O)<PZ5XS\,:_X4U.:RE,
M%Y%I_B'2KO2+R2TG7F&YCM[R1H)1S'*%;M7YMZK^S%^U+\0/@SI/[(WC^_\
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MY5#X _:3^+.BVMN#S;Z?K-WIGC2V&W/RK+)XHN95  !W$CJ2?LZOC+X"1?\
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M$=?UO0-+U36/#-W<)Y<]SH6HWMK-=Z5/*GRO+92PNPZG/-=G10!\1?M=D_\
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M>:^T:^+OV6/^2M?MT_\ 9T.G_P#K/OP1H ^T:*** /GC]K?X;1?&#]E_X_\
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M[4Z_\1X6%.,J=ZS]G&&+53%J$;1DIK#S4J,(1C^<>@_M??$#PSXTL_"/Q/\
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M:<ZE2=6I3IQC.I*=64JDG.:<KSDY:ZL****XSK"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@!K@E6 &258  [220<#/;Z]NM?F9\!?@5^WEX<\!Z+9^*/
MVAOAAI%[8>+?'VH6>C^+?@A??$CQ5I'AS6/B#XBU71]-N/'[?&/3_P"T9F\/
MW=BD-U#IMJMG \%B;0+9"(?IK10!'$LBQ1+,ZRS+&BRR(GEK)(% =UCW/Y:N
MV65-[[00NYL9,E%% 'YG^)?V5OB]JG[8<?Q%L8?!B_"6_P#BIX,^.%_XSFUJ
MZ7Q_I6M^#_A%XB^%0\ Z=X<.C2VDVFWDFJV?B.UUF36A;6[-JEM/I<KS R^;
M^-?V5?C+HW[8?P=U[1/VLOVI[N'X@?#'XI>"O''C&/1_@M<VWAO0?#-[:^-?
M!FC0W:?!=]'TG[5XCU*[C#ZA;S7^JVULEI#=*R2/7Z\5^*/_  4'UKXSZO>_
M"[Q#XF\,6W@RS^'?C_QC-\._@_&_BKXHZ;^U-K\NGZ5:>"].O]5^'UCI:?#?
M4[.X>XU'2K#Q/YL1N1-*FK1K#,C 'Y6?\%*/^"!>H?M)_M$R_%/6?AY/^T==
M^(-+LK>;XE7VJ>%_ WC:[NHD6*=/'T/@K3?!&CZS>0"*-;/6_P"R6F:SQ#-+
MO0BM/]E__@B_^T?\%/A)\2/AG\-= MO@UX1AT^Z:U\$7'C)M0C^)&HWFH'4+
MO3+B_BN[Q?L!E+SQ76HS" 3LD,85-Q'];&@SWEUH6BW.HZ>=)U"XTG3I[_2C
M+YYTR\FLX9+K3S,"1,;*=I+8R@GS#'OR<YJ_=1336MS#;W+6=Q+!-%!=I'%,
M]K-)&RQW*13*\,KP.5E6.9&B=E"R*R$@@'X#?L!?LJ_M5?!?XHZU\+/'WBSQ
MS\(_ _C+X4ZG\1XHOAY/H&I6NG^,= \;Z)X6M],U?5M:\.>)_#=M?:IH.KWF
MJ6NF:8;>_FBLY+NX,D,#)6%XR_X)(?'77?VE;KQ7;_%P7?@76/%:^+;OXJZC
MJ@7XJV$AN5O)9$M8=+33I/$UO<9&G7EO!#H\96*0VD4"&SKSCXF:5\=_"GPQ
MU3P]XC\6?M!>*M-TO]J/]LFT\'>*+Z?Q7>^,=<^*PT#1[K]FN2_N-(M_-'AF
M3Q'/J,/A.,I'X6AO(K:UFEAMHE8?T>^"#KQ\&>$CXJW#Q.?#.A'Q&'"!_P"W
M3I=K_:VX1?NPWV_[1N$?R YV?+B@#\NOBK_P2HM_BKH45GXK_:V_:0\>:QI4
MDESX>N/BAJ/@3Q)I.FW<Z"*XF>PT#P5X3NY6D@'EJ4U%%3 :2*=B37<_!7_@
MG1JOP)\*/X9^'7[7/Q_\%6^IW?\ ;'B&P\)V/PB70K[7Y(D@N-1LK7Q9\-?%
MFK62RP0V\30/K5Q'^Y$B+$79!^F=-?[K?>^ZWW,[^A^[C!W?W<$'.* /S \=
M?!7]I+0/C7\!/ >A?MD?M1ZAX*\?VWQ:N/B#X@_X1OX%WAT%_"/A_P /W_A"
M%-3M_@DECHAU;4;_ %&!SJ"SG4UA$%FD<MO(S^W?\,K?%K_H^O\ :C_\ /V?
MO_G(U^/'C+5]4C\3?&[3_#E]\9KW]C^?XH_!;5OBUJ5DGQ<'B'PZDNE?$.R\
M=>'O%,NO)<^,KSXA3^-[;P3JOBR\\"F?PJNBW7AE5+WHU":OW*_9!;XEM^S-
M\&6^,/\ :?\ PL<^#+/_ (27^V@JZOY@N+H::=3 )(OSHPTXW7F?OS,7-Q^_
M,E 'GG_#*WQ:_P"CZ_VH_P#P _9^_P#G(T?\,K?%K_H^O]J/_P  /V?O_G(U
M]IT4 ?%G_#*WQ:_Z/K_:C_\  #]G[_YR-'_#*WQ:_P"CZ_VH_P#P _9^_P#G
M(U]IUA^)WUA/#?B%_#RJ^OIH>K/H:,$*OK"V%P=,5A)^[*M>B $2?(03N^7-
M 'YK>(_@O^TGIO[0GPR^'&F_MC?M2W/P\\2_#[Q]X@\5>)O^$<^!DXT[Q'H5
M[HL/AVP368O@BNG::+VWOKUGL+I);B_-N)+>2-4D ]R_X96^+7_1]?[4?_@!
M^S]_\Y&OPI\/:[\79_">I:=\3S\4KGX8)\1;G5?CQXQ\*V?Q8TS6X_CIJ?PV
M^):>#_ .HZ7.)M0NSX;^,-I\/VU'Q+X3@;0KU+[1;?4[J2PAC:#^DG]GL_$(
M_ ;X,'XMB\'Q2/PM\!GXC#4!&M^/&_\ PC&F?\)1]M6$F(7?]M?;/M C)3SM
M^TXH \,_X96^+7_1]?[4?_@!^S]_\Y&C_AE;XM?]'U_M1_\ @!^S]_\ .1K[
M3HH ^+/^&5OBU_T?7^U'_P" '[/W_P Y&C_AE;XM?]'U_M1_^ '[/W_SD:^T
MZ* /S,^)WP<_:,^'GC#]G8>%_P!KW]IKQAH_C'X^>'_"GQ&LKWPY\$]1LK3P
M /!GCOQ/?W-Y<Z1\&K2?1+2ZUOPSH&B7>L2SQQQ6VKRVD,L%_=V<\?Z9U_-A
M\0E_:$TOXZ_M0Z+HM_\ $77/"D%SXLUC]H+QYH.K>-I-6N_A?K'Q1\#3>%O"
MNE>%+BU6W\-:CX+^&0\;:5I\W@>ZU";7?#,5_J426LLZVS_KU^P ^M2?LW:$
M]])XKF\-'Q1XS_X5=-XV_M3_ (267X2_V[<?\*_DU'^W%36\MH?E>1_:Z)J
MM_*%PBM@  ^U:*** "BBB@ HHHH **** "BBB@ HHHH *^;?BW^U?\&O@EX_
M\%?#;QYK&K6GB+QLMC<0R:=H.IZKI/AS3=6UC_A'=%UCQAJEE!):^'-*UKQ%
M_P 2+3+R]8)<:D##A5!>OI*OSF_:E_90^*7Q@^+D/B/P-K?@^P\%_$+P7\-_
MAY\5'\01Z@VO^']&^&'Q5E^*VG:MX3CMF%M?W>M7$K:%/:79B6U^2^\Q@"H
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MXT33]0^%OQJ\3?"#X\_LW_&?P7??#GQ%\3IK^W?3/#X\"^(O%,5C):WUOK$
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M-;OQ1\$O%?C+3[>[^*<7C?6[+1;&XT+PMI'B(RRZW8)<_:KY]&8B/28(6O(
MZAP#^V&BOY\/^"'M]^RKXBU3X_:]^S%_P58_:4_X*26UA:^$-'\7V'QWU+QM
M>:?\,;F\:]OM*O/#T7C'PIX9/VG78;6Z@NI]-%W#MM&BG,<RD'^@^@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB@]#_ %Z?C0!\1^#/
M^"@W[.?Q CM9/"E[X^U/^VM'\8Z[X*4?#?Q= _Q)T_X?73VOC1_ARL^G1_\
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MBBB@#Y;^//[4.E_!#QO\+OAO!\/_ !C\1?&OQ:L_'NI>&]&\*'28%BT[X<:
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MI-]JA>-[B^FO1.TQE$KN >?^ O\ @HCX$\;^!_A+\39?AMX[\/\ @'XW^._
M_P /?AWKU[<^&M0GU'6_'\NM1Z&VJ:/I6K7>I:%;!-#NI;I]2AB>)9(EV%RP
M7Z%TW]HG1_$UC\<7\$^$?$_BS6O@/XWO/ /B/P]:)8V%[K&MV&D:3KER="N+
M^YAM)[5-/U>!UEFDB+R1RQ*I8#/R#H/_  3EL/!/[*'P*^#'@35O!/AWXK_
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MA.#@(6SVI9/^#G_PM" TW[)WB:%2<!I?B)H$:D]< O9J"< G&<\'TKSWX&_
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M]2I7HUHJ^N$K4\4_W4N9_IG_ ,1/7AO_ *-)\5?^'!T+_P"0J/\ B)Z\-_\
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M .C2?%7_ (<'0O\ Y"K^2.BC_B&/!?\ T*9?^%V/_P#FD/\ B,_B/_T/H?\
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MZS/\:KLWWQ"T>T\B.VL?%;2V6_4X;46=J;1;L-+:-;Q&,HZ#'6:C_P $N?\
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MJ:7M%)352RKVYU.\U/XE-\R?-J'_ !"#A:]WCN*6_9>PO_K!6O[!PC3E1O\
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M'?\ @B3_ ,%./"'AB?P5X4^*_P +/#?A&Y\7Z-\0)_#NB_&2?3]+;QUX=_Y
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M.=[IWAO65U*$6^I"[TV"T6'&HVX\F^\L)]JC++-O#'/Z.^)?^"DO["O@_P
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MR_ZBO)_?Y!_Q [@3^3.NG_,TA_=_Z@O)_?YL_FD_XA]OV[O^@U\ O_#F1_\
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M-VU<QC<^.=JY;'.,4OK#_D7_ (%Z?W?7\.^B]FOYG_X#_P 'U_IZ?&GF1_\
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MS?9X;@7K6XM'9I>&A24RQIB1U5"&HYX;>R_\GEVC'>U]E]ZOHV[.TOYW_P"
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M'_SZ6/\ X!6W_P :K7V[_D7_ (%_]KZ_T](]FOYG_P" _P#!]?Z>GQQYD?\
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MVE]$MOAGH5W\.OC9:_&_2T_8PB^!7C_2O$6L6GPH^$'PB\%>"? =A\>O ?Q
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M^-M$N]!B\70)8>%)O'MM>VVLCRO[7_M>!+JTO;>0-*_FMM\ /VR)=4\%:?\
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M^';B?Q/8^*+S1?.TR#Q# S(I[2Z^"7[6O@[X6:)XN^ %W\=?%.L>,_B!X_\
M@-=^$_B%H]]\,7^'?P+^--AX<TN\^*/AGP/K?Q%\=Z]ING?"/7-'U;Q)X<N_
M%FMMXT^T>(-66VBCTDZ<K?KG_P -4_L\CXCK\)O^%P>&1X_.JSZ%%I)&MKID
MOB.RM7NY_#5MXP;2AX*N/$\%NCG_ (1VW\1R:RTH^RQ63W3+ ?1? 'Q,\%?%
M>TBU7X<^)$\9Z;=::FJ6VK:19:S)IU[ISZEJ&C&>UU*ZT^WM;LQ:II.HV-S;
MP3RW5K+:DW,$44MO),E%?S/3SO:S7Y=5;L/F:7PJS[IV?GKN]#\1K7]FW]K'
MPU\>?&FG:5XZ^.-MXVT#X@Z[%\%O'&E>#M1UWX>:M\%++P5)IG@G0_%_Q6U_
MXL6WA'3]$ENL#Q'H]Q\.+WX@Q:Z\%U:7&H0K+<K[+^P1\)/$?A7]K#5/B%<_
M!CXW_#733^QUX-^'7Q-\5_&#5=<U.R\9?M!Z?XYT[4O'EWX5D\0:]KMQ):ZA
M-;WFL'4M%-GX7U.RFLCH]L@M9HX_U\.JP#Q ?!Y>^&O#3%UHZ4=/U0)_9[79
MLEG^U?9/[,-P;I2GV'[7_:00>>;06^):W/L.J3,T7V34)7AVAXS!<R-%D94,
MI4F,%<E00HQDCBGRKN][_K]_FK:?BG*ZMY+]/ET^7?H?B1X?\-_%CQ+\!_$/
M[) ^!OQ:L?'FL_MJ>)OB1;>,_$_A>XTKX6>#_ EO\?)OB9!\2+'QM>2+IMS=
M2^';5;?1]/T9IM8N[K63 (%B6Z*]9/X,^*WA+]F;XX?L.S_ KQYXY^(OQ-\>
M?$]O#?Q/L=*L)O@_XTT[XE>+W\2:7\9?&?CJZN/L_A_7/#-C,D&K:7K2+XLC
MN=%LH=$MKP/ 5_4G2?B;X%\06/C>]TGQIH]]I?PTUS6_#/Q O3?26^G^#M>\
M,0M<^(-,UR>]6WM[2?18$::^D5I+>)%)29SP?&M"_;0_9<\1:3XIU72OC?X:
M&E>#;'2M7\2OJMCXL\.-9:+K>HQ:1I'B"VL/$7A_2;W7/#VH:K/;V%MK^@VN
MJ:2US<VR->(+B)G+)6UM]W2U]UOI>_Z6'S-]-GY[Z?U;SUN?E-KG[)'[4^B?
M!_XQS'Q3\8_&W@*+]L&/QC\2_P!DVR;PO:Z5^T;\#=.E\&KK&K^!M6GT*;Q5
MIOB6_P!8T6T\9_9AKF/$\&AWNA*+"6]BEKN_$7P$UG^U/'GB_P 7_#+]J/P7
M$/VUOC#\4?A1\:_V8M2M+#XX_"+PSXR\.Z/8Z5?VG@RZT_7V\5>"_'.F6R^%
MO%%F-&U:73Q:O]I@BB<W1_5CXO\ Q_\ @_\  (^%/^%O^.[;P5<>-M2O]&\&
MV<FD>*-?U3Q%J>DVBW^I6>DZ7X3T37M2E?3[-TN;J1K:*"&)U+2@D"O.-8_;
M?_9<\.V7A'4]8^+JZ<GCRS\17W@^U;P/\4Y-=UO3?"5T+'Q+J,'AZU\$3>(;
M33-(NSY%U?ZAIMG9NV3;RSIE@6BKJZVUV\M^NNGEVU'S/>S\FOE>VGE_G<^>
M-*\*_M6ZK^P!\4O#_DW5I\==?OO'5[X3N+70O#OPR^(_B_X?:GXJ%^+SQ)I7
MATV^@^&?C1XO\(OJ]I<7=L]G,=9N-.O[W[#J,UQ'!\<_%KX*^.O$<G@K7?V4
M_@-^TQ\,O#OA_P (?$'2HX_B%KWB:W\4V?B;6_$?P<GU"X\,MXE\4ZOXWT+2
MM8L]'\21W,=]?6MMJLMIJMSI\#:7>1&7]BO%/[1_P&\%?"_0_CAXM^+O@O0O
MA'XFOM"T[0/B-?:G,WAS5=2\2ZBNDZ)8VUU;VT]S]MO-4;["]O-;136%S'.F
MI+9BVN#%Z"OCWPK-XX?X;KXFL9?'Z>$;7Q])X6\^=]7'@J\U"YTBR\2G,9MV
MTNXU*TNK&&07+2F:"0>2$PY+)]>B]?)I^?X_(E-KI;5WW\E9ZVTW\F_D?A=J
M?[-7[3/ASPI=^//"6@_&J7XP>./B]^V-I'CF\/Q \6W=S)\(M?\ A7?GX/66
MGZ1=>(FT/0]+3QQ%IY\'7>E6%GJMAJ1.V]$4KJ?0_"?@CXO^%S\1[_XC? ?]
MH[XJ?M1MH5S=_##QEX=\?>)/#_PIE^&J?!?2]+TKP-K6NMXC3PII6IPZW%JF
MD:WI_P#PC]]X\N?&5P-=L)IK>1+F/]P&M-02(W#VUXD.U29VAG6+9GY"92H3
M;G&T[L9Z5XEXM_:*^"G@+X@^&_A+XQ^*&@>'OB%XN?3QH7A6];5GEGFU>6YA
MT5-1U"TT^YT'0+C6[BRNK?1(_$6IZ5-J]Q T&G+<RM&CG*E;7K?6V_;\-.J'
MS-[)?)-:*W9^2N?A9^SM\"_VI!\>?!.IZO\ #/XEZ7\(=._:-_9%^*]I;:_H
MOC'0?#_AB^\,^'=6TOXN7NCZ1\0O'GCGQ6EIH-_<0VVJ:]?2Z!_PD\F=8M_#
MMK%(AKZV_:S_ &?/V@/'OQ8_:_\ B%\,(OB!:Z[_ ,*%_9\\.?!/5M-\4Z[#
MHP%IXK\77'QYTOP)X3A\4:#X<N_'>M^!ITTIKC439W=W/=:9;V6L:9<B&]M_
MV#D>8,R2O+O4LCB1W+ @X96W$G((P0?3!Z5'N88PQ&TY7D\'U'H>!R.>*%%)
M6^?SM;3MW0N9]K??Y7O=];?B?@EX1_9<^*?BS4OA]H%\G[1^O_ Y_%/QNUS4
M_#7BC3O&7P*TSP]>M\#M/L?",&FZ,GQ<\7?$F;0M1^(\4]U ?%'B*WMY_%(N
M+K1[/^R)(Y'R/#'[.W[6/@?3O@E9^&-"^-]J_B'P+^RSKOQOOKGX@>)]5UB[
M^)?A#X^Z5_PF]YJ5WJ_B&[M[+4K;X5"\BUVRT]+/0]4TB)%U6RNG\V1OZ!FD
MD8DM([$X!+.S$A3D DDDX/3/3M2;WY^=N<D_,>21@D\\Y'!SU'%"@M[N^G7^
MG^(*;MLNGWKJ^[9_.[X;^"/Q[MO!WQP\%2^&?VEH? ]SK'@/Q#'\3[_PCXXE
M^)^N^)M,UGQ!_:GA#XG_  K?XQ.GQ3\+B>Y34_$_C3X#>+/"T>L:?<:1'I^B
M!-/F@/06'PT_;#U+1_"5WXR^%'Q9TGX0:1\/_@SIGQ<^%/@?QKXRN-;\>?#+
MPY\7[F]\::3X-M=4\1KXRTOQCKWA-X-6UCPPNMQ^.(]"7^P(]>NIX]K?T">=
M+E6\V7<@PC>8^4'HIW94>RD"D\R3.[S'W!MX;>VX/C&[=G.['&[.?>CE\WM;
MHM/N_P PYWV7X_E?R/Y_K7]ESX\>/;[Q3-KGA+X[Z;\(=(^"/[8FI_LR^!=8
M^(_C;1O$?@?7-7U3P3=_ ?1_%O\ 9_BF#6[KQI#K6G^*]7\$Z=XJU/5KO2-$
MU"*PU8D,;6/[$_:HT?XS^(_V9_V9/#UW\.?%?C37=5?PO9_&F[TN'QGK6L^!
M-13P<L3:YJO@7X=^)/!_B#QQ//KGFZ>UJ?%>BZ)I%XXU;6+O[.JU^GA=R22[
MDE@Q)9B2PZ,23DL/[QY]Z59'1BR.ZL0065F5B#U!(()![@G![TU&VS^^WE;I
MLK:+[@YG=.RTO^.Y_-U\,OV8_P!K[6_@AK7B/XG>&/CK_P +L^&?[''@S2O@
MU;7_ (Z\6:3/IOQT\/?&3QAJMK<)HFD^,+K2]9\5P^!Y?#\%\->OO$MI/HLI
MTZ\NM0DB\]?>_ 7P;^+MS^US^S5XM^('PB^-6H_%GP/^TI\=?&7Q@^-NH:OJ
MUU\&)OA'XH\.:_;_  HAT&UN=>N/#,:V&EWFD:%!IOA_1+/6-(O[>]76)'$\
M<K_N5YCD@EW)!R#N.0>F1SP<=^M'F2;=F]]G9-S;!WX7.WD]>.:7*M]>GX6U
M];*U_7NPY]U9)=%V[[6OU^?H?G;X7\1Z]\(OVUOVO=4\2?"7XRZUX9^->F_L
MYP^ /&O@KP!JWBKPA=R^&?AKJOASQ"FJ:SIL<L&D'1]6N8H+W[;Y8CC8S#,8
M)KY/M;7XDW7_  3G^*'[**_ 3X\6WQDL=,^+,]O:W/P[U6#PQK;2_&KQ!XPT
MZ#P[XK91H^J7>K:!>VUYI,-O<E[N1_(C'G*RC]PUEE5=BRRJG.461U4YZY4,
M%.>^1SWI?.F( ,TQ (*@RR$*1T*C=A2.Q&".U.WGW^YN[_X <WEV_"W_  ?O
M/QZ^.^I?M ?&CQ#+\5?@/\$OBIX;\0>$OV6M;_9LTC6OB3X<NO!GB'7O'/QG
MN=.TF:^CT;4IH=7G\!_"G2#JWB;5O$%S&+:'5+KR='$]X'SXY%^R5\:?@VOQ
MA^!OCWX+0_&']G;XE?"_X,>.K*7]EC7=2\(:S\/_ (T? [5M*T/7O'_A:\\2
M16=TWQ>\16<D7Q-L;6"WEMO$>L>&5M0MQ>3QV\O[S-+*YR\LCD J"\CL0IZJ
M"Q) /<=#Z4@9E&%9E (8;6*X8=&&",$=B.1V-+E5T^ORL^FUNV@^?1)+;U?9
MKST]3X&_8IT?XO:=KWQCNO&NM?%GQK\,9XO .E_"SXA?M)^"?#OA']I3Q!-H
MFB_9/$VF^/K_ $32=!O_ !?X;TJ=8&\-:]XBT;3[_P ^XO[6V2XM(HKB3[WI
MS.[G<[N[8QN=F=L#H,L2<#ZTVFE9);V);OJ_+\%;_APHHHIB"BBB@ HHHH *
M*** "BBB@ HHHH ZWP/_ ,C)8_2;_P!%-7T'7SYX'_Y&2Q^DW_HIJ^@ZY:_Q
MK_"OS9U4/@?^)_D@HHHK$V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU#31_P (UKUO<W&DVFHZTVNP(D%IJ_\ 9,4FNVCN3"IF('ZQM^T-\$6\&_\
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M)!J.I>&-(NOMNF:+<,7,1L[*[)GA"1K)O)W.RY%=6L\R.LB2.KJH56!Y"C@
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M0.0F3M!]A1RZ)7V=[NS:>FSZ;+N/GU>B5XJ+2T3MU_K[S\!O^"A?B'X[>-]
M^-/@3XS67Q;^%::_\#? L?P$^%OP,N[_ ,?> ?B9XUNOB3I(^(.F^/-7T?0]
M0A\0WMG9VUK(^B7USI:Z5X=1]3A:5P67E;[XD?M4?$/]J3PA\.?A[XN^/WPM
ML?&'B7XM?"+QAI^J:MXBU-/ >GZ=\$]5?X?>.9-$3P9_PKSX?^%/^$PL=%N_
M EU_PEFH:_J,LDC7UDL4DRQ_T1QSS0AA%(Z!L;@I(!QD#/X$CZ<53U2VBUK2
M=1T+4C<3:7JMA<Z9?V\5W<V<DMC>1-#<Q1W=I+!=VKO$[*MQ;313Q$[XI$8
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M:IX%\#^/?%/P]UOP]\-O%'BW2;Z_TN70],\7W9-@+N]U+3+ZQTEKM+6#4KJ
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MMN-Y;;?M+C*6^[S=OGN""L(/F$,#MP11RK73?^G;M?;3Y6NPYWIY?I_PU_\
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M7#JMB56_TJ74--EM(]3L&;*+>V#RBZM68%1-$A((%?2-?/WCG_D9+S_<M_\
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M (1R:.=M;OO%OB#^TH_#K>'+G3K=-.NT>ZFOYH2%/1_ ?_@GI#=?LWZ#X/\
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M>(O%]WX+^*G@;XD>(?AO:?LC^)O@S\0M"^*/@T> -#^%NKWOQ#O_ !'#\"/
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MKBVNK::.XMKFWF020W%O<0L\4\$L;*\<L3LCJ058BGT %%%% !4]K_Q\V_\
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M0[UB&6F9,K  3,4 H<4[:O3;4.>5V]//33HO7\3^>7XA_L;_ +4?B?P)XO\
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M%% !7S=\41J9O/$JZ&UJFNMHMV-!>_#MIZ:V=.D&E/J"QXD:Q6^\@W8C_>&
M.$YQ7TC7S]XZ_P"1DO/]RW_]%+6U#XW_ (7^:,:WP_UW1\6?L90_M@V_[/\
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M+K4+O3[BW2WO+Q721OZ-RQ.<[<GN$0$?[*D*"J?["E4Z?+P,,=8I %EM;&<
MAE%QI]C<A6&,,@N+>4(W&2R;68_,Q)YI.%[:[>5[Z16NOE^@^?LK;;.STO;6
MWI]VFY\=_L#Z)XE\/_LM^"-/\1:7K^@V<OB#Q[J?@'P]XI%S'X@\/_"S5?%=
M_>> -(U&WO2;VQ$&CR>=8Z=>?Z38Z;<6=NX542-/L6E9BQ+,<D]3^@ [
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M:1=7-XQO+B>Q\F2:Z)N')F)>FT[W3^6MK:=GY7TWO82:2VN_E_D_)?Y,_/\
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M&TXO)YD5Q) KRJN6/Z[VTV7_  _?<5Y>;MIM>SNGT\TCYEUC]F#]KG5_A?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4]K_Q\V_\
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M\'?AM8>"T^&/Q;T?5;[57CU%]*\7?"FX\2:+;WMZ3>W>M:O:PHA,$!'NC?\
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M2^&GP[M_",T7Q&\5>._VB/#\%CJ>D>)-?G<: Z:5JZSWNEO9_+?0S"WU#9L
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MO? 7>K^:B1K7ZH44N6.NF_\ P/\ (?-)]=M=E_D?B1\%?^">?QY\,>(OBO\
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MD*/;O^5??_P/7^EJ>P_O?AZ?\'\/,^5_LMU_SZW/_@/-_P#$4?9;K_GUN?\
MP'F_^(KZHP/0?D*,#T'Y"CV[_E7W_P# ]?Z6I[#^]^'I_P '\/,^5_LMU_SZ
MW/\ X#S?_$4?9;K_ )];G_P'F_\ B*^J,#T'Y"C ]!^0H]N_Y5]__ ]?Z6I[
M#^]^'I_P?P\SY7^RW7_/K<_^ \W_ ,11]ENO^?6Y_P# >;_XBOJC ]!^0HP/
M0?D*/;O^5??_ ,#U_I:GL/[WX>G_  ?P\SY7^RW7_/K<_P#@/-_\11]ENO\
MGUN?_ >;_P"(KZHP/0?D*,#T'Y"CV[_E7W_\#U_I:GL/[WX>G_!_#S/E?[+=
M?\^MS_X#S?\ Q%'V6Z_Y];G_ ,!YO_B*^J,#T'Y"C ]!^0H]N_Y5]_\ P/7^
MEJ>P_O?AZ?\ !_#S/E?[+=?\^MS_ . \W_Q%'V6Z_P"?6Y_\!YO_ (BOJC ]
M!^0HP/0?D*/;O^5??_P/7^EJ>P_O?AZ?\'\/,\"\%03IXBL6>"=% FRSPR(H
M_=-U9E 'XFO?J3 ]!^5+64Y\[3M:R2_/_,UA#D5KWUN_6R_R"BBBH+"BBB@
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M.@^$+VW^)A^%\]WHTWPQ\,#Q%\--'T^'1YI/BC?-HWB[Q)?6,NI/)IGZ:_\
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MXM_MI_&/]FU/V3=1^ EEX9^&GPM^"&F^'?'/C#X"?'3PG\>/^$*L]:^(>O\
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MF_Q%\0?'7CB^\2?'>'1_B*?%NK>*/A)IGQA\0Z7\&KOXA>./A6WP9\4?%Q?
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MP\<:Q\'?#?B*ST;0IK'7XWUN^CT+] OB7_P2R_96^)_B:[\;WP^+WA#QS/\
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M8Z)\,_$6B:/-\)=$3Q)XX\)WL%]-XY\$2:EH^EVMA9F?2/&>J2S10'[6L_\
M@E!^QY::I\2[V3P]\0=1TGXB^'/B[X5T[P5JGQ/\87_@+X0Z1\>[@W?QEC^
MWA&;4#I/PAG^(MT(IO$ESX1ALY;@V\$<)MX$\H]IJG_!-S]E;6+CQ#=7WACQ
M2\WBBP_94TW5S'X[\31++:?L8ZC=:I\!TA5+X"W;0[R\G?77B"MXI1ECULW2
M*H !\I_";_@JSXY\9>/? "_$+]F2Q^&WP.^+_P 5/VL_@9\+?BJOQITW7M9U
M?XH_LL^+?'^DW">)?!MSX*\/Z?X3\#>.?#7PS\8:S8^+KOQE<R>']8T>ZT;6
M-'73FM/$-WX?8?\ !;_Q1+H7[1T2_LT^$?&/CGX+R_!.;P3;?##XW>)M;^&/
MQ9TCXW_$.;X;:)J.A_%3QI\"?A_IMY::7K*Q7=SX@\"Z1\0_ VIZ<+J71?%]
M_+!'%<?0W[+G_!(+X4?"<>,M>^.7B?Q1\;O%?B7QU^UYK6D:!>^,_&@^#/@C
MPW^U;\1O%WB#Q"_@GX5ZGJD^@^%O'UUX \16_@7Q/XRTN)+[4X1K$EF]I!JL
MD0]"\'?\$?\ ]CGP;8:C816_QD\2_P!J>%/A7X%N+WQI\;/'WB>_B\&_ _QM
M%X[^$?AFRN-0U1A8:-\/]2A72?#MG9QP1VGADOH+^;9.RD ^>- _X+&^(KK]
MJV[_ &<-=_9;\43:3X!^)VC_  '^-WCWX;I\</B;:^!OB[>>"M$\5Z[=Z)J&
MC?LXVGPNU?X2>$[OQ3X=T;7_ !EXK^+/@'Q;8))JVL7/PZ@T^TTY]6R_V;O^
M"A?[27[4/[97['T[_#F#X._LF?M&? 3]I;XJ?#>T@\7Z+X[U/XK^'_!FM>"+
M#X?^)O'$<G@G0=4^&?C"'3M2O-<'@S0=?\4:0=)UJV.I:_<W\+65K]^:I_P3
MS_9XU7]HB;]I M\4=,\0ZEXUTSXH>)_AKH7Q8\;:)\!O''Q7T3PLW@S2/BIX
MX^#6FZI;^"_$_C^P\/Q:3:Q>(=3L)9II?#?AJZNX[BXT6SD3GO@=_P $S/V8
M?V>OC1HGQQ^'$?Q3A\0^#='^(_AGX:^$O$'Q:\:^)/A?\)O"/Q5UFR\0>,/!
MWPO^'6JZE/X;\&>%KC5K""[T[1]+M4M]*/F16/DPN8P ?#WB;_@HI^TU\(?V
MQ_V]OAUXD^&_A?XE^$?"GQ%_8.^ O[(7P[TSX@6GAS[?\5OVG+'Q7#83>.?$
MDGP\GN_"WAWQ'+;S^(/&^M33>,I/!MEX3LK#PYH&MSZO=-']?:5^VCXH\:?L
M4_MB?&#Q;\.=5^$/Q@_9:\-?M*>&_B1X(\(>-]%\5)I/CKX,>"]>\01:A\-/
MB/K/@S^R-9T[6]-AT?7/"NO^)?APD5I/?0QZ_P"#KI+.YL+GN/BM_P $XOV9
M_C'XZ^-GQ'\76'Q!M_%GQZLO@X?&&H>&OB5XK\-KHOBW]G^^N-1^#OQ2\ 0:
M7?0Q^!?BMX#N;J8Z+X\\/BUUE(F,$TLT)*'H;;]D#X5_"_\ 91^+G[.?@+PA
MXC\;^&OBCX<^)MI\1K?Q/\0-:N?B/\7]1^+=IJ5C\2];\5_%75I[G7KOQ[XN
MT[5]3C3Q;?7#7%K?&PD4Q06L:I,Y*$)3DI-0C*348RG)J*;:C""E.<K+2,8N
M4G913;2-L-0GBL10PU.5*%3$5J5"$L17HX:A&=:<:<95L3B)TZ&'I1E).I7K
MU*=&E!2J59PA&4E^6&K:A^T_\0/VG/\ @GCI/A7]OG]J[X??#;]M;X+^/?C#
MXM\!VNC?LI:U+X,F\'?"7PAXXT/P]X8\1ZE^S5-?FTN]0U6[B\1W.HQWT^H!
MY'TMM%1XH;;],_VK/VH/BK\#_$7P8^"_P ^#.F?M%_'SXM6/CG6=&\,^-?B?
M;?!OPW'X+^%GAN'4O%OB36/&\'@CQI$FN7VJZEX9T+1-#M?"\-IJ&I^(&N+F
M_P!&TVPGE'A&D^ M3B\5_LU>-?"G['_Q'M/$'[/7@#Q#\-OV5[OQ7\0I=)M_
M#/@_4?"6D^"_&5O\<[%[RXBT6_N?#VBP?\(E+JB:U?ZO<(@AGM;^Y=U]I^)?
M[//A+]O/PMX<U;XP^"OCA^S]K7P]\1:M)\._%7@;XGZY\(OC;IT.K^'+_P *
M^.[1/$O@+4+?4].\'>)X=1O=(GT>6]GMO$UAINF^(3'#'+IH@X,-FF$Q554:
M*Q7/)2E%U<!CJ%-QBN9OVM;#TZ:7)*G-7FN:-6BU?VD+_69UP'Q!D&!GF.8R
MR'ZO2G3I5(8+BKAC-,7"I5G[*,'@<MS?%XR4E7ABL/4Y*$E2KY?F5.HXO XA
MP^-/$_\ P61U+1OVKM/_ &;M+_9,^*>L1>%M=^"W@OX\7NFZ3\4?%WC+X9^.
M/C+X6T;Q3_9>E6'PN^#7Q$^$FMZ1\/+;Q+H$7CK6O%GQM^'CV\4NI:II&G:I
MI%E;WU_\)_!__@JM^U_X'U7Q9XL\7Z?XH_:BL/#GP@^+>I1_#/PQX8M[%(]>
ML_V\=,^!FA_$77;_ .%_PT\9^/H/!?PX^'E]+)XHG\*>"?&%Z-!L[G5V\-ZC
MJ*?:A^T3?\$OOV4[?XA>#OB!X?L/BCX,C\*VGPLM]5^'W@KXP?$#PU\*_B==
M_!/2X]%^%FM_&'P'IVM1Z1\3-?\ !VE6VG6&GZMXG6\NKBVTC28M2:]6P@"X
M]G_P2B_9$TF/4)?#NF_%+PIKMWH6NZ'IOC#PK\7_ !WH/C'PL_B#XQV_QYN=
M>\)^(;#58KW0O$EG\2[6#5],U>V8RV=FITA4?3'>V;T3XTY _MR?$?XP?\$L
M/CG^V;\(O"O@'0?B=X:^!_QW\6^#;+2?BOH7Q(^'+ZO\.-$\2W&G>,-"\>:)
MX>GDU/1Y['2H_%>E>'_%W@?PIXL2X6'PGXX\*^$=4_M&.Q_./X+?\%3/VRO!
M?Q$\3^(/C/\ #G0?BI\(-,^$G_!+>^^)0T;QYHGAZ[^#_BC]K'X>W \8Z[\.
MM/MOAM!J/Q;O==U^>Q\7ZQH.NZCX,T_0[%)=/\/Z@=GD7'[@?#']BKX"?";]
MFWQI^RKX8T+7+KX6?$G3OBC9?$9_$'B75=:\8^.[OXT-K;_$KQ!XG\77,PU;
M4/$GBB3Q#J<EYK DBN$>6-H/*,,>/(/#O_!+O]E#PYX1\0>#(M*^(NKZ?XIT
M7]FC0?$&I>(OBAXPUOQ#JEA^R1:RV7P2-SK=YJ#WK76@64HM-4N@XF\0P06\
M>KM<B%* /E/XL?\ !6'QQX3_ &J]?_92\'?"'X6^+M1\1:'\;M+^%/CSP]\9
M_%FOP:5\2_A1\*_$OQ"A\*_&T:9\#[GX8_#S5;U_"]\NH^#]%^,'CCXC^'M(
MOO#>LZ_X(L+?7DCM>.U3]L#]JR'_ ((K_L[_ +4VL>+=/\-?M&>.]-_9DNO$
M?B[0;?0?$MOJEO\ $/XG^#="UR^_LZ\\):9H=K=^)/#FK7"WNFV?A]8]%N+R
M6WTVZEEMH;P_:.G?\$K_ -DW2_C(WQNM+#XH+XCA^)_Q$^,&B>&6^+/C0_#?
MPKXZ^+W@[7_ _P 5]2\,> 1J*^'M)A^(^C>(KF7Q?:QVKQZKJ=AHNH.8YM)M
M-GIEA^P3^S]9_LK>#/V-9[;Q[K'P0\ 7?@^Y\+:?KGQ#\3ZIXITZ/P#XML/&
M?@_3O^$QN+TZ]/I>@ZKI>GV]E8373PII%I#I3!K1=A /A?Q7_P %DM"^&G[3
M_P 1_@O\0OAEX5OOA?X,\ ?'OQ_I_P 5OA-\2_$7Q)OT@_9_\/3^)O$_ACQI
MIX^$WA_X7:%XXGTZRNX[SP7X5^-/COQ1X4O)=,MO%FD:0]ZYMO&_VJO^"F?[
M6?P"^%_[+/QN^/WP(N_V8O#.L?M;_"_3_&VD?##QWX7_ &BM,^,'P!\8_L__
M !0\>WOABVUC4/!?@K6O!_BS2?&&B:59^+O-\/Z1H_A^TT<:_#\0;CPV^KS6
MGWMX:_X)/_L=>&?B4_Q+C\.>/M;ECUOXVZSI7@+Q-\3O&&O?"CP[#^T=I6NZ
M;\;?#WA_X<7NH/X;TWPS\1+CQ!<Z]K^CI:/%/XDL='UF-X[G2K397\%?\$F_
MV2?"5AX5LM83XQ_%>;P9\0/"OQ T+5/C7\;/B#\5-5@_X0GX=>*/A7X7\"SW
M/BO5KU+KX8:3X,\9^)M/B\!SPOHD\VK7-Y>0W%P590#Y/^-G_!97QI\%?B#X
M!^$\W[)>N_$CXE/\,/!WQ;^,GA#X/:Q\6_BW<>&?#WQ$UIX?!>@_"W6_AK^S
MQXL\+_$#Q;J'AI'U^[3QSK?P?\*Q31R6.G^*=3M/*U66K\1/^"C/[1GQ)^._
MP#TWX+?#(^ /V8IO^"B6E_LJ>+?B]?\ B?3-3\;?$HZ%\'_%WBGQGH6J?"?5
MO S2>!/!$_BG[%I6F^++;QK+XMEUGPC=6USH>D:=J4<EW]::M_P27_9-U:Q^
M'^F?:OCII%CX$\%1?#"\@\._'OXEZ WQ,^%=CXLF\8Z%\,/C!<:5KEM=?$;P
M+X6U*XEL?#&AZ]/*FB: QT&SF33"UN>IN_\ @F)^RU<?'G2/V@;:T^)^D:YH
M?Q=M/C_IWP[T3XL^-=+^"<7QOMO!Y\ S_%5_A-:ZDGA.7QKJGA,)I&L:K)9L
M=2BC2:XB:Y!F8 X;_@I)_P %$M4_8)T#0_$&B_#OP#\4W;0]7\6>)/"&K?%+
MQ+X9^)$OA;1YTBO=3\ _#_P%\(_C#XF\3VFFJES)XA\2^(K#P3\/O#6_3(M:
M\:VDVHJD/B>J?\%:_'%M\;+;POIG[+MK>? B#XY_LI?L_P"N?%>]^,D%CXUM
M_&?[86@:#J?PSOM(^%\'@"_L=4T'0-4\0Z?I?CRZN?'VEW6FPN=0T2TU]$E@
MB^R_VI/^"=_[-_[8'BVR\:_%^T^(,6MI\,/$_P %=?;P%\2?%?@"U\=?"3Q=
M?#5M8^'?CRV\-7UDOB;PL^MI#KMOIMXP2#5[>WNPS&)5$4'_  3F_9@AMTMS
MX?\ %UQM^*_[-OQKDGN_'OB:XNKGXA?LHV6@V/P>U6ZG>^+S6^G0^'-,;Q!I
MS'['XGG6>;6(KA[F4L ?EU^PW_P4L^+NN>,/  _;D\9>#/A;I^OZW_P49U#4
M/%G_  MGX?:-\$-#\-? ;]JBS^&/A?1O%MYXG^&7@S4H+WP:NHCP-X(UZ+QI
MI4.NZ#I*>(/%>GZKX@\0I!I'TG:^//CC^W7^T?\ M-Z)\#_VTK_]G_X(?LU:
M#\++#X:ZK\!M/^#7Q A^+OB;XF^"Y_'<GQ#^(_B3Q_X/^(6GWWPWL4M;?2?#
MFB> KCPU+K6F_P!KZI+XL29K9;;ZG^%G_!-G]E?X1?$ _$7P[X:\4ZUJL6K?
M'?5M,T3QSXUU[QMX,T$_M(^.M,^)7Q8TW0_"/B*XO=$T[1M;\<:7%XALM+BM
M3;:/?7-^VG+ EY,K+\;O^"<G[/'QN\:R_$)K[XN_!OQ5JO@RW^'/C2__ &<_
MBUXO^!T7Q+\ 6)<:7X.^)%CX$O=-LO%VAZ/!/?6>D6^H6YFTZPU+4;&UGCMK
MEH@ ?!NDZO\ M8?M8?MH_&'X,Z%^WOXN^#N@_"?]C/\ 9@\?Z-J7[+?AKX%>
M)?A1XN^+_P 2=?\ C?H'C?QJ9/BG\-_BAXEU'PC>:EX!T6?3O"-AXVLY=,L8
M[O2'\0SW_FZL_"W?[?7[:7CW]F3_ ()8?M Z3>_#+X?>'?V@/VD_@#\*/VB;
M[1M(NM7USQ]?>-/'7BOP;KFC?#[2]:M[K2/!O@;4K/PS'XHF\1OJ&O:[?#5$
M\/:/%H::>^N:E]Y_$'_@E+^S)XT\8'QAX8\1_M#? >2?X+^ ?V>]3\-_LX?'
M_P"(?P5\&:U\(/AA'XCM_ _@W5_#'@[4[/3KRQT*S\6:_8VTY1+UK/498I+E
ML(R_2'B[]CSX >,/AW\"_A/<^"AH7P\_9O\ B-\,?BE\(/"WA+4K_P ,Z9X8
M\4_"![E_ V(],FA:_P!(TYKN?[5I%ZTUGJ6[=?),V6(!^-/CG]L_]JKX1?MW
MW&C_ !2\:?&;1K'Q%^W/\._V>?A;^SA#\$+-?V;_ !3^R?\ $[3_  WX;\/_
M !Y_X7M_P@LMY??%5?&NM:S=W?AZS^+<-SIPT 6=]\-UTK[1J9^_?VE_%7QQ
M^+?[87PT_8Y^%?QS\1?LS^%(O@AK?[0OQ&^)7P\T7P)K/Q9\7*OBRZ\!^%O
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M8ZI'I?C#QCX*FL8-/3Q-JT4NHZCH^_3-1>XMW(KU32?^"=/[+VB7WAK4=/\
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MZ1\0];^$GA7]FSX[#XJ:K/X!UKQ#X-\>W.A6WP@^(GPWTK1OAWXS\,7EG?\
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MHNM?!_3? 7ARU^'FK?VW>'4-6?4O"L5@NDWLNH7Q^UW4US;22RSJDA?='&5
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MOKO[/Y^'=E\.-)\ _%CXF?'GQ/K7A.U^*_C#PGHW@FZ\"V7AK5+KX0Z?\1?
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MS1V>H6?DW-LDLBQ2*&((!_.]I7_!2[]LWX@_#OX7^#]$\;?L[?"WXM6&@_\
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M!/B;Q/I^I?"SQIXL\%+)XKT?24M]>BT;7?$ESIFED^%;_5-6ATQ8W_IAL/V
MOV(=+^$6K? '3OV3OV?[+X)Z[XEMO&>L_"VV^%GA"'P/J7BVSCM(;/Q)>>'T
MTL:?-K5I!86<%MJ+PFZ@@MHH(I4B797;C]DO]F!8?#5NO[/OP=6#P;X1\'^
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MLKW3);^]UCQ-X T_PKX)UVRO+V?1+C1O!^B/%IT-[]LN;D _#7]O/P+^S_\
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M^.R^*%QXJ\47_AB[USQ=X/UK1M&TS01-IEYH5O>V6J'4KK]8OBY\&_A/\??
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M?PLU#1[[X?6GPEO=)O? 'A6ZTV[^%E@L:V/PVN;&?2GMI_ 5FL42VOA&6)M
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MT;\<=.U?2/B%KWCOP?XN\+Z[X?\ ^"41T#X S>$]2LO"?A&'XF^//%*ZG<>
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MM)\8ZGX,U+P[;:]XBM=0M_#>M/>KH_B0WMM?ZGIUU''?V$,UN'D^Y[;]E_\
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M2[/5=5L?$S76GZ]=6J:EI5G:2<'K'_!9/]J?PGXT_: U[PKXN\(?%_X+:O\
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MB+PIXMT'X%>,OVS/$_\ P34\':AXT^(EEJ7COX<?LY)XI_9[\=>(?$&I^'?
M6OZUH>C/J/Q,N='2S\(6FJ7V@6FIWFJ6%WJL]U=PQ*_]/WQ6_9U_9_\ CL^E
MR?&[X'_"+XP2:':WUCHLGQ/^'/A#QY)I%EJ<]C=:E9Z8_BC1]4:QM=0N=+TV
MXOK>U,4-W-I]E)<)(]K"49XK_9P_9Z\=Z5XST+QM\"O@_P"+]%^(T'A2U^(&
MD>)OAKX.US3?'%MX$MOL7@B#Q;8ZGHUS;>(H?!UG_HOA:/5H[M/#]M^XTD6D
M7RT ?SW3?\%./VP/'O@#PUI&B?&;]G[X+>*/A[\!OVW?C1XK^-OB;X>OXB\
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M+]C']M[]J/QQ^W1XF^!7[0WC7X;3>$OB!I?Q<\4_!'PMX$\'Z5XA\*ZAX/\
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M%3/^"B-_^S)H_BW3O%?PFTGQM\+/C-^UWX/_ &@/$&G>&_@[X[^)*>$/V?\
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MH_:6^+/QL%[J/QM_9>_9M^'_ ,+=&_9.A\:?!+QY'8^-+7]H:]_:*^%2>/\
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MXF7PWHFFZ(OB'QAK[Q2:[XJUP:;;6PU7Q'K+V\#ZKK=\)]2U!X8FN[F4QH0
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M;OBG2= TFY&C2VT<DVK"_OOL4D*/)=AD4D 'X;_LX?$?5OV:?!G_  4%TO\
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M:S8L] 'YL?\ !/\ _:>^'/CO]F_X(_ S3OV/_B+X7\#>/;OXV_"6YO\ X'^
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M;34/B&GAB.?PN?#^F_\ "BK;4=>T+7/%UE9:O$]U<:#'+_2_8?#[]F_P3?\
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M7-Q->3QQRW#R2(K  _#'Q9X4_9#^,'[37[?_ (D_X*%^.X=#^)WP(\2:);?
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M_:#^*'P\\._LH^&/AA\2]%_9M/[3/QUTGX<>*?C[X^\*>'_$MG\'?#Y^%7Q
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MT^_^$NE:KXWTC2;G]HIOA7/\?9?B5X:T?5K_ $G?J.A:!X2TW4W&AFPEE_J
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MV\&P^&O&NO0:=_:6J6'@21M:^&6HS:787LO]HM>-_4)10!^'%W\,X[/]J?\
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M7_#&D?#&^\0?LR_#6#X0W-E9Z#I\6E:5I</B236+RRU/6DMO#^MR^'(-%O\
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M(T+0K;]HU_%/PFM;&/P_X\EU*234(O'6EZSI^H0:!J,4VH7D=I>E[AOZSZ*
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M/'CGQ#\&8?!'AYOL^A?#R?3?&.FZ;%X'^*FEP:7X@UVXN1ID>N:BUS;VT?\
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M"#X>V<-O;>!]=MM6M-7\.W-Q=S:5<VLL5W'])>+?V@OC+H?[6OA:'XP?'O\
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&444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img143810944_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img143810944_2.jpg
M_]C_X  02D9)1@ ! @$ D "0  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $@ _T# 2(  A$! Q$!_\0
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M(#_P4#_Z2*>(?_#)> /_ (FC_A ?^"@?_213Q#_X9+P!_P#$T ?O317X+?\
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MQ#_X9+P!_P#$T ?O317X+?\ " _\% _^DBGB'_PR7@#_ .)H_P"$!_X*!_\
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MBGB'_P ,EX _^)H_X0'_ (*!_P#213Q#_P"&2\ ?_$T ?O317X+?\(#_ ,%
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MQ#_X9+P!_P#$T?\ " _\% _^DBGB'_PR7@#_ .)H _>FBOP6_P"$!_X*!_\
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MBOP6_P"$!_X*!_\ 213Q#_X9+P!_\31_P@/_  4#_P"DBGB'_P ,EX _^)H
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MBGB'_P ,EX _^)H _>FBOP6_X0'_ (*!_P#213Q#_P"&2\ ?_$T?\(#_ ,%
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M\(>.=;30?#^C:WK'C3XB^&=.\>>/I;KSYKOP/\(I_'?B"RM8HIKFTC%]9^:
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MT7Q9KIL=3BT&VL-=MO"WCR/POK\NC:WI^J-9I9K/*F1^S#_P5R^#/[3OQ"^
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M9OCA^SMH/Q^^%VF?\$^_VD?VO]._;)^)O@W5/ 7BN\_:;T#Q(?&NC?%#Q/\
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MG#/\;/#'ASQ+X:T;4&UGP9X@TR;5[7X<7=[=7GB/P'<7D,MG+;NDMT_[<T4
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M/C#6=0\%ZA)\./!5[!8V_A3P/"-%\6WD<S:[=I&[RS^9_LW_ /!'GXP_"/\
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M#-LNYH]DLF%K7_!)WX^W6E?M!_#;2?C'\#8_A+\4/^"EOP\_X*(^ KN]\/\
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MA!XI?XL_$[X[>"O@;^QE8?'3X9:I<:S:?L+_  I^,%]8>&=+O? _BFWTK4_
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M_@I5>7$6E^+Q#?\ P\\2'43'\,;-7TY9%\>P?;SYM_.(?#*X^34)MG[YL_\
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MUU\//C-\-;UK_P ->)YO#4\T5GJ>DW1GO[#5M)%PFRROW:U>1K=8)_CG1?V
M?VZ_CWH/[1/AO_@HA^W9X?\ B1X0^,_[/&O_ +/GA[X5?LV_#@> /A;X<E\0
M3)J!^,GB'2-?TS2[C7?B3HNJ00-ID=K#:VUW9">TU'5VLI(M.M_V:HH _GD\
M)?\ !&GXI6O[+W[3'P-UU/\ @G9\.O&GQ8_9QTC]GKP'X_\ V:OV6]5^&.MZ
ME-:ZWH&J:_\ $OXX?$&Z2[\9ZMJGBVW\/62:OX)\'Z:/"*:NJ:W GG*;=_T7
M_9Q_8W\7?!+]K3X]?M&:UXU\*Z[H'Q?_ &=/V5?@II7AO2+36H-<T;5_V>_#
M=_HFNZYJ<U]:Q:;)I7B*XO?M&BQ6=S->P0+LU&&WD7,GZ"44 ?AUXZ_85_X*
M8^!OVT_VOOVH/V+OVI_V3/AAX4_:SU3X4ZCKWA/XT?"3QA\0?$NG?\*K\!6G
M@[3$^U6^@:AI5FTURVL7CG3;EDN+:ZLDN%6:V;/)_'G_ (),_M&?'W3/VZM2
M\5?'CX+)\0OVT/A[^PAH=WK-EX4\:Z;X>T#QS^RR^@WOQ.UZ[T>UM)9(/#WC
MW5=-U"X\#Z7I+SW.C6MU:6^M>489#7[XT4 ?B;^UE_P2-U/]K'XC?MS>)_$G
MQ4\*Z!X>_:E^"G[,O@GX=VX\/:GKVI>!/B1^S9KTGB?2O$'CG1[Z&'0_$W@C
MQ!J6-.U+1+&]>]NM$O;Z.6*&YC@,M+PA_P $OOBMHW[.OQX^'[^%/^"5_@7X
MA?%S5_AZT7@;X6_L-"+]F?7?"7@,W%S>>&/BI;ZYJ=O\4/$E_P"+]7O)-;LO
M%>F3VVK?"G4+='\")*+VY$7[?T4 ?F/_ ,$P?V"/$G[!/P^^,7AOQ'XH\ R'
MXM?%23X@:-\)?@LWQ//P$^!^BV^EII5KX3^%7_"Y/$OBKXBS1:P_FZUXGO=?
MU,FXU-[>&VCDCM#>77Z<444 ?"WQI_Y/Q_82_P"N7Q;_ /31!7]!>F?\>%I_
MUQ7^M?SZ?&G_ )/Q_82_ZY?%O_TT05_07IG_ !X6G_7%?ZT 76Z'Z'^5?A;_
M ,%(_A?\9M0^,WP5^-?P;O?"]KXC^$J>,$BM_%FG:AJ5C</XHL[2P\U;6R79
M<+#:I=H\4TUN5EDAF1WV,E?NG7*:]X,T+Q'QJ=G#<=?]8BOU],@]>] '\P9^
M,O\ P48!(^T_!+C_ *I_K7_R91_PN7_@HQ_S\_!+_P -_K7_ ,FU_2<?@OX%
M/_,&L_\ OQ'_ %!I/^%+^!?^@-9_^ \?_P 30!_-E_PN7_@HQ_S\_!+_ ,-_
MK7_R;1_PN7_@HQ_S\_!+_P -_K7_ ,FU_2;_ ,*7\"_] :S_ / >/_XFC_A2
M_@7_ * UG_X#Q_\ Q- '\V7_  N7_@HQ_P _/P2_\-_K7_R;1_PN7_@HQ_S\
M_!+_ ,-_K7_R;7])O_"E_ O_ $!K/_P'C_\ B:/^%+^!?^@-9_\ @/'_ /$T
M ?S9?\+E_P""C'_/S\$O_#?ZU_\ )M'_  N7_@HQ_P _/P2_\-_K7_R;7])O
M_"E_ O\ T!K/_P !X_\ XFC_ (4OX%_Z UG_ . \?_Q- '\V7_"Y?^"C'_/S
M\$O_  W^M?\ R;1_PN7_ (*,?\_/P2_\-_K7_P FU_2;_P *7\"_] :S_P#
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M/_P'C_\ B:/^%+^!?^@-9_\ @/'_ /$T ?S9?\+E_P""C'_/S\$O_#?ZU_\
M)M'_  N7_@HQ_P _/P2_\-_K7_R;7])O_"E_ O\ T!K/_P !X_\ XFC_ (4O
MX%_Z UG_ . \?_Q- '\V7_"Y?^"C'_/S\$O_  W^M?\ R;1_PN7_ (*,?\_/
MP2_\-_K7_P FU_2;_P *7\"_] :S_P# >/\ ^)H_X4OX%_Z UG_X#Q__ !-
M'\V7_"Y?^"C'_/S\$O\ PW^M?_)M'_"Y?^"C'_/S\$O_  W^M?\ R;7])O\
MPI?P+_T!K/\ \!X__B:/^%+^!?\ H#6?_@/'_P#$T ?S9?\ "Y?^"C'_ #\_
M!+_PW^M?_)M'_"Y?^"C'_/S\$O\ PW^M?_)M?TF_\*7\"_\ 0&L__ >/_P")
MH_X4OX%_Z UG_P" \?\ \30!_-E_PN7_ (*,?\_/P2_\-_K7_P FT?\ "Y?^
M"C'_ #\_!+_PW^M?_)M?TF_\*7\"_P#0&L__  'C_P#B:/\ A2_@7_H#6?\
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M-E_PN7_@HQ_S\_!+_P -_K7_ ,FT?\+E_P""C'_/S\$O_#?ZU_\ )M?TF_\
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M'_"Y?^"C'_/S\$O_  W^M?\ R;7])O\ PI?P+_T!K/\ \!X__B:/^%+^!?\
MH#6?_@/'_P#$T ?S9?\ "Y?^"C'_ #\_!+_PW^M?_)M'_"Y?^"C'_/S\$O\
MPW^M?_)M?TF_\*7\"_\ 0&L__ >/_P")H_X4OX%_Z UG_P" \?\ \30!_-E_
MPN7_ (*,?\_/P2_\-_K7_P FT?\ "Y?^"C'_ #\_!+_PW^M?_)M?TF_\*7\"
M_P#0&L__  'C_P#B:/\ A2_@7_H#6?\ X#Q__$T ?S9?\+E_X*,?\_/P2_\
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M\_!+_P -_K7_ ,FU_2;_ ,*7\"_] :S_ / >/_XFC_A2_@7_ * UG_X#Q_\
MQ- '\V7_  N7_@HQ_P _/P2_\-_K7_R;1_PN7_@HQ_S\_!+_ ,-_K7_R;7])
MO_"E_ O_ $!K/_P'C_\ B:/^%+^!?^@-9_\ @/'_ /$T ?S9?\+E_P""C'_/
MS\$O_#?ZU_\ )M'_  N7_@HQ_P _/P2_\-_K7_R;7])O_"E_ O\ T!K/_P !
MX_\ XFC_ (4OX%_Z UG_ . \?_Q- '\V7_"Y?^"C'_/S\$O_  W^M?\ R;1_
MPN7_ (*,?\_/P2_\-_K7_P FU_2;_P *7\"_] :S_P# >/\ ^)H_X4OX%_Z
MUG_X#Q__ !- '\V7_"Y?^"C'_/S\$O\ PW^M?_)M'_"Y?^"C'_/S\$O_  W^
MM?\ R;7])O\ PI?P+_T!K/\ \!X__B:/^%+^!?\ H#6?_@/'_P#$T ?S9?\
M"Y?^"C'_ #\_!+_PW^M?_)M'_"Y?^"C'_/S\$O\ PW^M?_)M?TF_\*7\"_\
M0&L__ >/_P")H_X4OX%_Z UG_P" \?\ \30!_-E_PN7_ (*,?\_/P2_\-_K7
M_P FT?\ "Y?^"C'_ #\_!+_PW^M?_)M?TF_\*7\"_P#0&L__  'C_P#B:/\
MA2_@7_H#6?\ X#Q__$T ?S9?\+E_X*,?\_/P2_\ #?ZU_P#)M'_"Y?\ @HQ_
MS\_!+_PW^M?_ ";7])O_  I?P+_T!K/_ ,!X_P#XFC_A2_@7_H#6?_@/'_\
M$T ?S9?\+E_X*,?\_/P2_P##?ZU_\FT?\+E_X*,?\_/P2_\ #?ZU_P#)M?TF
M_P#"E_ O_0&L_P#P'C_^)H_X4OX%_P"@-9_^ \?_ ,30!_-E_P +E_X*,?\
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M^"C'_/S\$O\ PW^M?_)M?TF_\*7\"_\ 0&L__ >/_P")H_X4OX%_Z UG_P"
M\?\ \30!_-E_PN7_ (*,?\_/P2_\-_K7_P FT?\ "Y?^"C'_ #\_!+_PW^M?
M_)M?TF_\*7\"_P#0&L__  'C_P#B:/\ A2_@7_H#6?\ X#Q__$T ?S9?\+E_
MX*,?\_/P2_\ #?ZU_P#)M'_"Y?\ @HQ_S\_!+_PW^M?_ ";7])O_  I?P+_T
M!K/_ ,!X_P#XFC_A2_@7_H#6?_@/'_\ $T ?S9?\+E_X*,?\_/P2_P##?ZU_
M\FT?\+E_X*,?\_/P2_\ #?ZU_P#)M?TF_P#"E_ O_0&L_P#P'C_^)H_X4OX%
M_P"@-9_^ \?_ ,30!_/9\#?!/[57QC_:>^"'Q2^-=_\ #S^R_A$_B9;*T\)^
M']7T6]NH_$VFR6<L;I.9[>=EN1;RB62:'R8HY55)6D&W^F#3@5L;52,$0J"/
M0^GX5QFC_#7PMH<XN-/TVV@D!R&CB52".F"!_GMTKOU4* HX & /84 +1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5\^?M#_ +0^D_LY^&]*\4:U\.?BS\0[#4;N_@NH_A3X//BVX\/VFFZ?
M)J5YK/B3??Z=;Z/HT5O$X:_N;@1B0$, JNZ_0=?&O_!0?Q[+\.?V-OCWK]K<
MO:ZA>^";GPII4B.L;-J?C2ZM?"EI%O8KM69]7,;[<N49@BLQ (!0_9\_;A\)
M?M':]INF>$O@U^T%X<\/:MH6I^(;'XD>./A_::+\-KBQTPHC+!XLMO$&I65U
M/=R,\5DEJLZ2O!<;I(UB8U]EKJ>FO:O?)J-B]E&2LEXMW;M:QL"H*O<"0PJ0
M64$,X(+*.I&?R&_:;U'PW\#_ -C?]EK]GO7] O+G1_'EK\/_  '?ZK??$+4?
MA'X"T!_#^@Z9J]]'\2?&&E6&HWUMX<U2]+P7&CHD U=(;I9[I%MVBG_.);V?
M6/@-^U5HG@N/P=X1T#X[_M5_ G]G?PAX'^'-WJ__  K>QU/2S!JWB;6_"FF>
M(HK?5[2TU,QZ1J=S<W%AIIO(IKA%M1$%AC /ZEFU33$2XD?4;!([0QB[D:[M
MU2U,P!A%PQD"PF4$&,2%=X(*YR*ECO;.9YHXKNVE>W6-[A(YXG>!)4\R)YE5
MR8EDC_>1LX4.GS*2O-?A1\:?@9\!/@%^T3^S/\*/B/-=:7^S=XHTGQQ\1?BE
MK_CK5]9U'1OB]\;-"TF+2O#L7Q#U.\FGLK^2"SCBGTCPND5MI;2W[6]EIN9M
MC?+^F0:[:?LD?M/?$KX1R^(M(\!?$_\ ;#\/>!]6UR>3Q+YVB_L[>$%EL(;3
M5[VQ%SXHTOPG9RZC::/KDUD9=1T_P[*^G;86A(4 _IIN/$&A6FEWVMW6LZ7!
MHVF133ZCJLM_:II]C#;IYD\MW>&46]ND*?-(TLBA 06QD5SGPW^)?@GXN>$;
M#QW\/-=MO$OA+5I]1@TO6[-)DM-0&F7]QIMQ<6HGCBE>U>XM96M9S&J75N8K
MJ O;S12/_/)K?ACPSX<^ 7[='Q"\(^)OV=?%?PSU/X9^ /"3?"GX#)\0-;^'
M7A;XG/XBTW3/#_Q&M[CQ?80:5-J-M:ZBVH7]]HMWJ"C5+&"ZOV@N89I)/V!^
M GAOPQ\,OV(](/[/D7A_6+J+X,:AXET74_!\=IJ%GXR^)*>#&-SK0ELQY>LZ
MEJOB:P2WFF<O+<211VSM^["J ?90OK)KIK%;RU:]1/,>S%Q$;I4P#O:W#^:J
M8(.XH!@@YP10;ZR6Z6Q:\M5O74NEF;B$73H 6+K;E_.90H+%@A  )S@5^$?[
M&.F?LJ^-T_9OO)-4\<^*_P!M5[CQ3\4O'?BGPU=^)9O$=AXJMI]2;5O#GQUU
MO;)!H_A20O!IMEX5UQK:WN7B3[);HUZ3=?,/PS\.^)OBGXLT.3Q=\3_@G\/_
M -JJZ_:<N]<O-9\8W/Q9_P"&E],OM \23(/ PT;2]+N_#^D_#N_T"W2#2(BU
MOX9GM)(%N+Q;LS+& ?M_XX_;<^$W@+4?VD;'5=*\:7EO^RYX;\)^(?B+JNEZ
M;I$^FWDGC*.-])T#PS)<:[:SZAKJ-)Y5Y;7L&F6T$RF-;N4LA;Z9\.^,=)\0
M>&?"_B9S)H,7BS0])UVPTO7Y;.QU>WAU>QM[^&SO+9+J>);^WCN4BNH;>XN$
MCG#(LL@ 8_SJ^*K^3XD_"/X^ZK8W-O<:E^V7_P %&_"OPFT,1W $NI>#_ 6L
MV\0%HC,/^)>4L#%B3Y$6]:27;((\W_VN/$'PW_X7E\6O']O+\-?C2F@3^#/A
M1J7[+'QRT?QYX0^+FA/X?%EI$%W^SA<:5=6]_<6.L2J-3D\1^&E@DF>:Y-R9
M[7RGNP#^D>BN6\#6\%IX*\(VUMI.HZ#;P^&=#C@T+6+ZZU/5=$B&F6WEZ1J.
MHWUQ=7E[>Z8N+*YN;FYGGFF@=Y)9&)8\=\??B18_!SX%_&;XMZG<K9Z=\,/A
M5\0?B#>W3O%&MO;>#O">K>()93).\<*;%T\D-*Z1@XWLJY([<MR_%9KF. RO
M TI5L;F6-PN7X.C%-RJXK&5Z>'P]**5VY5*M2$$DFVVK$SG&G"4Y.T81E.3[
M1BFV_DDS\:Y?^#@'X-:IXF^(.A_#+]A7_@I;\=-%^'/Q%\9?##5?B%\$_P!F
M73_B'\/=2\3>!M9N-%UN/1O$FC_$)HIXA-"EU#%=PV6H+97=G/=6-L9UCK1^
M._\ P7N^#W[._P 0O#7PS\??L/\ _!1[_A(O&K>%+#P2^F?LY:0VG>-O%'BG
MPEHOB[_A"/!5SJ7Q$TR3Q=XP\/PZW'HWB+1?#T&HS6&O6&IV,37*6HN)/SX_
MX)&?\$I_C7\0/V(OV?/CU!_P4E_;@^ J?&PZQ\<=<^#7P=\8Z5X7^'$4_C'Q
MEJNJK<6]C<V%Y=S2>+-$@TS4]5O[B21[F749#&IA2+/W1^V(Z_&C_@N9_P $
MN?@(E_-=:3^SI\'OC_\ M<>*]+/EW CNM3L'^&_@+5+S+&42+XAT:1(IY5"B
M24O"S2^8M?Z5Y[X:?1)RGQ@XHX R#AK$\;Y'X;\)^.&9<<8_!\:<?Y/F&"S#
MPGX;QF89?+$ULSX=PV5XB>?\09+7R&DLAJ8S+8O-X5XXF2I8%8GXZEC,^J9?
M0Q=6M'#5<97RR&&A+#86I"<,?6A"?*H5G->RI5%5?M5&;]FURZRY?7[S_@MA
M\(+'PS\+Y+C]DK]NV+XQ_%^/XEZUX/\ V7KSX%Z-H_[0:_#WX3+ ?&'Q4\0>
M%-?\?:3H7AWP$DC7D&BWVJ>*(-5\03:5J2Z1H]T(8VE]*\1_\%A?V3++]GS]
MF3X_> [+XM?&<_MC:_?>$_V<_@[\+O \&I?&?XA^*-"NKFP\7:+#X:U_7/#N
MA:,_@F_M)['Q3J>M^*+#0K&X$+6VJWEM<V]Q)^%__!9?QWX9\2_M\_'[3?CW
M\9/'W[*?_#.7_!/KQ1<?L1:_\';R7P-\5/VH?BU\9K9=,UWX>VGBZ*PN=5^(
MGAI-<DA\&WOPFT*YLXW74=4UBZN+0/?WD>I^U!_P40U3_@GM_P $]/\ @G3^
MR+X'^%WP2^!O_!0#XO? CP1)HC>+;;PMX+^'_P"R%I7C.V;0_%/Q<U[5O%MS
M+;>"?%?B+5)=8N)1J-])!9Z[;^+-4\1/J']C0:1K/HY?]%'P^XNX?\"LPX0\
M.>(\9Q3XHYQ3S;&\-_Z]XS!<.8'A?,N$^,.,IUL3Q9C\BQ$\?PKP=D]3PZK\
M5YMP]A*F;Y-B8<7<,9GBUQ+G7#%/*YGGF+P]7,X8C&48T,%3]G&M]5C*M.O"
MOAL.DJ$*L>2OB:GUM4*=62IU(O#UX1]C3KN?[5:M_P %DOV6+#]CZR_;"TWP
MS\:?$>D7?QVT_P#9?D^"&E>"]'@^/]A^T1>:ZF@W/P@O?!FL^*M*T-?%^F2/
M_:-U;V_BNXM)]+,5SI]W>R3Q0-]G_LU?M!^*?V@]$\3:SXG_ &8_VB/V99/#
M^JV>F6FB?M$:1\-]&UOQ0ES:&[EU3P];?#KXE_$FVDTNR;9:7,VJ7>ESF[?R
M[>VGCCEE3^8A?@%_P2H_9\_9A_X)U_ 7]J;XL>/_ (^_!+XE_&[XR_M(Z[^W
M%\.?BHWAG]F#7_VI=,T!K?Q3?_$OXF^$_$MMXETZ6ZFTP^$/AC)HFKVNOO>:
M/<3WNN0ZG)K K]2?^"!\_P 9]0_9+^*.L>/==^).O?!/5OVGOC%<_L:77Q=O
M/%&I>/7_ &7(]4M+?P'<WFH^-L^++S0[Z\BU>Z\.3:\S7<FGN9XB;*:U9ORO
MQG\#O"?A7PCXRXTX"RGBVA' ^).89=D?$7B#@,WRBAG7"^*XPX@X8R7*>"*D
M,UP]+'<093/@?B'&<4Y+Q;PM@<_P.48^ABJ[P>*P,:>+[<NS/'U\?AL-BIT&
MYX.$ZM+"RA-TZ\</1KU*F)3@W"E46)I1H5*%:5*=2+BN:,FX_N)1117\%'U
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MN;74+8VWOOQ3\+?LY^./VY_^"6_A3XG?![0_AEX9\-_LBZA\3;KX:?$R>_\
M$OBC6]9U?3+JW^%_[/\ -X@\875[JOC?7O ?B=)[[0?#M[>3W7VZ:]66(RW
MM4O$>).*G5S#"8/+\LH8G"YED^74)8S-*E:$I9GFU/*ZE;$/!X*>%H?59+%S
MGA9X^..B\+.,\+>R?-E'T*,APV!X-XAXAXQXWS3(L]X+\1N,\TI\.\!X/+,5
M3I\#\ XGCG Y9DL.(^)\/GN;//:-7(*.%SW"\)U>%J]'/</5PV?-1G.G_32V
MN:*D-U</J^EI;V,RV][.]_:+#9W#%56"[D:4);S,SJJQ3,CDLH"Y(S!=>)?#
MEC.UK?>(-$L[E%1GM[K5;"WG19$62-FAFG215DC=)$)4!T964E6!/\9?P_\
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M[>;B:"! 7FEC+1Q+\SLHYK^2OX_?M(_#GX6>._\ @M-XHUWQ GA_XJZOX9\
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M+S3=8UV:.WC@N+Z>614C"QQGD_\ @MEXL\%ZO^UK_P $\O@S^TC\3-2_9?\
MV2["[^*GQ\UO]JSPQ<)X/\?>&/C/\,/#-Z? '@CP#\8KC3=3B^&FMWWFKJ+Q
M64#ZMXNDGT_2[&.2YM;>-_W+@GPI\!>-<!X1X.'A?GN'S/Q%I>-/&>)QV4\=
M<3YIC5P%X4ULQKY5_8'#$LFGF&=YEQ1C.'N(^'O[*PL'FM3#X"$\%6PN95JN
M+P7FXC'9IAYX^3QM)PP;R[#J$\+1A'ZUCE34W5K^UY*<*$:U*KSRM!.;YDX)
M1E]TVG_!9W]D)OV7?&_[3^MV'QA\*Q_#OXVM^S-XJ^!FO> 8Q\?;3]HLSPV]
MO\&+/P;I6MZGHNJ>+[PS>?;R:?XJN-"%K!=S7&L0&SN4CZ+PE_P5N_9MU[X
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M2V32K\ZC=)?2R1_Z3^Z'E"W*2&7]Y&'\S_;BU.4?!>V\&6DJI?\ Q.\>^"/
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M\)(=-OK6>T?P3XO\8&X&IZ1-')'+>:U<7!?)VU]J_$+_ ()N?MY_$WXPZO\
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _A7TW]J;X<_\
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MX)Z?&[X1_"OXX>,OAEX=^#GQ[^%_[1?@CQ5XX^!'QP\'>"=5U;5_A[XAU!O
MNN:%XV\&_$/P(^O:UIFG:[H%U+;ZQH5^FE:G!'#:[[@ T?A_^RI_P4,\)_!S
M]H7]G'4?V^-0U_2]8UCP4G[,O[6_BWX?>&?%O[47@'P!JGV<_%;PIX_TV'3_
M  Q\.O%WC318K6]LOA9\4;JPN[U/[=CU7Q7H&IWF@V\%WX#_ ,$H_B=\0?\
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MJ1Y,-4:<5BK^SUC*U_;^SYW"4XKVZPF-=&TFI_4L5LZ:4OTNHHHK(T"BBB@
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ML&H'PEYEW"BH=*O[Q]'>:ZEM3=S>!?L-?M'?M&_%_P"(^F^$OB-J>N:VFA_
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M\=>.?%N@> _!&@WVL6]K?3Z?8ZEXG\3:5%>7EM9W4T%F9Y8H9&0"ORO\?_\
M!/OX/?LY?LD?!K_@F+^S=X0\)1?$W]IG6O@YX3^-GQ(\(^"M-\&:YKOP5^!_
MBSP_XR^,OQQ^(T.E3WD<,K^'-/F\": -2U6XDU'QG\0]'T;3+F:22=K;[!_X
M*L?L[_%W]IKX+?!?X9?#+X.>"_CWX.TG]I[X/_$KX[?"'QS\0--^'>B_$3X1
M?"^XU;Q9+X*?5M7T+Q#IMXFM^-[#P2;_ $V^T]K6[TFRU"*5U+I0!QOA']O3
M]H;X9?%OQI\*?VP?AS^SE!'HO[+GQ6_:ET_QQ^RQ\7O&7Q'T/POX:^#%QI$'
MBK0?BOI7C_X?^!]5\*2^(XM<AN? OB"U>]TK6)=%\0:8\2W5DTJ>+>&O^"CO
M[</AKX9_LQ?M#_'3X(_L=6/PA_:1\8_L^>%[#X;?"W]H+XBZ[^TQI0_:3USP
MUHOA"WTGP;XB^%>E^#O%?BGP;;^*[+Q%X\\,:7XI$EOX?T3Q1>Z??O'I3RGY
MNU[_ ()A?M&^*_#G[7^I_ []E[]GS]@'3?V@?V6]*_93D^ GPJ^*=EKVF?%&
M?Q?\4?#]]XZ^-_Q-\0>$_ _A;PKHFI_#?X1W7CWPG\--+T32=3\1ZU/XLUR+
M7=8LK!]+LXON/3_^"6OPC_9N_;*_94_:2_8U_9U^!G@SP[X>T+QK\'/VB/#T
M6BZ'H,EIX!U7PVVH^ OBY\.()-'O8M/^*OA#QKI%OX=UV_T:31M6\7?#_P 9
MZ]INJ:C=C2=,BC .OD_;2_;"^-6I?$WQK^Q5^RW\,/BI^S]\'?&?C?P%)XO^
M+/QIU?X:>-/VCO%?PQU74/#OQ"TS]G/0]%^'_C#P]!HNC>+=&UCP5H?CGXF^
M(?#V@>+?$=A=R:?!:Z!:#6KIG[?O_!2K7_V0O@-\-?''@GX#ZSX\^.GQ&\&Z
MO\7+KX!>+M8M_#&O_#CX*_"_PSIWCC]H3QW\0[_1E\0VNFK\*= U"S\/-!8R
MWMIK?C[6]!T2POIK:YGNHO/?@[\'?^"DW[-OPEO_ -BSX-^#_@ G@G1?$WQ!
MM?A#^VKKWQ"O[J]\$?#+QWXY\1>,K'4/%W[-LG@R6]\7_&7P19>)+O2;*WM_
M'%I\//%VMV&EZ[KFH6%C<:MI4O&^+?\ @ES\9OVHO%_[67QM_:+_ &B?C+\+
M/B/\7OA]XP_98^%G@GX*>/\ P;'X.LOV4='TJ]TGPS8?$4ZO\--;2X\5_&7Q
M9>ZW\5/BM9>$7T2PL'U_3/!UG<W5MX8L[E #]P-"UBQ\1:)H_B#2YEN--UW2
MM/UC3KA&#)/8ZG:0WMI,C+PRRV\\;JPX(8$<&M6OF_\ 8[\(_%7X?_LI?LY>
M /CC:Z%9_%_P%\%OAQX'^(T?AG5I-=T"7Q7X0\*Z9X=U:]TG5I;:SEOK/4;C
M33J$4LEM X^TF-D#(:^D* "BBB@ HHHH **** "BBB@".::*WBEGGDCA@@C>
M:::5UCBBBC4O))([$*D:(I9W8A54$D@ FOR7TO\ X*>0R_\ !,CQ]_P4(UCP
M3X8L]2TSPK\5_&'PX^$\'C))+KQCIVB?$#Q'X)^#EE>7QM7O;'5/B6MGX7O+
MFVM=.NCI\_B$6UJMSY2,_P!^_M,Z-\3O$G[.GQV\-_!2'2Y_B_XC^$/Q%\/_
M  P36]6_L+1T\>:WX3U;2_"MQJ>L?9+\Z=8VFM7=G=75V+*Z:*&%V6"1L*?Q
MO\:_\$0?V=M'_9^_8O\ AA\(_P!E_P#9VL/B/\,_BW^R%?\ QX^+P\-:%HWC
MB[\!_!C6-!\8?%CQ%I'B9-'?5->\5^.M=\)6VFW4,YMWU>W\3:I=W4L?E%:
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M%GB :?H.GZ#INEQ0V.C7!FU/Q#IT4A17S7@8^!/P[U7]MG]E?X+_ +//P_\
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M'XS\:KXPU3P)XNO+;P9\0O$0\5R^'-6TG1;2[M7T W,<&+\6O#G_  57^/\
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MIXJ%[8B5BJE6ISI5$I0J826"FK;T)4\UI./:]LYQDU*VE18>>]"!_.[\5_\
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MCN+JVLH'N[B&V2>]O)5@M+2%IG19;JZF98;:W0M+/*RQQ(SD VZ^+=-_:?\
MA]\;9M(\.>"T^)GAGQ#977P/^)1TWQ?\!?$\FIZO\._'_BV:ST'7M.T;Q+I=
MM):>']3ET;5-.UCQO:IY_P .C&^JZF+">&$-]I4 %%%% !1110!$D$$4DTL4
M,4<MRZR7$B1HDD[I&D*/,Z@-*Z11I$K.6*QHB A5 $M%% $/V>W^T?:_(A^U
M>3]G^T^4GVC[/O\ -\CSMOF>3Y@$GE;MF_Y]N[FIJ** "BBB@ HHHH ****
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MGPO\"?A_8_#_ $#XO^%_B#X\^(.A:?X8O_A?XH^(/B+X9Z'JWC#5]8@T'1_
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M8HH,LQBBBC,K[G,<4:%MJ*!-110 4444 %%%% !1110 4444 %%%% !1110
M4444 ?C+^U-^T_\ M6? 3XU_M?3)XM\!WO@+P1^PO-\8_@=X'TKPE/*_A?Q3
M'\3KCP5-XY^(6NZG<O<^)M11)!J$VAZ?#I7AG3-'TA+=A?7-W?:B?,%^,'[2
MQ_:8@_8*_P"&F/'#:/<>+;/Q _[28T'X<_\ "U4TJX_9FO/C!)\-HIO^$1/@
M,%O&ELGB*&Z/A:361\/&D\/FY,075Q^TVN_"7X9^*/$&L^*O$?@;PWKOB#Q%
MX N_A5KVIZMIEO?S:Q\.+Z_N=4O?!>I)<K)!>>'KO4+NZNKC3IXGAFEGD,@9
M6(KPH?L'?LA#X9'X.CX$>#?^%>'Q6OCC^Q,ZQ]L'BV/33HD>O+XD_M3_ (2A
M+^/0"?#<;KK01/#!/AI$&A?\2^JNO8*DHVJK#*BJMVVZJS'%8B-677FAAZU!
M.2?-5E0^K34<-)253:E6A4B^6FIJ4Z:A#5+ X3#M)[6G6HXCW6FJ:Q#Q4/\
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M+DA9.,7+G:YI.2G*4O>=24:#PJ]K>_M8_5Y2I.-7GBXSG=-SFY?#GP1_8?\
M#7P9UW]GK6D\>Z]XM_X9X^$7Q(^'6@6FJZ5IUHFM^*OBUXJT#Q3X[^*&I2VT
MKM;^(=8ET22Q-C;*;6*VU74#Y\C2 5]QT44I3E.RD[J+J-))))U:U3$5+))+
MWJM:I)+:*DH1M",8II)-O6[4$VVVW[.G"C&[;;O[.G!-[RDG.3E.4I,HHHJ1
MA1110 4444 %%%% !1110 4444 %%%074XM;6YN6$C+;P33LL4,MQ*PBC:0B
M."%6FGD(7"0Q*TLK82-2[ 4 3U^8_P#P63_Y1J?M0_\ 8#\ ?^K>^'U?#?A3
M]O+]I#5_#>IQ>,?BCI7@2)=)O_&TWQ &D_#K6M.L_$,7P9\:>./"GPRM[NSM
M+GP_X4C\;>./#?V*/X6>-EF^-6BZ?H]SX=U'4DU'Q/I-S'I?\%9OVL/&NH_L
M._%?X2^(/V2?VH8+[QA\//@!J?B/XSZ1X(\'3?L^>$M8\6^+?AAXDUNUU3Q5
M>?$:W\8V]IX0O[BYT+7G'@:YFM-3M7@A2\C'VD@']!5%%% '#_$Q+B3X=>.X
M[2WO;NY?PCXB2WM=.\6?\('J%Q,VDW:QPV/C;?'_ ,(C=R.0MOXD\Q/[%E*:
MCO7[/D=)HBNNBZ0LBRHZZ78*Z3Z@=6G1Q:1!EFU4ECJ<JG(DU LQO'!N<GS,
MURGQ6>RC^&'Q#DU)]!CT]/!/B=[Y_%/AF]\:>&5M%T6\-PWB#PAIK)J'BC11
M$'.I^'[%TN]8L_.L+=A-.AKJ/#_E?V#HGD?9/)_LC3?)_L^QETRP\K['#Y?V
M+39B9M.M-F/LUC*3+:0[+>0EHR: ->OS"_;L_P""H?PA_8QE'@FSTV7XH_&F
M[M$O(_ >DZA%8:?X;L[F)WL]2\::X8KH:7'<G9)::3:VUUJU[!NF,5I;-%<O
M]S_'/XK:+\#O@]\2/BYXA=5TKX?^$=9\1S(PS]IN+*U<Z?8J-Z%GU#46M;&-
M0ZDO<* 0>:_EI_X)S_L<ZM_P4-^-?Q#_ &GOVEFU3Q#\-['Q=<:CJEO<7KP'
MX@^.+BXCU%?"TTD16Y7PGX?TV2U@U*&T>#S;=[328IH]]P\?].> /AGP+G&5
M<8^*_B[5QD/#+P]C@Z%;+<!5GA\;Q9Q)F+O@>'\)5IU</6FE3Y)XJEAL5A*[
MEB\'*6*PV$^M5Z?C9IC,33GA\#@%%XS%<S4Y).-"C#XJLDTUJ[J+E&2]V5DY
M<J?H&G_\%O/VW_'EYJ%W\,_V:/ VO:/;%6-OH/@_XJ>-YM.BQM_T_4]!U%("
M[.&8.]I:(?NK&,9J?1O^"^W[0/AUOL7Q(_9U^'\][%=,9Q9:AXR\&W"VB/LE
MA-EK2ZTZ7,;!E\Z0I&K_ "/ "":_J$\+^$?"O@C1K/P[X-\.:'X5T'3X8[>R
MT?P_I=EI&FVT,*".-(K.PA@@7:B@;MFXXRQ)))S/$WPW^'GC6*6'QCX#\&^*
MXIX7MYH_$GAC1=;62"0DR0N-2LKG=&Y)9D/REOFQGFOJ7XZ?1RKXFMA,5]%3
M)8Y(I1AA:N#XYSC#9U"E!<JJ8BO3P4'6JS7O2@L7%*5U.M7=JA@LLS>,5*.>
M5'5M[REAJ;IMZ?"G)V2:_E>^R/PZ^''_  < ? 766$7Q1^#GQ,\"95BE_P"&
M+G1/'VGR'=&(U,8G\.:A$&#2,[_99418P%:1G"C](O@U_P %$_V-OCL\5IX&
M^.?A"VUJ9_+3PYXQN7\$:\\AX58+'Q0FF"]+D;4_L^:[#,54'<Z!O+OC#_P2
M5_8<^,!N;N3X30_#C7+DS.VN?"N_F\'3--(A5))M(@6Y\-SK$Y61$?1ARNS<
M$+ _DO\ &/\ X-_/'FGS7M_\"_C9X>\46*R//8^'?B7I%QH&L1 ,&A@3Q#H2
M:GIMU+'G N9M)TW)02$JS[4]["Y-]"+Q(INE@<]X\\$L[JI*C1SMSSSAZ%:3
MMR_6)_VU.="._M,9G&3*VK<4G$R=3B3!V<J6%S*FOB=.U.K;T7LES?X:=3;9
MG]1<,\-S%'/;S13P2J'BFAD26*1#T:.1"R.I[,I(/K4M?Q4W/P*_X*T?L3P7
MU]X;M/CGX7\-Z>8Q>:A\-_%"_$;P8T!;?&\VBZ?=:];QP':/,EFT* P;O+DF
MA=F6O7/AK_P75_:Y\!2P:3\4?"'P]^)XMXXXYQK&DZA\/_%$B1!XWF:?1P;
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M*&6^B_=6@ HHHH **** "BBB@ HHIKLJ*SNRHB*6=W(55502S,Q("JH!))(
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MX:^ X[NWOK2Z3PGH27%MJ?C'_A8>HP2KIUNKQ7WCLO+_ ,)?=(P(G\1^8_\
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MVHSZ/JZ:9J%I?OI6K6R1R7.EZDMK-*;'4;>.:%Y[&Z$5S$DL;21*LBD_D?\
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M8\1:U''?[%OO'_Q!T[P\+C31!GSAI_A_0?$36UX;GY1 U_<0^0-YF$C>6O\
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MG"]])4XPE[VFBG*I3I0>O[RI%2Y8WFOW;K\)_P#@DU_R>[_P7/\ ^S_/"O\
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MN?A7_@J9IM_;_&?]DKQSX>\'>#/C/XL\$VWQ5U71/@=JG@/XW>.O%^I3P?\
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M%+C7K_Q=JESK4G@[1)]-Z/\ X*R?#O\ ;<TK]AGXK7VK?M"_!>Z^".@_#OX
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M"_'GCNT\+^&M9O[CP!!J-C;W<E_I_BV 2:3=Z+-;3VNI//!'/!,J>4_Y,?\
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MRM*34)3Y&DWR2J49NIRO[,IT*51SM9RI4I.5XTVU] ^!_!/A3X;>#O#/P_\
M NA6'AGP;X-T/3?#?AGP_ID9BL-(T72+6.ST^QME=GD*06\2(9)I))YF#2SR
MR2N[M^*/_!)LD_MN_P#!<\DDG_AOOPH,DDG"_ #X?JHY[!0 !T   X%?MYX:
M\2^'_&7AW0_%OA36=.\0^&/$NE6&N^']>TBZBOM+UC1]4MH[S3M2T^\@9X;F
MTO+6:*>":-BKQNK \U^(7_!)K_D]W_@N?_V?YX5_]4#X JY\_//VG-[3FE[3
MGOS\]WS<_-[W-S7YN;6][ZF<.3DC[/EY.6/)RVY>2RY>6VG+:UK:6M;0_=BO
M OVI=4\9Z/\ L^?%R^\!?#+PA\8_$ \"^([?_A6_CWQQ;?#CP?XITN[TF[MM
M:L/$/C&\T[4[32-).ERW3W\ES!%%-:)/ U[8F07<7OM>;?&67P[!\(/BK-XP
M\.W_ (O\)0_#?QQ+XH\)Z7!)<ZGXH\.Q^&-4?6_#VG6\,D4T]_K6FBYTVTAB
MECDEN+F-$D1F##FQ/^[U]8K]S4=Y).-E!MJ:<9W@UI)<LFXMV5['1A_]XH:-
M_O:>D6U+XU\+4H-2ZQ?-'6UVD?AO_P $W;74&^+_ ((U?Q;8#PXTW[',OBWX
M<W'Q%_;'\2_M&^)/ /PI\3ZMX>MX+']GKPUJ/PL\$:#I'PUM;[0TM_%GBCQ%
MK7C/QC]FT'X?Z5>7[Z1/;S7G[;? ?4=)U;X._#K4M"^+%U\=-'O?#&GSZ=\7
M[Z30IKOXA6SH3'XEN)/#.G:3H#RWX^9CI6FV=GD?NH$&17X!?\$I/BII'CWX
M]Z;IFL:UXC^*?C+PO\&?B]X2^"MMJ_[1/ASXTZ#^SY\,O"^O?"N2#P/J5OX:
M^'/@R]B?QWI/B'P-I<_Q#\4/KNLWVJ_#S7O"EHT]OI+WUY_0]\,AXR'@#PF/
MB'X=\)>$_&PT:T'B;PWX#U.[UGP=HNK;3]IL/#NJ7^DZ%>7VEPMQ;7%QH^G2
MNIRUK&>*]+%)\N'DXSBJE.O5@JDE*7LJN88VI3YFIS7M5"45B&G:6*5><74C
M)5:G%0:;JI2Y^1T*;DMG.G@L+3GR/DI_NG.,G03A%QH.G"48.+C'NJ**YSQC
MXJT;P+X2\3^-?$4\EMH/A'0-7\2ZU/%&9I8M+T.PN-2OWAA!4S3+;6TABB#
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MXN;J"436%S/:2?GK_P $R/VF_P!G76_$?BSX?:+\6/CC/\0/&^K+IOAWP/\
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M6M,EEJ'T7^R%<^$=+^#W[%6FVOQ/\-^![G7? _Q U+PU\*?AU\0/^%D^#_C
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MW>ZN)[R[>WL/B1XTM('N[VY>6ZO;MXH4:ZO;J66YNYS)<W$DDTKNWU;^T_\
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M4E\$812LE%:WJVLFM%*4I*"^&"D[N,6[R<>9N2YY3E>37-RJ,8_N!#_JHO\
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M\W4O[/\ 88C-\!F^5T<%B<7D>.H8&5?$X:.(=;#8_#4:U7+\5B*N%Q=##?\
M.AEG&64YIAL9B*M>&"Q%&C7DZ6/K0@YUYTJOU::J.I!5HSQ/LXS?-!QE)*JX
M1DIO[V\7?\%3]!\,>'_#.F7'P1\5:-\7M?\ B#\2/A'K6B^./%?A[P?\#/AI
M\2?A=K%MH^OZ/\1OVE;V.;P+I-KJ?V_3]6\')8V&H>(_%^D7)ETWPY%<V]U;
M0<KX>_;"_:&U7XQ:?XSO->\$1?!V;]MNV_8<OO@U8>'(KR=KC_A70UR\^+^B
M_%&6XMM9U.^/C:.8:=HK:-!X>O\ X?M#=BW@UEC>C\B9_P#@Y:_X)+? 7X::
MM\(?@K\!?CY\7O"%UKFJW6MV7B7P[HAM/B)>>*[NXUCQAXP\7:[\3O%NL^(_
M%.LZYJUS-<:M/XLTZ34-4GF)D,-M%%&GFOP(_P""^/\ P2"^*_[35AXL^(W[
M/GQK_9ONM9=;JQ\9:SXJN-2^$.A_$&[T"Q^&%CXXG^''@3Q$_A_PKXT@^']W
M/H/_  M.U\.Q7^A>'=-9&O;>7RKH?!KZ!/TPZ.4U^(ZGT>N/GEN#PJQ>(I5,
M)@:>:.%'ZGB,5"CPW/'RX@K>TP\,7AZ5*EE^*QD98E3A3>(PC4>A\4</S3PW
M]KX6-:I.<*=2,I2C",HXB%&4ZR@J3G"<\-6J6G1IMX:4+RI8B43]POV@/VR_
MCQX!^-/QY\1>%]8\,V?P;_91^*'[,/PL\6?"R]\*6]]KOQ>7X_V'A?4O$OB.
MW\:37\6H^&-3\*VWCO0H?!6FZ5:36&JWNBZM'KD=XFI6@T_YWM_V_OVMM-T?
MX"?VGXL^'^J:K^W?X*^&/B[X4W$'@"WMH/V9KSXD?&KP5\/[C3Y;2/5S)\3=
M(T3P7X]L[[3KKQ-+:WEYXZT9HKR=]#U0:;:?I[H?[('[)_Q!UKX8?''0M.N/
M&ZZ5X=^'-YX9\16OQ+\7^)/"7Q$L_A]93-\*/&/C>U_X2.\T'XJ^(/!MOJ$]
MUX2\8^+HM>UBSDN$N5U"62WLWMJVG?\ !.O]DO3-+\=Z/;_#K49-/\=6-GI0
MBN_''C>\?P%H^F>+C\0-(T?X1W%QK\EQ\)]*T7Q[L\9Z19> I="AL/$-O9WL
M"JMA80VW\D\BPE66'QF&JJMAL5*&)H554H5E&CAUA\5A:D9.-6A6Q&.B\2U*
MU3+>66%HSE"4HGT4I*<6X<L92P_+&HDG&->513HUU!-PG#"4>:E*%E',G-5,
M1&BZ<6_CCQ1^V!^USX5^!VO7>CS_  H\6>*?@K^W9X;_ &7OB[\4]?TZ\T67
MQ)\.KSXK?#+PU!XC\*?#S0TNM&@^(/B'0?B);Z9JT$^M6/ASPYJ.G:GJUG97
M0EL]+MOVD4Y52>I )_$5\W:5^R3\!])^$EO\$H_!]Q?>!%\;Z5\3-1CU?Q'X
MCU;Q%XD^(ND>-M.^(T/C?Q7XMOM4F\2^)/$MWXTTJQUS4M2U?4[J34)8$M+E
M7T]5M%^D@   .@&!]!64I0=-1LG4512E445%32P.7T9M16D(SQ=#&8B-**48
M+$::RE&.=FZLII.%-PE&-)SE/D_VO%UH7E)7G*.'K4*,IMN4O8I-M1C*1111
M6184444 %%%% !1110 5YC\:-%\4>(_A3X^T+P7I'A;7O%.K>&]0L=%T;QK#
M]H\,:C=SQA/LNJ0G]W(LD1E^RK<%;/[<+;[:Z6@F=?3J* /A3]DO]G/QC\,[
MF7XB?$2W\/1^._$MCK6G:]'J.EZ)KOCNRL8]5@7PR'^(>BS1PE[G0[*T'BG1
M4_M[3I-0@T]M*UF&TL%MG^ZZ*9(YCCD=8WE9$9Q%'M\R0JI(C3>R)O<C:N]T
M7<1N91D@ ?7YC_\ !9/_ )1J?M0_]@/P!_ZM[X?5<UC]OKQ;H>J>+/!EU\"K
M"[^(_A&]UZXU71-(^*^G:GX6L-%\'?#"Y^+/C?1]2\:VWA1K.'XF>%]!_L32
M;_P;9:?J-@FK>*M"NKCQ+:Z7+<3Q?,__  5O_:Y_9F\3?\$_?C9\/+;X[?"6
MP^*WQ \"_!/Q#X8^#^K_ !%\':=\6=0L_&_C[X8>*/#4$/P]GUH>*9K[4]$U
M&TU"UM;?39I)[63[5 )+8>=0!^P_Q&^%WP^^+N@0>%_B5X3TCQCH-IK6D^([
M/3M8A>6*RU_0;D7FC:S92Q217%GJ>F70\^RO;::*>!R2C@,0>,^$G[-?P'^
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M,FG?LU_!2UD^+%S\<]OP_P!!FB^+=W%<PS^.K:[M_M=IK)BOI)=02,VL\-K
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M'X>>(M5UF^77OA=#>:1IEKI&@Z=H=S):_P#"':5?2+>R^'[FTACDO'LYY1^
MU?[9GQ5^%'PN^-O@76_AO\9? /@_XE_#S7HXO[=\(>.]"TWQ'X<OULYDN[::
MZTW5H+BT\ZRN(H[JTN@BSV=Q$EQ;RQ2HKC^=7XW_ /!&O_@@#H&J^*(?$7PW
M;PUX@U:&YNCIOPS^*WQ7O'T*2_>6U#>'M+T[Q#K/A[3KC3YT>:'2[JWFM[1H
MQ]HT][8^4_\ L#]&;]L-P=PQX:<.\&>/_"W'^;<6<,X#"Y-'C3A2ED^?+B;
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M@P./P>94(XG!5XXBA)M*<5./O+>+C.,91E%Z-.*:84445^;G8%%%% !1110
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M:0VZ?#SQMJ]Y<:YK'A#1+CP]+H'@Z+6+'1-9N_#'V;4-4M+AVA>']]*_-O\
MX)SZG^U?K?A[XK:Q^U)\._ W@^^OO%UD?!_B#0?#OA#PIXU\:6%O92V]]?\
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M\$_#C3EB@N+AMY\2:D\JV\\<#+EKVQ2/+/O4A7P/E;)P:_-,Z=K[QEWO=J"
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M+E/+"L_]M7X)_P#!7C]DC]DW]H7]IFT_X+(ZKXVNO@=\+?%'Q'M/"-[^Q'\
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MOM7U749?#&EM%9Z;ID$UU?W+#^UI6E2&W@EE,<$<L[QINAC?<F[$\)_M%?\
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M1FX>&;,(\W^,_P"V9^W_ .!M?^'O@SQ!\,?VKI_%WQ*\1ZKX5^'F@?#WX/\
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MA,FXPC*,>:;KX6$H7LXTJF(HPKSOI%N%*<W&\HPBTZM2<:=-QJ?N]\&OC?\
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MJ?C>/3/ L7B"ST"ZU3X<W^N^$DT#2=7U&ZMM5T[0M62PU,37% 'ZY_#;X?\
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M9_#'1H!+^T+XNN/#OB$ZCKFG_#R/6;JVTAI+.?0X)+I95MK:>TGN;F>Y%Y"
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MK9V5EIUM%9:?:6MA9P!A#:6=O%:VT(9VD8100(D489V9V"( 79F.223:HHH
M*JO964EY#J$EI:O?VT$]M;WSV\37D%M<O"]S;PW)0S107#V\#SQ(ZQRO!"TB
AL8D*VJ* "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img143810944_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img143810944_3.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #  C(# 2(  A$! Q$!_\0
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M'42 CY".X;&*4V\X*J8)@SYV*8W!?'7:-N6QWQG% &;_ ,-E_M5_]&@>&?\
MQ(+P_P#_ #+4?\-E_M5_]&@>&?\ Q(+P_P#_ #+5H&&4 L8I JML9BC *^<;
M2<8#9XVGG/&*Y>3QGX/AO?%VFS>*O#T6H_#^PM-5\>6$FKV27G@O2[_3;C6+
M'4?%-NTPET*RO-(M+K5+6YU%8(I["VGNHV:&)W !L?\ #9?[5?\ T:!X9_\
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MS:;>V=W9WZ^;FTNK6X@G"20NJ@&C_P -E_M5_P#1H'AG_P 2"\/_ /S+4?\
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M5M6\:>+M%\(Z>CZK<6UY%9P6]SK,=W<2M;R_N8'4 %@P^4I/VR/VK8I'C?\
M9 \,!HW9&Q^T%X?(W(Q4X/\ PBW(R#S6A_P51/\ QC+:C_JL/P)_]7#X*IU[
M_P ?EW_U\S_^C7H RO\ ALO]JO\ Z- \,_\ B07A_P#^9:C_ (;+_:K_ .C0
M/#/_ (D%X?\ _F6JY10!3_X;+_:K_P"C0/#/_B07A_\ ^9:C_ALO]JO_ *-
M\,_^)!>'_P#YEJN5D>(/$&@^$M"UCQ1XJUO2O#?AGP]IUSJ^O^(==O[;2]%T
M32K)#+>:GJNI7DD5I86%K$#)<75S+'#"@+.Z@9H M_\ #9?[5?\ T:!X9_\
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ME:75YIUKI[W$E[:V\UQ;"2*-G'2-#,F=\,JX1Y3NC<8CC4M)(<@?(B@L[=%
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M_B%<:7Y1N/MT/@]M0&NRV_V8&Z!2Q+&T!NU4VP,H .V_X;+_ &J_^C0/#/\
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MB6!]7M?A/XF\4W_B\^#1\-K:66QMU0QZ'7WC_P -<_LP_P#1=OAQ_P"#U/\
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M4Z?_  US^S#_ -%V^''_ (/4_P#C5'_#7/[,/_1=OAQ_X/4_^-4 ?B!\0O\
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MWPX_\'J?_&J/^&N?V8?^B[?#C_P>I_\ &J /RA3]@O\ ;%\+^-?A[;6,]_\
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M]H3]@KXR>!?@%^P%^SWH$GC#]HWQOJ/BGQ%X?\<Z-XIUWX;>"/#_ ($N[?\
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M_P#1=OAQ_P"#U/\ XU1_PUS^S#_T7;X<?^#U/_C5 'Y0^%?V!/VP[/\ ;2^
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M_9B3QOL,5AZOL/9UZ4I?(G_#NCX!_P#0 LO_  !M?_C-'_#NCX!_] "R_P#
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M1XF,FE*AF<\+53:3BF>1_P##NCX!_P#0 LO_  !M?_C-'_#NCX!_] "R_P#
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M/]@67))_X\;7N?\ KC7W]10!\ ?\.Z/@'_T ++_P!M?_ (S1_P .Z/@'_P!
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M<2XNK#A#B"5/"\.8]5Y8'/\ $3CE[C0R3&QPN)EA,UJN.!Q*P]=T:\U1J<O
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MOV4M[(]O-J$[3PV4$$1G,MS))&D)W?:YT4RG\?OB[_P7?^#]CXXU?X9?LI?
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MO]B_X.^'/^$YB\:-XE^/=AXXL=&\//I/[0MYHOQ5TGPYX%\-ZSJ7B'PS\/-
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M2:AX8E\?VC,]AXJL_ ^C*UK?Z:\T<5TU@1XC=;9IHD#6ZP%54[P/WUK\7_\
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MY,5C.JE:=\)AW_U\JPE7J+6U.A&$X\F(5_JNBBBOQ8]$**** "BBB@ HHHH
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MPV7X7"X>ZJUL17JU94Y5\37KU<1BJU;$5:E67\=/A7_@W&C^*'@)?BM\5?\
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M7+RQ;BI-<\.;X?B/P@\2^$.%,+QKQ7P5Q-PWP_C.(L1PK0QF?9!G.4*6>X7
MPS*ME\GF& P]*-=8*HJ].E*JJM:$*\J5.:PV)=+V:BBBO8/S8**** "BBB@
MHHHH **** "BBB@ HHHH **** "JUY9VNH6EU87T$=U97UM/9WEM,H>&XM;F
M)H;B"5#PT<T3O&ZGAE8CO5FB@:;333::=TUHTULT^C1^5'[25U^Q5+\%_P!J
M_0_"MA\%!\1-'^#'QGTG5(?%VB./#UEK^F>$=:\K3=<N-4M8](2>'4;=CIMO
M!.+Q'BO'TA0?M(?[4\&S6UM^RKX3N+VRL]3M(/V?] FN]/U9HQ87UO%\.[-Y
M[34FG@N8A:W$:M%=M/;SQ>4\AEC=-P/Q7^U%XR_8[F^#W[646B0_![3/B,/@
MW\=K;4/$/CSP_';^$V\1P:)K=I<Q:]JM_';:=-=W'B33[E=.M1=0ZA?76G:A
M_8^=TC3?=7PODAA_9Q^'<MU'/+!%\$O",ES#$P2ZDA3P)I[31QNR2!)W0,J,
MT;A9""48#:2IK36K3=+>5W&[3NX]>2^JZ[[[CC_$5DTN=63WMIOHE?IV\^B_
M-/PQ\?-;_9;_ .";ES\4+-=)O?&6@^#KG2/"T"Z<(--N?&_BSXG^*="T.]GT
MY)Y'>"UGN8;Z:QF2%[I+$P,1%,&3@_ G_!)[Q/\ 'C1_#7Q-_;._:<^-GQ"\
M9>)])M-=UCP7INOR:=H/A\ZQ:PWO]@0"^-_IL7]GI,+:>#2O#VE:?#-')#9V
MRP*K/P7Q<L_!GB#]CG]C?X=^ +&[TOP+\5?VD_A7H^GZ+J?CK0_'5Z=,O/B;
MX\U?4$FUS31I-GJ,T-TCO,ZZ'&]I(HTVZO[RYM)'7^A(      #  X  Z #L
M!7PN-PU;B+B_-LIQV-S:EP_DV09'-97E^;9IE&$S'-<YQ6<O'RSA95B\$\WH
M87+\MRJG@\!F$\5@<.\9CZJPZJXER7X3F?#.7^(_B7Q-E7%+QV8\+\'</<,4
ML#P_3S+,\OR?%Y]Q!BL^S#-<PS7!Y=C,)1S:=++,'D>&P>&S".)PF&I5L7*G
M1YL5*;_*C0/^",/[!6B<S_#OQ-K[?NLG6/&^MQ[C$."R:&^BQL6_BW(0N2(A
M&.*]!7_@D]^P,H _X4-9G  RWC/X@$G QS_Q5/)[Y]>1BOT6HI+PN\-_:.M4
MX#X1KUVU*6(Q?#^5XS$2DK6<\1BL-6K3:LDG*;=DELCZ*AX'^#6'AR4_"OP^
M:NFY5N$<CQ%1M;.57$8*K5D^EY3>B2V2.<\'^$?#G@'PKX>\$^#])MM"\*^%
M-'T_0/#VC6AE-MIFD:7;1VEA90-/)+,T=O;Q)&KS2R2OMW2.[DL>9^+-M\-&
M\"ZWJOQ;M-)N/ _ANUGU_5Y]:@EN+338;*"9'U%5@5KF.XMXII1!+;#[3&[A
MH"LFUAZ37"?$[4? ^E> /%6H?$I+&3P+;Z3-_P ))%J-L]W:3V$KQPBW>VC5
MY)I9[B2&&V2)?--T\/E,LFUA]Q3ITZ-.%*C3A2I4H1ITJ=.,:=.G3IQ480A"
M*480A%*,8Q2C&*22221^G4*-'#4J.&P]*G0P]"G"A1H4(0I4J-"G!4Z=&C3@
MHTZ=*%-*G"G&*A""45%15C\W=>NOV;M0^-O[!=]\ K/X0QVC?'SXB 7.GZ:N
MG^.FTR?]EWXGW*OX*6]MK?5'\%WEK)HDNNR68_L*79H0BS=0NL?L/[<^OP:)
M??LS1QW#V>I:I\>_#5BEPNNZCH_FZ,\;_P!LZ<(M+\VZU&6]S9-!;K;Q?/;$
M#5=-$C"Z\;\0^(?V=]5^/'["D/P-3X3Z4'_:%^)\]SI46C0Z1\0K^S7]F3XH
MR2:IX&AG6WOW\$%;G2?^$@O+&";0;HMH<=O*D\!%?2/[94?A*>S^ ]KXDU?Q
M%I.H7/Q[\$+X4'AS1/#FL2ZKKL/VRZ_L?4V\1ZMHL5KHUW807;ZA]@N[G4;B
M* +9Z3JES'# -U;V^'YN9+ZS@^92?O6=:C=-I-V:>B2NXM*VMBY:PK*UKTZZ
M:V:]R:U;Y;23U;=E&2;=K7/R&_9P^ '[0O\ P4NT#X@_$3X\?M9_$KP;X4\)
M_%3Q3\/=(^'WPN;1K?PS-9:#Y$T)L9;*YD\/FVL['4K+3(]1CT_5;G59+.;4
M9]1G6YC(^F[+_@A%^R.I$FL_$7]I#7[@_-))=_$'PQ:(\S#][(%L/ -O*-[D
MN%:>3;P"SD$GZ,_X)=>%-=\+?L\^+CXE30%UG7_CW\8]>O6\*W[7WAV2:Y\2
MFUD;2-\]U+:V:2V4D,5K-=W4ZK$)IYC+,RI^D-? \,\/\.9A@JF>YQPAP/G6
M<9UF>=YQBLQSG@SAW/\ $*69YQC\93P^"Q?$.38K'87+<+0K4L+EV"I_5J&$
MP5&A0HX:A3IQIQ_G;P]\(. >(.%,HXCXUX/R?BSBC/88G-LVS;BW!?V_CZV(
MQ^.Q6*A"+SI8OZIAZ%&K2H8;"8:%##4*%*E3I4HQBC\6I_\ @A!^Q=/C;XI_
M:*MNN1;_ !2TU0V1CD2>#I,8Z@IM.>23@8[3X0?\$6/V0O@O\2_ WQ5\.>(/
MC_K7B/X?>(;#Q/H=IXK^+5QJ>ASZMIDAGL)-5TVST73#?06]P(YQ:_:(H)9(
MHUG26+?&_P"N-%?>4:>5X:'L\)POP-@]%RU,%P#P5@\12<4_9U*.*PV0TL30
MJTF^:C6HU85:,TITIPG&,E^AX/P=\)LOQ%'%8'PSX#P>)PU:EB,/B,-PGD=&
MM0KT)JK0K4JE/ QG3JT:D5.G4@U*$TI1::N%?$GB#_AB;3/B/XC\(ZGIGPGM
M_B?IMM(->T_Q'HLCZ98)KWA_6]2AD\62W=LWA^#0M4L+G5IKM]1F2QN;F>;S
M"=4E@+?;=?&'CGQ;^R#%\4/$=CXIL_ANOQ1L4NH-?USQ;H*/HNF2MX/OW$OC
M/6KN)-(M="&B236=Y/JMS#8&:<6QF74&5D(?&E[STD[0^.^BNM]-6I>JUZ/]
M(^Q/?9/^ZFKN\U;5)7?2RN[I7.3_ &++B&S_ ."=?P@NDL/#^H6]K\";V=-,
MTJ(2>%KVW@L-7=;'3($L]35_#]S$H@LH5T^_5M->*,6ERI\E_BR^_;5LOV"?
M^":WAW]H'5/ NJ_$KQ5;7,WP_P# GPRT>VA\)7_COXF>/_BK<^'_  KI<S-H
M6F?V+;374OVK4;C_ (1QKHV-NQL[>Z>>V9_N?]@VYA3]@3X#W:#3-0MU^#B7
M$8\)2FQT>^@6'49$'AF9)&^R:9<Q@?V+*DK>1:O;.LA"!C^,/_!0&_\ #+?L
M(_L1W.A>%?%7AOPM8?M?> OB);>&X[;Q%\=(=$;P!XU\8^-A;>,]9TKQ3X:O
M-#TQ;W36AU+Q3J-GJVF:5<2?V?.)I;I$D_1O!_ \)8_Q+X4I\>X>IC.",)CU
MG'%^#I5L3AIXSAOA_#XK/LZP;Q6"G3QF'IXS+LMQ.&J8C"5*6)P].I.M1K49
MQ5:GXW$>91R?A_,\UG5CAZ>783&8VK7DH25&EA\+.I4K6FU#]S!2J6J6ISLE
M-MJ*/G_]IO\ ;<_X+$VSWNF_%O\ :1_90_87U>[M4NK3X*_ +P2/VDOCIHT,
M\49CLO&?B/Q'<7_@#PG?R1S,ZD^(+348C&+A-*DC,4;_ )Y>"?!O_!3#]JW5
M;[3(OVO?V^OCTLS2QWNF>"?'6N> _"5JLTJ[?[0D\)/8Z)I:,0C>1)>V$";'
M* HK$?K;_P $_/\ @GC<_M1P>+?VK/C_ &&J>+?"VIZQXEU?P5X"O=<NM'O?
MBYXIBN;N[NKWQ+XF*O>V'AB76 -*6YA4RZE=?:YY773[,P7OZS:+J'[5?A'P
MOX7U#PO\/M+^!VB6/P)GUS4OV>?!_@#P_P#$#0?!OC2W\8Z5X8D73/%FB1>'
M=2\2:C9^#[Z\\=V_@^TM[:]U6^TB/1GOIQ+<O+^*9/\ 29^E3XRX%9SPSB_#
M/Z*WAEF+5;A[A_P:\*.!\NX\QF6/GE@\=BO$SB+*<[\1<-*K1IJ=#,)\6U*M
M9RC7^ITZ%:EB:_\ %/"&1^/7T@L)1XRS?CC,O!_PWS-RK\.Y)P[?%\9Y[E-6
MHH8;,<=F.+M2RJ&*I5(UL+B,'AZ,,53O5HY1&A*AB:_\U#_\$.OVS_$<,>I^
M)/A_\2?$L]BT>J01>.OVHO$6NWK7EZLD#RQ6NH_$>X@&H6\-W<),X6*6"&6=
M5E;<ZM_5S_P3H^ GB#]F;]C_ .$GP9\5:8=&\0^%;+6WU;2VUW6O$C6-WK'B
M#4]9>V;5];U/5IKEXA?!)/L-W_9$<@9-+B2U";ODG6?VC?VV-.\*?$/XF)IT
MUA\,OA3\-O$&IP:_XK\!0:#J_P 3M:;Q=XUT7PMXFL/"#>'9-8GL=0T.P\.Z
MNVBZ?=^%K_3Y)8A=:3JB:E%!)^EG[//B?QWXQ^#/@3Q'\3;"?3O'.H:;=+X@
MBN-'ET![N>QU74-/MM8CT>=8I["UUZPM+36[*&>VL)S9ZA!)-IFERN^GVWIX
M27B34K5J_&?CQXZ^*>$K4X*.3>*'B7GO&&2X7&1JUITLSP649C/ZK@<RHTJF
M)PU/$4Z4*E+"XO$48I1K32_H/PX\$\!X;YYBL]H<>^)G%V)QN65<JJ4.-N*?
M[>R^DOK.$QL\3A,/]3PRH8J+5.C&K"4H>RG6@D^=R/9Z***] _:PHHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *^&?V_W\&ZK\#]5\":Q!X'E\=^+M*\9
MZA\+I_'WA32O$>D:?JOP^\&:U\0/&>H66HZWX:\5Z3X.UV'X;>'O%T6A^+KS
M2+E=&U.>VNDM[MXQ:3?<U?/O[0O[,/PD_:@T#0O#GQ9T[Q'=V/AO4-8U#2+C
MPKXT\5>!=6MG\0^&=8\&^(+5M7\(ZMH^HS:;KGA?7]7T35=.FN)+.]L;Z:.:
M%CM98J)RA**2<FK1YK-*72334DU!VERM/FM;2]UK1E"%6$JBDX1=Y*-N:22;
MY==+2=HR_NMZ/8^?O^"=WPEU_P"%7PK\5&7PH/ ?P_\ '/BK3O&WPK\':EXD
M\+^./&.E^%M5\'^'5N[_ ,5^-_">CZ1I^N2:_K4-]J^B6ERVJZCH>BW%KIMS
MJC*D6GZ=[#9?!OQ#X.^-?QL^*_@K1_ ZP?%KPQ\%?#]SIP>;P[>W6H>$O$GQ
M ;QYXGUR\TW1KH7VKOX:\96;Z#-*+BXU+4-*2PU&ZL+3RKI._P#@C\#/!7[/
M_A$^!_ 5]XWN_#R7$,UI!XY\?^+OB%>:9#:Z?9Z7::;I>I>,=6UB_P!/TBTL
MK&WBM=+M;B.R@*O)'"))9&;V.MZTH5)RY4W3E3C2Y9Z.5+V4:;IU+2=VXQM.
M46E*2YX*'NJ//0YZ=+EERJ<GS3<-E45=8A3IW2<;5(J44^9J/NRE/WI2_)_X
M1_L,?&X^$_&G@CXG?%J3X,6VE?"?X5_L]_"OQ_\ LE^+-4\-?$Z]\ ?"7QAX
ML\667CSQ'K7BOPE/I_ACQ7XM7Q)#H^K^%])L?$6FV-M%K3VVO3?VNBVWYAVG
M[,5QX#_X*-?\%"/@)=_M=_M :]JGQ)_X)9?!6STOXV?&WQE;^/\ XD^$KG6?
MC;\3M-73-$G\-Z+X5OY_#2M 7O=,TNR.J1P:KJLL%ZLTL,B?U.5_._\ \%4O
M^#?SP3_P4[^/K_'_ %;]HSQ+\&_$B_#?P7\-[.'P[X'M]<N;/3O"4GQ*N9KB
M/5O^$KT*=UU>^\>:9?36;P-%!<^$=-='<W$ABPQ47C*-:C6DVJU&M2G-.4)/
MZQ[25:IS4ITIQG4J5:E64J4Z3C.;]DZ24%'U\@S;$\.9[D_$&7\L<;DN;Y9G
M&#YJ6&KTX8G*<1AL1@XNACL-C<%6ITWA*,/8XS!XS#580Y<5A\3"52%3B_\
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M#/;>'- M[J)X+J#1-*AN89/]9#/%8P)-%)R?GCD5D;D_,#R:VJ]$^."BBB@
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M5>4=WOI'XWY1_71Z=!V;C/1NT;O^5=I3T?NIM7VTOK'=>;_L<ZOI%A_P3?\
MA7KFO^(]/LM"M?@%J>IZOXLT16L=*MM+33=9N;WQ#HZ"2X:ST^*U\S4=.433
MFWMQ"!++LWM^*'[:T>M>)O\ @GU^Q9'%H/QDMY=:^*?B#4?[5\(^--7_ .$.
MTA+R]\3Z;I4'QRN]52WU/QIX5\4Q:FL/AVSN[&T>#Q7%I5T+AM.M;<7G[;_L
M4>'(?B-_P3M^"_A:;Q"OV?QK\$CI$GBCP_IMM:0RPZ]!J-NVM:3HVIC4K2"U
MN([DW=II5^+^V2VD2RNC<Q!R_P">?[?WP)L_A\__  3N^$&[XB^-;*T_:#N+
M"U\:KJOAWPMX$LI_$OB+19VT#QGX!\-Z1:V^KR7UC<7%MX(71M+-AX>.D:E=
M:@D<MY;RR^=G>/EEG"GB!B*>(CA:^(\-/$;*L)6E4A2Y<9G7 O$F3850G/%X
M)*K/%9A0IT8*K4E5JSA3IX+,YSCE^)_*_'&4I>$/B!AX2Y*F.X:S/*Z<[M.-
M7.:*RBDHM*5G*KC8)-1;4N5J4$FS]Q?A%X'L/AI\+/AW\/\ 3+:WL[+P=X,\
M.>'HX+1/+@$FF:5:VUS*BY)S<7*37#L26>25G8EF)/HE &!CTXHKHPF&HX+"
MX;!X>$:>'PF'HX:A3BDHTZ-"G&E2A%))*,80C%))))62/TG X/#Y?@L'@,+3
MC1PN!PN'P>&I02C"EA\-2A1HTXQ22484X1C%))))))(9+%%,C131QRQ. 'CE
M19$8 @@,C@JP! (R#R >HI]%%=!U!1110 4444 %%%% !1110 4444 %%%%
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M6-$U>739O#OF7]WJ>EZ/=V\4$,/ZCV,K365G,YR\MK;RN3C):2)'8G  ZD]
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M+W?_ /![5\!!+>+HW[ /QZOH#]H32)K_ .)?@RPEO)8O,"+>6UIX=U1+3YU
MN$MKK4&@Q( 92@S_ %0?\$ZOVU-%_P""@G[*?@+]J+P[X7'A30_'5WKUII]I
M;ZEJ&KZ7>CP_J<VD7M]H^HZMH'A;5KFPCU.VO=+=]1\/:7-_:&FWPAAGLOLM
MY<P_ ?X&>,/#7@/QQIGC_P"$/P&T+78)-2U#X>:=X+\#^!M-T>'6=9L[_5M8
MO7CT_1&M;4:QXJOWU&_DO(+BY.JWFMR.UYIS6,DWJ_[,_@/QM\,_">M>"?$V
MB^%?#WA_1-;"^"M-\'>'_"7A?19;;4;&WUCQ;K=KH?@V*VTS2HO$7CS4O$NL
MII\UG#?0M=R37,DS7(\L<;.2YHOEC&5T[J7,TK1=M91NG).VE[7Y79=$^\I1
M\U:[4FOY96=GWLFE='TC1114@%%%% !1110 4444 %%-WI_>7_OH?XT;T_O+
M_P!]#_&@!U%-WI_>7_OH?XT;T_O+_P!]#_&@!U%-WI_>7_OH?XT;T_O+_P!]
M#_&@!U%-WI_>7_OH?XT;T_O+_P!]#_&@!U%-WI_>7_OH?XT;T_O+_P!]#_&@
M!U%-WI_>7_OH?XT;T_O+_P!]#_&@!U%-WI_>7_OH?XT;T_O+_P!]#_&@!U?D
M[XW^#=TO[77B7Q1X[_8_\6_'WQ+XH^(W@'QA\%/VE=*\7>%]%TCX'^!_#'AW
MPO::GX3NM:O/%>E^./A^_AOQ#I/B?Q"=!\'>'-9LOBL/%!L-3:X:ZU*WM/U@
MWI_>7_OH?XT;T_O+_P!]#_&G%N%2%1?%#:][:3IU$U9J49*5.-JD)0J1CSQC
M.*G*X[2ISIOX9JSMOM*+NG>,XN,I7IU%.DY<DY0E*G!K\*)?V7/V@X[/XU7$
MWPCUO5O!WQ9ALO&/PG^$EEXVT[2I_A%\*-)^+_A_QE\7_P!DNXU236+>Q\.W
MO[26B+?^+AJ>DW:Z!I.J7NI?"G4-5T_PQH6B7<V_X6T_7O@C\1_@E\8O@_\
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M +Z'^-&]/[R_]]#_ !H =13=Z?WE_P"^A_C1O3^\O_?0_P : '44W>G]Y?\
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6Y?\ OH?XT .HIN]/[R_]]#_&B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img143810944_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img143810944_4.jpg
M_]C_X  02D9)1@ ! @$ D "0  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #F T,# 2(  A$! Q$!_\0
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MPYTS0]0MAJ5X_AV/2KB:WGL_A_\ :<_X)1_ []CK_@B5^W+XN_;&_8H_8?\
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M\3/$.O?$'6/B_J6H#2OBGH_BCP-H<LJ>+/#MUI^LPU^T?_!63XQ6VE_M/_\
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M[PM*FM?#;PY\5--UCQ;I)T>:U'C'7S->3  _HKHK^,_XR?\ !1[]KW6OC/\
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MPI\5]>U_1?\ @J/\=O\ @J_^W;\7OV6K;P)X*&F:S\(_#_AGQ;\0/#'C._\
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MGX4+X+M/^"Q/AO\ :"\4^'O^">?[<G_#>?[>_P 7_"OPOU[PWH7C+QE^V?\
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MYO&6B^/-=@T_4-<MO"9\)^'+R"RM0#^]2BOY%OV4?VT?^"B'_!0?Q;_P2[^
MMG^T[XD_9\UCX@?L??M7?M/?M5_%+X>_"GX;6_C+XL_!K0/CJWP!_9@^)7AK
MPU\1O!_B_P ._#OQ%\6+#11\0;&Y@T:XT6WAU[5M3T[0;BU@T>TM?ZW["U:R
ML;.R>[N[][2TM[5KZ_>*2^O6MX4B:[O)((;>%[NY*&:X>&W@B:9W:.&)"$4
MM4444 %%%% !1110 5E-KNB+9RZBVLZ4NGP71LI[YM1M!9PWBW M&M);DS""
M.Z6Z9;8V[N)1<,(2GF$+7!_'#XH:+\$?@M\7OC/XCFCM_#_PC^&'CWXFZY/*
MVV.+2/ GA75?%&HN[;6(5;32YB<*Q/0*Q(4_P0?LM^&_C'X&B_80_P""8WQ>
M;7_%WA__ (*C_M(_L(_\%8]-O[JW#:?IGA.>W\4_';]L3X4W[RB6TMO[#\=?
M"#X6:[I5H\<C7NF^,]6O9R]R8#, ?Z&%%?R'?LU?\%(/VP?BE\4?V!OCU-^U
M;9>,/%O[<_[??QM_9]\7_P#!-;1O!WPS/A/]G_\ 91^%=W\4M#\2>.+JZM?#
MH^.ND_%GX3GX>>#O%OC3Q7XM\8KX=U@?$-=)C\):=IXMVN?J3_@M)^VM^V1\
M,?VG/V?_ -DK]E_Q1=?"30?&7[.7QU_:.\>_%32OBE^S/\$O$5Y-\-M3T7PQ
MHF@Z=\3/VN=#\2?"'3O"?@R\UN'QQ\4M!L-$N?'>N>%)('T?5?#.F:=JVJL
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MX^"G[+W[>7[2G_!3/]J3Q]\1_C'\9OVHO@OX!NI-(^(-OX*_92^!=_\ &/\
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M&OZ1KL?BC2M9^(]I;>&XX/&NI:;XEAB\06%YXC349[/6XUU2W>.]'GU]044
M?G9\:/\ @GWI_P"T/^VC^SQ^U)\8_C!XA\5_#3]D^:^\9? 3]E^+P9X0TOP+
MX9^-^I:0V@R_&/Q'XS@MY/&7C'4])TXI/X3\-ZA-:Z+X6UNWMM9T\M*+F&Z^
M\?%WA#PG\0/"_B#P1X[\,^'_ !IX,\6:3?:!XH\)>*]'T_Q#X:\1Z'J=N]KJ
M6C:[H>K6]WIFK:7?VTDEO>6%];3VMS"[Q31.C$'HJ* /GCPS^R)^RGX+\ ^$
MOA3X/_9J^ WA7X8> O'VE?%7P1\._#GPD\!Z+X(\(_$_0K_^U-$^(GAOPMIN
M@VVB:-XXTC4L7^F^*M/LK?7+&[5;BVOHY45A]#T44 %%%% !1110 4444 %%
M%% !7"+\+OAJOQ)?XRKX \&#XN2>#5^';_$\>&=&_P"%@-X 75_^$@7P2?%_
MV/\ M_\ X10:]C6O^$?^W_V5_:H%_P#9?M0$M=W10!PGC'X7?#7XAZGX'UKQ
M]\/_  7XVUCX9>*8?''PXU3Q9X8T7Q#J'@+QI;65UIUOXM\'7FK65W/X:\2V
M^GWU[90:YH\EGJ<-I=W-O'<K%/*K<G\0_P!G']GOXN>-/ 'Q'^*OP+^$'Q+^
M(7PHO'U'X8>.?'WPW\'^+_%WP[OWGANFO?!'B/7]'U#5_"UT;NW@NA<:)=V4
MJW4,5PK":-''RM_P5<_:5N/V2/V OVA_CC::%\3=<GT'P[HGAM'^$/BW3?A_
MXY\-#XA^+=!\ /XYL/B#J_@WXAZ=X!T_P)'XE;Q;KOC6Z\$>)T\,:+I%]K"Z
M5-):(T?\>_P+^-'[4OCWP'\;/V<?A5^UEX_;PY^T9_P5(_X)O_LA_!WQ]\(?
MVE/VE/CC9^#+/2O .K?';]J+XR_"3XQ_M&&'XNZGX5\6^#?#/ARWUY;NRLOA
M7XINX+JX\':(/ NN0RWP!_;/K/["?[#^L_%E?VA/$/[(G[,>J?'"S\5:?\04
M^-.L? _X9WOQ.M?&FA26MUI7C,?$"]\-R>)H?$FCRZ?93Z?KXU5=1T][*UDM
M[J(VT12;X:^!/V*=%_:0^-NK_"/P-^S=H_[63Z7X3UG]H77/ 'A/X=Z=\=9M
M'\;PWE]X,U#XK:UH.G0^-9[/Q7!H][?:)-XFNW364TZ6\MS<"W\U?XW_ -J"
M^UCQ-\!_VOOAMXJ_:;_:7L_V7/'?_!?WX0_L8_#KQ[X[_:)^-.IR> ? 6C>#
M=,T?]LO6?&/Q&C\0IJNN_"'QC-)\0=#TSP5XHN;[X>:9XGF@3PQI%OK-OIMY
M%^G7[$?CK_@H9JOCG]L3XQ?L4> ?AK\;OA%XI_X*$>+_ -F:PB_:;^.'Q*T6
MT^&?[-7[&7@3X6? KPEK_P *8)8?$VH>)M1\8:_;_%#5/$6H7U]#<ZSK'A^V
MU74SJVHZY->0@']$/C?]F_\ 9Q^)VJ>.;[XB_ WX.>/M:^(_A#PYX(^)%WXP
M^'?@_P 2ZGXX\!^&M=G\1>$_"7C*?5])O+KQ#X3T3Q+'<ZWH6AZPUWI%AK23
MZA8VL=XLDH[72/A;\-/#_COQ7\4M"^'W@O1OB7XZTGP[H/C7X@Z7X8T6P\:>
M+=#\(1W<7A31O$GB>ULHM:UK2O#45]>IH6GZC>W%II2W=R+&& 3R;OX4K_XN
M>$?!GQ)_:R^)EI^T?\</AIJ'QM_X+W?";]D7XI>+/%/QO^.]Y=? /]BKX%>*
MM3^+$NF>)KC6O%5U=^!M.^,_CWP?X]T_P7I\8LXF\+^*]0\':,UAX0N[O1IO
MI;PO\?/CY^UWJ?P.N/!GQW_:(\"Z)_P4@_X+O?%_Q3X UC0_&OQ \$Z_X._8
M _85\!:O;:KX4\+Z9?747_"O],\67W@234_$NC-I=II\^N:E<2Z_I-W?1S6Z
M@']$O[-__!+3]FWX'_$/XQ_&CQWX2\!?M"_'+XI_M=?%_P#:XT+XQ_%'X2^
M+[X@?"37OBE%X=TVQ\%_#3Q'<:;J>L^&]"\$>'?"NBZ)HU[IFI6-[="W>_G2
M*[F<U]-WG[&W[(VH?%>7X\7W[+O[/=Y\;Y_$F@>,9OC%<_!OX>3?%"7Q;X5@
MN+7PUXF?Q[)X>;Q2VO:#;75S!I.K'5/MUA#/)';3QJQ%?QY_L.>+?VCM1^(O
M_!-#X@_#_P#:)_:\\=ZW^T-^UO\ \%2_B3\*/AG\3/VA?B;X[\&6'[!7[.OA
M[XHZ=X'^&'C7POXIUVZM_'=]XX^)C>$QI/Q'\>W.M>+;9[JSM-"UFQL+&QBM
M;O[&'[97C_2_&G[*O[0WAS]IW]I_XX?M'^'/@5^W%^T-_P %JOA]\1/&?Q'O
MOA#\"-#\!?"_QEK'P]^%?B7X)>*/LWP]^ 'C#PU\8]"\/>!OA#X=\ :%X8\4
MZWX:TC7M0U@:OHE\MV0#^P?PM^R#^RCX'\:1?$CP7^S1\!/"/Q!A\;^)_B7#
MXX\,_"/P%H7BR+XB^-M%G\-^,/'<?B'3-!M=53QAXI\/75SH?B#Q&MT-7U?2
M+FXTZ^NY[2>6)ZH_8S_9#76OB]XC3]EO]GF/Q#^T#I-SH/QVUV+X-?#R+6/C
M-H=\V^_T?XI:G'X>6]\>:7?O^\O[#Q/-J=K?2?O+N*9_FK\RO^"-OPC\<? [
M_@F]\*_VL?C?\1_VF/VB?VA_C)^S+HOQM\?6WQ(^+/Q#^)%W!I.M6/B/XP>%
MOAS\+?AYXEUZY\+^%]0CTKQ7:Z*;G3]+3Q+XFU1+.#7-<N["STFPTW^:']G[
M]O/]L;Q[\9_CW\>?V5/B=\2_$'BQ?^"8W[:G[6NH?"#5?VEOCC^UMXG'Q!O/
M%7A?PK\)?AW\3? GBWP5X!^ 7A/XQ_ >_O\ 4/$VD_#C]FKX::0-#T&QL? G
MQ#&M:Q))/K0!_>-/^SU\!+K5=9URZ^"GPHNM9\1_"RU^!OB#5+GX>^$Y[_6_
M@M9/<RVGPCU6ZETEYM0^&=M)>W<D/@:Z>7PS&]U.RZ8#*Y;S*S\"?L3II.F_
ML(Z?X)_9O'AVS^'UC\5-*_9*LO"_P\/ANU^&&G?$"UGTWQW:_!J"P.C0^#[;
MXG?9+FRUQ-!72_\ A,ECN8)SJR>8O\>OQK^)7PJF_P""8'[<_P 3/V8OV\_^
M"@'QSMS\'OV+?A]\2?BKXX^*WQJO?@3;_M<?%/XA>&3XX^-'PS^.\^NZ;K^F
MR^%=)\4ZPG[07PA\!R:7\%_#$$&C>'O$GAL78AT6W[/XD:EXJ^&WP]_X*1?&
MK]F7XO?&QOV<O^"75W_P20^$'P(D\,?%#XC:A'XI^&GP.UWP?\;/VH_+NI_%
M-Q=>*[/Q9X6^+#6>MVFK2W%GJWAK3-+T.^A?2;&RM+8 _JR\:_ S_@GQ\ /A
MCXAT3QY\&_V3?A!\(/BK\7?!NL>*=$UWX=?"OP9X!^(GQRU_Q=I<G@'4]=TF
M?1K#0_%?Q*U/QQ%H\WA:[OK:^\0S>(X;"?3)/M\,+KZ]XE_9I_9J\<_%_P ,
M?'GQ?\!O@GXN^/'P]MH+/P=\8/$7PT\$:[\5?!=JHNGM;;P]XZU'1KKQ5H$,
M8OKV2UBL-3M5B^UW+P!3-(6_F%2X_:5^+OQ?_P""<FK?&#Q[\;/!'Q!_X*=_
MMS>//VY_&?PBMO'?CBQMOV?OV$?V0/@=XDU[X*_ &#P[I&L1:;X6FU_1M?\
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M&;XH6_Q?^.&OV9\;W'P_\9^+M"^(^A?#KP;\&=0\8-:^&KZU\%:YX8\$^"O
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MKPMXM^#>H_%;X<:)<:Y^QEI'[1WB!?&<UYX\L)? 'BW7=1L?[.6['B.:>"P
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MZCHKY<_X:\^%G_0O?&__ ,1\^-/_ ,Q%'_#7GPL_Z%[XW_\ B/GQI_\ F(H
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MH **** "BBB@ J.6/S8I(M\D?F1O'YD3;)8]ZE=\;X.R1<[D;!VL <'%244
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MK*0592,@@C@@CD$<$<BEKD-#YE_:\_Y(C=_]E*^ _P#ZO7X<5]-5\R_M>?\
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M>)_#97Q+X6&J?\)%X=9=9TRQ8?FS8?\ !.3X\^'O"/Q8T;PEXI^$VF1_M!>
M_P!H[X.^*?"FN:U\0O%%E\&_AU^T#XETC79-7\'?$+5-,F\=?%SQAH4A\;:Q
MJT7CQ_#D?B'Q)XLTVVM=?T3PWX2L;&\_;&B@#\J/AY^P1\4/#NN>!/#&H?%2
MV\(_#GX$^!_VM_"7P7^(OPTO;B+XY27W[56OV^HVOBK6[7Q5X8U;P#HOB?X0
M:7]K&D:A<6GCW3O&WBV/2O%>LZ'I4%K>Z!?_ "K\#/V>O%_[._\ P6Q^&VB>
M+_VJOVD?VJKCQ+_P2\_:1U6QU[]I'4OA/J6L^#8;#]JK]E"TGTCPJ_PF^$_P
MFTZ+3-8>>*\U1=9TW6;U[JQLC:7UI LT$O\ 0#7XBZ7\5(/'_P#P7\T7PE%\
M/_BOX/D^$G_!,W]HSPM/XC^('@2_\*>#OB,VL?M-_LB:XFO?"'Q%=SRV_P 0
M/#6F*QTO7=8T^*W@TO6O+TZ022R$H ?MU1110 5_GS_\'2GASX;?M-_\% ?A
M+%'X,L=2\$?L*>"OV=-)_;2\?V6I7FFZS?Z#^U9^T%I&F?#KX*P7UG(PL-5T
MSP=_PF?C^QU Q1W%G9^+=1>&4RPQQU_>[\4OB3X1^#?PT^(7Q<\?ZK!H7@7X
M7^"?%/Q!\8ZS<LJ0:7X8\':)?>(-=OY&8J,6NFZ?<RA<@NRA%RS '^%+]I7X
M ?$'XO?\&^_[6O[:_P 1--OM-_:"_P""F7[4'_#<VJ0R$_VKX=^$O@.'Q3XL
M_9V\ VTBQJ[:/X;^$W@*UU308U,SQ6GBR1$E<A2 #^\+P7X3\,> O!WA/P+X
M)TJST+P9X+\,Z#X3\(Z)IV1I^C^&/#FEVNCZ#I5@"\A%GI^E6=I:6N7<^1"F
M78\GIJ^?_P!DWXC0?&']EC]FKXM6TRSV_P 3_@%\'OB%%,C;UD3QE\/?#OB(
M,&ZD_P#$QPV>0P(8 @BOH"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH _(;]CF[M;#_ (*<_P#!:>]OKFWL[.U\6?L&3W-W=S1V
M]M;P1_LAZ0TDT\\S)%#%&H+/)(ZHJ@EB ,U^I>M>/O!'AU;EM;\6^'M,-E-H
MD%W'=:M9)<6LOB6]AT[P^D]L)FN(CK5]/%;::7B5;R1\0%PK$?D'^SYX/A^(
M/[?O_!=GP--!IUPOBV7]BC0(X]6@^TZ:+G5/V,K"TM);V#9*9+>WNI(9W"QN
MX$644N%%?;FF_LJZ;J7Q,UC7/B#H?@_Q1X2=1KNG74CZ@WBB^\47,G@Z:TM-
M646MM$FB>!9_!XE\'21ZG<2Q)J\L0M+)8K@70!VW[4/_ "+OPC_[.8_9W_\
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M[57[*%E'IWA#4_%I:Y\-Z5?"Y>YU>PLG,&I7<%A<2JLEFI< _H$KX/\ VB-
M^)=Y^T3^SEHWA7]HWXT_#3PM\4]8\=:'XH\(^"(/@U+H9@\$?#7Q#XPL+O3Y
M_&OP@\9>(K*_U'5K"T35I%UY[>>RC:WM;6S:1I:^\*^2?C;_ ,G*_L5?]CE\
M;O\ U1?BV@#\R/\ @N_XI\0?%KX=?LO_ /!+[X;ZO=V'Q(_X*9?'[P]\*?%=
MWIDP35O#/[+GPSGL?B3^TQXT58DDE6WM?".FZ;X=N%,*07EIXCO[43Q/M!^O
M?V^?@IX4\0?L\?!#]G31-&M=.\%:S\1/#_P9T#P]:1*MG8:!=?!'XK>#] T>
MVA(*+:V=M]AM(8L$"*)4 Z5\2?L6E?VY/^"Q?[<G[<ETPU;X/?L-Z%;?\$X?
MV8KEG-QI5W\1+2Y@\<?M8>.=( 46O]HVGB6\TCX>P:U:O<#4/#[36:W"QPR0
MC]7/VC/@#\3OC7KWPOU+P?\ '*U^%ND_#'QMH/Q%M=%E^%>C>.WU?Q;X>BUV
MTL[FYU/4O$FC2VFFR:?KLUM/I]O;F0S6\5U'>QEGB(!\0_\ !OW\0G^(_P#P
M1T_80U*XF:34/"GP@?X5:K%(V^:RU#X/^+/$GPPEL)B2<2V<?A2&%DR=FT)G
MY:_8VOP'_P"#>$7'@K]F7]KO]FS4+E9=1_9._P""EO[:7P42-;5-/!T5OB#;
M?$/1=2ATZ-Y(["RUF/QS=7]G:I+(L*.T88A03^_% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!^1W[%_P#RE"_X+0?]CC^P3_ZR
M)H]?KC7Y'?L7_P#*4+_@M!_V./[!/_K(FCU^N- 'YU_M9Z)/)\5O@;K/_"$?
M&.[MX?C]^SE$?&>F_$Z*Q^$5BX^(MHGV?5_AJ?'=M+J>H+YOD/>KX%O ;R[T
MRZ^W8L3)!^BE?G/^UGJ_P^C^+?P,TJ[^*OQ L?'TOQ[_ &<Y+#X76>K:U%X#
MU.T/Q&LW74-0TN+0I]&GN6MTO+EFEUJVD^TV-C(RB2*"*?\ 1B@".:&&XC:&
M>*.>%\!XIHUEC< A@&1PRMA@&&0<$ CD"H;-KQH ;^*WAN?-N 4M99)X1"+B
M46K"26*%_,>U$+SIY>V.=I(T>1$61K55)[2">>TNY&F$E@TTL'EW-Q%$3/;O
M;R>?!%(L-VHBD8QI<QS)%)MFB59D1QI&2<7"5TKN49*+E)34))12YXQ4:LN1
M5)6<DHQDE+EY))IWNM]FKV35UJW9N\5?E6S;:=KW27UU)9PB:.RN;[$B+)%:
M>29DB.3).$FEB\T1@9\J$O/(2%BC=C@?..B:U\8?C'H=IX@T6Y\ ?#[PAJTD
M5WIEKJFF:MXS\=::^G7,<L:Z]:PZKX?T#2=<AO[=[?4_#S'49-$N('M;N\N[
ME)[9/HZ#4+*YL(]4BN(_[/EMA>+=29@B%J8_-\^0SB,Q1K&"[F4)L4$OM ->
M#?!^X;5_'7Q=\4>&K9(?A=XCU'PW=^'+^+?'9>)_%T&GW=MXY\3Z3:R6]L\=
MA=RQZ-IDVH*+BTUS4-*N=2LKF1&EDE^HR-K"Y;GV.6!PBQV5QP%;#X[,<.L3
M1ISGC882IEU+"8J3P4\QK^WCCJ*J8?$5HX7*L=RT51^LUJ7!BDZE;"4O:U/8
MUW5C.E1GR2DE2]I&LZE-*JJ,.1TI.,X)U,12]_FY(OB_'?@A-,M?#'PQO=?U
MGQ%XL^/WB0>'?&OQ'U1-.MM6N?"WA#1]5\9ZOHL5IIEK:Z=I^G7VA:3J?AK2
M](T^RCTZU;7M1U"Z2:YN+N:Y\5U'Q.-&M-#\<K#;RR:E\4?CI\<H+*9FMFN-
M2\+>5\"_A[X?\Q6-O&]Y?>(?"]EJ:Q[(YX([F^%U%(DBR?57B"-?&GQR\!6.
MF.1'\&8=8\8>*;MD)A%_XY\+:YX1\->'(&S\U]/8WNK>(;]L 65G9Z4A#G6$
M,/R!\<M"B\,1^/M(U.[-M:^%?%.M>,;&8@1VP^'GQFE/B"W(WNB;?"OQO\$:
M9)=1*]O8V^G3::DP=KM(;S]5X.Q$,PKY3E6/FY8C'8"GF6;X=4U3J3HYQ6SC
M)EA</0HPA&A'%9=/@:>6X+#1I86AAZ.&K8:E2INI(\',8.C&O7I)*%*LZ&'F
MY72EAXX7$^TG*;?/[.M'-57JU'*I.<YQG*4N5'/O;FZT[2Y-/CO]7U[Q -&N
MVOK;[-8ZGXQO/&FI:CI&B^*_%'B<_8_%VH:K\3;K3-;U#P?\/]!\5^#_  UX
M8\"Q6=[K6KP66^&?#TSX::?X@\"^*/B#X_==<\-^"M0GT.X\/Z!K-AH.ESW=
MAK<GAL_VB=!LAJ/@_P !>&Y6N[[Q%JC6<>LWL-MJ6M6NGSK:Q:YKUWX>>)K/
M4M$U7PU<W]CH&M:3I?PGL(/&%Y<VMMHOPVT_X&7WC"_U+QQJU]>/!%!8^']"
M;P]HBPWLD,NIW7B'3;?46AM-3N)D]1N/"EYXUU_QKX[T7XI>'-.\8:5I\/C.
MTUBP@T+1O 7B+X:^(VU$^&?$.D^,?"ULFK:EHDUMI5YIVN1>-&\=Z7-JFFZA
M#)8265U:7*_?8S'XO)L3B\)4Q$<JA1QN$J?VBJ>.GB:F&J2RYJAAL3@,/.."
MIX^OC:N50S.G.EBLOA@HXN>$Q%1X?$TO(IT:>(A3FHO$.5.I'V-Z:A&<?:^_
M.G5FG5E1A2CB'1<94ZTJKIJI"*E"7S?XL_9U\7>!7M]3\%6]WX>N]6MGU*U\
M/6_B2Z^(GPZ\>,5;4+#3/ _CO6_[-DL_$D5C"9O#V@>+] M[J\D@DN/"WB&Z
MNH;'R?(?!OQNTOQWKR^%/#TL<GA.[T'XB2(%:X\^T;2_ OBZ77EGO7D5;C2=
M9\9Z?X/U"UG0&X;Q#HVF7EW,->O[^;4.W\2_M#W_ ,,9M,GUCX9W>NZ99:_8
M^*=-MOAY\19-(^&6J>(-#N4U*'7?$G@36]"OG\*V&FZBUIK=]<^#I]#TO4/L
M,L$FEPBZDCE^9/A+H>D:CX]@\7>!-4MC-<:EXS\2:Q'K$<-CH5CI^K:I8>*;
M?0FOI)9;:'PLNL'^T;]VO!:Z?H4FI7:WZ-J]O:6WZ]D64YIB\@S?&\94(UYT
M<!6_U?SVG5P]>E*N\/CHU/K]:AC\TQU'$X25+!?4JN:UUBHU*^+PWUB4:T\N
MRWY[%8C#T\7AZ66R<5*M#ZYA7&<6H\]!Q]E&5&A2E"HI5O:QP\'3:C2GR)QC
M6K_K3^RZVH0^/K6\O;I8+7Q-\-O%4-C;- %2_OO"?QN\=2ZM#!L>**P?2(?%
MNDO%8I;MYUEJ&;=8+:Q8'[]21)-Q1T<*[1L48-M=#AT;!.'4\,IP5/! -?F!
M\.YKBQU"UTO0))[IM.^*WPZG\'WH>1M4@U;4/&.M:%XLTB0D+*_]L?L]:/H7
MBWQG9W7E?9[F]@U'5H(-5NX$/Z=P6UO;"06\$, FFEN91#&D8EN)V+S3R! -
M\TKDO)(V7=CN8D\U_&GBOAE'B&6/<HJ6,4X1I1IQIVA1]G7HU5&_/*B\)C<-
MAU6G=U<9A,<H1A0ITHK](X?G?!JDDVJ=FY-MW<DXR5]E+VE.I-Q7PTZE)MN4
MI'S7^UY_R1&[_P"RE? ?_P!7K\.*^FJ^9?VO/^2(W?\ V4KX#_\ J]?AQ7TU
M7Y:>\%%%% 'X\?\ !6?XH_'.+5?V&_V1O@;\;M6_9=OOVYOVF=0^#OCC]I/P
MY:Z5/XR^'G@;P=\*?''Q5U3PS\.+K7;:ZTG1OB;\5+CPG:>"O!FMSPSW6G7-
MU>/IEN^H/!+!\K:_XD_:\_X(H^-/#GCOXZ?M)?&;]O#_ ()>^.]<TKPM\5?B
MC\<AIWBG]I;]ASQ9K^HP:7X?^)7B7Q?X>TK39OB?^SIJ^H75MI/B^6[TJ'6?
MAW/-87]C%-;>?#KWV[_P6)\0?\$_M$_8]N[;_@HKI^MZU\*M=^(G@O2?AIH7
M@"S\5W_QNU/X[RW%Y)\.O^%!P^ Y;?QG;_%:RECU*]T;4-$NK..SL(=4.LW*
MZ)+J$,_G_P"R/_P4'_X)R_$O]A_XBZ;J'CKQ=X*^"?[(O@;PW\%/VD?!G[>V
MC:MX6^+G@KPW=>$8]+\/6_Q]T;XG+=:AXLNOB;X?@G2SU.>37O\ A8>IMJFG
M6XO];6]TZ, S/^";'QZ\??&/]N__ (+':!K/Q8UKXE?"GX;?'?\ 9DMO@7I\
MGBA?$W@KPEX,\;?LUZ!XQO1\/7M[BZTRUT'Q/J%^NOROI4S6>H3SK? O)*\C
M_1O_  4<\#ZGXF^#GBK6++X'_#_XFV^@?#_Q7-=^+O%GC>Y\,ZUX!16LKHW_
M (=TB#PWJZ>(+B..VDU-+:74M)5KW3[2V+ND[.GYZ?\ ! +PM^P]:VO[;/Q&
M_P""=_P4_:4^&7[+OQ,^+?@"]\%^,_CG#J=AX#^*UQH/A;6K&_U#]G/2/$VG
MQ>-;'X3^%5NK;0[)_%.KZQ=.[V]E;)HT6FOI%M^B'_!1J#X R_!;Q@_Q5UFR
MT[QQ'\/_ !0WPXM+GQ;XIT"2_OA)8L(X=+T/5[#3M;8ZH--C$.K6E[$7D6!D
M$$TRN ?H59<V5I\Q;-K;_,1@M^Z3YB,G!/4C)P>]6JK66[[':;_O?9H-V0 =
MWE)NX& .<\  >E6: "BJUQ.\!M@EK/<^?<I Y@\K%LCI(QNI_,DC/D(4"-Y0
MDEWR)MC*[F6S3<6DF[6E>UFF]'9W2=UKW2NM5=:BONNV_P"?S^054O9;N.TG
MDTZWAO;Q%Q!;S7/V6&60.%9)+E8K@Q!1N)/DN=R[=H)R+=?*7QK^(MA9V6N_
M#SPHE^@LFAO/B+J.ADV3Z?9Z[]IN;3P=I&IHV]?'_P 1M5FL='T^"UAGN-.T
MO5=5\0RM"VG1[O9R')L3GF84<%AH.3YZ52O.4'*A0POM84ZE6O*-2E+6I4HT
M*%*$HU,5B*]+#49+$5:,9\^+Q,,+2E4J.RM*,$FN>=2S<8P336B4I2DTXPA%
MSDN2,FJ/Q:_:)TO1+I+;PRNCYTJ>^QXTUJ"[U2TCN8A+I6H#P3X9TN:"^\87
M-A--/I^JZM>:CX<\':1<[K>\\133+<VT'YQ_$']I";Q5=2B'Q-X@^*6KZ4+F
M>*U2TT75O#VG".)\7>I6-EIK> M!NC*GEK+I^C^.+_1[F$X\9Z=(A%>4^/KS
M7_CM\5M ^#NFQZ=J=CK.H)I'V*QU"\TSPTE]I%O/JVIWR7.G/9O%X1\,>&X-
MOA_2YA*FB>$K>'4X[6YU?6=2N)_J;X<_ KX6?#G3O$OB2R^(.N/?^#/"NN>-
M+72-$^'-GX:T;Q3H.@1P3W^O?#K7/$UEJ]MJZQWS6&EGQOHT44\:?8=3DL4N
MY;?5KC^R<IX/X)\.<JRVMFF'Q&-XEQF#I8K!9?3P5;&2GAL77J8;#U,;F6'P
M>,Q6 H8^LL30G1Y<NP,IT:M6E%RI8QK\VQ&8YGG6(K1H3ITL#3JRA4K.K&G:
M=.,)SC3HRJTX5ITH*G-2O6JI3C%NTJ:.4^"7QC\0VWBEM<^.OPV\*W[V;V<E
MK?>+[OQ5XL\<SLC$Q7.C7/C7Q#J.G:%<P0V\,OAZVM=!LD\32PI::?J%O=2V
MUU/]<IJUI>:?%X&BN;?4](N_VG/ _BS3WMFDDMO%?P\^+^H7GQ-TB\O(7"K>
MVW]I7&N6TD+0?9E7P['+(LAMYI3Y%\7?AB-$\ W-OJ&JW'B7Q!X"^#_C+XE>
M,+PW5WJ<?AK7KOQ3\/\ Q)H/A'2[_4)KZ^L+2YT^Q\<6?A"/4[R_O8EO-7UV
M6,B_9'\W_9>\1ZQXT^*GP.BR+A-.MEUB]O(%$&G:A!9^%_BAJ,5S$O,$;Z$G
MQ#'A/3;.TDEC6QTJ=4V2VMW%;^/G&!RGB;)LVXVRFG#!4<GHXNH\!3K8KZE1
MEDF'Q&,RO'8..,J3JX:.+P4,5["":FJ>;4<3"E4P^&P[H].%JXC XG#Y7B&Z
MLL1*E'VTHT_:R^M3ITZ].K[)1C-TZCASOX>;#R@Y1J3J<W[+VL M;:WMA+/.
M+>"* 3W4K3W,PBC6,2W$[?--/)MWRRM\TDA9SR34]%%?QJVY-R;NY-MONV[M
M_-GZ2E966RT05S7C/_D3_%G_ &+6N_\ IKNJZ6N:\9_\B?XL_P"Q:UW_ --=
MU2 \O_9=_P"3:?V>_P#LB7PL_P#4'T.O=:\*_9=_Y-I_9[_[(E\+/_4'T.O=
M: "BBB@ HHHH **** "OA#_@J7_RC'_X*,?]F)?M=?\ K/\ \0:^[Z^$/^"I
M?_*,?_@HQ_V8E^UU_P"L_P#Q!H \EU+QCX07]GK_ ()Y>#F\5>&U\7GQE^Q7
M=CPJVNZ6OB1K5_#FE3K<+H1NAJC0-!').LHM2AACDE#>6C,/O?XU6&BZO\+_
M !GHNNW&L06NKZ'?VMLOARYFM_$ESJ<%M+J.G6OAW[/-!-=:U+=6,9T^P20#
M4)D%G*KPS2(WP-J7@SP<?V?/^">7C1O"7AAO&0\8_L5V2^+7T#27\3I:+X=T
MF%;9-?:T.K1P"%G@$27:H('DAQY4CHWW/\>]6N]/^%7CNWT>VU/5=?NO!WB:
MXTWP[X??18_%7B*WT_3'EU72?";^);FR\.1>([VRE:RTBYU^[M]&M=0N[:?4
MI%LTF( /P%^"W@_4?V^O$O[?6F_$[1[K3O$O[.WP@MOV;-!U;Q=\2H]>^'FF
M_$SQ%X3B^(<WBA=)\*V>G67PUU70]/\ ^$5N=>T30S<^)/ D.NZWI-SK::G<
MRPV_PO\ \$2_B!_P@/PK/A+X/^,M5\6_$J_\0_$GQS<>$--U/5KS_A(/AEH?
MQK\0Z#\3[94\3E?AK:>*_#VJZ;)XA\-VVGF6Z'PLURQU#3=+LO$NJ7>I7'TC
M_P $P;+XA'3=#;Q18WOPYM+S]H[XO?#?7?A!8:?HVB6WA/1_C5>^)/A]'I'B
MP>%M8U[PYXA\?:7H/PPC\7CQ3;:EJ%CKFJZR+VUCATZU%B-__@FQ^S[X7^'%
MGH'P%^'_ (<^)?COX=^#?C;^TWX2\:>/?C[K?AKPQ8>$_#=CXW\4Z?XNO?A"
M^A7=W-K2^--0N=&GU;P=J#^'+=]+TR_\8:79+=V<5]* ?O;X)\4W'Q4TW6?$
MNCVWA.1]$@L_#EQ\1/ASKNE>*/&&M:CHUSINI:GX9@N'TS26TU[-Q)::]I5]
M=/;[M3CDL90ZSI%]&7>NBR>\$^DZTT-I_906XMK!KU+Q]4N#;>7:0V<D]TYT
M]BDFIR26\4-K _G^8\22LGB/P<^&^B?#SPEI6OIX \->'_%4?AV+1[7P]X U
MJ[UK18M"TZ.TLM+M?#EWK,]I'>RW^C:5HMQJ&J7"QWFHM;6[7MS)Y$>WZ*4D
MJI(*D@$J<94D9P<$C(Z'!(ST)H 6BBB@ HHHH **** "BBB@#YI_;'_Y-;^.
MG_9/=;_]%I7T1I?_ "#=._Z\;3_TGCKYW_;'_P"36_CI_P!D]UO_ -%I7T1I
M?_(-T[_KQM/_ $GCH O4444 %%%% !1110 4444 %?C#^Q=JFHWOQ-LY/CE;
M_')OVMU\<_$+0OBQJUEXM^"I^'=X+?7/$E_X9LKO1_ WBP^(K;P/+X$L?#VK
M>'/!6K:1+KWA^TM+ >([ :CI5YJ!_9ZOY4?A>WP:^ OC'X7_ +5FJ:?^U-J/
M[+FM_&F_O_A+K:_"3X.1:O?^(O@+X4_:>CL/$OCCQ_HOQAO?'OB3P7K?A7QC
M\7M;L]:?P)I_BGXKVOAWPU'KT<!G&G>(P#[O_P""C_B+]E#3?C3I-I-)\5[[
M]L;_ (5_I?\ 8NB^!1;3?#R3P3>:QJB>')OC-_PM_6/#W[.=AX<;5[?5XY+Z
M7Q!HWQ2@T]KBXT>Y\B+3"OW;_P $_P"?Q9<_LQ^#Y_'.B?L^>'?%<NJ^)WUG
M2/V8O&'B+QQ\)[2X;6KIHUL==\36EK?'Q"UN87\5Z?:RZIHVF:\U[9:+K>M:
M;#;:E<_FG^U^OC[X@?M&:UJ3:/\ M,^)O!^J^/?V%K[X*W/P7NOBM;>&O$W[
M-[^(F\2?M=6=A8_#W6=,L];L]:\-WXM_']M>6;^*M1T)M$TW29%2WLO(_2+]
M@N#X@V7PK^(FE^-=#^(?ASPYI'[0OQKL/@II'Q1L_$-CXPM/@2OBN2Y^&\-S
M%XOEF\6G2X+"YNK;0/\ A)9&U:'0X+"UEQ#;P  'VY14-Q<6]I;SW5U/#;6M
MM#+<7-S<2I#;V]O"C233SS2,L<4,4:M)++(RI&BL[L%!(^$;/_@I+^RUJ_@+
MPU\3?#FO>-?%'@OQ%;_%779=4\/?#GQ=?S^%_A[\$_B7J/PD^)7Q9\8:3_9L
M6L>'_AGX>\::;/;CQ#<V#3:GI).OZ3IU]HMKJ%[9 'WI7XCZ9\1-?\9_\%^]
M"\-ZO\(OB1\.M.^&W_!,O]HSP]X>\9^-5\&#PO\ &2RU/]IW]D;5KKQ3\,3X
M9\7>(];;0-!N6&AZP?&^C^#=8_M5T^P:1>Z?_P 3!OTA^'_[6GP<^)GQ+E^%
M_A;4/$,FJW</CR7P?XDU#PQJNG>!/B7_ ,*I\1V?@_XJ1?#?Q?<0C2_%4WP\
M\4ZA::)XCCMGBWSR2WFBG5]*L[[4+;XP\5JP_P""Y_P*8@A6_P""4O[4BAL'
M:67]K?\ 9&+ 'H2H="P'(#*3C<,@'ZS5^+O_  6E_:UA_88^#_@/]I^)/M/B
MCP!9?'/2OA?I0@DNG\0_&;Q[\&?$?@?X2>'H[:&.66X.H^.-=TB2X@CB>1["
MUO2H&TLO[15_"1_P<)_LM?\ !0?]JC_@MA_P3V^"_P  OB[IMYX9\8>%-*^+
M7P,^'^K^)OL7@_X*^*?@%XG;Q'\4_B]XY\(W\$FB:G*MN=(U'1M6^QZYK7B:
MWL)_!.GZ>38"VO0#^J3_ ()1?L@W'[#O[ O[//P$\0&2Y^)EIX3;Q]\<-:NI
M'N=2\0_'/XH7MQX\^*VJ:G?2EIK^XA\6Z[J&C6MU.S2G2=)TZ%CB%<?HG4<*
MR+%$LT@EF6-%EE5/+660* \BQAF$8=@6"!FV [=QQDR4 ?@=_P $R"_PX_X*
MJ_\ !=GX#3IY$5Y\<?V8/VG=%@48AFM/CU\#?^)Y?)P$>676_"9CN60L5DC"
MS8<@']\:_!'PVQ^%G_!R7\2M+<-:Z1^U;_P2J\%>+X6&0FJ>.?@%\?KWPK,'
MQA6>S\%^)(MA8F54W #RV)'[W4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'Y'?L7_\I0O^"T'_ &./[!/_ *R)H]?KC7Q]\$OV
M6;OX1?M4_MM?M(S>-K?7K7]KK6OV?M6LO"$>@2:=/X#7X(_!VR^%<\%SK;:M
M>IXB/B2:T.MQ21Z9HPTN-Q8.E^RF[;[!H ^+/VJ/$_C6#6?@UX:MOAMJEWX.
MN?VB?V=9KSXC1^*?"EMIMA<'XFZ1*UA-X:N-13Q1>,L\%K;[[73Y(3)>QSAS
M#:W!7[3KXI_:I3XIG6_@RUG/\/5^%X_:)_9U^WPWEKXE;Q\^H_\ "S-)#_8+
MFWNU\.I:FX-D5%U:M(+9;T%C,]N5^UJ .4\86U]J&CZGI,,&HG3M3T+7K74+
M_0=0AL_$UD\MCY5HOAZ*ZMI;2;4K@RSBWGNKBWAL[B*!W2=9&$>WI=I;:=IN
MFZ=:QO!;V5A:6EK!,4\Z.WM;>*&..0(=ADCC5%D*93<#C@BOAK]O+]JZ7]F[
MPO\ #KPWX8^%7Q2^.GQ2^,WB76M$\"?!_P"$GA[5=4\1^-['P9X?N?%OC2PG
M\065N^F>!]/_ +%MXK:7Q'XAN],TOS;Z'3AJ5E<WL-U#Z+^S!\:]+^+7@CPO
M=ZSJSZQ\1-,LH/#OC6W_ .$+U7PU-X$^(=MH&FWWCSX;:U#=H_V'7O#=]%NO
M!*;>UN].N="N[.:^BO[.YNFN6_O-I6ELDWS<KY59M:.5E)WNHMM*32BQWZ>6
M[MI?7H^FRZO2ZW/4_B[X7N/'.C6N@:7<:5?:GI.I6'BNY\%:Y=RVN@>-],L1
M>6P\.^)I+6WO+J#1;J^FAO([A;.^MX]6TO3S>V%_8K=6<T7AWXL6,>I6/A#Q
M]H,OPM\5W0C@T;2=8O;*Y\/^(0BLJP^#_%-F(M'UF>%(\OHV+'7K2!H)+G1X
M(Y4->O*8G9V0QNZ$Q.RE69",.8W(R5(#*Q0X(W!L<@UR&LZ!H&I:?=^&O$F@
M/XE\/7<&J:M?2:]%!KM@DK7GVDV9BOI;B]$Z?:I9-*CM;5HK&WM!#;RV[Q6T
M;^]ALUP<\%0RK,\)4K8*A.M5P^)PU:=+'8*MB?9^WJ4:3DL!BJ525*G*K2Q6
M'^MU84X4*69X6G"#AR3H5%5GB*%11JS48SIU(J5*K&%^2,I6=:G)*4E&5.?L
MXN3G*A4DW?FO&/P^O)M5N?'O@34KG0?'\-C#&T(NY5\+^-$TT2&QTCQGI 86
M]ZGD2W6GZ?K<8BU;0UO/M%K<2Q6ZVC_('Q;N;3XLWFCZV;;3]-M_B9\([+PW
MX?T/Q7>6EA9:Q\0O!GQ)MO%/BCX2:O<7VS3[;6;BPTO5M&2+5E2QFO[:2ZBC
MG?32J?1UIX+\7>!ELM9^$&JZWX@\,RZ?#>GX<^.O$5U<Z1/93O;O%:^%]=UZ
M&_\ %/A/5+6P=Y-/T[4)+OPY,R#3[Z#2)6&H0>5:M<^ _$NJ:K96'B.Y^#WB
M7Q1J<MQXD^%/QM\)VMSX%\9ZF[QQW5_#X>UZXATFZU#4;L19\1> ?$H_M2YC
M%W<1:E)*LLGZ-PCB/JF)H8ZAC/[5IY?"G]0S2GA\1+'Y7A:2Y_J6=9?@UC<Q
MH8:A6HX+$X2M2CCLNIPH8G+:.8818VOB\M\;,(>TA*E*G]7=:3]M0E.$:6(J
M2:C[7"UJCI49SG&56G4C)TJS<H5Y4:GLXTZWYI?$?P5^T[X0@U/1? GPV\2:
MO9W<6LVNM2:GX%U>?4O&]I?S,VJ>'_&DFKZ-=^";W3]3LVM;?4;W2KSQ/H^I
M7&EZ7+/#]ET;2YS3^#/Q=^-&EFUM_B?\*_[(\/VT.@Z+I#6S>&]2\(Z=HO@.
M]N-5\-:=J>F>&-+\,:?!HOA+6-3O+_1O#SZMHNC:GKDL9UV6YBAC@/Z-6WP@
MU?3K\62?!S]FGQ#]NEE6VU/5?B?XYNK)$M%2XU";0_!6O^&_$L>D0:/#<HUY
MI>C:S!#+;QVZ/<6=NUN+?!^)_P $=$TS2_#U]+XLUKQ-XR\::A;1:%H/P=^&
M/P[LAJNDH]K<M<>'K&WGT5M*\/Z"+Z&_UOQ5JOC62.32I+.WN[BYN);**X_=
MZ/BIPQF&$AP]F^4<-8RKC9>UIYO1H8B>=JI2A]9KXOER#.,XI8*&&Y(XAO-Z
M>$E@Z5)*%*-.E6E@?DY9#CJ-1XO#XC&TU22B\/*<8X9J;4(T[XO#8:55SYN7
M_9Y5/:2D[R<I057S+4?"7P[^*SWOBC7;Z#QK9Z9IVN>-?&NHKX@L/%NI^!=$
M\,:)+=QW&KZJ#=>$I/B!\0=7D>PTCPO#]H\'>#?#L5['H>B3W]B^JME^&/@G
MX=U'6=(\+V&G6NFW]_XEC\(KH6D175AI6C^*XO!\'CWQG>ZT\-S9:[K&D?#;
M3=1T?06O)[F#5O&'BO5(K62Z\.Z#;I!7<VWP:_: U*2&**#Q_>6=O=P78M_&
M^M:+::;#J=M(DNFW_P#9>H_$OXB:/?I:NO[V[O?#.JR6"DRV&EW5VL!C^O?A
M=\/+WP+:CQ9\0H]&3Q1&UYHNEV/A>XUS7]'\/:5KVMVQED74=3L8-;\0>*?%
M-\NGZEXU\6:I9QSW-U&EO"+/1=/17^(S_CJAPYEM6GEG%-+'P>'JT,LRW+\R
M6+^I8B,']4J3I1C&-*%*510E*='#JK@*4W[66:R>*S+U,'E<L;6BZV E1:G&
M5>M6HN"JP;C[1*3=Y2DHMI*4[59)65!*G1ZCX:?!?PK\-$AN;.2^UO7TL%TT
MZYJKQ+]ELRPEGLM!T:RCMM$\-Z?/./-G@TBQ@N+TK"=5O-2F@BF7U:*6=[BY
MBDM7BAA\G[/<F6%UN_,C+2[(D8RP^0^(V\Y4\PG='N7FK%%?S3F&9X[-<56Q
MN98BIC<5624JU:3;@E)24:4(.%.E3BN:$*,(*C3A*2ITXM1<?MZ-"E0IQI48
M*G3CM&*WTM>3=Y2;T;DVY-I7;UO\R_M>?\D1N_\ LI7P'_\ 5Z_#BOIJOF7]
MKS_DB-W_ -E*^ __ *O7X<5]-5P&H4444 ?AU_P5,\8_#SP+^W/_ ,$3_$_Q
M:\5>#O!GPZT']J?]I+6]9\0_$+7-'\.^"](U?3_V._BNOA35-4U;Q!=6>BV%
M_9^(+JS3P_>7EQ%+!K%S:K8R+=RQ9_.S]H+1/^"6O[7W_!=2'QE^T'\?/V;O
M''P*\ ?\$]?@W\0'\,WWQZ^'D'P+^*WQ^T#]HGXW^&_"DOQ8MXO%47A?XD>(
M/A?X%U62]\.^$==GO4L;37[._P!0T^XTL16US^N/_!6_Q3^QUX?^%WP8T3]J
M']CJT_;R\>?$?XPVGPZ_9=_9FMO _A3QMXJ\=?%S7- U6_U"71&\;7%GX8\(
MZ/H7@_1]8UKQEXUUR]MM*\/Z#8O<7;.SP1/^$>J>$/V1OC?XMC_9H_8F_P"#
M=O\ 9AU']L_X?6NHZ[^UE\)OVJ?#/PK^%W@7]D_26O([;P&/$OCKPCI7BG1O
MB=J'QLL"^O\ PNF^'>I75EJ'A2TN=?O9$BM;NTM0#^N3X._&+X"?%C1+F'X
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M[+^)_B2\U_0+$VFH?"GQ'H'P\\(ZUI6I6/P2\4WFO:AH'P_U!/#;7<*^$[R
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M7IFH:SJ$B[E0+:Z9I5M=ZA>2EF'[JUMI9-NYMNU6(_/_ /X*9ZYJWBO]@/\
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MVO=>A<Q2:='I<\NI6VF7\-KJ$^E^(7M(I)?#=X-*UJV7Q!#IBW^BZK9&:SE
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M_L[W6DZ):7]NYC$A!&EVKW%]+8Z>EO\ ZJ.P6ZBM;$+Y"I#M*#O5)*J2I4D
ME202I(R5)&02#P2"1Z4 +1110 4444 %%%% !1110!\T_MC_ /)K?QT_[)[K
M?_HM*^B-+_Y!NG?]>-I_Z3QU\[_MC_\ )K?QT_[)[K?_ *+2OHC2_P#D&Z=_
MUXVG_I/'0!>HHHH **** "BBB@ HHHH *_G#^%>G^)?B[\=_#OP^^(W["GP]
M\+?#O7?'_B;P%\2O VI)\1],@T#7OB9HWQU\3?&KQUX T[4/B.O@?PAX?\+>
M%]/^$'@OQ'XF\/>"+>+X[^)OC1\0;/PE=Z=IW]J6+?T>5_.C^P9\2/A[X/\
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MU#4[76O"FJW.O76K7/ANSM=)T?18OV'HH _,OP1_P3NCTK6= \->-OB*FO\
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MK?QT_P"R>ZW_ .BTKZ(TO_D&Z=_UXVG_ *3QT 7J*** "BBB@ HHHH ****
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MO)-.T7P]+I$/B'5KN"T<6]KI$VOSVVAQZG/(%^ROJT\>GB?:;HF'<I_RSO\
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M]DLKNX@_3:*6*>*.>"2.:&:-)89HG62*6*10\<D<B$I)'(A#(ZDJRD,I((-
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MLL_@_1?BM\>/&=]XQUCP=X5N9F=[S0_ FE3:)X+M=1#M%JCZ!-J=NQM[R(T
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M7E-\LODA9'G:*/[+;R0PQ3HTK_-A_;A_9%4NK?M"?#-3'JD.AR!O$$(,>MW
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M#_$GA+QM?^#/A'97&D:NWQ"UK0? 5JT?AF#Q-<Z6+GQ#IT37FKL \C#]+?\
M@O\ _L!:Q\8].US]H_P*?$WB#XI:;\-[;0/!O@V#[6/"7B*/PG?MK.K>%M4N
M[/1=9DT#Q%J=C/->^#-3A6QD\0:LESX7OKV*W>U+?:_[7GP0_8$^'/[4/PA_
M:+O_ ((>'](_:HT?]H?X0^)_$O[0][\,/B%J6I:%X3U&\U.+6[J^^+\VBWWA
M/1M%319[K3[G3WU^WLM,M;E;!;*T\R&-?NCQ7_P4'_87\(^'H?$7CK]J?X&>
M%/"6JM!96WB#Q?X[T/P_X9U)]1@DDMK2VUC6[BSTF]>_MDEDMX(;F5KJW222
M))(E=A^G>$/BMQ/X,<:X+CCA/$U</F6%PN+P-54I86$L1@L9&/ML-*6-P.9X
M54ZE2E1E557 XB-2$)4^5<_/'P^(L@P/$N65<KS"$9T)U*=6/,JC4*M)OEG:
ME5H5&TI22Y:L&F^9/2S_ ,LBQO)?&=CX0TSP_H5UJ]]\2_%7A3PCX5OO"^IV
M-OXND\<ZS')L\!WE@^J6>L^&+NSU:SELF?7-/LH]4FCM;[1;NZL+N%F_O0_X
M)W_\$U_B[^S=X=G\2>);&]^#GQCO_"L$,/BNQ\<>&OC'\1I-'TV]76[^S\,6
M&J:5IOA[_A(M8LKNU\&>)I_$=M)9265I83WK:UJ$=E?Z=G^ O"O_  ;J>%_V
MJM*_:B\$?M)_L@2_&,:_'J'A71;+X[_"[5-"T_Q7?POIL%WX:\.PW,VK-JER
M\\"V6GQZE=VJ75MIJ6&GQ&RLHHOV<E_;;_9*@FO()_C]\-X;C3;,:CJ$,VN)
M'/I^G/YVV_OHGC62SL7^RW&V[N%BMV^S3XD/DR;?WCQ2^FWXK^+N64<LXMRK
M@NK]7DU#,<-DE6EFE3#JK"O#"XW_ &YY+F&$J58M8O!XO(IX/$4G[/ZM3=2O
M.K\ID/AAD'#M>5?+L1F<>=*]">*C+#QE9Q<Z7[KZS1J*-O9U:>*52$O>YW:*
MCZEX<^'$5LD6KZOKWBK4=>OHH+F_NKK4Y]/;[6M[)?6[KIUE<RV>F2V]M*-*
MN+#3Y?[+DMD=&@E8K-7I4UO$K37D<""]-JT N8X(6NS$I>5(%D<*7196,B0O
M((C(22!N)KY>/[<?[(:HTK?M"_#$1KI7]NM(?$, 1=#P3_;;.5VC1\ G^U"?
ML. 3Y^!49_;H_8^ D8_M%?"Y5ABTR>9CXDMPL4&MN(]%FE8@".+6)"(])D<A
M-2D(2R:=R!7\AU\97Q%652K.ZE4J5%3BHPHP]K-3G3ITH*-.G2;22I4X1I12
M2C!)6/T2%.$(J,5LHIMW<I<JLG*3;E*5MY-N3W;;/J+36G?3[)[HW!N6M8&G
M-W#!;W1E,:ES<06KR6T,V[/F1P.\2/E8V*@&KM?)A_;O_8X4J&_:0^%"EI)H
M5#>*;,%IK;4DT:YA4$@M+;ZQ)'I$\8R\.J21Z=(JWDB0G:/[97[+@)!^-W@8
M$<$'4)L@^A_T:N><N:4I64>:3ERQ248W;=HI:)*]DEHD4E9)7;LDKO=VZOS/
MIFBOF<?MD_LN$@#XW>!B2< #4)B23T 'V;DFJMG^VO\ LGZA;I>:?\>OAW?V
MDC2I'=V.L_:[:1X)7MYT2XMXI(7:"XBE@F57+13QR12!9$91(SZBHKY=;]M?
M]D]+R'3G^/7P[34+BWFO+>P?6=M]/:6TD45S=P6C1"XEMK>6>"*>XCC:&&2:
M%)'5I4#*?VUOV4%O(]/;X\_#Q=0FMI;R*P;6,7LMG!)'#/=QVAA%Q):PS2Q0
MS7*1F&*66*-W5Y$4@'U#17RVO[;7[)C"_*_'WX<L-*=H]4*ZVK#3)%MDO&34
M2(C]A=;.2.[9;KRF6UD2X($3JY@'[<?[(;*KK^T+\,F1]*.NHP\0PE7T, $Z
MTI"8;2 &4G4QFQ&Y<S\C(!J_MC_\FM_'3_LGNM_^BTKZ(TO_ )!NG?\ 7C:?
M^D\=?G+^U'^V'^R[XP_9W^+_ (:\,?'3X=ZYKVM^ C!I&DZ;KD=W?:C+XDFA
MLO#B6EO"CR3#7[V1+71G13'J4[".T>4AMOZ.:<C1Z?8HZE'2SM4=6!#*RP(&
M5@>05(((/((P: +E%%% !1110 4444 %%%% !1110 4444 %%%% 'Y_:7_P3
MY\ 2>)KX>.?&?B/Q[\*+#PQ^TEX2^'_PIO+:'P]_PA>C_M;:V=:^-MO+\0/#
M5UIWC763=QS:AX>\#75M?Z#J/@KPUJM[9QWVK:I%INM:?^,'[17_  ;G?L??
M&O\ ;!M/A_IWP&^(G@?]EOQ;^P;\;/#VM?%?P_\ &_XH>(M1\$_M,3?'3X$Z
MC\++S38_B+\2_%UY?:I9>"M.\?:M;Z!J>@ZG\/=2@M+EM>LI-8BT2:W_ *H*
M_&[Q]\7/BQIW[:%IHVD_$_QZOCT_MA_"CX7:!^SX+W[/X"U?]D'6_@/IGBGX
MA_$U?!HTR2/7DT[Q5<>,]>O/BS+>&YT+Q/X7T_X=Q:GI\$+Z%JX!\T_L7_\
M!L?_ ,$W/V4OA'+\/O&6C?$O]H;QCJFOWGB#Q%\3/$WQ6^*_PNN=1>6*"UT[
M2;'P=\'/B%X.\,V&DZ1:6X%LU_#K>MS7=U?SW6MRVTMI8V'UO_PXK_X)=?\
M1NOB;_Q)C]K#_P"?E7ZX44 ?D?\ \.*_^"77_1NOB;_Q)C]K#_Y^5'_#BO\
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MX ^ [C]GGQJMIX2M-;_9<\0_LG^&?&WQ*^+WB3X46.D2V,.M-\1[KQWXFO\
MQO;WELWA_7]!TKX?P7VF6D9\-ZF ?OC1110 4444 %%%% !1110 4444 %%%
M?D]^VM^WS\8O 7[2?PD_8$_8A^$_@GXT_MF?%OP-K'Q>U^]^*GB35_#7P._9
MO^!6BZLOAZ3XN?&2]\,6=_XMU:'7O$AD\.^#O!OA:"+6-=U2"4R7ME$UDM^
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MY6:1%,;?C_JG[<G[:/[9'[2G[0_[/G_!-'PY^SSX4^&/[(_C2/X2_'?]K_\
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M(P#]$9OV<O <VFW&EO=>(1;7/P"_X9RD(U"W$G_"!^1-;_:E;[$0/$/ESO\
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M?PGKOC2^T+P;X>\2ZB^N>)[O0O#>FZOK$NE:,ES#-J%S::=<M:0OY[J$5F4
M^VO!'C_P+\2]!B\4_#KQGX6\=^&IKFZLH]?\'Z_I?B31VOK&3R;ZQ.HZ/=7E
MHM[8S9AO;-I5N;28&&XBCD!4==7X"?%33_C)JWQ?^+7Q ^%?A+XS_#OX _M!
M?&KX>V$WB31?"7QM\,O>7'PV_9U\5Z/KOQ%UWX;?!^Y\#_'>72OB'XTO? O@
M7PC>1:_\,K?Q#XE^'VF:CXMUJ;PI_8$6N>>_L_\ C/\ ;KUK4?V%_A'\6_$/
MQW\*^+_VEOV<OA_\:/CM+K%S=6OQ!^$7B/\ 8M;4]*^+.A7WAV^N;RY\/:Q^
MT/JGC7]G72]6TR9K[2?$NJ:+\3'OM0OVUF=KH _H]HK\KO\ @GM<_&71O#OQ
M@\)_$>?XH^-;;P[X8\!WVD?'?XBW?QT\/R?$'Q1-I'BC3_%-GJ'PD^/LVH^(
M/A;\2-'FT72=?^)MA\.O$FO_  ?N]3\6:9%X.DTJZTW5],B_.;]GGQ9^TGX_
M_9Y^"OC[X7>*?VX/%WPU\8_ #]GO5OVMO$GC+7/B%J7Q-U#Q#>_&KP)+XWUC
M]GZ[\03C44UN]^"TOQ!OO$>H? X1VEY\.)?!U]X8W?$1M&D(!_31L3?YFQ?,
MV[-^T;]@)8)NQNVAB3MSC))QFN3N?&'@3P_X6USQ/=>)_">B^"_!L6N?\)'X
M@FUG2+#PSX6A\*RW4'B0:SJC7$6EZ*GAR:RO8-;6]FMAI,MI<Q7PMW@E5/P'
MUI_VL- U71/'7A_5?VJ?&WP]\.?%3XH6O[/7P#\2S?M$^%_$_P 3/A))X[\
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MXOCTJR7Q)?\ A_2[FXO-/T.YUH0_VA)I-G>75Q=P:<;C[(ES*TXB\W#CIZ*
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M6SO(IK>26QU&TM;ZT=XV:WN[:"XB*RQ(ZZU%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
H* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img143810944_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img143810944_5.jpg
M_]C_X  02D9)1@ ! @$ D "0  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %V SD# 2(  A$! Q$!_\0
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M "-1_P ,K_LR_P#1OWPA_P#"&T3_ .1J /T7_P"&R?V2O^CE_@5_X=/P7_\
M+FC_ (;)_9*_Z.7^!7_AT_!?_P N:_.C_AE?]F7_ *-^^$/_ (0VB?\ R-1_
MPRO^S+_T;]\(?_"&T3_Y&H _1?\ X;)_9*_Z.7^!7_AT_!?_ ,N:/^&R?V2O
M^CE_@5_X=/P7_P#+FOSH_P"&5_V9?^C?OA#_ .$-HG_R-1_PRO\ LR_]&_?"
M'_PAM$_^1J /T7_X;)_9*_Z.7^!7_AT_!?\ \N:/^&R?V2O^CE_@5_X=/P7_
M /+FOSH_X97_ &9?^C?OA#_X0VB?_(U'_#*_[,O_ $;]\(?_  AM$_\ D:@#
M]%_^&R?V2O\ HY?X%?\ AT_!?_RYH_X;)_9*_P"CE_@5_P"'3\%__+FOSH_X
M97_9E_Z-^^$/_A#:)_\ (U'_  RO^S+_ -&_?"'_ ,(;1/\ Y&H _1?_ (;)
M_9*_Z.7^!7_AT_!?_P N:/\ ALG]DK_HY?X%?^'3\%__ "YK\Z/^&5_V9?\
MHW[X0_\ A#:)_P#(U'_#*_[,O_1OWPA_\(;1/_D:@#]%_P#ALG]DK_HY?X%?
M^'3\%_\ RYH_X;)_9*_Z.7^!7_AT_!?_ ,N:_.C_ (97_9E_Z-^^$/\ X0VB
M?_(U'_#*_P"S+_T;]\(?_"&T3_Y&H _1?_ALG]DK_HY?X%?^'3\%_P#RYH_X
M;)_9*_Z.7^!7_AT_!?\ \N:_.C_AE?\ 9E_Z-^^$/_A#:)_\C4?\,K_LR_\
M1OWPA_\ "&T3_P"1J /T7_X;)_9*_P"CE_@5_P"'3\%__+FC_ALG]DK_ *.7
M^!7_ (=/P7_\N:_.C_AE?]F7_HW[X0_^$-HG_P C4?\ #*_[,O\ T;]\(?\
MPAM$_P#D:@#]%_\ ALG]DK_HY?X%?^'3\%__ "YH_P"&R?V2O^CE_@5_X=/P
M7_\ +FOSH_X97_9E_P"C?OA#_P"$-HG_ ,C4?\,K_LR_]&_?"'_PAM$_^1J
M/T7_ .&R?V2O^CE_@5_X=/P7_P#+FC_ALG]DK_HY?X%?^'3\%_\ RYK\Z/\
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M_P#D:@#]%_\ ALG]DK_HY?X%?^'3\%__ "YH_P"&R?V2O^CE_@5_X=/P7_\
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M!7_AT_!?_P N:/\ ALG]DK_HY?X%?^'3\%__ "YK\Z/^&5_V9?\ HW[X0_\
MA#:)_P#(U'_#*_[,O_1OWPA_\(;1/_D:@#]%_P#ALG]DK_HY?X%?^'3\%_\
MRYH_X;)_9*_Z.7^!7_AT_!?_ ,N:_.C_ (97_9E_Z-^^$/\ X0VB?_(U'_#*
M_P"S+_T;]\(?_"&T3_Y&H _1?_ALG]DK_HY?X%?^'3\%_P#RYH_X;)_9*_Z.
M7^!7_AT_!?\ \N:_.C_AE?\ 9E_Z-^^$/_A#:)_\C4?\,K_LR_\ 1OWPA_\
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M &9?^C?OA#_X0VB?_(U'_#*_[,O_ $;]\(?_  AM$_\ D:@#]%_^&R?V2O\
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M5@DNUBCE<;$8L0#_ "-?M1Z)\//C%\#_ /@K9\:/V'?@MXA^'7[%GQ2\*_\
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MY^'FE6%OJ4EUJ'C?P98 WOBKPM:Q2ZUH%H#<:I9VT0+5ZK7\C7P9\.>*]/\
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MX[W"+^USXA^$4NG>#[:WOQX8\,P7OB#1O"^EZ-J,7@%5N[C2=.273\U]#_\
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MD] !DGZ 5RG@KQWX'^)7AVV\7_#GQEX6\?>$[R[U33[/Q/X,U[3/$OA^ZO\
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M^'/#NB6$9FOM8US6M2FMM/TK2[*(&6[O[ZXAMK>,%Y957FOPE\ ^-?V^Y?\
M@H'X[_8OG\5_%/6OA_\ LI^._P!I3]KF#XM:WJ=Z;3]H7X._$SP5H4W[&G[-
M/B;Q"\B)KFD>%OBCXK\8:1XHT>6=(;G0OA]IMNSHEH7MORQ\!_'7]O/XZ?LE
M_M\:+\:_BGXX^*%OK'_!-KX_ZU^T!\+/$/A_XQZI>?"3]H=_$TVD^%?"EE#X
MQ^"WPW\'?!_QE]@CU#33\$?AAXB^(/A_5O!MO9^-4U)KQ?/D /[.=.U'3]7T
M[3]7TF^M-4TG5K&SU32M3T^XBO-/U/3-1MX[S3]1L+RW>2WN[&^M)H;JTNH)
M)(+FWECFA=XW5C>56=E1%9W=@J(H+,S,0%55&268D  #))P*_F8/Q(_;.\)_
M'[]G3_@G_P"$?B#\7-+\*_MH>%_V(?VC?A;\6;'5+JTU3]GC]G;X1_"??^VO
M\)/#NI3%;W0+;4=?\!>$M/\ #>E1P"WTZW^)FI6<[Q-,4NOT6_X*>?%/XA?#
MC7_V)X(OBG\7?V>_V6?&_P"T?JVA?M>_'7X%1ZK'\0_A]X-M_ NI:G\+=+'B
M+1/"GC36_!WA;QA\1(;71=?\1V&A3O(8[+2[BXABOO(O #])?!_COP1\0]+N
MM<^'_C'PMXYT2QUS6O#-[K'A#7M,\1:79^)/#5])I?B+P_=7^DW-U;0:WH&I
M12Z?K.ERR+>Z9>QO:WD,,R,@ZJOXGO _QB_:P^#W['_[/.D_#+XF?$KX/? 3
MQ_\ M:?\%,M?^+?QUU>V^+/PO\8:KXTTSQ@NM_ 73/''B#X5_!?XE?$#P;=?
M$"2ZUC6M*\+6OPXT?0OB#XTM[7P9KNJ:+IOFVA]_^.'[6'[3VB>+?"7AK]H/
M]L+]J7X&_$!_^".'A?XY>$O#WP,\*>*?",GQ'_;,N/BAXLTGX=2>._AM;_#[
MQ%JOAKQ)X^TZ#PWIOB'P3JNE>&+/Q#J\EWX;U";3H(?L! /ZN;7QSX)OO&6L
M?#FR\8>&+OXA>'M"TKQ3K_@2VUW39_&.B>&-=N+BST3Q'JWAN.Y;5].T+6+N
MTNK72]5N[2*QO[BVGAM9Y9(G5>G=TC1I)9(XHT*!I)9$BC4R2)%&K22,J!I9
M9(XHU+9DED2- SNJG^3CX^?$S]N_P)X^_:P^./@OPOXB\*_M5ZI_P2S_ ."8
MY^*VK^'/".I7=_X#U#7OBC=+^T3K/AO3=(T'Q/+;>(?!.C:GK=_J,&@:%XDU
M;P="-1U/3M"N[C1884X;XF>(?CY\5?V/OA/\0?C7^T=\>/%'P)^%_P#P5U^
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MCU_P0\\4?M4CPA\7X8/B!9>%?VL?"_B7POIVEW/PYT1O"UB^F:^GA/5M89/
MUY+J=[XMUG2[2_UFWUK4[]Q-Y?HO[2O[<M_^PG^V'XQM/V@OB+\5-$\.>,?^
M"?T/P]\>6UK\8O&'BGPO\0_''Q<\"V_[0'A'P]\0/B[\%/A1KGB2W70+^6/Q
M]X"TCPIJWA_X1:^UUX:T?6IK"3- ']@#*R,R.I5T8JRL"&5E)#*P/(((((/(
M(P:Y.[\=^"+#QIHGPWO_ !CX7LOB)XFT+6/%'AOP'=Z[IMOXQ\0>&?#TUO;:
M_P"(=%\-RW*ZMJ>B:'<7=I!J^J6=I-9:=-<P1W<T3RQAOPQ\"?';XMW_ /P4
M)^)_A#XR_M%_M:^!?C-I'[=GB3X=?"?]C_X?_"NX\:_LY>,_V((_"4$_@SX@
M>(+&[TG1O#6A>$M7=[OQ#XH_:3A\>ZKXK\,^)+:+P[#X<NHYS8Q][_P4E^+7
MQ[^'O[2\.G?"?Q7X]\.Z%;?\$KO^"A'Q&M_^$0M;J2&W^,'@G2M+G^&?B&TO
M+73[B:+Q?H]R99O#D,$RW,EPB&"TF=MK@'[=T5_(/XV\>?MV^&_AU\;M>T?]
MM#]N2YU3P)_P20_96_;K\-17?B#2KN34/VJ/&NLZ;I'B[PY,6^'(O/\ A &T
M\W,FJ?!>TDBLKNZNI-0UX7D]D'7TK]ISXU?MO7/C?]N;XC>"/VE_VI?AY<_!
MGXO?\$K=!^$/@;P&;1/A=:Z;^TS\/?!UO\?;EO!&L^"];LO%UE'>:I?:N-)D
MNIM"\->(5DO;VR-XY50#^JZBOYC_ !C\>_VK?@1%\3-)U/X]?M*^)/@[^RW_
M ,%SOV?OAMXP^*GC-]7\8^-E_8=UWP'_ &Y\2=)^)GB3PYX4BU3QG\)T\3ZE
M:0:A=0Z/<I:)<6.FP3"V2T@CS/ OQ^_:I^.\?P4TO3?VA?VG/"G@_P",7_!=
M7]HCX*7/C+PT=9\)>,[3]D%? MUK/@CP?IQ\5>%9)_#/@6SC:%_#4NMZ%G0+
MRX%[ (M5L8FM@#^H.BOY$?B'^U1^W]H7[/GP0\-ZE\<_BSX7^&/AO]LG_@H'
M\%/BW^T[XPUKXD^%?'M]H'P7U!(_V6M!^(?Q5^$/P=^)?Q TZ/Q,MQJD.F:K
MI7P_>S^)_B32-)\,^(_$-AIMQ<F;]BM5^*/[<FE_\$:-2^+NB0:MXQ_;KMOV
M6&\4:1<I\.[[0?%^K^*9+B/R?%+?"K6M*@OK3XA0_#^1_%$OA"^T&&67Q9;M
M%_89>1=*8 _62N1\0_$#P%X1UKPGX;\5^-O"?ACQ%X]GUZU\#:#X@\0Z5I&L
M^,[GPMHTGB+Q/;^%=-O[J"\U^?P[X?BEUW7(M+AN9-+TB.34;U8;1&E'\T7Q
M2_:8^-^@_LF_$?6?V,/VN/VP?V@/ ,7QS_9)T+XL?'KX\_#[QAI%Q\!_ ?C?
M0+^;X_K\.?C[I/P]OOBKK6D6/B&'0XOBK?Z#\%M9U#]G.WU.XL/",VJ2SNUG
MS_PY\1_M%_%#Q9_P21\7_&SQ5K_Q@&F?M*_\%2[+X>?%"[\._$ :AK7P4B_9
M.UC2? .H:UXC\>^"_ WBKQIIDVH_VEI'@[XH>)O"'AG5/B3H=OI>JSZ;]M:5
MY #^H?P?XR\(?$/POH?CCP!XJ\.>./!7B>R_M+PWXO\ ".M:?XB\,>(-.,\U
ML+_1=<TFXNM-U.S^T6]Q!]IL[F:'SH)HM^^-U'25_%OIWQE_:0_9Y_8B_P""
M95UX8^.OQC^'O@;1?V,+V\O_ -FWX7WOQ+^"?Q6\;_$N#XW^,WC\0_#KQ\/@
M#\7_ (3?&/QY+HIMM M?V</B;)HT-W T>MM:_9-6BU(?V1^"]8NO$7@OP;XA
MOM+U[1+[7_"/AG6[W1?%=E::;XJTB\U;1+&_NM,\3Z=IY.GZ?XCL9[B2VURP
ML,65GJD=U;VBI!'&B@'2T444 %%%% !1110 4444 %%%% !1110!\9?\%"?^
M3//C)_UZ>%O_ %,=!K]DOV?/^22^!?\ L5M!_P#37:5^-O\ P4)_Y,\^,G_7
MIX6_]3'0:_9+]GS_ ))+X%_[%;0?_37:4 >UT444 %%%% 'XA_\ !0#_ )/+
M_8,_[*9XY_\ 4/BKZ,KY8_X*>W?BKP?\</V6/B]H?@#Q'\0=)^%?C/Q9K?B+
M2/#+6L>HFVU'P_;Z=9JLMX?)@$TQDQ,\<D:^458 R(3\[_\ #QF__P"C3OC3
M_P"#GPO_ /&Z /TOHK\T/^'C-_\ ]&G?&G_P<^%__C='_#QF_P#^C3OC3_X.
M?"__ ,;H _2^BOS0_P"'C-__ -&G?&G_ ,'/A?\ ^-T?\/&;_P#Z-.^-/_@Y
M\+__ !N@#]+Z*_-#_AXS?_\ 1IWQI_\ !SX7_P#C='_#QF__ .C3OC3_ .#G
MPO\ _&Z /TOHK\T/^'C-_P#]&G?&G_P<^%__ (W1_P /&;__ *-.^-/_ (.?
M"_\ \;H _2^BOS0_X>,W_P#T:=\:?_!SX7_^-T?\/&;_ /Z-.^-/_@Y\+_\
MQN@#]+Z*_-#_ (>,W_\ T:=\:?\ P<^%_P#XW1_P\9O_ /HT[XT_^#GPO_\
M&Z /TR$D@1H@[B)V5GC#,$=DSL9D!VLRY.TD$KDX(J6.[NXMGE7-Q%Y:LD?E
MS2)Y:.P9U3:PVJS ,RK@,P!()%?F1_P\9O\ _HT[XT_^#GPO_P#&Z/\ AXS?
M_P#1IWQI_P#!SX7_ /C= 'Z;M=W3RB=KFX:95*K,TTAE56!#*)"Q<*0Q! ."
M"01R:C$LHC:$22"%F#M$'81LZ\*[)G:6 X#$9'8U^9G_  \9O_\ HT[XT_\
M@Y\+_P#QNC_AXS?_ /1IWQI_\'/A?_XW0!^F\5W=6ZE(+FXA4L&*Q321J6&,
M,51E!88&#C/ YIOVBX#1,)Y@T&?);S7W0[F+-Y1W9CRQ+'81EB2>37YE?\/&
M;_\ Z-.^-/\ X.?"_P#\;H_X>,W_ /T:=\:?_!SX7_\ C= 'Z:K<W"[-L\R^
M69#'ME<>69?]:4PPV&3_ ):%<;_XLT?:+CR?L_GS?9^OD>:_DYSG/E;MG7G[
MO7GK7YE?\/&;_P#Z-.^-/_@Y\+__ !NC_AXS?_\ 1IWQI_\ !SX7_P#C= 'Z
M<&\NS'Y)NKDP[/+\KSY?+"=D"AP H(!  &T@%<$ CF/"GA;PWX$T+3/#'@O1
M-/\ "_AW1A<?V7H^CPFUL[)[R]N-3O9HQO>:2ZOM2O+O4;Z]GEEO+[4+JYO;
MN>:ZGEE?\[O^'C-__P!&G?&G_P '/A?_ .-T?\/&;_\ Z-.^-/\ X.?"_P#\
M;H _3-YI9%"R2R.H=Y KNS*))#F20!B1OD/+O]YC]XFGPW5S;AA;W$\ ?[PA
MFDB#=OF",H;CUS7YD_\ #QF__P"C3OC3_P"#GPO_ /&Z/^'C-_\ ]&G?&G_P
M<^%__C= 'Z;175S"[20W$\3OR[Q2R1NY)))9D8%LDD\D\DGO43N\C,\C,[L<
MLSL69CZLS$DGW)-?F=_P\9O_ /HT[XT_^#GPO_\ &Z/^'C-__P!&G?&G_P '
M/A?_ .-T ?IN]W=R1^3)=7#Q85?*>:1H]J'*#8S%<*>5&,*>1BE:\NW:)WNK
MEGA.86:>5FB/K$Q8F,_[I%?F/_P\9O\ _HT[XT_^#GPO_P#&Z/\ AXS?_P#1
MIWQI_P#!SX7_ /C= 'Z9>;)L:+S'\MW$KQ[VV-( 0)&3.UG ) <@L 2,\T_[
M3<&43F>8S* %F\U_-4*-J@2;MX"KP #@#@<5^97_  \9O_\ HT[XT_\ @Y\+
M_P#QNC_AXS?_ /1IWQI_\'/A?_XW0!^FXN[L2M.+FX$[#:TPFD$K+_=:0-O(
M]BV*CDEEF?S)I))7("EY':1RJC"C<Q)PHX S@#@5^9G_  \9O_\ HT[XT_\
M@Y\+_P#QNC_AXS?_ /1IWQI_\'/A?_XW0!^F[7=T\0@>YN&A& (6FD:(!?N@
M1EB@Q@8P.,<4W[1<>=]H\^;S^OG^:_G9V[,^9NW_ '/E^]]WY>G%?F5_P\9O
M_P#HT[XT_P#@Y\+_ /QNC_AXS?\ _1IWQI_\'/A?_P"-T ?IIY\VZ)O.EW0#
M$#>8^Z$ E@(CG,8#$MA,<DGJ:19IED,RRR+,=Q,JR,)"7!#DN"&.\$ALGY@3
MG.:_,S_AXS?_ /1IWQI_\'/A?_XW1_P\9O\ _HT[XT_^#GPO_P#&Z /TU6XG
M141)YD2.3SHU61U6.7_GJBA@$D_VU ;WI!-,!*HFE"S\SJ)' F.XMF49Q)\Q
M+?/GYB3UK\R_^'C-_P#]&G?&G_P<^%__ (W1_P /&;__ *-.^-/_ (.?"_\
M\;H _36*YN( P@GFA#@!Q%*\8<#. P1EW 9.,YZF@7-P(F@$\P@<DO")7$3$
MG)+1AMC$GDD@Y/)K\RO^'C-__P!&G?&G_P '/A?_ .-T?\/&;_\ Z-.^-/\
MX.?"_P#\;H _34W-P009YB&1(F!E<AHXCNBC(+8*1GE$/RH>5 -++=75PJK/
M<SS*ARJRS22*IZ94.S!3CCC%?F3_ ,/&;_\ Z-.^-/\ X.?"_P#\;H_X>,W_
M /T:=\:?_!SX7_\ C= 'Z:K<7"1- D\RP/G?"LKK$^>NZ,,$;/?(.>],FEFN
M(;BWFFGDAN[22QN8S-)B6SEB>%[=B&SY?ER.J $>63NCVL 1^9O_  \9O_\
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M/$DF?,2.61%DSP=ZJP#9'!W YH6ZN41(UN)UCC#A$6:0(@D!60(H8*H=20X
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MEV\BS-=7#2JK(LK3RM(J,"&17+%@K D,H(!!((P:_,C_ (>,W_\ T:=\:?\
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M *AWOO\ ,W-OW;]^X[]^=V[=G.[/.[.<\YS7YG?\/&;_ /Z-.^-/_@Y\+_\
MQNC_ (>,W_\ T:=\:?\ P<^%_P#XW0!^G#7EVTJ3M=7+3("J3-/*944]0DA;
M>H/< @4QKFX8R%IYF,VSSBTKDR^60R>82V9-C %-V=I (P17YE?\/&;_ /Z-
M.^-/_@Y\+_\ QNC_ (>,W_\ T:=\:?\ P<^%_P#XW0!^G*WMXC2,EW=*TIW2
MLMQ*K2M@#=(0X+G  RQ)P *J]22>2223W)/))]R>37YH?\/&;_\ Z-.^-/\
MX.?"_P#\;H_X>,W_ /T:=\:?_!SX7_\ C= 'Z7T5^:'_  \9O_\ HT[XT_\
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M"U4)# BQHH&  H _I[5IT4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!117\]O[?WP"T']KK_@KO^Q[^SA\2OB%\>O"_P )[W]A[]IKXF:AH/P3^.OQ
M-^"<FH^,O"WQ7^#NCZ%J^KWOPY\0Z%<:H+'3_$.JVL4%XSIFZ1F)6(1LX1G4
MK4:$$G*JL7*[E91A@\OQF8U7L[R=+!SA".B<Y1O*,;M$G&%*K6FVHTGAE9*[
M<L5CL+@::U:LE4Q4)3>K4(RM%NR/Z$J*_E1_9C_X*)_M!_L_?LY>,_@-X<\<
MZ-^TK\0O _\ P4W_ &JOV(?V:_B)\?\ 6/B3\3OB+\0O@=\!]"M/&]GJA\,?
M!3POXK^+7[1GC7PA'?O\/-5UCPY9Z=9Z9;6\/B?QMXEL+#1[I+WU'P3_ ,%^
M=:M?@-\+OVE?CM\%/"?PO^&7QS_8-_:#^/WPEM[;Q+KNHZWXC_:I_9>^)>J>
M /'_ .SB);O3[2W=/'EE<>$_$_PQ"6D/B::"Z\0:5J=G/=Z.TS#Y72>(I\\Z
M/U?#8F+=.4:CIXO)IY]1A[+WFZ[P%.5Z4'4OB>7#4I5:DZ?/7LZD:OL*D8PK
M+$5\,TIJ4'5P^;?V-4E"HU'FHO&*<XU)1@UA*=3%58TJ4)N/]+M%?AY_P4L^
M,O[26F_\$P?@K?>,-7G_ &=_C-^TA\5?V(_@K^T!KGP?\0ZKHE[\&='_ &A_
MB[\//"GQFT_P%XTU&5=7T"_TO2-=UCP5I_B^2>"_TZXOCJUG+:W:VSQ==_P2
M"U#Q3X4N_P#@H'^S#<_$#XA_$[X7_LC?MN^)?@_\#O$WQ3\::S\2/&^E_#_4
M_A1\+?B)/X U7Q]XCNK[Q!XGA\">*/&&NZ5IL^N7U[JFGZ=+;:1<74D=C"D>
MT:$Y3Q\&XIX%XF$VI1G&I/!5<FI8F,)0;BXK^WL!*C4BYPK*.*NZ7LJ+Q&#K
M0]G@ZD6Y+%K#RBFN1PIXNEFE3#R:DU)RE_8^-C5ARJ5*^':YU5J>P_96BBBL
M#4**** "BBB@ HHHH **** "BOQ+_P""WN@7/CSX?_L$_"63QC\2/!?A?XT_
M\%,/V9_A3\0+SX5?$/Q9\+_%NK>!?%ND_$BWUW0[?Q=X+U/2==L;>]6"WE?[
M/=@">VMYPHF@ADC^&_"7Q[U__@E%^T9_P4J_9]\"?%OQ=\;?V>?@9^R_^R[\
M?OA7X9_:P^/'BCQA'\(/CE\<_B/XF^%C_"H_%O6=/\;?$9_#_CTV^A^.]%^'
MWV+Q/XNU74A/I7@;39;WQ#:K,4OWBJ-^Z_K.,PF'BO?=>O@<LPF:UHOX?9*6
M&Q3C1;YE4KTU2?(ZL&*;:J*$$I.&&P6+KMOD5*CC\SQ&58>4;I^U:Q5!.LKP
M]G0FZJ<_9RB?U,45_.!\(_\ @M7\;KM[V\^/'P1\ >"O!OP5_P""@7@7]BS]
MJ3XA6]E\6O -EX5\)_'+X::?X@^"WQOTGP3\6]%T#QIX"T.#XB^(?"G@OQ_I
M7Q*M%EM='\2:3XFT^>VAN9K:S_2W]C3]HKXG?MY?LB>/?C9<Q6'P&T7XM>*/
MCUH'[-GC7PDQUCQ'8?!72/$'B'P'\*/CCJMIXIBET8^+=>CTF;XB6&E/:/X=
M33+C0HYHKF&6Y:1SA4C2JU8PYXTJ,*OQ1IJ3JX3+L=0I)U7!1JU\)FF$K4X3
MY7R?6>:SPF)5)Q<7.E"4N3VE7V=[.;BHXC'X6I4Y8<TI4Z=;+<3"<H*23>'Z
M8K#NI^B5%?SM_P#!(CX8^*M"_:B^/7C/X"_'K]J;X[?L$67PB\-_#>_^+W[3
M_P 4?$WQ,L?VH/VT=!\;:B_Q2^/?P!/BJXN9M+^&UAH5N_A#Q#KWA.+2_AOX
MQ\7RS1>!;34=(\,#57_HDJI0484)J2E[:E[3EY91<%[6I3BVIQC+DKPIQQ6&
ME*,)5,)7P]6=.E.<J4)N_:5Z;BU[&HJ=[Q:DW2IU)*\7**J4)U)8;$P4I1I8
MNA7I1J5(P5291114%!1110 4444 %%%% !117P7_ ,%2O'OC3X6_\$W_ -N3
MXD?#CQ3K?@CQ]X&_9<^,_BGP=XP\-:A/I7B#PUXCT7P-K%_I.MZ-J5JR7%CJ
M6G7D,5S:74#K+!-&DB,&4&LJ]54*%:LTY*C2J57%-)R5.#FTF]$W:R;T.C"8
M>6+Q>%PD)*$L5B*.'C.5W&,J]2--2DEJU%R3=M;+0^]**_ES^%!_: _X)]?'
M3_@E7XB?]N3]KG]JCX9?\%!?#GBSPM\>OA%^UQ\2O#OQ:_X1;7-&_9JO_COI
MWQ.^$'B:Z\.>$]6\ 6_AK5]$N='\2Z9?:C>Z!>:!K$4VL7<%Q:0WR>B^!O\
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ML?&K_@M[^QY\-?AU^TWX$\'_ +'OA_XD?M5_LSZW\,=-^*/AZPU_XU_&_P
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MNZY^UUX$^ GBGXMO\-=*\'?%!_$OAGX=_"?Q7I4TR_"GQ?J'B&VDUCXC>/;
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M$'AZX\.R?$WQ _CFS^#FCZ!X<^+NGZ6\>DK\/$\8:K\6O%.M>&]=\&Q,VO\
M_"62^&-.T!/MZ:9)J^GSZ-*8[7$9_2K2;E#!"P#,&8+D;BJE0S =2%+H&(&
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ME.G_ $(EE!4%@"Q*J"0"S ,Q5?4A58D#D!6/0&D+*" 64$] 2 3R%X!.3\Q
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MY*ZG.]"HZ4H-PJTZ=6KS04:2K_:=%%%8E!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 45Y3\;_B?9?!SX6>,OB'>0R7<F@:1/)I=
MA#%)-+J.MW ^S:/8K'&K/Y<]_+!]ID VV]HMQ<.1'$Q'*?LP_&4_';X-^%/'
M5Y"EKXADMSI7BRSC@EMH(/$>FA(;^:SCE4$Z?J(,6J:>\9DB^R7L4:R,T3X^
M:GQ=D%/BZAP-+'07$N(R&OQ)2P'*[O*:&-I9?*LZGP>TEB*C]G13=2=.C7JJ
M*A2DSZ&'"V=U.%ZW&4<')\/X?.J.05,;=:9E6PE3&QIJ'Q>SC1@E.L[0C5JT
M:5W.HD?0-%?!O_!0#XV6GPR^$=KX1L/%'Q5\%>.OB9XF\"^'O"7B;X9^"?'&
MJ_88[[XF^!= \00:S\0?#_@_Q'X6^&D=_H_B"YLX-;\6ZKX:8++/<Z/J"W-C
M)+!G/^S_ *]J'BCQAH7AKX@?M$:A8>$M1TK3)-3UG]L3XGZ)<WUSJ7AW2?$3
MF/3+/PGKZ06]M'J\-JDDFI227$D4LABB7:&^E/GC] Z*^"?^&8_B!_T._P <
MO_$V/BW_ /.ZH_X9C^('_0[_ !R_\38^+?\ \[J@#[VKX(_:_P#^"8W[$_[>
M'BKP+XX_:B^$5]\0/%OPVT'6_#'@O7])^)WQ:^&^HZ-H/B.^L]2UK2UG^&'C
MGP<U[;:A>Z?9SS+J/VLAH$$91<J?.?C'\*_&'P;^$7Q4^+VJ^)OC_K&E_"KX
M;^./B1J6D:=^VY\5(M0U6P\#>&-4\3WFFV$MU\/$MHKV^M]+DM;62Y=($GEC
M:9EC#$:'BSX=6&AZ'\!M1T3XC?M5:UJ/QX\5:#X8TO3]2_:K\?Z%9^'CK7PY
M\6?$9[[4M2M['79;I;.S\*3:8+>TTW=<W=[#,)888GRG&+<6XIN#<H-I-QDX
MR@Y1;UBW"4HMJS<92CLVFTVE))M*22DDVE)*49I275*48R2>BE&+W29W>J?\
M$QOV%-2^%_P/^#EM^SUX:\+_  __ &;=8UC7O@AIO@#7?&OPYU?X>ZEXGMKJ
MR\9S:1XP\">)O#OC*>/Q]8WU]9_$*#4]?OX/'<%Y<CQ9'J[R%Q\:?'K_ (([
M^ OB3>_L$_L_?#/PE\&/A;^P5^QI^T';?M5W'@.6/QYXM^+&K?$?0]8\::_I
MGPN\&2^(;V_\.>'/@[XH\0>,#KOC9KS6;W4BFF0>'M%T*WTV2*YM/L?_ (9C
M^('_ $._QR_\38^+?_SNJ/\ AF/X@?\ 0[_'+_Q-CXM__.ZK2,YQJQKJ<O:1
MQ5#&MN3?/BL+.%7#5JJ;_>SH5J5&K#VG-%SHTU-3IJ4)0X1=*5'E2A+#UL*D
MDER8?$PJTJ].EI^Z56E7KTY.'*U&M4E!QG+G7U%\;?@A\)OVD/A7XS^"7QS\
M!Z#\2_A5\0=*.C>+_!?B6WDGTK6+%;B"\MRS02V]Y97UA?VMIJ6E:KIUU9ZI
MI.IVEIJ6F7EI?6MO<1\G^S-^RS\ OV.OA5IWP4_9N^&^D_##X<:=JFK:]_8F
MG7FLZO>:IXAUZX%UKGB3Q'XD\2ZEK/B;Q1XCU>=(VU'7?$6L:GJMRD-O!)=&
MWMK>*+PG_AF/X@?]#O\ '+_Q-CXM_P#SNJ/^&8_B!_T._P <O_$V/BW_ /.Z
MJ(^[SN/NNK&,:G+I[2,)<T(SM;GC&7O14KJ,M59E2]Y04O>5.4ITU+50G./+
M*4$](RE'W92C9RCHVUH?>U%?!/\ PS'\0/\ H=_CE_XFQ\6__G=4?\,Q_$#_
M *'?XY?^)L?%O_YW5 'WM17P3_PS'\0/^AW^.7_B;'Q;_P#G=5\S_&B[\7_L
M^?&/]D_P6_B[X]#6?C1\:?"6FV&J7'[4WC3XA>%[;1_#/Q(^%L'C#0?%O@SQ
M1X/TFTUO3/&'A3Q=JVBPF&Y$VFW7EWXVR1PNH!^QU%%>,_'[XC'X7_"_Q#XE
M7P5\6_'CRP/HT>B_!'PK=>,/B#!+JUM<V\>KZ7I-E=V5S'%I;XN)M0CG!L7$
M,P5CC ![-17Y+_!3X >&O&_PF_9HNH+3QAK7BOX@_LY>$OB=XT\1^._VB/VF
M8M3O]>N]"\!/?R2V>@_$N"WCO]1U#Q+J%[JI_<PV]TBV]K;"(L8O:?\ AC&U
M_P"@9:?^)#?M;_\ STZ /O\ HKX _P"&,;7_ *!EI_XD-^UO_P#/3I1^QC:9
M&=,M<9&<?M"_M;$X[X!^*@!..@R/K0!ZW^UM^QA^S=^W/\-=+^$7[4/P\;XD
M^ =$\9Z-\0M'T>+Q9XU\%W6F>,O#UKJ=EHVO6.O> ?$7A?Q!;7FGVVL:E'!Y
M.J)$#<F1HVECA>/P_P %?\$G/^">OP]_9]^)'[+_ (4_9I\*V/P>^+^LZ)XD
M^)FF7FO^.-;\7^,_$WA>\L]1\(^)M:^*6N>*-1^*,WB+P7J&GV-[X*UJ/QC%
MJ'@^ZM8I_#=QID@9F\R^%7P[^%/C_P" /COXK:GX#\7Z;XG\%?$OX\?#3^QM
M/_:;_:8NO#^HW?P=^-'C3X2V.LB]N?B'!J=M:ZZGA>WURZLS:RSV!NYK&*:Y
M\E+B3V'_ (8QM?\ H&6G_B0W[6__ ,]2E%**J**456E&55)6564'2<95$OC<
M70HN+E=IT:35G3C8>LJ<GK*DFJ3>KIJ7.FH-_ FJM5/EM=5*B?QRO\K?M6_\
M$CO!GBC]D_\ :)_9:_8U\-?"[X2V_P"VQK?A/3/VIO'_ ,8O$/Q@^*6LS>&=
M&TJ#2;KXF^$K'7/$?B.;Q+\<["UTO1VT?4O$FN:'8:GJT$?B/Q)K-[JNGV_V
MG]-=#_9T^%FA?LWZ5^RE;:%*OP8TOX.6?P)'AZPU#4- N)OAY;>$(_ \NF1Z
MKX=N=*U33+F\T%7AFU+2+RPU"*>:2ZM;F"YVRK\Y_P##&-K_ - RT_\ $AOV
MM_\ YZ='_#&-K_T#+3_Q(;]K?_YZ=-I2IUZ4TIT\2Z*KQFE.-2GAZ-2AAZ,H
MRO%T:-*M7C3IVLE7JQ=XN,8B;C4HU8/DGA_;.C*'N2ISQ%6E6KU8N-G[2K.A
M0<YWO>A3:M+G<JG[('_!*_\ 8:_8-\7:MXW_ &5_A!J_PT\0:UX1_P"$$O6G
M^+GQG\<Z0GA0:G8:NNDZ?X;^(7Q!\5>'=(CCU#3;.:*XTK2[*[A2.2"*=+>>
M>*7]"J^ /^&,;7_H&6G_ (D-^UO_ //3H_X8QM?^@9:?^)#?M;__ #TZJ4YS
M45*<I*$7&"E)M0BYRJ.,4V^6+G.<VE9.<Y2M>3;E1C'FY8J/,TY625VHQ@F[
M;M0A&*[1C%;)'W_17P!_PQC:_P#0,M/_ !(;]K?_ .>G1_PQC:_] RT_\2&_
M:W_^>G4E'W_17Y(_M(_!K2?V=_@CX^^,U_X,7Q3:^!;+2+Z?P_:?M+?M9Z5<
M:G#J/B31M#GABU*7XE7L=G+';ZI+<0R-:3JT\,<3JD<C2Q_=/[)=]J>I_LO?
ML]W^M:KJ6N:M=?!OX=RZCK.LWUUJ>KZK=GPMI@FO]4U*^EN+W4+^Z<&:[O;R
M>>ZNIWDGN)I9I'D8 ^A:*I:E?V^E:=?ZI=BX-IIME=7]R+.SN]1NS;V<$EQ,
M+73[""YOKZX,<;""SLK:XN[F7;!;02S.D;?E-X,UZS_:,OOVAOBQX<^)_P"U
M--H^G_M#^!?A;\/_  ??>-OBM^S'9:)IFO\ PV^!DMU93>!];\$>'O$VCV5C
MXI\<^(M7BU?5_"5Y?Z_:RP^1>W5H+6Z0 _6:BO@G_AF/X@?]#O\ '+_Q-CXM
M_P#SNJ/^&8_B!_T._P <O_$V/BW_ /.ZH ^]J\F^/'P5\"_M'_!;XI_ /XG6
MVI7GP[^,7@3Q+\.?&UIH^I3Z-JESX9\6:7<:/K$.GZK:YN-.NY+*ZF2"\@'F
MP2$2)RHKYB_X9C^('_0[_'+_ ,38^+?_ ,[JN"\!?#E/%'QU^*7P)\1>/_VH
M?#FM?#3X<_";XD-KND_M:_$/Q+I6MZ?\5M:^*&AVNG1PW6C^&[S3[W1;CX87
MLMT[Q7-O=PZK:&!XW@F4S.$:D)0G%2A.,H3C)7C*,DU*+3W33::ZIETZE2C4
MIU:4Y4ZM*<:E.<6U*%2$E*$XM:J49)--:II,Y+]GS_@B_P#L2_L^>)9_&$5G
M\;OC?XDB^&GBOX.>&-2_:8^/OQ/^.:_#GX9>/-#'AGQSX0^&6G^,=>N-*\!V
M'B[PXL>@:W<^'K&SU2;1(AI,%_;Z?)/;3-^&W_!+3X'?L@7(^,W[-?A;XE_%
MWXT?#7]F7Q5^S%\)/ GQW_:4\=ZCX O/@OJ.MZ1XE\/? V?4O$VE>/K'P=X"
M\.:GHMI:^'+G3_"6IW.CZ?->Q7L&L-<ETZKX7?"OQ-\6?"$?C;P]XL_:%LM&
MNO$?CK0+*'6?VU/BA!J<B>"/'7B3P/)>W5O8^!;^UMFU*;P[)J,=K%?7?V6&
M[CMWN)9(G<^A?\,Q_$#_ *'?XY?^)L?%O_YW57.4Y\UZDU*5&KA^=-<RI5H8
MNG5BKIQ?/#'XZ,N:,E)8S%*2:Q-93B"C%Q?)&2C5IUN67-RN=*6'G#6,HS23
MPF%:Y)1:^K8=IIT:3AYO_P $B/V '_X)Q_L;^'_@=KLGA*Z^)?B3QKXY^+'Q
M7O? QU.?PE#XP\=:U)=6?A;PO?ZY!;:YJ7ACX>>$+7PS\/\ P]?:K;VMU>:;
MX:AO3960NOLL7=^)?^"6G[!7B7]HKX,?M3_\,S_"CPY\9/@9XF\;^-/"NO\
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M95;C]H;]K?'S 'C/Q3!QSQD XZ@'B@#] :*^ /\ AC&U_P"@9:?^)#?M;_\
MSTZ/^&,;7_H&6G_B0W[6_P#\].@#[YN8%N;>>V<L$N(98'*X#!94:-BI((#
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MO_PE_A3PUXYL-1UZ35+BU_X171X;.XC\-63Z9)4^-WP/^$OPG_X)@?M@Z/\
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M%% 'GOQ; /PJ^)F0#CX?^,R,@'!'AS4L$9[^]>??LH #]FKX'$  GX9^$R2
M!D_V5 ,G'4^YKT+XM?\ )*OB;_V3[QG_ .HYJ5>??LH?\FU? W_LF?A/_P!-
M4%?GE;_D[&7_ /9O,Y_]:3(C[NE_R;+'_P#9=Y3_ .L_G1Y1_P %!M1?3OV:
M]2V:^- ^W_$_X$Z8Y.@W&O#6DOOC1X%B;PX?LX/]B?VUQ:CQ%/BVT=B+B9@I
M!KZ(\$?\CS\9O^QO\,_^JT\%UX+^WQ)>Q?LU:^;+7-,T/?\ $#X(Q7AU*Q6]
M_MBPE^-'@*.Z\/Z?NU/3!9ZKJZ,+:QOQ_:+6LA++I-^Q$8]Z\$?\CS\9O^QO
M\,_^JT\%U^AGPAZC17X)_M7?$[]J3PQ^U]^TQX7\$?$WXXV?AC4OV:;W4/"E
MKX<^&?Q5OOAW^SKX0TOP+I5[XB^/&GS:!\-M;\.?&3QOJ_B]?$/AG0_"OA#Q
M1J'Q+\.:Q!:W-AX+U2PM+L/RGQ;_ &J/VFK_ /9T_8Y'@R/]HOX;_$N_L)_[
M:TS3?"WBOQWXO\6_%G49XK/]D_PY\7M<U+X5RR0?#O\ : T71O%WC/X@QZWI
M/A"X\&6\FDZ)\1]8\&:Q'%#>@'ZY?MR_\F3_ +87_9K7[07_ *J;Q=7G/B[_
M ) ?_!.__LJO@G_UF#XPUZ-^W+_R9/\ MA?]FM?M!?\ JIO%U><^+O\ D!_\
M$[_^RJ^"?_68/C#0!]UT444 %%?+7[:OB?X^>$/V7OC'K?[,7AI?$OQNB\'Z
MG;>" 3I<[^&[N]A:UO/&]MHVL:CI%GXJU#P5I\EUXETOP>=2LY/%6IZ;::&D
MR"]8U\"?LJ?M)?M<'XH>!=<_:?\ !GQ5\'? F\_8=^#.JV=_K7A7PEJKWWQ:
MED^']OXS^(WCP>!=4USQC8^./''B3QE<^'+?X>0>&-/@\(:1X8N/$&I65M'J
MVI2Z. ?M!17Y5_\ !*_XH?M'?$WP;\=)OVEK?XB)X[\/_%B72]6_X2UKO_A$
M-%\6/IPG\;> _AI!K7PP^&FN6V@> M6,&C726<GQ!\ 33-;77@+XC^);2XU1
MK7]5* "OR*_X*)?\G6?\$RO^RZZM_P"IU\!J_76OR*_X*)?\G6?\$RO^RZZM
M_P"IU\!J /UUKA?BC-+;_#3X@SPWVOZ7-#X)\4RQ:EX5T5?$?B;3Y$T2^9+W
MP]X?;3]777-;MF FTO26TK4EU"]2&T-C="7R'[JN$^*5[%IOPS^(6H3^(G\(
M06/@CQ3=S>*X]/@U:3PU%;:'?32:^FEW5I?6VHOI"(;];*XLKR"Z-N(9;:>-
MVB8 ^6OV126^&7['K%YI"W[%7@UC)<Q>1<R$Z1\(B9+F )$(+B0DO/ (HA#*
MSQ"*+9Y:_<%?#W[(K"3X9?L>R"<W0D_8J\&NMT46(W2OI'PB9;HQ*J+&;D$3
MF-414,FU410%'&_MGZU^V;8_%[]DN']G;P+XBU[X0V'Q=T35_COJGA#Q=X+T
M?4-4TR\N7\-6GA7QCI7B?3[K5U^%VG6.LZAX[\3:KX1FAUJXUCPYX:TF66WT
M:35XK\ _1.BOP=^!GQ#_ &F[?]F3XTZ+\=/#_P"WJWB'73IL_AO4/#_@7Q;J
M/QFT3QK\// ?PXD_:&NO"UW;3Z;JL?PNUCXKW?B*Y^$FB^'-;T[5OB)X&LO$
MNE?!E?M(TN%/U8_9%G^*%S^R_P# .3XU#Q&WQ8'PJ\&0^/[GQA:KI_BO4_$M
MMHMK;:AK7B32Q%#)HVMZY)$-8U/0KM/[1T.\OIM(U-Y=1LKJ5P#Y1_9Q_P"3
M._CM_P!G3?MN?^ME?%NOTXK\Q_V<?^3._CM_V=-^VY_ZV5\6Z_3B@ HHJ&Y\
M[[//]F*BX\F7[.7 91-L;RBRED#*'V[@74$9!9>H )J*_F)N]>_X*;&/]G70
M_"\7[76HZ3IOQ^O?"WB?QUK7@CQYX6\5?$.ZE\4? J[\77WCSPGK'C/Q7I_P
MS\":%%;_ !ETKP-X\\5ZOXA_9WUWP99:E)I?@^'Q#KG@W5HOT4\)^,/VJ]:_
MX*;7*2^$/C#<_LN:W\-9]6TG4M5B\9^"_AWX%TNU\#>'[*T?6-/U: >"?%?C
M?Q)\5X?&%@/!]O9V?Q0\.Z1'I7C.\U9_ =S9Z5< 'ZQ4444 ?"/_  4T_P"3
M%_V@O^Q?\-?^I]X3KV']D#_DU;]G;_LC7P\_]1C3:\>_X*:?\F+_ +07_8O^
M&O\ U/O"=>P_L@?\FK?L[?\ 9&OAY_ZC&FT ?1M?G=\-]4?5O$_[74TGB/\
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MB+QSI6OZ3X<\8^*]?TOQ/I7B.7Q?X5\&>$O"VAZE* ?MA7P[\//^4B'[4O\
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M.:SX+UWPY;7'A_PY'H]S\.;[PI/X?^(VE'QQ?SRH =W\8/\ E(#^Q1_V1?\
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M!KJRABMI8T7M: "OR"_8F_Y/_P#^"C'_ &/NC?\ IF\/5^OM?D%^Q-_R?_\
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MUS6)KY_!NA?!NT\33>+[73)(/$^KBYAM9(_W9_X*6^$M*\8?L>?$ZSU[X]?
MO]F;0-(;P_XGUWXS?M'?!KX:_'OX3>$])\.ZU::G>G7_ (:?%K4-,\%:Q=:C
M%"=.T:XO+L7]AJMS:W&D0W.I+;02?S0_\$P_A/\ MC?'']L?X4_&7X8^,/V.
M_%/[ _@#Q)9:Y9_M%^-O^"9/[*G[(7Q-_:%FL);F.6V_96\&>%;+Q!\8M/\
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MXPUZ-^W+_P F3_MA?]FM?M!?^JF\75YSXN_Y ?\ P3O_ .RJ^"?_ %F#XPT
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M[_@II_R8O^T%_P!B_P"&O_4^\)U[#^R!_P FK?L[?]D:^'G_ *C&FUS#/?\
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M *C[6[MKV$7%I-'<0,\T0EB;<ADMYI+>= ?[T4\4D3CLZ,.U?D5^Q-_R?_\
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M)(0'X5^%"%!8EB%' +$D@9)S7U-6104444 %%%% !117R;X0_;A_9A\?^/\
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MZ+>:MI^I:AXRL%O+4Z3?:9;:G_9=[<V[W%G)Y\8/U;X(_P"1Y^,W_8W^&?\
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M\M+/%E;2730F[F6$75RL?,%C;%O-O+I\1VT"O-(0BDU<8.;C&%Y3E)Q4$O\
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M<7ALOP<\5F-;#Y7E<JV-H8/ T;2KXS$S4*\,#&4:6#<*<:=10Q5:<%_X(_\
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MOH<FF^#[$A9S*BXT.R35N$Q!)NUEUEB'SIO)>O-RC/HYYE>79OEV6YDL+FF
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MQ/EFLO$(\-2F(?V5F6.2^(O+62/<EYH0;Q#;-+HJM?")O'FDJ\B'3/%Y,?\
M:>XKX)\5NI_LGQ)#X7N-C+I!$GGW\Z7VG;"W]I^'UE\1V'VC0X)KY.UHH X;
M4/B#H^F^?Y^E^,YOL\&L7#_8? OBZ_W)HGB"S\-W2PFST:87$US>WT-YI4,!
MDEU?0X[KQ!IJ76C6=U>Q.G\?Z1;P7]P^E^,733GUV.9(? _BV::9O#VL66B7
MALH8]':6^2[NKZ*XT62T69-=TJ*\UC2&O-,LKJZB[>B@ _SZ?SHHHH ****
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MTJE&IF>58;'RK5_J>/Q&,S2>"QL(X?\ CKZ17TA<=X9Y_P  <%QSBGX>\/\
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M_P#]L3Q]^T+\3?B#X"^+M]X!_;(_:!\0^#?V5OCQ\4?!/PCCU3Q9\)Y8]/\
M OB*6"V\'W?Q?T#2-$\"Z):WMUXQ\*Z9;:E=ZGXFBAT2UTW4C"^U-4U1:=1Q
MDL-%*G%.,8RI8F,*%"UG%P=*IC*T81DXX?V4)N2>-A3C-9MU7RQ<U]:NJDW&
M3G&I@HSQ&(^+FC/V\:%)RFE*LJDJ<8S6#G5?Z?\ ["W_ "9-^Q]_V:[\ ?\
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MUSK.I:SJ-M?:/;R6*/X7L],T_0;'1[.YO8TTTW5[>75Q^=W_  42_P"3K/\
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MSAF#R!FW-G<=_P#;,_9T\/\ [0WP&^)GA'7;BRTS4[GPYKTV@^+3H=OXAO\
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M]/$N.*PE>E+#8J#YJ.(J8M8G+\PQ.)4I3C2J+#.A\KX.> 7"O@W@ZV X;RO
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M71% U*\TW3[>74I=6T&R\O.E13Z;;PVRQ"WC_K3_ &@?V2=+^--V\D7B77=
MTG6]/NO#?C+0=)U&6PM==\.3Z3>V=FD,\*DZ3=Z5?ZAJ.HK>VMK<ZS)/>BZT
MO5-%U*QL+VW_ )3=3_96_:6NOC?%^R)\0WGU;X=?!^]G\7R>/KK1M%\9^(OB
M;X"T&STC5_"L%]IEC=7EKX6\:61U.[N_['TN]UOQ9#I%M<:I87\]SH*:[?\
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MN-($\;92[B:)HU4HS?KW);6TLT%Q+;P27%KYOV:>2*-YK?ST$<WD2LI>'SD
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M/A#\/[/5]!UNT?3]9T748?#&FK=:7JUA*3+8ZG8S;K:^LIL36EU'+;RA9(V
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M^I+^R!-J?ARQUW3WGAL7@N],N#I$MXUI>V5HUQ./Z2O$7@OPIXMO/"FH>)=
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M9RO-OBW\(OAW\=/ M_\ #7XJ^&X/%O@G4]9\'>(+[0KF\U&QAGU?P!XS\/\
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MJ_645>2<Y<E'$5=W0PV(Q"AM[1T*,ZOLT[/E<U!Q4K.S>D9.R?SU_P .0/\
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M[5_X23P[_P!!_1?_  :6/_Q^C_A)/#O_ $']%_\ !I8__'Z^0/\ AB'X6_\
M0A_LX?\ B*?PD_\ D>C_ (8A^%O_ $(?[.'_ (BG\)/_ )'H ^O_ /A)/#O_
M $']%_\ !I8__'Z/^$D\._\ 0?T7_P &EC_\?K\V_P!HS]F;P'\(/V>_CO\
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M\&EC_P#'Z^0/^&(?A;_T(?[.'_B*?PD_^1Z/^&(?A;_T(?[.'_B*?PD_^1Z
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M3SRRO^IM %.\U'3]/"-?WUG8K*6$1O+J"V$A4 L$,SH'*AE+!<D C.,BJ/\
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M*_X23P[_ -!_1?\ P:6/_P ?H_X23P[_ -!_1?\ P:6/_P ?KY _X8A^%O\
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M5\#?^R9^$_\ TU05Z#\6O^25?$W_ +)]XS_]1S4J\^_90_Y-J^!O_9,_"?\
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MVFG?$_4;?4]1U?XH6,/B:_D!ZKX>?\I$/VI?^S6_V0/_ %8/[6= ';?L5?\
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MP\\6>(M.N]8\)LKV?'_'CXS?#=OV]?$OA/X+?MA>,/\ AK'P%I/B"[USX/\
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M\4EX4T/Q-<7=[K<M])XB4:/965UZ9\._^"5G@7X,^)_B9I/P+\0ZY\!?A?\
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M:%X9L8!\.O$MOK?BF^U[^P_B1KOBC3+_ ,)Z+K,-E-X#\47FBVNH7/@VF?\
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M@_M%?MR?$OX^_"+_ ()/_&OX@?#7PK^U/XO\%>.=0U__ (*3^'O@O\$_&?Q
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MR9_C5X#6+3_$AL]*U3[%X1O&/EZ_?W?]FV-M:X-UK&GHWFGZ%\$?\CS\9O\
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M)-6Y'5G3BWK>7M73E4C*"E"5/EGSM3A?^I:/_5Q_[B_^@BGTR/\ U<?^XO\
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MM]"U?1O WAC6VO8K>:]U*ZT:[NX(KK^SM3MVMIVKZ^\$?\CS\9O^QO\ #/\
MZK3P77@7[?FJ66F?LTZX+W4[W3/[2^(GP.TFS-G8O??VA?WWQJ\ I:Z3=[--
MU'[%8Z@ZF&ZU!OL"6D9WOJEB#YM>^^"/^1Y^,W_8W^&?_5:>"Z_0SX0X#]IO
MXP^%O@IX*TOQ+XLU"?2=/UCQ'8^'EOY-0\/Z3HSW#6FHZK#IFN:QXLL-3\.Z
M18ZH-.EMI+^_MH4A7=+)?V,$$ES'YI^R?\6_"'QT^$NE>-?"?BG3/%.D>++B
M;Q-X4UC4KZYU?7;N./QAJ>H:O:)9:\MUKJ6_@W69+C2;.YALY-'L9U4^&[R#
M2K6R^S_G;_P7S^(MC8_LSZ-\+M*L=5OOB%XW\36DGA:ULK34(;O9H.J^%KR7
M5]*U:XT36_#VE)HVJ:CH>H:QJMQ:1ZMJ7AW3_$_@;0M4TR?Q/J$M?*'_  3,
M_;0O/"OPX^)VF^,--UJ'X7^!KN(:GK\=KX8_X2?PAXC:*/2]3T+2-3.G:1?>
M($CU;1HM3T9-466#Q'%KL#VJZA=_;K"Y_M;A7Z/N-XB^C%1\2LJPN)EG^)XS
MEAX8>K6HTHXO*<#BJ.7X6O@,).G+$8[$8S,LP6$P?+.EAIK+<UPM/ZUC:U)8
M#\XQ7'^1X;Q!CP-4Q^&EF_\ 8:SB6!A5C/$4<+.K."K8BDGST*4G1DZ=1I\[
MT?)RP5;]T?VW3$W[&7[66NW,MS87-]^RG\?+6XLKI(WC@A_X4[XUO$TR^EA,
MEK9S6]S,\CW9GC,\J1V@E<21(>5\1VLUKX>_X)V127MW>F/XL^$F>:\6V,\O
MG_LR_&>:.)VMK:UB5+0.(8-D*R-! @G>:7S9I/%_VQO&VA_\,F_M2CQ-X@;6
MX/''P-_:+\)Z+9O80:+:O%KWPBUGQ#X?B^(/A2?3GT>;6;V"S@'ASQ8J:/J.
ML:,^CV;VECJUY<6#=+\3[B_GTC]@S6)KW3]/\+1>*O#NGWLUY;ZI::I8:F/V
M:/BC?V.LWVI6&L:/J5I86$D5_:ZKX=LPFJ7#?9+D:QID,DT4G\J9ED.*PF(P
MN&Q$Y4XXBBJE.K+"553J1IUYX>G1P:JTZ>)JSYY5:-.%6-*=2<*?,U:#I?H$
M*L9*3CJTU=<RNN91E>71::WZ+9:Z_IQ5-I1:RLUU=@I>74,-E$T:IY3M J_9
MD=!NE,LD4UQOEY7>R A$6N8U6[U2TTZRO=/@?Q#K4&BR_9Y+4FUTJ\O;LZ9
MEU=V,<\\\=G/*S7B&![N2SL8+T0FYF,:30:T99_#<M[J$5KH&IW>-)$FMRQW
MHL!JFKP6EI;(VBW=LMW/?7/V"+2X;:\CN&N[BR221KA9(7\6C@N9T7*K#V>(
MK_57R<DZZGSZ3AAI/ZU[-I0E[2-&,Y<SHJ/--1GHY;JSNES=4K?XOAOOI?SZ
M.W)?$CQ%-H5T-9M-)N-7UCPI9:AJ-EI&AV&GZSXFU;2M1TTVL\>FC5M0T;3_
M  [<2:HMNL6HWD][::C;Z=>Z6BB]NHXHN=\67/Q5N()CI7A[X=VKV>M7']D^
M']1U&ZN)]8AU"]\.06.NSW+C1K&2RTO1]6\<ZQXET6.WNYM1U.TTS3],U:)Q
M=WLOD_BCXA>'-1\8VGPRU:2]N=?\1:3X<\8Z3?6]U%]BM;,R79U?3-.G\1Z(
M^OS:WI7DIX@71WTQ=0M]*O;;5[!M/O;2 VW+6ESXVU*UTKP]XDN)KSQ-X(MM
M#T^'6-+U67P7#JWA/6G\2::-<\5:9KU_X@T'QWIMY#8+<>*/#7BB6WU>RBTS
M5+V**Q;4I]1U#]5R[AFKA<)EE?$X? T:N'I4Z\?[3I59_6<NQO\ "KP@\9AL
M,\"L?+$8?%SJ5(8W#SQM:6!J3E1I48<%3$0<IQ4IOFGR/V;^&<4FXN2A)QGR
M)./V9**YTKW/0[[6/!::G9^*GOO!^J>(_%?AZS@\?:9H7B*+QKH^M>'0-=MK
M&X-VFDZAJ]SX)FUV;6+"#P^]YIFC:K=6[:9%IWVN6YE;W/P_;V]KX6MO&'A[
M4/M!U?3M+\1/'>'4+^Q31GTV#4Y?#WABPN+R&3PWI\UM@:99HDT6EEU>33[D
MJ8C^8'P/^(L'Q-\3Z7:7G@3X>W>JZ?X?MWT3P9X)FF^&>L_#FU\'>.M<^&7C
M3QI!?0W5KX=\0?#KQA<>$_$.NZ9I'A*[\3:3=:-:6CI9QV&J/J.M?6_QZU3P
MMI^H>&M-TZTL-4A\&ZC;^(];\)VOB.#P[X4T[0/[9\,^&K?Q5XIOC+H_AJ.^
MT>YL+K0M%T+Q#J4MQ*L]^\5M=V=I>0VOL\3\&XG!9]EW"U:ICZ6-DJBQLJDL
M'BL/#"X1?[-A)4:N-I5/8PG]7R[#XW&RPV%G[!1P6(QV!H8;%U,L/B>>E5Q#
MC#D3?(HJ?/+6TI6C&2<G:53E@Y3:DE.G2JN5-?*G[1'[4FC_  R\1>![KQ)X
MIT'3$\2^.M!\)Z!=7&I:EHOPW\%6NEV#>,/#6N^.;XX\*Z&_B*#Q4VEW]_J5
M]+))HMQIVJ1Z!J.F07]UH7YZ?\%3/%^G^-/"W['>L:3HFIZ-I=W\>_"^HVC:
MA8G3TU"YU/X__L>2Z_?6UK'=75C;+=^)(-6U%;&P33TM+/4+%I],M)[F0-R?
M[27[2/PIG^(?Q%^$9N+>/1=;\7^!_A1K7PXL_!^G>/-6\ ^+-+@UB&'XD_$_
M0O#UG!XF\:W6F^&]1;48X+/5)XM#@\4Z#HWAFQAU> VVE<1^VM\0S\0/@9^P
MK<-)>)_9WQLT!+32+S0DT"Y\.Z)<_M-_LIOX?TW5;&3Q%XGU.U\0:CHJ6/B.
M_LM9U&&ZM[+6--:TT^WL)(FD_3O&CPS_ -5/"#AO.Y9%F& QF*Q&6QQ&+Q3K
M4\+BL%F6&H8_ XK#4*>#CAHU*3=3+9QAC,7@Y4Z:S'#XRN\UHO$>/E&<T\7F
M^,P2Q$*DZ2E)4TDIP4+TY*=YJ:4JD9RC)TJ;FXU*<8VH5'#^O6O#/VC_ (@V
M7PU^#WC'7K[2?BWJL5YI=[X?C/P0^'^K?$OXB:3<:U87EI#KVC>&=(T;7Y'_
M +'8_;'U"^TF\TJQDCADU&&2W+(WN=<9\1M1M-'^'WCK5K_4;O2+'3/!_B6_
MO-5L+.34;[3+6TT:]GGO[/3XK#59;VZLXHVN(+2/3-1>XEC6);*Z9Q _\9'U
MY\H_LB-N^&/['C;KA]_[%/@Q]]V@CNWW:/\ "%@]Y&$B$5VV=UU$(HA%.9(_
M*CV[%^SM9U%M*TVYU!+2XO?LPB+PVH@,JQ23Q1373"XN+6-K>QAD>^NU6;SV
MM;>86T<]R8H)/C/]D=UD^&G['\J2-*DO[%G@^1)G79),DFD_")TEDC*1&.25
M6$CQF*(QNQ0Q1%3&OJ/[6WCBP^'W[._Q3UW4[B[L;*[\*:MX;DU+3WMO[3TN
M?Q38W&@6%]I-M=211ZCJ\>HZA:1Z3IJR*][J,MM"#M+5Z^0976SO/<FR?#P=
M6OFN:8#+Z5-1E)SGC,52H1A&$)1G.4G4M&G3DJDVU"G[\HF=:HJ5*K5D[1IT
MYS;NE91BY/5Z+;=Z+KH?C%\*_P#@H+_PM;]M77?@7<:7HNIZ7I=]X@M1K>C7
M]CJW@GQAXLGUR&YL/"L&N3^+?$]S\/3J<6H7ZZWX/UO1-2F\61Z3K-]+X>T!
M_#DJK^O_ ,+?B)8>(KRQTG2O#$]OHLMYIMQ9:/"?$4.K^&M2ATV>34;SQ=9Z
MU#% ^C7NI6RW_AW4K*WLX9+FYL)];L;#6M3A67_/STKQ9\?/@5>^'_B2)=7U
M:UU^[U/Q)XA\/7NLIKUC-I=WJ]\OB;0DT_1-->'QTZVVLN+*#5-2A2_@BUF'
M3O$5N\T6JVO]*?[+?[2WQ<\!Z+\,?$?ACP#X7^)&FGP_H7PP^)VICQEIDPU_
MXC^/_%%MXD3P5X-U&XFG\0WE_>>'O$%E\1[K6M<.J^$;/P/ING:1HOB'3;71
M=4MQ_JA])/Z*>6Y+E>4YGP1B,DJ8*KE%+(L+"GGE+"X3&9[D\,3'-<PKXC%X
M[#X>AB<5CI82AAZ<Y*E3K8GZK1QJRYTZ$?P/PG\9,B\1L-F&*RO$_6H8/-\R
MP5=TTJ\J<L'CZN!E1FJ5*].5-X>I.=*4N>--*HU5DI57]-?#R;7M,_X)8_%'
M[5#=>*5\0_%K]JJ74+O19_,L?#]U+^VC\5;*ZDTZSU2YANV\)R369NM/73TN
MYTFN+J62)H9FN(OV0T7Q<^O:6;G19M"URYFN[X:9>6-_/%X?U;3[+7&L;R:Q
MU..#46GFTJT*P7QCB>WFUF*2WADBM9%N(OY]/@QJGB%/^"9GQJ\1>#/"6A6G
M@SQ/XB_:1\4Z+K&G:P]S_;UIJ_[:_P 0[G2O#&A^&;'7KGPWILUO"?$%M)XF
MOCIMAI]I<: FF2:EH=G-]D_;O2_'VL7-A=:;K^F)X>\86_C71](M;6<ZUHVA
MZC=02KJAT[39=!AU:]FTZ/PY8WTUO-J4\EEXANK+4[J[@TOPZ\4$/^:F+X>J
M1G44:6%Q=2FLNJ5%2KX>GB:$:D9*M#&8##XFNH1PLZE+#8GV.)P\J$*,GBZ%
M&O-UL/\ NT*R:3NXI\Z5U)Q=K-.,Y15^97<;J2DW[LG%6E]"/.4N((/*D83)
M.YF5H1'%Y/E8616E69FE\P[#%%(B^6_FM'F/S.-\7^)K[PK9$VVG:KKFI:O<
M7%OHIMM)GFT;2;EH(4MG\3:C: )I&@6\S->:AJ]ZZ"&RCO"C-)##$]>Z\9:=
M;3>&8=:L_P"QM;\1ZK'X=TJVD*ZC?6]_J.F:KJ\D<%YIUGJ6GE3IFA3Z@\HN
M18&&!1?3P2I'!)%J.M^']6BL[&_U2\AN+O5M5TJ:318]1FTX#PGJ<>HZ_I^L
M236,^EVVG30:4=)UB75(H!<VEY?:=IUVK7:R'Y_"8"K2Q&%J8K 5:^%;E*JJ
M<)5(5J5.6(E*O3JT/:^TPU-8>I*K4P\TITZ%6$9)<U0UE-.,N624ME=VLVHV
M33M:3YE923:;7H2RR^'_ !K;OI$\D-S$FGZ/KTUOIFIS)=26MOKS7V@ZC9Q6
M9,,VCZO=Z!+<Z?>17+?;[2,P%7@F8GJ5U-+O3K>:'R[*\U&QMI[73];4VEU%
M+?0-);VNH6)<7$4X*2Q3VP!E62"XB&6B?'!C7M-T47E[86C33Z1IL":G9VVC
MZ?/K&H:)!JVHVT%];3:9):,MC8RF_OH[06;(EFFIMIFG75UN0\GKEU$L6M^)
M#IEK9ZS;:'X@_L!-0TO4[+0[JRM-?GU.#5M4UMMEI*;ZWU6SN++2?$D-O'I>
MMP:U<V1M;*XO[U^V.63Q-2%&*Q%+#+$16%A-NMRXJM3I*NI4Y.G&-*<8X>I5
MQ"3A#"TX<\YU*<H.?:*.KM*5KRLK:)NWS7O)+=R>UF@GBM-)UWQ#H.B07'@<
M76L:%J!N-#\.^')VUS5]5O7CU :=>7<LCQ3WVCV"Z3?:E=Z=;0:4WBJUM[+5
M'U&V:"S]0\-7F@:I-<:KX<,D]I<HUI>WRP)$EQJ&DR#33#?R7D4>N3:E916Z
MVP-XS01VZ;5_>LQ/QE\1O^$2U3QGX1FA2[G\16FAZQXJU77],US4K#7+JU\O
M0=2\6Z?H$>B$_#^WU:Y@T/PQJ!O?$VH+ W@K7M3UGPK<W$2V\DOT_P#!OQ1/
MXO\ #G]N'Q!'K>G:E;Z-J&BV[3:?<7VD:;>Z/:2I97UW:.;O4)5G\Y6U/58;
M:]OYX[FX6".W>$5]!Q%DU7#Y#@\T<L0YU:%&.*^LT8T8RG*I'!P=.M'ZUB,P
MAB7@?K>'GCL3A?JDZ..I0H2FE?*C44JLX>[HVXM.[M92U5HJ'+S<C45+F3BV
M]V?'/_!6AI$_8@\>O##]HE7XB_L^-%;^:D'G2#X_?#4I%YT@,<7F-A?,D!1,
M[FX!KTC_ ()G_P#*./\ 8#_[,L_9<_/_ (4CX'R/P/%>=_\ !6+_ ),E\<?]
ME(_9Z_\ 5_\ PUKT3_@F?_RCC_8#_P"S+?V7?_5(^!Z_-[Z)65TV[ZW=[63U
MM96;5DG[SNVN6W8?9VIWZ:7INH:G);WMW'IUC=W\EIIMG/J&HW*6<$EP]OI]
MA;(]S?7LRQF.UL[='GN9VCAB1I'4'\T/V?O&UM\18/VF_&EE9_%G3+37OVYO
MA#=6^D?&SP/J'PY\>:+%_P *]_9<5-'?PCJVA^'M5T_PWIR@6_A6;4["6_OM
M&6WN;K4]4E=KR7]/:_/KP+JUCK/BS]K2XT_5K_6(K/\ ;J^#>CW$^H:?)ITM
MEJ&C_#?]EJQO]'MXI=+TDW.GZ3<1/9V&HK#=QZA;1I<QZKJ:.+MT!^@M?EI^
MV+XAUW5/BK\.?#MQJVK>"] O;Z'PQJ2IJWAM;J[ANO$Z:C ]K9W-_ (T\>VG
MAZWCT?[1#XAEUA]"E\/:9%X(^(,?AUO$'ZDNI9&57:,LK*'4*60D$!U#JZ%E
M/(#*RY W*1D'^&'_ (*B?M??$A?^"C7CWQ]X:^R>)]&_9^\/:EX&\,):W5CJ
M>E> ]>\+ZA:ZCXME\:>&+*[_ +.\5ZUI36DD\6BZ_P")-'\'KH'B"XNM8T_^
MTWNK2X_K+Z'OA+FOBUXD9M@,KK9?A:F0<)9OG"Q>84XU80Q=2-/+<NPU*G5J
MTL/[3%8K&Q<JM1U)T:%"M4HT,55C'!XGXKCOBO*^$<IPV.S;%1PN'Q>:8++8
M3G-14JN)J-J$4KRG-PIS<:<$Y2LW9*+E'^MWX1_$;2OBUI\Y^&NM>"_'WA>P
M?2RMSH&J:?\ \(,UE/IK6,-WX7B70#/]B+?VY'X@TZZM[OS+K^Q5L=0%O=ZG
M(O(?#8K9_P#!13]J.T+HD(_96_9!-C:6NGR16]M9P?$']JBV2(RQ"2+S4DEP
MD0, -NR^5;[+6:4_G[_P3<_;5L_BKX \":3!<P>*M0\'Z)X:\*W'AFWTK2]2
M\0^*-(T;PGJ&K:+\2M3U_P #V.IZ?IWQ&L]0\-2> -9\(:UJ]TFHS:++K&D_
MV7]JCT^Z^K_A[\4[;4?^"BWQSTNWM+W1]7\1?LL_LA'6])O)+"W\1>$M6A\7
M_M-ZQ:>'=9T6]#WVS55U6"TN]>TS3-7TW2X'1[V;3#JFEWU?G_B_X<9_P9QM
MFO#.)RB>"AEU7%<L:M>%2O+#T:4ZD<9BJ\L-@XU95Z>&E75;#Y;AH2G7A@8N
M>-F\/'Z#+<=0QF$I8FG6C5C5C"49PUA)3Y;<B4I:/F5DYR]U>T^%<S^D/V*Y
M$M_V?O#-LL,[++\0OC\BR(CRQ0B+X\?$Z3-Q,S,8P^-D;.3YDA"@Y(KZO2XM
MY6"1SPR.1(P1)4=BL,IAE8*K$D13 Q2'&$E!C;#\5\<?L;:AJ0^ &DK:?V5'
M97/B[XZ/INK2S-=6MIJDOQ\^+2%M1B6>SCO-->=M)CLDT[4/MEXTEZLK62+;
M3R?4VAZ#9:*P"V,#W,<-[,VMF*T25WUO5KO6-6L+9AF\M[ :@XO%MY'>)A);
MEYKFY@EFK\8="G&BYU*EJMH\E.+51S4HSE.4Y.24)PDZ-.5).=76<W%147/T
M[N^FVNO;:WJFKM/;97-34M6LM)M;F]O9DM[:S^SM=3S;XX88KB985D,GELKX
M+<I'N;=M5MI=37DOBWQ+9Z5XEFMKGQC=:#%!:K9WUQJ.IKI5M;)XA%[/9'1D
MGT"YTB^UJ*^T_3[32UU 7\LNFW&MFR)GT_4$E]4NKZQN8) EVJFVU"SBE474
MEA(EQ'J<<44,C%1((KFYA:!49/(U!-\*.\4I:OE/XLZ8^M?%G3[;Q=HNO^*/
M!A^'&L66L:!IIDA\+Z;IWB#7("/$6IZA9ZKI.J7U]H\_AJT:YMK6QO+W2],U
M'4=2TF]C3[59S?2\)X#"XO'5*6-56C3AA,=5K27U>5:2HT:$X4L)A\5&G1J8
MFKS5:4(5Z]&C-XBBI5.:"IXC&O*48)PLVY025Y6UEJY.-VHJR=TFU:5EU7NF
M@2IXA%Z=7A;Q!H'Q TZSU2!X&EU;PGIZ1:'I>FW_ (=M[B[F6Y>"[NK74=6M
M;S^Q='TZ]2>0O''J<I%YU'B-1"+*\&C1:E#&7L-1F>YM[<66B:A-:V^IR2)<
MW-I!/:1P 7MV)9&6&VL998XIK@00R>5^#M:\1:Y<?#Z+6K5;2UM_"=IK\?BG
MPW?O8>&=:\67$VJ>']>\-'1]6T]-2_LZ.POK/Q#H,5_;6E\TH2WN#%>65Q&W
MHGB779+.WU2*W>Q671M/M=1%YJ>LVNGZ==7?FK'+I>I);^=?PQ&WN;*>:=[%
M=/E;4;.(39\U8\<?A,10S6CAXQI2Y$X?5X8I.E&$:SRZFO:4JE*]5X>EA*>(
M:5*NZD)?6:"E3J(J,DZ;;;UMJXZMV4]FGIS-N*U27PNUB]8ZK=ZY#%<Z-!/9
M:<)KRWM;ZZ73;JPU.U%G ^GZS8K9W\TUUI-Q+*RV3I/9SW A>9XA:26\LVO!
M;7?]JWUW=1:<;<06UOI<T"3C4EA8&6_BOI)"83&UTL3VJVX&$5C-E\&LV;2X
MD$)D@EM-+LA);VVCZ-YHMKN'5H4M+N/5-.M8!#,EO<3RS1-"3';KYEY(ZD28
MZ.-41$2,*(XU5$53D*J !5'7@* ![5X>(J4XK_9XQC3J0G32Y$YPBZD:EIU^
M=RJUG!4U5=E""J2I025S1)]=;6Z[Z?RVT5[V[V3/R,_X(G_\F667_8[#_P!5
MI\,J_7:OR)_X(G_\F667_8[#_P!5I\,J_7:N$H_,.Z^(5IXY_;7^,]C::7\9
MM%_X0O\ 8Z^(7A>XL_B)\.]4\%^ [^YL?B39QS>(?A5K>KZ#ITOCBRUAHBNN
M:S8:OK6CI;6/AF33TT\7TK7_ .B7@7_D2/!O_8J^'O\ TT6=?&'Q!U:PN?VQ
M?&6C0ZK?7&HZ7^PMXXO+W1Y=/DAT_3+?5?B+IB6-[9:D=,@BOKC56TV\COK:
M/5M2>P73;-I+/3!>QOJ/V?X%_P"1(\&_]BKX>_\ 319T >=?&[X@R_#?2-/U
MU]1\*Z383M>:=<WWC34M>T_1?M$D<5Y:VD(T&RU"YN-3N8;*^>/%I)):6<%Y
M>KOBM[BWGT_ 4'BY=1&J^(Q872:UH%D]G+_8MWI?B*PL!J>IZI9Z=XCN;Z02
MS7FF6VMQ:.;#[- XGTRYU=_*GU>YT_3_ ,/_ /@KW^W?I?[./Q@_9W\(^%/$
M7Q+T7XF:S=^(M>M_#NA6^EZOI/CSPY;P-X1G\*1^&]0N[34=*U_Q@VMZOI_P
M\\56MUIVES>*]'DL?$H&G&RFE_0#]C/]H/PC\6_A3::W\-/!6M17^A6[:%+I
M[>*M"OGQJFI:A?:A,S/XM\40:MJ6@-I]KI>KSQ:QJMY/KUMK.B6[)<Z5?6\'
M](9SX,<59#X+<'>(E?*)4\IXR>.Y,?B*6'I<M"EFF+P&'G6JXJMAYX7#/&82
M,:&*P=7%T<9"I.&*H8&I@&L5X%#.L%B<YQV54ZZ>*R]476I*3O'VU*%:*Y8I
MN3E2;D[QCR\MHRG>2I]7^T'_ ,GM?\$]_P#KY_:I_P#5.Z?7H'P?EMHOVAOV
MO_M$@C9_B'\(EMP6=?,G7]G[P9,R80@/BVBN)-CY3$98#>JD>.?'FYUR]_;6
M_P""?UU+9PV*22_M2SZ':O/>I<F63X%6!>V\41+:F&VCAOFG7;:2W2YCLY%9
MIQY;>E?!R>PU'X^?MB^'M:O;:#5K_P 8?!Z.[L-.U2^TVYEE3]G[X?7%Z='N
MH9=.U62WAW[EN[-HY8XN)FBD$L:_STL,XSM-N48*]?ZLXU:E.FX<U2:49<LH
MTHNU2\XPYTZ4JD'>2]WF^5]KZ)]E?HWTW=M;=#ZZ1%O)[#4[?4+K[(+.XV6D
M)M_L%^E_]CFM[RX$EL]V9K2.!A9F"ZMX@E[=?:8;AC;M;W9&=0"B>82\:D;@
MFU&=5=\MP?+0E]HY?;M7DBJ:7DCWYM!:3" 6TDQO'694,T=P(?LX#0^6Q9"9
MD?S]SH,K$4S('7^HV&EVDM_J-Y;V5E T:S75S*L4$32SI;1J\C$*I>XDCA4$
M\R.J=3BLG"I*=*G&FY.7+&C3BE*<U4J2<(/V24IU)2DXJZ]H](I**A%/17UV
MW[+1=]E;7M\[E"^EGD=XIK"Y2*W-S=6MW;W:!FELH;>6V8QB2&("9YKE%AOY
MDM"UJ!<92=-N!J,\<\UAJ$ME)!J TA-573]7T^.^_LRXT]4E<YM)[M;?5XH-
M6N]/:[T5+](Q-<&5[J*.VAES?B)XETGPQI]_KFHW^@6UCX>TZ;5->BUFRFN7
M:RDBGL[62&8:E86MO"JS7R7GG0Z@TEO*5CM_,*)/S.@_$73=4TJ[L'\,7"6^
MGNVH:!]COM$N;+5_"ZZII]KHGB73EENH)[.VG:_::"PU:P@NU@TF^D>*X#V0
MOOH,%EF-G@J6/HX6<\/[3ZO4FG[&*E-1YX*6)JJ%5N-7#5YPHQE'V<X5)2HP
M]HI92J04G%R2ENOPM?EU6O-%-VUNE=GH]A>:,EUIUQ'Y>I:WJ-A%I<VIZ=9F
M<2VNCSS"7[3<VT2VUK86]_>730"1HHWDN)3:)(!)LZ86\0N3=X?SF@6W)\V7
MR_*21I% @W^0'WNV91&)67",Y154>>>$I+VSOHK"[TC2;E'M&M;'7_"FGVUI
MH6FZ5I5KIUO::-.)#'=6QFNA?FRL;&;6;.U6T=+BXTUY+:PC[JZM[+6;">U>
M626SNT>&273[^ZLY2%<JX@O]-N+>[MY$="C/;7,4BLK(6'S"O,Q]*-'$QC[2
MHZ<HQ4ZT)QJMTI3DHQC23H^S]G3@H1P]5TFW2YDJ=.4.6XNZO975[)W6ME>[
M=^KU:OH^KWN(SLT@>/8%?;&VX-YB;%;?@<I\Q9-K<_)NZ,*_(7]B;_D__P#X
M*,?]C[HW_IF\/5^MA.H2F_$:+9O$3!8/<F.[M;D&&"5;Z2"!X;I DSS6K6[W
M,3N(#*-JR(]?DG^Q-_R?_P#\%&/^Q]T;_P!,WAZO/E'EMK"[2TC+FM>,6FVK
MQN^;5*3<9*491BU8O^OZ_KT/U]HHHJ "BBB@#\8?^"H'[=_['/@?PCXS_9\\
M;>/OCUXL^+7P\\0_ _XI>,_A?^QSX:UKQA\7O!EGH_Q+\%>,_ 4?Q)U^RM!X
M'^$_@OXAZS9Z!X>U"]^)GB;PO::SX;\13K:-/;W0E'ZK?#/6/%7B?X6>$=<\
M1?#V;X,^,==\*6.HZG\-M1U/0/$MS\/=;U"R$\GA[4=4\*7$WAO6+G1KF40W
MT^AW<^F7,\4HL[J:$K._Y_\ [;W[&7_!-?\ :8U/Q _[1O\ PKGP1\9)-&TN
M&\^)'@_XO6GP)^.D=EI36FK>&(]9\4>'/$?A[5O$^EZ7/86%_H6B_$*T\4>%
M8'MK:X31I(XDQ[Q^Q'\5M*^*_P"PO^SM\6->\4^+;C2/'/P6\):S=^+OBMXJ
M\,ZCXXO;35=+BMXM5\9>,?#6D>$_"^H^([U'CEOM:T71-%L+V^F^TV=E;^:D
M8JC1G6P6)ITX5*N*>*HQ<:4I*$IXREB*.%AA7!>UC6K+ N-=35:4:E*C+#N'
M-5C4UFTJV'DO=I*#C^\49S]QT*DN>F_=G352O6E2Y>12IS<*JDU"9^8__!-W
MX:_M:^%?VI8+_P")_B/XBV]I'\*/B;)^T+XB^('[<.E_M->!_P!JCXA3_$#1
M-*\#_%?]GGX*VNNZI+\!O!'A"?3/&&FZBUIX<^'%CHT6M:?\*KGPYK6H>')-
M7M/WONO#GA^^UO2_$M[H>DW?B+1+#5M+T;7;G3[2?5]*TW7GTZ76]/T[498F
MN[*SU>32-*?4[:WECAOGTVQ:Y24VD!3\DOV,_P!@NP^"/QI^&_BW4/VM/ WQ
ML\-_L[_"/XB?!O\ 9M^'_@OX3_#CX<>+?"_PW^(OB/PSX@\0_P#"WO'/A#Q3
MKNJ?&/5;*?PUI2VE^NA>!]$DUJ[U?QCJVA7_ (KUJ;48_J/XS_M&?%7X2?M"
M:;X9O?"?@R;X'C]FWX__ !>-_;ZKJU[\2_$WB[X-P_#S4I-,@L%L;;0O#'AR
M/3_%=Y9++)<>(=6UO4WAGC@TBSL&34NG%TJF&CA:%>C5H5:>#QDY4ZV%>%JT
MZ-*698M\]-)03E@8>[3PZ]A34HX.DG"E<QH0G5K5_9^_*K7H**53VBG4J0PE
M!\E2;56HO;R;=3$VKSM*M4M>*/43^QM^R,W@#QE\*#^R]^SW_P *P^(OB5_&
M?C[X=CX.?#U?!/C3Q?)<QWK>*/%/A=?#PT77?$'VN**X36-3LKG4(Y8HWCN%
M*+CX9_X+::1I/A__ ()1_M#:%H.EZ=HFAZ*O[/.E:/HVD65MINE:3I>G_M'?
M!FTL--TS3K.*&SL+"QM8HK:SL[6&*WMK>*.&&-(T51XI\(_VV_VQ/C3HG@[X
M9Z3XZ^&7@/X\_'7X@^&+WPIJ7Q*_9%^+_@&P^#OPIU[X4?$#XJW.I:;\/O%W
MQ@L+S]H3PQJ-S\.]1\!> OB;9>*OAN=3U"+Q)J?B/P7I;Z186%]\R_\ !4;_
M (* >%OB%_P2SG^'?Q&\,>/[7XW_ !P\,? W5KB_^'_P9^*^O? NWUK0/VL/
M!OA;7;B;XL6VAZSX'\%Z;J.L> ]:U#1])\8>,8M7M=+U#0X;J:ZN-1LY;S*5
M&K3A/G7(H3P]*4&]Y+#WC%<MXR6&@GAW)-P4HN%"52G%R4*I"<H<K4W*-:K&
M:6BA/$5(N;;M*+Q-2G.LHM*I**YZT83E%/\ IZC_ -7'_N+_ .@BGTR/_5Q_
M[B_^@BGUB:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 4M2U+3]
M'TZ_U?5KVTTS2M*LKK4M3U*_N(K2QT_3[&"2YO+V\NIV2&VM+2VBDGN+B9TB
MAAC>21E121\X?#C2]0^,'B^S^//B_3;K3_#NCI?V?P$\):I;F"ZTS0]1BDLM
M2^*VMV<A,EOXI\?6#>5X>L[B.&\\+>!)XK.>*TUKQ+XFM(JNN-_PT/XZN_!=
MLTC_  3^&6OQ+\0KM-C6/Q3^(.D2+/#\-H]R.E[X,\%W@MM2\?/&QM]:\30Z
M?X,D,MGI7B^PG^ING2@ HHHH **** "BBB@ J&YN;:RMKB\O+B"TM+2"6YNK
MJYEC@MK:V@C:6>XN)Y62*&"&)&DEED98XXU9W8*"1-7Y\?\ !5_X?_%+XK_\
M$VOVU?AG\%/#WB+Q;\4_'O[/GC_PGX+\*^$I/*\2>)-5UW2VT]M"TB0W%H!=
M:K9SW5C@W,(:.>13(H8UG6G*G2JU(Q4I0ISG&+YK2E&+DHODC.5FU;W8REVC
M)V3UH4XU:U&E*7)&I5ITY3T]R,YJ+E[SBO=3;UDEIJTM3Y@^,WPI_91^+7[1
M7P/_ &CM>T;]@_QY^PAX)E^*'Q-\:_%#6&^#.N?8_P!NS4O%WPB\.?##QGH?
MC&V\\7_B_4-&T'5- U^)-7N;C6-=L?"<&IZ=?:S8Z-);>^_\%<O#/[%7C#]@
MOXU^&?V^VEA_9_UVRTK0VO=(T+6/$WCG3OB/K^H1:#\,;[X6:!X=LM2U[5_B
MC!XPU/31X+TW2["\>_U1UL[ZVGTF?48G_F,_9J^">@:+^W=X@^(?B3_@AG^V
M9IOP)TW6?V>-8^ 7[,.AS_ JT^ WP$^-&@^%=/\  GQ0_:8^(WP-TCXK1>%K
MWQ_.-+\+77A[Q=<Z1J=[ING:;K.K3V$?B;4(+R'^HO\ X*:?LT_'S]I_X"^
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MMO"ESJ=M:_IEX;\3>,?%G@[]A_0].\1W^E7VG_&'P7!>^()?$_@[Q>PUF_\
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MQ/X<\)^*[+7?%_P^TO7M:NO")US2+;5O$NAW5PD6;S1M.M=9\2VUGX1N]?\
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MCR/QS\/]%\-VVL:S8^'_  MX$\1>'/"^BZ;K6M:9INC6UAK&I6UU\K_\%C_
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M-EIGCKX9>&M5B\4:'JM_K'B;5K_3;6];3/"5EX<\,Z+HOAV']B_ V@6>M?\
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ME4FZ\XTY)-*<'93J5(N3]B?P>;CX!:=X6\$Z*-2\ :;\0M?O;>R\8Z7K6I>
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M'<T445XYH%%%(K*V2K!@"5.T@X93AE..A4@@CJ#P>: %HHHH **** "BBB@
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M_P"*DMUX-TS4]$M/%HUB^N;S4+^VLO&^OP:EINFI';:==S^*=-L9;;3?T/\
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MKUU/S?\ ^"L7_)DOCC_LI'[/7_J__AK7HG_!,_\ Y1Q_L!_]F6_LN_\ JD?
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MO+>QCM=/:/3TOOL5GI>G0QWM[>RRQ7%Y/<WEQ_!OC7XOYEXIYW5XBS.:>/\
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M>Q:9I6EZ+9Q:=HVFV&DZ?;C;!8:99V]A9PK@#$5K:QQ01C  PB*, #L*_/\
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M*XTW5;&SU/3KR,PW=AJ%M!>65U$2"8KBUN4D@GC) )26-E) .,@4 ?RBZO\
M\%4_^"@&L_M$Z7^QMXH_8?\ CZ/V@=?^#_C'X\:9\,-9\/?LHC4KKX<>%9=2
M\+:EX@L-8B^,,NDB?4]>@G\&Z!<Z;K"2ZAJ=Y!-:WD>AFXU6'[D_9\\:?\%
M?CU\)/!?Q7\)>!O#-CI'BMYO!M]H?Q$U/X=7/C3PW=_!_P 7^*_!UU;^.IK*
M7Q!IVIZIX?\ %?AG5=-OM0TOQ#XFGU=_L,L\NH6RR20_N*_A?PS)XB@\7R>'
M="D\6VNERZ);>*'TC3W\16^BS3BZFTB#6VMSJ4.ERW(%Q+I\=RMI).!,\)D
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M3O8V^T>:;SS@]_\ :GA@:)T'PW\&6QTXPZ.R_P!DGPX=/SJ>L.+<^$_[1_L
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MF\00Z!<WL&I7.AQ:R8#J,>CW&HVMK?SZ8ER+*6]MH+J2!IX8Y%\W^*/[/'P
M^.%QI%U\:?@;\'OB_=>'X;JWT&Y^*/PS\%>/[C1(+YXI+V#2)O%FB:M)IL-Y
M)!!)=1V;0I</#$\JNT:%>6#]FL)RQC_L[S%5-9)2CCGFK48:M1Y'F%*I*4U.
MI*5"4(5*=.JXK>5;G^L<_,U5H8.G3V]VIA88&'M)I)<R<<-6IQ@FH*-=3G&I
M5@IO^4:#0H9]+_X)[>./!@\.7WC_ /8JT'_@I_\ &_P7J_@V7?\ "[Q-K7P$
M_:2^#=Y\5;;]G^6WWR0?L\^/?ASJWQ&\"_"S1[/[1%I7@O4M+\//-J$NEB\G
MZCQUXI\1_%7XV?MB_M@?"+4O$-]KG[5?_!-GQMX]\#:[X*758/&I_9"\%_M7
M^!/AYX:U7P1%IB'7K35=<^!6D>.?B=X=?0XQJQU?QO;W%A_Q-A 1_5[;?#7X
M<V4?A^&S\ >"K2+PGX=U#PAX5BMO"NA01^&O">KPV-OJOA?P^D5@BZ-X=U.W
MTS38-0T33A;:;>PZ?8Q7-M*EI;K'/HO@#P'X;NM(OO#O@GPCH-[H'A6V\"Z%
M>:+X;T;2[K1?!%E-#<V?@W2+BQLH)M-\*VEQ;6\]MX>LWATB":WAEBLT>*-E
MUC4C'V:]G3G[*&8)1JP4Z52KF>'Q]#%5JM%M7YU4RV,:4*D8TZ&'QE!2:Q49
MT\8-Q]LWS<U6KA)QE&;C4HTL'B,#B*%"G5<6^6$J>82YW#GJ5Z^&Q$K2H2A/
M\?M2U+_@E_\ #S4_A%XD_8YU3]G?P5\?1\&/C9-\"?&7[/=C8ZOX=T/P1IWP
M9U/6M3\:_M(Z3\'Y_MWBGX)>'&TGPQJ=W)\2XM4:3QP/#T6@_P#%9W\<C?)/
M[.7QP\9_%K]G#]M+X*?'7XU?%#XH_%G1/V26_:7TKQM<?%G]FWX^_!:SU72+
M'Q->Z#\6O@%\6_V??!_@;7? ^FW/C_PSH_B;PW\(OC#X6TOQ3X7LM&L-2\.3
M:M8R:W<1_P!"_@?X)_!GX8ZQXF\1?#;X1_#'X>^(/&LXNO&6N>!_ 7A7PGK'
MBVY666<7'B;4]!TFPO=>G$\\TPEU6>[D$LTL@;?(Y/FGBW]DOX+:Q\,?'_PE
M\$>"/!WP<\)?%K5K.]^*T'PI\$^%?!=QX_TV74K:Y\5Z9K\NA:7IZW=SXTTB
M.]\-ZWKMRESJXTG5=0%O<)<2)-'G*3DJZYZBEB*$J49SG[1X6K4G7E"M2ERJ
M4?95JU/$U:M.,9UY4)WH>UJ8:I@BGRP>'O&G;#UZ527)#D5>G3='FIS@FU*-
M2E2J4*=&<Y1I*K"U94H5Z>*V/AKXU^)_C[]F#X8_$/3M)T.#XN>-O@O\//&,
MFB^*#=V.@VWC'Q+X1T36M5L-6_LT&\M;6VO[V\A=+5?,C:-44  X\\36/V[E
M!#^#OV:9#G@CQ)\0(L#TQ]EDSZYR/3%?7]O!!:P0VMM#%;VUM%'!;V\*+%#!
M!"BQQ0Q1(%2.**-52-$ 5$4*H  %2U\UQ)P[+/\ ,/KM#B+B?A^G%5(1P>0X
M_"83"RC.M4JQG5IU\OQ;E6C&:I*<90C[.$$H)J[][A_/HY'@%@Z^0<.9Y4;I
MSEB\ZP6+Q.)C*-&G2E"G4H8_"*-&4J;J<LHRESU)MRU27QM/K_[>413R? '[
M-MSN!+%/%OCJ/80> ?-M$+9'/RY QS5?_A(_V^/^B;?LX?\ A8^-/_D>OM&B
MOG'X?8MMM>(WB-%?RK-\E:6VSGP]*6MF]9/=VLK)>_'CG"I)/@'@&;7VI99G
M*;UZJ&?QCY:16F^K=_B[_A(_V^/^B;?LX?\ A8^-/_D>IH/$O[>"R W/PS_9
MVDBP<K!XW\8PR;OX2))+"X4 'J/+)/8BOLNBB/A_C(R4EXC^(S<6FE+-,BE%
MM6WC+AMQDM-4TT[M-6&^.<&TT_#_ ( LU;3+L\3^37$*:>FZ:?WL^/)O%?[<
M<<3/%\)/@+<.N-L*?$;Q-&SY(!P\NB+&N 2QW,,@$#)(%4/^$U_;N_Z(A\#?
M_#GZS_\ *JOM*BG4X"S.;3AXF^(M%))<M/$\(R3:=^9NMP?6E=Z)VDHV6D4V
MVU#C?+XJTO#O@&H[_%/"\3I[)6_=\4PC;2^U[MW>UOBW_A-?V[O^B(? W_PY
M^L__ "JH_P"$U_;M[_!#X&_^'/UG_P"5)K[2HK/_ % S7_HZ7B3_ .#^"_\
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M_MI_]&U?#K_P]-I_\HZ/^%D_MI_]&U?#K_P]-I_\HZ^R:*7^HN=_]'5\1?\
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M/\0E?;_JNMCXY?XZ?M-HQ4_L<ZXQ&.4^+W@)E.0#PP7!QG'US3?^%[?M-_\
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M]QHTA_8T^([!1DK'X^^'TCD#LJ)>EG/HJ@D]JI_\-*?';_HR[XJ_^%CX&_\
MDJOM&BE+@WBYOW?%SC**LKIY%X;2UOO?_4:.ZTM;S\AQXLX52][POX6D^C6=
M\?1_#_6Z77_+S/B[_AI3X[?]&7?%7_PL? W_ ,E4?\-*?'?_ *,N^*O_ (6/
M@;_Y*K[1HJ?]3.,/^CN\8_\ AA\-O+_JB/)_?Y%?ZV<)_P#1K>%__#[Q]_\
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MTYRF_P"\K0_Y]5'!.^LERQG&4E]B3C-<].\I4I7IU.6K"<(?D9_PY_\  _\
MT?O_ ,%9_P#Q8A\<?_DZO(_C_P#\$C?$&F? KXS:C\!OVY?^"K6L?'"Q^%GC
M^[^#NE:E_P %$?C -.U'XH6_A;5)? =G?_VQJMMI)LKGQ0FEPW::G<6]@]N\
MB74\,+/*G[GU^</_  5-UCQQHW[+9F\*ZQ:>'?#-Y\2_ NG?&+Q#JOC'X@?#
MWP[H_P (KJXOQXDG\7^.OA/97OQ-\*^"[S54\/:5XOU;P-_9^NIX=U#4;==;
MT*QN+W5[+&<G%1MRWE4I4TYRY()U:L*2E4G:7)3@YJ52?*^2"E*SM8TA'F;3
M;LH5)OECS3:IPE4<81;CSU)*/+3AS1YIN,;J]SZ^_9ZTWQ]H_P !/@EI'Q6F
MO[CXH:7\)/ASIWQ'N-5U./6M4G\=V7A#1[;Q=-J.L13W,6JWTNOQ:@]WJ4=S
M<1WUPTETDTJRAV]@KXX_8!\52^,?V1O@YK#:/JVCVZ:-JND:6=4\9^/OB';:
MUHN@^(M7T71?%7A;QI\5H;?XG>(? 7BO2[&T\0_#[4/'\/\ PEK^"]1T)-;G
MO+U)+VX^QZWJT_95:E/7W)RC[T>65DVES14I<DK?%#F;@[Q;NF8TY\\(RTU6
MO*^:-UH^65DIQNGRS2M.-I+1H****S+"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:RJZE
M7574]58!E.#D9!!!Y //>G44 %%%% !28&0<#(S@XY&>N#VSWI:* "BBB@!"
M 000""""",@@\$$'@@C@@]:CBMX(=WDPQ0[L;O*C2/=CINV*,X[9SBI:* "O
M'?VA?C-HG[.OP(^,?Q\\2:1JVO\ A_X,?#/QK\3]:T/0#9#7-8TOP1X>O_$5
M[IFD'4KFRT\:E?6^GR6UD;Z\M;07$D?VBXABW2+[%7A_[3/P6M_VD/V=_CC^
MS_=^(KGPC;?&KX4^//A=/XJL].AU>[\.1>./#6H^'7UNVTJXN;.WU&?3%U W
MD5C/=VT5T\(ADGB5RXQQ/MOJ]?ZNKU_8U?8+W-:W)+V2]]J'Q\OQM0_F=KG1
MA/8/%898IVPKQ%'ZR_?TH>TC[9_NTZFE/F^!.?\ *G*Q\(?L]_\ !67X8_%"
MW^(]I^T3\"?CM^PSX@^'OPFT;X]2:)^TKHOA86GC/X'Z_J\7AFT\?^"==^''
MB7QSI>OQV_BBXL_#>J>%U:#Q5;:GK'A^"'1[QM;M%KZ<\+_\% /V-O&?A!/'
MOAO]H#P1?^$6^%?Q/^-4FM2'6-/@M?AI\%==MO#'Q;\0W\&IZ59WFG3_  Y\
M07EGI/C#P]?V]MXFT.\O+2*^T:+[3 9/STTG_@C]\8=<^'OQ/L_CG_P4,^)_
MQ?\ C;XG^#GP_P#V?_A?\6].^#7P^^$V@_"+X/\ @/XC>'OB==^#(OAK\/=6
MT]?&<'Q(USPSI>C?$[5-4\8:=K'B'PA;Q^']/O=#"R7DW@'Q._X(Z>,-'\%_
ML@?LN_#VXUGQOX)L/VQ?C-\<?C[\<M+M/A_\(_"?AC]FGXP:T_C3XX_LSWOP
M^M?$FI^(_$6E?&K66\-^&O#]EX5TB^LK#3O#$>I>*]7TN32[:76>UQHSK1IQ
MFJ4:C]E3J.,YPC4JXRI1P]7$7Y73IT,%5PV,S)IJ/M<)CL/@G4^LX.4.*#J1
MI<]2+G*%JE:"G",Y4Z6 IU\13PT5&U2I6Q]+$8++X2ESNEBL%7Q7*Z&*C/\
MHV\/:]I/BK0=$\3Z!=C4-"\1Z1IVNZ-?B&XMQ>Z5JUG#?Z?=BWNX;>Z@%Q:7
M$,PAN8(;B,/LFBCD5D&O3(HXX8XX8D6.*)$CCC10J1QHH5$15 5550%50
M   *?64^7FER*2AS/D4VI24;OE4I)13DE9-J,4W=I):%QYN6/.XN?*N=Q347
M*RYG%-MJ+=[)MM*R;;U$(!QD X.1D9P?4>AY//O2T45)04444 (%5=Q"@%CN
M8@ ;FP!N;'4X &3S@ = *6BB@ I&565E90RL"K*P!5E(P58'((()!!&".#2T
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img143810944_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img143810944_6.jpg
M_]C_X  02D9)1@ ! @$ D "0  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %V KH# 2(  A$! Q$!_\0
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M-S;317%O<11SP3P2)+#/#*@DBFAEC+))%(C*\<B,R.C!E)!!J6OX(?'.N?\
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M_:Z9IMG&\B0I)=WU[+!:VZ/-)'$K32HK22(@)9U!QM&\>>!_$7B/Q7X.\/\
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MF\.?$KQ5X#T-Y_!MYK2>*]8\):A/ ^E#YMU+Q3\5/VJ/^"=?P>^&7[07Q?\
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M?$S]E^^B^'^G^+H!\$_"-UJ7ASQK\+_#'P_\8Z7\+K>2P\5F^US5]/@M+/\
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M3X\\>?#/PU^UY^W[KGQ%^%EOX7F^(W@_2O\ @I=^U+>>)/ ]MXWL;K5?"/\
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M\/1VDXM-0DO-$TCXO7FHP1V%T5L]4DBB9=/N62UOV@F=8SQ/P9\(_MQ>-?\
M@VA\17WA_P ;?%_XL_ML_M"_LG?$OXNZ1KVM^(;_ %+XK:YJ'QPU+6?&NF:+
MX=O[F:.XL]9D^&.O6VE^%M,THV<5EJ$MI9Z'#:_Z(B>'_#WXI?L,:9\)/"WC
M?]C#_@F3\>]!\6?\$[OV*_C/\0O!W[0-[^S?\0_V?]3^%_QEN_A'/X-M?@A<
MV?B#P[X6\;_M#_%#XD:O>W$OB:RT^P\=Z!:ZC;2>++W5+C4)$OH@#[X^&?\
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ML+&*"UMHM[,WEPQ(FYF;&22=.BFNRHC.YPJ*S,>3A5!).!DG !/ )]* //\
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M]F/7_'WPI\':5KVO>+OAGX1^(4MU/K-E'H&M:;:7!TF2^TZY8VD3@%OX*?\
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MIXE\ V/P^TB:?XX:)X,T6[:+6+_0KZ5KG6KE6Z_X[?%K]M3XS_L:S?MSZO\
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M]LAFC/JA;XX$J>!R,&OV)HH _''_ (</_P#!/+:B_P!B_M-;4D,R ?MQ?MC
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M4I>:C_@A#_P3T"A!HW[3801- %'[<?[8^T0N=SQ ?\+OQY;-RR?=)Y(IL/\
MP0>_X)XV[^9!HG[34,F"-\7[<7[8R-@]1E?C>#@]QT/>OK+XE?M->)/AM\1-
M/\ VFA6WCC6K#PKX0M-<L5U+3/"FEW/C#Q/:>)M?OM3GUJ\BOWTC3/#?A+P-
MK?B+4K9;>X0:=J5JREIHX5FY7XT_M4^,].^%GP%\5^!M#UOP]K7Q:T74?B'X
MDTS3O#ND>/O%'A3X:^&/!,WBOQ/J.G:%JFM^%M+U:6UEO-"A6XGO[7S+2Z>2
MVMI;MXK8^9@_#CB?&U<GC3HX.G1SQ<^"Q57&4HT_8O 8O-(XBMAX*>84\//+
M\%B,53KK!3IU5!T:<IXA2HQ]S,O&O@7+*'$DZV)S*MBN%9*EFF P^65YUOK/
M]KY=D,L'AL94=+)ZV,I9QFN#P-?"O,Z=;#RJ+$5H4\%*GB9_/0_X(1?\$]1,
M;D:/^TZ+@YS/_P -R?MD>:<C:<R?\+PW'*_*03R..E(W_!"'_@GHYD+Z-^TX
MQE=))2W[<?[8[&22/[CN3\;R79/X2V2O;%>E^'OV_?$GAS2/[.^(WPU_M_6_
M"_@:UUCQAXB\)^(-'MK&[\0:GX8T[Q?H/V#1Y#<P1>&M1TG7O#UEJ?B:WU>[
MT_2];O[E8K:?2[07;[K?MQ^);S68=.LOAW9G6-(UO4_#%YX;TCQIHVNZ'XOU
MVZ\4>$O GAU=)\<)ID$-EIDWB+6_$-REZNFRM):>$=86YBC:(HOHU/"'CNG5
M<'EF$E1?,Z.,AF^5O"XFFX<]"K2D\6JL:6)C*A*E4KTJ,:<,5A:N*>&HU547
MC4?I&^$U?#QJQSW,(8E.$<3EM3AW/XYA@JO.J>*H8BFLN=&>(P,X8J%>CA*^
M)J5JN7X^AEZQN(P[I2\ \0_\$ ?^":GB[1=3\-^+?!'[0'BKPYK:B/6O#WB7
M]LS]K?7]!UB,.D@BU71M6^,]WINHQ"2..3RKRVFCWHC[=R*1K1_\$(/^">4,
M=K%#HO[34,5C''#911?MP_MC1Q6<,2+%%#:QI\;U2"*.)$BCCB5$2-5C50B@
M#UVX_P""AM]9Z3#<7?P6EBU/5[3PW=>&XH_B!IL^A7D>N0>-;[S-:U[^PHDT
M%+O2O!%YJ_AM)+.\GUO3]4TF26/36EN5MO:/AE^UG=?$OXGZ'X'M?A?J6CZ!
MX@/BZUL_$M[XFTRXU*WU+P/X;\*:SXFBO_#-G:RR6^GZ7K'BF'PC-JBZI+#+
MKT0BMXY86>2/AQWA?QOEN'Q.+QN3TJ&'PF&QF+K5/[7R6HOJ^ PZQ6)G25+,
M9RQ#A0YZD:>'56I5]AB8T85)8;$*GZN4^/'A9GF,P.7Y7Q)6Q6,S'&Y=E^%H
M?ZO<3T9/%YMBW@<#3KNODU*&#C5Q7LZ52MBY4*&'>*P4L15I1QV$=;X^?_@A
M+_P3XDW&32OVGI"T;0L7_;E_;(8M$S!FC)/QP)*,P!*GY20"12)_P0C_ .">
MT<:Q)I'[3J1+OVQK^W)^V.$7S 5?"CXWX&\,P; Y#$'J:]G^#O[4GQ(^)'[2
M,7A0ZAH\GPP\0^*_C9HWARR_L31LS>'?A<+72].UC2]?TKQ-J7B"76;[Q!%J
M)U.U\3^&="T/^R55M'U&^O6@B=UM^W'K6C:E\1!XB\*^';W07U7Q7??"'6I/
M&%AX<MM=T#1?'T/PSTS3];2:QU&2RGUC6-,\3ZUHVI0-?SZW8:5?0VNEQ""W
MDGZJ_A3Q?2Q?U&EA\#B\6LOR_'RH4,=3IRA_:.,QN!A@G+&+"0>/PV(RW,%B
M\/"<HT88/$5(U*D*4VN'"_2!\.*^7K-:^,S/+\NGF^<913Q6*RRM6A4_L;+<
MJS6KFD89;+'U5E.,P>>90\OQ=2G">(JYE@Z$J%*KB*<9>*#_ ((0_P#!/0
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MR<@'/ IS_P#!";_@GQ*T;R:5^T^[Q,7B=_VY?VR&:-B "T;'XX$H2  2I'
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M06FH_$74O$EWJ&GVMOI>E>&]'1[R"WA%U>QMT#_@J3XFU7[!?7/PETRQBNM
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MUJE>%"?MG-1EC"?BX\0HSQ7@3/!U,/0I1K4Z68*OE"P\)YC@**H2Q4Z>9X?
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M^R'JG[-'ACP_!%J>KRZ?J>N> M:OK?QH;[6(KG1=7L;*/0VTJ#BY7Y[^%O\
MP0P_:/\  PUKQYXD_:L^&WC;XW7G[27_  3T_:7B\0ZUX ^)&K^'-?\ %W[#
MVF^/_#6MVOC&3Q#\2]9\43Q_%K1?&YU=CX?U31=(\&:[:#2]!\/Q>&X[>SC
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M^(/B%H-OID&HW>J176N_#ZZU:Q:.^G(L-5O=,5VLH+69H  >.:A_P6:E\)?
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M^&?AJRM-%\)_98(8-,T^WB@CA*J*]AA^#_PQM_BY??'J#P3H,7QDU/X>Z?\
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MO:WUEK@<VU_)%<26-Q:3PL > ?\ !)73;C1OV>?BUI5V-0%UI_[8W[5]K/\
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M&!M*G>/3[F[>Z:%9_P!BJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+>8\7B_N+S5/VL?[)O\ 4]5:9/$4NL6-G=6%S;>%1=)-^VM% '\V/CSX$_\
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MHGB%/C7XLN=3^%<WQ2EUJ]\2V>O>.[#1;G7]1L/&6E_#B/PU:S:8/I[]HO\
M9G_:/U+PA^Q9K?PE\->+;?XL?"']E_Q]\+=6U/PK\0+/PU-X)\3:[\/_ (5V
MNI6!DDU[3M DU+Q#I'A#QUX+\,>+(]/U>#P[XPU/PYJC'3K01:M8_M)10!^*
M_P 2+#X[?#C]@O\ :-GU"'X\>#--U?X\_#0? KP3>_%"*\_:(\+_  =\1?%+
MX)>'=0\&O\1K?Q/K$FDZSXEU6?QXN@VVH^-]6NM"\/>(;'2[_P 0Q1KY-CYG
MK'[.7[>NL>$_B_JGA'6OC;X1GL/ =S!^S/X9\0?&"+5?%'A#PCKO[1EWJ/B?
MPAXGC'CD:1XC^+DG[/L.K:-X/UGQ/XJU!/"]KXB\/>'8_'5IK>DSZYI_[X2Q
M13H8YHHYHR48QRHLB%HW62-BK@J2DBJZ'&5=5888 B2@#\7=,^$?[>TO[-M]
M\.[7RO$/@O4_$?\ :UEIOQ>U'[#^TMHEA;_&?P[KGA_P]HR:;XN^(/@&#P)I
M7A#3[F:&T\:_$?Q+X\M-*:33+K4I[V*RMH?$O$G[$/[4'C^'X.Z-\0+3XI^-
M]$U+Q]\#?BI\6;#QE\:+W6=+TKXA^!?VH?%>N3:[96K^*#_9UKX>^#VH:,!H
MWAF)='N],TO1+?\ LV]\0:1%*/Z#Z* /YZ?&'P[_ ."B'C7X=6FCWGA3]H_P
MOJ'@'X2_LY>!KHV'Q'\&ZS%\5/BQX&M_C];?$GQ%J6G>'?C'X(\63>!M8UC5
M_AA>-XUT3QSX7\73W*>'?$=YH&O:5X:U7P\^WJ?P0_;\%WXAO]1\,_%2TUKQ
M-=>*M4^%UK\,_C3H=CH?PS^/VIP_"4:9\2OBSJSZOX?;XB?#.WTG2?$FD@ZG
MHGB>6YBTSQ79ZAX*:]\::1J"_OW10!^9/[(?P;_:0^'GQ:L/%?Q1UGXDZEI?
MC3X;_'>3XGQ>+/B3<>+_  VOQ%C_ &DQ>_!A_#_AN\UG4K;PS#!\%KW4[;3(
M?#5M8Z?!H(LM+UY9-8LK<CX3^#G[)/[=.G>*_AUX%\6>*?C7\,_ <'@/P=X2
MT"?X8:]X1A\'?#[P-+\+_%.B_$C0/%U\?B=I\T'B>?XDZC:^)H)]"^&OBWQ!
MJ$Z>%;WP]XXT2RTC5K*T_HBHH _GJ\5_!#_@IMXST?X?^-/&WB3XQ>&=?\4O
M\1D\4>"?@YXN\):UJ'P]^)'A"3X;?#KX%>,(QK?Q1^'WA>S\*^)O"G@CQS\3
MM;NS>^--'TCQ+\2'M_%WP^UJY4&T[?PA\"/VN_AU\<_A%K,VC^/6^'6G_%3X
MJ:W\2M,OO&>A:-\&;'X?>+_C_P#'#QCXT\=3R>'/'VERP>)-;\&^)O#FO:UX
M*\8_#;X@:!XUMSHFFZ%K'P\OM(U1U_=ZFNB2(T<BJZ.K(Z.H9'1@5965@0RL
M"0RD$$$@C!H ^0/V"K?6+;]E3X9)JD&HVNGRW/CV\\#6FK+(FHVGPIOOB1XN
MO?A%;3I*JO''#\,I_"B643*&AT\6D+ -&:^P::JJBJB*J(BA410%5548554
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M?TZ3QWIGAG4?!FG^*&B8ZK:>%M6U.PUC4M#AFW[5L;S5-+T^]FCV%FGM(6#
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MUJSL[>?6])\,^*M)\22:1.X6.XBF?3YO/^SPW9>VCNI[2U\\H"88G;RE[2@
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MQ1EU&R_:D^,>DV4]_P#$3PA)H?B[6H+73(;>PBTS7-6U+2A:6MI ;+9:VWE
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M7Y%\F;Q)8:1(^D6.OR:E::4QT^&VKY>^,W[=7[+'_!,:70OA_P#MA_';PO\
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MGQL/Q3\-KIGB)EM/B!H-E"^LVLEM_9TFMZ<+FXTQ?$EKIS$_8IHM6L=0\/\
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MOB/3KW3O*U+3)["2UO(;J.[TV[=;>\@M_P"A:@ HHHH **** "BBB@ HHHH
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MXN4U&_L+>^OK>%[>RG=/*_VL/^3;?C3_ -B#KG_H@4 ==\1KGX@VGASPK/\
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M):^A_P#@B.^NO_P3+_9N?Q/_ &'_ ,)&T/Q+.M_\(S)KLWAW^T?^%M^.O/\
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M\*ZM=7N@P_%7P;-KVJW\'B?0=:6.V\*:+!J/B!9K1K98OLDDM['>P1B"NP]
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M?ZK=:Y>VEI!;W6L7T%C;7FIW$4:K+?7-OIEK9:=#-<N#+)%96=M;(S%888T
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M;^']5\0W"7.MZM9^&].ALFU75)(E2!;S4KA)KZ:"VCCM+5I_LMI'';0Q(O\
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M^,O_  0-_P"4;G@O_LX#]LO_ -:U^,U?LU7XR_\ ! W_ )1N>"_^S@/VR_\
MUK7XS4 >!^,O^5H#X,_]H?\ X@?^M+K7UO\ M->%?BN_[&__  4!_95^"GA/
MPWXT^*EI\*?B/?? #P%XIL-(U+1?%?@CXPZ/KM[HWAFUTGQ"ZZ3JSZ%XC_X3
MCP7H5EJI&DQ7&F>&+&_DCLY Q^2/&7_*T!\&?^T/_P 0/_6EUK\W_P#@M-\!
MO@Q^TK_P78_8^^%?[17A;Q!XP^"\_P#P3[\3:OXKLM ^('C#X=W.@7;_ !Y\
M5>'O#OBPZQX+U;1]1FM]-\2:YH]KJ5G<7)L&TV]N+RYC8V$+1@'K/_!LQ^R_
M\0_V7?$7[4VEZ)\"?BQ\&OV9_%'AOX5RV^H_M&^ T\#?%C7_ -H;1)->TWQQ
MIOAV;5[.Q\6:QX!TCPY_93ZBEVLWA2P\7WEP_@V>:+4-6E?^MVO\_'_@K-_P
M24_8;_9!_8J\6_'_ . O@+XF^$?BUX,^+G[.^DZ!XAU;X_?&3Q?;6%EXG^,?
MACP]KD$FA>)O%VHZ3<FXTN[N+>)[BU=[.1EN+8Q3QHX_T =-_P"0=8=_]"M>
M3R?]1'U/>@"[1110 4444 %%%% !1110 4444 5[JW6ZMKBU<E4N(9('*EE;
MRY5*. R,CH2C, Z.KH3N1@P!'QMX%_97OM&\3^'[[Q?K\.NZ'X=\.>&K>U6T
MU;Q)_:5SK7A:\TRXT&RNH[^>>UD\/:!<:9+K>GS^=_;%SJ^MZG%?22665G^T
M:* /Q8\+^ OV5OV8/^"C7B3XSWWQHU,?$_XO_#3XI:;\7M5^)=Y8:!H*:II.
MM_"[5-'L] :W\+^&?#J7,>F1S&:VTR\OW&GZ>]U<*K++.WZ":I^V[^QUH7V0
MZ]^U%\!= &H0376GG7OBGX-T0:C:6T2SW-WIQU35[07]I:P,MQ=7-H9H+>!E
MFFDCB8.?7_'/P[\$>,+O1_$'C"V24^$=.\6P65U<7GV6RL;'Q9H;:)XBFNM[
M+;X;2@ZI<S$?8_FF1E.XU^,W[<?[$O\ P3__ &M-?^%MI^T!\/?B;XNTO]FC
MX<?%OX/> O#/AJ]O?"VF6FE>./!?A7PYJOB75O%.AZF-3U/2O$_AM])\*>&+
M[['J!&J7TFK/:VJQB](!^DNG_M^?L-:O=PZ?H_[8?[,NLZC<MLMM.T;XX?#?
M5M1N7/1+:PT[Q'<WEP_3Y889&Y''-=6W[7W[+:R-"W[0/PE69+B.T>%O&^A+
M,EW-$9X;1XFO!(MW/;@W$-JRB>:W'GQQM%\]?S6?L7?\$/\ _@EM^RAJ_P -
M?CS\/_"/[25[^T-X/UC_ (3_ ,*:[XFN9[N\LB/%?AT+\-KGP'-XKG\$ZAK:
M^'M>M-.COY;O+Z9>R:[/=V^IPC3A_1OX$^'_ ,)_BW+J_P 3!X%U#2I[WXK:
M/X[LKJ_9X(->U?P7X.M?!_A;Q3IULUO %T:\\,7"1-8/"(FOX[EYO-GC,K@$
M/B#]J_\ 8M\2Z1=:#XI^/'[/^O:%JL=NEYH^O^-?!FIZ3J4):"^M%N+#4;R:
MSO8V9;6]MA)%*CC[/=1 @Q2'6@_:M_9,U.XM->M/CC\&]3N8(+NRL=;M/%GA
MW4)(K:>:'[?9V>J6]Q,4AEN+2#[9;P7 1Y[:(3H9(%"^2?$[]C[]EGP]X7TS
M6_%'@7Q%?Z3X:G\"Z+;1:)J%Y<7EO%9V7A?X=:%<7$:W%MYEI8Z=IVCMJMR\
MN_RK>ZOV6:X=EDN?LGQ?#/P-IMO\#/AOX*\;W7A'1[_X@^)++Q9XF\,6-IH^
MFV6L>*5U_0])74X[F^DU%=9L/$,U[X?O+LVVH7>E:>\VI6EG=O\ 9D .L\!_
MM"_L7_#;PAHWA'P1\;_A+I'A*P.JRZ):GXD6FJPDZAJ&HZ_JKVVJZOK.HWE\
MIO+S4;Z7=?7"6D'FJGD6=LL</23?ME?LE0E'N?VC?@K"076)[CXA^%XOF\N*
M218WEU!<MY,T$KJASY,\$C#RYHF?I+?]G#X2VOA7P7X-B\.8T+P!:^([/PW"
MUR[3V\'BKP[K_A;6%N;DCS;QIM'\2ZK%$TY8P32Q7$>)8(V'B/Q3_8[_ &98
M/!NI>)/%/@;7]4TKP-8ZSXJ>RT"_NY=6ECM?#/A_2KY;.V6:V%Y.VB^#M)CA
MMY)XX_.AGF+HUS,Y /5K;]KW]ER^C\ZQ^/\ \)[^'S&B\ZQ\;:'>PB50I:(R
MVMW+&)5#*6C+;U#*2H##*+^U_P#LM,(67]H'X2LMR\T5LR^.-"9;J6V$C7,5
ML5O"+B6V6*9KF.$N]NL,S3*@BD*^.?LX-\+_ (<:M>_!SX=>%?$^K>'M;\<>
M+O$L&N:QH5C;:;H%C<6*106UE<)-J%_K.DV^K>']3\.R:QJ:Z=<QZM;E9(YK
M:XLKB?Z&L?V?/A9IT'@BWM?#RK%\/=;\;>(?#*O,9/L^I_$"#Q);^)9+G>I^
MV17$7BS61;0S[H[-I8&@"M;0E0#DC^V;^R6HW-^TA\%E79'+N;XB>&%7RIDB
MDAEW'40OE31SV\D,F=DL=Q!)&S)/$7\:_:)_:B_9R\:_ #XK:/X/^-WPS\4Z
MIK7A+5](TBQ\.>+=)URYU/5IREI#IEC%I=Q=O=:A)=.ELMI"'G$[K&R*V0-[
MQ[^R!^S3X=\$>(M<UGP-X@U'1O#G@K3+:^L-#OKJZU>X\/\ @3P]X6TRPM[&
MW\ZV$][#I'@30U=VGB:ZEM[B:>4-=3LV'^S"/A/\)M0/P*^%_@_QKJ/AW5/&
M_P 0?&EAXEU;P[:KH>@6NMWE[K4MO%K*7-]>WUDOB*UUK0K.^U-+"Z;4+.9-
MCVPLIK@ ^AOB9H'Q:UJTT)? .M0:"^G7\<JO;WIMY+FUN?!OBC3KI/$-K>6D
ML%Y:V>O77A^\TRVLI5F6Z@^U7.Z*V,3_ "[\1_V:?B+\3OV9OBKX#\9_%N_\
M :G\6_"\'A+Q5K'C>^A\3S>"?!>GZAK9ANUUC3]<TS2KCQK-IU[IT5WXE,ZV
M)BM+:"[M+RXM_M3_ *+51U/2],UO3[O2=9TZPU?2[^%K>^TW4[2WO]/O;=\;
MX+NSNHY;:XA; W131NC8&5.* /@G_@FAX$T?X*_LA>"_A);>.+#QO:?#?QG\
M8_"EOXS%Y:%?$\&F?%[QM''K>Z*[NHB+S?PR7,ZMM!$C9K[\D2TO83%*MO=V
M\JHYCD6*>&1-P>)RC!T==R!T8@C<H93E01\*ZO\ L9_LN_#V]N_BEXL\+^#+
M30="^('C[XFZS%>>!] _L<CQ_I=OH1T:]M+#3)'FTC0[MH=2TM%MI&347:Y=
M%=Y96_E^_:K_ ."!/P?^*7C*YN?"/_!1KXN_##X@_$O]K'XJ>)M7T#17U^W^
M%WA/PWXWUBPU2_\ ASX3FT^W6]L;#P;X>TJRC\%7]^O_  AEIJ<OBBRGU"VC
M5(D /[,--^'/PG\,7FE7>D>!/AYX>O\ 1X=2MM#N=-\+^&])O-+M]:FNI]7M
M]*FM;&WFL8=6N+Z]FU**S:)+^:\NI+I97N)6?C=>^ 7[./B?PMX[\%:U\)_A
M+>^%OB?/J-[\0-&'A/PO;VOB_4M3LAI-]K.N?9;.&2^UR2T$=LFN2R'5K=HX
M6M[R*:*)U_#+]BK_ ()G_LA_L.?##XO?";7/V@O%/[46E_%[PU-<:%XY^+7A
M]?$GQ5\&:C'K?BGP-K\OARXELO[.L;+2KJ2SN[&TAE@UJ>ZT75]22TGTVUCF
M/Z@Z]_P3A_9\URXU&==!TG31J%SI-PL5CX7T&..T72OA1K?PP$%N%MTQ%=3:
MPGC6Y!YD\4Z;97;%F0O0!9^*?_!-;_@GY\:-"^'6A?$3]F?X,Z[;_"G5?A]K
M/@G5O^$<TBT\3:<_POETV3PI97_BRU2+Q%KVBV\&D6ECJFDZ_J>I:?K5@)K;
M58+I9I"?R0_X*7_\$)?V1/C!X8^+/Q/^!WP,_8_^%OBS4=);XAZ[XSU6S\5?
M#^Y\-^,?"NHZ[XW\0_$.[O\ P+JYT+6K'6]-AA\*/X4NM \/Z1I+ZQJ7C6YU
MB^N],T_2Q]4_$[_@G=^RQX'\1)JEQ\1+'1_$'AKQ3\+O'E[X:\0^'%ET.X\/
M#QKIL,^GW5OHNGSW5S9:]9>'=?M&@MA,D++/<:K'#I(N9Q]OVO[-'[)'QVT;
MPGXJ\'_#7P!!H'AGXBW.JRR6'@#1;.U\5/X5/B#PUJ7A_5;6]TV(WOAJ_NKR
M2Z*O"]O?K:6-PB20.C$ _P Q3]BKX)?L5_M(?&WXQ>#/VE/#/CG]F+0]:T_X
MG^/M-UWPWH>A^/-&^&7@OQ%?VFO_  [\/>!W\?RZ;XE\02^)/$MW=>!O#GQ!
M\5R>*-#\62ZQI&FV5KI"SV6OQ?V<? G_ () _L?>-/V=O@_X.^''_!.;P_\
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MV>LR7^NW=@-5UBZTR"TU/Q#=H!'9W5U+)?/:AA714IX>.'PU2GB)5<14]O\
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M7\%_"\3C^%L6WQ*\0WL:GNL]C%,O.8>F?QE_X*Y?'W]M7PWI'P/M(_#/Q/\
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M-TLF4_<_C+_E: ^#/_:'_P"('_K2ZUXY^V?8V.J?\'%7[.^EZI8V6IZ7J?\
MP2,^-FG:GIFI6EO?Z=J6GWWQPURVO;#4+&ZCEM;VRO+:62WNK6YBE@N()'BE
MC='92 ?E9_P5M^,_QY;]A[XX_LO_ +3"? +Q)\4/"ND_\$_OCYIOQ+_9E\9Z
M]XR^'FM^#O'W[1VA^$4T3Q@/$-NEYH7CZ+5] FUFPO;2XET'QWX<OO\ A(]#
MMK"WBDME_N_TW_D'6'_7E:_^B(Z_B^_X++_L^? C]GG_ ()6_&O0_@/\'_A[
M\(-)\2?'S]E+6/$%CX!\-V>@QZUJ4'QU\'V]M<ZG+ &N;L65NS6VG6LDYLM+
MMF:WTVVM(&,9_M!TW_D'6'_7E:_^B(Z +M%%% !1110 4444 %%%% !1110
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M>I6#^+M)ADAU=-0_I#C4HB(SM(415,C[=\A4 %WVJJ[F(W-M55R3A0, /HH
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MU*\\-?!KPYJ?QK\464YM+^7PO=6MC\/O#MT.7C\5_$V]$GANPE@ <3Z3H?\
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MP7_V<!^V7_ZUK\9J^?/^#8W_ )1K^(O^SR_VO?\ U;.H5]!_\$#?^4;G@O\
M[. _;+_]:U^,U '@?C+_ )6@/@S_ -H?_B!_ZTNM>3?M@_\ *QQ^S3_VB8^,
M?_J]]9KUGQE_RM ?!G_M#_\ $#_UI=:\F_;!_P"5CC]FG_M$Q\8__5[ZS0!X
M!_P7X_Y1A?%'_LM7[*O_ *OOP=7]<.F_\@ZP_P"O*U_]$1U_(]_P7X_Y1A?%
M'_LM7[*O_J^_!U?UPZ;_ ,@ZP_Z\K7_T1'0!=HHHH **** "BBB@ HHHH **
M** "BBB@ KSH_%[X6#QC8_#[_A87@X^.-2FU.WL/"B^(--;7;JXT8L-4MH].
M6X-R;FR9)EFMR@F#VUVJHS6ER(O1:_-[P1^QQX\M_%_PBUOQ)XF\+Z=I_P %
M_B[\1?']K?VGA\WOCOQI+KOBWXFZKINIW7BF'5H+,V'BOPW\37T7Q1HGB30=
M6O?#UYX>-[X1O]/EUJYND /T''B3P^=<N/#(UO2CXBM-.L]7NM#^WVW]JVVE
MZA=SV-AJ$]CYGVB*TO;VVN+6UG>-8YYX9(HF9T8#7:2-2@9T4R,$0,R@N[!F
M"IDC<Q56(49)"L0, X_&/XD_\$L_'_C35/B-=Z)\=?"OAY?'#SVSZU+\-+G4
M_&^J0W'B?XD>,+/Q-XN\37/BEWU'QMX9U/X@0:7H6J:-::(3H'AK3+/S[%V4
MVV_X7_X)Z_$?4?$OAWQOJOQ#G\(:AX"_:(U+Q5X!L=9:;QAJ6@? [0-5LKSP
MSX-@2TUYO"T]UK^JCQAX@DGU6RU+5=$L?&UG;V^I6.I:#/;7@![G\3_V _#O
MQ+^*7QU\:W_QZ^*_AOP!^TC'\,H?CY\&- C^'5MX6\<Z5\,_#</A+3M$F\4W
MW@V]^(?AS0O%.@VJZ5XOLM"\4Z>^L6$E[:VUS8+=2M7SW\3?^"9W@+P[=_&'
MQMX*^(&H^+_BY\8/ ?QX^$/P^\)_%OQ5X5\.Z%'_ ,-!ZMHOB_5K"?QII?@;
M4?B1X@N/AFWA2#7_ (96MS>ZS>^&_#_AFU\/Z9%;V=O'J=GO^)/^"?OQ%^('
MQ8^+_P 3-4\3> O#EOK'Q@UGQ?X8\+:AX>U?Q+H_Q9\-7MAX.M;/1/CZEIXI
ML$\2>$-"F\/W.H^!_"UA;Z9-X<UR1-4N9KH"2"[VOA+_ ,$W=6^&'Q=\*?$B
M^^*NF>/++P9XS\%^+M-L?%GA2]U76=1U70? ?BCP+K'B:;7=7\0:OJ&A^)[F
MP\2M_9D6CW)T"V%E&RZ;;//,M 'UC\*?@E\.])_9)T7]FK0_&+>(_"%I\(=:
M^#^N^-],U&SN=9UV^;2M3\'?$/QA<WDAOK<^*-3\42^(M8UR>Y2Y2/Q-<7PN
MXW=98SF>&O@C\'?"?C_X'^.+'Q_=W6M_LY_"F^_96T#3Y=;T.YM;J+QI%\,9
MX+;Q5!:V8NH_&D\'@/PU/I]O#+IL+PZO=2MITD=U9M!\5>-O^"7GC7Q5XPU3
M7$^..D1>'I],^)EK9^'E\':IH]S<_P#"Q-:UG7SI6MZ_X;\3Z7JU_I6CZSJ,
M&KVC33W$!O(VCDT:2W61;ST[3?\ @GEK5C\#/'_P@/Q4TF+6?'OCKP%X^U/X
M@Z1X'BT'6;[5/"O@#P[X*U&+6+32-4LX;TW \/02Z7>PS6LUK:2"":)Y4$K
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M>Z;-KMZHDU*:,]+_ ,%&_$RZ!^R]XFM!X<\;>([G6O%WPGAMK?P7X/USQ=/
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M]_\ !&G_ )1S?!3_ +'C]I/_ -:5^*]?0G[)'_*<W]H+_M%[\!__ %HCXA4
M>^^'_P#E8#^)G_:([X6_^M=?$6H?^"YO_)J'P/\ ^T@O[!/_ *TCX*J;P_\
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MG/C5_P""WX-__.KH_P"%*^/_ /HYSXU?^"WX-_\ SJZ^AJ* /GG_ (4KX_\
M^CG/C5_X+?@W_P#.KH_X4KX__P"CG/C5_P""WX-__.KKZ&HH ^>?^%*^/_\
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M@_:[\(: -#NI20=4M4\*?%;1(XM3@,CK9ZQ(K:CIXFE2QN[<3R!_E*U^ /\
MP;^V6?LOQD_97@W:_;^*R+?]O[6;4'Q3:S+<6WB9OLO[0L'F>(K>=%FM]<DW
MZI!(-\-TC,Q;O_VPO^".W[)?Q7\6?L7:Y\+?V8OV)?A9H7P6_;!\$?%OXR:?
M<? +X7^&4^*OPLT[X?\ Q-\*7GPN6'0O!"6GB:76O%GBWPGK-OX:\2$Z#>76
M@07DBOJ-AIRG[8_X=M?\$Z_^C!_V+/\ Q%GX&_\ S"T 6]-_;S_8 TC3M/TF
MP_;9_9(BL=+LK73K*.7]IOX17<L=I901VULDEW>>.9[NZD2&)%>XNIYKF9@9
M)Y9)69V^:?VEO'__  2M_:UM?"5I\5OVV/V=I4\!ZI_PD7AUO"7[7WPN\--8
MZS;SVMW8ZQ<+IWC0QWEQI-Y9V]W8?;$EMH9E/FPRQNT;?1?_  [:_P""=?\
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M *TCX*J;P_\ \K ?Q,_[1'?"W_UKKXBU#_P7-_Y-0^!__:07]@G_ -:1\%4
M8O\ P7]_Y,*\/_\ 9XO[$W_K2GP^KWG_ )F5O^P\W_IQ->#?\%_?^3"O#_\
MV>+^Q-_ZTI\/J]Y_YF5O^P\W_IQ- 'P]_P &QO\ RC7\1?\ 9Y?[7O\ ZMG4
M*^@_^"!O_*-SP7_V<!^V7_ZUK\9J^?/^#8W_ )1K^(O^SR_VO?\ U;.H5]!_
M\$#?^4;G@O\ [. _;+_]:U^,U '@?C+_ )6@/@S_ -H?_B!_ZTNM>3?M@_\
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MAHUY)J&D6/B*P\/:=::U::7?S102WNG6VI17,-E=R00O<VZ1S-$C.5'H%%%
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M+T;]JSP[\"M=EL=*^,_BCQ#K?P*\1ZK9C5O#/@7P1X(\1^#([7PU\1];M7\
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M[5;?P#XN^"?B/XF?#9M"OK+0]'LH_$Z:MX;U&Q\5Z==6TUDME%;SZ5J,_FW
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M2WOIM(\*74\MM)>:[I6K)>VL4,,2-]KU$L$"2>:L,2R^6(?-6-!)Y*LSK%O
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M/'EMXCUG1]2N6N-,O;0QP+%]IT44 %%%% !1110 4444 %%%% !1110 4A(
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ML"?MB^&/B3^T1\%/$_[%WQ=_:%\<_&'XK_%_Q#I/Q;\.^$])\2?"_P".%O\
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M_@IOX)UCX^:W\,_'/@GX>WW[0^BZ/8>*YM(\*R:D_AKQ!I6EW^FR>/\ X?\
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M^+/$$'BOQ1<V]I'=16-FWB'Q-:VGB#64L[:"+4=8M+34+M);JV@EC /]HO\
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MKAK[P#XY\1S^);F_U3PUXBMK?PT_BS3]'.B_VAJ7A?3+S3;C20;F.?U3B/\
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M:5HQF\&:%((_B&NB?#;X4"3Q[J\3Q:M?Z'>>$(IO!MK/;^&DU/4([(&'[/\
MVZ_@G\7/V@?@)/\ #?X-^)-*T'7KSQW\/M9\26&M^-O'OPWTKQOX \/>);/5
MO&/P^OO'GPPBE\>>%K;Q=IEL=-GU/PWY=[Y1>U>5;6YG#3_L0>!/VF/A?\!O
M"?PX_:FU#X8^(_B!X%TC0?"MMXX^&_B'Q?XBD\>:9H>B6.GCQ3XRN_&?AWP_
MJ:^*[^X@E^WL#JGVM46^N-1EN[B95 /L"OYP_A5\.M4\ ?\ !7S7/"$7P_\
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M7CG]G_P?XN^!>HR:/+\0=4O-:^(6B_!GXL>(+74/'WP;\+^--6U/6=3U#1M
MN=1;0]0UW6+KP3>>%6NHEMOMY/\ AC&'P#\+?A?:>.?@S8> _@MJ'P\U/X9^
M'+#XG>';.R\+7?PI^R#P&;1H/$23W$6A"QM1'#>RW,=V(O\ 3EN2[EE["O\
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MQHSV_AK6!K?B.07-KXNN]<,FJS?9(]7\.1:;9IIL3ZA-<37UO_57_P $\_\
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M_AT_ W_R]K\R_CI\9_\ @DI^P%=> OVC=)^%'[/E]\1/'/QO\%_!_P /Z_\
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MTO7-;\">,-(\,:C?:3XDU#PWK-KX?U+3;V/3KZSUJ6PG&ES6U_+%/'9NM[Y
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M&[[%HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWB/Q)\.? 7@K]C_X9M\2?A1XEU_1]7\/ZCK?BKX@>&=1U/P/K,?@'P$/A_\
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M\/?#K5=!^*'[//P*\1> =.\:?MC:#\5?A%HNK?$S0?C!\/M;\;?#?X?>&?\
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M\5> ?A=^RC8P_#OX>>'+WX.Z?XT\,^-]?DU/4K[QMK6L6NJZS;Z9>>)[=-5
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M\4^-%^*4>HZJ8_AEXKL9;7XO_%CPU\7/&>DZOX7\;?#KQ%X7\4Z#J6J^&8-
MNM%\2Z3J=G>>';_4([D/JQL]6LP#W/QO^U#9>'/V>_"WQJT[P+XHL?$'Q)UG
MP!X'^''PP^(,,'A#Q-??$GXJ>,=,\ ^"?#'B22SF\06.EV;^(M7MKO5M>T:Z
M\0Z3_P (Q;W?B30KO6]+:SN;KXH\5_\ !5VW\&_#[XW:UX@^ _C/2/%?PT\6
M_M ^#?A_JNL3Q:=\&?C/KO[/GC>+PSXET?PIX[ NO%.GZO-HDDOB:)==^'^G
M:'?Q:7K]AX9U_P 1W&A:@T?O>J?L.:1X!_9(^'?[/_P1U":;6_@+\1_!OQP^
M%-UXMN=/TC3=4^(W@?XK_P#"X7T35;?PQH-GH'A/P;XLU6ZUWPI'H?A'POI_
MA[P3X:UN'3_#&AV=AHMA9IPWB/\ X)>?#OQ]:>-M)\<_&;XYZQX+\6ZW\8_&
M?AKX<W>K?#]]#^$OC3X^Z\/$'Q"U?P=JEI\/[77-6%J9M1T3PC8>,-1\1Z3X
M9TO6=;;3[(WE^EW; '5>-?\ @IO\ OAG\4/&?PF^)/A?XM>!_$WA?P1\1O'^
MC1ZQX?\ "-Y>_$/1/AIXB\*>%-1C\(>"_#WCK6_B=IU[XJUSQKX<MOAL/B)X
M$\!V/Q&MK]=3\(7VJZ6IO*Y?6/\ @IGX=\+_ !\\!? KQI\#?B[X'\8?$[P)
MXAU3X>_#'Q18>'+?XZ>/?B%X>^(&B^&;SPIX&\(Z9XEU3P!XJ\+V?@O4-4^)
M^N?$;2?BC<>%O#7A+P[K=WK]YIW]EZ@MKR[?\$@/@+<>*=>\0WWQ'^+$]KJ+
M_':YT72[1/AGI%]H6K?M ^+?#WQ \5^*;[QQI?P[MOB%X\\:>'?&WA#PEJW@
M/Q1\1O%7BN_\.:;H%IX887_AZ:[L)_1?&'_!-[PK\2O$%I\1_B?\??CCXV^-
MVA^%X]#\#_&:<?"O0O%7PSUG3?B/X7^)?AWQ;\.=,\._#73/#'AC4=(U/PE8
MZ'?Z5%H]QX<\7^%M3\2Z'XSTC7K;Q!?[P#Z#^'?[1C>)_"7QTU#Q!X'UU/''
M[//CWQEX$\<> / =M<^-M>UJYT/2].\6^$KSP3I\-O8:AK+^/_ GB/PKKNBV
M%U;6$\%]JT^F7,BQV+W\GR)X._X*;>!OC3^T!\%O@9X#^!/CG7F\2?%SXH?#
M/XH:UKVL?!S5(O@CXV^&/P<\+_&G0KN6\\$?$KQ]X5\4/J^A>+M/,L_@[Q/J
MNI>%I;;5+'5;:S\0V;:+)Z[HW[''_"P_A/\ M@^#_CA>W.B:O^V;X^\6:UXX
M;X=:Z\5_X;\(P>%O#'PL^'NG6&NS:?':ZAK$'P_\ ^&[_P 2?:-%.AZAJNIZ
MQH=UIFH:$K)=\O\ !_\ X)I?#OX-_$KPQ\6]"^*GQ&O/&GA[XEGXDS(GA[X.
M^%_"%Z]Q\"=$_9XU'P=8>!? WPQ\,>&/"O@VZ\ ^%O"\EMI_A6PTG4-+US29
M=0T_5(8M6U2TN@#(^)O[9/[0WA#Q5^UIXB\)_![X4>*O@?\ L;:YH=M\2([S
MXC^*=&^,GBCPT/A)X&^,'C;Q!X,TA_ \_@)+OP]X:\87K:/H>L^++9O$-UX<
MFLYM1T9]5M)H=+XG?\%2?@-\(O'G_""^-/ 7QPM'OO"7BWQQX5UZS\+>#;ZV
M\<>%O WA^S\5^)_$'AKP?#\0O^%KQ^&[+PY+JVJV/B_Q'\.O#_@WQ##X6\10
M>&_$.L7MM96NH==X_P#V#;/Q]XU^.&J2?M!?&7PW\,/VDO$/AK7_ (W?!;PY
M9_"VT\.>-$\/^"_"/@"^T"/QM<_#RZ^*GA_PWXN\+>"M*TCQ7IVA>-K*:]L;
MO7+6PO--CU:;9Y5K7_!,OX:^&/B'XO\ CGX5NO%OQ!UJ#6?CQ\0/#7P*U6Z^
M%_@WP;XM\2_'3X9>(/ASXP\&^,/B1:_#"\^(NK>%;O1=:?1/!C>*_$7B*+X9
M:(EKHWAZV/AZPM](0 ^]/#/QO^'_ (HT7XF^)[349]/\)_";Q'K_ (;\4^*]
M7ABLO#TLWA;1--UWQ#JVC:@MQ,NIZ!I5OJ7V.XU54BA;4=/U.UA67[&TC^'_
M +&?[4-S^V/\.OBOXPUSX4ZA\,M/\)?'OXN_!;3O"GBJZ34M9U[PCX&U&TL]
M \6>)M*FT^TCT"_\;Z!J-IK=[X-G&H2^'8[Y='U"^NKV"["1_!']C'X>>!/V
M)_ G[&?Q'M9_B)X/L?AW9^%OB*VH:WKD-UXUUS4+T^(_&&K7>O:7>:3KPEUC
MQ;=7^IB[M;RQN0LD<:""("!:/[.W[%F@_LE:UJEI\"/&?BNR^'?Q#^,7Q4^,
M_P 7_#/Q!\0ZW\1]7\0:[X]T2PLM!TKPUXE\57>IZQH&E>%=4T^*^\QK^XU7
M6H6E37]2U>X=+B, V-7_ &G_ !!H'[6^A_LQ+\"_%]KX.O?@OX_^)FG?%V?4
M?#T&D^*M5^']QX$@NO GPX\&V%[>>(=7DL+3QK9IJVM:_!X4TR'5/LFD:#'K
MRM>WFGW_ -D+]ICQ%^T[H'QGUKQ/\(=:^">I?"K]H/Q_\%(O!GB?Q%H/B+Q1
M-IG@_2O"FJZ7XD\2/X7GO_#VBZSXAL?$T%_<^&-*USQ'#X>5XM-N->O[^&[,
M?KFN_!SPYK_QJ^'GQSN]0UJ+Q1\-O _Q%\!:+IEO/9KH-YI7Q+U'P1J>M76I
MV\EC)?2ZA9S^ ]*32Y+;4+6WBBNM0%S;W326[V_ ^#OV?K_X4ZSXEU'X6>.;
M_3;3XH_M,>(?V@?B]9>)]/TG6_[:L?%/@6+PQJW@?PM+#IUG)X?T]=7T+P=K
MMCJ$DEUJL']FZG9RZC<6VHF! #B/CA^W)\,/V>_BY\./A/\ $?P=\3M/C^*/
MC3P!\.O"_P 1XM,\&VW@&\\;_$K68] \.^'],AUOQSHWQ"\9/::M>Z':^+-5
M^'/@#QIH'@=O$FAOXOU;14N+EK3QKP3_ ,%5?@1XZ\.Z-K=A\,_VA-(U/QWH
M/PI\2?!CP7X@\"^%M.\7_'72OC-XI\1>#O!4_P -[./Q]=:5;"36_"NMMK#_
M !%UGP!!HNA6J>++Z:/PI<0:U)M?&/\ X)J_"SXR_M WG[06K?$7XD^'];U3
MQG\!_B'JV@:':?#6ZM;SQ7^SIKN@Z[\/H+7Q5XD\ :]\0="\#SW'AVPE\5?#
MGP[XLTKPCXAU5KOQ%/I\.O7MWJ$])O\ @F'\'K;2_A!%H7Q#^*^@^)O@%\(?
MA!\*OA%XTM;_ ,'W>L^$[KX(>,M0\9^"?'SV>H^$+K0M:\333ZMJ_A_Q)IVK
M:7<^$=>\*ZOJ>D7'AV)KD7<8!Z5\ ?VO/$?QQ_9Q\<_'BS^ ?Q#@\0>&/BU\
M;?ACI'P1L)M!'Q,U:?X5_&+Q'\*M+BU1/$>J^'?"_AW7=5&B0:UXDMKSQ'+H
M'AB&34&A\0ZS8V,5_>?&.H_\%)-=UCP'^Q_\8O\ A1_@OP9J'Q?_ &?]7^//
MQ(\:>./#_P :_B'X0_9^\.KKOA#PS<>'+WXF?![X+^,;'0X)&\3^([C6?&7C
M&\\#^$;+2O#-Y?7LO]FW\EU9_I;^S5^S_I?[-?PWN_A[IWCGQQ\2;C5_B#\3
MOB?XB\;?$6XT"X\5Z_XN^+/CO7OB'XJN[T^&-!\,Z'!:KKGB&]ATNRT_1K2&
MPTR*TLU$GD>8WSA>?\$[_"Z_!SX;_ 7PS\?OVA/!OPP\'?"6;X$>,_#6A^)_
M#$NG?%WX57VHQ7VJ:/XMT_5?"-_I?A_Q/J%M_:.@O\1/AU8>#O'$'AS7-8TB
MWUJ.&2P?3P#[ ^+/Q?\  WP6^%GBSXQ^-M0N5\$^#]#&O7USH=C/KVH:E#<2
M6]MI5AX?TW3EFGUG5M?U"]L-+T*RM-QU'4=0LX(Y%6;S%_-+_A[W\,O"GB#X
MN^'?C-\(_B+\(_$O@+XG77@3PQ\-O%NM?"C0?B;X@T+P]\'O 'Q6\:^-M6'B
MGXE^'OA;:Z3HD?C_ $?3M+M?"OQ2\8ZGXI.I:-;^'[*_\07&I:#I7W5XJ_9]
M@^*WP5^)_P "?B_KKZOX,\<7VN:;X:/@VWC\(:OX!\$0WUE>?#O3M#U.SC8M
MXE\ 7&F:;JFE>(;BUE9M3L;,WL&H16TC7?R:O_!,+P^_BW6/B[J'[2/QLUW]
MH37?&6L^*-0^-?B'P[\!=<U$:1XB\#>!? &M> ;'X>ZC\'KCX4V/@Z?3/AGX
M&UFQAA\%'6]*\5Z!'KECK4?V_5+.^ +=O_P56^!GB#Q'INA_#;X5_M&_%S2_
M$GC/0OAOX%\<?#_X?^&9?!/Q ^(GB?X&:7^T=H7@_P +ZKXK\?>%;P7=[\)=
M4_MZ?7O$&F:#X,TG4;&^\,ZWXGTSQ(+32KOH]"_X*=_LZ^)D\':SH.B_%K4_
MASXIM/A/%JWQ>B\%6</PX^'7B[XX:&NN?#/X=^/[V[\0V_B+3O&&OK>:%I5T
M=#\->(?"WAW7?%7A?2_$WB?1Y]9MR/0/#_[#'PS\/>*O#/B^+QA\2-4U?PQ^
MT/;?M*P3:SJN@7;ZIXZM_P!G>V_9L>RU>2#PW:O<:'=^$+8:]=0VYM+]_%<L
MEU'J$6E;=(7QCPE_P2P^#_@S2/"G@G2/BC\96^$VC1?"74O%GPHN=5\'OX9^
M)?CSX&Z;:Z=\-/B%XLU"'P=!XFM-8TE](\+:IJ^B>%M;\/\ A#Q-J_@SPQ>:
MWX?NA:ZA#J8!FVO_  5R_9T?PGI7BC5_ /QS\&S>+M+^$'B/X:^'/'_A_P"'
M/@;5?B5X1^.5WXZLOA_XOT35_%'Q2TOP-X3T&^N?AOXM@O7^+'C#X<ZC97%I
MIMFVG27OB+PY;:K+=_\ !3G3]"^+?BSX<^)/V9?V@[:T34/V6O#/PR.G:+X+
M;QGXV\=_M,^%?'/BNT\'ZWX.U[QUX?F\"WO@VS\"ZRFO7_B._M=)MAI.N7%Q
M?06MOI4^L=?JO_!-WX?RZ5H-EX9^+/Q0\+WF@?LY?"W]EYIKC2OA)X[T'Q1\
M,/A=K/C35[>P\>^!?B/\,_%G@KQD?%'_  G6K6WB2TU30_[,)L]'OM&L=)U"
MP-S/4^'G_!,3X-?"_P 0?"75O"OCWXJQ:3\(G^!FH:3X6OM2\*7VEZSXA^ '
MA[XI^%?!NMZK>2^$QK5K'=:%\7O$]CJGA[0=2T?PS%';:*FAZ1HT&GB"4 X'
M]H'_ (*N>$/@U=^._!.D_ #XT:_\8_"^@)XO\.?#K7)?A;X9O?&_A#3OBW\-
MOA7XH\06UG_PLW4?%7@NTL)/B9H>O>'1\4/"O@5O'.D3V^I>$!K&E//J%OLG
M_@J/\'_#.M:IX>U[X7_%^ZNM(U/XB:SX^UWP1X)T6Y\)_"_P3X*_:<\4_LN:
MAXM^).J:SXOT:=[S3O''A:X?7K#P59^--6N](@O?$/AO3];T2QNKBVY:#_@C
MS\$K:\\0W-O\6OB_:QZAIOQBT_PW%:67PBMKKPW/\:/B1\/_ (LZ_P"(=6UV
M+X7CQ)\3_%VE^-/AAX+DTKQ/\5]9\9ZG+X?TA/#6KR:GITLH?U&^_P""9'P=
MU/1_B]I6H>/_ (JSS_&OP7XY\&^+]42_\(6]W#'\0?VC_&_[3^OZQHT$'@]+
M"QU(>/\ Q]K.G6$<EI<Z;:^&8;"P^PR7D,NHS 'I7PN_;N^%GQ;^,GA_X/>'
M/!'Q@L1XXTWXR:S\,_BAKWA'2;+X4?$[2O@+XMT'P/\ $J^\'Z_:^)[_ %P1
M:9XE\16%II:>)/#/AV?Q%8K+KNA17_A][35+KYT^'O[=GQA^,7[0_P 7?@=X
M MOV7],U+X=?%?XN_##2?"GC#QC\:Q\1M7'PRBO8K7Q'J2Z/\)I_ VGVFLSP
MVVI3V-GXHU&>QT6241S76J(+*LK]F+]C7X[^ ?VKM%^(WC2X_P"$0^!GP/\
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M^/QQ;Z__ ,*_USPQ<7L^G^!M1\+Z7XA\6>'?!VJ>);/Q7>R:/;[_ ,)?V_\
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M(=-@\ ^*]4N/"'AS5/%LWAWP+K)A;PQIECI,2:2H!Z#K_P#P4DTS3_A1X_\
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MU[;2?&]_XW\&Z=X>\7ZM]ON;GXB>#?!LWB'P7I>M^.? =KXO\+:7<ZF-:_\
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M-/CYX^T&XN?B3:WT_AKX<^)#9><NH:?INO>+['4[&;X>:)XON/M=K:;'A_\
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MQDU>+X<^)O!/[6OANZ\.SP_"KX?>,? OBGX.^%=-US0K_P"'.B>!M3U3X_\
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M2K6]BNO%&FQS>'-)622U33]#U[Q)I=A9'0_#U]=:?KFLV@TB/3]/N4NM,68
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M]$NIW'P?^"GAFWMM:N/"?@/PMXJ^(%KIL":Q/;VFGZ_\2/BYXW5+&R+W[O\
MVAXB\;>//$<<%E#(TL][J^I6]M;J,P1JMY\3OA#_ ,+<LO@Q>>*/"DWQFO?!
ML?C^V\#.T%UXL7P/8:U/96GB6>V6&66QT9-?MKR'2[J\DMX[C4K.^.G"6>SN
MC$ ?F#^S=\:_B%X/_9/_ &QOB7XBOO%'Q#_X*"_"6S\<:O\ M*_"#Q9KNMZY
MH_@OXM>&?"NJZQX!\._"CX<Z;?QV^D?LWZWX<6SUSX,ZKX1TW3M6^*O@MVU;
MQ+K&I_$E?$_]E?.OQ6_;:^//A"V^$O@GX3_MI?!KXUZ5X_MO&_B?Q-^TCJ=_
M^S]\(/#W@/Q=X?\ A]X$U?PS\#-8\9ZQX<\6_!68>*;OQ#XG^(D>B2>'])^*
MB>!_"NHZ!%KK:AI\WB.[_H1CL;""\N=0BL[2'4+^*UM[R^CMX8[R]AL?M#64
M%S<J@GN(K/[3=&UCE=UM_M%P8E3S9-WG7C!O@YX#\,6<7C>W^'_ACP?J/C#P
MOHEE;:[8:'8>'[OQSXW\2:=X:\)6,-K<VZ6#^(?$?BG6-,TG2<1?;+W5K^VA
MB9IIER ?BY^RO^T!\3_$'[8=CJ/Q?^)MOIVDWMQ\=-8\8Z+I'Q"\0WGP3TC4
M(O@!^Q)K21^%)?%-QI]N?!6F>(_%GB*_\'7.J6%C+ OB2]NDA@O-6O6N/8?^
M"LW[9'Q+_9D\/VFG_!OXDWO@+XB6_P #/CS\9]-M+[2/@SIO@OQ"WPOT[P^-
M*M/$?CCXT3ZE)K,AUC6+>RLO@Q\&?!.O?%_XARZBL]AXA\#Z1H]SJ=]^I=_H
M/PR^,?@W4;+4]&T+QCX-\6QZAINJ6][IY%KK45I?BPU*UNTFBM[J6-;W1DM[
M@/A9A8Q F2!(B>RU+1-#UE[*76-(TK59-*NOMNG2:E86=\^FW@0J+NR>ZBE:
MSNA&Q7SX#'*$8C?M- '\Y?B;_@H1^V?X9\/>)OC=H'B_0_B-::W\5_VB?A5X
M'^!&G?##0IO#VE6?P]_9%TKX[>'/%-OKFB _$?Q/K.@^+K/7KK4--CU^XL]>
M\%7!T2+3$U^S@\0O]&?LI_'KXAV^N?\ !5;Q?X5_:+/[=-Q\'?#?P?\ $WPH
MUC33H<_A?4/$$7[+Q\:-X&T3P[\+V@\'6\^K^)5@N=5B\"V5CJ&HIJ]A8ZF;
MSQ38WE]<?L+!XA^'MKXTM?AU;:CX8M_'<?AR?Q]9^$X#8Q:['X7%]%X8N?%-
MOI\:K.FF_;[B'1)=1C4(TLJ6;2$,$KH='T'0?#\#V>@:-I&B6S/ODM='TZST
MV N2S[W@LH88RY+NVYER2[-G+$D _G9\?_MB>+O!D7[.GQ/?]NJ+X\V5I\/_
M -H#XB^-]3^$_P /?".H'P)K+_LHS^(K/PMKWP[\">*_"_@GQ]'H7BX'Q/X,
M\*_$G4?#^M>"5*OX]\73V,4FOP^2C_@I;^U79^&/B]<:I^T#X&AT+X+_ !LO
MK&ZO-,\6_L@^)?C[XL^'LWP&^$OQ%^Q>%'-CX2_9D^.=[X!UCQ?XLUCQI\,_
MA3X@\%?$[Q%8:?:>#_A_\0-:U[2M1N[_ /HYU#Q=\$O!NNS^ KN_\#:)XCFL
M--\57/A&WLM/359=,\?>)D^']CXCGT6QM7N'L?$OB>5?#<^KR6Y@NKH207MP
M(8I631\4P_"7P9HFD1^*])\&Z+X=36+.'1XK[0-.71[+6;.RU*^LIX(DL)+/
M3)K&PMM4GAU!UMH[*%;C%Q$)2' /P/\ B+^WQ\:V\4_M$>%]1^+6B^(+#4O#
M.M>)OA1H7@:R^'&J>$_!&A^&OB5\+--;1OBEIFB:QX8_:7_9]^,/AWPYKFWQ
M=X7^+MEXQ\">/O$'B];?X=>-=&B\/KH>I^E:_P#MU>/M ^&WB_X@^+/VO=/T
M7XD^,/B)KGPZC_9=\&_#/X%S>.OV?-3TSX^3?#OP]%>>+/B7XF\,:%\.+/5?
M#MK9:;XI^(W[3,^N^"6U+Q%;^,O!^ER6,>D^#]9_;SPN?AWXSTNR^(OA&#PG
MXATKX@Z'HNM6GC'1[33+V'Q?X>O+.VOM O\ ^V((6?6--EL6M+C39)9IH5@\
MAH-JJF-2[\*>$;DZY+?>&_#EP?$<5LOB62[T?3)3KT&FH$LQKCS6S'5(K",!
M;87YG2U0!8O+7 H _%7_ ()F?M-?&7]HOX\Z[??%7X@KXOFT+X'_ !4\*LN@
M:YI-]X-UN;X9_MN_'#X:^'/'"VW@^ST3X?ZMXGU?P-H'A^VU#QIX3\,Z#I7B
M:RAM-0TG3;+2;FUMQ\K67[:W[>-G\/[OXJ:K^TSH=]##^RAX^_:Z/A.+X&?#
M:RT=+SX:?M1S_".P^%R:F+676E\!^*O >HV?_"9ZE)=3>.4\6Z5#KOA#Q5X8
MT>ZN_"\O]#_P?^)7P=^,'A"W^(?P4\2>$O&?@F[NM1T>R\6>#UMY=$OY=&NW
MM;^'3]1MX(H+^SM[N-E2YLWFL)ROFVT\L9#GT0Z/HVSR#I>F>6UM)9>2;*UV
M-:22_:);3RS%M-L\W[^2#!B:7]ZR%_FH _G;^*O[?O[4^@6WC*_\"_''P/?>
M/?$MQ^TWH?BCX*7'PY\):M=_L4/\(?C-X<^'GPI\2^*K:Q:V\7:@OCS2[VVL
MM3M?BI?_ &/QWK?C72/$OPR72?#&E265UK^+?VU_VDO"'BGXW?!GQK^U3X<^
M%ME\ ?$'[4R>'?VCO&WPP^&B7OQP\8_"KX=?L\>/OAG\"M4\/MI5AX&_MFZM
M/C3XIU37=%^'>BZ3\2_'GAOP;I*>"/['OK3Q5J=Q^[WBG6?AAX%N;/4_%UUX
M0\-7GQ%\4>&/ MKJ&KQZ98W7C'Q=J)DMO"/AIKJ6-9M8U:?R)(-$L9WGE58V
M2U5%7%8_Q@\;_!CX2>!M2^(WQJU7P9X2\!^'];T'4K_Q)XNMK+^R['Q-JNJZ
M?X:\,W<9EMKB23Q%J&LZEIFB:(]K%+JMS?WMG86.^::*,@'XW^'/VOOVJ_BA
MX)^*/CNV^.W@/X+?M&^'+/Q-<>'O^"?GB/X?^#]3\2R6'P]^'/A'XK3EKS5Y
M[7XJ6^I^-]&LO%,3^,+[[=X$M=(\4Z7I&F:/IGBO2$UBX\5^,?[</[0=CK'@
M[]KOX<?$_7/^$5^+7['GQ[^*?P(^!GB#1] \/^"[OX=:A^TC^SGX.\%?$KQ'
MI>H:1/XAU/Q)\//@EXNO_P!H/Q;>.UU>>$='74M-U:*/P4-?M=2_3OXH_MJ_
ML :WX'UG4/%7[1'A[P%I_P 0]/N?AP?B3HR^(_!7BYDO+S3K)=!T7QF_AJ+4
M["_NM1U?3;'2;:.42W6J:C:VVE12ZC-"M>M>$/VB_P!CJUO?A'\)_"GC[P/-
MJESX%T'_ (59X:6QU.]U&P\"ZEI5WI&AOY][IDUQX=L=7TCPY>V\;>(+G3)M
M4L],G>;[1$A<@'R#\._VJ?VD[#]A_P#:R^+]]XB^%'QK^('P;F\7S?"OQ#X$
M\7^%?C'+/H]OX1\/:_'+\59/@GX2\"^ =;\0^"+[5]9U*]TCX:Z;IZZMX,TO
M1K*_^P>*Y-7N'\!^*W[8OQ'\"1:EX9\)_P#!1WX5>,?#GA;X/_&3XO\ ASX^
M'X=_!;4H/BO\6? VE> )O"G[*LUSX;8_#CQ+=:G'XBU+Q=<:/\*],T3XQ:_H
M>IZ1H'A^XAOO#.N:[K7Z=>&_VT_V*+3P)XJ\1^$OCK\(+/P#\-M6T?0?$$F@
M:G8VFF:/J?B_4;N#PW;:=I-A;Q2ZFGB_5(M17PW=>'['4+/Q-=6NIOH\]^]I
M>M%[AX NO@Y\1OA_X.\5_#5/A_XL^&FI_9O&'@;5O"]GH=_X6>8R3R0:]H36
M4#6-KJ-O<R7:275ND&H65]]L@G,%VEQ&H!^#MO\ M8_MV>._'/A3?\>(?@_9
M_%GXD?M5^!6^'%G\%_AOKFH?!J'X!?LWZ#\<-)T^TUCQ3IE[J6N>,H?&0UGP
M5XPN/$ZW^CW?A>9X-+T#0O$]G'XDK"^'?_!3#X^Z]J=E\1-9^/7@+4M0E^(?
M[.?AK5?V0_"GPLT77?%&B_"?XH_L&_"S]H+XF?&:WMM/O/\ A:_B,>#?&WBO
MQ)XST&6TU;3?"7_",:)<?#W6GN=<U+3-:T[^A7P?XJ^'/Q!MM5U;P3J_A?Q5
M:Z!XO\8>#M7O]$DL=0CTOQMX7U2\\,>.-!NYX%;R-=TC5K"]T77[9F%S%<VL
M]I=9,;*.=\!? WX8_#;QA\3?'GA/PY;67BKXL^++;QEXPU><B\NFU6U\#^"/
MA[#::/+.KR:%H8\,_#[PO$=!TU[?2VO;6?4S;?;+VYED /Y\_@E^WK^UK\;O
MBSI7P2\-?M):?!H/CSXC_LQ-HWQ1D\*?LV^.?B7H?@CXH_#S]I#Q+XQTM-)^
M%T&O_!WPMJVKWOPK\'7NF>&->N/BCXC^&\=]J6D^)/%GB:\NX4LO*O"'[7'[
M;'@#X&7<?@W]KN?Q+?\ P;^">H_$_P 17GQ%^&WP[^('B'Q/\0_$G_!0SQW\
M!Y_!_P 0+^.VTG4M+T#PUX"M%3_A&]'N?#OBJQU*713'KNGZ3IYT:]_J&OH/
MA]\.]$DUF?2_#OAC0],GMF:YL-$M;:WM+C4M06TMY(H=,LBZR7.HZGM,D,63
M+>2RR,!)+)701Z!H$9NQ%HNCH;Z1Y;\1Z;9*;R6:X^V22W>V$?:));K%T[S;
MV>X_?L3)\U '\Y_Q/_;I_;2\!^//%'P+LOC!\.;67X7^(_VB[32/V@?C#J_P
M6^".C?%3Q)\.]=^'USX,^''C=M>\!:SX/U"/P_X=\<M>>.O#GP>T+P9\3?$O
MA<:1K_A?4=)NM.U]K[C/VB_VN/VR[_X5?M 7=W^T%+X=T_XBW'_!27X1^$O#
MWPS\$^$](G^$47[,W[/OB#XM^#?%G@GXB/I2^.=9\5OJGA#6_#=SX@U.:"UN
M/"_B"RU?2_#WAWQ=HD.MS?MW:_M<_L6>-/B9!\&(OBU\)]>^(\/Q&U7PI9>%
M[Q()R?BQX6FU*QU30-.U._TX:'/X^TB[TC5=.?3[+4I-?BOM/O=.BC-W;RP+
M]7R:5I,H<2Z;IT@\R\E<26=LX\W4(GBOY'#1D>9>P2O'>.?FN8I'28NCD$ _
M&[]G']KGXG:I^V[9_ ;QE\>M ^,'@GQ-H7B&P^'47PO;X'^.=%>S\(?#7PAX
MH?6OC#;^$IO#OQF^#'Q$8Q:AK-WXCU+2O&_P!^)$?C[PYIG@.]\(WMSX=M=0
MI^)/C%^T%XQ^-YT'P'\9=2^$VI?$S_@HMXU_90U2Z3P[H?CJ3P-\%?@G^Q_\
M0_BUI=AX0\)^,HM1\'Z)XS\>^.-,MO']_P",-2T+5KJ\\->(=+TJ>SN]-LM*
M%M^NUBGP_P!*\9/HVF:;X?T[QLWA.VOI%L=%M[/4V\'V=Y#I%G&^I6]E&#I=
MI=6MO9VVG&[*P"WA\JV2&*-EJ:'\+_!OA[QUXU^(>CV$MKXA^(#^';WQ2@O)
MI-)OM:\-:1/X>T[Q-#I$C/96/B6?PX]IX>U/6[..&]U71-'T73[Z2>'2K4(
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M'7@B"WL_"_@GQ!^RS8_%F]_:B\6W5O%=?'#2_!GAGQIJ,_B36M9$G_" Z;X
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MLX;ZPAN9OM<=W%"(%N-\IE61926 /Y[_ (.?M[_M%3^%?@+J4WQ6\*6OB_\
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MNT$>'++QEKFI>(?'\6@_$CQ[IOQ,_P"%?7_@NYTSP^]E!NZ?^Q1^TKX+\=?
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MI5Q+<7^A:+HAU*\UN[M9M;U*>[@*17][/;Z9!8:9';6,!10!W-%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
0% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img143810944_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img143810944_7.jpg
M_]C_X  02D9)1@ ! @$ D "0  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $# U@# 2(  A$! Q$!_\0
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M]SJGQ*T#PY;0W5U<ZI#=:! ;> 7EQ]CTN>WU*0 _I0HKY6_9W_;7_9B_:B\
M? SX@?"3XN^#=1A_:-^')^*?PG\&:SK^BZ%\3/$GA"T:XMM?O+?X?7VHKXEF
M?PCJEEJ6B>+6LK&\L]#UC2]0L[J\_P!&,A],D_:!^ L5M\3;R7XW?"*.T^"E
MXFG?&2ZD^)/@U+;X2ZA(KO'8_$V=M:$7@.\D2-W2U\5-I4[*CLJ$*2 #UVBO
M#M._:=_9KUCX7W'QNTG]H7X':I\%[.\@T^[^+VG?%GP%??"^UO[J]M--MK&X
M\?VVOR^%(+RXU&_L;""VEU99IKV]M+6-&GN88W\3^+_[:GA;PIXL^$_@;X)3
M_!/X^^+O&WQ_\/\ P1\?^&K7]J;X+_#OQ%\+H+_3'UKQ%KB^'_$>K7NM^/O%
MWAC2'L=5;X0^%[ ^.]7TV_BO[.VCM%\UP#[=HKQN]_:+_9\TSXIV?P+U+X[?
M!K3_ (VZA!!<V'P=O?B?X)M/BG?6URAEMKBS^'L^N1^+;F"XC!D@EATAXY4!
M>-F49K&\6?M6_LN> KOQ#I_CK]I/X!>"[_PEXETCP9XKLO%GQB^'?AR[\,^,
M/$%@VJZ!X4\0VVL>([.;1?$NMZ8K:EI&A:DEMJFI6"M>65K-;@R  ]]HJ.*6
M*>*.>"2.:&:-)89HG62*6*10\<D<B$I)'(A#(ZDJRD,I((-24 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%?GS\,OV^M%^*7_!1;]I/
M_@GYH/PSU9;O]F/X,_"_XJ>-_C"?$NGSZ!/K/Q6-G<^'_ ,/A>/31J%KJ:Z/
M<7.JR:G+JTD#II]U;FRA?RGD^S=<^)_PT\,^,_!WPX\2?$/P-X?^(?Q$CUJ;
MX?\ @/7/%N@:3XS\=1>&[1;_ ,12^#O"]_J%OKGB>/0+%TO-:?1+&^72[1EN
M+XP0L'(!W-%>*#]I7]G,Z#J_BH?'[X*'POX?^(/_  J37O$@^*G@7^P=$^*I
MNK>Q'PRU?6/[>_L[3?B";V[M;/\ X0R\N(?$?VJYM[?^S?-FC1M[X?\ QL^#
M7Q8O?%FF_"SXM_#'XEZCX!U9M!\=6'P_\>^%?&5[X+UQ'GC?1?%EKX<U74I_
M#FK(]M<HVG:Q'9WBO;SJ808I H!Z;17S[I'[6O[*GB"[^P:#^TU^SYK=]_PL
M&T^$OV+2/C/\.-2N_P#A:E_#/<6/PS^SV7B2:;_A8-[!:W,]IX,V?\)'<0V\
M\D.FND,C+]!4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%?E/_ ,%!/^"KGPW_ &'O'OPL_9[\'?!OXM?M<?MB?'#3]1UOX7?LN? ;
M3[6]\97OA?27GBOO&WC/6[XOIO@;P7'/:7T$>M7UM?S7#:;JMQ!ISV&E:G>6
M@!^K%%?E/_P3R_X*J>"_VX_$7Q]^#_CSX(?$[]D#]J/]EZ;0)_CA^SQ\;I=+
M?7?#/AKQ7IQU7PUXUTGQ-IPMM*U[PKJ-FOF2ZA]ETY[-9K&ZD@?3=4TR_O/N
M_P"'_P"TE^SK\6-&\9>(_A9\?/@M\2_#WPZ>[C^(.O?#_P"*?@;QEHW@62PM
MKF\OH_&6J>'-=U*Q\,/96EG=W5VNMSV+6UM:W,\P2*"5E /::*^<!^V/^R&=
M:\$^&A^U3^S>?$7Q+M_#UW\.= 'QQ^&)UKQ_:^+KH6/A2Y\$Z4/%'V[Q5;^)
M[TBS\/3:%!?QZU=$6^FM<R_)4GQK_:;^%OP?T7XH6;>._A+J/Q<^'7P@\2?&
M&'X->)_C3\-_ACXDU7P[HUM<1:7J>M7_ (UUJSM? O@S6_$*6GAN3XC^)[:W
M\(:+>WJRZC?!(7C(!]%T5\L:+^UC\-?#/P'^$GQI_:>\9?!G]EJ7XH>&O#VK
M-H_CWX__  OO_".GZYK^GV^HQ^&_#GQ:&K:-X(^(92&Z@:SUKPK//IVL02Q7
M>F^=:S0ROZWXZ^-/P<^%_@2+XH_$SXL_#/X=_#*>/3IH?B+XZ\>>%O"7@2:+
M5XO/TF6+Q=K^JZ?X?DCU2#]]ISIJ!6]B_>6QE3YJ /3**_-7]NW_ (*7?#+]
MC;]GGX0_M ^$- L?VF-+^.WQY^$OP"^%FE_##X@^&UTWQAX@^+.KWNEZ=JVB
M^,+:'Q%HFHZ?IJZ==SRBQ6X6ZD5+=;BWW/-'^E0S@9&#CD9S@^F>,_7% !11
M10 4444 %%%% "-T/T/\J*&Z'Z'^5% "T444 %%%% !1110 4444 %%%>._$
M/]H?X _"/3_$&J_%7XX?"+X::7X3U+P]HWBG4?'_ ,2/!W@^Q\-ZQXNM9K[P
MII&NW7B#6=/@TG5/$UE;SWGA_3K]X+S6;2&2XTZ&YA0N #V*N.^(GC*P^'7P
M_P#'/Q!U1&DTSP+X.\3>,M1C3.][#PQHM]K=VB[0S;FM[&15VJQR1@$X!Y/X
M2?M _ ?X_6&K:K\"OC5\)_C/IF@7<%AKM_\ "KXA^$OB#9Z+>W433VUGJ]QX
M4U?5HM-NKF!&FMX+UH99XE:2)612PR_!O[3G[-OQ%\?:Q\*?A_\ M!?!+QS\
M4/#WV[^WOAQX0^*G@;Q+XZT;^RY/)U3^U/"6C:[>Z]8_V9-^YU'[381_89<1
M7?DN0M '\=/_  26_P""-GQ^_;$_8#T'XU^/O^"D_P"VG^SM\-OVT/'?QJ^,
MGQ8_9?\ A!<Z/X.\-:[:^._B1XCT?5YK[6+\7&IKJ'CW0="TVXUR]N-(FAN;
M*XCM([:XL5AED]A^'7_!,']E#]H__@MUXR_9C\3_  IE\0_L5_\ !+;_ ()Z
M? 3X&^!_A)K5SXBD\%>,O&'C_P 0ZE\2;-?'UPMU8Q>.S;7OB/Q%XOU^SOVO
M++6O'5AI6MZM!-+IL,(_K0TSX\? _6_B=K'P3T;XR?"O5OC)X>LCJ.O_  FT
MSX@^$[_XE:)8"*"=KW5_ UKJTOB?3K58+JUG>>\TN&-(+JVF9A'<0L_JU '^
M>9X^TSX"^&?@M_P6?_9O_:@_9M\2?%;_ (*V?M%?M.?$KX7?L>_#'5/@+X@\
M9?$*3X(>1X>\+?LC:S^S;XJMO"U_H'@_X-?"W2EO=<M=2\+^(=#M-*TO0+#3
M]1:6./1[>O2_^"CNF:;\)OB-^S7??%[XR#P7^WC^Q9_P3I^%?P!O/AE^V_\
ML>ZI^U%^QG^WG.W@VW\1^,=+_9]\06EIXQN;OXQ:MXXN%\">*_%D6CZ)XCU6
MX@TFQBU2PM;/6[NO[K? WQ2^&7Q.T+4O%'PV^(O@7XA>&M&UK6_#>K^(? _B
M[0/%>AZ5XB\,W#6GB/0=2U;0=0O["QUKP_=*UMK>EW5Q%?:5.K0WT$$@*U@^
M$_CW\"_'UEX U+P+\9_A1XTT[XL2>(X?A;J'A/XB>$/$5E\2IO!\%W=>+8O
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M:Q9VEQ-<::VJ:;)'?Z<+R.$WMFZW-MYL)WUT% !1110 4444 %%%% !1110
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M+*+7]3T;1;C3[76-7T_1WG74+S3-*NM7TJVU*_M[>2TL;C4]/@N98I;VV60
MVZ*\.\)?M.?LV^/OB%JWPD\"_M!?!+QG\5=!-^NM_#3PI\5/ WB'Q]I#:2Q3
M55U+P?I.NW?B"R;2W!34UN-/C.GO\EV(6(%=_>_$;X>Z;XZT/X7ZCX[\&V'Q
M+\3:#J_BGPW\.[WQ/HEKXY\0>&/#]Q9VFO>(]$\)3WT>OZKH6BW>H6%KJVKV
M&GSZ?IUQ>VD-Y<0R7$*N =E17-:;XS\'ZSXD\3>#='\5^&]5\7^"H="N/&7A
M73=<TR^\2>$K?Q3;7=YX9G\3:':W4NIZ%#XBM-/O[K0I-4M;5-6MK*[GL&N(
MK:9D=I?C'PCKFO>)_"NB^*?#FK^)_!$ND0>,_#FEZWIM_KWA&;Q!IRZQH,/B
M?2+2YEU#09=:TETU328]5M[5]1TYEO;,36Q$M '\47[$G_!9+]A']D?_ (*#
M_P#!9SXQ?M2^)OBGX<\??'K]L>#P1X"B\/\ P0^)?Q L[KX._LX:3JOPX\,:
MQ;:]X3\/:G8P6VNZA+J4L6G2/#-]ETZQO65TNHV'MW[2/[>GPBT[_@MI\ _V
MR_B3H?Q/@^!GPK_X) ^*?C5^QQILOP8^*%_XH^.7Q&^.$MWXBU/3?"&A:=X5
MOM0T7Q8WPOOVTO7-,\00Z--X?AT^]?7IM,CA??\ U5^)/VCOV>O!O@"X^*OB
MWX[?!SPO\+[37[[PG<_$;Q!\3/!>C>!+?Q3I>KWOA_4O#,WBS4-:M]!C\0:=
MKNFZCHM]HS7XU&TU:PO=.GMH[NUGAC]2T/7=$\3Z-I?B/PUK.E>(?#VN6%KJ
MFBZ[H>H6FK:-K&F7L*W%EJ.EZI837%CJ%A=P.D]K>6D\UO<0NLD4CHP8@'^?
MA\/?@'K'QA_X)S_\$-_V4?B/HVIW-_\ \%+/^"HGQ#_;-_:+MK.QU32]1O?!
M>C>(O&.O:Y_;5[ MK<VC7_@S4]&2*\GN(+F2&VAGTV2&6W@>#W_XO?"?QQI/
MQ;_X.>_B!^P;\([[X6)\*_V7_P!G+]E'X=^#_@/X)'AL^(]2MO#NGZA\;O$/
MAG0_".GV!U7Q5I?A'2O$]NVJ:5;7/B"".XFECFFOIH&G_ML\1?%#X:>#_%?@
MCP)XM^(?@?POXW^)MUJUC\-_!WB+Q9H.B^*OB!>Z!8?VIKMGX)\/ZE?VVK>*
MKK1=,_XF.JV^A6E_+IUC_I=VD-O^\KYY_:V^'W[/7[2/A4_LI?%SXU:O\,O%
MGC;3V^(_A.P^%WQYNO@G\?+6R^'=_!J%YX^\"7GAW7M,\63:/X7NFC77[T:?
MJWA9(;@VOB&UFMY1$0#^-[X#>'O^"?'[0G_!2?\ X-]/@Y^P9\,K/3]%_9_^
M"GC'XX_'GQ]IWPK\2?#Z#Q+K_P -/AQ!J&AVGCK4=;\/>''^('Q%\*_%K2]<
M;Q/XFF&M_P#"/^)O%YT./53+JMY8VO\ ?!7Y"?LY_L<_L-?L7^(=6_X* ^+?
MVL_'OQT\6>-OAEH_PST?]L?]LW]J/PY\2K72_@]J.K1^)-,\%_#_ ,?7:>$O
MA[I?A7Q%K<,6LK)I5M+?:Y>(734KB.:>.;]1?AY\2_AS\7?"FG^._A3X_P#!
M?Q-\$:L9ETOQA\/_ !3H?C+POJ+6TAAN4L=?\.WVHZ5=/;3*T-PD%T[P2JT4
MH1U*@ [:BN.\!_$7X??%3PW!XQ^&'CKP=\1_"%U?:OI=KXJ\!^)M%\7^'+G4
MO#^JWFA:]I\&N>'[W4-,FOM$UO3[_1]7M([II]-U2QO-/O(X;NVFA3Q;QU^V
MK^QS\,+C3;3XD_M7_LV^ +O6(=4N=)M?&?QP^&?AFYU2VT36K_PWK5SI\&L^
M)K.6\M](\1:5JF@:G/;I)%8:UIM_I5T\5]9W$$8!]-45R"_$+P"_A[P[XN3Q
MOX0?PIXON- M?"?B=/$NC-X>\477BJ:"V\+VWA[6EO3INM3^)+BZMK?08M-N
M;F36)KF"+3UN))HU;4TKQ-X<UV]U_3=$U_1=8U'PIJD>A^*+#2]4LK^]\-ZU
M+IMAK,6D:]:VL\L^D:G+H^J:9JL=CJ$=O=2:;J-C?)$;6[MY9 #;HHHH ***
M* "BBB@ HHHH **** "BBO*O%GQU^"/@.X^R^.?C%\+?!ES_ ,)OX8^&?V?Q
M7\0/"?AV;_A9'C;3DU?P;\/_ "]7U:S?_A-_%NDR1ZIX:\*8_M[7=.DCO=+L
M+JV=)2 >JT5Q'BSXF_#?P'JW@O0/'/Q!\$>#-=^)&O\ _"*?#O1?%?BO0O#N
MK>/?%/V9[S_A&_!FG:O?V=YXHU_['%)=?V/H<-]J'V:-Y_L_E*6'"W?[3G[-
MUA\4X?@;??M _!.S^-5Q-!;P?"*Z^*G@:W^)LUS=0?:K:UB\"2ZZGBB2ZN+7
M_2H+9-+,\UM_I$<;0_/0![C7\F_[2O[2G@O_ ()<?\%XOCQ^V/\ MD_##XO7
M7[/?[3'[&GPG^%7[/_[0/@/X9^(OB?H/@7Q'X#U.SN?'OPHOH_#=O?:AH6H^
M*]7TU=?$$%N99&GTRXDA.GZCJ-]9?T1^/?VY/V+/A7XLUKP'\3_VNOV9?ASX
MW\.2PP>(?"'COXZ_##PCXET&:XMH+RWBUG1-?\4:?J6ER3VEU;7,27MM TD%
MQ!*@*2HS;?C7]K_]D[X;>-['X:?$/]IS]G[P+\1M3BT.?3O /C#XQ?#WPWXS
MOH/$[!/#4UKX8UCQ#9ZW/%XA9@NAR1V3+JQ(^P&XH _EL_X*$?'/]LG_ (*%
M_P#!)7]N?]H#X1_L3^._V9?#WCSXM?"[P9X&\46_A'4(OVK_ (_?L3>&_%%A
M_P +*\??$7P%HUGI_CNS\(G2XK9H/!NGZYJ%QK/@NW\2PVC/H2IJ>I_G7K.E
M_#[P5\ _^"FG[=/[-W[4O[/?Q&TW1?\ @FK=_L1:W\)?V+_V!OCU^R3\(/$]
M[\:O%_AWP5\//%%_K7CWQ/XD\/\ CGXG>!=/U;5[#74TAIO&.CV/V"UUZ6QA
M@O#=?Z"&I^+O"FBZ[X:\+ZQXG\/:3XE\:2ZM#X/\.ZGK6FV.N^*YM!TY]7UR
M+PUI-U<Q7^NR:+I*/JFK)I=O=-IVG(U[>"&V4RCH: /XF/VR/^"3OP*_X)_?
M\$1/@9^T-\)?@U9:O^U=^S'XK_85_:?^*WQ5N+:_UCXL^.==^'WC3PJ_B3P[
M'KE_)JE_I/AWP^GC*_T3POX9TL6FAZ!H.CZ59BV2&Q:<>/\ [7/P;^-&N?\
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MP,_9>_X)/_\ !1#X@:IJ=AX7^&GB'XP?LI?$_P 9^,[C4X]9O?\ @GA^T/\
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M+..2>6:YF\F!&GN9I[F8R3S2R/X_X,_9\BT3]I?XP_M-^)_$$7B;Q;X[\%>
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MA;QAI?P0U/4?C+X7\":GJ/P:^'$G[2D4,WP(TOXG>,I);63PIJOQ)2]THZ;
MVE7L.B#7O#[^+KCP['K>G/<?H/0 '@'O[#K7\?GQM^#K?M@?\$O?^"=5EXDU
M=K7XH_MI_P#!4;6?BGXN\;V\]U;ZAI/QL\6>&?VR]0\&:K#=R017]C'\,=4\
M+^!?"VEVZPK)IGA_P79Z1 ODP*I_L#KXV^#W[&7P[^&-IK/A76-/\-^/OAUX
M=_:6\3_M/?L\^&_$7AJ"YO?@'XV\<#6M9\1Q^%M2N+FZA'V#QKXV^)FK^#M1
ML+'2;[P[H/CN_P## >[M;2*YE /YU?B!\<[C]O;]H'_@ES^U)JD4D-G^SI^U
MA^QA\ -0T<CR[;PY^UQ\6/"'Q/\ &G[7'AZ:%D5X-7^'%KX&^&G@BYM9B9(;
MC5;T-%!/&4&?XKT?0OA?^RO\>OCUX?\ #?['_P"W3_P3O;]I7XJ_&_XE>'OB
M%:^+OV9O^"DOPK^(9_:(UGQ1XP\.:7\0]-GF3QC\:_A7\5QJ%G\-K+Q/<?"K
MXBZMX9T3PCX%TV]O([FPEO\ ^HK3_P!EO]G'2+2RL-*^!_PPTVRT[XWZA^TM
M8VMAX.T6TM[7]H+5KC4KK5/C-%%!:1HOQ'U"YUC5)[SQ9C^U[B2_NFDNF,K9
MXG6OV$OV,?$?QC3]H37OV7/@7J_QL76;#Q(WQ,O_ (;>%[GQ7<>)=*&-+\37
MFH2:<QOO$NF85M.\0WB3ZS8R)'):WL4D4;* ?"?[87P^\$?M=_ML?LH?L?7W
M@;PQ<?#6#PEJ?[<_[5@U?P?HCZQX\\&_"_Q/X:\+_L_?"/Q+=WNGSWSZ3XL^
M,VHIXP\6Z->$#6-#^$=UX?NI387M[:W'Q!^U5-=? 77O^"BO[??P*_;%^&7Q
M)^(?P\_:=^"_A_Q;^R-KWP#^&=[8:IXD\'^"_@O\,?#_ .S!XB\2^+]&U/XR
M/XS\7Z'J=MK'PK\3?"C5O"NE)K_BBTO+'2?%L;ZV9OZ0[?X:^ +3XBZI\7;;
MP=X>@^*&M^#]'^'VK^/H]+M5\5:AX'\/ZOK'B#1/"EUK(C^VRZ#I>M^(-:U6
MSTTR_9H;_4[RY6/S96:O+/$G[(G[+GC'XTZ'^T;XK_9]^$/B+X[^&AIIT/XL
MZQX"\.W_ (ZT^;189K;0[V+7[FPDO7U+0K>XFM]"U.:274=$@<Q:7=6D850
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M(_9_\">$M4T:;0=*9K.S.L75WX?L]++Z?HUK;NS,P!^FE%%% !1110 4444
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M!&DGNKJ>**-1\S9(! /R+_;E_P",G?\ @H9_P3X_8=M0;_P7\+M9U[_@HO\
MM&621I-:GPW\"[E/!O[.7A[6%8-$]IXF^//BF'Q(MC-M>Y'PW^T(DL-O.%_9
MNOQ+_P""2WB'0?VL/BK^WE_P4QTO6=+\4^&OVC?CH/@#^SSK6G7$-Y;0_LP_
MLDQ7GP_\,WVG2([2V=K\1?B9?_$KXB3VLZPS7$6KZ5>-'Y#6C5^VE !1110
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M\\.V7B;PIX7LK_X2ZM\9(;/XJ_"O6H_#FC^)['PI<^'[K1?'&C:C:_$6XO\
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M9[7P1HGA0>*;I]+\0^$Y+RXU76]9/@[2%U2R\1Z5:C7-6-@;73OH>@ HHHH
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M) GBEN-1@MV,P_FI_P""Y_[-?C/XO_LL>#OB-_P6Q_X*/> OV2/ P^*ND?\
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MDUS#<+<S?Q ?\%9?!_\ P4L_8(_X)<Z_XF\7-X)_9@U?]H[]H?P++^T)\3-
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M#H6BV-MIFCZ-H^EVL5EINE:5IME%#9V&G:?9P0VEE9VL,5O;6\4<,,:1HJ@
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M%XX\*Z?-HOPH^&TS):>&]',GC_Q?;V/A31X%OOQN_P"#-'X1?$OP!\.?VO\
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M _FU^(/Q$^&_[+/QZ_:W-Y\<OV6;'0_'7[1_B'XEZY;_ !P_X)S?M9_$W7?
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M9O'_ (>L8IM6\ 1-:6L4OBJUTQ)=5TI";Z'UB@ HHHH **** "BBB@ HHHH
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MS-!XIUF7PSJ?AZV\4Z+X<\+L%E\3>)M>T;2_#WA^UGM;W6-3LK.[M9YO)_\
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M?M':9X69#<SO\9?B-$GCTS^6LM_X*\-?"GPH\QL_%BLX!P7[8?BV3XE?'_\
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M-X!\$KKGB&!9M9U?P9::2 ;/_!)3_@CO\9_V\/VW_P!GG_@J!X"\!:!\#O\
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MMO#V@^'M=\5+J/B37=+UI+*&2.U56 /UTK\=_P#@MG_R;5^SO_VD8_X)^?\
MK3/@>NL_9X_X*"_%'XL?$;X$W7CGX.>#O!W[/G[8-W\:;3]F;QAHOCK5-8^(
MMF_P<M];UVS/QF\+7_AS3-"T0?%#P-X9\1>,O#8\)^(-<_X1@:;%X?\ $ADO
M[Y+J#R#_ (++_$?X>>)_V>?V=M*\-^/?!7B#5&_X**_L 2+INB>*M"U74'2'
M]I?P0TSI96-_/<NL2*SRE(CY<:.[X1&8 'ZF?'R73X?"GA=M2O?C18PM\5OA
M5'#+\"X=:G\42WLGCC1DL[7Q*NA6=[=)\+[NX,<'Q/EN8XM+B\%/J\FIW5K9
M++.GM]>(_'O7M/\ #WA3PQ=ZE\5/$7PAAN_BK\*M(A\0^&?#5OXIOM>O-7\<
MZ-86?P^O+"Y\->*4LM&^(-Q/'X3UG7([&RGT/3M3GU.'7-$DMQJ,'MU !111
M0 4444 %%%% !7Q!\<O^"E?[ G[,_P 3)_@U\??VN/@7\)_BG:^%+KQM=^!?
M&?CK2M*\0V7AJTTZYU8WU]922,;*XO--L[B]TG2;IH=8UN!4?1K"_P#.A$GM
M/[2_[2WP4_9!^"7CW]H;]H3QSI7P\^%7PYT>75_$.OZI(#)*_P#J[#1-$L$)
MN];\2:[>M#IF@Z%IT<VH:KJ5Q!:VT3,Y*_XN_P"WO^TOH7[<'_!1'X]?M/+I
M%_X,\&?'SXY2>+M*TKX@WFH7]SH/@2_O=.TS0T\27.AJ=0%G:>&+.SDNK;P_
MYTEC8*;#0Y;@6UI+( ?U<_M<?\%DOCO_ ,%@?COXO\*_LS?"7PK9_P#!/7]G
M+5[;5[SQG^U-KZ?#7]E'4/$>DW7VK1OCK^V;JUW/:1^+O">AW5O!JWPG_94M
M[VZN/&6II:ZKXL\.^--1M[?PC:_S*?M9_#CX\?MA_MU:[XD^%OBSXQ_MWZM\
M;?B%X:\'^%/VD-#^"/B+P!I/QR\;:)H?A?PUKX^&WAB#1;>Q\.^#?!=_;KX7
M\,6&VU30O!NA:-J.I6>BV;BUM?[%_P!B?_@A9JG[?%I\-]<_:*E\9^!_^">/
MPUN(M7^%7PU/A*]^ ]S\?S))'*=9^&?[/T%W/>?L_? W7H%61OB1\5M1\8?M
M;_&K398M3UOQ+X'T?4E@D_M:^&7PJ^&OP7\!>$/A=\)O OA?X=_#OP#H]MH'
M@SP=X2T:RT70/#FD6L7E16>EV%G%'% '7<]S-AKB]N))KJ\FGN9YI7 /G7]A
MG]B;X$_L)_ K0/A+\$? L7A:6^M['7_B5XFU6_?Q+\0OB5\0[JQB.O>,?B5X
M\O=^L>-/$MU>/<(-0OYVM;*UV:?HUKIVE0V]E%]DT44 %%%% !1110 4444
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MTUM8/8:"L&CZQX[L],DU'7=+F\/W.JV<LOZ0_P#!*O\ X-S?AW^R[\*8M/\
M^"AGB;0_VZOB=HOCS4O$GPX\/>+=>^(_C/\ 9[^$.C2BUDAC\(_"OQ_J2>$-
M4\6:UJD=WKVO^)]:\$"ZAN+FVT_3 JVMUJ.J '@W[5G_  <5?\+U_;9\)?\
M!+7_ ()NII&K>(/V@=:\&?"C1_V^=/N[OQEX/^'FI>-KB)?&WCGX7> K7039
M_$9/AOX<_MA-/\57'B.'PBGB_3KB^G%_X?T.XFO_ .E/]D?]DWX0_L6?!#PW
M\"_@SI=]#H6D3ZAKOB;Q5XAO7UKQY\3OB!XBN#J/C3XH?$OQ1<*+_P 6>/\
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MW-K*/B#/8F:+X?-([VR^*VTPW,$T(:,^JT %%%% !117Y\?\%(?^"F?[,/\
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MK\8-:^ 7Q&_; \6ZW^TYKWBVV\'_ +,GP-^)NI6<_AKPV+ZYOO!'AGPY<_\
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M#Y7U']B+]D_5/BK\/?C7=? WP3'\1_A7I7A;1O >L6%M>Z5INAV/@2TNK#P
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M7Q)^$7C:PFTCXG?$*S\'W%_X^^*_AO3;Q-0O$TG3[Q8M,^$OPONI]-@$^O\
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M1C9D-*LGZ:44 (JJJJJJ%50%55 "JH& J@8      P!P*6BB@ HHHH ****
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MIT\71X=X4XASKB#%973J5X4ZV=4,MJY=1Q4XX/$8BC7J4*=3_19HK^/+XO\
M_!T'\>/A9\,_%-WXN_X)9_&#X5?$&VT9[30O$7CWQ5K%Y\,-.\63%+>WG\2@
M_#KPMJ0T>&=S*MC;ZQ!?7[K'8K>6C3&ZBY_]F_\ X.[?@U+\%A-^U9\ _B#:
M_';2K76Q(/@SIVDS?##Q=<VT;R^'EMKOQ/XL.N^%;C5"8K+5EN+;7+73IUDO
M[5[F"1;&'Y+(OH&_2<XLX/EQQP9P5D/'>0_V[0X?H5^ ?$?PYX[^N8JOAEBO
MK&$K\(\4YSE];!T(3H0Q,_KT:^'GB:,JF'5'VE:G^%9YB*O#&9RR;B;+,\X;
MS2&%>-J8'B'(<XR/%T\,JCIJK4PN:8+"8F-.4XRC&HZ7LY.$HJ?,K']EM%?R
M5? +_@[D_8W\3_#Z34_VCO@[\6_A1\2H-=O[/_A%OAW9:?\ $_PU?:"%2?2]
M:MO$=_>^#+FVN)%D:QO]*NM++Q75L;JWN9K6Y5+?SK]J7_@[K^ .D_#>1?V.
M_@IX_P#%WQ;N]3M(8)/CEHVG^&_ &CZ.KN^H7UU'X5\97^OZQJ+QJD&GZ?;R
M:=;+),UU=WVVW%I<]U']GC],RKQ)_JQ_Q ?BVEBUF4,LGF=:>4PX;A4G-0^M
M_P"LJS&625,M@G[2>/H8VKAU!.TW.T'Y,.*>'9P51YOA(0<'4?.ZG/&,8N3Y
MJ,:<J_/965.-*52<K0A"4I)/^QJBOY$['_@[D_94_P"&:%\6:A\&_B,_[5%M
MX6TO[5\(X+2*U^&>H^-IIXK351I?Q(-YJ%[:^%;13-K$+ZCH2ZN]F$TM(Y[W
M-T<KQ#_P=G_ +6_V:WUKP7\*?$_A3]IO4/"]VDOAKQ,VFZQ\.?!_BB.<VWVY
M-3M]1T_7?%VFFV!U/3+"WTC3[BXFDM]/OY(56XG/Y[QG]#WZ5/ 678G->(/H
M]^++P>'S_P#U8B\EX.S3B7$XS.94YU*%/+\!P]1S/'8[+L7[-T\)Q#AL-4X<
MQ&(E##4\V>(G&D_T'@CAV/'^;X7)LBXFX&PV)Q$N>KB.(>-N&>&,OP& BZ7U
MC-<PQV?9EE^'PV!P<*JK8J+G/'0I0JN&"J2IRBOZVO&WC3PK\.?"'B;Q]XXU
MRQ\->#O!NAZGXD\3^(-3D:*PT;0]'M);[4M1NG17D\FUM89)66*.25]H2*.2
M1E1O$_V9OVNOV??VOO!MYXZ^ /Q"T_QMHNF:Q=Z#JT'V:^T?6])U2TCAG:#4
MM!UBWLM5M8Y[6YM[NSN7M?LMW;3*\$SLDJ1_RN?!'XX_\%/O^"YG[..O1^$?
M'_P0\(_!32;?Q/X'\=V5KKES\.=>\?\ BVQL;?4XHO%V@Z*?$GB(Z/#;ZIH\
M<%CCP]X'U2ZQ<7QU&.&X@MN&^"O_  0L_;QUGX4VWB;PM\4_@/\ #[74\4:I
M<V-GH'C:XO/%-[#9I%8!IOBM\,-/UJU?3?M,-P;;0%UNYCTZZ26YGAM[N:2%
M/XJXTSGQ6X0XPQW#F,\'>-,MEP_4QF6<2Y3Q1DN-X;S_ "_/,-54)X.O2QBE
M# RI<E54Z.)H3K9AR5JF#YJ%)5I?Z \$?1%^C'7\.,WK^)WTT/"+AOQ,Q&?9
M-_JY/@GB/!>('!V&X9QN&Q-3VN98;!87+\TS3'X^4(5JN(R[,<)@>&L// PS
MEO&XV>#H_P!DOQ:^,?PM^ _@G4?B/\8_'?AOX<^!M*GM+6]\2^*-0BT[3H[O
M4)A;V-E$S[I;N^NYCLMK*TBGNIMLC1PLD<C+U7A3Q9X9\=^&M#\9>#->TGQ1
MX4\3:9::SX?\1:%?6^I:1K&E7T2S6E]I]]:O)!<V\\;!E>-R <JV'5E'\$G[
M>W[!?_!2GX*?"0_$+]I/5O$'CSX1^"]0TVWO]9L?C;XB^*/A_09KLR6-EKVJ
MZ'XCU#[?HEL\TZV']MMID=M;W%_#9RRP?:X_,_KM_P""3WAGQ%X/_P""=?[*
M>@^*M&U+P_K<'PYDOI]*U>RET_4(+/6O$NOZWI,T]I,!-$M]I&HV-_;F54>2
MVNH9&1"Y0<O"7'.?\1<38_*,RX0Q_#F!PN4K&T:V8T\2J];%QQ.'I5*2J3P]
M##3IRI8F,X1IIU(^RE.4I1J*-/X[Z0WT3?"_P9\!>#/%3@SZ0'#7C-GG$GB3
MC.#\;0X/J91+A_!973X?QF;0J0IX?,\SS2GFN!KX*C#,OK56%#V6<X"DL+A:
ME%5<?^AU%%%?J!_!H4444 %%%% !7X;_ /!P9\2_#/P6_83\#?&7QJ]U'X.^
M$G[:W[%GQ+\5-81+<:@?#_@GX]^%/$.JQZ?;N\:SWTUI8216D+.JO.Z!V5-S
M#]R*_$__ (+U^"?"?Q+_ &-?A-\./'NAVGB?P-X^_;R_87\&^,O#=^TZV.O^
M%_$G[1'@[2=<T>[>VE@N4M]0TZZN+:5[>>&=%D+12HX5AK0E2A6I3KTW6HQJ
MTY5:*FZ;JTXR3G352/O0YXIQYHVE&]XM-)HVZ)^3O9^3MK9^6I_,7\5_^#S[
M1_$MI>Z1=?\ !/?X=?$K3K+XH^'O%G@BU\6_$R>\T_2/#GA765UC0]5U>UO/
M >HQ+\4-*U"RT[5= UO1E@TS0]3B%W#!++:P/-^N6F?\'B/_  29G\$:1K^J
M6?[25CXQN_#.G:KJ_P /]/\ A/;ZI<Z3XBN+&*?4?"L'B2;Q)I>A:F^FWS36
M*:TDMKIM]'$MXGDK+Y*>:?&W_@T&_P"";;Z0+WX?VO[55UJFK_%OPM)'IG@3
MXE?"_3I/"7PZUW7;33_$=DQ\>>&8;+5O#_A+3+JYUZXO9[S4?'-U9:;]@T@Z
MCJ$PCG_HI^"__!.C]ASX!_#?P1\+?AW^RU\#;;PYX"\*Z-X1TF^USX8>"?$?
MBG4-/T2UCMH;WQ)XIUC0KK6O$.M7KH][JFJZG=S75]?SSW,K!G"K]_XAXS@O
M-..\XQO"^#RO(^$Z\<LEEN7\(X'B197A%#*LOI8NCA:''.?9GQ$JBQ<,7/%U
MLQSC&QKXYUZN$]E@*N&I4>;"_6(X>"KWJ5TY<[K2HQE+WY.-_JE*G1LX\J2A
M3BU&W->?-)_Q3?\ !2#_ (/)?$GBWPCX#\/_ /!,OX>>,?A)XADUG4+_ .)'
MQ#_:*\!^"-9O#I-FMF-%\/\ @7PYIGBSQ;HC#4YGOIO$6L:V@NK6V@LK/2;6
M.:ZN;ZW^Q/V(O^#D7_@H7^W=X&\*^$_@[^S+^P=X0^+6DZ1;:+XU^(7[27[8
M.G_"7POXU\5+;PVW]N^ O@\]I;>/6L+N[;[9=:9IFJ^)8893+I]G>A51D_H*
M_;F_X(I?\$\O^"@/@WPCX/\ C%\$-&\&R>!M:N=:\->*_@EI_ASX7^++/^T(
MH8-5TJZO])\/3V.JZ-J<=M;-/8ZMIEZ+>>WBN;"2SG,SR_"O[9/_  ;.?L&?
M&/X(^&/"7[-_@;3/V=OB;\,?!]CX<\)>*-%:]N-.\;6VC6AC@B^*"B22]UO7
M-0D!EG\:1^9K"7,S/>6NJV:0V$/M<-9?X!4JLL9QSQ-XL_V=B\*L-3PG!7"G
M#..S[(\?"O2]IFV.PF?<3Y9DV>Y0\*INAE>6YKE6;UJU:K[3$4/[.H4L^]S)
M<)B<^S#!Y'7S;AKA>C7JRC1SO/J.8O**5>I?V-/,\9DF5YGG>#PU2<G3J8R&
M79K2PS5"53"K#NKB,%_(E_P3TO\ _@L/^T+_ ,%N_B5\"+O]O#X@?!?XO^+/
M%WQ?T;]HOXJ>#?B%H?Q)\ V7@_PP^HW>OVGPA\+>)]1U3P!XJ2VFMK'3_AE:
M:#I_V[PI8R1ZO;)I<&CZL(_Z(OV\?^#4O7?VKOAC<ZP/^"E'[5/QH_:@T_6X
M-6T+Q?\ M=^+SXZ^%3V,\;V^MZ%:>$O#>D17W@;[?&+.6TU;P^^I+:G3XK.X
MT>\MY_,MOXZ/@IX._:C_ &9OVEM*\<_!K5;KP#\6/@SXJUJ[\)>-K:VM-4CM
MM6TF/4M*N%ATR\T_4TU"&^LGOK+4+'4-'EA%E/=)?01H&Q_0!%_P=1_\%(/A
M7\,M3\'_ !/^!7P(\4?$R=5LO"_Q@GTWQ!HVGQ3PNGVN?7/!.A:T-$UV]-NK
M^5%IVH>%(8;AVGFL9X%6U'];<7?0H\,^,>.>$N"?HB?2I\#O'?.N(.'<GS7$
M\(X_Q+X-X?X^A7S18G'3QF69%2QM;"YGEN#R..&S',\LP688OBK)^3%_7<E]
MG+"RJ?0<1>$'C[P!PQF7&7B7X%^*7!O"N69EB\MQ7%&8<$\0T^',/5PN)A@>
M;%9I5P,*.%P^*QTGALNS'$>QRS,ZCC# 8NO-3C'^G_\ X(Q?\$9OA#_P2E_9
MSTCP3JEI\.OBS^TAJVNZQXJ^(GQ_M? &E:?KTMWJJ6MM9^#_  CKNI6MQXKL
MO!7ARPLH8;"WN+^W?4-0N=4U:XL;-KY+*U_:ROXT_P!GO_@[U^#-S\,O#$/[
M3/[-'Q6@^+MM:7-MXPU3X,1>&=2^'>JWEO<%+/4-"M?%/BNP\0:6=0LC%/?Z
M7>->QZ=>^=%;:C>6SPLA^TU_P=R_!Q?@EXB_X9.^!/Q-M_CW>W5II_ABX^..
M@Z%%\.=!M)G)O_$&J)X5\:7.JZU>6L"&/3=!B;3X+FZE2>\U%+:WDMKGX9?L
MZOI@?ZV4^$9^$6.AB:F=QR3^V'G?#M3A^G*6*>&_M.KF5#-*KAE,8IXJ6)^K
MNJL+::P[JRC1E^8?ZQY5]3>.]M6=!4?;W^J8I/DY5*R;HJ'-JE\7+S:<UM3^
MRRBOY0_^"<7_  =!?LR_%+X)2I_P4$\9^&O@7\??#_B&YTN5O"7@CQ]?^"/'
M7AM[6TN-+\4:;'IEEXI'A[4!<2WVF:OHMYJLB))8P:C:.EOJ"VUMA?$O_@[
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MYI4NG7,RZ3K]K$5MY=/DTZ--6L5$\6I_:XI;:XBZ,K\-_%?/.&,ZXXR/P?\
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MAWQ#IECK6A:WI5U%>Z9JVDZG;1WFGZC87D#/#<VEY:S13P31,R21NK*<&O\
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M8H(H;'Q.G@'QI;7V@?"_3KE"_AW1M)DMX;B"VTS3VEBCMKB2\^SM;_X)B?\
M!,[1OBC\'->U3X1_#SPS\1/#NKSZE\/]%O/&>HV5_P#$'6-*D@U,3:WH6L>(
M9KWXGW>AW$4.H@ZG'K$UN,)?&6P;[.?\]/0?A_\ \%1]8_X* ?%+Q'X5\?\
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M*A5PV.P,L'[=N:@JV%SFCFF"K0=5TZ6#QE59A2^(/^"0/_!7+_@F1\5OV;?
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M^TE;_$#6VUS5]2CM=#AD3PROPY_L*.R6&[%J=;-^_P!D3,8C^I=1_P"#9_\
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M@G>ZMEM(Y9XDCN8&?U/>A (=2&4NIW##(,9<<\J-RY8<#<.>10 ZOQ:^(/\
MP3I_:#_:(\5:1X3_ &@_'7[.^G_!WX=W7[3%[X+^(/P3^'.I^#/CQX[3]H#X
M?>/_ (8:9HOQ!T;[-9^!/#&D^$O#/Q$O;[Q@/"^LZ[%\7/$WA?PMK&K:?X8:
M*]BF_5/XT_&7P!^S]\*?'7QI^*&K3:+\/OAQH<WB+Q9JUI87FK7%AI4$D$<D
M\>G:=%<7MVX:XAQ#;PR2%7W!=H)KT\21E@@==Y02;-PW^63@.4SN"YXW8QGC
M.: /S>_9/_9>_:1\'_&&R^-W[4GC7X.ZYXI\ _LV^'/V5OAQI/P2T[Q=;:)J
MOA+3/$]CXL\4?$WQG+XS@MKS3/&'C74M!\+PIX*T-=2\/>$;/2+E+7Q)KTNI
MO-;?I)7$_$7XC>!_A+X$\6?$WXC^)-.\)> _ NAWOB3Q;XFU-I?[/T/1-.A-
MQ>:A=_9XIYS%#$-VR&&6:0E4BC=V53UUG=V]_:6M]:2K/:7MM!=VLRYVS6]S
M$LT,JY .V2-U<9 .",B@"Q1110 4444 %%%% !1110 5^?/_  4&U+]LVX\%
M>!/ 7[(GPY\2>([/Q_XDO]+^.?Q#\ ?$'X8>!?BS\-/AA;:;YEROP>;XL7^G
M^%!\1?&=Y,N@Z7XMU!KZ+X?6":EXEM-(U/78M$CB].^//[=?[*_[,_CG1?AG
M\9_B?-X8\>:_X3;QWIOA?2O 7Q+\=:F?!J:Q/X?/B6_C^'_@WQ3'I&D'6;:Y
MT]+S5Y;&.2XMYQ&66*1E^AOAY\0_ OQ9\$>&?B3\,_%F@^.O 7C+2K?7/"WB
MWPQJ5MJVA:YI5T&\J[L+^T>2&50Z203QDK-:W,4]K<QPW,$L2 'XB:Q^S!^T
MS\-](M=2_9D_9&T;1/#GQ@_8)3]BB]^"OC+XW>!M-UK]FSQ#X:\8_$B_\)?$
M;QIXPL;SQ)I'Q/\ "&M:=\3M=U_QS)X,U3Q!\0;O7[&"9+/5+[7]2N]-_9?X
M#_#-?@K\#O@S\'%U(ZROPF^%/P[^&:ZN8S"=57P'X0T?PL-2,)),1OAI0NC&
M22GF[2217JU% !17P[\5O^"D7[%GP1^)?B[X1?$_XUV_AGQW\/X]!F\?6'_"
M"?$_6M%\#0>)M%M_$>BW/C+QEX>\%:MX+\+6EUH%W;ZU-=ZYX@L+?3]+E%_J
M4MI;!I1]JZ;J6G:SIUAK&D7]GJNDZK96NI:7JFG74-[I^I:=?01W5E?V%Y;/
M+;W=G>6TL5Q:W5O))#<02)+$[QNK$ \B_:"U'XUZ1\+M:U/X >"O!/Q)^(=C
M>Z).OP_\>>(KWP?I?C/PLNKV:^-/#ND^*[1);?PYXNU'PLVJ0^#]6UJ"?P[;
M>(CIXU]8]*>ZN(/Q;^%'[&_[3_P)UGP3^TE\+_V9] T"P\"?M/\ Q?\ B1X)
M_8.L/C3X5EUGP/\ "?XX_ K2OAM\0;S1_BMJT\_P]3XB>(_BSHY^,>J^#?\
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M\+>)M'\,>&=/M#K6OZQ9>(=#U728=/L+22:^NK1OL7GQ212R 'M%?C9^V1X
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MG^S#^P1XR^!7Q%^&FJ>,/C1I7C_X5?LS^"/BA\-_V5_ FE?#N+PAK7A+PO\
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MP]\*_P!M+XC^-?CII<6JZ7K.E:S;6GAKX;ZW:ZKXG6WGMVN=$U)K>W-T\DD
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M3?B+_P 55:&R\8VNN0V4-P3I2Z>MI_PCA/APZ57W'10 4444 %%%% !1110
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M>BZAX=U:"?4=+NM#DC6\NM/:Q<?<5% !1110 C=#]#_*BANA^A_E10 M%%%
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MSA3.,US# XCAO-,=DN7QPWUBC6S"N\OI_N#1117UI_/04444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 (W0_0_RHH;H?H?Y44 +1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5P;?"SX8M\1T^,;?#CP&WQ=C\+-X&C^*C>$/#Q^(\?@E[_^U6\'
M)XX.G'Q.GA9M4)U)O#ZZH-)-_P#Z8;0W'[RBB@#BF_9B_9K?Q#\3/%S_ +//
MP-?Q7\:M&G\.?&/Q.WPF\!-XA^+7AZZB2"ZT'XF:T= .I>/-&N8(HX9]+\4W
M.JV,T4:1R0,B*!9UW]F[]G?Q3'=Q>)O@)\%_$<6H>!-!^%U_%KOPM\#:O'>_
M#+PMJB:YX8^'5VFH:%<+<^!/#FMQQZQH/A&8/X?TC5$34-/T^WNU$P** +VJ
M_ +X$Z]\4?#WQPUSX*_"76?C3X2TS^Q?"GQ?U7X<>#M1^*/AG1]EY'_9/A[Q
M_>:--XLT73/+U'4(_L&FZM;6NR_O$\K;=3A^?U_]E;]F#Q7\/-/^$7BG]G#X
M"^)?A/I/B&[\6Z5\,-?^#_P]UGX>:9XKO]1U'6+[Q-I_@K4?#MSX;LO$-[JV
MKZMJEWK5MID>I7.HZGJ-[-<O<WMS+*44 >YVUM;65M;V=G;P6EG:016UK:VT
M4<%M;6T$:Q06]O!$J10P0Q(D<44:K''&JHBJJ@">BB@ KDCX!\"-XW3XFMX*
M\)'XD1^&W\&Q_$$^'-'/C=/"$FH)JTGA5/%9L_[>7PW)JL::F^A+?C2VU!%O
M6M3<J)045M1Q.(PWM?J^(K4/;T:F&K^QJU*7ML/5257#U>24?:4:J252E.].
M:2YHNR$XQE;F2=FI*Z3M);-7V:Z-:H=X@\!^!O%FK>%-?\5>#/"GB;7? >JS
MZ[X'UKQ!X=T?6=6\&:W<V<FGW.L^%-1U&SN;SP[JMQ832V,^H:1-9W<MG+);
M23-"[(>8UKX&_!/Q)\1_#WQB\1?![X6Z_P#%SPC;?8_"GQ3UKX?>$M4^(_AB
MTV74?V7P]XXOM(G\3:+;>7?7J>1INJ6T6R\NEVXN)0Y179A\YS?!J,<)FN98
M50P6+RV"P^.Q5!0R['RJRQV BJ56*C@L;*O6EB\*K4,1*M5=:G-U)MRZ=.7Q
M0@[RC-WC%WG"W++5?%&RY9;JRLU87P[\#O@KX0^('B?XL^$_A!\+O"_Q4\;0
M&V\9_$OP[\/_  GHOQ \76S26\S6_B?QEINDVWB/7X#-:6LIBU74KN,R6UNY
M7=#&5L^ _@Y\(?A7?>+-3^&'PK^&_P .-2\>ZPWB'QUJ'@/P/X8\'WWC37W>
M>1]<\67?A[2].G\1ZPSW5R[:GK$EY>L]S.QG)FD+%%:5\^SS%4\11Q.<YMB*
M.*PN!P.*I5\QQE6GB<%E?(\MP>(A4K2C6PN7.G!X'#U%*EA.2'U>%/E5DJ5*
M+3C3IIQE*2:A%-2G\<DTM)3^TUK+K<](HHHKR30*YWP_X/\ "7A)]<D\*^%_
M#OAF3Q/KMYXH\2OX?T33-&?Q#XEU%((M0\1:XVG6MLVK:[?16UM'>:O?FXU"
MY2W@2>X=8HPI14N$)2C.4(N<.;DDXIRAS*TN635X\RTE9JZT>AM#$8BE2KT*
M=>M3H8E4UB:,*LX4L0J,_:4E7IQDH552J?O*:J1ER3]Z-I:G/S_"3X4W.F:O
MHEQ\,OA]/HWB#Q6GCS7M(F\&>')=,UOQS'=V=^GC/5[!]-:UU+Q6E]I]A>IX
MBO8I]76[L;.Y6\$UK Z*/A)\*A,ER/AE\/A<1>.F^*$<X\&>'/.C^)CP"V?X
MB)+_ &;O7QT]LJV[>+E8>(&@ A.H&,;:**Q^J86Z?U;#W223]C3NE%RDDGRZ
M)2E*271RDUJW?T5Q!GRC**SO-U&<ISG%9EC5&4ZE*E0J3DE6M*52C0H49R=W
M.E1I4Y-PIP2P]9_9^^ WB*P@TKQ!\$OA%KNEVOB;5?&EMINL_#;P;J=A;^,=
M=F-QK?BR"SO=%GMX?$VL7!,^JZ]'&NJ:A,3+=W4SG=6'XL^&OP]^'WP^\;ZC
M\/?!'A3X?:I'X 7PW#J_@+0=,\%:S;>'] ANI-!T2TU?PQ;:5J5GI>AR7=U)
MHUC:W4-MI4ES</81V[S2%BBN;$8+!TZ.)K4\)AH55AJJ56%"E&HE&C.,4IQ@
MI)1C[L;/2.BTT/;R7B3B+%9GDV6XK/\ .L3EU7.<#*I@,1FN.K8*I*MF5"O6
M<\+4KRH3=6NE6JN5-NI52J2O-)G'?L=?!+X7_!#X/1Z;\,/"T?AR+QKXI\5>
M/_&%W+JNN^(-9\4>,]?UFZ75O$6O>(/$VJ:SKNJZC=I:6T1EO=1F6&&".&W2
M&)0E>U'X3?"MM6@UYOAG\/SKEKXIU'QQ;:T?!GAPZM;^-=7TZ#2-6\80:B=-
M^V1>*=3TFUMM+U'Q!',NK7NG6\%E<W<MM#'$I14Y=@L'3RW+J%/"8:G0H8;#
MNC1A0I1I46H0FG2IQ@H4VI^_>$5[WO;ZF_&7$O$>,XWXQS7&9_G>*S3-,\SB
M&99EB<UQU?,,Q@\5B,.XX[&5:\\1BXO#_N''$5*B=']TUR>Z/T#X5?"_PI?Z
M)JOA;X;^ O#6J>&O#4G@SPYJ6@>#_#VCW^@>#YKX:G-X4T2\T[3K:XTKPU+J
M0&H2:%8R0:6]\!=M:FX DKFM/_9W_9_TF[\8ZAI7P,^#NF7_ ,1+*^TWX@7N
MG_#+P597?CK3M4D>74[#QC<VVB13>)[+4999)+^UUM[Z"\>1WN(Y&=B2BNEX
M+!-03PF%:IN4J:>'I-4Y2@J4G!<EHN5-*G)QLW!*#O%6/"AQ/Q+3GB:E/B'/
M(3QD*5/%SAFV/C/%4Z&*ECJ%/$RCB$Z\*.-G/&4HU7*-/%3EB()59.;Z+Q#\
M)OA7XM\(Z;\/_%?PS^'_ (F\!:,NG)H_@GQ#X,\.:UX1TI-'MS::2NF^&]2T
MVYT:Q72[5FMM.6ULHA96[&&V$49*UA^._P!G_P" WQ2.DM\3O@E\(_B,V@6"
MZ5H3>._AMX-\7G1=+5U==-TD^(-%U Z=8*Z(ZV=GY-N'56$>5!!13J8+!U8S
MC5PF&JQJ1IPJ1J4*4XSA1;=*$U*#4HTFVZ<9)J#;<4FPP?$_$F7U</7P'$.>
M8&MA*^,Q6%K8/-L?AJN&Q.8QA#,,1AZE'$0G1KXZ%.G'&5J;C4Q,80C7E-1B
MEV_@_P %^#OA[X>T_P (^ ?"?AGP/X4TE94TKPQX/T'2_#7A[3$GGDN9TT_1
M=%M;+3;)9KF::XE6VMHA)/+)*X:1V8\?;_ KX(6?C/6?B-:?!SX5VOQ"\1VM
M[8^(?'EM\/?",'C/7K'4H([;4;/6?%$6D)KFJ6M_;116][;WM]/%=011Q3I)
M&BJ"BJEA<+*-&$L-0E##.+P\)4:;C0<(\D'1BXVI.,/=BX*+C'W59:&-+/L\
MH5\RQ5'.LVHXG.85J>;XBEF.,IU\UIXFLL1B*>95H5E4QT*]=*M6CBI58U:R
M52:E-*1KGX4_"X^![;X8GX;> 3\-;);5+/X>GP=X=/@>T2PU*/6+%;;PG_9W
M]@P+9ZO%%JMJL6GH+?4HX[Z$)=(LH=%\+/AC!X<\3>#H/ASX#A\(^-;W6-2\
M9>%HO"'A^/PYXMU'Q"P?7]0\3:(FGC3->OM<95;6+O5;6[GU-@&O9)R :**/
MJN&NG]7H75)8=/V-.ZH).*HKW=*2C*25->XDVN6S8?V]GEIQ_MG-N6IF$LWJ
M1_M'&6J9K.I3JRS.:]M:682JT:526-E?$NI2IS=5RA%KJ(]#T6'14\-Q:1I<
M7AV/2UT2/08]/M$T6/14M!8)I":6L(L4TM;$"S6P6 6BV@%N(A"-E0^'?#?A
MWP?H>F>&/"6@Z+X7\-Z):QV.C>'O#NEV.B:'I%C%GRK/3-)TR"UL+"UCW'R[
M>UMXH4R=J#)HHK14Z:E&:A!2A!TXR48J4:;<6X1=KJ#<(MQ346XQ=M%;AEB\
M7.E5P\\5B)4*^(CBZU&5:I*E6Q<(U80Q56FY.%3$0A7K0C6G%U(QK58J252:
M>U1115G.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "-T/T/\J***
# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img143810944_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img143810944_8.jpg
M_]C_X  02D9)1@ ! @$ D "0  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "M GH# 2(  A$! Q$!_\0
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MQ:W,E_-!:6\URG5+P*\9HU\PPLO"_CE8G*LPR7*LPH?ZMYI[;#9EQ(\-'A[
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MS:Y9_"?7O"W@3Q'XCFO=2\/:>UYJ>D:SHNG6DFN:7JZ7BMH$&F?V=<WESXA
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M:Q'I.J2:;"[WJ:=>M"+:4 _FT\!?\%T?BSH-I\1]?UOX!Z[^TY;_ !"^+_\
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M?"L^!WA<1/+\PE7Q]+A"%2>9T,SE',Z?M8<>9C3RK..,JN&>%Q6,S+(LIQ.
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MH_R4>#?V"_VJ+/\ 90_X*GV_PV_9?\<_LZ?"/]H7X:^#M"_9Q_8AU7XDZ?\
M$3QC;>-=%U:TN/$_BV"27Q!>Z'X7;6H"\2:2VN%IHD6![B:UTBPGG_0+0_V:
M/C=I_P"V]_P2:\?Q_"?7K/X?_ W]AOQU\-OBKXBB318M*^'OC;4?A/::)IWA
M36(XM2%R+^YU=);"$:9:WUDLX<M<I&QD/[JT5])Q#]++CCB2><SQG#_#-/\
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MQ5)X9\1Z;I6LVOC3P%::@UKXNBR[K_@L/\&_@UX=?PS^VGX&^)7[*7[1FE>
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M?XM^)?B+7=#TB?0](FNM>%G;Z;80Z?--<W$%OIEA86UJ UQ<R8#L9IG+2/\
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M'G@32(?$^E:-=6>HW/C36-2D:WGLX)([$VK6S)<RNS1Q?&#]G#XF>-_CK?\
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MX)G1>+O"_P 8OAW)\7/&WQW_ &Z_^"DWQ7NOB=J_PQN_&FK^);+7O#/AS3O
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MTGPKI'[/7[-W[+H^-W[7#2?#-/&%XFH6_P ,/&VJZ3X%\+>(+OQ?!K=]):W
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MN:+-*OV.&YFG):W_ %,L/M?V2W_M VYOO(@%Z;02"T-V(4%RUJ)F:86S3!S
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M9+B;; TDB1N(>']WF^*&H0:I;Z<D<#ZTMQ;1+9Z5-&WVJZNH(C%IUO+IUY+
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M4 %%%% !4$US# "9' ]L\_Y_3UQ5;4+Z.RB+,><$]0.@R>O' YQW^F<_E?\
MMH?\%$/!?[-\TO@W0;.'Q[\6KB%9SX6CO6MM)\+6]S%YEK?^+[^!9)8))T9)
M;30K,#4+J B:XEL;=HY'^ XLXYPW#\OJM",:^-:NTW[E*^W-;>3_ )5J?:\"
M>'_%?B1Q!A.&>$,GQ6<YOC%.<,-A^2$*6'I.*K8S&XJO.EA,#@:'/%5L9BZU
M&A"<Z=-U/:U:4)_I]/XCLXCM4[CSC&3T[<9YZ<?IU _';_@NKX)\3_%W_@FW
M\:!X,UO2=#U/X5:CX1^-^H)K:WPM=8T+X8ZPNMZCH\+64$[IJ,S?9[S33/&+
M.2\LHH;N6WAD:>/\;?'_ .WC^UM\2;^ZN;SXLZ[X:L9W<Q:'X%2'PKI=G$S;
MDBC^P(-0G,8 7S[N_N)WP6=R2:^,_P!IS]J']J*;X-ZK\+;3XP_$K5K;X\:_
MX9^#VM:=J>K7WB"QF\*^+M4A_P"$VEU"+4%O$M[!/!MAKL4TY>W0-/'$)DDF
M3/P_#OBMQ#@^),FQZ5&I2PN:8/$5:+IPY)X>E7I3Q$6Y7Y5[&,[S:;A93M=6
M?]>9Y^S\X\PG!^;9AF7&?!M#'TLLQ%595AGG>*=2O*E:A@J6-66T%/%UZ[IX
M>C&&&E1G7J*'MN27M#[3_P""!'["'Q8U_P".&E_MG?$SPQ/X?^ .C>%[+7_@
M7J6N75B^I?%CQK<>&IO!$'BZST6.>34+/P[X;@O?'&K6NJZI!9MJNL:YI%_I
M4-S:(]V/[-00PR""/4<BOYU?V1O^"GEE=CPO\-?C/H&@^!$MK+3O#_A?Q7X7
MLX]&\'6]M90PZ?I.CZCX>@06WAF&*VCAM;2XTXC1X?+2.2VL8R&'[M>$?&4&
MIQPXF2:*1%9)4=61E9058,"RL&7!4@D,""I88-?I:\8EQYGU6IF6$I99*2CA
M\NP].I*<*6&IN7L:52I.SJXB2DY5JRC"%2K*3I4Z5-0I0_DKCGP3XS\$<?#A
MOB_*ZF$Q->-3&87,:<X8G*\ZH\T(5,9E..H_NJ^'A)PC/#S]GC<&ITH8_#T*
M]2TO4:*:K*X#*001D8QT[=/6G5]9N?!A1110 4444 <]XK@\*W/A_5+;QO%H
M$_A6Y@%OK4'BE=/D\/W%K/+'$+?5(M6SILUM/,\41ANU:&:1HXRC,R@\MX'^
M*7PY^(WA;P]XM\+^(M-N]$\3>'K?QAHPOI5TV_F\.27'V>#6I=)U$V^H6MB+
ME!"MU<6T<23!$#A]@K@OVC?@KJ'QJ\/^";/2K_PK'?\ @3XB:-X_@T'X@>')
MO%_P\\7#3])UW0IM"\9>'(-0TR:^LX;?Q!+KFCS1W1.G>)M'T6_:WF2W9:^
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M_P!DE\5_^D+4?L&?\F:?LV?]DE\*?^D*U]!_S2O_ '<'_O./SW_FZW_>/?\
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MLM7RO=+5>76^S31[GXWU>WG$K*5P=W3 YZ=<XZD9('-?&?C>ZB:1B&X+<].
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MQ\?P>.OV)?A%;%S_ &O\/[?6/AMXBM7&V>QU;PIJUU!';3Q_>C?^RKC3)L,
M2LH.*_0VOQ9T?6H_^"='[:GBS0O%);2OV4_VPM=/B;POXDD!BT'X;?%]V/\
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MB\MQ^$JV]IAL;@:\\-BJ$[-Q;I5Z<X<T6XRMS0;BTW:HHHKZX\@#P#7Y,_\
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MJPN'67X>3P%+'Y97Q>"G&K+"8:J\%2Q-*I7G"EAD_P!]***\[^+7Q!L/A/\
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M-J4H.*9CB)U*="M.E%SJ1IR<(Q@ZC<DGRI4U.FYZ_94XN2T3O8\)T7_@L/\
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M0SXEZI\5/VL?'UG/=/-HOP\N(?A]X<M ^^"V@TB-)-8N(E!(6?4=;GO)[E@
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MB2)KKP/J-P,.^B>+5MX(W8QV&M:G&HDIL4Z30PW$$L5Q;3HLMO<P2)/;SQ.
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M6FJIX9XBJY);*48*^G,M6?GFWQ%NO%.H2>'/A!HC?$;Q!YK6MQJL$L]O\/\
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MUO+.ZACGM[BWFC:.6&>"17BEADC+(R.C*ZD@J>H_&3XI_L,ZIX-UB^USX17
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M-E$;7Q9X:64(]YX$\:Z?XA\):C;B2WETI'E\]?R/^-_[>O\ P4<_9X^-^O?
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M(^(VC?!*#Q-9WNAP0>)?C9K,6B7J>!M-TB6]EU^VT_3],UZVO-2\8:CIMMI
MDMKVVT^/4&C@DN/AZWA)X;XS#SPN(\/^#L9AZ]*I3E3K\.Y77_<U<?B<PG03
MJX5RA#^T<7B\7&$))0K8BK4IJ//=?HF&\7/%?"XBAB\)XD<;8;$4:M'$4YX;
MB;-\/^^P^ PF4TZTX4L7"%6JLOP&$P<JE6-2I5HX>G&I.:C=^W?";]G_ .$O
MP6T+PWH/@'P5HNFGPKHLFB:;XANM-L+SQ=/:W4QN=3?4O%$EJNKWT^JW9-WJ
M+27 CN)MN(DBBBBC]IP!T&*_/3X+_M<>+_B[\?K/P3'H*^'O >LZ9XGUC3]*
M\2:!J.@_$+28M*^&GP'\76>G>(;2ZOF6SU&WUCXD^([>]B-FJRV,&D/ 557G
MNOT+K[+!Y;A,HPN&R_ 8+"Y?@J&'I4\+A,'0IX>A0H4J=.A2ITZ5*,(0C"G3
MA3C%17+"$(]$CX7,,?F&9XRMCLTQF+Q^.Q52K7Q&+QN(JXK$UJM:K4K5:E2M
M6G.I*52M4J5).4M9SE+>3;****ZCB,+Q'X8\->+]'O/#_BWP]H?BG0-0$(O]
M#\1:18:YI%\()H[B 7>F:G;W-E<B&>**>(30N(YHHY4PZ*1_/M_P4N_X(G>!
MOB_X'^-?Q=_9<\#W>N?M>?%;XO\ A'X@R7_C+XCS:1X<M=-N;FST3QMH.BP7
MAM] T7P_/I;MXBGM+BWOM4:]T\1:5?(@MM+;^B:O@3]M;]I_XD_L[ZG\/8?
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M4DDE:P4445!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'F>WZ_\ UJ:E):*4DDK))O;:WI;2P[ON_O9)@#H,45'YGM^O_P!:CS/;]?\
MZU2(DHJ/S/;]?_K4>9[?K_\ 6H DHJ/S/;]?_K4>9[?K_P#6H DHJ/S/;]?_
M *U'F>WZ_P#UJ )**C\SV_7_ .M1YGM^O_UJ )**C\SV_7_ZU'F>WZ__ %J
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MX6_X2X78\!7E]=G0O[,_M[P]Y']J_;/+_M'[=+]C\O<+.XW87E_VQOV$-?\
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M/Y4]BMZU]*+F]M+C3T__ ((Y^!O$G[/O[3GPT^.GQO\ ''Q;^-'[67C[PO\
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?_K4>9[?K_P#6H DHJ/S/;]?_ *U'F>WZ_P#UJ /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>17
<FILENAME>fate-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-05T12:23:09.2207+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.fatetherapeutics.com/20241231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:fate="http://www.fatetherapeutics.com/20241231" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" namespace="http://xbrl.sec.gov/cyd/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails23" id="DisclosureIncomeTaxesDetails23">
        <link:definition>100020 - Disclosure - Income Taxes (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesDetails22" id="DisclosureLeasesDetails22">
        <link:definition>100030 - Disclosure - Leases (Details 2) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100040 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100050 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" id="Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity">
        <link:definition>100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100070 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" id="DisclosureCybersecurityRiskManagementStrategyAndGovernance">
        <link:definition>995455 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" id="Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>995465 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements" id="Role_DisclosureCollaborationAndLicenseAgreements">
        <link:definition>995475 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAward" id="Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAward">
        <link:definition>995485 - Disclosure - California Institute for Regenerative Medicine Award</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestments" id="Role_DisclosureInvestments">
        <link:definition>995495 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>995505 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipment" id="Role_DisclosurePropertyAndEquipment">
        <link:definition>995515 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureAccruedExpenses3" id="DisclosureAccruedExpenses3">
        <link:definition>995525 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>995535 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersEquity" id="Role_DisclosureConvertiblePreferredStockAndStockholdersEquity">
        <link:definition>995545 - Disclosure - Convertible Preferred Stock and Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>995555 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReporting" id="DisclosureSegmentReporting">
        <link:definition>995565 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefits" id="Role_DisclosureEmployeeBenefits">
        <link:definition>995575 - Disclosure - Employee Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingencies1" id="DisclosureCommitmentsAndContingencies1">
        <link:definition>995585 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>995595 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995605 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995615 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables" id="Role_DisclosureCollaborationAndLicenseAgreementsTables">
        <link:definition>995625 - Disclosure - Collaboration and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsTables" id="Role_DisclosureInvestmentsTables">
        <link:definition>995635 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>995645 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" id="Role_DisclosurePropertyAndEquipmentTables">
        <link:definition>995655 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>995665 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>995675 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersEquityTables" id="Role_DisclosureConvertiblePreferredStockAndStockholdersEquityTables">
        <link:definition>995685 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>995695 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingTables" id="DisclosureSegmentReportingTables">
        <link:definition>995705 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails" id="Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>995715 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" id="Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails1">
        <link:definition>995725 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" id="Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2">
        <link:definition>995735 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails3" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails3">
        <link:definition>995745 - Disclosure - Organization and Summary of Significant Accounting Policies - (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails4" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails4">
        <link:definition>995755 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails" id="Role_DisclosureCollaborationAndLicenseAgreementsDetails">
        <link:definition>995765 - Disclosure - Collaboration and License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails1" id="Role_DisclosureCollaborationAndLicenseAgreementsDetails1">
        <link:definition>995775 - Disclosure - Collaboration and License Agreements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails2" id="Role_DisclosureCollaborationAndLicenseAgreementsDetails2">
        <link:definition>995785 - Disclosure - Collaboration and License Agreements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails" id="Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails">
        <link:definition>995795 - Disclosure - California Institute For Regenerative Medicine Award (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails" id="Role_DisclosureInvestmentsDetails">
        <link:definition>995805 - Disclosure - Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2" id="Role_DisclosureInvestmentsDetails2">
        <link:definition>995815 - Disclosure - Investments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureInvestmentDetails3ShortTermInvestmentDetails" id="DisclosureInvestmentDetails3ShortTermInvestmentDetails">
        <link:definition>995825 - Disclosure - Investment (Details 3) - Short Term Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails" id="Role_DisclosureFairValueMeasurementsDetails">
        <link:definition>995835 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetails2" id="DisclosureFairValueMeasurementsDetails2">
        <link:definition>995845 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails3" id="Role_DisclosureFairValueMeasurementsDetails3">
        <link:definition>995855 - Disclosure - Fair Value Measurements (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentDetails">
        <link:definition>995865 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" id="DisclosurePropertyAndEquipmentAdditionalInformationDetails">
        <link:definition>995875 - Disclosure - Property and Equipment (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
        <link:definition>995885 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndLongTermDebt2017TermLoanDetails2" id="Role_DisclosureAccruedExpensesAndLongTermDebt2017TermLoanDetails2">
        <link:definition>995895 - Disclosure - Accrued Expenses and Long-Term Debt (2017 Term Loan) (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" id="DisclosureLeasesAdditionalInformationDetails">
        <link:definition>995905 - Disclosure - Leases (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails1" id="Role_DisclosureLeasesDetails1">
        <link:definition>995915 - Disclosure - Leases (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails2" id="Role_DisclosureLeasesDetails2">
        <link:definition>995925 - Disclosure - Leases (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureScheduleOfSubleaseIncomeLeasesDetails" id="DisclosureScheduleOfSubleaseIncomeLeasesDetails">
        <link:definition>995935 - Disclosure - Schedule of sublease income - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" id="DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails">
        <link:definition>995945 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Additional information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails" id="DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails">
        <link:definition>995955 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Stock option activity under all equity and stock option plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails" id="DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails">
        <link:definition>995965 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Restricted stock unit activity under all equity and stock option plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockBasedCompensationForAllStockAwardsDetails" id="DisclosureConvertiblePreferredStockAndStockholdersEquityStockBasedCompensationForAllStockAwardsDetails">
        <link:definition>995975 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Stock based compensation for all stock awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityWeightedAverageAssumptionsUsedInTheBlackscholesOptionPricingModelDetails" id="DisclosureConvertiblePreferredStockAndStockholdersEquityWeightedAverageAssumptionsUsedInTheBlackscholesOptionPricingModelDetails">
        <link:definition>995985 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Weighted average assumptions used in the Black-Scholes option pricing model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails" id="DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails">
        <link:definition>995995 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Schedule of common stock reserved for future issuance (Details )</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails" id="Role_DisclosureIncomeTaxesDetails">
        <link:definition>996005 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails2" id="Role_DisclosureIncomeTaxesDetails2">
        <link:definition>996015 - Disclosure - Income Taxes (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails3" id="Role_DisclosureIncomeTaxesDetails3">
        <link:definition>996025 - Disclosure - Income Taxes (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails4" id="Role_DisclosureIncomeTaxesDetails4">
        <link:definition>996035 - Disclosure - Income Taxes (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" id="DisclosureSegmentReportingAdditionalInformationDetails">
        <link:definition>996045 - Disclosure - Segment Reporting (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentProfitOrLossIncludingSegmentExpensesDetails" id="DisclosureSegmentReportingScheduleOfSegmentProfitOrLossIncludingSegmentExpensesDetails">
        <link:definition>996055 - Disclosure - Segment Reporting - Schedule of Segment Profit or Loss, Including Segment Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefitsDetails" id="Role_DisclosureEmployeeBenefitsDetails">
        <link:definition>996065 - Disclosure - Employee Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails" id="Role_DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>996075 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsDetails" id="Role_DisclosureSubsequentEventsDetails">
        <link:definition>996085 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="fate-20241231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails23" xlink:href="fate-20241231.xsd#DisclosureIncomeTaxesDetails23" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesDetails22" xlink:href="fate-20241231.xsd#DisclosureLeasesDetails22" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="fate-20241231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="fate-20241231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:href="fate-20241231.xsd#Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails" xlink:href="fate-20241231.xsd#Role_DisclosurePropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureAccruedExpensesDetails" xlink:href="fate-20241231.xsd#DisclosureAccruedExpensesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails1" xlink:href="fate-20241231.xsd#Role_DisclosureLeasesDetails1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails2" xlink:href="fate-20241231.xsd#Role_DisclosureLeasesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails" xlink:href="fate-20241231.xsd#Role_DisclosureIncomeTaxesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentProfitOrLossIncludingSegmentExpensesDetails" xlink:href="fate-20241231.xsd#DisclosureSegmentReportingScheduleOfSegmentProfitOrLossIncludingSegmentExpensesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="fate-20241231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" xlink:href="fate-20241231.xsd#Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:href="fate-20241231.xsd#DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="fate-20241231.xsd#Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:href="fate-20241231.xsd#Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails4" xlink:href="fate-20241231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails4" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails" xlink:href="fate-20241231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails1" xlink:href="fate-20241231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsDetails1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails2" xlink:href="fate-20241231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails" xlink:href="fate-20241231.xsd#Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails" xlink:href="fate-20241231.xsd#Role_DisclosureInvestmentsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2" xlink:href="fate-20241231.xsd#Role_DisclosureInvestmentsDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureInvestmentDetails3ShortTermInvestmentDetails" xlink:href="fate-20241231.xsd#DisclosureInvestmentDetails3ShortTermInvestmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails" xlink:href="fate-20241231.xsd#Role_DisclosureFairValueMeasurementsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetails2" xlink:href="fate-20241231.xsd#DisclosureFairValueMeasurementsDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails3" xlink:href="fate-20241231.xsd#Role_DisclosureFairValueMeasurementsDetails3" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:href="fate-20241231.xsd#DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndLongTermDebt2017TermLoanDetails2" xlink:href="fate-20241231.xsd#Role_DisclosureAccruedExpensesAndLongTermDebt2017TermLoanDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="fate-20241231.xsd#DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" xlink:href="fate-20241231.xsd#DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails" xlink:href="fate-20241231.xsd#DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails" xlink:href="fate-20241231.xsd#DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockBasedCompensationForAllStockAwardsDetails" xlink:href="fate-20241231.xsd#DisclosureConvertiblePreferredStockAndStockholdersEquityStockBasedCompensationForAllStockAwardsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityWeightedAverageAssumptionsUsedInTheBlackscholesOptionPricingModelDetails" xlink:href="fate-20241231.xsd#DisclosureConvertiblePreferredStockAndStockholdersEquityWeightedAverageAssumptionsUsedInTheBlackscholesOptionPricingModelDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails" xlink:href="fate-20241231.xsd#DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails2" xlink:href="fate-20241231.xsd#Role_DisclosureIncomeTaxesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails3" xlink:href="fate-20241231.xsd#Role_DisclosureIncomeTaxesDetails3" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails" xlink:href="fate-20241231.xsd#Role_DisclosureCommitmentsAndContingenciesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsDetails" xlink:href="fate-20241231.xsd#Role_DisclosureSubsequentEventsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="fate-20241231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="fate-20241231.xsd#Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements" xlink:href="fate-20241231.xsd#Role_DisclosureCollaborationAndLicenseAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAward" xlink:href="fate-20241231.xsd#Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAward" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestments" xlink:href="fate-20241231.xsd#Role_DisclosureInvestments" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="fate-20241231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipment" xlink:href="fate-20241231.xsd#Role_DisclosurePropertyAndEquipment" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureAccruedExpenses3" xlink:href="fate-20241231.xsd#DisclosureAccruedExpenses3" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeases" xlink:href="fate-20241231.xsd#Role_DisclosureLeases" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersEquity" xlink:href="fate-20241231.xsd#Role_DisclosureConvertiblePreferredStockAndStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="fate-20241231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReporting" xlink:href="fate-20241231.xsd#DisclosureSegmentReporting" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefits" xlink:href="fate-20241231.xsd#Role_DisclosureEmployeeBenefits" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingencies1" xlink:href="fate-20241231.xsd#DisclosureCommitmentsAndContingencies1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:href="fate-20241231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="fate-20241231.xsd#Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="fate-20241231.xsd#Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables" xlink:href="fate-20241231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsTables" xlink:href="fate-20241231.xsd#Role_DisclosureInvestmentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="fate-20241231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" xlink:href="fate-20241231.xsd#Role_DisclosurePropertyAndEquipmentTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureAccruedExpensesTables" xlink:href="fate-20241231.xsd#DisclosureAccruedExpensesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesTables" xlink:href="fate-20241231.xsd#Role_DisclosureLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersEquityTables" xlink:href="fate-20241231.xsd#Role_DisclosureConvertiblePreferredStockAndStockholdersEquityTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="fate-20241231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingTables" xlink:href="fate-20241231.xsd#DisclosureSegmentReportingTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails3" xlink:href="fate-20241231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails3" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureScheduleOfSubleaseIncomeLeasesDetails" xlink:href="fate-20241231.xsd#DisclosureScheduleOfSubleaseIncomeLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails4" xlink:href="fate-20241231.xsd#Role_DisclosureIncomeTaxesDetails4" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" xlink:href="fate-20241231.xsd#DisclosureSegmentReportingAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefitsDetails" xlink:href="fate-20241231.xsd#Role_DisclosureEmployeeBenefitsDetails" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CommercialOptionExerciseMember" xlink:label="fate_CommercialOptionExerciseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_DeferredTaxAssetsCapitalizedRdExpense" xlink:label="fate_DeferredTaxAssetsCapitalizedRdExpense"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_UpfrontCashPayment" xlink:label="fate_UpfrontCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ScientificEquipmentMember" xlink:label="fate_ScientificEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PrivatePlacementOfPreFundedWarrants" xlink:label="fate_PrivatePlacementOfPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockIssuedDuringPeriodValueToCollaborativePartner" xlink:label="fate_StockIssuedDuringPeriodValueToCollaborativePartner"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_WeightedAveragePreFundedWarrants" xlink:label="fate_WeightedAveragePreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockIssuedDuringPeriodSharesToCollaborativePartner" xlink:label="fate_StockIssuedDuringPeriodSharesToCollaborativePartner"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CaliforniaInstituteForRegenerativeMedicineMember" xlink:label="fate_CaliforniaInstituteForRegenerativeMedicineMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageRemainingContractualTerm" xlink:label="fate_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CollaborativeArrangementAggregatePaymentsReceivable" xlink:label="fate_CollaborativeArrangementAggregatePaymentsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_OptionExercisePayment" xlink:label="fate_OptionExercisePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AchievementOfStockPriceAppreciationMilestone" xlink:label="fate_AchievementOfStockPriceAppreciationMilestone"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_LesseeOperatingLeaseCashRentPeriod" xlink:label="fate_LesseeOperatingLeaseCashRentPeriod"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet" xlink:label="fate_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FairValueAssumptionsExpectedVolatilityRate1" xlink:label="fate_FairValueAssumptionsExpectedVolatilityRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PeriodForCumulativeChangeInOwnership" xlink:label="fate_PeriodForCumulativeChangeInOwnership"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AssociatedWithCollaborationServicesMember" xlink:label="fate_AssociatedWithCollaborationServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CandidateTwoMember" xlink:label="fate_CandidateTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_RestructuringPolicytextBlock" xlink:label="fate_RestructuringPolicytextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_MinimumAnnualPaymentsToMaintainLicenses" xlink:label="fate_MinimumAnnualPaymentsToMaintainLicenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_OnoLetterAgreementMember" xlink:label="fate_OnoLetterAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CollaborationAndLicenseAgreementsDisclosureAbstract" xlink:label="fate_CollaborationAndLicenseAgreementsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ShortTermLeasesTermExcludedFromCalculationOfRightOfUseOfAssetsAndLeaseLiabilities" xlink:label="fate_ShortTermLeasesTermExcludedFromCalculationOfRightOfUseOfAssetsAndLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockPriceAppreciationMilestonesLiabilitiesNonCurrent" xlink:label="fate_StockPriceAppreciationMilestonesLiabilitiesNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ImpairmentOfRightOfUseAsset" xlink:label="fate_ImpairmentOfRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_TransactionPriceOfAgreement" xlink:label="fate_TransactionPriceOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_IncomeTaxReconciliationPermanentTaxDifferences" xlink:label="fate_IncomeTaxReconciliationPermanentTaxDifferences"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardMonthlyAwardVestingPeriod" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardMonthlyAwardVestingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_Fairvalueassetslevel1Tolevel2Transfersamounts" xlink:label="fate_Fairvalueassetslevel1Tolevel2Transfersamounts"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_RepaymentPercentageOfAwardAmount" xlink:label="fate_RepaymentPercentageOfAwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForTenantImprovements" xlink:label="us-gaap_PaymentsForTenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:label="us-gaap_IncomeTaxExaminationYearUnderExamination"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_NonRule10B51ArrModifiedFlag" xlink:label="fate_NonRule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_NumberOfDisbursementsReceivableUponExecutionOfAward" xlink:label="fate_NumberOfDisbursementsReceivableUponExecutionOfAward"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AmendedMSKLicenseMember" xlink:label="fate_AmendedMSKLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PatentsOneMember" xlink:label="fate_PatentsOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_LiquidityPolicyTextBlock" xlink:label="fate_LiquidityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_DeferredTaxLiabilitiesDepreciation" xlink:label="fate_DeferredTaxLiabilitiesDepreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PerformanceBasedRestrictedStockUnitsPrsusMember" xlink:label="fate_PerformanceBasedRestrictedStockUnitsPrsusMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ConversionOfPreferenceShareToCommonStock" xlink:label="fate_ConversionOfPreferenceShareToCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PercentageOfDiscretionaryContributionsDescription" xlink:label="fate_PercentageOfDiscretionaryContributionsDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_SublicenseConsiderationRepresentsAnAssetUnderAscOtherAssetsAndDeferredCosts" xlink:label="fate_SublicenseConsiderationRepresentsAnAssetUnderAscOtherAssetsAndDeferredCosts"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FinalPaymentFeeOnDebtFacilityAmount" xlink:label="fate_FinalPaymentFeeOnDebtFacilityAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivableNonaccrualNoAllowance" xlink:label="us-gaap_FinancingReceivableNonaccrualNoAllowance"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_MilestonePaymentUnderDeferredRevenue" xlink:label="fate_MilestonePaymentUnderDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_JanssenBiotechIncMember" xlink:label="fate_JanssenBiotechIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="fate_StockIssuedDuringPeriodSharesWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AwardAgreementExecutedDate" xlink:label="fate_AwardAgreementExecutedDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PersonnelCosts" xlink:label="fate_PersonnelCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_InvestmentMaturityDateRange" xlink:label="fate_InvestmentMaturityDateRange"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtTerm" xlink:label="us-gaap_LongTermDebtTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ShortTermInvestmentMaturityPeriodRangeStart" xlink:label="fate_ShortTermInvestmentMaturityPeriodRangeStart"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_November2016PlacementMember" xlink:label="fate_November2016PlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_TrailingStockPricePerShare" xlink:label="fate_TrailingStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockOptionAndIncentivePlan2013Member" xlink:label="fate_StockOptionAndIncentivePlan2013Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ContraResearchAndDevelopmentExpenses" xlink:label="fate_ContraResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_MilestoneThreeMember" xlink:label="fate_MilestoneThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FairValueInputsStockPriceSensitivityPercentageIncreaseDecrease" xlink:label="fate_FairValueInputsStockPriceSensitivityPercentageIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_IncomeTaxReconciliationNondeductibleCompensation" xlink:label="fate_IncomeTaxReconciliationNondeductibleCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_JanssenAgreementMember" xlink:label="fate_JanssenAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableInterestEntityMeasureOfActivityAbstract" xlink:label="us-gaap_VariableInterestEntityMeasureOfActivityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_Fairvalueliabilitieslevel1Tolevel2Transfersamounts" xlink:label="fate_Fairvalueliabilitieslevel1Tolevel2Transfersamounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PatentsFourMember" xlink:label="fate_PatentsFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ClinicalProgramsExpense" xlink:label="fate_ClinicalProgramsExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AmortizationOfSubLicenseConsideration" xlink:label="fate_AmortizationOfSubLicenseConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CollaborativeArrangementAnnualPaymentsReceivableRecordedUnderDeferredRevenue" xlink:label="fate_CollaborativeArrangementAnnualPaymentsReceivableRecordedUnderDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_RepaymentsOfDebtIncludingPrincipalAndFinalFee" xlink:label="fate_RepaymentsOfDebtIncludingPrincipalAndFinalFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_TaxCreditCarryforwardBeginningExpirationYear" xlink:label="fate_TaxCreditCarryforwardBeginningExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PeriodToTreatAwardAsGrantIfAwardNotTreatedAsLoan" xlink:label="fate_PeriodToTreatAwardAsGrantIfAwardNotTreatedAsLoan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CommonStockMultiple1" xlink:label="fate_CommonStockMultiple1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FirstJanssenCancerTargetMember" xlink:label="fate_FirstJanssenCancerTargetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLeasehold" xlink:label="us-gaap_ImpairmentOfLeasehold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockPriceAppreciationMilestonesPolicyTextBlock" xlink:label="fate_StockPriceAppreciationMilestonesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockOptionAndIncentivePlan2022Member" xlink:label="fate_StockOptionAndIncentivePlan2022Member"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FtEightOneNineMember" xlink:label="fate_FtEightOneNineMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AccruedClinicalTrialRelatedCostsCurrent" xlink:label="fate_AccruedClinicalTrialRelatedCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_WarrantsExerciseTermsDescription" xlink:label="fate_WarrantsExerciseTermsDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_EmployeeAndNonEmployeeStockOptionMember" xlink:label="fate_EmployeeAndNonEmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockPriceDecreasedByTenPercentPerShareMember" xlink:label="fate_StockPriceDecreasedByTenPercentPerShareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_IncomeTaxReconciliationReserveForUncertainTaxPositions" xlink:label="fate_IncomeTaxReconciliationReserveForUncertainTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PurchasePriceOfPrefundedWarrants" xlink:label="fate_PurchasePriceOfPrefundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_JohnsonJohnsonInnovationJJDCIncMember" xlink:label="fate_JohnsonJohnsonInnovationJJDCIncMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ResearchServicesMember" xlink:label="fate_ResearchServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_UpfrontNonRefundableNonCreditablePaymentReceivable" xlink:label="fate_UpfrontNonRefundableNonCreditablePaymentReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CIRMAwardLiabilityNoncurrent" xlink:label="fate_CIRMAwardLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FairValueAssumptionsExpectedTerm1" xlink:label="fate_FairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MunicipalNotesMember" xlink:label="us-gaap_MunicipalNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_EarlyTerminationFee" xlink:label="fate_EarlyTerminationFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_EmployeeRetentionCreditPolicy" xlink:label="fate_EmployeeRetentionCreditPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockPurchaseAgreementMember" xlink:label="fate_StockPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StraightLineRentAdjustments" xlink:label="us-gaap_StraightLineRentAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PatentNumber" xlink:label="fate_PatentNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnuallyAwardVestingPeriod" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnuallyAwardVestingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_MilestoneTwoMember" xlink:label="fate_MilestoneTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_MaximumPercentageOfCommonStockOwnershipTogetherWithAffiliatesAllowableAfterExerciseOfPrefundedWarrants" xlink:label="fate_MaximumPercentageOfCommonStockOwnershipTogetherWithAffiliatesAllowableAfterExerciseOfPrefundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ProceedsFromCIRMAward" xlink:label="fate_ProceedsFromCIRMAward"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_MilestonePayments" xlink:label="fate_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" xlink:label="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_OnoPharmaceuticalCompanyLtdMember" xlink:label="fate_OnoPharmaceuticalCompanyLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AmendedAndRestatedExclusiveLicenseAgreementMember" xlink:label="fate_AmendedAndRestatedExclusiveLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PatentsSixMember" xlink:label="fate_PatentsSixMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue" xlink:label="fate_CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AdditionalCancerTargetsMember" xlink:label="fate_AdditionalCancerTargetsMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PreferredStockConversionPrice" xlink:label="fate_PreferredStockConversionPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_NumberOfDisbursementsReceivableBasedOnCompletionOfCertainOperatingMilestones" xlink:label="fate_NumberOfDisbursementsReceivableBasedOnCompletionOfCertainOperatingMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestAggregateIntrinsicValue" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_MaximumPercentageOfCommonStockOwnershipAfterChangeUponNotice" xlink:label="fate_MaximumPercentageOfCommonStockOwnershipAfterChangeUponNotice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_RedmileGroupLimitedLiabilityCompanyAndAffiliatesMember" xlink:label="fate_RedmileGroupLimitedLiabilityCompanyAndAffiliatesMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PrepaidExpensesAndOtherAssetsMember" xlink:label="fate_PrepaidExpensesAndOtherAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AwardAgreementForResearchAndDevelopmentDisclosureTextBlock" xlink:label="fate_AwardAgreementForResearchAndDevelopmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PreFundedWarrantsMember" xlink:label="fate_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockPriceAppreciationMilestonesMember" xlink:label="fate_StockPriceAppreciationMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_DebtInstrumentRepaymentPhaseFourRateMember" xlink:label="fate_DebtInstrumentRepaymentPhaseFourRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_UpfrontFeeMember" xlink:label="fate_UpfrontFeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CollaborativeArrangementPercentageOfReductionOnMilestonePayments" xlink:label="fate_CollaborativeArrangementPercentageOfReductionOnMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_SharePriceFairValueInput" xlink:label="fate_SharePriceFairValueInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxUncertaintiesAbstract" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_Fairvalueassetslevel2Tolevel1Transfersamounts" xlink:label="fate_Fairvalueassetslevel2Tolevel1Transfersamounts"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ResearchActivitiesExpense" xlink:label="fate_ResearchActivitiesExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ScheduleOfMilestonePaymentsValuationAssumptionsTableTextBlock" xlink:label="fate_ScheduleOfMilestonePaymentsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_GladstoneLicenseAgreementMember" xlink:label="fate_GladstoneLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PatentsFiveMember" xlink:label="fate_PatentsFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AwardFromRegenerativeMedicineInstituteTable" xlink:label="fate_AwardFromRegenerativeMedicineInstituteTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_OperatingLossCarryforwardsExpirationYear" xlink:label="fate_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_DebtInstrumentRepaymentPhaseThreeRateMember" xlink:label="fate_DebtInstrumentRepaymentPhaseThreeRateMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ProfitLossSharingPercentage" xlink:label="fate_ProfitLossSharingPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="fate_StockIssuedDuringPeriodValueWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_Stockpriceappreciationmilestoneincome" xlink:label="fate_Stockpriceappreciationmilestoneincome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CommonStockOfPublicOfferingAndIssuanceOfPreFundedWarrants" xlink:label="fate_CommonStockOfPublicOfferingAndIssuanceOfPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockPriceAppreciationMilestonePayable" xlink:label="fate_StockPriceAppreciationMilestonePayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FacilitiesCosts" xlink:label="fate_FacilitiesCosts"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_MilestoneOneMember" xlink:label="fate_MilestoneOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAbstract" xlink:label="us-gaap_InvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_UnrecognizedTaxBenefitsResultingInNetOperatingLossAndTaxCreditCarryforward" xlink:label="fate_UnrecognizedTaxBenefitsResultingInNetOperatingLossAndTaxCreditCarryforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_EnterpriseValueMilestonesLiabilityAtFairValue" xlink:label="fate_EnterpriseValueMilestonesLiabilityAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_DeferredTaxAssetsLeaseLiabilities" xlink:label="fate_DeferredTaxAssetsLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_Fairvalueliabilitieslevel2Tolevel1Transfersamounts" xlink:label="fate_Fairvalueliabilitieslevel2Tolevel1Transfersamounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PatentsThreeMember" xlink:label="fate_PatentsThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="us-gaap_OtherCurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockPurchaseAgreementAxis" xlink:label="fate_StockPurchaseAgreementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AwardFromRegenerativeMedicineInstituteAbstract" xlink:label="fate_AwardFromRegenerativeMedicineInstituteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PatentsSevenMember" xlink:label="fate_PatentsSevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PatentsTwoMember" xlink:label="fate_PatentsTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AddtionalAmountAvailableForFundingUnderAward" xlink:label="fate_AddtionalAmountAvailableForFundingUnderAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_EquityPremiumOnSharePricePerShareUnderAgreement" xlink:label="fate_EquityPremiumOnSharePricePerShareUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CompanyReceivedPayment" xlink:label="fate_CompanyReceivedPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_OtherSegmentExpenses" xlink:label="fate_OtherSegmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants" xlink:label="fate_PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CandidateOneMember" xlink:label="fate_CandidateOneMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockPriceAppreciationMilestones" xlink:label="fate_StockPriceAppreciationMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AggregateEquityPremiumOnSharesIssuedUnderAgreement" xlink:label="fate_AggregateEquityPremiumOnSharesIssuedUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockPriceIncreasedByTenPercentPerShareMember" xlink:label="fate_StockPriceIncreasedByTenPercentPerShareMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CumulativeChangeInOwnershipPercentage" xlink:label="fate_CumulativeChangeInOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PercentageOfTaxCredit" xlink:label="fate_PercentageOfTaxCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_DebtInstrumentRepaymentPhaseTwoRateMember" xlink:label="fate_DebtInstrumentRepaymentPhaseTwoRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_SublicenseConsiderationMember" xlink:label="fate_SublicenseConsiderationMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="fate_DeferredTaxLiabilitiesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PotentialAmountPayable" xlink:label="fate_PotentialAmountPayable"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_OperatingLossCarryforwardsIndefiniteLife" xlink:label="fate_OperatingLossCarryforwardsIndefiniteLife"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_DefinedContributionPlanMinimumAgeOfEmployee" xlink:label="fate_DefinedContributionPlanMinimumAgeOfEmployee"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_Rule10B51ArrModifiedFlag" xlink:label="fate_Rule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PercentageOfCommonStockOwnershipUponPreferredStockConversion" xlink:label="fate_PercentageOfCommonStockOwnershipUponPreferredStockConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" xlink:label="us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CorrespondingAssetForSublicenseConsiderationPaid" xlink:label="fate_CorrespondingAssetForSublicenseConsiderationPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToEmployees" xlink:label="us-gaap_PaymentsToEmployees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_EnterpriseValueMilestonePayment" xlink:label="fate_EnterpriseValueMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:label="us-gaap_FairValueInputsQuantitativeInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ProceedsFromResearchAndDevelopmentFeesReceived" xlink:label="fate_ProceedsFromResearchAndDevelopmentFeesReceived"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AwardFromCaliforniaInstituteForRegenerativeMedicineAbstract" xlink:label="fate_AwardFromCaliforniaInstituteForRegenerativeMedicineAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CommonStockIssuedDuringPeriodSharesPrivatePlacement" xlink:label="fate_CommonStockIssuedDuringPeriodSharesPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CommonStockMultiplesAndTheEnterpriseValueMilestonePaymentsTableTextBlock" xlink:label="fate_CommonStockMultiplesAndTheEnterpriseValueMilestonePaymentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CandidateThreeMember" xlink:label="fate_CandidateThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AwardForFirstInHumanClinicalTrial" xlink:label="fate_AwardForFirstInHumanClinicalTrial"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_LoanAndSecurityAgreementMember" xlink:label="fate_LoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_EmployeesAndDirectorsStockOptionsMember" xlink:label="fate_EmployeesAndDirectorsStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_EmployeeRetentionCreditMember" xlink:label="fate_EmployeeRetentionCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ConversionOfPreferredSharesToCommonStocksShares" xlink:label="fate_ConversionOfPreferredSharesToCommonStocksShares"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_RefundableTaxCredit" xlink:label="fate_RefundableTaxCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:label="us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_DebtInstrumentRepaymentPhaseOneRateMember" xlink:label="fate_DebtInstrumentRepaymentPhaseOneRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockPurchaseAgreementDomain" xlink:label="fate_StockPurchaseAgreementDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_InducementPlanMember" xlink:label="fate_InducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FirstDisbursementAmountUnderTheAwardPayableForNextTwelveMonths" xlink:label="fate_FirstDisbursementAmountUnderTheAwardPayableForNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:label="fate_AwardFromRegenerativeMedicineInstituteLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="fate_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_GrantAward" xlink:label="fate_GrantAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FirstDisbursementAmountUnderTheAward" xlink:label="fate_FirstDisbursementAmountUnderTheAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FairValueAssumptionsRiskFreeInterestRate1" xlink:label="fate_FairValueAssumptionsRiskFreeInterestRate1"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_UpfrontFeeAndEquityPremiumMember" xlink:label="fate_UpfrontFeeAndEquityPremiumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:label="us-gaap_TypeOfRevenueExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ConvertiblePreferredStockPolicyTextBlock" xlink:label="fate_ConvertiblePreferredStockPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" xlink:label="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ClinicalDevelopmentMilestoneFees" xlink:label="fate_ClinicalDevelopmentMilestoneFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_GrantIncomeFromCirmAward" xlink:label="fate_GrantIncomeFromCirmAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PercentOfTaxableIncomeOffset" xlink:label="fate_PercentOfTaxableIncomeOffset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermInvestmentsMember" xlink:label="us-gaap_OtherLongTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockIssuedDuringPeriodSharesForPrivatePlacement" xlink:label="fate_StockIssuedDuringPeriodSharesForPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PercentageOfCommonStockOwnershipForPreferredStockConversionChangeUponNotice" xlink:label="fate_PercentageOfCommonStockOwnershipForPreferredStockConversionChangeUponNotice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PatentCostsPolicyTextBlock" xlink:label="fate_PatentCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CollaborativeArrangementAggregateMilestonePaymentsReceivable" xlink:label="fate_CollaborativeArrangementAggregateMilestonePaymentsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CommonStockIssuedDuringPeriodValuePrivatePlacement" xlink:label="fate_CommonStockIssuedDuringPeriodValuePrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AccruedExpensesAndLongTermDebtDisclosureAbstract" xlink:label="fate_AccruedExpensesAndLongTermDebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CommonStockCapitalAdditionalSharesReservedForFutureIssuance" xlink:label="fate_CommonStockCapitalAdditionalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AmendedMskccLicenseMember" xlink:label="fate_AmendedMskccLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FTFiveOneSixMember" xlink:label="fate_FTFiveOneSixMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_NumberOfDisbursements" xlink:label="fate_NumberOfDisbursements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ComputerAndOfficeEquipmentMember" xlink:label="fate_ComputerAndOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ShortTermInvestmentMaturityPeriodRangeEnd" xlink:label="fate_ShortTermInvestmentMaturityPeriodRangeEnd"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CollaborativeArrangementPotentialAdditionalMilestones" xlink:label="fate_CollaborativeArrangementPotentialAdditionalMilestones"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CommercialOptionExerciseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Option Exercise Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CommercialOptionExerciseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial option exercise [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CommercialOptionExerciseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial option exercise [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_DeferredTaxAssetsCapitalizedRdExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets Capitalized RD expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_DeferredTaxAssetsCapitalizedRdExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Capitalized RD expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_DeferredTaxAssetsCapitalizedRdExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized R&amp;D expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_UpfrontCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront cash payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_UpfrontCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Cash Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_UpfrontCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront Cash Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ScientificEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scientific Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ScientificEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scientific Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ScientificEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Scientific equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PrivatePlacementOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private placement of pre-funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PrivatePlacementOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement of Pre Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PrivatePlacementOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Private placement of pre Funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax computed at federal statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Deferred Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockIssuedDuringPeriodValueToCollaborativePartner_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of stock to collaboration partner, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockIssuedDuringPeriodValueToCollaborativePartner_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value To Collaborative Partner</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockIssuedDuringPeriodValueToCollaborativePartner_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate value of stock issued to the collaborative partner during the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_WeightedAveragePreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average pre-funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_WeightedAveragePreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted-average pre-funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_WeightedAveragePreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted-average pre-funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockIssuedDuringPeriodSharesToCollaborativePartner_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of stock to collaboration partner, net of issuance costs (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockIssuedDuringPeriodSharesToCollaborativePartner_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares To Collaborative Partner</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockIssuedDuringPeriodSharesToCollaborativePartner_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of stock shares issued to the collaborative partner during the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Adjustment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CaliforniaInstituteForRegenerativeMedicineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California Institute for Regenerative Medicine</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CaliforniaInstituteForRegenerativeMedicineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">California Institute For Regenerative Medicine [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CaliforniaInstituteForRegenerativeMedicineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">California institute for regenerative medicine .</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost related to unvested restricted shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Tax [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive gain:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Exercisable at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected to vest at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Expected To Vest Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based Compensation arrangement by share-based payment award equity instruments other than options expected to vest weighted remaining contractual term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CollaborativeArrangementAggregatePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate research and development fees payments receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CollaborativeArrangementAggregatePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Aggregate Payments Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CollaborativeArrangementAggregatePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement aggregate payments receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock awarded grant value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon vesting of restricted stock units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Other Observable Inputs (Level 2)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_OptionExercisePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option exercise payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_OptionExercisePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Exercise Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_OptionExercisePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option exercise payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AchievementOfStockPriceAppreciationMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Achievement of stock price appreciation milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AchievementOfStockPriceAppreciationMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Achievement of stock price appreciation milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_LesseeOperatingLeaseCashRentPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_LesseeOperatingLeaseCashRentPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Cash Rent Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_LesseeOperatingLeaseCashRentPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease cash rent period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets and lease liabilities, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Right Of Use Assets And Lease Liabilities Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in right-of-use assets and lease liabilities, net.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_FairValueAssumptionsExpectedVolatilityRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_FairValueAssumptionsExpectedVolatilityRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assumptions Expected Volatility Rate1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_FairValueAssumptionsExpectedVolatilityRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value Assumptions Expected Volatility Rate 1.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued payroll and other employee benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Salaries, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PeriodForCumulativeChangeInOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period of change in ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PeriodForCumulativeChangeInOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Period For Cumulative Change In Ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PeriodForCumulativeChangeInOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Period for cumulative change in ownership.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Changes in the Fair Value of the Company&#8217;s Level 3 Enterprise Fair Value Milestone Payment Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AssociatedWithCollaborationServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Associated with collaboration services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AssociatedWithCollaborationServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Associated with Collaboration Services [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AssociatedWithCollaborationServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Associated with Collaboration Services [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options generally vested on anniversary grant date (as a percent)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CandidateTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Candidate 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CandidateTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Candidate Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CandidateTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Candidate two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_RestructuringPolicytextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_RestructuringPolicytextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring PolicyText Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_RestructuringPolicytextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restructuring PolicyText Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock and Stockholders&#8217; Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_MinimumAnnualPaymentsToMaintainLicenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum annual payments to maintain licenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_MinimumAnnualPaymentsToMaintainLicenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Annual Payments To Maintain Licenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_MinimumAnnualPaymentsToMaintainLicenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum annual payments to maintain licenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_OnoLetterAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ono Letter Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_OnoLetterAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ono Letter Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_OnoLetterAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ono Letter Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CollaborationAndLicenseAgreementsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreements Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CollaborationAndLicenseAgreementsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">No definition available.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ShortTermLeasesTermExcludedFromCalculationOfRightOfUseOfAssetsAndLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term leases term excluded from calculation of ROU and lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ShortTermLeasesTermExcludedFromCalculationOfRightOfUseOfAssetsAndLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Leases Term Excluded From Calculation Of Right Of Use Of Assets And Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ShortTermLeasesTermExcludedFromCalculationOfRightOfUseOfAssetsAndLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short-term leases term excluded from calculation of right of use of assets and lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal amount of the final fee payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Annual Principal Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockPriceAppreciationMilestonesLiabilitiesNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Price Appreciation Milestones Liabilities Non Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockPriceAppreciationMilestonesLiabilitiesNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock price appreciation milestones, non current portion.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockPriceAppreciationMilestonesLiabilitiesNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock price appreciation milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Terms of conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Convertible, Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Opinion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ImpairmentOfRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Right of Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ImpairmentOfRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Impairment of Right of Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ImpairmentOfRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Right of Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, issued shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_TransactionPriceOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction price of the agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_TransactionPriceOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Price Of Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_TransactionPriceOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transaction price of agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_IncomeTaxReconciliationPermanentTaxDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_IncomeTaxReconciliationPermanentTaxDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Permanent Tax Differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_IncomeTaxReconciliationPermanentTaxDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent differences.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardMonthlyAwardVestingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Monthly vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardMonthlyAwardVestingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Monthly Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardMonthlyAwardVestingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the monthly vesting period of share-based compensation awards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_Fairvalueassetslevel1Tolevel2Transfersamounts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">FairValueAssetsLevel1ToLevel2TransfersAmounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_Fairvalueassetslevel1Tolevel2Transfersamounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">FairValueAssetsLevel1ToLevel2TransfersAmounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_Fairvalueassetslevel1Tolevel2Transfersamounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Assets, Level 1 to Level 2 Transfers, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_RepaymentPercentageOfAwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayment percentage of award amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_RepaymentPercentageOfAwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayment Percentage Of Award Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_RepaymentPercentageOfAwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repayment percentage of award amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForTenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate tenant improvements of the premises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForTenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Tenant Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationYearUnderExamination_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax examination, year under examination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationYearUnderExamination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Year under Examination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Rule 10b51 Arr Modified Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Rule 10b51 Arr Modified Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Rule 10b5-1 Arrangement Modified</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_NumberOfDisbursementsReceivableUponExecutionOfAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of disbursement receivable upon the execution of the award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_NumberOfDisbursementsReceivableUponExecutionOfAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Disbursements Receivable Upon Execution Of Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_NumberOfDisbursementsReceivableUponExecutionOfAward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of disbursements receivable upon execution of award.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AmendedMSKLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended MSK License</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AmendedMSKLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended M S K License [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AmendedMSKLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended MSK license member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PatentsOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patents One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PatentsOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Patents One Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Estimated Fair Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_LiquidityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Going Concern Assessment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_LiquidityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_LiquidityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Exercisable at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_DeferredTaxLiabilitiesDepreciation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_DeferredTaxLiabilitiesDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_DeferredTaxLiabilitiesDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities depreciation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PerformanceBasedRestrictedStockUnitsPrsusMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Based Restricted Stock Units (PRSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PerformanceBasedRestrictedStockUnitsPrsusMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance Based Restricted Stock Units (PRSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PerformanceBasedRestrictedStockUnitsPrsusMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Based Restricted Stock Units PRSU</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, option to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ConversionOfPreferenceShareToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred shares to common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ConversionOfPreferenceShareToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Preference Share To Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ConversionOfPreferenceShareToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of preferred share conversion to common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PercentageOfDiscretionaryContributionsDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of discretionary contributions description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PercentageOfDiscretionaryContributionsDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of discretionary contributions description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Less:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_SublicenseConsiderationRepresentsAnAssetUnderAscOtherAssetsAndDeferredCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublicense Consideration Represents an Asset Under ASC, Other Assets and Deferred Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_SublicenseConsiderationRepresentsAnAssetUnderAscOtherAssetsAndDeferredCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublicense Consideration Represents an Asset Under ASC, Other Assets and Deferred Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_SublicenseConsiderationRepresentsAnAssetUnderAscOtherAssetsAndDeferredCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublicense consideration represents an asset under ASC, other assets and deferred costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_FinalPaymentFeeOnDebtFacilityAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Final payment fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_FinalPaymentFeeOnDebtFacilityAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Final Payment Fee On Debt Facility Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_FinalPaymentFeeOnDebtFacilityAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Final payment fee on debt facility amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancingReceivableNonaccrualNoAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Receivable, Nonaccrual, No Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancingReceivableNonaccrualNoAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale securities, recognition of expected credit losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_MilestonePaymentUnderDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment under Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_MilestonePaymentUnderDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Under Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_MilestonePaymentUnderDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone Payment Under Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_JanssenBiotechIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Janssen Biotech Inc</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_JanssenBiotechIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Janssen Biotech Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_JanssenBiotechIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Janssen Biotech Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements Nonrecurring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Nonrecurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon cashless warrant exercise (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, shares, warrants exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AwardAgreementExecutedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award agreement executed date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AwardAgreementExecutedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Agreement Executed Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AwardAgreementExecutedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Award agreement executed date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net of deferred tax assets and liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net of deferred tax assets and liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Vested and expected to vest at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PersonnelCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Personnel Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PersonnelCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Personnel Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PersonnelCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Personnel costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_InvestmentMaturityDateRange_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_InvestmentMaturityDateRange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Maturity Date Range</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_InvestmentMaturityDateRange_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment maturity date range.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements Recurring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss on investments, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CIRM Award as a loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ShortTermInvestmentMaturityPeriodRangeStart_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short term investments, maturity start range</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ShortTermInvestmentMaturityPeriodRangeStart_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investment Maturity Period Range Start</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ShortTermInvestmentMaturityPeriodRangeStart_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short-term investment maturity period range start.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_November2016PlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">November 2016 Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_November2016PlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">November2016 Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_November2016PlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">November 2016 placement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares to be purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible asset amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Basic and Diluted Net Loss per Share Attributable to Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Performance stock, granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Asset, Finite-Lived [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Anti-Dilutive Securities not Included in Calculation of Diluted Net Loss Per Common Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk&#8211;free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_TrailingStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ten-trading day trailing average common stock price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_TrailingStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trailing Stock Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_TrailingStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Trailing stock price per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockOptionAndIncentivePlan2013Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option And Incentive Plan 2013</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockOptionAndIncentivePlan2013Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Option And Incentive Plan2013 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockOptionAndIncentivePlan2013Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to 2013 Stock Option and Incentive Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate debt securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ContraResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contra research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ContraResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contra Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ContraResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contra research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, net of issuance costs (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Exercisable at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_MilestoneThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_MilestoneThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_MilestoneThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone Three Member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Matching contributions under 401(k) plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_FairValueInputsStockPriceSensitivityPercentageIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sensitivity analysis fair value inputs stock price increase/decrease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_FairValueInputsStockPriceSensitivityPercentageIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Stock Price Sensitivity Percentage Increase Decrease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_FairValueInputsStockPriceSensitivityPercentageIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sensitivity percentage increase/decrease in stock price used as an input to measure fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Financial Statement Error Correction Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of collaboration contract asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost, Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income expense in change in fair value of the stock price appreciation milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_IncomeTaxReconciliationNondeductibleCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-deductible compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_IncomeTaxReconciliationNondeductibleCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Nondeductible Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_IncomeTaxReconciliationNondeductibleCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation nondeductible compensation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of stock awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_JanssenAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Janssen Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_JanssenAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Janssen Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_JanssenAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Janssen agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture And Fixtures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax position description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Likelihood of Unfavorable Settlement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, issued shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from equity incentive plans, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableInterestEntityMeasureOfActivityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Interest Entity, Measure of Activity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_Fairvalueliabilitieslevel1Tolevel2Transfersamounts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">FairValueLiabilitiesLevel1ToLevel2TransfersAmounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_Fairvalueliabilitieslevel1Tolevel2Transfersamounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">FairValueLiabilitiesLevel1ToLevel2TransfersAmounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_Fairvalueliabilitieslevel1Tolevel2Transfersamounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock purchases under the plan (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PatentsFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patents Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PatentsFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Patents Four Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Vested and expected to vest at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ClinicalProgramsExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Programs, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ClinicalProgramsExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical Programs, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ClinicalProgramsExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receipt of first disbursement under the Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Collaborators</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AmortizationOfSubLicenseConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of sublicense consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AmortizationOfSubLicenseConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Sub License Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AmortizationOfSubLicenseConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization of sub license consideration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Voting Class A Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Class A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CollaborativeArrangementAnnualPaymentsReceivableRecordedUnderDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative arrangement annual payments receivable recorded as deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CollaborativeArrangementAnnualPaymentsReceivableRecordedUnderDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Annual Payments Receivable Recorded Under Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CollaborativeArrangementAnnualPaymentsReceivableRecordedUnderDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement annual payments receivable recorded under deferred revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_RepaymentsOfDebtIncludingPrincipalAndFinalFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayments of debt amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_RepaymentsOfDebtIncludingPrincipalAndFinalFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Debt Including Principal And Final Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_RepaymentsOfDebtIncludingPrincipalAndFinalFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repayments of debt including principal and final fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, outstanding shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_TaxCreditCarryforwardBeginningExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_TaxCreditCarryforwardBeginningExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Beginning Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_TaxCreditCarryforwardBeginningExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward beginning expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of the Company's expected federal income tax provision (benefit) to the actual income tax provision</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PeriodToTreatAwardAsGrantIfAwardNotTreatedAsLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period to treat award as grant, if award not treated as loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PeriodToTreatAwardAsGrantIfAwardNotTreatedAsLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Period To Treat Award As Grant If Award Not Treated As Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PeriodToTreatAwardAsGrantIfAwardNotTreatedAsLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Period to treat award as grant, if award not treated as loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CommonStockMultiple1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock multiple</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CommonStockMultiple1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Multiple1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CommonStockMultiple1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock Multiple</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of restricted stock unit activity and related information under all equity plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_FirstJanssenCancerTargetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Janssen Cancer Target</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_FirstJanssenCancerTargetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Janssen Cancer Target [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_FirstJanssenCancerTargetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">first Janssen Cancer Target</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLeasehold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment charge on right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLeasehold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Leasehold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockPriceAppreciationMilestonesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Price Appreciation Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockPriceAppreciationMilestonesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Price Appreciation Milestones Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockPriceAppreciationMilestonesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock price appreciation milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets measured at fair value on a recurring basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total assets measured at fair value on a recurring basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockOptionAndIncentivePlan2022Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Option And Incentive Plan2022 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockOptionAndIncentivePlan2022Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Option And Incentive Plan2022 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockOptionAndIncentivePlan2022Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Awards available under the 2022 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_FtEightOneNineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">FT Eight One Nine [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_FtEightOneNineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">FT Eight One Nine [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Payments Under Non-cancelable Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected recognition period of unrecognized compensation cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from private placement of common stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Company's Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AccruedClinicalTrialRelatedCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical trial related costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AccruedClinicalTrialRelatedCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Trial Related Costs Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AccruedClinicalTrialRelatedCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical trial related costs current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash and Cash Equivalents, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_WarrantsExerciseTermsDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Terms of exercise</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_WarrantsExerciseTermsDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercise Terms Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_WarrantsExerciseTermsDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants exercise terms description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segments [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_EmployeeAndNonEmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee And Non Employee Stock Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_EmployeeAndNonEmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents an arrangement whereby both an employee and a non-employee is entitled to receive in the future, subject to vesting and other restrictions, certain number of shares in the entity at a specified price, as defined in the agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_EmployeeAndNonEmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee and Non Employee Stock Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockPriceDecreasedByTenPercentPerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock price decreased by 10% per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockPriceDecreasedByTenPercentPerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Price Decreased By Ten Percent Per Share [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockPriceDecreasedByTenPercentPerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock price decreased by ten percent per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_IncomeTaxReconciliationReserveForUncertainTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reserve for uncertain tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_IncomeTaxReconciliationReserveForUncertainTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Reserve For Uncertain Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_IncomeTaxReconciliationReserveForUncertainTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation reserve for uncertain tax positions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PurchasePriceOfPrefundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price of prefunded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PurchasePriceOfPrefundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Price Of Prefunded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PurchasePriceOfPrefundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase price of prefunded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Vested and expected to vest at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Closing stock price as of measurement date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total fair value of awards vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_JohnsonJohnsonInnovationJJDCIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Johnson Johnson Innovation J J D C Inc</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_JohnsonJohnsonInnovationJJDCIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Johnson Johnson Innovation J J D C Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_JohnsonJohnsonInnovationJJDCIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Johnson &amp; Johnson Innovation-JJDC, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ResearchServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ResearchServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Services [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ResearchServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research services.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_UpfrontNonRefundableNonCreditablePaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable upfront payments recorded as deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_UpfrontNonRefundableNonCreditablePaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Non Refundable Non Creditable Payment Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_UpfrontNonRefundableNonCreditablePaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront non-refundable non-creditable payment receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CIRMAwardLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C I R M Award Liability Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CIRMAwardLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CIRM award liability, noncurrent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CIRMAwardLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CIRM award liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_FairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_FairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assumptions Expected Term1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_FairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value Assumptions Expected Term 1.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction-in-Process</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MunicipalNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Municipal securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MunicipalNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Municipal Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible Preferred Stock (if converted)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Stock (if converted)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_EarlyTerminationFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Early termination fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_EarlyTerminationFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Early Termination Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_EarlyTerminationFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">One-time option to terminate the lease, subject to certain termination payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, weighted-average discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_EmployeeRetentionCreditPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee Retention Credit Policy</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_EmployeeRetentionCreditPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Retention Credit Policy</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_EmployeeRetentionCreditPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Retention credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate purchase price of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public offering of common stock, net of offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment charge on property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Impairment Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Asset Impairment Charges, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Lease Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock purchase agreement [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total intrinsic value of stock options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">R&amp;D tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">R&amp;D tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StraightLineRentAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Straight-line lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StraightLineRentAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Straight Line Rent Adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PatentNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patent Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PatentNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Patent Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PatentNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of weighted-average assumptions used to determine the fair value of employee and nonemployee stock option grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnuallyAwardVestingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annually vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnuallyAwardVestingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Annually Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnuallyAwardVestingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award annually award vesting period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_MilestoneTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_MilestoneTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_MilestoneTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone Two Member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State tax, net of federal tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The Premises 2020 Lease Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_MaximumPercentageOfCommonStockOwnershipTogetherWithAffiliatesAllowableAfterExerciseOfPrefundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of common stock ownership together with affiliates allowable after exercise of prefunded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_MaximumPercentageOfCommonStockOwnershipTogetherWithAffiliatesAllowableAfterExerciseOfPrefundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Percentage Of Common Stock Ownership Together With Affiliates Allowable After Exercise Of Prefunded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_MaximumPercentageOfCommonStockOwnershipTogetherWithAffiliatesAllowableAfterExerciseOfPrefundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum percentage of common stock ownership together with affiliates allowable after exercise of prefunded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity By Class Of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, by Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value, 12 Months or Greater</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ProceedsFromCIRMAward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from CIRM award.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ProceedsFromCIRMAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From C I R M Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ProceedsFromCIRMAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from FT819 CIRM award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock price appreciation milestone payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments during the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Decrease related to prior year tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease related to prior year tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock And Stockholders Deficit Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock and stockholders' equity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of reconciliation of the Company's expected federal income tax provision (benefit) to the actual income tax provision</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_OnoPharmaceuticalCompanyLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ono Pharmaceutical Company Ltd</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_OnoPharmaceuticalCompanyLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ono Pharmaceutical Company Ltd [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_OnoPharmaceuticalCompanyLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ono Pharmaceutical Company Ltd.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AmendedAndRestatedExclusiveLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended MSK License</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AmendedAndRestatedExclusiveLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended And Restated Exclusive License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AmendedAndRestatedExclusiveLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended and Restated Exclusive License Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average assumptions to determine fair value of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders&#8217; Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetRentableArea_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Rentable Area</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetRentableArea_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Rentable Area</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon vesting of restricted stock units (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive securities (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock&#8211;based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PatentsSixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patents Six [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PatentsSixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Patents Six Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable upfront payments recorded as deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements Upfront Payments Recorded Under Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the amount of upfront payments received under collaborative arrangements is recorded as deferred revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on disposal of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Disposition of Property Plant Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on disposal of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AdditionalCancerTargetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Cancer Targets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AdditionalCancerTargetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Cancer Targets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AdditionalCancerTargetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional Cancer Targets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PreferredStockConversionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PreferredStockConversionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Conversion Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PreferredStockConversionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock conversion price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_NumberOfDisbursementsReceivableBasedOnCompletionOfCertainOperatingMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of disbursements receivable based on completion of certain operating milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_NumberOfDisbursementsReceivableBasedOnCompletionOfCertainOperatingMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Disbursements Receivable Based On Completion Of Certain Operating Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_NumberOfDisbursementsReceivableBasedOnCompletionOfCertainOperatingMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of disbursements receivable based on completion of certain operating milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expected To Vest Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based Compensation arrangement by share-based payment award equity instruments other than options expected to vest aggregate intrinsic value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock units expected to vest at December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of allocation of stock-based compensation for all stock awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_MaximumPercentageOfCommonStockOwnershipAfterChangeUponNotice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of common stock ownership after change upon notice.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_MaximumPercentageOfCommonStockOwnershipAfterChangeUponNotice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Percentage Of Common Stock Ownership After Change Upon Notice</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_MaximumPercentageOfCommonStockOwnershipAfterChangeUponNotice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum percentage of common stock ownership after change upon notice.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Vested and expected to vest at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost related to outstanding options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_RedmileGroupLimitedLiabilityCompanyAndAffiliatesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redmile Group, LLC and Affiliates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_RedmileGroupLimitedLiabilityCompanyAndAffiliatesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redmile Group Limited Liability Company And Affiliates [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_RedmileGroupLimitedLiabilityCompanyAndAffiliatesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redmile Group, LLC and Affiliates.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PrepaidExpensesAndOtherAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses And Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PrepaidExpensesAndOtherAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PrepaidExpensesAndOtherAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid expenses and other assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AwardAgreementForResearchAndDevelopmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California Institute for Regenerative Medicine Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AwardAgreementForResearchAndDevelopmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Agreement For Research And Development Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AwardAgreementForResearchAndDevelopmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Award agreement for research and development disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-Funded Warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockPriceAppreciationMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock price appreciation milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockPriceAppreciationMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Price Appreciation Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockPriceAppreciationMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock price appreciation milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of sublease Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Other Nonoperating Income, by Component [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale, Maturity and Collection of Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale, Maturity and Collection of Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_DebtInstrumentRepaymentPhaseFourRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan Repayment Rate Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_DebtInstrumentRepaymentPhaseFourRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Repayment Phase Four Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_DebtInstrumentRepaymentPhaseFourRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument repayment phase four rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value by Liability Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value by Liability Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_UpfrontFeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_UpfrontFeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Fee [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_UpfrontFeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock for license agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for license agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Issued for Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CollaborativeArrangementPercentageOfReductionOnMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of reduction on milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CollaborativeArrangementPercentageOfReductionOnMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Percentage Of Reduction On Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CollaborativeArrangementPercentageOfReductionOnMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement percentage of reduction on milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_SharePriceFairValueInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sensitivity analysis share price fair value input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_SharePriceFairValueInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price Fair Value Input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_SharePriceFairValueInput_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sensitivity analysis share price fair value input.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Software and Software Development Costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value per share of employee options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Impairment of Right of Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements-building</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Uncertainties [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Dividends_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends declared</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Dividends_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Dividends_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Dividends, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in the Company's unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_Fairvalueassetslevel2Tolevel1Transfersamounts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">FairValueAssetsLevel2ToLevel1TransfersAmounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_Fairvalueassetslevel2Tolevel1Transfersamounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">FairValueAssetsLevel2ToLevel1TransfersAmounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_Fairvalueassetslevel2Tolevel1Transfersamounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Assets, Level 2 to Level 1 Transfers, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ResearchActivitiesExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Activities, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ResearchActivitiesExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research Activities, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ResearchActivitiesExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public offerings of common stock, net of offering costs (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ScheduleOfMilestonePaymentsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Milestone Payments Valuation Assumptions Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ScheduleOfMilestonePaymentsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of milestone payments valuation assumptions table text block.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ScheduleOfMilestonePaymentsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Determine the Estimated Fair Value of the Stock Price Appreciation Milestones Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General vesting period after first year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, existence of option to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_GladstoneLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gladstone License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_GladstoneLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gladstone License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_GladstoneLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gladstone license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PatentsFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patents Five [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PatentsFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Patents Five Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AwardFromRegenerativeMedicineInstituteTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award From Regenerative Medicine Institute [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AwardFromRegenerativeMedicineInstituteTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award From Regenerative Medicine Institute [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AwardFromRegenerativeMedicineInstituteTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Award from regenerative medicine institute.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforward expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits that, if recognized, would reduce the effective tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_DebtInstrumentRepaymentPhaseThreeRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan Repayment Rate Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_DebtInstrumentRepaymentPhaseThreeRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Repayment Phase Three Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_DebtInstrumentRepaymentPhaseThreeRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument repayment phase three rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ProfitLossSharingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Profits and losses sharing percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ProfitLossSharingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss Sharing Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ProfitLossSharingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Profit loss sharing percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total fair value of stock options vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon cashless warrant exercise</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, value, warrants exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_Stockpriceappreciationmilestoneincome_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">StockPriceAppreciationMilestoneIncome</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_Stockpriceappreciationmilestoneincome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">StockPriceAppreciationMilestoneIncome</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_Stockpriceappreciationmilestoneincome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock price appreciation milestone, income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Losses, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrealized Losses, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CommonStockOfPublicOfferingAndIssuanceOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public offering of common stock and issuance of pre-funded warrants, net of offering costs (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CommonStockOfPublicOfferingAndIssuanceOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Of Public Offering And Issuance Of Pre Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CommonStockOfPublicOfferingAndIssuanceOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock of public offering and issuance of pre funded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockPriceAppreciationMilestonePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock price appreciation milestone payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockPriceAppreciationMilestonePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Price Appreciation Milestone Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockPriceAppreciationMilestonePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock price appreciation milestone payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_FacilitiesCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Facilities costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_FacilitiesCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Facilities Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_FacilitiesCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Facilities Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_MilestoneOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_MilestoneOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_MilestoneOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone one member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market fund</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares used to compute basic net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Increase related to prior year tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase related to prior year tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to terminate lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Terminate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_UnrecognizedTaxBenefitsResultingInNetOperatingLossAndTaxCreditCarryforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_UnrecognizedTaxBenefitsResultingInNetOperatingLossAndTaxCreditCarryforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Resulting In Net Operating Loss And Tax Credit Carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_UnrecognizedTaxBenefitsResultingInNetOperatingLossAndTaxCreditCarryforward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the amount of an unrecognized tax benefit that is directly related to a position taken in a tax year, which results in a net operating loss and tax credit carryforward.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, authorized shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful lives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_EnterpriseValueMilestonesLiabilityAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Enterprise Value Milestones Liability At Fair Value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_EnterpriseValueMilestonesLiabilityAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Enterprise Value Milestones Liability At Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_EnterpriseValueMilestonesLiabilityAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Enterprise value milestones liability at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quoted prices in Active Market for Identical Assets (Level 1)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Common Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General And Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_Fairvalueliabilitieslevel2Tolevel1Transfersamounts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">FairValueLiabilitiesLevel2ToLevel1TransfersAmounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_Fairvalueliabilitieslevel2Tolevel1Transfersamounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">FairValueLiabilitiesLevel2ToLevel1TransfersAmounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_Fairvalueliabilitieslevel2Tolevel1Transfersamounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Impairment loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PatentsThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patents Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PatentsThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Patents Three Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Current Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockPurchaseAgreementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockPurchaseAgreementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Purchase Agreement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockPurchaseAgreementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock purchase agreement axis.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of pre-funded warrants, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AwardFromRegenerativeMedicineInstituteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award From Regenerative Medicine Institute [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AwardFromRegenerativeMedicineInstituteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Award from regenerative medicine institute.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PatentsSevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patents Seven [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PatentsSevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Patents Seven Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase related to current year tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PatentsTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patents Two Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PatentsTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Patents Two Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale securities, recognition of expected credit losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other-than-Temporary Impairment, Credit Losses Recognized in Earnings, Credit Losses on Debt Securities Held</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Credit Losses on Debt Securities Held, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Credit Losses on Debt Securities Held, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental schedule of noncash investing and financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AddtionalAmountAvailableForFundingUnderAward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Addtional amount available for funding under award.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AddtionalAmountAvailableForFundingUnderAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Addtional Amount Available For Funding Under Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AddtionalAmountAvailableForFundingUnderAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional amount available for funding under award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AddtionalAmountAvailableForFundingUnderAward_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Addtional Amount Available For Funding Under Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, Cash Equivalents and Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_EquityPremiumOnSharePricePerShareUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity premium per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_EquityPremiumOnSharePricePerShareUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Premium On Share Price Per Share Under Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_EquityPremiumOnSharePricePerShareUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity premium on share price per share under agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CompanyReceivedPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company Received Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CompanyReceivedPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Company Received Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CompanyReceivedPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Company Received Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_OtherSegmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Segment Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_OtherSegmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other Segment Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_OtherSegmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other segment expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net change in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public offering of common stock and issuance of pre-funded warrants, net of offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering Of Common Stock And Issuance Of Pre Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public offering of common stock and issuance of pre-funded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic and diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accured Interest on investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Operating and Nonoperating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share issue price (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CandidateOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Candidate one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CandidateOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Candidate One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CandidateOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Candidate 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockPriceAppreciationMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock price appreciation milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockPriceAppreciationMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Price Appreciation Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockPriceAppreciationMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock price appreciation milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AggregateEquityPremiumOnSharesIssuedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate equity premium on shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AggregateEquityPremiumOnSharesIssuedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Equity Premium On Shares Issued Under Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AggregateEquityPremiumOnSharesIssuedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate equity premium on shares issued under agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockPriceIncreasedByTenPercentPerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock price increased by 10% per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockPriceIncreasedByTenPercentPerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Price Increased By Ten Percent Per Share [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockPriceIncreasedByTenPercentPerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock price increased by ten percent per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected to vest at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expected To Vest Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based Compensation arrangement by share-based payment award equity instruments other than options expected to vest number.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CumulativeChangeInOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative changes in ownership percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CumulativeChangeInOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Change In Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CumulativeChangeInOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cumulative change in ownership percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Exercisable at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale securities, realized gains (losses) on sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Realized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Realized Gain (Loss), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PercentageOfTaxCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of Tax Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PercentageOfTaxCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Tax Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PercentageOfTaxCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage Of Tax Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_DebtInstrumentRepaymentPhaseTwoRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Repayment Phase Two Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_DebtInstrumentRepaymentPhaseTwoRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument repayment phase two rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_DebtInstrumentRepaymentPhaseTwoRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan Repayment Rate Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_SublicenseConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublicense Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_SublicenseConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublicense Consideration [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_SublicenseConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublicense consideration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Right Of Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of deferred tax liability attributable to taxable temporary differences from right-of-use assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of stock option activity and related information under all equity plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock Options Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value; authorized shares - 5,000,000; Class A Convertible Preferred shares issued and outstanding - 2,755,086 at December 31, 2024 and 2,761,108 at December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment in accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Californian</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">California Franchise Tax Board [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of the change in the Company's unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from public offering of common stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Letters of credit outstanding amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letters of credit outstanding amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letters of Credit Outstanding, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Related Party Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PotentialAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Amount Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PotentialAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential Amount Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_OperatingLossCarryforwardsIndefiniteLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards indefinite life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_OperatingLossCarryforwardsIndefiniteLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Indefinite Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_OperatingLossCarryforwardsIndefiniteLife_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards indefinite life.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_DefinedContributionPlanMinimumAgeOfEmployee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum age of employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_DefinedContributionPlanMinimumAgeOfEmployee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Minimum Age Of Employee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_DefinedContributionPlanMinimumAgeOfEmployee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents minimum age of employees to become eligible for participation under defined contribution plans.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_Rule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rule 10b5-1 Arrangement Modified</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_Rule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rule 10b51 Arr Modified Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_Rule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rule 10b51 Arr Modified Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred shares to common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and summary of significant accounting policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PercentageOfCommonStockOwnershipUponPreferredStockConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of common stock ownership upon preferred stock conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PercentageOfCommonStockOwnershipUponPreferredStockConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Common Stock Ownership Upon Preferred Stock Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PercentageOfCommonStockOwnershipUponPreferredStockConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of common stock ownership upon preferred stock conversion.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregated by investment category and the length of time</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Holdings, Schedule of Investments [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CorrespondingAssetForSublicenseConsiderationPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublicense consideration paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CorrespondingAssetForSublicenseConsiderationPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corresponding Asset For Sublicense Consideration Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CorrespondingAssetForSublicenseConsiderationPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Corresponding asset for sublicense consideration paid.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, outstanding shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments To Employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses, Less Than 12 Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Losses, Less Than 12 Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_EnterpriseValueMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock price appreciation milestones potential payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_EnterpriseValueMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Enterprise Value Milestone Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_EnterpriseValueMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Enterprise value milestone payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsQuantitativeInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Determine the estimated fair value of the enterprise value milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsQuantitativeInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Class A Convertible Preferred Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ProceedsFromResearchAndDevelopmentFeesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development fees cash payments received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ProceedsFromResearchAndDevelopmentFeesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Research And Development Fees Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ProceedsFromResearchAndDevelopmentFeesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds From Research and Development Fees Received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AwardFromCaliforniaInstituteForRegenerativeMedicineAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award From California Institute For Regenerative Medicine Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AwardFromCaliforniaInstituteForRegenerativeMedicineAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Award from the california institute for regenerative medicine.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AwardFromCaliforniaInstituteForRegenerativeMedicineAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award From California Institute For Regenerative Medicine [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of significant components of the Company's deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award considered as a loan, interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Stated Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares to be issued upon conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CommonStockIssuedDuringPeriodSharesPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private placement of common stock, net of issuance costs (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CommonStockIssuedDuringPeriodSharesPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Issued During Period Shares Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CommonStockIssuedDuringPeriodSharesPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock issued during period shares private placement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CommonStockMultiplesAndTheEnterpriseValueMilestonePaymentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of All Possible Stock Price Appreciation Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CommonStockMultiplesAndTheEnterpriseValueMilestonePaymentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Multiples And The Enterprise Value Milestone Payments Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CommonStockMultiplesAndTheEnterpriseValueMilestonePaymentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock multiples and the enterprise value milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CandidateThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Candidate 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CandidateThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Candidate Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CandidateThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Candidate Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AwardForFirstInHumanClinicalTrial_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award for first-in-human clinical trial</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AwardForFirstInHumanClinicalTrial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award For First In Human Clinical Trial</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AwardForFirstInHumanClinicalTrial_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Award for first-in-human clinical trial.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_LoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan and Security Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_LoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan And Security Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_LoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan and security agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_EmployeesAndDirectorsStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee and Directors Stock Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_EmployeesAndDirectorsStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employees And Directors Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_EmployeesAndDirectorsStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employees and Directors stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_EmployeeRetentionCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee Retention Credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_EmployeeRetentionCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Retention Credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ConversionOfPreferredSharesToCommonStocksShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred shares to common stock (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ConversionOfPreferredSharesToCommonStocksShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Preferred Shares To Common Stocks Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ConversionOfPreferredSharesToCommonStocksShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of preferred shares to common stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_RefundableTaxCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Refundable Tax Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_RefundableTaxCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Refundable Tax Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_RefundableTaxCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RefundableTaxCredit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional shares authorized (as a percent)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Additional Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the percentage of additional shares authorized for issuance under an established share-based compensation plan as a proportion of outstanding capital stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity method investment, underlying equity in net assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Underlying Equity in Net Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_DebtInstrumentRepaymentPhaseOneRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan Repayment Rate One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_DebtInstrumentRepaymentPhaseOneRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Repayment Phase One Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_DebtInstrumentRepaymentPhaseOneRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument repayment phase one rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Investments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNetNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Collaboration contract assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNetNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration contract asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNetNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNetNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockPurchaseAgreementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockPurchaseAgreementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Purchase Agreement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockPurchaseAgreementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock purchase agreement domain.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_InducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inducement Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_InducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inducement Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_InducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Inducement plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_InducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Awards available under the Inducement Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_FirstDisbursementAmountUnderTheAwardPayableForNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Disbursement Amount Under The Award Payable For Next Twelve Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_FirstDisbursementAmountUnderTheAwardPayableForNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First Disbursement Amount Under The Award Payable For Next Twelve Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AwardFromRegenerativeMedicineInstituteLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award from California institute for regenerative medicine</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AwardFromRegenerativeMedicineInstituteLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award From Regenerative Medicine Institute [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AwardFromRegenerativeMedicineInstituteLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Award from regenerative medicine institute.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of common stock reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Stock Reserved For Future Issuance Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of the common stock reserved for future issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_GrantAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant awarded</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_GrantAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_GrantAward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant award.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_FirstDisbursementAmountUnderTheAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Disbursement Amount Under The Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_FirstDisbursementAmountUnderTheAward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First Disbursement Amount Under The Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value, Less Than 12 Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_FairValueAssumptionsRiskFreeInterestRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_FairValueAssumptionsRiskFreeInterestRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assumptions Risk Free Interest Rate1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_FairValueAssumptionsRiskFreeInterestRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value Assumptions Risk Free Interest Rate 1.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_UpfrontFeeAndEquityPremiumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront Fee and Equity Premium</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_UpfrontFeeAndEquityPremiumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Fee And Equity Premium [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_UpfrontFeeAndEquityPremiumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront fee and equity premium.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Expense Information Used by CODM, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expense information used by CODM, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfRevenueExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Type of Revenue [Extensible List]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfRevenueExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Product and Service [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ConvertiblePreferredStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ConvertiblePreferredStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ConvertiblePreferredStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; authorized shares - 250,000,000; issued and outstanding - 113,928,279 at December 31, 2024 and 98,627,076 at December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Changes in fair value of stock price appreciation milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in fair value of stock price appreciation milestones liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of stock price appreciation milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Fair Value Of Stock Price Appreciation Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in fair value of stock price appreciation milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ClinicalDevelopmentMilestoneFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical development milestone fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ClinicalDevelopmentMilestoneFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Development Milestone Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ClinicalDevelopmentMilestoneFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical Development Milestone Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_GrantIncomeFromCirmAward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_GrantIncomeFromCirmAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant income from CIRM award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_GrantIncomeFromCirmAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Income From CIRM Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_GrantIncomeFromCirmAward_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Grant income from FT516 CIRM award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market fund</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PercentOfTaxableIncomeOffset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percent of taxable income offset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PercentOfTaxableIncomeOffset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percent Of Taxable Income Offset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PercentOfTaxableIncomeOffset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percent of taxable income offset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assets Measured at Fair Value on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLongTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Investments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLongTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Long-Term Investments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockIssuedDuringPeriodSharesForPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock during period for private placements (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockIssuedDuringPeriodSharesForPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares For Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_StockIssuedDuringPeriodSharesForPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares for private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PercentageOfCommonStockOwnershipForPreferredStockConversionChangeUponNotice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred shares converted into common stock percentage of ownership change upon notice</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PercentageOfCommonStockOwnershipForPreferredStockConversionChangeUponNotice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Common Stock Ownership For Preferred Stock Conversion Change Upon Notice</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PercentageOfCommonStockOwnershipForPreferredStockConversionChangeUponNotice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of common stock ownership for preferred stock conversion change upon notice.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PatentCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PatentCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patent Costs Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_PatentCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for patent costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale securities, impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other-than-temporary Impairment Loss, Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses, 12 Months or Greater</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Losses, 12 Months or Greater</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares used to compute diluted net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of segment profit or loss, including segment expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Receivable, after Allowance for Credit Loss, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Renewal term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance-based restricted granted, none of vested Units Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future minimum payments under the operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected to vest at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expected To Vest Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based Compensation arrangement by share-based payment award equity instruments other than options expected to vest weighted average grant date fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CollaborativeArrangementAggregateMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CollaborativeArrangementAggregateMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Aggregate Milestone Payments Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CollaborativeArrangementAggregateMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement aggregate milestone payments receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CommonStockIssuedDuringPeriodValuePrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private placement of common stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CommonStockIssuedDuringPeriodValuePrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Issued During Period Value Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CommonStockIssuedDuringPeriodValuePrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock issued during period value private placement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AccruedExpensesAndLongTermDebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses And Long Term Debt Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AccruedExpensesAndLongTermDebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses and long term debt disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for license agreements (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Issued for Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Treasuries, Commercial paper. Non US government securities and Corporate Debt Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury debt securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate contractual rent expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Rent Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Leases, Rent Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CommonStockCapitalAdditionalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional shares reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CommonStockCapitalAdditionalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Additional Shares Reserved For Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CommonStockCapitalAdditionalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock capital additional shares reserved for future issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion and amortization of premiums and discounts on investments, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AmendedMskccLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended MSKCC License [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_AmendedMskccLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended MSKCC License [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignGovernmentDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-U.S. government securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignGovernmentDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Security, Government, Non-US [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_FTFiveOneSixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FT516</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_FTFiveOneSixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">F T Five One Six [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_FTFiveOneSixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">FT516.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets obtained in exchange for lease obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_NumberOfDisbursements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of disbursements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_NumberOfDisbursements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Disbursements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_NumberOfDisbursements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of disbursements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Unobservable Inputs (Level 3)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining weighted-average lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ComputerAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer And Office Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ComputerAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer And Office Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ComputerAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to computer and office equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ShortTermInvestmentMaturityPeriodRangeEnd_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short term investments, maturity end range</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ShortTermInvestmentMaturityPeriodRangeEnd_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investment Maturity Period Range End</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_ShortTermInvestmentMaturityPeriodRangeEnd_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short-term investment maturity period range end.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Compensation Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain on available-for-sale securities, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total financial liabilities measured at fair value on a recurring basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Liabilities, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total short-term lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CollaborativeArrangementPotentialAdditionalMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative arrangement potential additional milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CollaborativeArrangementPotentialAdditionalMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Potential Additional Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fate_CollaborativeArrangementPotentialAdditionalMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement potential additional milestones.</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_CommercialOptionExerciseMember" xlink:to="fate_CommercialOptionExerciseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_DeferredTaxAssetsCapitalizedRdExpense" xlink:to="fate_DeferredTaxAssetsCapitalizedRdExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_UpfrontCashPayment" xlink:to="fate_UpfrontCashPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ScientificEquipmentMember" xlink:to="fate_ScientificEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_PrivatePlacementOfPreFundedWarrants" xlink:to="fate_PrivatePlacementOfPreFundedWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_StockIssuedDuringPeriodValueToCollaborativePartner" xlink:to="fate_StockIssuedDuringPeriodValueToCollaborativePartner_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_WeightedAveragePreFundedWarrants" xlink:to="fate_WeightedAveragePreFundedWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_StockIssuedDuringPeriodSharesToCollaborativePartner" xlink:to="fate_StockIssuedDuringPeriodSharesToCollaborativePartner_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_CaliforniaInstituteForRegenerativeMedicineMember" xlink:to="fate_CaliforniaInstituteForRegenerativeMedicineMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageRemainingContractualTerm" xlink:to="fate_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageRemainingContractualTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_CollaborativeArrangementAggregatePaymentsReceivable" xlink:to="fate_CollaborativeArrangementAggregatePaymentsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_OptionExercisePayment" xlink:to="fate_OptionExercisePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_AchievementOfStockPriceAppreciationMilestone" xlink:to="fate_AchievementOfStockPriceAppreciationMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_LesseeOperatingLeaseCashRentPeriod" xlink:to="fate_LesseeOperatingLeaseCashRentPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet" xlink:to="fate_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_FairValueAssumptionsExpectedVolatilityRate1" xlink:to="fate_FairValueAssumptionsExpectedVolatilityRate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_PeriodForCumulativeChangeInOwnership" xlink:to="fate_PeriodForCumulativeChangeInOwnership_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_AssociatedWithCollaborationServicesMember" xlink:to="fate_AssociatedWithCollaborationServicesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_CandidateTwoMember" xlink:to="fate_CandidateTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_RestructuringPolicytextBlock" xlink:to="fate_RestructuringPolicytextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_MinimumAnnualPaymentsToMaintainLicenses" xlink:to="fate_MinimumAnnualPaymentsToMaintainLicenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_OnoLetterAgreementMember" xlink:to="fate_OnoLetterAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_CollaborationAndLicenseAgreementsDisclosureAbstract" xlink:to="fate_CollaborationAndLicenseAgreementsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ShortTermLeasesTermExcludedFromCalculationOfRightOfUseOfAssetsAndLeaseLiabilities" xlink:to="fate_ShortTermLeasesTermExcludedFromCalculationOfRightOfUseOfAssetsAndLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_StockPriceAppreciationMilestonesLiabilitiesNonCurrent" xlink:to="fate_StockPriceAppreciationMilestonesLiabilitiesNonCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ImpairmentOfRightOfUseAsset" xlink:to="fate_ImpairmentOfRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentAssetsMember" xlink:to="us-gaap_OtherNoncurrentAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_TransactionPriceOfAgreement" xlink:to="fate_TransactionPriceOfAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_IncomeTaxReconciliationPermanentTaxDifferences" xlink:to="fate_IncomeTaxReconciliationPermanentTaxDifferences_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardMonthlyAwardVestingPeriod" xlink:to="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardMonthlyAwardVestingPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_Fairvalueassetslevel1Tolevel2Transfersamounts" xlink:to="fate_Fairvalueassetslevel1Tolevel2Transfersamounts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_RepaymentPercentageOfAwardAmount" xlink:to="fate_RepaymentPercentageOfAwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForTenantImprovements" xlink:to="us-gaap_PaymentsForTenantImprovements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:to="us-gaap_IncomeTaxExaminationYearUnderExamination_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_NonRule10B51ArrModifiedFlag" xlink:to="fate_NonRule10B51ArrModifiedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_NumberOfDisbursementsReceivableUponExecutionOfAward" xlink:to="fate_NumberOfDisbursementsReceivableUponExecutionOfAward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_AmendedMSKLicenseMember" xlink:to="fate_AmendedMSKLicenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_PatentsOneMember" xlink:to="fate_PatentsOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_LiquidityPolicyTextBlock" xlink:to="fate_LiquidityPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_DeferredTaxLiabilitiesDepreciation" xlink:to="fate_DeferredTaxLiabilitiesDepreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_PerformanceBasedRestrictedStockUnitsPrsusMember" xlink:to="fate_PerformanceBasedRestrictedStockUnitsPrsusMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ConversionOfPreferenceShareToCommonStock" xlink:to="fate_ConversionOfPreferenceShareToCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_PercentageOfDiscretionaryContributionsDescription" xlink:to="fate_PercentageOfDiscretionaryContributionsDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_SublicenseConsiderationRepresentsAnAssetUnderAscOtherAssetsAndDeferredCosts" xlink:to="fate_SublicenseConsiderationRepresentsAnAssetUnderAscOtherAssetsAndDeferredCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_FinalPaymentFeeOnDebtFacilityAmount" xlink:to="fate_FinalPaymentFeeOnDebtFacilityAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableNonaccrualNoAllowance" xlink:to="us-gaap_FinancingReceivableNonaccrualNoAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_MilestonePaymentUnderDeferredRevenue" xlink:to="fate_MilestonePaymentUnderDeferredRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_JanssenBiotechIncMember" xlink:to="fate_JanssenBiotechIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="fate_StockIssuedDuringPeriodSharesWarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_AwardAgreementExecutedDate" xlink:to="fate_AwardAgreementExecutedDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_PersonnelCosts" xlink:to="fate_PersonnelCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_InvestmentMaturityDateRange" xlink:to="fate_InvestmentMaturityDateRange_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTerm" xlink:to="us-gaap_LongTermDebtTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ShortTermInvestmentMaturityPeriodRangeStart" xlink:to="fate_ShortTermInvestmentMaturityPeriodRangeStart_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_November2016PlacementMember" xlink:to="fate_November2016PlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_TrailingStockPricePerShare" xlink:to="fate_TrailingStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_StockOptionAndIncentivePlan2013Member" xlink:to="fate_StockOptionAndIncentivePlan2013Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ContraResearchAndDevelopmentExpenses" xlink:to="fate_ContraResearchAndDevelopmentExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_MilestoneThreeMember" xlink:to="fate_MilestoneThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_FairValueInputsStockPriceSensitivityPercentageIncreaseDecrease" xlink:to="fate_FairValueInputsStockPriceSensitivityPercentageIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostAmortization" xlink:to="us-gaap_CapitalizedContractCostAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_IncomeTaxReconciliationNondeductibleCompensation" xlink:to="fate_IncomeTaxReconciliationNondeductibleCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_JanssenAgreementMember" xlink:to="fate_JanssenAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityMeasureOfActivityAbstract" xlink:to="us-gaap_VariableInterestEntityMeasureOfActivityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_Fairvalueliabilitieslevel1Tolevel2Transfersamounts" xlink:to="fate_Fairvalueliabilitieslevel1Tolevel2Transfersamounts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_PatentsFourMember" xlink:to="fate_PatentsFourMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ClinicalProgramsExpense" xlink:to="fate_ClinicalProgramsExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollaborators" xlink:to="us-gaap_ProceedsFromCollaborators_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_AmortizationOfSubLicenseConsideration" xlink:to="fate_AmortizationOfSubLicenseConsideration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredClassAMember" xlink:to="us-gaap_PreferredClassAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_CollaborativeArrangementAnnualPaymentsReceivableRecordedUnderDeferredRevenue" xlink:to="fate_CollaborativeArrangementAnnualPaymentsReceivableRecordedUnderDeferredRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_RepaymentsOfDebtIncludingPrincipalAndFinalFee" xlink:to="fate_RepaymentsOfDebtIncludingPrincipalAndFinalFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_ShortTermInvestmentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_TaxCreditCarryforwardBeginningExpirationYear" xlink:to="fate_TaxCreditCarryforwardBeginningExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_PeriodToTreatAwardAsGrantIfAwardNotTreatedAsLoan" xlink:to="fate_PeriodToTreatAwardAsGrantIfAwardNotTreatedAsLoan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_CommonStockMultiple1" xlink:to="fate_CommonStockMultiple1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_FirstJanssenCancerTargetMember" xlink:to="fate_FirstJanssenCancerTargetMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLeasehold" xlink:to="us-gaap_ImpairmentOfLeasehold_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_StockPriceAppreciationMilestonesPolicyTextBlock" xlink:to="fate_StockPriceAppreciationMilestonesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_StockOptionAndIncentivePlan2022Member" xlink:to="fate_StockOptionAndIncentivePlan2022Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_FtEightOneNineMember" xlink:to="fate_FtEightOneNineMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_AccruedClinicalTrialRelatedCostsCurrent" xlink:to="fate_AccruedClinicalTrialRelatedCostsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_WarrantsExerciseTermsDescription" xlink:to="fate_WarrantsExerciseTermsDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_EmployeeAndNonEmployeeStockOptionMember" xlink:to="fate_EmployeeAndNonEmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_StockPriceDecreasedByTenPercentPerShareMember" xlink:to="fate_StockPriceDecreasedByTenPercentPerShareMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_IncomeTaxReconciliationReserveForUncertainTaxPositions" xlink:to="fate_IncomeTaxReconciliationReserveForUncertainTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_PurchasePriceOfPrefundedWarrants" xlink:to="fate_PurchasePriceOfPrefundedWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_JohnsonJohnsonInnovationJJDCIncMember" xlink:to="fate_JohnsonJohnsonInnovationJJDCIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ResearchServicesMember" xlink:to="fate_ResearchServicesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_UpfrontNonRefundableNonCreditablePaymentReceivable" xlink:to="fate_UpfrontNonRefundableNonCreditablePaymentReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_CIRMAwardLiabilityNoncurrent" xlink:to="fate_CIRMAwardLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_FairValueAssumptionsExpectedTerm1" xlink:to="fate_FairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MunicipalNotesMember" xlink:to="us-gaap_MunicipalNotesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_EarlyTerminationFee" xlink:to="fate_EarlyTerminationFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_EmployeeRetentionCreditPolicy" xlink:to="fate_EmployeeRetentionCreditPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_StockPurchaseAgreementMember" xlink:to="fate_StockPurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TenantImprovements" xlink:to="us-gaap_TenantImprovements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StraightLineRentAdjustments" xlink:to="us-gaap_StraightLineRentAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_PatentNumber" xlink:to="fate_PatentNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnuallyAwardVestingPeriod" xlink:to="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnuallyAwardVestingPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_MilestoneTwoMember" xlink:to="fate_MilestoneTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAgreementsMember" xlink:to="us-gaap_LeaseAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_MaximumPercentageOfCommonStockOwnershipTogetherWithAffiliatesAllowableAfterExerciseOfPrefundedWarrants" xlink:to="fate_MaximumPercentageOfCommonStockOwnershipTogetherWithAffiliatesAllowableAfterExerciseOfPrefundedWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ProceedsFromCIRMAward" xlink:to="fate_ProceedsFromCIRMAward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_MilestonePayments" xlink:to="fate_MilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" xlink:to="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_OnoPharmaceuticalCompanyLtdMember" xlink:to="fate_OnoPharmaceuticalCompanyLtdMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_AmendedAndRestatedExclusiveLicenseAgreementMember" xlink:to="fate_AmendedAndRestatedExclusiveLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetRentableArea" xlink:to="us-gaap_NetRentableArea_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_PatentsSixMember" xlink:to="fate_PatentsSixMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue" xlink:to="fate_CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_AdditionalCancerTargetsMember" xlink:to="fate_AdditionalCancerTargetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_PreferredStockConversionPrice" xlink:to="fate_PreferredStockConversionPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_NumberOfDisbursementsReceivableBasedOnCompletionOfCertainOperatingMilestones" xlink:to="fate_NumberOfDisbursementsReceivableBasedOnCompletionOfCertainOperatingMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestAggregateIntrinsicValue" xlink:to="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_MaximumPercentageOfCommonStockOwnershipAfterChangeUponNotice" xlink:to="fate_MaximumPercentageOfCommonStockOwnershipAfterChangeUponNotice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_RedmileGroupLimitedLiabilityCompanyAndAffiliatesMember" xlink:to="fate_RedmileGroupLimitedLiabilityCompanyAndAffiliatesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_PrepaidExpensesAndOtherAssetsMember" xlink:to="fate_PrepaidExpensesAndOtherAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_AwardAgreementForResearchAndDevelopmentDisclosureTextBlock" xlink:to="fate_AwardAgreementForResearchAndDevelopmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_PreFundedWarrantsMember" xlink:to="fate_PreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_StockPriceAppreciationMilestonesMember" xlink:to="fate_StockPriceAppreciationMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_DebtInstrumentRepaymentPhaseFourRateMember" xlink:to="fate_DebtInstrumentRepaymentPhaseFourRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_UpfrontFeeMember" xlink:to="fate_UpfrontFeeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_CollaborativeArrangementPercentageOfReductionOnMilestonePayments" xlink:to="fate_CollaborativeArrangementPercentageOfReductionOnMilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_SharePriceFairValueInput" xlink:to="fate_SharePriceFairValueInput_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="us-gaap_IncomeTaxUncertaintiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Dividends" xlink:to="us-gaap_Dividends_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_Fairvalueassetslevel2Tolevel1Transfersamounts" xlink:to="fate_Fairvalueassetslevel2Tolevel1Transfersamounts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ResearchActivitiesExpense" xlink:to="fate_ResearchActivitiesExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ScheduleOfMilestonePaymentsValuationAssumptionsTableTextBlock" xlink:to="fate_ScheduleOfMilestonePaymentsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_GladstoneLicenseAgreementMember" xlink:to="fate_GladstoneLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_PatentsFiveMember" xlink:to="fate_PatentsFiveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_AwardFromRegenerativeMedicineInstituteTable" xlink:to="fate_AwardFromRegenerativeMedicineInstituteTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_OperatingLossCarryforwardsExpirationYear" xlink:to="fate_OperatingLossCarryforwardsExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_DebtInstrumentRepaymentPhaseThreeRateMember" xlink:to="fate_DebtInstrumentRepaymentPhaseThreeRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ProfitLossSharingPercentage" xlink:to="fate_ProfitLossSharingPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="fate_StockIssuedDuringPeriodValueWarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_Stockpriceappreciationmilestoneincome" xlink:to="fate_Stockpriceappreciationmilestoneincome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_CommonStockOfPublicOfferingAndIssuanceOfPreFundedWarrants" xlink:to="fate_CommonStockOfPublicOfferingAndIssuanceOfPreFundedWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_StockPriceAppreciationMilestonePayable" xlink:to="fate_StockPriceAppreciationMilestonePayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_FacilitiesCosts" xlink:to="fate_FacilitiesCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_MilestoneOneMember" xlink:to="fate_MilestoneOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_InvestmentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_UnrecognizedTaxBenefitsResultingInNetOperatingLossAndTaxCreditCarryforward" xlink:to="fate_UnrecognizedTaxBenefitsResultingInNetOperatingLossAndTaxCreditCarryforward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_EnterpriseValueMilestonesLiabilityAtFairValue" xlink:to="fate_EnterpriseValueMilestonesLiabilityAtFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_DeferredTaxAssetsLeaseLiabilities" xlink:to="fate_DeferredTaxAssetsLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_Fairvalueliabilitieslevel2Tolevel1Transfersamounts" xlink:to="fate_Fairvalueliabilitieslevel2Tolevel1Transfersamounts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_PatentsThreeMember" xlink:to="fate_PatentsThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsMember" xlink:to="us-gaap_OtherCurrentAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_StockPurchaseAgreementAxis" xlink:to="fate_StockPurchaseAgreementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_AwardFromRegenerativeMedicineInstituteAbstract" xlink:to="fate_AwardFromRegenerativeMedicineInstituteAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_PatentsSevenMember" xlink:to="fate_PatentsSevenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_PatentsTwoMember" xlink:to="fate_PatentsTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_AddtionalAmountAvailableForFundingUnderAward" xlink:to="fate_AddtionalAmountAvailableForFundingUnderAward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_EquityPremiumOnSharePricePerShareUnderAgreement" xlink:to="fate_EquityPremiumOnSharePricePerShareUnderAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_CompanyReceivedPayment" xlink:to="fate_CompanyReceivedPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_OtherSegmentExpenses" xlink:to="fate_OtherSegmentExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants" xlink:to="fate_PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_CandidateOneMember" xlink:to="fate_CandidateOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_StockPriceAppreciationMilestones" xlink:to="fate_StockPriceAppreciationMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_AggregateEquityPremiumOnSharesIssuedUnderAgreement" xlink:to="fate_AggregateEquityPremiumOnSharesIssuedUnderAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_StockPriceIncreasedByTenPercentPerShareMember" xlink:to="fate_StockPriceIncreasedByTenPercentPerShareMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber" xlink:to="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_CumulativeChangeInOwnershipPercentage" xlink:to="fate_CumulativeChangeInOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_PercentageOfTaxCredit" xlink:to="fate_PercentageOfTaxCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_DebtInstrumentRepaymentPhaseTwoRateMember" xlink:to="fate_DebtInstrumentRepaymentPhaseTwoRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_SublicenseConsiderationMember" xlink:to="fate_SublicenseConsiderationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="fate_DeferredTaxLiabilitiesRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:to="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LettersOfCreditOutstandingAmount" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_PotentialAmountPayable" xlink:to="fate_PotentialAmountPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_OperatingLossCarryforwardsIndefiniteLife" xlink:to="fate_OperatingLossCarryforwardsIndefiniteLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_DefinedContributionPlanMinimumAgeOfEmployee" xlink:to="fate_DefinedContributionPlanMinimumAgeOfEmployee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_Rule10B51ArrModifiedFlag" xlink:to="fate_Rule10B51ArrModifiedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_PercentageOfCommonStockOwnershipUponPreferredStockConversion" xlink:to="fate_PercentageOfCommonStockOwnershipUponPreferredStockConversion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" xlink:to="us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_CorrespondingAssetForSublicenseConsiderationPaid" xlink:to="fate_CorrespondingAssetForSublicenseConsiderationPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToEmployees" xlink:to="us-gaap_PaymentsToEmployees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_EnterpriseValueMilestonePayment" xlink:to="fate_EnterpriseValueMilestonePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:to="us-gaap_FairValueInputsQuantitativeInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ProceedsFromResearchAndDevelopmentFeesReceived" xlink:to="fate_ProceedsFromResearchAndDevelopmentFeesReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_AwardFromCaliforniaInstituteForRegenerativeMedicineAbstract" xlink:to="fate_AwardFromCaliforniaInstituteForRegenerativeMedicineAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_CommonStockIssuedDuringPeriodSharesPrivatePlacement" xlink:to="fate_CommonStockIssuedDuringPeriodSharesPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_CommonStockMultiplesAndTheEnterpriseValueMilestonePaymentsTableTextBlock" xlink:to="fate_CommonStockMultiplesAndTheEnterpriseValueMilestonePaymentsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_CandidateThreeMember" xlink:to="fate_CandidateThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_AwardForFirstInHumanClinicalTrial" xlink:to="fate_AwardForFirstInHumanClinicalTrial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_LoanAndSecurityAgreementMember" xlink:to="fate_LoanAndSecurityAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_EmployeesAndDirectorsStockOptionsMember" xlink:to="fate_EmployeesAndDirectorsStockOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_EmployeeRetentionCreditMember" xlink:to="fate_EmployeeRetentionCreditMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ConversionOfPreferredSharesToCommonStocksShares" xlink:to="fate_ConversionOfPreferredSharesToCommonStocksShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_RefundableTaxCredit" xlink:to="fate_RefundableTaxCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" xlink:to="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:to="us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_DebtInstrumentRepaymentPhaseOneRateMember" xlink:to="fate_DebtInstrumentRepaymentPhaseOneRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsMember" xlink:to="us-gaap_ShortTermInvestmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:to="us-gaap_ContractWithCustomerAssetNetNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_StockPurchaseAgreementDomain" xlink:to="fate_StockPurchaseAgreementDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_InducementPlanMember" xlink:to="fate_InducementPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_FirstDisbursementAmountUnderTheAwardPayableForNextTwelveMonths" xlink:to="fate_FirstDisbursementAmountUnderTheAwardPayableForNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="fate_AwardFromRegenerativeMedicineInstituteLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="fate_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_GrantAward" xlink:to="fate_GrantAward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_FirstDisbursementAmountUnderTheAward" xlink:to="fate_FirstDisbursementAmountUnderTheAward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_FairValueAssumptionsRiskFreeInterestRate1" xlink:to="fate_FairValueAssumptionsRiskFreeInterestRate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_UpfrontFeeAndEquityPremiumMember" xlink:to="fate_UpfrontFeeAndEquityPremiumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRevenueExtensibleList" xlink:to="us-gaap_TypeOfRevenueExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ConvertiblePreferredStockPolicyTextBlock" xlink:to="fate_ConvertiblePreferredStockPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" xlink:to="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ClinicalDevelopmentMilestoneFees" xlink:to="fate_ClinicalDevelopmentMilestoneFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_GrantIncomeFromCirmAward" xlink:to="fate_GrantIncomeFromCirmAward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_PercentOfTaxableIncomeOffset" xlink:to="fate_PercentOfTaxableIncomeOffset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermInvestmentsMember" xlink:to="us-gaap_OtherLongTermInvestmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_StockIssuedDuringPeriodSharesForPrivatePlacement" xlink:to="fate_StockIssuedDuringPeriodSharesForPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_PercentageOfCommonStockOwnershipForPreferredStockConversionChangeUponNotice" xlink:to="fate_PercentageOfCommonStockOwnershipForPreferredStockConversionChangeUponNotice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_PatentCostsPolicyTextBlock" xlink:to="fate_PatentCostsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue" xlink:to="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_CollaborativeArrangementAggregateMilestonePaymentsReceivable" xlink:to="fate_CollaborativeArrangementAggregateMilestonePaymentsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_CommonStockIssuedDuringPeriodValuePrivatePlacement" xlink:to="fate_CommonStockIssuedDuringPeriodValuePrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_AccruedExpensesAndLongTermDebtDisclosureAbstract" xlink:to="fate_AccruedExpensesAndLongTermDebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_CommonStockCapitalAdditionalSharesReservedForFutureIssuance" xlink:to="fate_CommonStockCapitalAdditionalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_AmendedMskccLicenseMember" xlink:to="fate_AmendedMskccLicenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="us-gaap_ForeignGovernmentDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_FTFiveOneSixMember" xlink:to="fate_FTFiveOneSixMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_NumberOfDisbursements" xlink:to="fate_NumberOfDisbursements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ComputerAndOfficeEquipmentMember" xlink:to="fate_ComputerAndOfficeEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ShortTermInvestmentMaturityPeriodRangeEnd" xlink:to="fate_ShortTermInvestmentMaturityPeriodRangeEnd_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_CollaborativeArrangementPotentialAdditionalMilestones" xlink:to="fate_CollaborativeArrangementPotentialAdditionalMilestones_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorOpinionTextBlock" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CIRMAwardLiabilityNoncurrent" xlink:label="fate_CIRMAwardLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockPriceAppreciationMilestonesLiabilitiesNonCurrent" xlink:label="fate_StockPriceAppreciationMilestonesLiabilitiesNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="fate_CIRMAwardLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="fate_StockPriceAppreciationMilestonesLiabilitiesNonCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:label="us-gaap_TypeOfRevenueExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" xlink:label="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="fate_StockIssuedDuringPeriodValueWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="fate_StockIssuedDuringPeriodSharesWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ConversionOfPreferenceShareToCommonStock" xlink:label="fate_ConversionOfPreferenceShareToCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ConversionOfPreferredSharesToCommonStocksShares" xlink:label="fate_ConversionOfPreferredSharesToCommonStocksShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CommonStockIssuedDuringPeriodValuePrivatePlacement" xlink:label="fate_CommonStockIssuedDuringPeriodValuePrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CommonStockIssuedDuringPeriodSharesPrivatePlacement" xlink:label="fate_CommonStockIssuedDuringPeriodSharesPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockIssuedDuringPeriodValueToCollaborativePartner" xlink:label="fate_StockIssuedDuringPeriodValueToCollaborativePartner"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockIssuedDuringPeriodSharesToCollaborativePartner" xlink:label="fate_StockIssuedDuringPeriodSharesToCollaborativePartner"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants" xlink:label="fate_PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CommonStockOfPublicOfferingAndIssuanceOfPreFundedWarrants" xlink:label="fate_CommonStockOfPublicOfferingAndIssuanceOfPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PrivatePlacementOfPreFundedWarrants" xlink:label="fate_PrivatePlacementOfPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_24"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_25"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fate_StockIssuedDuringPeriodValueWarrantsExercised" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fate_StockIssuedDuringPeriodSharesWarrantsExercised" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fate_ConversionOfPreferenceShareToCommonStock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fate_ConversionOfPreferredSharesToCommonStocksShares" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fate_CommonStockIssuedDuringPeriodValuePrivatePlacement" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fate_CommonStockIssuedDuringPeriodSharesPrivatePlacement" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fate_StockIssuedDuringPeriodValueToCollaborativePartner" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fate_StockIssuedDuringPeriodSharesToCollaborativePartner" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fate_PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fate_CommonStockOfPublicOfferingAndIssuanceOfPreFundedWarrants" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fate_PrivatePlacementOfPreFundedWarrants" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_24" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_25" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet" xlink:label="fate_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ProceedsFromCIRMAward" xlink:label="fate_ProceedsFromCIRMAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" xlink:label="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_GrantIncomeFromCirmAward" xlink:label="fate_GrantIncomeFromCirmAward"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="fate_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_CapitalizedContractCostAmortization" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="fate_ProceedsFromCIRMAward" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="fate_GrantIncomeFromCirmAward" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_Rule10B51ArrModifiedFlag" xlink:label="fate_Rule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_NonRule10B51ArrModifiedFlag" xlink:label="fate_NonRule10B51ArrModifiedFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="fate_Rule10B51ArrModifiedFlag" order="14.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="fate_NonRule10B51ArrModifiedFlag" order="15.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CollaborationAndLicenseAgreementsDisclosureAbstract" xlink:label="fate_CollaborationAndLicenseAgreementsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_CollaborationAndLicenseAgreementsDisclosureAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAward" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AwardFromCaliforniaInstituteForRegenerativeMedicineAbstract" xlink:label="fate_AwardFromCaliforniaInstituteForRegenerativeMedicineAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AwardAgreementForResearchAndDevelopmentDisclosureTextBlock" xlink:label="fate_AwardAgreementForResearchAndDevelopmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AwardFromCaliforniaInstituteForRegenerativeMedicineAbstract" xlink:to="fate_AwardAgreementForResearchAndDevelopmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestments" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAbstract" xlink:label="us-gaap_InvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipment" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureAccruedExpenses3" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AccruedExpensesAndLongTermDebtDisclosureAbstract" xlink:label="fate_AccruedExpensesAndLongTermDebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AccruedExpensesAndLongTermDebtDisclosureAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" xlink:label="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReporting" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefits" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingencies1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockPriceAppreciationMilestonesPolicyTextBlock" xlink:label="fate_StockPriceAppreciationMilestonesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PatentCostsPolicyTextBlock" xlink:label="fate_PatentCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ConvertiblePreferredStockPolicyTextBlock" xlink:label="fate_ConvertiblePreferredStockPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_EmployeeRetentionCreditPolicy" xlink:label="fate_EmployeeRetentionCreditPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_LiquidityPolicyTextBlock" xlink:label="fate_LiquidityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_RestructuringPolicytextBlock" xlink:label="fate_RestructuringPolicytextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="fate_StockPriceAppreciationMilestonesPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="fate_PatentCostsPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="fate_ConvertiblePreferredStockPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="fate_EmployeeRetentionCreditPolicy" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="fate_LiquidityPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="fate_RestructuringPolicytextBlock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CollaborationAndLicenseAgreementsDisclosureAbstract" xlink:label="fate_CollaborationAndLicenseAgreementsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CommonStockMultiplesAndTheEnterpriseValueMilestonePaymentsTableTextBlock" xlink:label="fate_CommonStockMultiplesAndTheEnterpriseValueMilestonePaymentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ScheduleOfMilestonePaymentsValuationAssumptionsTableTextBlock" xlink:label="fate_ScheduleOfMilestonePaymentsValuationAssumptionsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_CollaborationAndLicenseAgreementsDisclosureAbstract" xlink:to="fate_CommonStockMultiplesAndTheEnterpriseValueMilestonePaymentsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_CollaborationAndLicenseAgreementsDisclosureAbstract" xlink:to="fate_ScheduleOfMilestonePaymentsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAbstract" xlink:label="us-gaap_InvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" xlink:label="us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureAccruedExpensesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AccruedExpensesAndLongTermDebtDisclosureAbstract" xlink:label="fate_AccruedExpensesAndLongTermDebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AccruedExpensesAndLongTermDebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" xlink:label="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="fate_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" xlink:to="fate_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_EmployeeRetentionCreditMember" xlink:label="fate_EmployeeRetentionCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableInterestEntityMeasureOfActivityAbstract" xlink:label="us-gaap_VariableInterestEntityMeasureOfActivityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ShortTermLeasesTermExcludedFromCalculationOfRightOfUseOfAssetsAndLeaseLiabilities" xlink:label="fate_ShortTermLeasesTermExcludedFromCalculationOfRightOfUseOfAssetsAndLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_RefundableTaxCredit" xlink:label="fate_RefundableTaxCredit"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PercentageOfTaxCredit" xlink:label="fate_PercentageOfTaxCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToEmployees" xlink:label="us-gaap_PaymentsToEmployees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLeasehold" xlink:label="us-gaap_ImpairmentOfLeasehold"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ImpairmentOfRightOfUseAsset" xlink:label="fate_ImpairmentOfRightOfUseAsset"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fate_EmployeeRetentionCreditMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityMeasureOfActivityAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="fate_ShortTermLeasesTermExcludedFromCalculationOfRightOfUseOfAssetsAndLeaseLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="fate_RefundableTaxCredit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="fate_PercentageOfTaxCredit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_PaymentsToEmployees" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OtherIncome" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ImpairmentOfLeasehold" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="fate_ImpairmentOfRightOfUseAsset" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ScientificEquipmentMember" xlink:label="fate_ScientificEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="fate_ScientificEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails3" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_WeightedAveragePreFundedWarrants" xlink:label="fate_WeightedAveragePreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="fate_WeightedAveragePreFundedWarrants" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails4" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_JanssenAgreementMember" xlink:label="fate_JanssenAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CollaborationAndLicenseAgreementsDisclosureAbstract" xlink:label="fate_CollaborationAndLicenseAgreementsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_UpfrontFeeAndEquityPremiumMember" xlink:label="fate_UpfrontFeeAndEquityPremiumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FirstJanssenCancerTargetMember" xlink:label="fate_FirstJanssenCancerTargetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_JanssenBiotechIncMember" xlink:label="fate_JanssenBiotechIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockPurchaseAgreementAxis" xlink:label="fate_StockPurchaseAgreementAxis"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockPurchaseAgreementDomain" xlink:label="fate_StockPurchaseAgreementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockPurchaseAgreementMember" xlink:label="fate_StockPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CandidateTwoMember" xlink:label="fate_CandidateTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_UpfrontCashPayment" xlink:label="fate_UpfrontCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ResearchServicesMember" xlink:label="fate_ResearchServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AdditionalCancerTargetsMember" xlink:label="fate_AdditionalCancerTargetsMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_OnoPharmaceuticalCompanyLtdMember" xlink:label="fate_OnoPharmaceuticalCompanyLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CandidateOneMember" xlink:label="fate_CandidateOneMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CompanyReceivedPayment" xlink:label="fate_CompanyReceivedPayment"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_SublicenseConsiderationMember" xlink:label="fate_SublicenseConsiderationMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_UpfrontFeeMember" xlink:label="fate_UpfrontFeeMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_JohnsonJohnsonInnovationJJDCIncMember" xlink:label="fate_JohnsonJohnsonInnovationJJDCIncMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AmendedMSKLicenseMember" xlink:label="fate_AmendedMSKLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CandidateThreeMember" xlink:label="fate_CandidateThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:label="us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AmendedAndRestatedExclusiveLicenseAgreementMember" xlink:label="fate_AmendedAndRestatedExclusiveLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CommercialOptionExerciseMember" xlink:label="fate_CommercialOptionExerciseMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_OnoLetterAgreementMember" xlink:label="fate_OnoLetterAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AmendedMskccLicenseMember" xlink:label="fate_AmendedMskccLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockIssuedDuringPeriodSharesForPrivatePlacement" xlink:label="fate_StockIssuedDuringPeriodSharesForPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_GladstoneLicenseAgreementMember" xlink:label="fate_GladstoneLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AssociatedWithCollaborationServicesMember" xlink:label="fate_AssociatedWithCollaborationServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_EquityPremiumOnSharePricePerShareUnderAgreement" xlink:label="fate_EquityPremiumOnSharePricePerShareUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AggregateEquityPremiumOnSharesIssuedUnderAgreement" xlink:label="fate_AggregateEquityPremiumOnSharesIssuedUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_TransactionPriceOfAgreement" xlink:label="fate_TransactionPriceOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue" xlink:label="fate_CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_MilestonePaymentUnderDeferredRevenue" xlink:label="fate_MilestonePaymentUnderDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_SublicenseConsiderationRepresentsAnAssetUnderAscOtherAssetsAndDeferredCosts" xlink:label="fate_SublicenseConsiderationRepresentsAnAssetUnderAscOtherAssetsAndDeferredCosts"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AmortizationOfSubLicenseConsideration" xlink:label="fate_AmortizationOfSubLicenseConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ProceedsFromResearchAndDevelopmentFeesReceived" xlink:label="fate_ProceedsFromResearchAndDevelopmentFeesReceived"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_OptionExercisePayment" xlink:label="fate_OptionExercisePayment"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ContraResearchAndDevelopmentExpenses" xlink:label="fate_ContraResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_MilestonePayments" xlink:label="fate_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ProfitLossSharingPercentage" xlink:label="fate_ProfitLossSharingPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CollaborativeArrangementAggregatePaymentsReceivable" xlink:label="fate_CollaborativeArrangementAggregatePaymentsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CollaborativeArrangementPotentialAdditionalMilestones" xlink:label="fate_CollaborativeArrangementPotentialAdditionalMilestones"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ClinicalDevelopmentMilestoneFees" xlink:label="fate_ClinicalDevelopmentMilestoneFees"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CollaborativeArrangementAggregateMilestonePaymentsReceivable" xlink:label="fate_CollaborativeArrangementAggregateMilestonePaymentsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CollaborativeArrangementPercentageOfReductionOnMilestonePayments" xlink:label="fate_CollaborativeArrangementPercentageOfReductionOnMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_UpfrontNonRefundableNonCreditablePaymentReceivable" xlink:label="fate_UpfrontNonRefundableNonCreditablePaymentReceivable"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CollaborativeArrangementAnnualPaymentsReceivableRecordedUnderDeferredRevenue" xlink:label="fate_CollaborativeArrangementAnnualPaymentsReceivableRecordedUnderDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CorrespondingAssetForSublicenseConsiderationPaid" xlink:label="fate_CorrespondingAssetForSublicenseConsiderationPaid"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_EnterpriseValueMilestonePayment" xlink:label="fate_EnterpriseValueMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_Stockpriceappreciationmilestoneincome" xlink:label="fate_Stockpriceappreciationmilestoneincome"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockPriceAppreciationMilestonePayable" xlink:label="fate_StockPriceAppreciationMilestonePayable"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_EnterpriseValueMilestonesLiabilityAtFairValue" xlink:label="fate_EnterpriseValueMilestonesLiabilityAtFairValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fate_JanssenAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_CollaborationAndLicenseAgreementsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fate_UpfrontFeeAndEquityPremiumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="fate_FirstJanssenCancerTargetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fate_JanssenBiotechIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_StockPurchaseAgreementAxis" xlink:to="fate_StockPurchaseAgreementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_StockPurchaseAgreementDomain" xlink:to="fate_StockPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="fate_CandidateTwoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_UpfrontCashPayment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fate_ResearchServicesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="fate_AdditionalCancerTargetsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fate_OnoPharmaceuticalCompanyLtdMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="fate_CandidateOneMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_CompanyReceivedPayment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fate_SublicenseConsiderationMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fate_UpfrontFeeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="fate_JohnsonJohnsonInnovationJJDCIncMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fate_AmendedMSKLicenseMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="fate_CandidateThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fate_AmendedAndRestatedExclusiveLicenseAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fate_CommercialOptionExerciseMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="fate_OnoLetterAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fate_AmendedMskccLicenseMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_StockIssuedDuringPeriodSharesForPrivatePlacement" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fate_GladstoneLicenseAgreementMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fate_AssociatedWithCollaborationServicesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="fate_StockPurchaseAgreementAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_EquityPremiumOnSharePricePerShareUnderAgreement" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_AggregateEquityPremiumOnSharesIssuedUnderAgreement" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_TitleOfIndividualAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_TransactionPriceOfAgreement" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_MilestonePaymentUnderDeferredRevenue" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetNoncurrent" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_SublicenseConsiderationRepresentsAnAssetUnderAscOtherAssetsAndDeferredCosts" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_AmortizationOfSubLicenseConsideration" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_ProceedsFromResearchAndDevelopmentFeesReceived" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_OptionExercisePayment" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_ContraResearchAndDevelopmentExpenses" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_MilestonePayments" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_ProfitLossSharingPercentage" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_CollaborativeArrangementAggregatePaymentsReceivable" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_CollaborativeArrangementPotentialAdditionalMilestones" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_ClinicalDevelopmentMilestoneFees" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_CollaborativeArrangementAggregateMilestonePaymentsReceivable" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_CollaborativeArrangementPercentageOfReductionOnMilestonePayments" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_UpfrontNonRefundableNonCreditablePaymentReceivable" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_CollaborativeArrangementAnnualPaymentsReceivableRecordedUnderDeferredRevenue" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_CorrespondingAssetForSublicenseConsiderationPaid" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_EnterpriseValueMilestonePayment" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_Stockpriceappreciationmilestoneincome" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_StockPriceAppreciationMilestonePayable" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_EnterpriseValueMilestonesLiabilityAtFairValue" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_MilestoneOneMember" xlink:label="fate_MilestoneOneMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CollaborationAndLicenseAgreementsDisclosureAbstract" xlink:label="fate_CollaborationAndLicenseAgreementsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AmendedMSKLicenseMember" xlink:label="fate_AmendedMSKLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CommonStockMultiple1" xlink:label="fate_CommonStockMultiple1"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_MilestoneTwoMember" xlink:label="fate_MilestoneTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_TrailingStockPricePerShare" xlink:label="fate_TrailingStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_MilestoneThreeMember" xlink:label="fate_MilestoneThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_MilestonePayments" xlink:label="fate_MilestonePayments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fate_MilestoneOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_CollaborationAndLicenseAgreementsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fate_AmendedMSKLicenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_CommonStockMultiple1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fate_MilestoneTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_TrailingStockPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fate_MilestoneThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_MilestonePayments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails2" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CollaborationAndLicenseAgreementsDisclosureAbstract" xlink:label="fate_CollaborationAndLicenseAgreementsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AmendedMSKLicenseMember" xlink:label="fate_AmendedMSKLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:label="us-gaap_FairValueInputsQuantitativeInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FairValueAssumptionsRiskFreeInterestRate1" xlink:label="fate_FairValueAssumptionsRiskFreeInterestRate1"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FairValueAssumptionsExpectedVolatilityRate1" xlink:label="fate_FairValueAssumptionsExpectedVolatilityRate1"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FairValueAssumptionsExpectedTerm1" xlink:label="fate_FairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_CollaborationAndLicenseAgreementsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fate_AmendedMSKLicenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_FairValueInputsQuantitativeInformationAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_FairValueAssumptionsRiskFreeInterestRate1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_FairValueAssumptionsExpectedVolatilityRate1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_FairValueAssumptionsExpectedTerm1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharePrice" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FTFiveOneSixMember" xlink:label="fate_FTFiveOneSixMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_DebtInstrumentRepaymentPhaseOneRateMember" xlink:label="fate_DebtInstrumentRepaymentPhaseOneRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CaliforniaInstituteForRegenerativeMedicineMember" xlink:label="fate_CaliforniaInstituteForRegenerativeMedicineMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AwardFromRegenerativeMedicineInstituteTable" xlink:label="fate_AwardFromRegenerativeMedicineInstituteTable"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AwardFromRegenerativeMedicineInstituteAbstract" xlink:label="fate_AwardFromRegenerativeMedicineInstituteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:label="fate_AwardFromRegenerativeMedicineInstituteLineItems"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AwardAgreementExecutedDate" xlink:label="fate_AwardAgreementExecutedDate"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FtEightOneNineMember" xlink:label="fate_FtEightOneNineMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_DebtInstrumentRepaymentPhaseTwoRateMember" xlink:label="fate_DebtInstrumentRepaymentPhaseTwoRateMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_GrantAward" xlink:label="fate_GrantAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_DebtInstrumentRepaymentPhaseThreeRateMember" xlink:label="fate_DebtInstrumentRepaymentPhaseThreeRateMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FirstDisbursementAmountUnderTheAward" xlink:label="fate_FirstDisbursementAmountUnderTheAward"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_DebtInstrumentRepaymentPhaseFourRateMember" xlink:label="fate_DebtInstrumentRepaymentPhaseFourRateMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PotentialAmountPayable" xlink:label="fate_PotentialAmountPayable"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FirstDisbursementAmountUnderTheAwardPayableForNextTwelveMonths" xlink:label="fate_FirstDisbursementAmountUnderTheAwardPayableForNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtTerm" xlink:label="us-gaap_LongTermDebtTerm"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AwardForFirstInHumanClinicalTrial" xlink:label="fate_AwardForFirstInHumanClinicalTrial"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_NumberOfDisbursements" xlink:label="fate_NumberOfDisbursements"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_NumberOfDisbursementsReceivableUponExecutionOfAward" xlink:label="fate_NumberOfDisbursementsReceivableUponExecutionOfAward"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_NumberOfDisbursementsReceivableBasedOnCompletionOfCertainOperatingMilestones" xlink:label="fate_NumberOfDisbursementsReceivableBasedOnCompletionOfCertainOperatingMilestones"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_RepaymentPercentageOfAwardAmount" xlink:label="fate_RepaymentPercentageOfAwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PeriodToTreatAwardAsGrantIfAwardNotTreatedAsLoan" xlink:label="fate_PeriodToTreatAwardAsGrantIfAwardNotTreatedAsLoan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AddtionalAmountAvailableForFundingUnderAward" xlink:label="fate_AddtionalAmountAvailableForFundingUnderAward"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fate_FTFiveOneSixMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="fate_DebtInstrumentRepaymentPhaseOneRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fate_CaliforniaInstituteForRegenerativeMedicineMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AwardFromRegenerativeMedicineInstituteTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AwardFromRegenerativeMedicineInstituteAbstract" xlink:to="fate_AwardFromRegenerativeMedicineInstituteTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="fate_AwardAgreementExecutedDate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fate_FtEightOneNineMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="fate_DebtInstrumentRepaymentPhaseTwoRateMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AwardFromRegenerativeMedicineInstituteTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="fate_GrantAward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="fate_DebtInstrumentRepaymentPhaseThreeRateMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AwardFromRegenerativeMedicineInstituteTable" xlink:to="us-gaap_DebtInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="fate_FirstDisbursementAmountUnderTheAward" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="fate_DebtInstrumentRepaymentPhaseFourRateMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AwardFromRegenerativeMedicineInstituteTable" xlink:to="us-gaap_VariableRateAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="fate_PotentialAmountPayable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AwardFromRegenerativeMedicineInstituteTable" xlink:to="fate_AwardFromRegenerativeMedicineInstituteLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="fate_FirstDisbursementAmountUnderTheAwardPayableForNextTwelveMonths" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="us-gaap_LongTermDebtTerm" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="fate_AwardForFirstInHumanClinicalTrial" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="fate_NumberOfDisbursements" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="fate_NumberOfDisbursementsReceivableUponExecutionOfAward" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="fate_NumberOfDisbursementsReceivableBasedOnCompletionOfCertainOperatingMilestones" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="fate_RepaymentPercentageOfAwardAmount" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="fate_PeriodToTreatAwardAsGrantIfAwardNotTreatedAsLoan" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="fate_AddtionalAmountAvailableForFundingUnderAward" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ShortTermInvestmentMaturityPeriodRangeStart" xlink:label="fate_ShortTermInvestmentMaturityPeriodRangeStart"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PrepaidExpensesAndOtherAssetsMember" xlink:label="fate_PrepaidExpensesAndOtherAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ShortTermInvestmentMaturityPeriodRangeEnd" xlink:label="fate_ShortTermInvestmentMaturityPeriodRangeEnd"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivableNonaccrualNoAllowance" xlink:label="us-gaap_FinancingReceivableNonaccrualNoAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fate_ShortTermInvestmentMaturityPeriodRangeStart" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="fate_PrepaidExpensesAndOtherAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fate_ShortTermInvestmentMaturityPeriodRangeEnd" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_InterestReceivable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_FinancingReceivableNonaccrualNoAllowance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_InvestmentMaturityDateRange" xlink:label="fate_InvestmentMaturityDateRange"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="us-gaap_OtherCurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MunicipalNotesMember" xlink:label="us-gaap_MunicipalNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermInvestmentsMember" xlink:label="us-gaap_OtherLongTermInvestmentsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fate_InvestmentMaturityDateRange" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ForeignGovernmentDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MunicipalNotesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ShortTermInvestmentsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_OtherLongTermInvestmentsMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureInvestmentDetails3ShortTermInvestmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermInvestmentsMember" xlink:label="us-gaap_OtherLongTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MunicipalNotesMember" xlink:label="us-gaap_MunicipalNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ForeignGovernmentDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_OtherLongTermInvestmentsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MunicipalNotesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockPriceAppreciationMilestones" xlink:label="fate_StockPriceAppreciationMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockPriceAppreciationMilestonesMember" xlink:label="fate_StockPriceAppreciationMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MunicipalNotesMember" xlink:label="us-gaap_MunicipalNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="fate_StockPriceAppreciationMilestones" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="fate_StockPriceAppreciationMilestonesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_ForeignGovernmentDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MunicipalNotesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetails2" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockPriceIncreasedByTenPercentPerShareMember" xlink:label="fate_StockPriceIncreasedByTenPercentPerShareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FairValueInputsStockPriceSensitivityPercentageIncreaseDecrease" xlink:label="fate_FairValueInputsStockPriceSensitivityPercentageIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockPriceDecreasedByTenPercentPerShareMember" xlink:label="fate_StockPriceDecreasedByTenPercentPerShareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_SharePriceFairValueInput" xlink:label="fate_SharePriceFairValueInput"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" xlink:label="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_Fairvalueassetslevel1Tolevel2Transfersamounts" xlink:label="fate_Fairvalueassetslevel1Tolevel2Transfersamounts"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_Fairvalueassetslevel2Tolevel1Transfersamounts" xlink:label="fate_Fairvalueassetslevel2Tolevel1Transfersamounts"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_Fairvalueliabilitieslevel1Tolevel2Transfersamounts" xlink:label="fate_Fairvalueliabilitieslevel1Tolevel2Transfersamounts"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_Fairvalueliabilitieslevel2Tolevel1Transfersamounts" xlink:label="fate_Fairvalueliabilitieslevel2Tolevel1Transfersamounts"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_VariableRateAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="fate_StockPriceIncreasedByTenPercentPerShareMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="fate_FairValueInputsStockPriceSensitivityPercentageIncreaseDecrease" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="fate_StockPriceDecreasedByTenPercentPerShareMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_SharePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="fate_SharePriceFairValueInput" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="fate_Fairvalueassetslevel1Tolevel2Transfersamounts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="fate_Fairvalueassetslevel2Tolevel1Transfersamounts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="fate_Fairvalueliabilitieslevel1Tolevel2Transfersamounts" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="fate_Fairvalueliabilitieslevel2Tolevel1Transfersamounts" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails3" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AchievementOfStockPriceAppreciationMilestone" xlink:label="fate_AchievementOfStockPriceAppreciationMilestone"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" xlink:label="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="fate_AchievementOfStockPriceAppreciationMilestone" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ComputerAndOfficeEquipmentMember" xlink:label="fate_ComputerAndOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ScientificEquipmentMember" xlink:label="fate_ScientificEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="fate_ComputerAndOfficeEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="fate_ScientificEquipmentMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureAccruedExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AccruedExpensesAndLongTermDebtDisclosureAbstract" xlink:label="fate_AccruedExpensesAndLongTermDebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AccruedClinicalTrialRelatedCostsCurrent" xlink:label="fate_AccruedClinicalTrialRelatedCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AccruedExpensesAndLongTermDebtDisclosureAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AccruedExpensesAndLongTermDebtDisclosureAbstract" xlink:to="us-gaap_AccruedSalariesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AccruedExpensesAndLongTermDebtDisclosureAbstract" xlink:to="fate_AccruedClinicalTrialRelatedCostsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AccruedExpensesAndLongTermDebtDisclosureAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AccruedExpensesAndLongTermDebtDisclosureAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndLongTermDebt2017TermLoanDetails2" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_LoanAndSecurityAgreementMember" xlink:label="fate_LoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_RepaymentsOfDebtIncludingPrincipalAndFinalFee" xlink:label="fate_RepaymentsOfDebtIncludingPrincipalAndFinalFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AccruedExpensesAndLongTermDebtDisclosureAbstract" xlink:label="fate_AccruedExpensesAndLongTermDebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FinalPaymentFeeOnDebtFacilityAmount" xlink:label="fate_FinalPaymentFeeOnDebtFacilityAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="fate_LoanAndSecurityAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="fate_RepaymentsOfDebtIncludingPrincipalAndFinalFee" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AccruedExpensesAndLongTermDebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="fate_FinalPaymentFeeOnDebtFacilityAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ImpairmentOfRightOfUseAsset" xlink:label="fate_ImpairmentOfRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_LesseeOperatingLeaseCashRentPeriod" xlink:label="fate_LesseeOperatingLeaseCashRentPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForTenantImprovements" xlink:label="us-gaap_PaymentsForTenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_EarlyTerminationFee" xlink:label="fate_EarlyTerminationFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeaseAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fate_ImpairmentOfRightOfUseAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fate_LesseeOperatingLeaseCashRentPeriod" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForTenantImprovements" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_TenantImprovements" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fate_EarlyTerminationFee" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_NetRentableArea" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermLeaseCost" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StraightLineRentAdjustments" xlink:label="us-gaap_StraightLineRentAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_StraightLineRentAdjustments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails2" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureScheduleOfSubleaseIncomeLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_SubleaseIncome" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockOptionAndIncentivePlan2013Member" xlink:label="fate_StockOptionAndIncentivePlan2013Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_November2016PlacementMember" xlink:label="fate_November2016PlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_RedmileGroupLimitedLiabilityCompanyAndAffiliatesMember" xlink:label="fate_RedmileGroupLimitedLiabilityCompanyAndAffiliatesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" xlink:label="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PreFundedWarrantsMember" xlink:label="fate_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockOptionAndIncentivePlan2022Member" xlink:label="fate_StockOptionAndIncentivePlan2022Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_InducementPlanMember" xlink:label="fate_InducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_EmployeeAndNonEmployeeStockOptionMember" xlink:label="fate_EmployeeAndNonEmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PerformanceBasedRestrictedStockUnitsPrsusMember" xlink:label="fate_PerformanceBasedRestrictedStockUnitsPrsusMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PercentageOfCommonStockOwnershipUponPreferredStockConversion" xlink:label="fate_PercentageOfCommonStockOwnershipUponPreferredStockConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_EmployeesAndDirectorsStockOptionsMember" xlink:label="fate_EmployeesAndDirectorsStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PercentageOfCommonStockOwnershipForPreferredStockConversionChangeUponNotice" xlink:label="fate_PercentageOfCommonStockOwnershipForPreferredStockConversionChangeUponNotice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PreferredStockConversionPrice" xlink:label="fate_PreferredStockConversionPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardMonthlyAwardVestingPeriod" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardMonthlyAwardVestingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnuallyAwardVestingPeriod" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnuallyAwardVestingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CommonStockCapitalAdditionalSharesReservedForFutureIssuance" xlink:label="fate_CommonStockCapitalAdditionalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PurchasePriceOfPrefundedWarrants" xlink:label="fate_PurchasePriceOfPrefundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_WarrantsExerciseTermsDescription" xlink:label="fate_WarrantsExerciseTermsDescription"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_MaximumPercentageOfCommonStockOwnershipTogetherWithAffiliatesAllowableAfterExerciseOfPrefundedWarrants" xlink:label="fate_MaximumPercentageOfCommonStockOwnershipTogetherWithAffiliatesAllowableAfterExerciseOfPrefundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_MaximumPercentageOfCommonStockOwnershipAfterChangeUponNotice" xlink:label="fate_MaximumPercentageOfCommonStockOwnershipAfterChangeUponNotice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fate_StockOptionAndIncentivePlan2013Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="fate_November2016PlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="fate_RedmileGroupLimitedLiabilityCompanyAndAffiliatesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="fate_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fate_StockOptionAndIncentivePlan2022Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fate_InducementPlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="fate_EmployeeAndNonEmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="fate_PerformanceBasedRestrictedStockUnitsPrsusMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="dei_LegalEntityAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fate_PercentageOfCommonStockOwnershipUponPreferredStockConversion" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_AwardTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="fate_EmployeesAndDirectorsStockOptionsMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fate_PercentageOfCommonStockOwnershipForPreferredStockConversionChangeUponNotice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_RangeAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fate_PreferredStockConversionPrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_Dividends" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardMonthlyAwardVestingPeriod" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnuallyAwardVestingPeriod" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fate_CommonStockCapitalAdditionalSharesReservedForFutureIssuance" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fate_PurchasePriceOfPrefundedWarrants" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fate_WarrantsExerciseTermsDescription" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fate_MaximumPercentageOfCommonStockOwnershipTogetherWithAffiliatesAllowableAfterExerciseOfPrefundedWarrants" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fate_MaximumPercentageOfCommonStockOwnershipAfterChangeUponNotice" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockOptionAndIncentivePlan2013Member" xlink:label="fate_StockOptionAndIncentivePlan2013Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" xlink:label="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_EmployeeAndNonEmployeeStockOptionMember" xlink:label="fate_EmployeeAndNonEmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fate_StockOptionAndIncentivePlan2013Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="fate_EmployeeAndNonEmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" xlink:label="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageRemainingContractualTerm" xlink:label="fate_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestAggregateIntrinsicValue" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="fate_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageRemainingContractualTerm" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:to="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestAggregateIntrinsicValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockBasedCompensationForAllStockAwardsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" xlink:label="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityWeightedAverageAssumptionsUsedInTheBlackscholesOptionPricingModelDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" xlink:label="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_EmployeeAndNonEmployeeStockOptionMember" xlink:label="fate_EmployeeAndNonEmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="fate_EmployeeAndNonEmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockOptionAndIncentivePlan2013Member" xlink:label="fate_StockOptionAndIncentivePlan2013Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" xlink:label="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockOptionAndIncentivePlan2022Member" xlink:label="fate_StockOptionAndIncentivePlan2022Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_InducementPlanMember" xlink:label="fate_InducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fate_StockOptionAndIncentivePlan2013Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fate_StockOptionAndIncentivePlan2022Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fate_InducementPlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_IncomeTaxReconciliationNondeductibleCompensation" xlink:label="fate_IncomeTaxReconciliationNondeductibleCompensation"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_DeferredTaxAssetsCapitalizedRdExpense" xlink:label="fate_DeferredTaxAssetsCapitalizedRdExpense"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_IncomeTaxReconciliationPermanentTaxDifferences" xlink:label="fate_IncomeTaxReconciliationPermanentTaxDifferences"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_IncomeTaxReconciliationReserveForUncertainTaxPositions" xlink:label="fate_IncomeTaxReconciliationReserveForUncertainTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_DeferredTaxAssetsLeaseLiabilities" xlink:label="fate_DeferredTaxAssetsLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_DeferredTaxLiabilitiesDepreciation" xlink:label="fate_DeferredTaxLiabilitiesDepreciation"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="fate_DeferredTaxLiabilitiesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="fate_IncomeTaxReconciliationNondeductibleCompensation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="fate_DeferredTaxAssetsCapitalizedRdExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="fate_IncomeTaxReconciliationPermanentTaxDifferences" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="fate_IncomeTaxReconciliationReserveForUncertainTaxPositions" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="fate_DeferredTaxAssetsLeaseLiabilities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="fate_DeferredTaxLiabilitiesDepreciation" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="fate_DeferredTaxLiabilitiesRightOfUseAssets" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails2" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_OperatingLossCarryforwardsIndefiniteLife" xlink:label="fate_OperatingLossCarryforwardsIndefiniteLife"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PercentOfTaxableIncomeOffset" xlink:label="fate_PercentOfTaxableIncomeOffset"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_OperatingLossCarryforwardsExpirationYear" xlink:label="fate_OperatingLossCarryforwardsExpirationYear"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="fate_OperatingLossCarryforwardsIndefiniteLife" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="fate_PercentOfTaxableIncomeOffset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="fate_OperatingLossCarryforwardsExpirationYear" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails3" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_TaxCreditCarryforwardBeginningExpirationYear" xlink:label="fate_TaxCreditCarryforwardBeginningExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CumulativeChangeInOwnershipPercentage" xlink:label="fate_CumulativeChangeInOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PeriodForCumulativeChangeInOwnership" xlink:label="fate_PeriodForCumulativeChangeInOwnership"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:label="us-gaap_IncomeTaxExaminationYearUnderExamination"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_CaliforniaFranchiseTaxBoardMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_TaxCreditCarryforwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="fate_TaxCreditCarryforwardBeginningExpirationYear" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="fate_CumulativeChangeInOwnershipPercentage" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="fate_PeriodForCumulativeChangeInOwnership" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_IncomeTaxExaminationYearUnderExamination" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails4" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxUncertaintiesAbstract" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_UnrecognizedTaxBenefitsResultingInNetOperatingLossAndTaxCreditCarryforward" xlink:label="fate_UnrecognizedTaxBenefitsResultingInNetOperatingLossAndTaxCreditCarryforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="fate_UnrecognizedTaxBenefitsResultingInNetOperatingLossAndTaxCreditCarryforward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentProfitOrLossIncludingSegmentExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PersonnelCosts" xlink:label="fate_PersonnelCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ClinicalProgramsExpense" xlink:label="fate_ClinicalProgramsExpense"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" xlink:label="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:label="us-gaap_TypeOfRevenueExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ResearchActivitiesExpense" xlink:label="fate_ResearchActivitiesExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FacilitiesCosts" xlink:label="fate_FacilitiesCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_OtherSegmentExpenses" xlink:label="fate_OtherSegmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="fate_PersonnelCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="fate_ClinicalProgramsExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="fate_ResearchActivitiesExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="fate_FacilitiesCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="fate_OtherSegmentExpenses" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefitsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_DefinedContributionPlanMinimumAgeOfEmployee" xlink:label="fate_DefinedContributionPlanMinimumAgeOfEmployee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PercentageOfDiscretionaryContributionsDescription" xlink:label="fate_PercentageOfDiscretionaryContributionsDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="fate_DefinedContributionPlanMinimumAgeOfEmployee" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="fate_PercentageOfDiscretionaryContributionsDescription" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PatentsOneMember" xlink:label="fate_PatentsOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_MinimumAnnualPaymentsToMaintainLicenses" xlink:label="fate_MinimumAnnualPaymentsToMaintainLicenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PatentsTwoMember" xlink:label="fate_PatentsTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PatentNumber" xlink:label="fate_PatentNumber"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PatentsThreeMember" xlink:label="fate_PatentsThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PatentsFourMember" xlink:label="fate_PatentsFourMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PatentsFiveMember" xlink:label="fate_PatentsFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PatentsSixMember" xlink:label="fate_PatentsSixMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PatentsSevenMember" xlink:label="fate_PatentsSevenMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="fate_PatentsOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="fate_MinimumAnnualPaymentsToMaintainLicenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="fate_PatentsTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="fate_PatentNumber" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="fate_PatentsThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="fate_PatentsFourMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="fate_PatentsFiveMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="fate_PatentsSixMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="fate_PatentsSevenMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_GrantAward" xlink:label="fate_GrantAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CaliforniaInstituteForRegenerativeMedicineMember" xlink:label="fate_CaliforniaInstituteForRegenerativeMedicineMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="fate_GrantAward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fate_CaliforniaInstituteForRegenerativeMedicineMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="fate_StockIssuedDuringPeriodValueWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="fate_StockIssuedDuringPeriodSharesWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ConversionOfPreferenceShareToCommonStock" xlink:label="fate_ConversionOfPreferenceShareToCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ConversionOfPreferredSharesToCommonStocksShares" xlink:label="fate_ConversionOfPreferredSharesToCommonStocksShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CommonStockIssuedDuringPeriodValuePrivatePlacement" xlink:label="fate_CommonStockIssuedDuringPeriodValuePrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CommonStockIssuedDuringPeriodSharesPrivatePlacement" xlink:label="fate_CommonStockIssuedDuringPeriodSharesPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockIssuedDuringPeriodValueToCollaborativePartner" xlink:label="fate_StockIssuedDuringPeriodValueToCollaborativePartner"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockIssuedDuringPeriodSharesToCollaborativePartner" xlink:label="fate_StockIssuedDuringPeriodSharesToCollaborativePartner"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants" xlink:label="fate_PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CommonStockOfPublicOfferingAndIssuanceOfPreFundedWarrants" xlink:label="fate_CommonStockOfPublicOfferingAndIssuanceOfPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PrivatePlacementOfPreFundedWarrants" xlink:label="fate_PrivatePlacementOfPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fate_StockIssuedDuringPeriodValueWarrantsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fate_StockIssuedDuringPeriodSharesWarrantsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fate_ConversionOfPreferenceShareToCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fate_ConversionOfPreferredSharesToCommonStocksShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fate_CommonStockIssuedDuringPeriodValuePrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fate_CommonStockIssuedDuringPeriodSharesPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fate_StockIssuedDuringPeriodValueToCollaborativePartner" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fate_StockIssuedDuringPeriodSharesToCollaborativePartner" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fate_PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fate_CommonStockOfPublicOfferingAndIssuanceOfPreFundedWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fate_PrivatePlacementOfPreFundedWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_EmployeeRetentionCreditMember" xlink:label="fate_EmployeeRetentionCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ShortTermLeasesTermExcludedFromCalculationOfRightOfUseOfAssetsAndLeaseLiabilities" xlink:label="fate_ShortTermLeasesTermExcludedFromCalculationOfRightOfUseOfAssetsAndLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_RefundableTaxCredit" xlink:label="fate_RefundableTaxCredit"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PercentageOfTaxCredit" xlink:label="fate_PercentageOfTaxCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToEmployees" xlink:label="us-gaap_PaymentsToEmployees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLeasehold" xlink:label="us-gaap_ImpairmentOfLeasehold"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ImpairmentOfRightOfUseAsset" xlink:label="fate_ImpairmentOfRightOfUseAsset"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fate_EmployeeRetentionCreditMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="fate_ShortTermLeasesTermExcludedFromCalculationOfRightOfUseOfAssetsAndLeaseLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="fate_RefundableTaxCredit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="fate_PercentageOfTaxCredit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_PaymentsToEmployees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OtherIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_AssetImpairmentCharges" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ImpairmentOfLeasehold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="fate_ImpairmentOfRightOfUseAsset" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ScientificEquipmentMember" xlink:label="fate_ScientificEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="fate_ScientificEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails4">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_JanssenAgreementMember" xlink:label="fate_JanssenAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_UpfrontFeeAndEquityPremiumMember" xlink:label="fate_UpfrontFeeAndEquityPremiumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FirstJanssenCancerTargetMember" xlink:label="fate_FirstJanssenCancerTargetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_JanssenBiotechIncMember" xlink:label="fate_JanssenBiotechIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockPurchaseAgreementAxis" xlink:label="fate_StockPurchaseAgreementAxis"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockPurchaseAgreementDomain" xlink:label="fate_StockPurchaseAgreementDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockPurchaseAgreementDomain" xlink:label="fate_StockPurchaseAgreementDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockPurchaseAgreementMember" xlink:label="fate_StockPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CandidateTwoMember" xlink:label="fate_CandidateTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_UpfrontCashPayment" xlink:label="fate_UpfrontCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ResearchServicesMember" xlink:label="fate_ResearchServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AdditionalCancerTargetsMember" xlink:label="fate_AdditionalCancerTargetsMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_OnoPharmaceuticalCompanyLtdMember" xlink:label="fate_OnoPharmaceuticalCompanyLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CandidateOneMember" xlink:label="fate_CandidateOneMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CompanyReceivedPayment" xlink:label="fate_CompanyReceivedPayment"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_SublicenseConsiderationMember" xlink:label="fate_SublicenseConsiderationMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_UpfrontFeeMember" xlink:label="fate_UpfrontFeeMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_JohnsonJohnsonInnovationJJDCIncMember" xlink:label="fate_JohnsonJohnsonInnovationJJDCIncMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AmendedMSKLicenseMember" xlink:label="fate_AmendedMSKLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CandidateThreeMember" xlink:label="fate_CandidateThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:label="us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AmendedAndRestatedExclusiveLicenseAgreementMember" xlink:label="fate_AmendedAndRestatedExclusiveLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CommercialOptionExerciseMember" xlink:label="fate_CommercialOptionExerciseMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_OnoLetterAgreementMember" xlink:label="fate_OnoLetterAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AmendedMskccLicenseMember" xlink:label="fate_AmendedMskccLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockIssuedDuringPeriodSharesForPrivatePlacement" xlink:label="fate_StockIssuedDuringPeriodSharesForPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_GladstoneLicenseAgreementMember" xlink:label="fate_GladstoneLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AssociatedWithCollaborationServicesMember" xlink:label="fate_AssociatedWithCollaborationServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_EquityPremiumOnSharePricePerShareUnderAgreement" xlink:label="fate_EquityPremiumOnSharePricePerShareUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AggregateEquityPremiumOnSharesIssuedUnderAgreement" xlink:label="fate_AggregateEquityPremiumOnSharesIssuedUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_TransactionPriceOfAgreement" xlink:label="fate_TransactionPriceOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue" xlink:label="fate_CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_MilestonePaymentUnderDeferredRevenue" xlink:label="fate_MilestonePaymentUnderDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_SublicenseConsiderationRepresentsAnAssetUnderAscOtherAssetsAndDeferredCosts" xlink:label="fate_SublicenseConsiderationRepresentsAnAssetUnderAscOtherAssetsAndDeferredCosts"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AmortizationOfSubLicenseConsideration" xlink:label="fate_AmortizationOfSubLicenseConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ProceedsFromResearchAndDevelopmentFeesReceived" xlink:label="fate_ProceedsFromResearchAndDevelopmentFeesReceived"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_OptionExercisePayment" xlink:label="fate_OptionExercisePayment"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ContraResearchAndDevelopmentExpenses" xlink:label="fate_ContraResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_MilestonePayments" xlink:label="fate_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ProfitLossSharingPercentage" xlink:label="fate_ProfitLossSharingPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CollaborativeArrangementAggregatePaymentsReceivable" xlink:label="fate_CollaborativeArrangementAggregatePaymentsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CollaborativeArrangementPotentialAdditionalMilestones" xlink:label="fate_CollaborativeArrangementPotentialAdditionalMilestones"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ClinicalDevelopmentMilestoneFees" xlink:label="fate_ClinicalDevelopmentMilestoneFees"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CollaborativeArrangementAggregateMilestonePaymentsReceivable" xlink:label="fate_CollaborativeArrangementAggregateMilestonePaymentsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CollaborativeArrangementPercentageOfReductionOnMilestonePayments" xlink:label="fate_CollaborativeArrangementPercentageOfReductionOnMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_UpfrontNonRefundableNonCreditablePaymentReceivable" xlink:label="fate_UpfrontNonRefundableNonCreditablePaymentReceivable"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CollaborativeArrangementAnnualPaymentsReceivableRecordedUnderDeferredRevenue" xlink:label="fate_CollaborativeArrangementAnnualPaymentsReceivableRecordedUnderDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CorrespondingAssetForSublicenseConsiderationPaid" xlink:label="fate_CorrespondingAssetForSublicenseConsiderationPaid"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_EnterpriseValueMilestonePayment" xlink:label="fate_EnterpriseValueMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_Stockpriceappreciationmilestoneincome" xlink:label="fate_Stockpriceappreciationmilestoneincome"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockPriceAppreciationMilestonePayable" xlink:label="fate_StockPriceAppreciationMilestonePayable"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_EnterpriseValueMilestonesLiabilityAtFairValue" xlink:label="fate_EnterpriseValueMilestonesLiabilityAtFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fate_JanssenAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fate_UpfrontFeeAndEquityPremiumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="fate_FirstJanssenCancerTargetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fate_JanssenBiotechIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="fate_StockPurchaseAgreementAxis" xlink:to="fate_StockPurchaseAgreementDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="fate_StockPurchaseAgreementAxis" xlink:to="fate_StockPurchaseAgreementDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fate_StockPurchaseAgreementDomain" xlink:to="fate_StockPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="fate_CandidateTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_UpfrontCashPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fate_ResearchServicesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="fate_AdditionalCancerTargetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fate_OnoPharmaceuticalCompanyLtdMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="fate_CandidateOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_CompanyReceivedPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fate_SublicenseConsiderationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fate_UpfrontFeeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="fate_JohnsonJohnsonInnovationJJDCIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fate_AmendedMSKLicenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="fate_CandidateThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fate_AmendedAndRestatedExclusiveLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fate_CommercialOptionExerciseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="fate_OnoLetterAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fate_AmendedMskccLicenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_StockIssuedDuringPeriodSharesForPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fate_GladstoneLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fate_AssociatedWithCollaborationServicesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="fate_StockPurchaseAgreementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_EquityPremiumOnSharePricePerShareUnderAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_AggregateEquityPremiumOnSharesIssuedUnderAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_TransactionPriceOfAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_MilestonePaymentUnderDeferredRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_SublicenseConsiderationRepresentsAnAssetUnderAscOtherAssetsAndDeferredCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_AmortizationOfSubLicenseConsideration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_ProceedsFromResearchAndDevelopmentFeesReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_OptionExercisePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_ContraResearchAndDevelopmentExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_MilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_ProfitLossSharingPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_CollaborativeArrangementAggregatePaymentsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_CollaborativeArrangementPotentialAdditionalMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_ClinicalDevelopmentMilestoneFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_CollaborativeArrangementAggregateMilestonePaymentsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_CollaborativeArrangementPercentageOfReductionOnMilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_UpfrontNonRefundableNonCreditablePaymentReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_CollaborativeArrangementAnnualPaymentsReceivableRecordedUnderDeferredRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_CorrespondingAssetForSublicenseConsiderationPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_EnterpriseValueMilestonePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_Stockpriceappreciationmilestoneincome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_StockPriceAppreciationMilestonePayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_EnterpriseValueMilestonesLiabilityAtFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails1">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_MilestoneOneMember" xlink:label="fate_MilestoneOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AmendedMSKLicenseMember" xlink:label="fate_AmendedMSKLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CommonStockMultiple1" xlink:label="fate_CommonStockMultiple1"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_MilestoneTwoMember" xlink:label="fate_MilestoneTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_TrailingStockPricePerShare" xlink:label="fate_TrailingStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_MilestoneThreeMember" xlink:label="fate_MilestoneThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_MilestonePayments" xlink:label="fate_MilestonePayments"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fate_MilestoneOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fate_AmendedMSKLicenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_CommonStockMultiple1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fate_MilestoneTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_TrailingStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fate_MilestoneThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_MilestonePayments" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails2">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AmendedMSKLicenseMember" xlink:label="fate_AmendedMSKLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:label="us-gaap_FairValueInputsQuantitativeInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FairValueAssumptionsRiskFreeInterestRate1" xlink:label="fate_FairValueAssumptionsRiskFreeInterestRate1"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FairValueAssumptionsExpectedVolatilityRate1" xlink:label="fate_FairValueAssumptionsExpectedVolatilityRate1"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FairValueAssumptionsExpectedTerm1" xlink:label="fate_FairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fate_AmendedMSKLicenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_FairValueInputsQuantitativeInformationAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_FairValueAssumptionsRiskFreeInterestRate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_FairValueAssumptionsExpectedVolatilityRate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fate_FairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails">
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:label="fate_AwardFromRegenerativeMedicineInstituteLineItems"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AwardFromRegenerativeMedicineInstituteTable" xlink:label="fate_AwardFromRegenerativeMedicineInstituteTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FTFiveOneSixMember" xlink:label="fate_FTFiveOneSixMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_DebtInstrumentRepaymentPhaseOneRateMember" xlink:label="fate_DebtInstrumentRepaymentPhaseOneRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CaliforniaInstituteForRegenerativeMedicineMember" xlink:label="fate_CaliforniaInstituteForRegenerativeMedicineMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AwardAgreementExecutedDate" xlink:label="fate_AwardAgreementExecutedDate"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FtEightOneNineMember" xlink:label="fate_FtEightOneNineMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_DebtInstrumentRepaymentPhaseTwoRateMember" xlink:label="fate_DebtInstrumentRepaymentPhaseTwoRateMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_GrantAward" xlink:label="fate_GrantAward"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_DebtInstrumentRepaymentPhaseThreeRateMember" xlink:label="fate_DebtInstrumentRepaymentPhaseThreeRateMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FirstDisbursementAmountUnderTheAward" xlink:label="fate_FirstDisbursementAmountUnderTheAward"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_DebtInstrumentRepaymentPhaseFourRateMember" xlink:label="fate_DebtInstrumentRepaymentPhaseFourRateMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PotentialAmountPayable" xlink:label="fate_PotentialAmountPayable"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FirstDisbursementAmountUnderTheAwardPayableForNextTwelveMonths" xlink:label="fate_FirstDisbursementAmountUnderTheAwardPayableForNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtTerm" xlink:label="us-gaap_LongTermDebtTerm"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AwardForFirstInHumanClinicalTrial" xlink:label="fate_AwardForFirstInHumanClinicalTrial"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_NumberOfDisbursements" xlink:label="fate_NumberOfDisbursements"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_NumberOfDisbursementsReceivableUponExecutionOfAward" xlink:label="fate_NumberOfDisbursementsReceivableUponExecutionOfAward"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_NumberOfDisbursementsReceivableBasedOnCompletionOfCertainOperatingMilestones" xlink:label="fate_NumberOfDisbursementsReceivableBasedOnCompletionOfCertainOperatingMilestones"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_RepaymentPercentageOfAwardAmount" xlink:label="fate_RepaymentPercentageOfAwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PeriodToTreatAwardAsGrantIfAwardNotTreatedAsLoan" xlink:label="fate_PeriodToTreatAwardAsGrantIfAwardNotTreatedAsLoan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AddtionalAmountAvailableForFundingUnderAward" xlink:label="fate_AddtionalAmountAvailableForFundingUnderAward"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="fate_AwardFromRegenerativeMedicineInstituteTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fate_FTFiveOneSixMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="fate_DebtInstrumentRepaymentPhaseOneRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fate_CaliforniaInstituteForRegenerativeMedicineMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fate_AwardFromRegenerativeMedicineInstituteTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="fate_AwardAgreementExecutedDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fate_FtEightOneNineMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="fate_DebtInstrumentRepaymentPhaseTwoRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fate_AwardFromRegenerativeMedicineInstituteTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="fate_GrantAward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="fate_DebtInstrumentRepaymentPhaseThreeRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fate_AwardFromRegenerativeMedicineInstituteTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="fate_FirstDisbursementAmountUnderTheAward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="fate_DebtInstrumentRepaymentPhaseFourRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fate_AwardFromRegenerativeMedicineInstituteTable" xlink:to="us-gaap_VariableRateAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="fate_PotentialAmountPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="fate_FirstDisbursementAmountUnderTheAwardPayableForNextTwelveMonths" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="us-gaap_LongTermDebtTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="fate_AwardForFirstInHumanClinicalTrial" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="fate_NumberOfDisbursements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="fate_NumberOfDisbursementsReceivableUponExecutionOfAward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="fate_NumberOfDisbursementsReceivableBasedOnCompletionOfCertainOperatingMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="fate_RepaymentPercentageOfAwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="fate_PeriodToTreatAwardAsGrantIfAwardNotTreatedAsLoan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fate_AwardFromRegenerativeMedicineInstituteLineItems" xlink:to="fate_AddtionalAmountAvailableForFundingUnderAward" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ShortTermInvestmentMaturityPeriodRangeStart" xlink:label="fate_ShortTermInvestmentMaturityPeriodRangeStart"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PrepaidExpensesAndOtherAssetsMember" xlink:label="fate_PrepaidExpensesAndOtherAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ShortTermInvestmentMaturityPeriodRangeEnd" xlink:label="fate_ShortTermInvestmentMaturityPeriodRangeEnd"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivableNonaccrualNoAllowance" xlink:label="us-gaap_FinancingReceivableNonaccrualNoAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fate_ShortTermInvestmentMaturityPeriodRangeStart" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="fate_PrepaidExpensesAndOtherAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fate_ShortTermInvestmentMaturityPeriodRangeEnd" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_InterestReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_FinancingReceivableNonaccrualNoAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_InvestmentMaturityDateRange" xlink:label="fate_InvestmentMaturityDateRange"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="us-gaap_OtherCurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MunicipalNotesMember" xlink:label="us-gaap_MunicipalNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermInvestmentsMember" xlink:label="us-gaap_OtherLongTermInvestmentsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fate_InvestmentMaturityDateRange" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ForeignGovernmentDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MunicipalNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ShortTermInvestmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_OtherLongTermInvestmentsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureInvestmentDetails3ShortTermInvestmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermInvestmentsMember" xlink:label="us-gaap_OtherLongTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MunicipalNotesMember" xlink:label="us-gaap_MunicipalNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ForeignGovernmentDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_OtherLongTermInvestmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MunicipalNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockPriceAppreciationMilestones" xlink:label="fate_StockPriceAppreciationMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockPriceAppreciationMilestonesMember" xlink:label="fate_StockPriceAppreciationMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MunicipalNotesMember" xlink:label="us-gaap_MunicipalNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="fate_StockPriceAppreciationMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="fate_StockPriceAppreciationMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_ForeignGovernmentDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MunicipalNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetails2">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockPriceIncreasedByTenPercentPerShareMember" xlink:label="fate_StockPriceIncreasedByTenPercentPerShareMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FairValueInputsStockPriceSensitivityPercentageIncreaseDecrease" xlink:label="fate_FairValueInputsStockPriceSensitivityPercentageIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockPriceDecreasedByTenPercentPerShareMember" xlink:label="fate_StockPriceDecreasedByTenPercentPerShareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_SharePriceFairValueInput" xlink:label="fate_SharePriceFairValueInput"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" xlink:label="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_Fairvalueassetslevel1Tolevel2Transfersamounts" xlink:label="fate_Fairvalueassetslevel1Tolevel2Transfersamounts"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_Fairvalueassetslevel2Tolevel1Transfersamounts" xlink:label="fate_Fairvalueassetslevel2Tolevel1Transfersamounts"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_Fairvalueliabilitieslevel1Tolevel2Transfersamounts" xlink:label="fate_Fairvalueliabilitieslevel1Tolevel2Transfersamounts"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_Fairvalueliabilitieslevel2Tolevel1Transfersamounts" xlink:label="fate_Fairvalueliabilitieslevel2Tolevel1Transfersamounts"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_VariableRateAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="fate_StockPriceIncreasedByTenPercentPerShareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="fate_FairValueInputsStockPriceSensitivityPercentageIncreaseDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="fate_StockPriceDecreasedByTenPercentPerShareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="fate_SharePriceFairValueInput" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="fate_Fairvalueassetslevel1Tolevel2Transfersamounts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="fate_Fairvalueassetslevel2Tolevel1Transfersamounts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="fate_Fairvalueliabilitieslevel1Tolevel2Transfersamounts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="fate_Fairvalueliabilitieslevel2Tolevel1Transfersamounts" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails3">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AchievementOfStockPriceAppreciationMilestone" xlink:label="fate_AchievementOfStockPriceAppreciationMilestone"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" xlink:label="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="fate_AchievementOfStockPriceAppreciationMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ComputerAndOfficeEquipmentMember" xlink:label="fate_ComputerAndOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ScientificEquipmentMember" xlink:label="fate_ScientificEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="fate_ComputerAndOfficeEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="fate_ScientificEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AssetImpairmentCharges" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndLongTermDebt2017TermLoanDetails2">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_LoanAndSecurityAgreementMember" xlink:label="fate_LoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_RepaymentsOfDebtIncludingPrincipalAndFinalFee" xlink:label="fate_RepaymentsOfDebtIncludingPrincipalAndFinalFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FinalPaymentFeeOnDebtFacilityAmount" xlink:label="fate_FinalPaymentFeeOnDebtFacilityAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="fate_LoanAndSecurityAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="fate_RepaymentsOfDebtIncludingPrincipalAndFinalFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="fate_FinalPaymentFeeOnDebtFacilityAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ImpairmentOfRightOfUseAsset" xlink:label="fate_ImpairmentOfRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_LesseeOperatingLeaseCashRentPeriod" xlink:label="fate_LesseeOperatingLeaseCashRentPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForTenantImprovements" xlink:label="us-gaap_PaymentsForTenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_EarlyTerminationFee" xlink:label="fate_EarlyTerminationFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeaseAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fate_ImpairmentOfRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fate_LesseeOperatingLeaseCashRentPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForTenantImprovements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_TenantImprovements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fate_EarlyTerminationFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_NetRentableArea" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermLeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockOptionAndIncentivePlan2013Member" xlink:label="fate_StockOptionAndIncentivePlan2013Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_November2016PlacementMember" xlink:label="fate_November2016PlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_RedmileGroupLimitedLiabilityCompanyAndAffiliatesMember" xlink:label="fate_RedmileGroupLimitedLiabilityCompanyAndAffiliatesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_EmployeeAndNonEmployeeStockOptionMember" xlink:label="fate_EmployeeAndNonEmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PreFundedWarrantsMember" xlink:label="fate_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockOptionAndIncentivePlan2022Member" xlink:label="fate_StockOptionAndIncentivePlan2022Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PerformanceBasedRestrictedStockUnitsPrsusMember" xlink:label="fate_PerformanceBasedRestrictedStockUnitsPrsusMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_InducementPlanMember" xlink:label="fate_InducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_EmployeesAndDirectorsStockOptionsMember" xlink:label="fate_EmployeesAndDirectorsStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PercentageOfCommonStockOwnershipUponPreferredStockConversion" xlink:label="fate_PercentageOfCommonStockOwnershipUponPreferredStockConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PercentageOfCommonStockOwnershipForPreferredStockConversionChangeUponNotice" xlink:label="fate_PercentageOfCommonStockOwnershipForPreferredStockConversionChangeUponNotice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PreferredStockConversionPrice" xlink:label="fate_PreferredStockConversionPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardMonthlyAwardVestingPeriod" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardMonthlyAwardVestingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnuallyAwardVestingPeriod" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnuallyAwardVestingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CommonStockCapitalAdditionalSharesReservedForFutureIssuance" xlink:label="fate_CommonStockCapitalAdditionalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PurchasePriceOfPrefundedWarrants" xlink:label="fate_PurchasePriceOfPrefundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_WarrantsExerciseTermsDescription" xlink:label="fate_WarrantsExerciseTermsDescription"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_MaximumPercentageOfCommonStockOwnershipTogetherWithAffiliatesAllowableAfterExerciseOfPrefundedWarrants" xlink:label="fate_MaximumPercentageOfCommonStockOwnershipTogetherWithAffiliatesAllowableAfterExerciseOfPrefundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_MaximumPercentageOfCommonStockOwnershipAfterChangeUponNotice" xlink:label="fate_MaximumPercentageOfCommonStockOwnershipAfterChangeUponNotice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fate_StockOptionAndIncentivePlan2013Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="fate_November2016PlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="fate_RedmileGroupLimitedLiabilityCompanyAndAffiliatesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="fate_EmployeeAndNonEmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="fate_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fate_StockOptionAndIncentivePlan2022Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="fate_PerformanceBasedRestrictedStockUnitsPrsusMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fate_InducementPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="fate_EmployeesAndDirectorsStockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fate_PercentageOfCommonStockOwnershipUponPreferredStockConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fate_PercentageOfCommonStockOwnershipForPreferredStockConversionChangeUponNotice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fate_PreferredStockConversionPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_Dividends" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardMonthlyAwardVestingPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnuallyAwardVestingPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fate_CommonStockCapitalAdditionalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fate_PurchasePriceOfPrefundedWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fate_WarrantsExerciseTermsDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fate_MaximumPercentageOfCommonStockOwnershipTogetherWithAffiliatesAllowableAfterExerciseOfPrefundedWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fate_MaximumPercentageOfCommonStockOwnershipAfterChangeUponNotice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockOptionAndIncentivePlan2013Member" xlink:label="fate_StockOptionAndIncentivePlan2013Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_EmployeeAndNonEmployeeStockOptionMember" xlink:label="fate_EmployeeAndNonEmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fate_StockOptionAndIncentivePlan2013Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="fate_EmployeeAndNonEmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageRemainingContractualTerm" xlink:label="fate_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestAggregateIntrinsicValue" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="fate_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageRemainingContractualTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:to="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestAggregateIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockBasedCompensationForAllStockAwardsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityWeightedAverageAssumptionsUsedInTheBlackscholesOptionPricingModelDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_EmployeeAndNonEmployeeStockOptionMember" xlink:label="fate_EmployeeAndNonEmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="fate_EmployeeAndNonEmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockOptionAndIncentivePlan2013Member" xlink:label="fate_StockOptionAndIncentivePlan2013Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockOptionAndIncentivePlan2022Member" xlink:label="fate_StockOptionAndIncentivePlan2022Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_InducementPlanMember" xlink:label="fate_InducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fate_StockOptionAndIncentivePlan2013Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fate_StockOptionAndIncentivePlan2022Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fate_InducementPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails2">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_OperatingLossCarryforwardsIndefiniteLife" xlink:label="fate_OperatingLossCarryforwardsIndefiniteLife"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PercentOfTaxableIncomeOffset" xlink:label="fate_PercentOfTaxableIncomeOffset"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_OperatingLossCarryforwardsExpirationYear" xlink:label="fate_OperatingLossCarryforwardsExpirationYear"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="fate_OperatingLossCarryforwardsIndefiniteLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="fate_PercentOfTaxableIncomeOffset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="fate_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails3">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_TaxCreditCarryforwardBeginningExpirationYear" xlink:label="fate_TaxCreditCarryforwardBeginningExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CumulativeChangeInOwnershipPercentage" xlink:label="fate_CumulativeChangeInOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PeriodForCumulativeChangeInOwnership" xlink:label="fate_PeriodForCumulativeChangeInOwnership"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:label="us-gaap_IncomeTaxExaminationYearUnderExamination"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_CaliforniaFranchiseTaxBoardMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="fate_TaxCreditCarryforwardBeginningExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="fate_CumulativeChangeInOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="fate_PeriodForCumulativeChangeInOwnership" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_IncomeTaxExaminationYearUnderExamination" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentProfitOrLossIncludingSegmentExpensesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PersonnelCosts" xlink:label="fate_PersonnelCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ClinicalProgramsExpense" xlink:label="fate_ClinicalProgramsExpense"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" xlink:label="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:label="us-gaap_TypeOfRevenueExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ResearchActivitiesExpense" xlink:label="fate_ResearchActivitiesExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FacilitiesCosts" xlink:label="fate_FacilitiesCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_OtherSegmentExpenses" xlink:label="fate_OtherSegmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="fate_PersonnelCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="fate_ClinicalProgramsExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_TypeOfRevenueExtensibleList" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="fate_ResearchActivitiesExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="fate_FacilitiesCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="fate_OtherSegmentExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PatentsOneMember" xlink:label="fate_PatentsOneMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_MinimumAnnualPaymentsToMaintainLicenses" xlink:label="fate_MinimumAnnualPaymentsToMaintainLicenses"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PatentsTwoMember" xlink:label="fate_PatentsTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PatentNumber" xlink:label="fate_PatentNumber"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PatentsThreeMember" xlink:label="fate_PatentsThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PatentsFourMember" xlink:label="fate_PatentsFourMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PatentsFiveMember" xlink:label="fate_PatentsFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PatentsSixMember" xlink:label="fate_PatentsSixMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PatentsSevenMember" xlink:label="fate_PatentsSevenMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="fate_PatentsOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="fate_MinimumAnnualPaymentsToMaintainLicenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="fate_PatentsTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="fate_PatentNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="fate_PatentsThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="fate_PatentsFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="fate_PatentsFiveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="fate_PatentsSixMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="fate_PatentsSevenMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_GrantAward" xlink:label="fate_GrantAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CaliforniaInstituteForRegenerativeMedicineMember" xlink:label="fate_CaliforniaInstituteForRegenerativeMedicineMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="fate_GrantAward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fate_CaliforniaInstituteForRegenerativeMedicineMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="fate_CIRMAwardLiabilityNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="fate_StockPriceAppreciationMilestonesLiabilitiesNonCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_CIRMAwardLiabilityNoncurrent" xlink:label="fate_CIRMAwardLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_StockPriceAppreciationMilestonesLiabilitiesNonCurrent" xlink:label="fate_StockPriceAppreciationMilestonesLiabilitiesNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesDetails23">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilities" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="fate_DeferredTaxLiabilitiesDepreciation" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="fate_DeferredTaxLiabilitiesRightOfUseAssets" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="fate_DeferredTaxAssetsCapitalizedRdExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="fate_DeferredTaxAssetsLeaseLiabilities" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="8" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_DeferredTaxLiabilitiesDepreciation" xlink:label="fate_DeferredTaxLiabilitiesDepreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="fate_DeferredTaxLiabilitiesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_DeferredTaxAssetsCapitalizedRdExpense" xlink:label="fate_DeferredTaxAssetsCapitalizedRdExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_DeferredTaxAssetsLeaseLiabilities" xlink:label="fate_DeferredTaxAssetsLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesDetails22">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" xlink:label="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="fate_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="fate_ProceedsFromCIRMAward" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="fate_GrantIncomeFromCirmAward" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_CapitalizedContractCostAmortization" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="13" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet" xlink:label="fate_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ProceedsFromCIRMAward" xlink:label="fate_ProceedsFromCIRMAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" xlink:label="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_GrantIncomeFromCirmAward" xlink:label="fate_GrantIncomeFromCirmAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails1">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureAccruedExpensesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="fate_AccruedClinicalTrialRelatedCostsCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_AccruedClinicalTrialRelatedCostsCurrent" xlink:label="fate_AccruedClinicalTrialRelatedCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails1">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_StraightLineRentAdjustments" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StraightLineRentAdjustments" xlink:label="us-gaap_StraightLineRentAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="fate_IncomeTaxReconciliationNondeductibleCompensation" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="fate_IncomeTaxReconciliationPermanentTaxDifferences" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="fate_IncomeTaxReconciliationReserveForUncertainTaxPositions" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="8" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_IncomeTaxReconciliationNondeductibleCompensation" xlink:label="fate_IncomeTaxReconciliationNondeductibleCompensation"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_IncomeTaxReconciliationPermanentTaxDifferences" xlink:label="fate_IncomeTaxReconciliationPermanentTaxDifferences"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_IncomeTaxReconciliationReserveForUncertainTaxPositions" xlink:label="fate_IncomeTaxReconciliationReserveForUncertainTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentProfitOrLossIncludingSegmentExpensesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="fate_PersonnelCosts" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="fate_ClinicalProgramsExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="fate_ResearchActivitiesExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="fate_FacilitiesCosts" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="fate_OtherSegmentExpenses" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_PersonnelCosts" xlink:label="fate_PersonnelCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" xlink:label="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ClinicalProgramsExpense" xlink:label="fate_ClinicalProgramsExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_ResearchActivitiesExpense" xlink:label="fate_ResearchActivitiesExpense"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_FacilitiesCosts" xlink:label="fate_FacilitiesCosts"/>
          <link:loc xlink:type="locator" xlink:href="fate-20241231.xsd#fate_OtherSegmentExpenses" xlink:label="fate_OtherSegmentExpenses"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="fate_AwardFromRegenerativeMedicineInstituteAbstract" name="AwardFromRegenerativeMedicineInstituteAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_ConversionOfPreferredSharesToCommonStocksShares" name="ConversionOfPreferredSharesToCommonStocksShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_AwardAgreementExecutedDate" name="AwardAgreementExecutedDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_CollaborationAndLicenseAgreementsDisclosureAbstract" name="CollaborationAndLicenseAgreementsDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_MilestonePaymentUnderDeferredRevenue" name="MilestonePaymentUnderDeferredRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_IncomeTaxReconciliationPermanentTaxDifferences" name="IncomeTaxReconciliationPermanentTaxDifferences" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_CandidateThreeMember" name="CandidateThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_DebtInstrumentRepaymentPhaseThreeRateMember" name="DebtInstrumentRepaymentPhaseThreeRateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnuallyAwardVestingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnuallyAwardVestingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_StockIssuedDuringPeriodSharesForPrivatePlacement" name="StockIssuedDuringPeriodSharesForPrivatePlacement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_AddtionalAmountAvailableForFundingUnderAward" name="AddtionalAmountAvailableForFundingUnderAward" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_DefinedContributionPlanMinimumAgeOfEmployee" name="DefinedContributionPlanMinimumAgeOfEmployee" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_ProfitLossSharingPercentage" name="ProfitLossSharingPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" name="ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardMonthlyAwardVestingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMonthlyAwardVestingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="fate_CollaborativeArrangementPercentageOfReductionOnMilestonePayments" name="CollaborativeArrangementPercentageOfReductionOnMilestonePayments" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_LesseeOperatingLeaseCashRentPeriod" name="LesseeOperatingLeaseCashRentPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_PrivatePlacementOfPreFundedWarrants" name="PrivatePlacementOfPreFundedWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_OptionExercisePayment" name="OptionExercisePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_MilestoneOneMember" name="MilestoneOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_PreferredStockConversionPrice" name="PreferredStockConversionPrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="fate_CommonStockCapitalAdditionalSharesReservedForFutureIssuance" name="CommonStockCapitalAdditionalSharesReservedForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestAggregateIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestAggregateIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_PatentsThreeMember" name="PatentsThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_ResearchServicesMember" name="ResearchServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_ShortTermLeasesTermExcludedFromCalculationOfRightOfUseOfAssetsAndLeaseLiabilities" name="ShortTermLeasesTermExcludedFromCalculationOfRightOfUseOfAssetsAndLeaseLiabilities" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_PersonnelCosts" name="PersonnelCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_PercentageOfDiscretionaryContributionsDescription" name="PercentageOfDiscretionaryContributionsDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_LiquidityPolicyTextBlock" name="LiquidityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_StockOptionAndIncentivePlan2022Member" name="StockOptionAndIncentivePlan2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_InducementPlanMember" name="InducementPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_AmortizationOfSubLicenseConsideration" name="AmortizationOfSubLicenseConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_GrantAward" name="GrantAward" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_AwardAgreementForResearchAndDevelopmentDisclosureTextBlock" name="AwardAgreementForResearchAndDevelopmentDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_FairValueAssumptionsExpectedVolatilityRate1" name="FairValueAssumptionsExpectedVolatilityRate1" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_MilestoneTwoMember" name="MilestoneTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_EarlyTerminationFee" name="EarlyTerminationFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_GrantIncomeFromCirmAward" name="GrantIncomeFromCirmAward" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_OperatingLossCarryforwardsIndefiniteLife" name="OperatingLossCarryforwardsIndefiniteLife" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_StockPurchaseAgreementDomain" name="StockPurchaseAgreementDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_PatentsSixMember" name="PatentsSixMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_ConversionOfPreferenceShareToCommonStock" name="ConversionOfPreferenceShareToCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_PatentsFourMember" name="PatentsFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_StockPriceIncreasedByTenPercentPerShareMember" name="StockPriceIncreasedByTenPercentPerShareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_SublicenseConsiderationMember" name="SublicenseConsiderationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="fate_AwardFromCaliforniaInstituteForRegenerativeMedicineAbstract" name="AwardFromCaliforniaInstituteForRegenerativeMedicineAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants" name="PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_AwardFromRegenerativeMedicineInstituteTable" name="AwardFromRegenerativeMedicineInstituteTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_MinimumAnnualPaymentsToMaintainLicenses" name="MinimumAnnualPaymentsToMaintainLicenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_MilestoneThreeMember" name="MilestoneThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_Rule10B51ArrModifiedFlag" name="Rule10B51ArrModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_UpfrontFeeMember" name="UpfrontFeeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_CIRMAwardLiabilityNoncurrent" name="CIRMAwardLiabilityNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_GladstoneLicenseAgreementMember" name="GladstoneLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_Fairvalueliabilitieslevel2Tolevel1Transfersamounts" name="Fairvalueliabilitieslevel2Tolevel1Transfersamounts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_CommercialOptionExerciseMember" name="CommercialOptionExerciseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_JanssenAgreementMember" name="JanssenAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_FTFiveOneSixMember" name="FTFiveOneSixMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_PotentialAmountPayable" name="PotentialAmountPayable" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_MaximumPercentageOfCommonStockOwnershipAfterChangeUponNotice" name="MaximumPercentageOfCommonStockOwnershipAfterChangeUponNotice" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="fate_EquityPremiumOnSharePricePerShareUnderAgreement" name="EquityPremiumOnSharePricePerShareUnderAgreement" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_NumberOfDisbursementsReceivableUponExecutionOfAward" name="NumberOfDisbursementsReceivableUponExecutionOfAward" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_AssociatedWithCollaborationServicesMember" name="AssociatedWithCollaborationServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_StockPriceAppreciationMilestonesPolicyTextBlock" name="StockPriceAppreciationMilestonesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_PerformanceBasedRestrictedStockUnitsPrsusMember" name="PerformanceBasedRestrictedStockUnitsPrsusMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_PatentCostsPolicyTextBlock" name="PatentCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_StockPriceAppreciationMilestones" name="StockPriceAppreciationMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_UpfrontCashPayment" name="UpfrontCashPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_StockPriceDecreasedByTenPercentPerShareMember" name="StockPriceDecreasedByTenPercentPerShareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_NumberOfDisbursements" name="NumberOfDisbursements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_CollaborativeArrangementAnnualPaymentsReceivableRecordedUnderDeferredRevenue" name="CollaborativeArrangementAnnualPaymentsReceivableRecordedUnderDeferredRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_November2016PlacementMember" name="November2016PlacementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_StockPriceAppreciationMilestonesLiabilitiesNonCurrent" name="StockPriceAppreciationMilestonesLiabilitiesNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_NumberOfDisbursementsReceivableBasedOnCompletionOfCertainOperatingMilestones" name="NumberOfDisbursementsReceivableBasedOnCompletionOfCertainOperatingMilestones" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_JanssenBiotechIncMember" name="JanssenBiotechIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_PatentsSevenMember" name="PatentsSevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_StockOptionAndIncentivePlan2013Member" name="StockOptionAndIncentivePlan2013Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_JohnsonJohnsonInnovationJJDCIncMember" name="JohnsonJohnsonInnovationJJDCIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_FairValueAssumptionsExpectedTerm1" name="FairValueAssumptionsExpectedTerm1" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_CollaborativeArrangementPotentialAdditionalMilestones" name="CollaborativeArrangementPotentialAdditionalMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="fate_CommonStockMultiple1" name="CommonStockMultiple1" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" name="IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_EmployeeAndNonEmployeeStockOptionMember" name="EmployeeAndNonEmployeeStockOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_FinalPaymentFeeOnDebtFacilityAmount" name="FinalPaymentFeeOnDebtFacilityAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_AmendedMskccLicenseMember" name="AmendedMskccLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_CollaborativeArrangementAggregateMilestonePaymentsReceivable" name="CollaborativeArrangementAggregateMilestonePaymentsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_ShortTermInvestmentMaturityPeriodRangeEnd" name="ShortTermInvestmentMaturityPeriodRangeEnd" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_MilestonePayments" name="MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_ContraResearchAndDevelopmentExpenses" name="ContraResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_LoanAndSecurityAgreementMember" name="LoanAndSecurityAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_PercentageOfTaxCredit" name="PercentageOfTaxCredit" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_EnterpriseValueMilestonesLiabilityAtFairValue" name="EnterpriseValueMilestonesLiabilityAtFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_WeightedAveragePreFundedWarrants" name="WeightedAveragePreFundedWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_CommonStockIssuedDuringPeriodSharesPrivatePlacement" name="CommonStockIssuedDuringPeriodSharesPrivatePlacement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_CompanyReceivedPayment" name="CompanyReceivedPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_CommonStockMultiplesAndTheEnterpriseValueMilestonePaymentsTableTextBlock" name="CommonStockMultiplesAndTheEnterpriseValueMilestonePaymentsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_CommonStockIssuedDuringPeriodValuePrivatePlacement" name="CommonStockIssuedDuringPeriodValuePrivatePlacement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_TaxCreditCarryforwardBeginningExpirationYear" name="TaxCreditCarryforwardBeginningExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_InvestmentMaturityDateRange" name="InvestmentMaturityDateRange" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_PercentageOfCommonStockOwnershipUponPreferredStockConversion" name="PercentageOfCommonStockOwnershipUponPreferredStockConversion" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="fate_ClinicalProgramsExpense" name="ClinicalProgramsExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_AchievementOfStockPriceAppreciationMilestone" name="AchievementOfStockPriceAppreciationMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_PatentNumber" name="PatentNumber" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_StockPurchaseAgreementAxis" name="StockPurchaseAgreementAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_CandidateTwoMember" name="CandidateTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_RepaymentPercentageOfAwardAmount" name="RepaymentPercentageOfAwardAmount" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_ComputerAndOfficeEquipmentMember" name="ComputerAndOfficeEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_EmployeeRetentionCreditPolicy" name="EmployeeRetentionCreditPolicy" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_AwardForFirstInHumanClinicalTrial" name="AwardForFirstInHumanClinicalTrial" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_CorrespondingAssetForSublicenseConsiderationPaid" name="CorrespondingAssetForSublicenseConsiderationPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_AdditionalCancerTargetsMember" name="AdditionalCancerTargetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_DeferredTaxAssetsLeaseLiabilities" name="DeferredTaxAssetsLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_PercentageOfCommonStockOwnershipForPreferredStockConversionChangeUponNotice" name="PercentageOfCommonStockOwnershipForPreferredStockConversionChangeUponNotice" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="fate_DebtInstrumentRepaymentPhaseFourRateMember" name="DebtInstrumentRepaymentPhaseFourRateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_EnterpriseValueMilestonePayment" name="EnterpriseValueMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue" name="CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_DeferredTaxAssetsCapitalizedRdExpense" name="DeferredTaxAssetsCapitalizedRdExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_AwardFromRegenerativeMedicineInstituteLineItems" name="AwardFromRegenerativeMedicineInstituteLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_MaximumPercentageOfCommonStockOwnershipTogetherWithAffiliatesAllowableAfterExerciseOfPrefundedWarrants" name="MaximumPercentageOfCommonStockOwnershipTogetherWithAffiliatesAllowableAfterExerciseOfPrefundedWarrants" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="fate_Fairvalueassetslevel1Tolevel2Transfersamounts" name="Fairvalueassetslevel1Tolevel2Transfersamounts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_ProceedsFromCIRMAward" name="ProceedsFromCIRMAward" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_CaliforniaInstituteForRegenerativeMedicineMember" name="CaliforniaInstituteForRegenerativeMedicineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_Fairvalueliabilitieslevel1Tolevel2Transfersamounts" name="Fairvalueliabilitieslevel1Tolevel2Transfersamounts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_OnoPharmaceuticalCompanyLtdMember" name="OnoPharmaceuticalCompanyLtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_DeferredTaxLiabilitiesRightOfUseAssets" name="DeferredTaxLiabilitiesRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_ImpairmentOfRightOfUseAsset" name="ImpairmentOfRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_PatentsFiveMember" name="PatentsFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_DeferredTaxLiabilitiesDepreciation" name="DeferredTaxLiabilitiesDepreciation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_AmendedMSKLicenseMember" name="AmendedMSKLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_RestructuringPolicytextBlock" name="RestructuringPolicytextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_FacilitiesCosts" name="FacilitiesCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_OtherSegmentExpenses" name="OtherSegmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_ScientificEquipmentMember" name="ScientificEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_PurchasePriceOfPrefundedWarrants" name="PurchasePriceOfPrefundedWarrants" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_FairValueAssumptionsRiskFreeInterestRate1" name="FairValueAssumptionsRiskFreeInterestRate1" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_FirstDisbursementAmountUnderTheAwardPayableForNextTwelveMonths" name="FirstDisbursementAmountUnderTheAwardPayableForNextTwelveMonths" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_UnrecognizedTaxBenefitsResultingInNetOperatingLossAndTaxCreditCarryforward" name="UnrecognizedTaxBenefitsResultingInNetOperatingLossAndTaxCreditCarryforward" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_EmployeesAndDirectorsStockOptionsMember" name="EmployeesAndDirectorsStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_DebtInstrumentRepaymentPhaseOneRateMember" name="DebtInstrumentRepaymentPhaseOneRateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_PatentsTwoMember" name="PatentsTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_SharePriceFairValueInput" name="SharePriceFairValueInput" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_EmployeeRetentionCreditMember" name="EmployeeRetentionCreditMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_TrailingStockPricePerShare" name="TrailingStockPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="fate_ScheduleOfMilestonePaymentsValuationAssumptionsTableTextBlock" name="ScheduleOfMilestonePaymentsValuationAssumptionsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_CommonStockOfPublicOfferingAndIssuanceOfPreFundedWarrants" name="CommonStockOfPublicOfferingAndIssuanceOfPreFundedWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_UpfrontFeeAndEquityPremiumMember" name="UpfrontFeeAndEquityPremiumMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_PeriodToTreatAwardAsGrantIfAwardNotTreatedAsLoan" name="PeriodToTreatAwardAsGrantIfAwardNotTreatedAsLoan" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_DebtInstrumentRepaymentPhaseTwoRateMember" name="DebtInstrumentRepaymentPhaseTwoRateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_StockPurchaseAgreementMember" name="StockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_AccruedExpensesAndLongTermDebtDisclosureAbstract" name="AccruedExpensesAndLongTermDebtDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_ResearchActivitiesExpense" name="ResearchActivitiesExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_FtEightOneNineMember" name="FtEightOneNineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_StockIssuedDuringPeriodSharesToCollaborativePartner" name="StockIssuedDuringPeriodSharesToCollaborativePartner" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_IncomeTaxReconciliationReserveForUncertainTaxPositions" name="IncomeTaxReconciliationReserveForUncertainTaxPositions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_ConvertiblePreferredStockPolicyTextBlock" name="ConvertiblePreferredStockPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_StockPriceAppreciationMilestonesMember" name="StockPriceAppreciationMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_RefundableTaxCredit" name="RefundableTaxCredit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet" name="IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_PrepaidExpensesAndOtherAssetsMember" name="PrepaidExpensesAndOtherAssetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_FirstDisbursementAmountUnderTheAward" name="FirstDisbursementAmountUnderTheAward" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_AmendedAndRestatedExclusiveLicenseAgreementMember" name="AmendedAndRestatedExclusiveLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_RepaymentsOfDebtIncludingPrincipalAndFinalFee" name="RepaymentsOfDebtIncludingPrincipalAndFinalFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_Fairvalueassetslevel2Tolevel1Transfersamounts" name="Fairvalueassetslevel2Tolevel1Transfersamounts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_FairValueInputsStockPriceSensitivityPercentageIncreaseDecrease" name="FairValueInputsStockPriceSensitivityPercentageIncreaseDecrease" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_ShortTermInvestmentMaturityPeriodRangeStart" name="ShortTermInvestmentMaturityPeriodRangeStart" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_AggregateEquityPremiumOnSharesIssuedUnderAgreement" name="AggregateEquityPremiumOnSharesIssuedUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_ClinicalDevelopmentMilestoneFees" name="ClinicalDevelopmentMilestoneFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_NonRule10B51ArrModifiedFlag" name="NonRule10B51ArrModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_UpfrontNonRefundableNonCreditablePaymentReceivable" name="UpfrontNonRefundableNonCreditablePaymentReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_OnoLetterAgreementMember" name="OnoLetterAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_CandidateOneMember" name="CandidateOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_WarrantsExerciseTermsDescription" name="WarrantsExerciseTermsDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_CumulativeChangeInOwnershipPercentage" name="CumulativeChangeInOwnershipPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_SublicenseConsiderationRepresentsAnAssetUnderAscOtherAssetsAndDeferredCosts" name="SublicenseConsiderationRepresentsAnAssetUnderAscOtherAssetsAndDeferredCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_PatentsOneMember" name="PatentsOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_FirstJanssenCancerTargetMember" name="FirstJanssenCancerTargetMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_PercentOfTaxableIncomeOffset" name="PercentOfTaxableIncomeOffset" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="fate_ProceedsFromResearchAndDevelopmentFeesReceived" name="ProceedsFromResearchAndDevelopmentFeesReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_StockPriceAppreciationMilestonePayable" name="StockPriceAppreciationMilestonePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_StockIssuedDuringPeriodValueToCollaborativePartner" name="StockIssuedDuringPeriodValueToCollaborativePartner" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_Stockpriceappreciationmilestoneincome" name="Stockpriceappreciationmilestoneincome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_IncomeTaxReconciliationNondeductibleCompensation" name="IncomeTaxReconciliationNondeductibleCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fate_PeriodForCumulativeChangeInOwnership" name="PeriodForCumulativeChangeInOwnership" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fate_AccruedClinicalTrialRelatedCostsCurrent" name="AccruedClinicalTrialRelatedCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_TransactionPriceOfAgreement" name="TransactionPriceOfAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fate_RedmileGroupLimitedLiabilityCompanyAndAffiliatesMember" name="RedmileGroupLimitedLiabilityCompanyAndAffiliatesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fate_CollaborativeArrangementAggregatePaymentsReceivable" name="CollaborativeArrangementAggregatePaymentsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546443867152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 25, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">FATE THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001434316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FATE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 369,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,597,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-1311552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12278 Scripps Summit Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">875-1800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Portions of the registrant&#8217;s definitive proxy statement to be filed with the Securities and Exchange Commission, or SEC, on or before the date 120 days after the conclusion of the registrant&#8217;s fiscal year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pursuant to Regulation 14A, in connection with the registrant&#8217;s 2025 Annual Meeting of Stockholders are incorporated by reference into Part III of this annual report on Form 10-K.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young, LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Fate Therapeutics, Inc. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(the Company) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546447514912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 36,056<span></span>
</td>
<td class="nump">$ 41,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">3,539<span></span>
</td>
<td class="nump">1,826<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">243,012<span></span>
</td>
<td class="nump">273,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">9,302<span></span>
</td>
<td class="nump">14,539<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">291,909<span></span>
</td>
<td class="nump">331,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">27,657<span></span>
</td>
<td class="nump">980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">64,384<span></span>
</td>
<td class="nump">96,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">46,508<span></span>
</td>
<td class="nump">61,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">10,227<span></span>
</td>
<td class="nump">15,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">440,694<span></span>
</td>
<td class="nump">506,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,365<span></span>
</td>
<td class="nump">4,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">21,348<span></span>
</td>
<td class="nump">27,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">393<span></span>
</td>
<td class="nump">685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">7,416<span></span>
</td>
<td class="nump">6,176<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">38,522<span></span>
</td>
<td class="nump">39,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_CIRMAwardLiabilityNoncurrent', window );">CIRM award liability</a></td>
<td class="nump">5,070<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">77,849<span></span>
</td>
<td class="nump">97,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_StockPriceAppreciationMilestonesLiabilitiesNonCurrent', window );">Stock price appreciation milestones</a></td>
<td class="nump">527<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; authorized shares - 5,000,000; Class A Convertible Preferred shares issued and outstanding - 2,755,086 at December 31, 2024 and 2,761,108 at December 31, 2023</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; authorized shares - 250,000,000; issued and outstanding - 113,928,279 at December 31, 2024 and 98,627,076 at December 31, 2023</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,716,335<span></span>
</td>
<td class="nump">1,580,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">268<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,397,994)<span></span>
</td>
<td class="num">(1,211,732)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">318,726<span></span>
</td>
<td class="nump">368,417<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 440,694<span></span>
</td>
<td class="nump">$ 506,217<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_CIRMAwardLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>CIRM award liability, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_CIRMAwardLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_StockPriceAppreciationMilestonesLiabilitiesNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock price appreciation milestones, non current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_StockPriceAppreciationMilestonesLiabilitiesNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546443579568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares</a></td>
<td class="nump">113,928,279<span></span>
</td>
<td class="nump">98,627,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares</a></td>
<td class="nump">113,928,279<span></span>
</td>
<td class="nump">98,627,076<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Class A Convertible Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued shares</a></td>
<td class="nump">2,755,086<span></span>
</td>
<td class="nump">2,761,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding shares</a></td>
<td class="nump">2,755,086<span></span>
</td>
<td class="nump">2,761,108<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546446272336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 13,631<span></span>
</td>
<td class="nump">$ 63,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Type of Revenue [Extensible List]</a></td>
<td class="text">us-gaap:LicenseMember<span></span>
</td>
<td class="text">us-gaap:LicenseMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 135,001<span></span>
</td>
<td class="nump">$ 172,596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">74,169<span></span>
</td>
<td class="nump">81,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment loss</a></td>
<td class="nump">14,737<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">223,907<span></span>
</td>
<td class="nump">254,044<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(210,276)<span></span>
</td>
<td class="num">(190,511)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">17,288<span></span>
</td>
<td class="nump">17,186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones', window );">Change in fair value of stock price appreciation milestones</a></td>
<td class="nump">819<span></span>
</td>
<td class="nump">2,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
<td class="nump">5,907<span></span>
</td>
<td class="nump">9,882<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">24,014<span></span>
</td>
<td class="nump">29,583<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(186,262)<span></span>
</td>
<td class="num">(160,928)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive gain:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain on available-for-sale securities, net</a></td>
<td class="nump">253<span></span>
</td>
<td class="nump">1,869<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">$ (186,009)<span></span>
</td>
<td class="num">$ (159,059)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, Basic</a></td>
<td class="num">$ (1.64)<span></span>
</td>
<td class="num">$ (1.64)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, Diluted</a></td>
<td class="num">$ (1.64)<span></span>
</td>
<td class="num">$ (1.64)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares used to compute basic net loss per share</a></td>
<td class="nump">113,685,177<span></span>
</td>
<td class="nump">98,411,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares used to compute diluted net loss per share</a></td>
<td class="nump">113,685,177<span></span>
</td>
<td class="nump">98,411,162<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in fair value of stock price appreciation milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfRevenueExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfRevenueExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546446821280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Gain (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Preferred Stock</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 483,939<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
<td class="nump">$ 1,536,497<span></span>
</td>
<td class="num">$ (1,854)<span></span>
</td>
<td class="num">$ (1,050,804)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,294,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,794,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, net of issuance costs</a></td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of restricted stock units</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,071,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_ConversionOfPreferenceShareToCommonStock', window );">Conversion of preferred shares to common stock</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_ConversionOfPreferredSharesToCommonStocksShares', window );">Conversion of preferred shares to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,441)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock&#8211;based compensation</a></td>
<td class="nump">43,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on investments, net</a></td>
<td class="nump">1,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(160,928)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(160,928)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">368,417<span></span>
</td>
<td class="nump">$ 99<span></span>
</td>
<td class="nump">1,580,032<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="num">(1,211,732)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,627,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,761,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, net of issuance costs</a></td>
<td class="nump">295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">680,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_ConversionOfPreferredSharesToCommonStocksShares', window );">Conversion of preferred shares to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,022)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock&#8211;based compensation</a></td>
<td class="nump">41,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on investments, net</a></td>
<td class="nump">253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants', window );">Public offering of common stock and issuance of pre-funded warrants, net of offering costs</a></td>
<td class="nump">74,531<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">74,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_CommonStockOfPublicOfferingAndIssuanceOfPreFundedWarrants', window );">Public offering of common stock and issuance of pre-funded warrants, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,545,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_PrivatePlacementOfPreFundedWarrants', window );">Private placement of pre-funded warrants</a></td>
<td class="nump">19,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(186,262)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(186,262)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 318,726<span></span>
</td>
<td class="nump">$ 114<span></span>
</td>
<td class="nump">$ 1,716,335<span></span>
</td>
<td class="nump">$ 268<span></span>
</td>
<td class="num">$ (1,397,994)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,928,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,755,086<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_CommonStockOfPublicOfferingAndIssuanceOfPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock of public offering and issuance of pre funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_CommonStockOfPublicOfferingAndIssuanceOfPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ConversionOfPreferenceShareToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of preferred share conversion to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_ConversionOfPreferenceShareToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ConversionOfPreferredSharesToCommonStocksShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of preferred shares to common stock, shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_ConversionOfPreferredSharesToCommonStocksShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_PrivatePlacementOfPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Private placement of pre Funded warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_PrivatePlacementOfPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public offering of common stock and issuance of pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546446813648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (186,262)<span></span>
</td>
<td class="num">$ (160,928)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">18,962<span></span>
</td>
<td class="nump">18,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">41,496<span></span>
</td>
<td class="nump">43,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion and amortization of premiums and discounts on investments, net</a></td>
<td class="num">(9,080)<span></span>
</td>
<td class="num">(11,398)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization of collaboration contract asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(892)<span></span>
</td>
<td class="num">(41,541)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones', window );">Changes in fair value of stock price appreciation milestones</a></td>
<td class="num">(819)<span></span>
</td>
<td class="num">(2,515)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">14,737<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">942<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_GrantIncomeFromCirmAward', window );">Grant income from FT516 CIRM award</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,113)<span></span>
</td>
<td class="nump">36,654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">5,237<span></span>
</td>
<td class="nump">12,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(1,661)<span></span>
</td>
<td class="num">(28,940)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet', window );">Right-of-use assets and lease liabilities, net</a></td>
<td class="num">(4,421)<span></span>
</td>
<td class="num">(1,408)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(122,874)<span></span>
</td>
<td class="num">(132,263)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(730)<span></span>
</td>
<td class="num">(6,153)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(317,750)<span></span>
</td>
<td class="num">(358,810)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Maturities of investments</a></td>
<td class="nump">330,698<span></span>
</td>
<td class="nump">477,628<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">12,218<span></span>
</td>
<td class="nump">112,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Issuance of common stock from equity incentive plans, net of issuance costs</a></td>
<td class="nump">295<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from public offering of common stock, net of issuance costs</a></td>
<td class="nump">74,531<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of pre-funded warrants, net of issuance costs</a></td>
<td class="nump">19,996<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_ProceedsFromCIRMAward', window );">Proceeds from FT819 CIRM award</a></td>
<td class="nump">5,070<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">99,892<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(10,764)<span></span>
</td>
<td class="num">(19,513)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of the year</a></td>
<td class="nump">57,047<span></span>
</td>
<td class="nump">76,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of the year</a></td>
<td class="nump">46,283<span></span>
</td>
<td class="nump">57,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of noncash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment in accounts payable</a></td>
<td class="nump">$ 140<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_GrantIncomeFromCirmAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_GrantIncomeFromCirmAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in fair value of stock price appreciation milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in right-of-use assets and lease liabilities, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ProceedsFromCIRMAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from CIRM award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_ProceedsFromCIRMAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546443526416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (186,262)<span></span>
</td>
<td class="num">$ (160,928)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546446737888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_Rule10B51ArrModifiedFlag', window );">Rule 10b5-1 Arrangement Modified</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_NonRule10B51ArrModifiedFlag', window );">Non-Rule 10b5-1 Arrangement Modified</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_NonRule10B51ArrModifiedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Rule 10b51 Arr Modified Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_NonRule10B51ArrModifiedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_Rule10B51ArrModifiedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rule 10b51 Arr Modified Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_Rule10B51ArrModifiedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546447982944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management, Strategy, and Governance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 1C. Cybersecurity</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">implemented</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and maintain a cybersecurity risk management program that includes processes for the identification, assessment, and mitigation of cybersecurity risks.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conduct annual cybersecurity training for all of our employees and periodically </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engage </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party consultants to conduct penetrating testing and vulnerability assessments. Additionally, we use automated tools designed to monitor, identify, and address cybersecurity risks. Further, we have a process to evaluate and review the cybersecurity practices of our key vendors prior to onboarding, including through a general security assessment and contractual requirements, as appropriate.</span></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face a number of cybersecurity risks in connection with our business. Although such risks have </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not materially</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> affected us, including our business strategy, results of operations or financial condition, to date, we have, from time to time, experienced threats to and breaches of our data and systems, including malware and computer virus attacks. For more information about the cybersecurity risks we face, see the risk factors entitled &#8220;Our business could be negatively affected by cyberattacks or a deficiency in our cybersecurity system and infrastructure&#8221; and &#8220;Our internal computer systems, or those used by our third-party research institution collaborators, CROs or other contractors or consultants, may fail or suffer security breaches&#8221; in Item 1A- Risk Factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governance Related To Cybersecurity Risks</span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity process is overseen by our Information Technology department, which is managed by our Head of IT. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Head of IT role is currently held by an individual who has approximately two decades of professional IT management experience.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In addition, our Security Leadership Team (SLT), which is comprised of the Head of IT as well as leaders from our operations, finance, and legal departments, is responsible for documenting, reviewing, and assessing our cybersecurity processes, monitoring for cybersecurity incidents, and periodically reporting on cybersecurity risks and risk management to a committee of our executive team (Executive Committee). </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Executive Committee, which is led by our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, undertakes reviews of our cybersecurity program and assesses any security incident updates from the SLT on a quarterly basis.</span></span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Executive Committee meets with the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audit Committee</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of our Board of Directors on a quarterly basis to report on and discuss material updates to our cybersecurity program.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee provides oversight of our cybersecurity program as part of its periodic review of enterprise risk management and provides regular reports to our Board of Directors regarding our cybersecurity processes, including updates on the status of ongoing cybersecurity projects, the results of cybersecurity risk assessments, and the emerging cybersecurity threat landscape.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Additionally, the Board of Directors reviews the enterprise risk management program on at least an annual basis.</span></p></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">implemented</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and maintain a cybersecurity risk management program that includes processes for the identification, assessment, and mitigation of cybersecurity risks.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conduct annual cybersecurity training for all of our employees and periodically </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engage </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party consultants to conduct penetrating testing and vulnerability assessments. Additionally, we use automated tools designed to monitor, identify, and address cybersecurity risks. Further, we have a process to evaluate and review the cybersecurity practices of our key vendors prior to onboarding, including through a general security assessment and contractual requirements, as appropriate.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governance Related To Cybersecurity Risks</span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity process is overseen by our Information Technology department, which is managed by our Head of IT. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Head of IT role is currently held by an individual who has approximately two decades of professional IT management experience.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In addition, our Security Leadership Team (SLT), which is comprised of the Head of IT as well as leaders from our operations, finance, and legal departments, is responsible for documenting, reviewing, and assessing our cybersecurity processes, monitoring for cybersecurity incidents, and periodically reporting on cybersecurity risks and risk management to a committee of our executive team (Executive Committee). </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Executive Committee, which is led by our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, undertakes reviews of our cybersecurity program and assesses any security incident updates from the SLT on a quarterly basis.</span></span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Executive Committee meets with the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audit Committee</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of our Board of Directors on a quarterly basis to report on and discuss material updates to our cybersecurity program.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee provides oversight of our cybersecurity program as part of its periodic review of enterprise risk management and provides regular reports to our Board of Directors regarding our cybersecurity processes, including updates on the status of ongoing cybersecurity projects, the results of cybersecurity risk assessments, and the emerging cybersecurity threat landscape.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Additionally, the Board of Directors reviews the enterprise risk management program on at least an annual basis.</span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity process is overseen by our Information Technology department, which is managed by our Head of IT. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Head of IT role is currently held by an individual who has approximately two decades of professional IT management experience.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In addition, our Security Leadership Team (SLT), which is comprised of the Head of IT as well as leaders from our operations, finance, and legal departments, is responsible for documenting, reviewing, and assessing our cybersecurity processes, monitoring for cybersecurity incidents, and periodically reporting on cybersecurity risks and risk management to a committee of our executive team (Executive Committee). </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Executive Committee, which is led by our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, undertakes reviews of our cybersecurity program and assesses any security incident updates from the SLT on a quarterly basis.</span></span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee provides oversight of our cybersecurity program as part of its periodic review of enterprise risk management and provides regular reports to our Board of Directors regarding our cybersecurity processes, including updates on the status of ongoing cybersecurity projects, the results of cybersecurity risk assessments, and the emerging cybersecurity threat landscape.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity process is overseen by our Information Technology department, which is managed by our Head of IT. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Head of IT role is currently held by an individual who has approximately two decades of professional IT management experience.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In addition, our Security Leadership Team (SLT), which is comprised of the Head of IT as well as leaders from our operations, finance, and legal departments, is responsible for documenting, reviewing, and assessing our cybersecurity processes, monitoring for cybersecurity incidents, and periodically reporting on cybersecurity risks and risk management to a committee of our executive team (Executive Committee). </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Executive Committee, which is led by our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, undertakes reviews of our cybersecurity program and assesses any security incident updates from the SLT on a quarterly basis.</span></span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Executive Committee meets with the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audit Committee</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of our Board of Directors on a quarterly basis to report on and discuss material updates to our cybersecurity program.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee provides oversight of our cybersecurity program as part of its periodic review of enterprise risk management and provides regular reports to our Board of Directors regarding our cybersecurity processes, including updates on the status of ongoing cybersecurity projects, the results of cybersecurity risk assessments, and the emerging cybersecurity threat landscape.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Additionally, the Board of Directors reviews the enterprise risk management program on at least an annual basis.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Executive Committee meets with the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audit Committee</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of our Board of Directors on a quarterly basis to report on and discuss material updates to our cybersecurity program.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Head of IT role is currently held by an individual who has approximately two decades of professional IT management experience.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Executive Committee, which is led by our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, undertakes reviews of our cybersecurity program and assesses any security incident updates from the SLT on a quarterly basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546445635040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Organization and Summary of Significant Accounting Policies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Organization</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fate Therapeutics, Inc. (the Company) was incorporated in the state of Delaware on April 27, 2007 and has its principal operations in San Diego, California. The Company is a clinical-stage biopharmaceutical company dedicated to bringing off-the-shelf, multiplexed-engineered, iPSC-derived cellular immunotherapies to patients.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company has devoted substantially all of its efforts to product development, raising capital and building infrastructure and has not generated any revenues from any sales of its therapeutic products. To date, the Company&#8217;s revenues have been derived from collaboration agreements and government grants.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The preparation of the Company&#8217;s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#8217;s consolidated financial statements relate to its stock appreciation milestone obligations, contracts containing leases, and accrued expenses. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements include the accounts of the Company and its subsidiaries. To date, the aggregate operations of these subsidiaries have not been significant and all intercompany transactions and balances have been eliminated in consolidation.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s financial instruments consist primarily of cash and cash equivalents, marketable securities, accounts receivable, stock price appreciation milestones, accounts payable, and accrued liabilities. The carrying amounts of accounts receivable, accounts payable and accrued liabilities are considered to be representative of their respective fair values because of the relatively short-term nature of those instruments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three- tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></p><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1: Observable inputs such as quoted prices in active markets;</span></p><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></p><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash, Cash Equivalents and Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and cash equivalents include cash in readily available checking and savings accounts, money market accounts and money market funds. The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,056</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,870</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,227</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,177</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,283</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,047</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024 and 2023, the restricted cash balance includes cash-collateralized irrevocable standby letters of credit for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mill</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">io</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">n and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, associate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d with the Company&#8217;s facilities leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments are accounted for as available-for-sale securities and are carried at fair value on the consolidated balance sheets. Upon initial recognition of the investment and at each reporting period, the Company evaluates whether any unrealized losses on investments are attributable to a credit loss or other factors. Any unrealized losses attributable to credit loss are recorded through an allowance for credit losses, limited to the amount by which the fair value is below amortized cost, with the offsetting amount recorded in other income or expense in the consolidated statement of operations and comprehensive loss. Unrealized losses not attributable to an expected credit loss and unrealized gains on investments are recorded in other comprehensive income (loss) on the consolidated statements of operations and comprehensive loss. Realized gains and losses, if any, on investments classified as available-for-sale securities are included in other income or expense.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amortized cost of investments classified as available-for-sale debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest income. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments, which potentially subject the Company to a significant concentration of credit risk, consist primarily of cash, cash equivalents, and investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits and investments are held.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_36b18d82-10b0-4496-9bd3-0d13c236998e;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) and generally consist of furniture and fixtures, computers, scientific and office equipment, and in-process costs related to facilities construction. Repairs and maintenance costs are charged to expense as incurred.</span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The long-lived asset evaluation is performed at the asset group level (i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities). Recoverability of these assets is measured by a comparison of the carrying amounts to the future undiscounted cash flows the assets are expected to generate from their use and eventual disposition. If the carrying amount is not recoverable, the carrying amount of such assets is reduced to fair value. During 2024, the Company identified an indicator of impairment of its long-lived assets due to a sustained decline in the trading price of the Company&#8217;s common stock over the preceding year, resulting in the Company&#8217;s market capitalization being below its net asset value. The Company utilized observed market lease rates for comparable properties to estimate the fair value of the right-of-use asset and leasehold improvements. The Company utilized trend factors applied to historical costs, estimates of economic depreciation, normal useful lives, and benchmark values for orderly liquidations of the assets in secondary markets to estimate the fair value of the property and equipment. As a result of its fair value analysis, the Company recorde</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million impairment charge on its property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and equipment a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">illion impairment charge on its right-of-use asset in the statement of operations during the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impairment was recorded during the year ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:5.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines if a contract contains a lease at the inception of the contract. The Company currently has leases related to its facilities leased for office and laboratory space, which are classified as operating leases. These leases result in operating right-of-use (ROU) assets, current operating lease liabilities, and non-current operating lease liabilities in the Company&#8217;s consolidated balance sheets. The Company does not have any financing leases. Leases with a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12 months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or less are considered short-term and ROU assets and lease obligations are not recognized. Payments associated with short-term leases are expensed on a straight-line basis over the lease term.</span></p><p style="text-indent:5.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lease liabilities represent an obligation to make lease payments arising from the lease and ROU assets represent the right to use the underlying asset identified in the lease for the lease term. Lease liabilities are measured at the present value of the lease payments not yet paid discounted using the discount rate for the lease established at the lease commencement date. To determine the present value, the implicit rate is used when readily determinable. For those leases where the implicit rate is not provided, the Company determines an incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. ROU assets are measured as the present value of the lease payments and also include any prepaid lease payments made and any other indirect costs incurred, and exclude any lease incentives received. Lease terms may include the impact of options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term. The Company aggregates all lease and non-lease components for each class of underlying assets into a single lease component.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaborative Arrangements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC Topic 808, Collaborative Arrangements (ASC 808), to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, the Company assesses whether aspects of the arrangement between the Company and its collaboration partner are within the scope of other accounting literature, including ASC Topic 606, Revenue from Contracts with Customers (ASC 606). If it is concluded that some or all aspects of the arrangement represent a transaction with a customer, the Company will account for those aspects of the arrangement within the scope of ASC 606.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC 808 provides guidance for the presentation and disclosure of transactions in collaborative arrangements, but it does not provide recognition or measurement guidance. Therefore, if the Company concludes a counterparty to a transaction is not a customer or otherwise not within the scope of ASC 606, the Company considers the guidance in other accounting literature as applicable or by analogy to account for such transaction. The classification of transactions under the Company&#8217;s arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. If the Company concludes that some or all aspects of the arrangement represent a transaction with a customer, the Company accounts for those aspects of the arrangement within the scope of ASC 606.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For arrangements attributable to ASC 606, the Company recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration the Company is entitled to receive in exchange for such product or service. In doing so, the Company follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Price Appreciation Milestones</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company estimates the fair value of the stock price appreciation milestones associated with the Amended and Restated Exclusive License Agreement with Memorial Sloan Kettering Cancer Center (MSKCC) using a Monte Carlo simulation model, which relies on the Company&#8217;s current stock price as well as significant estimates and assumptions to determine the estimated liability associated with the contingent milestone payments. The Company accounts for the fair value of the stock price appreciation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">milestones </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in accordance with ASC 815, Derivatives and Hedging, with fair value marked to market at each reporting date. The assumptions used to calculate the fair value of the stock price appreciation milestones are subject to a significant amount of judgment including the probability of achieving a specified clinical milestone, the expected volatility of the Company&#8217;s common stock, the risk-free interest rate, and the estimated term, which is based in part on the last valid patent claim date. The Company remeasures the fair value of the stock price appreciation milestones at each balance sheet date, with changes in fair value recorded in earnings as non-operating income or expense on the consolidated statements of operations and comprehensive loss.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense represents the cost of the grant date fair value of employee stock option and restricted stock unit grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. Performance-based stock units/awards represent a right to receive a certain number of shares of the Company&#8217;s common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, and to the extent achievement of one or any of the performance conditions is probable, the Company reassesses the probability of the achievement of such corporate performance goals and any increase or decrease in share-based compensation expense resulting from an adjustment in the estimated shares to be released is treated as a cumulative catch-up in the period of adjustment. For stock awards for which vesting is subject to both performance-based milestones and market conditions, expense is recorded over the derived service period after the point when the achievement of the performance-based milestone is probable or the performance condition has been achieved.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, with the exception of option grants for which vesting is subject to both performance-based milestones and market conditions, which are valued using a lattice-based model. The fair value of restricted stock units, including performance-based restricted stock units, is based on the closing price of the Company&#8217;s common stock as reported on The Nasdaq Global Market on the date of grant. The Company recognizes forfeitures for all awards as such forfeitures occur.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more- likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">more than 50 percent</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee Retention Credit</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CARES Act provides an employee retention credit (ERC), which is a refundable tax credit against certain employment taxes of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per employee for eligible employers. The tax credit is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of qualified wages paid to employees during a quarter, capped at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of qualified wages per employee through December 31, 2020. Additional relief provisions were passed by the United States government, which extend and slightly expand the qualified wage caps on these credits through December 31, 2021. Based on these additional provisions, the tax credit is now equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of qualified wages paid to employees during a quarter, and the limit on qualified wages per employee has been increased to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of qualified wages per quarter. The Company qualifies for the tax credit under the CARES Act and expects to continue to receive additional tax credits under the additional relief provisions for qualified wages through December 31, 2021. In connection with the CARES Act, the Company adopted a policy to recognize the employee retention credit when received and include in other income in the statement of operations. T</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">he </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company received a cash</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of other income during the year ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No such amount was received or recorded during the year ended December 31, 2024.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non&#8209;owner sources. Other comprehensive loss includes unrealized gains and losses on available-for-sale securities.</span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Loss Per Common Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. The Pre-Funded Warrants associated with the January 2021 public equity offering and the private placement concurrent with the March 2024 public equity offering (see Note 9) are considered outstanding shares in the basic earnings per share calculation given their nominal exercise price. Dilutive common stock equivalents comprise convertible preferred stock, warrants for the purchase of common stock, and common stock options and restricted stock units outstanding under the Company&#8217;s stock option plans. For all periods presented, there is no difference in the number of common shares used to calculate basic and diluted common shares outstanding due to the Company&#8217;s net loss position.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per share attributable to stockholders for the years ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024 and 2023 are calculated as follows (in thousands, except share and per share data):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">186,262</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">160,928</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares used to compute net loss per share, basic and diluted</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110,596,272</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,153,852</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average pre-funded warrants</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,088,905</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">257,310</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding used to<br/>&#160;&#160;&#160;&#160;compute basic and diluted net loss per share</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113,685,177</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,411,162</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic and diluted</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.64</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.64</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Potentially dilutive securities that are not included in the calculation of diluted net loss per common share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.967%;box-sizing:content-box;"></td>
          <td style="width:1.16%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.357%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.16%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.357%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock options</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,722,674</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,850,841</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,214,064</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,065,087</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series A convertible preferred stock (if converted)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,775,430</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,805,540</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,712,168</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,721,468</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Going Concern Assessment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Substantial doubt about an entity&#8217;s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year from the financial statement issuance date. The Company determined that there are no conditions or events that raise substantial doubt about its ability to continue as a going concern for a period of at least twelve months from the date of issuance of these financial statements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><div><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU No. 2023-07, which requires public entities to disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about a reportable segment&#8217;s profit or loss and assets that are currently required annually. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The ASU does not change how a public</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">entity identifies its operating segments, aggregates them or applies the quantitative thresholds to determine its reportable segments. The ASU is effective for fiscal years beginning after December 15, 2023, and for interim periods beginning after December 15, 2024, with early adoption permitted. The guidance should be applied retrospectively to all periods presented in the financial statements, unless it is impracticable. The segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The Company adopted ASU No. 2023-07 during the year ended December 31, 2024 and have included required disclosures in Note 11.</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This new standard will be effective for the annual periods beginning the year ended December 31, 2025. The new standard permits early adoption and can be applied prospectively or retrospectively. The Company does not expect the adoption of this guidance to have a material impact on its consolidated financial statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement: Reporting Comprehensive Income- Expense Disaggregation Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which requires detailed information about specified categories of expenses included in certain expense captions presented on the face of the income statement, as well as disclosures about selling expenses. This ASU is effective for fiscal years beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546450459712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_CollaborationAndLicenseAgreementsDisclosureAbstract', window );"><strong>Collaboration And License Agreements Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Collaboration and License Agreements</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ono Collaboration and Option Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 14, 2018, the Company entered into a Collaboration and Option Agreement (the Ono Agreement) with Ono Phar</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maceutical Co., Ltd. (Ono) for the joint development and commercialization of two off-the-shelf, iPSC-derived CAR T-cell product candidates (Candidate 1 and Candidate 2). Pursuant to the terms of the Ono Agreement, the Company received an upfront, non-refundable and non-creditable payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Additionally, the Company was entitled to receive funding for the conduct of research and preclinical development under a joint research plan, which fees were estimated to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in aggregate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2020, the Company entered into a letter agreement with Ono (the Ono Letter Agreement) pursuant to which Ono delivered proprietary antigen binding domains targeting an antigen expressed on certain solid tumors for incorporation into Candidate 2 and paid the Company a milestone fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for further research and preclinical development of Candidate 2. In addition, Ono terminated all further research and preclinical development with respect to Candidate 1, and the Company retained all rights to research, develop and commercialize Candidate 1 throughout the world without any obligation to Ono.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2022, the Company entered into an amendment with Ono to the Ono Agreement (the 2022 Ono Amendment). Pursuant to the 2022 Ono Amendment, the companies agreed to designate an additional antigen expressed on certain solid tumors for research and preclinical development, and Ono agreed to contribute proprietary antigen binding domains targeting such additional solid tumor antigen (Candidate 3). In addition, for both Candidate 2 and Candidate 3, Ono and the Company expanded the scope of the collaboration to include the research and preclinical development of iPSC-derived CAR NK cell product candidates (in addition to iPSC-derived CAR T-cell product candidates) targeting the designated solid tumor antigens. Similar to Candidate 2, the Company granted to Ono, during a specified period of time, a preclinical option (Candidate 3 Development Option) to obtain an exclusive license under certain intellectual property rights, subject to payment of an option exercise fee to the Company by Ono, to further develop and commercialize Candidate 3 in all territories of the world, where the Company retains rights to co-develop and co-commercialize Candidate 3 in the United States and Europe under a joint arrangement with Ono pursuant to which the Company is eligible to share at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the profits and losses. The Candidate 3 Development Option represents an option with no material right. Under the 2022 Ono Amendment, aggregate estimated research and preclinical development fees have been increased by approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, for a total estimated $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in aggregate research and preclinical development fees over the course of the joint research plan.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 2022, Ono exercised its option to obtain a license to develop and commercialize Candidate 2 (the Candidate 2 Development Option). The Company exercised its option (the CDCC Option) to co-develop and co-commercialize Candidate 2 in the United States and Europe. As a result, the Company received an Option Exercise Payment (as defined under the Ono Agreement) of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company and Ono are proceeding under a joint development plan for the ongoing development of Candidate 2. At the inception of the Ono Agreement, the Company determined the Candidate 2 Development Option represented an option with no material right that is distinct and separable from the ongoing development of Candidate 2 being performed by the parties. As such, the option exercise was treated as a separate contract with a single performance obligation of granting and delivering Ono a license to further develop and commercialize Candidate 2. The Company has completed its performance obligation with respect to the Candidate 2 Development Option and accordingly, recognized the Option Exercise Payment as revenue for the year ended December 31, 2022. The costs of this joint development plan are accounted for in accordance with ASC 808, and cost sharing payments to the Company from Ono are recorded net into research and development expenses. In addition, in connection with the ongoing joint development of Candidate 2, the Company is eligible to receive additional payments upon the achievement of certain clinical, regulatory, and commercial milestones</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (as further described below).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Company entered into an amendment with Ono to the Ono Agreement (the 2023 Ono Amendment). Under the 2023 Ono Amendment, aggregate estimated research and preclinical development fees payable by Ono to the Company for Candidate 3 have been increased by approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, for a total estimated $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in aggregate research and preclinical development fees over the course of the joint research plan.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, following Ono&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s exercise of the Candidate 2 Development Option and grant of the development and commercialization license, the Company achieved a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million clinical development milestone for Candidate 2 and the Company recognized such amount as revenue during the period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2024, the Company entered into an amendment with Ono to the Ono Agreement (the 2024 Ono Amendment and collectively with the 2023 Ono Amendment and 2022 Ono Amendment, the Ono Amendments). Under the 2024 Ono Amendment, aggregate estimated research and preclinical development fees payable by Ono to the Company for Candidate 3 have been increased by approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, for a total estimated $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in aggregate research and preclinical development fees over the course of the joint research plan. The Company will continue to receive committed funding under the joint research plan from Ono through June 2025. The Candidate 3 Development Option expires upon the earlier of: (a) June 30, 2025 or (b) the achievement of the pre-defined preclinical milestone under the joint research plan for Candidate 3. Subject to payment of an extension fee by Ono, Ono may choose to defer its decision to exercise the Candidate 3 Development Option until no later than June 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Ono Agreement (as amended by the Ono Amendments), for Candidate 2 and for Candidate 3 (subject to exercise by Ono of its Candidate 3 Development Option), the Company is eligible to receive additional payments upon the achievement of certain clinical, regulatory and commercial milestones (the Ono Milestones) with respect to each Candidate in an amount up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">843.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in aggregate, with the applicable milestone payments for the United States and Europe subject to reduction by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% if the Company elects to co-develop and co-commercialize the Candidate in the United States and Europe as described above. In addition, in those territories where Ono has exclusive rights of commercialization, the Company is eligible to receive tiered royalties (Royalties) ranging from the mid-single digits to the low-double digits based on annual net sales by Ono for each Candidate in such territories, with the Royalties subject to certain reductions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Ono Agreement will terminate with respect to a Candidate if Ono does not exercise its development option for a candidate within the option period, or in its entirety if Ono does not exercise any of its development options for the candidates within their respective option periods. In addition, either party may terminate the Ono Agreement in the event of breach, insolvency or patent challenges by the other party; provided, that Ono may terminate the Ono Agreement in its sole discretion (x) on a Candidate-by-Candidate basis at any time after the second anniversary of the effective date of the Ono Agreement or (y) on a Candidate-by-Candidate or country-by-country basis at any time after the expiration of the development option period, subject to certain limitations. The Ono Agreement will expire on a Candidate-by-Candidate and country-by-country basis upon the expiration of the applicable royalty term, or in its entirety upon the expiration of all applicable payment obligations under the agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determined that the Ono Agreement, Ono Letter Agreement, and Ono Amendments (collectively, the Ono Arrangement) were within the scope of ASC 808 and applicable to such guidance. The Company concluded that certain units of account, specifically the grant of a research license to certain intellectual property and the performance of research and preclinical development, within the Ono Arrangement represented a customer relationship and applied relevant guidance from ASC 606 to evaluate the appropriate accounting for those units of account. In accordance with this guidance, the Company identified its promised goods and services, including its grant of a research license to Ono to certain of its intellectual property subject to certain conditions, its conduct of research and preclinical development services, and its participation in a joint steering committee. The Company determined that its grant of a research license to Ono to certain of its intellectual property was not distinct from its conduct of research and preclinical development services and participation in a joint steering committee. Accordingly, the Company determined that the research license, the research and preclinical development services, and the participation in a joint steering committee during the development option period, should be accounted for as one combined performance obligation, and that the combined performance obligation is transferred over the expected term of the conduct of the research and preclinical development services. The Company also determined that, subject to the guidance of ASC 606, the license to develop and commercialize Candidate 2 upon exercise of the Candidate 2 Development Option was distinct and separable from the development and commercialization activities, which are accounted for under ASC 808.  The termination of the Ono Agreement with respect to Candidate 1 did not impact this assessment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with ASC 606, the Company determined that the initial transaction price for research and preclinical development under the Ono Arrangement equaled $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, consisting of the upfront, non-refundable and non-creditable payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and the aggregate estimated research and preclinical development fees of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company also concluded that the milestone fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million paid by Ono to the Company for further research and preclinical development of Candidate 2 represented a variable consideration that was previously constrained. Both the upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and the Candidate 2 milestone fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million were recorded as deferred revenue and were recognized as revenue over time in conjunction with the Company&#8217;s conduct of research and preclinical development services based on actual costs incurred as a percentage of the estimated total costs expected to be incurred over the expected term of conduct of the research and preclinical development services. The Company recorded the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million prepayment of the first-year research and preclinical development fees as deferred revenue, and such fees were recognized as revenue as the research and preclinical development services were delivered.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under the Ono Arrangement during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, respectively. Such revenue consisted of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million associated with research and preclinical development services, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million associated with the achievement of a clinical development milestone for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024. During the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, such revenue comprised $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million associated with research and preclinical development services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized contra-research and development expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million associated with the joint development of Candidate 2 under the Ono Arrangement for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024. During the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recognized contra-research and development expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a direct result of the Company&#8217;s entry into the Ono Arrangement, the Company incurred an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in sublicense consideration to existing licensors. The Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of such expense during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company recognized </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> such expense during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Janssen Collaboration and Option Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 2, 2020 (the Janssen Agreement Effective Date), the Company entered into a Collaboration and Option Agreement (the Janssen Agreement) with Janssen Biotech, Inc. (Janssen), part of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson. Additionally, on the Janssen Agreement Effective Date, the Company entered into a Stock Purchase Agreement (the Stock Purchase Agreement) with Johnson &amp; Johnson Innovation - JJDC, Inc. (JJDC). On January 3, 2023, the Company received notice of termination from Janssen of the Janssen Agreement. The termination took effect on April 3, 2023, and during the three months ended March 31, 2023, the Company performed wind-down activities including discontinuing development of all collaboration product candidates under the Janssen Agreement. The Company was reimbursed for all wind-down activities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Janssen Agreement and the Stock Purchase Agreement taken together, the Company received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was an upfront cash payment and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was in the form of an equity investment by JJDC. The Company determined the common stock purchase by JJDC represented a premium of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.93</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, or $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in aggregate (the Equity Premium), and the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was recorded as issuance of common stock in shareholders&#8217; equity. In addition, under the Stock Purchase Agreement, the Company exercised the right to require JJDC to purchase an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in shares in a private placement at the same price per share as paid by investors in a public offering. In June 2020, JJDC purchased </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of the Company&#8217;s common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28.31</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. Additionally, the Company received full funding for the conduct of all research, preclinical development and Investigational New Drug Application (IND)-enabling activities performed by the Company under the Janssen Agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under the Janssen Agreement for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was deferred as of December 31, 2022. Such revenue consisted of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million associated with research and development services, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million associated with the upfront fee and Equity Premium, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million associated with a commercial option exercise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Janssen Agreement, the Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in sublicense fees to certain of its existing licensors. The $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in sublicense consideration represents an asset under ASC 340, and was amortized to research and development expense ratably with the Company&#8217;s revenue recognition under the Janssen Agreement. During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of such expense. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, there was no remaining balance on the Janssen Agreement.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Memorial Sloan Kettering Cancer Center License Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 15, 2018, the Company entered into an Amended and Restated Exclusive License Agreement (the Amended MSKCC License) with MSKCC. The Amended MSKCC License amends and restates the Exclusive License Agreement entered into between the Company and MSKCC on August 19, 2016 (the Original MSKCC License), pursuant to which the Company entered into an exclusive license agreement with MSKCC for rights relating to compositions and methods covering iPSC-derived cellular immunotherapy, including T-cells and NK-cells derived from iPSCs engineered with CARs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Amended MSKCC License, MSKCC granted to the Company additional licenses to certain patents and patent applications relating to new CAR constructs and off-the-shelf CAR T-cells, including the use of clustered regularly interspaced short palindromic repeat (CRISPR) and other innovative technologies for their production, in each case to research, develop, and commercialize licensed products in the field of all human therapeutic uses worldwide. The Company has the right to grant sublicenses to certain licensed rights in accordance with the terms of the Amended MSKCC License, in which case it is obligated to pay MSKCC a percentage of certain sublicense income received by the Company.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is obligated to pay to MSKCC an annual license maintenance fee during the term of the agreement, and milestone payments upon the achievement of specified clinical, regulatory and commercial milestones for licensed products as well as royalty payments on net sales of licensed products.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event a licensed product achieves a specified clinical milestone, MSKCC is then eligible to receive certain milestone payments totaling up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million based on the price of the Company&#8217;s common stock, where the amount of such payments owed to MSKCC is contingent upon certain increases in the price of the Company&#8217;s common stock following the date of achievement of such clinical milestone. These payments are based on common stock price multiples, with the numerator being the fair value of the ten-trading day trailing average closing price of the Company&#8217;s common stock and the denominator being the ten-trading day trailing average closing price of the Company&#8217;s common stock as of the effective date of the Amended MSKCC License, adjusted for any stock splits, cash dividends, stock dividends, other distributions, combinations, recapitalizations, or similar events. Under the terms of the Amended MSKCC License, upon a change of control of the Company, in certain circumstances, the Company may be required to pay a portion of these payments to MSKCC based on the price of the Company&#8217;s common stock in connection with such change of control.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> following table summarizes the common stock multiples and the stock price appreciation milestone payments under the terms of the agreement:</span></p><p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.44%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.9%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.9%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock multiple</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0x</span></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0x</span></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.0x</span></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ten-trading day trailing average common stock price</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.18</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.36</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150.54</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock price appreciation milestone payment (in millions)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30.0</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.0</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:5.147%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2021, the Company achieved the specified clinical milestone for a licensed product under the Amended MSKCC License and the Company&#8217;s ten-trading day trailing average common stock price exceeded the first, pre-specified threshold. As a result, the Company remitted the first milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to MSKCC during the year ended December 31, 2021.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To determine the estimated fair value of the remaining stock price appreciation milestones, the Company uses a Monte Carlo simulation methodology which models future Company common stock prices based on the current stock price and several key variables. The following variables were incorporated in the calculation of the estimated fair value of the stock price appreciation milestones as of December 31, 2024:</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:5.147%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.34%;box-sizing:content-box;"></td>
        <td style="width:1.64%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.64%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Estimated term (in years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.0</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.0</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Closing stock price as of measurement date</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.65</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.74</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The key inputs to the Monte Carlo simulation to determine the fair value of the stock price appreciation milestones include the Company&#8217;s stock price as of the measurement date; the estimated term which is based in part on the last valid patent claim date; the expected volatility of the Company&#8217;s common stock, estimated using the Company&#8217;s historical common stock volatility as of the remeasurement date; and the risk-free rate based on the U.S. Treasury yield for the estimated term determined. Fair value measurements are highly sensitive to changes in these inputs and significant changes could result in a significantly higher or lower fair value and resulting expense or gain.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At each balance sheet date, the Company remeasures the fair value of the stock price appreciation milestones, with changes in fair value recognized as a component of other income (expense) in the consolidated statements of operations and comprehensive loss. Amounts are included in current or non-current liabilities based on the estimated timeline associated with the individual potential payments. During the years ended December 31, 2024 and 2023, the Company recorded </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of income, respectively, associated with the change in fair value of the stock price appreciation milestones. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, the Company recorded a liability of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, associated with the stock price appreciation milestones for the Amended MSKCC License.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_CollaborationAndLicenseAgreementsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_CollaborationAndLicenseAgreementsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546443578496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>California Institute for Regenerative Medicine Award<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_AwardFromCaliforniaInstituteForRegenerativeMedicineAbstract', window );"><strong>Award From California Institute For Regenerative Medicine Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_AwardAgreementForResearchAndDevelopmentDisclosureTextBlock', window );">California Institute for Regenerative Medicine Award</a></td>
<td class="text"><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.	California Institute for Regenerative Medicine Award</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FT819 CIRM Award</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2024, the Company was awarded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from the California Institute for Regenerative Medicine (CIRM) to support the conduct of the Company&#8217;s Phase 1 study of FT819 in patients with systemic lupus erythematosus and, in April 2024, the Company executed an award agreement with CIRM (the FT819 CIRM Award). Pursuant to the terms of the FT819 CIRM Award, the Company is eligible to receive five disbursements in varying amounts from CIRM, with one disbursement receivable upon the execution of the award and four disbursements receivable based upon the completion of certain development milestones throughout the period of the award, which is estimated to be from April 1, 2024 to March 31, 2028 (the Award Period). Under the FT819 CIRM Award, the Company has certain obligations of co-funding and is required to provide CIRM progress and financial update reports throughout the Award Period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the conclusion of the Award Period, the Company, in its sole discretion, has the option to treat the FT819 CIRM Award either as a loan or as a grant. If the Company does not elect to treat the FT819 CIRM Award as a loan within 10 years of the award date, the award will be considered a grant and the Company will be obligated to pay CIRM, on a quarterly basis, a low single-digit royalty on commercial sales of FT819 until such aggregate royalty payments equal nine times the total amount awarded to the Company under the FT819 CIRM Award.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the Company may, at its election, repay some or all of the FT819 CIRM Award, the Company accounts for the award as a liability until the time of election. During the year ended December 31, 2024, the Company received two disbursements under the FT819 CIRM Award in the aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which amount is recorded as a liability on the accompanying consolidated balance sheets. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the entire balance is classified as non-current as the Company does </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t expect any amount to be payable within the next 12 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FT516 CIRM Award</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2018, the Company executed an award agreement with CIRM pursuant to which CIRM awarded the Company $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to advance the Company&#8217;s FT516 product candidate into a first-in-human clinical trial for the treatment of subjects with advanced solid tumors (the FT516 CIRM Award). Under the FT516 CIRM Award, the Company has certain obligations of co-funding and is required to provide CIRM progress and financial update reports.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the terms of the FT516 CIRM Award, the Company, in its sole discretion, has the option to treat the FT516 CIRM Award either as a loan or as a grant. During the first quarter of 2023, the Company elected to treat the FT516 CIRM Award as a grant. As such, the liability associated with the FT516 CIRM Award was derecognized and such amount was recorded as other income during the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_AwardAgreementForResearchAndDevelopmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Award agreement for research and development disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_AwardAgreementForResearchAndDevelopmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_AwardFromCaliforniaInstituteForRegenerativeMedicineAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Award from the california institute for regenerative medicine.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_AwardFromCaliforniaInstituteForRegenerativeMedicineAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546450545696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Investments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company invests portions of excess cash in United States treasuries, commercial paper, non-U.S. government securities, municipal securities, and corporate debt securities with maturities ranging from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_ac600eed-1df0-477d-b544-b5ccb3c5dacc;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> thirty-six months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the purchase date. These investments are accounted for as available-for-sale securities and are classified as short-term and long-term investments in the accompanying consolidated balance sheets based on each security&#8217;s contractual maturity date.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s investments accounted for as available-for-sale securities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.8%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:9.96%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.960000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.960000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.960000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.960000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Maturity<br/>(in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Classified as current assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market fund</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,491</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,491</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,206</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,291</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-US government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,994</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,995</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Municipal securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,490</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,492</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">170,169</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">228</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">170,327</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,903</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,907</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272,253</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">336</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272,503</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Classified as non-current assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Greater than</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;1</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,752</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,745</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Greater than 1</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,887</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,912</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total long-term investments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,639</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,657</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Classified as current assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market fund</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,273</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,273</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,811</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,804</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-US government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">999</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">999</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Municipal securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,997</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,144</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,107</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137,339</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137,398</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">308,566</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">308,578</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Classified as non-current assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Greater than 1</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">977</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">980</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total long-term investments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">977</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">980</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, of accrued interest on investments recorded in prepaid expenses and other assets on the consolidated balance sheets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews its investment holdings at the end of each reporting period and evaluates any unrealized losses using the expected credit loss model to determine if the unrealized loss is a result of a credit loss or other factors. The Company also evaluates its investment holdings for impairment using a variety of factors including the Company&#8217;s intent to sell the underlying securities prior to maturity and whether it is more likely than not that the Company would be required to sell the securities before the recovery of their amortized basis. During the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize any impairment or realized gains or losses on sales of investments, and the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t record an allowance for, or recognize, any expected credit losses.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546450609232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Fair Value Measurements</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables presents the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements at<br/>Reporting Date Using</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market fund</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,491</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,491</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,036</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,036</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-US government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,995</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,995</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Municipal securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,492</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,492</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188,239</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188,239</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,907</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,907</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets measured at fair value on a recurring basis</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300,160</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79,527</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">220,633</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock price appreciation milestones</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">527</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">527</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total financial liabilities measured at fair value on a recurring basis</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">527</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">527</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2023:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market fund</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,273</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,273</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,804</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,804</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-US government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">999</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">999</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Municipal securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,997</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,997</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,087</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,087</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137,398</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137,398</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets measured at fair value on a recurring basis</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">309,558</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,077</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">191,481</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock price appreciation milestones</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,346</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,346</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total financial liabilities measured at fair value on a recurring basis</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,346</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,346</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1 assets consisted of money market funds and U.S. Treasury securities measured at fair value based on quoted prices in active markets as provided by the Company&#8217;s investment managers.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2 assets consisted of corporate debt securities, commercial paper, municipal securities, and non-U.S. government securities measured at fair value using standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers. The Company validates the quoted market prices provided by its investment managers by comparing the investment managers&#8217; assessment of the fair values of the Company&#8217;s investment portfolio balance against the fair values of the Company&#8217;s investment portfolio balance obtained from an independent source.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no Level 3 assets held by the Company as of December 31, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3 liabilities consisted of stock price appreciation milestones associated with the Amended MSKCC License as described in detail in Note 2.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:5.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the changes in fair value of the Company&#8217;s Level 3 stock price appreciation milestones liability (in thousands):</span></p><p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.823%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,861</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in fair value of stock price appreciation milestones liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,515</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,346</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in fair value of stock price appreciation milestones liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">819</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">527</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:5.2%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">None</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> transfers between levels have occurred during the periods presented.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546443517120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Property and Equipment</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">508</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,309</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer and office equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,444</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,132</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Software</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,188</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,130</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements&#8212;building</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,485</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,038</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Scientific equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,895</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78,853</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, gross</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99,520</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144,462</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,136</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,626</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,384</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96,836</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:5.2%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized an impairment charge of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of long-lived asset impairment described in Note 1 above for the year ended December 31, 2024, which was calculated as the difference between the fair value of the assets and its carrying value. The cost basis for these assets was updated to fair value. The fair value was based on a cost approach which utilized Level 3 non-recurring fair value inputs and assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:5.2%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation expense related to property and equipment was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546450551344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_AccruedExpensesAndLongTermDebtDisclosureAbstract', window );"><strong>Accrued Expenses And Long Term Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Accrued Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued Expenses</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Current accrued expenses consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued payroll and other employee benefits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,710</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,563</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued clinical trial related costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,279</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,833</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,359</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,118</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current accrued expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,348</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,514</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_AccruedExpensesAndLongTermDebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and long term debt disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_AccruedExpensesAndLongTermDebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546443579536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has lease agreements for office, laboratory and manufacturing spaces that are classified as operating leases on the consolidated balance sheets.</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> These leases have terms varying from one to approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sixteen years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with renewal options of up to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as well as early termination options. Extension and termination options are included in the total lease term when the Company is reasonably certain to exercise them. The leases are subject to additional variable charges, including common area</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintenance, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">property taxes, property insurance and other variable costs. Given the variable nature of such costs, they are recognized as expense as incurred. Additionally, some of the Company&#8217;s leases are subject to certain fixed fees which the Company has determined to be non-lease components. The Company has elected to combine and account for lease and non-lease components as a single-lease component for purposes of determining the total future lease payments.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, the Company exercised its right of early termination for its Torrey Pines operating lease, which consists of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office, laboratory, and Good Manufacturing Practice (GMP) space. In connection with such exercise, the Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to its landlord. Termination of the lease, which previously extended through December 31, 2028, will now take effect on October 31, 2025. The Company accounted for this transaction as a modification to the lease agreement, which reduced the ROU asset and corresponding lease liability balances as of December 31, 2024 in connection with such transaction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, future undiscounted minimum contractual payments under the Company&#8217;s operating leases were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million, which will be paid over a remaining weighted-average lease term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. The weighted-average discount rate for the operating lease liabilities was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, which was the Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s incremental borrowing rate at lease commencement, as the discount rates implicit in the leases could not be readily determined.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of lease expense for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.474%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.102%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.102%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Straight-line lease expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,737</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,159</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,733</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,250</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,470</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,409</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future undiscounted minimum payments under the Company&#8217;s operating leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 are as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.823%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating<br/>Lease Payments</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Years Ending December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,361</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,050</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,382</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,293</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,602</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,976</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133,664</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,399</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,265</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As described in Note 1 above, the Company incurre</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mill</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ion impairment charge against its right-of-use asset during the year ended Decem</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ber 31, 2024. The Company applied a discounted cash flow method to estimate the fair value of the right-of-use asset, which represents Level 3 non-recurring fair value measurements. The estimated fair value of the was determined by discounting the estimated rental rates using market participant assumptions. The Company&#8217;s estimates and assumptions used to determine the estimated fair value of the asset group is subject to risks, uncertainties, and changes in circumstances that may result in adjustments and material changes to the estimated fair values in future periods.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546445620240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract', window );"><strong>Convertible Preferred Stock And Stockholders Deficit Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Convertible Preferred Stock and Stockholders&#8217; Equity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Convertible Preferred Stock and Stockholders&#8217; Equity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Convertible Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2016, the Company completed a private placement of stock in which investors, including investors affiliated with the directors and officers of the Company, purchased convertible preferred stock and common stock of the Company (the November 2016 Placement). The Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,819,549</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A Convertible Preferred Stock, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> par value per share (the Class A Preferred), at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.30</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">share, each of which is convertible into five shares of common stock upon certain conditions defined in the Certificate of Designation of Preferences, Rights and Limitations of the Class A Preferred filed with the Delaware Secretary of State</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 22, 2016 (the CoD). </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Class A Preferred were purchased exclusively by entities affiliated with Redmile Group, LLC (collectively, Redmile). The terms of the CoD prohibited Redmile from converting the Class A Preferred into shares of the Company&#8217;s common stock if, as a result of conversion, Redmile, together with its affiliates, would own more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company&#8217;s common stock then issued and outstanding (the Redmile Percentage Limitation), which percentage could change at Redmile&#8217;s election upon 61 days&#8217; notice to the Company to (i) any other number less than or equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% or (ii) subject to approval of the Company&#8217;s stockholders to the extent required in accordance with the NASDAQ Global Market rules, any number in excess of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. On May 2, 2017, the Company&#8217;s stockholders approved the issuance of up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,097,745</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock upon the conversion of the outstanding shares of Class A Preferred. As a result, Redmile has the right to increase the Redmile Percentage Limitation to any percentage in excess of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% at its election.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company also issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,236,837</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.66</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share as part of the November 2016 Placement. In </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 2023, the Company filed with the office of the Secretary of State of the State of Delaware a Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitations of Class A Convertible Preferred Stock which amends the definition of Beneficial Ownership Limitation to be </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the number of shares of the Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s common stock outstanding immediately after giving effect to the issuance of shares of common stock pursuant to a Notice of Conversion. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,441</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A Preferred were converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">167,205</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock. In December 202</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Class A Preferred were converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,110</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Class A Preferred are non-voting shares and are convertible into five shares of the Company&#8217;s common stock at a conversion price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.66</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which was the fair value of the Company&#8217;s common stock on the date of issuance. Holders of the Class A Preferred have the same dividend rights as holders of the Company&#8217;s common stock. Additionally, the liquidation preferences of the Class A Preferred are </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">pari passu</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> among holders of the Company&#8217;s common stock and holders of the Class A Preferred, pro rata based on the number of shares held by each such holder (treated for this purpose as if the Class A Preferred had been converted to common stock).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Option and Incentive Plans and Inducement Equity Plan</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2022 Stock Option and Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 9, 2022, the Company adopted the 2022 Stock Option and Incentive Plan (the 2022 Plan). The 2022 Plan initially authorized </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares, and in June 2024, stockholders approved an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, of common stock for issuance and allows for the grant of stock options, stock appreciation rights, restricted stock awards, performance-based awards, and other awards to individuals who are then employees, officers, directors or consultants of the Company. The shares of common stock underlying any awards from the 2022 Plan and a previously existing equity plan from 2013 or 2007 that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without any issuance of common stock, expire or are otherwise terminated (other than by exercise) are added back to the shares of common stock available for issuance under the 2022 Plan.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recipients of stock options under the 2022 Plan shall be eligible to purchase shares of the Company&#8217;s common stock at an exercise price equal to no less than the estimated fair value of such stock on the date of grant. Under the 2022 Plan, stock options generally vest </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% on the first anniversary of the original vesting date, with the balance vesting monthly over the remaining </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or vest monthly over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, unless they contain specific performance and/or market-based vesting provisions. The maximum term of stock options granted under the 2022 Plan is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under the 2022 Plan, restricted stock units generally vest annually over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Performance-based stock units/awards vest upon the achievement of certain pre-defined company-specific performance-based clinical achievement criteria.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inducement Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 10, 2016, the Company&#8217;s board of directors approved the Fate Therapeutics, Inc. Inducement Equity Plan (the Inducement Plan), the purpose of which is to enable the Company to grant equity awards to induce highly-qualified prospective officers and employees who are not employed by the Company to accept employment with the Company. Under the Inducement Plan, the Company may grant non-qualified stock options and restricted stock units. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were initially reserved for issuance under the Inducement Plan. In January 2021, March 2020, and January 2019, an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">470,822</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively, of common stock were reserved for issuance under the Inducement Plan. The shares of common stock underlying any awards from the Inducement Plan that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without any issuance of common stock, expire or are otherwise terminated (other than by exercise) under the Inducement Plan will be added back to the shares of common stock available for issuance under the Inducement Plan.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-Funded Warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2021, in conjunction with a public offering, the Company issued Pre-Funded Warrants, in lieu of common stock to certain investors, to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">257,310</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock (the 2021 Pre-Funded Warrants). The purchase price for the 2021 Pre-Funded Warrants was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85.499</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per pre-funded warrant, which equals the per share public offering price for the shares of common stock less the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> exercise price for each such pre-funded warrant. Given that the 2021 Pre-Funded Warrants are indexed to the Company&#8217;s own shares of common stock (and otherwise meet the requirements to be classified in equity), the Company recorded the consideration received from the issuance of the warrants as additional paid-in capital on the Company&#8217;s consolidated balance sheets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, in conjunction with a public offering, the Company issued in a private placement, in lieu of common stock to certain investors, pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,636,364</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock (2024 Pre-Funded Warrants, and collectively with the 2021 Pre-Funded Warrants, the Pre-Funded Warrants). The purchase price for the 2024 Pre-Funded Warrants was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.499</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per pre-funded warrant, which equals the per share public offering price for the shares of common stock issued in the March 2024 public offering, less the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> exercise price for each such pre-funded warrant. Given that the 2024 Pre-Funded Warrants are indexed to the Company&#8217;s own shares of common stock (and otherwise meet the requirements to be classified in equity), the Company recorded the consideration received from the issuance of the warrants as additional paid-in capital on the Company&#8217;s unaudited condensed consolidated balance sheets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Pre-Funded Warrants are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the number of shares of the Company&#8217;s common stock outstanding immediately after giving effect to such exercise. A holder of Pre-Funded Warrants may increase or decrease this percentage not in excess of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% by providing at least 61 days&#8217; prior notice to the Company.</span></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, there w</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ere </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,893,674</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Pre-Fu</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nded Warrants outstanding.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Options and Restricted Stock Unit Awards</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Options.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes stock option activity and related information under all equity plans for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span></span></p><div style="font-size:8pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.41%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.902%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.142%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.902%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.482%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price Per Share</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic Value<br/>(in 000s)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,850,841</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.71</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,210,625</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.46</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,438</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.57</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,293,354</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.40</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,722,674</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.99</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.83</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options vested and expected to vest at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,722,674</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.99</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.83</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercisable at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,328,404</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.91</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.91</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024 and 2023, the weighted average grant date fair value of stock options granted per share was equal to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.89</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.83</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023, the unrecognized compensation cost related to outstanding options was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, which was expected to be recognized as expense over approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.9</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total intrinsic value, which is the amount by which the exercise price was exceeded by the price of the Company&#8217;s common stock on the date of exercise, of stock options exercised during the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. As of December 31, 2024, all outstanding options had an exercise price above the Company's common stock price and therefore </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> intrinsic value. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total cash received upon the exercise of stock options was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes restricted stock unit activity and related information under all equity plans for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.41%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.902%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.142%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.902%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.482%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Restricted Stock Units</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value Per Share</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Vesting<br/>Period</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic Value<br/>(in 000s)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,065,087</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37.96</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,451,874</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.69</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">680,201</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33.68</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">622,696</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35.78</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,214,064</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.50</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.01</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,253</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units expected to vest at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,151,457</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.78</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.92</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,500</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023, the unrecognized compensation cost related to outstanding restricted stock units (excluding those with unachieved performance-based conditions) was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, which was expected to be recognized as expense over approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.7</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">years and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.0</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2021, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,997,377</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> performance-based restricted stock units (PRSUs) were granted, none of which have vested. During the year ended December 31, 2024, the Company granted </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> performance-based restricted stock units with a total grant date fair value of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, none of which have vested. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,062,607</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,020,617</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> PRSUs outstanding at December 31, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-Based Compensation Expense</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The allocation of stock-based compensation for all stock awards is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,520</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,849</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,976</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,610</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,496</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,459</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Option Grants Valuation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee and nonemployee stock option grants were as follows:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.343%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.343%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk&#8211;free interest rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.4</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.5</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk-free interest rate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company bases the risk-free interest rate assumption on observed interest rates appropriate for the expected term of the stock option grants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected dividend yield.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected volatility.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company based the expected volatility on the historical volatility of its common stock over the most recent period commensurate with the estimated expected term of the Company&#8217;s stock options, as the Company determined there was sufficient operating history and company-specific historical volatility to estimate the expected volatility.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The expected term represents the period of time that options are expected to be outstanding. The Company estimated the expected term using historical experience and anticipated future exercise behavior.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock Reserved for Future Issuance</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common stock reserved for future issuance is as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible preferred stock (if converted)</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ccecff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ccecff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,775,430</span></p></td>
        <td style="background-color:#ccecff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ccecff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ccecff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,805,540</span></p></td>
        <td style="background-color:#ccecff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock options</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,722,674</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,850,841</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,214,064</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,065,087</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Awards available under the 2022 Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,656,109</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,633,496</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Awards available under the Inducement Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">920,688</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">689,750</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,288,965</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,044,714</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock and stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546445634848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Income Taxes</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is a reconciliation of the Company&#8217;s expected federal income tax provision (benefit) to the actual income tax provision (in thousands):</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax computed at federal statutory rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,115</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,794</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State tax, net of federal tax benefit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,429</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,851</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-deductible compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,305</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,560</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,801</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R&amp;D tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,672</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,773</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reserve for uncertain tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,612</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,254</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,928</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,122</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,715</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant components of the Company&#8217;s deferred tax assets are summarized as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized R&amp;D expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">127,559</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">134,209</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating losses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,019</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112,810</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R&amp;D tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,126</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,492</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible asset amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,692</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,220</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,147</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,836</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,322</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,925</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,761</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">788</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">672</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">374,092</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">342,630</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,212</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,639</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,796</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,029</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,008</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,668</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net of deferred tax assets and liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">362,084</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">323,962</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">362,084</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">323,962</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:86.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A valuation allowance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">362.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">324.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, respectively, has been established to offset the deferred tax assets, as realization of such assets is uncertain.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024, the Company had federal and state net operating loss (NOL) carryforwards of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">689.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">644.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, which may be available to offset future taxable income. The federal and California NOL carryforwards begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2027</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2028</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, unless previously utilized. At </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had federal and California research and development (R&amp;D) credit carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The federal R&amp;D tax credit carryforwards will begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2035</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> unless previously utilized. The California R&amp;D credit carryforwards will carry forward indefinitely.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, (the Code), substantial changes in the Company&#8217;s ownership may limit the amount of net operating loss and research and development credit carryforwards that could be used annually in the future to offset taxable income. The tax benefits related to future utilization of federal and state net operating loss carryforwards, credit carryforwards, and other deferred tax assets may be limited or lost if cumulative changes in ownership exceeds </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% within any </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period. The Company completed a study to assess whether an ownership change, as defined by Section 382 of the Code, had occurred from the Company&#8217;s formation through December 31, 2015. Based upon this study, the Company determined that several ownership changes had occurred. Accordingly, the Company reduced its deferred tax assets related to the federal NOL carryforwards and the federal R&amp;D credit carryforwards that are anticipated to expire unused as a result of these ownership changes. These tax attributes were excluded from deferred tax assets with a corresponding reduction of the valuation allowance with no net effect on income tax expense or the effective tax rate. The Company updated the study December 31, 2024 and concluded there were no ownership changes during 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Future ownership changes may further limit the Company&#8217;s ability to utilize its remaining tax attributes.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company files income tax returns in the United States, various state jurisdictions, and the Netherlands with varying statutes of limitations. The Company currently has no years under examination by any jurisdiction; however, the Company is subject to income tax examination by federal and state tax authorities for years beginning in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2021</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2020</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. However, to the extent allowed by law, the taxing authorities may have the right to examine prior periods where NOLs and tax credits were generated and carried forward, and make adjustments up to the amount of the carryforwards.</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The change in the Company&#8217;s unrecognized tax benefits is summarized as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.92%;box-sizing:content-box;"></td>
        <td style="width:1.6%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.64%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.6%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.64%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.6%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beginning unrecognized tax benefits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,680</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,767</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase related to current year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,345</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,724</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase related to prior year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">687</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Decrease related to prior year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,901</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ending unrecognized tax benefits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,505</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,680</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company does </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t anticipate that the amount of unrecognized tax benefits as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> will significantly change within the next twelve months. Due to the valuation allowance recorded against the Company&#8217;s deferred tax assets, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ne of the total unrecognized tax benefits as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> would reduce the effective tax rate if recognized. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. The Company has not recognized interest or penalties related to income tax matters in its consolidated statements of operations and comprehensive loss since inception.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546533325904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Segment Reporting</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment relating to its operations. The segment derives its current revenues from research and development collaborations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s Chief Operating Decision Maker (the CODM), its Chief Executive Officer, manages the Company&#8217;s operations on an integrated basis for the purposes of allocating resources. When evaluating the Company&#8217;s financial performance, the CODM reviews total revenues, total expenses and expenses by certain categories and makes decisions using this information.</span></span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_2f454c57-baac-4705-a580-50decd7c868a;"><span style="-sec-ix-hidden:F_ec6c8190-36ba-401a-8dbc-a9e6f704f525;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration revenue</span></span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,631</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,533</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,684</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,454</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical programs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,818</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,289</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research activities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,692</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,768</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Facilities costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,648</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,005</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment expenses (1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113,065</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,528</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">223,907</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">254,044</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">210,276</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">190,511</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense):</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,288</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,186</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of stock price appreciation milestones</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">819</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,515</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,907</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,882</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,014</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,583</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">186,262</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">160,928</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other segment expenses include stock compensation expense, depreciation, legal fees, general &amp; administrative expenses, and corporate expenses.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546450374192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefits</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Employee Benefits</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective January 1, 2009, the Company adopted a defined contribution 401(k) plan for employees who are at least </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years of age. Employees are eligible to participate in the plan beginning on the first day of the calendar quarter following date of hire. Under the terms of the plan, employees may make voluntary contributions as a percent of compensation. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company makes discretionary contributions to the 401(k) Plan equal to 100 percent of each employee&#8217;s pretax contributions up to 20 percent of the IRS Standard Limit.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s total contributions to the 401(k) Plan </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mill</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ion and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546450543312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License Agreements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into exclusive license agreements with certain academic institutions and universities pursuant to which the Company acquired certain intellectual property. Pursuant to each agreement, as consideration for an exclusive license to the intellectual property, the Company paid a license fee, reimbursed the institution for historical patent costs and, in certain instances, issued the institution shares of restricted common stock. Additionally, under each agreement, the institution is generally eligible to receive future consideration including, but not limited to, annual maintenance fees, royalties, milestone payments and sublicensing fees. Each of the license agreements is generally cancelable by the Company, given appropriate prior written notice. Minimum annual payments to maintain these cancelable licenses total an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million. See Note 2 for additional information on certain licenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Litigation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the reporting period, the Company pursued claims in two lawsuits that were filed in 2022 against Shoreline Biosciences, Inc. (Shoreline) and certain of its founders and officers (collectively, the Shoreline litigations). The first suit, filed on May 13, 2022, was pending in San Diego Superior Court against Shoreline and four of its founders, Drs. Dan S. Kaufman (Kaufman), Kleanthis G. Xanthopoulos, and Messrs. William Sandborn and Steven Holtzman. The Company's claims included actions for breach of contract, breach of implied covenant of good faith and fair dealing, fraud and deceit, tortious interference, restitution and unfair competition. On August 9, 2024, the court denied the defendants&#8217; motions for summary judgment preserving for trial all of the Company&#8217;s claims against the defendants, with the exception of defendants&#8217; motions with respect to certain theories under the Company&#8217;s tortious interference claim (which claim by Fate was otherwise preserved for trial). On September 19, 2024, the court denied defendants&#8217; motion for reconsideration of its summary judgment ruling. Trial began on October 21, 2024, with a jury selected on October 24, 2024. On October 28, 2024, the parties entered a settlement agreement resolving the litigation on terms agreeable to all parties, pursuant to which the Company filed a request for dismissal with prejudice of all claims on October 31, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the second of the Shoreline litigations, also filed on May 13, 2022, the Company and Whitehead Institute for Biomedical Research (Whitehead) filed a lawsuit in the U.S. District Court for the Southern District of California against Shoreline and Kaufman seeking monetary damages for the defendants&#8217; infringement of U.S. Patent Nos. 8,071,369, 8,932,856, 8,951,797, 8,940,536, 9,169,490, 10,457,917, and 10,017,744. On June 7, 2023, the Company and Whitehead filed a motion to dismiss our patent infringement claims against Kaufman in his personal capacity; that motion was granted on June 9, 2023. On August 30, 2023, the court granted Shoreline&#8217;s motion for summary judgment and denied the Company&#8217;s motion for partial summary judgment as moot. Judgment in favor of Shoreline was entered on August 31, 2023. On September 27, 2023, the Company and Whitehead filed a Notice of Appeal with the Court of Appeals for the Federal Circuit challenging the trial court&#8217;s claim construction and grant of summary judgment in favor of the defendants; the defendants cross-appealed challenging the district court&#8217;s earlier denial of a motion to dismiss and partial motion for summary judgment on other grounds. The Federal Circuit docketed the case on October 5, 2023, and briefing was completed on June 26, 2024. On October 28, 2024, the parties entered a settlement agreement resolving the litigation on terms agreeable to all parties, pursuant to which the parties filed a joint notice of dismissal of the appeal and cross-appeal on October 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 20, 2023, a purported stockholder of the Company filed a securities class action lawsuit against the Company and certain of its officers captioned Hadian v. Fate Therapeutics, Inc. et al. in the U.S. District Court for the Southern District of California (the Securities Action). On May 4, 2023, the court appointed a different purported stockholder of the Company to serve as lead plaintiff in the Securities Action. On July 24, 2023, the lead plaintiff filed an amended complaint. The amended complaint alleged that the Company violated the federal securities laws by making allegedly false and/or misleading statements and/or omissions in its public disclosures dating back to August 2020 relating to the Company&#8217;s collaboration agreement with Janssen Biotech, Inc. (the Janssen Agreement), potential product candidates subject to the Janssen Agreement, and the termination of the Janssen Agreement. On September 22, 2023, the Company filed a motion to dismiss the amended complaint. On September 19, 2024, the court granted the Company&#8217;s motion to dismiss the amended complaint, with leave for plaintiff to file a second amended complaint. On October 18, 2024, the lead plaintiff filed a second amended complaint alleging substantially similar facts and claims as in the prior amended complaint. The Company filed a motion to dismiss the second amended complaint on November 18, 2024, and briefing on the motion was completed on January 21, 2025. The Company intends to continue to vigorously defend against this action.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 2, 2023, a derivative complaint, captioned Guarino v. Wolchko, et al., was filed by a purported stockholder of the Company in the U.S. District Court for the Southern District of California (the Guarino Action). On June 12, 2024, an additional derivative complaint, captioned Horrobin v. Wolchko, et al., was filed by a purported stockholder of the Company in the same district (the Horrobin Action). On December 3, 2024, the court entered an order consolidating the Guarino Action and the Horrobin Action under the caption In re Fate Therapeutics, Inc. Derivative Litigation (the Derivative Action) and staying the Derivative Action pending the court&#8217;s decision on our motion to dismiss the second amended complaint in the Securities Action. The court&#8217;s ruling on the motion is pending. The Derivative Action names members of the Company&#8217;s board of directors and certain officers as defendants. The Company is also named as a nominal defendant. The plaintiffs in the Derivative Actions assert derivative claims arising out of substantially the same alleged facts and circumstances as the Securities Action. The Guarino complaint asserts claims for breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and violation of federal securities laws. The Horrobin complaint asserts substantially similar claims in addition to a claim of breach of fiduciary duty for insider trading. The Company intends to vigorously defend against the Derivative Action.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company may be subject to various other legal proceedings and claims that arise in the ordinary course of business activities.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546445672960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14. Subsequent Events</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">California Institute for Regenerative Medicine Award</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 30, 2025, the Company received approval from CIRM for funding of a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million grant to support the conduct of pre-clinical and IND-enabling activities for FT836.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employment Agreement with Chief Executive Officer</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 3, 2025, the Company entered into an Employment Agreement (the &#8220;Employment Agreement&#8221;) with Bahram Valamehr (&#8220;Valamehr&#8221;). Pursuant to the Employment Agreement, Dr. Valamehr will have the customary powers and responsibilities of a chief executive officer of a corporation of the size and type of the Company.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546447053840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The preparation of the Company&#8217;s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#8217;s consolidated financial statements relate to its stock appreciation milestone obligations, contracts containing leases, and accrued expenses. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements include the accounts of the Company and its subsidiaries. To date, the aggregate operations of these subsidiaries have not been significant and all intercompany transactions and balances have been eliminated in consolidation.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s financial instruments consist primarily of cash and cash equivalents, marketable securities, accounts receivable, stock price appreciation milestones, accounts payable, and accrued liabilities. The carrying amounts of accounts receivable, accounts payable and accrued liabilities are considered to be representative of their respective fair values because of the relatively short-term nature of those instruments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three- tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></p><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1: Observable inputs such as quoted prices in active markets;</span></p><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></p><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash, Cash Equivalents and Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and cash equivalents include cash in readily available checking and savings accounts, money market accounts and money market funds. The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,056</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,870</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,227</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,177</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,283</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,047</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024 and 2023, the restricted cash balance includes cash-collateralized irrevocable standby letters of credit for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mill</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">io</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">n and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, associate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d with the Company&#8217;s facilities leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments are accounted for as available-for-sale securities and are carried at fair value on the consolidated balance sheets. Upon initial recognition of the investment and at each reporting period, the Company evaluates whether any unrealized losses on investments are attributable to a credit loss or other factors. Any unrealized losses attributable to credit loss are recorded through an allowance for credit losses, limited to the amount by which the fair value is below amortized cost, with the offsetting amount recorded in other income or expense in the consolidated statement of operations and comprehensive loss. Unrealized losses not attributable to an expected credit loss and unrealized gains on investments are recorded in other comprehensive income (loss) on the consolidated statements of operations and comprehensive loss. Realized gains and losses, if any, on investments classified as available-for-sale securities are included in other income or expense.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amortized cost of investments classified as available-for-sale debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest income. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments, which potentially subject the Company to a significant concentration of credit risk, consist primarily of cash, cash equivalents, and investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits and investments are held.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_36b18d82-10b0-4496-9bd3-0d13c236998e;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) and generally consist of furniture and fixtures, computers, scientific and office equipment, and in-process costs related to facilities construction. Repairs and maintenance costs are charged to expense as incurred.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The long-lived asset evaluation is performed at the asset group level (i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities). Recoverability of these assets is measured by a comparison of the carrying amounts to the future undiscounted cash flows the assets are expected to generate from their use and eventual disposition. If the carrying amount is not recoverable, the carrying amount of such assets is reduced to fair value. During 2024, the Company identified an indicator of impairment of its long-lived assets due to a sustained decline in the trading price of the Company&#8217;s common stock over the preceding year, resulting in the Company&#8217;s market capitalization being below its net asset value. The Company utilized observed market lease rates for comparable properties to estimate the fair value of the right-of-use asset and leasehold improvements. The Company utilized trend factors applied to historical costs, estimates of economic depreciation, normal useful lives, and benchmark values for orderly liquidations of the assets in secondary markets to estimate the fair value of the property and equipment. As a result of its fair value analysis, the Company recorde</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million impairment charge on its property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and equipment a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">illion impairment charge on its right-of-use asset in the statement of operations during the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impairment was recorded during the year ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:5.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines if a contract contains a lease at the inception of the contract. The Company currently has leases related to its facilities leased for office and laboratory space, which are classified as operating leases. These leases result in operating right-of-use (ROU) assets, current operating lease liabilities, and non-current operating lease liabilities in the Company&#8217;s consolidated balance sheets. The Company does not have any financing leases. Leases with a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12 months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or less are considered short-term and ROU assets and lease obligations are not recognized. Payments associated with short-term leases are expensed on a straight-line basis over the lease term.</span></p><p style="text-indent:5.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lease liabilities represent an obligation to make lease payments arising from the lease and ROU assets represent the right to use the underlying asset identified in the lease for the lease term. Lease liabilities are measured at the present value of the lease payments not yet paid discounted using the discount rate for the lease established at the lease commencement date. To determine the present value, the implicit rate is used when readily determinable. For those leases where the implicit rate is not provided, the Company determines an incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. ROU assets are measured as the present value of the lease payments and also include any prepaid lease payments made and any other indirect costs incurred, and exclude any lease incentives received. Lease terms may include the impact of options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term. The Company aggregates all lease and non-lease components for each class of underlying assets into a single lease component.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaborative Arrangements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC Topic 808, Collaborative Arrangements (ASC 808), to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, the Company assesses whether aspects of the arrangement between the Company and its collaboration partner are within the scope of other accounting literature, including ASC Topic 606, Revenue from Contracts with Customers (ASC 606). If it is concluded that some or all aspects of the arrangement represent a transaction with a customer, the Company will account for those aspects of the arrangement within the scope of ASC 606.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC 808 provides guidance for the presentation and disclosure of transactions in collaborative arrangements, but it does not provide recognition or measurement guidance. Therefore, if the Company concludes a counterparty to a transaction is not a customer or otherwise not within the scope of ASC 606, the Company considers the guidance in other accounting literature as applicable or by analogy to account for such transaction. The classification of transactions under the Company&#8217;s arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. If the Company concludes that some or all aspects of the arrangement represent a transaction with a customer, the Company accounts for those aspects of the arrangement within the scope of ASC 606.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For arrangements attributable to ASC 606, the Company recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration the Company is entitled to receive in exchange for such product or service. In doing so, the Company follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_StockPriceAppreciationMilestonesPolicyTextBlock', window );">Stock Price Appreciation Milestones</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Price Appreciation Milestones</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company estimates the fair value of the stock price appreciation milestones associated with the Amended and Restated Exclusive License Agreement with Memorial Sloan Kettering Cancer Center (MSKCC) using a Monte Carlo simulation model, which relies on the Company&#8217;s current stock price as well as significant estimates and assumptions to determine the estimated liability associated with the contingent milestone payments. The Company accounts for the fair value of the stock price appreciation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">milestones </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in accordance with ASC 815, Derivatives and Hedging, with fair value marked to market at each reporting date. The assumptions used to calculate the fair value of the stock price appreciation milestones are subject to a significant amount of judgment including the probability of achieving a specified clinical milestone, the expected volatility of the Company&#8217;s common stock, the risk-free interest rate, and the estimated term, which is based in part on the last valid patent claim date. The Company remeasures the fair value of the stock price appreciation milestones at each balance sheet date, with changes in fair value recorded in earnings as non-operating income or expense on the consolidated statements of operations and comprehensive loss.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense represents the cost of the grant date fair value of employee stock option and restricted stock unit grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. Performance-based stock units/awards represent a right to receive a certain number of shares of the Company&#8217;s common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, and to the extent achievement of one or any of the performance conditions is probable, the Company reassesses the probability of the achievement of such corporate performance goals and any increase or decrease in share-based compensation expense resulting from an adjustment in the estimated shares to be released is treated as a cumulative catch-up in the period of adjustment. For stock awards for which vesting is subject to both performance-based milestones and market conditions, expense is recorded over the derived service period after the point when the achievement of the performance-based milestone is probable or the performance condition has been achieved.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, with the exception of option grants for which vesting is subject to both performance-based milestones and market conditions, which are valued using a lattice-based model. The fair value of restricted stock units, including performance-based restricted stock units, is based on the closing price of the Company&#8217;s common stock as reported on The Nasdaq Global Market on the date of grant. The Company recognizes forfeitures for all awards as such forfeitures occur.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more- likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">more than 50 percent</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_EmployeeRetentionCreditPolicy', window );">Employee Retention credit</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee Retention Credit</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CARES Act provides an employee retention credit (ERC), which is a refundable tax credit against certain employment taxes of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per employee for eligible employers. The tax credit is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of qualified wages paid to employees during a quarter, capped at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of qualified wages per employee through December 31, 2020. Additional relief provisions were passed by the United States government, which extend and slightly expand the qualified wage caps on these credits through December 31, 2021. Based on these additional provisions, the tax credit is now equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of qualified wages paid to employees during a quarter, and the limit on qualified wages per employee has been increased to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of qualified wages per quarter. The Company qualifies for the tax credit under the CARES Act and expects to continue to receive additional tax credits under the additional relief provisions for qualified wages through December 31, 2021. In connection with the CARES Act, the Company adopted a policy to recognize the employee retention credit when received and include in other income in the statement of operations. T</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">he </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company received a cash</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of other income during the year ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No such amount was received or recorded during the year ended December 31, 2024.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non&#8209;owner sources. Other comprehensive loss includes unrealized gains and losses on available-for-sale securities.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Loss Per Common Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. The Pre-Funded Warrants associated with the January 2021 public equity offering and the private placement concurrent with the March 2024 public equity offering (see Note 9) are considered outstanding shares in the basic earnings per share calculation given their nominal exercise price. Dilutive common stock equivalents comprise convertible preferred stock, warrants for the purchase of common stock, and common stock options and restricted stock units outstanding under the Company&#8217;s stock option plans. For all periods presented, there is no difference in the number of common shares used to calculate basic and diluted common shares outstanding due to the Company&#8217;s net loss position.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per share attributable to stockholders for the years ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024 and 2023 are calculated as follows (in thousands, except share and per share data):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">186,262</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">160,928</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares used to compute net loss per share, basic and diluted</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110,596,272</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,153,852</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average pre-funded warrants</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,088,905</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">257,310</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding used to<br/>&#160;&#160;&#160;&#160;compute basic and diluted net loss per share</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113,685,177</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,411,162</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic and diluted</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.64</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.64</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Potentially dilutive securities that are not included in the calculation of diluted net loss per common share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.967%;box-sizing:content-box;"></td>
          <td style="width:1.16%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.357%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.16%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.357%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock options</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,722,674</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,850,841</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,214,064</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,065,087</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series A convertible preferred stock (if converted)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,775,430</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,805,540</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,712,168</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,721,468</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_LiquidityPolicyTextBlock', window );">Going Concern Assessment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Going Concern Assessment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Substantial doubt about an entity&#8217;s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year from the financial statement issuance date. The Company determined that there are no conditions or events that raise substantial doubt about its ability to continue as a going concern for a period of at least twelve months from the date of issuance of these financial statements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU No. 2023-07, which requires public entities to disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about a reportable segment&#8217;s profit or loss and assets that are currently required annually. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The ASU does not change how a public</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">entity identifies its operating segments, aggregates them or applies the quantitative thresholds to determine its reportable segments. The ASU is effective for fiscal years beginning after December 15, 2023, and for interim periods beginning after December 15, 2024, with early adoption permitted. The guidance should be applied retrospectively to all periods presented in the financial statements, unless it is impracticable. The segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The Company adopted ASU No. 2023-07 during the year ended December 31, 2024 and have included required disclosures in Note 11.</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This new standard will be effective for the annual periods beginning the year ended December 31, 2025. The new standard permits early adoption and can be applied prospectively or retrospectively. The Company does not expect the adoption of this guidance to have a material impact on its consolidated financial statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement: Reporting Comprehensive Income- Expense Disaggregation Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which requires detailed information about specified categories of expenses included in certain expense captions presented on the face of the income statement, as well as disclosures about selling expenses. This ASU is effective for fiscal years beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_EmployeeRetentionCreditPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Retention Credit Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_EmployeeRetentionCreditPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_StockPriceAppreciationMilestonesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock price appreciation milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_StockPriceAppreciationMilestonesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546443530704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,056</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,870</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,227</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,177</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,283</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,047</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss per Share Attributable to Stockholders</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per share attributable to stockholders for the years ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024 and 2023 are calculated as follows (in thousands, except share and per share data):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">186,262</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">160,928</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares used to compute net loss per share, basic and diluted</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110,596,272</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,153,852</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average pre-funded warrants</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,088,905</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">257,310</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding used to<br/>&#160;&#160;&#160;&#160;compute basic and diluted net loss per share</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113,685,177</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,411,162</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic and diluted</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.64</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.64</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-Dilutive Securities not Included in Calculation of Diluted Net Loss Per Common Share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Potentially dilutive securities that are not included in the calculation of diluted net loss per common share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.967%;box-sizing:content-box;"></td>
          <td style="width:1.16%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.357%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.16%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.357%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock options</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,722,674</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,850,841</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,214,064</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,065,087</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series A convertible preferred stock (if converted)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,775,430</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,805,540</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,712,168</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,721,468</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546445633536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_CollaborationAndLicenseAgreementsDisclosureAbstract', window );"><strong>Collaboration And License Agreements Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_CommonStockMultiplesAndTheEnterpriseValueMilestonePaymentsTableTextBlock', window );">Summary of All Possible Stock Price Appreciation Milestone Payments</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> following table summarizes the common stock multiples and the stock price appreciation milestone payments under the terms of the agreement:</span></p><p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.44%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.9%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.9%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.28%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.92%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock multiple</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0x</span></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0x</span></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.0x</span></span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ten-trading day trailing average common stock price</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.18</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.36</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150.54</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock price appreciation milestone payment (in millions)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30.0</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.0</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_ScheduleOfMilestonePaymentsValuationAssumptionsTableTextBlock', window );">Schedule of Determine the Estimated Fair Value of the Stock Price Appreciation Milestones Payments</a></td>
<td class="text"><p style="text-indent:5.147%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.34%;box-sizing:content-box;"></td>
        <td style="width:1.64%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.42%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.64%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Estimated term (in years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.0</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.0</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Closing stock price as of measurement date</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.65</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.74</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_CollaborationAndLicenseAgreementsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_CollaborationAndLicenseAgreementsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_CommonStockMultiplesAndTheEnterpriseValueMilestonePaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock multiples and the enterprise value milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_CommonStockMultiplesAndTheEnterpriseValueMilestonePaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ScheduleOfMilestonePaymentsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of milestone payments valuation assumptions table text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_ScheduleOfMilestonePaymentsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546443570608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Investments</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s investments accounted for as available-for-sale securities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.8%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:9.96%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.960000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.960000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.960000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.960000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Maturity<br/>(in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Classified as current assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market fund</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,491</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,491</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,206</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,291</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-US government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,994</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,995</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Municipal securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,490</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,492</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">170,169</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">228</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">170,327</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,903</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,907</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272,253</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">336</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272,503</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Classified as non-current assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Greater than</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;1</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,752</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,745</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Greater than 1</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,887</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,912</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total long-term investments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,639</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,657</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Classified as current assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market fund</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,273</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,273</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,811</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,804</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-US government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">999</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">999</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Municipal securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,997</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,144</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,107</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1 or less</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137,339</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137,398</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">308,566</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">308,578</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Classified as non-current assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Greater than 1</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">977</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">980</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total long-term investments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">977</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">980</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546445444416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables presents the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements at<br/>Reporting Date Using</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market fund</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,491</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,491</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,036</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,036</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-US government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,995</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,995</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Municipal securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,492</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,492</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188,239</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188,239</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,907</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,907</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets measured at fair value on a recurring basis</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300,160</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79,527</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">220,633</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock price appreciation milestones</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">527</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">527</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total financial liabilities measured at fair value on a recurring basis</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">527</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">527</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2023:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market fund</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,273</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,273</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,804</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,804</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-US government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">999</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">999</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Municipal securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,997</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,997</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,087</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,087</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137,398</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137,398</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets measured at fair value on a recurring basis</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">309,558</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,077</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">191,481</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock price appreciation milestones</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,346</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,346</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total financial liabilities measured at fair value on a recurring basis</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,346</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,346</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Changes in the Fair Value of the Company&#8217;s Level 3 Enterprise Fair Value Milestone Payment Liability</a></td>
<td class="text"><p style="text-indent:5.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the changes in fair value of the Company&#8217;s Level 3 stock price appreciation milestones liability (in thousands):</span></p><p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.823%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,861</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in fair value of stock price appreciation milestones liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,515</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,346</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in fair value of stock price appreciation milestones liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">819</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">527</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546450565408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">508</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,309</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer and office equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,444</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,132</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Software</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,188</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,130</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements&#8212;building</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,485</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,038</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Scientific equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,895</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78,853</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, gross</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99,520</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144,462</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,136</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,626</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,384</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96,836</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546450571520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_AccruedExpensesAndLongTermDebtDisclosureAbstract', window );"><strong>Accrued Expenses And Long Term Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Current accrued expenses consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued payroll and other employee benefits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,710</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,563</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued clinical trial related costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,279</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,833</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,359</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,118</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current accrued expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,348</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,514</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_AccruedExpensesAndLongTermDebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and long term debt disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_AccruedExpensesAndLongTermDebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546450464784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of lease expense for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.474%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.102%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.66%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.102%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Straight-line lease expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,737</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,159</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,733</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,250</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,470</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,409</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Payments Under Non-cancelable Operating Leases</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future undiscounted minimum payments under the Company&#8217;s operating leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 are as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.823%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating<br/>Lease Payments</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Years Ending December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,361</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,050</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,382</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,293</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,602</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,976</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133,664</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,399</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,265</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546450447392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract', window );"><strong>Convertible Preferred Stock And Stockholders Deficit Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Summary of stock option activity and related information under all equity plans</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes stock option activity and related information under all equity plans for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.41%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.902%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.142%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.902%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.482%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price Per Share</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic Value<br/>(in 000s)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,850,841</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.71</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,210,625</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.46</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,438</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.57</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,293,354</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.40</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,722,674</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.99</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.83</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options vested and expected to vest at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,722,674</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.99</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.83</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercisable at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,328,404</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.91</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.91</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of restricted stock unit activity and related information under all equity plans</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes restricted stock unit activity and related information under all equity plans for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.41%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.902%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.142%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.902%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.08%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.482%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Restricted Stock Units</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value Per Share</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Vesting<br/>Period</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic Value<br/>(in 000s)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,065,087</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37.96</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,451,874</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.69</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">680,201</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33.68</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">622,696</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35.78</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,214,064</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.50</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.01</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,253</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units expected to vest at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,151,457</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.78</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.92</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,500</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of allocation of stock-based compensation for all stock awards</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The allocation of stock-based compensation for all stock awards is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,520</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,849</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,976</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,610</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,496</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,459</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions used to determine the fair value of employee and nonemployee stock option grants</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee and nonemployee stock option grants were as follows:</span><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.343%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.343%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk&#8211;free interest rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.4</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.5</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Schedule of common stock reserved for future issuance</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common stock reserved for future issuance is as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible preferred stock (if converted)</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ccecff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ccecff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,775,430</span></p></td>
        <td style="background-color:#ccecff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ccecff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ccecff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,805,540</span></p></td>
        <td style="background-color:#ccecff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock options</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,722,674</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,850,841</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,214,064</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,065,087</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Awards available under the 2022 Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,656,109</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,633,496</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Awards available under the Inducement Plan</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">920,688</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">689,750</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,288,965</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,044,714</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock and stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546443583664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of the Company's expected federal income tax provision (benefit) to the actual income tax provision</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is a reconciliation of the Company&#8217;s expected federal income tax provision (benefit) to the actual income tax provision (in thousands):</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax computed at federal statutory rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,115</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,794</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State tax, net of federal tax benefit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,429</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,851</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-deductible compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,305</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,560</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,801</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R&amp;D tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,672</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,773</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reserve for uncertain tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,612</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,254</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,928</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,122</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,715</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of significant components of the Company's deferred tax assets</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant components of the Company&#8217;s deferred tax assets are summarized as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized R&amp;D expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">127,559</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">134,209</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating losses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,019</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112,810</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R&amp;D tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,126</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,492</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible asset amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,692</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,220</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,147</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,836</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,322</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,925</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,761</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">788</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">672</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">374,092</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">342,630</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,212</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,639</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,796</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,029</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,008</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,668</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net of deferred tax assets and liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">362,084</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">323,962</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">362,084</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">323,962</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Summary of the change in the Company's unrecognized tax benefits</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The change in the Company&#8217;s unrecognized tax benefits is summarized as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.92%;box-sizing:content-box;"></td>
        <td style="width:1.6%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.64%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.6%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.64%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.6%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beginning unrecognized tax benefits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,680</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,767</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase related to current year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,345</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,724</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase related to prior year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">687</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Decrease related to prior year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,901</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ending unrecognized tax benefits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,505</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,680</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546445613600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of segment profit or loss, including segment expenses</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_2f454c57-baac-4705-a580-50decd7c868a;"><span style="-sec-ix-hidden:F_ec6c8190-36ba-401a-8dbc-a9e6f704f525;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration revenue</span></span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,631</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,533</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,684</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,454</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical programs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,818</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,289</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research activities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,692</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,768</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Facilities costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,648</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,005</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment expenses (1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113,065</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105,528</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">223,907</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">254,044</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">210,276</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">190,511</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense):</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,288</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,186</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of stock price appreciation milestones</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">819</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,515</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,907</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,882</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,014</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,583</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">186,262</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">160,928</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other segment expenses include stock compensation expense, depreciation, legal fees, general &amp; administrative expenses, and corporate expenses.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546446804416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement', window );">Uncertain tax position description</a></td>
<td class="text">more than 50 percent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding amount</a></td>
<td class="nump">$ 10,200<span></span>
</td>
<td class="nump">$ 15,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge on property and equipment</a></td>
<td class="nump">13,400<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_ImpairmentOfRightOfUseAsset', window );">Impairment of Right of Use Asset</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_ShortTermLeasesTermExcludedFromCalculationOfRightOfUseOfAssetsAndLeaseLiabilities', window );">Short-term leases term excluded from calculation of ROU and lease liabilities</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fate_EmployeeRetentionCreditMember', window );">Employee Retention Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_PercentageOfTaxCredit', window );">Percentage Of Tax Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToEmployees', window );">Payments To Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fate_EmployeeRetentionCreditMember', window );">Employee Retention Credit [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_RefundableTaxCredit', window );">RefundableTaxCredit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ImpairmentOfRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of Right of Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_ImpairmentOfRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_PercentageOfTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Tax Credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_PercentageOfTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_RefundableTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refundable Tax Credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_RefundableTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ShortTermLeasesTermExcludedFromCalculationOfRightOfUseOfAssetsAndLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term leases term excluded from calculation of right of use of assets and lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_ShortTermLeasesTermExcludedFromCalculationOfRightOfUseOfAssetsAndLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of cash to employees, including wages and salaries, during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fate_EmployeeRetentionCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fate_EmployeeRetentionCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546448591008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 36,056<span></span>
</td>
<td class="nump">$ 41,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">10,227<span></span>
</td>
<td class="nump">15,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows</a></td>
<td class="nump">$ 46,283<span></span>
</td>
<td class="nump">$ 57,047<span></span>
</td>
<td class="nump">$ 76,560<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546446761728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details 2) - Scientific Equipment<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fate_ScientificEquipmentMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fate_ScientificEquipmentMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fate_ScientificEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=fate_ScientificEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546445435072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - (Details 3) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (186,262)<span></span>
</td>
<td class="num">$ (160,928)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Weighted-average common shares outstanding</a></td>
<td class="nump">110,596,272<span></span>
</td>
<td class="nump">98,153,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_WeightedAveragePreFundedWarrants', window );">Weighted-average pre-funded warrants</a></td>
<td class="nump">3,088,905<span></span>
</td>
<td class="nump">257,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares used to compute basic net loss per share</a></td>
<td class="nump">113,685,177<span></span>
</td>
<td class="nump">98,411,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares used to compute diluted net loss per share</a></td>
<td class="nump">113,685,177<span></span>
</td>
<td class="nump">98,411,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share, basic and diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, Basic</a></td>
<td class="num">$ (1.64)<span></span>
</td>
<td class="num">$ (1.64)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, Diluted</a></td>
<td class="num">$ (1.64)<span></span>
</td>
<td class="num">$ (1.64)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_WeightedAveragePreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average pre-funded warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_WeightedAveragePreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546448623120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details 4) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share, basic and diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">30,712,168<span></span>
</td>
<td class="nump">26,721,468<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Common Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share, basic and diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">10,722,674<span></span>
</td>
<td class="nump">9,850,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share, basic and diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">6,214,064<span></span>
</td>
<td class="nump">3,065,087<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock (if converted)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share, basic and diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">13,775,430<span></span>
</td>
<td class="nump">13,805,540<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546438437920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements (Details) - USD ($)<br> $ / shares in Units, $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 07, 2022</div></th>
<th class="th"><div>Apr. 02, 2020</div></th>
<th class="th"><div>Sep. 14, 2018</div></th>
<th class="th"><div>Sep. 14, 2018</div></th>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,631<span></span>
</td>
<td class="nump">$ 63,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Income expense in change in fair value of the stock price appreciation milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,014<span></span>
</td>
<td class="nump">29,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=fate_CandidateTwoMember', window );">Candidate 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_ClinicalDevelopmentMilestoneFees', window );">Clinical development milestone fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fate_CommercialOptionExerciseMember', window );">Commercial Option Exercise Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=fate_JohnsonJohnsonInnovationJJDCIncMember', window );">Johnson Johnson Innovation J J D C Inc | Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_UpfrontCashPayment', window );">Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_CompanyReceivedPayment', window );">Company Received Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets', window );">Equity method investment, underlying equity in net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_StockIssuedDuringPeriodSharesForPrivatePlacement', window );">Issuance of common stock during period for private placements (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate purchase price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_EquityPremiumOnSharePricePerShareUnderAgreement', window );">Equity premium per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_AggregateEquityPremiumOnSharesIssuedUnderAgreement', window );">Aggregate equity premium on shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fate_JanssenBiotechIncMember', window );">Janssen Biotech Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Collaboration contract asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_AmortizationOfSubLicenseConsideration', window );">Amortization of sublicense consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fate_JanssenBiotechIncMember', window );">Janssen Biotech Inc | Research And Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fate_JanssenBiotechIncMember', window );">Janssen Biotech Inc | Upfront Fee and Equity Premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fate_JanssenBiotechIncMember', window );">Janssen Biotech Inc | Janssen Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_SublicenseConsiderationRepresentsAnAssetUnderAscOtherAssetsAndDeferredCosts', window );">Sublicense consideration represents an asset under ASC, other assets and deferred costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fate_OnoPharmaceuticalCompanyLtdMember', window );">Ono Pharmaceutical Company Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_TransactionPriceOfAgreement', window );">Transaction price of the agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue', window );">Non-refundable upfront payments recorded as deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_AmortizationOfSubLicenseConsideration', window );">Amortization of sublicense consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,600<span></span>
</td>
<td class="nump">11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_CollaborativeArrangementAggregatePaymentsReceivable', window );">Aggregate research and development fees payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_CollaborativeArrangementPotentialAdditionalMilestones', window );">Collaborative arrangement potential additional milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_UpfrontNonRefundableNonCreditablePaymentReceivable', window );">Non-refundable upfront payments recorded as deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fate_OnoPharmaceuticalCompanyLtdMember', window );">Ono Pharmaceutical Company Ltd | Candidate 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_MilestonePaymentUnderDeferredRevenue', window );">Milestone payment under Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_OptionExercisePayment', window );">Option exercise payment</a></td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_ContraResearchAndDevelopmentExpenses', window );">Contra research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_CollaborativeArrangementAnnualPaymentsReceivableRecordedUnderDeferredRevenue', window );">Collaborative arrangement annual payments receivable recorded as deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fate_OnoPharmaceuticalCompanyLtdMember', window );">Ono Pharmaceutical Company Ltd | Candidate 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_CollaborativeArrangementPercentageOfReductionOnMilestonePayments', window );">Percentage of reduction on milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fate_OnoPharmaceuticalCompanyLtdMember', window );">Ono Pharmaceutical Company Ltd | Collaborative Arrangement | Research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fate_OnoPharmaceuticalCompanyLtdMember', window );">Ono Pharmaceutical Company Ltd | Maximum | Candidate 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_CollaborativeArrangementAggregateMilestonePaymentsReceivable', window );">Aggregate milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 843,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fate_OnoPharmaceuticalCompanyLtdMember', window );">Ono Pharmaceutical Company Ltd | Maximum | Candidate 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_CollaborativeArrangementPotentialAdditionalMilestones', window );">Collaborative arrangement potential additional milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fate_OnoPharmaceuticalCompanyLtdMember', window );">Ono Pharmaceutical Company Ltd | Maximum | Candidate 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_CollaborativeArrangementPotentialAdditionalMilestones', window );">Collaborative arrangement potential additional milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fate_OnoPharmaceuticalCompanyLtdMember', window );">Ono Pharmaceutical Company Ltd | Minimum | Candidate 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_ProfitLossSharingPercentage', window );">Profits and losses sharing percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_CollaborativeArrangementPotentialAdditionalMilestones', window );">Collaborative arrangement potential additional milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fate_OnoPharmaceuticalCompanyLtdMember', window );">Ono Pharmaceutical Company Ltd | Minimum | Candidate 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_CollaborativeArrangementPotentialAdditionalMilestones', window );">Collaborative arrangement potential additional milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fate_OnoPharmaceuticalCompanyLtdMember', window );">Ono Pharmaceutical Company Ltd | Ono Letter Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fate_OnoPharmaceuticalCompanyLtdMember', window );">Ono Pharmaceutical Company Ltd | Ono Letter Agreement | Collaborative Arrangement | Research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fate_OnoPharmaceuticalCompanyLtdMember', window );">Ono Pharmaceutical Company Ltd | Ono Letter Agreement | Sublicense Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_CorrespondingAssetForSublicenseConsiderationPaid', window );">Sublicense consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fate_AmendedMskccLicenseMember', window );">Amended MSKCC License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Income expense in change in fair value of the stock price appreciation milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_EnterpriseValueMilestonePayment', window );">Stock price appreciation milestones potential payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_StockPriceAppreciationMilestonePayable', window );">Stock price appreciation milestone payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_EnterpriseValueMilestonesLiabilityAtFairValue', window );">Enterprise Value Milestones Liability At Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_AggregateEquityPremiumOnSharesIssuedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate equity premium on shares issued under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_AggregateEquityPremiumOnSharesIssuedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_AmortizationOfSubLicenseConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of sub license consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_AmortizationOfSubLicenseConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ClinicalDevelopmentMilestoneFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Development Milestone Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_ClinicalDevelopmentMilestoneFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_CollaborativeArrangementAggregateMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement aggregate milestone payments receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_CollaborativeArrangementAggregateMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_CollaborativeArrangementAggregatePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement aggregate payments receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_CollaborativeArrangementAggregatePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_CollaborativeArrangementAnnualPaymentsReceivableRecordedUnderDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement annual payments receivable recorded under deferred revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_CollaborativeArrangementAnnualPaymentsReceivableRecordedUnderDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_CollaborativeArrangementPercentageOfReductionOnMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement percentage of reduction on milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_CollaborativeArrangementPercentageOfReductionOnMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_CollaborativeArrangementPotentialAdditionalMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement potential additional milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_CollaborativeArrangementPotentialAdditionalMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of upfront payments received under collaborative arrangements is recorded as deferred revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_CompanyReceivedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company Received Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_CompanyReceivedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ContraResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contra research and development expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_ContraResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_CorrespondingAssetForSublicenseConsiderationPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Corresponding asset for sublicense consideration paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_CorrespondingAssetForSublicenseConsiderationPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_EnterpriseValueMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Enterprise value milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_EnterpriseValueMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_EnterpriseValueMilestonesLiabilityAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Enterprise Value Milestones Liability At Fair Value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_EnterpriseValueMilestonesLiabilityAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_EquityPremiumOnSharePricePerShareUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity premium on share price per share under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_EquityPremiumOnSharePricePerShareUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_MilestonePaymentUnderDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Under Deferred Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_MilestonePaymentUnderDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_OptionExercisePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option exercise payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_OptionExercisePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ProfitLossSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Profit loss sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_ProfitLossSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_StockIssuedDuringPeriodSharesForPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares for private placement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_StockIssuedDuringPeriodSharesForPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_StockPriceAppreciationMilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock price appreciation milestone payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_StockPriceAppreciationMilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_SublicenseConsiderationRepresentsAnAssetUnderAscOtherAssetsAndDeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublicense Consideration Represents an Asset Under ASC, Other Assets and Deferred Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_SublicenseConsiderationRepresentsAnAssetUnderAscOtherAssetsAndDeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_TransactionPriceOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction price of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_TransactionPriceOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_UpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront Cash Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_UpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_UpfrontNonRefundableNonCreditablePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront non-refundable non-creditable payment receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_UpfrontNonRefundableNonCreditablePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's ownership percentage in the investee multiplied by the investee's total equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=fate_CandidateTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=fate_CandidateTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fate_CommercialOptionExerciseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fate_CommercialOptionExerciseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=fate_JohnsonJohnsonInnovationJJDCIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=fate_JohnsonJohnsonInnovationJJDCIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_StockPurchaseAgreementAxis=fate_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_StockPurchaseAgreementAxis=fate_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fate_JanssenBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fate_JanssenBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fate_UpfrontFeeAndEquityPremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fate_UpfrontFeeAndEquityPremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fate_JanssenAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fate_JanssenAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fate_OnoPharmaceuticalCompanyLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fate_OnoPharmaceuticalCompanyLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=fate_CandidateOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=fate_CandidateOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fate_ResearchServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fate_ResearchServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=fate_CandidateThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=fate_CandidateThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=fate_OnoLetterAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=fate_OnoLetterAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fate_SublicenseConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fate_SublicenseConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fate_AmendedMskccLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fate_AmendedMskccLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546438690848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements (Details 1) - Amended MSK License<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fate_AmendedMSKLicenseMember', window );">Milestone One</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_CommonStockMultiple1', window );">Common stock multiple</a></td>
<td class="text">5.0x<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_TrailingStockPricePerShare', window );">Ten-trading day trailing average common stock price | $ / shares</a></td>
<td class="nump">$ 50.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_MilestonePayments', window );">Stock price appreciation milestone payment | $</a></td>
<td class="nump">$ 20.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fate_AmendedMSKLicenseMember', window );">Milestone Two</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_CommonStockMultiple1', window );">Common stock multiple</a></td>
<td class="text">10.0x<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_TrailingStockPricePerShare', window );">Ten-trading day trailing average common stock price | $ / shares</a></td>
<td class="nump">$ 100.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_MilestonePayments', window );">Stock price appreciation milestone payment | $</a></td>
<td class="nump">$ 30.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fate_AmendedMSKLicenseMember', window );">Milestone Three</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_CommonStockMultiple1', window );">Common stock multiple</a></td>
<td class="text">15.0x<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_TrailingStockPricePerShare', window );">Ten-trading day trailing average common stock price | $ / shares</a></td>
<td class="nump">$ 150.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_MilestonePayments', window );">Stock price appreciation milestone payment | $</a></td>
<td class="nump">$ 25.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_CommonStockMultiple1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Multiple</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_CommonStockMultiple1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_TrailingStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trailing stock price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_TrailingStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fate_AmendedMSKLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fate_AmendedMSKLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fate_MilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fate_MilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fate_MilestoneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fate_MilestoneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fate_MilestoneThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fate_MilestoneThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546438583520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements (Details 2) - Amended MSK License - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Determine the estimated fair value of the enterprise value milestone payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_FairValueAssumptionsRiskFreeInterestRate1', window );">Risk-free interest rate</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_FairValueAssumptionsExpectedVolatilityRate1', window );">Expected volatility</a></td>
<td class="nump">85.30%<span></span>
</td>
<td class="nump">84.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_FairValueAssumptionsExpectedTerm1', window );">Estimated term (in years)</a></td>
<td class="text">14 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing stock price as of measurement date</a></td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="nump">$ 3.74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_FairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Assumptions Expected Term 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_FairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_FairValueAssumptionsExpectedVolatilityRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Assumptions Expected Volatility Rate 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_FairValueAssumptionsExpectedVolatilityRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_FairValueAssumptionsRiskFreeInterestRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Assumptions Risk Free Interest Rate 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_FairValueAssumptionsRiskFreeInterestRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsQuantitativeInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsQuantitativeInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fate_AmendedMSKLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fate_AmendedMSKLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546538302736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>California Institute For Regenerative Medicine Award (Details) - California Institute for Regenerative Medicine - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fate_CaliforniaInstituteForRegenerativeMedicineMember', window );">FT516</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_AwardFromRegenerativeMedicineInstituteLineItems', window );"><strong>Award from California institute for regenerative medicine</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_AwardForFirstInHumanClinicalTrial', window );">Award for first-in-human clinical trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fate_CaliforniaInstituteForRegenerativeMedicineMember', window );">FT Eight One Nine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_AwardFromRegenerativeMedicineInstituteLineItems', window );"><strong>Award from California institute for regenerative medicine</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_GrantAward', window );">Grant Award</a></td>
<td class="nump">$ 7,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_FirstDisbursementAmountUnderTheAward', window );">First Disbursement Amount Under The Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_FirstDisbursementAmountUnderTheAwardPayableForNextTwelveMonths', window );">First Disbursement Amount Under The Award Payable For Next Twelve Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_AwardForFirstInHumanClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Award for first-in-human clinical trial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_AwardForFirstInHumanClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_AwardFromRegenerativeMedicineInstituteLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Award from regenerative medicine institute.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_AwardFromRegenerativeMedicineInstituteLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_FirstDisbursementAmountUnderTheAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>First Disbursement Amount Under The Award</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_FirstDisbursementAmountUnderTheAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_FirstDisbursementAmountUnderTheAwardPayableForNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>First Disbursement Amount Under The Award Payable For Next Twelve Months</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_FirstDisbursementAmountUnderTheAwardPayableForNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_GrantAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_GrantAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fate_CaliforniaInstituteForRegenerativeMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fate_CaliforniaInstituteForRegenerativeMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fate_FTFiveOneSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fate_FTFiveOneSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fate_FtEightOneNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fate_FtEightOneNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546445439728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Available-for-sale securities, impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Available-for-sale securities, realized gains (losses) on sales</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableNonaccrualNoAllowance', window );">Available-for-sale securities, recognition of expected credit losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=fate_PrepaidExpensesAndOtherAssetsMember', window );">Prepaid Expenses And Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Accured Interest on investments</a></td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">Treasuries, Commercial paper. Non US government securities and Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_ShortTermInvestmentMaturityPeriodRangeStart', window );">Short term investments, maturity start range</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_ShortTermInvestmentMaturityPeriodRangeEnd', window );">Short term investments, maturity end range</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ShortTermInvestmentMaturityPeriodRangeEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term investment maturity period range end.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_ShortTermInvestmentMaturityPeriodRangeEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ShortTermInvestmentMaturityPeriodRangeStart">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term investment maturity period range start.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_ShortTermInvestmentMaturityPeriodRangeStart</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableNonaccrualNoAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of financing receivable on nonaccrual status with no allowance for credit loss. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableNonaccrualNoAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-8A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=fate_PrepaidExpensesAndOtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=fate_PrepaidExpensesAndOtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546446351072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market fund | Current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_InvestmentMaturityDateRange', window );">Maturity (in years)</a></td>
<td class="text">1 or less<span></span>
</td>
<td class="text">1 or less<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 29,491<span></span>
</td>
<td class="nump">$ 35,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 29,491<span></span>
</td>
<td class="nump">$ 35,273<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury debt securities | Current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_InvestmentMaturityDateRange', window );">Maturity (in years)</a></td>
<td class="text">1 or less<span></span>
</td>
<td class="text">1 or less<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 40,206<span></span>
</td>
<td class="nump">$ 82,811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 40,291<span></span>
</td>
<td class="nump">$ 82,804<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury debt securities | Non-current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_InvestmentMaturityDateRange', window );">Maturity (in years)</a></td>
<td class="text">Greater than<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 9,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 9,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Non-U.S. government securities | Current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_InvestmentMaturityDateRange', window );">Maturity (in years)</a></td>
<td class="text">1 or less<span></span>
</td>
<td class="text">1 or less<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 2,994<span></span>
</td>
<td class="nump">$ 999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 2,995<span></span>
</td>
<td class="nump">$ 999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalNotesMember', window );">Municipal securities | Current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_InvestmentMaturityDateRange', window );">Maturity (in years)</a></td>
<td class="text">1 or less<span></span>
</td>
<td class="text">1 or less<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 2,490<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 2,492<span></span>
</td>
<td class="nump">$ 4,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_InvestmentMaturityDateRange', window );">Maturity (in years)</a></td>
<td class="text">1 or less<span></span>
</td>
<td class="text">1 or less<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 170,169<span></span>
</td>
<td class="nump">$ 47,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(70)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 170,327<span></span>
</td>
<td class="nump">$ 47,107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Non-current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_InvestmentMaturityDateRange', window );">Maturity (in years)</a></td>
<td class="text">Greater than 1<span></span>
</td>
<td class="text">Greater than 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 17,887<span></span>
</td>
<td class="nump">$ 977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 17,912<span></span>
</td>
<td class="nump">$ 980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper | Current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_InvestmentMaturityDateRange', window );">Maturity (in years)</a></td>
<td class="text">1 or less<span></span>
</td>
<td class="text">1 or less<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 26,903<span></span>
</td>
<td class="nump">$ 137,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">26,907<span></span>
</td>
<td class="nump">137,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">272,253<span></span>
</td>
<td class="nump">308,566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(86)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">336<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">272,503<span></span>
</td>
<td class="nump">308,578<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherLongTermInvestmentsMember', window );">Long-term Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">27,639<span></span>
</td>
<td class="nump">977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(16)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 27,657<span></span>
</td>
<td class="nump">$ 980<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_InvestmentMaturityDateRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment maturity date range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_InvestmentMaturityDateRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherLongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_OtherLongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546448970880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Fair Value Measurements Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value on a recurring basis</a></td>
<td class="nump">$ 300,160<span></span>
</td>
<td class="nump">$ 309,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total financial liabilities measured at fair value on a recurring basis</a></td>
<td class="nump">527<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Stock price appreciation milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_StockPriceAppreciationMilestones', window );">Stock price appreciation milestones</a></td>
<td class="nump">527<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market fund</a></td>
<td class="nump">29,491<span></span>
</td>
<td class="nump">35,273<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Treasury debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">50,036<span></span>
</td>
<td class="nump">82,804<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">2,995<span></span>
</td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">2,492<span></span>
</td>
<td class="nump">4,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">188,239<span></span>
</td>
<td class="nump">48,087<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">26,907<span></span>
</td>
<td class="nump">137,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted prices in Active Market for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value on a recurring basis</a></td>
<td class="nump">79,527<span></span>
</td>
<td class="nump">118,077<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted prices in Active Market for Identical Assets (Level 1) | Money market fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market fund</a></td>
<td class="nump">29,491<span></span>
</td>
<td class="nump">35,273<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted prices in Active Market for Identical Assets (Level 1) | U.S. Treasury debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">50,036<span></span>
</td>
<td class="nump">82,804<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value on a recurring basis</a></td>
<td class="nump">220,633<span></span>
</td>
<td class="nump">191,481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">2,995<span></span>
</td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">2,492<span></span>
</td>
<td class="nump">4,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">188,239<span></span>
</td>
<td class="nump">48,087<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">26,907<span></span>
</td>
<td class="nump">137,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value on a recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total financial liabilities measured at fair value on a recurring basis</a></td>
<td class="nump">527<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs (Level 3) | Stock price appreciation milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_StockPriceAppreciationMilestones', window );">Stock price appreciation milestones</a></td>
<td class="nump">$ 527<span></span>
</td>
<td class="nump">$ 1,346<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_StockPriceAppreciationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock price appreciation milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_StockPriceAppreciationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=fate_StockPriceAppreciationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=fate_StockPriceAppreciationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MunicipalNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MunicipalNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546445723568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones', window );">Changes in fair value of stock price appreciation milestones liability</a></td>
<td class="num">$ (819)<span></span>
</td>
<td class="num">$ (2,515)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_Fairvalueassetslevel1Tolevel2Transfersamounts', window );">Fair Value, Assets, Level 1 to Level 2 Transfers, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_Fairvalueassetslevel2Tolevel1Transfersamounts', window );">Fair Value, Assets, Level 2 to Level 1 Transfers, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_Fairvalueliabilitieslevel1Tolevel2Transfersamounts', window );">Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_Fairvalueliabilitieslevel2Tolevel1Transfersamounts', window );">Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Fair Value Measurements Nonrecurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value on a recurring basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total financial liabilities measured at fair value on a recurring basis</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_Fairvalueassetslevel1Tolevel2Transfersamounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>FairValueAssetsLevel1ToLevel2TransfersAmounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_Fairvalueassetslevel1Tolevel2Transfersamounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_Fairvalueassetslevel2Tolevel1Transfersamounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>FairValueAssetsLevel2ToLevel1TransfersAmounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_Fairvalueassetslevel2Tolevel1Transfersamounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_Fairvalueliabilitieslevel1Tolevel2Transfersamounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>FairValueLiabilitiesLevel1ToLevel2TransfersAmounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_Fairvalueliabilitieslevel1Tolevel2Transfersamounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_Fairvalueliabilitieslevel2Tolevel1Transfersamounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>FairValueLiabilitiesLevel2ToLevel1TransfersAmounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_Fairvalueliabilitieslevel2Tolevel1Transfersamounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in fair value of stock price appreciation milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546446254144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 3) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones', window );">Changes in fair value of stock price appreciation milestones liability</a></td>
<td class="num">$ (819)<span></span>
</td>
<td class="num">$ (2,515)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at the beginning of the period</a></td>
<td class="nump">1,346<span></span>
</td>
<td class="nump">3,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones', window );">Changes in fair value of stock price appreciation milestones liability</a></td>
<td class="num">(819)<span></span>
</td>
<td class="num">(2,515)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at the end of the period</a></td>
<td class="nump">$ 527<span></span>
</td>
<td class="nump">$ 1,346<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in fair value of stock price appreciation milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546448523264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 99,520<span></span>
</td>
<td class="nump">$ 144,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(35,136)<span></span>
</td>
<td class="num">(47,626)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">64,384<span></span>
</td>
<td class="nump">96,836<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture And Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">508<span></span>
</td>
<td class="nump">1,309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fate_ComputerAndOfficeEquipmentMember', window );">Computer And Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,444<span></span>
</td>
<td class="nump">3,132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,188<span></span>
</td>
<td class="nump">2,130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements-building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">59,485<span></span>
</td>
<td class="nump">59,038<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fate_ScientificEquipmentMember', window );">Scientific Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 35,895<span></span>
</td>
<td class="nump">$ 78,853<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fate_ComputerAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=fate_ComputerAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fate_ScientificEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=fate_ScientificEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546445314800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">$ 18,962<span></span>
</td>
<td class="nump">$ 18,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge on property and equipment</a></td>
<td class="nump">$ 13,400<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546446945008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Current accrued expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll and other employee benefits</a></td>
<td class="nump">$ 9,710<span></span>
</td>
<td class="nump">$ 10,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_AccruedClinicalTrialRelatedCostsCurrent', window );">Accrued clinical trial related costs</a></td>
<td class="nump">5,279<span></span>
</td>
<td class="nump">8,833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">6,359<span></span>
</td>
<td class="nump">8,118<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total current accrued expenses</a></td>
<td class="nump">$ 21,348<span></span>
</td>
<td class="nump">$ 27,514<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_AccruedClinicalTrialRelatedCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trial related costs current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_AccruedClinicalTrialRelatedCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546446182320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Additional Information) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_ImpairmentOfRightOfUseAsset', window );">Impairment of Right of Use Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> These leases have terms varying from one to approximately sixteen years, with renewal options of up to ten years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Net Rentable Area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future minimum payments under the operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Remaining weighted-average lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease liabilities, weighted-average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember', window );">The Premises 2020 Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_ImpairmentOfRightOfUseAsset', window );">Impairment of Right of Use Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, operating lease, existence of option to extend</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future minimum payments under the operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">16 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | The Premises 2020 Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ImpairmentOfRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of Right of Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_ImpairmentOfRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546541425920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease, Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StraightLineRentAdjustments', window );">Straight-line lease expense</a></td>
<td class="nump">$ 12,737<span></span>
</td>
<td class="nump">$ 13,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">3,733<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Total operating lease expense</a></td>
<td class="nump">$ 16,470<span></span>
</td>
<td class="nump">$ 15,409<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StraightLineRentAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the adjustment to rental revenues to measure escalating leasing revenues on a straight line basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StraightLineRentAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546445282976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details 2)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 14,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">11,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">11,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">10,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">10,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">75,976<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">133,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(48,399)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 85,265<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546449209072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Equity (Additional information) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 09, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>May 02, 2017</div></th>
<th class="th"><div>May 10, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,288,965<span></span>
</td>
<td class="nump">36,044,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Issuance of common stock from equity incentive plans, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 295<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=fate_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares to be purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,636,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,893,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_PurchasePriceOfPrefundedWarrants', window );">Purchase price of prefunded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85.499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_WarrantsExerciseTermsDescription', window );">Terms of exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Pre-Funded Warrants are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of the Company&#8217;s common stock outstanding immediately after giving effect to such exercise. A holder of Pre-Funded Warrants may increase or decrease this percentage not in excess of 19.99% by providing at least 61 days&#8217; prior notice to the Company.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_MaximumPercentageOfCommonStockOwnershipTogetherWithAffiliatesAllowableAfterExerciseOfPrefundedWarrants', window );">Maximum percentage of common stock ownership together with affiliates allowable after exercise of prefunded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_MaximumPercentageOfCommonStockOwnershipAfterChangeUponNotice', window );">Maximum percentage of common stock ownership after change upon notice.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=fate_EmployeeAndNonEmployeeStockOptionMember', window );">Employee and Non Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share of employee options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.89<span></span>
</td>
<td class="nump">$ 4.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Issuance of common stock from equity incentive plans, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,210,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=fate_PerformanceBasedRestrictedStockUnitsPrsusMember', window );">Performance Based Restricted Stock Units PRSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of awards vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Performance stock, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,997,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,214,064<span></span>
</td>
<td class="nump">3,065,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected recognition period of unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Performance stock, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,451,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost related to unvested restricted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,400<span></span>
</td>
<td class="nump">$ 38,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Performance-based restricted granted, none of vested Units Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,062,607<span></span>
</td>
<td class="nump">1,020,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred shares to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember', window );">Non-Voting Class A Preferred Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of shares to be issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,097,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember', window );">Non-Voting Class A Preferred Stock | Redmile Group, LLC and Affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_PercentageOfCommonStockOwnershipUponPreferredStockConversion', window );">Percentage of common stock ownership upon preferred stock conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockTermsOfConversion', window );">Terms of conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Class A Preferred were purchased exclusively by entities affiliated with Redmile Group, LLC (collectively, Redmile). The terms of the CoD prohibited Redmile from converting the Class A Preferred into shares of the Company&#8217;s common stock if, as a result of conversion, Redmile, together with its affiliates, would own more than 9.99% of the Company&#8217;s common stock then issued and outstanding (the Redmile Percentage Limitation), which percentage could change at Redmile&#8217;s election upon 61 days&#8217; notice to the Company to (i) any other number less than or equal to 19.99% or (ii) subject to approval of the Company&#8217;s stockholders to the extent required in accordance with the NASDAQ Global Market rules, any number in excess of 19.99%. On May 2, 2017, the Company&#8217;s stockholders approved the issuance of up to an aggregate of 14,097,745 shares of common stock upon the conversion of the outstanding shares of Class A Preferred. As a result, Redmile has the right to increase the Redmile Percentage Limitation to any percentage in excess of 19.99% at its election.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember', window );">Non-Voting Class A Preferred Stock | Redmile Group, LLC and Affiliates | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_PercentageOfCommonStockOwnershipUponPreferredStockConversion', window );">Percentage of common stock ownership upon preferred stock conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_PercentageOfCommonStockOwnershipForPreferredStockConversionChangeUponNotice', window );">Preferred shares converted into common stock percentage of ownership change upon notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Class A Convertible Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,755,086<span></span>
</td>
<td class="nump">2,761,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_PercentageOfCommonStockOwnershipUponPreferredStockConversion', window );">Percentage of common stock ownership upon preferred stock conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred shares to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Class A Convertible Preferred Shares | Redmile Group, LLC and Affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_PercentageOfCommonStockOwnershipUponPreferredStockConversion', window );">Percentage of common stock ownership upon preferred stock conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fate_StockOptionAndIncentivePlan2013Member', window );">Stock Option And Incentive Plan 2013 | Employee and Non Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to outstanding options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,400<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected recognition period of unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fate_StockOptionAndIncentivePlan2022Member', window );">Stock Option And Incentive Plan2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued</a></td>
<td class="nump">9,500,000<span></span>
</td>
<td class="nump">8,000,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,656,109<span></span>
</td>
<td class="nump">8,633,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fate_StockOptionAndIncentivePlan2022Member', window );">Stock Option And Incentive Plan2022 [Member] | Employee and Non Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock options generally vested on anniversary grant date (as a percent)</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">General vesting period after first year</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardMonthlyAwardVestingPeriod', window );">Monthly vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of stock awards</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fate_StockOptionAndIncentivePlan2022Member', window );">Stock Option And Incentive Plan2022 [Member] | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnuallyAwardVestingPeriod', window );">Annually vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fate_InducementPlanMember', window );">Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">920,688<span></span>
</td>
<td class="nump">689,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_CommonStockCapitalAdditionalSharesReservedForFutureIssuance', window );">Additional shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470,822<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=fate_November2016PlacementMember', window );">November 2016 Placement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,236,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issue price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=fate_November2016PlacementMember', window );">November 2016 Placement | Non-Voting Class A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,819,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issue price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_PreferredStockConversionPrice', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_CommonStockCapitalAdditionalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock capital additional shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_CommonStockCapitalAdditionalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_MaximumPercentageOfCommonStockOwnershipAfterChangeUponNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of common stock ownership after change upon notice.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_MaximumPercentageOfCommonStockOwnershipAfterChangeUponNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_MaximumPercentageOfCommonStockOwnershipTogetherWithAffiliatesAllowableAfterExerciseOfPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of common stock ownership together with affiliates allowable after exercise of prefunded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_MaximumPercentageOfCommonStockOwnershipTogetherWithAffiliatesAllowableAfterExerciseOfPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_PercentageOfCommonStockOwnershipForPreferredStockConversionChangeUponNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of common stock ownership for preferred stock conversion change upon notice.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_PercentageOfCommonStockOwnershipForPreferredStockConversionChangeUponNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_PercentageOfCommonStockOwnershipUponPreferredStockConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of common stock ownership upon preferred stock conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_PercentageOfCommonStockOwnershipUponPreferredStockConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_PreferredStockConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock conversion price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_PreferredStockConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_PurchasePriceOfPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of prefunded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_PurchasePriceOfPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnuallyAwardVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award annually award vesting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnuallyAwardVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardMonthlyAwardVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the monthly vesting period of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardMonthlyAwardVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_WarrantsExerciseTermsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants exercise terms description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_WarrantsExerciseTermsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockTermsOfConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of conversion terms for preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockTermsOfConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=fate_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=fate_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=fate_EmployeeAndNonEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=fate_EmployeeAndNonEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=fate_PerformanceBasedRestrictedStockUnitsPrsusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=fate_PerformanceBasedRestrictedStockUnitsPrsusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=fate_RedmileGroupLimitedLiabilityCompanyAndAffiliatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=fate_RedmileGroupLimitedLiabilityCompanyAndAffiliatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fate_StockOptionAndIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fate_StockOptionAndIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fate_StockOptionAndIncentivePlan2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fate_StockOptionAndIncentivePlan2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fate_InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fate_InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=fate_November2016PlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=fate_November2016PlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546446187744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Equity - Stock option activity under all equity and stock option plans (Details) - Employee and Non Employee Stock Option<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the beginning of the period | shares</a></td>
<td class="nump">9,850,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted | shares</a></td>
<td class="nump">4,210,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised | shares</a></td>
<td class="num">(45,438)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled | shares</a></td>
<td class="num">(3,293,354)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the end of the period | shares</a></td>
<td class="nump">10,722,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options Vested and expected to vest at the end of the period | shares</a></td>
<td class="nump">10,722,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable at the end of the period | shares</a></td>
<td class="nump">7,328,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the beginning of the period | $ / shares</a></td>
<td class="nump">$ 13.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted | $ / shares</a></td>
<td class="nump">6.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised | $ / shares</a></td>
<td class="nump">6.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled | $ / shares</a></td>
<td class="nump">13.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the end of the period | $ / shares</a></td>
<td class="nump">10.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options Vested and expected to vest at the end of the period | $ / shares</a></td>
<td class="nump">10.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Exercisable at the end of the period | $ / shares</a></td>
<td class="nump">$ 12.91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at the end of the period</a></td>
<td class="text">5 years 9 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options Vested and expected to vest at the end of the period</a></td>
<td class="text">5 years 9 months 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable at the end of the period</a></td>
<td class="text">4 years 10 months 28 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at the end of the period | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options Vested and expected to vest at the end of the period | $</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options Exercisable at the end of the period | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=fate_EmployeeAndNonEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=fate_EmployeeAndNonEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546533369040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Equity - Restricted stock unit activity under all equity and stock option plans (Details) - Restricted Stock Units (RSUs)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at the beginning of the period | shares</a></td>
<td class="nump">3,065,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted | shares</a></td>
<td class="nump">4,451,874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested | shares</a></td>
<td class="num">(680,201)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled | shares</a></td>
<td class="num">(622,696)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at the end of the period | shares</a></td>
<td class="nump">6,214,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber', window );">Expected to vest at the end of the period | shares</a></td>
<td class="nump">5,151,457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at the beginning of the period | $ / shares</a></td>
<td class="nump">$ 37.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted | $ / shares</a></td>
<td class="nump">5.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested | $ / shares</a></td>
<td class="nump">33.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Cancelled | $ / shares</a></td>
<td class="nump">35.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at the end of the period | $ / shares</a></td>
<td class="nump">15.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue', window );">Expected to vest at the end of the period | $ / shares</a></td>
<td class="nump">$ 9.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Vesting Period</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Outstanding at the end of the period</a></td>
<td class="text">2 years 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageRemainingContractualTerm', window );">Expected to vest at the end of the period</a></td>
<td class="text">1 year 11 months 1 day<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Outstanding at the end of the period | $</a></td>
<td class="nump">$ 10,253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestAggregateIntrinsicValue', window );">Restricted stock units expected to vest at December 31, 2024 | $</a></td>
<td class="nump">$ 8,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation arrangement by share-based payment award equity instruments other than options expected to vest aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation arrangement by share-based payment award equity instruments other than options expected to vest number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation arrangement by share-based payment award equity instruments other than options expected to vest weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation arrangement by share-based payment award equity instruments other than options expected to vest weighted remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546538589504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Equity - Stock based compensation for all stock awards (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 41,496<span></span>
</td>
<td class="nump">$ 43,459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research And Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">22,520<span></span>
</td>
<td class="nump">20,849<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General And Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 18,976<span></span>
</td>
<td class="nump">$ 22,610<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546539907120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Equity - Weighted average assumptions used in the Black-Scholes option pricing model (Details) - Employee and Non Employee Stock Option<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions to determine fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk&#8211;free interest rate</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">87.10%<span></span>
</td>
<td class="nump">89.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=fate_EmployeeAndNonEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=fate_EmployeeAndNonEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546444031040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Equity - Schedule of common stock reserved for future issuance (Details ) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>May 10, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions to determine fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="nump">43,288,965<span></span>
</td>
<td class="nump">36,044,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fate_StockOptionAndIncentivePlan2022Member', window );">Awards available under the 2022 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions to determine fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="nump">11,656,109<span></span>
</td>
<td class="nump">8,633,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fate_InducementPlanMember', window );">Awards available under the Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions to determine fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="nump">920,688<span></span>
</td>
<td class="nump">689,750<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions to determine fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="nump">10,722,674<span></span>
</td>
<td class="nump">9,850,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions to determine fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="nump">6,214,064<span></span>
</td>
<td class="nump">3,065,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Convertible Preferred Stock (if converted)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions to determine fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="nump">13,775,430<span></span>
</td>
<td class="nump">13,805,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fate_StockOptionAndIncentivePlan2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fate_StockOptionAndIncentivePlan2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fate_InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fate_InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546446163216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Reconciliation of the Company's expected federal income tax provision (benefit) to the actual income tax provision</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax computed at federal statutory rate</a></td>
<td class="num">$ (39,115)<span></span>
</td>
<td class="num">$ (33,794)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal tax benefit</a></td>
<td class="num">(8,429)<span></span>
</td>
<td class="num">(4,851)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_IncomeTaxReconciliationNondeductibleCompensation', window );">Non-deductible compensation</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_IncomeTaxReconciliationPermanentTaxDifferences', window );">Permanent differences</a></td>
<td class="nump">22<span></span>
</td>
<td class="num">(2,305)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">8,560<span></span>
</td>
<td class="nump">12,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">R&amp;D tax credits</a></td>
<td class="num">(7,672)<span></span>
</td>
<td class="num">(5,773)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_IncomeTaxReconciliationReserveForUncertainTaxPositions', window );">Reserve for uncertain tax positions</a></td>
<td class="nump">8,612<span></span>
</td>
<td class="nump">4,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(135)<span></span>
</td>
<td class="nump">1,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">38,122<span></span>
</td>
<td class="nump">27,715<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_DeferredTaxAssetsCapitalizedRdExpense', window );">Capitalized R&amp;D expense</a></td>
<td class="nump">127,559<span></span>
</td>
<td class="nump">134,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">147,019<span></span>
</td>
<td class="nump">112,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">R&amp;D tax credits</a></td>
<td class="nump">63,126<span></span>
</td>
<td class="nump">55,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible asset amortization</a></td>
<td class="nump">8,692<span></span>
</td>
<td class="nump">9,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">1,147<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">7,836<span></span>
</td>
<td class="nump">8,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_DeferredTaxAssetsLeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">17,925<span></span>
</td>
<td class="nump">21,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">788<span></span>
</td>
<td class="nump">672<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">374,092<span></span>
</td>
<td class="nump">342,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_DeferredTaxLiabilitiesDepreciation', window );">Depreciation</a></td>
<td class="num">(2,212)<span></span>
</td>
<td class="num">(5,639)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="num">(9,796)<span></span>
</td>
<td class="num">(13,029)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(12,008)<span></span>
</td>
<td class="num">(18,668)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net of deferred tax assets and liabilities</a></td>
<td class="nump">362,084<span></span>
</td>
<td class="nump">323,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(362,084)<span></span>
</td>
<td class="num">(323,962)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_DeferredTaxAssetsCapitalizedRdExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Capitalized RD expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_DeferredTaxAssetsCapitalizedRdExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_DeferredTaxLiabilitiesDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_DeferredTaxLiabilitiesDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_IncomeTaxReconciliationNondeductibleCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation nondeductible compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_IncomeTaxReconciliationNondeductibleCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_IncomeTaxReconciliationPermanentTaxDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_IncomeTaxReconciliationPermanentTaxDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_IncomeTaxReconciliationReserveForUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation reserve for uncertain tax positions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_IncomeTaxReconciliationReserveForUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546443963360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 362,084<span></span>
</td>
<td class="nump">$ 323,962<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 689,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforward expiration year</a></td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 644,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforward expiration year</a></td>
<td class="text">2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546449085072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 3)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_CumulativeChangeInOwnershipPercentage', window );">Cumulative changes in ownership percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_PeriodForCumulativeChangeInOwnership', window );">Period of change in ownership</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember', window );">Californian</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationYearUnderExamination', window );">Income tax examination, year under examination</a></td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationYearUnderExamination', window );">Income tax examination, year under examination</a></td>
<td class="text">2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 45.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_TaxCreditCarryforwardBeginningExpirationYear', window );">Tax credit carryforward expiration year</a></td>
<td class="text">2035<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">California</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 37.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_CumulativeChangeInOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative change in ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_CumulativeChangeInOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_PeriodForCumulativeChangeInOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period for cumulative change in ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_PeriodForCumulativeChangeInOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_TaxCreditCarryforwardBeginningExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward beginning expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_TaxCreditCarryforwardBeginningExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationYearUnderExamination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year being audited in the income tax examination, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationYearUnderExamination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546447975824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 4) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Change in the Company's unrecognized tax benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning unrecognized tax benefits</a></td>
<td class="nump">$ 59,680,000<span></span>
</td>
<td class="nump">$ 52,767,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase related to current year tax positions</a></td>
<td class="nump">10,345,000<span></span>
</td>
<td class="nump">9,724,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increase related to prior year tax positions</a></td>
<td class="nump">687,000<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decrease related to prior year tax positions</a></td>
<td class="num">(207,000)<span></span>
</td>
<td class="num">(2,901,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending unrecognized tax benefits</a></td>
<td class="nump">70,505,000<span></span>
</td>
<td class="nump">$ 59,680,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_UnrecognizedTaxBenefitsResultingInNetOperatingLossAndTaxCreditCarryforward', window );">Unrecognized tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that, if recognized, would reduce the effective tax rate</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_UnrecognizedTaxBenefitsResultingInNetOperatingLossAndTaxCreditCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of an unrecognized tax benefit that is directly related to a position taken in a tax year, which results in a net operating loss and tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_UnrecognizedTaxBenefitsResultingInNetOperatingLossAndTaxCreditCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546450437504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription', window );">Expense information used by CODM, Description</a></td>
<td class="text">The Company&#8217;s Chief Operating Decision Maker (the CODM), its Chief Executive Officer, manages the Company&#8217;s operations on an integrated basis for the purposes of allocating resources. When evaluating the Company&#8217;s financial performance, the CODM reviews total revenues, total expenses and expenses by certain categories and makes decisions using this information.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546444944256">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Schedule of Segment Profit or Loss, Including Segment Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,631<span></span>
</td>
<td class="nump">$ 63,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Type of Revenue [Extensible List]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">us-gaap:LicenseMember<span></span>
</td>
<td class="text">us-gaap:LicenseMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Less:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_PersonnelCosts', window );">Personnel costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 43,684<span></span>
</td>
<td class="nump">$ 63,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_ClinicalProgramsExpense', window );">Clinical programs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,818<span></span>
</td>
<td class="nump">40,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_ResearchActivitiesExpense', window );">Research activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,692<span></span>
</td>
<td class="nump">18,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_FacilitiesCosts', window );">Facilities costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">26,648<span></span>
</td>
<td class="nump">26,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_OtherSegmentExpenses', window );">Other segment expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">113,065<span></span>
</td>
<td class="nump">105,528<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">223,907<span></span>
</td>
<td class="nump">254,044<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(210,276)<span></span>
</td>
<td class="num">(190,511)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,288<span></span>
</td>
<td class="nump">17,186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones', window );">Change in fair value of stock price appreciation milestones</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">819<span></span>
</td>
<td class="nump">2,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,907<span></span>
</td>
<td class="nump">9,882<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,014<span></span>
</td>
<td class="nump">29,583<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (186,262)<span></span>
</td>
<td class="num">$ (160,928)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other segment expenses include stock compensation expense, depreciation, legal fees, general &amp; administrative expenses, and corporate expenses.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ClinicalProgramsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Programs, Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_ClinicalProgramsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_FacilitiesCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Facilities Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_FacilitiesCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in fair value of stock price appreciation milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_OtherSegmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Segment Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_OtherSegmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_PersonnelCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Personnel Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_PersonnelCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ResearchActivitiesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research Activities, Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_ResearchActivitiesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfRevenueExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfRevenueExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546450550224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2009</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_DefinedContributionPlanMinimumAgeOfEmployee', window );">Minimum age of employees</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_PercentageOfDiscretionaryContributionsDescription', window );">Percentage of discretionary contributions description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company makes discretionary contributions to the 401(k) Plan equal to 100 percent of each employee&#8217;s pretax contributions up to 20 percent of the IRS Standard Limit.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Total Company's Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_DefinedContributionPlanMinimumAgeOfEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents minimum age of employees to become eligible for participation under defined contribution plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_DefinedContributionPlanMinimumAgeOfEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_PercentageOfDiscretionaryContributionsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of discretionary contributions description</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_PercentageOfDiscretionaryContributionsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546445671904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_MinimumAnnualPaymentsToMaintainLicenses', window );">Minimum annual payments to maintain licenses</a></td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_MinimumAnnualPaymentsToMaintainLicenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum annual payments to maintain licenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_MinimumAnnualPaymentsToMaintainLicenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45546445793104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | California Institute for Regenerative Medicine</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fate_GrantAward', window );">Grant awarded</a></td>
<td class="nump">$ 4.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_GrantAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fate_GrantAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fate_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fate_CaliforniaInstituteForRegenerativeMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fate_CaliforniaInstituteForRegenerativeMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>88
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?.IA,@)I,8LH]0([S+"#&3IAWE1\QT2&^ _8Z&M>MT,OU997L)L,9[T->6A
M2J@WQFT:87\X!">PHPYVY(3]12J6OP!A9!8MP8DWG@"F&:4X\">F:-R!C)T@
M_Y+EPXMF0&P9VC"(1B!-JR2>0)AT").?C#[P>Z6>VE'7:WVG,<Y1R94-9V(@
M"'T:^R.<IE42QG1B.6&O)Q[/B?4S(&5*E \HY\##J-*$NY";10,WTS/@&'4(
MQP\#+QZ!MIB%.(PF5A<>T"5VHKZ%<:]$JME2;ZA6A-A<(1XAX^&WF04XBB80
M]MR&G72R^MPN=D<!B3F>8V@NDU-8/0UA-P\=5K@#%C7'U??"9#P;+7:!%Q(\
M5;>>?[#_(E&0"W8O<J$$MRL#[.2Q7Y4&KQ7M-.F>U+";U3K6W;&G*<K%)E,E
M- S&XV):^1&>FC8]G6$WGP' JN$]GUD!FI1$,/6-+<%B%@78GX#84Q=V<]<U
MWW"8.ADHESTO&WL-+8R4T#% TRB,IW:LGK2PF[7&^^Q@?L\[QMV!N(&NR@K=
MY*G(QV--:+$*<31%$CV?83>AG>J" 70K4I.I:!R0L8"QF8&$F)@'I"<TXB:T
M]<?;3X@]LBKK@#Y96PN3F@)O()^//8-I-2$.2$]>Q$U>SJD &@')S4MF!#&9
M*XIB?\PB%K,D@GYB(HM!\^8FN#LETV]H!RP,.F$'VV(J6'LD4(@<V%F6]ME!
M3%(+#%*V&,%.,C&-24]^Y"=-F"P*<="+AUY,EGH8>)E.3&5W/#LM(&OK^?\#
MG>;<\REQ\VD[3%N99[RJW[V)@:$O6DFJGNP-]ZO2ZFM%.\V]IU7BIE7HPHZ<
M4.LJS-%;[\SS,+!LA:#];O@%8HV"CE+\JVVV#$"@!0KFGN?IOPNTSD$JH?=H
M+:'5@)4(W(P&40\>HJXU-[8M7J-J!1=Z<2\0F4<!!(M#Q!2ZAH:ZN =-^'P
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M/H,Y*\NCL?)!B[PX75H+K45:W.X8C9DT ?#_1@A]?# ?J \HE_\!4$L#!!0
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MHP.CE\S0;$BC+]Y5OQK&R9RB\M$9C$JL<T>GJZDP5L2ED6[%KJ2]81]XCG@
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M#6GK]@)B!VZ0.C)'Q;O28P7^5\ +5L/[(3N]NO"6:RK#)LD)&&VZS62(Z*P
MFE0T8$N 8-I:J:-<.P'7B=Y8=/Q3X)!W0>A>EP:OA/*=Y%JS^ZQCV<4][.K.
M(&'<@NZ+O';[O),-UR).<ZWT?(5H$!*A32]325#8JOTWB/V*K2EEY_GU'LA*
M=*Z9T4K0"N@WD('@IT+YA3R'CXE<R(3ZP3+5*(ZJ#=Q**DW,=4O4CHAY$K(?
M0S.B2^JH)+S#0FW][,$3ZIA5]9%]'VOWW\,P>)W* BZ"LW[X^/[ZQXY?E"%(
M;>&M=^N><"H#< H^51 3ZI@4M%U@6/4 $3JW0M*K#H94K):RJL!<.04V1%6)
MCDL:]9TU-.EF%\#K'<*&2FA(=E@S1TU^Z_/0'SRAV.%] C2BT,:3&67VAMKW
MQ'&'\ZDS$5C@;(>.4-/L+592B8,?"=RSYOJTGOIC2) -(YTHJ#:S3E,I9IWI
M%S/T!I3-D)78T1K';X2M$&OZXSV,_/:DQ=)O U;L'CJL+*A/5V&EZ",["!7.
M/I>(GS" "Z<1:1]T@F4X$]A 1"3@&%W9=88K"T^(1NGB+2BP:A4;U!#,(3Q^
M& XDTN)\8AOF:DPF=G[(]6#M75,PB-(351^@<]06_+ 1X,9/DG"QSJ%Z3X';
MM'<TOGSNY8O/NEJA$?-2<5.YUMB^ 13,#/N-_MQOZ:^& W 1_-9Q5X:\R.>:
M)MR3\3^H@@C/:2VK;]CQ=C9VH8IH";PS\_MR X$SA6DVYH6XNQ.DI1O=#7GL
M)3\,9AT1R@E'O<@2P/6.."1HSS'F17.,>?%5CC'GL'1N/ U]>J?X?./1I%\5
M"%ST6/RRL?CE5[=XRY&J7^&_Z.S4 ^^K!MY73X#WFG9-[-+OFL[\H:HO'_HU
M;<F'_<;@_<<;W&SYC^M-*#"^0A&A.*>X_5[>^)V'OC\7T^:23@%P]V'7^FV:
M<67[?/NY\>WG;^?;EJ+HMVQW2/__.*3W)'$T;G\)'3\VC3<0XT6S1=F6FEO4
M[8Y.NZ/3[NBT.SKMCDZ[H],7')VBSA.^Z,MXK9/0:*[EM.T$5W<ZVR-(K]^6
M'97MJ&Q'9?\ E?5UBDG;*2:/[135+Q4^A*$>*3#_8/_HMW!'@=^8 OORK'W1
M(NI]YV%3GEU15X:]G5]QMJ9*OY(=U>RH9D<UNU/3CC)VIZ:6H]H7YZ(GO3FG
MK6S>M&GRRJYM?![^67Z+ZBV/'*+VJ5GTI,=F?\>';1S<;\"_JE/T0=X^]HN>
M\MSOC(C:45ZO;W4>!7F_ =]^"]*'8_M\+WKT [[-1Y$.BD](XUYC-K^C^Y^@
M\KY8M8\VHR]XMOFH-G,5RA?E&6J^IW7VF_)0ZQQUWI GVO)_!^!?",Q=>%F^
MN=O\K<%Q>,.^G1[^4.$#)]:CZ,ZP=+SW"BW0A'?_PX73A7_??JJ=TYG_FOH]
M,TW ^$QK5U^0@N8O,([^ E!+ P04    " !S@&5:7-RY1;PA  #5:@  &0
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M87=YH;]_NL.]VEO]].6?_S0_GWW[P/%._?%.'UK]7TWMAS>;3]4?V"]]]P=
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M;R$!%5O3;WWJJ=7N&PRUV'11WHV-^53=B%$+JZ1O#@]+F03TSOB\$A++T2)
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MVW1NV//N";M@1[WMN8D /L,^B-#:=WPP3S-5[X.E$AP$J.PS63MVK'SZUOD
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M97[B"W=Q3X>.PNFX+. WD]F)EP/_!SE>1-8H3<7QDQ/U1I3+ZY018]G8\SW
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MTODJT#0Q.6$/FZ.\RR)9$PP@_0D(&O$CIC@\#F(A'2_"(]M,YF/QL-;P>:F
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M@L2U4A .IZ:3JSJDCO$.'K$@S4C +:+);.ICS'-D9 BM3;XRY![W!%\W'+.
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MV:\7\!]Y=S8 5K,'*#EU#RTR+<&PU\2?.^'<ZPYL>/QW^]'@RV@Y(G?*&OD
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MG2Y;92 H517^BZ>6AP.%U?@;"G&K$'O<X2"/\D?AQ-V-T5LR+ UK?.%=]=H
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M9PTG'BZF(4B"]XH"V[REUQX.B@L2]LWUQ;^]&;\17GA-UKK \B*8\TO>9$X
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M&A]F,1V&YZ1CUZ@H7ESH@)I$V)PR!(]*B<CYM0 4^,74'Y !&M:CHNG7F.>
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M)=LO5JW=:_6%LE:5[N-*< @]+<#O2Z5L^X4.V/V=Y?;?4$L#!!0    ( '.
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M&1O?70,W'R1P:;&F+=R[3N?DA])>L^MUIPS!J J8$*H<2)&'JM<ED@]?&Y2
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M#XQA857G+_6=LO1$\)\-O<E0.P$ZKY2RT\(9F%]YF_\ 4$L#!!0    ( '.
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MW?=+6N(PCH2OPES8 M.'&3,0!@VE^TVL.6JX0;_[07Y04L B0ZZ:TNT6Y0W
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MQ?H^4W=K Z !LP9UPS^U)<BFWO: ?6]9TXZ+)J)903AJ7Z@?P7!7:O9"_;)
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M)R+(#]+L(90/*/WG7ND_/^R$@E^D,>WJJ/N:#\8'8S^-68&OAQ;EGJ)4AH\
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M]AT4@3-9: >/*MC^F.$8(G9># Y9ONQ<8PB%I^30CC!K(!%#G&*Q4"XU-29
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M5-/X(T79-.]/LW"Z"CU_K1V](&&ZHR<;C1>@\XW6[KCP#KJ?@/E_4$L#!!0
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MO3NN -1?!5>0^T;0&+ LZ8;1A,:8J7:[=WDZ+\1_PF[< ]&3/2Q-\0!;:5(
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M#PHL62/LG=I\QJV>@>/+E3#M%S:=[X"<\\9856W!E$'%9;>RY^T[' #&X1N
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MZF9+MS"R<>_Y2AJ:#L[<TCA&91WH^UI*<UC8!,. 7_X'4$L#!!0    ( '.
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M5<D\UT,N]KL'1-D HNS)($+HUNB3SD%]JI8V_V:MH2948,2H@NX"P%XQNXO
MV5/EW4_WP]%V^=P*SW:/O1QZ[([]@2#[[#Z4U/0X:4KMD4?#S(N=&)N@>PK)
M'II;W<G0A3U4Z^^NB.&N&IUT%8NON*CL9=Q=I811U#I@%WB1,M]WDCAQ?"_'
MBI^$(16+?2??-66+/J#J9<_G6+B2+,,++W?2>%.7L-8$&=:K)&9AXGA1Y*1^
MM+/T3+:>>C6HN7W0:O18VYCNU3>L#F_FD^ZI>$?>/;C?<S47Z+<*9GC4<U/L
M853WB.TF1B[MP_%*&GR&VN$"W_V@B #W9U*:S80$#/\D3/\!4$L#!!0    (
M '. 95K;2_ >1@4  (X-   9    >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM
M;+57:V_;-A3][E]!N$7G &PM4>\\##3)AA58NR#).@S#/M#RM4U4(C62RJ._
M?I>4K"2KXK88]B619-YSS[T\YU(ZOE7ZD]D"6')75]*<3+?6-H?SN2FW4'/S
M1C4@\9>UTC6W>*LW<]-HX"L?5%=S%@3IO.9"3A?'_MF%7ARKUE9"PH4FIJUK
MKN]/H5*W)]-PNGMP*39;ZQ[,%\<-W\ 5V-^:"XUW\P%E)6J01BA)-*Q/IF_#
MP]/4K?<+/@JX-8^NB:MDJ=0G=_-N=3(-'"&HH+0.@>._&SB#JG) 2./O'G,Z
MI'2!CZ]WZ#_YVK&6)3=PIJK?Q<IN3Z;YE*Q@S=O*7JK;GZ&O)W%XI:J,_TMN
M^[7!E)2ML:KN@Y%!+63WG]_U??B6 -8',,^[2^19GG/+%\=:W1+M5B.:N_"E
M^F@D)Z3;E"NK\5>!<7;Q3I:J!G+-[\"0V35?5F .CN<6H=V">=G#G'8P[!F8
MD)'W2MJM(3_*%:R> LR1TT",[8B=LKV(YU"^(5%("0M8O <O&@J-/%[TU4+)
MN3!EI4RK@?SY=FFL1FG\-59SAQB/(SJ[')J&EW R13\8T#<P7;QZ$:;!T1Z^
M\< WWH>^N$+[K=H*B%JC^$LE2U$)[I6,3^P6R)FJ&R[O?S $[AH4.:S(&E:@
M>45$5ZS%8ANM;H2WT&P)$M;"'A"K/ "6W3ZS>*P;>_F.=^,:LZQ5A<X7<D.$
M(7Q_+:]>Y"S,COZ/BLA,2%RC6L/ERAP<3OX KGNY$A0;U$O03G 3)SBGNFCB
MQ()(3>N8<#N0,9;;UBI]3S2W0%Z2&8D*&H8).>AN(IH5,3F87%GW._*@1.*
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M\\$E+'()BQW!&HX-:L<&7?3)(TM Z&G&D,+/V@Q)K'<IR$20PCRW&=/-I%P
M4AEF:-A#!8@$F&ISI)-RK",N8;$C6,.18>W(L%.]/T I$-),F41 2A32&[!4
M>C:9Z8*IF3AMGI34H:6:_?MI$NA)K6?UTZ[F+:6&>Z6BSA8>*Z8C6$/,TUK,
MTTXQ;VB!B= G#X62#(L5(#VX"Z$/0D*]V!4*OJ])0=M'Z'4)/]U5JS_8TW2_
MU%L].QMYK)Z.8 T]SVH]SP[54X]/>^XS#X\2T)64T"KBV?Z0Z^]IV%GML6N!
M2UCL"-:0^[R6^[Q3[EO\3.B:MJG:&7CLWN@2%KF$Q8Y@#?4O:O4O?N1IYL*E
M8RYAD4M8[ C6<"SH;?.-7N>,F6=<J*]Z Z4H!YWA262?X3G)U_K CY:"4Y3@
M/%GGI:]F&;M[M/;: )03O""Y/@:UN_A!_3K!H#;!:#.M._98UYS28E>TIF\[
M>6+0J5M,BYR_ *![4'IW,<Y,R]//W[= %R#^:36C$WKLG')*BYS28E>TICWA
MUI[P1RZ%56VN?'-)BYS28E>TIF_;?#SH3!XGLS+[POK@>[=$#SK%*V=5JRE.
MTVVGM*BB7>R>L4_.FF?(N+70L"[4E'";( ?=V>P,OYCSKD0/'+VN4NV#VF4*
M.G5*BRI:,SOLO3V%QQ\6:VJX36F#[ISV3F4@T U+.(56Z5PFG--@/\D=!GLY
MKM,Z8U>TIL#;-#?HSG,_WC[1?Z@CF^C&'VV 2UKDE!:[HC6-VN;/P=D/W4A=
MIKI3I[3(*2UV16OZMDW$@^Y,_!Z6:Y;B10YZ$^W80YVFY4YID5-:7-$:B^S^
M3N'O7!U1$"M[9R>1'=OE'4O]M;X7O+*W86^^7YO[0GLEM<64EXVW6*P(DSI[
M6VJD/A7H)HGR_JY\4;RP%U0+KA2G]C$#G((P!?3O2\[5ZXNIH+Y%G?P/4$L#
M!!0    ( '. 95I?!W2?X@(  &X(   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,V+GAM;*U676^;,!3]*Q:KID[*RC>IN@2I#:JVAVE1TVX/TQX<<@E6P::V
M$[K]^MF&T'S0**KZ OZXYW#/L:_-J&;\4>0 $CV7!15C*Y>RNK)MD>908G'!
M*J!J)F.\Q%)U^=(6%0>\,*"RL#W'B>P2$VK%(S,VY?&(K61!*$PY$JNRQ/SO
M#12L'ENNM1FX(\M<Z@$['E5X"3.0#]64JY[=L2Q("5001A&';&Q=NU=)J.--
MP$\"M=AJ(ZUDSMBC[GQ;C"U')P0%I%(S8/5:PP2*0A.I-)Y:3JO[I 9NMS?L
MMT:[TC+' B:L^$46,A];EQ9:0(97A;QC]5=H]9@$4U8(\T1U&^M8*%T)R<H6
MK#(H"6W>^+GU80O@!J\ O!;@G0KP6X!_*B!H 8%QII%B?$BPQ/&(LQIQ':W8
M=,.8:=!*/J%ZV6>2JUFB<#+^P9>8DG^X602Z0+-F_1'+T(PL*<E(BJE$UVG*
M5E02ND135I"4@$#G"4A,"H'<3^@S>I@EZ/SL$SI#A*+[G*V$HA,C6ZHL];?L
MM,WHILG(>R6C!-(+Y+L#Y#E>T .?G [W>^#)Z7!O%VXK:SM_O<Y?S_#Y)_@[
M0!-&A7)O\6+WE(, *IL!Y?DMH9BF!!=HI@9!%9@4Z/?U7$BN2N1/GYU- D%_
M OK8N!(53F%L5?I;? U6_/&#&SE?^LQ]3[+DG<AVC/<[X_UC[/$$B]PXG.H&
M/*W(&A?:S3X+&ZK04.F#<AW[D1-&(WN][<UA5.!>#IW=J.1H6F\4'72B@Z.B
M[T#M$Y)*:&3W26T(HBT1KMKIPSVI/5&A.]R+2HXF\T:I82<U/"KUGDE5)%KE
MX&")!V;A^:X92.2LIOIPDCF@M*M$-2TVI:8KT,1FZCKLW2GAX1Z(O$M_S[[#
MJ'#H!/OV'48-HS!ZV4^-+_;6X:YOXN^8+PD5J(!,X9R+H2+@S>W6="2KS'D_
M9U+='J:9JQ\"X#I S6>,R4U'7R'=+T;\'U!+ P04    " !S@&5:^XVY?DD"
M  "Y!@  &0   'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6RUE6UOFS 0Q[^*
MQ:1ID[9 R-.4 5+3=-I>5(L:;7OMP %6C4UMTS3]]#L;@C*I\&)JWX ?[O[^
MW1T^HJ-4][H$,.2IXD+'7FE,O?9]G99043V1-0C<R:6JJ,&I*GQ=*Z"9<ZJX
M'P;!TJ\H$UX2N;6=2B+9&,X$[!313551==H E\?8FWKGA3M6E,8N^$E4TP+V
M8'[5.X4SOU?)6 5",RF(@CSVKJ;KS<K:.X/?#([Z8DQL) <I[^WD1Q9[@04"
M#JFQ"A1?CW -G%LAQ'CH-+W^2.MX.3ZK?W.Q8RP'JN%:\C\L,V7L??%(!CEM
MN+F3Q^_0Q;.P>JGDVCW)L;,-/)(VVLBJ<T:"BHGV39^Z/%PX3.<##F'G$#KN
M]B!'N:6&)I&21Z*L-:K9@0O5>2,<$[8H>Z-PEZ&?27ZJ@@KV3-L4B8SLV^H0
MF9,]*P3+64J%(5=I*AMAF"C(3G*6,M#DPQ8,95R3\"/Y3/:XA@9H3VX>&E9C
MY4SD&V2T)_EIQ[-I><(!GBVD$S*;?B)A$,[_=?<QM#Z^L(\O='KS ;U;)EC5
M5"^!C#K:R[#6-4TA]O!KUZ >P4O>OYLN@Z\C6+,>:^;49P-8.X772IF32SF,
MI6OV!I3SGG(^FKP;;1A^^)"11D/><,+Q!NF7*,=U0G("JO0(T:(G6HR7DSX-
ME7/4\3\3M>RQEJ]4SN4;4*YZRM4KE7-<9S%<3O^B$]FF?DM5P80F''*4"B8K
MK))J&V4[,;)VS>D@#;8Z-RSQWP+*&N!^+J4Y3VR_Z_]6R5]02P,$%     @
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M,8#W*R'T\\9\H/\1D?P'4$L#!!0    ( '. 95H=<O#3=0,  !<.   9
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;+5776^;,!3]*Q:3IDW:BOD(I%V"
ME*:;MH=M4:-NSR[<)%;!9K:3=/OULPVE(:5HG<A+@\'W<,[Q,;V>[+FXDQL
MA>Z+G,FILU&JO'!=F6Z@(/*,E\#TDQ47!5%Z*-:N+ 60S!85N>MC'+D%H<Q)
M)O;>0B03OE4Y9; 02&Z+@HC?EY#S_=3QG(<;UW2]4>:&FTQ*LH8EJ)MR(?3(
M;5 R6@"3E#,D8#5U9M[%W M,@9WQ@\)>'EPC(^66\SLS^))-'6P800ZI,A!$
M_^Q@#GEND#2/7S6HT[S3%!Y>/Z!_LN*UF%LB8<[SGS13FZDS=E &*[+-U37?
M?X9:T,C@I3R7]B_:UW.Q@]*M5+RHBS6#@K+JE]S71AP4>-$S!7Y=X!\7A,\4
M!'6!=<ZMF%E95T219"+X'@DS6Z.9"^N-K=9J*#/+N%1"/Z6Z3B7?Q9HP^H=4
MGK(,+:OU1'R%EG3-Z(JFA"DT2U.^98JR-5KPG*84)'IS!8K07*+P+7J/Y(8(
MD!-7:58&VTUK!I<5 _\9!IZ/OG*F-A)]9!ED;0!7RVDT^0^:+OU>Q"M(SU#@
MO4,^]L,.0O-_+P]ZZ 2-Q8'%"Y[!^Z8W8\ZE1"6(RJ5W)GDTM7YG--^J8]F5
MR@HV[(8U^_M"EB2%J:,WL 2Q R=Y_<J+\(<NS0.!M1P(&P?"/O1DIH/SW@K5
M6Q9)2+>"*IL@RNK<O.TRH$*-+*KY'NV2 ,>>[T7CB;L[%/=THA_%OA<>3&P1
M'S7$1[W$Y[PH]+Y8*I[>H>^EV22=">]%>>E*#036$APU@J/39#4:TH&!P%H.
MQ(T#\4FR&C^)H(=C7\<P/,KJTXGGXQ$>AUYW5,<-[W$O[VN02M!4+T\=UQM&
ME69]O;SI)MP+]](5&PBLI?R\47Y^FLR>#^G 0& M!SS\^%\<GR2U->QA&B/]
MW<31<6H[)@8XTKF-NV/K'30@7B_U)0A#=(;FG.U *'J; UKH9@Z$:,+\AJY0
M6CV'K%M)[UM>NII#H;4]\1\]\4\3Z1IW*!<&0FN[\-@W>;U-R?^'.GCZ+0[B
M>!0&^#C573/'>#0*\5&LW8,6NP"QMB</B6Q37'6FS=WF=#.S/?W1_4MSZK&M
M^R-,=63Z2L2:,HER6&E(?!;K1D!4IY!JH'AI&_E;KO2QP%YN],D-A)F@GZ\X
M5P\#\X+F+)C\!5!+ P04    " !S@&5:^"B[D[,7  "NG $ &0   'AL+W=O
M<FMS:&5E=',O<VAE970T,"YX;6R]W6UOV\BAAN&_0O@4!UU@&^M=<DYBP#'?
MR2&#I-OSX>!\8*2Q3:Q$JB3E),7^^%(2;6HL9BQM;A1=-+*BN8:QXB<<Z>'H
MW=>\^+U\D+(ROJV66?G^XJ&JUF\O+\OY@UPEY9M\+;/Z=^[R8I54]9?%_66Y
M+F2RV U:+2\'O=[D<I6DV<7UN]U]'XOK=_FF6J:9_%@8Y6:U2HKO'^0R__K^
MHG_Q=,>G]/ZAVMYQ>?UNG=S+S[+Z;?VQJ+^Z?%86Z4IF99IG1B'OWE_<]-_&
M5[WM@-TC_I'*K^7!;6/[1_F2Y[]OO_ 6[R]ZVR.22SFOMD12__(H;^5RN97J
MX_AG@UX\S[D=>'C[2;=W?_CZ#_,E*>5MOOS?=%$]O+^871@+>9=LEM6G_*LK
MFS_0>.O-\V6Y^W_C:_/8WH4QWY15OFH&UT>P2K/]K\FWYAMQ,* _^L& 03-@
M<.J 83-@>.J 43-@=.J <3-@_'+ ^ <#)LV R:DS3)L!TU,'S)H!LY<#)C\8
M<-4,N#IUAG[OZ9GKG3SD^<D^^=GN/SW=_9.?[_[3$]X_^1GO/SWE_9.?\_[3
MD[[_"W^Y_QN_^W$QDRJY?E?D7XUB^_C:V][8_<SMQM<_)6FVC8?/55'_;EJ/
MJZ[K'ZME\B4ODOT/:[8PPG1>__1+X^:^D+(.@JHT_FK**DF7Y2_&WXS?/IO&
M7__RB_$7X](H'Y)"ED::&;]E:57^6M]9W_[[0[XI:ZG^NGV 2)?+>H;RW655
M'_5V[LMY<X3V_@@'/SC"OB'RK'HH#2M;R$7'>.^5\0,-<%E_NYZ_9X.G[]F'
M@5:,\L<W1F_ZJS'H#08=!W2K'WZS+NKA@]WP7L=P4S_\LUR_,?JC[?#^K&.X
M]7/#;?UPD7PWAOW=L8\Z1COZT?XF>V,,>S_\SKFG#^_ZSGGZX::<O]$=O'_Z
M\&''\."5IWUSKYT]/.$O7?-G[YI=G'[P7=_YZ/3A_8[A\>G#>YJ?P.%S:@UW
MWO"TU'I*JHX#^["'1MW0]N3K;;E.YO+]17UV5<KB45Y<__=_]2>]_^GZP28Q
MD\0L$K-)S"$QE\0\$O-)+""QD,0$B44D%D.8DD>CYSP:Z?3K3_)19AM9KY?F
M^7V6_JOS/.6#UC@WBDC,)#&+Q&P2<TC,)3%OCXUWV'9%_WC='TZ&];^TCX<9
M<_RHR7 \'*J/"L@#"TE,D%A$8C&$*>$Q?@Z/L38\O&R>KZ0AOZUWZZYZL31_
M2++[W:V[)"V,QV199TM^9U0/TJC7A//?C751K]*,9%T?SCS=GP6MTJ6L?S.3
M76NL#]I#.#=[2,PD,8O$;!)S2,PE,6^/30Y293#J]4<OLJ?C45?CV<OL(0\L
M)#%!8A&)Q1"F9,_D.7LFVNRY3;)%ND@J:70M"C]H!Y^;&B1FDIA%8C:).23F
MDIA'8CZ)!206DI@@L8C$8@A3,FCZG$%3ZL6<*9E')&:2F$5B-HDY).:2F$=B
M/HD%)!:2F""QB,1B"%/R:/:<1S/].5%]1SI/EL9"/LIEOMZ&4;NZ,NYD]PI+
MBYZ;321FDIA%8O;LZ 6-<:_74]<4#CFC2V(>B?DD%I!82&*"Q"(2BR%,R9RK
MY\RYTF=.OEK)8I[6J1.O=^=!UK?MUZ4TA%Q]D457XFC)<Q.'Q$P2LTC,)C&'
MQ%P2\TC,)[& Q$(2$R06D5@,84HR]7O/T;2M5#'KLT:"(@G53%2S4,U&-0?5
M7%3S4,U'M0#50E03J!:A6DQI:CX=-!C[P)OO>N3L:"(U$]4L5+-1S4$U%]4\
M5/,;[? -LW[O:'$;H).&J"90+4*UF-+4S!FTF3/09HZ?/V1E?3;T]*N79?GC
M_@3)K_]G&K?U77/C#^/S[NWZCYMB_I <EJH[(TH[Y]D116HFJEFH9J.:@VHN
MJGFHYJ-:@&HAJ@E4BU MIC0UR=HF=1^K4O?1+C6JF:AFH9J-:@ZJN:CFH9J/
M:@&JA:@F4"U"M9C2U'QJF]7;2]TT9UJ_K>^*/*N,>5(^&.OD^P_#2<N<'4ZC
MSG>F7IR]F^BD%JK9J.:@FHMJ'JKYJ!:@6HAJ M4B5(LI34V=MI+=UW>R;_/5
M.LF^&Y_D7*:/<F%\U"0/VJWN'Q=M=Z\;'$4/VIM&-1O5'%1S4<U#-1_5 E0+
M44V@6H1J,:6IT=,VLOOZ2K;USTU:?3=6LGK(%T::/<JRVD;/K\8F6\AB^3W-
M[@VY?U":&9FLC*0L9=592M+/=78V38ZRJ?.L""UGHYJ-:@ZJN:CFH9J/:@&J
MA:@F4"U"M9C2U&AJB]I];>_RVBO+39+-=]>BS?/5*L^:R]$6FV*;2FM9I'5F
MW>7%]@*UQ^UE)>ME?3C-+B)U6NTW!/FE,ZK0<C>JF:AFH9J-:@ZJN8VV?8.X
M/9M],U/_O?#0.7U4"U M1#6!:A&JQ92F)E5;X>Z_TN$^3*<ZEO;!TQD[:&\;
MU4Q4LU#-1C4'U=Q&FQVDSF#VYN7E]!XZJ8]J :J%J"90+4*UF-+4W&EKW'U]
MC_OF_KZ0][L3GZ>W_/>7ZK\X8^I,(K3/W6BOOH*-5K51S48U!]5<5/-0S4>U
M -5"5!.H%J%:3&GJ%H5M:WN@;5T^O8Q4VZMTL]*? ^FI<Y.GT0[_];UZ<_5B
MIP@3G=-"-1O5'%1S4<U#-1_5 E0+44V@6H1J,:6IP=/6L0?Z.G9["B35",J?
M7O[IC""TGMUHRGY:D^.3'W12"]5L5'-0S44U#]5\5 M0+40U@6H1JL64IF;0
MH,T@?3W[8Y'/I5R4QEV1KXY?BWZY&OMU]RY:?6?Z] +W/"^[WU#33WQV3@V.
M<FHXZL@IM'R-:C:J.:CFHIJ':CZJ!:@6HII M0C58DI3<ZHM7P^TY<EK/\G*
M4F;&AS2OY/QA>\U(9^B@Q6M4,U'-0C4;U1Q4<U'-0S4?U0)4"U%-H%J$:C&E
MJ=G4%J_KFUL?N#"DD:A\(C43U2Q4LU'-0347U3Q4\U$M0+40U02J1:@64YJ:
M3VU%>_!:1?LPG^9Y5A7)O.E"=H846M-&-1/5+%2S4<U!-1?5O$%']7[:?[D:
M]]%) U0+44V@6H1J,:6IZ=.VM ?ZEO;-*B^J]%_[\,GOC'+S9=E\<%H=166Z
MD/M@ZDPBM)2-:B:J6:AFHYJ#:BZJ>:CF#XYK^]/!T4XDZ)PAJ@E4BU MIC0U
MB-I.]D#?R3YM]R,]<G;DH.5J5+-0S48U!]5<5/-0S6\TY4JAP? X<]!V-:H)
M5(M0+:8T-7/:=O5 WZXVY9TL"KFH0V<7/IV)@_:J4<U$-0O5;%1S4,U%-0_5
M?%0+4"U$-3$XWC5]U#\ZGXO026-*4Q.G[54/]+WJCC?*C#^,3_5,25%_>9,M
M#+/=K;\SC]!V-:J9J&:AFHUJ#JJYJ.:AFH]J :J%J"90+4*UF-+43ZEN2]A#
M;.OL(=K!1C43U2Q4LU'-0347U3Q4\U$M0+40U02J1:@64YJ:3VU7>TALG:U'
MSHXF=.ML5+-0S48U!]5<5/-0S1]V;)W=/WH?+D G#5%-H%J$:C&EJ9DS:#/G
ME:VS.Y=R3]L\VE(:2;V::RY?^[B_=J0SE= F-JJ9J&:AFHUJ#JJYJ.:AFH]J
M :J%J"90+4*UF-+4\&H+VT-LM^PA6MI&-1/5+%2S4<U!-1?5/%3S42U M1#5
M!*I%J!93FII/;6F[O@DLZ+3(V=%$:B:J6:AFHYJ#:BZJ>:CF-]KA@FYX_(Y5
M@$X:HII M0C58DI3,Z<M8@_U1>SN!=W3O=I//-++9P<1VLE&-0O5;%1S4,U%
M-0_5?%0+4"U$-8%J$:K%E*;F55O='DZP-1S:U$8U$]4L5+-1S4$U%]4\5/-1
M+4"U$-4$JD6H%E.:FD]MHWNH;W1__L&E)/6B;C??=B_M)-M?Z+;_3 #CYO/M
MKT9>/=0W]Y\%L'L-??%4T_SA;B;Z(SD[W]!:.*I9J&:CFH-J+JIYP^,B=]<U
M<>BD :J%J"90+4*UF-+4X&IKX4-]+3S.<N/C0U*LZBDV53I/EL;3YRB%5?<+
M46A)'-5,5+-0S48U!]5<5/-0S4>U -5"5!.H%J%:3&EJ3+5=\N$5MOY#2^.H
M9J*:A6HVJCFHYJ*:AVH^J@6H%J*:0+4(U6)*4_)IU);&1_J=N_]>)%F9S'?I
M]/SA ?7:3A]5>O3<J$(U$]6L1E.N?YH=;9IIHY,ZJ.:BFH=J/JH%J!:BFD"U
M"-5B2E,SJ"V&C_3%\"C/_E;(NTVV2+XLI;%IVIG-YV^7NWY!L9 +(RG;EYDT
M5P/KISL[G= *^:ACL_#C3TJQT$EM5'-0S44U#]5\5 M0+40U@6H1JL64IJ;3
MH$TG?87\9S9?TM-G)Q%:&T<U"]5L5'-0S44UK]&4E[R/RDI^QZ->]IG0PPI1
M3:!:A&HQI:GITG:\1_I-N4_K4.J1LW,$K7>CFH5J-JHYJ.:BFM=H2HX,)\=!
MTO&PCG(D>FPAJ@E4BU MIC0U3-I"]DA;OCSX-*2MOMNL9/_6_/-F)<:=E*6R
MLI+IXW;5U9DZVMG.3AU2,QOM\"_RH&L===+#;/38'%1S4<U#-1_5 E0+44V@
M6H1J,:6IJ=-6LD<G[XW]*(VD*)+L?O_)1^N\JG])DZ61+!;I=I%4WURE2UE6
M>=;]T6SZN<[.'+2D/3K>LGEX_%JP==K#;/38'%1S4<U#-1_5 E0+44V@6H1J
M,:6IF=/6JD?Z';'QEXS1[C6JF:/C'94[7S(^Z6$V>FP.JKFHYJ&:CVH!JH6H
M)E M0K68TM38:=O2(WU;6E\Z-/XP;NOU5KK8KL &G3&#5J!1S40U"]5L5'-0
MS44U#]5\5 M0+40U@6H1JL64IH96VY0>[2N.0 5QA%:D4<U$-0O5;%1S4,U%
M-0_5?%0+4"U$-8%J$:K%E*;F4UN1'NFWVQ9/+P@]+=^:Z\Q.V?A?3Y\=6&AG
M&M6L1GMU>8>6H5'-134/U7Q4"U M1#6!:A&JQ92F)-&X+4./]67H>+T[19+?
M9#%/R^<\Z@J>\7$ON#\8O_QQO-5/>&ZBH)J%:C:J.:CFHIJ':CZJ!:@6HII
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M:JN9TQ;$IS]9$.]:T1$?YJ(_KK-C#.V3HYJ%:C:J.:CFHIJ':CZJ!:@6HII
MM0C58DI3TF[6]LEG6)]\AO;)4<U$-0O5;%1S4,U%-0_5?%0+4"U$-8%J$:K%
ME*;F4]LGG^G[Y*=]F(L>.3N:T/(XJEFH9J.:@VHNJGF-=OAA+N.CJW!]=,X
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MX(J7L$6F]'4;S\M08=>YMJ7*7SQ[;9Y'>@:-GL%%J*F0FI<+H*>0+H$>2(K
MM'TU!3*]4G6E@NQ,JCCLX4&$PTZ_=W(-?QK%G<'I-?@'I;9 M:@[D(94KDKC
MRE.SVC2Y25W;3];OJ/FY7O4;QG7.!Z86O-0@<$Z006= ^:%<-W(3(ZNZH,^D
MH?90#W-JX*BL >W/I33[B3V@^4N0_ )02P,$%     @ <X!E6H%7/+-V P
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M;FI/E+:#>;\20C\W[ !--;OX#U!+ P04    " !S@&5:<8^_SE$$  !I&0
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M.I1ELUF,XX"VR-(8DM#O2'X7Q=M:FO=BS611W3,\ITLO8.\J :'9](UY"4<
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M6GB0:N4T8RM!]RFKVK78-6Y14(/UT3X)_:TW^TI@1RJDG0KI_ZDCTM?4[97
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M\'V=9%@P?29+%+0REZI@AD*U\'6ID*4.5.1^& 1]OV!<>/' S<U4/)"5R;G
MF0)=%053SR/,Y6KH=;SUQ U?9,9.^/&@9 N\17-7SA1%?LN2\@*%YE* POG0
MN^Q<C'LVWR7\X+C2&V.P3NZE?+#!-!UZ@16$.2;&,C!Z+7&,>6Z)2,9CP^FU
MG[3 S?&:_8OS3E[NF<:QS'_RU&1#[]R#%.>LRLV-7'W%QH\3F,A<NR>LFMS
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M_X$F(5_S)2P7]3?:-['80DDE)"L:L!I!D96'7_JS$>($0+P+ *<!.+\*<!N
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MJ:OT.L;:C3>8\PK3WX'I^>B<,Y5)])4ED&P#N)I@S=)_9#GW>Q%/(3Y" ^\
M^=@?=A!:O-Q]T$-G4 =M8/$&._ 6&6%+0)0AE0%:\*(D[.&S1"LF(.9+1O]
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M*6;!50 I9JPIS9/<?L6V'D<PD:5VO[#UOI-1 $FCC:S:8&)0<>'_V5O;A[V
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M2+<@:;</Q3XP\MD6*I$:23OIO]]1DN4746J'Y8LM47>GYSD>[R$U?9+JF]X
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MMDMKO[?X\(RUJ$&3-PLP/,WTKQCJR\."O'GU*WE%4D$^;^16<['4TZ%!Z!;
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M3+\NRS#-9,2:P3']NBS#-),=<MXEZ(%EF&8RZNEZ%-/O@6689C+RK@V&Z??
M<DPS.;%FPC&@ <7DF&)R8L4,TH5Y,L?<DO_2$;0=7Q+P88;)R?LP0WQIP(=Y
M)B?VS, @GU]-^)B89W)BS^QC_L'F[KQEXQJW7OJ8Z,=@Q)[9FV0=;M"88W)R
MQR#3K>R+CXDY)B=VS-Z$ZW D,;_DG5_&W<[V[+1T#T1!^8\[O77K"RZ+F6'M
M3_^549JU'PXL&RF_NW6WZD;S<O>Q\.Y#Y[/_ %!+ P04    " !S@&5:EW=R
MY"P"  #V*   &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=I+3N-
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M_RGKO7/K/XX?GV5GF_XMGXW_$5R\ %!+ 0(4 Q0    ( '. 95H'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ <X!E6G[PSC[N    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ <X!E6IE<G",0!@  G"<  !,
M         ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !S
M@&5:?%!M\_P)   C.0  &               @($-"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ <X!E6NXI72U)!@  PAD  !@
M         ("!/Q(  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0
M   ( '. 95J;[E(5[ (  "$*   8              " @;X8  !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !S@&5:W'[$'4H%  "L%
M&               @('@&P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M A0#%     @ <X!E6NY(,TU !P  ?#4  !@              ("!8"$  'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( '. 95I2BC\#'@<
M +<>   8              " @=8H  !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"% ,4    " !S@&5:IX92V4L"  "F!0  &               @($J
M,   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ <X!E6E1%
MU=AA @  P@<  !@              ("!JS(  'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;%!+ 0(4 Q0    ( '. 95HH8<VKI0@  (TQ   8
M  " @4(U  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !S
M@&5:7-RY1;PA  #5:@  &0              @($=/@  >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( '. 95HD%=DA\!<  /E7   9
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M970Q-2YX;6Q02P$"% ,4    " !S@&5:7BRK1JD"  #T!0  &0
M    @(%0CP  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (
M '. 95JP!$ZXA <  -T1   9              " @3"2  !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L! A0#%     @ <X!E6HY?KW3T$0  [CH  !D
M             ("!ZYD  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M% ,4    " !S@&5:WHQH^,,)  !S&0  &0              @($6K   >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( '. 95JHT]UQM00
M /$)   9              " @1"V  !X;"]W;W)K<VAE971S+W-H965T,C N
M>&UL4$L! A0#%     @ <X!E6F/D'H-0 P  6@<  !D              ("!
M_+H  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " !S@&5:
M"L^@R;(+   )(0  &0              @(&#O@  >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+ 0(4 Q0    ( '. 95J"^((B.0,   X'   9
M      " @6S*  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%
M  @ <X!E6AD!7"SG(0  $'(  !D              ("!W,T  'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !S@&5:58KU7ST%  #[#
M&0              @('Z[P  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M 0(4 Q0    ( '. 95H5X*NY:@,  ! (   9              " @6[U  !X
M;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ <X!E6H-E,'HB
M!   J@H  !D              ("!#_D  'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6Q02P$"% ,4    " !S@&5:?4GM:VT$  "G#0  &0
M@(%H_0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( '.
M95J3416@#@,  (L&   9              " @0P" 0!X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L! A0#%     @ <X!E6L^.,[&T @  Y 4  !D
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M=#,T+GAM;%!+ 0(4 Q0    ( '. 95J;>A8 Y 0  %$=   9
M  " @5<; 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @
M<X!E6E\'=)_B @  ;@@  !D              ("!<B ! 'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6Q02P$"% ,4    " !S@&5:^XVY?DD"  "Y!@  &0
M            @(&+(P$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4
M Q0    ( '. 95K!5Y%5DP,  % ,   9              " @0LF 0!X;"]W
M;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ <X!E6AUR\--U P
M%PX  !D              ("!U2D! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX
M;6Q02P$"% ,4    " !S@&5:^"B[D[,7  "NG $ &0              @(&!
M+0$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( '. 95J=
M'IEJ3 ,  !(-   9              " @6M% 0!X;"]W;W)K<VAE971S+W-H
M965T-#$N>&UL4$L! A0#%     @ <X!E6OQW">;_ @  '@@  !D
M     ("![D@! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '. 95IDZT7L@@,  /4-   9              "
M@?=C 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ <X!E
M6N_W."!# P  BPH  !D              ("!L&<! 'AL+W=O<FMS:&5E=',O
M<VAE970T."YX;6Q02P$"% ,4    " !S@&5:WMP#VM@#  !U$P  &0
M        @($J:P$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0
M   ( '. 95K<#1%-E@(  (0&   9              " @3EO 0!X;"]W;W)K
M<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ <X!E6H;<4_2+ @  !@<
M !D              ("!!G(! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q0
M2P$"% ,4    " !S@&5:X@O%#= %  "!)P  &0              @('(= $
M>&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( '. 95H,8SI,
ME0(  .D&   9              " @<]Z 0!X;"]W;W)K<VAE971S+W-H965T
M-3,N>&UL4$L! A0#%     @ <X!E6J/7\3_7 @  Z0<  !D
M ("!FWT! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " !S
M@&5:XG=47:\9  #L;0$ &0              @(&I@ $ >&PO=V]R:W-H965T
M<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( '. 95IC*F1^E@0   $3   9
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M970V,"YX;6Q02P$"% ,4    " !S@&5:-!'?&Z\%  "7%P  &0
M    @($=KP$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    (
M '. 95H%+VWU)@,  !8-   9              " @0.U 0!X;"]W;W)K<VAE
M971S+W-H965T-C(N>&UL4$L! A0#%     @ <X!E6@YM&H)M P  N@T  !D
M             ("!8+@! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"
M% ,4    " !S@&5:JD'UO4$#  !M"P  &0              @($$O $ >&PO
M=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( '. 95K+6D3>"P,
M -(&   9              " @7R_ 0!X;"]W;W)K<VAE971S+W-H965T-C4N
M>&UL4$L! A0#%     @ <X!E6K*;3G0)!0  $A(  !D              ("!
MOL(! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    " !S@&5:
M IX-GBD#  #6"0  &0              @('^QP$ >&PO=V]R:W-H965T<R]S
M:&5E=#8W+GAM;%!+ 0(4 Q0    ( '. 95J80Y;040(  -8$   9
M      " @5[+ 0!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%
M  @ <X!E6@.4:G$F @  W@0  !D              ("!YLT! 'AL+W=O<FMS
M:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    " !S@&5:D?VW&54#  "L%0
M#0              @ %#T $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( '.
M95J7BKL<P    !,"   +              "  </3 0!?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( '. 95JFTT)4*P4  &PM   /              "  :S4 0!X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !S@&5:EW=RY"P"  #V*   &@
M            @ $$V@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " !S@&5:UD@C+O<!   K*   $P              @ %HW $ 6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     30!- !(5  "0W@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>260</ContextCount>
  <ElementCount>416</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>80</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance</Role>
      <ShortName>Cybersecurity Risk Management, Strategy, and Governance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995485 - Disclosure - California Institute for Regenerative Medicine Award</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAward</Role>
      <ShortName>California Institute for Regenerative Medicine Award</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureAccruedExpenses3</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Convertible Preferred Stock and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersEquity</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Employee Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefits</Role>
      <ShortName>Employee Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingencies1</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Collaboration and License Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables</Role>
      <ShortName>Collaboration and License Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestments</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipment</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureAccruedExpenses3</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeases</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersEquityTables</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersEquity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReporting</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails1</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Organization and Summary of Significant Accounting Policies - (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails3</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails4</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Collaboration and License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails</Role>
      <ShortName>Collaboration and License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Collaboration and License Agreements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails1</Role>
      <ShortName>Collaboration and License Agreements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Collaboration and License Agreements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails2</Role>
      <ShortName>Collaboration and License Agreements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995795 - Disclosure - California Institute For Regenerative Medicine Award (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails</Role>
      <ShortName>California Institute For Regenerative Medicine Award (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails</Role>
      <ShortName>Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Investments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2</Role>
      <ShortName>Investments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995855 - Disclosure - Fair Value Measurements (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails3</Role>
      <ShortName>Fair Value Measurements (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Property and Equipment (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Leases (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Leases (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails1</Role>
      <ShortName>Leases (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995925 - Disclosure - Leases (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails2</Role>
      <ShortName>Leases (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995945 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Additional information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Equity (Additional information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersEquityTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995955 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Stock option activity under all equity and stock option plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Equity - Stock option activity under all equity and stock option plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995965 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Restricted stock unit activity under all equity and stock option plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Equity - Restricted stock unit activity under all equity and stock option plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995975 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Stock based compensation for all stock awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockBasedCompensationForAllStockAwardsDetails</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Equity - Stock based compensation for all stock awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995985 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Weighted average assumptions used in the Black-Scholes option pricing model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityWeightedAverageAssumptionsUsedInTheBlackscholesOptionPricingModelDetails</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Equity - Weighted average assumptions used in the Black-Scholes option pricing model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995995 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Schedule of common stock reserved for future issuance (Details )</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Equity - Schedule of common stock reserved for future issuance (Details )</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Income Taxes (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails2</Role>
      <ShortName>Income Taxes (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Income Taxes (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails3</Role>
      <ShortName>Income Taxes (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Income Taxes (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails4</Role>
      <ShortName>Income Taxes (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Segment Reporting (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails</Role>
      <ShortName>Segment Reporting (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996055 - Disclosure - Segment Reporting - Schedule of Segment Profit or Loss, Including Segment Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentProfitOrLossIncludingSegmentExpensesDetails</Role>
      <ShortName>Segment Reporting - Schedule of Segment Profit or Loss, Including Segment Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996065 - Disclosure - Employee Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefitsDetails</Role>
      <ShortName>Employee Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefits</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996075 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingencies1</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="fate-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996085 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureSubsequentEvents</ParentRole>
      <Position>69</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="fate-20241231.htm">fate-20241231.htm</File>
    <File>fate-20241231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img143810944_0.jpg</File>
    <File>img143810944_1.jpg</File>
    <File>img143810944_2.jpg</File>
    <File>img143810944_3.jpg</File>
    <File>img143810944_4.jpg</File>
    <File>img143810944_5.jpg</File>
    <File>img143810944_6.jpg</File>
    <File>img143810944_7.jpg</File>
    <File>img143810944_8.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="643">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>95
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "fate-20241231.htm": {
   "nsprefix": "fate",
   "nsuri": "http://www.fatetherapeutics.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "fate-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "fate-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 314,
   "keyCustom": 102,
   "axisStandard": 28,
   "axisCustom": 1,
   "memberStandard": 40,
   "memberCustom": 34,
   "hidden": {
    "total": 15,
    "http://fasb.org/us-gaap/2024": 11,
    "http://xbrl.sec.gov/dei/2024": 3,
    "http://www.fatetherapeutics.com/20241231": 1
   },
   "contextCount": 260,
   "entityCount": 1,
   "segmentCount": 80,
   "elementCount": 844,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 643,
    "http://xbrl.sec.gov/dei/2024": 39,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_4b833be3-96ed-48b8-9d9e-6292de58d8fd",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4b833be3-96ed-48b8-9d9e-6292de58d8fd",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100040 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_4b833be3-96ed-48b8-9d9e-6292de58d8fd",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4b833be3-96ed-48b8-9d9e-6292de58d8fd",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "100050 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity",
     "longName": "100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_6199ef4e-6533-4919-aa08-7b8879357aa9",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6199ef4e-6533-4919-aa08-7b8879357aa9",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
     "longName": "100070 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_7fc491c3-db47-4e1f-9c36-5199ecfed9ff",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7fc491c3-db47-4e1f-9c36-5199ecfed9ff",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance",
     "longName": "995455 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance",
     "shortName": "Cybersecurity Risk Management, Strategy, and Governance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies",
     "longName": "995465 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements",
     "longName": "995475 - Disclosure - Collaboration and License Agreements",
     "shortName": "Collaboration and License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAward",
     "longName": "995485 - Disclosure - California Institute for Regenerative Medicine Award",
     "shortName": "California Institute for Regenerative Medicine Award",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "fate:AwardAgreementForResearchAndDevelopmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "fate:AwardAgreementForResearchAndDevelopmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestments",
     "longName": "995495 - Disclosure - Investments",
     "shortName": "Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "longName": "995505 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipment",
     "longName": "995515 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureAccruedExpenses3",
     "longName": "995525 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeases",
     "longName": "995535 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersEquity",
     "longName": "995545 - Disclosure - Convertible Preferred Stock and Stockholders' Equity",
     "shortName": "Convertible Preferred Stock and Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "995555 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReporting",
     "longName": "995565 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefits",
     "longName": "995575 - Disclosure - Employee Benefits",
     "shortName": "Employee Benefits",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingencies1",
     "longName": "995585 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureSubsequentEvents",
     "longName": "995595 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995605 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables",
     "longName": "995615 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)",
     "shortName": "Organization and Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables",
     "longName": "995625 - Disclosure - Collaboration and License Agreements (Tables)",
     "shortName": "Collaboration and License Agreements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "fate:CommonStockMultiplesAndTheEnterpriseValueMilestonePaymentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "fate:CommonStockMultiplesAndTheEnterpriseValueMilestonePaymentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsTables",
     "longName": "995635 - Disclosure - Investments (Tables)",
     "shortName": "Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "longName": "995645 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables",
     "longName": "995655 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureAccruedExpensesTables",
     "longName": "995665 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesTables",
     "longName": "995675 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersEquityTables",
     "longName": "995685 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Tables)",
     "shortName": "Convertible Preferred Stock and Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "995695 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingTables",
     "longName": "995705 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
     "longName": "995715 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails1",
     "longName": "995725 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 1)",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_4b833be3-96ed-48b8-9d9e-6292de58d8fd",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4b833be3-96ed-48b8-9d9e-6292de58d8fd",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsNoncurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2",
     "longName": "995735 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_db4ca2c8-7dec-42f6-9326-27fb5b437f80",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_db4ca2c8-7dec-42f6-9326-27fb5b437f80",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails3",
     "longName": "995745 - Disclosure - Organization and Summary of Significant Accounting Policies - (Details 3)",
     "shortName": "Organization and Summary of Significant Accounting Policies - (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails4",
     "longName": "995755 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 4)",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details 4)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails",
     "longName": "995765 - Disclosure - Collaboration and License Agreements (Details)",
     "shortName": "Collaboration and License Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c1b46ce1-8237-43cf-86cd-6a985c5ce0ca",
      "name": "fate:ClinicalDevelopmentMilestoneFees",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails1",
     "longName": "995775 - Disclosure - Collaboration and License Agreements (Details 1)",
     "shortName": "Collaboration and License Agreements (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_e3dc601c-f824-4b78-bf0e-07dae896ef9c",
      "name": "fate:CommonStockMultiple1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "fate:CommonStockMultiplesAndTheEnterpriseValueMilestonePaymentsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e3dc601c-f824-4b78-bf0e-07dae896ef9c",
      "name": "fate:CommonStockMultiple1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "fate:CommonStockMultiplesAndTheEnterpriseValueMilestonePaymentsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails2",
     "longName": "995785 - Disclosure - Collaboration and License Agreements (Details 2)",
     "shortName": "Collaboration and License Agreements (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_8f2c86db-20b2-4603-88f9-51afe5ae61e0",
      "name": "fate:FairValueAssumptionsRiskFreeInterestRate1",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "fate:ScheduleOfMilestonePaymentsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8f2c86db-20b2-4603-88f9-51afe5ae61e0",
      "name": "fate:FairValueAssumptionsRiskFreeInterestRate1",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "fate:ScheduleOfMilestonePaymentsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails",
     "longName": "995795 - Disclosure - California Institute For Regenerative Medicine Award (Details)",
     "shortName": "California Institute For Regenerative Medicine Award (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_4dd02f91-14ae-4ec9-ba06-e9a1c6c69591",
      "name": "fate:AwardForFirstInHumanClinicalTrial",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "fate:AwardAgreementForResearchAndDevelopmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4dd02f91-14ae-4ec9-ba06-e9a1c6c69591",
      "name": "fate:AwardForFirstInHumanClinicalTrial",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "fate:AwardAgreementForResearchAndDevelopmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails",
     "longName": "995805 - Disclosure - Investments (Details)",
     "shortName": "Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2",
     "longName": "995815 - Disclosure - Investments (Details 2)",
     "shortName": "Investments (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_cc863354-869b-4206-b33e-59e639b10e95",
      "name": "fate:InvestmentMaturityDateRange",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cc863354-869b-4206-b33e-59e639b10e95",
      "name": "fate:InvestmentMaturityDateRange",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails",
     "longName": "995835 - Disclosure - Fair Value Measurements (Details)",
     "shortName": "Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_b416aca9-c7b0-442c-b1c2-2934711580f1",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b416aca9-c7b0-442c-b1c2-2934711580f1",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetails2",
     "longName": "995845 - Disclosure - Fair Value Measurements (Details 2)",
     "shortName": "Fair Value Measurements (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "fate:IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4b833be3-96ed-48b8-9d9e-6292de58d8fd",
      "name": "fate:Fairvalueassetslevel1Tolevel2Transfersamounts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails3",
     "longName": "995855 - Disclosure - Fair Value Measurements (Details 3)",
     "shortName": "Fair Value Measurements (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "fate:IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fbf420d5-255c-421e-9863-8fd4aeac0e96",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails",
     "longName": "995865 - Disclosure - Property and Equipment (Details)",
     "shortName": "Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_4b833be3-96ed-48b8-9d9e-6292de58d8fd",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4b833be3-96ed-48b8-9d9e-6292de58d8fd",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
     "longName": "995875 - Disclosure - Property and Equipment (Additional Information) (Details)",
     "shortName": "Property and Equipment (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R51": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureAccruedExpensesDetails",
     "longName": "995885 - Disclosure - Accrued Expenses (Details)",
     "shortName": "Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_4b833be3-96ed-48b8-9d9e-6292de58d8fd",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4b833be3-96ed-48b8-9d9e-6292de58d8fd",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
     "longName": "995905 - Disclosure - Leases (Additional Information) (Details)",
     "shortName": "Leases (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_4b833be3-96ed-48b8-9d9e-6292de58d8fd",
      "name": "fate:ImpairmentOfRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:LesseeOperatingLeaseOptionToExtend",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails1",
     "longName": "995915 - Disclosure - Leases (Details 1)",
     "shortName": "Leases (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:StraightLineRentAdjustments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:StraightLineRentAdjustments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails2",
     "longName": "995925 - Disclosure - Leases (Details 2)",
     "shortName": "Leases (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_4b833be3-96ed-48b8-9d9e-6292de58d8fd",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4b833be3-96ed-48b8-9d9e-6292de58d8fd",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
     "longName": "995945 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Additional information) (Details)",
     "shortName": "Convertible Preferred Stock and Stockholders' Equity (Additional information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_4b833be3-96ed-48b8-9d9e-6292de58d8fd",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_780d7cf9-0c20-4ef0-a014-ce112efe3de2",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails",
     "longName": "995955 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Stock option activity under all equity and stock option plans (Details)",
     "shortName": "Convertible Preferred Stock and Stockholders' Equity - Stock option activity under all equity and stock option plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_d2feccdf-3708-47ad-92f7-48fa021ea96b",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d2feccdf-3708-47ad-92f7-48fa021ea96b",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails",
     "longName": "995965 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Restricted stock unit activity under all equity and stock option plans (Details)",
     "shortName": "Convertible Preferred Stock and Stockholders' Equity - Restricted stock unit activity under all equity and stock option plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_e07453e5-70e2-4589-84ee-63184d1649d3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e07453e5-70e2-4589-84ee-63184d1649d3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockBasedCompensationForAllStockAwardsDetails",
     "longName": "995975 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Stock based compensation for all stock awards (Details)",
     "shortName": "Convertible Preferred Stock and Stockholders' Equity - Stock based compensation for all stock awards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e07a21dc-a40b-48ca-81a4-731bcea56eb4",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityWeightedAverageAssumptionsUsedInTheBlackscholesOptionPricingModelDetails",
     "longName": "995985 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Weighted average assumptions used in the Black-Scholes option pricing model (Details)",
     "shortName": "Convertible Preferred Stock and Stockholders' Equity - Weighted average assumptions used in the Black-Scholes option pricing model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_228a9429-468e-442d-a38d-9b5441b82b3c",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_228a9429-468e-442d-a38d-9b5441b82b3c",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails",
     "longName": "995995 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Schedule of common stock reserved for future issuance (Details )",
     "shortName": "Convertible Preferred Stock and Stockholders' Equity - Schedule of common stock reserved for future issuance (Details )",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_4b833be3-96ed-48b8-9d9e-6292de58d8fd",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "fate:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4c6c4dd6-4ab5-46a0-bc89-10dab775b034",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "fate:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails",
     "longName": "996005 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails2",
     "longName": "996015 - Disclosure - Income Taxes (Details 2)",
     "shortName": "Income Taxes (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_4b833be3-96ed-48b8-9d9e-6292de58d8fd",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fece1b4a-7679-43ae-91f1-803e3e834572",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails3",
     "longName": "996025 - Disclosure - Income Taxes (Details 3)",
     "shortName": "Income Taxes (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "fate:CumulativeChangeInOwnershipPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "fate:CumulativeChangeInOwnershipPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails4",
     "longName": "996035 - Disclosure - Income Taxes (Details 4)",
     "shortName": "Income Taxes (Details 4)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6199ef4e-6533-4919-aa08-7b8879357aa9",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails",
     "longName": "996045 - Disclosure - Segment Reporting (Additional Information) (Details)",
     "shortName": "Segment Reporting (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentProfitOrLossIncludingSegmentExpensesDetails",
     "longName": "996055 - Disclosure - Segment Reporting - Schedule of Segment Profit or Loss, Including Segment Expenses (Details)",
     "shortName": "Segment Reporting - Schedule of Segment Profit or Loss, Including Segment Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "fate:PersonnelCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefitsDetails",
     "longName": "996065 - Disclosure - Employee Benefits (Details)",
     "shortName": "Employee Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "C_df4185ff-6291-44b2-b42f-fe0d6dd2b4c5",
      "name": "fate:DefinedContributionPlanMinimumAgeOfEmployee",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_df4185ff-6291-44b2-b42f-fe0d6dd2b4c5",
      "name": "fate:DefinedContributionPlanMinimumAgeOfEmployee",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails",
     "longName": "996075 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "fate:MinimumAnnualPaymentsToMaintainLicenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7b598b8d-7ac7-457d-9009-819763ca7cc2",
      "name": "fate:MinimumAnnualPaymentsToMaintainLicenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsDetails",
     "longName": "996085 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "C_f1dea256-3b9e-495e-a654-b31799d22af3",
      "name": "fate:GrantAward",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1dea256-3b9e-495e-a654-b31799d22af3",
      "name": "fate:GrantAward",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fate-20241231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureAccruedExpenses3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r53",
      "r56",
      "r1073"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r832"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accretion and amortization of premiums and discounts on investments, net",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "fate_AccruedClinicalTrialRelatedCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "AccruedClinicalTrialRelatedCostsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued clinical trial related costs",
        "label": "Accrued Clinical Trial Related Costs Current",
        "documentation": "Accrued clinical trial related costs current."
       }
      }
     },
     "auth_ref": []
    },
    "fate_AccruedExpensesAndLongTermDebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "AccruedExpensesAndLongTermDebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses And Long Term Debt Disclosure [Abstract]",
        "documentation": "Accrued expenses and long term debt disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureAccruedExpensesDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current accrued expenses",
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current accrued expenses",
        "label": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll and other employee benefits",
        "label": "Accrued Salaries, Current",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r777"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r144",
      "r619"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r67",
      "r150",
      "r615",
      "r656",
      "r657"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Gain (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r8",
      "r15",
      "r497",
      "r500",
      "r559",
      "r652",
      "r653",
      "r981",
      "r982",
      "r983",
      "r991",
      "r992",
      "r993",
      "r994"
     ]
    },
    "fate_AchievementOfStockPriceAppreciationMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "AchievementOfStockPriceAppreciationMilestone",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of stock price appreciation milestone",
        "label": "Achievement of stock price appreciation milestone"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "fate_AdditionalCancerTargetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "AdditionalCancerTargetsMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Cancer Targets",
        "label": "Additional Cancer Targets [Member]",
        "documentation": "Additional Cancer Targets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "totalLabel": "Additional Paid in Capital, Total",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r832",
      "r1152"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r671",
      "r991",
      "r992",
      "r993",
      "r994",
      "r1081",
      "r1153"
     ]
    },
    "fate_AddtionalAmountAvailableForFundingUnderAward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "AddtionalAmountAvailableForFundingUnderAward",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Addtional amount available for funding under award.",
        "label": "Addtional Amount Available For Funding Under Award",
        "terseLabel": "Additional amount available for funding under award",
        "verboseLabel": "Addtional Amount Available For Funding Under Award"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock\u2013based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r405"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "fate_AggregateEquityPremiumOnSharesIssuedUnderAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "AggregateEquityPremiumOnSharesIssuedUnderAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate equity premium on shares",
        "label": "Aggregate Equity Premium On Shares Issued Under Agreement",
        "documentation": "Aggregate equity premium on shares issued under agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r873",
      "r884",
      "r894",
      "r927"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r876",
      "r887",
      "r897",
      "r930"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r877",
      "r888",
      "r898",
      "r922",
      "r931",
      "r935",
      "r943"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockBasedCompensationForAllStockAwardsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r442"
     ]
    },
    "fate_AmendedAndRestatedExclusiveLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "AmendedAndRestatedExclusiveLicenseAgreementMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended MSK License",
        "label": "Amended And Restated Exclusive License Agreement [Member]",
        "documentation": "Amended and Restated Exclusive License Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "fate_AmendedMSKLicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "AmendedMSKLicenseMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails1",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended MSK License",
        "label": "Amended M S K License [Member]",
        "documentation": "Amended MSK license member."
       }
      }
     },
     "auth_ref": []
    },
    "fate_AmendedMskccLicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "AmendedMskccLicenseMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amended MSKCC License [Member]",
        "documentation": "Amended MSKCC License [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "fate_AmortizationOfSubLicenseConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "AmortizationOfSubLicenseConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of sublicense consideration",
        "label": "Amortization Of Sub License Consideration",
        "documentation": "Amortization of sub license consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anti-dilutive securities (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails4",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment charge on property and equipment",
        "label": "Asset Impairment Charges",
        "totalLabel": "Asset Impairment Charges, Total",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r31"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r112",
      "r146",
      "r171",
      "r201",
      "r209",
      "r235",
      "r239",
      "r281",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r490",
      "r494",
      "r532",
      "r611",
      "r709",
      "r791",
      "r792",
      "r832",
      "r851",
      "r1040",
      "r1041",
      "r1098"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r151",
      "r171",
      "r281",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r490",
      "r494",
      "r532",
      "r832",
      "r1040",
      "r1041",
      "r1098"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetails2",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets measured at fair value on a recurring basis",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total assets measured at fair value on a recurring basis",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r509",
      "r819"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets:",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "fate_AssociatedWithCollaborationServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "AssociatedWithCollaborationServicesMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Associated with collaboration services",
        "label": "Associated with Collaboration Services [Member]",
        "documentation": "Associated with Collaboration Services [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r856",
      "r857",
      "r880"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r856",
      "r857",
      "r880"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r856",
      "r857",
      "r880"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]",
        "terseLabel": "Auditor Opinion"
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "terseLabel": "Unrealized Losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "terseLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r290",
      "r610"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain",
        "negatedLabel": "Unrealized Gains",
        "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Fair Value",
        "verboseLabel": "Estimated Fair Value",
        "label": "Debt Securities, Available-for-Sale",
        "totalLabel": "Estimated Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r290",
      "r508",
      "r604",
      "r819",
      "r823",
      "r1006",
      "r1085",
      "r1086",
      "r1087"
     ]
    },
    "fate_AwardAgreementExecutedDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "AwardAgreementExecutedDate",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award agreement executed date",
        "label": "Award Agreement Executed Date",
        "documentation": "Award agreement executed date."
       }
      }
     },
     "auth_ref": []
    },
    "fate_AwardAgreementForResearchAndDevelopmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "AwardAgreementForResearchAndDevelopmentDisclosureTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAward"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California Institute for Regenerative Medicine Award",
        "label": "Award Agreement For Research And Development Disclosure [Text Block]",
        "documentation": "Award agreement for research and development disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "fate_AwardForFirstInHumanClinicalTrial": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "AwardForFirstInHumanClinicalTrial",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award for first-in-human clinical trial",
        "label": "Award For First In Human Clinical Trial",
        "documentation": "Award for first-in-human clinical trial."
       }
      }
     },
     "auth_ref": []
    },
    "fate_AwardFromCaliforniaInstituteForRegenerativeMedicineAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "AwardFromCaliforniaInstituteForRegenerativeMedicineAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award From California Institute For Regenerative Medicine Abstract",
        "documentation": "Award from the california institute for regenerative medicine.",
        "terseLabel": "Award From California Institute For Regenerative Medicine [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "fate_AwardFromRegenerativeMedicineInstituteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "AwardFromRegenerativeMedicineInstituteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award From Regenerative Medicine Institute [Abstract]",
        "documentation": "Award from regenerative medicine institute."
       }
      }
     },
     "auth_ref": []
    },
    "fate_AwardFromRegenerativeMedicineInstituteLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "AwardFromRegenerativeMedicineInstituteLineItems",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award from California institute for regenerative medicine",
        "label": "Award From Regenerative Medicine Institute [Line Items]",
        "documentation": "Award from regenerative medicine institute."
       }
      }
     },
     "auth_ref": []
    },
    "fate_AwardFromRegenerativeMedicineInstituteTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "AwardFromRegenerativeMedicineInstituteTable",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award From Regenerative Medicine Institute [Table]",
        "label": "Award From Regenerative Medicine Institute [Table]",
        "documentation": "Award from regenerative medicine institute."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityWeightedAverageAssumptionsUsedInTheBlackscholesOptionPricingModelDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408",
      "r409",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location",
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r1113",
      "r1114"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location",
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r319",
      "r1113",
      "r1114"
     ]
    },
    "fate_CIRMAwardLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "CIRMAwardLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "C I R M Award Liability Noncurrent",
        "documentation": "CIRM award liability, noncurrent.",
        "terseLabel": "CIRM award liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CaliforniaFranchiseTaxBoardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CaliforniaFranchiseTaxBoardMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Californian",
        "label": "California Franchise Tax Board [Member]",
        "documentation": "Designated tax department of the government of the state of California."
       }
      }
     },
     "auth_ref": []
    },
    "fate_CaliforniaInstituteForRegenerativeMedicineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "CaliforniaInstituteForRegenerativeMedicineMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California Institute for Regenerative Medicine",
        "label": "California Institute For Regenerative Medicine [Member]",
        "documentation": "California institute for regenerative medicine ."
       }
      }
     },
     "auth_ref": []
    },
    "fate_CandidateOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "CandidateOneMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Candidate one.",
        "label": "Candidate One [Member]",
        "terseLabel": "Candidate 1"
       }
      }
     },
     "auth_ref": []
    },
    "fate_CandidateThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "CandidateThreeMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Candidate 3",
        "label": "Candidate Three [Member]",
        "documentation": "Candidate Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "fate_CandidateTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "CandidateTwoMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Candidate 2",
        "label": "Candidate Two [Member]",
        "documentation": "Candidate two."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of property and equipment in accounts payable",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22"
     ]
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalizedContractCostAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of collaboration contract asset",
        "label": "Capitalized Contract Cost, Amortization",
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails1",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r141",
      "r776"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market fund",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1083",
      "r1084"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r98"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails1",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of the year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of the year",
        "totalLabel": "Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r75",
      "r169"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r75"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental schedule of noncash investing and financing activities",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails4",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r147",
      "r148",
      "r149",
      "r171",
      "r192",
      "r193",
      "r195",
      "r197",
      "r203",
      "r204",
      "r281",
      "r330",
      "r332",
      "r333",
      "r334",
      "r337",
      "r338",
      "r358",
      "r359",
      "r362",
      "r365",
      "r373",
      "r532",
      "r664",
      "r665",
      "r666",
      "r667",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r697",
      "r718",
      "r737",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r966",
      "r988",
      "r995"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of warrants",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares to be purchased",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "fate_ClinicalDevelopmentMilestoneFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "ClinicalDevelopmentMilestoneFees",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical development milestone fees",
        "label": "Clinical Development Milestone Fees",
        "documentation": "Clinical Development Milestone Fees"
       }
      }
     },
     "auth_ref": []
    },
    "fate_ClinicalProgramsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "ClinicalProgramsExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentProfitOrLossIncludingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Programs, Expense",
        "documentation": "Clinical Programs, Expense",
        "terseLabel": "Clinical programs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "fate_CollaborationAndLicenseAgreementsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "CollaborationAndLicenseAgreementsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration And License Agreements Disclosure [Abstract]",
        "documentation": "No definition available."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementAccountingPolicy",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaborative Arrangements",
        "documentation": "Disclosure of accounting policy for collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "fate_CollaborativeArrangementAggregateMilestonePaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "CollaborativeArrangementAggregateMilestonePaymentsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate milestone payments",
        "label": "Collaborative Arrangement Aggregate Milestone Payments Receivable",
        "documentation": "Collaborative arrangement aggregate milestone payments receivable."
       }
      }
     },
     "auth_ref": []
    },
    "fate_CollaborativeArrangementAggregatePaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "CollaborativeArrangementAggregatePaymentsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate research and development fees payments receivable",
        "label": "Collaborative Arrangement Aggregate Payments Receivable",
        "documentation": "Collaborative arrangement aggregate payments receivable."
       }
      }
     },
     "auth_ref": []
    },
    "fate_CollaborativeArrangementAnnualPaymentsReceivableRecordedUnderDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "CollaborativeArrangementAnnualPaymentsReceivableRecordedUnderDeferredRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement annual payments receivable recorded as deferred revenue",
        "label": "Collaborative Arrangement Annual Payments Receivable Recorded Under Deferred Revenue",
        "documentation": "Collaborative arrangement annual payments receivable recorded under deferred revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration and License Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r123",
      "r133"
     ]
    },
    "us-gaap_CollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement",
        "label": "Collaborative Arrangement [Member]",
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "fate_CollaborativeArrangementPercentageOfReductionOnMilestonePayments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "CollaborativeArrangementPercentageOfReductionOnMilestonePayments",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of reduction on milestone payments",
        "label": "Collaborative Arrangement Percentage Of Reduction On Milestone Payments",
        "documentation": "Collaborative arrangement percentage of reduction on milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "fate_CollaborativeArrangementPotentialAdditionalMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "CollaborativeArrangementPotentialAdditionalMilestones",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement potential additional milestones",
        "label": "Collaborative Arrangement Potential Additional Milestones",
        "documentation": "Collaborative arrangement potential additional milestones."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails1",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "fate_CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-refundable upfront payments recorded as deferred revenue",
        "label": "Collaborative Arrangements Upfront Payments Recorded Under Deferred Revenue",
        "documentation": "Represents the amount of upfront payments received under collaborative arrangements is recorded as deferred revenue."
       }
      }
     },
     "auth_ref": []
    },
    "fate_CommercialOptionExerciseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "CommercialOptionExerciseMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Option Exercise Member",
        "label": "Commercial option exercise [Member]",
        "documentation": "Commercial option exercise [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureInvestmentDetails3ShortTermInvestmentDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r329",
      "r845",
      "r846",
      "r847",
      "r848"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r103",
      "r612",
      "r696"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingencies1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r323",
      "r324",
      "r769",
      "r1032",
      "r1037"
     ]
    },
    "fate_CommonStockCapitalAdditionalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "CommonStockCapitalAdditionalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional shares reserved for issuance",
        "label": "Common Stock Capital Additional Shares Reserved For Future Issuance",
        "documentation": "Common stock capital additional shares reserved for future issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares reserved for issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "fate_CommonStockIssuedDuringPeriodSharesPrivatePlacement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "CommonStockIssuedDuringPeriodSharesPrivatePlacement",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private placement of common stock, net of issuance costs (in shares)",
        "label": "Common Stock Issued During Period Shares Private Placement",
        "documentation": "Common stock issued during period shares private placement."
       }
      }
     },
     "auth_ref": []
    },
    "fate_CommonStockIssuedDuringPeriodValuePrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "CommonStockIssuedDuringPeriodValuePrivatePlacement",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private placement of common stock, net of issuance costs",
        "label": "Common Stock Issued During Period Value Private Placement",
        "documentation": "Common stock issued during period value private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r841",
      "r842",
      "r843",
      "r845",
      "r846",
      "r847",
      "r848",
      "r991",
      "r992",
      "r994",
      "r1081",
      "r1145",
      "r1153"
     ]
    },
    "fate_CommonStockMultiple1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "CommonStockMultiple1",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock multiple",
        "label": "Common Stock Multiple1",
        "documentation": "Common Stock Multiple"
       }
      }
     },
     "auth_ref": []
    },
    "fate_CommonStockMultiplesAndTheEnterpriseValueMilestonePaymentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "CommonStockMultiplesAndTheEnterpriseValueMilestonePaymentsTableTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of All Possible Stock Price Appreciation Milestone Payments",
        "label": "Common Stock Multiples And The Enterprise Value Milestone Payments Table [Text Block]",
        "documentation": "Common stock multiples and the enterprise value milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "fate_CommonStockOfPublicOfferingAndIssuanceOfPreFundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "CommonStockOfPublicOfferingAndIssuanceOfPreFundedWarrants",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public offering of common stock and issuance of pre-funded warrants, net of offering costs (in shares)",
        "label": "Common Stock Of Public Offering And Issuance Of Pre Funded Warrants",
        "documentation": "Common stock of public offering and issuance of pre funded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, authorized shares",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r697"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "terseLabel": "Common stock, issued shares",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, outstanding shares",
        "label": "Common Stock, Shares, Outstanding",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r61",
      "r697",
      "r715",
      "r1153",
      "r1154"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "terseLabel": "Common stock, $0.001 par value; authorized shares - 250,000,000; issued and outstanding - 113,928,279 at December 31, 2024 and 98,627,076 at December 31, 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r614",
      "r832"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "fate_CompanyReceivedPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "CompanyReceivedPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Received Payment",
        "label": "Company Received Payment",
        "documentation": "Company Received Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Components of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Components of Deferred Tax Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r97",
      "r156",
      "r158",
      "r163",
      "r605",
      "r625"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "fate_ComputerAndOfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "ComputerAndOfficeEquipmentMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer And Office Equipment",
        "label": "Computer And Office Equipment [Member]",
        "documentation": "Represents information pertaining to computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer Equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r126"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r781"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction-in-Process",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "fate_ContraResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "ContraResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contra research and development expenses",
        "label": "Contra Research and Development Expenses",
        "documentation": "Contra research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetNetNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetNetNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Collaboration contract assets",
        "terseLabel": "Collaboration contract asset",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent",
        "totalLabel": "Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent, Total",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r378",
      "r381"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377",
      "r381"
     ]
    },
    "fate_ConversionOfPreferenceShareToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "ConversionOfPreferenceShareToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of preferred shares to common stock",
        "label": "Conversion Of Preference Share To Common Stock",
        "documentation": "Value of preferred share conversion to common stock."
       }
      }
     },
     "auth_ref": []
    },
    "fate_ConversionOfPreferredSharesToCommonStocksShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "ConversionOfPreferredSharesToCommonStocksShares",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of preferred shares to common stock (in shares)",
        "label": "Conversion Of Preferred Shares To Common Stocks Shares",
        "documentation": "Conversion of preferred shares to common stock, shares"
       }
      }
     },
     "auth_ref": []
    },
    "fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock And Stockholders Deficit Disclosure [Abstract]",
        "documentation": "Convertible preferred stock and stockholders' equity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Class A Convertible Preferred Shares",
        "terseLabel": "Convertible Preferred Stock",
        "label": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359",
      "r362",
      "r845",
      "r846",
      "r847",
      "r848"
     ]
    },
    "fate_ConvertiblePreferredStockPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "ConvertiblePreferredStockPolicyTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock",
        "label": "Convertible Preferred Stock Policy [Text Block]",
        "documentation": "Convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares to be issued upon conversion",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r35",
      "r60",
      "r90",
      "r368"
     ]
    },
    "us-gaap_ConvertiblePreferredStockTermsOfConversion": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockTermsOfConversion",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Terms of conversion",
        "label": "Preferred Stock, Convertible, Terms",
        "documentation": "Description of conversion terms for preferred stock."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r35",
      "r36",
      "r60",
      "r89",
      "r91"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureInvestmentDetails3ShortTermInvestmentDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r808",
      "r810",
      "r819",
      "r833",
      "r839",
      "r1142"
     ]
    },
    "fate_CorrespondingAssetForSublicenseConsiderationPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "CorrespondingAssetForSublicenseConsiderationPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublicense consideration paid",
        "label": "Corresponding Asset For Sublicense Consideration Paid",
        "documentation": "Corresponding asset for sublicense consideration paid."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails1",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails2",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r173",
      "r174",
      "r342",
      "r360",
      "r562",
      "r582",
      "r609",
      "r778",
      "r780"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "fate_CumulativeChangeInOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "CumulativeChangeInOwnershipPercentage",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative changes in ownership percentage",
        "label": "Cumulative Change In Ownership Percentage",
        "documentation": "Cumulative change in ownership percentage."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r865",
      "r954"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r865",
      "r954"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r956"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r956"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r869",
      "r958"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r956"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r949"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r861",
      "r950"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r861",
      "r950"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r859",
      "r948"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r859",
      "r948"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r859",
      "r948"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r862",
      "r951"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r864",
      "r953"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r864",
      "r953"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r865",
      "r954"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r868",
      "r957"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r866",
      "r955"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r863",
      "r952"
     ]
    },
    "us-gaap_DebtInstrumentAnnualPrincipalPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAnnualPrincipalPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndLongTermDebt2017TermLoanDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount of the final fee payment",
        "label": "Debt Instrument, Annual Principal Payment",
        "documentation": "Amount of annual principal payment for debt instrument."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r52",
      "r53",
      "r100",
      "r102",
      "r175",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r830",
      "r989",
      "r1033",
      "r1034",
      "r1035",
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award considered as a loan, interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r340"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndLongTermDebt2017TermLoanDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r830",
      "r989",
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r175",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r830",
      "r989",
      "r1033",
      "r1034",
      "r1035",
      "r1091",
      "r1092"
     ]
    },
    "fate_DebtInstrumentRepaymentPhaseFourRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "DebtInstrumentRepaymentPhaseFourRateMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan Repayment Rate Four",
        "label": "Debt Instrument Repayment Phase Four Rate [Member]",
        "documentation": "Debt instrument repayment phase four rate."
       }
      }
     },
     "auth_ref": []
    },
    "fate_DebtInstrumentRepaymentPhaseOneRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "DebtInstrumentRepaymentPhaseOneRateMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan Repayment Rate One",
        "label": "Debt Instrument Repayment Phase One Rate [Member]",
        "documentation": "Debt instrument repayment phase one rate."
       }
      }
     },
     "auth_ref": []
    },
    "fate_DebtInstrumentRepaymentPhaseThreeRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "DebtInstrumentRepaymentPhaseThreeRateMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan Repayment Rate Three",
        "label": "Debt Instrument Repayment Phase Three Rate [Member]",
        "documentation": "Debt instrument repayment phase three rate."
       }
      }
     },
     "auth_ref": []
    },
    "fate_DebtInstrumentRepaymentPhaseTwoRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "DebtInstrumentRepaymentPhaseTwoRateMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Repayment Phase Two Rate [Member]",
        "documentation": "Debt instrument repayment phase two rate.",
        "terseLabel": "Loan Repayment Rate Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndLongTermDebt2017TermLoanDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r35",
      "r36",
      "r48",
      "r89",
      "r91",
      "r175",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r830",
      "r989",
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureInvestmentDetails3ShortTermInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Fair Value, 12 Months or Greater",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r294",
      "r798"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureInvestmentDetails3ShortTermInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized Losses, 12 Months or Greater",
        "terseLabel": "Unrealized Losses, 12 Months or Greater",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r294"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureInvestmentDetails3ShortTermInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Fair Value, Less Than 12 Months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r294",
      "r798"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureInvestmentDetails3ShortTermInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized Losses, Less Than 12 Months",
        "terseLabel": "Unrealized Losses, Less Than 12 Months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r294"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available-for-sale securities, realized gains (losses) on sales",
        "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)",
        "totalLabel": "Debt Securities, Available-for-sale, Realized Gain (Loss), Total",
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureInvestmentDetails3ShortTermInvestmentDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Investments",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureInvestmentDetails3ShortTermInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Fair Value, Total",
        "totalLabel": "Estimated Fair Value, Total",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r292",
      "r798"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureInvestmentDetails3ShortTermInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized Losses, Total",
        "terseLabel": "Unrealized Losses, Total",
        "totalLabel": "Unrealized Losses, Total",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r293"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Deferred Tax Liabilities, Gross, Total",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r101",
      "r466"
     ]
    },
    "us-gaap_DeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Revenue",
        "totalLabel": "Deferred Revenue, Total",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "fate_DeferredTaxAssetsCapitalizedRdExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "DeferredTaxAssetsCapitalizedRdExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Capitalized RD expense.",
        "label": "Deferred Tax Assets Capitalized RD expense",
        "terseLabel": "Capitalized R&amp;D expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Tax Assets, Deferred Income",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset amortization",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "fate_DeferredTaxAssetsLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Deferred Tax Assets Lease Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating losses",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net of deferred tax assets and liabilities",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net of deferred tax assets and liabilities",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "fate_DeferredTaxLiabilitiesDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "DeferredTaxLiabilitiesDepreciation",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation",
        "label": "Deferred Tax Liabilities Depreciation",
        "documentation": "Deferred tax liabilities depreciation."
       }
      }
     },
     "auth_ref": []
    },
    "fate_DeferredTaxLiabilitiesRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right-of-use assets",
        "label": "Deferred Tax Liabilities Right Of Use Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from right-of-use assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Company's Contributions",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r386",
      "r398",
      "r808",
      "r809",
      "r810",
      "r811"
     ]
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Matching contributions under 401(k) plan",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "fate_DefinedContributionPlanMinimumAgeOfEmployee": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "DefinedContributionPlanMinimumAgeOfEmployee",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum age of employees",
        "label": "Defined Contribution Plan Minimum Age Of Employee",
        "documentation": "Represents minimum age of employees to become eligible for participation under defined contribution plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization",
        "terseLabel": "Depreciation expense",
        "label": "Depreciation, Depletion and Amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r201",
      "r214",
      "r239",
      "r791",
      "r792"
     ]
    },
    "us-gaap_Dividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Dividends",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends declared",
        "label": "Dividends",
        "totalLabel": "Dividends, Total",
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r92"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r856",
      "r857",
      "r880"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction Flag",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r856",
      "r857",
      "r880",
      "r923"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails2",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Federal",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "fate_EarlyTerminationFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "EarlyTerminationFee",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Early termination fees",
        "label": "Early Termination Fee",
        "documentation": "One-time option to terminate the lease, subject to certain termination payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails3",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net loss per share, basic and diluted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails3",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r190",
      "r192",
      "r195",
      "r196",
      "r197",
      "r200",
      "r484",
      "r487",
      "r505",
      "r506",
      "r606",
      "r626",
      "r784"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails3",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r192",
      "r195",
      "r196",
      "r197",
      "r200",
      "r484",
      "r487",
      "r505",
      "r506",
      "r606",
      "r626",
      "r784"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Common Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r199"
     ]
    },
    "fate_EmployeeAndNonEmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "EmployeeAndNonEmployeeStockOptionMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityWeightedAverageAssumptionsUsedInTheBlackscholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee And Non Employee Stock Option [Member]",
        "documentation": "Represents an arrangement whereby both an employee and a non-employee is entitled to receive in the future, subject to vesting and other restrictions, certain number of shares in the entity at a specified price, as defined in the agreement.",
        "terseLabel": "Employee and Non Employee Stock Option"
       }
      }
     },
     "auth_ref": []
    },
    "fate_EmployeeRetentionCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "EmployeeRetentionCreditMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Retention Credit [Member]",
        "label": "Employee Retention Credit [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "fate_EmployeeRetentionCreditPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "EmployeeRetentionCreditPolicy",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Retention Credit Policy",
        "label": "Employee Retention Credit Policy",
        "terseLabel": "Employee Retention credit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected recognition period of unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost related to unvested restricted shares",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1072"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost related to outstanding options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1072"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Common stock options",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "fate_EmployeesAndDirectorsStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "EmployeesAndDirectorsStockOptionsMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee and Directors Stock Option",
        "label": "Employees And Directors Stock Options [Member]",
        "documentation": "Employees and Directors stock options."
       }
      }
     },
     "auth_ref": []
    },
    "fate_EnterpriseValueMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "EnterpriseValueMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock price appreciation milestones potential payments",
        "label": "Enterprise Value Milestone Payment",
        "documentation": "Enterprise value milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "fate_EnterpriseValueMilestonesLiabilityAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "EnterpriseValueMilestonesLiabilityAtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Enterprise Value Milestones Liability At Fair Value.",
        "label": "Enterprise Value Milestones Liability At Fair Value",
        "terseLabel": "Enterprise value milestones liability at fair value"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "terseLabel": "Entity",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "verboseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r965"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r136",
      "r160",
      "r161",
      "r162",
      "r176",
      "r177",
      "r178",
      "r180",
      "r185",
      "r187",
      "r189",
      "r202",
      "r282",
      "r283",
      "r316",
      "r375",
      "r474",
      "r475",
      "r481",
      "r482",
      "r483",
      "r485",
      "r486",
      "r487",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r504",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r541",
      "r543",
      "r559",
      "r623",
      "r652",
      "r653",
      "r654",
      "r671",
      "r737"
     ]
    },
    "us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentUnderlyingEquityInNetAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method investment, underlying equity in net assets",
        "label": "Equity Method Investment, Underlying Equity in Net Assets",
        "documentation": "This item represents the entity's ownership percentage in the investee multiplied by the investee's total equity."
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "fate_EquityPremiumOnSharePricePerShareUnderAgreement": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "EquityPremiumOnSharePricePerShareUnderAgreement",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity premium per share",
        "label": "Equity Premium On Share Price Per Share Under Agreement",
        "documentation": "Equity premium on share price per share under agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r873",
      "r884",
      "r894",
      "r927"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r870",
      "r881",
      "r891",
      "r924"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "fate_FTFiveOneSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "FTFiveOneSixMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FT516",
        "label": "F T Five One Six [Member]",
        "documentation": "FT516."
       }
      }
     },
     "auth_ref": []
    },
    "fate_FacilitiesCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "FacilitiesCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentProfitOrLossIncludingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facilities costs",
        "label": "Facilities Costs",
        "documentation": "Facilities Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetails2",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r509",
      "r522",
      "r819"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetails2",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r509",
      "r522",
      "r819"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assets Measured at Fair Value on Recurring Basis",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1083",
      "r1084"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class",
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r523",
      "r821"
     ]
    },
    "fate_FairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "FairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated term (in years)",
        "label": "Fair Value Assumptions Expected Term1",
        "documentation": "Fair Value Assumptions Expected Term 1."
       }
      }
     },
     "auth_ref": []
    },
    "fate_FairValueAssumptionsExpectedVolatilityRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "FairValueAssumptionsExpectedVolatilityRate1",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Fair Value Assumptions Expected Volatility Rate1",
        "documentation": "Fair Value Assumptions Expected Volatility Rate 1."
       }
      }
     },
     "auth_ref": []
    },
    "fate_FairValueAssumptionsRiskFreeInterestRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "FairValueAssumptionsRiskFreeInterestRate1",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Fair Value Assumptions Risk Free Interest Rate1",
        "documentation": "Fair Value Assumptions Risk Free Interest Rate 1."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class",
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r523",
      "r821"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r507",
      "r509",
      "r510",
      "r511",
      "r512",
      "r521",
      "r522",
      "r524",
      "r569",
      "r570",
      "r571",
      "r802",
      "r803",
      "r808",
      "r809",
      "r810",
      "r819",
      "r823"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Class",
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r523"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetails2",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r509",
      "r510",
      "r512",
      "r819",
      "r1086",
      "r1089"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r519",
      "r520",
      "r521",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r603",
      "r819",
      "r824"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quoted prices in Active Market for Identical Assets (Level 1)",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r386",
      "r391",
      "r509",
      "r522",
      "r569",
      "r808",
      "r809",
      "r810",
      "r819"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Other Observable Inputs (Level 2)",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r386",
      "r391",
      "r509",
      "r510",
      "r522",
      "r570",
      "r802",
      "r803",
      "r808",
      "r809",
      "r810",
      "r819"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Unobservable Inputs (Level 3)",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r509",
      "r510",
      "r511",
      "r512",
      "r522",
      "r571",
      "r802",
      "r803",
      "r808",
      "r809",
      "r810",
      "r819",
      "r823"
     ]
    },
    "us-gaap_FairValueInputsQuantitativeInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsQuantitativeInformationAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Determine the estimated fair value of the enterprise value milestone payments",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "fate_FairValueInputsStockPriceSensitivityPercentageIncreaseDecrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "FairValueInputsStockPriceSensitivityPercentageIncreaseDecrease",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sensitivity analysis fair value inputs stock price increase/decrease",
        "label": "Fair Value Inputs Stock Price Sensitivity Percentage Increase Decrease",
        "documentation": "Sensitivity percentage increase/decrease in stock price used as an input to measure fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value by Liability Class",
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r523"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Changes in the Fair Value of the Company\u2019s Level 3 Enterprise Fair Value Milestone Payment Liability",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r518",
      "r523"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetails2",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r509",
      "r510",
      "r512",
      "r819",
      "r1086",
      "r1089"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at the beginning of the period",
        "periodEndLabel": "Balance at the end of the period",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r523"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r507",
      "r509",
      "r510",
      "r511",
      "r512",
      "r521",
      "r522",
      "r524",
      "r569",
      "r570",
      "r571",
      "r802",
      "r803",
      "r808",
      "r809",
      "r810",
      "r819",
      "r823"
     ]
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsNonrecurringMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements Nonrecurring",
        "label": "Fair Value, Nonrecurring [Member]",
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r509",
      "r510",
      "r512",
      "r819",
      "r1086"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r819",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1089"
     ]
    },
    "fate_Fairvalueassetslevel1Tolevel2Transfersamounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "Fairvalueassetslevel1Tolevel2Transfersamounts",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FairValueAssetsLevel1ToLevel2TransfersAmounts",
        "label": "FairValueAssetsLevel1ToLevel2TransfersAmounts",
        "terseLabel": "Fair Value, Assets, Level 1 to Level 2 Transfers, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "fate_Fairvalueassetslevel2Tolevel1Transfersamounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "Fairvalueassetslevel2Tolevel1Transfersamounts",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FairValueAssetsLevel2ToLevel1TransfersAmounts",
        "label": "FairValueAssetsLevel2ToLevel1TransfersAmounts",
        "terseLabel": "Fair Value, Assets, Level 2 to Level 1 Transfers, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "fate_Fairvalueliabilitieslevel1Tolevel2Transfersamounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "Fairvalueliabilitieslevel1Tolevel2Transfersamounts",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FairValueLiabilitiesLevel1ToLevel2TransfersAmounts",
        "label": "FairValueLiabilitiesLevel1ToLevel2TransfersAmounts",
        "terseLabel": "Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "fate_Fairvalueliabilitieslevel2Tolevel1Transfersamounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "Fairvalueliabilitieslevel2Tolevel1Transfersamounts",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FairValueLiabilitiesLevel2ToLevel1TransfersAmounts",
        "label": "FairValueLiabilitiesLevel2ToLevel1TransfersAmounts",
        "terseLabel": "Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "fate_FinalPaymentFeeOnDebtFacilityAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "FinalPaymentFeeOnDebtFacilityAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndLongTermDebt2017TermLoanDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Final payment fee",
        "label": "Final Payment Fee On Debt Facility Amount",
        "documentation": "Final payment fee on debt facility amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureInvestmentDetails3ShortTermInvestmentDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r291",
      "r295",
      "r296",
      "r355",
      "r371",
      "r502",
      "r529",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r624",
      "r798",
      "r819",
      "r821",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r833",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1082",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089"
     ]
    },
    "us-gaap_FinancingReceivableNonaccrualNoAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancingReceivableNonaccrualNoAllowance",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Receivable, Nonaccrual, No Allowance",
        "terseLabel": "Available-for-sale securities, recognition of expected credit losses",
        "documentation": "Amortized cost of financing receivable on nonaccrual status with no allowance for credit loss. Excludes net investment in lease."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r601",
      "r602",
      "r772"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r312",
      "r313",
      "r314",
      "r315",
      "r601",
      "r772",
      "r800"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r772"
     ]
    },
    "fate_FirstDisbursementAmountUnderTheAward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "FirstDisbursementAmountUnderTheAward",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Disbursement Amount Under The Award",
        "documentation": "First Disbursement Amount Under The Award"
       }
      }
     },
     "auth_ref": []
    },
    "fate_FirstDisbursementAmountUnderTheAwardPayableForNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "FirstDisbursementAmountUnderTheAwardPayableForNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Disbursement Amount Under The Award Payable For Next Twelve Months",
        "documentation": "First Disbursement Amount Under The Award Payable For Next Twelve Months"
       }
      }
     },
     "auth_ref": []
    },
    "fate_FirstJanssenCancerTargetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "FirstJanssenCancerTargetMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Janssen Cancer Target",
        "label": "First Janssen Cancer Target [Member]",
        "documentation": "first Janssen Cancer Target"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureInvestmentDetails3ShortTermInvestmentDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-U.S. government securities",
        "label": "Debt Security, Government, Non-US [Member]",
        "documentation": "Debt security issued by government not domiciled in United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r833",
      "r1045",
      "r1142"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r877",
      "r888",
      "r898",
      "r931"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r877",
      "r888",
      "r898",
      "r931"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r877",
      "r888",
      "r898",
      "r931"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r877",
      "r888",
      "r898",
      "r931"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r877",
      "r888",
      "r898",
      "r931"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "fate_FtEightOneNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "FtEightOneNineMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FT Eight One Nine [Member]",
        "documentation": "FT Eight One Nine [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture And Fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on disposal of property and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "totalLabel": "Gain (Loss) on Disposition of Property Plant Equipment, Total",
        "negatedLabel": "Loss on disposal of property and equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "totalLabel": "General and Administrative Expense, Total",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r721"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockBasedCompensationForAllStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General And Administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "fate_GladstoneLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "GladstoneLicenseAgreementMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gladstone License Agreement",
        "label": "Gladstone License Agreement [Member]",
        "documentation": "Gladstone license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "fate_GrantAward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "GrantAward",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant awarded",
        "label": "Grant Award",
        "documentation": "Grant award."
       }
      }
     },
     "auth_ref": []
    },
    "fate_GrantIncomeFromCirmAward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "GrantIncomeFromCirmAward",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Income",
        "terseLabel": "Grant income from CIRM award",
        "label": "Grant Income From CIRM Award",
        "negatedLabel": "Grant income from FT516 CIRM award"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r856",
      "r857",
      "r880"
     ]
    },
    "us-gaap_ImpairmentOfLeasehold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLeasehold",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment charge on right-of-use asset",
        "label": "Impairment of Leasehold",
        "documentation": "The adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r31"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total",
        "terseLabel": "Impairment of long-lived assets",
        "verboseLabel": "Impairment loss",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r31",
      "r84",
      "r820"
     ]
    },
    "fate_ImpairmentOfRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "ImpairmentOfRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Right of Use Asset",
        "documentation": "Impairment of Right of Use Asset",
        "terseLabel": "Impairment of Right of Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r85"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockBasedCompensationForAllStockAwardsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r319",
      "r320",
      "r514",
      "r518",
      "r523",
      "r649",
      "r651",
      "r722",
      "r772",
      "r822",
      "r1115"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockBasedCompensationForAllStockAwardsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320",
      "r514",
      "r518",
      "r523",
      "r649",
      "r651",
      "r722",
      "r772",
      "r822",
      "r1115"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails2",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r451",
      "r452",
      "r459",
      "r471",
      "r816",
      "r1079"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails2",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r451",
      "r452",
      "r459",
      "r471",
      "r816",
      "r1079"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority, Name",
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r1079"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority, Name",
        "label": "Income Tax Authority, Name [Domain]",
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r1079"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r446",
      "r451",
      "r456",
      "r457",
      "r458",
      "r464",
      "r470",
      "r476",
      "r478",
      "r479",
      "r480",
      "r669",
      "r816"
     ]
    },
    "us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationLikelihoodOfUnfavorableSettlement",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Uncertain tax position description",
        "label": "Income Tax Examination, Likelihood of Unfavorable Settlement",
        "documentation": "Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority."
       }
      }
     },
     "auth_ref": [
      "r1077"
     ]
    },
    "us-gaap_IncomeTaxExaminationYearUnderExamination": {
     "xbrltype": "gYearListItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationYearUnderExamination",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax examination, year under examination",
        "label": "Income Tax Examination, Year under Examination",
        "documentation": "Tax year being audited in the income tax examination, in YYYY format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r132",
      "r188",
      "r189",
      "r201",
      "r217",
      "r239",
      "r450",
      "r451",
      "r477",
      "r629",
      "r816"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of the Company's expected federal income tax provision (benefit) to the actual income tax provision",
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r448",
      "r449",
      "r464",
      "r465",
      "r469",
      "r473",
      "r663"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r816",
      "r1074"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax computed at federal statutory rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r816"
     ]
    },
    "fate_IncomeTaxReconciliationNondeductibleCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "IncomeTaxReconciliationNondeductibleCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-deductible compensation",
        "label": "Income Tax Reconciliation Nondeductible Compensation",
        "documentation": "Income tax reconciliation nondeductible compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r816",
      "r1074",
      "r1076"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r816",
      "r1074",
      "r1075"
     ]
    },
    "fate_IncomeTaxReconciliationPermanentTaxDifferences": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "IncomeTaxReconciliationPermanentTaxDifferences",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent differences",
        "label": "Income Tax Reconciliation Permanent Tax Differences",
        "documentation": "Represents the amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent differences."
       }
      }
     },
     "auth_ref": []
    },
    "fate_IncomeTaxReconciliationReserveForUncertainTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "IncomeTaxReconciliationReserveForUncertainTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve for uncertain tax positions",
        "label": "Income Tax Reconciliation Reserve For Uncertain Tax Positions",
        "documentation": "Income tax reconciliation reserve for uncertain tax positions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State tax, net of federal tax benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r816",
      "r1074"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "R&amp;D tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r816",
      "r1074",
      "r1076"
     ]
    },
    "us-gaap_IncomeTaxUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxUncertaintiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Uncertainties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r599",
      "r986"
     ]
    },
    "fate_IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetails2",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentProfitOrLossIncludingSegmentExpensesDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails3",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Changes in fair value of stock price appreciation milestones",
        "terseLabel": "Changes in fair value of stock price appreciation milestones liability",
        "negatedLabel": "Change in fair value of stock price appreciation milestones",
        "label": "Increase Decrease In Fair Value Of Stock Price Appreciation Milestones",
        "documentation": "Increase decrease in fair value of stock price appreciation milestones."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "fate_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets and lease liabilities, net",
        "label": "Increase Decrease In Right Of Use Assets And Lease Liabilities Net",
        "documentation": "Increase decrease in right-of-use assets and lease liabilities, net."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r877",
      "r888",
      "r898",
      "r922",
      "r931",
      "r935",
      "r943"
     ]
    },
    "fate_InducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "InducementPlanMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inducement Plan",
        "label": "Inducement Plan [Member]",
        "documentation": "Inducement plan.",
        "verboseLabel": "Awards available under the Inducement Plan"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r858",
      "r947"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r858",
      "r947"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r858",
      "r947"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Operating and Nonoperating",
        "totalLabel": "Interest Expense, Total",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r209",
      "r213",
      "r219",
      "r239",
      "r540",
      "r791",
      "r792"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndLongTermDebt2017TermLoanDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate interest expense",
        "label": "Interest Expense, Debt",
        "totalLabel": "Interest Expense, Debt, Total",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r352",
      "r356",
      "r804",
      "r805"
     ]
    },
    "us-gaap_InterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accured Interest on investments",
        "label": "Interest Receivable",
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable."
       }
      }
     },
     "auth_ref": [
      "r978",
      "r1155"
     ]
    },
    "us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentHoldingsScheduleOfInvestmentsTableTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregated by investment category and the length of time",
        "label": "Investment Holdings, Schedule of Investments [Table Text Block]",
        "documentation": "Tabular disclosure of data and information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments."
       }
      }
     },
     "auth_ref": [
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentProfitOrLossIncludingSegmentExpensesDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r212",
      "r239",
      "r791",
      "r984"
     ]
    },
    "fate_InvestmentMaturityDateRange": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "InvestmentMaturityDateRange",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity (in years)",
        "label": "Investment Maturity Date Range",
        "documentation": "Investment maturity date range."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r627",
      "r659",
      "r660",
      "r661",
      "r662",
      "r745",
      "r746"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureInvestmentDetails3ShortTermInvestmentDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Type",
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r742",
      "r744",
      "r748",
      "r751",
      "r752",
      "r753",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r843"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureInvestmentDetails3ShortTermInvestmentDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r742",
      "r744",
      "r748",
      "r751",
      "r752",
      "r753",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r843"
     ]
    },
    "us-gaap_InvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r135",
      "r248",
      "r249",
      "r530",
      "r531",
      "r1107"
     ]
    },
    "fate_JanssenAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "JanssenAgreementMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Janssen Agreement",
        "label": "Janssen Agreement [Member]",
        "documentation": "Janssen agreement."
       }
      }
     },
     "auth_ref": []
    },
    "fate_JanssenBiotechIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "JanssenBiotechIncMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Janssen Biotech Inc",
        "label": "Janssen Biotech Inc [Member]",
        "documentation": "Janssen Biotech Inc."
       }
      }
     },
     "auth_ref": []
    },
    "fate_JohnsonJohnsonInnovationJJDCIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "JohnsonJohnsonInnovationJJDCIncMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Johnson Johnson Innovation J J D C Inc",
        "label": "Johnson Johnson Innovation J J D C Inc [Member]",
        "documentation": "Johnson &amp; Johnson Innovation-JJDC, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseAgreementsMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Premises 2020 Lease Agreement",
        "label": "Lease Agreements [Member]",
        "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031"
     ]
    },
    "us-gaap_LeaseAndRentalExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseAndRentalExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate contractual rent expense",
        "label": "Operating Leases, Rent Expense",
        "totalLabel": "Operating Leases, Rent Expense, Total",
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Lease Expense",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements-building",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r557"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee Lease Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r558"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee Lease Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r558"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "fate_LesseeOperatingLeaseCashRentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "LesseeOperatingLeaseCashRentPeriod",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee Operating Lease Cash Rent Period",
        "documentation": "Lessee operating lease cash rent period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, existence of option to extend",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Payments Under Non-cancelable Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted lease payments",
        "terseLabel": "Future minimum payments under the operating leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, option to extend",
        "label": "Lessee, Operating Lease, Option to Extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToTerminate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseOptionToTerminate",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option to terminate lease",
        "label": "Lessee, Operating Lease, Option to Terminate",
        "documentation": "Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1093"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1093"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LettersOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Letters of credit outstanding amount",
        "terseLabel": "Letters of credit outstanding amount",
        "label": "Letters of Credit Outstanding, Amount",
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r104",
      "r617",
      "r832",
      "r990",
      "r1023",
      "r1090"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r140",
      "r171",
      "r281",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r491",
      "r494",
      "r495",
      "r532",
      "r832",
      "r1040",
      "r1098",
      "r1099"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetails2",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total financial liabilities measured at fair value on a recurring basis",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Liabilities, Fair Value Disclosure, Total",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r1083"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Financial liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "fate_LiquidityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "LiquidityPolicyTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Going Concern Assessment",
        "label": "Liquidity Policy [Text Block]",
        "documentation": "Liquidity."
       }
      }
     },
     "auth_ref": []
    },
    "fate_LoanAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "LoanAndSecurityAgreementMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndLongTermDebt2017TermLoanDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan and Security Agreement",
        "label": "Loan And Security Agreement [Member]",
        "documentation": "Loan and security agreement."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtTerm",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CIRM Award as a loan",
        "label": "Long-Term Debt, Term",
        "documentation": "Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1085",
      "r1086",
      "r1087"
     ]
    },
    "us-gaap_LongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term investments",
        "label": "Long-Term Investments",
        "totalLabel": "Long-term Investments, Total",
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndLongTermDebt2017TermLoanDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r1033",
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndLongTermDebt2017TermLoanDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r33",
      "r1033",
      "r1034",
      "r1035"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r328",
      "r402",
      "r443",
      "r512",
      "r598",
      "r648",
      "r650",
      "r658",
      "r688",
      "r689",
      "r743",
      "r747",
      "r749",
      "r750",
      "r754",
      "r770",
      "r771",
      "r797",
      "r806",
      "r812",
      "r823",
      "r824",
      "r828",
      "r829",
      "r835",
      "r1042",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105"
     ]
    },
    "fate_MaximumPercentageOfCommonStockOwnershipAfterChangeUponNotice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "MaximumPercentageOfCommonStockOwnershipAfterChangeUponNotice",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum percentage of common stock ownership after change upon notice.",
        "label": "Maximum Percentage Of Common Stock Ownership After Change Upon Notice",
        "documentation": "Maximum percentage of common stock ownership after change upon notice."
       }
      }
     },
     "auth_ref": []
    },
    "fate_MaximumPercentageOfCommonStockOwnershipTogetherWithAffiliatesAllowableAfterExerciseOfPrefundedWarrants": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "MaximumPercentageOfCommonStockOwnershipTogetherWithAffiliatesAllowableAfterExerciseOfPrefundedWarrants",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum percentage of common stock ownership together with affiliates allowable after exercise of prefunded warrants",
        "label": "Maximum Percentage Of Common Stock Ownership Together With Affiliates Allowable After Exercise Of Prefunded Warrants",
        "documentation": "Maximum percentage of common stock ownership together with affiliates allowable after exercise of prefunded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "fate_MilestoneOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "MilestoneOneMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone One",
        "label": "Milestone One [Member]",
        "documentation": "Milestone one member."
       }
      }
     },
     "auth_ref": []
    },
    "fate_MilestonePaymentUnderDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "MilestonePaymentUnderDeferredRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment under Deferred revenue",
        "label": "Milestone Payment Under Deferred Revenue",
        "documentation": "Milestone Payment Under Deferred Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "fate_MilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "MilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Milestone payments",
        "terseLabel": "Stock price appreciation milestone payment",
        "label": "Milestone Payments",
        "documentation": "Milestone payments during the period."
       }
      }
     },
     "auth_ref": []
    },
    "fate_MilestoneThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "MilestoneThreeMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Three",
        "label": "Milestone Three [Member]",
        "documentation": "Milestone Three Member."
       }
      }
     },
     "auth_ref": []
    },
    "fate_MilestoneTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "MilestoneTwoMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Two",
        "label": "Milestone Two [Member]",
        "documentation": "Milestone Two Member."
       }
      }
     },
     "auth_ref": []
    },
    "fate_MinimumAnnualPaymentsToMaintainLicenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "MinimumAnnualPaymentsToMaintainLicenses",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum annual payments to maintain licenses",
        "label": "Minimum Annual Payments To Maintain Licenses",
        "documentation": "Minimum annual payments to maintain licenses."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r328",
      "r402",
      "r443",
      "r512",
      "r598",
      "r648",
      "r650",
      "r658",
      "r688",
      "r689",
      "r743",
      "r747",
      "r749",
      "r750",
      "r754",
      "r770",
      "r771",
      "r797",
      "r806",
      "r812",
      "r823",
      "r824",
      "r828",
      "r835",
      "r1042",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market fund",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "us-gaap_MunicipalNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MunicipalNotesMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureInvestmentDetails3ShortTermInvestmentDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Municipal securities",
        "label": "Municipal Notes [Member]",
        "documentation": "Short-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76",
      "r78"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails3",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentProfitOrLossIncludingSegmentExpensesDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r78",
      "r107",
      "r138",
      "r155",
      "r157",
      "r162",
      "r171",
      "r179",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r188",
      "r189",
      "r194",
      "r281",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r484",
      "r487",
      "r506",
      "r532",
      "r622",
      "r717",
      "r735",
      "r736",
      "r849",
      "r1040"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetRentableArea": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetRentableArea",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Rentable Area",
        "label": "Net Rentable Area",
        "documentation": "Net rentable area for properties owned."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Adopted Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r877",
      "r888",
      "r898",
      "r922",
      "r931"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "fate_NonRule10B51ArrModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "NonRule10B51ArrModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Rule 10b51 Arr Modified Flag",
        "documentation": "Non Rule 10b51 Arr Modified Flag",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Modified"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentProfitOrLossIncludingSegmentExpensesDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income:"
       }
      }
     },
     "auth_ref": []
    },
    "fate_November2016PlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "November2016PlacementMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "November 2016 Placement",
        "label": "November2016 Placement [Member]",
        "documentation": "November 2016 placement."
       }
      }
     },
     "auth_ref": []
    },
    "fate_NumberOfDisbursements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "NumberOfDisbursements",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of disbursements",
        "label": "Number Of Disbursements",
        "documentation": "Number of disbursements."
       }
      }
     },
     "auth_ref": []
    },
    "fate_NumberOfDisbursementsReceivableBasedOnCompletionOfCertainOperatingMilestones": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "NumberOfDisbursementsReceivableBasedOnCompletionOfCertainOperatingMilestones",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of disbursements receivable based on completion of certain operating milestones",
        "label": "Number Of Disbursements Receivable Based On Completion Of Certain Operating Milestones",
        "documentation": "Number of disbursements receivable based on completion of certain operating milestones."
       }
      }
     },
     "auth_ref": []
    },
    "fate_NumberOfDisbursementsReceivableUponExecutionOfAward": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "NumberOfDisbursementsReceivableUponExecutionOfAward",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of disbursement receivable upon the execution of the award",
        "label": "Number Of Disbursements Receivable Upon Execution Of Award",
        "documentation": "Number of disbursements receivable upon execution of award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r999"
     ]
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office Equipment",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "fate_OnoLetterAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "OnoLetterAgreementMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ono Letter Agreement",
        "label": "Ono Letter Agreement [Member]",
        "documentation": "Ono Letter Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "fate_OnoPharmaceuticalCompanyLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "OnoPharmaceuticalCompanyLtdMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ono Pharmaceutical Company Ltd",
        "label": "Ono Pharmaceutical Company Ltd [Member]",
        "documentation": "Ono Pharmaceutical Company Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentProfitOrLossIncludingSegmentExpensesDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentProfitOrLossIncludingSegmentExpensesDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]",
        "verboseLabel": "Less:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentProfitOrLossIncludingSegmentExpensesDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r785",
      "r998",
      "r1000",
      "r1001",
      "r1002",
      "r1003"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease expense",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r831"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total lease liability",
        "label": "Operating Lease, Liability",
        "totalLabel": "Operating Lease, Liability, Total",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, current portion",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Impairment of Right of Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, weighted-average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r555",
      "r831"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining weighted-average lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r554",
      "r831"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "fate_OperatingLossCarryforwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforward expiration year",
        "label": "Operating Loss Carryforwards Expiration Year",
        "documentation": "Operating loss carryforwards expiration year."
       }
      }
     },
     "auth_ref": []
    },
    "fate_OperatingLossCarryforwardsIndefiniteLife": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "OperatingLossCarryforwardsIndefiniteLife",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards indefinite life",
        "label": "Operating Loss Carryforwards Indefinite Life",
        "documentation": "Operating loss carryforwards indefinite life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "fate_OptionExercisePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "OptionExercisePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option exercise payment.",
        "label": "Option Exercise Payment",
        "terseLabel": "Option exercise payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and summary of significant accounting policies",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Summary of Significant Accounting Policies",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r79",
      "r80",
      "r96"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "totalLabel": "Other Assets, Noncurrent, Total",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total",
        "terseLabel": "Unrealized gain on available-for-sale securities, net",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r623"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]",
        "terseLabel": "Other comprehensive gain:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized loss on investments, net",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r154",
      "r280"
     ]
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentAssetsMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Assets [Member]",
        "label": "Other Current Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other current assets."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r47"
     ]
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income",
        "terseLabel": "Other Income",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r628",
      "r719",
      "r755",
      "r756",
      "r757"
     ]
    },
    "us-gaap_OtherLongTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLongTermInvestmentsMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureInvestmentDetails3ShortTermInvestmentDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Investments [Member]",
        "label": "Other Long-Term Investments [Member]",
        "documentation": "Long-term investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r1142"
     ]
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncurrentAssetsMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current Assets [Member]",
        "label": "Other Noncurrent Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentProfitOrLossIncludingSegmentExpensesDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income",
        "terseLabel": "Other income",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentProfitOrLossIncludingSegmentExpensesDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Income expense in change in fair value of the stock price appreciation milestones",
        "totalLabel": "Total other income",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "fate_OtherSegmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "OtherSegmentExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentProfitOrLossIncludingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Segment Expenses",
        "documentation": "Other Segment Expenses",
        "terseLabel": "Other segment expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available-for-sale securities, recognition of expected credit losses",
        "label": "Other-than-Temporary Impairment, Credit Losses Recognized in Earnings, Credit Losses on Debt Securities Held",
        "periodStartLabel": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Credit Losses on Debt Securities Held, Beginning Balance",
        "periodEndLabel": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Credit Losses on Debt Securities Held, Ending Balance",
        "documentation": "Amount of accumulated credit loss recognized in earnings for debt security held for which portion of other-than-temporary impairment (OTTI) was recognized in other comprehensive income (OCI)."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r118"
     ]
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available-for-sale securities, impairment",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-Sale",
        "totalLabel": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Total",
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI)."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r875",
      "r886",
      "r896",
      "r929"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r878",
      "r889",
      "r899",
      "r932"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r878",
      "r889",
      "r899",
      "r932"
     ]
    },
    "fate_PatentCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "PatentCostsPolicyTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent Costs",
        "label": "Patent Costs Policy [Text Block]",
        "documentation": "Disclosure of accounting policy for patent costs."
       }
      }
     },
     "auth_ref": []
    },
    "fate_PatentNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "PatentNumber",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent Number",
        "documentation": "Patent Number",
        "terseLabel": "Patent Number"
       }
      }
     },
     "auth_ref": []
    },
    "fate_PatentsFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "PatentsFiveMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents Five [Member]",
        "documentation": "Patents Five Member"
       }
      }
     },
     "auth_ref": []
    },
    "fate_PatentsFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "PatentsFourMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents Four [Member]",
        "documentation": "Patents Four Member"
       }
      }
     },
     "auth_ref": []
    },
    "fate_PatentsOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "PatentsOneMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents One [Member]",
        "documentation": "Patents One Member"
       }
      }
     },
     "auth_ref": []
    },
    "fate_PatentsSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "PatentsSevenMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents Seven [Member]",
        "documentation": "Patents Seven Member"
       }
      }
     },
     "auth_ref": []
    },
    "fate_PatentsSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "PatentsSixMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents Six [Member]",
        "documentation": "Patents Six Member"
       }
      }
     },
     "auth_ref": []
    },
    "fate_PatentsThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "PatentsThreeMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents Three [Member]",
        "documentation": "Patents Three Member"
       }
      }
     },
     "auth_ref": []
    },
    "fate_PatentsTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "PatentsTwoMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents Two Member",
        "documentation": "Patents Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "us-gaap_PaymentsForTenantImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForTenantImprovements",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate tenant improvements of the premises",
        "label": "Payments for Tenant Improvements",
        "documentation": "Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of investments",
        "label": "Payments to Acquire Investments",
        "totalLabel": "Payments to Acquire Investments, Total",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_PaymentsToEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToEmployees",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Employees",
        "terseLabel": "Payments To Employees",
        "documentation": "Payments of cash to employees, including wages and salaries, during the current period."
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefits",
        "label": "Retirement Benefits [Text Block]",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r384",
      "r385",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r400",
      "r401",
      "r810"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "fate_PercentOfTaxableIncomeOffset": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "PercentOfTaxableIncomeOffset",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent of taxable income offset",
        "label": "Percent Of Taxable Income Offset",
        "documentation": "Percent of taxable income offset."
       }
      }
     },
     "auth_ref": []
    },
    "fate_PercentageOfCommonStockOwnershipForPreferredStockConversionChangeUponNotice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "PercentageOfCommonStockOwnershipForPreferredStockConversionChangeUponNotice",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred shares converted into common stock percentage of ownership change upon notice",
        "label": "Percentage Of Common Stock Ownership For Preferred Stock Conversion Change Upon Notice",
        "documentation": "Percentage of common stock ownership for preferred stock conversion change upon notice."
       }
      }
     },
     "auth_ref": []
    },
    "fate_PercentageOfCommonStockOwnershipUponPreferredStockConversion": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "PercentageOfCommonStockOwnershipUponPreferredStockConversion",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of common stock ownership upon preferred stock conversion",
        "label": "Percentage Of Common Stock Ownership Upon Preferred Stock Conversion",
        "documentation": "Percentage of common stock ownership upon preferred stock conversion."
       }
      }
     },
     "auth_ref": []
    },
    "fate_PercentageOfDiscretionaryContributionsDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "PercentageOfDiscretionaryContributionsDescription",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureEmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of discretionary contributions description",
        "documentation": "Percentage of discretionary contributions description"
       }
      }
     },
     "auth_ref": []
    },
    "fate_PercentageOfTaxCredit": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "PercentageOfTaxCredit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Tax Credit",
        "label": "Percentage of Tax Credit",
        "terseLabel": "Percentage Of Tax Credit"
       }
      }
     },
     "auth_ref": []
    },
    "fate_PerformanceBasedRestrictedStockUnitsPrsusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "PerformanceBasedRestrictedStockUnitsPrsusMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Based Restricted Stock Units (PRSUs) [Member]",
        "documentation": "Performance Based Restricted Stock Units (PRSUs) [Member]",
        "terseLabel": "Performance Based Restricted Stock Units PRSU"
       }
      }
     },
     "auth_ref": []
    },
    "fate_PeriodForCumulativeChangeInOwnership": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "PeriodForCumulativeChangeInOwnership",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period of change in ownership",
        "label": "Period For Cumulative Change In Ownership",
        "documentation": "Period for cumulative change in ownership."
       }
      }
     },
     "auth_ref": []
    },
    "fate_PeriodToTreatAwardAsGrantIfAwardNotTreatedAsLoan": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "PeriodToTreatAwardAsGrantIfAwardNotTreatedAsLoan",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period to treat award as grant, if award not treated as loan",
        "label": "Period To Treat Award As Grant If Award Not Treated As Loan",
        "documentation": "Period to treat award as grant, if award not treated as loan."
       }
      }
     },
     "auth_ref": []
    },
    "fate_PersonnelCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "PersonnelCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentProfitOrLossIncludingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Personnel Costs",
        "documentation": "Personnel Costs",
        "terseLabel": "Personnel costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "fate_PotentialAmountPayable": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "PotentialAmountPayable",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential Amount Payable",
        "documentation": "Potential Amount Payable"
       }
      }
     },
     "auth_ref": []
    },
    "fate_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants",
        "label": "Pre Funded Warrants [Member]",
        "documentation": "Pre-Funded Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredClassAMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Voting Class A Preferred Stock",
        "label": "Preferred Class A [Member]",
        "documentation": "Outstanding nonredeemable preferred class A stock or outstanding convertible preferred class A stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "fate_PreferredStockConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "PreferredStockConversionPrice",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price",
        "label": "Preferred Stock Conversion Price",
        "documentation": "Preferred stock conversion price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r841",
      "r842",
      "r845",
      "r846",
      "r847",
      "r848",
      "r1145",
      "r1153"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r358"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r697"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, issued shares",
        "label": "Preferred Stock, Shares Issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r358"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, outstanding shares",
        "label": "Preferred Stock, Shares Outstanding",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r697",
      "r715",
      "r1153",
      "r1154"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "totalLabel": "Preferred Stock, Value, Issued, Total",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "terseLabel": "Preferred stock, $0.001 par value; authorized shares - 5,000,000; Class A Convertible Preferred shares issued and outstanding - 2,755,086 at December 31, 2024 and 2,761,108 at December 31, 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r613",
      "r832"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "fate_PrepaidExpensesAndOtherAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "PrepaidExpensesAndOtherAssetsMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid Expenses And Other Assets",
        "label": "Prepaid Expenses And Other Assets [Member]",
        "documentation": "Prepaid expenses and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "fate_PrivatePlacementOfPreFundedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "PrivatePlacementOfPreFundedWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private placement of pre-funded warrants",
        "label": "Private Placement of Pre Funded Warrants",
        "documentation": "Private placement of pre Funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "fate_ProceedsFromCIRMAward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "ProceedsFromCIRMAward",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from CIRM award.",
        "label": "Proceeds From C I R M Award",
        "terseLabel": "Proceeds from FT819 CIRM award"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromCollaborators": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromCollaborators",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receipt of first disbursement under the Award",
        "label": "Proceeds from Collaborators",
        "documentation": "Cash received from collaborators during the current period."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from public offering of common stock, net of issuance costs",
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from private placement of common stock, net of issuance costs",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from issuance of pre-funded warrants, net of issuance costs",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from related party",
        "label": "Proceeds from Related Party Debt",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "fate_ProceedsFromResearchAndDevelopmentFeesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "ProceedsFromResearchAndDevelopmentFeesReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development fees cash payments received",
        "label": "Proceeds From Research And Development Fees Received",
        "documentation": "Proceeds From Research and Development Fees Received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of investments",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "totalLabel": "Proceeds from Sale, Maturity and Collection of Investments, Total",
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock from equity incentive plans, net of issuance costs",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r10"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r243",
      "r600",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r774",
      "r807",
      "r834",
      "r835",
      "r836",
      "r838",
      "r840",
      "r1038",
      "r1039",
      "r1044",
      "r1112",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1143",
      "r1144"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r243",
      "r600",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r774",
      "r807",
      "r834",
      "r835",
      "r836",
      "r838",
      "r840",
      "r1038",
      "r1039",
      "r1044",
      "r1112",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1143",
      "r1144"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r155",
      "r157",
      "r166",
      "r171",
      "r179",
      "r185",
      "r188",
      "r189",
      "r281",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r484",
      "r487",
      "r489",
      "r492",
      "r493",
      "r506",
      "r532",
      "r607",
      "r621",
      "r670",
      "r717",
      "r735",
      "r736",
      "r817",
      "r818",
      "r850",
      "r983",
      "r1040"
     ]
    },
    "fate_ProfitLossSharingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "ProfitLossSharingPercentage",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Profits and losses sharing percentage",
        "label": "Profit Loss Sharing Percentage",
        "documentation": "Profit loss sharing percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r557"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r127",
      "r130",
      "r131"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r143",
      "r620"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total property and equipment, net",
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r557",
      "r608",
      "r620",
      "r832"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r127",
      "r130",
      "r618"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of property and equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r557"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful lives",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "fate_PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public offering of common stock and issuance of pre-funded warrants, net of offering costs",
        "label": "Public Offering Of Common Stock And Issuance Of Pre Funded Warrants",
        "documentation": "Public offering of common stock and issuance of pre-funded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "fate_PurchasePriceOfPrefundedWarrants": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "PurchasePriceOfPrefundedWarrants",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price of prefunded warrants",
        "label": "Purchase Price Of Prefunded Warrants",
        "documentation": "Purchase price of prefunded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r328",
      "r384",
      "r402",
      "r432",
      "r433",
      "r434",
      "r443",
      "r512",
      "r572",
      "r581",
      "r598",
      "r648",
      "r650",
      "r658",
      "r688",
      "r689",
      "r743",
      "r747",
      "r749",
      "r750",
      "r754",
      "r770",
      "r771",
      "r797",
      "r806",
      "r812",
      "r823",
      "r824",
      "r828",
      "r829",
      "r835",
      "r843",
      "r1036",
      "r1042",
      "r1086",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r328",
      "r384",
      "r402",
      "r432",
      "r433",
      "r434",
      "r443",
      "r512",
      "r572",
      "r581",
      "r598",
      "r648",
      "r650",
      "r658",
      "r688",
      "r689",
      "r743",
      "r747",
      "r749",
      "r750",
      "r754",
      "r770",
      "r771",
      "r797",
      "r806",
      "r812",
      "r823",
      "r824",
      "r828",
      "r829",
      "r835",
      "r843",
      "r1036",
      "r1042",
      "r1086",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in the Company's unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r870",
      "r881",
      "r891",
      "r924"
     ]
    },
    "fate_RedmileGroupLimitedLiabilityCompanyAndAffiliatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "RedmileGroupLimitedLiabilityCompanyAndAffiliatesMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redmile Group, LLC and Affiliates",
        "label": "Redmile Group Limited Liability Company And Affiliates [Member]",
        "documentation": "Redmile Group, LLC and Affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "fate_RefundableTaxCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "RefundableTaxCredit",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refundable Tax Credit",
        "label": "Refundable Tax Credit",
        "terseLabel": "RefundableTaxCredit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction",
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r560",
      "r561",
      "r1097"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction",
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "fate_RepaymentPercentageOfAwardAmount": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "RepaymentPercentageOfAwardAmount",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayment percentage of award amount",
        "label": "Repayment Percentage Of Award Amount",
        "documentation": "Repayment percentage of award amount."
       }
      }
     },
     "auth_ref": []
    },
    "fate_RepaymentsOfDebtIncludingPrincipalAndFinalFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "RepaymentsOfDebtIncludingPrincipalAndFinalFee",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesAndLongTermDebt2017TermLoanDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayments of debt amount",
        "label": "Repayments Of Debt Including Principal And Final Fee",
        "documentation": "Repayments of debt including principal and final fee."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails1",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails2",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r173",
      "r174",
      "r342",
      "r360",
      "r562",
      "r582",
      "r609",
      "r779",
      "r780"
     ]
    },
    "fate_ResearchActivitiesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "ResearchActivitiesExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentProfitOrLossIncludingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Activities, Expense",
        "documentation": "Research Activities, Expense",
        "terseLabel": "Research activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "totalLabel": "Research and Development Expense, Total",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r772",
      "r791",
      "r1106"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockBasedCompensationForAllStockAwardsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research And Development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "fate_ResearchServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "ResearchServicesMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research services",
        "label": "Research Services [Member]",
        "documentation": "Research services."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r871",
      "r882",
      "r892",
      "r925"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r872",
      "r883",
      "r893",
      "r926"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r879",
      "r890",
      "r900",
      "r933"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "totalLabel": "Restricted Cash and Cash Equivalents, Noncurrent, Total",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r120",
      "r169"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r974",
      "r987"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units (RSUs)",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "fate_RestructuringPolicytextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "RestructuringPolicytextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring",
        "label": "Restructuring PolicyText Block",
        "documentation": "Restructuring PolicyText Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r92",
      "r616",
      "r655",
      "r657",
      "r668",
      "r698",
      "r832"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r176",
      "r177",
      "r178",
      "r180",
      "r185",
      "r187",
      "r189",
      "r282",
      "r283",
      "r316",
      "r474",
      "r475",
      "r481",
      "r482",
      "r483",
      "r485",
      "r486",
      "r487",
      "r496",
      "r498",
      "r499",
      "r501",
      "r504",
      "r541",
      "r543",
      "r652",
      "r654",
      "r671",
      "r1153"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentProfitOrLossIncludingSegmentExpensesDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue recognized",
        "terseLabel": "Collaboration revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r201",
      "r210",
      "r211",
      "r233",
      "r239",
      "r243",
      "r245",
      "r246",
      "r379",
      "r380",
      "r600"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r720",
      "r773",
      "r782"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r831"
     ]
    },
    "fate_Rule10B51ArrModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "Rule10B51ArrModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Modified",
        "label": "Rule 10b51 Arr Modified Flag",
        "documentation": "Rule 10b51 Arr Modified Flag"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock per share",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of accrued expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails4",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Anti-Dilutive Securities not Included in Calculation of Diluted Net Loss Per Common Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureInvestmentDetails3ShortTermInvestmentDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Available For Sale Securities [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails1",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "fate_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of common stock reserved for future issuance",
        "label": "Schedule Of Common Stock Reserved For Future Issuance Table [Text Block]",
        "documentation": "Tabular disclosure of the common stock reserved for future issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of significant components of the Company's deferred tax assets",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Basic and Diluted Net Loss per Share Attributable to Stockholders",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of reconciliation of the Company's expected federal income tax provision (benefit) to the actual income tax provision",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r816",
      "r1074"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of allocation of stock-based compensation for all stock awards",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r312",
      "r313",
      "r314",
      "r315",
      "r601",
      "r772",
      "r800"
     ]
    },
    "fate_ScheduleOfMilestonePaymentsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "ScheduleOfMilestonePaymentsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Milestone Payments Valuation Assumptions Table [Text Block]",
        "documentation": "Schedule of milestone payments valuation assumptions table text block.",
        "terseLabel": "Schedule of Determine the Estimated Fair Value of the Stock Price Appreciation Milestones Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherNonoperatingIncomeByComponentTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of sublease Income",
        "label": "Schedule of Other Nonoperating Income, by Component [Table Text Block]",
        "documentation": "Tabular disclosure of the detailed components of other nonoperating income. May include methodology, assumptions and amounts for: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r557"
     ]
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Cash, Cash Equivalents, and Restricted Cash",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r98",
      "r1111"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentProfitOrLossIncludingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of segment profit or loss, including segment expenses",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r406",
      "r407",
      "r408",
      "r409",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of restricted stock unit activity and related information under all equity plans",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of weighted-average assumptions used to determine the fair value of employee and nonemployee stock option grants",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of stock option activity and related information under all equity plans",
        "label": "Schedule of Stock Options Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in stock options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of the change in the Company's unrecognized tax benefits",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r815"
     ]
    },
    "fate_ScientificEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "ScientificEquipmentMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scientific Equipment",
        "label": "Scientific Equipment [Member]",
        "documentation": "Scientific equipment."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentProfitOrLossIncludingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r112",
      "r201",
      "r206",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r246",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r315",
      "r321",
      "r322",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r788",
      "r791",
      "r792",
      "r799",
      "r837",
      "r1112",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1143",
      "r1144"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r201",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r222",
      "r224",
      "r225",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r246",
      "r786",
      "r789",
      "r790",
      "r791",
      "r793",
      "r795",
      "r796"
     ]
    },
    "us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingExpenseInformationUsedByCodmDescription",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Expense Information Used by CODM, Description",
        "terseLabel": "Expense information used by CODM, Description",
        "documentation": "Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r225",
      "r239"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentProfitOrLossIncludingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r242",
      "r245",
      "r787",
      "r788",
      "r794"
     ]
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible Preferred Stock (if converted)",
        "terseLabel": "Series A Convertible Preferred Stock (if converted)",
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r976",
      "r977",
      "r1043"
     ]
    },
    "fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnuallyAwardVestingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnuallyAwardVestingPeriod",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annually vesting period",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Annually Award Vesting Period",
        "documentation": "Share based compensation arrangement by share based payment award annually award vesting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General vesting period after first year",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Vesting Period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expected To Vest Aggregate Intrinsic Value",
        "documentation": "Share-based Compensation arrangement by share-based payment award equity instruments other than options expected to vest aggregate intrinsic value.",
        "terseLabel": "Restricted stock units expected to vest at December 31, 2024"
       }
      }
     },
     "auth_ref": []
    },
    "fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected to vest at the end of the period",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expected To Vest Number",
        "documentation": "Share-based Compensation arrangement by share-based payment award equity instruments other than options expected to vest number."
       }
      }
     },
     "auth_ref": []
    },
    "fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected to vest at the end of the period",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expected To Vest Weighted Average Grant Date Fair Value",
        "documentation": "Share-based Compensation arrangement by share-based payment award equity instruments other than options expected to vest weighted average grant date fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Performance stock, granted",
        "terseLabel": "Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at the beginning of the period",
        "periodEndLabel": "Balance at the end of the period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Restricted Stock Units",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at the beginning of the period",
        "periodEndLabel": "Balance at the end of the period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Grant Date Fair Value per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding at the end of the period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of awards vested",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityWeightedAverageAssumptionsUsedInTheBlackscholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average assumptions to determine fair value of stock options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityWeightedAverageAssumptionsUsedInTheBlackscholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityWeightedAverageAssumptionsUsedInTheBlackscholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityWeightedAverageAssumptionsUsedInTheBlackscholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk\u2013free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r406",
      "r407",
      "r408",
      "r409",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435"
     ]
    },
    "fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardMonthlyAwardVestingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMonthlyAwardVestingPeriod",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monthly vesting period",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Monthly Award Vesting Period",
        "documentation": "Represents the monthly vesting period of share-based compensation awards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional shares authorized",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options Exercisable at the end of the period",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options Exercisable at the end of the period",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total intrinsic value of stock options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value per share of employee options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value [Abstract]",
        "documentation": "Aggregate Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding at the end of the period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at the beginning of the period",
        "periodEndLabel": "Balance at the end of the period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r412"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at the beginning of the period",
        "periodEndLabel": "Balance at the end of the period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r412"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Options Vested and expected to vest at the end of the period",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Options Vested and expected to vest at the end of the period",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options Vested and expected to vest at the end of the period",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Performance-based restricted granted, none of vested Units Outstanding",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional shares authorized (as a percent)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Additional Shares Authorized",
        "documentation": "Represents the percentage of additional shares authorized for issuance under an established share-based compensation plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityWeightedAverageAssumptionsUsedInTheBlackscholesOptionPricingModelDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408",
      "r409",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r410",
      "r429",
      "r430",
      "r431",
      "r432",
      "r435",
      "r438",
      "r439",
      "r440",
      "r441"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetails2",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Closing stock price as of measurement date",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "fate_SharePriceFairValueInput": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "SharePriceFairValueInput",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sensitivity analysis share price fair value input",
        "label": "Share Price Fair Value Input",
        "documentation": "Sensitivity analysis share price fair value input."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options generally vested on anniversary grant date (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Outstanding at the end of the period",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "fate_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected to vest at the end of the period",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Expected To Vest Weighted Average Remaining Contractual Term",
        "documentation": "Share-based Compensation arrangement by share-based payment award equity instruments other than options expected to vest weighted remaining contractual term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of stock awards",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityWeightedAverageAssumptionsUsedInTheBlackscholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options Exercisable at the end of the period",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options Exercisable at the end of the period",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding at the end of the period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options Vested and expected to vest at the end of the period",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total fair value of stock options vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share issue price (in dollars per share)",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in shares)",
        "periodEndLabel": "Balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "fate_ShortTermInvestmentMaturityPeriodRangeEnd": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "ShortTermInvestmentMaturityPeriodRangeEnd",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short term investments, maturity end range",
        "label": "Short Term Investment Maturity Period Range End",
        "documentation": "Short-term investment maturity period range end."
       }
      }
     },
     "auth_ref": []
    },
    "fate_ShortTermInvestmentMaturityPeriodRangeStart": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "ShortTermInvestmentMaturityPeriodRangeStart",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short term investments, maturity start range",
        "label": "Short Term Investment Maturity Period Range Start",
        "documentation": "Short-term investment maturity period range start."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Short-Term Investments, Total",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r979"
     ]
    },
    "us-gaap_ShortTermInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestmentsMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureInvestmentDetails3ShortTermInvestmentDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term Investments [Member]",
        "label": "Short-Term Investments [Member]",
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r760",
      "r761",
      "r762",
      "r775"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total short-term lease expense",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r831"
     ]
    },
    "fate_ShortTermLeasesTermExcludedFromCalculationOfRightOfUseOfAssetsAndLeaseLiabilities": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "ShortTermLeasesTermExcludedFromCalculationOfRightOfUseOfAssetsAndLeaseLiabilities",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term leases term excluded from calculation of ROU and lease liabilities",
        "label": "Short Term Leases Term Excluded From Calculation Of Right Of Use Of Assets And Lease Liabilities",
        "documentation": "Short-term leases term excluded from calculation of right of use of assets and lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Software",
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails2",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentProfitOrLossIncludingSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r112",
      "r137",
      "r201",
      "r206",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r246",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r315",
      "r318",
      "r321",
      "r322",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r788",
      "r791",
      "r792",
      "r799",
      "r837",
      "r1112",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1143",
      "r1144"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails4",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r147",
      "r148",
      "r149",
      "r171",
      "r192",
      "r193",
      "r195",
      "r197",
      "r203",
      "r204",
      "r281",
      "r330",
      "r332",
      "r333",
      "r334",
      "r337",
      "r338",
      "r358",
      "r359",
      "r362",
      "r365",
      "r373",
      "r532",
      "r664",
      "r665",
      "r666",
      "r667",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r697",
      "r718",
      "r737",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r966",
      "r988",
      "r995"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r61",
      "r64",
      "r65",
      "r136",
      "r160",
      "r161",
      "r162",
      "r176",
      "r177",
      "r178",
      "r180",
      "r185",
      "r187",
      "r189",
      "r202",
      "r282",
      "r283",
      "r316",
      "r375",
      "r474",
      "r475",
      "r481",
      "r482",
      "r483",
      "r485",
      "r486",
      "r487",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r504",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r541",
      "r543",
      "r559",
      "r623",
      "r652",
      "r653",
      "r654",
      "r671",
      "r737"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r202",
      "r543",
      "r600",
      "r659",
      "r682",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r697",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r716",
      "r720",
      "r721",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r737",
      "r844"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r202",
      "r247",
      "r543",
      "r600",
      "r659",
      "r682",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r697",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r716",
      "r720",
      "r721",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r737",
      "r844"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r885",
      "r895",
      "r928"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common Stock Options",
        "terseLabel": "Stock Compensation Plan",
        "label": "Share-Based Payment Arrangement [Member]",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of preferred shares to common stock",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r35",
      "r61",
      "r64",
      "r92",
      "r349"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock purchases under the plan (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r60",
      "r61",
      "r92"
     ]
    },
    "fate_StockIssuedDuringPeriodSharesForPrivatePlacement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesForPrivatePlacement",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock during period for private placements (in shares)",
        "label": "Stock Issued During Period Shares For Private Placement",
        "documentation": "Stock issued during period shares for private placement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for license agreements (in shares)",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock issued",
        "terseLabel": "Public offerings of common stock, net of offering costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r60",
      "r61",
      "r92",
      "r664",
      "r737",
      "r764"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon vesting of restricted stock units (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r92"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised",
        "terseLabel": "Exercise of stock options, net of issuance costs (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r60",
      "r61",
      "r92",
      "r416"
     ]
    },
    "fate_StockIssuedDuringPeriodSharesToCollaborativePartner": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesToCollaborativePartner",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of stock to collaboration partner, net of issuance costs (in shares)",
        "label": "Stock Issued During Period Shares To Collaborative Partner",
        "documentation": "Number of stock shares issued to the collaborative partner during the period."
       }
      }
     },
     "auth_ref": []
    },
    "fate_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon cashless warrant exercise (in shares)",
        "label": "Stock Issued During Period Shares Warrants Exercised",
        "documentation": "Stock issued during period, shares, warrants exercised."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock for license agreements",
        "terseLabel": "Issuance of common stock for license agreements",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate purchase price of common stock",
        "terseLabel": "Public offering of common stock, net of offering costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r60",
      "r61",
      "r92",
      "r671",
      "r737",
      "r764",
      "r850"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock awarded grant value",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock units",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r60",
      "r61",
      "r92"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options, net of issuance costs",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r61",
      "r64",
      "r65",
      "r92"
     ]
    },
    "fate_StockIssuedDuringPeriodValueToCollaborativePartner": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "StockIssuedDuringPeriodValueToCollaborativePartner",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of stock to collaboration partner, net of issuance costs",
        "label": "Stock Issued During Period Value To Collaborative Partner",
        "documentation": "Aggregate value of stock issued to the collaborative partner during the period."
       }
      }
     },
     "auth_ref": []
    },
    "fate_StockIssuedDuringPeriodValueWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon cashless warrant exercise",
        "label": "Stock Issued During Period Value Warrants Exercised",
        "documentation": "Stock issued during period, value, warrants exercised."
       }
      }
     },
     "auth_ref": []
    },
    "fate_StockOptionAndIncentivePlan2013Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "StockOptionAndIncentivePlan2013Member",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option And Incentive Plan 2013",
        "label": "Stock Option And Incentive Plan2013 [Member]",
        "documentation": "Represents information pertaining to 2013 Stock Option and Incentive Plan."
       }
      }
     },
     "auth_ref": []
    },
    "fate_StockOptionAndIncentivePlan2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "StockOptionAndIncentivePlan2022Member",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Option And Incentive Plan2022 [Member]",
        "label": "Stock Option And Incentive Plan2022 [Member]",
        "terseLabel": "Awards available under the 2022 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "fate_StockPriceAppreciationMilestonePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "StockPriceAppreciationMilestonePayable",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock price appreciation milestone payable",
        "label": "Stock Price Appreciation Milestone Payable",
        "documentation": "Stock price appreciation milestone payable."
       }
      }
     },
     "auth_ref": []
    },
    "fate_StockPriceAppreciationMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "StockPriceAppreciationMilestones",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock price appreciation milestones",
        "label": "Stock Price Appreciation Milestones",
        "documentation": "Stock price appreciation milestones."
       }
      }
     },
     "auth_ref": []
    },
    "fate_StockPriceAppreciationMilestonesLiabilitiesNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "StockPriceAppreciationMilestonesLiabilitiesNonCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price Appreciation Milestones Liabilities Non Current",
        "documentation": "Stock price appreciation milestones, non current portion.",
        "terseLabel": "Stock price appreciation milestones"
       }
      }
     },
     "auth_ref": []
    },
    "fate_StockPriceAppreciationMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "StockPriceAppreciationMilestonesMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock price appreciation milestones",
        "label": "Stock Price Appreciation Milestones [Member]",
        "documentation": "Stock price appreciation milestone."
       }
      }
     },
     "auth_ref": []
    },
    "fate_StockPriceAppreciationMilestonesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "StockPriceAppreciationMilestonesPolicyTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price Appreciation Milestones",
        "label": "Stock Price Appreciation Milestones Policy [Text Block]",
        "documentation": "Stock price appreciation milestones."
       }
      }
     },
     "auth_ref": []
    },
    "fate_StockPriceDecreasedByTenPercentPerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "StockPriceDecreasedByTenPercentPerShareMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock price decreased by 10% per share",
        "label": "Stock Price Decreased By Ten Percent Per Share [Member]",
        "documentation": "Stock price decreased by ten percent per share."
       }
      }
     },
     "auth_ref": []
    },
    "fate_StockPriceIncreasedByTenPercentPerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "StockPriceIncreasedByTenPercentPerShareMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock price increased by 10% per share",
        "label": "Stock Price Increased By Ten Percent Per Share [Member]",
        "documentation": "Stock price increased by ten percent per share."
       }
      }
     },
     "auth_ref": []
    },
    "fate_StockPurchaseAgreementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "StockPurchaseAgreementAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Purchase Agreement",
        "label": "Stock Purchase Agreement [Axis]",
        "documentation": "Stock purchase agreement axis."
       }
      }
     },
     "auth_ref": []
    },
    "fate_StockPurchaseAgreementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "StockPurchaseAgreementDomain",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Purchase Agreement",
        "label": "Stock Purchase Agreement [Domain]",
        "documentation": "Stock purchase agreement domain."
       }
      }
     },
     "auth_ref": []
    },
    "fate_StockPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "StockPurchaseAgreementMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Purchase Agreement",
        "label": "Stock Purchase Agreement [Member]",
        "documentation": "Stock purchase agreement [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r64",
      "r65",
      "r81",
      "r699",
      "r715",
      "r738",
      "r739",
      "r832",
      "r851",
      "r990",
      "r1023",
      "r1090",
      "r1153"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock and Stockholders\u2019 Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r170",
      "r357",
      "r359",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r369",
      "r370",
      "r372",
      "r375",
      "r503",
      "r740",
      "r741",
      "r768"
     ]
    },
    "fate_Stockpriceappreciationmilestoneincome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "Stockpriceappreciationmilestoneincome",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "StockPriceAppreciationMilestoneIncome",
        "label": "StockPriceAppreciationMilestoneIncome",
        "terseLabel": "Stock price appreciation milestone, income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StraightLineRentAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StraightLineRentAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Straight-line lease expense",
        "label": "Straight Line Rent Adjustments",
        "documentation": "Amount of the adjustment to rental revenues to measure escalating leasing revenues on a straight line basis."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureScheduleOfSubleaseIncomeLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease income",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r831"
     ]
    },
    "fate_SublicenseConsiderationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "SublicenseConsiderationMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublicense Consideration",
        "label": "Sublicense Consideration [Member]",
        "documentation": "Sublicense consideration."
       }
      }
     },
     "auth_ref": []
    },
    "fate_SublicenseConsiderationRepresentsAnAssetUnderAscOtherAssetsAndDeferredCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "SublicenseConsiderationRepresentsAnAssetUnderAscOtherAssetsAndDeferredCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sublicense Consideration Represents an Asset Under ASC, Other Assets and Deferred Costs",
        "documentation": "Sublicense Consideration Represents an Asset Under ASC, Other Assets and Deferred Costs",
        "terseLabel": "Sublicense consideration represents an asset under ASC, other assets and deferred costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r564"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r564"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r564"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r564"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r564"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r565"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforwards",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward",
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "fate_TaxCreditCarryforwardBeginningExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "TaxCreditCarryforwardBeginningExpirationYear",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforward expiration year",
        "label": "Tax Credit Carryforward Beginning Expiration Year",
        "documentation": "Tax credit carryforward beginning expiration year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardLineItems",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Line Items]",
        "label": "Tax Credit Carryforward [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Name",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardTable",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Table]",
        "label": "Tax Credit Carryforward [Table]",
        "documentation": "Disclosure of information about tax credit carryforward available to reduce future taxable income. Includes, but is not limited to, description, amount, expiration date, limitation on use, and related deferred tax asset and valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityByClassOfStockTable",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockBasedCompensationForAllStockAwardsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityWeightedAverageAssumptionsUsedInTheBlackscholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary Equity By Class Of Stock [Table]",
        "label": "Temporary Equity, by Class of Stock [Table]",
        "documentation": "Disclosure of information about equity instrument classified as temporary equity. Includes, but not is limited to, description of share, value, share authorized, issued, and outstanding, redemption price per share, and subscription receivable."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r34"
     ]
    },
    "us-gaap_TemporaryEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityLineItems",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityRestrictedStockUnitActivityUnderAllEquityAndStockOptionPlansDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockBasedCompensationForAllStockAwardsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityStockOptionActivityUnderAllEquityAndStockOptionPlansDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityWeightedAverageAssumptionsUsedInTheBlackscholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock",
        "label": "Temporary Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TenantImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TenantImprovements",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tenant improvements",
        "label": "Tenant Improvements",
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants."
       }
      }
     },
     "auth_ref": [
      "r1109",
      "r1110"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual",
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1004",
      "r1096"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual",
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "fate_TrailingStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "TrailingStockPricePerShare",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ten-trading day trailing average common stock price",
        "label": "Trailing Stock Price Per Share",
        "documentation": "Trailing stock price per share."
       }
      }
     },
     "auth_ref": []
    },
    "fate_TransactionPriceOfAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "TransactionPriceOfAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction price of the agreement",
        "label": "Transaction Price Of Agreement",
        "documentation": "Transaction price of agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureInvestmentDetails3ShortTermInvestmentDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r355",
      "r371",
      "r502",
      "r529",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r624",
      "r819",
      "r821",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r833",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1082",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "us-gaap_TypeOfRevenueExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfRevenueExtensibleList",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentProfitOrLossIncludingSegmentExpensesDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Revenue [Extensible List]",
        "label": "Revenue, Product and Service [Extensible Enumeration]",
        "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureInvestmentDetails3ShortTermInvestmentDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureInvestmentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Treasuries, Commercial paper. Non US government securities and Corporate Debt Securities",
        "terseLabel": "U.S. Treasury debt securities",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r783",
      "r808",
      "r810",
      "r819",
      "r1108"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning unrecognized tax benefits",
        "periodEndLabel": "Ending unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r460",
      "r815"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease related to prior year tax positions",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "terseLabel": "Decrease related to prior year tax positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r815"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase related to current year tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r815"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Increase related to prior year tax positions",
        "terseLabel": "Increase related to prior year tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r815"
     ]
    },
    "fate_UnrecognizedTaxBenefitsResultingInNetOperatingLossAndTaxCreditCarryforward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "UnrecognizedTaxBenefitsResultingInNetOperatingLossAndTaxCreditCarryforward",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefit",
        "label": "Unrecognized Tax Benefits Resulting In Net Operating Loss And Tax Credit Carryforward",
        "documentation": "Represents the amount of an unrecognized tax benefit that is directly related to a position taken in a tax year, which results in a net operating loss and tax credit carryforward."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits that, if recognized, would reduce the effective tax rate",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r815"
     ]
    },
    "fate_UpfrontCashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "UpfrontCashPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront cash payment",
        "label": "Upfront Cash Payment",
        "documentation": "Upfront Cash Payment"
       }
      }
     },
     "auth_ref": []
    },
    "fate_UpfrontFeeAndEquityPremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "UpfrontFeeAndEquityPremiumMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront Fee and Equity Premium",
        "label": "Upfront Fee And Equity Premium [Member]",
        "documentation": "Upfront fee and equity premium."
       }
      }
     },
     "auth_ref": []
    },
    "fate_UpfrontFeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "UpfrontFeeMember",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront Fee",
        "label": "Upfront Fee [Member]",
        "documentation": "Upfront fee."
       }
      }
     },
     "auth_ref": []
    },
    "fate_UpfrontNonRefundableNonCreditablePaymentReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "UpfrontNonRefundableNonCreditablePaymentReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-refundable upfront payments recorded as deferred revenue",
        "label": "Upfront Non Refundable Non Creditable Payment Receivable",
        "documentation": "Upfront non-refundable non-creditable payment receivable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r122",
      "r124",
      "r128",
      "r129"
     ]
    },
    "us-gaap_VariableInterestEntityMeasureOfActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableInterestEntityMeasureOfActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Interest Entity, Measure of Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureLeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease expense",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r831"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetails2",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsDetails2",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_DisclosureCaliforniaInstituteForRegenerativeMedicineAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "fate_WarrantsExerciseTermsDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "WarrantsExerciseTermsDescription",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Terms of exercise",
        "label": "Warrants Exercise Terms Description",
        "documentation": "Warrants exercise terms description."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment, Total",
        "terseLabel": "Weighted-average common shares outstanding",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails3",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares used to compute diluted net loss per share",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r197"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails3",
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares used to compute basic net loss per share",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r197"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "fate_WeightedAveragePreFundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.fatetherapeutics.com/20241231",
     "localname": "WeightedAveragePreFundedWarrants",
     "presentation": [
      "http://www.fatetherapeutics.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average pre-funded warrants",
        "label": "Weighted-average pre-funded warrants",
        "documentation": "Weighted-average pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-8A"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-8B"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-8B"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-3"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "SubTopic": "320",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>96
<FILENAME>0000950170-25-033510-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-033510-xbrl.zip
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M-NJ$P*Z^__?]@P8,UG%S=F$6+.'U;]MWM%2^T^1_CD&JG-VR$)=N'>[AF!K
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MZ8G(#J21 BKV4F/<CU=2V:A=O2=IWV1[[HR;?G<T;HW/G>XI_K8RQJ87I>C
M@#PBB#$9.-:^C QSF$L*PALNJ\W&>$IC\SOT1WLE$E@N%(P9+-%8X,$^!'A!
M4LQEX3F/U?HE]G)KIGS V)T#+$D]*1!Y227]=7#4'P[ZTW]V^_W!I]:#\->_
MOMX"Z/%0NKD4P34&7'[9T?U%B-?U&Y9*(!2QRV(B.[W*-@5X8N181S?G2"Q+
MD6@? 8K"%96KC7JI1)94=<Y7M6!;I [4DE$C(U'.HY-< -UZBZY7+&:H4J"\
M6KI=$5?-0G?+EX!56J-SL%M!%F)S!%TDE0O<.YYT=<>B=X2/_A44TC#W?^L.
M1CD>W:UM5M,M[9VRBD9%C U@.7EI27!)$$M#24R%F&1U*2+UF[:+Y*RYBM56
M9=H^%2E'GEC2C@#BD;A2!FLX(_"AO&C&G8O5:HQ%H VQ1AOWY[)8E#!,$5X$
MT(ZPB3BL;:Z*49P;RZ2OEG:>]G1N@64??=+&:ZX)5BT'4\5A#DH"0T@D 9][
M%GFUOJEUE>IE<VAVC&,7&&:R (2I! 8;*R*BSD8H3:VMMA+%M0S%2[4G1DTW
MCJ8[\7N_"Y)S__?GB3-+5@Z#PPWF;4@A#+&FC:#$N,E BZ;UXLRG%+"39*G%
M\%!@VDEL:Y&4P;X*QF&5'^ FE0Q(\@1JKMK\T&5D^3Z$ KYZ#LKNPF+5B-7
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MCHLT&:)400A%>-MI@AM-/'JED@^ZZ)@ NE2[";=$TSQ*D>]EL43VOB@,Q'#
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MLU#T(@0/1G' ''[)*"66&:PUSYB@QC&PCFK;S17 KH_BMGX2<HD);!U'N ,
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M#A@P9I>J;5_Y39Z[_4$9??8-UDF9_7HIDV9K,%PA/U[@L1CM2$C8E=LD07P
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M'_O>7CX9-*,7G;94\>C/+[HPVF&.P$Z#7O"]WF $&[PHSIQ3_, JZ)_O%NI
M;NE.,OEVLG@DVWJYB[CY[MWOFV\Z>]L?WN\==#[\OK?_^^:[@\[!^P[8!P=@
M!'28Z+S?ZS#U0_JQ\WZG<_!OVYU+IL.YV;"Y=8"7F1/RIJ6?L3S\B^)M52'?
MXDR*G4'3&1WE3ND.@>HZ9]DWG?;H_"X<>-<0;L&!S+I0##>$%JJ)Y%(2ATG
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M<%PP;-M-9I("//BRK$%;NGA28&3RM6GB<.FU^<3P41PT39YU_&PU6--@*O$
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M[9WMO>UW6]LU"M<%V*31.I^8=D1%8#UIN2+ ;XEH5P"T.D&SMXMR\ UW^W$
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MGGU 6RU+P_&,[BG2H*")9# 8?:RB#3*PQZ?E'?.0#FM8YHK/?1YE\(@#G-U
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M^PJ)@)2W'3M %? 5DL225UYV>?G^O6&0A[&<KK$IE78(TW&XD RS'[NOFE@
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M#,=0NT#;#;2E+""$.[;&6M^TTY6&^=%=DZJI$$YN<#9IJ5;A[^X6F&1NTW+
M/&+$2AKG*(H5$<)5R\[4JU2T>H*67\$5KOY8M-ED8Q6T9]A@,H#7ZIJ_A@'Y
M*80X$*>8XQ[RD7=@#-<X)F2S<O\USX9U,^F5XC="@(U\+ZU_'(X,4(O%RN^T
M[^G&;$Z[H.12]1UY6]7J!CXHZ9YTP]9D\%Y>(CK4=QGW0SL=+CDJ%%1J$=&'
MS(5GZ)8&-F6I[OR(_6 +/9NVO5D01XS768JTIN3JH+B0RR^&+$JG4 8M7IBI
M?V+YD\^0^*51+1SW'4>S(BEAM7OG#N$$^46/,'9ZS!C?<4H>.)?E\N75@"=[
M:3Q_^#@S]3KJ6'%HZW-__G_G[_?=]'B.GBC15!>X=LG%@/00J 8:#_[PR^N_
M_OGYX;/3RL,9AU6T *MQPD()<;IGSZ-QEJKD)LK2Q*%:TUIII3C=OL_MU\FY
M'5*-C]OB&MK9M':W,Y684,;$QM\=PLEZM9ME)O61JTH@TQD<MUI7.+#CY=N+
MH7-P(=OEL.F8^\$S[.*5,M9M)8;EDYF6([$QAVTD>39KS&V]^?OY-F<^5)3D
MP1G]<'E^)G#CE_P?+Y%18"-7?9)3((:ET,]*T#(O,Y)?RCV'XPX%'4N!<4@"
MBV9IZ;@8]+Z6A 'O8\/SX+\GL0!R*?\8R#O2>,D"V8_+ +<]T>='#XY#@C#Z
MZ#D5I(D<6V1"%LHE3*S^Y&D6:*86N3*E"# :*>NB2?IE!DXIHD-'H^R@F*_/
MX>II&QIQ:A?+U,/5$QD2VUP1V6QUV-HMNFX+PY<B;8Y9I0"]*H#PM9.0'.IT
M.F1KW2EW#4=EM>)] 8S_.5N>MAZ=;'?H'"=9[_3_UJ^'_5YP%GT,J(\!/68,
M*,JYND+7Y#@A<1]#&/9C)Z13TK:M<H#KCK0L<&!JPT15I:T06:22F8?\;@T;
M;Y81=-X90^=")8O99G>J4F$89C0=6<5[JTR(ID/BJ'$EZ9EV5'V3DND>C2D0
M= 634BXQBD$RH5-=$I.HD*T6:E()74B1 VN_:O2''AE#[04%Z(E@&[/:T P5
MAA@)/]'JQY81)S!\%_K+UM^6/5CT^P"+'O=@T2=OQ&S:M_9@T2=EM?5@4;O?
MUC&VD%[7U11WE(IWLSNEC5I$N'T@B;@;'2"F9'OJG8NS$S]K0WLTVM3(59_@
ML)-220"T %O6V%:"NW,NAL.YA [G,M$XE^SIX5Q:45K.5*7O\*+ .*@2!Q(<
MJ>1D=%#-7G8XW'OY,M@ZO]@[. 8(.)@K0_'K0M&)&@L8N)Y0R$M2,;+R-E15
M+C2."8R!B<$N(85S<?@W@!M/_C;0UCU?AK2SA)1RG[3-W6=)*O689JD)HCNZ
M$U2R53Z_MGA;X78EJV52"AI]I6C5TB7O$K@^G#WW7Z,I*;9&VU(>S$$Z+(NP
M*29*)R#:AR>)!:;D5#K#OD@C\2Y\CT*F96N\;3_>YU>M;G/CIP))QA' L>[5
M01X=<Q&/U4[PSE)/M"5E.#PI:1M>.YJ_89C-A3PA!6NJ'F!NB'80?#4I(BX)
M_##4-**Z6X;!F6;J#_%C@JTW-%80]NT8[HN74>J?M8/G@^#H&7.V[)T^.PBV
M]G?W][:W.29[$PF58Y:F4XX#I@F6]\[A(J"H)T(JJETD01\I+)LJ-'BZYTU8
MD4T(M#F TU61D<I#]X_H*"=UZ8N]^Y&F^N,06AW=32Z.3B!JCDY^_7W[CJB.
M$<*WBC.NWL%%X3RJ0D0W7,%0"_Y*:N,TN)IQW8D_2I@9V*@FU(X(STTXT:>T
M<M[]H\X CI8SXS[;.S<5Q=0R'HZ9ZYU9:?IBMB5"]^[85@I2N0!$A+#.VG"%
MLO PZ0"&2P" /FSU^SE[R2AC8VTUM5:GMJKE$#2+N:&B%^!,D<9*ANYB[8LP
M"R?1M1"6=/(%PJC\%E&\/@3>A\ ?-P1^Y1D>^8QI[]8B2-9Y,$[@T08&!U&B
ML@WD$(!M$V8X?&NQUZ\#"!-$B\]!@*LGP#>:+A(5<:13WFP]FA"9)IO"5)JY
MFT6+W  <HFPB+=,8FZ,,NL,D/NO#5RT>R+T^HH9QLDEZBR>B]W?@B31ZA"?Y
M_G#:P>?0,*\!U_LGM GS9)%P3038B0EMF74&#"0FOA\Y8C?WHGMNIL]=E+M<
M\141\.^9$/GWZL9ZL];&,JK]TG=;@W?1@M7:.@;VG=S*3W'2^54O@ R.QO<)
MB* 6]H5_7-]EZ746SGN2ZMHDK0@4K<0TT;\,C'\#XII83:Y1RY?K*O8,)N"-
MZJ:Q;W7-#?5:-X843R<K*9[L&+XP/Z2#^KBULY O+/IP[__^CX?&=)D91D7B
M57%S!4DK,CA>PQ?U^%T,[,/Y^VWRAQ:S$&R\-,:M#^_/SK>#.!V7>368A/+4
M4TL^:_DU2:)FI2T1H.?YF"LCB<$V!!-<+J+-/"V&-,%YF0_9(S/IYJU?;OY^
MP?$HO_EH@S:67V[2TG5B_4F:I)E=M6J) L#K]#$S$/\)IZ\M1;2$!M#.?@Q)
M$XIJT*2#QOK%A0/K>F IC,MF*) #S.G0A<?<!&F$?<2[A'1@E'_$0# +&QJY
M[F7/?[>'UT@,A R+]D($.J_/4&ZN[K:;!]O$G$G:'/J\"4Q"B!]-ZQ9<Z9TH
MM-=E2P;^,$@>T>F!L10?'(/N3,#S1EI)G- VC0B7:N*0SOJB>HVDM%J;A7#6
M$,][M?QWJ>;5F-Y.<'1X, CV]@YT'&]O[W@0[._N'6M>"9X$)S?S@&R^6 #=
M=?$E6&@/Y4XOCT:"X33?@R-8#XK4(RAQBI2ZHHFK%/_Z$6:: Q2)2B<K_?G^
MI[Y6Y7A6F$_]2L?P@<9"C5AXDV3&3H"ZBY-]O3=.3GAK/-]^>)"-E,N0]LK?
MJJ$MBWG%">O[/O3AG<?9SGI46@Q5+ $O6FMR,ILM-4CND?3,TDT2%SX#)T3W
MQXBI&F.!(4*9&&:45GJ'@2[FE!ATVE2/3?VK)<CIW8"^7G3THN.S1,=$$W5S
MTPI@"<B#A%?#";/P.D1$+/C[;V?#>93/PX*9T;9XQVXW=S)J\I(2]2JFY"7,
MK9?&+0+GT2=Z0+R<+V8I'1)A6Y-4<RV)Y'L<7.(2Q^J&G:G^6/3'XI'Y"26X
M :)[K3P1Y])^SA-0H#<;I3\?K/]$9/@&^3Q%<A=U_['4;)4D0D2:C.CD(S 5
MJ_*CFD<A!X1Z2=%+BD?=VS8"('*"55]8QTQH<<(MMO3N[*7(_:WP&BW*(HOF
M2%63P-A[[F),+#,^J23E6&Y=8M NRI5@)2<=@J,K =>7T3RQ,IJ3OHRF+Z-Y
MBF4TWVL.XX'*2/.._L;2>A[V"9\*!Y/$I2VA5[P,'",V_.@Z&S9)N&N#CURG
MW1@C6T$KS4\3"J4!>IT##<2Q,&%)$RY8G5ZT*4O0[ZS!\J:7V"=X"[9>GH,%
MW,7>]$6QW@>XX+?M8.OM^8?=PV?[SX_W$<$_/ "7Q@WP_YAZ!MJHB1O$5NTI
M@R#YK_VC4]L@U(8F/(L U^SMG^I/="Y'\ZIGV])?T+Q60XQ6E0V!S3>YCF6A
MO%ROL(EP)SW^2PSL$4!G +M<"^3]>9V2G!9K+QCY/TDE@L=\I?&P0I"B&40]
MSOPP=SRCNI-.DLHFXHILP:19;J2MB]\^Y-N@WPTXCRY4&LD2F71ISZ51S":K
MIV%>+C.>J#)SV;!\F4PRD#)M79Z?O;W:1D0*$:"!3J'=8C]$$TZJ;>T=_K3-
MS95 LT=_&\I+&S%:]]#S]U?;/".,S!."."$XGX 5@-%BTD\6+Y[0(LYRK^C;
MT.Z?.VYCT[:3GY:.N*1B8IL9<'X?9/I,3@-.0250[KWCVKD(KZ\-^9(4C=/F
M'@1[^\'6\9Y\Y2UM5SKMG-N]B<BLC9="=%79;/=HA3F0]FS<-=)]B@&V"8;"
M_BI($/[*P^.?^*+]PY\&?('!DNX$_S2=$O0#-*QBI1S"'XWLD;6(DBXQ<?Z&
M<W$,7S5@2J2GIV4FQ2^=]+/8W.H3B9)<8*\^%2V8;W\0K?)0%<Q0.D?;[O78
MOM"XQ1]D A_ VNYV)<M?DN!Y;)C\&9O!LOQ^QZ!:M]&H1VK%F=8$3FNC%9:,
MEBW)8TB*-*Y)(" H;M( X7KWLH;&7Z?[1$5Z]IGR/EKW..?R)<>;<\:[(S'U
M$0WM<?CV#[S>S%J=3KFNM/W\_<9($-05<H-HVPH0*O=O+8T2I'""9C5D/C%+
MM5CI&6A[-I@(^1(11,<*$W%)U<'N<!(N^9H4@T2OCQ;RF55E4SQ>5HE]*JT_
M<H\,2=2U<&,VQ'6AKU->S BHL%,1RF7]:,B2A K1ISK% 2%W16_Q#I=SX.HZ
MV(*M]6F7$VK32_*2_ACTQ^ ;' /89.B<%@95?2&\I!80G[JB)%8[$3= 9PX[
MWO9)^-<_[Q\\/]5MN"+T4P/TDE1(DC(3Z<!0CQ:%Y&"3M/($1VTPIY,)#6<(
M#C(]0DZ2Y'U.M3\K&Z$RV*L*D7GS@XVN)(+-L@';9+J/H+6]ZL:9K3OW2L>G
M<3D!8 %!I%#8=3U3*B3OY^[F=5_+[]VLG%M@$]O1G#1[-B9I,+_>.SPXV=M]
M?GCXK]V=/Q;7?PK"N&C_0V6//CLX6'PZU5FRO>?[]!]_^KF/,+0V7_"HM=</
M[.OF3FJ=T#Z0Q*(6U@GS(^&>Z?(SS:MY]=LK/YI/AR[7#=4TWT5<+LH\2-1B
MEDD;T-_><OQ7_YD6(J-O1M1$KN3(_[.#W9/GQR<2U;6?ZH?V=#2%FR*Z"MS[
MN$O0P&@&(ZS;X^4X3A=HK3*C59P@JKP4*G%?;&R]CLMMO[@#172T[6EQ.;L[
M".B"X12QX<J++97TEJ0%ABQM@O-EP.S^WD\C14;S'#H@4=N-5K#2RY;C*N%M
MF*&MZU^.=Y[;?(&-.9W3YJ9)2:*0'B&&AO2O>*],E.?&E7'0QUZ^?[-=H?1?
MV0-7]D=K/*I]C_3594\G+/R:RUN-OC['V;O"8=ND)>23<;;(HM@=BS!)TE)@
M6X8T1O<JE$]!F>?^\7"IPFR8QI/@;)J! B8XFRO^E^%9'M%_WF(H)JUIHT.F
M8G2BT'R)$[0XV,U4C0VS-IGE#6' @!,^E5MUC*A;THDD-!PT3/.5N/20R-+?
MWHI5)*=.C]@R'(7@OLD^2NLFD;@O+W\[^P6-$UZR;)X%ESE":+^Q(#YS;8=_
MR=)RL>U(FHVFR,?@XH&!SAQLHRA=Y*1KZ+Q?G%T.]W\-MJY,IV=YYJML60@S
M&9EN)LD0G)GG70)'LZT?2[)D?Y<$ZMGYY8?A:_KPZQ("V)$9G57Z(I_K5.]E
M'"?(:W\0,6_N])YZ<!!L(>&J@MWAT;X)CX?N@J-] UNGR2"G:JH?(3KSW2\T
M8>]FRYQ$)VV47^)T5!F,/_Z=HV"K\?@#[^E"ERT+9J9U&PP>W0' <+6.69E^
M;FEX/:CP'F&7(&DZ"[G=F]4GIN>8M:O)!Q7FJ GJJI7)$V^=O<I)00)")9U=
MN2OY4-BT31-R#G72\:!-_9XCK:W1G)=>/*<2/L48;4[6A4JM%MKQO6QQAL=L
M4O'./QB2RX&F17SCL%R8#8"7R(V;).CJNJK'*SXQW^EYCU?L\8I/&J_XE$W@
M-0N#@#\7#P;*A=XV2:&0M \^)SN331P_*FN:DY,H#G+2BEQ#9W26(*Q@:'9E
M+.PMU=BL*YB[$3A?-0]?M0(S!5?-V+M RDP40\ DG*;-%C8V0;20";%EGL8W
M'@VV =E8]:FI%*Q/)U:M*F;+&!-#Q@@M$PW(F J"KP($H&@JU^J =5?Y27#Q
M^_O+JV +G3B2R$R);2D/E4\VY'9+MWD_UJ!-=!I.:6VCK-!A!@D/CKB95<1/
MX$!*JGL'<J^O,@.^+^20_;/FR,\$]B9HCC%)W>E4FLK2KQ=J+ 3&AP/M@/A6
M%,^X99!$,2:9T "Q_?7/)R>[1Z<' 9E)#*_+D? E4[AN1EW!CI*5Z ;AG;^_
M&@2,J!M4$75N36B+6MB)3'IS3B7* 7L2+["]D/W.@8;.9I,MH\>55\ZH: ^!
M[G6%0/=:0J!'Q[LN!'IX?*!#H!L]J]\R-O*-VY9MQ!QL3GSHS#7X_*##%SI8
ME&^2?. 0D973G5$B!'#=!YEX]R#@UE0&H-L9;_DRX2 )Z/I-*KZPD\]SP0S5
M[@,=-%S:7;HH5*.6EVGTNY-OG^&^>U HB=6)%@: V+GS]U/$E<^$EF,6?:T'
M#4\4)IQK+'C%2,4"\7Y_=?LT%.)W)K;6FHQ7"4K]V8#5.[ ]?2;6T7HI#9J?
MH4MI5)M[IPEW]MX)7IIHJ#6T9+/K @0;49/M+G4$]7H61TTE^$ F5\0A9U)B
M8R*7"ZX,V76;O1+U=O4E''2LBP01(9DR':SY/<*'AA<Y2#\]]/ENFSRI- +F
MT:8+E;#P$O"7R=%E\_O,:T=?E/7+E3IRFEWB$C.!;QE*$P)NO*$2C]=]N8+$
M'@)B!9']6AJHGJ?HR Z@CVY]6D-NZXMHD>GG8K^NJ0-Z8MQ[$^/N'_7$N&M,
MTD.)<>\D_:9CP"))ZG[D)'A,YAKGT\)D+G$'TS/"JYYJ:RQ]]S# L\DG<A;.
M%TIG$OAO0Z_HS?2YGY$]E4FK&.FCH:;2<;2HO-]!8 TU)S]Q4/>_6=K/F"R3
M+MQDBZ-/3CRQY,3>;I^=>/(ABDW[UCX[\477V_7'FT?C+%7)392EB8O45YB4
MH4NZU)+'ZCQ2Q2T;F,)NS&XO:<]85TZ MEP\;/&40ZFI?GUQ-@P7W"RII?)X
M+4W*3/1B,!AN,*9<]RU]Y.S'*.P6QO3Q#"2!R;626 *>S/4EWE,']:[O.6,J
MDOOQV]^/V=ZQ:)N.A-(E3@)$^LU"G:T6$4DF3.]UEMXBR5#K;[@?;/W]U?O]
M[6 4<<L9PTGMS\J"6Y(IPU&O.XUI@BKF%75O)9$YA''!\*&]HY/_-<DJ%=XP
M:N/\8N]9L#5+\+_;P>MQK9^C-7?(0Z,EL@.X87>:',U)>IL8@GF30?"Z!6+'
MC=+)DJQ \@@G#/MN(U%%3\SS\^W32GO)R]^&QS_C'VY0TY)W[19^??_:X^MW
MK "29_MD%X.=N(D9>4H^F>U& $02($+5UY[_W_G[?6\>W&UU:ZUZWX=?7O_U
MS\\/GYU6[B43D;=,2RY%F,=M8*S]:)]6FQXT(FP')_YQ]@9;YR?W>Q)B7P0T
M]1-)+](FAT?MO37_,OT6*I&QWDGZTW__<P8Z#AQQ;>8*BXL)_^8EVBVA1C4D
MU_X_)#-&P=9F4\G]G40T;?8HV21W9-N4XMM9)+%;?BH44)X;/J&OX.$5Y49-
MYX 5OW"\<.M*3_WR9A9[_ 95.R1O,JY(0T:$+IKP%;5.$MK(('U(NS^.K+W!
MG51CW 30N&O.B+"]*+J!M"!C6>F(:KJH_75TC^P,E[C1D;;]W?V#X(I,(S#G
M0'Q5FTA!N/*W!%M7EQ_.MX.S)"GIP6\4<_X/VCOE<LN!X]-<ZU_^\IHJ=^TE
MLG1$;NI J%,\!4F:+&;J(1NTW.P=:TC=-ZI-H.&VYB00[U%6>I +_%_@&A*F
M*#(:=#3>INCT]I+:2DYQ"1U R)H3715-A\6&X:TF7F,(P[_4K]^#UX\7RP@/
MA+;E4'I+)^V<0 L6%S-;5\[Q0:"YHESW%&9P4U7U<J5-WJYV<X5H_#4J;4>*
M=LMVK1NMD75V+^CLPD/E OR&HLBB45D8*F4VL!$^%7N/]VBH7^L8E<'*/HXY
M:6W,[>#O#US*&U3GD_S4IE->CGQW?N?XBRWO_B;MM?,P?Q..AN1\_1HFZJ-I
M("YYY&V3AK*^D.X2D_KG'IX8]P:N.F>N[3O+(7(3^>=YE$_3&$X)[P2^\?D1
M[3^RT66M;VCCACKWC&N,N\PYNI8.17X,67K=P_B7W%7J7).A%-!6*4IZZ73O
M'=,F'6H]S'%XS\_>>\1(S=;:@2_ET$ADJ$OU/6*U;EDB7GO-:9>^;R3Z1L9-
MU 6;32%A3!VMW"K=KFH#W4@G;E/ 8(\0;+T+9+C?!3+<;ZNS/ME;I\YZ,V+&
M=V65G_"B'70MVD$;,O39_C=:M/;$U/>[;!N\27_$$!FIT?\)DVJ=NP^4L5 H
MK2.5PW>MSWILPP*M>8IP<B.:L)+Z%SZ"_<.]PZ-G:%V;)M<Y^ & =W!0!'I>
M2SMUMA>8LV7W%-VNW[E&Y5W !;YZ[[3&?* Q_'<BHGP:8'%A6S!27FO*%MMD
MM&R2QR*E,N#&%ZY6P^.5-77!IB.&7-X!N8(UF[-AXO/6B=^VMO%2-TQZX,%3
M Q[L]<"#)V\.;]JW]FT<'GL+G-D@^F& ^'AP\)P$=3U&?JN\N+MA.*TVKM8P
M:"917T'L/^!Z-%.%P642'D]ZE2*]0 :!G&HFUU]D$2DUB12*1\VJQA4/<D30
MTJA;P.XK5'WX9 BUJHQN.J&[*C.@][KAV7M-A/6JJH??QT7*F.(C4_4@;ZCP
M1X>.\]^T"C"1:=,!X(%5#U7T-WW61;@,3MJX&- P._SH@T4<A+U2""*VBE ;
M:DHF^:2<#*VQ3T5A]H8.B#2K5?#<1A6M(T,D+4*3N$47T4::2($F&3V<)]#M
M&)##SL+D/\NY"E[Z.2R,T@>(8WXJ_=*W[=2:A[.QZG7[KK\7&0GWVG<7PSU^
MRX?+-P?^<_M0S&9Y]8==7OUAFU=_=.QY]4<'/>6=E_>^?YW._1RXMC(=(XIU
M046M5*8NB]L<EOO(\E;OYDY0V-:K7UZ_WW8ZZA[N4%_:<6?5PM'^OI1VO/V5
MNV#TM1T=LW1';0=-7T=QAR#Q?$PF'B.9T#,R%$RG$355""2\M_O^[.+]=E"H
M\2Q!U<:RHQZ,"1T43!(#CI/T;*(TRW^S6(OU=JY6&'$ TKG*T;&*;DQ=%6,7
M(Q\KLA,(K,LB8N\J,^$2N8J%AE0U78-W<(E(.%Y60#;K--D2.C4T(1I7.FT-
MA%:,I,5'M?1!M-SPB?-4X21=6/BF(Q6!">PS>NHYI;E!ILK:P^M-XTYPWGF9
M9"5S#] SH%>AY1DH3%3N27?:2ISYI@_\#Y.F3-B7$"VAYT>65^!(Y"B /$_C
M.#0\,?>P3 UYW*S/MB^W[)U -Y$2*7-7*TW/,31]JBBX O227H3*(V2..7'+
MZ6,/D,WOLX\?JKG*F/O34>;7%E(#%>9+%9/41W2*>YN:#E@;:1M^8Z'ERYVP
M@0,G$>/A=7@=&1E<9J2%E=/!A\.]ER^#K?.+O8-CAAW/I993)VDE=$I;-DOS
M*&]H\+PDWT0^R.*2RX6&34N1L'-+SB\._S:@?Y[\;:!3^7P9CKCM@NN';NV-
M6@+G S.J&3@%M73-F7\1A()EYO,<K &)]^=P(L!W.[<D&]0+(?@C3UL5NF.O
M+FCEB95.91L$2@?4O-42"]M,*R"A 47?._J9_]D*1M\[>@ :/2RO6:H8S6DB
M[RW8ZZ\%^^9D TFLJ>(> QH_B;6&(/R:6G= X^+-,"D!1]*5*^ZHLC///^9F
M)N0@&;J)AT AY,"1.%-Z ::.9-2?6#,KO;RM)NY:$+@<!-0($SX$)'&'4B#C
M68VY0U3:DA8="[+;:\(<W[!*!(,L<LWZ5>%3 3)M$HX)AMR8W&S@F,@N"9=:
M$-)$<]7RN!E4P_%)2@AK76[4 I4\[5Y"JZT^##W%9O26%'QIEOOP#U&=MF#&
M]JMKV%"+E*O7&DE,$:42+F;)K!&Z6C:(5B=K.+Q6.DC)8A0#,%+9A2G9@'12
MH!;\Y,;TE?[S;\-X_LSVC]5-ZBLD@I4-_<&CXQ#F'*^FRP+Z"L;SB4?Q,1*7
M8>O-W\\EZQGL#9,RCDD5V6,VJ#8*'71Z;KF'*R2QAW'24F"DIKFK4R9/X*3=
M;-I! QA9="?6!LNT_M+ ]+^^5KFV4BMBU"Z?4U;QTFQ4WM%Q-%62BL?>PJZI
M;*U;]EYE@PFUU!^2!T=4NFV+&BO!%_><G-"#E!&*W0!CC8/U^OAQ8PJI?.!J
M3[%O*DQ1 S2NF%3-5TWCK >FZUTS]M]:FO5VLK3<RP3IL05/'5NPWV,+GGQ^
M9].^]?O$%MR5Y3KJRG(=M6:Y/%;3_</G/T:6ZX'&BFY1\-MROIC1PWJ/LMD%
M2S>;7[_WE8U:.' DXD)WT,49X&.CVU5WFV#&A!X]/]H].#AL1VI*B$SZ0YGP
M\0LT7V*,R!E#*6 ?:7"H;YAH!"CH)$SJ0[>JTE 6@&8FI'E6MK<Z#<#1;? G
M6524GZ)Y.#)!)GY&FGNA'OF+&>'+^@B3-+C'(%O?W?EJ:[FM8-+SD4>F84]P
MGL:QNN:WO)^I4B="0"MQ_GX;B8<;CJR/X4.NA4VZ7RMW._X5/=U_6PWD>4N^
M+T>43P3(TW=)[_MO?BT59*61.>/GS0.^2<ZT%0*M_*8-T,4"_1!PS=;9\.(W
MDE7)?SW;%D"A"*&JM"<EF\:(R\=:);MN!:&+R%O<^Q8D#,0%1)T%#'*@&6TC
MM.O:]BRTFH@\QS78>O=>JDU1_GN;UL:%:E-D$V.$"TQG(_O<K8O?2,:@-1<P
M?(5^*(<;7/YR"P)+HNH:J;]U=;%]2G)L ="##K/IOVW;:6X%QS2H8&OSO(]Y
M/J#OP9=8=57])!ZS-R5)L^* AGS^'B-\Q_^DX>I.$C:>@&2#2-\:D8)5Z, !
MZG:& K6K&P T\[_:.E];ZW_-J%)..B4DDX<HV85"SWCF2-1S:2=]?3DOQ6$+
MWOWJ&+5FLHANUN@U?[TN3D]V!W1<:"<!"_#_D/[^F1R!D[W3ZXNW9_PQ/'N\
MI?X:%Z>':UR]1Y/2]VWN]<8WTALOC=YXFP;?J^IX:50'1%J,LRXR1X=0N<]B
MG3W_+GRR24, -+UW%&QQ,QVE/I)PR^'LZ02SP1C,HDR$\/:@I5^V+O:J^#XZ
M"&P'Q/;NV""ARX3L9+0>&@33,HZ7],8B'#<0 V^YP=]2,AP-G:G[(SA\.U[-
MR&AI">!E4%W5>PWY#)0\S7N88<!C =IX37K&439F 4M?VMY2X$X@..,L!<XT
M9= .QFN3W=@*0/N0.FBU^OU6N$[OT-<V]@'->5L47L+5.M9-HYTANP:JN<K7
M=(>MUP18W=6S?#,":-\S&/Q95YCL64N8[/#9T3IALA]CU?KDRE-+KASTR94G
M?_(V[5N_2G*E=XEZE^BQ7*(/'N_"9OD]']I;7;6TEES5WJK+M/P1TU,/J%B#
MI]!:L=:=8K)H9Q-Z9/_2A6Q7%;"MB-$)+H[S:W2PDD0W'W&(X\K'.4__8:]C
M[D3!/G-.CKRCY7\$,.SR*DR1YWV8GX5J;3[EO@9SJBN;*ZD\E_^[G2GI;DL.
M4YF!(1+%S:;GK8,Q28,9LRRK4;Z;H3/[II=?-U_/58*.UN^,K%93P2:!\_P'
MF<!U4>%A!2CX!*"CFP;2IJ?;LCT-TRZ9#'<=</:[EV_.\VV1L#;BQVT+)W1Q
MQOT_H9;*)/IW"?3]!$6,TN53QZW4HA*ITI$LQF%VH?-],'-[--!#4KM>YP;=
MN@([:C'(MH0O7MX5X&RMA&JBMY_8-MTPA/,H2B>(6H+!&.NCVZS*4NJD6BU#
MY['68@FF4:R#GJ;R+><H,:^OJXED; :(BO$?0O?L@J>V\LH$;5$PQLU7I)WE
MO\OH)HSYH8YL8_]HI9VT1]_6GA48F1Z?^[L@2IG3 2SU3<^.@+3F4G(] !R0
MN:()XEH[T%9O+)_'M]I$J/T&/8/0Z[^^..-)P\Y!V>(E31HYDM<F.(\W7&3E
M=;!U^?9B&_77<:3YD^_5)]1C[];%;JCC1+DHK>]'Q9:@B#Z/S=>I?9TOS[U:
M:2Y%251)FF0Q(V=PS/L2Y;IS%)V>_2\Y6&_>#(*KJ[&,@>1Q%3YF!=$B2XN4
MU@.[;@X46\5OJ.;3I1'L%'.%/!*$>05?-7A(CF'0Z(SJ@%Q<N"T3KA,26]:
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MINZ_?]@%2[/H&N9^=>7NL&*T>)OP33ZPO<L:\<*FB"*NK9?082MAP2L@*T!
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M>6M,B<,[Q7*ARQNG8&MCOT!E<.JZGN.% <6+<-&E6VX @CB@A&-(I=*Y3\Q
MR=.(HX_<(HI+2$8J4=,(VM,W#23*-0C^)UR@#H5<F' 2#H*S$@QH<:29Q<@U
M#CFKH1,:_ FZ_63(?4R1 !!6O%9DD&V\19_$(D<&E0N2A-2/& 9:5 F6C:>H
M$@9MSA#-1++.:V\9CP/_EV>*9T@P-)JA@+Z'EOECDMX.9^GMP'QHQ>#2]#-)
M>N-H/VC_">PB:O1GK,$PC.%E;"L+Q#-?S</AG%<E^]B$8EFO3?,%POA+@=X9
MAQ,UUUO<9EFBA+9]46I;RIX'1LU9(!3L-^,#&ZO01$GN+JW4YE;3BNW3S)Y,
M.I,VI6J4">_#R4 3J';O7VRG:1I'*4ZSF."*@7YLI!^"UP(-\29VS; ^>_1S
MVUDQ_!IF&PD)UYU[1@YCUPL1LE*2QESUSO0VX7@* W7<4-MN$8I,"!@=Y4)J
MV$:7FR7$'?Y39US?(N4P()I6-\?L^N055X<[T&KGBQYC>R RJ51J>3L'[:X:
M9ZI#$<V:QLYD<.56Y@1R#;\YE;/Y3';JT\8QV0VLOVR=2ZE(FT"1D:@:YB2\
ME7"V>B2LN,LPX-!+6 0;I6KV+HOD, "$EVD[.9C:?EIEU_!3\W*$1DS,76;4
M2B F.+9 :G"==K/0XL^8GG211LH:*AY7JT OC+.;13<Z;83/P?7>=\AT3*+I
M5($@Q/'(X/M[J5RS%,=@WBE@(^6 RO*Z&RG%$=^1@V$W<A^2:6!8Y"TP$+3K
MM("=K)2,=%W;LUJ-',71?33M=$\W FY:2F E0;"<II.M0N]#O &J3U%>^'$?
MQJ OW;?>_1X['V0P3$M80]9LUJS(+CRU$[R+N1,:.M;]]<\G^_N[I^^C_&/P
M.@3#3(Z?]O;YISQXKV)3[MP9?^5G[)U*SLC9A5%B&\\&J3%L\$PR4-.Q-#/G
MJ5[#3F2E9!1"YSGI&U1W >E:5DV65@L]EK\?O$Y7--_OM,3NI=(:MJ+84F*.
M'5@[C]\'GT,"@AK3[P>-<8)U*BY/<5C&O:GQ4%/#><]MTMH(?6. [ESM-&,.
M9-UF3N(]S&ZIO-5[6I?:%W>2RX88"#/Q^X+Z]JCEGJ^:[-475O($UI?-Y\@_
MSE,2 F6,X*:F;A:N?/V)_@Q*;\%,^9MU*OI!O&:78ZA>Y#Q9L6E8;=SE1;&S
MKPM4Q-,(P&/"#/*^U5][<[N%!86)9&ON7ZHC\K4C9]M:Z2'/TCD:(,-I%Z<A
M791Q-7A4M041*@ZO594!_N#P@>?B*S9!_MLF'5U#;"R%>[+,N@!0;R!_+[=O
M)N8MIO?/2+O&RR&WU682:][BOEV>,R)-@")UTWP<L^G"U8Z,4)7V#7YR#OMC
MSCWKN4E[0?;4&1EK+$]LXDZ<<0/\ZCBJ#"K[M+"*@1T:>BPY^  (>O@!<9TK
M>++]W8,]W+2_>WC8.PZ^BJY0%1D_T=K^%HSW3XQHIL()&;4259%JO)=1.E<3
MCBF^MR!T3U:1V&!FJ)J*]T5 2_#':)_*!N!^TO'2QX5H/[(J4^O&@9P)ZPCX
M0$8F=[*@TBG:"5:&QIQL67G-6".HBJ6I''!JILP0S\K7BL-PZV(3MJP/>D[_
MBF!U4K-M&)NVB,LLTCW+L>F5 'LLN1C"S)/*+"_-B]R0##=95*W,.S3,M1C4
M7!_<EE4)ZP>773,X6WQQY0"O\!D_\R#OG\A!WG_>'^1J!(#M @F]UZ/MN<P>
MMLS5F#;2(G?'U1UHV6G^V46?E:1AG_L!H$Z+0TK^_3W>L<$-;Y@^,"!F,Z8*
MGG=#NR$>3C-5/S)S<L#"),KGE2.+75Q*88O)*%3-.8$I* \04B:3W)Z "$TC
M##1;&SW#!<:3A9J9EKO@:)H,/:"N;VM(!6NVZ?-5.4];[C/X]W?Z]Y,!J:W!
M_NX>C_)D\.SYWN#H^&!;!WET@-E;"1$G3+/EY0,%I<J?SVM;F9;:)$;A?^BI
M-U$RL)1_M&^$^]W8]C8,[$SZ00.=PQ+("J\Q*1ECR;MV"ET6J[3?8)!F9:QB
M0[3-X-IBZDZ?I[)JGRNRGHG(.MCK1=:=(HL45]/\^)^=X"*D71[\$H<3J;JP
M8HO.C?UUN\/>9=G2W*[.JY2M=O[^\NK=^R$L&O9#V;?2;4,XM\FGN9(0L0?!
MW^200+E^FCBS\*>0Q-8,NK9]5A"GXPIXE@UF@:&9?B5D>$^,HR7>GB:J-^?-
M0L=-!EC!W(ZC'#UKO/-D$S\U)Q3G(U/_+J-,,-?<SM"3@;8;%_\!^D/DB7BX
M+1;]@T[<BBC#FB<R[#Z3TI3EX*0_@'?;#"X[R::[5?O((K8LHCVD_Q $?20(
MSC=1DJ@\+4)F0&B/ Q8=RI&C,L=']TS3=B9+#:;D#SJA.3DK<KD?9:QG2XT_
M[2O%<!(NN!I@KN;88>8:?H6V6+!;O684WG/J?H,.UON\NQ4V^C%"3IE3@632
M."=? EI5JQH+:6J\5FI5E\*MTN17&L.-EOXG^:Z_U)Q<[#T+7H^YLFM1:%R_
ME^6K^'<^XQ!] X;SP?N2SLA6Y?OTIXGA9[]%EU3C5\.!)*Q$1KYRDSN8&;6/
M\U@^(??/WN>0FV]_W:A 3X^Q?>(8V^,>8]MC;'N,[2;;0*;G[K=W&D>JN 5-
M")FI1YH]I;=7'^(POKGZ]?Q\'4=PX2(]M5!$@V713[9(05 IJ))6,-U2[#WM
ME%2@BC(X!*YOTT9@S8Y.$HJZBRF9BE+!Y')UE59H'HUC5RA,NZ(,+].520(
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M= T\3-TEJ'ODN$Y@UP%>SQU&=Q\NY]#+(XLL98C1QBK)I5L5^YY=MX=?/9F
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M[@]P6F)*5F(AF7Y)?H?9MO6N@U^!F_0 E>;5]+Z6QUTI(LM<5@!W^5]"@=D
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M.%X$XD&N'5.%T<*SF*(FJ!/.-3+A02E9DE-FZDZSL\8$HOW(=60NV3M%>#Q
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M/@/C*])="K-.T: &DJ2U=EZ4@"A_$AHY&(\IUTQELWA7D?=6T?QP.A+,5*9
M+K'%9*BM\'.9)U*.?-7#9Q"YK*"PQT2;2%JJA-HD@[O7RU&FC!,@\TKBG5TV
M;K]R=8B]DFO;+J&_)Q=U.\VV_TW1;1!;:C(K\I'>RVP>#S'A+\Z[Q^M0F_LO
M]< IHR""X0.;.UY4-QUMI*7E[O))]3;L._,#Z/W?P,F%R49*0"^;"K);IW!>
MW5W17)=RO/?53[QWAQNE4#$E!UKYZ#Y [OS\-CV3LFUBKR[LJY'KF$MGE89]
MNEV_4]*3\))]0#6JS0HD9QR8H5M5_/QD3*40#\=GM)?I2*07SMFG_CVHDO1
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MRXW$,HI,6?TNQY\>/J%O;4K#5+/K'6V&7*5!M.R@C#(GC%J[- [#Y7KT5;X
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M+*Q">401,&PL 'PQV'1VMG*EI2JZETJ M].$'U]-[.<_'#W)4*!Y=J"J-L7
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M >&G/'DRKG6TKXK>J7&)Q](7,-#%,)2;[2 'MZ1H8EJ0?)9V1P%U..M<57T
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M0N*&35N5HI8R=E>T,-N.3 2-"4S6JP]&X]7UE#R7.E*[QF%?#*&QHCU,2/)
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M%.7(E8@ 7(;3W(*C:M8%+@)?OVIVFL=A<D]L0F28#]I8(=H.[T= OMZ:]DG
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M24%>/'CT\)AEG/??O/]^N9.FR?Z'/ *F"USDO.<>">)RN6$Y8!K?V^(GV@I
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MX]D<W^] A*0N3QBMQEHRW/!I=C4B>XP!A/==QRY2R->^N$(+,+N!O BR$>7
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M8\/<,-J2_]0TOK*[Y-6&>X9['=X]34T-U:)=[<\6)CBBWS(O>5&=A0RF?CB
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M:3<TZ_E-'KO<JD'H-TC\R;<M!MKU$$II&UX\8)9Q7A;MLFCO=]$JNA\3?)@
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MI5,."0[4/XD&9C=K G1V@M8TC\PA(>_3)59J1$]*2*;DD[@3G+<YY3SS;-0
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M9L- M3CGM48KVXXU@^5F\OB1X9O=Y$@[FVR_19+Y/M5<SAW(*A(PBP@:]YY
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MYHE9RHWA68GX!3$_80-3O@-_WT>2,7.(IOV46B++L^.X>(LQ!)$ORGS66 ^
MM\ASS2DU^"T5#WKD@9 T,KZ(,N0:)5R@2RDD/R$O\LTZ-E/M:50XY:CJ*K90
MK(WF,SB+FNB:8 2EB36$N.6""%B0#::_@4"9LU>\6*/8'(M^V[&.+6)'[2P#
M!=HTH)0-9B;/%,<TU/N2CV="H;BI&!J20WG/WRS[9BVR\'+U2UO#+".MTW;:
M0J'<3[,\,Q%:@5\PIU#-"[ZX*B4P3,EEX/*O_O;MA!7JNU^^?/I5,B$%[J:8
M<EN+5@4:8GNG_#*\VT9Y2$WHL3X,U?DD&<,$(;U-Y@WM&Q21UKB4RF*$9H#;
M:&%,H0MF-D+F%@>A'] QA#^+=Y#YPY:-EPN.QPOF9V:]QF9;WK;\@<C(X9+;
MJHZ*D'))L;;L\J$Z!SP^\JT4G#8K^%YUIME?)SVI1N7S!S@"JBER\4#  #03
M^2_("=7GCRBRJMGIT58X75(EGX,>5(7I:,0J\JNTO!C,J94@-/SB8Z.'HZ=]
MC6/'-L? 5L-PFJK&S'2"%ID=J+*V@.<: Q?.9V71'#?C')8T\S&G[<5IBL!.
M4UUBU<)=-J&/R^V)M O:E#"<TVUW56VD/S54YVO//X$. (W';Q>R01:AU&7/
MAG*X89"LG,G))L[=0@85$SDUD^/(U.TX\7T&W&<IS5N3^LD'?-;7.4YF,K6$
M&:H_;Q3F%&=7ET)4=>+7-TBVRPX44K%MN$V9=NC_]'[6#3HNFY8!V+L#O%FP
M$#XD#4^@FB6,2$(,:_627V:_(#" A2,TU/4F!U9LJ3:[+1Q^OL-A;(Q.U4S#
M[>J?-U6MI?CCMU)?]HS+%H9 <"!?DK, 5"P4=$S:Q2K]200R#.^UB)T ZV@3
M_!2E"?'9E7@&&Y+C_<*?K]YE\EF&2BO;VAM%X0IF^TGY4S@38?Q,M%9IIIU*
M$M$'YEDZ]=)S&U <_RDKJ,SXADNZ!%*H#XQ195\2]])6OAP% X9.D"V!>QGC
M>@G9.Q^\/OJ56_*9KQ6^43R^N):>160P7W4>24'%9KR.;\C,NR.$UZ(!,.-G
MVE0> C8"4LV8-#X6G/OA:X)M^)7=S$>?,2*.\]C@DP1R:IOP]&.0KS#D;W+=
M#?7WNX=]9GP 3\4"HN;<%(JT8+X9[32X]4V#FPW3NC$N4JD,*870X0H;9IU;
MBSD6,D57R&'0,^XBL>J H:=3C.@QX"L>/D^D%)(#G5]?@OG%&P4]"#M \EJJ
MW16>2.R+* [8DWJDA,O5_T38G"RP:.M[-QZV=;YOC^;'L8N@2CMNE17K.FAG
M!</R<-H5\H8XN@PCKG8I(*[/T&NKV=*'W3@@V:C@>I711(YI),N%4^_:"K.*
M<T7,P/.T::$]!_='QB.)J=VU73VAZ>Y+9#5^SLS:V4548DZ2<61V/0V'/2.S
M"(5.QRS$S+6CNKYR21 7BZ@HG$7XZ'' 6WCKI@. 3OR,!JYE4RF;.42_I0%*
M.B^B)@$->PSO34*L.LD(S)Z-\?J-%FW81/+K]\RFCJL$07J*1H_[5I!!5IJ\
MR!6W9#0Q'V9Y[0IUWH+QE9@E)^N6ID6XVLVX*R4LIU.5D&)N$()XR>?R%SF9
MVF)M%[FLO0=KO&[T"JH= H;:C1-V)_@RMI(H#&W&)F5$Q%>.%ERNCR6<Q/UC
MPNY<=%N$#I5]5U%*9W9$Y*O0V]U 9-)P$XV@8\RP]K 6AB.#HBJ!-Q:CE7TR
M#TS9.6'1S8>S2<O1^\!@+06W^R8^?>L-KCBYP]G$.I](F<5AA!8P-=MX\#'A
M0GN%Y0[E:Z>EO) D)COE.APFR)GZG2#'4N.K#QY7M<=4(,SE..@N=%6UR2]S
M@'L.M\I57:Y?<T= 17?08-QW#BBN%][VC4]Q=?UD/<"9OJ:@-D:0;SQ4]SZ.
MH[=[6W-[AARW"4)=6>4Z@=M-Z,?F1DA=I!SQCBEAFNF!TWY3KM"F-\<N/,X]
MQWO6[ .&Y/+'O",M6+:'AF7[8L&R+5BV!<OV47LZ=%19.B %B,]T,R19&3F[
MDI/U"*UEDCF92SH5D=*$) @Q!I(4X:GZY7RW]9)_B8N4^19.]HZFL6W(HE=Q
M 2*D6G3[Q'2)NXMS+MCQ%?*Y&%W=E(0_P%=#]*Y-/^[(1[QJQ\' 9"228\Q%
MZ@#&0YLVV?T=?&U24>$NNQ#9A58[[.W6_'00'I<>\ B&Q<UKC/TBVY+>U!V]
MW9)<6=.)\\V+'YZ+_\$E_Q<OGWX5?H%'6MU>8W7UQ?.?]5K3AEJ]W/2^]6&W
MOX'7SF]$*AA<O9 PN'=V<KZ/F@X_#=/AFS1D/O#M^4P#)N!*85#R=:W<D_<W
M.H?"5;+1K(=G;*)W!D<IOC[F78*_-=<C(KPX=, B3SR='>5/:#+)?N)9Q*R@
M%IIX1XNG-C^MB%%"6FC./'<J9^+-=XM,&9K32\S?RON)&#9ATR+9OA2@]*O$
M^W*(J\O5"TT/%31!_K)'C(DI<&?JO;(V.Z>A9T/YHY&17&07:B^$?X.]-T%#
MA5&G:_-@*31P! S)L[<_TN/)Y<4DEXF5J.@.$HV!<[_F@@6![TPZQPO[,=A2
M$G]X';B9PL#$[*6!KX5_E/4HW=AF4P);<;>J7$A#3\HC!PU@"5[:.?M1>X^"
M"N8U>J.:NJ)K^&#1AG$B[';7=J_]:J*=UM]55!WY_"M.%F&V>3Z%*!%1]2$(
M]Z7X,S,3A/3+W?24IIVO.I&E8-YUP)C69S5B^+));=CZE#?I:>9_R<!]M([)
MSS-Y"SE+8GHF\E5T/P''M1FH:?$:&1,:75 3!==<]2BU%?^'M47<X'&S<NAI
MQM4JQE>0 XVE?*;8KP^1P^.S=&9%B@ \BRA2PFBXF:@!=9X@W("-+:>4L#(5
M<?+J)%]2XBZ5$0B2=T2)#@(5U/SDO=V$*2$4[[%M?>N".Q)+#&1:+[&%E+8]
M^7'[=C>/2$>.E,1*!5Z:(>#XYO.%IRFJ"%7E@QK5%>Q6/7AYYY7K^#3$<6AW
M K)-]'BV5OV-L$?\B*48.G%^J> ,EY7R7$DL?O$NP:,??WG^RV.:+EE@+RB5
M1(_R344[Z;I??<O'H,97/RLEPJ,7WWS[\V-AL^O;6I$@3OG&TO7&1UJMA!("
MPI<R+$P,'/DKO*:R$?)ER'=]!0Z$=^:?Y9SY#ES!H1:3P ?30]A,AUGB/ZG1
MP"3\])A+6'BLJVL O^5\-Y%+/OGZU0BQI%R+?O7T:Y]VQ;%>=^RITP/CU<C^
M],GQU*Z)3!?=1)@:]/TJ<2.99P6'^A.<W>NN(B5*:B%;_:.'/WWGW.HYHAVN
M.^>\LO2VPL:,U0%>1D\AS@7\YPN8K4RG$&Z)A+:@F[>6@&\# 0.W2,O9;LV)
M\\S7X 8.8EPP0G"EX-*<#-@&I+=]^O^4FOUDMX@ZSN=KZM2=<GP96S^%E\64
M\"X\FP!%8,X'9Y<X3L?U"%LLL00Q- ]&L1OK:XH0<$ZPQ@Y_F&/5$]?& T6T
MM7Q*.7Y,\I#Y19*T2PQDB<K=;P%$2?S"?/'"E"S,(U)9U5T?!%-G='.P \8G
MD(P5Q(5Y3N?8I!(=VG, MM#+>%;9A!U2HSBTC> ^,PH&Q>PTO<BR-MJB+YD-
M;E3X!UCRXU[:Y<244@&@W]JT"B^:0P\Y/UE>BZ> ,93& B:<E=Z_"%)&['C!
M00%O:= 8;F*\?L[?TEP)*2YCLDAW8M;W%R4L><A?6C);LO<[%T$;9ZIXRL&8
MJ)D2%-47&<^! Q0>O)9Y(+I+7;UVM2P[?+D,-P"7FRZO-N7W*"):(@CV;NP'
M7AP'(:7DI4?D9)&S2.\EXN8DW>2Y)>_?6*";FOC+<TOE)5.-4B^ CY]9IFFB
M+8)SJ%TK1F!D+CX-"#ULR^(B:*:1.9"SKH^@8KTDF-%6UBN0G8Y.>%Z%"]3F
MF!]VTO@#0$K!?\%UV>#+8YE7W2FJG<_+WS&_6=WVSL8^I702*RZ(OJ\]QJ%1
ME7N3R:!?.[]G!;2]*(&T:1U]']B)"42'WD,Z,EL]($BV=A1;H#J"CZZ<PJ P
M^R$-:5B/J/7[K!2W]6VL_N#/2[<];$N[!RY*ZN6C?DIT6M&3Q_][NXG>DO45
M3)2X3XV1&N_B-R[TD:D,S/R^]PKMYM3=/1?VB0,X8#N*V,G)2&?KR&/#":9+
MH\8&/<Z"TP.OQZ'=;E>V4=B7QM2T)P\O'6;P"LN9Z%A:[W6?K@(H4%9#X,[C
MI1">@I=#_AF6M-Q'NR!_R2CL3;D2T^XR8N2B.)-7BK?5]0VVW$><#;/^OIHE
M95=6MV!NCO&<Z.4R\XI:UZ*<MZATW(_]B_^,NUY &YNRT#K!0 ?>!D-/XOE$
MQ*3/4%!:$&\/ O'VY8)X6Q!O#Q'QMIR0RPGY?HR,VH>%YALI7G8$2"FPJZG9
M8/GP?YR7 =CIV9FVB:%@3'U4XT6R]NQ)2I-;)5E *6'%">'9Y%]<B[,]^ 30
M**1SJ- #GAZ%\TH4V]M^IT42=UEU'V35:15/=%J(\4$T+"+RB_AC'BXK7 -P
M>XRCP""NM:R'# [8I<]YB4RKWF+;BVW?KVU+]2;"_^AI0L@"9C&,P.$11#W$
M:6&O[C3Y(&L%G.U]6UEN$DEKS&9JO\85L1C_8OSW:OP*P&;X3I9(,2@MW;1"
MVW.V$2\:G[E)C_M0B3M52CN438]K!4JK.>NK2I%>2JVX#1%IK18DE?1G[V /
M(*) G_07W&#"O<24<=*A@#AWU(M5Q9MF)&R4)4R (-\)E^OT4X&K]GFC"*<P
M%,4W)7GZ"B_G1'.'NGL-=924^K1CHF6\KA=^L)^LDD:%.;Y;0R^$#G?%;%!-
MH"GRL'<DV:62#^*_K]K+U0]()S,<]MP<4-AI3M\@TR<C#^]Y0Z% !6R#^'TY
MQXU%]A6Q"GM0%1:I:BS^P!3_.']SEHDE#F$T$TQO8X;0@AL\19][4UY?<S&;
M^(4-F$THE,H^YMHZ?M_R#O][)^B3@[1!^/<2V"&.C%]0!>81/&!.W_955?9J
M4&PZ?HRP1)A=CCG?^L-N#QL$!9"$J94H<K/:P=>0*-FWAJ/ ,0Z_$;:T,&ZR
M#^Q)Q['30/US1&0>1R8G\U!^D406/GTTIDP+E!U<=$.XA]KZ_N;0"[(2^^+&
M@0O<LM',OR>$_K/$HF^T$-<]S*?(0].<;CQ<WR-UQ,!#3X_<5&D%"<_$17BE
M?#VLKJM;,A!8M)XD!W:-];HE3# N+L%KQ<56WMU@:_SI!M%(3W,[Y_HD5^9L
MP3U[KH7"+*-.F MNAK*L9]/7WH&*2:^;0?CO7'-;=6VC9/S,HIZ+A):RY4=[
MH'^7 @B87@=!5?N1(*Y:5B]T?</C7Z C6.BZS@$)O&U/JI2^=:6,OE7"40++
M7I=Y<Q'P+'C!RY4%SAB8PKS?(2SXS!5DNA;C\T0[M 0$W#C?/I/N-WXCPA6G
M%'VU!>>HZ;.KJ8KA!!IC3DODG0K[BM^E%)#8!^F!#,0G('S2QH0:]E1D%A21
MOV(*"RD")3_7-O#H2.$2/)74?11M.OX#RJ$=A"@;ZBE!M7+8U"_H3&;M)\_M
M?90*-VQ"N4QFSSZ"0PQWP-:3GF(ORI[7'0&6YLA;&8LZT7N?F526O\M:60Q_
M8GA^))U%6B6Q98E=&.DY?K6(4^S<C?2%A3X [T6;/E+V";V:,$?DK>@W3-9$
MLD!U?3+,C*EJ$<07'=NP*-DQ10U5[7=G<,Z&-%HS_,<!RB4SB4]G5D1P\KS
M_&2#N'.V/T/V&J+SMD!LG7]NH$DN$1IJ!2PJ@KK4,PU6-U1U.E1R%L(;_R$E
MVE2PW)4;[K 9U=SSZ/X7[4:$]PCW9.RE@>G6ARG7>. .?]>N_8_A-'G89^L'
M0(/^'%[I%)\7J1.<)=0;^/T1&'[3WB5\GCDRNH@&\!@9VX-\I^_;PK]A@NU
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M(6U9 A:S7LSZ7LS:I-O 1(4?;&+8;7/=>@ZBG>LH$W+MVE#:ALOU*8O)78D
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ME"P@BOSO&V)VT;IIN%S>OI0,%1:6D/WVKKMUFHKLVQI;SN!US+"ISRLKSBT
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M*RYQYI#*=#[+(+:^P5(46DU@H+JP\=Q$Y(I*H**/)&,C:[.\B<WFY#&'AVN
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MK2.9*V85W#&?ZK,G3[[0)/>L 5 ,2#: [L_!#9XK9JZS5D.A.;KI3MJM!\<
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M\GG^&KAP& 0+ %&M?!!1)N8A,7%;]P/ZW_ZRU/8Z?SFM?R\NF01RA=/A=P"
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M_ 68WV4^\H)2:]$Y!UGOD(EIW77)A0NA54LQ99CBLZ2>6BK2*Z*H?:21&Y.
M<D+2 /#*W-+I[C),_>RV*6=^=-TPV)E1,9Q:EDW+[AX<8YJ5&:-BLND40QEX
M<+(+'B;)K'?$-[:0M>C#;7_6?&72LTM,;O!>1J>5=_DYQ'$XPKH>9U;EEWB@
M]7!9.%RNIQ)R%\X)]L19IH!"."!H1#&1OT_HZ++(?#RC%HC@0G5%H+1L:PS.
M[")3FM(MF?1PNLF'A*$S\PU3<(J:G"+2NTY+@?YTPZ>"XRUDT(27EHKTRK
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MK689+(0 WQ&TZY9XLJ-)Q["(^8;O%/0H=V1V([+;B!-\AJ.(3B0 XW*B: H
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M(S$Q3ZB.)4P@ Z$Q(GKD++M5:#$00A-#[!0% (G#9;H;$M76Q%&+2!3@&I@
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MJG[85?US<%.K%-^Z0A]^A5H8M,&@U"!U@N4$Q',C%J WA7,?@T6+5;J2B55
MZ@GS1CP4ED=_EX"'#CX@0#AQ-W+X%MI'J:T)PC=L)FN0:IFIXZ')>3HA#0,K
ML.:>.GK0)<F^%?PT/V,'/GZ#'B(4I!&VD2US884+J#'&\XGA'X@[,MW-KNR?
M8W-*Y<KQ4&!3%12H4*:+U'8!?(A- <_' _99H;T<SL>3'T)@J.ZDT";P&F(J
M=(2"J9RCOMZM=VKW]<CT  H:.3/IIM_XQ&JM#S>U0&[>&D$@$2&P&;07B$+7
M#L>6>L5PDN:(/N.(@*@1-(<QDIE1.%JPP&1=&%UO+)A@.YF!S+"+?X/X(BV
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MW M=P6FP'!3U+6</I5)<0=\2HC=[F95BUEF%QRXB" KT%XUH94A@P@-VIP/
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M/Q:8Y&/Y01V>(;_^0NG,@!8C\'(&L?P8#K;%8_["F?ZGIX=JO]=8O$, W[L
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M=1Y4>R*T;-Z5,;1K$9>F-6;,9%C$C$;Y!0T*DN8X7B((3ZH;G,D.)@V7LJE
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M)"Y'*] D+MQB&06KE$:I3OA?K4?O0E^E@)?WWFY0\V*CU"/;M.,YZ?]'<A-
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MT:S=-MDLJE::\\F9<#B2>GQ*W^8OI(FIG0]>.X#V4DLA*BI39F=./SH8)TC
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M( 7 23V0S#1^SSP'^7"% ,I9S'G>-\B^'_0;$(]">+]9?9I2SZ3F8L+2JAY
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MKFDHLT?1]SN7X\'X>XR/M%U$7VZ)!*IZB$?DZ7*F;RQ+._/Q*4.T2$SK0]R
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M:"WKT?>\JC5=G^M+X<$CUZIKO0 6VT^XKB9=GK;+]17\YE]$BY1"E*V@=X.
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M)<EHU5=W6,MV'?HM_'%QAVI/O&VL[/42P0W3I0Y+R-Y+.]90/O8%0^G=6^1
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M<,T"/\0R#"N&YB'\JFY@"ZF"L[,H\<'TFMQ5[S%$J?&=Z%G"/=6YZ&E6I-K
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M7DF!,>^2FNC\ HTF]W\]JDR?1>,B*:)]'5R&7/H7$N2]6%&"P+VMYDI,+50
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MW2,J;=N'>7RURB^ _YN=G9QG9R<3>#$0#YV=0M0YV\?(:'HZG9[-S\[/'A(
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MFH9<.>7]3G1B//<,[QT9M2\A>]2"636718NTFO1@\"9@2M#50"XIN*(8EWE
M=?R^#+W<?\CY(P3)+5J;1S$,[NDI4SINV\=Y0_X%!XZ.+!PRO &Q.PGG#^K#
MS(E22GH-GOD//_=O6 ZVB.GI9<$:B'(2:$?U^[K#=5B%O\/HC:,\?&+H>= Z
M1TJA2YB<-2XHH6@.Y-4;BQ.[,. K;.-P+QK<3QE.9/)C#2?&6;I_.DT/3V#%
MGZ7GAP?IV?$)_?-XFIZ>G](_C_;3XT/X[7DZA<\=G>^GR70_/3H^3<^GIWP
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MZW]=7-:H/U?>2LQLW.A"7>PQO=@+92C(#F$,;-+%-4M*&-,.\<4/\#:*JL8
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M>%/54-<<')CC6^)GD1PO:W=-M)JA.9]H.+Z\&%=A%P5$C04E_+OU+?;^8-
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M,X[,OIH2VK%HUZP5P+Q9OQVITL=T_IK3!J]ICP .]Y'6O&=O?>_U88OW/?-
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M\E%=M4*&DSE3G%29GJ!;-Z4=:2-.]ER"6\S9K:K&K%:T4R$=3"9OD4YB2<F
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M7OF3OL369M&])R8+^?NI.PQ:4 WLH2Y7*>,IE"7 5$9))Y/@I18(FB2+SB1
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MEMO#*W.Z^I&MM3D&@FVC;?(;OM<X9_4,,VUSM"KI25C#HJIXJ2>D4?6^W:2
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M9I2>97R/]\%FBJ_XHM]7<UZ#<$/Q_<N?S'=<*PARDZ6>97H12\S83F/3MYW
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MQ?\5UMZ[MY(JP4L\" *3^SU5WLGC3-UL/)5)SJGS4PI/FQM9])*29[Q__1<
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M:H2M"//7EB*E<HPHL;8H"7'"LI>8/\ ]P#UD4@PB2//?B>3._I__)0C&WZE
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M1$7WH@Q>P\HX-L4 = (%.B0%>GX=K*JG-'\%!0K* )3!<2D#L*9 &8 R &4
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M V1[<0WRE",R '$ <0!Q '%[@3C&L<Z=#/A4XN"W,:V0\*) JG"B4(7$GFY
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M[A$FA*#@>!"DO:*H*(S-R\+EOGA6.N?+^!I?CE[R<D3R GR,$Y!&P #@.L"
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M*7O?:A#H"; "L *P DQXT$P(J@^X#E0?,.$),B&H/N Z4'W A"?(A*#Z@.M
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ML5$2WY. *2YG 7EB&?U2$Z0]4PC;4I?ADZ6E?#50P:-"Y*.<$L"6XY%AP!;
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M.2MNIEE;CRN;S9EB(,0=O$WP1$H.PE8] H?I"^3OCN;D].A8&7*Y]ZUN@9X
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MH7DN'5$(.YX'_PD[I'.KD>4*"ZR,# _8):@]\M# B,IR)"7$[. \'( =@!V
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M;/D#)7]0M#M,)CL9)2\+RWQN")(84\2\H4AJ7:"\%(HZXK2Q:A=Q\==5\D2
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MNB;AS9R4_0IF_YJET'62E[:+-"70Z)BGW9X%<K*D)&^"%1?I-\K2[DD4M"Z
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M7MK=T5)WZ>9H'*0<A]DX[?;TS[[_F+Z/7U#WU31N8ZB^E7B\I=M*BK.8Q":
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M? \EU"#C>TW!X?@.S#<<WSZ::$V<ZYC66'K44Q6;I(?UVDB[U?[^]S9:ST%
MDR%[=Z+9N[Y0\)L0ZT@,UP]9_@2IL,PR0:-51++HB0B<$L-$08I"FV"BU1FG
MQRCN:.3.FTKL_)X@F&J(H,I/_&,M>MZT8X$WDF:5C.IFR[*;<F0T.Y,Z/V-%
M3RH_AK-YDN0:E,%+9K@7HPR,4[*0,0-Q'AP10AAB!)/$1:.D<E13OX-;?)^Z
MB&^C#+0ZHY*?*3GH@D<ZFGUJ1!B<PR,XAWB/6,&K-C"@?1+,@R5P[Q*M6V,
MG+1 >L)*SON *CQO:X)++AT.H.6,@F5@ M@(C!M"*<UY3D,10GB(:YF&<6Z9
M$N\6H8*#;M"@'V@S\+-,J3.=R7Z8#/<&DAA.\:!8!L5R(BPY*);K%8NC0;M
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M#[KP,I,%#:Z?VCT_8U2<97M+MH>3>I(G=5 -)TC!4V:X%Z,:"DF5E8J33)H
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MC$<MRF\C5WDRE[%2'/SA\;)-6+4B%GTS],AV)7K9$>9N1C:?1JY](-[L;Z#
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M5-M_R/XVV&R<:L1:?KRF>ZM^(3=#,+.F6^  >Z>@=-4]&9H^BGJ)Z7W32R)
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M<XHI;LZ%]UE&HC<11XMKHH3+")6@BZ4WUJBCL'DB>"4PJQJD=PD1]O^8R2K
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M-56KMV'G,;(-XM2&9AG1@.GR&;FK>0<@.EDN3(73@SIC8<95_?QGN!I4M)N
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M8>48SG*.Q2J? <"( HY5V8@"]H<"9/"*B<S !9M E>+!5UXA6E%=,"K;L'&
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MY+=?J<#C3O-%9515$7U79CTH;R-$H004S[TQU?J@-G9,UUB58%F#T#J!$KR
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MB&EK3IJBP/%/"T15=)1GJQ8YOO]C%VK%4'J Q+?3Y>OA47F*C+7^%'5ZCM]
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MOW"%>_HTJ@T:^=-]G@G<"4IDEC&6(6Z910ZV9?[-!V^B#FT'LTU1F&@)4EP
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MN^<K6<[,C'6,Z8 E0<X*AS@)8,9:QU'2D45OE':R-=F1TMS(B1K$I<Y#7F@
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M_1E7S_#N_26O^JX9"O67/P#C_ 1\LR5[XS!>/M[7N]/KN\!^G=H+>?.?P'X
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M?_K$,Y]X&NV#>85O_CWU.N5]VZ<]JR?$M@VXO5%$>V,_,"VPR_G7-VFQ7<G
M+M2Z8SJ'O&LZQVG/K=M.VR<KM@\B_7_5X=L?L\OZ3V[RW9_7;8]#LV]'IWR]
M (L7^7U2RU6H=:#I2D5^/U9^/Z.15)'39>.7C7_"&Y^5C=\1!:WV4IW\H+1.
M>/T>VG81[!9_40=&0OP4A^.K'&CJ3LUX-^IN3[6.O)M,^W#"O4R1>(<9\1BU
M<\EAZU1$Q#J*N*<2:4(HDIQ@+YSRU+5R?B)6EI+@D>5Y#H+V%LZQ'"E&G(]6
MR.CX[?#7(IZU7EJS'NY:1/GV5)Q-:4_03E1G=V5+OH#T.EW0+?*_R/_7(O^%
M),00DA SD2 NB41&YHHY0DE.!_6"T]OR7UM'C P,26-!_@? #$=I0(8);*TF
M@"BM0J'CRG_<T]P4^7_T-OH[++H3ZZ-_.A;=7^(H3NRP-NAL@*,&T]G$YCRW
M(DK/ ]/WZKD["1%SQ(Y@#R9G-WCX*%5ZD1JM,=).&3#M<FZS"PH)S0'9M;+$
MAI8Y*%).E/8(OHZ(\Y!+0.!$I[T4V <=VOG01U4'B.X9M;MJHQN[^2FNX;*?
MNT*L B^%'0N\W&]M4F,5]@ O&EN "@.68TP,*1\<8(L.3K3*;> +3J01B"FJ
M$$\L>R@U1YB;F"(6A$OSTMY&23KA;7R-\/*2,<;U HOZ1@<&L_54^_I^ZP^
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M'FW7@\&.Z"G%"NR4B.7)+,ES[=1F+FC>%;"#/-#"YI%D>4C9>#K(W%_LUJ)
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M#LZ;ZPJR%&3YAR.)L:@32@% A4N-D;-4(8*E#2Q%'O2S1D<?%UE$3S)3D.6
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MK3O=V29.]YUYY5,DBQ;[4J*&I&RK/_T#5)$4M3CQHJ4DX4Y/;$M<JE H #\
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M[X(M1$%6&AI0[X*?+.XGV&AG:D=(#AP4;MAK>=*T)/JI2;_3-.!I9ZO/F2=
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M[E@V0\'OZP:/& L]-H@#_FQXMS7I;Q@N27]50!T%\!0!=5^K(2_6M,DR7Y&
M/0YX]\0*KP<LDK;*H<\OF'O<1D(0VI[+6:@;B6/K3A0:.@L9.H)MQV))$'G\
M63UTA9$@I%;=A+'V_F[*4C!-NV=X2I@*3RX/3'M7;=OK:,$DZ1K2-3O4-4;
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MS>/ M0>&;IEH AC.0/<'"=,C+PQB;Q#9(=M(0[/6;/@XCO(11_GV<,.AA#6
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M@-3J6RA3XGP:9EPYT^"I57G^GP(VPB,HJP9#'T65+K ^!IXQ"'7#"P'+VC[
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M.)6K8AJUZ$C0773"6B9,EPR+S'^^]+<6%7E9ZDR,$C'=TG#B9C,NC@AV/$#
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MDW3H6*:+T9SO7.8$"S'\&>,ZZ#6_N 4#@:3QJI>NCH&XB_*X3@&/9=+T#9:
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MP^Y"L?'Z($MU$=<70\2-MYWL0\8=-["24+<LR] =QW)TQF.NFP,CBKD=&O'
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M5YJJ<:5X\EE: =FCQTAKM%LUY":,V\];=;1RL+R/(W=MP*ER +22M1!7=YI
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MN[+4KDL)8*=E51.&5TX6$GV(/L=/'\+PI#1WB^'-X\#P*SUM]]G/9C3)\IF
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MU8CNE]0'NX/WX%+D]9BV<>TWB<G%O^3:K-."*QK/+]S^;(<Q S776YN>,_L
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M44^\&PG3L21T%?L.?^#K\KO*FLT7Q*.IXIE"*IRT[%JW24RIRZ$^*7S;6+9
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M,>X5*@!)W%@1M^\)$] =?KX7?@5X5MO.TUV4\5/(GZ+HXH6#A31%&%2VG];
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M^?.)E;S$XV6,,=L_6ZAM1[TD 4F>;!5]?&ZVH+2O^!#D58YQ:#QZ6?9N=?:
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M?)##8]/+<I@B04E+V3+A\&)0#B7*O (=7*Y$VC.F__#[^"'0X&#Z5SL+9:3
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M)"%Y //W*J8^CN/*# ^Y>TGQ8BFJ@UTZ%;4!X4RXEN?M%JL5M2/J+-D=M<+
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M['W/L^*O2S@/N\X.*!;G!0*>6'E9H^PWV]ME3_7#2YK3( N?NU]+E21THD6
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MG.'_&J82NT$X[%23'G17;/4J>5#SU'VFG1RSP*&M@?"@BLX/X4S/&IDY%(J
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M3(?CI8[:'I&^=#=MF!;=2S]N1$40MPJ^"YAW_H/((T(?SSK-$ 9%(0)T G=
MO(HK1#P4^43>:/4<::?V29MD3X'EP\\R%ZS4UHRHUCQ096$[W-2^HB^4I1AH
MDU?H7E ZP)R.C.A)*<0:=+&D^G(U]#M)90JSO8IY<MFW8+#J[_#MWUXCD/,
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M;(@J7\N2;GD/<20P"1H=/N .:EI(E'<S(CL<J+ TQH$]QO'^5><\+_''($X
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ML^X!5RV:2-F&%&)**K&#VOA!KNE9K8K%8-2K068XYI_@_P.QCOBE&Y*0E$-
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M+D.0YPNXT02LX4L0,TC\ DJR@%$(0 <,PL_@V']( 7B=[RJ&JP%^W>T^:IK
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M&:.-3VO<96[V[#8B\GLMJ^Y^2AD7 Z0JRXZ,Z4HB>=$B?X4C8J^4;B%Z@YM
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MFQ'=G$L/Y)7<$&[XZ1JPO] @N^&_.?D&+Z41(8Z /((")Z!#:0%Z5T2$\K%
M7M2,\CM1)&M\>LBCTH))2?)TM&'[%?&4$]6G1M7,"*-9: MW??;J\F6UW\0T
MQR#D8OTUIR)JW*T0$J6=I>NS'5"9.XV8N]!I3Y&U)5X&;OF-\VM.B=N\ (=:
M5O-/!;%$NB:1TANH))DZFDA08>7C?Q4_:N:C* :X#YJ$5)8N9O7EX![?5N)D
M+]:8:BC]4,N4L1M18(P8M?U@O^TV&]";CYE -1$I28J%Z%5"-@F>SCA9I]E&
M[& R@Y<QG>O+M74?JW,[,FK;MG#*1;*G"O- 2^1&57E[0_5NAI5$%V1?6)(H
M;";3U">@AQV'V*^,IV!##SK5B?$.:>:=RJXW+0T#W2$=_7+&];$T]T'1_N^/
M__'QXSG9<@O]!83_T4*E54429^2WLX\?/\+__9&(M*LY&) O-"MBV'(LJ:6R
M"MBL4P,@S05]FOW^MUS8'WX'46E^D4/;C_SF?$8^??STG_@"?^1WY[/SCW]H
M>N0W[O'YMC'_.A'H((J+'52F),@&'5WLBL]I\1=:/ 1Q-SQ@WCZX9_)VX@FX
MV@9A"/9##BF\/N"(7*DNMW@IGMCRB6J <"N(\";(*RT(-.)>619SZR&)@YN,
M?\?/<0ZLZA<I/TC[J*-5PITC*/6N!ZNJ0+1@P0B>HJWA^,)8-[!:>-%=6Z&0
M+F,R]N!?LBSRWW-N<UILZ6#9/\I.O9]1:;! 6SGBA[9&.T&K:C#2JSC?IGG
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M=MJB*3.?2^FXL8DE9/OH J<+R)6&)9/A'>K':JK)K[_$S^?VXV\ZBI8B%/?
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MR1-3[(C"J+J.@U=']:3VGDJI)J7]E$MUP_*7Y93O #QO1..@W#F=R2-4L>M
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M&L"O/KPS5Q2J&N%"@_PH>1%O\#-<\QY(]661.#TX+,ZW1K?#(M<V-*)6-0T
M+AS],*))#*_!'\5WO:+A<Q+_8T<]P^BF&T XF0N4HN*U*Z2XD(A %EKF-+1@
M-07^S,^H/(I#@>GI%%>\ILH#I!:]]A+H-1JYO^'VU?_:9,R(D$A^D?_UB822
M;C:Q" +/DTC8)D\T@<PO0P30<:NPVL"-H=1*B6_ 'V>FR0,L1SY.0T(J5TWN
MQSW[XB4^U[."]<33FEH^LDQ[UHH=5,@/W'&YIC"G018"^,@5?:$L19"W&TKS
M)0TI/\([)4,HZ?@=1D8^64-N/V*O*"N%9+*]":NNG+JJP/)&%%C*,9@#](DU
M!M 264Y?ZVJ*6+/VP3[MW19H8,P+ QD:.@YX*>)B5\ %?DGYV8"Y&B_TGG(C
MA=O=74F9,3PH@CT&KDXWBODR=K-$M4M4P^]E0*K101P8#.D@+I,9G%@/#N32
M9/;@;&0?WLTJ*44=3EXJ_LR7JKNKX@S;  OM/R$*G1<707["K<=V^"MI!,1-
M7;.W>.K>E^:E->Y5,Y/C:F'I"]A\?NA9U?9NP.&M^A9^X]JF"5HWTEUC(#I+
MP/MNV1,\#XQ<\W;N;XE=0;2(!H%-M. ?EM.4:0-IC^;E.164HKGB'IF!F WQ
MH+ JD+S;7:F &RU954&4:K$:.8>P:'=57:7 6SU]E]MI>AQRN@FISC^J,NO;
M+;BG:5X +QL6L46F@J2[U:32K '0G6\HA*5!,N.6I&@3*>ZFJZYM.I@6 %I3
MJ@>-S$1I8$1,.X,Y182G293'0@E2/Q5JHO@.3U9=:?Q(%8X_EAJY+T7SJ/MA
M)Y'.9KZUQL!]Z9D:@R4M L!94#EXW3U\=J 9T"="]Z2^_2C!E)=+"#-IB5[<
M>%;I7ULE_$,6O_!''U@0TJYA="D+$#5" Y]\&'^4?(@3^>W^,/7QL"(,NB:T
M"0] ?:%JS'2#4Q^ 6BF450 JM^1(#(1(!5.;]K:Z>-S70^DDUWGXCUV<T5:F
MZV[96T=0IDQ0U?8L9=D$J;!ZSSS3ECM3N427]6:]'2>E5C_S^QTKXBVC<']?
M/=,#&3AN'!YSQB"3+!<@)[@3/&"NU=S.M:JE(KE-L!IJC)H."-T!C #Q+I##
MB5HY$=Z07_R52 \S8/L.E(T>.%4^?T2VD]L@P244#P*-Q.HYHSW0EVMYQ!E_
M6&_]9M4NHRQ/MFX/_:\N-<]Z:,=[&&;<3JK#Q_8139*B %D)&B$4*,UR#^4X
M?2NE JE2CR:,7$]02(HS?)4%B<B77E)PW9[JSU$4Y$8>$0*GH$0CF;HW3:PX
M;9K=Q%E>W"9_VFV"Y)(_%8<!6V5QQQHP$9].,[(&\6=Q<O8,#9!0MD *:&):
M"C);-X@GHV1RFQ"4391PLIJ>;LWY!8?FSZV1<)<& "<GHZFO\R=^O$ ?NYL+
M(!F-(26;:.$3THA9RLP;E?%C5/2K564EZJG*E7:!DN_<]P'E/)2V!/Z4W7ZU
MHW^A0;;ZEIY,^0"MS,B^6*!PUD/MWXQ :X0W-W'M[>_QT\=/OW-;4Z/JJ9'J
MC5^GBS3+;4;W[GN*:D)2L\DV2G3N4U21E;43E^]F]3SYZQTI6JV3T@J7YU."
M](F6G.] )M6D([S$ZA1BAY*G2J6A+-:D-W@.[)5'BN$A!E%9C0UCQC=V/637
M#U\@<3&$^!WF&;@=F]*7M*18M9DF@G*HU^^':.&*T,CK)M&+:I4]<""5;#AN
M$S7'N- JM?R.N?B=/Y!RCY%)IR/ :LKS;:M: 03H++9;.G=<&>1#\9KS^"VS
M/W,,72@H".AZET3H(5=,BYU),Y1$8J@6QZZ#7*&3['NYGJDFSKD1< CD+3^
M\G;]G69AG-/\-A&9 #_3^.FYH-&<?RS!$U5_QZ!=IXN$%.2LEFD:0R+7.G;@
M;#^Z8 YPT?:#)7C!F;J>@+4E.PP(.HIR0G6:R%[KIT3\U4,N'&0<"HS;99S_
M77P/\%/'(]R(M>@D0>Z$5&)-VH"@F:W0$*78$ Z8[W@/T N[N3VURE'* &?R
MAMQ>N>INGA5_E=Q3W7T=4M!H^\I*W?1CGI^,(FK3$!B@+V')R5SV?W8K'[;@
MPZ0-%VBYY .F?&]%)]S:[R,;(ON$Z81?6V:ZL$9;7AE,%W]-P]O.4@<I*-L2
M T:P;X5"&$KGP@J.NB !-!]N0,;YL[J9G#WBU(3V% )MG:AI@)1"42@$[=G(
MZQ*<4MQFG'OT(,6M>+VG7+O(4#E\!:W8*^^.^/MM\ID6HL"KDRF)PL@&6[,(
M-69B&+%!S*\L@&X#\X[]E- Y'P56&@#1D$6=,2.F+7*M!X W)\OJ? "XJ#RQ
M;B 85H:<K]2;SITO&ZI& P_I-4"4EDM&XGD2U1-N#+!-U^Q%U9HB0,9(0D,F
M3@E+QV/=IJ?1J)2HH/;7GO*I3CX2U0:DZL7R!3^T,L">E)?)SREN)K1ZY_V1
MBRZN^'&LX=RZ0]Q*;%<2%'AT/FI46UD-+=[XUU@>!M*MC"3E'^2_QK _1\P!
M/XP\:"TM"*HA(%.UET:KTN";074(Z$,,E.% J,X]5.R5<9W/!H<8[V2+M&OC
MW#(!9\PUP&6^_DP9^Y\D_99\H4&>)C3"$JZ30WXHDX#0L[^#5*+$BGHUISR<
MO2I4NA8,I94D1K=+O?FU4&P2#U#]M4@HE&/WE.&G96.--^'"IZF87(R5$G9+
M/6P"]!.*>O%W.=.VXC= K6.C=::UWJ+64+0"" 7.;^[SZ&\[Q?28+FF8)F',
M*+\R"J@(@/9>I9=!_OR0I2]Q1*.+UZ_\$+Q-= K=/"SB%X$+U ?BE>D/Q&0S
MU2.\QC, )N>_A9\1'W 'YS'?D5.=91CHWOP:1HXU#IKN#%[])>;'!^C0#_!G
MZ!-1G0+CYL-7,8P_6-F:IF\>H<2^/*=9L:+9QJ(#[;YKHM0SP,PNTXQZ\BOT
MIQ2S]5D-I8]83YIT'+BP84_K#5]'2R9*]*0T4I.DM4!V6]1,"9XI7A-ON#N
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MM-,W)>5B8JZ0K+:-%&5/1BE6UH=?":50M:LOIJ5/Q4HX-$_.G?EV]@T%;)D
MUGRT2):0$);%R=-%D,=Y[]4%HCFBV@.?H?7U(=^O;)]@!Z8^#G(=V_F&U2&H
M*RTISWQP-Y0*)>_2Y*EW)"40.AR04K]ZR=D4EQ=4S#NBDL$1$*&+JQVL&\'@
M(K*T;]+L(>.'6T$?6""*G3N9::K2I5H;%&'+$BX6JSVVHEDH&@\E'8TO0C37
M(R)G7O@E13M$-"39<U2*/-0(R<:(;FW2JC<"3<B@47D-R/A2XU+P<5(C;8,5
M6UM\2_A"?HZW. IV5-X0NPG'_-=MFGQ.BXY\50]5@KA0A.L1**]*%5BF?4A5
M5TDH(@4[WB.28)?>Z]"5;3S)&5*JO-.]D)]5.<?#8N>3X17H"_G\K@>MV9"4
MJZBTP,R2$A]D*5M$+DT<O/J*<VY^MJ N=<I6@YP+PC!@XCR<V+,>RJYH1<B:
MB!XEI(P]<%_NL3(> B"FO4SS(N\QD4Y()2AV(MUG]9Y[3X[K3YLJ(G*I%#D0
M+!YHD @-<>,3FH?0NO-];7]A5X\%^[O-)LA>14:]OGQ,63NY3H\H2AO@=JR]
M!!>O\MH.XWV3T7_L:!*^SK_'G0*&EDRBA4Y0)[9''?(+2/3)<%]C\'&#EQ%(
M(A_JB\C'F8:LKEP31Y/_S^]*FJZKX+MPGAES)<WSRR#+7OGF@*AO7685@,\-
M*#S@QKN?38>JZ1U5VOU D*V RRSC#$IY2^U,6&7;_GRSWI[2MC5=T8INMFG&
M3_';S9;OQ0)%/,_W'[*=@+E*1VD.1VENG;2Q[L;[&@+;:7L&&2=GA6J6F'8E
M&/,1]L?[&IT:N&'7(<H1-\!;!41<J!PG 57PQ(V-N&,"HA&+ >/0%CPAG5BS
M.I<^U>F&=*$0+A88PJ$9-T=VFQW#U!C^6+>LF@J>!:QD#5]!^,7Q1_[GPAT#
MU+A&J E.X%_CXQXZI32BHHLS8G42GW<]Q!6BQ,\[B& NUE<QV_'?=L:7LA>5
M:NHLD#2&RF4M B980BTB)5L R8Q$%PR1$[??Q+-3'Q/KV*U1.XK&X/Y5Q]WB
MYZ_H@J<SUO$XL"Y#X.^J7448L* %+E[E'_N\=]<0%VR@A1F2B\HG_-_&/8U*
MF[\EEXIOLW0=%[!M,C1+XR1D.ZQ<5$_X\L@H]N@E#6G\ M/QF1:7W<'>-6MV
MI@5/2156T<+(/((4Y](//GRO4V=MZ9V4'I &:$D3^BU@D-74"3M-B"&0]C4Q
M->2J;24M4JJM/*AV,D>V))#^";FC ;:*[X0A_W&5PJ^LHU0<LR=S"G;FP=9,
MUZ*K K9,=A;L0/CUK'SVBR[_6H>^DNR-YRW?2\X><72A^B"+<?">H&8$K,0$
MRN_XN2F(Q/E5)"Z\ +F^E6:KRW8K<C]V"4!3P[[+]12)()(@U[D)X$Q):[HE
M\O@F3N+-;J-5L]AMK. %=&"R6A_:@QN)XUPI&[Y&?[U\?82)P/O^*R!'W@=)
M(,LGGV/@%LF*U^ODB?\NNF'!J;>@4C,"H=(T1+ E@DT1V1;Y!5ISG&M\ZDXH
ML!(-,7:N'=MRCRQOC96+)M:\7?$.Z#AU5[@V=:; 1@AU!_#%4  ]$2#V(H?U
M7T-YZ, G!P[\"WG@DX8#7P%X6IK(2F#$7Y;*& M@)2P 4G,/B(I(T,DJ'_G7
MW!V3OHW&V&-]#H.RT99;SRF:>2PU50BEL36'J:GF3N4<TNH7]TW-H?+\H85"
M(IA#@V[A&+:BI09^_O2486Q  Q:HT\O<WSK=Y)5\"\?"M6GB76$=;FK# #"C
M8' A5+/61?G=#$@-N\\>&/MS"_8L#\OYX_K;T'GL]6(2W'GZK"IZJ-:'5-/7
M9^CSY[]4W#$B@W/B0V"%9'610V,UD:B']%M(Y%[]VA=AE2LT5A0)Q*-:,9$/
MK,MM1I\!#?9%UOU^IJ(2^%;YF1_ Z<U-@()?N1]W!:;>I0BTDA1<6X8.\1-A
M$LI DZ8KZ.M^Y\JS)KUEU?<'<)3^,".?Q=[ >P2P"\KQ+SM%[%Z!_5'NEW.<
M!L/2\V43,':QR^.$GAQK%I((BB)*ULB[7KIZ^>Q_&R*X%9FZZXAQM#<TYP6^
MZ(!'XB%+0_"<0.TGY#WF.0Q Q/\2KU_YC_,DPH?YCZMGR.'H7-V^WV^A^X,!
M#]TC_N&:/LW0\ZNZ162__%6HR#QGB>H.F5>J9AQ2/4R9R?R17WJ"L$,L#-.I
M53M(:@$M83A!9-99-2V_J.:FK7R5(;22,(]3SV 0$"4@@D$P'(/N64+WE4^+
MWT.ND<"([[03ME;2PW?!N'0@%-!P<5YJY_T,@MHY6\U=13"G\)AQ1%1KKG7_
M^F658<7*J\GHZH.&7DK%_#"P=&D6Q@'C%SMNV_X'V"3DZQ?RE/*7$MPG32ZV
M3-/,( .WH-6$V^F,1RF;\#^^_ =1@L5'GD]0);F4^<QI78Q(;Z@F& ?A^_02
M=E4F-^Y^'%1H*/--?L>7:F9ET4Q")3D[E8!1CE'[0IVZD]!D3R5U11T?U=26
M9^ RV,:\N7D4809KP,3.O6RC(.ZT*G4C*C\TL\F%O1!1>U2]R3DDVR364,B$
MR.4>5NKW,B+[_$6A')E@_R+QQ4!M991E%%TC&[@>_A.[#OFR(C,!K&M)'Y=;
ME=O=*AETFV@X!%;#8&I**CEA5:@,B1Q@QV+3 72W3GQLZG<M,2@?[.9^@"'1
M+0KV-MGFS&<M/>09!ODSOQR_Q!&0DP%%V6UR$R=\F<(M/2SB%U'R<.*UJY0[
MHL220,N=OH9RIL$9B*">JBF(7WY -KJ8S[?1W;3HX6K=5R:9E:I5B0U??X<K
M14Z1BJ [^X_DOE&I$8^:[\=+@L0DALN0"54&RUL>R<B'2=WT>\P,+25_UA)!
M5&\%5XA;-QGO'M]<[O._A^&=\-9TND-*>>3^R_]<7A(IT0]^9&^J5%U[@ZBD
M$4W2C"^/Y$?M4BF7#G;W87Q.>9_ C]'HM9FD>G(MVBZFUQDQ;<P(*OW%VR2V
MU)O5"LUD"9CQ3F/,I:,E\:8R-$A92;EAP23WCC^38I@QLK^$*YJD&VY7%6GV
MWTYWJIO53?Q"%PG]$G_O_@$C;<+(^RN7X@U9$1!%N"S"A?DY&+IWOW(BX(C[
M0S._>$6DETL6Y'E75"Z41%#49/K/:EWWA;O%)YQBY# ,V)_Y,9)',7(*=?]H
M+P,6K],LB8.)*:'#7N!7#S#2"P19MF!OQ^H23HS%FE^*<6TL'HL@3N Z?OU=
MP+]RZ\(!*"LV>Y:NSW80VA3 ]ZEL&VCMJ&Q=A$"Q9"=]9/$3[A[./SN/@\(J
MX\';%*!49&$-Q[4]'!6WOS\P6+T;->$"7J4;WMWIHAWVIQ/;HP[Y1<CT#XT'
M2@I?@*HS[N9;UO)(H 1.2:>&]?<^--(7MP:4.Z/A?,(:'@3S:U#34^D\WK0>
M#WO?'M]<#*0#\;=)D<5)'H>"=+8SPDH/+KG6XJW"*MZ:664>6@=%?>.Q['A*
M4V3O3K:#89 B18/PDS_N>+].BL&5O&;:AQ+9(L>O!"OU?X%APRGUOW(5;YD'
M?Y?SVV3+%_<=\ /_IONU\$O\E,3K.(0BPJ])^@@Q?TD0!\V0#]@0^8WSW,D>
M]5.^'XLM3 B=$:F-/^*LTKVGXG%<4C!NU1\A4_B\&UR,%*>+1#4\G+@3^L"1
M<:VPG-L:F$'-YVQ&0]S[7"+-J(0> -O+YDFT6/,OBL(1* C"NSMOI&S,=!?2
MB18_*:W8$0KY<=+VK5GEG%C2+610@7D76Y4M?-T6<ET:@,8,_5JI& :JNN&V
M4/7+<YH593J_^Z# R)7()E^"B7>==&+"QD9$04(I2VHC6T*C#&W):>K*;#4K
M)(9$-:&*4;$1<NV. ]BMKC4$!-[.665JS<3*RE.<6YAE]P4H.VZ[@-NHN'Z!
M1=8308P22H34R6C!6A3P4@Q6JH>Q+XX/7%(?12%E>KNM%S=WC\J4EI@DX;-\
M"2!X0MHTN$:TR\/RBGCEJFTHOH::YRKNM86('?UM)_8P5:1]JF5Z>7L4_\&,
M_,CM %V*+5$M=2_0(N"]>*^C5:K,Z'?(?#*0##%RS>#R3S TX(W?3T_B(3]=
M# /7K)S9(R@[;Y/W%Y?PK[#<:Z[7:QH6%K #^/67X#,N]V2FF%WY$FF( 32'
M .8;R.T?JOI>0OOGBTP0;Q04"V*V_%<Q?%>NX %UPP");9HF5MN.X0*KH,K\
M+(7/N4\D[*T0.0T-6*7S4IIW<.N.\] $:UU5Q6?<S0D(W^<T$0"Y!_'WEBEC
M-X(RK!<BC+V0ALAW\<4'W\7$A]9[E%-KU>#!;9Y*?_G!%ENC'EN3!-R=9'LM
M*JJ ;MOBA=R(1)@(PI8&T!$M.P"QXQL%^ X?@SQV#TS<ZP#(M64)G=GS:@1/
M2RU[8S^LF\^["?^V-)2UL ^[</X16YRT-R>B1BDQ '6)O71?NV(Q @7$W=TW
MC=RX7450SQ.P1'==;%_Y&?K*9>@.A V"5OJ0 J=Y;%?>:]S2CM2';1BE6]6D
M77"OX4J'0;'M=1A8TPC89H-NS09CN']'(W T7NV!M7!,Q&2>A27E@RQ47>4_
M'NBM?.+_@J> ;HLS,77R]766;FPLRQ:\7W&3021+%H>O>BK2M[^+X_Q_!U)4
M0W((>"EAGZJJ6.&XMG4[XO%!U2F58L!@WRFXQJ89JC\UCLYW+,XV'[.QOW39
M7N,XN&QP%$.ZW_3=-S;'O3G\-UQSMDIP'?"1+Q4X8^U3/NJMX97[NN7_2 0>
MB%A^-4WJCXQBX4%TQ_@"H):N:9'5GQJT\XT^ZHL4/OCU5<POXT6:Y8L7_G?P
M7.A0O:W9B2)&,6?\L@7@?/2*BO_>)G6>OZ99/.:]42@((>_/P8:*(J,F5<I/
M#+\!? EC!/N-PTJR6FT?:'UR>"6J\/>+]4-&;X!_*_H9[>,BKZESQ#NC6%(M
MH4#]:WF47-"$KN-B7MS0B&8! PMLQ[>"5_,^U[;EX^JO@5$,6>WL5;\076T^
M)_:^,OP2W\?^L$I+-R)@(DN:/N WBQA4;0-YSZU@;O8"=3PWH/Z_>'N91J5)
MW/_D\'-7B:\<WIL.O3!2&T8'MQ?9E]UCJ/YE!]G3[%3KYD3AP\_^7@CO;I_N
M/AFCV(D;T^";]M_V?/FA56C$])$ /C5@'Y.+U:3DB:)&,0SZBBZ.1P#C,/=W
M66H?+9*EBB?R!SZGB0XO7D!T<=5FW_<F?"0'%A@- B0^!D!>_@5?PFTE>VT_
MN?:^,OPF9K!>X#8=<\L/MMLE?>)6H=AV[FD4AW'2ZMI\HX!1+/KKS9:EKY1*
MQH-F;YY..$#'78Y!-?OO$(SZG!9_H048V$\)>(",)/%2-36CZ2,9K#.CF I5
M>*O+]"3=3^-0M3X\"E7VI?G"_6./S_3(5T>A9E??MPQ^P+:^#PG5A=O]R*:'
MWY;=@2GL);_5E;"7AI0"XN]UNW5<_1O%=Z'])?-=\9S"'6>_QW#?\\.OP(.\
MK76ZUH:PYYMEC&(F]SE4^+VTX'L$6/;P%"[J'S.^33>'2T\0-(XAJ%Y;6K?C
MO(K#,G37+6Q'_>.?8KY_9.'S*Z(ZM 65CGMS\+O(?!?%19K!;E&]<UA_&M=<
M6% =G]J]!7L>'X4Z)]L?=WN3*CI+'?ZX*.>UM(6<&Y\:Q<P" 6,A"1A7O*7V
M8[OYR>%G8!X^Q_Q[$2$O/%+0EIUO^9TB%*$?G:E6FYBWO#R\JG? ;DK+^#&0
MQ@ L7>*$K2EX^)7AU:I'PRMXJ>A LU%18YI_IO7/[%1!PP^![3#<;<HW@I]2
MQN<.\%@A('E>T_H-[XYBR^&6_V5&^7E]&639ZUJ4X>R_,AQX911J-7UI>6-,
MZ+@W1J&4"%+A785_.G#[Y!VE2<B_&Y/:ME?)MTD8A=*2-_A+P (@5965ATW*
M-3\Y_'8B=O:;-+O<;78,KZ&JU'KQ+:%9_AQOZPDD1[PTBOG1&][^H I&46S
M/C2NRTDA>Y>NBW:&7QO\E$C!M*'1SW'Q;+DJTD01(;>$/(Y^<U E\ZSXZT.6
M1KNP6"@BZ>K%M^V9<2SO.(D+ON9>(%FGX!\@Y ((\^7B]3[X&_] %6M#XZH]
M_O51J'M%C:W-?V:"MS&);"[%Y@RGP^^-0L&3?<;X/^ -YIL,&K(YWZ)#J)MY
M:H\2]-W0\!O6)?C8(O[3ZEO:&HRM/C**F;>&/A<A?JNX:<5_R@,DYVC8<$\4
M,?QLH7N7[ZO"[8ME2T73(7OPX5',H(Y1@VN@?98:'AM?2IL%'9.E(=P]<GY
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M%O^&4HBV@G0@Z?$UMP9 @HMP?8-BJ)91/@8GN5KD18'!/F>'#L(A@F;:N*%
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MI:'NMRW2UQZ;1)3'T.U#@PLY3S'9_60U)9J/5KF[D9GS?.Z*(QB9?T?R5%_
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MJ I2L!1V=2G3"0!5!5,I%.O@.X&B@M;2L+]PA&:W<>/YZN1)UFT,N;>'/KU
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M$X4?*$[AT=USN:;7-%K]!AG[X;^[*," )% =-3U.)XLJ5'T59@]M-=*<O8?
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MGA!N90;(\-9#!MT$T;.?S ^1;3 B\,%QO"A?#$F Q(?(Q1@36>$X8M3I0ST
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MQ8>'/.#O4#[)%"]9QFP>S!NE>Q\EG"OD(WS+ @$_X8S4S?^+UZB,CB IN6&
MRJ )P0,@G&#,M*YB2C?D<4RV<9;$U3_W<9R\48C_^<^;:[$JH#11-Z_8T:B:
MK\__MPIZ$7 )SE!CKS@>IG+WFN/LI3)1G\Q7E&^3X#Y^0UE.JV)AA*71(8PW
MY>?W\2/*R^8-G$=U^#IF" *+E"2XD>A#-$PLPSRE&Q8E)94!B^AGFSN4DK+8
M2QJ+=OM.?A-1MV2&_D>P;#"C@$SN6$.L(/O-]Y6907^P"87C/LL*%-P4*2F!
M@-(P"6A<8G:7I%V?+5<)&;*&9AB^1%Z0Y4D\X ;)IN@^^RQ+,.WCBTJB%%KQ
MD'*!6WTR!",B/FP?'2-;Y:;#]G"[!07Z)/RS%Q7H$7VGG_ S?U7F:J:H5I#"
M,J;H:^&2OFDU6;/H:N@2NN_$!J^\P3^Q]I&5^)0#,6(5FZ6H?82"C 2$DYT1
M99 4]1)RV(&3-1]2PTY+26.Y%IZ&:+AV$803%UPI(,?605AA(XD')1'<5!F8
M*_2&XJ++GO2MJQG6KV&$Z&M5?;DJ+$KS;)92ILEA]%4K\#ZQ@$B%;BQ\D\CN
M N^2>QT4)T^CGJ_0OFP:DRUBNHF2XV0^;<E4=Y,[8OXZR7H*BO;EM4NO29I7
M9;3PTUV\/C VRI9D529:] [06U#FZ/1)JLSA(5TI,9;Q_X(7[YWK+1B^DC6P
MQ<R#-THS336?-+:OY0ZA[&AQ8Q'7P!5T:YDM359@.V0/U/X@$J(3^JR83$=I
M'@B9J>E OD&O*I)2;XKAEYF)X?X@_1=I'>8/2981L;?40*HVDYQ;PQUNKR<$
M><OPRTWJ5WJD%F,9^E-1(.>H)9,F$CEK':0A&V*&PTAO&[W,1) \)3FI$NM%
M)Y=53;P<YC%F(=W0X"'$:=5@7/67W2'.QF5SIJ:='I,XDXA$ZTU%38UFMRL4
ME.5EE[$2SSQ[33.NKT<BC1^;'>-?R@:^Y)?JB\6G-F*5J>@PC@LOZM.*+O5Y
MU/K:8<>+9_LD/HKA^5V2<G2N)R]D2IR#U]!M]Z/I)"D6(ZE]L4OW3#N?9(H)
MC\*>6'^\/=9;B>4:XV)W_-:P:E#,<2-()QH)N")?NFA\:1-'O+NL.'.B\\^.
M7>H/B_S."U/ZZ1!J8"_@;%% $R4=V(4!]55"@%PC2=[S2%3RX-B20I"Z[PCP
MK*)M9T/O2'DUA9)&XS+-ZBX5O'("H-$BO1G"L@-'XAB<$>\(3G@7Q@129G./
MU)-RVIVPV,GXCB)#J=9+S3KD:?^@T2!E(J*B '7')_7D=4>0P>,>6K'A/-NP
MWQ1MVA*NPES\5F&^H?*(([@1E0XVA1SG;\F@W,7Z79$EZ8-&QJ51K7HU@.;5
MD*2J.X(/$9?0B1!'.(-:=7!91G_+"*0@ICN"$A&M:,:)(^0B$;>&UHGJVCCZ
MU0M 8T/I\B@4-VB7]Q8^Q([@0W1S="+$C6LSHBJW[E+"1Q&&K2-"1I[XEC6\
M3J)Z%J>6O\(R#H[@@76[="+"C5NEH-4H55?J-%>0U\5P%"D*]*]$(XZCX8Q*
MNS5B6%4_'$6':=]PTP[=JDX"N8V&6:^>:@441S$TS$7!J['B,/ BJW.[1HNC
M0(XS&DI*Q#B*B_/T7H7"-)#Q D2Q4=(L(>-Q*G&E45C(471,(J[P"B"9P-EG
M)T06E3I,CF)G;$2%XV"/>\,5"TTYBI/SWG)N62O(V #R@G?<KI Q-IEIH5F*
MS%&$3!5X/J(2F@F,_N3.6SZBY)JC&!OVOLN*N#F*A'&O/;]BG*-HT// ,XK5
M0<8'D"=>$HH'&8.V]='A]0A-8/./[KQNTN*'CN)GV%LVH, B9'P X5]2!SMD
M' *0T?GE,$T@[D_S(CZ%J$/(6(1 ?FK%3$U@\<_SHD5^9B]DY-F6X0;7IC6!
MS+_,BQ*5XO8AX]$V48XI-VP"GW^=%UT*4KDA8P_ *ZU:#=H$&O_;?33*RU,;
M<?O/)4Q13_EL(RB>2VB%6M5N(RB<D;]+M4JX$3S.QJJJLVZY$4S/P/HSI$ZZ
M$1S.R(0QJBR[$:3.0"GG%GTW@K"Y*(Q#J],;0>8,]!U1J7PC.)N+<J-6T-](
MN-0,M!RU!@)&L#=7!<84M<U 6Y&W83""N1GH)ZK]'XS@;RY:QZC.%$8P.@,=
MY)P.&49P.@,51+%/AQ'TS44A.:^%B!'4SD4].;^#B1'TSD63&=,\Q4B0[ ST
M&@-=7(R@>BY*T/"F,4;0.1<=Z5;6O\8(]F:@)PWIK6,$AW/1E50[_AA!XES4
M(]XUYK0A4L/EWW_LH!)__V^-CQF?MC"-WG.:M73<;0N5W[]__SW9.C$S>'M:
M@B3[/;XN/QY[+/V8>^])G.P./U(,K_!_?KT),W).18I:*048@]ULB^P&Y5X8
M99]^L-=.6_]Y1]VFVQJ_PEJG47,!<1UT&?@B:T@;F:;4P<C054QUZVT4AVGM
MDS=*+]JS-&^@'/]V0K>LMT6U3^ZP23<Z.+VTL7OUN=9(7MA(H4/8[+&:R9=;
M=:-/P[RAVCMJ[G9)3"6JKT64A_L(?6)MASG.U.5N%*H47.[3*,W[P&P,"T#Q
MAI7^U=^/8+0Q_#2K;8@PU!@'MFWZI1OEA^Q&:3ZOFB4K@$;)I8.8*C(^>!NI
M610%N_0K ( \VU8HMOCI>+E/;0^7X8+M,RVL.V'-GKFXR$0:C^/5_/1=QDN)
M0\-!IW/P'GR^> \NW@-7O <7,_849FQXMN"SKU#M&+Z/]T6>_;_"(U6"*?G>
MQ^LDW95L\C6C>7^<ZS%P$<WHK[]]D67%CKY&V2K,?KO#1'!/CA^_82L\D&D-
M5Y\\P:Y)@+V?H^#GA-1M)I[[0?OF39]PYR\HW0W>;SG)WBM2UT3B<?_3@(O5
M^V+UOIAX+V9,!XPH%S/F2%8V5"2ZF*/X%H0!LMG%$#,,C5QA\5+2?!PB*]GU
M4D]9+.@UI.49& .]*,0L/0Z]^SC#7+[(T5V2KM &Q:C$T5<4A#Y&R.*[EP:5
M:7"L99!G/R!+ES41^M];[XMGTANUA&X+B-+7LRQL@Z=;4Q-)D0JRE[20Q!\R
M!@+9--=\)AWN.@!U:_E)K9GL<M4]PR5SF(V-9MSF#OW=,L;JMC.]W&$VL(S1
M<_C.MZ@R1EU,Z[,QK;?O,]Y&Z8A\(EO!9TXD7CYIJ$^VQMY^]M*0)@7CO0B>
ME-XP$!L6<F+&0!<W??;#P8O65Q8\^?0]> T34E_-$&[?D8]W$-S@C[A"'GNT
M[H<COPTWVQQ?\4<A_ICC)F1@+]^3\0RL/5GSKK]@;3"G!\;:5N/3*;%%HG;.
MP%=GNFZ:"],LQWKE:Y%F9:C:CCR0M,C#RQ9Q<:DT;T(LWR5%.A[)G=F:]WVJ
M]T1Q5&>']_?(&6GAS*NOQGSY$;WG+]]1A+ER$N=;IAI_YHK6'MB')-X0\QFA
M#?(OYWGM#3-BADA2BL;[^!_%SHN/A:Y>\,L><=\EX23-NWPLR.58KIOGS*0&
M]L I=G.J5O-M3TO%XK>:5%M:<_G8F&6FA>0*\Z=@&5\GNWV$RFU<HS3',M[R
M6.:P63UN,(C#UM<,^XD--ZIDE1(7Y2 L>*1S@!A]FGXBVFPI:-;R5# #"1?0
M_4;1]FXOR4N*O%)&6F147KHO4?N8Y/0CA/_^D'A=163<&M8.JEG0]^1X2%*>
M'LL?K_LE"(+2$5&2\N+-"Z/JU;PK:/FHLKT"CYT-FN]<4- Y7H=3;,80FS_H
MD .E!$6^^;]=UI]GKG8$ Y6UPP *:DN**ZC@Q'6)C/J=/I4L>SIHX'6U@&:9
M[D$#?HGF&Q1D(//*U80PP'X/&B5*3P3/F-_DCBQ3M".0BYZ&<: [\B28BFX=
M[@. C"9IV.O82)%9!K/J$\$Y#AA'HU('RAE,3X^CH&M]7#N^)<@H,<XXINL:
M/P&5:&$<3?^>XW'7>FY+U[<(&2E&[XM(UX>,%-,W1LV_ZWCHO9:[U/4@0\;)
M)%>IKQM!1HGIB\1SXCN:=C$9<Q$%$IC W035\<_%'3_ZP 1")NC\I=$O(PR"
M,(&>"3I[:4$/)_K"!$HFZ,AE#B6R$! 3")N@Q]84"!L8:6)$$77%A"4/7#&"
M'@<4]3'!,$9PY8J*-CSTQ@BZ'!#$%<)WC*#&%7E\6/20^UG0]_$;9BG-XH?6
M:A^>:J(TL?[L1>@92R 8S2&2%C<<MH;5*,?3AKI;%94C5)FI.:#N>9ND5+DZ
MT<I7+R<[.)1\=T4J"> 7*67&F@Z9;NU KKS(BWWTO$4H?R#?0/@9/RF/.QP4
M ,)\-\&$.0!A*GGO*<52:QB0PB%QAHB?<DDX+^U(RFZZI3S-7H<E4@!DC=*3
MUQ4_<\OU71ACY(9>=!)!,U*6.V-_)#PHK5]A#5'?GHD4B9_-PXD%"QNM"2;8
M*_O91ZR T_%&7XA5[2M,\2&U5_4V9H:XJT^V=LRULMOH1<X\+,9 :YNF//UE
MZ\4O:+?'^E1ZN-]AMI\2!#\D6286WC@ GKDH4!EWA;PH_ \*ON [0J 8)>[V
M%K'-5./-B0Q)DP+?3PLO>DP6491\)Y**F,O*IX,D[>L4Z]>4%A$QA2:;F!S*
M?7SKI3&&*6M^OHS;1_H/%'59U"1?Z5SBSEE:<M>H*-4]'0VM/!M)PQ5>T)A2
MBEV7Z;Y-XA%I:(Y@0A3+K@<5SL>VJ^OC)PN\BE[L.#I,J!Y-BA*IEY!1IUSU
M>H#9LU65F:>Q0D:*&N^5*..MCFA:J<\1U(F8M27<F>7N$R8;3"$D40,$9#R9
MYEU\B<+1D&IM>@C+PN-H=*PVG)QK0'(TDG8BW;9O<W(T>E8;OM3-5HZ&U4YR
M,\^W?\TQCL1>$\U+((GE0)*SP5IA6DI#TIGCVLNV6&@G_]S^N\ L*B(DQOZK
MT!5[UI+6$/$UB='AJY?^AG(2?B8&D3-8L^>Q+^^3K',J[;-\C:+A%KV+QTT1
M=4_@_F8,!++I:XS%#7XT_D-5"B%=*$R<(U"&&C]<HLH<BRIC<W;!.0@F7%Y$
M*'>+"N3719H2LQ\_^DXZ_!+(=(FZFRY Q-6HNZY^T-$>=DF:$YWW.LGR*R_C
MPC5X&;OLA33-&\9A.#/LD5V2HG 3?TG>4!H3,FIC7 B0VERH).G[Q:Z(2,K7
MES3)LF]Q6EG_B!WF"JTQ<"_>^S@Z55S;GM98Q)C5[XD)+Y<<,G,HT#/M(/L+
M_^$;OHX]Z31)B3TQ1P-NIG@.T-/CWQIR *9N9'MMBZ>\VZ&4O.A/WAZEDM-E
MC05SJB>LM\] \>"XTZT!R/!DBZ^?8()=>>58#445$,FD2XSLG&-D=5@4FCCC
MF:H=1]-Y43)"8SEHS"B%K_'MZ.U(#[F-UQ%<B.+1="'#D?#A2VSY($S(K=!-
M7)S'G!W!EN@R38<N1ZZ;KFA]N?W<<31<HO0O4?J7*'VW(\S'NQT<Q]@('LYS
M4CB."=-L7-$S AF+ICFZ2 ;[Z-D+FKQ/CJ/1]"5E.[(@(VU>^40NY<Z,\!TZ
MCC+3MT_BFH2,/=/7D&7K^^C)5YK<OXZCT?RE9'J2/WHFF[J7VG%,F:8OD3?<
M\21 TZB3^> =S/)C)?A5^7T_,2CE4D)Z,E!GFODGWMQU$N=A7"1%1Z-^2K+R
M,J L(TFZGSX?^R.-P,#@+P&2/'5)8[LD<UR2.2X1@ZJI 6YGI.CEX0WM='0U
MVG._\Y(DXFQ8K LD?R2[)06-"[SF+[GDP-@]Y2D8F^P[+[DUIJF"?2ZC#INS
MU"5S9IHSTW%?U5:^9'?,.;O#,)*&&V) X_.2[ #)CNYJA*T"ZM2-7S9],I>0
M8^O,YA)R/(MWKR?..8[>2U2NO5= CWMYGJ'*4\5CN12BK-M<Z#@^YQ.K[%)4
MKF%KIN/HG6$$KTL1J^.,JHYC[1*@Z@RMC61WH"((.WT"[KPP_=F+"O256GA0
MLV. M;#!>E-E!B6^& ^A]QI&%;.D&PV6\8H<7XIO"Q[PF. 3JWZEJ:>]P^\Z
MRK5^A[U8 0U@B((3]:UO#46-#=?0G"[ XA7S4,_/.? K3M;=33Q/_-^>TM!'
MB_T>(S,L5=$PPDI5$O=JNZG-L4^C5X<&E[E+T;\+%/L'4923PDP(8-4__B/$
M7#CUMX<'](8B-<A$D^T#UWP7^CL51D@.6^/C@&J_6#NPZO4?LY^+3@9T?*8.
MUY&7B7HIB.?8!T4L75!QXEN<O&9842)2Q7V\+TC'P@3K0U'YXG4!4[NWQK[W
M@E+=WVN??<ZB@TDIT ^7B.7S@)T+8ZN#CHDUW_ZM/A87&GFQZ/0!EUGWUWWH
MA)>16A]SFT-FVJ=:2AP9U6\^B?,8!#/L@\%21@?K!]V9\P3+_FO=$'E/;$A-
M1.Z,MP^"VUP?$"TT]?0:*C6.))H*U,@YRKAY:7%QR?#3\]1_'OS4?[8-!E?+
M&:H573+NM)#03X-)Z"?;8,PHV\U(TI<;V4U&?-&M$%M]'ES08?;RF(YACMJZ
MIXO<60H9+\J1N-H]_4PB%+EH(:-1,8MCD,N6B2 U)Z$CJ!)U_)@(5[-I]W'I
MWS7B%O+]EDR",N?*<@2KBA<6"%H=N=N7?E%Z.:&R9U'>W("I@#N.'M/&W ^2
MNCU9?(.RHC$WQ Z)AV.^*RQOWUR08\H<H, \0:-PJ 0HBPB6*18]1Z4CV%&4
MY#2C9TX2F=2O*["R:7QT'4&D(KW9PZ0CI#GN_>2$4TBM)CW7-.2B D9,O*H.
M;LB( 6?C%1KT(&/2E/9IMUW)A-B94OG\&,5CC*A+G^>&'%/JDNJ# KE8"KCG
MH2L$0D:>L1>!'P#D.#JF? +<:QAJB^/_9!(YD[=Q-,JIINZ#/&$!HBGOIL/%
MB&#0H<3A"AF!X$CQC!I%H,KKJ%76^7PIK7,IK3.#TCH_>VE(=K#"-T204=4;
M!F+#PA0HQD!CV9[WL4^<]"BX.KR@^ DS0LPJ\#_/6R]%*DF?*@MHWGU'A#WM
MY9D\QWGXAMEVM1%O4V_P!I7_LL Y<T7[;&*FU8WFG^N:-=GJ\!Q QFQCK.)(
M[J-9A<H"%OLXXDW0;7+PWQB@&\7URFT^Q,0F;ZSF/75YW'U<?]]R/:9$W'D+
M7G+QYI&>*WC1W\A7>!1]$8W:>DGHOY_K(K7>+BDPS^,]X.H+3+#[S]67?QJ[
M>_X"IG8?G8[\C -07V4J.,8=A?HJE_3"#YY>",,BV->'(>-,P0C(UY<94=%*
M>BQHA"C%'?*,'CQ"<")0T*(K7XL] 31R+S'1<"(J6;H^Y" ;& ^;M?SP"6.5
M!KUU2H88QQ%B7#9MVGOF$A-BY'7D6Z?F%>^@&6UG&M#FY<"?,%7-^>Y"EL-6
MS>#OSS/ WQA+I0E<_F7.N!08ZTS@\J^SP^4 *ZX)A/[W[!%Z-H6"BAD;T)+M
MITO@V"5P; :!8\.*BUUZ9X'OG>5VJ586MG\)\VTON#EK1S>?\K,KWE-%@=.U
M!ISL^=^EV9&[\+<A/AFR-ZFFS'+A#IK_X<)F+J[IBVO:H@5_\NS_2Y%75[QJ
ML-,8Y^#M-BQR7%Q. GO",*GFXI&R[5J!;*5Y2A/\K.<'C#:2A+POZYM0(XTU
M&\UQ3T^1%^?-C<D,+PH3[24%^%L4%!$F*^XN1<82Y>G6 .3NZTN:9(-/K)P$
M#YBKPPO^6H%51V4F/+#(UH2&')69]NP>18I9)ZF$$@=WX3OY2=)\BC_!7GJ(
M[Q>[(L*L/+A!I^<&_QPA^A['P6*7I'GX'_IW[H%P0-:VO&8SQW6RP](A2O%W
M+-=K_-;6W\3/ Y/.@7?!'A'O8(13[#U7R3K_[M$+<OSQABA&"=W:=9)U>SYT
MWROE^?:2F8C MTVBX'ZW3Y-2GA8#)9JA.Y'/#_'B(29NA?O 'VRQU5:<Y6GA
M$UYR3[C)!K-86=,PP11GS8_JPFPKI%!96G3<0#$./3)9$S12E*Q_ P10)<0T
M!3S(V%&V,@_5IY2PU$0N9"R=<['ZHG[+GB<0I1TWRHUC-?K$\KFBCTU0BL*]
MX]9)S<\7U1+FBA(QXQF@<#B>+# 204)UQ?$8_S&\1: A.1ZV/Y) Q"J7@ZX*
ML9=B$01A"<!]O$[27?4L7UP7%]?%4 !5!#L.<$I3[98<PN^%%Z;T%=UZZ:87
M'"89?+&\7"PO ^E]MJJ.6%/D7#8'7]Y.D #6@?'-#6[?]RC.$(W!2.+-"TIW
MI.;VYS]\^@OY^2'Q8NN%@<F&[JD<I/+J\D9;?(F:&Q*]JJR1]EPIF!SRBARD
MKF3.8,T.%$*-1)<L"\(?%E@81F(OBF2&YOVMT-X[4!UNN2[/TH^*((PW3VD8
MTUX3U *'N<0=8L:F#UL #&D(0B>80\%L? 1-U[T @?"311P77E33QU-)/TH,
MAC-5=^$]0J[5VIAJES'9Q)WGT]#0!<V-9%T%E6G6CN >B[E8$<^KUY-LC8-Q
MUDAGI6_)0]R6*1F/GN/2M9A[U$8LV2OE.!84B&#,8P@9*\H.3(&HUS+[,M]/
MR!A0<W"+Y (1_"XXL17[%9^' K.-AB?4MD>_%#QQQG$'FBK35!*6'/>5#: -
MIISEH.WE9':A'K\,I)_C 649*C=X@S(_#?<58H3F%MDLBZ&@K(V)S"^B&?;B
MX F!HH?P#07X-GCQ)L3;*?.FK@Y?O7\E::.O&Q.L(2M !/.TQ4=O)U;9AZ[R
ML< U9+K(TKP!,O[M!"[^Y=<5WA?+0M3^;/HM,8V&W4\GW=97?)R[8L?=6/MS
MNS'VM5:K$%W?&VOY35AB;0Z_N/&&[HZX.9;KZR1N]5MF/@W"B=.2BO<N)I76
MY[JKF-3^L.5Z%6ZV^)]O6<EW6)8\T7!0E+ LW_ODEHI^ RBA,Q$44+>8N^)=
M^6BY'@T??PU0H*Y0C+Y[$;F7 X!KSM+MKV)\'6D-O2H+<H=)]Q!49X%"^Y$D
M" :Q^IJ+Q6O97'MI?I6U\BY)7U#LQ7DS)I,7X26<8PT4Y?UKW#3G"MQZ:70X
MGBX^:H[CDS7,&OH>44[N&M'[%BGR.+CKCK)X)_,<I1D615(4A/FRR#.L"Q!+
M.].[ICP-%).IB\D<K]P-MXJ=\G1K +;W]@LB0A$*%F_XKQO\'A%=K2ED?N(
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M5@E]3_A"$O\U_9OH16*.-Z1NDLKX-V&*?#PQ:S!F :]1G0J/QS2Q^VV?Q.7
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MKX#"+5&O$E'?'&&U!M#H4+HOK$(.K=J>';X"&F(^ ?"2S^IC'EN^ 30^E"A
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M 1%NI"4-YPS]1UJ #L>MUJ.$X%,"R> 7&#*:U+U# AU0<G/@5Z[4A@7^ P3
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MRORE,<E>*R-%6S\3*,7)FA\ZCE&^_XJQ!UIM4#?&H,Y&_;C%+H'%E\#B@1D
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MX:<C'@9- 6H/JC7GE^\)1Z=N? *2+PD]=$<[SM'N$?R@XM=CS(+GU;OUTNA
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M8M3I?<!,=XA^&2=8?$QWGH_P?K!Z7?E-'_*@30<* T$>?$,P:"A7IS8EI;3
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M/+C9#<K\--PW(Y7EXR:WI,M]O,6NB*C%L,PDOH_K/+"3"%6?F-I@J/(5NYK
MBD229T3U6,14N2ZEALQOJ-NTHFEI66N% VM=TJ&'NHHNZEWI_M]!7FAJ=*BZ
M!C6K+72<"I)1($&K[B$MWTI6*,WER_6ZD0(C'J/_]NH(U&FF)++K#!-I]U@
MDY7(J#(+S!4<T$>1:0/O=+-6'>V._"AP<XYRH@EG@B$+.6>FX.W)27N-D]X=
M3SJD5[V%"_E@,."KN"!8SD&L-@585?"ICZQ9C%[B5!3,<P<G)7UC?4@@O;6#
MN61C01J2RJB65MVL%8J(&9V*5YT^D\K#H7!$A:JWQ"Z,5PA)35.:#=2SF0F'
M@*%H.:@K%! F1??Q$.[P%H*Z>GN5J8U?^5/MBK9<-W8V2'E/VIKEC*XN$S1S
M.5]"^/N/!"^9OT4[[__\?U!+ P04    " !S@&5:'CY4 #8R   =Z@$ $
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M<GE]3TZG,L#Q>6GB%2A%0CS0Z=3[363!W#OVO?%P_&2'CO.EG=$KF$DGEWV
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ME%%[3>#8&";H&8(<5IEK3G#6'23]7"U0",_ B,A0<H/HI:B_3;[Y(-9C^$=
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M!,!2_8K-CS8$U[8,X3E#5.N_O>WOL&$6T0=JBC[[  H>.KQ_YQH,NSST$$M
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M;>U<VW+;.!)]GOD*["23LJM$67)L)Z&TJ5)D)>NML>RUM%L[CQ )B8A)@ .
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MKE@P5S3O5,8^A+$_-YQ]=LV4P*4(*9A=^YS')@FGW 01/&<6OQ?/VB>M3O<
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M-8!3-70"#'R!-MB7_<A*E+-68)_;SHMU(EJ=X$NMSEV^ &];TL+Y+:XX>KM
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MLJ76C]D(VW/(P3GFT;=4,?VU;W-I#$IF%3'?\HTH:@H&[]@8X9L&P3/"#NS
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M*R+>4\NJMT6)HI1 OB@V;9W<88"Q67?;O1S=,9RK1KI#PU23&,3Q0E@7+*3
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M-W!ERD\0A!#<MFJ&?E-R>H;M[CC5L\<5?*C_X$WJ75 ([&)3B&*:BJW];3'
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M9WEKQT.>BP=O7M7=U3';3.8JC50(K&149[LX>]79H,F$<VS-7F'YA>MF4!H
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M@W"C42XEPE5"]%S,* ^2P"H+T$#I4"QH9G]S WG"\PS+G"H5^0NFU$U>A -
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M,3M?/TXUDY?Q)L.!-@MC-7DE1(.C;]I%M%'"<YV?SC%!4U;?%J@B)N'/R!M
M+UB"(H%G5S@9?4_P3X&IXWI,+I6H-7E!RRHAO^,=;T7>O;L^43Q.-6+=XCGV
MAL%*#LEK7!U&",'HB6+Q(%(?OZI6= 5.5U0TR\)Y!P\RRKU*I4T_,Z8PV)OR
M)%K6E.)A6M]7.GMT;$'S;Q7.?\QK,81_+WT^4OJ\3[P*=7#+ZNX,]F9@B]')
MPPZ$MGW=[K:Y>#@TUZ!BRM=T6]N*]6)LJMP7SQ9C6Q__"U!+ P04    " !S
M@&5:2]P!!;,(  "I,   #P   &9A=&4M97@S,5\Q+FAT;>U;77/;-A9][Z_
M-M..,R/*DAUGMY0V,XHC-YI-;(^L9+*/$ F:6), "X"2U5^_YX*D),NRHV3=
M-MLJ,[%$X@*X./?@?L!P/W5Y]NH[UD\%C_')^DZZ3+P:?@J.N^UN_[!ZA,!A
M+=&?ZGC!K%MDXI_?%SR.I;H._U'<]G)NKJ4*>>GTWV1>:..X<KWO_:"QG&UT
M"9PNPD[[1*K>KX%4L;@-@^->+E60"GF=NKJMT%8ZJ55H1,:=G(G>5-\&5OY*
MLTZUB84)\ ;3](MFAD0K1R(B['8*5^M5S=?S;0G/9;8()S(7EIV+.1OKG*M&
M<*J=TSEDG;AU <_DM0HSD=!2^M2]F6:>2B<"6_!(A(41P=SPHK<Q]V/3^;8;
M810M16DE_.KG,G9IF$@71&@7'L$?GW5?=GK]0^KQJG]8X#\ ]<#^EHLV9(?-
M54<ZTR9\UO'_>@]C,*^L.-59_-N ,KQ-Y50Z5M%T"<V.H'2//J/(([A$4$"8
M;Q:8T^%X,CH;G0XFHXMS=G'&+L>C\]/1Y> =&WX:GGZ8C#X.\1H2PS$;G+]9
M:S\;G0_P%=_J]B\']JO9]HVC>OEA?/5A<#YADPLV_O!NR+K'/.B^..#//8;=
MD[A^ N"3MT-V!:3'H\EH> 743]\.SG\>LL'II+5'M$%T<,4&;RXN)T,P< U<
M .>)>]PY6F(Y&+\>G ^O@HM/[X;_)ABIY:C3.?I]-_ZV*+ KG$^-WJC%7O/4
M\)Q]Y!G/16I:+!+&R63!7,I=^! T?CT4<)4+7[1/CH]_V%1P#:V7?PZPNFTV
M8BF?"6;$3(JYB(&1M&R@5,DS-A:4K3"MV)DV.>MV@G\QG; S[@2;I )JB=+)
MR+;82$7MWA[9%;)';=#0 D^ ER_8C=+S3,37HE4!;"ID8XWAE7:,.G*I&%<+
M5BIG2H$% .8<HQ'DG.5X,A)&27B$5X;I'$'>Z4KNGH 2D;"6FP6)Y/Q&8-ZU
M,2W>Q5 &4V;DSF@.$HBDB<H<8@K=H0G22 ;0HI39DGZL^L^%$?4@M(!<V@QY
M,'!A<^E2+- 6(O(*TK@%5-,QECE#MYA-%^LP[(FS1ISC1X@C6"(53$-67IFB
M!=9 ',UFK5VJ!'N64XV [U%6QA@3YE[#O06J2),M&%9DB6A$P"Q;,:DVHMV8
M&LK&OOAHD42900#TT;"QG\YZ?2)N4Y9D>FX;;AEQ+:TS*'X8IY>5WM"RM481
MVRAS3]L]2]98\J)-#G@-TA^?W1YUNC_U;$V$.N31?M1)(O'HT1XQ;H2W*^PD
MIYD@_)D F::9M"F)DU@.7T3^B)YC::-,VQ+]:'ZCL\K A=&1B/':L@/8,Q8@
M2&6TX6V4<G4MV  .8%QFD/!)X<F!>.Z[^J20GJI'2>F8JHA%XS/R$FM\J^Q/
MNNP\47)GH@03T3HW60@)"GX/I@0U&<CP#;/NDNWO+W[Z"Y"-M]D;8:$54/=A
MX/.4:%&$BGAI=^]"H6(J8-YZIBKXZ-)@ /B&F;3>XT!**#\.97,K7[7N[ZHS
M$?"ECCXKF[=J7TB-$GX+NEB=R9@[K^C4REAR(VD!LHJ1W@,K&JFT%+?\]K(^
MR'G_I*V 0@[^D#H5'$2-RHR36\6RO!*K^(<>531=3P+P;2I($%9$?Q$_Z.GV
M?/1\G&[R<6<'<H^6N[N>G=D)1L]D3*3C5BM./I9;$)92*F(B-W'#"O!4\JG,
MI%M0D-PV+>T13R#/C8K>=T374C+ORF_K!16E*<!-ZX-Z%&D3>P5\<G8M%&)U
M!HJB113$?1)!XEG1$'M$%O"F>R(^3L2HS88SGI7>>Y"51)(@7Y(SX&NWY#VK
M(+V#.ZP>M^="GGCH"%=FJXQKJDOWL J[.&R^E!:43B:?S]O9M$E4_5X2%130
MIT>#[[GS*'=B.+'**O>M2U5@G=GXENT<^@+?19%21U%IR(AK86G;L+FV#@UT
M2(;!;(21?BD1UC#VP4-]$O 1?F5#O-8=E8#P-2R5M_Y<H=+L>:57RNTRBI-'
M\OP5L7?5'I+:C2Y0J=Z(K"YH-^1;_SM*CY+VKUACG'QUC>%/E.*&W:V5GR"W
MM<ZOE<L@@GQ!&+^7V*UTX\CNG#9V&3K]"XR9Y](Y(1YSRU.-Z$P"L82&?I0#
MT!!>T)*7Q2<EF<WN$;^4$@OP&Z54D:]]G^^+B<\6$X,,:0OTDN ,U6%4T452
MP,AUV%LF]7/!;RB.56F,CV0^ ?/G7\UYPQ=1I\Z_JRIXBV?A,3I:L70L#].L
MSMO0!U1!>M6JHJE%*+5E#FL .+^:VJEO/9K91\J=TOT! F)BL)%;L)_PS@<,
M\.>.-55:53"1:J:SF:"(HOAU?7QJ:G\E\B+3"X'6>:HK)\7O$!'$>9J(V_X=
M?YOU+9F*;:S;^?)G"YWI,D2OOJ9 BM'(6!6)!QE?()FM1*I)NIU.N_-#(X_%
M9;RP(K15220:=/SOY:M^_G8%YC?-Y%2@53LV;/K70I"*EU<7_'0O_5S+VQ3U
M\IKK%(<N?J#?BYWZX8O9U*Z^VN$M,<<J@RF<TTWH?P;T8KL-[R_@SB42J7HS
M"M'(R6JNX'6O$6FX!*FGOR321=<GXNA.Q'L#&H3L/3?P[2<M=M0Y.KES+62+
MS;X.JN75FNI-^Z3 @N@$Z4\ XJ$]7&[@]4G\"#,$-#C#T.9(NX,(&ZCWI)._
M'KP=#]ZSCX-W@_?#M^-MUMOOG,]=L/K:6U-/MCW^_S?!QN6!/0_W/'QJ'GKQ
M4#J,%'W)32N#VH<R?U]5G*92)&QX*Z*23OO8156![_FZY^LWPM>#R^H7"2B,
M5C0EZIXM"Z::M,\?8RT^J2SX0^JH/_ J<W,[/,JXM42K:Q'<+9B@Z]KU\;7+
MXDDF;H/J!(MNB,/,9:YZL;0%2JN06N]1T-\IOW?)_#^EI0.^1DW?-1 JWM\^
M?^3V^>H.>KKTMO4:I,JD@G*.F[I.O=L :*O7E;6]+^:)$R;DV9POK'>__4/Z
M0X-7W_4/_9\H_!=02P,$%     @ <X!E6FMQI5.I!0  3!\   \   !F871E
M+65X,S)?,2YH=&WM65%/XS@0?M]?X6/%"J2F;5H*;-)%ZD+1H;NCB'9/>X]N
M,FE\.$[.=FF[O_[&3E+:4%AVQ2ZL5"1HL<<>S\SWV9YQ-]8)/WE#NC'0$#])
M5S/-X:3_V6FWZFZWD?^+ HU"HCM.PP51>L'APTY&PY")B7><S?V$R@D3'IWJ
M]#>69*G45&A_QTX:LMO*$$>GF=>L=YCPOSA,A##WG+:?,.'$P":Q+OJR5#'-
M4N%)X%2S6_#'Z=Q1[(O1.DYE"-+!%E33S4H-42JT$0'/;6:Z6%>NS[=]$4T8
M7W@CEH BES CUVE"12DX3K5.$Y35,-<.Y6PB/ Z1,:5KAI=J9C'3X*B,!N!E
M$IR9I)E?T?V8.MMW U(84T0JP%H_8Z&.O8AI)\!^L!Y\]]8];/K=AAEQTFUD
M^(L.M8[]D49+$X>JU4'*4^F];=H?_V$?S/(HCE,>_ABG].<Q&S--<I@N7?-$
MI[BMKRSD$;\$N "0K]8QI_WKT<7YQ6EO=#&X)%>?KH>?>I<C,AH0]YA\J@_K
MIW4R[)_:7K?=:=:^W7O?#:E7[KK>D/3.!E>C_MFJW[;^*?U3PN9]\Y ,SLGH
M]SX9]JX_]B[[0V?P^<_^/Z1W.C(]K6:S]9#;K+EFQQ?:.ZAWVNW=ZF*?B:>;
M-NVGNO*Y/7=1(Q]I+&E"_J:<)A#+&KF23 0LHYSTYQ!,S>E&!E'$ I"$BG"E
M_YP)BE_Q6]F?1N2<:B"C&'#-@(,#52,7(JB3/1T#>?=VWFJZ@7\-$Z:TQ),X
M;PG]_1H)4X+#8+P@.)5FT8(P06@0X'&*:H#,F(Y7-@N[21"J" W33$-(LJE4
M4YR2Z)0,(3#GLX4$+LKH'E(YI@*4,YAS6)!>H$V/@40-^ZFND3%5.,TTPW')
M@MR(=,8AG(!7@8RY-02<*O5A!^.4.!Q-<8!# @;L:'<&<J>,; $$$W0#J];Q
MKA\RE7&Z\"(.\U50'6)8_YTJ8WD9(BOC*$VE]BUZ'*-1>6:EG)G 5G!V%VB#
MX:/=UP.\@_I1I^4>'1\>O&^UCPZ.6IU=?X:A=<82Z(UW Y#A.OG2.TP8 QWK
MI$>\LG.RY^Z7 5JYS^5*W69SMS+C:Z&>CIDB/2&F2)]K,/=2@K@[3V5"W*;S
M1XG:.Z;4#*YQ?4%,[-B<)"R@%NC80+6F08P(-IP0!(J;2(5X1M,*Z:(IYTBX
M-,DX0TLLQ\P "?]-F;285F8M):'<]A[=)ZDD;F<OW%]R"S<*B3=BG*$_#V(J
M)E 2S'W?/B![;J>D[=%QLN^;C63)*G-IO+LZ;MGUNMC5^D79!7AZ1,BFG!ZF
MA^+Z0G.FY+RRE(LHDXA_7(PR2*_9(X=S@L- FI,-.S*$OJK94='RQ,,)0YL"
MVC,1I:8\)TJ*^+0ZU7T*UQ_ _,_.$5\J*J1RDFHZYK")RR9;]XL\VBS,S(Q6
M&7$'P99."Y$E#NN(Q$(>C>,T4^ IR"B&8DECFSCFXVSZC_IEJ?R6*=PL.=,+
MKQQ?"*%4N [[0ZMKF>X7YI7Y?D.'#XP[>-(X_"*KJRMJ#S82&Z.U0G7[US$-
M&PQ8JW(PX=^:,R2@O, *-ONE2(DEE'J!*L93$?HDV)TA"#SR%Y5X='9J>.5K
M==:J%ALB]A5'Y69L\M6R^).WU#L9VI1R%O[R7FRHQI*_JTKL#+<4=TL\.U2"
MNZ<3('_\9U5>9"FW19:R*7Q;XCQ>_OO>FMYSLN/Y'>+BT)_)@DJZO 7B%HC/
M#D0K[C&-,P7?X+(KO(4R4[^R5]+3F$%TOX2S!>P6L*\%L'N;2HT&N_<*B_N/
MP18_36+P(IG4"[ZV58HE&9V LYXR[:SE["OOF3;##YG,:SHFXYDF8KUR4H6@
M??:\]PZZL70 (MP^D#[R0'J7]\?+[;:PH2C+V.)+GJFN=Z!K\^8\VG;?I9$&
MZ5$^HPME]]]NP[R%G[SI-NPK^O]02P,$%     @ <X!E6LI>+B@,:@( -(H"
M !(   !I;6<Q-#,X,3 Y-#1?,"YJ<&?LNWDX5/T?/SPE"6F2K8BIA&Q-BZ4D
M\VU!B,E>Q-R2;&D2,F7,*6)"<I=P1TR2;&D20TDF9O M1?:,,ELE^SF5<>YF
MYOB=GM]S_9Y_GN>ZGNOY_?N,Z_ACEG,^[^VUG/G,TL<E 6:MJY.+$V;9\F68
MO]$_S-(8YA!FV?_FX\])_G?/L6SI-49]U;)-"HT*R[9@EJLO4U!?ML3%X#"8
M98K_\PV8__.Q;+G""L652JN45531-[#68I8O4U!8OD)!47'%"O359/1US IU
MQ76;=QY8J>$9HK0E5G/7U5NEJPP/UK5I>?6!6W>?NI"BK**MLWZ#KI&QR393
M,RMK&]L]>^T.'79T<C[BXNKMX^OG?_Q$0.CIL#/A$9%1<?$)%Q,IERZG7DM+
MIU_/R+R=>R<OO^"?NX4/RAZ6/ZJHK*I^5M_ :FQZ_J*YG</MZ.SZ[YNW_0.#
M0\,C'T=Y0I'XR]=O$]\GIZ ?/W\M2!;A?W__B6L91N%_A?Y_&Y<Z&M?R%2L4
M5BC]B6O9\L0_;U!?H;AYY\IU!SR50F(UMNRZNDKSX*W2NC9EP]U>H-:I"WTJ
MVENMA$;0G]#^C\C^WP66\O\ILO\5V/\5%P^S6F$96CP%=0P!@R#;'F1B_O_C
M?QZP/Z(2!R'$T6A$>58:*J.R7MK8-7$8HU*10[FPYN'=^[<)ZZ,"%(>O"OI6
M__?PK1[$;*B!(HSH+30ZO5,&,T4ZDCUP$A3H"8\L85;,P_J@7CL.]"2,\B42
ML);9CN452>IAH=0?&0@HIK]F:B#=%W<9C70P-2ENPN 7D :71[[98BUBSJK&
MV!X=:'B%/]H\8+FI!+<V<.S3F\0OP!D&Z$<>G>ADL,)GTFIER\&*UY> B-I]
M7<%[P*VMUG "=G99M-36)4Z8HSS]-]QCW@7)^==DH?I#]VB&('(UII(2$U_)
M]Z][<4]U+%;AG.P]/ *B0:M"/\4F,Q D[ES"@"Z,M$* 2QC-Y3#6VF/!'S_;
MV*#G/!8./SJ$Z%./@67P[DZV&A4(P;:-I4.DJPGN*BZGLIRBBY3/GGM4^&-8
MLC>,^G[-Y3T9IPK,"YDI>=ML!GW.[^@<J3!]OYT<%JB?P>%L2,\67V\+J3[H
M%5?E<G#JQQ"G:\W8C2"+J"KK]6]^GOJ:^E"\WN6YW1WPSLY='/_;K3BMX#N#
M8>M]OH&]2DN8MB1V!&,#C;^$P3BL@P\21@-%C)DQJ2,R:+ #5A/JXX1D>JM#
M5#!^H%6/XCIV['DK+,;-ZH@LS3E+& 7[L-CR0Q7=B2) @6)+'#K]X8$Q3WQ,
M^>L468<S#UMVR30-N0Z:\KN$:/Y:F8D\ES[C+G5"+^I(!DXQ5\&!!U[ _S :
M_#.HZDR9RQ"R$786#=_=+V$E"+HO]N-_67JY![H&1K]AA42,[!R=M+%=Z\K>
M WLCRF[2..KJ?GM+$3:5 !*9VI_@)8S ^:K#?MA?$I@E<I9I);G#=P7$JW_+
M+H(W7PAC MU!@!/C+%R3_5#-Y%#,A622:PK?I]\ZZY73.,_=/_C5<<O;ND =
M7K;.6_)%?N<7<S31#\+*--J0790B2>0 6[@-)*=0$Y8PBH=9N1(:.-]5'.=Q
MF]]),* :@DY NFY)@9",FR[0T> [KQVQCC$_/+0U]]A B.W5[3HG]U4H>_IJ
M5EO8@P/G(DD:KL=O[#_JKEMW8Z'&PD9)W<7'^T:$__NO,^5^-PWN@%# 3]_/
M5O>GJ_NNA1KG*;>GFQ6K_%V4%<5HZ@RIWE.YU[<\K\G+:FKDCGE2TS6VX!%I
M_2:X5^H,%TA.POL%08&2?'DS(*@H,9>G &?4XD3A7&P6;Z1]F8 TZMSVM W2
M$^?<I)K&B:;ENYT'[$W4N#\8:ZA;!UJVVGM:MW_BJ[[L-D[J?4 0Y!+6$J*9
MO$!$I0^->@N<)_6?*M%(#9#G(+HR(WEF^E4PG$NS8@B,7X@KAA-R].$FD<XU
MZDY1495)?T)05/?1_F^OZH<<):S[QK7;LVW*S#;[_IOJNX1).8.,))*6T91D
M*\$1F8;QO/ MTD/2I<9(_R/;! ^ 2QA$Y44Y!1 O8=):362N0WAKXG7=$9E%
M(#GE>E,=Y>GG+'T/Y8;S[9U='D>,7&)*W#*#5Z"GO02TN="4\.VSNR67Y2DB
MT""ME#9FPVB<[YSF:Z)-YVT$560C!,K;[G;;X/4&*A S8T1X,3OV,>R 7*IE
MU4AQZ@Z/'OT>_Y:HD\LO:+J!GRMWYCU)=,8>4E4I?'/0]_Q>C\#K'4[%HC)=
MGZG8E6;GLXNC_LDT=?Y\O_*Q^U3U^-L^W^AAKJOVU[@TBW,A.9R03_(ES.6R
M\EM"7Y=@JY"#+U^5>P[+?98PJ>FMVV ^BF9$%T1=9@[9U L)F7Q65Q?_"N%9
MUU7K'+4H_V9BQMDY9!O5N4\\?.Z7F]PN C_[Y*\/5N\=3^</^R2D1&H5>X[2
MORYF)Y!7 6UKV(*R<660WT:ZL81I".<N84:G)A#E!:DKTH]CS;\F9Q VR#RA
MJGA;V+(BX)/,!DX3_DN-2:Z)"E8>EL6($HK:+WZ=$PV8N+UH^4=[2%;^VU;R
M2\X@",I0R&5@J2;@1-<\;/R((?SHH"P[B!:F OSI#QNBC>'4YZ!-R3T"O;M\
M\K?CS>:$,5S*Y>+O+_LMGYPSZM]NP7L[3WQ9Z';]W(4.XCWJ<GD:.QH_*FUG
M&U#WA:"XG@PG0UG'Y16R#974/; <VB?)02M9Y@;5B":X?'ISWK7F^/%5PRU)
M(E*Z6^5Q^-R^R(<[CT=X1F[ZK)HT^J7D1V=G]-D'U0/I9CY?UY\RL8\K]Q9)
M[E1_@=H$3W]ZM6AN.Z.U<_W;F\>J]/9<&,CSW< Y8>==HFUM:/HAL]WLJ5]6
MQ9XSC!.=?JE^=ZI]7WN5II=''JCZ&>?N%7=#UBT@R3;&2)TFO:9(FNQ(( VG
M1(T%33H(SP@=1!YP=& )$XY5EB7VRSRE]G#.Z^:#%'H[:05M-SPANI@6(R!K
M3M,<!LZ=_34&:,!' B+S"[\\'O[P^6/UUF%D#=J.[2160GH.%-V%,W PH/66
M[ 0M&$^;N'S>Q&L>\_429A7M@YUQ 8@3X:_%P_B6G=)]U 3(ECN+=^NS#ZF%
MKUI;[AI#UF$53DX.CUR^F\]W^UG[+3WL,VR$IG4)(W].6PWO%@&<9!0NNY@R
M*IP .0LZ>F<FX@1XGCFB,F'+!90H)@)W3H8A' U*.34@XTC_+S4';GGS9/-,
MX\BXR4!9?<--CC_K\!WBCXG.'-BH0*:EXRO/0TQI[]EJP&FR?M0;Z %?L,A1
M"^6R]0%!%42-SWK-KE_D$/4F2_ X9:JR,)J-@?$'P;G42L?R P]Z1;M7UHC<
M]FFK:>9N>1/CP+J=6Z6BW.;#\4@W\,[UN %IO)ML3PB:VNO3_MC#/\"7G63S
M5&OSAJ$+-?+28F.QF=?C,NN-CG9#XA6S?IJA!1X/(Z?7'#^EO[KS3@0S7$^\
MV60];58 ^"]A0I<PL"E)IHGWE3]#N69T6O(1#I/NF'38*&\AG":M1?J"E]?!
M2GCN(3%P39>=VI","V[M1[8V92TD^[L-6K#D^TY<W8)T>I(?3IUR6\5*/O;Q
MDXM-DTS;$%$9@OPE%M < ZR0)$!=,TWE<$W[$D;)_@3$$8%PG3#G)K#!/D8X
MBW6\><+>O R;CEO^J]0VM0&W7B_ZEBUW'D=AN()S?U>G1_NDY2\@)/DM0B@P
M-B#9#;,JJ1= 6YF& U_$Z$ ER".J+DC( B*(L%D>LZ.&G\I>:97A)>H5XMLW
M/Y9MH2/J^!6U[SR/2&;(+)?2E/'^H,-C#_MZVVE#*"V2QD(EK^#W4*B8SB7"
MQL.U K8ZE0J[E,NTX5EA;RH.](LFIK<JPQP!'VN1(4R#YN@5U TMR&@S*#JB
M_;;_1&=:TI= M? C@V4GQ"]VTI8P=<=]9_KS';QS+W?N+K%[%.3^F1!IIEYU
MM2+X@L>N/-..]E=;/_NFOB)$6KA):CD*ZSOP%[VO[?#YJ5SK7:';LWZT+X7:
MYWWM3I4O\/)7$1&V),Y.0YSC\KM49:D]54->:*\C6L)<)X!N\D1$15'J,KV$
MT<.W;B51" +KZN#HBR4Z^8,4MV--0PE!YMR=$1(=GG_Z?$QZ51PVT^K?<PG=
M@?MW_9Z*0=,$'O^3T#8P4:;1)6#/#(%%DCB0,$N7^M'>M>Z6/W'8#9>)G646
MJORKI-4T-9C0J<M,:=E=%4'#@4^J<#=8:L[BE37ECPOWM_Q^-RF,=JLS&H@Z
MXM"'U:M .@B-XW?8!H'N*%(=AR]W+DHRY;F('JTCV'8HAHTRKR[=I\]AF<P<
MC 4)Z?$$S$EG<*=W>_/[X;_739.&5]A.5T^K&]^WB&ER7]V"X\[#)LZS19#6
M$N;,6*T.HEQ6254?!L)ZK]0AW:TK(.?76-A<G\G!:<%%DF0WQ3H@;0FSEC6+
M%WQI<MC4=V[CIR@='9N:1Z364@"PO;<N(K2Q^<FZXN C+ ]*(>LO9O<V[[QS
M6ZK2*]Z?*?-(J>4\92HJMSA:.-C8-E>HY+H3;Q?=F]TCG!PH]/1.K:P\?8RY
M/R"N*B"^?M2SZ(ZO;M[YN*97?FXS1-B6(:)WXGC$U_RFD=G/T!+&-PCO+[]/
MB%[":$?\)J?%M(354+*$71RVBDP%["D0=+_$8<:C_56CPX6;:UJ?\L^EC+_!
M.])Y\[K^AW;*(N%L,*F3H$J(9JR%%R6S<('T%'4[M#BK)(V8Y#%F'%%JH<B+
M:'NB"=I+F+!NK#*EIK,15=35" 8>$)04B%[B%2F'G)L_/'[2LOE\83X]><5[
MBQ&E8_E='B\"4?XCC.X3+F%DFB2)I?P?ZE[I)JHZ6B\7ZH8<04[ZC'U0A?$M
M,0'>!J2W>-9&_TV9]A^V9F@V9204P/M/)42RW(HO(./^4J/F+ 7%2O>GZ>3>
MWG0<Z,+GO122LI&-TY?1S@(Z@W? WB!9I,_NR$EE/,OADF&+U<@.>;[#>NJ!
MIX/G$I+U2.!(^\OY:]$KRCB%Y8,C"&Y@(<8)Z>_\^OF)GSRLV/C\^?3="M:R
MU=OU\.VN4?;U>1:$P;*L*E?[GU6'U#W_&@0'?*L/-.=5GA)[I05D'O[W:UKG
M@8=3HMCUGURO%=[V?@R1555RSW^I/8@+^,)M]RDSTHVO"0E@.A7EC#-T 4$#
M>P--AV*.J-I"NUU 0OOG4.&B3*.H@Z$"A"]AKA265)!%!ZJI(?*'5&)(Q7'*
M@#-TY>F(Y<SI_GB&5G2A$:ODEO"?7Z\.;&J)"&O->WNT9)G4#VB+) CNXY83
MHL@JLI4C]AI24^0];Q>,E5P>LM\G)O!RVADXJ]XT BL\AV9$B3XPA/Y/$C*[
M&*OTEC!TAN*,3*<V*H!.MWI)NDY^/'6!'_G,O<KCUH[K,/$&6Y!+8N%S:)NH
M[A [@R H=-A:<!BNDSI_Y[-R,I UDV@+^.\+VB>@R_"6YMZ-0^>H 6RLAN A
MC_;P]Z_A.MY4%=.]^N2A1\#][R.7 [I6//W%UB8([I(:29TY&;2=J 1$K4*Q
M@<5S.!8R%.470!4BT@PS$FVWBZI2/.6GR.\6$%9]@#FUA%&;0]8&GYR4%%S.
M3JL=K[C_7?=;WL//+>J'5FOGQSI&&_AL+!@R"O[4/44*\*S/S-MH;91U;YUG
M%N6>GZ'^'E.G\FV'5*]6V!,LOGJKE9\C2<H/SA%F27X78EP]:X+LK8*?W4E.
MQZFF7QNKK/:@O$LX,I*5ML=OSO[/4M;+GU-1<Z:X VW9OV7'X%0H3G(>')G)
M1;E]45Y"U1/$: C]L^S#Q>15LMW#-%M9,EHP3=G.I\-4_[!'P:U-$$'J27C6
MXE+I_""JND2G<,0%=$HC)U>-3YF*;1A@,)\7'0PO0R_A"/*[&"MEZ^",.*D#
MK9NM9D\4$K5E6T'2+ [4.%HD<IXU?3(FLP-[V_8G'8(9P'V9YVUH8B3@YR%H
M(NV<_6Z'FNB*[N0';LBMZ"3R(#487?)?R A;M\5=Z@L7= "@N_FL%6VDU1*.
M@\Q%6'J+)7I5O[X&LAI\2#31?G<V#"1V,-,#HF2:18CZO-[DC@ U.[ULIYAP
M]U37YE<#LQ8QPD)<O25;MDXJ8>4ZP4T/808*DTR9XW-X 14U2IW8&ZU&,)H;
M1?* +%+$O]YJ)2_"XZVQ=-2@;!ZF*9V,T@E0ZUB8_@3G_.>G8YZPJ2[+&6E/
MZ5D_'.+N4^9QT_"(V\JGK++UU?GYQK4NIVI,>^;*7;TZ3IE[QIT<J+CV.N3>
M'?-3>79W/D5[U!K-.VML=#0EW9[&KK8K<\XWW7:P8<?3<J^18U69G?Z><>7I
M>4%$ U3?>;+/X4=#VPFLBM>,47]A^,S[1]0-:')\:5Q^O4ZV@P7U #PMPF8C
M>X<-X1?B7@4*T!' ;"O6\0*TIW3G;RS(O:5^TH/]U@2=Z+^#)Q.;?19+M@XO
M[*L9BSXS!4218?S$+.$^W#HF)+\F8)#>)0S6P1@UV3=:L<@@0[\!=S-8'YZ
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M:61D":/0:BHSAU_&HO#.AWJ[4)VNVD+W@2U+:0-\\,1^;S'QBH/V='X^;C2
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MLA/[&73+N830%<?^[=OGMA#3)=,^A*AH2)WA"D^P8B89#)2<A4-BP0%$N4!
M&LN5I)!YQ0XF3\K!$1$^4SB2D \[AS^"H[T^/'F45(L]?"+^7Y94'S]SL8#-
M^UW[RW3U1=N-P*RE%$O[C*J.WHXQ<O8BJB?'F%=*]K^$XTJI>M#LR,Q+M-T"
MGL$FCV2!\"%A5N5<RUX4UFR*43Y*S75$?8"Q44._25]/3O7QR-.33X-5(V;3
MV)V%!;)U<8B*+Y2*,L4L +T4XV<\199F6![>&[2]$M-B!"8B*IGL5;7E\J)6
M ]C$!3Q)6(9LB3H&XSI&2%I4+5%@,O;(H'5,J!_2-?*MI:E9=8MJ38;)<$-%
M,"7#T<RKAK2#.Q#SQ/7<PWJ5XWNL/;3C2S=># J(+UTUX&96&V''(HQ=*%_?
MGZTY[V55*=CF:FHU,3-,\MY@W3/VK1*\E+W-]][7?=]\+CVLXLASAFC;@#;_
M!8"G(%:2H> M:8>*Z9E4++@H0<DOY1RMGPUZHQ"*$W1=H;I5\R;'MT ;;31D
MF^!DP>3=;^F61*<1*IELO82YYGS]?O--/;>QP#>R)8SQ-^<YVA]A<&D)<XZ)
MBV2K,ZENZ( &SQ,A^@P>RI$TP&11[PK*;LG- 9F^U)+2*^Q*YW?\)K?C>&[<
MUCU],U8Y>ORI<5W%^\/V2ML980DBGY2W8^\'MA\NXUG-?^1+G@]0_2$2-P,=
ML5 8E_A0=DI^IT5/JD')$78LRC2].3^IUA^6,&?XRT=/'H\87P82Z64P06TQ
M70;/J756U1BS$BN#HG8Z5ATRJITLO-22*^R5:=1+)D%L.RF;O6*!_%%)I-3!
M7T:-A7'XF='*2/X&@N!I+N4=U0[6ORK!+J.:/UO"I!T*>0"?X1^)F'5/9R:6
M1S7_-[.3U^G6.,#[T3_K-UQBHZE3+[GS<Z_0O[WT>H=H=\6!-XZ?/?(-GAQ:
MWUO\PU[Q^,&'IC^].X;TC:[EA?=,#G:'9%RVM7?0O>DU73EN\[7J>CKEJXY.
M3]W@R5+3;;UJ/^=GI-(HI(^F#]K*UHT#8V*O''%B9AA\0$H"VD@T(UCL 75U
ML%=31MI(*ZEZ0C?^6NJ6#PFU2@<A9[K,4)1,/#YD[4YLOTR^)D,]''M-O/L6
M+#9@\K?SV,QVEI)<4UY"$-3RFQX24"4N*&G%RYFM.L@[ UUY$4%060APU4(%
M7:FMFE/!A%QQP6LU+,<!\P(N$[HGBAY5B?:]D%F*8_!<A]4W^Z>#BSB%?JCL
M7R5_/_4XW>9JK3%$3B4]I<\RP=2 1DB[%*W<RWX'F^ECM*X?2/N%DS*4I5/N
M?W?8V_A"7C1G7?3^S'R[4R<NI?!(0VNS[;-(KZA\_[4-=E;G3_ .G(64I]_3
M5( V_!(F&OV8W;W?K *91B*7L6XNGI2"$.0EK:K,3CQLGLS,V23_AZ9.=>LC
MM^P7,58C/<.+[)5;&D&M+X4VI=N+*B@I$=8Q_N[/TH=YXYZ:'L\F_:)+:DJU
MUCL.51V\]^!5T8WH,U:E3H\-__NJEMI<@ T9MCPAG*!W^1VKPH>K_-MNV<YH
MO/.J[(;I\#V]N&_%%OJ1?A6FME$4:F?CI1/"HB_<@=J4AY^WF=VN^,ZN9\NT
MQ8C*3B@I$%UT'/489-N&'4UT0K-.[AW#BP@S/T%INYT56R.G"Z<N,P)[RJNV
MR,@-1<>&)D Z_1=#>9*7\'K(\LG*FEB17I%?:V;WH0&F)1<8403PI.5 *)XW
M\IJ]CBTHKA\'VK;+<$*<$M#F$/\9$,ZW63JR!0]XV*S']NI"4D;^3CA<I)0C
M<Q-\;UTS60MI=%TLU.HIJYI<5.=_3X_Q.#&TQ=/>#;N@ZB[=,R Y_ZW Z/*G
MO'!RI/VN"GJ9,X\%^5;96=<E6-R)[-7^?A LUU8M\=W_L%;+3O/?26=!Q?6$
M.NNHZLC/U?&3PZ5IJ1?./3Q?W5"V8>AVF*;GB7Q-3T?,_].A)5C"L/ =<H($
MD!<B#M3S@_-;GM;#[B @,N&N;"[.VW(34*5X^PS-Y-U%CH6]8C6EN<6V.BIE
M+F;*T(%/::&H^L%LZ0KJ6=CP$76/O+35>(P:7=??JDM)/2PO^#6_;(JM_9BZ
MNW;JXJ+=>.VCX[(C(_;[A9<:&NH'QCR&:0.5CT6]7J%DS9R_]T*Q-?8V6XIU
MHH:V#::9)%WH.1][HR@F4GNPI*KA,:NN5=='>+W4[NVOTH![4^4U>7O>N\:Z
M]IYPM'I2^'+$C<$)?YV31< YF,BVRN_(K*5[:!_XX/'B1$15#V*?_.!@^;U5
M YK/:'$38C]"K?I!\._D4&Z)E1L6%Q@00!D3#&<+E&NW#%J[*QP;;)".OA^Y
MJ_ST1 QQGC2[#+4AIG".,*>#GYT%C@C]4?H7SX_^E'C!_Z(P^U*\HF0;_+U$
M4U[1NIWR=CZH#F1R<W207ISB[*^7I8]AP]=V"]P/<K9O84AM!]FZW>;N\KU9
MSF*G4C$CLYDY@Q7EJ %M9@1!-4&)^L<^S$&X]'D'-4IOFZ[.S/M+-=&(0C]U
M9P5,X)*46\(,:B#_-XRVDKT?&HH=Q@)OOBF[S3L2$'A$[YV9P^D/K0HR?]!V
MUE2,N\%688?P80MZ.SN5H;Z$B:#+JZF U!(.?$VJ\^U*MS\ 9?Z83%!+J'6P
MG*;M&$1,(PA8>^^JBC&J,_C3?7#$N=4_?\C B/*H:<Z+/KQ9,4(@S.YX[^1Y
MSN"-[]NRM *+P!JBFO>RU>UY >K%KDL8THUH5]<\5U_3V&WO^^Y,)&;F:V W
M[&EX..U:$F+A<^GKY;A:X@8+S>_#=S8[_O75ZT[HK*&7AMQC"4-_BHRQ&W"=
MY)L3B/*D="V,D]R4_[.$"2-E.VR =:# 3H?M<#L-1_6!B\7F]/YR.).V"CXW
M[4I6>U(,=G*.-SX??$(-K'E8^*Z.J%7^JM[0[%]\USR\G3#K6/:9QN/KHLR$
M&\4*V5SVQS)$N4\\1DIG-Y"YC R<-@NO*#L*+6%N6-'[L1UJ)H*<](995:\/
M7U"Z2=!F16YL"C9B4Q:F'V5;E%TYN87)H6V #T#SPL59!3$A Z<"A&'A[?1V
MW.BBR&36D# ;(P9&E837V,\64ULT1+CLD1^!GZ>]3\K\^AV,QV2>6<*FZPEZ
M$><6YM/_GLIZ$'7+]%ES^ ']=\&7((+$';X*X;IP^E;3A(\%B*JW@#"*E3R
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MEA/TN;)+L[8-U1_DET!;R:/_P=R;1C6U=5V#L4$$1*1'0*(BT@E1!%$$<FT
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M=C$65,*2H(IB;7'?ND/GB@96UY-/M3W$6TD4ZV#?S5R\2RE?R 5KF+L$:%W
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M@-?G]Z=8W^<_LC'F)"XA)3&P"#SDK0@(?.GW% W<2:O&M)_$2<A%GF4G30=
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M6T<'2)RIT66L6SXR!TMCWR'X"6_"RMX^C!0,4C]@G#]RZV YN%-<,'#@D*1
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M9[\E! D3T=2E[G3B!1>@B]X,G1J8S^NR].K4SUO7I><QM!,Z\7\-MP=2ATX
M 6[N$,K&[@8I*4AW$.HR\;>?SE;==,]=S"_0VV$/8N,*0BU'O\G?;U#O<$*U
MOFVLY[??/L]C_<SMQ<2\!+8_OI4\4U8Y:B\++;*C'L^PS7D4OL3_(;36V]PJ
MQ#JTO<S<X$L9^\PP+ W2:/*1?F^)P0!\YO]G.VA>#TP$<2.AAW24%<!#MJ=S
M\OH2.<PKG"$NJ+X\2[.3Y32)-#!A[(7"JWNY(-F'_C(^G:[1;6U02>*:JO=C
M\IJK\+%E_=[*R-\8R0T^YEV$P5A@NSH=1X7UR$GVH9M)W84'(/$<" W<1TA
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M4N[<!"$<FX.3]B#WAA'.=+Z^5D**KH6<<L=$Y)S69'@J'_G^Q<PK?4]W",)
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M24XWF.>'U2N8VWQO_M3P<N2C.-C145U+#^UNM-'5#<X)5%63US*_?GT@;G?
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M<#-PL2R0GGI%G)JZ*E?6\@GRS$&_QF4VKY/PUX^UD_ @9B=_A3,\V**A-5C
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M5AO]<%Q\X?TS8\7Q<\1)J&1^!ILWS&?0EH[H0A3C1SMP9G\IW5 3W <37)%
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MG0SN3D_D@H3QIX +Y$Q(XBZ)J$RI?5JYLNU/DC527ZY?:>U!)[3SDX.?RMR
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M75\H1IO3.G3KO\+D=/\L#Z2[,D;V*8OXBN92!)^#/?I.Y7& VM/DX W2&D6
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MD1"\SXCJ4S]GI1*?\SG!<$I,I1V;4$UHT2Q&+&GR>:J\$=-7/.44%$T6R S
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M5%QYY<C:.%ZM0,#7=,VPK&Y1KT #@@WU4"*&6*F)0"6D>+; X@Z\RS%HA0F
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M5^'7G8RT:_[FO^->578*\I8NQIC:][^T4WA4\2%F Q.ON9H.X58+KW9?OD5
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MY)4?[W#XPCW\8JCJ#?#'N^L@ 9Z*X"JF8"0XU/W@Z!]-0,-CC/@,;>^"OK]
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MG)F02_]S6MG&MC7NGS)@6] KY#[;.R(5D>W.Z[KHD&51-DT1G?EN"\8[IG0
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MAVL? .=W1"S;J#CV*.BU(]*;4FDI4W(JRW^X#'YI?^FV3GN.:J@#Q>RR#>D
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M-=8_;>OQ3Z$,]W[12WK)O/?)$8%Z;R2G%&-//6_\VC.0@>S;;5RYA;E!Z(*
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MX?@E&.B)S7LK< U'2!Q$8JOQ ,:GJ*T</-&5RTKDZ7-WT5_^L$F!"]4U(=G
M9?2.P]5:ON6XT^/WB[\JIP3/N)YV7-SRX1FI%,B^5@-T6!=-M=G7AVO%P>'-
MP@"_=ER-'UW+S.<E&F<!&&4_QQB"%GY<4XY?ZH:*W8Z(!>-Q]4Q(LL<&3Z.C
ML5$M WXV94SA6X\C)3W;\NL%1L9LZ<J7S%Y?1(;-QSX?[HV/)$:90I%)=FB
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M).")!+<$.=0E;:[7-N2*SV%RYX+@D.B.X_GN@BI$4"]E7Z\H)N+$K>#Y;0A
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MX:!/S&7#=V?G['*_[2(D_F9\HOGQU](4-<&4B0;A::[@D"#/  &>4^8%@CN
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MKP[6ZX//+AY(EY!_^68D9VU?GF.P16\)/;7N'@HE]V74.4;W5M8&*HAP?NV
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M.!IN;:SQ88INK].UK$&WX3[U\M0@)U)%8HB.X$#?DY1QAX?YNYD(")9S$7S
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MDU<0S"EE70^_4Q7B>G1:*8U0HDAM("[)LO3H^S>Z6^!4IBF5;L4F=!#$OI.
M')32G9<3LWK G\/AR&11*N-5%BCF=G '"91G>?*2GB%4!JO>D3M>Y5L;-+Y1
MMMK=P39-\]539$)!K6W(4E\UWQ28ZT2FPG\?@<M<XIBKOW<7T?/3S9H5(BZJ
M:F'6 '2%=DV1)*D/12BU../#\!GD:_Q<P*"DWK%&P] HPPI<VMTA]5Y5F&A/
MSF"+K<"J<I#:2540JO)OC+19Q !5/0@YLQ N^KWPS!CEY#3N*HC\=]@0WA"S
MVVM>%3X"5Z9[+-9_CS[QKGP1?@SH)K,)>Z[38E1)X55](9A(U!*B/I)_H-P3
ME.0BF,V=7M1T)4(*L>/F\!_9,E@3.WBPCYT1SY7(PT3]V99YK>6LGOD'H]1+
M4??JIEI1%BDGOF1\N]IYKE&STLGEZ,C7D$<++?V(>_9.:>F&6D_B\!_D"^VT
MZLINY=U)'RN:_^#J,T _-_(US6<S-<V)=/(ZG9=1KMDWV8U91L.F&+Q+8S@D
MP&E7LNJ!2BQL#G2EP]I;YN)TPRK6_YWTQ:#CK!IC&$D1F\0TG89),WW6C%]/
M]M 5H?0@SN+E?/1XVY#!684#G[A6ZA/K?![NB"AB1[SY1\%X8!OBAE3E'P=3
MF* A\?ZL'I@6PMWY'G^.PDW(2</O_'O"GI!H@L_CBCD *C7$9'>[P1\U>F9^
M+]#1Y0\,8TQKG"_%6OS0*7PM?+CH5MP;'JX7[*FEP]@X[3*CZ?-A]5[6-:/
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M57BN^B#IZ$60F-TH #B>4%\-EL2>%\_D"C1-AHKPT=>X.V$G1X]UW3[]^QT
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M=]_"Q,0::8KK;5/^+DXAH!M4F)2YA2%EYK7RZ"W4.*-++'N[OK3E47_L"(4
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M)7:^M^XE$.=J86&6")LO/08-6KYZ;7LCY_,[2KM.@@TN,"\738.WR\,MM>0
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M#V4BMB^YU]Q5+XGI,ZQK5CM\>E1LIDZX/ ;X&I2!P_G?"?2%BO!CRM)5O5K
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MM9?ZG:HS3O5TC5XG(J&$ 1P[U%*.Q=B<I/,]Q1$+Y'5\UH5<I!53\/>AHQ;
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MPUG-[9Q\=>,A4UE#%LV0T*B",C7TG!;#-31O@/()J(()E\1^;]G*.)<>RD9
MB$3B;E0 !ZG$GN*Q_Z$;,1:9*H:RSF@%MDE5WZ*GKE3].>[4M-'E'_.R4/1?
MR@9 ,S">F,K9SJ'&0W1SC]G+5":*KXS%SJ&VDG;OI=/*@0><P=(.]<HT:OY!
MR.4Y>EUR"W#;')+F3MZ^]2?F]P8*N0TNOS,/398:KO]P;"0K-1W/>J,FGI]M
M/.Q4_0#:7'KT";C!T&5R5K "CJ*CLJQ(+?\:55;SW#84MGRL(>6JS#X"[:R4
M9,^21O9L:WR9(5O(WP%:WHK8B<?^C::[9;_..A^><5]BXE)/<KC17*G^C-2\
MI.\4%HXH85HQ^U,6LU.\#>2B1 4E\#FXH5,O3:':X;F0M!KT=,9M4T%AJ%6D
M"'&OHEZJW82^JH97IZ4NL_67[N/2N/M[G%XO1DL->,R[6 >EXVG,$0I'Z9./
MD3K"1RR!E/,X,H>:)"RF?-8*)*>U$KR<1:!*1W!F>4E=0MJOY;0%#&;(2I@A
MK8"A>YGY;1]YSP,HL(?+G9S^Y?N2_M8:-_>A3O.G[!%)(R$O'&[*U=*<0#<M
MQTE"D&AJ*)^@YDH.>OY5EV[F>JO1?X*X]'ORQOO0*O0)9-_7(.'.)>:=(O_8
M)%Z*O*NRK$]FQ LG9BF;)?T?L*!;0^.2!OXG^+C#S1WNGR*)N12W">I2G\AV
MRDJ0>1HI4TO+ F131?RUCU!/Z4XH[(PNAOX1]J4[$>V_096I;9/$GXI:T)"\
M!F6^ ^LGPG)&LT-*M$5/G<>5H4J4ASG$&W:@?Q7/,0LH#G''CH[0L7.]?D&I
M5)@J]UX6S#"[, ]T^ZHONYQZ9N+JPH(;:ZT4AU@<Z6P&Q;UW<.++[O0LFY#^
M:1M;KXB>6N8)BW][OL&'>@W\EV4(98F7C\UQ\>B?C/[327RL+Y49!04!B^'4
M4;VUAIA[GB=SG7@9KZT'[F[;B;DMXHK;X_SE36B"H,0'.^R7S:P;9CD-29MM
MTPDOS![X4>] D;CG5[7]S9K2^E<@6T=A98[D/X3!<&TL'M0E@TO&Q21F'MV1
MRJ MPM;T8AO1C9$J\?*HL4"GAT]8.5\]19URM/GDF$I614<9__GM&% CG2O<
M>Y_0WV.T87?IT1-&72BT\QG3-<79A5]#MM4QB<0E(? PHYV)C!X%)8G(;Z#"
M[-C'E0>'MX73M*XXE3G%.3>C^G[NF?3$@/RUL<=\;SC@/A.,JXW735);B^^\
MQ<>IZC"0BLN!NH.Y-(;HS-+O*](0<HGVN+%QV@(_^EWLZ1!7EX,Z=,PYYU^?
MMSCTT]2WDLR55>,9S2W?SOKOL(#<JCCM=/)^;==^\7KLA$G@2[?![%48$6?D
M16BD].69=J(CB9R,NH;3@:>J>(9CPQI7R_G+>_$4&KX+F>:LN/5&R(1<?6[J
MPMBA7K^(7PAW)2YYI Y029[0]8FH0.<IYQ51EU*"L!4(K8/F@I% ,D*#+XX3
M"11O.G0$:<Y/XY2<=??HW=;0E5D;B1?R,/U 'WGSR%I!J,IVY*?^C-D//>]+
MG5N^*S2<ZI+1'PDFS9!S51+?"J1KW4@RBA6BUN^I@K8^11O87NCL16SG0W/_
M;-FK5I3/= 1;YRWDUR-&R(CJ,CG\X;$4RGKD53U[?6Q@S$U7:3/;O>$:6;AP
M1>0LNSW.V_031D.E,%T6&]EA#Y0ZRRM(9GO3R%J$=)GMCQU\#05HIG(H3N+7
M:5]>A9WU-C#- ?JFOR[=M37^\$^*/2VBHB^0 SFIE:R,+V)^V?"TY>?%_R,,
M[C#\;:HQ;V'+_S:_X5B)G<;4R\6KP3]P:8<CL$)MI +7+ZDKTY]_S$E16F*D
MT@[.:FA+IB8V4-46(7!,V^\7JJ:V\S> 4CN>EJ>/#:+[GY]LR<H=3=:IP392
M@=AUK(QV 3N.Q&M'N9RD DXR\_*\17W=\^.9Z XXHAEQ#>-<&+%$E+*LF,X(
M2A 2T$9SQH[VZLE'M%/N+.+7B+E8LEC3TH#Z5#X,$<8EE_D4^C'F+9X-F:VK
MC6M>9#V(_1/:VOMA<@K;+=[20_XL Z7"<F4V1'@HD;D1X;K;5"EA4:CN+,+L
M&$K-A.VR*U@"61E3JB=(RYCYP@:PH=^;M WK2IR 8HT?L_^(VQ[8-SQZD;QK
M8<\VAF2U* S]F[.6M1CFRJEYZI4-RD*Q'W+J!C+;2=F$J&3T12RE%'^E4E*(
M.5:,C;BBSEQR0-T8>W5_6E=ZX;S%OIL#=]<1R\M&,2<2?*TW0^R!.$]R1@%)
MRK8VY6)A.EL2S)&G[M%RY%E4&;695CQ#S1MQ0/:69J<3\ERN/0PLE2K71$=W
MP?H0V> L=QM3M..T3V7%MI:?#XTYS!J(R+>T8LKZIR(0IJ4-*-I<A/H@+=&-
MW3]"!-D:H[*D;.0:<I&XS*QH,G]<WBE>CV3(7ICM)?DSM9&=S50'D=5=L/&+
M?ARTSG_"%/H-"5:ES+G?J-A[[G[6 N7;&CV*O!,/T"Y=?SS NJ@PI/>D9[*P
M<%UZS'/JP!Y9%0Z3%O!)=X]_5F+6\/;!6WS/4)[]-Q_XWJ6QN8,[!#K: AC>
MT T%GU?% .:#HTJ84TA?*?YLHDQ]R;P).XA0"YFB5#3GRR>(6OX=%*.96I/$
M]FA&2F6I-F$]#<HU$*6Q;QWB+DFM>FN[1WHU^%J-;!&H13W-RXC&>(B.2U,M
MYO(,><=%*F)-=ZF:JZ7JQ1#1L]@'(\(EM%VFJFFZ$X._$Z2B1=$]Y,75=^,<
M4:^Q;OP/?(=IG8>3K[P_VS_B^+A_?5_4G3E7F( Y28X@/J4:X?)CD"7R'NB\
M1_7)5C*ZI5*GS!]4Y/S$?#MOH5N+AP!RS"UH,QIP@;(4Z.3N_BA5)G N2F:[
MRF'U1U#0ZXT]=Z^)8H1)D0QF:OI<^CFCE?GW4KX?,LL+Z7CJ:V)V7,66/T=F
M+A?  I?W[BN[IR0G:VX>X&0/YDJR?>DKWX)M=(S,.]J;IM^ 3CL]%>Q]:I;V
MCACW%[I^_N^4(ZZT@;C2"IT']S/3\>PL$Q-;GJ*\3I[K\(2:8/;!C@,&W&4*
M-12B'LHB<<#[06X1MEBGM&/QC6T+G?OVIPU*\LWNL2E/@ OCZ3;^D-30T?''
M%XO^SAK%'%WES1%XELXH3A/F2 @B9Z1&<Z#$2$ENXJ\'$^@9&=T6.EZ+?6.J
MA$A(5V><#6*6:()W:$G%Z52[9+[S&_8&O])BWU8?G9SN,"4Z<I=@ SRUJH)&
M[]V?62W6D("79R>]))K6?M-!4SJIP&D?.@"NP/0A1H=Y0Y&<[DH^HB'EF8E/
M345^0JNC*65-W%H&9XE2%ISX-:A)AHU4L$>KHJP!M.C7C6LF*]"3U^Z-208#
M^8*Y+3#U+=T0BU)X*/%+,4B9RVJ6TYPASX6-8YGD'3JB&PB):405;34$VV3)
MQ_B"4Z]@T66#^YJ1?V3N%HT()T_!;:0N4H,?WPVF^GB5GCOE\>PGYA7R.?R,
M%P!KF%0D6)0NM!D8'R&  &20.:B44R@(OPB-U)TM0FTZZ?;S%BE?45SWPAS'
ML84[/VCN T#<J98)$"Y#"L==)>6'T] RUG4TW2;H=M8#F_\N 5&XG=%RX ]"
M)$<J7@-(P54%8LH$M3XQG^((F!&H7!3868TXZP1XZ@5=<HFS7Q"#0SCPB-H1
MS-0J9%/+&'-V97,W&[&6@+Q&DOYE(&E5.S,YP[QL!W[@P!S#LOZ&F$T(\P+Y
MW-+F"VJ86PQ1JZ&O4!\>NGVBW6#^]!'2.LZR:G<G #JZTO-Y<W/IH3YG&='!
M3Y@7]U%+F2RIB;WU66_IP;" /].(;ZNDUXE-D5+)X%[13D0G9:\T_3IO<5(?
M:4@S_4KVTTRX1:ABWS007<?='27H)?'FJ,-#NY_T8$')FB&2'<OJFS<5DJ1I
MX4H6_YWY0W?FM:9RH>D.]3OZ0(RA!G7$&64G%-2+':D>G[<@>  :S,+CF]H!
M6ED!=%JE0:XH\)VR9LU;?(&0BLD!=U@37^-(YG,2I5W2H7&"FE MS>%3E2C8
MYV;U@S\O$'BW<>\4L$;#P$O8F]A)7X1YWV$K6YSU/+3*\"D]?S!2'AL>"\K3
M=;1+5 LL"C5AI]BK.1W-C]ZL1\[6W&'MB$0F#5)XK7C=X_ZX[G=#8;W38R*M
MPOR"WBC1>QKWL4>H'Z?3B*SX R &(>H(F$.B7-U ZU!SV<Z@*D.GIT8UJLQD
MS+4!R2BD;!@+X"]#(+8K$%:P2/2?>@[6OWZ'TO+T:?,6CJ%58^9/>NOTC1_K
M.7OUG'CJ0%//P2=]&P!S>6D_L2$@GYKRU+,%)18),[#S:.2%&68>>SWZ5V]D
MV32BIM1H2C(B7G\04<^M-3LE324\CUV9OLBM^PSU(\EWS &ZX7M0Y"EGYJCM
M9JBV8(!"')=8IV6:0N  F=HY6;P2'*H!PE!4MM!*S1JG ""-0]39T*)$N'5#
M3_0;R$/K[1GR)LWF!NGJWOI'S;U"[3,+[(WIWKR%YA[?C]LQ;]$LZ<!7I\UA
MX% #N8!#QCTI%,O4Q;"A&=$9^/WQ(,3T4]H4D;5AJ).^Y(/8-1:<@8E<OR*:
M&\NYD[,,HZ/WZ,O?1Y8Q,4^S\^M&J]YMTU-1R"SF2)(;YBU6"?:C56W#BT.
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MLLK^U9X?>CY$D)UN5+-0'F>*Y6UI *)$7-@$+?86]WNTZ&Q\V@<$!K?&\_<
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M_MKP6-S!<\&.(J++M%"<TT*NQ&2*$I22K]C49?$EK+\CQH\>R6T96M]%\Z@
M;K_/_*7^6M'8-;:"81OK?/QG(RNT-N,J/O#/M..CU\QSM!M0MN !<_SZ;5Y
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M!T,M&]G".V,)K=MC%9:E>841/=%?;[P.\%M :?#D>K;07=*--WI]O!Q4_&6
M;:=4Z^R'2?^GV),.6N!]H [KD\'S!WVS3R=P$-.I"%B9NQ]^R. P!MFM\,,!
MW@[Y"_K*V+*-6'W>:;SV;39_,^]+G)$G=\%*5$YNE*[)VB-JU=!Z'+Y,.O)8
M3['V'+F@ZO5HD6)YKYQ3P8U 2N5T2E^!AO3O>/]=UWKY/QY&L<7G!+*(8T_
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M'"\Z(O][-0]<KX@MKE<QK\'8,<KJ=Y!,-QY8R64;_2P=BU;S-LM!/=Z%SA7
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M]*&<OSY,3\[K?A&TTNKP__\S;[;__P!02P,$%     @ <X!E6LU\[P #Q@0
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MVD[7X'J[IX( I37R[W>A1;+]-5L\5CP2:E73R5)7V&[$" ?Y^='V0J+K1+[
M""^195'B7^1]/$<'(T&M=]60N"4_I/,UK=_OG+&^?&DMWY4/7Y/8Q &7@6[7
M[>O/HB_3'9+ M&O"V:5G@-U*]@>\"%L6*809-#<"(!1T1C=?%^!'3^@*)Q^
M>-=1BO78*X][5R2CY10,(I^O],MK*I:9/VFKOC5\^OXMWT>N*!3KY#[N !3B
MO)^##]]:9%);WX90PH\":_V&!R !<WDW1/R@[$],W;?2DVUS9!K26QZX_?VE
M9DHFV?4$_71;*^ITV\4Y7-V=V?;V)N?,N/U(FAB;MY^^THMO#A_ 9,>-)Z-
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M,*E=2X,VSC$2]+YO?_MMX+QX,9G\0S2X 1$G>":D>S8HLZ0E(^C$CA(#!!R
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M>-*ZY5C"\VP%I"%=:I-#T8]TS[,/(W7G*M" /<X44H' 4&'9K!.0KYV-$Y#
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M"YW$ \7K49<1\?G+7>@Q.YY#$D#EHA.O1G0;!G2L0*U9[R>$WG0*NK_Z4M,
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M7^&< 1<2YAOX#K]\0;D[M=ZE'\2:GZ:]6C#L\>F2#,RFF>W6JC?K<Y-ZGG*
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MI[5!8-%\\P;RGW7" 'MBL]!:PJ';R*$U+IWFQ;(&UMY&#[CJ?&>66"'&_?3
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MH@=P=S3BX80&:P?USU9LM5*WSKM/1N?-.<\P=^@V8)H_5#&)4N003$Z!M76
MD&UK#5AK[@!JZP-H6++L8HC(ZHG_M.5\W<7P&H*SU:K*1'\O6Z5E7QWK:<'Y
MX(O;'F4OQRBM^VG1B1J]X0;E@+YHZ!67G+I2S*)M;P.FW"%,U;CC)&43-(X>
MI-M4A<U6-P#VO&[]DM*9IN4]N?KC6K\<VH)2[?W*L<R/'*ZON&=BP^J#12I%
M_H>_*N2+2%BP58>*70='K2].+B@3#H&-2%F(Y3(XNC7]$NOLK=JM=(>Q\T97
MK^3OP>UW6RJ4T,'W*12D*\@&T7S-?5 S6-!5O)UQX#Q4TF:K#Z REC1,6,,^
MJ#M(T3JS=V,&:@@6UC=@<GIN"=D\(T]X:C7K70KNL_#W^%17>E)?JHL)N")@
M(C1FZV<"AQ=\C];(D?WQ,]0DK,4\DRLQ3S,NNATQJKQ^YWSS[ I616@HEAIR
M,]^UL/5A].[^%+\%R^J<%2][&#$0N"$P^_-VFYSAKP\)41F1O8H0B\W8-434
M%D3T-:"V3%\/&:.E)*5,++ %_NJ)PR.=1?OKBPZ;SL)5L)Z<,<'**=SE_I/:
M4:B@OO_I6.TGLP,^JO6Z6(GHQ6,J34"O>)1$:39&;I3@R",GBK2FTM%.0!X;
M*?MQ]$*H4P44Q^(+TM:9KMB\6]'^]OBB1MGG"8I!KLFK$FG,4[U'\+NB/Q=(
M/ZQF$J.BI\9[\-S5+Z&@J@N$>()=N?F@EA.Z<L$2/?<[!D\&?G8YUL7_]KG@
M/'S3?&*W1*'30=F<]++:1S_M-TOCO274%R/1?0NIUBZ\5KM3H'4>PQ2$=^"B
M.E6DV,UI)5 6,MU6$<B+$\4\#O.Y?: D)#^Q<!*SU<_;YT1?4\'3T.T<G[?/
M3>+FQ5L@<!*57&0)5MRQUK%VJ0KSAPWA%^$*LX[M+5^;X_A+JP8^YB6/QPBU
MO/<VZFY#!KF"T5K#*[7EEQ4BK7PU>XXBU*$ @1:$>005M$T8#UM[@YBN(BV(
M7$9@LL1P!MA+,9.]:2/#FC !LB&$>U\U;E^J%:$FFU6V.Z7]%C]*C>.Z+SM@
M9]'.U;N,+00$^S8^F2A#GEK8]"24L6V Z/7DA^:!W!%'* 5Q1R&$:'QC"GNS
M*<OUK$#&:=QUL/92_NA2C-%A V0S:WT OT5/:HJ62'ZV!FOK34 IT9&@%\LR
MB;TE$@XC2)AJ.X3G^F$Z;R>63&*2&,K@TFIB%<]&IGU"[0&I)S#84%!X==CJ
M2ZZ+C(>O'N)?>RGWLZNIC'6SFK; ,KO5G356N)!F;0BB>+H=?)5Y7-#<N"_4
MS8N*SVYC:!=AC9.O5FL-7(I==JA[:'W;H1&/?SJFW)*P(R9  E(4%_E1>C*)
M]1G?WC+"ZK'CJ=[U98EW0)%<PZ!N%LFHZ/U(5XM7>P%A3B0G-N/@#,9J'Y=_
M9.'+_3@=AC6=%:7C;15^]<<4<*,#:["+F#L^@91$TUE7$W8HCHM(6(,IDK;_
M>$NT)_2HQI$,9Y9]OJ?QOUYZF2O "M\4M8/,6P$[S_,VZ)D);)36 0^9P.F%
MT1EWG8?34Q3H^-5-A948HIGFP4$R=]V@]<52@L((M_/!E+ 7_O=?>1T"TLZZ
M.OD9J_A@SV?/AK<A<(WIL_D@9@[!96XG8E=31/8A39X(&?*E&#C;PE:NODAX
MYA5(3J:[13^VXV*V?L1:V'OV+[,F5 ?Z9WTV+;\KBKG*UTX\+#CY?=$A%?:;
MRN/,=7,74IGRQ/V@/T)#Y )%33&W$*S89#C?C)E4I)=]%+NPF4#U_+#4@W$:
M?+3=5;F3[\YJ\?A<]EX%Z_27H7RW@AE\C@6$,C8<$QYVXN;F<6.:BG&ALO%Y
M([I>E#/U0UK@QN:4 =]MR.R.<$+6/O  MG+VIEF'\&:40L4/-3TIKBM:O 4$
MO-B<L=LT2N1"*D+>.B:\DH Z^\%6C]#;I;K2E4&7N2'A&'=<0+ONZY7[=6FX
M=1%\CXR2V[OKR?R"D5S<J4_X<W;L/V8">8=AZ6J)T?0GVH,9M(O<!*"T:/>P
M*/B644UT.:T#OI&(083D;]Z3<IG2Z0\#ON1.G'(K:\K#&Q6H_7:W&ODLT:_=
M*!G4Y3]?<-@JWA]6O+,&2<?P.,DC$\H27Z[0Q1:;CWP97K)!M#F>BPFEV^"N
M[VF*_M?W7.:\[?C3 OX)QZ_C:8^5"/BJRO]_3+%U]A2\"Q._!H,MVBBR,2JB
MT#*"B0NHFTI'35+@W94/)G#!'?YZ@S4-Z7"' 3[N4M$WWC>!>'YS5/5QF?"]
M;VX8G+1#((>9N.+1$A9C+_28B\/R7'.+J:+=SP:1]-!=*U=K#;DQ>WU]8P).
M]=4.L\>A)-]^/'+.H%$#81\]+O1]-1OB+_MNW!2%1=]IQC1XM5^<-#2:/=:_
MU(U7%QT&_1_4S+;<YACE%VT#UV")=+_*LOMI&T8\O6ZG9R09QM\8VU%,_/<Y
M,YO!V Q);/:&4:AXBK939#>,L]T+F9SNJ[:. 4VF$&WG7C2-&"''>0@V1Y&
M[_ :P[ )]LVC7NWYK@M)*F^WF!Y!(N?Y-/KOOYQP[,M22RY<<@=B _$RX)\'
M2G'GG[5P$B-#S61"KOJ,S73.C)SI1\Y'U&"<!QN$/QZU#C2ZZIZK;QE8DE&O
M#,B?^#9Q(E"_L> ;&=(]TS6' \X'[.@7G3"^%R#61VP',X92@.\"$V83A"Z5
MN E5]H(&@=RI('*%JD \.XJ\T3JP"G)QS&:CE.G!3PG,,WUGORV@L]9@Y_LB
MS <5ND_GG6EJ>O%WE^E/AVV/X-_JQ5O=_N0/72TG3V8Q 1?RQT,C A^ D5<)
MY?$Z>C/H9M$@EF=+L;@7P=PV+8:#<E66TP.^MYH\\RO2Z YY<-,\G[3CF6-M
M9D-TA?<G[TD)'2JO&AGR#;^_>E6D[NM[/O#%RY<O<O8T-S<GJ#E5%(7N#$C=
M$>"9Y7TY\&2?]^?86,?)7I%"DGCK*^$)\?@:K$ZZG4-!;4<%4%(MB]F&5W$W
M[$?,R$D"'\T40-C13R"?P6KQ:-M<>3UX5_.;/EDX3L7O$>..:-G!FU$FKQ7Q
MG\G;1>%"._$'!%P4!=QP7LVQ#@ 6T-"#R05%@K0O^)U=G&R[OK^A>-NTYL$^
MI CU-.QF"SDADA_=<3NW+#"@LCNRPK%\FN'NUZ7F&KD^,1)6 YB(M[Z48&-^
MM92Q3W0"<@2P@N>0D\0J:Q(-+1P[QE "J.]BHHQ,6T68:O[I*EI'>:C/:E%Q
MI6)@U(TG$QA'I:>]N<WL[[-P",-<3_[12-1>@[$HDPOB"R,_PR4-ETA,M_N<
MA+P1X^8+@FR(#[+:$9I$Q<E6)-L'WTY+$I 4Z,T4GQ>@>9Y1IA$5/##BXV0Z
M^CXS,"I"<#NH"&EH9&:,OV6R=YR=LWJ&S-(5O\,LXIG2*. SP6L-EA.Q3E0M
M"7L$YN073IJ$X7O'W+E)KY&C5FWDS>*]T]_;+5%L3+*M):A#1:0N%F_W#AM9
M]A2(Y8!IH/.9HE/(H[J',_DU V9S48?:FZ[MR/R\!BOM'741S$"&0B=Q#UF*
M81MF:P%% @MGH%? 0'N1%0-P: 81[8@QT@[ZR.(+I%%#0>Q8BY5,Z(3]W2\G
MOT;?4.S9=3W//JH#">E\GX.#-?0#:S EYF74'9)Q=IO/.])N@#U&8=6LW[G8
MZJG!N,##V0Z_]WWA%5;\C-,Z=/>(SL<LIZ7(U6QFX*+'R358<'$LT*56'6XG
MS<)L/K;![='63-8&2V>[;2<?'7!4V+OWCO+1'8^VT5)13>BY&@#+Y=PC'2#:
MK3ZR50PA;0$TX\@\M,(,=:I7-DS!)S0_0L<[O36QN.H"!^/G?)R%#0[%F_4,
ML3./;;LROY%8(I27S&4@:K*H&#@CB^CTH;U&4"R5O&S7,YN?@[I)).U&&HNL
MX'OL=I ?RJMQP-HQ&C9HBEUN+C1<J*YXN"]SQWQ)<U0ZIGZ51I[,XSQ'\V\)
MS47G5Q]&KL$2)K9",16B,P"WKP3LNFNMS"TTZ6 H#/+G'PV:%I+M6U([UU^-
MX!\?WN(_['169IQLV7^IRCA2]*]$\]E*>O4"4\\1*6HN\VCWQ'L)M%.KE6)M
MD=/SI/;A_*0T(KQL#')O)VU^/L@;NEC?3T=5=E=O,>.?_3G\=LIC:.+DF%*3
MK\Q!W(3W/MCJ@J0S0D!7G.;5CA$=%LNMP;[VD*X2;T@>) %JFS$S&#^&;R<_
MCV+3QDSLFZ!"7I7I>>W!175'4)>UL,6/D#+EJM#;23K2'_2B;]&J8,%26D]M
M^DI)D<6@_SN5\>7)U?NHH-V2YK8)@1L9Y"^%_P'42-$H:0P!A$G/C0K/BR>V
MDX;&'#OXOEP+ED2.^SBFV!H2Y8"1^(CAYJ&EF)V&*@2Z>K5C%!;/Y5MU[.T+
M&-Z=?;I >-!Z(!2[+XM_3VHEXG\:Q?PAU#>33S<6:7LAOO 6J:NX/KB=HT2\
M#+4)[8G[@9$[]#U8C<Z:*E^HZ\0(WM\W98.*#ZF@),0K/[&F:L8GH5N[,:>P
ML/2YBTGZ^%[O?:>IIU?_1@46ZKL.-%!1HPN3*]ZA/C&Y#RYG$5' NY_:1<58
MY<*G3M9CV!Z3,KIQB:L)_?G?_H[!00&_ZR2<^R<CMZYHPW]\2>;M"%F*J!@X
MV3OZO6O%(C6"LXN@SI-.(,J7^OHXUH1^N.#=4THH[W5JJJ</$E%/O?V<E&:W
MU80'A^]2O5G7D/SO).()YKDNOU!H3OI,WCS'L!!W,Q47,:D(^#QMWC3ZU:KI
M!9\P2\V7076M$TD\6<T5_1C'DT.&_><_/VJY>S;D<V!3+@'] ./FQ2.+MB^(
M-Z_!*LAMB#\["T$\] JJ0'8PD\FJUOC *3("RGC;.>4(U)2.F>>N&"640@%.
MKVX9\6+'WOJFX)=DZC7>/[YAN2E1KV:WM*#]_UU&Z">!7>GJ;750^),/D8CM
MO3RDTK2FFJ^KD:_'B[HT]ZP3Q3Y%5@\"0B/XAHKO&<+#69=3XC9TND8IK9-X
M35] 7GR >&PUATA^0M!R'!&Y VE3B7FU3KQ7E34.=9,+FS#3/CFT%*.(5]18
M[52KEP[Y>7^/B<6$J7/200#9*&+AXW=!3M\2SH)]5H1H8,8);HU$5!E96\@U
MEC<@&A+HB 9I"DG;E1I"NG)7\R="EI!]>LB#B+XSH97UZ]29#3+Z9+O[9Z2_
M);53[J[!&KZSR*,!7$$2EY;FB=E$=.466O""TXA>W%G:1@C/6_^ Z,1#;2>\
M.O9A[)>GTZ4ZW/KW*S+Z7P>4CNV;((:OK^OLFD6-!O/@*6)]\7O,1L8^0K_O
M3I'O%"JI2'V$Z&3[(,P@0I@>]+/=?-#(8*YM;_\$;]*Z;[Q*?^N+=)*'\DS1
MX358)K)C#2;0A^+68*X6D;^:YW378#J1PL/D43V@69RY%;;2F:KW:)/3WA,4
M@]K,#C73+">M#2?[U@5'W=SCH7PL*&BWWH8L&*V8I"H>)M?K=O;NA/*XG'84
M!;55K 5];^-?LW;DXC<3!DX,+]4<N?+=O#E[->/MO+<1W]#H_KB?__FT A<L
MY5/O(>?CQ0_(DU240@1S,ZF#O--ZW47>9Z\34#/(:;_=U8ZX6[03N!^5Q]EN
MNUOD#/J5>$^3%(#$G+)LJHM.F:(KO@:KTJW1G-C@O6!&G:6&X.R*OR,%?JL)
M3"PF!;$3%6BCSLV;ZP#5Q5OX/.;HC&^,+P_#5ZV%=-N;/,4[^J^(#IBF1W$Y
M<:YTP? :3-V+I_/4WVKD1<N@:72T;TIDS_&(5ZZ#_:[FG_-'O6=ITZN1S\AA
MD3S,KC58*/(.LQZ5.$?T X6\WKMB14+TN<%-.65AFB8CAA$TOI_C7YESBU3'
M(,;@]\2].B]]U;&4YZ]/C.CH)=^&.C$?68(^^A[\&FRR@J,\K*W]=\@:3(JD
M$FJ"M[$>[1E:>+!]IZ97[LM]YF)CS-]KL.:H.7TA1F2Y^MA63?S!_P"%MR!2
MZN8N5; , [A#-?&:6P"/!0IC(^'I+S_Q4)X?L,#"'HWHB78 &07U#L-$>URP
M>7U)(_W:IS>:N3-'LW Z<\5^<])+JI-,=0**ATJ(0.TB2+%75.^)-'B^FR/1
M<*B895E6U/AX5HTX^3O*AU1VT530;*RP<U?7'N.W679Z3@$1_K'S\V/MP]]6
M!(2:*W,UWUZ]>EDX?!C'KYD*E8BX'0D9>I<<LQPO*;NY*,!HW^/$6[HD0J85
M^OI() N:5X#14\5\M%![G.@$U4TADR?D5_-LMX@\@?_X2S"0U^:_UW5?Z&WS
M$B5;-7";#SXUTB7-:O4&IC\"N]AO6E#CA-O=F#AC58>Y.HL!3G)&NSO5KM:4
M$QV@8N%YD8O$ C1J:+EG=Z(:DC)*L[Z->-07O>47V6QUW3K0$U*K$[@&<SB8
MLBLWX>\-I<LQ1W^AUDM"5CCY,EGC_V+M/:.:ZL*H07PM* @1I%=%I%>EB^05
M!02$2.]$1:1$B B1 ($HTJMT!0&IH05$""A$(H2B(E)"D:"!)()T$H5PA1"&
M=[Z9-3-KROI^S(_S[]YU[[GG>?:S][KGV0=U9R1&Q@. T4WB&5/]70:R?"8R
M')*,',,H8/8?/(R>K*L<YJ&N:<L\' BO=POH^-IRI,/V2=-RH6[UBSJH2K]\
MK*&(^UY^TP+OAU+&-1#9>[@7S<\YQOX7H#)*G?;23821=*+).1)N"&3&%&X?
MF)5&JGXH.2LCSW A%L?TTX90LJ\@ 2'"C<6- .'&^(8F?%6=,WKT]?O"&VA(
MZ_P@1A5N%K6]3&AZOW[(3,B>JSQ%Z7^,+C@0NFNY"!4T,4!Y ]*WY\ I$B*U
MC%@2,=P],]48,A<=>HT!34)3SWK0FI&AT/>XE $[?[XL_[0+K]\_H43='S@2
M%WWV7]GG8%Z";V::R8F#8#L#ZSK5R>3N;HKO4FL!.FN1[?8XH+T&97Y0->/I
M&TGZ9,<2,693HO$A&J]X*S2QL""NO"5[KI])F?GXB76\+,JZ]L\BX1\2;?8Q
M.' C6?88"L:<[2=(&)_G_J"9L,\E$/:$7LS;71A<]@K(=#E@WF#^Y6'?:*K-
M:?.H^LM7;49:W["FFC_F__DPS 75,X=WP6A#(([]::8L9^@<59^#S4QU/+0Y
MW#N</ OJXD.*]A).QZ@@B:8,T<?&TM60!F117\GYKE3;T<UHH^E0^6U]P1*W
MC',)%.'\A06_Z^IE^0&">HS,Z1S6_%XNX;X=[2 +_633NJ2!+/3<[!MP\J8U
MS MNRA1)#ZC12:U>=O&689H7E*\H7A^_%M6 \[]?1:K6R(JN\E,X2RUE.$&G
M(327M>A=94^V,6".NER#W.?JD17LDD9YCJ!$Z9*S![R(FVU52NU_JXL!HFD>
M"R[M;YJ9@O>4-#7M-G=MS"4--Y[-5*:5YN]S,:S 3\'B[-#=*-0]8(L)H:XU
MK6[7QGQ!@W1EIROZH+SK*)M70-% C#;3I5<R\P3;M&5RZX=U3ZCGHCX8I&,C
M:I,&:/ST\K2N"10M>$-..MORSOF1<S +YNO7-.Q["US]6:G\V?^M7>/_AR%.
M[G]%MLVJ"ZSW0]2TO<!  WDQWP86*+.ZQ:WM<E^_:OZ%(1[Z_ ZB<PR+1=_'
M^'&&9QEV05'TIGY-'K8Q9)K4QQ%G9":O;\'YT#WA>I@Z2K%B/T>6T=]^H*8$
MEL@9F2%S0PH4$#\RL(=HQEAOH07@:H11")J'+-_23O0^U_2O]^ (MM\8[C*,
MZI?1NG;.(Y$8&=<ETY4O'4EWF SSUXEKO1(>@M:HI<XAZN7;VV/=)()T)/.X
MXKCE77YRK[HQ8X<]@9DY0BO[RM1Z6*8 4-J_SP7"7X37PV1%%5J8Z&2=X2-#
M]/Y\(H1I++"XS^4[B=(,BJ 5:_RQV]O:JGZA^TENX^/-0[M%9D(WCVDFX2VI
M&\?].Q*3C=T:%P\FMYYS_-T$8N-4X"-WD_1JC];DXV_'=6U,85&J2L;3/FE#
MH<9VB0C[#Z^;%F8'"*T'(=24"'VMN9HXEYD$;AGNF2474*?ZWO/V<>2\-&E'
M(IW?4^U$LNCJ@5ZJCF/4CN;QU?6[;P4;6!WIG<J_9;<O7+ANC;;JR"C"!+)<
M#B#RMF]=P%367Y='$ND-HFTN=L%\\]_=OP^HG1YXY]1F+:DQSRW^#T&&P\7I
M)?Q#"-SX-LOR 0OK8.]F'O(OT6QE_(R1F/C)V'N/K2ZC\R%M B?;0B*."?T>
M\>C/ZG^M].WQ&2[D2S,+HUY?L3K/R\E5<4.5B]'N[X,A?D>ES)1=[']5>)ML
M';57V:RJ=PZ8;AIGBW[!7_AL;/XQ%"3V\'X,FKIU_%[JI<]O)KQ=\=>6?5W)
M;C",E)Y/[E1(12&$V[T\P23SG:VM5:5#%;@:?:N4[/,!*D[PT^1#9I!Z"*"8
M8TN1>E5U2 LS /YJN="DH'S1W?PIZ^X;+TT;)U)Y<TN6AN1@+*\K]62&BWQS
M$X[*A,=KB-O/]E)DBDMS71%8/><'(;%U!6H>-8L@.^^C#!>6"<#'D/W XG Q
MX$^Q&V&P:--M!U$31=\IG)L&_,N]V^?WQN^8)U^[WFSVN#F-GJ^SSY6VSW7<
M1"I@]D2,<F"'_A.=2T'! ]3MM(W6SO=@R.^-M2U5."CPXO1W-]UW;L[+DKDI
M'FC5A3]9>K546]<3?M]N5)S\HQ_;Y_,:4!J4M-<-M)AQJ;(N;"BG)J1?&JKU
MR']YI\C9^9)!74&\E!E-)A3RI*QW&L3S2\K&.?/DK?HY+<2D1QZ]N;GJ<86[
MP<OE-O4!D&UEQ%[C10&W?KT\2ZO?)L\S7.=O,J]GERTR.SI**Y3/<,)V.. #
M)E*TT]XWFP3%$7I*N=EF4QSUP!C>\4V"**1AJ>. +Z:LMKZH;F'T34RD%<!5
MNGGPX9^DLH*SPF\('7K)PZFTZ!ZZ:D6FG )JF9)7M-ONM(YOA3'O'7!)/2+_
M"^R 7!_/R^QD [Z<CX:*7ZC>:O5]AM&>_0D.+GQ6^2I(2_L2E9?UACWI/%]O
M.E29%SU-#\M!."RD->87[*)E8S*?:QY"#ASJ?M&4Y"JU(OW\KECPF8I,XEVQ
MSX:^QB:J6E]^+]ZNGR#26]3NAIRJS9NHUSUYDKJZ8A^26_FS8AXJ18!K3F>R
M0IDO&-Q]I;+@1)1CAUGC6_)#?W)U6;L-GA)4'="P-I]Z(>[.N9/0P\]4EZ!<
MP I1]C1*G#HL"URTDVB/Q[M5=3?X1R8E>*!QWSS7?U=I?4W6N9;G>S=+.+?V
MB M5<^WO ;NA[%5T@=F>!]41YT<C'%MQ=P=<+!D_V(6/\FJNT([?)AE_3,!H
M/!'P;ZI4/9L/\U*Y<RWB]Y3*OWOHO1R4MM\<9'J%ZO=8'6]=A6Q$'T&Z#Q([
M,K"5\B,>EFC_,5QOD&^8R._/KH57)6>\!J0^?[3T/&7U*318OH\I$OIDZ.%G
M5[4*D/BP2J_!PSO:=DYE8N_ 6*=XI]6758;V&#%S2T5Y<BKA-,J8X9'(EF#,
MI "\Z<SO$)H(W#U!-O-W(3(OY=-OE3>#L$FLQ$$<OWZX:OX/1);'\?5X,T">
M6+F9B^%Q2/-U!IO9F0FS$O]HV9D)<?U/CD-_YW># !CUZ$#&084%2;)O3VU=
MK (LH,RUMJ=S()Y%;]4I5 1=/=2#47/ Q'I\NEL&&@-"D58#MIV3NGSV1_ZY
MY$EN6 E!P(\...WJ S/4DQS-,1U(0FEK4Z]F:B0X(T8"0F\ZAM3O<T\O36XM
MUB=&NB0O,%BU#1Y P4W&C_9TDD?S9+8-M_,(VXYVJ6A(#Q:>L&*%PUO*E.V]
MUL!6,J=6^\J1%MU\-$)FP:P@[KT%5:0)G+(%/0I$=8N0P7&Z;OA0FJQT8*'<
MI_IESK$BLT(^64]&3)%009=\@5USK*SFZMH9)GB:^,%;AL&]-L \!DZ6/8&7
MG(.0+_7+'@["WT)!&:%])@IO@8MTPK%9Y/J:[M\U8VZ:4\9*S^PI=6-G;\BI
MY3O"4$$W&WC$NRI+RDW0A+FOF9]/O)/:P*BC($3F\;VN8_]MLWX6\Y4<GYBN
MB9T:F&&KA_H&E2T-4_4D2GO?Z4+$ECE<8P/$0>V8X7K+&J#ERD38H$?0C<6I
M^_G5?^>L]=WJ-P*RJA)<Q\R3?Z:/^M[D-?]:Y6S&'?OQ^BV0^&%=X.G<!J#@
MU]]T-) \G*9SP$!42,:WJ5AHC[<RHS<_OTNYX 8P3"\]SK9F0C+/,@G]_NM?
MWOCOX%@%M$XL'YT1.7"TJ[R%8AX[,O/XT$[3*]1-1FD__$DX6A O@ A!4 FG
M@8N][2+0^T]7"^,K6?D=)<4U2^2\L@B^ZHKJ0+T"9]')ON]FH7"Y^HZ@1W]*
MOT$X-U98#_:YWMA1X7MRPM1"T=7+BO$F7/Y=HE,< U0(8Y) U>0&."M>3^=*
M^R "!]$=C,4BZYVF4%YUW_GDQ!1@Q !$[2?,TD["*^RC(#E!:[%L%[LU]&NS
MMRU[J?M<]V!FA0O4(!,04F\B6%,!5C03WT8Z%^?I[?F:+S3"X(KZQ" 7Z;MQ
MCM;1CZ] C;!Y37(G"\< KS93+TM$[6FZ /%,'YI()4J= 9F#QXZI;B2A1=A!
M.G?)BSLB+SWTW-63E2-H32++O"+Q5"_I>^.(2WF]ISQC3#DSA/;MM9Q]+KY$
MYE56T%Z!L1=C=FX@$>R'YD&>=F?"DU#A<_YX]']*7P5X4M:4O#EXO'5P^G9B
MS\$]K>\-JA)J:1Y:Y/=?*Z>@/GD^3X2B]KG8 MM79%M=>KP4_SNH:/AF 4U_
MS8/Y"CG0X]Z>HHD=08*IT'AC<?KE\!X;QA\6F@3]DD@D@'3%-Z\VS"ZW_=KU
MZ7/9SK'$>GTYXWHU)$ Q2'IU3Y_S7/8&9Y#PQB]]C8T.W?6*F=JI3J?O<Y%)
M?1*.._>>5@6H;1/XT/<@_RQK*!Y GP/C'F7M<,1JB3VP0I-G*A#HZ?:&XO.X
M49\6$FG3)$7Y_QTEWM'0)P"BS5Y]C.IR^SX7+J:(@?8 <EZA-$@Q7.S+'<S,
MN"U__-6#"KM5D/R*^7C<Y#3R%;:/[5(XQ$IY/0L$>H'=\;^]*>KVYS.NR^]:
M4-6W4Q1'-#>')5'_,C1[(:)(M-O[T:TUEP^%#Q<GG44?'/\1AO6XQOD^-3^&
MJ/>O-,>WEC#EH=J2']-=_?Z$T@<>=XD"%:Q28(VZIT^%I__GJG$:V)Z;)2:9
MJ .\5C@&*\>'T;SI,2M@PQCHHX@#V$:;H-H#&-IY>=4[?X!H(M69 *LOXH4*
M>FIE]^NB[_UG%(RTZ.D2 WR9YMM7@2SF.9IF$LJ"V=*_31 0I7'BJQ?!@FQA
M>M %:R]N!P8XE4[2YL?6+MHMY3,S!;74::H19R>(%[R47X%NC^YSP=!'8/M<
M;:))!!^L[-6I#6,WJN;3 &94KXR.XV.DR>@]IDDQ]2-;\NC'>_E_>D>J*_CK
M:[IE3M]H19[KX+W\Q2IB2, 5W6UJ(M=L+[S/=1<=-V]YY-AAVE1?U7G(U=CC
M!HOFJG&,8?;I%NI&_,'LH0)LU%.:?I\-[ HSLP>2A#YI;,<HZ*6HX2>-S]6"
M>YM$E[Q5IK;>^L'/.32?VU61E+0^KA'K'I^ 5$C'TJ\,H[@!409F#K+VB^EW
M%;"C2J*/+T425JL8L;L.N/9Q1/HU;V\/MCW0 N<C?FI8EDC[N,0E0%,6$#OY
M)F>(*R9_:H&O\Z ^%!Y\QB;O&<$V;_&]-P1?()A^J")V;(/6M#I-@\N;-\<[
MA#0$HD&<LQ3/ZS\+8""^I]ER003,Q-^#A#^JG<R179)]L[WF=/>D*+A%<>TJ
M8\:-J;YIJI,/CI\5T= PX6&;9RQ3@=3KN#%V1%!3X-F,L0YYVY"6,X<WEU,R
ME'U*E!;B)Z]7IY]/N6;H=B[K:D6MM%-N@L/W4X'_>]L$?H8NF[G&$68K :E,
MF5^#TW--QX#$WI#*ST-"[9'WBD)"?.!RF*_VM*V@N6B"WC2_(59IK-8;IR)4
M/N^,NVZ/$<;7.6;'R>&_5Q9\^8IUO5EECW-3(E78(@(MU\0<4E_^9.<ZH,^-
M^3=];(I%MV>FGFV=8#LQH7V<XT 6@S5,W8C5M?&  F@J%D*<\A8 !NEK$-M6
MQG#WW:>._CG>A FUC4:-&0>!WL+(@-\VX4IQ'T67?H!9<PP30D6 8H\,-_-7
M&@I1L^RM35J/D00>]9"WH:0[#!YW:UJ0?52ST5+.DK9%3<"G2LK,5^9*>/@D
MR_DL1DV4TL=H1,35J\!Y5LP%;^9%JM=I%[QA_78Z[ZVC:.90%9AWWEN(?MSJ
M],.?]58.3"V\30ZMUKR\M^["RPBZ>9UM:\5:=)KG.5.G,I<2[%*W7;&E5<A+
MP5\8>ZW=.RG 'Y>]5N-#U3!MMP$J1(;B;^2#E)NE<:=,7=4C0XDV$)I /.IR
M!;).,EED_;*]R-NX%59;UI<P^7Q]O")2V'R*10'0X%1XZPG\::;&S)7$WH-H
M/EN)G.$(8-Z-H.QHI?$=MF58 '.=\?-1BW5TK5#SF.[=-YTIH!:OV6\VM](4
M553S[HI_*5]XL[.N4E3WHPQQO-LI8*"HJ'3:2C=/-<K%W*[AU9*N_OB?+U66
M9O2:ZF45:WK+2\SJ1*GZN\MU85[6N[IN5JF%M:+"K'3AO\SHW7!T('#U0\Q9
M()01U5>B/(Z/8D*[H?RMZ0H[^US6I#/O2&PO/[TZRIG6"9& M9\YEF/8QKL3
MFR_R)7_(K8O@"!EZXH;.T/:@9>"U1VEB9$8G8QW,S_8%TAN!Y<_7QF9Z9D$<
MT141;S'S:(4]_ ^X_5NF6H$[ZLWT)^GW/4<*1[0RKG@)4%'K=CD[A:FI=2\5
MDXCFJ'$?92OCQL:<[+@)L4YK 25;(6'+'CO/C>0+8?3[#KF^JX4O_>^<YW7.
M/2<>JN(<DEK+[6[%+!/O1_PP^*S.R;"#\J-N[;4&X;DKDE "C*G>KDO,<9;L
M41POE,=:MS%>XB!_EZ<T=7Z ;#O'-8KSU>V_#EN/PS75[?6U[\R$_*:86^M!
MVTN[ ]B^=8#[%L[KDNV8/#._"$&;%J30#[ _+H>ZD*L+%UN$_;P^]6_ Z'I+
M\X2,_.M)A)">LZ"ELM>W@<30VE$G:L'D2XE:U2ND8C,)Q\6)W'GSBP@?<8>F
M$V,YL4[E=4:>RWFV-KZE\P(-BQ!I\],+&,DAVU.A]4:M]*/.=H[?*^S3J';*
M,<NV/!C56DC16ITJ;38>W+J1'*/!#B6Q>7T8*[V4XXPP66XH[5XM.+VUV:=^
MMH]V.0K2S."CE(Q"Y!^-!$I$MR?YC>NL5'G,6+Y*,8Q]HP769 OLM7/.LV\"
M6^7 (W5X-[G@J;$3DYOV]:"Z'/<!'-P8G#(J)%&&Z]W;]C$V0C83=U@F]8"R
MSB><: R;\9'[)#R]JPTY2^Y09G0%V?E(QHL9\_.+?;_FZU*477S]C@KI:9[2
M.(8GIRH>:V\R]@#SN;S8S.A9W.O:WA=W9825)PK[[\P_+5,:FW>H/4%=<BQ,
M=W-X6=O3J))G:& :NO KL"C>\--_?3.Z[.M[U:B+<YFGW  7HK<($][7=*H]
M(1@?TA! X+N_MK4]@A?WBY".*_SQO?G[<;_"Y?6K_'F5[OC"A.K;[V!(5H\E
M;88U^U]_,*]EC'BO[HNXR-\ ^";3:,:\P[: KL#8[%(,^H<U7<D920X*>^MK
M8^'H[P(A;2G-VK[-\G/(D'!3@'D7UEL<]JZ4EGB>VJ<PP6.K@CC/'XPT>Z=A
MZX]QWN?J<&AI]_6DJU4X3#OUC\;MM6HM67[^BKOV/: ?A<_.MOSS^U-=E..#
M(-F[=M!C,4/[7*V9O>!4&=71!I0;G/K^HBDTM@ JA+?6C;LXH% :T83<L".A
MI#'B"P^?S5C,K6E$V[-<_J[[A:@AGU@VOB&R2 SY'85V^F7K;K3 )C11A*R!
MP0+6 ]LE4MDVO .,I<+YI@3Z&\9<K,5;B>K.!JA;-Q7&VYL />7Q?2#\WC5%
M75R,[) 2386:+SOC5+YD'AA'MPN=RKL^B@'%C]<[.11?=ZC&&-JGU@]^$C?X
M97%Y$'83D\3B?,YSLK^)*%/2Y]'&J.#.^YZW+59T%OIEE*&=[EP[6V)GORN3
M M2ML+XQVHIA>D6U;!W@10!3!2P-0#]HHQ1MY"97^D7=$]-: U!77P6^EG>!
M^@2=V$2F4VIK7L0&<*/T4^1O2 WSQ5 (_(@9 T2Z]0?":6-5Z@KA,-N,65W<
M!./(9E"&'0ZXG9WZ=QFC,9VME 7+8(VP3ZN-MULZ>=2V+.7NXA[^^XG3^,NS
M$:;90"N<O%"E$1SXL%X4DE^!\#&R*[8*K<9(/(NW[/ZLLT!#PWVE/H.D+2VK
MR=FU,M:.Z<KF%0^L<LN<;V(,G![D*AJ8!EYX*=2U6-ZE\&;O+?Y4&%1@%IGX
M05;06+K)GPQZPK:K0H)[R9??9Q!H4!#*['W'&%N]=HG)BTF@*"-4#]2QO>H[
MP6@E]R'=WB")"1ATINE#87_!W%^\^AQ$%MD"9=X"DGP9"_&W80C%1 =J6'T0
M;7 HU''7])O'DA;%4K@JHU;2$HXVKI7B:IZQV.DLCIIEE+J/ELIC(F.&+&]3
ME-L=2J=_JQE[63@435<6+BQL7]V-4MI&S]1ZW_R5%N10/##3<,&J5!%\J7%"
M%U) UB/9S8_OIJ2PZ2/@N5>L6<9CI$M?R47@/%/49E)W(V%GHS_(Q8SQQ=E;
MOHTQW!.DZ2*2;Z(QL25?2#:0="+)6Z_8J-[&ORVD_"9S]9UJ1^BOT1G#$!+>
M0H- A4LAH="Q+?0_2S(R#$Q2ZTST15=F6JE@ Z'56#JDZH6&!/DK[^#-W\M^
M=OF'*\SC-X[Q_+)D]$>=L )/;RG0[1T)H?;Q=^=Y&,1/?6/UNDHJN+.R 9*D
M^9=^0ZNSVB\-,L_7BGWRJ>VV>JE2Y2Q<:VD>YIL4FQOHD)IN:1]76=OI&*S!
M8[R2>S [P'R7M0,\[))FK'=2][D.'[#:Z'XL%2H##'N.H2Z7]X6&S V#4!<G
ML*UPT663<^_RD=BRMK;.=Y#5=UBR_U:N-JY(UC!D4?8_][K4TA2H<(PBX$S\
MX)Y1P)BB;L?A3]/$3!2ARR*CQ'IO))&8S]&P,;(YU32CUBLC/:ZS.ZJ69D4@
MW\YSRE.5>'$,;IX7N/7:28E4QI-3L_PU3R]/S49-:BRN3ODS3,!=B&ZK'5H;
M8?725^P3MO97A%=@:\UH7P_6BH3A"<'PM-A,$,?[KKPS+TJ[M>CP<M[0TE3"
M_&%:E1"GL;R+EP%:>_]JA5Q*/%!BRR:23)GF>I3IZ\3>G6A.<MGP;3]?JG1X
M[TYB(EX7I89PHW=-^J8WI%'.!IT-!K]1]](,ECMU777#:GY@_NWWMLH NM+G
MM+K0CO" /W6A#W(L3>[FYCAGIP8.J>K,FO-J]=P[E7?CO/]DFJ'A7_AZQS,G
MN2)<T7PV/.^38M@/TO7R%-6XM?_7O7?<K J@K($M#AQE:M)LGU!7-(4"N\1'
MKDV2;6M:3#+,MK:J"RYSWN9_.D]<C'1ZO]I1TOBL_RM+)*=6N]_;E</-@!!+
M'Y=R$6 ;TY0-JLN3&!!0X+)7$0:2I@ %S@SS%EJ0@PL#GJ)SL-H0FKH#;39.
M1W6?2PC([.%( G!::A0WXT9FY5*D^E#N#B>UVCVP/3^\W1FT8\&LIR7&F_"Q
MM9A^O5"):<JRM\R(VAU1=_.B.X7Y95C/P/!'.\ZE%6ZN5H/"$U_KT5%!/E*A
M%XB[O\>R)' HT5TMS@BX)1K3=W:NZ7#,9XK"7@GJ"O/P $4'\(FBJ4,^Q$@S
MMJIKF4\_E$B6#GBK,<[/K^>$7YXN!/-=#<<N[:34C.%"?$.E3 WG_OT7;+=X
M0-H7C/VB:5C]GIVA[2>;TOJ]'-4V'*C<WZCK#4>&A+C4HG/]%GXRF^@8;2+
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MIV</?Z.[KV"W0"<63508Z&ZT +)1,C.^Q!!X1P/*F??2*V>08*(,%].54=W
MMUYV!^/6.:YAO[QR)8'7PU!7"9MV/W_L8D2X%%AB/#O7SZD)9B50+^4-E?#\
M4V;L+)O_IJ%F%^QCE-/S]2+++O>EDJ73MB4","U\$%)9B+%_B%'3,W%R/)>$
M26@:MAQ#1&/:,+9B258F$_TJB/(E;XOJ;S%],0)MA737\9CS; <F*%WC(/_
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MXRJ$1.^*",I:J_ZSSS7=$60TR/K(-,-\('"C;C+0JUM-[,/-$RAH%=#4TV7
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MOV/Y<XJLR[R7N,^E? +(/&"H68RB?2[G@;XZKEW;_Y9O<"/E%T=H@"T,8CT
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M/CO:^JQK5Y"KDRG^NADE*PR7VD7SS#Q&^MQX1#M6B'CSD"7>LG=JB153]<I
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M:I7_*2H$"UAL/07 O#TC(<W&BJ)9D(T*266P5J.\/Z]U-5%X,VD_P9Y(>5V
M%!O2ZJAJ/Z:"X#ZYFCM-^_8RTSS%36S@_;?N[Y^6H3</:J+.^U(XF"(,?3!"
MH+<;D98R)SW$$ $BR'G\"R8?Z&$).PFRYG44MU4+3W+.DRN.%%.:?-N=H<7A
MC*_W(S2\CVO^MC<[FB=7WSD6D$[7W7T.*M-QW1+'Z 9)1%?J@# #"C0640_D
MNY@G0//@L_FT-20$A=$94MI4[)^(B;JPRKP^IFT;5-+0F$0]"*D8%@D0>0/]
M3JJEQ&ZG/8.?@0J@3'KS-F,6S*,+;\31D$^CY,W+_/X4%B/I7 137;MQU0!G
M<K"18';Y<N&%7-O1JAW8V=]#SBE0VLV+'^R:C(19M6@U&Q4T2C2&3=MS@1*/
MJ4>F>8!)1[+Q_ KS!)#6F79VK07:'$Q_0ML=O^4=Z4.MB5]HC+UE?6\8K8RD
MG<?8I>X;U+41TLB:I6]UM&-/P]/I<0Q^I7%ND56H..@#'+*0F6I#(6E3.#*L
M86<@$:U+M[X#<,56S&_QS:T)CN<9Q(U8#R-CF)7\3Z2_9YHKC.\:78N=,T@I
MX7+:@]4&;'75)!0*@:_V3="!=)\>"GAW2]N@>EGB&/-K7$?[<8"4$%H@9 9\
MS:] P4T'M^PVR?M"Y#Z:EIQ;1//B>#71/"+RB8>OQPL0&8>93SED.:X8 )5$
MA?5 I<:) ?.S8=17H!'09#@:<.FY#7AM?E:]-V\OC7'>AUKP6+X^M%S]N:JB
M-T> HJI*QMSBB#$A]H_(FQR4..NZ8O N<<B:6K.^1_MWS[I0EYO2D8V&R:0C
M@&+J]\R99?OZ;VZ@QU*/T]A$/"&IO%HQ)%*LLU"D=G0GQ=G:!-%Q"Y]7 .5(
M(]Q!7+(]:&2( 2,&SS"^\%-@TY$M2,FWHKM8H30YY+'Q7,%4V"GIK#][W>?E
MK0'"Z]@%*CZFK-13<9&$<2\S1VC73W&<_D[(T6VE#4QAN]KEP$A \JMYDI =
M3)3DTSK#Y=R!%<(394L4-%-Q0G%(M%B-3//\R](X_0#E'B@?J6U8%0_M0: V
M)%:JM\E\.IRV-*CRP7/F)=377P[TU,I]*[ 1D^BF"C1U*<?.:= 5*=';'%M<
M:3$0W@O#^!H&SSR<K>]Q3ON1C7P1JD(.+D)8NLVYN:SF_DDM?F=P8Y;=G64<
M3#\:)*V#5VBN$K1U\] .C!>UY !ZO05;UOW^",42LH>/]+PR.TJ?TBM4R %,
M)"[6:9[?BP]$JX8AWSE_S.6"_+W!]T]3TJYU/=4<O$Q9WZ<I<^N4SV)%_>8N
MQ<Y0=V)KJ!P8-D1>667 PD!\U+%!J)0?]FQ##J&!!WS>+=@N0#_96!-QJJ"%
MPU53+*FU&?_BWO-H&'"OAL4 6,3$/&Z'TJ4D_MV1!P.?G6S(>9RK?M5@ 1NG
M!N>>T0\OM/TU8>8L-=:]=B)O<='@6;9D!Q[&%?51B,D+'*3,Q=!SF",T7%R4
M(LIG@?L%,4#YQ79?&\28?NHY($0FU<_NYD=0C92&)ZR&0X\8SC?XFRM;<^QB
MG^5H'L*1O2'^)AL)S7%0U0Z)&FS7HF^]8$KHAI7[SIT!!LA;?#,@8>H-87R#
M&%EB]*[;\R [. !9X2>:DSAT*Z?2L[PDS,)57NKO+GWY57^0M.MT<&3)IN*Z
M*.<8MCC4DC.]$$]7-P-P#&E[S1ZLEP=2V[1HQD6&0#/T>/\X<83)*[]6H6R6
MS:[6XA33V)AAV+.Z?^>_5!%4YJ :*HO*-)J(.L<X _1/D,\+FJ?90[5'5+=X
M&"XCF";B13\J]@S*;,%N-,0'H(^IH C.E'/?7!PF YJ):H ?95IY-USVJI&0
MT)&FW@ &UI>4.["<#%M0!Z!0,>0M4;0> #33Q[!/:]Z,B7(DF;K]$9OA$*NH
MJ=G1@G%"ZP7&BW%^ 0IV@T:AS<-&'=GM@W1*)R4.SC<_$L"\ -X@,Y63])MS
M?AF)+A9PK:TTW>C^;GXKN;H]H"'S-KHB6:GP >;2IIN\\A&4=2B_P)[!M32#
MR",3.7<Z;W=,H=H\3N5#2%?.D PBINGJ3$R,!U^K">&2Q7V/7JG,VQ)O;O]E
M^_3*QVCV?RXDGS-X:'#"_N4*[$3[6=]KB$%?[!FFQ,HY5%E_PQ9O!PX%NUT?
M!Z\-=WK\?ERRJ3;UEOX8+NQE1\C['F_OS,"?3FW0>D*DIQ' S ^O6FLIP[Y=
M$0V1.<(,FS&DXO:!YN>3%T2JMP*_)\[-77"T1[^7W/SK1L8QEB6&O8\?#L7:
MU2@:26A+2<E]H5KIK*5EZ-G4V-#8-%3M$3TWS6XK&2OL:9MZN=C6<,C6AH6E
M!GO(X@[[?:-FBLS\9!!#VHZW'Y10(-:/HH_1$ ?0U>D_/;\Z-6?[2W^\IKM,
MSSKW%\]JWYCY=F> $_B<7"->UWJI@K-*YU0[YG_XH^<VQ&'H?[-1%(S9_RMJ
M,$H%J.DYPJ^<O(DN<WXPV "\@_$VP<:23A<!TKT)VASTL-OTK23D1; +;?T
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MVP;>F0XA(?E5KD<6;\Q/[_*8),-1Z?6;OD+X#@*E U[_(7'Q,G$KX-S#I>'
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M8\EB@QE<Y=GOOP]FG/WTZ611:W,*[$_ZB 3WL5JVA;B26W/U8A,4LV@M/<
MRMN9:^)SHJIM9EH5T8!'>=*<Y=?]61ZZKV]ECVWBC/\9\ZP-M;-Z%I$$+__?
M6J:HZV9"9A3Q(S!0HBCWWC'$D*4*Y#KLF,H@R1A2&&^[-09_#G[/K9@>T\F4
MNHO$VUA#RI7>4[ZUJ3'[NO 5](=1]O<-MI^Y/%90"%LZ7,1\2$GF Z?JY%DH
MU5P4)K931DPD/R&K116I_U(JPC\&^(K<YB_K;F)J63-34,H(!W GMA^+W,YL
M AMZROQCGMCL-/?E?C \PHWQ%,_F_QBU"&R&<UWB$>ABPE"[;!-(2;S:OPP[
M")Z-+X$HAUOOQV;?/DL+5"@N_[Q!9U4/[57RNR]BX\HO^C#^_]TP]R=<1)YU
M$>'3,(V6':BDL3T@/I5H YAT4>LI=V3:H3EVL43/H))ST,BI/D18#:Z9FR9R
M/X6+J' I:<R.TJ;R-O]8TU,C_EWTKO13NJHD?BE59@;-G/AW+=^'H'CTHYBX
M%YR7; 949W\#M]]#L7STL(BR 8O1:'@;/M.1=6AA1UZ0:O*OOZM_.U!&'_QH
MKM]XJ7>F5&O%GWA047(4G+L73OTTT8'9P&$S-6F]PU21 8'%1JX'LREA<Q%B
M\O$AF:&[H/5J-RO? C3C-H=5-V_O'QG#2G1O^GT:.S*T)2CM_8760$DXI K"
MY45\=@C$M"/W-O7-(K=*Y0Z^LQ?N+EPR/>DW:L>RSV9+&(^. B.X0#5^=UD5
MSR6FLIWT;DC5ZJ!X=<C$=U\Y"BZ P5+-7DDIB$XDGT>O&J/52;? %9"*4D4(
M#\ZQ%B+9534J',^7 "H9X1 ];KA[M"'M4.>,#\<B/,UV>K#DQ4O/BA'XBVT7
M#YJFQ,G6M2Y>)$0*R0E2.V%-@%_PHW:&7N*X:L(E>2&H78:U<RCMJ ;%5(1;
MD*"W 4?:'LM5MVLW=''L.]\:X^=:GZ6TIM_&T+$LR8'L<OJ$XL]M0*3DS%(E
M6FPRSD_T;$HK _DLE#+I[>VR>'"D Z-5I]$KZ$W,[8#K2%U$5,4IHXV<"%R-
M9N>/:9F.+5+KI:PWT<<=YW@AJ!(3=>NYOU%3!PI SXWD^D!!=HG$G:F"-)(#
M6MF;P SN[!9[R'9)73D(5=#I,(CO2HTY,N&91]\S9CZ \! 2MGS,G+4\'X82
MUV,;^9>]ZB:E6Q6"UQ=^@KW74CC_BJ?W/$/7!/;H_C\1Y2<4!1,L2\@DLA.>
MB&F(G.T>+Q::;SL)^0,HD6H<W0MWX2:H>8)+RUOE!9K,ME81K:!ZT=*!WTN7
M)=^^N3%,S@V'\M)BCXFK_,R:FF,J/=Z1"?^3U4IDP-)SYN5%/*]; $\A*6!P
MUR?UR2F_+94^3^MR?+LCM;+L%9-^C=Z8;A,FX*)BI_=ZVSS)TBO*V&+W=WIU
MP9 >2)&80C'CZ%@-H@Z$P19+33A7&>;2W5!=)0;+(S;?:RXK!R9$=O>D$3>7
M2FT^_\2$ZC;W,..+^CK$XH$?OAW&SFO3M1TE\N &YQ.8ERP5II9A1B@L-6UL
M&^4(J%*ZZ.@H2$/VN_29;P558W]1E:36<4)N<5 9%#^>!:)H!7ZY@]&WDD9R
ML^XKZ/4^)GW@/U=-8:@1N@2C<ZG('5C2+L!KME>P#-L$P059:26$\,F%5F[N
M>.77] DO4/SKD;MV9WE)R WR!1]?K&-U[0?QQ6^N<QM9F&*M$XH3\YVH3RGD
ME#'3I2JZ*R+**$-N_=LM[U&5QNMCMEQ-C*<*$UZ)#"_0+E]^H 16*8<?-'_C
M>#5L/G8$@A8=Y>EN.]EL&=L;W\N&JWB0EF&KD&;$+=G^:-B4)X91"EJ*N,G@
M/DO=I8(C5\D-#:[A"?WFW_;ETK!9W_1$N^(6XYUA9 >J+EGP*!\%F,07,B"_
MJDFF%MTK#.0+LXJ%ZQ!H884-MEJJ74GBY"AVUFV<1JE?J;U_2_];KO!FF-F.
M?IN!8,:S>H_#/<K?%X,7C.#0=IU*H_J*:3+0%+[6A2T.Z&5C](Q&Y([8D)O]
M%)N/&&)L]?61JMZ H,BBT>F<F1!>?&FQWS*,73LPRJZ)C+F^GO1!7OSB S3E
MH]L[0HA\G3-T+PBBE717XC!:1//QMP@T7N#_5RBW^7A<&?$0QY)HI\PN^&Q3
M6ZZ:_K>[7EY8GMG8_HM!>56_NR514' %41?2!BA"G<JGWKA(Y@:2$>3U^L:,
M?M!#3C7M-%!+P16U572</ZB3%H4/UF9S9QZG1QF?WF[[:#;\_Q"9_MV?SL9+
M-VD#70(9<QFVAKB408]:/"WKX=-<NGJ'R6Y+*0B7 B@%-1SM"L7*=KP O\A)
M01IU4_CFZQ!QA4UZX6K;AQ\L(@RM0V_UV+2.EF28LG&+-XKNH))1T);(]EXU
MZ*9L/14T[:(^"YX5+GJ1/I !#[P:<8.L&^($+Y[S(20NXCN8>N$EF4135-R<
M-&K[,NP^J2\L*F)%5M]OW-^!G)J(73Z!C5E<&]G(?Y^\/ZCI,N0 4DNJ!G6!
M+FXO&@9HZ(1EF!)R,_33@U,WYCJ+E\NP\( ?6^=6Y(M#A]\&W[Q>WJ7<S3Y<
MM>I-WP.!_N_0GYC[?%6F,(RX&:H"ZA;=%S<2W:'KXV28(696-+=H1NAB^5(3
MTXLE)\%4ZG/EPY^7_GD3B[?LMBA,AL%S,$KDJ\NPI+<BU+ /8QNA3F"9+C?_
MAXF67-(6PF?I/JHW6DVJ5-^'U$:Q%^LTH+_?5H3:KA-X9^D1[2(BJCH"*QMK
MS!\^LXJ[OG(Q*T]^ ?8L/;DJ146(# _-=1D9I4RTC6E#\0)_DW- ?$]3$LD,
M,NTRVMH$E-^CS2786]O9Z09L3_4?FFL8,< =\PUH;V[,OAFUAM;:EX%404,[
MO.XTI/;>TZ?>L>FQ>VW7K#LKMIRM F5R@^?G_N^[ BC4M19TW3 AU%FU)N=P
M.%D7NLF^=6O,'.A->B2.5'.]VI JO'GAQJVH8+E!$SSV\HV,;ZC9,2'J2K#N
MU9#N 7I9=:I2=1 ?S]#+=1";GH""1&FF[!Q,"B+&J$Z4YXM1.P<E&&IZ]!&=
MA4L:<XY]]U?^]*3MF"9L;8 MC&"6Z#)=*"@\QL$'(H/M(UV^I8FIOV>H"4H
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M'V13A4]'-+Y<V7=AJD&\KYU_Q>/W[__8ND4;NB!/<3ADUXD\(+\DSJ3^?'U
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M2!9"S7? 1=F8RMQC5],X!"7B1>"K[B*W/R3[=8XCR?U[MQ#*BY>F?IC9:#(
M(F:^C'RZ&#$?@06TJ+8G9MRZZ5]6B'TZ>CM%-.\9??D5@U.5H;KL0,AV#/71
MJ_?H&V-_UM;^;*FNQ2+.FU0]QS/[];\>8#L%&-> 81J\;XXC2ACMW/G?6'7>
M :^C4+"SW!Y!H$TPN-\E5HVYO<*^57$S,R\>?*9RB*FJ&X^_;3;ON**[K(HX
MUA*O _SU!&3CL>]<&(K$):"F! 6_2>N*@TC3-JB><>TLM 'S$8@6G86R2R@"
M#]%E*<RDDFGSRID?*%5K(N36"GFV[>Q>WT8B(L_K\<FQALIC>V%&4=[H1X
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MR%/*T3?G*A7>)_/Q6=MYV5^S/S$" IWXSO:E:;+!M<#/>E2Y9FV1I#X=H5L
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MFV[4[OEFUK"BP4-H'(=/0ZLB57<FLCS<(8WAK8FLJ:?O26@*'>C7)&+@7?_
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M-G=TO@S,GBC-N7%=(X6:9-R M55*A5MW#QQ+(+1H&*=V=FVWSHZ]+B]7L'F
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MO"+";N_K05[0BW*'Z JSBJR0?TONWGFQ+>(*!0I;XTIOHW11"WU@T7;>V8M
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M:\ #8+"'?U8(FBR\_2S+CH06BZ"N"^L>@MBEO[*'E_O/"C1/8$<0]T/S6\K
MQ.VH*TPBD>%YD,.\&#4*;C A;(@0WC)T29*TL+0H*90_BDB!.+X%LRU;+S_N
M;WL+8/KT62?:C37D0[QODUW@W/IUDYH?8.>[PQ0JGD3U_+YTD&\X6K5C!'Z.
MA8W\>_3W,X3KG\.#LD]^^3P6W(AIT;J,*S?9-C8O5[D,CU7W,;/+YDK4HW>A
M]6TFH9<;HG^1KV87L!G[W#O'+I_&EFG<US_Z3YE^8J?]  N17$ *H@U&D/K\
M0/^<'5! 2Z"H)G0JP#K/TSF:HCN%T29 -I5$W&"PEU_72I0VX,+KG>A>:5U<
MVW,H+E,IJ&QXK/+N8G-'4_PE3E+>(0CB"2AD,$1P=)&=I$-0-!Y]C1Y8L'\+
MI4C00:XC%UB92E,%YCVMBU^9K.(J=!= RYQVL#N58OANQC2BS&QG]]*+Y.NQ
MSPU/R^Z5 6<.0:=. ,-TG_ZNLW@.S^LTF6S:IBO]B(PZ3Z'JKS<2MS, L^KV
M\(AYJ# P[ 0D% >HE@_R-<7% )8B>K($F^4F4EUW&'KX_0\H3$C?8M^(\0B(
MH!OL9!YED2Z0&Y"W&'4,+02P+QS<1&5\%(?0E'O< ?A.;2L^1U$7(XJ"$X@K
MD\-P#*3>#18T^_VEYIE[/WZ_.+9O00O^F(56!HQH-93L_C=Y'0.$F@1Q%IK4
M7J55/FK[:KLD)4V5\'>%ZV-OPYG'>Q%NI4JF2;ZLIHIY6X_E_D=5]O^[%.++
MW\/(,OF8RH#=1G)@-G;J1X!P>G&XPG6XKR^,9S@X-$CMV7/"6;F_M]8>O"\=
M8>&B.U(#G](RNA_GIN*W6MO.FR)P_JW\>851>&H1]TJ6<F$,)?+TB&\U/BW8
M.E-$\=83>:&PYM<#B)-CL@4,-L"SYO?#U3D^IEP^?"[-@'N,C.'.#]<GX@!9
M0N/:IC_X+$--\6&K;/S;%P>-B\<U6ZH_8RK=HC?[>1( 9UR  9CQ_]#U[O%,
MAW_<_SI*DIQS7"4Y$SF4TSHAQ)S/+$G,DH0,LY6<CT4H0L['63*49F)#DIS)
MQ&SKY)1]"GVRF=OWON_'_7O\[L?W_N.SQS[_;-?CNJ[W^_5\;=?G_0[UXUQ"
MMW]:''LG+Q_S>8<I#@39Z6I.1MIW%&U#>KUO?CI_$.6C0HQ2Y\J%A$H5FK.)
MK^@*&I](3*&7-?^)N]TJ\W&+_/A&WU0FC:ER['5;L6X!__RS0W<IN@[[,]TJ
M,YZ=S)AX/)+Z4O4*(5NO<QK[HZN]M90%FT[K%63[4:?^"L74@ZJ>[A$E<3RM
MUWYJ[_5P>_[5%,MT/.W_=@D/7K3>_S*C(K1B[CTW-LH,@LEET&E1) /\PMR^
MK0K,<8,NJ%20I(!O.9BZ^(?C.+\3]X2TX%38 >Y%?O&,CI5Y:MZ<-&#X<^ZD
MDZ)/S],;6_ZRCP>EK<52U!U.],L^?D6ZJW#_P\]%JW:=1\Y/'EW8*R+H!V91
M?.0!;%H-.J3'0SZ7"1-:G%Q%U?YLGTUHK:ZDS\#F$G_U_E;!_TAGW^N7@9SW
MC=L%58*]&TK%[3T9:[UQ [CED1]_W4^O;WD+N.0XKB?$]_1WX0I/'DUSC&5J
M)66_BM,@<AXSA0[,['/#KZDI^JE"8I^9X;1AK=L0KIP 1Y?WKD1^/6OZ+:MZ
MF<(QF\;8L"<?,&8#J/HN%EV"53.63 U#$]M)C3-VP1$YKF.T.:?L*>>48YXU
M1>XK&A7T@UB UT<GTN-AMX:F<^;[5BSFY62\V'\?DO71JI1>'G3$V"IO9(GF
MG\!MIN:U%TP/Z-6\R5BAA\:YIM<Z".GN6BOZ+_\WRW9FZLX&N+,1:6NXPZB^
M;O+Q"8P68:%=,J5;O9I2,+B1&XFJ0I49?+@2GC9];7SW:1H]@(8^U5DB4,3G
M@4O BK*5EO]P/,&P;KH8]B2R6 YT!\R%Q,$!)CR9O!MC#U25,#OT6?9 7Q<A
M/3KW0:$MV*/1F%LS@[OI;K.5Q?0?]Q\AJ!-_O&PCE?Q]RS)(BH!*<H^!]0P3
MJ&/+2$2(*-< Z$LB=ESG?5M>#B^ZY,'^5%OM'N3:%LK[/3G:^_V[46'ADW_S
MB4JY4?:(3'GC"5(L:_4SCC'T+GE-:'JF:VX?\!%WF"R&,0;?"NU0CHA!?!G@
MFF!L76:-:@BT@W47'M5 V.=0VOH9;]^LF^B,V8\W:HP.N#WU,@^ ;$V:T9+?
M* 75?5T_"[GQ.\KDG_'?:E<H:T@6'</(CS.V9JU*>LW.H,.Z-N4VWN*]W!:F
M-G<<X6?BTKWB4/]*Y+V_T9GE4<H7\S;NN8QY>5T=D VT9+%B<*!RV[NWLP+S
MN%3U\$[H+!C)BKQ/D@(NTET0ARW$_O.(+R#D 1=$:R' I+U3P)>?(RCRR<?A
M5U:"3XS?7B'L*:RYGG"(N*OEOS[_T($0QDY=*X%B>ZE['G!LT"@EV4,_V\DZ
M,0%\\J\);8$0PL#2/>@^W'R#Y*,KS"D*HK5ZN5^.>K T_@S7;:M ;USX G%?
M@F8+-$G><))P,JP=53D\?B,9"JW1^_?P/V6S7<!8!GVZ9 /?^M$!.X @KE)"
MQ-!Y*WMNMX'>@"K .X*!Y_E)-_<C_1A9TH/U _Q;<UOZ*B6[Y=[M6=M,S53Q
M*U;^GO*P1Q>I?MO0^*YRN._RAPORO17_5\+]7Y?0@!"H8O[XQ><@^JNIS-LM
M=-% ["E$IKZ\ +NJ%M8SB&(@NG&'Z4M8(0 _3OM+C>D0,)]<)93%&'GBH69M
MJ8.C+(]QW9\!@>4(;6S.5B9&M I]J4M>JZ-M$B/#]$;US!E-<,V8.!'0@&F0
M0CXU@S(D+>P]%7S)&] OJAA"Q>P5MM@UNJP+JFLH. N'W+Q)$-N1RS($QO'A
M/"QAK23>H#T<JP&X4O%:% E#]6C71+TL&33!;AQCPK0TAC%6DS:PIT?U\'N7
M).456T<UUY\UXO$VG0GJZS,)$[IKJ9:V/[BB.52L-J#534_^ZZ/QT&94HH\%
M32/&0KN%JM$QE@#AP0JQ9EF]14B >V$,HUV-;'<N?N/?< FG5Z&:/P6==I7(
MMJD/.G'E^\YDP5,[I4U/!97(D QB&8A,A  7"@BQ5E?. *L;UP /S%6VZX/U
M;8@@1A \PX EM3?65Z'[*(9B-,7&CBA6S#.N[D:]5BK)=DX2<.Y+=:$X$S-'
M:<?HP] NH4,+9$'0@OVGFP;/C("G%& 3&-Y*-FW@@X999%M!2=KDY+1"[+W%
M8&G:D*4@[@2IJ:O*H\L/Q9])HVF+J<*_&W!/XO8K3,!NR>W9P -R)?=YJHMS
M)E,K&(4@\OZQ\LDU6.*=GP5!7%- J>N?+[OW!>]TQV1 >_M;4L?-R1;4D##%
M]'$-S2( A3K4&8OM:RL1)FQ#_+<A#Z9*)(AF[%6J9U82%IK3(WU^-#A<*C@D
MH^; 5+1<NIW[S[]_]<OFENS&@DM3!8RFJ^/.ECD)U_"-.@.1RTW;$$74QL(V
MI+ET;!NR7H(],#5:+ F6LU=[YY2!OW$D!98<']5'#?2L63"$46WX+,FI?^S8
M]^H;D2OU2,-['8<N;R5N<&P<8P2)&3]BGS=DIDJ%_4'\E\\=YJ/I_2O<"1]8
M*EP 8[15C#7US,L,F9[:> V*LMXN)9AZS* ]>\B*.PH78$*E?$_]1*<@CA!^
M-49]-FM_MO^(\*8_0I7WI>3@5W"* \6.X@X%!]-8S@"\:TC.$XPZLI(-$_O\
MTZ"@.J'QQ.V#_<%,&3E]AM25:R,9%?H'()O%*@H%9[^G3%ZIO)QMX)B+GKVD
M4/NKH>)(S$,XH0AV Y[ZF!NRE8^%<-TSKWP-D<<HL6T[PT=V'PF2-)0K"[),
MA-2;U9B%R33NGS*W?R>^YOW_U5'[5\VYQ-4!2UE"--P['[5A##]+$&$V7,76
MS/N;0B"9'BSLWO 87$TFF3'5!-[*^7Q:[2HV'%[57V *X+5<6X&\7,76Y_U[
M@WX+C0IL7:18$7?PU)'</'8K.#^V9V7KH_Z]1Z?.T_4&*7V'K+/W_XB0.A9P
MZI4ZUX\A9V'7,AJ^#1%'W^8XDU_RQE^-J:\/ZBS9D<;XWXT'WWK1'E.8MAO-
M\;+O(..^548_<X$)Y[G4IY8F902HFV",PIRCCDLW>?WI4+E0:Z[ZZ?>K].?Y
MZN.JEP8_LIW.''1B3RQ]2,T\D1'^8D'%UNGK%X6@Q[EC>?U:T9;F5G9WXSM+
MM.06YM1SJ AV*M>[#=#8R"F#EV6E&7J9'F_I!.YEL:#I,!&A- U%-CRQD72A
M"MZ V-$8&YAY9ZS\$&),?6T@K=Z_-=,Y6W6SCK41 DZ4G2H$%+I]#D\1Z:D%
M.]2!S))>(@0S9YH"*G[FFTH!D@^Q1[A:K2.)]5L/Y5/J+LY)3R[/-[V,D]-A
M4M^@;QSR7-\+C:=MM,4R[VQ#A")*A-%G8LG5A(9BV7&]K(/_E$>-#1.KI%&#
M1RA'(V^T%WRF/GB:8&<37"*'/A;X"/UTQS>54R(5)V>H?%3#\R.:TL>^FSUT
MY@1\5M1._JJI\/IZG,%L1D96'17(U+]#&:/X-Y65U5T2MPHBU;CDJ0DICY?5
MFMNW&(X54FLLVY1'NR_E-A@O7C<-$.I^:AA&,#:_OOC'\"[%.:U4>MPO@<#O
MV+#X0:?#PRZ5\J;BC;?7U7\YA(/A,"7=SNF=O)Q863>+)$M,Z*Z*+)'/;14;
M\X>RTK*$$29?2PYBCX(2<G!J=.\K("C1<\G&HF\8WS'1EG>;L$?VV'VC?O&V
M;D2&?O$^(&8:(PGF!@-YK$O _@3@#/,6_<C77,R]8CU@30F1WVTJ8^.[HM<W
MPCUQ8X=Y-%[]?&C#T6A,S>&?<\!Y*0))\2]>CP2? BR2?-\"ZM<1AST&\ N/
MOZ  '?Z][>I:X2<G_+0?'XL1+[(Z,K]R;.JITHH"V_:[T?3:4+*/W.2M-=S1
M1>Q>0)"74T.;<P,#J 6:)?JU]1Y@W->KCQ=>NKEWG<R7S)9H<:B4,+]QY^FE
ME&:2.4$C4]$Q3^)NBW$$/BFN]*ASKB'PH]1#+$HQJ696RKE2JK>$6!U  B.5
M2G\U8%[^"J5>4#(67TTN:7NR8%XI==:EVO +0-A;UYOK;NX8ONC%I8%A'!VN
M]V3UR)H0%(3U3&Y#^!7!"596BB-:G^5=2!E52N)"V6/F[+\/=+W-IRP E]K0
M8+Y,KEDD/BB?=C6Z85A@P+]X4UDN/:)_%OL1*AV,,7CA@\!H3G*M 8%N>M-4
M.D9N/OCF'Q_IHMZ'K%4)S.5\NW'2R<V$R=KDZA&2D/(HD7\UGKVHSUEIO'TC
MU\EU&?:0IXPQW+&'B>&K4N@SO3L8+YFP'JQ*]WHY29SU^>2I0DRKO1%'M[N)
MM%]9J2A6":9\J3"Z?2)OOX#N[;2<*LQM\$)#D*G!*'$UQ4?@-1D,CJQV W^+
M,@4-][+QD_B#0U64AB]></&66E)&?O_-I^57ND6Z0[()6ZBAW" "QU!M\7?U
MRL_>3/V#3U@.>'Y5(,/M@P@U]O998SA,O4G82<7FS?1KS)ELCBIJZ0]V3F=#
MW-^3W\!%L^C@2+B_X5W'#&B=M7B2TZKT8>>Z"\K>6I_H#WWV T)IG8';$"FN
MSHC6^I7.@)!X6ELW/:7]2=YF#ZMEJD?#B/$KEV%RAG%Y[,(]B4]CW>7G'_84
MJXUH0)<%ZXI.J93N_LZ *B% -8[U+'9L3AU@TD""?7LSF,-$2*)A7G',T;[N
MQUS]EVSS<M]Y^MZJUW,G,KJ#/"I[*EM;&&.,_!S.Q?WC%>,2LE;TRO8?Z3P)
MC I[@M>!JP.MNS=/3AK2TZCW\@WUG_..>7KRZQ5YVHWB_0IF.)%V;UKBOQCG
ME47]2LDH,/^"]XEAE=!BWF'YV'W=VQ#AUIU%%9_%7,\^R1:*)\DP<B>-?>O+
MD=;X+Y\VKVXFQ$NT;MXK +X$B< Q9;M.!I697U,-_!'5<<NZ/NX#RZ58:9=L
ME3#>;(AFZ(8>DDK.1<Q6^[RBC.-3"[/M*P]TW]T(=U2MLLD=H=2A/WX(_Y'4
M9_SI;KG+Z:_.J-^^RN:%&>8U(QOC/QGE X.&.4\8\M&#6I]6A#:0X#13Z!"H
MT-5>G6#LRZ ?LF; [^]@LS4$D!I9U1V0H:=(E_0(96V2+"N"[%@?.UZVLC=]
M**?'M5;TW&B2IXT'/#K9 ]L0,8S"!DP"Y'O'4QSAN@<#S:RLU#5X,SCEWA'"
MS]4?(ZDP@X48](?A' UK[_:F$AO@5TM$^5+;:6^+.Y.2IY ^5USTG+:N[%@>
M6#?N*(FO%&/&=AZ<[4N* %<%VS82*@JPY<BP*OHLTJ.XI&;:RIJ&6&C/S9W-
M^*HXZQ 3R7\RI67F)KU/_B!I=-WF]EBOO$3[2+BE?Y+'Q KW0L50Y8+HQ?,%
M<HYVJ2MX=<7D5RE^;_.4TE_.[3<S\U'[5.HI?!&MZO0/-9&HQM^?:N^\V.T6
M-+XTMC$5H>J4[E5NXN]2F/%<U3E^L>30-]'*BT3MB" 5NTIC?:6=^V6D[=%4
M9V6G<&+\L:_ER@O2$6*$H8-A25^S>?TEDEJWI'F<\T H4)Q0RQOTV<?>_T8I
M*\()=_!GL?QCS 7 K\\%\%SB]S?T0AFTN;CJ(&AS")^9"U_5;79=_8T]#DIR
M;,&A'KHPR68;<D RE3CKY\X.6%%32E[1:CEP?-C8 H_._H00Q.BQ;1/JLL2(
M[9-)IS(4R6]0H:?2*CT6-BM?Q'M)1AE@&\"9C0>@[[Q1Q^XQ]RGLN+$E W84
MS;+I&''0<+4QE6";/]YJ;E@2693XL_7$P^2-=:SAE8HG/G,#<J0;M^>,U+22
MR8=?LR,321&X1C=T"(6L/KKF[7FE'7#^5I+TK S8ERZ=6(@Z.W[;-U/.W$WS
MB%Y^P1_^2[U[Q/6(Z&J3BEJF4MYP-F$0+F3X1%M3)[VV3] E5VP))9W3W=X<
M+X*2Y)],<PQSZ&=/6KLXEL*U\5+VH;4^8DN^3W(RX VC]<X<F3\7S^9:G<E!
M,JJE-<[6W.69+D)?#?6JP22X1L-<04:G#-KOG;1K/&\_<AMR:#G\]Z-IC%8P
M/SX"FFI@^*LRC)EVC@O#SZ'L??2^VB.CEZ/GGD5N6!\HEW)>PR72=Y%/+N&@
MIL+HI+YMR$$N L74VH=Q!#L *)/0,QO9HQ;%"!'S\II!T1 4&YGN@MU!?RYO
M.K>6X$J_+,SY/ Z63]',4;VR%'5&MZ2NS529/9A77_73M?C$,%ZOX^:I0HN1
MQHA84T%7YP0=GV #>!Y#<[7L/#]2PS=7DN_D]>9&\C'TX5Z6';$#:(N_]8OX
M5'[)N;4=.)41$EKE:7&B1[&W]%!;K>(3X0\+,H-WF\RS#<M/WX0P'-/"HM<J
M+>=KSSEUNY1*#R>JN-ZAVM7'U[LXJTRD$5;$+5S*ZE=4)GJ[SQ8\SC7SB\9H
MY=K52W=ZU)3#1<V;R\\QBHY^2O!PJW,JMPW_6A,#NUGK&!Y;9(56&1#D-R]\
M\Z^2&3*-H/+.@I6  %6ZY'Z$C1H<[.0X@N9+O;2Y(F;LI:L=': @>ZA+19PD
MF8VD447[JD!"SV3R@/]-W]=N6IJ*$1F(ZX"/+*@ L"@^)QXZC9!ET.09)BQN
M'9Y>0$\C186QC%)(9P !BG1K6L-_^C+(HT^-+KF]3EF6"]%-2I09..#/7EH(
M^^+EDU;[J&W)>RJ="_73SP^)80X)N@\U6J T4P0GWU;.##:81;NY6U;VZ8V:
MELI-NT@0 ILUNER$);MZLD KS.F(-R1=8XL7)<(S-%R@5R"4MHG;^")Q=&CF
MYBAY9.,G7GN(YK,O27:U)^"PZJ"?I4.Q2)&'FL!![6I[/UF3#%G#+H.3]8WH
M6,]I^^?^T5[CIYM#?Y3+!RM2SOG5KOBFU-HV4S\T%QDD.&ZTU#=<M^N0[#=(
M=E;MMM]:U<!<5M"T:J1G3M&;E-+#._G1%/@H!LJ,M78?P]T<2L!*#FMJFAX'
MGW>FD(U0!8-?BPW !-TLYE6+>G"W"N/MR]Q4&IRO\-;+CZ60S3T;F: V*TN$
M:[/CLCUW;&=25A7HRX8R&TL862(43)4G+(TVE71KS42P);!X<S8X.W RYK/>
MI4--'>,Y,X.JFA\X#C]8N*XEF!@8T^7(M6&?!Q"I8RXY%)H85F%,J7-"\E*<
M#-[U?:9 BK--$0FP6CI#'3WN=[#_VWO1%UE,+<I"Z@%2Y/STU?;LP)%D+KSL
M7([KX\B^RF.>3(3#XP,WFKQF=8H&A&4GG)A7-YS98(.Y1-AS%3\Y)8>C[_^,
M]OGZYC,5I3AF2K;8[F;L)ZO#%4N.V*_'#X;!DWZ[C1 2*<SRHQ^JA)WM:N/S
M%:_**[)J5"Y-$^LL9ARLB\ZIAI;KK=J&U?Z3B>&<X/JSH7&D2PQ"O&%DJK'2
MC<Z]V/U@9,\>:T#Q4V4D($0]@VXUP;'D)C*+:I:$:5U,-4%-VC;$NBVS-U9^
MQKYEZM2K1/^[V5I?<$TX"D&::PQ&,6LP_OO?5FHE8W $%%F:/4DZT59"X<F%
MMS2_2A4\I8'PD1;S**39U),S-UO&:/ 8S57ESB>=CA;,$,&!!A]TM-:1P&S4
M9FP='?$S=+%5J,%M^NP^+2W=GM<&K9.-!]1"=?D%=A\(*V!A+(%RAE(\1JT1
M9%$1(L:25: U16=GC$)'8,GA,QE&%J_)><JW5E:_$U^_YICT?,PQ/_Y@W.9$
MV],:OT.4$IF2[__($NB#KZ],Y*D))^%5B3]=:M,(#DX_1RN>?UUTJEFR?>X/
M9T;6JCH%6UD)W)*WR/5W>^J'O%YI=?:62;1VI4.'LF^M8_KB1-T_D7B5.NU:
M14?_P-Y*U'A:X1I-=4=?W18G):*KGD4%UR!I"42#/(/),,4>_&SE1Y2ZI,0?
MZJ#LRT$9M;X3VBXN>V6EWR#4QVRJ"I#$,1<D7AJY6!"MNV&:JSN*K"JPT?U5
M$%U5,%+5ZFLFYG#T_UGF:1Z^DEU\$DX38&FV1 37;$.Z/1DXT-D!(]#.YF4Q
M\*[S)JW-!&*KAQ>NA5Q?1YS</&1(2)E/G!M&9Y_%)SZ4=34\=4KGW-8&88">
M5L*W#;E)EP?K6?K/MR$M+@GSG?R\8:'*G]L0*/FH!YC/^#:*;OUQ^96IW.N6
ME^,1(08>;/Q&4V5=8#OMXE2V:I=8^]5HF\T.RGUL(;+W&Y$C&K41BKZ%SYCZ
M_"G8K/^!\3;D54Y_VY_(J+WK64A"_JW.ZUK3J7W=/AIL,83 VH*Q)"O8D1/I
MPY[H+6\8K+(D""*YE]M7LDU+?R#;1Y?NZI>UX]/9"/X-WC9DP/G"NGQ),"K
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MU11=K%4,NG^?.7E[4;C3IJ8"I.CF*0FFYJJ?K/,EMS/SIU1ZP_H8R/FE">R
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MFAC^D'+T#%._EN&MSQ:T=DUHR7!9A HAT.BXMI$>L3^%GN[70YQQTP$;I>W
M>E^&YZ7F9D _S_3LDJN/XD[ _KEL",_@6C)+#O3/KR8]1M)L2 A:@>G35LW\
M@B54SFWO\Y;J+OU/?#D*9O><69@/8<]+$][UGJE8^*"GD-PP4YM0F4#]L"I\
MM/=L\FCZ#_,C&?OLS>NJEJH]O(BO#;3BCU6G]%K9U51+.:*C553="IX^-PZ6
M%@D>SK4X.O'DFWOWVI<)B5J+WV%41%-(*DG=&%;.U0)1\P-IWJ(;%P"EKA51
M:DC# NU>Y0NN$^ 7N"%_'+#YD@\,UOIX!TE'-.2?7M(_PU^6)Y/L5DUCU6W^
M71;'B7#-6]CY]S&253VQU=@A\EXP)KH]^X)FQ@NT-A'OR81F29@L3_)48GT$
MWEJ?NAXA:#4A7/'F]]?/.(^?C6Y 7L1A:^>J;_*N*OU,V7JKLW5G7W]J 61?
M!>%5U)1[-<4!E9X/Q(IPZ_C?*>=\BLRDO,V%G<209HPZAJR*1Y+N]04GVU\.
MV;G2@I:J]BG@ -]R&,?\,SJ-*8\_TCYA;+8!SW)MY\L(X1U;R&LE:TQBE3[3
MT3'=C\S\ J ;LYE%93\+GN@L2IB>>C3M,1LXW%]^PN9DL+=K>J?OD.A"-"(3
MH\?F,/X^_,45BJKF#9!%6]@E&Q/%)9(9X4()M#]@21]M\D7[B^(/ YYOQD.D
M/ZFT"$Y)XQ,>)+]7*#X);11S'L@XDV+[?"4AM:H6^TMLZ>+SV4,VA[Q5K+2I
M:E9%03KA6X5QE;)F$6:.WQ]6"\3KY/)W@\_". ALA(KM'>>7ZR\G_*1L'[;7
M6C4XVT88. ^7+;YY/53<DDN2R,MK;6U]]'EFIDOLM+MGGYB=AYFT:B51^YV$
M6*;X;EVW)^;BY\]+BM],5?LZ\S;XURS=>RN",U1CU:_XRL5;?VWLUT'ELD?=
M_^6PV_^\.HN@M!@F/9%WB#=6; Q&1C%*DAT%893VJ4SN&60-^BU5@GP"K&<6
MWAQK>4TR8'/@8[K6'<H+- :YA%(L)RDR&!'*5 L3_S SW?NMLVR1VPYN0SAJ
MO!$?(X#>ZS>_ G]GV)H&I*-5$7P8>\ UQ?A2)>;2UK-U(7X/DLO?SL-KP4:7
MR2_'8<T1.Q8TGF!])<+F#,?5)>H6][+22V'(KDU4Q8> T;7IP8Z>TD)X\Q/:
M+&O%I=<:_67F"RN+>!&>KW_VCW@3X@ ZGW=0DCUC.6%JB ZYQ):D9@F#A/E.
M:E8\_4 #T6 DYP),%'N,ZT?L>,NN>C:/&G2Y[%FDK)@PZH.:ND.YF;7W^\D\
M95(O9[2;'W_K%K[Q=O$&<VYT3B!MVMG!^DUI@D+>XF5$K@]CHC("D>O^7O8@
MF,:D+UM4<:T 6,^0W )"I(7 ![*82NG879B+;'*+_(-J5"M."!/ ,45N-A8Q
MBJP$3_S:&-42=EL<7I)\Z#:Z>ON6WXW'V2J]S'=[1!D$KM@E1F0//!F[BQV2
MP(6R4HS/L4J6"8?[ 9'OGR:U!,$P)IE0MH0]T0HZUE.^%[((7>5@F&L!Q^X!
MU+;U3>:GJ?"2VYDWEOR@0%-,\PSO:#4<FM]G X=]="W :&U#XD)!.,,URW@/
M(1 ARG4,G=?B^[(PIS-!EIE=D+Z3UH.0TMVQA&!2=P:@R:("LX+65HF<*X!I
M15NQ:#,QN[^1.7;;=[R4(YFOC^N&/< )8/EP79>,[?W8%(HC>'>&VMDT5UB/
MLH2E&+LRST1A.V77BUZ5@]5>DW/]NUX7D=+VMSPH< E(2;[X0KZ/(Y9")!S"
M!+.-O]F!>S9RP.8RVLS#07))P^Q"L6ZK3-COAE?HLN_.$$BDB&$V]A,AG;S;
M;!MR@+YBP/%'J[\5'X_8P2W):RZ?1LDP=EX3H_"AQ)T#ECR9A"?*1B>O?0Q3
M)C0'0LI2_R!Y.ICCK>,W1C6Q*MQS;1.E'8:W:#?F]-GC'O$>R87+O=W6!N.3
M#"T)UE_!6R,I\?2WRM!O+X0LRTCYS.H^0AQLSZVUV$LL@Y[.)-C!9<RE4).J
MA"A@3Z^A4#R^):T^T*RGA_Q,ORW67VYY^'PWTJ\-*7WV_;U=5_1B&)&]N'B$
M#-%S2)@K"Q;.PU-]H&,M?*,AZP0(6&T.W,SWK[,0"[.LGD4$YN>WLGU.ZO2I
M>5J>^-#T/M,1M?N\B0X)QW+M*83'D\7C-NFV^=1B74"_G"^!)PNJ]D]$0(^B
M!QQ<O VL'QK/?#Y_";%44)[5O"!MTC&[15&]O"=R3@,(2.(*,(K">N75QE?6
M<(?!,-O7$Q&Q5@O)J9.?I@6,@NU\W&\$OYR9H1),!JF//;MD<ZR2Z09<$79)
M,O8X6 >GN3*Q1:%52]&]A:&5F&-LD\TBNJ"I'.+L(\3L.]8MGW, 54UP&Y*L
M*8Y9,;B*LME]SD4[5@ 2+?1N-?XOXG"XMZ,'<+L<FD)6!WGKQA: 40_C@+>%
M)SK.,S!:A^PST.TCUJQ2A@ZP\:X7SWCS]IG-RLJ7K%^Z__NXN/C'.?18MS0N
M61VC%,O,V#W4(UVA%5J-CEYR;7KH3DXXT^YIHV\Y^2O\*$PW]/19EMZ8W2XS
M!9V: 9V:]>L0[B?5BO;,$LC'OQMWLMQOOTC'WF:-8\-WW4UEK4.33?>-[I&#
M]\I+-QWD]PMM6 #N0_;F/-LZH-=O"?R8W_QU!,VA;*;5JEX?O9U9KSE_1>U5
ME^;A9:"M\<K1?BG(.DT-0&P,[\14]5+);NS)G\5[0?OY6".J1&N[=]5;IG=
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MJ]O[YN%=,0*/0\N77":C<VL\"Z-<%,*")4N.6++VGSOR2&C82KGL/DP;%@A
M*0A0>6A9$?#%?&XP504=69'+8\P4[I#J1&/ 6'A),NYP\%=C_D;%R5LDVSS
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M1=4"2=UW/">8@2T#6Y!EZ0K"M1'A+O05U6#N&A(&*O9%*=*]O'Y31UYZ>WF
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M85VK"?'Y B/A8LQ*"RO4; /6FJ[*FNH4/_,,^AZJ2I#?+*Z'9I"VF8L_)T[
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M=I!FGFW8]*JJK<_BEH]7X25Z (.DPRAINRV(DGGT[!8DM?!( [D#(6^NRLF
M3$,EP#O>EMWC>0GMT[EEG^9/J%RO(?U) D11(I)1R9LBV<;5)FIO07Y.MR$Z
M:;6*Z3BX&2%XB&#/'>%--(#((GSHC( E8706@2:G[/<,BAHO\Y\U >_G,-,]
MFR;7]NA68PDGFDY,UR3V?'>Z^3SXA@N:N:$5CG59_M;6064!EUA2^#<#?7U(
M)H7W'ORNVQR=+X6;#6?1,_?5ES2=:!HB[IV'[;MDW%:K6<Q@!#Z$Z3WY1\I'
MD]LOW)W+-P9K9[N$IS?SP@?W$]^2E-KT<.7H*X)+0"J2NQ>GBL>XAN?PZ339
M,%JR<G59Z*S*11QD]%?:FX8*"TO[T=@\LR>^=^]1/VQ!$K6 [YL';9;)6Y 4
M9Z[;%B1GC4VK+UN*G85!!9)@6B5!&ESDWUJ$R=\*BT83E$H_"4=0,N'VK56V
M#3&F9V?CD*-&F:^G3HP4KCW1MSS<6[V8(G] @SEF!I_;I\)&"*11/!L0.\-H
M:!\EGL"PE(RJ/$6):+;YHAZ5IF8*8KF6O=3C-/<<K*43+JGE1RQ[;43WQ;WI
M0:N/ <,&MPPG);RB;_+M]]S,1?:1:Z'+50"J4^TD ^$/FYSD]*6&9T [A=JC
MA., G9<'(&.%QG,;'VBX(I^!%X$Y1,WA2JHJ2.U;5GRYLRJ=P:Q^??@-WK_5
MOEDP2BKUXAT#)C0RF3#>A\NVA]QX+\&JV$+ZW==]8L_>:HWF(<'KI'VDH6[B
MQ!8$S$;(DW[C_H"]12WY<B,X):QE"_ZQ()8$]91PJ-!TL]8\@%O1M1&P[ \P
M>@MUP)1J3TNV2OOE'NY/T4/2'>ZX IETG"1XM)O5%-=@@; ;VEG$1",^U2WL
M6L3VK=N@LLF26Y#K[3=Q&>3ZDUR;'A1SW0I(:%BA_T-5QN<8,"5ZF=CU9-UJ
M B+&),U-*",%YZGZ>25.>J:^M]^L,5\)6CYXN?783=RS2=Y18%+'0&"(7'YF
MLOT4K<&MQ]_W87J%E)_Z_>X[T,/Y$8TI'IJEN4UNWSKXYU.[@-Y8Q80VBR+\
M'2FD]_CSH3 ^UM3"JWNCYWNRN66Y9OWUDQ&5BU%Q_3&O@F2WM7SC+=@41NZ)
M//#(J_ZO_R0#_W]<.K!NF<4'@7F5TTIU(PW0_3U^MS>,[E=%&"4^"2^OO(7]
MD];>U-12.#YN>[=RA(XU?_A<M^;L@:K48V*KBNRRY<59/?LNHBX8RTUCT_X]
MI?K?#P@P@1_?_#=3,2T\4R&H)2G5?">)X^4=[9(ZCM@WT;,OVX*66%U=WZG[
M(N+SX6;WI]51JC#AWB3^Z:!0SX8U6@]* BU+ZJ*VM7%-THB*8!%=J#Q$,.-Z
M+GQ'@I&<*HP'M=[> 6')A9=A]#(J5Q$%P9/!^C/WQG)N+AIL0?Y<$4,)C+E:
M=%MS?T[\",&>?P%<YZ6_&96Q,%MN%![B_IK6RMN"G(\_((F84'#@I#T,>I_X
M)2V0\/9 KE8>][M -I.=V8V$+)+V$2QG88JV[!5IO!LO B!6/LB G_UAF#DQ
MZY;O.O3XHOK[.V!&:72,+T/M$AYC<+PW4&Q"N$TX@1(3F5$ID@O HF,#KI*O
MU@)KF>F_FM=BU%;MTGK4=HT95(=-F?3"#^:QMZ/F&+DYH=9E)Z?Z9)G7!F[E
MK#<.VZY2NEG@\3)Z9A))@N# 56"(<I!;,M68,FN@ IK1J=#A!JF[#AAV9GP;
M"AHKRT$DAUL8?U@8["I4'A?8,8RC;JWWVFIZV>;?=.+QFY;:^1IH6)T\C>>:
MP?E-L&5O'NEB(F+;E,JN@2:=ICMY"6SL7ENI>,]2&GM*%CE.0+[:?,R<7U=D
MMG^NL=]5@+VCYRJ,[G\BM*_?@MP+8BVRI$CL:U,$)ZY6%V^(H#0+F]C 8KH\
M28EMY^'J@FVC5 TDUX >$N0JU!II@"TA99E!$8R[#$4FQO)4IRY0\U#C_%^P
M\WBZ<*\28,"F)5>:G^8J]''$XZN-+ RNC!H.8"X#CK54I7$R/>]H 0>A:/,B
MJ%?>:Q*Y;RXJ;F$D*/%8_2)?U<0EQOC;_-+1<R,8<A.R8TJ%HY\)-$ZU!7 0
M"AC3TBI?')9-$L<H?VV9"#3AM<!;JR72CMWPJCIM/?Z#83=*[=8/7M97;\WR
M<FEJS'+ZF?A&Q.[5P*Z'LQF6L_)-R2+>T?+Y. LVE,\1)<8K"8?0Y2 5E4K:
M9T1*:A(J<B.Z/>HC"4XOYZ*,<EYM08"4R6F6177L#O2MUTBYD,B8$-%8W4+[
M:(E<JX5 6?3SF.!)H3P\J00FO6C[ F_OPRVLF)4?JR+85(*3?X!QKP(I',1>
MD.4\=BBK_PK7.B$4HU]4ACR1,SGP\S,DA@[@9E4S>T*Y*I>P9^8*CX$N7$4O
M,)2S>6#*!O\Z2/F6<=1]<KG7->M7FJ_'#;%VO;R))R[9 ]V2)N=M>7F_XWAW
MP',<:%(>K0]Q$$][E]9-5H)K3^.K#$&#R2N9%X&<C&+TM#) S+>8M%$B7S%6
M4%2^7W+VE-GG($TU:_S?C)%?_[$.QG^LC3&(4B,%TG82I$>NCY2-MIE5"JZ*
MI*G(\>Z#RT[C*5; 8 K\R()KIHP4]%SS>+5ZC4@&.659C?QZ&;X'6UF]EK+T
MBWU;ZXT3ZCSC"VR9SI?!?^^E25?#3Q%.#H=#TWP4P52AI,A;!.(FAM=[XSH8
M<$038$7O!YJZB9)@Z?BZZ1:$OFS6,:W9$M<-/P&4QH;Z^7):[36I5@ZN8SV
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MC_[H<V3H_74HG>G_F>MC4Y\XM9]I^2>#C>K<@DP8<!B]_YZ"#Q7 N-\[J#J
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M7?/CK1426W7X*#X]),@S'1W$4/'36$7ID#KA)/1*&D(VF( %*)P/#46$F\T
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M=E,=9L_H.HV-@"DE?++#'[WTM3D)Z3![,G?697YA%O'H@,T^Q;Z=MT9HW,7
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MG1\*7^R]\RD?[))[OC#X5>^*X*LSM?$%. ?,#5-^8?:J9$UL4ZJ PD2L0EO
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M!P[]J+ABNAKI[YRA][7Z( 'Q$=K\BUX[X9JN/>-VQ6)4M.:U6=9</+73QF:
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MVHDR:Z<T&_#\6DWVV2^&^XW(1%]'PYAE71\5.F)1F_BI$2H0%^HY47 O1H7
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M5PZS:WIVQA[VODX]::%D1*HQ#KK29@PQH=<%AJ8ZKE$%5L*.1.$B:%S.TY6
MGWC!UDV0&&TM"H/X1Z]X!:CFX%GSRI=Y2C5YX8^*IJ)\%JI?^;L8_:Y+QC^;
M[C;O%!3==%8*"0H0N073N?<,]&QGK:(+56-/-Q_!(DJAVYM#$::K\23XTR%T
M"M5T0MAU[U=3425O/:?7LHNKCC!\ZZOO:Z5^>,$VVOGI2=\*YZ>R0'1Z@P'M
M(&<,$[_C .E2_')I#,1N<?\FJ#!Y$Q2C#_3\5T^)E>?M?_.^>D,Q?(),#:B=
M7'^(U)>D $99#4"H17*[A\31U3O0J]7-V6W,R8YFA0]?=]VM4[O]H7B$\@T.
M*&^" F8WS)4KX9^%6@T,0"A]?>/ZQZ _I_"KO9N@-(WKN,4>**=$B+5KHX9I
M1G;86:J$*&5E-"=[6VVH/_V4Z[4^O1OK9L;@X("0&Y][^<\5'WY*2?01MR!H
MC:@I1)\\<#6UW'5DZP<1\+*G^)[8[KOB'_9E!&^"[N.8\ TB<6G)/$_@*PP%
M(4%8%A3BU?XR_GY_L9<V_%1KC^S5&Z&5=[P#[35/G+YD\T[,3%MF:[@!"WD8
ME8I8B1_Z$_2F>N;9-I&?:,=GMYN2M.\WJ/S-2.D;E$="#@+EQN!*2]O^8IG9
M?X:?X=+J77X$DY$T:%I8PO1T.<VS2DAC(V71QR_7]^GNS3P)5@1@CN]Z2'9%
M#N3177 _.H'0F49_<5W^3)-Z@B1*X.2+' JLK W'M@94Z85G>G300<@'BZMD
M>&.KQN@F:-\FZ#UE'0Z?GMK A],V&J8G9X&(?SF<4_JO6,N"5W'X\GBVS;SQ
M.@PMS>Y*PD(!93L@B+O.]KT#.8@^O8LLC:C9!%794#, R_F1=8?W4&F(X51>
MS7U]_AZR7K\1W)\>D5*%E'/8%9WB>@,6[DI;D^>!DTF&S'FS&8%NOQF4U:CC
MKWHC:Z/HE96OKS_*+E@@J6W=EV.[3XUH:&<_0V]N QEWH<PN$G4]Q;(.GA)T
M57T])TGYHT9OYY-=U$-);SDB@1_4*(F&QUX](QQ"A,U_63-87D5Y.;S]>:*U
M_?+!>GAVI!<-QPWGE/ZH+!<.K";6"!AI@RN:!?"<5DB_;BA0]VZ'BY A?/%N
M5,HF*&'ML=>^-]S:-G-[3P^+?K[+BP[V>HI=P"6NI8'J^=^G3;&)5T.?64RT
M(W?.';"MY@#[QM((@@'HSDV0'PR?XJ[QAA6T;60EO!%(9$K+(!@R["QG'G)N
MEE6PE4H&TS R9MH\,!6KW%?<CV.I]!F*)+:.J?$NY?F,C)&.F=KWX&<P+3,W
M W7:QS3SU8**KU(G2(W%5UD_K*G4/P9O5)<- =%G^U&CU^AC-%@O86QFC67P
MK Y=E'KX1OK8V':M=X''LM/%OT6('7D6>K%3$HH:@+)M9QJ=&QJ%9*>@!)<V
M4Q?XI,IK(=EKI)R8V_%38D/(P)F/H&J! F6,V0:>+\K>L&Q?RQ!&>I##;OX9
M[FH+4@QM2FU^@SFX\1ABXK]M=N4N%]E*D?=7W>C/ZP@PO;FNE&(47V)-\T@C
MY1Q1+R$.2H\<7[& 5N&;]!,IVR&[ <9IX 96%IA\7WB4ZX5GXR2TTK#*Z$PJ
M2Y!OE%("R+.1MYTW03 '!4!CW"['!&ZUCB*%S!B9HKZXNL=!JUXWP )$/QN%
M;X)ND&IK&U*,9(IRQB:48)'N\C(WU3UOJELXGY3:+7N.][#_^-#PRYPCNX9&
MO&]M3'S(4,L%<E\N[7%R2HVD1#S+M MME(,AA>VD?]2MT=4/7QS4K?KIO$"+
MIF^"=+T::I%-TH"6RYS6N,,0_"Q04HS.7;F3-:YQGZ=]L7MYWI@J.^7^/):5
M$9]7$"<INIH@4!N:*=Q/&SD#H!0.Z/*AK!<%'O;WS+I087-V5[&]#*Z]&I(.
M$\X>\W&" [L>?8TV/MGT:T>S%,;X*N*)Q#I>!-W'3$S?S^,DFKF55ZUV^+(S
MI.$S@RNO_;&[,NG]5X9?]=B&-5MD,,#R0*(%UR6A>A.D@JZ?M.:NQF-TGWD%
MC.VGH;0]_ (-@M0<[E0@#26&S9[[%=T3U8,X_KCY1KL2A$XS'G=ICG%I\MH!
M)"/979(60CQ9N2&<^7EMI=?KG= O^UT]_4>6RB7679$EN+E\;8+31[0<? YP
MGT6DWG5 2%T6L[M5/FQ"KC<?8+0,-M(^NBV&AC8T>/ZH2-=%1/O1@@L#!6BX
M8+O=.'PW\![C#K#6+='>+9N@76:>O,IFAAQ$9X8BC=U=>YNO_!)]L@FW'6/)
M3:$*Y+G0!'G/?C"5OC:UMN@?E7A/GX.R;J#$2;]]=O74ST46@R\3@I'DTL;%
M;@=#3  'EWY2B#*5(0GHMSD"$6RCHO)I#1 7VC*$W0=[@JZTXQFWS$=3(S+]
M]XWI0@Z1M(O1OG;5)$:9;G%DVF^"*@R8393$G.*6)I!0S/Q.< M9FI>3YLT&
M2Z 3[2KO+&T@S_3/9RXZ]+\:9KJL&PZ\2@Z1O2]+>B[U2<RPYZ?=QW710I"C
MQYS1R$W^7LF)^3\FXYI.9DCD7>D?)=J:+X<BV;7'&ZN1%'A^Y2JE@(!OKG<?
MI)4&O<H<04ZJK>3\6MW!7-LH$H)$HP0[NVL>6B2DBN*8 SQ])J45+HK9/VBV
M-?K%#$1BD*SPN;P,'4TUG<](#IL'VW,IJ;KN'@46<&JMZLN9UT-G4=MJ:OTT
MN6G2 O&?/'M/J#W7-P.'X(!F&3O)&IWK,""?V9;"8L2V4[':W9 ]V-X<6GA4
M1=$X7J&=#4O@X1+XQJ(C^7:'W%U'O=Y)HZ)Z)9<W7).N:_Y62C]Z(%?".W#H
MNN<70LWQZFSL#6?JH6]W;">,3JV+%GV\O.M-S9Y<E?.RLB*_3YS5E.WN"XT-
MJH^JC5C_&/ RO)H00" $*1*ZS]EJEM:,?0OKT57G5"_/+H8+KF-,-D$BA8-A
M^LKHDRV]F%O="T7<VA;.$(>]LT:;.?L@>@KJDR$^ U'J-WCQ/2@H1P7CAQ2,
M^(3U?,@[W?JM4W)AGCJQ"4H5LH+SX-1!R+:-A[@;#"ETQ2)[MS.XVK@E*,(9
M*&)N@K8A!#(]9BKK>_@N/!VODP"1V\&N(;X 8B_6TPQC0MWZ#$:A#C'*=F=1
MAW9[=/@&J9J]Q5V%)8:HNKE55@:*UQBUIOBJG9*]_IB7X?[8YO>==S_U'U8;
MBDD?LCY=4/)P;GL\\D$FUOFGO;3"XR<#C04YE*#&W0\*>3.TCM(_Z[(<\ $Q
MV3T>]5,,HN<2\'*,<;XO*'"I\<@)78."@Y\Z;'L)U[;O=J[WR@V03, C=__!
M-DCX,K9KT/#G!;V!]Z!+Y+_0FQ&+P3"&_/3- '=UDG)4T.=<60NS^A.5F;:Z
M/F@]Y3F:,^_*X?2S7W>V+^Z1T[L8JWYX3-NUD/U]Q*'V[@FO[V[/JZK23Q">
M6FKFRE5:F[WS3G,;LVX^HGWTQ+;J_V!TFR#ZVB;(X>Q*S+?_HEJX?Z9:?=3Z
MA43VO 2,!XVO"'.0 4*O5-E96@TNO=#56QIU;[,;\QR-_V15\UUL1XM9Y"Z1
MQU+^VD0Y]*T.KVZ2;B3NB0<ZOU5FQABRF\OO&:X@5+A/\5[55P_F^T[\K%6B
M^YNJ?7P0&/\LS74!)?*WSMG,T1:A?#&!M)"8_;3\3PIL\PC,7W)8G\:UD3M_
MX!^[NCU6<DK1=H0=^CH#2ETX9'*S[A"$N^M5)]*Y%W/\J1"A>;OI!^-9&U*?
M[&#N@]5G7Q$,YO<[Q 7GK%ZLR_R]IN:#N*[.0R_KX_=M:G$?-T%94?"Y)2$9
M+_J/K_=U"9]+/Y#_D:"MZ*9V^X<;117BM^$C2_V-PM?2XK\IA1-$Q_ H.8>@
M:(F?IPRKNC_N3M;_.C1CJZ+H_0EK,Z1[3"U8,NVUSOO@(T]:%VL8^1)9M=^G
M.__.R!K_1D15_C<B.N2RZAQECX\N]R\K0=0[/_(Q*BGS-QX<S%D)5T55!>FV
M+G_[8:TD<7:?=:8;0_;I84W>98,"[[.T*L)QSQ[-GF5/9??7U0,&:8Z?Z+T!
MNC"[QF3?2G+5HVLCNM6?]=Y2][#NW_G?6>O'?V:M*Q! ^-S;O@D"$2C @-KX
M)@@/ _.W"'GB^*7H"+Z08VW9!,T+6RCZRP #X_\TP.T,,'_-5?A%Q5KA1XHQ
MN,5I;Z%;G!E\__\'WK[[+^[R7WBDB:-'(;_@_[7I"/:O34?D^K^U6S9?>#PT
M&-)Q'8I3WO=I2':]=>I,I%AW^H."\+XK*9?YC']]PS^O?K6^HC"@ZY<X2ZGX
MN(N&^ER/^^#M)#@@M/!CXZS^?ZDTQ"B+PY'5F=<,C0S;0DB5.]O>]6>AR/G/
M49F16IG1 \=XJ=][6[PK @D)1VG0^G&%(PL=7Z?(M-)5H5?^4P6*_*-/&F=A
M (V;Y0$TL!FWHVQ220=>8/RX6O$&^KN!=E8KZ??:))(Y"RQ_I0M1%%#+S0_9
M0?=7-NIM3MY---.=4$LJ]DB"+8WI\-IC^=OUXY[PTDN+@"BD!IIBSQ6++>[7
MW6O-$TM#!<!F-XRISB=U&:;9$SF/7EQI52"[_W3.K#1E7E]K7U5&9E3D8:"#
M!4O8KL[_#(@.P3\&Q'+#S%H8=I_#]L8J;>+'9["*$OS*B:/J>FKOYDK>&3_]
M.EQ.^/SBZ=?.R;?RQXJ2W=K*TA*VOZZD*ER&7JTYTKI8&2#^>H0;_N?9$R?,
MG/X&$%9_C9^N?XJ?SS^&=F[<[7L>LJ(6-&(QTH#,;@CFY(8;3:9.WOM&:]>0
M1H)AW#<HNYU\J\3FY/$RS![=/8+!C"9.F64Q,4D#NO^3A_S+KQ;>65IY6MF_
MI6[-@[OB/E"X^@X+:P+U_Q9U^C__ETGJPNH:L5SQX/FF*[.^Q/(<FE<+=;):
MUXC4*=WO7$&I=_$HFG.F[EWE@-E>!-NC\XCNCG%X=4-E0]7Z%KA8WO<QOZOZ
M^^9-UQCSB'4C="C;C+&]NNL>1*J/'XJH< ?@3J]SS]?'[#_#L_M1/ QX>_+.
MNP< H3:T!9'7+Z=SZ:E.-IK<UJ/)$Y>U!J'U#9B8L#[6,O_DU$;6PB_D=X *
ME7UA]#_5&CSJ<^=;U[6F!,<&S41?8ERXH[E)_)/C,%RBUUXYP-LM2-J"USG0
M6O!,0V70S$[CSS7UA">K4?%I9>M6; N%U9LV.A_@^U_S7.9MU\W1V@Z#U?HR
M0CU!.HK&M4=1FC?LN^Q[@ZL[?2![II1F(XEH][XSO6'K!-@%2D]@@3[*1(>9
M,_BEIS?25_Q]UBQXU LK&,%%K/61$]\N_M\JA)E6NY=\#V0OH-:&ER:=6@@#
MJP-.<"ZV>@61<S*[S\SJ^95IETP/VP^P)&9=Y-X;HF?N-=Q14?PIN6Z :U(G
M27+)76WU6FV,I!PO*)=,8"(3<#N$Q)$OU6?(&:[@ OM9D&(A)]M%$^Q#Q[)H
MR7.&Q%T8>U*0O0=.!OU(7T>WVO5ITE?7=Y<N"](A&A@KKE8K7GRJT!Q 5*"C
MV[#2/ 7'CN+9>L-7QSP\#1M;<G+#>ZUT22Y&N8/&?W8B8JZB=KHXYQZUW=E3
M3KC$P[5"$[%;:&'Z$N@&CYZE##D ;SM8S9'RTX(%=+IX]/!-S.-K&E\@:G+"
ML\P_JYZGE]P=>_#SJ?*.]7/EV;G.QT)NE2H'Y6?3&J\+.O,886L>+L47_*=M
MRZO#B@D#) YJ(BB;3\%+2^*:#L_QCX[#18"<+G;"'4@VDSBRG^TR#T.6S$ 4
MWPV@["PM>)3FDQGQ]5JW49(1CH-ZQ&I=)ZI78!2I\&"_UPSL1WI:8.ZQZJ8?
MOS;966#.<=OOD* L: *T:C76S#R:#1X>:=T$O:UM+_]U^/.^Q#9G[!' @4U4
M#RC4\V DA.?F\8^AY=M48_!)U9*:GE_MRA$N<NV^.*.\'^XMY1LP_]S!/*/L
M:,*,<TTWHAX5ZQ^1=3!W]P^KZV^2SW<$[90.T;O 3]X=N,#8M^7KI95;[3A?
M! [A$Z1+6*Y2#D\/&_*.#*JXZ*6R4W_'I_SL?L4PT=T/1Z3$R[XGG@M?*CO
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M#2F@E=5X(/!&MW!J2+?* 95-$)UJ[L3RZ)R3VW14'/Y&0\]"14G"PA?;;K-
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MG,.7UUK!;SP1J%EP-T&MT)K<.X0@,V\6,9GNVT:0/P?(7F5U)=)I2?QH@GN
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MB0<PJD0N/Y !TC@K.XEEG(4)LW68/!)--!%;-T^6E1:(TU;]G<Z^?)#D?,!
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MSDNR.5(OJ5ESAD9[VTY*-*#W:PZ3TC]-4@%LEZO!^9EQH=RF@\E"0DP/I.$
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M?$[0W*, ]]^[I7/KY&2$>?R>E+5_^"?_F'[]0@-4JRC2TH)B+/K&Z&G/1XS
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MDI(%,6^]1HN=@B+S[*F)>S,7O2XR$R2]/;A6/'.0R77I1+PW25G9 ,44F*I
M81+V4+%P$YC$;6(KM:54R[GANBP5?W$/!SH*;H)AOK&A/(_NW>X%'JPJ4E''
MGU2H[5 EJNY@_T']HIR5)F]Z'50R4&6"RM9#V?2%XZ5F3/)X5/R;(&-G(%!%
MZZ%>:-3;V1U_)8+?[8V_F!ZFBY3Q#+YQOBL<MBO XF#?Q@^(=QF(\%)M6S-/
M?(0]&1,<=9OFUKMB=KZZ3NATZ6'7U(_1'Z/="FUA5JHO4_]\.W+G7R1E[MJ
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M8K?5I\;L=(Y2>K>'77DE)W,$7)EZ@ ]8VM$9R/F\#$O#J]8UK$/\$7(8)7O
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MS$=X%.BV!$M5UV.-N)V=E=HT]3W48;(O_S+8R</A'Q%V$'@9W)#42?SCB:W
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M[^3?EWU]1[<W0Y5-E4WHHXL^S 6O"03-T._I<<S:]#2L.!<AVJ$Y&0E:BQ2
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M7-]S8"4?%4"HV^^]'5B'=/"ATIBB%@:35J!Y@0M[Y OHS<,4!)LJ,/OG"G4
MJ<3[<!TNTJ4&$*NH"$*[)Q!@J7O!_%>!WE+DOF"81W\P2T^M,W\6IK ."7:
M"HX)\Y8BUB$,S0Z*,A$LX1IL& (%N-T&,*:V4>0E@0ZZ"ZF.NTI[7HE5Y9IU
M9DK!K/NRQQQKP="(XAEW^N.?#8-R#L#6VNK125'*71.=YZQCKY_9,B;$&E)5
MEVS4!JQ#?%.IR0=_N8[<^7K:T)BN>C-YXJKT!]TP]S%[V?/4R//L/.VT0W+@
M_E0%.NCJ^'4=DKO&[([B#4Q-6_@)*M;^P0B6>X@&:85:'X3WX4K%@HL X1Z*
M<@3#"-;F,%,I<M.79UQ(T6=A4C>'?N=]-5 &PYP(+?5HQE)6F-^!FF)W)N-;
M!R/&[]8?I;^?< -XHGG//0T*0-^PX*+-8 :+\)!G JLU25QVV.K> UNP _RM
M028@^2EO\2E@+#<YMC)87=J+-9G4B1&J7LAO$7D3V)5.[;L^9P=I$47QMMJA
M)VZ,VQVNW?+BEUO<P2C^YZN<QYSD*Y^>'3BQN\/NK#MCG"&NN6UAE.T;K EM
MUFI('?GSS<'P[C^J5G7V6K7)[(IL=O8'07-T1%]TX,P_CW7(-@A8P;?"'+\F
M)(03)##?Z9/5]^ ND^L0U3F8K$C#F/@6O-MS$2PK"8B.[7F(58ABFVNSTML;
M],+_51]H;DXYFT/CV;.C](K[@XT^5F7<0.W;4+UF?@0#>XH+:SD!/UV)&6M#
M*,$E62B&KS58]@K46+7A1CYE(1(M=@WY@QG<P@G8?[<J-_6]!E/9TW"MLAD5
MEZ1@7;*3KLIP>=2-]Z> _3#B-X7!XIH6^.VOW6K=9"5'1:>L,(5O=SN\H ?Y
M)N6_7)T$G2W*LZ>_*]WI.*( -%R][G/M/O?$/Y<MJ<PV>M$VK9L-3B2.,&)I
M&G^B<!?XEQ\"IK#R/=OY5H@-"96WX^X88.O'L\S-VG!Z8!(WO:/0$&QZ'6!A
M3B+B=V&A7$0\=I-/(&NN(,:*S+47+CTF>BC4/'"KI\:<]_X34MW16-TA-.,]
MX/(WL%?=XOBT$FPK%LF/PL) !\"A75T=+SL3W4PL2Z@;8R::)J8O0W=@]D)5
MQJVVTNOS(A;32SWL8Y$JW?XH>'WF?FIO0 #-]/5H<2;,^&J:Y(G?N8U1?XM#
MW]6^_[+YMX^FCES]J=&RS6)]OUHCGWQUW[ZGXG'Z4;<BW0^[[O27RQX3O&N_
M>_!7Y#AI"C>S@-?/AAE7?7&KC%E &ACH'/]#YQF#=(#6 :NU7%".@@JTF/(4
M':Q^>MNA#8<XH05LRTDC*P Z[>(MJ>73S@AILL?_XNM-HYI(H[9=G$!%0 %!
M0!('!FV&J$S*D*BHB#2D'0 !0QH1&6)((R!10J(BLT@++;0@1&:5(0H!%$("
MA$&E$2202!!"DE;&0)5,)1GXZ/><M<YY_WQ_LM;S(VM5K=K[WM==3SU[X\<R
M$G7YBN3HS>;!@_3TX+;&ZZ6%8?SV1NV<G'W&?Y&)I  NV83<Q]K2Q6YV$)MV
M9:Q5/;7HD/\V-PQDUP;JUO@U] ZY$)@6?R\%0_R(+*%%0G,O6X+LIZA2U8?Y
M./WE^]%.9AB*^A'GVR^FRO2RMRJR=<,V72Y.W'C29W_]?8/+C_^>O7X97YQJ
M?&N/3M#Q?XZ;NZZ_ZQF#3QW9T'1VVK"*[F94Q7;_Q473O/;9MMX]MQ^IS!W=
MM3L\N^G.]#1-('A_A=^ YU-BNN,6O;[*4E:5[I?)PJ%"X)8[JA6U2>8#VK7Z
M[ZV!3H,;.IB::X0=6QZ"W,&SF=LR,C39J',O'27,:(_SZV0Z-FW2/07%%(;X
MP_NK\?ZB'^.>KVL;?BNP&IM+A=>-IW_'IC2P=)F')WI%"+[#F$IKLUV+3L&N
MOAF9ZG.BBFANIN?Y=($UZ!S: -/,P[QE H+V9B\\F>.=Y^7FOO\"/>=LT_W+
M/E6\Y3\V';4P9"2::+J,L_$.:_(8Y4I8>I!Y5K QD6C+W/(UPOW/+8&Y)NLN
M$(/N_7-P]Y%?W W.]&Y[_#SD^NF; ?F'S;=IMW?7'3^&F?M'4I9#&1_0KLRL
MDP@P_%AK21U]?I8<1FZA[J*$P--7RKLP:%'IIU=)2Z0"Q!"9HA9F6W_+WCL=
MB939XT\NBU#MEV>OOJ9GAT2G%1>&9-?Z?K7,6O+K3GK$/Y9%E V# HFKU./R
MZ.5)\@YYL<**^LC?#-HI/4O,$PG:MLBT2M E,CTH0XA*@ZD!O/M9+2NDT<T-
MC$<6*FQ]QG39Y:]3!7LS_-\T8LBN1HE$&6W"3\ABHS>2]@,E_EL@2E&^ ?OE
MRVG?P79=;YXOL_ 5CKR_*582Z\M=C#OQ;< FW<_[W9\?XBAQYCE:2LE^-\)4
MJ#(;^=],%=D^\%&Y>%5I/1'YO;N#GU]0459=446,]P*/]M&K8KST9QN*H7/#
MOKG?$=M"5NJKWPBF]&_EU:NF%#9LL_5K+SQ:G]G$B8F1H_X>*,KCN.#,+ MB
MYI@9Q2A#5BB:K[64"EF!Y6U(9<@3W"_N3;7)2((=E3]C.%1,HK8OJNV;ZA5]
M2@-53F&<.[R78)H J\VA'C1-S%Q5^HU>#R9E1*-TH:WLMH:91DQ^<WMV30Y(
M,)!AY$4&(E82V9SD"(YWH),%=-X#UG4L_R8J6;$!1-T/IPBUY?DR-*H=CS@;
MAVIS*R?"1K]WXAU:'R/+BR=RCA![+_"JJE22*RWF"I6'6&6"G#\"=S:=W?GG
MN:7ZWJ/IC\2[\D6A[;'O?K3?/_3'R?OK2M7JGG*/ZKC\WG\NFSMI75E!MYXW
M<C,?#_[PM.#DQ6]&-.V?X0I3G$+?KWIJ^/5%5]+!)C__4=]HWK<I,H[\ ;6=
M[!#&4J&$R'\CN?=10BPNMN6&E[\@J>?VS[47F#8A#\*4<KSK@>PZ<7ZP,*?-
M"=&Y)4;44;=].,1W0_XV?]?"J9CO4U\ELD]0JPB>!J=KM ZSDOX@!4 @&-O"
M7TZ@!&OL)D7'76QKQ">L*K'A?/5I\75J^9IN6V9M6U72J+*@LMV%;V*B*XF(
M\Z]Y@E_K:N)_8PZ24F[9+;PN/.^Y[]&N_1?.=>$WVKXQ._SUGS=^+MKG9FX'
M;];+,,I"_Q:QW^C0JW^[#Z=R1VUB?M?N.?K(V.?Z?B6T[<\XN/71$>.8( Y+
M(+^EF>DAJRC-*>_^T=#K1B8J^KGDK8"WQ%EJ!^6)R?FX5^1NQ2[(#T2W'<80
MJ6T@1!4V)# /NT<+3P'9#>)\=8X;HP\?/, P#A#A[4X,1EOH&^[[J @UKU2K
MZEFL-!7YT=;U@CAQ;XN:VY(+9 R,M\*V]3.UR=QE@1J=QH\94]#$K 1_RW=O
MP6O>=_S?"04:8?:=CR.!;C9\N\TU+<C_B#F7X_PLWX']V.?0(]9M#Z[+HS7$
M.7C(Z+_=R=^S-N[X?B)B]VMF_[H+$QWH_2JY$3<C_BQ>YWFK,^W-)?REY%_N
M:8<=W=&I>>C0^K&MNPEQ=0)W?%F.I!POG=GJ[LMKG.>0!3S!2YD <FA#;LU:
MXX*9NLIIE*;?F$I'AA(.1=](/@;,=0F&:A4ZV)ER@M@IMO-6#F4G4GF$N&ZN
MJI*TXQ@N%L>*]]_;'^U)@$X2ZK;0G\Y9TBRC%N7Q\B1'[]#;P :A2L(B164"
MOD6&TTU<Q/PN,^N;C5[BX!W-\"()]BS',4CHA]!Q-4VQ%FR Z+YJ,>S<,U5[
M&_NL>T[R7!\'^@6=7QQ^\,3'^#XWZKHW<=9<8KGOMG9 $+$\\>SH[T>UCCR]
MVR*XNRD0D11U&C0?/:Q/<FGG3-Q2Z,==R@QRW\K](5)8V&\4'=UK%W/1#?&7
M;@_LT@W;DW>/5I DY)RZS-CF&U7SP\=O-M8WC> :LH?)+L+Q>.MFLS;*;L&:
M.AO*;&X*:CWRI$'D8;QH@XBUQ7^:I6&=D5*PC_Y9A=V[&YH^F>?!K&GL0] G
M9J-H:L0T+P[!VL ]-/O2NP:JUM95)=V%WLWD 7WX ]0UP1!KR1\L*)8Z$ 6B
MX/:,AUAMZX,T8P@_)H!#*FV-MZAE(:._ %;0FZL<V3'AW':9+X\N"6:3=>N3
MSJ4J".O"<I=RBMD!?^3$H!B5SA7[N[8];IS)//C[_1#C*^-:)\P)V[H<OU^*
M+(C\\Z!;T$E)^J5-GI=2#PR>/Z&J;QY2N.^XQ_L_S=TR/3=98I$I_OQ)0FMI
M/>MY)+[L0W3_=-63N@:_"8H=2]T:RW<6HSLI=^$Z$L8Q$6&S8HCRFC?3"JJT
MV.62:;#24"$ZF7D0"@7S+O?) H$&S&#1(PO=]ER-#MIZ/S\,1%:,A@K=+QA:
M_<:9U3Q8]N</[-9*:]1.DH$\GVDQ[6^,'6)UV9'A\I+Q-9R,EOJ2/VG),)"&
M6$.56"Z&5;V:HFZKPSN.A"ZOR3 GB-8:K(W<WX_0]60"'[$]I7YAMOWTQZM*
M[M]Z=VTN"1R_+'8YJEA(+?RRDGW5]=]Y5Y,/.=?Z?#_ER5H-._)+V]TL-\]?
MT!O+-,K9^/W2Z3___?;!U/27J;ER_ PO?R7F3@:UFX-W6)A>GEJ4S)O.$$1I
M3GYC+JWH;3A_#8Y""^+\"@4*W=W:4<J214SP;UFM^D[_9DVN1-5?A!Z7@/I$
MW,58@Y0H6YYJF->M>WB$-OK&! KN&"S]5<'3(6\%O=X(-5+A.G.K2B%FM&WD
M?K:XM_4G22W4-)%R?1%X,O":M(O'A/NA'A1G&@Q+,V:&\8?GZGIWGA!-(*HM
M ^HNI>2B)M3AZA/9BGT#,C\=JB:4Y<.QEAM<&$RY_I9ZKK_T;4%;:^2/#CS!
M:;"][0!09?[IWVO<[V.JAQYMGZ.[F0Y)9$/WM^UYF_-QWM(3=2\<YNG\\9Y[
M1>GU059U]JJ2Q8)FJ%WIG&#E#G:\:$ &RE\HX- GWA(2L$NZSF4:D:[V1U$,
M2+M EZYWT49I7E""F):@4["6[[04+ZM0A0XG*D/BL'D?H2Z,O+L_JNP= _B6
M/OJ7Q=S3$9.?*NVC]CR>:%6I2R,9^R;["<"<;F6I([>%H+1II%# =(R:K-B=
M[G8"0&28#IK*<TEXBXX!A3+T1)2Q@[AS4>VBA&D(=#X1Y^_[/MKMGAE[>>LP
M]6O']9-ZKA>L[A^=.N12MMEH1]_]$[M$CVW;F5<.^PUWL?XY[.?GQV_KAVW+
M4&.</_5C!]NAV$I]U^,.4X-%N6_#]:7YT54EXD$??!QANGYJU.\G-1FN',["
M4=,$=>@60H9^</("94WZ=%E!U(Q19/\,\I#,=)"$*2/90E@1[2%*S1@* EY/
MKK@DDU21Z:(01[ORTR+W<TZX\\T#?/%%9GWL'Q:1\ ?D;A;PBFD@BX!B*\A#
M^O![08"4Y"2G64LE?EVLK64,(/&ER(S%S^CTS7Y>8-!GTVS7GAF:A6N\0KW1
MOS!!LZQ3;4:*1BSF$#O[SRC2N[6>23[,[E@'GWFY=6NY=*NG/8FQ[3#WH)(/
M_D:P4N+YB/(O7Q,"'AY13;M]TD[//,\GXY_V@M"C_GS)M]C)G=5,[/.?4C-\
M;6W_$G>4>BN/:JAH63%-(:&D%M!^-*B30YNPO0G%=S52[Y*<1(\CX<F.**#6
M$\3(Q^]:IY\97<@;WJ&<89H?6.Y/*?DRV:!S:W;G^?WH-Z$^:9K_W$1?7%%R
M4%)26M>R]J/]!'<JYZI!$^'M?WVB+BW]_Z>C_/:_E\?%C8O8I_,YDBP U2F@
M9[2@4EF;D+ME$6#2C$",,DC#X77%=G>%L1G:1"0&U6Y[IZ3_"WOG4LY-<,IV
MZ<)D@UOHR\EEY=&IXPV_E XV4UM\+98?,/:/L;9-(_<-.&)>$0/9^B;QKXA-
MWJ?<O3OL$Y^4GPZ.IDU%M#C2FP?+4ZIG+QQI<:Q4?===4/:_/\XQNFM/O:"T
MDGEVJ\J%?TZ^V/A&2>N<63#W0[2,5:9[Y[8##8/Z $]4J,G362%SZR"-I=N@
MSDL*2!!Y)\GV2CUDQ\&<#LK0!A\PYK[+?0LZ:H?L-Q#Y#AA?RX7[UVK?],\&
M#2)U!?X39*=5I0?>7F"<I+KJ>L/C[O"5AX=\81M:L&]XDBV$4/ 7GL@K3WII
MRM^1">1TY"-$Z!2&B@B;4&#81SYDE^P86![&5^M*<G2/$;U<%.B%V7G9<C#$
M6 _0_[&PPFE])^8B>QZ]J6JE"UN;#:=39Z2O3HLKTE%BU-UPO$+/]PI6=KP1
MX_7= *MZV?=K<WJ/9&2PYR^=E2<EWI^9SS@0&7/5=N#2Y/O>.U[*W6_E%:M*
MU_W0&M#%#F\J#&GH"T5VZ3\9?2Q4\QJ_Q$RUP%UXW93:J1C$P]WUL_\R1P3?
MYRY-^[_IOX$WS;8NF')JZ?]O>.2PY[]-4;=^---'%WLL;C1,!Y?U>N3%,*EF
M9"31;2E&7ECI:#B61D@3U,)3R6:R[4"O#&&H<A(Z/#9$1R21[9A@<!J]R1.*
M!HN[X!K7(%8%9'6<]3ID^,1?T,6N3)])NU]&#W <+<JO''ZX2%5%!5.'-XR5
MMZ\J)0EVD6Z/T?1E?LV RR.FCC^TU-NB.  LKBHERRAE'=+#_C+;09M=<"RH
MG! JT@8(#[]S%D;\QS%OZYL'U.@KDK_L"$E9B\67Y&6LX'RM2V!!^BM9&&!<
M5@M,6AATW;D9IKO,(^OB3Q2ZJ6).A39&3[F_$.2E10:5A&:&Z==]C>PRUSER
M:GBZ<)!I 1WA"/]BZ=#AVXF1[05J/Q:&;M1U@,;,A.<C9:550R%G3;AS$A/,
M+\0YFM>&X!>73Q,)@]8?JB359<K613E>HWG#Y7YD6*Z*-77(=[)V&H\@<Z?(
MRI#!TB'YRX4*1-**?+P5K16"TG-T!O*62/VD$^(O#(QP>BV^5<)&UT,?1)3M
MQ KVJ 5/!!YM'LCM8OL^RB+O>YUTB1/M=U:__9\Y>.8=N#[Y_:I2G6ZJH\9+
MZ&(;93-Y/]%.M(GVWW&941UY$7EO-VB KJN7OR"=%U'2[&%U0DQD*R_;_TB!
MPGL-8#9]IZF_J_0EHL\#7*H!%.R17O@XD#*,UE#T4VKG4F6N%40[-E6?"</!
MS/JLY<&7>'0S]ZB4A0J4F@NK_<?748R?7^C-AD2>J>]][DIL#]*IYNOP:8.7
M2(<QRC!M++A#([7 & I8\]JY&FE[@*IE-L9^KG-:E!=GP&[,7V[OL>KTK4K,
M$T[C ]WJ!Z*= EWK ,R_RW="W8)8;YK2+KQFX,X:A:I?KC!K:AK&,KE^"Q1
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M9))!GNQA#G76;U5IHK3J!8D@0\R?L6'"IQN1YO*'S#V* ;C6_\Q[5B-V+W5
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MS$2\1A##<"C<W.4$P$N5A!QU!]>P*JP2/[WQ?6,AR/><1$8Q;4?B+AR\-]5
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M@SXJ;?BNED6CBZFA3=3Z?JH58^R4BE'$9[QD5@X5 816YB9XJU2\>3*+'<_
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MJF;FTR*^9[<?TF4]XB3  9+'FC^ *G9P&.W]LYH!E*/KB%=6]YL=)[Y26_C
M:20:.FM[O4RU'[(6=%- YCB_G:D#'P2("72?0,#E] #>\*3TN_"<X\AU%(<(
M45%<N#CQ$#%1U'FFCVX3-F;0^U/O7&??K#3-]<E\-A/:*1<<Q'D]\?*E[X<>
M%-)M7O.V0B2)7S78=0:U*:8EPP^KQI@Y3B+#N,K->NE&(S$\H#AHL;T@M2-O
MS;W7;X)?VDRLW&%PD7V;7;N,2,,?9*C'AZ),6L5Z\$'HH(PP?&]:IIY,C*ES
M7E<9]'E,WE[G[9% =RT8_>@]5!B6:C]]XNF!MU"$9VW=X)8#/MU;?-M7?)I\
M-_MQSH,9SWE?'*4(F<V?%+LR_8IZN'S E6,ZO1@8B[.4$EBYFU%:D--X#YI&
M'$_E)8R[_@D?+O2EE7:R@;_G,!OH1[/F.]@<XL/@<MOTJ(+)D;)P&\N^=VQN
MA_XSDLA1H0N]![6/@L'3# ?B)CI9^8@93$U ;\"R4+ E$"Z.IYL $9+:A#O]
M$E9[$_HB;]#/R7F.8T+?]13<D4*-BG2;':LM%;4F_K!![Y.:F*[>!BA8T3+S
M=9T2EW9YLG!,BW1WS!:\6?K(DV8M&/+; #&!&.EJ[J^-+N%[!QJ):P?-B$U/
M3;PON(_4VO@3TT[ZB<9^WDKPI)]6YM>P-,CBM08M*DW0HP-I2H]L[VSM25#I
M/>VU*_?WZ\T#JFD]%X1R+,8@^)![ZN/)R-._EF"[1OUN5?F]]?8<:=]3O7Y[
M7E.]S4A]?3\GQ%CE'3=1Y#K++8<;^&S7C'EF_ +)2(6$ R C6>H.Y!K(P*\?
M=QA@M1A (2CK]] -5+INYB-*=V!XG2&/^_2V93R"T5XL<L[8YIC N9>GO(/?
M2F.=[:5[@4=E$0E8TF;H[#+B*F<][<I"LVH#'U#=1@O0PPT=BZ34L&F=*R\F
MVT?%J3C2K?QA2^6<RQ+ZR(B=]TG[+TV_",7 F5&7%J8Q?C>9;XASD(YJM#)T
M!BR;7N-67Y:$H(BF/I.FZ&:6#GP.I,;#_M%6B3IEC"UU ^&41#NON?CZVL;,
MKNJ,8[?=WR^EJ&.9>X>S'2C@WZ7K@1;CC();4F1L?5I)/NU)?ZLWS"7I\/9"
MCAX@.Q9W-CHB#XI7Z%BH-7X8Y4UX;.K$4$WJ<;N:$/S%])=%-+''$WGAD#@D
MVX_UTF9GN?UG8=0MRN=GDZY+EA#_!R6KECC,:N5OXL 'I2FI46V1G]B@?4??
MU& ^JXUDP&%L]?OHL.]8=;!]Y/4\?V:X)/KT,N*'LT^<0W#"^BC+G@R95&FM
MTC(I'9ED.-4V0#T2FQU4-,211MRUM>O1HKFTH8$TZ.8R0AHHF$9K7)K,^H%G
MP1_ CI[N.GFO+;BK9-K$IF2*A2L--]QC9#US>XGBYP(\A7T&^8'H9)014%BI
M&8=E(8)1>T&/5O[ZCV,'@,R[<6]%A*1 4+=<YA-BW9IW+616?GW.ET$)N6QR
MOO]A?!\E*2#-UD=Q1LFU4%8PL&01\_:>X[\#+%_E@W1I2&YF^5%_A^0P3N)B
M1$<)WI1VI^.+3Q]6+;0'[#SWR&R"1&'I(V\/%+R-^.%96ORC6<9S&\7DU^3/
M)VMKYX>G9I<1B$E",/L-CR0B"<3KP[9#,<A8'TEGJSR1I),U%6)4>VP(F0:C
M']/.!(]]W]J<=:,O=5K$HX.$/P[43+"AN*5UOC3Y12BGA)6L5:BF-?] [*6#
M\/%[!H^ZK,F3@,;X6[96^HF,8UM&F:U'^4M7QZ[]T>^/#D"8RK D:+>+(!I]
MHFIP'AG+P/>=;UM&Z/-VT;%0B$E2HPOPI154JZ-Q7N63CTR]QK.!S#+:HS'!
M,4"564RN])DDC80.3QUZ5Y]SSW/8WFJ?C1@VLI84M#^.E,?@U\(44!SS8S\/
MZ4<9L^XKQ^TJ//K0#PY]%N+0[(WMN%]!2Q9<:&Q*]SY;%-SO.=(3X&]0\2C3
M0+1RSD]WL8(E?+2,B.FEW*@(+WKB<\MA&8'DNG7]\NV6,(<D^50P?D)E<UB/
MITS%+"-^HM4: =-Q=:[RI*%EA!Z[8]>Z<>5O&PG5;&??O/?,VOM[]M-8QNI#
M[7E;:+F[&C>A.YG:Y&7$VAG8'Q1W+JZYB].)PJ2R$E5.L.-0HU&%#V7QN7^1
MF[KRG!WZ5%N^Y4U&8R.7X,^[N//!]/PR MKE<@?GX*14RSJ<)DAP'J1OE;"2
M7ZO)TVXRSV00JV/0L8Q8K]H*H9OKRS/*I=/FD2&[.T1]L@Z1VPAE7Q<F_N'K
M"DQX]/GS5:91QT;->V##!,GH8^:J09X9%!\E3_W=S_=C";H-'4N1_#-3UNBJ
M&3\0Q'"BFG'NP)0R4G;L4!G.05)^_0LIVUG'D0SVU(VR(CZY\D0^7TC%MHR<
M:+QJU&'$U^$ [+.D05EDM:%7TB\!">WEF.-0 I#9PJZN2 (&PWMTWD[A]=5)
MB2BW^#NJQXBL>.S[EL9LKZ-L/V*SETG^>.Z$517I ':"9Z4FN!2HTZ^RUS8$
MCZ&9N4*WBVGR=K$!? NDN@$W^1)Q8JXY*+P+NQ11#A5,M$13#C>>\ =>1@;<
M^?A\G)UH[!!I/OCR!J4_<=XLN]7IE%@!]^HS-WUDF$!D\+R,F-R(+(-)0S#U
M$?2+H!6%:@+0K?(X;V51PCS)R-?<I^WFD/=@D2)5X!V4<2CZI4CU]V_=H;;L
MZRDH)7HML^68RHPVW>GNC?[V1/K)!BCPVPO7@2T-Z+10JX00NE&XC)W(UJWA
M)(WIU,6<R/8B&3TO"L[2K20'.'WMO1^F# PO:+O,C#KU^O.H#7I4'6K3%1+Y
M5S5_]^'5#Y.%E5^8'7RU5&B?YFO2/HE;V89A1&/(5>#-G26 KI(B00-S;;=)
M&]6()E<D K#QH=S?I6Z,"%.-PONE90OU/L,P]_5+FWF=;,3FSN1EQ!6VZ'F>
M\C[>VBH%1G)4KU7Z8,1,J61ZN$9-I2^)8#7;!?K'ZV[;+7!S,;WO"*(L7B6^
M,E1A<WW:58Q*#%F ;H3:)1.HOJ<<+:+?775?+-FB>I1-_#TR,K*(IW14V0=-
M,(5%<STOHQU46GQR&'_3.U#83L8VN2AB(&O00<)O-^O6$'05^* WTL]!.5)T
MLFEG4N.^0 L7!74=693!I12(:-<5Q]CG*_M_$.5K9S_W_*67V6(_OP\0DH"_
M?E.]."FUN0"9N+J6HN.8&T+"E$<%8VO[F=4AM4XN'=U2,F\[+:)CZOF:HKRW
MT"G/&BK2=WN&6I5G;SVZ*'#&>RI(@_Q_+O7P0YP(DGKT_9/JTYZ$?JV?:&ER
M)[+JKXGX C=":UV6N/V?1J?R2:8Y?#)0,GO4G<<#_/(JWEQ2(YR-C(V8&LKZ
M$WA?19O^=A,HYMCK1QFNVO?YST*]_3:JP_7JQTB'I&5$P*C/12@O@BF1WV;J
M8#$KZ*> C)Q\;6MD:F0A>QFAI0?Y2)>>;[=:LK@ 757M$9[.11UD" V'?JO4
M"OY3>?11VD4EG:>\+^=QWZH='N?-UGTFX)@_8=X<[U%X@M?32SNM6D9)K@ Q
M!LM9 9FTH38#F,0R_)XI4^-*CDM9)MB9'#ZJ1BW7O^]]9^'J=M05"+CK?95_
M:W-D^]?D2?ML/S-E$NYP'APQH++QI9_MQ\RA(;=E!%EL"H4*P(\1OT^+PK[=
M0XK!64NBKPO.#+SKSG>6E')T72,N8U.T,-<PSN4=*/OSBUK.QMZW0DKES)<'
MV6)>B@^:E;M./0UG)QFKA\)<LYD;Z&AP**=X$KU^#V^;6+WLMZ0$ RC9R442
M5I]%%B4(HK1]0XE E7/QFRF+:ZB]-0]J;$ZO&K"KN]KJ$2A31S\I55T.J!)6
M2XZ![.8]W('Q+C:+!/P!,=L/$9.8$AWP1VA4YAO8/L38EOD#T#[$?A*LUL W
ML0_&7\]UGUL4"B*; )-(?E:2J7 JSO"9?T7V,J)Y&;'UR\GY$=_,K^@D]&JU
MG&>BZ/ND&'62:,S+$WGFE<JL[<#"3*A$Z=&V'[+I2<7;L(876NHO9'K@-08T
MG(H20@J%-2/15IXQGCLHJ^-OY'^-E[Q1.B_I,+I%/:W,1'9M3WL.\P2(B9]C
MIQ VU3H2;ZO6@>&//*=)2,9:\B_/RY<1EUNN6M[ST;%H8^MAQ4;0HU=CES=_
M\>DFW]A]BQF(7;1V7K>+LD#A_O8LI[R@+'-4*/S^4?+NV&\71,-Y_U_NH>"G
M*:-9,?7&]A\^4/$/_J=X%]*\*WSJ,:-6_L>?J)C/I;%?S6XV#7*Y%Y811ZQT
MP^[/BD]GDMY_H',4/IRO\\_4TWF+#R7CN\*7$7@N 4*J:Z8>Z<*/D<A_SM[^
M2-CJO10!E\J7$;>GE3:_*-!CL!-A7(4*?*%.DOIE!-N'#6NJER0Q?X9+^C(=
MNHSX]0L3-)H_KOD0CMNH'MXPZC^'$R\KY8)^%5+R?WMP%R[S!4]=.5'\OH'_
M&?M_QOZ?L?]G[/]_QRZ9+:]P[GYF+]RB)=W^IV4SZLIGQJG%!(W7C"-WD8>_
MKO-3\[[=2\N(\4AUM3Y[IIJ830F;4TL0Z!9[[]C(I>R1/IN*$PZ9Q_16/=X0
MF+[*_*^8BT-CL[KOZYYIKC^@N%6__SZAY>-I)^NI:]^L[772?+?SHNCD+[,3
MD^__VUDQ<&02H):\MP\YQ*HL:;8=A$3_XQ!GW!ZZ(:VVK0U;\!>DRC@;Z,>L
M?OBS4Y7$5),4DZ1PK,EN!V;@5^/1;4:!%Y2W>693-U'VP&/&=]#[?/I.<"BO
M=+H^H<57NSWB4(0@Q+$=M55HQ]>'8MJ\;^88$H)OU9(V3%+*\9GA%I,967&*
M/*>R$X$<X<S_X>JNJ  XI<AOZ+.*[S!#^M(4PA3 .3R_0*E*71]7#4$Z4K01
MCRNU%B?7RV--2%"<M!09LR""99+<^U)"\MAZTDIHP;VJ_TJBKYWH55I2.'5S
MGYVW>QG[>N7:F>'D?I56+7#/C<$T@OB=3!3#DO8H2(7VZN30IMO3IQR&L@BM
MLQ;M(O2=.9_+ZW?I#WM.CMD+5\_$,7J?^.$\A&D+*_Y4]8W_>[UK2?^HUYN(
MP4S[Y+;/9T\N,M-AS !\"FI86@%=__;60:P,<GU,(JE_(@(C+6QME2%1NHPP
MFF9LKNNM(:Z!OW\&)132[G2V99U3%IV X@HI#ERW1Y0%+?NLRG^&ZG,:ASA5
M#>CA\PIW4-[*C&%NI%N"I Z>U2!^"TR'<F2<I-P#("$>=B[VI64*/'B8O_MJ
MHH+LV&:)YUR[*:Z5O;.?/-QKXJTW3OSA[3U2WL3K7]+ZYOJ_(IX0$AB^JJ9:
MV-^U^%6SZF9U9@_'C?U<';(RG038(&*\H.EE)*^HC$X$D<D5.":&!;M(2Y>R
M':TY&UTCQE-8"8>*XFM'35QKN*\SOQ]JM/A%X=WE*3H:53RF\>32B86J$Q/Y
MKPD_\A/J[5,?0I0SH+"#8P0%MN3NA@*D[ 052CA?&M:'0RXCUJ6TW519 7ZI
M!2/D.N/N8A_OL>'A-Z-3D0UO@S.]L37>E!=7;-C"QO\2)45/:[[,?8:9XV\5
MF*_B>2I$2'CP55.*?J,MT4S&$:71)/<!U<[GXSV&M/0.!CYS_*7W;!MSW1PI
M&8\'THK&V?ITMUZ[LR;L$*E73335N[Z&2]9]$% ^Q16U[4UY]J T.U.EQ06"
M@O$&(0[MS,UV:"WH? =* _I-K!M&,/%]0W-LXQO@-Y,Y!32J5#-Q6QJFSI6#
MK?XJJO+YIRZK,&_SH;@79HF#";-K_@TNRBJ5\\((-Y,S_VS&+W=I$O)1YR&C
MZ!TQ@>E/A=S';(6,G; 3% .:>$#5TE*QQL=(>2HN^D9(=!C>. BUOQ9$)S::
M;7LS/-)9,3:==>72I$5;9&,H92:^UV^F4VN-?!:SM![&*$MJ!X5P:-FW1P?>
MB77HYX$('Y06W]4(1 I8)CW85^5YE["S32U]MEG26]M9EWK[=#S;G/,O1?^U
MFC/TU[]!0_%BZ)TOIH(=SN?LO>"KLAW!$)N"9IH<JS\?%RK606BJY!9LAF?+
MG(@"(=,(U@;O*;K.#ES?L41-5IE#/L>!Z[<#?QXC=><]SPLZ1#^4RO8I:>NO
M%&_%Y@%'%7L 0C,SR9A@T$B0H>\R; <;"4 W3X>&=@;EB45#C0[CZ+CG92[E
MPS17@3OJG&K"K3[^.YMP,X'EDN=C]ZI_GNNO6&SZ=R"C1I92Y'.?/\,-P5$F
M\)*\J& 9805%!+Z[^6!I%=VP[SICNZ_W45F+53M)BWX1\$B.F1):'D\!6>T@
M).ZP*;R-LJ$>YYJJ@?J2[K59K=LT[$?"!D+ ,D(;FA:0M,(HYDRIE8"O!VO7
M555!'B"F.:*PJ]-O8U4=\!0(4;)$%7D9/><JA;!3MMO55XN[MN8R=\\CGG'C
M,N<$_\9U)^Z"B7CR_?NO-P<4&)=7:DB_S10"7PAFZN"U(J@5R(9@TXI*J;FK
M5)Y8VQTI4NE$^ EAC^)@T5 UO@20GX0N%T]%9N3_$D])/3XMB,3^U>V(3C]/
MKC!8\6M%.DEY1[6&EM^>A;F+._P8:KC0V&M'C,6;N^V>./,LQ.1\KTJ+1G$'
MV#$SM10G]N19WZ#%P<_3SP[RGNYS;;GK,7WUWU':]"U*%TE%I.F7BG.J"*4/
MS):,LN]RF0 1J1&,,@=8\>&8%+46O%Y>1-\'HN/HAX%?;"CME#)/V)*X6C2U
M&)%0P]3YZ#'4%[186U#XH*RG"+N0&"+'O+O3=>JFOVWVM:Y153>_4K.5..SA
M3=I WTM%BX,%K=[B.[G3'8>:7CW;ODA(Q&]Q:!L][34L)>U?)!DY=FU><KE_
MY4.OT=D+R$'XWT"P1/UDFQ/ET]5%S PA7A%59W.IZEJ;#N-ZGFOWO"%*?@;D
M=VI8ZZ?1^C@D!SX$=K8M(U"T ](U<:&4*&G3MB49JK*$PMX0=M+ JZJA;QZC
M0S%9_.O>T4*23_V;IMSL&]>[G/[XR?.I,AYO(/:AY>J<6Y(RJF_(-JFT?2&6
MQQ#.^1:S/-AC&;&B8FBIQ:&?A-OYPX*'-=]/E)A9W&%Y\?O5C.K_U(LZE712
MR.T2+JI!B\@L5TS-B*5L=24^?DG5(M9VN8L+ +4%JBU0[3C?G#8T+;VH%";C
MK#E= <S')-@#1,?2+TI+:IX6<K.&7-T'<0:/G'4?1!G6&4R6,XM&.P#?^MP=
M5&@'IV62OH:OXY+"VW]T7$GT':*[R$;U;4Z])*/UYE.C/+A#&/F\T\9A,[26
MN&RH=_C-%'Z][_ZISM,8RO6+&Y.5)<USZ-_RO\5M9AV1AN'W=PGE_SMB]8GC
M^.,C[S\PL&)FRR$&<D\$"4B@9<L( INCGE0T6;5["-:69C>8DSKPFE!F5$ Q
MQ)9P$J]76/S6(R'5O3D<6D!$8=WVN_PU\A+W ?N6C/Y[H@6-]'(NH$4= T\G
M//*"@P%,9RKFV-_\>C='%S!!P%I#QJ\$*C*+.O[Q)JSWAB*<_TZ6N5UQZ^X[
M&6IA\GN2\M*_O<TJ#WGXKW(\_<4I9=I!Z:/243.'+LSJMVF?L>6O)JZ&IMRJ
MS+!D 9%9U.'K_(FA"?6R?5A&2*VG[OXGH/Y# #W^5BU()I<1FL 7O,>2C1!>
M?*MF93@Q[(S^;X2.\^1?>/DO/T;X[TE,&$F:#(Y"RADH-L!$'GC/K!IE]I3W
MJ#2ZEQ%M9_\;EUS,_P\^-*@N+JA_GE=E%/W/R/^/1VYN-%HU*;4VIEDYK[Q6
M+=BV4]D??O6,II0B+E$?^-[5ZS1]UM'[.:8'[KZLZTP1^_!],)_7[7ST\.]'
MR3L1__7#>8F&K)FSVJ"!(E#YQQPGD:2CVCU%6C5O[BKCMI!6TM*EUY/&G0RD
M5QLDI%6TKO9>LM]N_FO8B .1.C),A\KL%-:!*R&2=[V^^=#0N1/?*?$</>C+
M$H&.5^;3]TE86G07M_ :SEKZ"<"AW=>HT:G\4I!')8TK^5!1+TZPS/HTZ'VR
MS()WAGKM]!OYMI>G7^@&:8 R!4W9P#A(\Q"PZY"I%8PMTX3:A9DEX)%@O*FS
M69ZF!N;,N!KDFPQYAQI:O7.W$U/8ZZD8&;1OO!AK;MU\TQVE/UAC3CP*69?1
M6*0A.A$3&Y;8>+(X): .^-;:J"60AZ-?J%'FX+?1=T)$$P$GEK<;0,)&*QB'
MO$20_/!@([D0JE;L!-IV=+E#@1&@R?BGOQ9CO:-%WC268%+*64,+K_U*_R&+
MF SO(B/C*[8,,FG\8-8P1<*?C0)X(Q)J6\,RPC3(_A QK5$#=&CEV4"A4GN
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M41Z5[ X:ZNVXW$LG^#O$USR=;])]?J[?YW9@FBPP=_9[=#)377/&R]C 6>U
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M;:/^[:0U/ .:0+JG=:+3;R]$&G<ZO<L"X";274-M2["#+Z8\;M8S%:HFW83
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MDT#JWH9>R.K)F$_FNY$!KSX!%O;VYV6A(1?R8^F;CL'Z]<B0]A*@Z?:@+F)
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M?]9]F!C6+8-\]/E0@(:=;H=QJ1SAJP52<^^=\$PZV9W5R;;R8+E".VF+0'C
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M=D&7D  UEXFE\(D"Q%%MW$(TCQ*;AFJHLJ$YG'T4'R]:"SDA;FV$M"WH4=C
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M/*AHMX&BD<KB)S%SN'GQW#F<-10 AC68)8'"][2!_)#>:7&*';%B/._A#'N
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M24RZP82B<V)&JH/0 )ZDD-SW#R\4#)6/AL]'O*53R^B*)21?_*13,;V!T:;
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M_APZV@DN[6=81O_):E=?Z;M2FU[I_/YP,R&7]E2!+JU6?WJAP>/P0W?:PLU
M:.GX+/;+R(,]I!-S.--(E38+]O.#^YL9@P_D*E[J%X;=")82<E.\UA$AAX9T
MV/NZUT=A=+%?Y4>??<P462*K3(VW?.C@WW591 (:7;SA[1RN9B0#IFB[Q'J^
M83'K=0B^M0.?UB!HCJ5@_+"8Y0'RU8SK'Y!W?$LL*=QI-^!!:JD"\JX*"$UV
MD^2Y7:TD>7G4ELSAZ&.W094K_6S=+%\5B=I$:H/!+@2',>%4FC"H(J8J1N$T
M';OU!T2>%3_ER-RZ@U+#RZZ19]#L/(?QK>35SYO>>DXZAB)MN?;IYVN>5P36
M\9(OL0;_UYQ[9R.Q;0JXN4T@2&/;,W0G?8HK7H0>?0*V*%3RK^]0C:1PPXG
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M71 M8E0VA9!442E2C$LK$(14J2*DF%I!@H1$00A['K7*(SP0%1$1$9%-(21
M$JBER$XD"-FJ[#+30IB227B'WW6]?_ /%PEG[KG/_?U\9\ZY#TUH1=QY!+17
M&V7,.0"M@KWP@'9_,)H,-; K%-D6OJ';K=#H: _!7TU:ZT=G)\:<>SAN2=Z0
M_&^- RZ@_A5'11WNT"AT#_D 5*]?NQ-$XRSERI6:+.TZ=LMVXE9]S_U#TF_
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M2'[SA:3@H2'P>?\6FPZT-LA&0_7]=MB9)$-^N+-T2U\$W*,4KI C'KWTO,"
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MH77HRRIPZQ%P3-0%.TG;J;DDN]^81*BNF ZUM_'6"/#(][#MU02P+[0;Y?^
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MKMB&BWD1/VVSH+1F_!7$KEK"3%>PH9=8V:$%33Q\( [Z6Q:\^RM81!+-FG9
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M(5\</CIR-@'W\]^N&+:3 -7%Y+M,&NR#QG,$=E$#0UJU#R^7N#T:9[C<*^_
MS_PX4#^F^JCW@E<H2+GA7_5P<^8KT]D6@CU,1W!,Q%[%^-7,S[]OZ#+BKR(Y
M4 ,3(A[#IYOS4V1\_X5$EA2W SY9#O=I"EYU\QW0BV090_1IKHHL.Z32H SO
MF17G@%?(9P(4P\Z5FV@-KC06\2VH3V-:0\YBG"FT_GWM.>6EG^?HG'Q2QNWI
M'VOOJ";Q TUDC8TN.ZX"4$HYM?2A" 7NT4-DRYO!RP+;\7JJ"<'!(T]AS#_R
MK.,%;4;IO;HW\&5Z_OMRMX;[I6;9)T2)25O#SOIM:T^Z[H>XMC>G*);WN!-)
M1@)[SYO\JTH'IV:<*YC%\#Y$-X?+6^S,;Q'V/H;)U%Z[WX>B!4 OTVMU1NE$
MT*O.R*BG*RZL\L>LP9 *NS)(X/==\(Y;4I))#2^5:L8WV%ZN(@_UB>7UV/3=
M<85X)3NUQIN<;+>$:2N,:)&;ZC?!W#/PL-87V=3'WY</)+MET7B;F#^ GY8P
M.?,1%8R4XV]1(QSY9.+\* J>_5W#KII[NH<HN7,UQ$;8^AG3#4Z  ,T3N ^D
M*5D5%0SYT;NJV52^02F3#(YHRE],7O<I3>.?5(:2[,/@7U7;DK:$AK&Z_A]1
M9Q;7U/6]_2@J D)0A@@(J:*B14A5!D5(VB*B(J9*%0%):A$AQ)A:0:(<$A4A
M#$)JK5"A$!4!$2'*J(@YD %J*2)C)"B9?I59SJD03LU)>,/_YKW@*A]R=G;6
M6L_WR=Y[[6#8,2JWH+&QX-4E["#'CG2:-Y2BR15<V2;<SNX&30UN$>B7](L(
MG:[A85ATR4\LVT@CD/0@% _RX6>ACBMM0OL&]Z2LMS7?5GT>_]%U>,+(YJE*
MJF-3ND)JL(9&LXS4MJ&O)5JIE7FE..]'8J2.>W^6EB'<;W4GUQC!8=(Q\4*7
M<\F]N/^]&]Y8N^WHEA]7FGYZ6<9I"P'/*C))5@8<0MH+-TU-0TWJ@8PTH\^U
MAGTE@ALN7DAR30*(%7XAF'* 0XXC<?2[+-_64!@;5" * _9&K43)FCWC:)PZ
MPK!N?(W[N)R3U?3TT%90^0C?6)"%AJC)V92U+Q 'E2"-:M&!VNR8EU)7-N Q
M+"X%IN8:C0S#@JY 3C3*"5(F$IKX$/!FW-?_GL V&=@$6=7.Y_\;U59Y8M?O
MK\$7+H3%UCNG03P2MA\BY!JKW,RU$G?HS%4-SQH(Z?$G"(!=4&/9O7&2-1#Q
M6,'*D1)W],U.5ON$T*FK6;<H_0V65,K ^MQS#:G[_OWPT1"2598<D%&I\T.7
M#7YL(:=6H8Y(7&4T,CBIFIO)J2'XX^Z2"5GG##;N!+%%+JU$4KR/ROUK2FB5
MPO\*23I14Z#]X?S7^&)%/6%:H>&M94TJYUNQ0W'?]0M-$6..4=L7,/: !VS:
MCI<7:&E(VSV6Z[<Y;7@LP-#0BXQEQ G^%UC?9]B>4++E!?0HDE9@6 L7Q5\L
M<>:=@&W#"],"*^04-IM&;6R2,LV!$WJ!?R@#7L"T^A5(^5GY1NPT$BQH)F#;
MT0P;]*7L94B=QDW"S(B4:=MS(:SH<L4-HO,8W6B>P=Z:,[4P+MO_F))J2;O@
M(9V_X1_XOQ/Z6N883T-HY:<M'M2DJD8[..G"9<A+95S_XX8T%2F3[= +A-_-
MC3K\*2CO0>'%IXPDIO/<W9*D:Q->$9H#Y;DG-]:Z7YK/(L7@A]S:77 #J)V:
M/R10YKU4.;.QW$&Y+&..E"&T;>YIV$6TD3MA,XY$OSU05G0IO-5GVV#)ZE5\
M^(O&,]Q0'_CIT27H].*>\),<YOC_4>XU*GY#(T*X%T]TZ"7%3X=H*^!<GEA'
MRDHV.#8CN^'Y@T85?1DGY:Q +6#^=TBZBIR6'.G<7N8KX6>33(S$0C.%?,I.
M>U.G0KJMGKW ,]&M>A!,<(XSF)O=0]V1.Y7H^A[.&4$.<3/,21,N]\T -J6H
MI]W4JPP.T"#_48@^"^YH$WK# 3(N<<N8+-_OO2S;8 N<1<C0G;"#_1[AXA+7
M06;B*S5_]D6T_CKG1X7-F! +C69R8IE7+G=P#?A)V<@6:%\.!VH2X1RIZ2V!
ME46NE73'3;?&]XV(=-\Q_-H$Y=>\?7FT<_,N,7L?7)13IYITOF-\QR2\W#<8
MP4%5AY"YJO&*_?V&KTX@KF(M:#V3**YX.QX:>U[]^]FP8RS\H3XO/3'(=_>O
MKU^/O.\,6O,0@Y;J:Q<PYV;DG<K@Z285GRMT>($$J6:&L@.HRK@T;Z9M L6^
M0)WZ)SPC_0\-<D0N:)9W7 4NL[>@2V^=-'3W>;!7L_(Y:40"DJK6'XXJXM@@
M+T2_+/D)#$"2#>:P+H0N=.0=Y@8AIT@W-%&\(?9\>"/46)\X3![6[=>731FP
MDRXKFJ%)Y _J,(L%[!)2LWOB>2PF3JSU;;XV:1/14,F?SVE7U,Y,:6 W->^:
MP<>8+4JFJ-L!H"(7-CTPAF"!FKPLWA',;7'SY"<RZ_]+)*RFG.BL'/_W!&5G
M](E7RT4OB]MV#*_]([]RFG.&.:3^ZV/4).D:WL*#N1GY<P%3[R\[;E@!385U
MPNI0>[(EV.ZP,30@PK"1>'5;X1Y66Y8LZO#-Z=#QK.Q?L!]PW^AK.30>EV3O
MAO0;R\E<A]%CL@@&<^:C"1(&W5V&#'*L6#,=> OB5^/LY?5PD+9)3<HB;NR?
MS]WW&;\F6CX\%/)@S'%S\<-Q@W-O/3VJ;B,^&& @/!V3SK<C*4NHEN7&1YQA
MV@'T01(]]/QT"P>BBHE;GD)YMY7@6K8$Q+6<HI4"3#U_RN!&#1+4%#\:O\S+
M!$R6*R173VF<XKVBSX4P+2GC]Y/U2O(059N0<Z*G)1#?RKQ>6<.Z/*_>5WIO
MHE-)LLS1?ZG3F/_%MZN9.L>I0X<O&38\_H1U>.6T EY]^_7#<R$V)_BK%C Q
MA"&"\C5?Q7!7^4Z]A\)5@\5*GD,"QQK%TY0S7"+NS2FH.V].8'F2M?,X?#'#
M2^]C4HYPOX-NOY=EG&N("G/^7[.=1!YU\.P_K/VFG]Y7&C,W>@'#7,"L14A:
M3AT2!G6HWH_F)78/>7+D49J9[%BN*HXK=$0&4TW4'9D&>[J/'[L"%FO3$%]3
M$;C\\,A*<'".:1T?R9>^3Q']S'K4_GI&+/.Y_+UCQM->X)+>B/HT!8^T5KAZ
MPD>Q>)FR*^(-R0SFP[H5[-<%"I-9AZ031$]6<^@9SA)D5%*R\Y8ZXZ;&(M2W
MG63I3SVO'DJTP*^0(YY&M."++A,KU6;>T]^.V-7?FN=*%4]Q4Y<TTSA5-]>?
MH=L.K(*/7X6X1X0#0EQ\\[R89#9QF7K%VSGLN\:!)'?0[.U[VL]18[]..!87
MU]Q+T:Y51U5ULLYM#L_W/E6EYBW^-'X<;I)VV6A&<Q8P<9PT]F9D2%7%LWB/
M<-0U3="\V(_'\Z)W+Z,X![;)"I.S:NK'O4-"0 O*T^=O/.\]CYB]<WARZ_K6
M5E,CM:-V8:W4U<2=!@7XI*"MVS1>B(,_W*X&ENIKT.C'J ^2JR.SW^"-"2\N
M/CXC^FP4!Z=47XF<FTV*JXH.EWR690'$PH'I&FY90J3'2($V-";\SD>/3?N'
M]!SM*7U%2S 4;E@YF0JW#XZV4QU:&#HBRT*]^:J_8=>+HK 6V#2;B$>JPJ#N
M H9ZBR")/F//<OKFV8D?>H$(8FER%2M')/]V(C+W[\O%TN[;GP_ &FV@/G\!
MD[ 5V'E>M\_0#:XT^)YD;??>W^)Z ?9M%>+A].Z,^X-=M^C;XY,=NW+[Y:<C
MJVC-*0FKY?X'+IYE')KXL++Q,S==B$-W0<'B+G>56QIJH2*M0CW?H+N$UCT&
ME['+5D7ER)Y0J%;NG0G-\;G5#$VOLM>RZ&7=B4U/FEC1/9H?IG_!MA%N\)M\
MIS\9$XV_@F@V1EU-.B.0\[29B [."8&TZ<;9O4*Q@TING8?FVYK )7-@#CPF
M=#=*2XQFYEK+"J&;; YOGI O-.]/HLI- ZDVR(:/,Q*?R.V#LRD,;#A"T%[1
M5X'QI&R\K= &F>E@>[0@L>K<9"U9_\LY?Z:*F0XZ,!IX7 NCV4:VX"7,94B1
MY#.[#*IK+]D&'7VE?HD_$))ZV<,I&M[T^D[9+564/NPX]] )Q>=33_17P!^=
M"2K[:LCTL/X6&*<C7+L\D\5HB7N,>C0B$:J5 +:2U?AZS_ZSZ(%+JMG>=KY/
M VUY^A_V\AS1N;O7Y%LVW-X0?7N8-T30_G "\#X'ULVT#:2U"5=#G"O^6\U1
M?^A9CEBX$DFM"5$S31#ROANT>XE&(X60)1=":\8<HY_D]84,?"CXKC[;O=+E
M. 85&14YQ?!.T1!LA)DZM5LK25XRJ=K'34V%9MI!>Z$#*["MQ.YY/ '%W04B
MF,MIE T(#2YH,^Q";D-]&NRUL+TO>Z?]3\OU\V)\-GL-_. F;=[H_PM"GOWZ
M6?&*DX#/)NX>G%W R"ND\@6,E&F'?@7%99'.=5_E/'7+0VFJXI2P-S5L<_9?
M1UA4L6-%9HG\?]&=#UC!$M)JX2:6+*QWCI#U9GR0N&'QA'.QT^&Z <;I'J_0
M?</:(E7%E%CG!SC %7E$5V S@H>:5!T\]J9WW9=@DW:75=#AJZJ9U8CHPX?/
MH8<_1'..]VUCS'C;G*\,V:1O+3D>(5C[[L]JGW4QPX:_298:N*,#7$.-D-:P
M2-K\GL0]B]T.S)+>NWXS(,0C=9+FXU?\<0^1OK#:EWV;P)>#_J%*2Y)(:"8[
M*R#$]7AZ,4W'>/;%EC/#GN>^)EERF*2EB^URZZBM'+F-$CLU#==I?(K<,NOY
M0XIVEVT(F0YS-80<+X&1)V"W]BZ3MGG#MCZAUR3ERT$C[.LOJ#VN<P\V0]?0
MX+IF8:\'5>)X/'?Y'[=&7HWY+6!$G&N@"4@GY'!J9>E$;S0".:^S1TJU6W(T
MI&F'^^-@?3 /"*X$_.&/5^$^423^VA=OT$L:_FK6L)IZ;5B; 6T#K5M6JYUQ
M8LJFIR!\_*8JEMOF?A<I(4Q?XD2TD'0KV=(16^28!GM5Z*3/)YJ,\4W9ZZE1
M$VP_)*X"V &5-5UKH3Z,>&P1=TE-PI;_[J6GJ'L8U=+'36_^'APY>&F3>7;9
M TX;:0'SHZ6)*NX&T70,K$UNM=QI=(<2Y[ #@T8?/-BM2KY^#V+FS#%6?!CY
M%-CO'WS/\X[6^<?)X!<-3<_[-@FS+\3XAW@TY?_WXQ*$CA,Q4L272:V"ZY0=
M,+Y=P"4]]9VFZSB*21=3A*SAY!E(3Y"K2E*:HUM;P,%YL<(2)<,'R8YD.#RP
MQ["#I=LW*-P1I+18P."_4?,MAE_%JE(F<_UIS1EY 29*_N(B2S-"U9D86BD;
M(=G4?W"4MJS?L 6@] GMZ'Q;I4RX>LBS3GE=?P]@0C(1Q7$[^BU2JB19=VL4
M=JA_CQ<6"0;.<V*25<%WPB-@8G-WLH>$_[0P?&JY;O48QQP-A7SWZW]C+ST!
M.,,%F8_1:+4@X_@"9A7PI=!<AH95#$<-O45ROH?^ZSM<G/1X2!X9%165L./K
M<_>:TC?D';O!('T73W& 9M)GG;&BD75O9HLMQ!2'OOII5W&SU:T*^5N:HTO!
M@R@IK8SV^3"?87NQT;XPZ;'U\- W#-OSPT%K-AY\=!>#_9N#;#7-\V<8G]NC
M\T8*5[;$0LF2D6WZQV#,G_[!J@;8HXR?U>*+SS*L'Q-+7%8L[BQCI!QYTW"*
MKLVJC[YLB:<, KY5:S='I72%D'_=6H9.XZ$C!+E&[2Q+JYGC.:-KC1-FZ+^(
MA\)(6!K)W-]7V47?APQ!.T/U^08LHCD"[1H  &' <T=^#C[ZC5H()TVR=GX=
MO4&]@#G85__6XA"A;YZOY4+D+&.]C3;'6@%$) H^K/D6/I.EW@O%28N^^[Q^
M(#'G]C-H 9.=F+M?KK!TE5!6#2X79&X[1Y1Z%=AKF_)]?GX[X6L?K@5_9R]N
MKCR/?@MQI@D:GOS1)]7,U"O81AT5B?RZZQ\JEVV[V*C/XH!P*^LBV1((O?5]
M/^JM&FN()IT8F+V46P)6LR9F.MRH\?*1=D5([\>/'O1NR1D+[/'O2RR^JOZK
MU"T,FWX[X?BO'^9C'2CGMN=&'+2^45Y,B/MK\L>O$F'2J5L_ 75_6/J?W564
M5BL[7GWPJ[:XW7/;FM8]"BNH>WG0._[9D;*C+\]:.K*RYVBG_F=DHI-),?G_
M^!_(?47TT-_Q=[C/?CVR;+'W.1"S>(4<''@<F=0=8UU0:7FZ8,3I& +#!+6$
MM([MC'"U1V&\9 &36;)Q$-T.4SL,'CW^[I7(!36.V[)5;8%UC'=7[6&X1@R$
MBR^G=](,ZWED:C_Y;;=V4/^ $T^2NVIO(\?@,.T>I ABME'-T?.Q]^)=O&%<
MEM"4.L1*V.V_1$5:':1BXJ1*_@V7[8,-QA)[[5-$R\!L;I2HV7DF8ZH^XO&4
M=_&^SF/7XO\W:EAID#AV3-6I&<%2?EWWU'.=E7%<A_GW_2A(DXHI3B%G? :E
M>.Q$N#7U).!\('%X]SE_T[*Q^8OG7^&R*9KPAH&*6JA>YF<;$EO=P?G,5.YA
MK@U459D![,\6R%^S 1^;A8Z-^8J@^N?/+OX:L*,])#^E\ZW70\>  &^+#E_<
M?<6TI^NG9;03)Y,''QWD]\-OD]=^VOWC$\-?175'SM_X[Q^' R&%/KG]OSGO
M?WZD^,O;V[MWA>MLS,@X0^U/Y><=&S3[;'=L>Z^!:8?_F/SVY4FO)_U?OKD[
MEF+^ZVU67_&7O__^0U5?V9U3=>OL+2#M?!O>W BTH!QO,'=0\^0:#5-"YK(W
MZW_SCRJ+YZ_P>F^JP>8);6E\#'M5&_1O1SO1&9EYP H1439!'V]IHLGM(QN)
M7PQX>G/P-*%WC^ ,%%J>$U,N/DVHURE6\U3SK61YCD8P+8/CU*-2\ ;G+7X5
M*98W9%3N-D5V.-_1X(5:#K#Q0Q/@4F\!SE<RC] ?L, VRMJ>EOVR_.,NA('9
M19@W_[!E+L2[7N9%\\A]743X6"&=&3+1GEC\=6/&@J73)$_-02EJHT^SOBE5
MX>T07:O+.ICX4C5V_V7.T6QG0MC 6<]STW=SOKOF_J<J GCX\;N#F>M^O01F
M+6"><*:BX"KU-BJ.[<GNQ"\Q;$2_2_<ZT==AV(G$JLC6K,=253=!MW2K=W5P
M:,GG^/KSMO2*(*_:X/B':^R"U"]XMTE6#49VT6@?(EMUFY%\<A;')6;QC 40
M@D1!II)F;-8L-4?X!02*!4-DD<%^P,,[E*XIN $LN9<0B157'Q:K,]+/)J5>
M$!F(/6A<%7!HT/LJ39FZ01S22%]+S$(*=)[ )IG13"]V.]V.G,))F2;OV']3
M3=!3L$S]^F4Y"B"?DN^B(4@GW"$F$ON(>-8^JOD$QW8&Q5:PDELO^W*!<$UQ
MC/@S]?KC'W*H1D+HCMMTNX:_J;ACO$+2_1:GW8QTP2N!"$2@^Q)8@7!AKZ@Q
M'PY48@QY?GJ#P#[UE@@.,N5Z''Y^J>( FU&_Y8<,CR]-MF=+-P0U[A==I08%
M+K;>&YP?V=Y_%^)Q?^PGKA<SF9H7;V=S;)OA])?E?,];=-,L-^LL[\SJV5?E
M?:J\_\I///[GU_>8K*']IO]*(6,(!NJ.HT1](=&%520>V8%<2%7BAW8J":B-
MBKT)#4#*2B<-'DB?+B*!T["7Z,B+@DVO$3>_0_[JG115B/*%;FGDQN8B$<FZ
M0M82HIK^.>#;E+6_;\,_6\#4CF9[<\P,;SA-I-:4:GJ$S!\+%4GQ%H:MR,XC
ML$O5P\DP%KM;([B.!JOQJUGVG6%@X;_0F,O:07_\^<KQP;"0\^?+>6O>1^TS
M>E9[G\:1D07,4_[4[P9WHXX7Z(L,YDTWV,O&+KHX(-O58="HD5*'218M 64-
M?>.7W:X*C%P%&"%SO/!L@>Q7FC8R9K@M=E/_OU$;R>Y/QPU6@#DTTS8NW#S1
MV"QL4"OL "IR]1'Z+2S+1LEZ_N:J2@5%+A\O/,Y==CGI=NYM7@:P_?[;85JD
M50[C7/Y@)E.P-D!;\?#DX27H6-?_'9YX5.W=+?><%[FL-\)OH*JK8^JFABEG
M:D_!8";;"IM^^<S=$3ODQ5W4WYK +44ZU6"6\$L$\&PH#A;#K*:.DN5(P"-Z
M$Q'/M$&2@_H3&8<'R+5&'&[[FG0N8&?'9<54J9J0:?Q4DP#UN?X1*99P/3)X
M>O,"QC3I/5ZU@.'ZV^F^1I<6:#[6Q3X"-O+5Q6T#_K$)7I/=7.&*FT)7VG'V
M!O E-_Q%4WVA0K>#^9:*-;2!3\/3-\,;#8[ZWPR8L3"6%/B^Y,N"$"1"J?.%
MEU%V/7O#](]9\?C-^'XFHR4T6<6Q>C=YO.]<VG?/>KQ>U;A>\E@?.X7&ZK88
M_E98SX+.8T(_Q!2Z)963I1:\Y10@Z EL>@7=_2B*)?^D>GG#D2K6@3;!R15_
M>J<(EH\W#FI=UCYK^72F9YLJ;YC,6O_=;TO^B]8M 2C(I$J!;%I<[_D1BV/M
M5',[P.7&KP5L()M-*JQ;4C<5B"U3VH5KD4F8!N#+NS7XU9-APPA3-=1?G3A-
MV-?4[]T9X"9NQKZ=?9YDZ2GJ^<@0QD!NJ!U/6P;MNU7>J?N6#EI4>Z*K=<%M
M.F_T?&\#Y[KCJ)B_CN6K-FWOOO[5!+_N=EYI;#FZ%S;Z:PO0:@*T6]]<] T\
M+V9F@:M;W&!?54WI?87' N9ZP]"96NI85.L"9BG1 O!"XDAM/"YHSL8C!-6F
M+C#3XQS;$8D3%?KPE#DY3+ON2TEJEALT</L/OT,]K&NC1T#^B0,>$4D. L_3
MS6M:>NT_D; &">GI:#K1^0"4(^;7X5J[<"I N+-'N*%3Z83-8-NDB7Y%/HD+
M+LI&\/#UYB_'^3_>DEQV_N=VV6M>54MH2GDGPV2HRRSWJR5(E)HZ/*,5('\2
M<6/-(SD0V"H'TX0>AD[\"J&KMXP+, )D:6""P'F"OT:#7/.JBL:I21DKRBJ
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MY4Y=U<QDA<!%':3:CJEI#2&GLC)>+D*/P.0V#C=R 2,A3#.M/ I9G.^)VP>
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M!.4+8$=F%D[;#>6HVIM2X":I'W]HFPKFY2H1+C33,6(/@;GH)I7.W=G4L.:
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M&B9IS^A!H2=BH:SFBD?3*/I\_S#=9E;)J-A@0;:?7(W\&AVB)N8^>K"5ID&
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M;M?)7UB"KV6S7><?7'C\EOI1BF$[ \>- )-C>$=:?DN#:]5;J$$127Y+O;E
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MW7F<YT/3(*QN!<U\3:4&200=YEOK;B4)9A*RO =+X;62P[#G,R!&VKWJ R5
M+C&<3)T;RIK31,V07SR#G4HKJ,=L^C5S,&4Z7;V+43BCL,J99N* 71"E37AC
MS!"S"N)F( 8*O,)?+UL:$N#8XQO\*+ B7O<X/"?($'^NVI4Q]J=<^^%E__<[
M3YUJ@ XUUCG\AQIJ<DF8?8U+^Q=U=(GV@#D20Y66IHFLR=G,38$D4;=N>PK\
MRT3S)FN+P=?PY:1N''4!9//]N1$!FQ94Y;6G_@'C(B-'7^W+W;E?A\3!7^=
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M(0XBBO9/;.D;JZ?=:I1SY.D17&,G:=@5Y4'=&7P[:<70[98Q<TB29=5.W#S
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ME[BR\XEK/TEL?X1<[_S])=BWF73--T)>$]AJ[?;[CXD5U$N>S?MB8QY^S[0
M@C7WM-NT?PBV0<X=G,S4QOL*<K[0C"0M*K.%4W(\N.:,\L/II$-(ICJ8.8HW
MX'LHR 7:;VYWI'R+6+Y'-_?-]5/G0*L(?UD(83_$$Y1RNQ+N!S(J%UY@!A'<
M JX$"#5(M,@Y= !#N6]@>CZ:HL"9,&H_2\)@?#YZ6E$3/Q\%.]7)#3^=KTZH
M+9O\HHU(B_!)LXGT"NESX/4V3/E$&)YR[>L0K 96:F[/XO2 [R!\QD8$A(-;
MHZS[F9NPB)Q=*J?ZFL(;EA);CL<N?J2"/=P7+BP*>2&L@YSN/IY\6S4&N,-W
M!A^J@IZV)KL7#ZG]-LR1,TB_X_+M"9H:88*1C<H$B8&[52RLS8#W,:,_Y!L#
M_35U HE;FDKKXZ\PQ,R9^1=HHMT!D(:TVTX!N])=9#]23)CK)M\^H7HN[500
M4AXS#FK_FO&'PW(M^!'EFTN%O4(HF&S&>-4J7 5*\Z,<\1:US$TTB:W #$U'
M@N%OORB5FP5#ONNEI69M'%/4]<%H0'3ZY3@/2C9S6]['D.#P9CQT,RI<\L\'
MVEK6J1JY9A@)J]#^X66IQ4'Z+7YX57(:B=4<PVH7ZC"\9#=N0[+S@.E#9!3U
M?S@A7 O8W4.B/H0C%[K;;X&M)RO#&5A,?\Z.<.6&!X*) HWU4#88 V:,K4'N
MRKBY9:90X5T9E6\F8Z]%$EOL5T'OV#*A,; ;2N@NX*4,+&T\&"%A>]\W?)J=
ML49Z1L\#9&[-R)]5U)YJLY:/[O4'EB&OL#B.V6?&#>!G!*>.0IQ;2,N9KGO'
M["%"!VG84=;=V7VMS D*:TVP:;4<L].4$[^A1IG7#2;-6#(Z(. L_%E8$^>=
MW1Q+SK+\B4&7_2NPZ?V,DM,<:3^_ 8*#ERY^9(Z6K85_%%IZD'*):Y!7D+J3
M9 I*GTJ,T(UJGP^ ,Z1BD;(C5 Z" 2D274-E^K[?7-*NW3+ L^IQ6M2Y]C;X
M=5#"A8:W10F>ZY)=?MP)!FJ=D)58\0NV4W*B=B N4%&[@!CYK6@?Q991(NO,
MY,VL<RNHB#\ZY1WUB\!I((E6$T<MOE!G'EZ3=>6U96/JKQ<E$>UVO=O*4PXC
M)R'A@9>]='=.MG9Y[XR[75C;PF=62B6#)!H,\W9[J:#:T]=/>1]2B9..38BY
M^8]N!0'DQ\-\KU3TEL]D?61]W09\!L8OAW!Y>#/B%NWHV"Z8U#8C3L.208.@
M24%&G(73\[#G^!'(_NX#)+SS39.6! =/I;*N<M&-LN _41(-Q[IP[E:W2/SN
MOGF43[_[QY>L=FD0K=*=8XN&0OCI)N>K)&DM!S_',<%D"399B4CB3OD92CT6
MH;SDS/N/@)_?,S=2RVR14*810FD1^W%S+B0?<*])[%PH8&>/''P.]3P;F.TV
MI35:_1#LD__G!FV)=CU TOQ&M$(4[66FB)>4?)5B+' ,JMPC!VT9*;+*:^A*
M&6Y=2 62IPU*F)LQIPJL^F:5430_^O&&PE-SKL><\X\(&B^OZ.TVC6D?T"YC
M=C:2UO%]8/U(Q%GM&0Z L-N3Q[0R<_A=%30DNTZRFANE[>5=G0N)W@,'C.4(
M=O8GASC\-3G,Y1D:3M1.)]1NW-EE?NR1%/?11\YID^1(EA&$4BX>CT;+A3;_
M,&PZFF-;P0Q* RG;-=DO?#X(\8%UVX3U45=\M\(E@0T-+PK)!M3P,#:OBK,&
MV'\[.()FY"/ZV3EG;"O!=5^^&@=W*BYQ(;;68">4S/=Q+N#1<Q=UUF&,LZ@S
MK)86B=[B6<T_"G8@=56,*GGG%=15UG4\'$F7"1M')NVWPT77?%TORRDYH0M)
M5F!\,UMD%?;MH;6[8_!/K"1KF-:3A43W/@\"2Z#?GR3)U6'G%*?/7YLU?(6W
MSVZ(]&5;AY^A?MDC_^6\Q?F<(4>!7D_H!^V_*[B_S;+%K[0&$PI.3ID5XGI?
M^QY\3LAG;D4]8<LJJI2;M4!O8U\K'BH 5LHENG'BL?SJ$498ZT]8PA!F^P;(
M"+@]<C_\$5;@\[K^AA![O]C#I0G5@RIK'90 =>:@SK"ARABYJC9&./*A?&%,
MHX:SJ$/E9C-70_HL\$*-<P?%$*^P:B%93>*AN\!FA 0/CO6U!<-ZI&RB5V\M
M'< ]9?S5W29.^-A4C01MT/;Q[GQ.H'3[^LC9K#%K9#WLJ+H@A&H6=::[(9>#
MFOJET2>ZVG^L)+I,$L*65TX_28,X"KLL-"Q%N$*[$8RGQ'-6$<U1#%XB\7N0
M.5D0S]7G%'2X5/[G ]BOXP[]J8;/5&+(<PKS<A>!'Z/D-&2H?4]Z5ME!6 <$
M]A2UC#E R9UMI*L8GNG? 'QD10+8@4&)>O_9PP^+\6VI3IF;&\MKV\OC0X=2
MF26;K(I_O_2^.617#52BRL-\Z,@D'N=[&<J4IG3@/SB!UP:):^&4?.9F= ="
MD<]<$<G:A5<?U073[1!VA\ (:I<C9QA1Z1ZW).VICWB5=FYIEJ=XU+)_LNZM
MD7SH$U'JA*W@=:R*M,;,3NN/6 -:U<7*$."1O@X2#EU9)6$TJ2Y#I)RYU_YM
M@Z912%J;PZ).6$\2)W?,K;=AQ$9HA821!\+_C0NG9WM,O36,?OIP'KP53D#-
MAU3-O6@8(?\"&$?/E)A- \&PE6H:(1.F);+N;/%*5HX6-P'6IV3P3\LI*X#P
MP3GU:4E[F%5JNC8K!L>NY@?:"3-X=CY'EUY^^IG.:_;HG/6#QO=J[FI7<+.8
MYJCC>X$^:DO.+6\C[H3"1&R6=>!5IGV[0C(=862 GI1SC9!@D:5X'W-SPLY#
M_;[N8E53Y:DHCXJ"L3SZYV,&U4V,IE9,.&8J/TT!WP..[NP4E>GT;(#/E2L6
M=2S14T@W'-_]!H1^Z9+-V$WV3FH=H*%\XJ9X:R?VSUABKJYXX9E*9R4K]RJ"
M^F9GOOGS[S^>'M"7!K;AD2U<U+RDA6,LC(E+XESG&/) "V"O)LMWI_HRTHDY
MPRZLR,A7\$;HGA1%^DZ1]2T 7TS(V3NO%!HQ[7C_4J!"&K@F"KSNY4W//_^Y
MQK7XU+9$%4!JHBM-Y?@"C'QYI8&J,D07 @\@R?)%'4/4Y3T8K:2UB,%<]"1\
M[&L[6!^-'FF V5=]?[H5SI@)@_>_E$_].B"P\Z<^(HFP9JD[<5R,%("-'U^J
MG<<XE@*, 5JVR.#83($AUD$KU"N]"@0F% :V 'A#XA9&D=2C,T=K%>_5',6Z
M*#.DZR->;?-K*8C#E_']MT6)C$MV-N3>C[</)5C,_N?YX _VXR2<@;8+-&4Z
M2( ?H<XL[2I$(I=<F>&16=;L]A"K/9!7CL"1X7.D=QEO$#!*4:3Y! O-XJS"
M?_[')CU0]//DI5OAU1]=\MU/KWZF_Y4CYR(NL4JO-"@*;P+L1EH@VG%X3HB:
M$5JP_N3Y>EN4)?3YY5F9D"W8H"E'S:#FSU_;PL^5/@YR*HJAR92TT$;.FWFC
M%8,I<IN2'-FO^]C3WI7*$O5Y5%\CX!M!_G*V<KV4FX_7FR$Z, @RO2),!IVM
M,]EAXGDV0'X*X!J0J]5(FER8B>(N4^$P*;F=9()D:Q/\99UY"=4\\(J8=2TI
MFS=843]$5P1H7!$Z;*8U(%6C!X:T!J@C'#9M\!@X#5^JD;L:MN,-F?@H5(?3
M2=PRM,V#I!1:?%J8OP80#]?7QC<V#V9X)*21^[==J)4/)"4+A#E1I[;5I9^5
M<[,I]:I<^2NN>&>'!$?$49G>D'.VATV^\(; &6)GNOI2,,S7CQ,G_-=1M4UB
MYN&WV^.UOB@UZJ;FOH?:DT=[-#S1 8]_4?[=<87TVVB@=C57'?=)4L]MQ]_P
M%#9884MIQ:COY-11E*;J?9\XJV<7=;*T]GG@AVXYKE68:SEF!@FST4#?G6 \
MHVGORR9^@FYX _*@,%PSE+?-7G'@M/O'%WGXAT"(^JQV1+(,/,^Y(C$2;-7V
M1RV'9UHB$]OP*P1V4TUE-LAQB'L,UL]#T^!D7O#;&KQ\28BK)BTE-D2SP.VP
M<<$CU OA2%]%TF2!-Z4?_H4G,.,[.20>4;UMX> 6=7XD6$Q2K%R9> 2G2H+U
MN(J<61ONC?<,<BO%:,YF46=]NWST&Y(9(UXA;Z:&)]4C=WP#'XRV<^-ZD0:*
MVY/*,X\JXOHB_J[WNC<)ZC)7TR@FZ&XX\30&#DVA"%>J_-;5JI5DQB.QM&9"
M##XCK4T?;_,FLWRIR0\Q(L0=RDU./Q%P]E%\:&-= ?F(@8E5$S%.?]Q9V23'
MY11+E&96UP"\Y[-D4B:I+K93*/:7X5BS$F\::,5\_U/[$\3_35]0>74N+H?'
M6;[Y\0#J]>@?@[/!RDO1F_;]TS8!ST]G+HW'<L:\'EVFM@;BD 0XN#V5JRR
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MF?.MV[3*H4:])V\L7,P.BV(UBO[*_A0K6X84C0/GX GEC&Q0EP>Q1#-Y3NM
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M]\$'-7HFX@\7/:  .^![^E@D&/H:%J*UG@2O5.%,@&@H5:+ ,7!'X S];D9
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M0UA)( S0'KSW<W(QW$1B5?1\YA>&!S(X$1(YW8-FQ,=9MD0G1J$ZY;4MT7W
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M4\ER@S/S4=ORJ!F^=B:C,*ELB(GS--%LM&!>M]3N</'TQ2NT5H4\$UMP2<=
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MCA"3A^<@[AIZ#M4#UWB[$+J,O ",!C+IST2MM,'R(*@L/52CD #97!L1_ZS
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MW/P!Q$'O!/NJN1RV(VLK8N9\16C.VHT$:X",RXQTUA9E(B/33-5&,0MCE@7
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M_-WMQ['R8T7]5Y^<K3&C^O/<V_2FN[LG^'%>S:.:F44ER<#7']>*%57D7+S
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M]RT<*R+2.PA1$%&*J%1I$=TT$1"07J(B)2!$!"1(2!2D2-V @( 0I4I7>DV
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M$B@?-L"J;*T%)E0OXC9*Z'=9(PNU+Z4OHN,A@E@=A.(B?,/C/G6,F%$:4$%
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M'P2_6KIBV6,8UV'=<^\)HZ%85MCF'/X>I2EA^YN2D:9647S/>)?NC8&U,?R
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M'S,"SCPW.,K_M_&9R.'(60F&/["Y<$H-(S0[A["@$WOKWR/U*"*91#KDQ8)
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MUD*_?Y]5U_A1)%18.)O6^LCE4ROR4ZN=_Q>RG^>>#T&HCJQI,:I4N3-WOFO
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M"Q<U9\YN5 4,E259:^LN;S#MB)$RX4 6V(*=GH,M^%SX($;G.$6;LW[Y,7@
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M#X]/0U7HLA_?%O6^UPM0/X"BV^R5A_,E=IVL[(MARGO(7L@"#835<S>TJAZ
MZ%U',5*RP>=")@^ZGASI!3-Y ;A?^I,(QI.'0</QG(BAK;58_X:<KUX$C7X\
MS%">53_C1A-%_DH7=3%M,<6)Q[%YUQH/7U!FPC-ACO0'KV(EUJ&\A,? 4#;.
MRUS?IS@IU&P!WETM/EQZTJC:,L J!$G6>L.J2='9JL<?\NP.9&];QB&.^BL[
MP6 550O-4\$J!ZVT5ZD(5&N$F8<NLLO1;$5C!S66%*'R!D+B68<>@A5\!R?E
MA7<S)+IF&SQCZ9@G^V!U% ZARYE9G+6P\II,;/P^XE5E1_R#,*.X"6:S EU1
M0U+_P=&ENB#=J33=2;PGF$"L.EJX@A[6U4C'(0=T.PO=!>QA+L\]^0;A--$:
M]>;V%?!WML2AF]^Y&!(PSN8[QD3Q-/S0C+5)Y_?X^'M?'W[3&JP>)'DD;B!W
MAL_KO&^0B-,T.G:IB213ZFXV\%;%38J7L[ZRJ,9P3S?-#;'(K4W"6-#>/*/L
M"!=;H-&P3T&6XTR1?0JT.HSJB5QL/E$^V?*I]$34^9K8((3C\&,.*GI*_;B5
MI#I&35 _U#(2,Y=KB+=%(\$5.68D2AJ32C/0\D+'4^#>HPSLFZGY8,?;B34^
MR(*%X?X,,S0:B?[:C!R6L0NNDWZIK[\"'8"3BM\,-F=L_7I(=TYWS]!6JL_#
MTYHU_9_"\UPC^AO540>?[UV:__[+Q3_&1 =R6W?TD#W/UNY:>VVUY2"K:%XG
MBKL$#0:0:C/M;:0.D,>7'D-)6LXDTVWT0!XV(RG6Y<-/)#/@W=D20T^*_V 7
M<E?T-GS2:Z\\P/UZT*L$74;CGR.Z:UF/_A]?%__D5I$]MCFF9)\T=<E8;,6=
MH5T/LUUPZV]Y+*^R7'<W^:39$9-].H5H0;\6CBK_Z-%JR_^0.72%[5&8F+%U
MUL&IDVN&GH#E4D^;'7Z.K5&5IYG+/7TES+2[H05=@XHS2<2L^!AI2D]1?(3[
MYXEOX'IX6%WO[=QY'9I&Z.[*5YC0WC*M6UWA(&M'*$=C"[P1"VV3+C4-'^36
M-R8BGYJE7N'^6J2KK+UR"YT8VEDX^*%X</#]LY;3I>DCO]ZLKT2X75SX%^S(
MJ*^:R3VIQ5SLDGF='WL>B'@R H^0 STSF]?I9N3P>&'F>?(<[@)TY9 S=B7U
M*&)^4_9;G_C(<&NHO"ZY,T24,.!4E#PXC0941WSPQ]X.N>KUE31JIY2#8J1'
MSNQDC'R3%DQ%1Y5IWA+@*D\KQ(J/Q6K7<A!<_JD<2>LF&5#=$-\NO"6<SKC&
ML:!PQB9YFD7-2&3.P][JN.20Y(+"ZPWIC<'IG1/H7C5K7B<AGL @&'&C<>G<
M9=RH-E]Y$G?J5;QJ#PHA%GQBKG@%U0U.ZQ1.CN&+VO'&< 'OBK\/B*X#W?R&
MR>$PWZQ9RA/41]J+F>I/3/JSZ]D''V/@V@G5NPH,B9G,QI@\Z#06K+>;>J$Z
M2ODF]YWV1PID,O04TCQM" N28L 5&6.%FB&%,N1"ST"8>7PH<11:0G7MI[I6
MO"K;6>G5Z/[(/2?,[^/?J?AV1 \UB9%HH[Z;:C=-Z^(FW#/D5-+2UG I*3MR
MF=8+O)6G[HZ=GB6NI&X WO"<-$!0\>(QQ??(C=?]VA9=_P*4R;'FI*/6/VGO
M4,P[3Z_'KQQ7ANU=\!(6*K^K:S4[J,X(CJY9H='VEQ%M#:T_<IFZ&HU6;:6P
M^+15@/U$K.G&6T.Z%%L_<(V%1@_@'7'7N%*WHHZ=%UL&*WER:8)'>P'' <I9
M'F=C>F%AB*MK7R+I60&ZPJH+:@S-17=CLM&U4@7=W;6=D"&V#E7>$U)=J_P0
M*YY2;*8Q1T]R0$QE!-4%Y"SB9'IZP_,Z84+/!8@MO]!92(D3AK0=R?'C9@B#
MWBGD11^+4R08=,5H!_.I8BI'M8'JH;WD+F%GI)FP];RV2*+)(+  :=!&K@9F
M7FNRI%<O;MB2P// I.-MT]I#+T.\%WCWSZ_BY9@\S7I84U1)$>Y^_G*HU4MJ
M[4\<2'+S],9,5+;WCMA)#A9K%Q)GPS#W-])U\4+:.HIIAXTU7%$@$2\[?EJS
M74M3E\I ^*%!A3/6()PROK^_<5]K>%1E1)RHI+ZYN?"2:F_5DR]S!?Y>L[.S
M@__3>SO'A8]LFO&/L"$MI^H.KVE#&&F>]HANNR@D73YMQR]HJ4A#"-)Q?N]J
MU.:=Y\\)G@0R6<K-LG%_ 1(<\RY(EYP:WIJXRT7M%-:,[&Q+,/K8",5I_IK7
MP18H;X++8M-&A5X$".U,'KYXEV/!;1U:,WA8L$U+3Q;XM8.)GU*[7EGX]J'A
M24_ GM?_%>ZN:\[XFO3X9&-#6]/5A-.$!M^I.>D5QYY?X+D.**,0?[."\AJ7
M&7:Q.$JB-K?RQUB-QC9_=V%F396:ISLDI1AACVA9:^<7G;R*B>0"RZ2KS0U_
M\(YQS=&%&BMU =Z>Z@K6/CA*V:\( *L0PTZQ(=5#ZF]UQ9+G/>A[C5V$T3]Z
M.F2GL0_YU[LM^<<VW _IV\*7&CSQ78-="RHU!M$2Q6):+\$<BE.),TH(2'-'
MG:V MA/F3LWK5%(WP6]?R)F9D,U6SJK8[S+0W?U';%/(YE**G71P[*6489JG
MUX6W'YSIQ0@D:AW0&SZX-<'ES;H.]5/N&98AE:!F:+/K(*EQ\2TQABO= >,Z
MN&: WL[!MA!-XFU6#^)W?*%AWLW4&;SU$#[\>]*P=#+2I7^*_7*VN3F<XL"V
MFM=9[WWV$$J7**[C-X()K28' #O85GF%[B><Q67-ZSQS;<>F]QL%*8F8D5B\
MY7 B82$E66X?Z>=0.VS\Y2[-#%K-/V/S_OA8_*_'_/YI[5UW98'JG-;-G*%3
MC%&F-+)8@LT48VA87!;J%"NY8M7.-&%SZ=\)N:BOA&P(_+OQ*Y&+95(F1FN,
MQX\&Q)>#2B*L[LU@[RH=6)MW)BFG)B-;*C]Z7'>$MEG3/R0VHKEK7D.&!V^>
MJ 6'E47#M"U@RVA74V%U/2S.HQI*#!G:$"!,;S7^.SQN)V=3OR=!IK(X?WYA
M4U@&,XJQTVW<^+^8Z3;5(?0W8"W#CD!2O2DI/"Z=U^&+;XC9.,&;Y/;(E4+\
M9DH-G[,<QJ:WKI5 =)LM(!_1[1[;,$A=*V694Z[&?E_&?##1<OS0^\_#BQ.(
M?/?$H!6A;R@K@2FL"%8W0=%0JG;-]O[P']0-+-"655,/RI!FF<T]28+Y,&],
M3\C9@2; &6428KI6J!IKC'98I6# /AD\G(U?BP8B">SZ"X_>BRE>LRM\D8B2
MKT7*<BU*0+'<)FB:#2=W,QLM,M8@A*D.&*ND@)N5VO#;KUE/&>W ;RI27@=U
M<K+^:/SE!A9/'=7Y?9:3\PC=#I\),8Y@+E>7*+]%M+#S#R8U?\O4*\2"S:PN
M;)HV478IT@B-BG;& HH6:F&;,A7^,W.)IYG*GNH_2"5+B7EC.]259UMC*JA.
M(#*)E84W@1VKX-&NEC,:'<0NFYIP0=:V(\!T+R!AT*U+-K34-^],)AVC+@5L
MU>]^B+<?C)DFJG:@V^#N#,\8:<(%_I@UJ%-Y4L.&-!N ;WL+)\NQD,@CYS39
MN,.^O#R(B)BSHA_WG)?VK@#X;GZ)V>#7Q.*@SG&536"TP_CU']-/4R^>9AKA
ML>B*0>ZO9#K6$#5#+)04]2-GLNA@;X?-SD'4A_R0FC1PN'UL"XB2:8,0NALP
M(6PN&L?9-NBI+YOL(2^F[D&6(\<YJP<;B\W[OP[.Z%Y8O9)KWOKC":90H&45
M7-;.RPD%G>21BV)9,CT1=VUL-8!*T5_8X*:,FV&IEX<&Q&"Z2**<XZ"<+'GS
MDQ&QFV,$+BRN>4@U 8&2R15"3%;2<S10^_$F/2YY=1GW%PS1>K!PT"HH5C'J
M)">T6YM*ZY[<@?UY);K#5!*L)V>@ZXV2"=UW0#BRAZQM):O9 +N?PYW9#3 C
MG;/A\3O/[76C7USI_*&A@LN=/HMRE6?F=:IFP5,X7*,/R5@C6&6U.A>_!ET&
M.I!X&=2!21,OXCC3WM+<X<ING TX'%0@5? (QJ<Y2X8TUM@,=RA=8TTY&'$0
M @?1194B<"_IS1[-O_Y6_(&A3_Y_GLWKGO;Z_WU=F!8+=01QHQB9\SI-X@Y2
MJMB(LVK2!M.71*2+FS!3?<@WOBGH5P0U"K^VFFE;^"F%*;"\>%]T*K_6[SPK
M<N+SB7X'QSI)_8OG&^U?3N[+NDUS#H,Z%FB\ !0,1JH_0R9XBR]$&02V0%,*
MU1%T+?WX$'IL/4U7?8MC2/5%6/P1CGDG)%WYW)V8S<C$VX)J>< [9W$CY6Q\
M_NIODQ>[OA[&S&;Y!.OW8(**P\X**[../M\YNK^E[G9H$'OZT;,#ZTV:X<KL
M].G,.]E5(97NP2:WMYS8D%K8-+.!Z/)(+E*^/9\?U'3'W";EW37T*QJJ[;]D
MJ.,0[2?-.X@=>@.2_(EM+)CJD["NDYI)-WH%F%R\N?I1JY7\"DG U:5MG71?
MQ,V@1B&NDKLL28/#W1<[FV-C8VN]I0KS45Y,=%UX>'7CT+O_&!\H+(V^GHR4
M"6&U[?<GQQ;\)].:R'N"OI;>H:M<&_QJZL5!*#9G(\)EX+=I6[J@#"10O>1'
MJ5ZUI\/&Z60A<7CFY>@=RZ$ZLT]I%5I0&CWF7Q6@>X#RXXP=^VG;_54'T"-P
M-P\2X:0.CTKTU54SN!&AM'GJIHPPPNUN;F$(_C>5A-4#40)1GF)Z[X\!RZ:2
MFFG?L$'/$Y=*__:O),46GH<_W"VX9#T[JQK!/FV]H%TOIT" ) <R'0N :V1>
M8\7Q2$HWMF&.YQ5^:%AC2K'S!1\0IO33"YF1O6#, EY6)Y_7R=3*;9TS9EFL
M9M7@[ =(ALEU;'61O'$7B55;K$.TNJRG6K_%9GJIPSZ?@_BW^;PJ5ORN$Y\E
M5=)SM\L0G\/E]+>;WO&$UXN/#M712P/=&\_-2()S[AP(<*6X;+G)^M^'32V#
MYTU868]E_X7?KXX.CANJEDX5;]E5B-#>5JQ[I*D /-4V<%*AW X^J+9H>FD8
M< 5F^FEM&I-#T$H+B-G3Y^"Y%E;Q+G?S,084^G[VO1F642SG8%%Y$[O.2ATX
M,[TC]KW?A7-WO[T=)7TSY)/@ RP1Q",\(Z,FA;A4S0ZPD7"&##::ITDS$XL]
M9*O'MI.O$<R,Q!U-P!?!=5YF9*)>CUAY,P&N08VWO$)Y86HNO;+$_N42BT/]
MYA[T;5=P<ARP)W5P,50]< E1\+22MY8R^3.22_-\@=@45X R"2M#"I+),#.2
MR2.8)B1!EI1160$=;T-IX(<M9L>FQ#\ 4=+>;/1$#?AB[\9"'8R4)5$MT"\<
M;0\S4$*1'.)QTR+UM:$I7^:,=P$I,%=VL4%.6CI18M+4 (=>QSO5<F$6^V7O
M(I F*'3E,\T_E_P63KW$HNAVXC?U:58*MCJ!H6\'&+W_.CK61L3H!QQ\@G.X
M7>WSS>_DCL$_A]M?FU#[$C^N/N@Q-O=85J8O_%18OBMKK^<?9XV51^K?S_Y/
MWK/(VQ*FG/DMQJQGTT!0AODR_:XV_2/7_SLYKH^]]3O48<#9!50=V*>*=E8N
M9.5)F-<QR-$:+!LW;::B:$3?ASNT/C$NY>:U1JG\4>* BU>*E,: =_X[>J @
MZ%VK%=P;/G3JM*=?[61+<M:&'&)S6W-CJO+<7>YIFD ,^W.M->WS.LWB+D8.
M<Y'&CI+637B6/&T/AW;>I![OX^RB!B-</O?&>5H_%C/[<I2$H7SJY>/7"5EE
MPZUN5<! /6/MK2*2TH*>EHCZ/2@;GS6GVZK2E$;J1[0-FL%Y'5T%WHFZ#WA!
M\#$7;A9DTMA+'\,.N'"-XK_%,Y=Z>LG>^'K#H3EY<QDN\SK+C]USF=[)FW8]
M&5L[YM]WWNO.K8D=$\,6V-C#.24VAP[EQN*BUT_X.)*B,]N#.O>D'_VBC:GG
M;M??CNTO&N<-MDOO*R*O/QHDBE6D^,W!^=4*MZ:/TX]/F3UEVPOOEBCM5ATV
M"RL_JF)/R":[=I8&[];*]V^'_E\W()<2T15DC7XL$JH<4)=[1B,D7LD6V"9-
MZD#2Z+] FI5'86&\Z_</S=F)Q!N:K>"F%J4RQ4NIL:LONENKZYK34:]:RH6#
M+P=</%(^#=6=/4%Z&AOJ_RUTB-18.1V/V$N3M32V6M/+,7P&:XEX&6V]7?8L
MEE'PO:(@^5)=; N4:<OD81=+X$]E1M-M%0Q\N3S/*2+_<,IHN#"E,I9%/E/_
M_%+\I_!Y'6!_L$C*R"79L(O/G6X1MQ<;'@9D&%*>@4_EX3(\M\O%>=B52?\@
M8T]EV.4X/B:3LP-F\MY8M0^W8*^3D[S6S>M$#CI[K>-U%B9PL\_.AE<B&^]4
M-KIO:=T\.#?P6X/EMOO''PY49K!N#P=^G"L^YIE2EGZHS3>K:O\YQM;5=[->
MW[Z?L&H_<V#[CK3]^_OX_=WOE%FJ[/LA1B>WKYX^?,/2Z?"MVW)]:AKLJUGB
MCX3R6HAIGL;(81F4YNCI)B.!]>-=Y/?Y\N%<U EZ\H7C-JA-W3<@BR1"=N1V
MP"S=^/3!A+)E7H=><&A(\00_6C<V(>*4)AGL/E_A8_17ON]G)KR?#&Q[^=SW
MW7)Z!F<#&@_(JLW0:=0&^%R"&=)Q@2(=:\:-)ZVF!B&O./Y&KL'(P68I(9=F
M_Q+$P#W^R$9&)<^1)6$LF6AAYY4\LRWPY30VI#H3SL81X!#F=2' 2* <+6VM
M 6PDG$^P="%G?=]#]80/EL&%$1#/0KS0)?R*J6R,L:RM&O434O414P''9N!K
M$,&(@I/&9*/16D]KRMI9*GEI%-)O]\=EFI9I%ZV ?5@"0]R2">YB_*YXR#!!
MLQ80),-YW-,U$;J\)L)2/)8:C2#OZE 7>)(D=(%,CU*]6]OH1Q''="G#?+(%
MF^9"6$:Q$X3=M\1DLCW\G[M@ZY.Z@H-#=^W=$NS59K;2YW=V3M>I7>53A2^5
M.-.2DS"(%18,?NDQ]C4HCANH1^BVE<3W*K<FJ1[1Y(/_MZH3CW^%_U5F^[D&
M'WZ];3!>>#_B,A1:E\G>1#3>_)]=.P/8L;);W1"FQJ#G"7IB>*:&F4Z"#VF)
M8\4 ZD"&QP4VZ]^A*0^ 8X_D#9.',^ZNCM\6^_W V$ID:X'?A?-E),J%PP._
ML7->M8;WI)0OKUS)K6^>CE(MI3J#"Q(2V(#ADS-$S.O.!#.*@H]=@3>F?2C9
M!,H1<VQF,LWY:?_6F;;X7X#T$78Y]6?X",?PN1 _JI<^G9A3IQN9$5M:XF]X
MU]7T4F\Z)*DF-&*RSM*L*1GCRC DO:E89DU4]B#_< U;79/@.7ZD*Q(S]9\*
M/VGIF^9I*(_'F 4@YKWMG.66O9EL_YP/8=\$[F/WDXXYWVOD+IOX5JYAGG=M
M!7*-H;7*$7CS(_7[I[>V!LB\]$)AJ)-@3?5#/-T5/(S1*SB>)UX]\\8I&,1Q
M;.'0W%;HAR[@=PR[&%I''1Q(4F!0![@YCXU=.F%QZ(O[;<K=758&B=$;Z'E6
ME8<-"WX-;;AX&YZ)?7O7PB@KWN<US)X8"+X4L378LGKFJ;-,+@Q6#48'[Z6]
MY;@N'WCX3U5H?BHK*)L],+[41[\_D;6ET;[OG_%*5]-O\5J'@']6Y%@*&%/6
M,$$VW/VH0!L0BEN)JKV: >QJ-C>5@T.8G;@L#D[]E.-&*0H>3K3O33>9L$QL
MQB\%"? ;E^D0,:\EAU(HY.>'_SWFZW7+[_%?L'I4M0#J<-*L@3J\N&<8HDH^
MM)2S+BYRE_H&-Y:I#_2Z+<+( D96) YD(>*]ZG*J\_!EUVS4MSJ>LZ[?CK2<
MDM)%LWJ>FE(7,L?O_X*0)I3F#B>'[CY]>WD?0?+P<@9=3LH55>9]W0TNP3P^
MEDW.2;R"[<2;U0^P4#\X17F.3(<,UZ4J(@>HOE$;F-DH"1'R6Y1,:<Q3(>[,
M[&_"<-^75UP<QKZ3'G V_7@&FVH(OQ0PX=3CU&V@4M:[JCA>8G'])-Q[_8PG
MX4KU!\HW95H]4L&6BA>-;OC:5CG:5"/E&@%L$&*7\_6)HT-CL:W/BP9.BO)J
M[WIWGFCWB?&#!MOY_=F52WQ^'ZK\4]#'>W<_"FG944KOE$Y\4!F,7%Q\Z],=
M2\__WJ[^EV5P_^V1+<22"WW"DI\:[67V>P[V9==L]3D0<#EK0TC)B9RJKUUU
MD43.8]8;\HA*8W!82F9 RSD6P%"S2B$?YZW4;#[^?S'VG5%-=L&ZL2(B1GI3
MHA1!JH5>D@\1$! BO0D1$2D1$ $)&A(5Z>T#!!2$B)10C72!D "A* A(ER*0
M1%&:O%'*JX1PXSEWG77N76?==;/6^R?_]MXSSSS/S-XS6 _@=09C+DXO_.%+
M8*RQ"_](NS&+*D21ZE&()8>0_.\SOON5+$']6#RT/_>* :9K4UV&U3#9*@3_
M3&R]I/:IMXCH>$:J@:1?F5%#H4[=U)V<:^M?6J>>?CW\YBY1Q\)Z.2=XS$+P
M3HX?4:)K*MBO>.VBO_V2ZN)8M(6=39GUG7@38?LDQ?_K$L=_7.3X!DW:A=0I
M@OHLJ7G8(S6*-)C;*8GJ7I-$ST+)K(W,V0P?>E#L\'?<'E90JDR&:\K"U_HJ
MU-7Q5:PLWKMXT57MN<XU9&0IRL4X2-B)8#;!PU2/H1QE<<KF3WAUZ;GY:_]-
M(GA@0^873<;&FOTH<D%'T1QA].2-QBP=4F$D7^>?L8PI#[GQ2C7VB$"68AX$
M ?_;[SD)O6];_U+J_+5DYN QMG8CN$4G\7.]NUN9C_0P R/;E:\/EQD+ ]F:
M=W)\4C@]=*ED7JP0?TS!=<U6.^OG;/MF^_#&?R.5$:O]VR<6G?+%A[!NV];8
M P!/(MOE)>9"YWV?AU@\ZP%]+8J-R4(<TXB\X X\#<<)3AB8^52YN2_?OU=-
MM").MQ:@A\+WU%VH'+K ?+]]"#< +6Q(HDBQ-,Y5Q@=XEDVS_V%5ZG&2Z3KK
M_%X=\<#<I8D1-\F&;. #QJU3;RMV%T+GJ6^V$MI&.+4@?+91:6'07@3@3(J>
MXU?ABJ,7W*W'-04 6^T"Z!Q$#%S,>='U$_ Z9FH\SZ>0;0N&$!>U-EUK/S44
M!$D_]]JOE;57.7/[N("92%.RS3^0G9"_98O6SU]+".B02'Q8D+>WS_Y&[?#L
MD*X -#K@L,3IMTUOGZ>+GTS0],ER<?=*%JY]<]7*\GA:OZ2E4%&U1:+<7=->
MUGNITINA8?+N)RY[>\N[7#[Y+SH!?.:-BO70/VL5%G 62(TCYR;">+5322>S
MMT^O]>5,M"T>KV+RQ1'0-'K!\5BW-"?K3W.^7:$YTFLK[K '[V5W(=Z+VU^R
MD9QW6:;;<OKY[HKE>>=-=7U&-DF?GN4&%/:V04;_%EU*7ST^M"_N5(* 7 WR
M9()&DKG!!P^_%R>O_NS]0D[7<O^4=<.\W]($(G+8S:U'8^)<^^%KU^*R&*'Q
MHG[CD+Z]_4JE$9=.S5PZ\<STQ./KYSZ,_L^/VSUDM\W8-YMV")1#[,O@>S3P
M-U<F] 5\0(]TZER;I_+.?-^4;"A#%[E:13Z0]7?=6$W)+%X<U[KW:\[_?O*'
MFM:J3/)@@#<^[(O+X.I8'^9;.^X$F#I/%<4B6&$9_AXB+&JL)N$P)L/:+7Y5
M<MMX8GT[6=VASJW"1::I45O4R>Z20F.6[BMUBH*9P_4]0'@G%%24)])6'<$Y
MMG(K!6@=(.]"^+%2E6Z8FN$39ETPB6SZ5C3\E!E=.5G:_43&1:!UC)@8L.Y+
M]@DN=7\O2BSQ%^RGL[SD7_SZ@TO=OHO=]Q%[,F=BE8]E]C<9R% .BD,(XD3G
MOA.$X*H8,]I]QV(F+-IUR9>BC#J GE5]"Q1B:B_'JZU'VJBMKO>Y5>B[^W?S
M6_<.?W\:2$+MI. @(,%Y(BPOI.-^]#88:YIA01Z18R'B1B[647-IKMI1):R4
MY$*3LN*8>.:B@2K],X\Q7&.XH'YB?-"\[MRL?'M^1 L)BAND\K 1] #M#EM0
MZA++@U"R1#G%@K1R 86:LC&])HAIM,UP83G%:QH&=9WSSTG^T<10M74DC]7S
M*OQ2<_=,Y T("#AR4OK1_* DJ,W0CJY#'L<:LGQBR&'S)"'GGC(PI(MS="*4
M*H3Q0HUX^URNYQ=##0620JML>\W,[)NK6_(/W@QSDK]\0A/GB6^7./EXFL.;
ML:TP/6W,7T^6%F#=/NLVW?EO^_YS;"2KP^S(V<Z*XS:F#^6"3<O37AY.$(8@
M_N'(LXT_XH1!V4[4,;+-P5KU&/:9DL]H/?:4=$98E8??'\,GY]W][U<V:'D2
MM22]GUZ871(J3POP.U)[]M2AET<I/S@]R,LWJ:UU-2F,I:E>GI:W,9,*K>3,
MZW5UT26A+H&O2[QCIC[S61I45G<F?=D72%$=P?MQ"?*<U*UA ]WY.O YG7!L
MTAT+!9^&SHFQ#[ ,<O))P%H/1S5GT&BB;E6JL]F]+BL?-OIUJ-Y*WYG56A[!
M%2!)0>5+-SHPGOR;F?^5V;KTKY%PAJ7P.3/5OLIL03G?=.M%R8NI%TKYE8ML
MBBP&G"M]XPXY0"Q-A/= )U<Y0YM4&5A]!!>MD$\)OMOP78CVNU\-O_.1S_;G
M.Z[F<B);FLI*_^>WY">;<E?&)\3V2OS@)POV;SZX*7AM\*OI<(06*\M([N?J
MI*#8U9_GR[QY9'_=4 <5DT9 -77)/D"A,Q^6:)3-M&YDF=$HBJQ[T6@&8@]F
MWSRQFT\]:FJ@,LUW?.I'-@EL<1A53XU38<OZE!OY^1']FI.CY^)-BS?EFW?4
M2,_J@SYMSVO52A/X)Z(W%%_6LA I9&1X@#<#+^ \C8GFR(/#@PR%%*PAHU0U
M3)'!@D6QC9E6VI83:P;*Y<4#*6IUT\[S#0FC,VX#>[YR=Q(?R#V,^RLXQ0F<
M"H&/S0OBO;C8\0](I>/CX 9@5($?1YP*HAA<XBP#^A0LS9X=VXC3. %K^[.S
M"XG74#Z=>+%I3/.R-$SX^[VK2[5+[R-]H,,$7HHA^PBX1?2?ZFF;2Z(>YIQ?
MU#NPKG>KI0RK CZB(^)$)=6*@P.YKKGCL=:1TU!U,/>!8:'JJ&ACZI&?TV_R
M-7SC_!>P0MMGL4* ,$4]0+;]C;\612-F CFZ3A"9]0"IQF^ G=0X38*H,\:2
M-J40KS!:-P@%+6A=<)D) V,?^H[:^!RR<4SSC$*"O"7Z4!5<>2>1K4V?.XR;
MFP,</LMV_#F82*\ZK2[!Z1'L*?XNZ9"23#13F:O9?/++(LLU5'2\3^6UI>7)
M.(/DOO1_7D+']-#-II4_>N,2!GZLB-@("W[X</EP^1Z5SH<0N1=.JLS<01&_
MV6.LHP7SB7\EFWM*KN%"?/'2PHKSDI-CVY5QP<AX9M,OTDGS@)5-<\G(!DN\
MWJ6H#YX <:5EVXX= #(9XF0$BX\^^,0 48)B[ZL'4U_[>_#4@_&E,]CS8.(#
MQL%A!="06:%^'(.B;4[ E1M&7!F;^B=4B6^;FC]J?G^M\G)$RF0T[ [TX[3R
MM*'I\-0N!-G20*TF/];/U9\^PVBN:VYXOH\6'!"R[_T1P"))6O=&>/+'&,>3
M48[H1Z#CK: 8RGYMH=EK UB%@H@)R=@H*?K8^L]=B(\1Q8VZQR!8.^JUW.TZ
MBI1OH9YQAG<U]H53Y'^]*A<PVB\Z)"?ZL2MH__4X^F.-!+D#B<?2NLL3^,YY
MU1VIEOMI]=?MCCAN AK]^X]U3%R02HQ)D$LFOCW7(Y!_(^%(K?BKA O*/T*.
MVQ0$E+ZT^G_/6]L#]FW;X49V(?4^;<AD?/WZ>\;<GEF0KQWVACPGSN'!P"R
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M7P:68YY,XWWFBZ^N.E0H;VVF)[!Y;$Q$V&\?>/['>S<CENPF'H2Q'@\\@";
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M1EV&S?-\E?J^Y9J3*>WF1]-^$OC"PCM[7!T,V++ ?>9#0"M6STC/.AL,JPB
MDE:7_,+1;&(R]4,J'1U-$%W>G[AE!NZQR5*T;:<<CS%617YJBNESTOGDY:G"
M6\M8_[?LQ4W'G-8;R0;F]QO^#?F!EU3PMRLZ9158(MO_ EMU@Y255E_GK/+.
M[HVGKH]0@F9WZ,2*J'F;7OYHHM_]$>KB[?]+J\X_H/!.2(E;\J"E==]:*B.3
M-0D2(D,F45!_)46@.V=2N$<!DX$77<C$20+2]06^Q9]O9="N<YCQV%N3/?LP
MN&9_!XD RIF!-:=W/Q+8+>C B)Z17W9 ,1'86O=KX+V>!E)ID)%V+6%,G16!
M!8F#297Z3L!&"OYIL,YF=4G+_A[U 6I)DP@IY\5[V'_J!D)7Q<?\]6_;Z?=:
M46WJ04>^T.MBYBC7A_>"',):%=QABXA$F$00Q]&^%R[HG[L'')\BRBS8MNPD
MF/L25+)&&/G$Q6N&Z%>"O=#TL4[?%NQV!,8>S=2Q%BN%VI%R+KZ9#P@VN*\/
M\) P="R^VKJ>A7@"%^*(YI1@)#HZ: @)BFQD$5=LI\:):#)$\-=JT F9<F9M
M<ZMD_$-)OL)00>.W%:X5-$ZGR08A+VP^9$ZPL,P6=B@A%U>+117(;%5=[9$K
M,Z]0ZRHZF97N9-*0D6Z85FDJ5#GH?V\"WM8MZC S\^;LRCO/BAK)EV&\L:([
M14+_1I_IXPGF)X#; NNKO!*8ZI8R[BM4@J*%R4;Q6RFUO9IKD+WJ8AK=9>7@
MJCOI4PTP0RATSL[6#GZHP/<NT8[,$^^F(<G43.R#2LE<W*T4FM<K!6_/I JY
M"]=$Y6K5Q!SN)WD*V9W^4CCZ,BOA0:*Y'O%DQM(F_##+;34%4Q&+T8\!='^I
M;PLD:+]K//89N."O&S!$GY$MULR0$#G0ER>4[@7UL[<HB%+Y;*V=[58=A-O9
MSBWF^,EZXA:"B^0XMJ2.O%AM;5A-PLEWP>.GK)!MN$,4CFKL*M?)Y0@QU KB
MTH_U*C"[PY<2=S.K^!Q>X"^LV>BE^?)5C,$,]#]$&S.)*4DQQC#MP&3.LPX/
M9?#9E(9[YO(C9GR89:7US(43\D%+ZM%?4Q5CLGU?)?0C:YR"- KD;\??-Y\A
M![.[D!VYVAQ4,BD[>W$<U39Q? AK6>[A'_YS(2MY**]R048N>;IMO<BP<'@X
MQ,W-7*5MH#05]J[O?%F@4*X,4!</"V(K0EMQA[_]1HF#V73#Y-SG>7.&*NGM
M!>7^#;EYP8J5Z>GI.1_,=39D9,0[#ODFW%_9U3Q#[5[1GJ(<FTIJKVAG5_3L
MYJ3[9'K9J;@NU'@:_+P^30LQ1XHMV1O>Q9+[,F$%1[X46:.W5#>U(R6X1S?5
M >_=!)$[!NZB:FY&3VB<3*AWZ/V-W!G=>Z O.\0'96!WJD?X):S5B>QVKYQ8
M76#VW:;,H>B0M-2-ELK(/1>'R/95?DIRP$1F1"7X##7PKB92QJP_Z$?#@*Z5
M[8U/*7WMK5\81_N0(6$AZO=H<KN=QX3X#8A;*% _HMEA0J(/B]\*\G]$C</:
M$N>^C7<  :T-1<.Q:SW[K1[EV\72)T[UK<0452YFO#]?V961?I)0]-U#]IB^
MX0>Z,H(,W8VXV?-])U%]!DJ&X0>YNP#(4_+E$'10@'[\B?>?AL@F/QAOK[A&
MHNGZ+K4%-Y5/?*UWA[-[-8M/^O69P_VW^'*;<,Y=M.7!I"[.$?5G!U$OBBRD
MQMU, ZRC,L^C!:V%H@T_)%=:4#1S+-QZ&/U)D_/4'RBY;8% P=Y%&AF'IU&4
M[HPAV<.'O5!.K;=" LLO*! >5SOGR)ZQB;H0JYB0&Y#<<KVT/,3S T6I;;*Z
M_*4'*JDRAG@H$)^ C,4#E_#@J6T!NJ+RPD_NB6_8/1+*Z'V9=*0B)N+28-6>
MSSJ!^S.]X,2'_KT/+_ZP,E53/=<I;/KA[DW*+V"#+]+)J\>:L8_4_%7ZL9.S
M-#SD(5*C)RZ[S9&BE>-T+V,]ZV1\49LN?>6>>3WY?9W=YZV+]TX@QL:EMDQE
MYCC-=L:)1$?C=HN<'!/7LP464HQQZPN!BK*M6@$V90=5UE?+^-ZSU%JC>;_7
MY%8#CSVMN?(EB?;'GF6@6@TR]*72RTQ,I<[^#JDZ\?7]]X2UY>ZBE);;OM9!
MOV[5&_AU !#^P9(=7OD2Y.T\_@2I1'"]9TIK!Q7C*$J<F<1BT+;]45!/--:O
M<%'/ _IQL&"PJ %HH[L49J@Z/[Q]U5/NG8WS@9%.S27'U6E)QP6N/LT9*>15
M_>6^BWVI%U!A0S*4"M:M/O-RT;R;J+S8760BVU7_J;ZFZ&2?^4XV(&"^G#HZ
M! KVU<5YG)SZN32:6.VD(.V>W/5>5M/Y>:=\;&>IF?"3S2&9T[1;9T,J8EK[
M2V*BG5@L?8LWDF.%;UZ;2#I2<!;_WU^"I#(K Q[IQZSE7/;@B%:4^#XZF1:@
ML5)6L3"<L8E[7>+<JF\5%A$9KNPP5,O1.F^E$R\GZORXTN++<)@QU+279.Q*
ME]&K?:24XQ4<43Z.$@A<7M*8\M/TKC]41;D2K 9[[;#KHO)U0;;/4O0.QTN$
M[P*_,*@T* 3WWX0F&%(%-KI'FK6B@%=8[0%$(%088]2!T^S/;F<>]N%06UZ%
M,J,:,F.#<D=I<D,EDW]JC*@2_GIRIIGYYNS!IOZ:1(FM6VSY()N-?X;5UXSH
M_:2*)JAM;>_O@Q?/?5](&T%*$QX>=9J^G5&'/K0B?5ITX$)RSQ>\\K; ;8AD
M0-:V0!LBYE$Y]Q$)3+\U!7F&%X>9L8TMKW(@J5Q4"=>?3.;@H\(00EC3M!;&
M1M1:J@B_ZSGH:CJP4A.!VC?BX61512%I)I?X-52]9DD-R:R+/T;D!$FLF_/R
M=)![7.8:5EM0,IA%6JT<;%,_2<=U&/!(93-E^'V&Q!:J.'@>FG2Z9!ZNAA3%
M$)HG(.#SL(( OA+XD8C2;Y/\-$SDNI>[+=I@C*X0K.;^_B]%$-T6".I26Y<%
M*R,K<-^H^U8H!^80HGR!^0DX&(('5.E9=6U(\85-LT2<]#S%L/$#V$T]$J@3
M8, U89=J_<[17$='A^-':C//?1^[^/",_"_>'L<9!%<:R;]1MG5]6^ [I!FZ
M64>!7A<<0R@I?4$\A1XI'"#?* )/6*>RPE-SM]I=IJ/DJN)9EB9 5?FPTHFA
MT,;L@-%(I$7O;4CI@F'H4.8YIO-HE_\W"Y7O3 5<\X:'8.\RD;NK"'L!] (Z
MVA[IMZ[&N(ST[6@IB!P7,4BVG+3RGVH3]X6?C;7F%&6-FT\N^] ]VS(?!9%=
MTJ?YV<3Q10XF1CC(8\;Y+N4U[QTI51:,6/<%Y]E0@53!SVPTA*O.::_W"YKJ
M$5SP@ .5O-KGK"ZSZP,UX[8M#.NR@G'PB:XB?&+FBX;.1&+ ZY(4H\Z(1M,L
M!BH!,4GHGYBG2I ?LAIY:I.UKT\6;!GSNW>89J7,9,KKR@"Y,TY@&\P[,7]1
M"<[1IT.5%L_A6W5#BMWF*=* _;LLQQC/;PH8XJ5:SRJ4B?^N37N.N.L<;,^4
M<\UGLAFZE,9RQ[D>Y!XKF,\]QG'3?SX?C@Q2C:D1\9;/.>$R[.!UN<C/Y8V$
MD[],J[#KIXF#[LB+!; /?G*VW<.5VO.U6MK^>M]&_$747.AW K:,_OI.KM6?
M7&#LO7KSS6?)JZ4)@JS4Y9"'E>#E*9EV1.SZM@#):R5Z6^"@)?<,)S5FC2G'
M'_0P!L,G45%\R=K!4$MTO(<0F.[G4^C?2K, B7I4T?1B_^<!#2$8O"DG,W:E
M\C@PG?)$J:""/S.7)V/:YZ 3<Z']]<T3*8Q-*YOQPRYTJ:,#1;O=3:7<U!W[
MGJ@P]GVZ)W?Y'V@/.O80XJ\W1).'"B4T(ADQF?EXI=*N:"Q;8W4-N=O9+\YY
M_W[Z(-E133<_*+6'M]3V_4/=FB6J)Y4K<4;Y[SS8"+Z0(L?KQ\!4A%6$'; D
M_:CHE6MI_B L**S&ZE[MOQK4D5O EU&7D?2GTTM)YZWK(/)=J&]A^*L\5>_W
M6/?F,35)EM(!()P&5TP_.>M[VX<V$/+5M:9 J@MF&J*O*MSN8+U!]ISZ05F'
M2NR(IZ_6MY(K(W4]!OM2AADZ?4*G\JG9J3?_)Z/__[6XQN#HUGE^7\-LAU8J
MY02P&OV;*C4&3FRUA<_2/XYA(J[T:5%VCX%(5E-N.I#6@CM/&M+@>FHEA24[
MMDZH =UYDTB)BT' PO"UX57L#;143&.$3-PJ+@K0;V&.VB)!L_QYZL=9.CZ:
M^O'DZQ".[919PMJV0"Q!CK]O 2&S"M,"2MIRU>5*6@E[YET<G\%UN ;]L'WZ
M,:']96.H.>G-U/A '3 L6V0_??[Y'%)R6Z!DX+K@] 97+$QK1WX]O<G_KW=!
MNR6LS&P2+VY6YN[B2BHJFBB"TE/E3N:%^WG_'#/.*1J<S(IP-=#45.H[>*(N
M(IZAK<T;Y730:RF'07V.&3W<0QU /L%_X.YACRS#W#G'6*A=&+S-#F-VU[;E
MW+\F>Q=K[(<;^KDP9*G0-S&BOOZ>IO-1V0I@<L6(_!N$K3/X[Q53$)X+W(!8
MM\,^76D4/? $)Z05ISX42CP$AGB Z"EW;4>.=9U7R8(A*FJIBFQ09J*?L*K^
M&P5F=LG$I*?4FHR:"64?[E&_B&T3X';QGE>1G?/!3$=@.3..6R'+-=J"+6RF
MQF+W10#"[/#4(LZ^V612!%0!;)7?D9V;(B4Q6*TM73#WBY&&8<?5 09$'H/K
MIJ&&8<8[14FPU#6@Y_L7KA7ON1>(?[?P(4!)@>/8_"FPABC"[T2)F-&0!Q?Q
MDOS#OH^ZM@5:J?$>:D 42EYSFE/W!"93N8C3'@R+L.P1!!V;I3/D* 0B_N;\
MA#P'G?#[5H5?#WK+ZY]]V/$MJ[]SH?91[Q %QC&_V!L)1_M?ML_O7%UH?G7?
M;!(65>H3^ @?LZ9E:)38/F'&(!:>G<\*O=.%?W@W.QR3R95$K0^]Y\7S]R,2
M0Q>-C'W8Z&3TW9WLZ+A$"1S1^U ;%!+)5G11"<T(DJ$Y=$F-_SC\_L7/E4@$
M$G*8[%? ?<M+V]FFF2A)?$!D@#FO@CKY%J[/\:Z=T#@;P$#0Y+>R$]&'%[,D
MF\?F ]@!Z;Z.+;@C.4H':W:$X/V)OA_ST38+D?K=8OIKR!B<V+UNU>CA!+X6
M1\5# NA.\7+5_/)>-@A:&1P>)YLKR&SW@FE'/2B)I=GXL3BO)]1X:<*HK,1U
M;#K'":4JFUJYPS)O--^PYZ0(A;QD:D*%#_K)#F4L-_XR?1,YKV$3;OX'7L+N
M88SRA9TY+J.M?,7J(?@!_F<E"4K"E$M.80/Y6YX8N1$=EOB]K[6?+4@7+DUZ
M[[LIE6<E>!%U?F8YC[Z1":6@/C@NZ?\]O (TSC&%N3 TV;(T*(V.%R-?RWB4
MFDR:)Y-,HW]?(3WV>W3I,*XKW^\&8QYX1K&KK]>ZORU@ Z):)^0!9&Q-ZD$0
M<:F/K,W*V?]%P\CD6ZB1?*2^1;_ZVR,IC.XO0Q?>QIRUU [\Y\[S7&?AJRM=
M36ZXD^#J:P[._O)C4$TM-A8N/AV<K%[WY /VVBPO[Q0RU[E$RCOE;-OLG^(S
M^='^5-><:[JG6].N$Q-*;!7CWBDY"TDIJ4GH)W8@G=G^6L\L3]V(J2XZ4%'T
MY656D+MIKXGD#=03I;?_-U=KQ^G5Y2[ <NKO$6;$0:[[9+*@':?V&8LJ/#Z/
MDP#&276Q*]B_*9\D@34!$''JV%M3B4V>MOUAA -@$%<Q+\#P3BX,V+4M$#5[
M\85^=1]Q*7_(^_TPXGKI6\A_^*<H@6V! (B(_[: 3#$@PD\&D&R-X2=XENP0
M_Q3V.I"$EX3)<@*F#A$4R<@I,[!:-1IFS-G3ZK*:I)[-DBZ%:?N5+61M1)$4
M3_ZBR]V-.4JN!L[V>?ZW@U/!<U19+&++>T?OVNH04REP $'OB?\&_EJ_FN;(
MB:418QF9K3N;!37_B]\EIYRE6TEXIHN7XUZBO&_H7[(81;E_9C?._98=7C[G
M^OWT#F)W#,_H+V5O"YR&['SZ^QUVP]R2W198U/35V;7!;+-";0FR2E+#"$O0
MPY@W?A-BG'V=F(C6S(S-\/BP**OS/\P]\Q;TPQO"*(2R:]$90WS71?L/:3*7
M[O@^(7Y&@JH+&!-N),MH6P#BBY"L"4=_IUUI !0H&D LC1I;1V/%Y+'=I=8N
MD#34:/J,Z-D.O))FWLV9+7;3<FURT??">ZO?;C:"B2KK15M2[)+WJ$/@LRU;
MRZ 09)KI0![Y6T'*0:_AF[E]OJ@K3X5?WWK*GG(4Q_NXCG:J^P4;?[WWL10[
M/(7D2I2P$5&X8^!&6\8#JA#N!(C;8-7]=;#0!RJ'4R@J ;EG>OD0K/8WTJK0
MF!_T@$H#=8<1.,.T2Q>'-F,R81N.COSSPY>PN@.!4-=,"V F/:+\,8Z*U2%<
MKP<C)K.37? 28PLA&)1)!G^JO4$IG460Z7JP?ECG)R:;QE"0;M"+KX)%IQ05
MS3\ G$;<7P<MYU]];G<?7P-IWPFGF[J??Q3KPRF,\O78^TV3Y%UC+JZ6@[JA
M$E03*?H?=?^&RZ#/Q_Z@]\3J%>R0S7.*/E\L\1Q0QYKKS^O3>(=@B0(;WY>Y
MB"G+U3B&@AYSY,'$-1>S5)*NU>5VE_MFI$"NY:/$D'?-XGPOB($4J+T#K04@
ML9)["TP$H.M[0:=AN<Q$K!>[!P(2VC,R@AI.59'\?O3#Q(H]2AEFWV]F.G B
M-XW^G/L^.O^Q?N\TPAFX3/N$(;"1D'OM>H7O1_:>&>K&U)VU6;?[V2WYV0^&
M>YA8&=>0(F5YT'QR[O;)/WYL#B9@8AZNT"GS6UW1I?=C^;)UE$:XX6^HRJE2
M'O'AKPN5;K>_(D 5K68M&=P 7H&+WPE1D?<VKWX K<EUK8!$U1K&;5D3-#]-
M1.:LD$HT&!]/)DX*[X]MI8A)SRN(3;1%A F_V[P_NVE*U 5W8(Q&V >7 O>P
M]*,J"TC ML!CF$8A)@#I],UL=EO AU$8[OBS5%7?)6=^YP)0Y<]A8=JY+DUG
M4N7(EI7L3"5O@V4YM5VTAV%G8(@69Y536S!-DU99,SWHR>;K;YL8Y]/W<EY]
MZAC'C#F<2,MX47) O7'_>R<G&W16S6A%?/GO=#<32\,T=!5E"=\HU=CHM0-#
M:?^[[4\P&GN']QHN@/OFP+G(R61I/25':C21:VNS,NH*FAG321*G'5)H'K72
MFVU9>W[ECS)-J__;&Y?7'O >O %DLYC-VP*[YE"'*%(@"@F$/^'J*W[QDQ/-
MNJLD_*"I,8N_SC9?F?G4V-#0U%2?N[*PL,#VF\EU# ]I5DHTB;#_E!H7+*LK
MJD#W&>G"*;6R'?2%GSM\Y9#N8_7.GZVTOO .[FSXL^4&O1R3 -C/?TLV$1KT
M[/)/0^J:OBA=/&,WZ*SI;'\]H>S4W!^WOAG_>=_Q&O=_;YA(L;/^3\]&J#J?
M 1?LY89LZ6-M4E&-(%T'+P2:T2<N#, 0@':[#$68,YNR#--B57KSIYH/^^OI
M;=Q'S?,U'IL7CL]]=$4&E,$ ,YC$F8?(/^>V!?86<>P<45(E("J8(]]*D,-"
M*W$]N?)@-2M2C85<5IE"I!*$^/M&+[+'Y11564RZEB#XT?3#-ZP8Q\*@N*X!
M:"?F=Q1X,"^SJ)(TK>B:)\6CW7_;EDBHQS \1WL=!Q:PH-%4::PG8-:QP1<?
MF@;JZ,C=*(RG)6=_:@5COB[$N4VZDLV30?7J)%J.#!D%C'L$(9;E[$09T45=
ME6T?KE$3$( UD]$_:1;#UY_ R+!].E(9#EJ)GE; ;&NDJPF'&0,_X,_\L%[/
MN=PFEYYT;\$0O[QK2Q4C.CHYF\H_#1)L^OHM>ZMP)S#M_>U <5Y8@8B<"-+A
MN:;6@33Z<'3VRWG:BUSRH,^9(PW!H0/H,VGVT]$/+'.S2XZT#U3KUI?(X,M[
MT]>BS4-ZEOJBU"87>A@A+F<3\Q0<R4SE@>G3'L5*":AOCLE<"18B'B[*0="V
M!13G#/$),-DI8V%;8#@!9EQ^Q;O_=P[$J2:CXT;_RG-GZ)?ZVJRKG6W*(5?H
MEGNKO\0M_MR-;S%$>"L#;R9D^1U@%*.0HO&1D\^]AD\DB$.G5"C5): %.G;]
MK O7$2T.E7>=RZ!"5NZ2Q:2?*%7IX$$SS95*I:[93QGSE#EB>EC/:,2Z#; 1
M#;L\%<%,SA5O!(:C*6? U,D84N1;S4IV11Q.'0,7;.2$/ZG4(1Z:SZ(0*P)P
M4A]C9C;HP?/2^M]\,QZ$#[N\7/_F-/Y9--R2H5;4=<"PHK"LGVAN&^)ZX;*$
M0]+-Z?Q*AS>.5)LS+BKZ7_K2KK_\(V?UTZ)(MN$-<>E+Z&F[$-*;,INT]"DK
MTAKDR<[7@XR9$ 7^#BC?/>>@) N@GX4:Z]-PL@#_M6P"[6IO:*+3TMJ6O->#
MAT(7T>+'7O@IYWJ+J/_\K-98QT[EB@>F;=W=J<LAGY4)()HJ=.B%>2M7 ,25
M&RQ)"@C^([#G":HN5XZC%<OU8HU#VBB20Z&KAT%/>H-]3".+%W&U(6'+<D@G
MTH9AU&5DT[]ZU"=FIN_GD&_)4]_O%>T+S;]0<2C G/C'F EJXGF$V6C\[W_
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MLD[F>;WU<TGNU(^%0Q?T<C4Y[LLUCG+XZ!J?AV&+E7#?PB<XMQV\H7FX+*"
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M>C?#%W6(#\/T7P-G)[L>_:*E[NA*3%KS!)03Q13"AKW#'NG':N5] F:3CR9
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MYUW'(0&A:%@8VX5V$*?;F,4R?\32@3H/EL%,*2@0/WN)/>;CV'L]97S4J7$
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M]?B'R5.HG7Y@&G$?[TSL3OX=T#6B/  J1CN)_S8N-40]'<'6$P&)30^^<34
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MQV^<U\N[J+ -*6O8AF21?@\@:!-<L^6N13Q,*XEU2+VYKRBV-&TJ</+T/6S
M0F:,:K*6=NO4FW/9IE@#8P/@:TEUR85B\RM;3W:3FJ:O*<4U.2>??)IE%>Q
MHM8E)$[)FML]T&=G_GYX/CUS_?]^.'DMY"_5&!?K3S+IYT^>N:1D=N: 1"ZV
MX*+<>6F3%+,3SQY>O[?7T@R"\\D7-!&J!,]VEKTK(%J2WB)".>C?4/B^9'8E
MDJ/5N@K&-&-D7 .-,:2E]OBI@5R.RA*E)5+L\(+A.-S&X1HMHQ419"3WO,]S
ME.GASG^_<\N(H"\PSA <Z.59!-;B(8 G[7T>UH<5%9-:T<Z*$N=A;*KZX.I\
MX_[JTD@=CQ$%<Z:.8;-,N;:35AI/A6K7*I0>^R_^W?\0=3+7*F'WIV(8!V]J
MB(I&'/49LHA.3E5[A+N6^3>G:YW[8I)Q@ZDRVZ"H/1#:&F75SH@YN@T9-;HO
M//PW>F>U3!^YTO&8?FY'ZY0B#I,>TF]X&O;O]'*T0GC(E)@XSAAHS7G",>\U
MF-BW4'OT=>.[)\W<AL3;&=)2=JZ,UV[SX=,CM_5-(D=_W3GQTF=LTYMS-)!'
M@(!#4U997K4#+*""KDL.9@4),UH551ZOZ[\OK,UB".0'?;*N#*__,[U_\P[I
MM9E.>@'V1%5#$NO%@&"G6OD:+$6VPY6WH@FWEA35:Q20;&A+D%K+@^B<FH+9
MHZCQ\8(5(M4@?P=R_>UE;KTQ#W+W"K)&/EK2C[ID).=3E>!X>1MR;]/P9FC5
MBCQ6.$;K:]DA]Q<WL*33.2?:SCUP.23=&4R]$%?L^LGRGKKOMXJA\)3J.8*4
MXJU@Q[[.8'OGZ6PE\P-W?GCEHY5KW'A; J0?+PL@(<F6H#,P8=/03U7+]W0!
MI9O3A]U0#X?T 5MRB!3Q1IU4SE$7^GW8^3U-_>:G4Y**8F5='QV,.E3BXLHH
M<AE!<SGN#(P/.LAOCV$MA^G6*EJML<?.W:V55QJ([94\44?:N-LFI?_KFF,#
M'Z40A_U\_ZQ4'U(RON6&F\>0;2-Z$!W2<>_M='_FO8P(RS&ZN4CZ:=)JJ^Y+
MR0;TAK^$G=F]Y_]Y0./"\3\L/QQ+>;!KWA_RJBJY,E]+,LC!]N"!O3;K;ZY;
M7+V0<5ZA];R!IZ[%Y:F!,D5+&>7@@A_O3=Y'#9BYBIQ5[/@W]>O5O9O_]RNF
M?H.(FX3'S.$$O#;8[MR/<RB>AQ[3T=:FJ:*'QV&<I&YB#1@:I=IO#FP\R[4I
M:XR)&9=Y_,5DY2#ANEFA'G%]A(*[5%!>44>(("#0K(F1C<D5(DRK (1AQ2YR
M%%/SY]VX=:+MR>7.[<RQX5B8<[%E&;:HQ2V'/B6V5.YC/TRU*.G8V!PJ#8_0
M&5L3H+).Q,LH)8RH_ROV&0DJP8);=Q:HSJWG)^/UX]6I2NRON?'*+NQX=9H:
MEG4R7KU'TT+B<LFSMOAB.<U7FB4/$;8+/Z&"_</;$/7NK33$HB.'*"B''AN>
M:X7@IGC7T(*C@P()>-I4-'A=(#\ \YSL=%\#Z_+&06+SXEOLX\^4KVLB&M?E
MAN-[BE.;W8+6B@N^+7RZV9 @8J>"-]A1,'MP\A@_#,\9'.KXLBEZ<J.]02@Z
M],#*;>TEZM)92[DM[L?\N(,?.2KK_]3_+[;>/"JI+OP7I]&<0G/6DM+4<JR<
M2A$J4S,S7^<II3)3)"4S$Q6A,L79-TTM)S+GD<RIG$AQJ,R<-;&4H2RGY&3B
M*0$O[^^W[EKWWO7]@[58+-CL\^QG?P;.?AX:XL]<W?$'#2O0Q:H1!@@3+X,6
M.*9]H8&M4^EX\_#(H.Q]2^2]?IS6);I_ZCQH@-5?1RKHH'T/<)9-?JZRD/MZ
M6UR'&Q^%5:#WYCX\=HQW4:BA;A&&.U7XJ02I(*0D/O@9.-1K5IZ(.+A8J#6^
MG@>30BNGY95[S5JB_97&&I>>%F4I/6_$S'SP,0PRS=EGWVKB+[DI#"80XI,!
M[F+;2#J<+'8XQ9;8I+5K[E#+7_'MW*'3/Z]4AW[Z3UG1JO7C%Z]T]:(R*H-"
M*R]HB[G*D+,2:1_K,#EN+C/EI-*4QXLS5D?[I,IWK[:UEV3XP/S^(I]WJK4(
M)QE'^) YH]%3>&0J^,!X?5,KI[-"W^_@H_K)G85Z7RO?V.;?^?.Z#BE0O;II
MP7_NL05I(*BKW)G[]ID2OPPM:&I^\**Y.4.M1;>4V_QAW[.OT#=_M'@O-]-=
M^)+/J29-6/#H5%>RT]Y'0CI*4.[.ON5E%RQ^0?W&6$:+V8>'/T6^]=VVWNU@
M%^7.DQUCA/?LZVQB4A+,C'M"7(,98XW!5\['AO@$-$VRSCSX],F:_<#Z=/'T
MT!\/6+&+^W<7,L<9=<\.F:-* M0\PM*1 FF^,>Y/Y*\M2/.[G[=-9=X(.'5V
MP@D_*,$;MD0W"I<"QW;S^'HTP&)]EE1B%0[C#.A>6_KG=?-.XH#ASAKH^Q[5
M0)=YP<"?!2KE=^O]OW%6A'_(H#8Q;O!Q'$$*EQA^J-%*!LR[L+G#/YZM,?HI
M[PGGZ1MOI=N@T_N2%ZPF)*CMD#"+3DOG-)QN:D&X3_>54X*\'C)D-?U.-32\
M2#_4)RUMO4.B36J<_W@+DCUG+"!$8\=N(:__H-!08.14G_Q-LA@>GNC3N;@P
M>^C?[I)W?=Z^JFA7Z7]O%4TG;#M=72ADB@=9>">RSVA-NV<P(_F V)IS(\EE
M,IAG6./K@W;;][$2/ODWG)I0.[AF):.PQ]]V[]X=CYK(+\G^&UL0U/?I8TAL
M145P6=K\K'A"OITLI]?HMO9+W4?OD]5.VM JPJ]T>>S^Y];G6&>WT__7(3,F
M=1\R8&@[W@F\SYEC81,H>'\T:_7A.PITQV>0V/NW+[T<?1M\XF%9.V=;U&48
MN!%5^Y-<7I?6.MB;N3@9I?>34NHQ2Y_&*.>[^WZS@N!$8JDWH ]\1=J!\,E,
M1IOW#WC GOIQ(^R^SU]PY33ZC<0MB*AF)=N0298,5.:UQF<RAR1:4HP[W'M%
M+$=K]6IV-^#TY37L],QTD,E$/R@T4%6!3R4RJJ-,X^]8P&BY<-43_#3_V O#
MC0-ZZO;QWNG3Q+/9D=?JQQ@M36FV7S7F'UV#ZO ^>JRAJHS_I&YJ;D'^_\X9
MR/\Z9Q#_#N1*0@CY$Y*N<K\'K92"/7V[ 25L ?NE/R9RF_<[]=WG5\X?O@R_
MTMK;\:_\=LJ$-UMMVM?(_L2%YI;=6LV)6J\\=UYR?/; *G#^J??N(P6>AV]5
MO'=-*/XK:-[!<1>(H@(XQ%Y44\L*&H Q-WI2;7K-FDBD=AW&$EF<CK/^"27]
MW9N1@Y9LQ<.!9DID:!U&56I$'VZA?Y_QHRGY@(QG&Z=_NDG2:91)5R!MC%)-
MA#//_TM>0=6"T:SF^DTGO#G'-':5TNYS'0]C28K0.J4XY:EX]%6LOU['^A:D
M)U6F*Z<E-X::H =O4_SFW?2"VM1&_F>,[- 2_U$6-7J!'];'F_0DP]P>]#
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MGF&F<O$(=5-3J/)EF_)+UP2]1+3#=G +PL(N;T& 9.9J-U4!MAUO ^30AF3
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MQILGA:&X0X!>)@S=XJD)O_L9.,/.)\K^5S\,P6N!12:/-B7QHLT.L60QO&,
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ML#S2KQ0]#&^>[&8M2AMQ.2)9IC274AL94BT**N$CYOICO#:NTJRQ*+'T4DF
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MBLR/SH/4#L"&M"YY/4APL&72L>G -1_KL7]:)HW%[09-'1LS1/=I2EFMN^?
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MBDSK!\_GO0,44D#+)$#IXBM#&KR8=E%S>[QVH:%DUO>GLT1W$TI"]84[2RS
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MQ1/W]S2QJ&G4!H7[J^URY6"#0!0K'.O4\*K0U79"M^'41#MAN! FSY*M]/M
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M3@HT]8EK(HOCWG?[;(=)+!;**ZNF:V8B<J(C:V>\2CLFZ(+$=<IW)"N=)^/
M?0&F<C88=SLX5,]AQ+XE(A2AB=<&[(6J-"T7^Q!A"I8-]$Z2&YL? 1@V<44I
M BCOGCT^8F3ASHKH53&WFN#9^&.9&YA4 WM5D>&0=J1_U>4>ZLAU'36K?1^6
M=*N5=5]J1V(.WS\=X;&!Z+V[ZP$V^-G*YT_O?CP^6@5?Q,S$8*6MQIR<DHH<
MH ^RM%]DN.=CW"H3'P<9.VP$%2B-Q*O%:RA]63NC\^K]0\VO[/<3MJZU@Y<<
M0S@%9D&/M7:6B[@9:X_6ND/=4M('H<ES\E1&P1:DL3R19XSLI2A.!^62EE&
MV'=N >=&2\T90*1+ !MM]^;\K]+>-"S)[>W_9N\&2S,S4]N:LLO42HT&IQ2A
M83NG.*2FIOS*2I&076F2(E0..*3N,G6G*3GE+)F@.4&*PZZV.:!06")0*AK)
M50[75L0_^W[S/Y[[N>_C>?&\.%]>Q['6.M?ZGM\/G->ZKBXM=^E-9\'U&PR0
MKL,(L_,$_5!@%W,7L"D[):HCH'(<I/S[HH7Y%V8[9P3-4*C+KX,W@6EV&S6-
MM&<VCO&I(9DV00CNL4.GRLU$V1O ,G;QOL:6IDZJ"Z"2) \OFPDU&IY73RFI
MG+6>2WAV.C\N8:U(6CN A]^ ]J+XL4O0-=HZ))+U"^%'8+L,2F'NP.J%=]-V
M$3;/7QA66(=$"C041]X3R&)3]CHD;1VBN@!-##7XWB _M0H/ =,%K[ZS>M&[
MW9_-\'AM2]48K!4MG;YVF!?P8LUP+9FY2QX,A@A9&?6 T6_<C@U"ZB]ROY>
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M9"4;!\TH=N9I&,R1H,U@ACAW#&&)G=B$3XN35B@+RF<PN0IC]ZU$G"3;HSA
MUAP'XX11_QD1-V79<OY:ATS6D!MA4NW5BT1$EF RMI>Z<28?H2.+3;6(AB6Q
M-!%[/H"UW<JJ>[<^<D63TT&&IH4#H4J"V,)+ZS 3KEJ@S\JD7R8>-XQCQ(&C
MWZX)&:.'+[4G]D=3W^<O/6Y>:XDFWR_@ICV;;0HF#:_ ^M1]Q2'9V=(%:E(
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M"*3B+]9.5N15L%(\3R'9RZ ][NN01!Y:8Y&U&?R)J-9 H)Z3M; +#33ZF,>
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MUY+3#/> ]GN65]ZU ^XNLN7$#E?Q6X<-07G0?^]&N@T<[EX.\!N>K^"(QJZ
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MH+W%=@"UFZ8Y@]@E6X"%J??5UX7VZHT'GD)46'4^.G;VW%WCWIZCVZZ47]B
MUE>,KD.:IJ5: %)<V?W)B%U [B$@-G^:68>\4*K0,>0FPLITEXX/!@$%Z\4#
MOJ*I_!B31)&Z?E 65]QM$Z3>DE;H2FBP2M CT.>P:04F+E'W'2I<.(_*=/T[
M#QUY5%CI^232AV;J0^=7?_.M=E*-.NKO=XF>#[/R<]ME%'2LW;OG386QX6W&
M:0+"S_.0-W&L)*VF1)<<KW'"=/^7W:0^CG&>;=A#3+E+29IAX)5<KJTHR\K\
MN\O7TZ7[[KW[>KKFGBM$"SUPF+&ZAS2!V :BKF-D0:OBJ]EB_$[Y<9 G'$P+
M*#8"633"N"\7;BHD\WELFW6(&ASZ-&A.H(G;2P>N]'_M@J;#3TRZ2W4#9<PR
MZ^P;T2'X7G^]WM& X02LC"74E1Y7\AQHLBQ],%EM N9C18/:$:P])J":$&8@
M43D%H)/EQM4$0S-WC6V$^-/(G0@S0N%I3HS!)>@.#V$FM(>)Y,)/7;&NJ2!U
M7;%(SNUP>ZOAW_8D[*MLL;9/6^O^D^I+H0:^#R^\VUZNRSW8>;OZ=-.+SXG5
M9:7BM!+*S4HD-B-+S^_ ZW=%MF^H]K2_Q;J'(C&<9=_8(MU.5R?JG,T=A+G<
M"JS>7G%=-M<W80@\LD,N!8Y!3XWN8^IL".9<Y%J&MVG*ATUJRS\&SQ9$W_\Y
M%+.\(S28GO?#T2A.F^R0)W@QWR/0!ON#URJ15XN.]P5MKA:ATY#/I=.O6+LB
M#!&L$;B6;I>!T61LLA)-]^'"7EFWK=$H,2%J9W=.2(J/<>".PM6!6U^B@PD+
M?YTM2"AIL'\E4%F'X%";S@@U?B$$",G24^4T=KO&A_F0M3HB3$1.=Q51=RJ&
MR7O@!@#M-)=YD,"9+&JH![3\.#$.^WZ\\B:\P+G9!PLV@>0^ODFM<%"5/X.^
M-B0O)#T>NH^UBRK_3UEJEF%YC661Y8P/#?[;P\ZJD:6LY !2)*%%58WO.$9S
M3[>Z*ON]UXE*?S1C-U3BL?H]O[G:R3+A\\-JQ'GNLZ5B?;[_PV=B53]DN=O4
MO/RB, '6TZ:2R+"XZ=D(.*?76Q7.JT?D!ZAM6FK%";\TY5Q(.'S0.J-_1#1J
M/MV1HG-;V/+G!4N2F^L^,I)IN*9T+5A6.C^[=S 5J16MP2_K\E$B&/]'*&@L
M'% 3WZ(*YW7 \#ZJ)CD"N2L2NBV(X]8"U//N'B9>?R8W8#$HW7'DC"N=,AZE
M#F8RI/XN/[YYJF^Y"[:)&"/KIY O"R@(*YESJOR@N! ZO@35E9NW\QJ( 6&B
M3^A)Z[NRQ LY8MUT!NMG DUDT]N^#DFVLWQ;/8O0'I7#P@&-<[)OM/K9@M#6
M\O,2;T+ZH$>&W;E_/FTZ<<"M'F[EV@U$9?2$Y:G^_N3)0[\CK]=NT!&F*1F/
M?-*K?;)>IAU":7[EU.M977]49EM[Z*U:(N&EW[/BAKQ#;S7<8I>Q)PZ:C-GZ
M*U(.E*;_]?1_T<?_1]1)@YU'8M:LYYUYT9WV02,PT7?80F?0FW%O#NWB1]KG
M3Q]"G:T8?P</![\M,/5X4W__#M8I'?*9H;2Z6GZC5@;!YV3HI$4+WP#.-WI1
M@ ]+]NU!++E:$LO]7<)KBRJY?3W<N/=+\@05AP^+";^Y/^_'AW$VSAR_S;MT
M.I*ERMR-;;'F%0C8M V1R[?B^.!#[K2/K#@YWH&5ZL_Q>!YRXV#4M?W18\EY
MF67\S),V_"0]SWS=PB94TX[E42^5PG^;YY5:6-:O!^L)N<EN#J*DTY$::-!3
M;?S/D0A8AWU"0T3Q 0]80./C_?2Q7T<Z4,(!:$^<5DCO?KXA(R)&_9@[9KH5
M0T,I=:7B75,Y(4LL7+YW%5"A+!KXGA]BO(9;E##KRV;YGSX6I#152PHRSA>V
MFZT%>.6YKSE]FXB8[F3>O'U]?SZRLV%6:?F*]">7N]';9V/U>!3%;B)BV"JC
MG3?:P,"9=C$-. RSHM,NB[;%2_%S'G9FU5%G@R::H$^^YVO.KI1N5B/?,F8G
M3JITS1F@NE:*'TQ"MT=L>,4T'85CA6LP=EM(<6))KUC]S!F6[#U@M919<0IS
ML7K.+HI2,UM RKB=L&V^C%UUP>K.O5-J[*_G_M]_B_T/H;)I':)*$^8_$-;B
MP0"FZBHRT8#:O8/<#2O]!Z$;.V9NU4+6<%ZR*+"W;JK %-0:P(-SJB3<@,JU
M?=RM6C;G05-9?(]>R+N,!J(%2*Z1V-S*7[*Q2UA.BC;+",19H7>XB@;<-NS*
M,_XM=N)@ 7IGR";^55YY0LCKT=T?H:C2._#V7NIFYAZP_Z0L/"4&IO[^0X1@
MN]Q9.+@+-!P\G6*@HZ$V6ZP;B*-_'K&HNY0^PO,H=&X?[;"IDIS^*%E6[!EC
M>!C&W\3>FMW'(VV4[P*<'EDB->7[07Q#Q)Q&"B[_[!A15S@W9]PL"^D<H";A
M1B;$*,)# =L_(+_9;K]JJ85U]])2WY@1O?UE"LI?.9Z\=<@D])74MR=@PF*4
MJ4$\-@KWKI9(RF<-?^V4V:0T,#(&CMF[)SA<B[+:NL!K?3@J6;KEKZ'F^B+8
M3%_?=</XAZ!^'9L,\E76785E3F^+'8N=K=95!2IP>SMNUTGL$$45V.+C+T:L
M$FP"%7V 85,XUK"L:H;?^2[GHD:J^?[6<SSSB\$.CI5)FPRG'2$0R)'-D,F?
MAC3<_MO'$O_'F,83H4(+)X]0W)ENA0&S$*WH5WQ2EA1.U&4N2VA(E0:I+#4-
M7)-6*3GTXSJD' .]=IQ\=7!U'&:"*F@[=&##']G"Y3LE+I<H78::Z?:$:/MX
M@D@VD:EW2B4%UA"#5.]2K?CSO%"FJ+A]NRKBP=-S([2HAJ@Z_ZW3><ZUY<2C
MX'7AFAI:UG=W$J8R$[H'<!E528MVT&47>.96S+']&/$6SJNA;[I')@1>JU=R
M&(^F)/MAF.;Q5$VCT"GER8%N)>J#V,E!M8A0C9$.X[)/$0H#.N,%IS"XD<Y=
M--+.3J'<DQHSQZP.F#)'\1=E-_J5_EI-4LDL9#<VY%R_;E$\4[!5N0MV4D^-
M$"V0W1HI-H:_#.%A5NJZ; ZHQ=::*?!;*BV)41M NN>[Q^L'%WY1/3R5LO'A
MY_VDF\A<0X&?,O^*>2&R>U6R8%8[2$%L;FV3=4JGRH2U:7+3IP,VE$5UI[7%
MX-5/AJ[FNR4\FX*FYOH8"UH>9[8DYJ#[1*EGLP(J1\A:V!K;NH2P+>=?AY7W
M5LT5#+ O?+J GM4K;A7A(I7 &+J/9X5S^N8:M6@0',R+\3AS;A0?=?EV>%O;
M'YF-29GV0?_?DOW_(WZN+\K-*\)IYU$QV(OAD(OJ%44=_LU#*;<>)'F=3-MU
ML>CQ^WV0D,=9KOOY2H0]5/LAT/7V]A+CBEK!^"D'1N>/\1[>'\$7.F W\>JO
MSUAZ77#HT("[S.VA;;38UYBFRO_?]R=R_</_ 5!+ P04    " !S@&5:+4W<
M^3W?  #:[P  $@   &EM9S$T,S@Q,#DT-%\S+FIP9\2[=U"3ZQ<N&@1$:D2J
MM-A!JB(=3%2V(""@5*D1$2D1(P(2,20J)714!!2%B @H"!$A@ B)D  B(M(1
ME!14NN13RK<EY62?>^^Y,[^]9W[N>^[,"9-_WO>=;]ZUUK.>9SW?!,&8@ G9
M[&CG8 <1V2 ".2W\@P@F(+80D?_-SU\/^=]]AHC@-41^$^3U!F-1D1V0#?(B
MHO(B CH$!H&(B/]?!R#_]T=D@ZB8^$:)39)2TL(#Y,V0#2*BHAO$1,7%Q<2$
MNPG"?8B8O/B6[?L/;U0X&22Q(TK1^/JMDDT[C]2V*;GU<W8=.'/IAJ24LHKJ
M5K7=>[1U]NJ:F)J96UA:V?YQU,[^F(.CNX>GE_<I']_@LR'G0L/"(Z)C8B_'
M8:[$)R8EIQ!2T])OY][)RR^X>Z_P4>GCLO**)T\K7]35DQL:FUXVM]/H'9U=
M;[K?#@P.#8^,CGT<9[&GOGS]-CTS.P?\^+F\LKH&_OGKK[A$(*+_*_1_C$M>
M&-<&,3%1,8F_XA+9$/?7 7DQ\>W[-VXY?%(B*$IAA_'U38I';I74MDGN/.#&
M43ISJ5]*>9<):S?P5VC_,[+?"^S&_Z?(_E=@_V]<XQ 941%A\43E(0@(GZ_'
M0HSKK38#I'9\II8R:,3I8WXE=2 54,4BPY3M$=%S6HA!+C3D<;CO!7+D(X/F
MUN^Y3WDOYL*_BS5MW%Q[_5K7'LH"Z0TTF_'CYJ(HOS>#COQ5-!LC,H/G?,23
MD3PUB10\L*T%(8"\(\/^ON3_Z-I> 806PA_&+X=I;15 Z#<X H@ 8CR$_X?%
MX2]P7=YC 204N0'STQ7TF<+G(#;9P !K;^(Q\@!%$[S/AJ;$(-4CXN#;\RU,
MI*]"99%S^R(:W5'1/8I6'A<GK!E.^N$7-(L.KR#E4<W:208&2UR?9^&4K;6O
MAI>K-PRL!;8D.I)?CL9.@#'54+L;5T=3+&.=@SV:&@?K>Q3/-;52BM7],)/A
M2L?$B>!YZCB)GR5*0X W V$"R#??G+\OU?M*?GA#DJD\LSM$5CUQJ^8?UW)N
M9K-JT]W1%KKEDHGPRWNSVK"QXV9?:QE;.R#G_D4J'@;=V="Y=T/5^7,ZK_6F
MU1TZ14.S*AX Z5^_ ,1$5BMP^;YY>LM!Y5(.OWW0$_B:5-AZ.Q!CY$0=O&":
MH6G?8;:XK^#(BY8! T.RDU_1T=/I5Z7#OY>>2]&^*%(K@,@6K'L*(/T/,:$"
MR!9IF@#"[3GYCZM>AAE3R(U@[DER/]>:W2<WWTQ>2UK&PWS"X^U((4^0DQ@5
MNG&]FD1F=;7!N=OA+4;5[W+D\JH[LRH8;S/S!]^\3I\7;UE\M?GXY:+JU$^+
M09E501B;;#GHSJ$3&]%<,^2BMP!B=YU%Y!XS@@H@/PWL_V'-,WAT>6^+<RRS
MB5QDZ*KZ,2R?LKN5\RCP]>2.>L[7Q97.>R$D_S!6[[+5P<FRT+B*B0CH)G+A
MCQ'VYUW&]#DS;MI[KNW>L8L"R"O\S2D+'-P]^V)4EXE(T;](@R>@D5DVK'D+
M]U/\3-5@E<CUH=B#7=6(A37U/)NTQJ;=WF\3WJDL*06\/-W*D;/^\-NA!8:S
MC7*0HMCM3 -K=D4&?#]W/Z>/)HMTSSDZ@-LQ/VGZP80D-A=/;U1+?ASO24A#
M&YT9J"%+- ^8^H74IWS]%K[< [9?J+^K[2Y$#1MZC:(/^O9U(:2X*!8Z#2XU
M=('TK%X 40%5_ >Y)UE5\[W&T9%/?7U15G^L>:FHF*GHCJS=[+!VB#2NOU39
MM..:E=%O@;X)K<Q%@DY,6;<$:!=2@2O"_'QAU+X!D!W)8>.5PYH-GT8^G)P+
M?W1J7D599>WB9]N*.;5WM;-6L?1;NG-6N1G6L'J7K1(G621%,+0S7@RGQ\&G
MQJ 50=_@)_KPG1Q^:615V*6&W-CHX,K*B,MNSF&]Y9,?/W]DD.[?=ZKR2]66
MW&58*5+Z+\KG;1X,0%^KE=]C1J*/ UU)*YKJ;"PP@34=?D9>M)IV :]'F69-
M5BAJR;2D7TZD7^HNGUW[=<.^[&"/:5[>\)N-.KM"%G%]<&;Q\5>I^BH]"1WV
M7M*-%IKO]^F(6O/5C5:K!)#20YP^_BX5@@#R9W[I/ZP]63F(/-8/[^61*V<+
M$1,7]M35JE7S:HI'1_-750JK.\IN!_0H3 :TE<V.IU28DE_TV,0G)"].=1HL
MAMZ2E?8::'%_-,/?Q7E?%LPVD@,)SN21&-FK?[S,<.]?:=7ZM;NXQW. +&V7
M/R* N+Y*'D"A>L)WW0C['&@><OJ8&/&WJ#I,]9R(0_HAC2U)I<()P,$]YRY$
MTN(]9!?@>--U^P:+D$N7;VXQ#R:L$ZYAT*R#Z^>N':"R7@@@$=1?)E 9(?H.
M8_ "R+T(Q#\M5I1@"(< 9V&.65EH1T#Y?E U"JY.&3)QFD]P?-M'#]1LS74&
M-B9&1T?\Z) CE<SM=PJJ"O]A]?E4X-'=K>^BWI;92^"!"2:N8,H S7I?!A2P
M G+HKK)AWG!M0.7:!6P"*Y6+*L%<>MN]8OT9[<EY.41M>!:S;F!L::K77?'"
MM2[\S>A/75]14TC\/_7A/_9F+*(+=N-R\P5RM3_W#!@0^0A$M\,UP>ML@W-3
M7<5JA&,?6J2G-GTM:(?O'UZQ--U=.\@U9S>Q"EUE(T;=N\)KGKG$O#1L&-U>
M@QM!OJ"FQ" V88AT?'WCZT@H#;'YT4OB:]S.8;@>J-MW!'C@Y2T_CD2DQ(:3
MDVM'Q+,^U8XSI"V_H*P+3ADFN175BWS_O2)&-3"4^$J!X"2#E5= %T (!=0M
MAEQKB8P%/NPC.$AK##SPBE,VM#<:Q?9#ROK-&4>,JFD./ZL-](NX.-[Z;-78
M/D$Q)VQ^_]*3#<1_RDG6.H(_!K<&[P.O3H":@#VSNJ*]&HLURF7G$YZ$,S8O
M+VGXS#7[:^DW</(ZDJJ"'X=7AUQNC(->2BX^<?KZB])X-1:JFZ*H@6^S:]D_
M*K%J-Q*])"2H;$8U!$?O/ZHH\I.XZ G\B3]'3/1E=.AP#?FF0^?)) E,G#WG
M1<2'F5"OX99P]J)*NU4\O"HJ\HK2 ^4UJW=Q<5O(+=27UX<@I_;]Z>@ZL7.U
M.MT^2P Y"Y79F/51'5:O0GCS*=.#*8"T&[QY8S-"X"K](8!T&H_G_'J&V(!?
MN0CJ%ET50& %^)6?"'Y6/.2M )+2PZL40&8^V!P00-+$60((/^3)/ZY6?E44
M<?U-%JC*N\6&;@Z#;_E SE'$5/D-M)BSB-#P42L*E:UYF3_AU!_CK-LMTUA8
M7/4TT$&I+#GYV:'NJ-AH_8OMU^J:KQ="&O\-ZTES:%,J[499XY[?7W&0[ ):
M7T:\X;TKO**G<U39EJ 2S/LN9^H/;G_($]>'@0R#O)Z.>\$ITV^O!,L !(]+
MK>6MSV:UE#Z0\8H8HL<@UUIXT]FU0DHK6_/"=\T#1_MCJN$J3=0ALK/CXJ/Z
MVMH7C=D.WVMJ=F>K[LCZ<FO8XZ:(^6]VVO&6X?HB:SNT_)Q5S?T*S&5KG=B]
MIKPCOT:Z_LAQ:3KVI9&:Z]F<KZ>Z,)T=YBM-*#ISQUDE_]W90^/%?S",OH?\
MF:VRAOZY67([YLLUR=?=K_?\&V;J_[&G)V>/_T/QKOP_#]D=CLJY(_]&6U1C
MT'>OXMZPS[:9)2$A<@<];HK*Q6>F0TK^1?;=ER?F-5&NB5[]Z&?DHCW?S?('
M/0<N/!RJ[VGRLD\K)P_I/RX>^":O?\G^&^U 5ZNF;8B+32@;MFBZ;L[= >QN
M3,3I<7&@):>O8RW?RRJ/F-QR!5"@:2D+5;;HZ?O5YD@>Y5;5G%GCBX^,3QT&
MK47M1\XT%>[=F7;OUC7(*N*W=+QE )J#W%"##6'C"5Y4-8I" /8PQ^L^_AG8
M];J!L9FK'<460*3#K3SK)N>:LUM98['>PS$]SKKO+0U7?"Y$NJ\;3UKNH2@#
MG0N6![57&WAW5I:D,(E=\=J+^SDJGAQ$LFD [ A@GWF>(B0YM SFJC\ )?*N
MEZ+4QD8V$H,JYX^,+-:WPMDQS:U.3B^WI4TU%)5"UO"_=?<Z4Z@RQMLA@U8W
MA]OSP02T":J<'5=)JC$D7]U4S76OGEMM5!FWRV5-)")RG\VI5>>5#7\K0E6T
MT@L:&G[Z^TGNR'H0DR737<1YVV1_YWM6Y\XL)X?M;V [=/07^P_MNI4.>?]O
M**""8&/[$--U9!![DJ4I%#C[%/+=7<T#-K:L]?4$OZ/#!B7YQW8W#:[H:>>/
M?%<M3S]U-G^KYI9CGU53W#9.?YQ^@]P3\*XL#]O8HS/W.K+[Y*=LB6I(Z#_9
M@G_V"JY>@ IA69H*/85J_I;[B(%YY95[B%-67(5'!\>R RZKZQ4Y!J@?N<$^
M]F78]-CRO'7/G_KG1_R2ZLA-36?ECRQ8^L -N;L);'V8Q#>PC#-GE!%G%;?:
MVM@^BPUGC?&W^X?C3C:MQ\"AD8=0+R9X=]4?NM%KZS<N>DR(ZD 6_T6S;3[>
M%4'3TWC^.JO[[6;5TS)?'40(GKM$,]-MTAKJKA@ONMF:YZ][W!"1B;IV>-OF
M8]MNROZ;-#PZ_>#".^.LJI=UZEF5T2GH@F3F#PRS_TOO39NGEU[G:?F%7.L\
MIOI%)O-6U\Z1?T,23RO Q,/#9.IF3*CC2'VU*[U8P<H-K#KTG-+8/((U&5_,
M62U/;?Y>)-TZDA^;8,[?HQ;6DKWS:@@_=R-(B9CX$3)V]L?C,4GQ5;/7A]O$
M:Z\=9GY9F1)6^%_8P4OID(I_8UC>ZHC>&\&C&=F!$GBY"+R\ !*2I4?C;Q;*
M)PNZ*2+^6P% ^F,4'5,.7'X57C*!W),+36'>7C$H;][2LZ577B<)[9^(K(QZ
M<_M1M_I&>Y$\PI&*$JTN,DX9-^:/W=F?.B]DAEPFB?],=@\U*B;G3_%9 61E
M%LJ_IB-JEZ[S< -U&]P:_]:V'H;^F$&W!;2L!]I(H[^XSKPJ_@Y0@96SN,3*
MPK-AZ<MHB; "8ETVM6Q\KG"EN^Y%TQ"RL_G\;(CBUZV^7TNROLI?G%!L=(3\
MDDK_<X*O-KT:)( \6N1,"2 23X42_E<_ON3=Q<^\PEH((&US>* 2PET"EA;N
MKWM/"!?^X._&]0=*?#!<02;"MI@:?6P.GZ#AM_(W82RU&"P\H4*8WHRS .,&
M91=6#9C.BHVM5T'#<Z#7L*',]2+'SJW5 VQ91Q1J!HX2XN*&+W^XH%BV'[N5
MO:2,! F.0!%A@56#C28/"R#AKIKS_9/<8V# .CH"H8SU9L/$>BHG WI9UAFN
M'[N7J;)A*GPI/-2FL:$?<VEB8725YH6H)W)&$750G@J:  ,/NO)-[;FF?0O"
M$AZ=8'7QH>X"2-8)B2_BI(7# HBX1C]\&[]G]C&FRCF7U?4:G^E$:J@V6E1B
M1SIU5'-PT/$,MD3&68Y6JP BJ;G2!IBVCB[\^0QC?;@Q9R&^O*[R4_@:11Y
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M',!%#O/V)8?1.[==W5SSNDW^4[P/P;+-J,^17,5H1P$DN>]*.;CDDDL_,,9
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M;Q(^F;L>N]P*2.6':/R4I=E(N,*3P&QILTXF6)5ZL!Q)_^1,Y[KFO(VZ8J0
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M:O\UA?A+$V3A&'&"?'-B=42^]B-D]MR/L0.;2S=3QBIR'NSE4!YBZ==,P5"
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MK7WA[9_>3/RC)OKUI8I O;!96EODX>Z"8B7I/*]0 P?EN*,%"]<B_^DRAIP
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M0TZ!P:<<GY=(-;!M4>X>44YQO0YD;]L06\S:VPLB[/94)E?& V3O\[R7$^@
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M)R*O58VH,O&F?3?\W>DA4?7^L,#@6G(_50_6#Q-$/]I+^+W/DX$518O5SP?
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MKZ<_\Y\I;W[[+COFTKI03J3&B'PI;$N'"HT7YVJ B$I0X?U.(AZ8<4DHF3"
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MRDQJX%-X#O.;E=8'PX.$$\Q6M&I8(NV?P)3* D#@F1_XJ)<JGE:G9(E4DOP
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M]5\N=VQG06EN,#W4]<WFHN]Y6[<VOE.,>0:<#6]^_HX0HZ@ >D1GPK:=D_^
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M1Q$R*5)-8R/&MCRSYZ"; ">F_;??YI7AE:QJ)87Z&AW9&N-7[PBC7W'G=H0
M5WW0;*,+"CA3\$3.CI ;OPQB#T31TH'Y+IS8"A-8O[?ZJ[_(XERW$\;N32'+
MPEL@V7X@SM=ON[<P\.=XU)Y+PH,/8R=L8J*/I1]T\3/,##5Y,;7K5%H#9R_
MEU6&75_&.!5K]:!.N5:[.96;.Q@5<1VRKSK^^G%P6HKZ9 U.D\?I1+_1B\H/
MEK,,]0C]R4SMBY8+MSZDEW1.++/+K1+&/$G]S#Z-_F#B854@G4SK=CWFG+[K
M(]&[05G74H9G#*+JT(,LV=5+G #J?RV$KN6@H^BR4#'>;O+8%SP"T:KPF;%,
M9Z)-,H-M=S/!G.#]E>%E(U(^,;#T?0SVD=[32%VU$OBGWQ1&":*AI*;J$HY%
M3(/*8FZQJ04=JMYP><'8O 2I7R2X[1]O6L0U@6'2+,\J\@][)!<7?+'6=D2^
MNU5@B>O2HS#FH ]47P_VP*=V===FU9$!!\,1R3<^\_Z<Z-C'NP$.,D5^OB-&
M_HH0[Y7$7-GUKO!C'#]RE"0:YX+_&W8MVOS]N1DDX^7*C7G__V84/4!1KL'E
MD81F77PR1I^I_Z>/8(CK)TP"+^'*0+W;%?S\A5W&U#$6B]Q@,G#2%Z(J.$DU
M2&CJKTO!PTX6=MR0SL+#),80,Z/<WW!%S__\-Z=^PY6]KHG$8E?:PB\DP_"#
M!41OCZB#9SDF?-'_QN,[+M^9-YH67H&A5S-U+,Q=RO;;<#\:;SF @ST0;]J,
M[R'3CR!"FB[? SW;PT3;2R0S[YRF!9FH.[6YM 3L>_1R8N$&:FD87=@_3QLC
M^KF&N?Q2?;!;7M9$4%.U:Q5'$QP;AMBSHP[[@#EV!9?)L#!VW=C#$E5R<9V*
M?;NJ,X":3R15C@X,E+;8\YV=1KW.:C[507^6FC>F?(9S<4!Y1T;)07X--%3_
MKX[,2C%SQ6)-[AN.Q??V:"6#<FYI&"O"RF_D6]N?DM%BY>T-AK:"S,Q[4'W!
M65S7*]SK";IN $NEG$%0[ +NC/18'N>H-#Y#^LD 2INF<WM'?A&2*0?;5"M#
MO,[9L],#=OF*"*K22LZ\1LH<W^JEZ=[4N'@Y(#\J94<H8!TTC:-2&K[QCD0Q
M?8ETF#T=1X:ND-CSDQOL]F]9J*C4#A%SZ-T..1YL&&,%+.DG*_C29.8,Q^EK
M9):RYE6.2^&5X1?6^W_6G<^+NYRI@L:*,7V43>Q%_@U$>U@[/_53%(&+.]J5
MV[C!7%^4NL:OMFQS[S?Y]\N]:)MA+VJRUR4"0H.4K%B;*M_ M-$;G^\T? 23
ME8O\3PUU^VLQJBY4(!Z[T (WFA5RC[GV'_B:4F 1;E7C56Z7P[\\!F44(HZ0
MH-/:Y\&!VSM"PJ? TEJ,U&M@<@@5%F'%^ED8UU,=/@UO(15UY5L> X9#.J3)
MGXCKFMZ+)E5-_1%^<G]]*K+]=6SO*\M)H( G-<T]! RF\%19?(=S\-2.4T#N
MU,JF^68/(A4!D/5Y_C&UW8[7.6G@CQTA']+HH51MQ8%#VJ(1>LJ6 +_T^6..
MW[Y:7)<PE$'PPJ_*5_*"&D%58/H*>#L8D*7M"(E4@!+B#R,5N\@=9R8@R#*P
M" ;VFTR!][5PS%.?C#/--[MON>U&R, (???6?_WHQR^F X0,"F,</UE#ZY %
M8TJ1JM+U&,V7:".F;#<E&7N<(U/ $-F5K1(=0)PV:]^K<A(DU):!2R;)-(0D
MQ"P^ MA$W%,)87RJ/5:H]>U1AG8^HLO')'^4-E:>[TP;I0><8I=#^E QML-$
M+V,VM,;^=(F&!]KKJ5>FIN*YMZN1:_J[FV6^YS$$K]_+Z3%3[[JN9':7Z6.I
M>/_59Y6_2O%]-Z<>%[:$?'-IL1++<?X8?<"CM0_5N']B(=T^STQ3?WH@CAO(
M?PJQ+^?I[)8.>WK R@&$$I<L-0$2A:<AD!NI>S%>3UR/^MG/MYNW&UG1O2*0
MRUY3C#H$J[2J@ 4&5B!OQ1GZ=86_UW\]N8C]J[D1*,^=5T05>ZD>0.?X<916
M_XO<U,+<DE,/?&&W#)@4.0BW<AO1O75V0OJGKH7PTW'#D%:1^'[\JS,M O,5
M'&/,&S[Y@)O#S[;4_\Q#@HG;_V!,6_B5'4H@@HWHY..8FUSWA\;K#[9V!>H*
MQIF-DT*<9P\XV,9:*+H.-T61O2U2LSQ_5;ED5\5A-S'>NZ(M_E]S \NC((4!
M36E3!T29R50+32:<+LN9S\(8E*(=6&PXV,NL ))3(>:6*NC2C^U(;H*82408
MC'.A_\L\CM9/Y1KPBZYGG]DZY7%%]T#>RR'J4+E3:T7-Q^(SW:ZN)UN<7)6<
MOKDP9OXI_GWMMVM^,MMC94?HW ?@"7:/P4"CTBUQK7R]VT&*LAG$E+*[)99-
M!G*3S&-N-UW4TXG[W6A]!.TZMU/E-EI+\?A5Y^VC&%%^F>6!4,0!8ILM R[A
MAP"7-GH:EE7,. Z/ E'[.]K&UVM_FDY 3E1X@??:3)C]F6[[>>=*IWTFPYN&
MF_KM9QT61-WM\==!<2">V=N%>X@0%QP!PU@Z*@<_0?:P[0G2WP6*0#"MA:1\
M8!I6<'5,CP&B3<0/>XD%.P*BIA7!+</Z%%: "4O[?<U $A*GS O>$=K[4?!.
MH-;$^=J<68OLD"F@$^2@(<24*>EQ @/YI: +*PF^!]ZA59GKW:MJN.[@ _W,
M^7M8]7TLV0>5./4U$O5+?T2P2A T!]H\SU.(J *MNN=EH"%1D[W<?+"&+:Z
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MM^A)D-I/==#OM^@I6N7"B>6/>EDO4"B;8K!P4GEBJ8.F!KW\4B',)=[%5F-
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MO-X>$]L%P20.\O?S8I+6T69<3RI8UB"R:R^UVE<!QGL\//.1@53]DL\I/+L
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M!)[1KUD! #9I 0 2    :6UG,30S.#$P.30T7S0N:G!GI+II6!-I%.\91$5
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M!2W+VKW][S'3I7/^7E =CMAIR8HN?97Q$F[)[5%:<;P,^V(%]QUO$254:+P
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MS#3%,LJ B_:%LCZA.#\PTI"(*R$7*$9)]'&K3QW+C+.*9O==;0Y1,E,@^SK
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M)Y!]^EF$KIG6WZ9T&&![:B[S"R7,\>P0C=(!VW1>XRA239(H ^P%K*DC6)1
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M/Q4XBT<0LA>U=#C*U[" .VXTIF-B'R3DFT=+<V4:Q"EW:3R61_=!WB%K2QP
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MPW@0-<<5.T =DP(W;AIS'6DSZ ;K&*6O1HK0ZVL"-!6C.EP$T7G<]5L'R3I
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MD8;1)>VI [ZD\;!46P>&Q,3'LO)9P=A$K[RH]C%)"W+@XQ*_2]2 ^E8&U=\
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M%WJ4)9: _3)"-;RV'HKF?[):YX>QC#WW(K=SM,:2(L!)U,D1-#JR"06N$;V
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MB='C^V+G:S&6Y"$C--0'*(EDTH(Y;/@CBN@"$/1OJR3M!LB:Y&Z?S@Z:IFP
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M!/5\RF:+NAY20K#JT+>XE>>@;_!MMMPV+C77>6Y!?)8[?7T9L:').43L2_(
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MIW 5<V(,-</T?\H[@+88G=G!M6OC)HL?EWJ['V<KM\NQ?'L3> *\+X_,#H[
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M%RO%#1GA0FA>*_;;9YQ-\:AKMFP$LE!HP;'SQVI0N(#J7]Z.CYQ<S2M5<G-
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M:DAA9H>M[DXIB#L+-T@D1A*W>_N%V+!C3_>%14@R:FMZF3D=M<QX?.@<Y5T
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MUT?']5UZ3?T"*,!CD)F5)MYMG'QL 1M\^8&?X>VU!2+::/:""/NLDM*UTI'
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M5"?&J[6%O2,@IF@)]NN$"'5I*,#M*.,FT+<.MV'U@6*V\+_\<P$0H3+U:)M
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M!BR_784QN;R>N%78EB_ O#BUHEF(XG,OQ4^*/!,F%W3YI$SG1F?&-ZR>O!=
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M'_:<%12=*=&5*U=(+D+*S2C &3?Z-Z0E0CRT/SU)U9(:$&.Q>A_MS43SZI=
MC:]LD->&U(?L5%AQ\5DEG92P?)RNJ]V-1SL+'O@8MA1XS:#G>H#BS@FGN2^
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MV8%N\JA<3*ZY,&JYI%0[-!XRC+U7S%D<?KP4]OB_<@;0X5L3"XE4#>[5*II
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ME!N4,G5LLE_:YZI*AT.Q6_ D1,-0C8%E(^;ZH>MS.L>&?\_0JGCZBA*0CO[
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M+' E.D*RC2HT)]!Y"=WHN#54!^H12H&TVX/@UKL.VUX7Z'9IK++*QI+'WDS
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M0FYXPT[*#>,=R[BK0T5=*PU?>9HZOPKMOKIKI<Z&RFV[]$]$7%DS&;!_LC!
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MH;QV?Q8Q[;@'AX*C':0\L1$?=<=*ION)A$D51HTZ+O5OKHD18PEN<!3$)'!
M#7D:9"3Q\.U(B>=\XML8;8M![(V:D*W"S7%[,^=E9VLF2"<"89>*3SA3^C(X
M'IH$7Y+RZ69#B /$E!BUXW 05H)%3;$-.UNE<*6Z=!7*B$NIF\3[0$:V8PIH
MR(Q/K!HG=F+UJ%H[P4)QSK'/6A<<]CSF%7\83+C=1V>::E_L^YJ'W3YI^V[L
M='S;F*D#S?T+G!Q;TI18/E!5\K[7IN,7.W/0Z7'(_<0_3+J]["I8IW[ZH\:V
MXDA>[,>2/6")IW/G2WVQM=G1,O>]7O['!WSTIQ1%\BNU.9LXYW]]GYB85[;O
MSJ8 ?<8%_BJ8!I' ;S[#C?V9?%N&P52(V8+QZ1KJA#FX[Y*I"\OY;MK20_C+
M"V&&OEUI@=XM,Y:/+P4,AP>DK+B0S3=5IB?/%Z#ZECQ91I)5-T[VZU$C$3PD
M(UY$;*&ZFR(H099Z&5GNY<2&-Z LI8!;&V_4P31X6?-K<FCAAC2EQOZA!UQU
MX98M"XHCEF=LWB3#K3T[K+6R(9['\_J_%0?,@PN^U]FZ_[6C9=3>^/#=%8^A
M]VNQ7([__1J2CL^Y?>H/=%MB?YXY?#U$[RZ1HGTXX,[A6J<8?_?^-^]">!0O
M44!][ NGPSX^@_XO_ZI2*J]<CTB[%\MJ*CU=4BTZ+IYV+53V.:<X&SJ?:>UZ
M.S?WMJ,G@1)#23 M>O.FW_),V\J$S0_NW.^0XL>$R(H?7UDL*NN0S1!;0IX=
M5X3 ZR !&-'NC*[,>Y!+^_G9K^2PJ5(K\>O&"T?:O[&:CITG%2ZT;C_)O' 7
MPA\<G8VOL^8)BJ5QI^,___*%#=FS.\A7B&N(DF)&DTT'>6QT)XC/IV^D-D@_
M7(W0R&A9Z_Z0VMQ-7Y[30]?C0X\D_2MSU4C)=52>U*^FT-TMLKK-E.?:4LJ2
M!]QW.#ZQ5P]Q$R'#*DQ]?Q<V\_NWSOG7'Q%-.[!!.L>$]7KEEM W&3D#Q\UA
M(NJQ.#4G3KK8V E%MU3B*MA,0:!9 P'%5XD%? >(USTB^F,K=5 VF ),%%;W
M&#8RDN]-AY1Q*]Z]Z!<)+@J (#9D'3CG 98+Y><@ \5)VB;P6W>\3]AI\7[
MJI;*VCN4W"M8]7=A[6LJ_6LG2GB2F*MCC[UJ2TPUOW%[VF7T6Y,AZVE68>.+
MPNO#G80NE#$A*W04AK2CRDIWLF(#[*Z\C9A3&^3Y@!TU#Z=+VS[(27@W]+,
M^'5J;M+#Y,!(Y,/\=L0"Q*9WUT2I,)JL;-CE0:SH6V9O'W^]D#O";5[-L";7
MFS7E* [34 F;[H(\)];S9E,5NV*0[6B> 7M#.,41^HB8^[&3,3;]39+,S,83
M5E/=N@@6(+.=\P]HO/O0ZVG^=I#9([A\_D.5M$SW+RTHJ;:.>( 9-"*?.AA&
MNJ4<5SC&"%:I, EX".5<[6QC*E$>"E9G*#;0UBC_386);J7(C)[A"]!)25)A
M&E*R%);(:YP9?$C*7 X?&%CL;1Q(8F@A PQ#Q/E3""G_,RT.($W.KZ*F^F:3
M]&(F;(H.#7>LQDYIH8R92WJFPOR#MA(TFG.0D2\CNDV0AI2\;)JHXR3($Z7<
MYJ\#L@3IW-IS6S@M>V/N4).=CM0&[5VYW3%J_Y7O%!;9>L2V.K( /J%P1F5#
M)%%20F[\UM6J)O&:?:L(I1K)>%T"_>"9U.\:Z4GV&C+MXJJ[P5"B=_-H\A/I
MXU$:KG(JMS3EZHG4"UO+OUMOVRES.N=\ZSM3PIL=5;@CSP5++*!M0+[TP64I
M-B-\]4"C22][A2BFGM)S-%W413[4,G(8Q"_B#"A&*<=6[W+JOIVPJ+70U-AD
MORYOS>A7/60Y%@CW4Y-;MRIOTRX #X32;]UXT;R\2'F'&$O6C7G:DS[:CN"!
MKIPN?'[XAD< .^>7AB''&7OR3N$<34TJ7EEW)?.WL:"QUV\L4T;X!\KCGN&>
M#"7-D)\+,EJVQ8.HKC@'AF-%J6UDX&"\K_PSP('UL[\>5K+@8.#DN R;2=>&
MERDO$0PASSU#?&,HOY/@!+H?0EZ.LAL2NC+N03E>4(_4PZ!Q/D^@0SO"Z:U6
M84Z&QF:[W5%A"(+(9K)(^$R@RW=$7I,-Z3:TA'SY$*0#B)$5%B!>7@595=)[
MQ(V=Y[\Q*_D#<)J4D8Y;1K"EOYK 0[7G?MPP;:NGJ$E9>2I,)'$531TB.<T5
M9U3U4#:)F@KOQE:J*>R@4 4=Z6&;.+$S"#@H$!2V(TXCQ.A01L$H6WTS]P96
M3QU<9,XNRC1I=B#*_+V+YSV;>.D=;>8;LN/-Y8HCQ>W"0ZV%DZ\^#+5?([1S
MI,1G[ 9Q/L$ LNFB+P?M1^<\ 8N=RJL,20ZY 3=;9M-#2B?^ [&!#X#L]GD1
M7KX +HKGU!2[:4% ?U;+>GUS/'B,)1D>7*@SD8W<DFB5M/A)<=CI$+ZB#A?X
M)(]"?DV$7-+:1=GY $?^AX"<?A<8;V<#32U$*5.#Y@?8?YO[\=KZ(H-;7H;R
M::^H9#!4FC [I0B/#13HT%=2BHMZ<5D$FUAG9WFI42?.<&H[.68N53W'])G:
M=_O_%"/__U-24XW].U!+ P04    " !S@&5:EI2Z"7;6 @!)"0, $@   &EM
M9S$T,S@Q,#DT-%\U+FIP9^Q[>SA4_?ONB$AB0@X14U$JA^E "IE*DJ1)!T*9
M5Q)#S%O(R)A5Y'R8%Z&(J9 0DQQS&HQ#)<DYE#$S)6=K%6-E3GO>O?>U]_6[
MOM^]KWY[7]?>_[SC^ORSYC/K6<_]N9_[>6Z,Z)-H'+'^Y'';XPB)51*(O\0_
M"-$HP@HA\7_Y^OLF_[?WD! U(1372-R2/"@IL16Q2E%"4E%"U(I (1 2J__;
M!L1_?TFLDI1:+2VS1G:MG'A#Y7K$*@E)R552DJM72TF)WPT3OX^04ERMM&7/
M$6EE!W>9K3<V[+V;_&2-SM&R9I6S/:#NOBLWPV77JJJI;]38MEUOQ\Y=QB;[
M30\<-+,Z9GW<YH3MR7/G+S@Z771V\;CJ><W+&^\3$!AT*Y@8<COB7F14=$QL
M7$KJ_;3TC </,Y_FYN4_*WA>6/2JO**RJKKF=6T+H[6MO>/-VW>]??T#@T.?
MAD=8;,[7;Q/?)Z>FH1\_%Y>XR_"OE;_SDD!(_H_4_VU>BN*\5DE)24K)_)V7
MQ*K@OS<H2JW>LD=:Z8B#C/L-Y:U[[Z[9<#3Y25FSK,Z^LZ#*E9L]:U5UC5G;
MH+]3^Z^9_5YBX?]'F?V/Q/YG7B.(=9(2XL.35$1@$$+ACJ=QB'$+ ,*Q*"U9
M^O(V[.!6]&K^H9<#1GFO^M 6>+8?BN$XDOC50?9;55G6Q?H*NT+VO5C/)$F=
MCHT*K/,1;DXBA'PJ;QO0T\E?*T(P"L;IPDM#$U3^AE>=QZ'N.7.>#!'5-F*4
MP<;*?>:?AL--M.1<7T6<Z:U<4P"&/9M$&\PKLG*V<B';LB%_N*<LV84.OA,A
MRM$"S>46%']+!59X_#&R!X"O4X?UA4FX<2>A%F:U"/%C@O*OE^AF&%::"'$-
MMV*Z< \#6WE3^8DV_+WTV4X1XK@ C!8AUO@IBQ#)SR47<4)-/>Y)$2(W U81
M(:*QS0#_=>Z_N4;[0($]@>$,82*/A12N']$3(70<1(AU--Y>$:*'3MHB0K1H
M'A,AOOH@!&HB1-1;00I]\IMP-<#J W$BA)'WO[GF^S-7N!'']11'(L-6(L2]
M_;$BQ)M^@*$O?$]?)##7 &!4#^:7QAV,M0C!>@5<I:T<!.[BX$"^.$)G)N9?
M+_$GQ6&<! ^!26;C>O%GY)\"/TQ0_P#Y#Y#_ /D/D/\ ^0^0_P#Y#Y#_ /D/
MD/\ ^0^0_P#Y#Y#_&R!KZ->QPY8A5\)1(^?&KZ;:Z_[9IL$_"SJ';$L;/, Y
M(BCO-']5=/>M[MJ5O0=UTHW3]6RO)*N>^)J8QDG>)&UC<_9"\OTHQ[-6J];H
M:@A],/[88=ZX303@"<2-;0,SFNE18QJ0PD,_5G5?98-RRVW'[**+]4+]'K]G
MOG:=1"5O#=>0_/"C":;6.D_>7-%?60WK%V-?\/>"]G/-[U\171D\2NF7K5U'
M^'\&+'0A;I=L<#B\6KQ0,0!X!OG+@OYIG_"=5Q*PA(QK3* ]$B'&'Z-^A  O
MO03WNS>)$-,HE;"-__4#_VYM&DH@>8TO1)-5ARP"()FV'$T0'4[:<R4(HP0S
MVLW&LEAT.3CTM++5=<)20ZC3ZXH^XSI,Q277T?CXS@=7]G6OVY*0\K1:D0.,
M2(Z;,M (;YR*4)=T';8'Q7A[Q4G?']L(IW&P,6X;P.X[]<=JN=E&M"?9R+:1
M]D+\X^E<Y]X_J.=[N](66T0(;)1KG8>N8CGE+0 ;:E=":+8?;3:;I\S7A278
M])&;"YSH=CMT(F:34(%(:-- ,HH)&L(/F'+/"2H'M1[6<8&S.&AT,UFA A(A
M$CQ!X2.<2Z9=XLFA8XTO^PQ*"4;NDM!W5_AN,5&?JRI(%Q<$?=1TG!9OH:;&
M5Z8+UTZ!F,-P =C9[K8)2[%[1GZS,A\+Z;,!AGL1T"+W%*8R1 B5"O0ZHN9%
M.BC]Q#0Z4.#2<3Z>D1GT\*5MD%RH*D)8]0*#9PX77X O/.<']=*]@;LK!<U:
MVE,&090$,T(;3@I'VMVSD%=7_3*ITQ'J*JU&1RV.OB70# VW5C7T_Y%C%U_G
MG;RQ(#Z,=@]7 <PN\([8O.@$E3G,9DIB(8OAW[@%(TO6(^YC*WOCKG</*[S,
MV3 89&O\]?4N1UFCP1W?;I2IER'$I8BKU(X%?W+4FD0(6-^KG?(I>+PZAJQ%
M;J-NJ-<7(:260+U[U[? BFP@TFTUG,L[3G3EQGWTMPCE,%>1E <"M12X'"MP
M(2KHT+Z34(. ?F_1SO#:$6.GY.R?'^@$X5L10I)L3GZ/ \^B1BQ'V6KAPE73
M],J!ZED_HPR>"IZZBBQ-Q'*/".)%"#PU:LAM3R_?BF-.B7$98C2L"JG )#0J
M0MNSM1\^QUOJQ E%B%/@M_J1=$I D7.\;9/,XK UL!T'GJ>.Z@C7&HY?/HPW
MO=V1($)X+"3AD(#G5[@KEX@>UTL2ZO+/P_L@CXX(CF5!/D6>9 ;(D-32T7':
M6S\*-^('+3?#Y:AV8.,4@*R7S;TT%H]<BSM4D=F>/\U4;]PF''*A1P#CE2($
MRA@[@N52/RZAAND,W!H=09I0&T:UWDZ*!K^?Z+?4Y2/@,#9:G1A]#!PHC39D
MQGR/QPT4U(-S)4F/JRR5!LXY-"8-E%9JIB-0?0TJ_'32;3B61^"KUPEJEPC2
MY$^HJNK8K8+T"@*\'=,&1(S8Q)KX85HS@^/XKCR'2T0S)F<^DOUIME%KY#.\
MP/J67S]2T]>HX6Q/8#%7V15>NM3I7^X\6D$>]N19 <U'30BP_O$2<(S'3JIC
MV>O8"6H,^/)/R!^<-(+;ZL1G"^=RU2C-D(^:-D:LH?ML8?L;8%1G2VUE[A??
ML\)>%VI[&D2/%FX](A-Q%6SJW:[Z0D*PV7?,%,1%!A%D)K5W0$ 4Z6 IWVIP
MWL)D7%[M\I#Q%[T+4$?,[.*ORM &R1:SL*7W:FY;!_T"LT*6S!/WV<9-_]"R
ME*7I1OIQ0J23Z+1)2^6/07058H%++\F$19''FT71V1C%F9'(TM0GWAJJJ;Z&
MW.(27Y>2Q9?.^$S'AYY20QG+RZE6OGC?=:G=NXXG,'X=@,]!*'9!FP@QJB^4
M+0R#9MC+<UIB%2AH88)G,2-/T2.2W%M01N32*#9<+.?4*&-@#<GZHZ6"_;@<
M !]>9"*)V)-#]=*UQK6'N \Y]M?0,;><@G.V-,;Y9N\UKQ!\AP=XQV$"!\-7
MIG ?"9[\W1Y5X(ASY<!P'S>U%B:PBU%R<#Q#N*,2HC&ZD40F(_50="0?^W08
M#F<Z]UCXLD8[[<Q]OZRO_#)P_Z;KZ!?7+L6_)(<LG'F^PO8<B?YZ3"YQ@5LI
MR"2IO"!6'P:7X_CZ^<1J#L"@*$QK;P/I\24>C6!!K+'^(5RK8^IT+3+VQ;.H
MGX<'9E-\Y5T&+\X;>.7H.1UBMA)&U+@ ;&:A2S;BWX)-P)?$%>_-X$XX%C)O
M=I/7-D[Y>FR0"<91U_LZ2K8J?C8 C96G )]P!^-K!]7-OO_R!+_/AD(\[J(@
MG^1PK7$WK,,2*X"XD3=O \9S=I/.0M_G#O)TB*'<N*$E/]<.C+Q)*%K%C;2O
M'OJC9TZH0;+K6S!:")+'.?6\-PMGVKIO^CAL^5#M_@*\HWKV%XCBGH,C05SS
M[<8G["D35!0=Q'9+"3MSY"#,W"'>^FE<%7UVE'>*Z-I2[3*4.DZ1G19/"?FI
M[.#9*=Y1ZQ=88S-:;/V!,:TX><VS/?,5B3X?1YM#;TD(SO,=X%'0=3PXVH#O
M#A5S9%J8]RR5^TN?E/598"'S#J$*N/]NX=CGK7:K2Q\6$S,N]+VHW#@1=_%9
MDOG. L-U92<QP0;7O\PGO_ 6;ND-[ (8(XUIM$FS@<2J@ES?6NU<K^+)VO:L
M$/7T/H?>RLN6OO'R1]LGMBL="<9;?#Q9L..[#.K=Z#1U3:,:WU402Q>/*_!.
MS&P &U 0O@NF@W84!'\+?!!<;F7*-&XA]X\A!.EDBRGR@<;4]AQ9"!.Q= C-
MEDE81"G#RZQ"\#%(B^'?R)_.V6Z_N9G5Y>HLIJQ-/\$0<,1X 1M(3B!SEL?;
M.RH^DP,8=\Q:_B'!@WK;,$ZB52N Q/C@8MQVP&J0*<L_'N"\U8MO=5L'AP3F
M'*R'I*F<BT;\(YQ#R!.#00UJ@=B\BX(LF_+^UH]WR ^GA6:@333?GH5:[3NV
M!VR,Y6!B9%QQ$D0[QZ&*+DQKXW["ND_/"MC68$YL4(!J+EN9)=A_8DG>&^^X
M;'/J56!M_8\G?WPOHG&*QZ/;D!2,,@9/@?5D6OU"V;@Y)%3.G0"K(S#C^2NT
M#EPXH,[?4C(E0BA@O+I']@^Q9!)*+-7YNT%'ZHUQFH*WY5KQ.!"31&%E[^IC
MW':*-^G2;W6QX0(QVNRQGV?53!\",H O&MZI4,+;)AREKR?0O0EQY%T0*E*$
M^*,8HTTL_1(H[NG+.>:P,L_C,LF^QT FFF]:2AP:[VX1:+)PB5? Q<;M8FJ
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M<_S[!DA=HURJ_2?:^W_-ZG^EQ[Y9T3&'?[[_6/BNI;?N6,'!-PEEAP,^'/Z
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M9Z4QC=7YP(2F0 Q@J+K0X^?JG6\"SI:K^+X@9@X%>K"H'4!4G\\Y6)E-CZC
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M#"F&+?.$6DFXG=-X.$X%(/82XZA-;KUS5O3-_BN&$VU :V_V+NA'EVE%91%
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M18-D!B]2B#TL8E/KAF_%M8"_5A&JHTTF]'3' H;+^KV[ Y@:VY#]F?ZF3<"
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M$)8MWVU?G;&JA5_XKSY^(6=[O)NNV&UDHWW+Y8J\OG([U%W127#+>/81E_^
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M_F/ !=Z>OF-  D+8C19"T?II'V<['1X<QE=$WB.J)"@FW^M3?C?D4P3A2ZJ
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M7S^AL5K' "@HVJ7)G*%-6Z2@+3\=E8$\T*R,!S0KLKO5-XWSI.J\(^FAS[G
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MSGJ?N+&^Y\UNO6FJG!/?5SZ7>[^^&_ \-3@G\>SERF?IRH)C&36@]<2F!6\
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M(9-FG>+!*ICG^/>,C$)&2)^O<[=2R(C/.UQ96IK@'(\*.2TX*QA4TE92!5V
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MX0="_M%Y3]6MMY]W<$;_L#?O:8TM.5]A.FKWM*I"KF."/9*N..R@?O/*YEV
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MGUHRAN3:4GD9&:'%PN.6/M,+9Y@!3J;MK+E1JI5WV&L7[;3([;0"\X#_<F/
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MYU:Y32 7MO2WG@'_%"ERUN1!_/2>4&(H$H>4W8@B^M.*SG3&W0)M>,6VW^/
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M6T%O4(;"=L6^,S92W$CBN[B-M6ROQ@:^\NZ[U3K=M8R\54+9./@]ZB3 M_'
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M15]!S^W8 Q:W6VR5U1%=:D3(^*FIQ65N.SNK1!P%B._]E!W,7JBSHQ2CSBO
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MM[3B0CS7-,+#KPR=\P1N,!:7S4P_.87NYWA+,#YO]ZJ_SLJJ@ZZ8K%IP_&Q
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M+9QW"+@(:=SGHZ6++LX(#<^:4QN!^>]M'-JV33I]YD*&Y9GZ80S^7-.(^M"
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M'+PZ5HEM13-?,[\W6 @0G@5C&WPTU#Q-@RS,[U#N*;0-:SM#=4ZH:ZT9,\:
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M8M,J5;>;ZJ:-B$LA3MICA57>.S%CX2D9$ZA;OPD)>+5O+7U._U2I/1F')#C
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M1\34H.W&_;W/<A5V=4#J')16$S_L8.[.BO 3 I.[X)I@-DL02@N_5!#)HH_
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M9(.J 2*M GRTU =_78MT'3C'D_KTTT7>%1FC,M)CW;LT(&AW/3ZQ)*%[_/V
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MT:GZ_G"[R;48!ZTE8Y;]1U"1@;[3'BR45&+@:@V&U&FNW#*V@9Z"<1S\3^Y
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MFOB6)P+^R^[#07%@J]?02?!A;C<9N,F[/'J\8Q1[GIW"8KU'L%K:-:-N%_F
M*0[>0I)P5S9=$O%FV  FYK<XW;9D;#H1K][M8>BLJ.<TM#6XSI-294;>'Q[
M<^6Q-B,C Y[#V%./Y*BA7JO/)TP=-')+OBM<F++@ZN8C35QR?MHWOD&JS;S=
MNG2Y<>[Z.O(Z]A@_2R@DJ'?H8@)QK#R(8+,0;"(-/R4 #*#W<4I-XP9<@*'3
MO(H-"CGR:"FOL0)?&5:A1"7R_JRE58<I/#G<V!*C;5U7"84.9W]GW<(.G';S
M,)+W/;QRPCK#R+ E^]Q(Z873SYA%VHU%UMDGPZIO<FX\1 <'G7,I=>3]]3!R
M;:6R"6U5YQDQY>W'LP7-N!:8D+?(NO5NZ"Z0U@67T:6H@@,LHU4CYK*_K#VX
MBWMI65EQ5$C94_%D>CK6MAB40<I2.QV,UYCK=N.\* 9I-R;=OY'=/%IE:A&G
MVSBQ-1U]^C-B= ="^V1PE[4#.<#3>LRY!NC");$AI6'3U/OMHJ8DE3\!E=3H
MP=\[#1QN<JWJ\SDN&>C5C43S2^L&,BDN$V]L)?O+@Q\:K01F'$@_<?',2U/4
M,:>K;G\574H#/[]>E;J^M.] T(6W3_QN4U-Q4*'Z('37I*C(MMLP\A,13%AG
M!5)I"FL Z.;F/3%2EFL GY:@?(PRCS?5-[83'#O\$QR&]=M0F:4A\1,#H5E>
M^=X!MBH?^(;Z<',#%5 +UJMDO@.Q&-F$?6IB.A06,16Y^3#HU#MH'_AUO$%,
M7%M8T:T-33^HP5F9G&WK@M=A$NJT5WI[7KV2?6*=<9_$=D6HF&[)5'#5,-_]
MO(D2!F-HD=7?9*<F.[=G"2GM3L%9R"G;X\XOEK=+"HH#<.R%I1\J];_8Z]EP
MW\4LFR/_# \HV"L^-+VIW7KJPXW^MQ4'[MRP^.(<1X]HO\/#3^#GRR@:[*^3
M*:OM%EP]3+U5&T!,BR;^CO$PNXS%D1]W*Y\&=M\:>H%!7D;A@X_6+VVW>S2=
M\?*119A:'#V@%#OIJ;+: \31?O9IXV@D2?U% ]^IB.,(&.?>H;DPX^)-0:UV
M>B 79D:=7JLYB5[S8;ST/K4N^^S- Z9*T9PQ&#Y/2K5G2 &-R3+-E-W 9(I
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M.IZX.7KO2YISJQ2JR^AKFF?'Z@1W>6$373%.(I#$=R"1B$."(9RX\J%\3@Q
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MOT?(1!13&?^HL!WQVQHD.3P PX?3!3AWIDJ=S1W?KAT(VP6?B3OU<6/P5J]
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M+[TO9,H]KQIWQ$5J';Z3+HD998IG$ME$3B1[CLA(#+(<T5\])WA/%XM)30O
MP&G;F^.#O46W@B-_VNJM5=U(59BQ/'+(:C_T]$#+O]O75I&@K:G)#L2"+[L#
MV9L#Y^&(_]E $=*2E&.@[P[D@LH*8P?RH)3]> ?RZ/M_;]VUO /Y7RY)-=R!
MA Y-Y;_%[X.'4#-W(#)D*$&E7EK0P6Z;G^R!/FA5SRSC:O%T$L_\]&0C[AD,
M22PVYJ7YJG<,?/(+0/U%P^1L'7*<6#^:%OI*>SFA#RY"V=_'H$XYMY_GFN'>
MMQZL :A]YK)";IO6($3^D"&"SYB'3VPI&]U'/X3.M1Y=&*UD-37G>K-[21%2
M6ZZSZ0FB)UW?Y878.NW:\!5(( [N0#[BK81-7RP<2"I%_\52\Q><\0 G([01
MN.?PS!,\M1W(E_C_S@;9%E*,__\M6!8X239YZB*6&&)7B#KXB4%PKL_Q5MR]
M>FGD6NRYW0R+<[LY-<*\_3?+\1X(T;2>9\JFOT4?% R9'V93A:AZ9^(&SQF<
M9<?_$%*P.2E0?)Y$$!BSOWZCU4P7<7S&R:D\/>;0 3D8N6?,NKX,%;]AHJZ0
M\SA.+P<\?KM[7F4D6<HS#?>Q\"A )YA+@7E;C&]=OL2,^,WQ5]-^@CV-P"0!
MIV1_JRA,)M<IK/4. $]32[_<*"/S+>$/-?L6H0-%IQYI[1JC=P>HV%Q-C+.Q
ML;X:G>CXSE])U-/:]9QV_]N*$Y"RW8?VE>Q NFP9]&WH=RJH+^QVUN:O.*ZY
M8!"_S]25C>8XCJQ0Q'%#K>H+;5P=$-:+TQIK(-W!B_-"JL):-W!*(/KZT.V*
M,,-#ME%1"\L^SZ8S>"5KWSS:GP0XW&H^3?J.!*^H)%,WC@D^J(!I>%'X+^4[
MYM3_/":^_Y>Y(=1Q__E_3W#=<+$S9^=A4V\?/KS+U<:J[<YDP:^=&ZH^:"8.
M24S<@8AJ$O#?X2^%S&^D;P="'/XOELDOT!0R(KF5N"+/(A&;Z/7XE2K-'N@!
M\#&K*>5Z#8-?B-TE0M#8@22CN1?!+88F8=.$>)"?9>N#PIHQ.HRYS@T.@4>;
MQWV^,A,24!+[!&_AM="N]\\P8IP;NTRA8##B/F'7*/R:_#;SCCGE_]%=$O]?
MB]?_MRN]559E T?%$ZS4GD$,["5LS2#*>+6)M\?N!!\M@]S;=_3>F7VJ]_9]
M.=PI#4YQHWDB;-A;Q%11+^G0!ES(:.LUZN,-A@@X\;RN+8X_&'R%6,R[!!(8
M>$+K&*=I.ZSS=F"Y-\I<HYTR GMYIJJZ+ *E.S%Y2O08NAH_GR>N*FS:\_@_
M;7*\2[.I5]:G8EX5,KTUFY\.=:KLELVY_34D!_7J2H#MU6M9-KIK/:EJNU9;
M/[1.Z*?+8]-G/1WJ25?>?9E%^LP,U*;N%_C5%:U<J92NO>=VQU$<[MK<3AZ-
M$:LR01@WOH@(BHL*+*X:DW$H"[!$J^6TQL_Y"?O*1_'=N%[/>-_:T3.WZP2K
M"E1UG"+6;)ARPD\P5F@,4KDG>2? 1"#)CU^!DP4#OMF#CQGK*4CRP1I&E6HW
M7!1_K</<_D&[\P')Q:W&UN*2VM?A,@H&C472):D)98[KH2>5F2?^@'M2&6KL
M=;[(!I*GX+4# ;;A_^GWKUT".0(#S?_?J'O/H":[L$\\5E3$B%1!B J(=)6F
ME,1&%R*]DT>1$A#R(" !0B+2FTA_!"$B'81("2 MTA] 1;H$(211D2:)2+@E
MA8WOSNS,[OO.O\SL[,Q^R(><)"=GKNN<7[E/.X1K3."=Q?? >28E_ZGD!9C
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M&;5:^:\]F#/Q_O(K;6I=27Y2K'!IY,/RF+W_.'?I)2F+ N*8<M,Q_HM_9L;
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M"Y)<H<B$4,@W!MN6!D:3+9GC@W0XWR/1HVSX#!,,/\;["#W5ULA4SV.T=&<
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M0Q6GFS5/?FEY8^DSD&]%Q(GH_!M2$&"LXNS3YNJKR$#Q53#?;B8N*+8!<26
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M[$LO_02S,MXH6AVSLLBUJE!F)75?.>]2H65GM])O9-1#1+=./Y-0?/\NTR]
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M?50>KK@\2S<;B@42W2=B_Z,5<!*2BL19REL:8&-M/B6:)$B8VKK >E";)\P
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MT1W^]:+#X6CXJ.&!Q:%H^+C+QI<&36&MV5I,WX!KHD)1TGP$@&G;KM%J<>O
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M95D(Z1O#M7DNK#Y?U6%C*DTUWARXU^>JBUF/!,8'WO\HK)F927F9^Q+WLA:
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M1["B I%E"UOUT1VXNLW4,:CJCBT./I/0R-M8AR4JKG6N[4'[<5VJ,2ZVV^1
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MJAI1L:CX/8N$BZ9W;V<F"V!'RV?<X%$/A\@U-E!=SB0[L<6D.F*U/BIHAJV
MFC0D=8SVT,87[8#!V:B5G!:^$YR8N.?OW<+:^%JC^*K%L:V2WMZ<60=>QV8V
M-_W0=-.WM41#96G64G?1\81>9 OAZ."_Z.U'F;N@0PGE?H3JZ"3!!4"C0F#
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M]<^RR+F\MAHD^B*L( 1V*%T9WB,#RY3I71!JU&LD+%,,0-#'ET+,T_>Y]#W
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M@DT7V40[ Y&-.!O,-O^<3*68?4IW2NW&1)X[V<&KNY9)]CR1L_*M<VITQ&H
M&0@9A7'<(8^I/<X<*Z!WY<ST9[IAB%8LO_W06*"7,FB\CT.BM4L0W("F!/VU
M0N7%R<,#5QB0_C*@[%,#-(&*^1=;/@1;7:VE]S*0OE,Q8X@T/G9L/_3PO,B0
M:R"2&">8#1*0901$X46 D@2'\7L4I\O3]A?Q(0F3,AZ1$VA6;B\[0]JDSG@J
MU7?P+H7N6P*B_QS,8T:@DK[7QF<4@FA>3B+BJ-!^^W$H9#^([716G#2E;9>M
M!=FQHF4&$5I6T7\L_2"H]%.A4/P(,_>OD8/:\<X[8FZM]8/1RDOJ4(%Q8UH(
M3R)-VW.(R(-&6JR8VF^.3#O$5HP3[H 31E[:C3&P@YX$6%_!0=%Q*:R3('&
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M%:%*'WR73_:N;><P%(0!P[]0&8W9Z$,(V<"6';&4,I0JNQB<8DW*-O<3?$K
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M;<*.F&$@G5^<)$NDF'04\VK!^:P[,%W^\D/MLSW<C_6:&5U6. %!\1W.4\]
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M?=MT7("MK=<P@ENN=CVU=&JM!KKY=D?L"WI[K]/2S^YUV*X(K6CR8*/0=>Q
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MLP_A;#ZL"<%43."Q[#FB5$?X-%;^"WY'S"ZSLZ6)E11$D[*'2>YZ8^GXVB7
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M>7*X: .QZ8T>FO_KR->OABIOZMTV.WRITV12#/></>(X*-VZO=VMXO=5LTK
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M&:7G5@E:M^=> :WI.T9DG>@7P-9M8&YN.(=5GH\-M1^<3R%O:^8D?RXT47M
M'+XW+%>;NSJX**8^5H9Z=SOE1&RUT9EJ8^D2?_]'MB^&G]K96=U4W'?L]JE(
MYV]6"4U.";4%_E1<3<*SX5%C0ZO$C+Y+R(4QQ.CDI[_2,QAA7E& <^6Q"E]V
M(<<WKK2(GY3K=!7Y@4/2IAF*'+&LG,K7] JA4;M/QL]T1+^+C5843W<)4,==
M3 _ZR2-]51"ZZ*)YCJ@#_6,:6XY&U_^=YQNJ(5C*T?_CWST3(7EO<.WKQPN$
MG8DTS5I!-\W5W#2GOE'[.A:/27!+QYV<QL9;D<A]6G49'SO0*!1:Z#H&C?E'
MQ:)UWT6EKB,7.LM/6!J6O7A7=B8*<JBD,;#1Y]LW1J,RT7W,A>A>-!Y:QS=K
MSE&8!NP.!3C4UD.%'2:,9&JI^U?+UCDR-8,%MP:;-,O4/M1XV[/LI7*?3 -I
MSLBXT"(G[[UL:[+K^=H+)76?TBRS>6R !"J2.O&0Q5S8H#_B -9D9!?BP,R,
MJ<3ISDJGQ#P'4VX--QV:Q1P#^5QKAN4 1G&L_SUK)Z O7[5FL:&#8_53_T/B
M@+-&W0_N5]M0)SA<HJ7?'87QY,OVA:6AC@0R@[>"A"8G3>?:2W+1O4,4YPEC
M(FY4J$<CJO#%SW)B([>.DXHX!9-7Y9CR\.&6U7^[ ?\/CURY6,.98@5^Q?VE
MN'-LCRCH,SDM'6CECW[-[*5PY4NB '.PDJ /E3L1TRZ^+17E,4^A*W!$4]'2
MSL.J7.&;JE,Q :S+M+\*H/[]#]Y_!+3)VW'HHZ9PJYH!@K1%P&(M+3RKX:Y6
M$6WZV+5,E>=WX27A/0/79!-@>\(O\T!A3/+"1\G(@(TS.Y=;L\XET*5)8LC2
MMV U/J8N]^P@ ;$?2T( VK$:O78GQ2C. QE+H^U0J2'&P$I ^;+#F=M%XGM#
ME4*-5A384%P((-BAGD0Z";WJQ8+*CD+UD+DB3*WR0E+LA@#"N9J)HV,8Z'.S
MMX&,*'=:[S]D'MKS8FJ[Q*;DF ^H[YLT>]J'N*VLR^J+Z=$YQ8MVI>Y%/\<6
MZXS/MG<CW5#[<\K@0;ZJDT.E&)\7[=7.D[RX)S\3T&P?[#V-E _4_K\=0_<"
M55Q^ WI_-%Y@=1?B(1B+D('R<SM()UL._O3>A0AS=.F"?-Q1O#".#TA>)W=D
MK;Z@O>:HTV6?M:@P\5%ZGJ&^Y0YCR/#3=<SHE&*OTF)2]"J)H%EAUJFJ-=Z[
MX[Z397TKA14&\KQWL/\)1Q0@DZMQVL#+;4'R=#17<4#/=T;PH->6E/Z';9^8
MF7X)T*>/3.:>!WK3WSSO*D UJ.;4O2[]&2P>:'FVJ429F<8]/,<V!/EGMI*;
M%)GW[9GBC"#V);"1]7@09TS3_:^WLNRGC!3V+6[_]E8D%[88+A'9GLM7ASCA
MX@#B79CN4_EO06^!,[-D>]]EJL]G-_S;*63NZ4'U3=5SF!'!GZBV78A@DSA;
M)KPW7 *T1C+%NFB=:8#?EQ^@CF!"BTP3D-(^F]_[SG'2H7^VZO#T&#(3*L74
MI/;Y;+KLJ9W4T9?Y'41A;+"50[$5]SYHU:LX$[RO3.AG&1MM/>_JHZ1K>Z>D
M&_K/Q\57B>J\\KZ8+'VD_%YZ0$_<V]SDNX[)O7^TOP'EKQ7'!AW7&[#A(9>1
M]Y3--)=#I?"V]CUX*9*G0\M%SFV@*G9-<QE]N2T0M@_OE?),YBS%C?B:T#/
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M#ITTF5*/=1H$()N;9="'AM5J,(F/=I[]#Q UV/SLLOVRL$BQ6WD(XG<D$;1
M*@Z=$I'6(:8!/.1SVQI )42>3PPKQ0IS.O:V */EDIJN!,<9?G;^O%/0K8_A
M@X9V/H [/XUAM'\X_L[Y1)KA"5\Y/3B[J=VY]>@3N8L_IJ "0]?]5GJ0;NZ
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M^>-?@X#ACB-M0 A?*S[;\V( ,-,MGKU+0-G>_SI_&M\D7/7_8VBE1FS7/?H
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MW;"UE<Z\_J^O*K"9T9;=GPMK@IA$ZF1VXLNHSX_U=(NVOMG;DFR0R5PL-ON
M/D'[.<M^.L_^@DN>V3WC/.O35;NOEOOHG-GD[[_!_^\0Y=A\ZS(B-#S6W"P.
MX6)+,3'H\#<WV?&AL"#BB.=DY8,T]J,'3I\/$VI*NVWT+ Z'[9B(L)SZLVGH
M152[\Y[=EU12[MTK@?G,W7!:&QIT09UPV7%ZXR;_]R=O!WZ^ #%X!(F^AK.'
M7/IZ6_7OYE>?W-[LZG_Y\N4MM9M?_+$IZ*=.M.J>9/4?=)+MK1M/;U!:_G^<
MJNOC_P102P,$%     @ <X!E6L<V;4OVJ ( H\0" !(   !I;6<Q-#,X,3 Y
M-#1?-BYJ<&>DNWE4$VGW-1I%F3'," A105$1X\#0(B3BA(B8=D1 B(J*(6*:
M5B1*2,D\B7%HI86&B BHB%%(B"(D0!AL;45F"4*F;A4AILK64"^I%+=\?]_]
M[C_WC[ON%Q8K696G*G7.L\_>^SQ5-?-N1HZSW+$M9!MNUNQ9N"O8'VYF!+<9
M-^O_\/7C(/^GQY@UTX*S,IYU;G:CP:S%N-E6LPRL9LVTXP@XW*RY_S, ][]>
MLV8;S)EK:&1L8FJ&#1!8XF;/,C"8/<=@[MPY<[!O4['O<7.LYEHO6A-D:+/[
MB-'B1-NU:5?+C=TV/6FUV],#NJ\[^FNZB:F]PWQ'IR5+/98M7^'MX^OWTWK_
MS5NV;@O>'K)C[[[]!\(/1D3&'CM^(NXD+?[,V:1SR<SS%S(RL[)S<O/RKUW_
M[<;-HM]O%=^IN%M957WO_H.Z>KZ@0?CT66.;I+VCL^O%GR][^_H'!H?>#4L5
M2M7?_WSX^&G\,_3UWV_?M5/P?Z9_Q#4+9_"_0_]_C<L*BVOVG#D&<XQ^Q#5K
M=O*/ 59SYBY:8V@=M-OH2*+-XK5IQK:;KI8_:35Q6[<'M#OZ:X^IO;NW8@GT
M([3_1O;_+;#T_U^1_>_ _I^XI#AS@UG8Y!E8X<@X%/6\ 0T5(DO [M:857"A
M2@U00%X:8J2H/=/INAKRK5V>LQ.<P66S_*K>3SA]J =6U#1&TAH32E^__\<Z
M).#I[\'.S_8'[F?C9G"M[03;IN0SNJ7(6GT.:LJD[X6FNJCP,DX7WACM'G."
M4\N9.=O!F_5*2K:_-P3K5.E1<$U,L8NSQ+Z(;?:VKZT(73CP!ZUXJ[ @!IU*
M$O"?/#6:Z)ILUH6SNX&&G+:P=:KJR0YHPV98 /(.# AJ#;L[BLW]2VO%VJ&<
M1VC'P_'D _ZO+]]Z\&YL>&=L7+JVT^C:6 K]Z9:;PM5A'N+1Z,AWTO=C8^];
MX^+BY@R%)R?O#6;0Z72&<UC@Z]?M?UT-FF/E]LJ[M['+-O[-Y(.[G'_B4./7
M*FJ>N$Z&V JUX_I,]CKV7W7L3M("?64 6<$9$6J/PG-D5DV.$&4K.'"C^1$7
MK%&1;BBXCLB&9#"AW^GFDSN?T$6<S766\4Z!5:5GA6]?)":1)\(1>Z[JG$!'
MPK*V4IS S64[%.PNZ1@BS&$%@[HV*YI_*EI];P;71H&.J-GS/TW9WRP^Y>!7
MN"2KNV#;G5Z)E2\D#?CG2O!37&HMR-/^KO^#Y/_9O_,J&*Q-@]T@S@'PF\D9
MWCA@BGHR;93V%>4C(<O2-Q0>?=7FK^6=J0IR_WO3M;&..0G+K6H<-M"EJU8M
M%*33:^[?:6AHR \M*"C(LYZ_,-V6MK28=O?XY65W"B/^OCJ\VRKB5GHZ'2Z&
M$Q2R[%<JZK"1DH!8I6A3!1#WDEC^QPP.I,BD>U2JCVHS.2.M;#%,5^"E9LJ;
M3W1^(S!>X=&2$!LQ$. A'YG!<:C6WS67#NQA'>SGT[*?)])\KSJ'W>L [C?1
MOY[B.H@3Q 5D<*=L1-91]I.>C_JPDD!>(3J7_49F@2[^M"=(MR6*+C82T_"7
MJ/,#_&[#,[AVQJ.)&=PLDB7-=19\7$&>->&ZLH>T&C$&+]]7A1E)M)%AQ1,7
M[DBID6$_&4T;T8K+2FIIVD@1Y][!S](#E72++Z7WQX6_4&G363?^HGLUC]Y0
M/[PV$AWY?LLK=P?+4/<]G2^AY\OGC/&4Y/U0E_JY0@PO\T@'CN'39(*B=LWP
MOXJX%IDUNVL&9T$^@L\I_@:X!!R1:SBR^JW"3-;R6N:0DEI8BQ#!=4JC+)'O
MR3)O?@D59-<HQ0M8/X-+<EJW/.D]=7IQG; ^.U$S@ZOGJ9?H-B$G])5L7UBL
M%*KWSN#FS@:[U5;@OQUBX>E**$-K!0/@WH.4X>L*QN0KL&8G5)3#-H)]->T:
M1?32B5; 3K1PO('D!'6U\0I=C2'JI2:JBF<;'U(]WAC87,4XAD,??B?DS^#,
MSJ:,XG<-B-QAH]#^ (K*F9/#=GK<SXI5C'C*+)&-?&'9YXD6J4OMFPK;:>&E
MA-J$TZ=/!ZP[XM(IL&AN^C?DV!.)&S&5VL*9O"WF$])F<"> =U*9=E]&%^"(
M$A%S/;:)08!7%+4'$MHO[.)!JV21>KYH33P%K%'DI%MW=4SO'ZS %[*,'DVX
M!D"[*N6UADI)U% 3HYP:?:A@6% #\P+]@O5U,SAZMS'+1O^(1=&M9 \1&J;4
MB7*O,UI'>+^\.4Y%Z.(93OB;S^#P,SAYM8SOT4DV9:T!95E W)Q&.$FNIDO.
MH:8]35$/Z:X;P%TE<3QFBF*"5NP9/4%,/AV& \YZA\NIB/7'S?H'"%YWCCU&
M-A2M8 ]0^03U>I C)[;QA@FM16-NL&95T?GC]]E];"]P::6*DB\5MW7V!:Q3
MO HS:]5&+AA;4-<$?L^(_U1<"C_K%Z3H0 _&7U0+M%\F#&['C]0']WW#2H K
M^,Y5EW'!O0D4!2<7.'R/[1I_@3)Y!I2@)@(%Q?*SO1.W@^C:_/'BMKR'$B4O
M^Q<I4RR1.7J1%H<\I)/6#)S5>P;U+4DY=<_H^\?C$$5QN5*EIRJVE4+.+<DS
M.-LF\MTH9D8,3#^NQ%(RRIS!;7G+V#F[.VH <3$L]\CECRZ>'(TR2]CQ[Z[L
MEV<2<?EQ:[N>!TM<_<'@PK\AVQASJ"B+%4W,0((!^0S.ODO!L1QW0LH<H-._
M72'=5S"LEMXX?T[JD?NM_UE#BMYFKWUC:?&AC4/V3_)BO>!9,[@Y/\.)"B"'
M:C"#.\V#EPT5'($K'S)SM-?UE0!-EJN-G,%U6,2VDY9!'3.XR0G0LZ/, Z2T
M'1P$K*(L3BBU_[:QS9[]-O; Q*> .+EAKTU'Y<$LK-!1$Q>L%-ST-U%3C#V]
MT;7Q>Y&PA'#M>^A-B2X!E1'FDVPC6#_!-PAYM:)%S)P#T%#[];LQLD/,]6>C
M1D;=)/Y !C_3K.;-L6%&[,E5\[=<PP'A8Q;0QS21&\T:SE%H+B'+5<VS+:(.
MOCTQ%."L]')KGPZ(_)@C,/E6"&PKVMM#)#Z\OO_M=WI4+?%@7W'B^:IXWR'[
M\,>M9\RO$L.I[=VM!11X>7BK"T5[0G^1[0CWJ99>5U'@9>))9]U:9.N@:,6[
M@R,'F;%:/VBTNYVS )9I%;#XN,5E3M7)L07PC3-RO"V-Y/+V2/Y//!]&7B,G
MF_=EF.>6]4@W@S-BQ<[@T@N8KU#3\10PYJ.V%BX!SU$SR8(O!>!'A69R5)6P
M3I6<BWA!?MH%\'E%@6$3]#&?7V@DW]4,:CHCBSJ[S8-3E!FZ3<PNU8'<:2)G
MB=/"^OIBLV7N.+0!78[$PW[@NB !1.GL+J":HWCF4=W/G.UU$*&#[,J,4F@S
MSC]X-6=H#>UFH[@@*=J-\K3?O:'AZ=/++SUSGC$7%N_/[;*I@]MG<,*N2<^$
MJG&GUUWJ2MW2J''71?Z_O_6)F,&=E&7TT!H5/2<NRPXZ;?U6MB8J>ONXGW6'
M8=7*RC_>A;DG1I_?];D:.H.:CH)G5%2U!)ONY?HT\3%9Q@&QX;4A;2J\&7JE
M'8#^F5)[@<'[88V.-#HZX>>4W$+)B?2XA,PU?*(H7==^X<G3 5;< ^:OO1/M
M]NK*^ ._T+/'SM#FK#L?A]B&:ZW!JOM@+&J2K+.")[2 _CHK#)*HIM2OY!9N
M2DX[?EBEW0U6MP&S3Q(,4&<Z:2$\ 3UF[MVT#UK*DT>;Q8#=V4A@.5PVBD34
M=PC#(ZM'#H2F;@O=OI%\.SI4^[<^WYLQ#X[JF!:K,W1>XS$VT*O/$.S1X52D
M-@"+NR2B-=<E4T_&B[\RHZ(:H5.1C%S"EO[C!92!H9!GSQ-\M=O5Q"WK&CM3
M#R*GX+6D132N<7='=[:;LD%8SK$Y*3.G<%@K2(OBQYQ/AK7!&3O!B % X2[N
M,<>]\8F*]HTRL%QK5IB1!+A004PY,F)F@U.(K=,0ELOZ< G7ELG0<N!H!66X
M0&$TR=%9C[%;,&PAJ3I')!FF0QXJ[[) >$K%-:<+1?.&$")& !;PA0T:R]<0
MIVMWM81GR21'@N@MZ_C&VN:W])AI290^ XCGPEXL:;(DU4\BFR,@#A=I?V_4
MWT57LI*@\"S4#<Y0R=014)\\N*TT1>) ,"49,XMU6\3U<+AN(;((',I.*NC.
MM2]X..[J N<]H-V<CLM"O+P*7PQ^:2'7RO"L8_!FI68!LU[!R417('X0N9T[
MZR%1Q<T1N4+=V3Z\!<PUJQSW&$%QF=]&]WR, 3^_F;QO1K>W/[KM^+Z5VPWQ
M>3,X9[8YRZJ/WTQ5!7?(L@G&_%+&STZ["AZP*-!45H!!=?QTQ:F1JO%DD><
MOR1A\\^D4\QZ_DUZQH>E;O\9(K]D(%95$NU*_3U 7L%>K:\0'^^V&*?."O#0
M;8"CM(6](B?66C$H;E^.,9PT&'60M8?A]\&5NI\Q%;$)B*I<%\WTG8J*7A<&
M&X#B*&B76(F?-SXUU=CQ\A.3LXTCT%<'Q.K<6 %8C=]!9:X^V/L]UFRHNJN*
M*^]JD<T%6M>SG2?(]1\OH8',4"5>8K&Y12KHZL0;L[L;5Y4J.%8PB5SHNAQ^
M=E::G+_JT1=OBA5M<%"ZORU>>IIC\4\;#CAXL^AF<59EK3YKH/E[H;K)X69X
MP_6.,[1DVAGKUPE)]#-F 7[V4Y:-H7.@#1TK=]5M^^NAR;^ '8L!>\FC-);C
M97YP,RANE19EG@VS:1_S[$/VJV9PILP+.HGK FA50YD3^#$W8#.MYO-@LM.J
M/"7>ZI5KVIWXQM_.#3H]$BZF'7!P<'CSF*#4:*L@0%T*,E28<WC7IV7 Y;J-
M&*/_A,Z&UVD/Z4L9P%%\-KKL*?R/BFC-Y"F'VC56LGBV-\AH;]ZKZ&JC2)<"
MEZ8YK5'#IP)F*7D9Z&*H.J=I@X)LNKK?2^!X]O?CSS(>P H%=3[:+VX@=WI
M<>F8NYFCKR3+'Y#K-)//E1NB'5JE[?>5Q.%JU,0#/,V0&FASN9+!9-]7UC"@
MQ'==!>["%Y:/.8<QPL.<I(['?KFVS$C;:WS8<?N*%LN@%PLOI>-_"5[8._35
M#M,[MKYZ!A=/O0R >\0$V@S.BGR2(7VE$J9]!\R0$W#!_=0[DG:1"6P#UH>)
MH6A!=1K)E)6D_P-=BCB C\IU_L@Q\'BM-))Y8DC1W4%PBF+6!:[53NTN_M+V
MX:O27PSNG\%)2U!31[!:*] +1>;L;M$Z>+2"M0'4M.&'J=J)9Y XY\[0JK-
M-F&6R"A866BF&FK39!?=;!!M%5Y" ^!>O''0JHR$,XM$?7R9]?N8AP?6CM[
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MG46,Y,2Y34,AWCT5R?L1:_0MV5CDQG35:!_!KW2+T;< /^?B63%6A)-G= 9
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M=9S<\G<_N?_DKC&RN$KM+FK5#'=AI:HS@ VB88;.A2G1\B!..X#5/;@UE%M
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MB6Q;B7ADH$32!+S/A#+<SKD$"F)3RN##Y!9<5E-M^#>XGQ_=H)>YVGLIW7H
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M ,[D>D4]%OC@4,[.8I5RC^(B_]W.5(N/! OW5P8AU/$6[-2/Q*%CG'V@BP
MLV+K%564GA6V/01>S##-$I]7-T1IG*LQ5=,<7-&K5HY4O>-Y*%!HI9>O$L U
MH)-XQL(\F4BQ8F4)$$=A>57G>\MIH\$+0X&/I.34Q8)$MAS7,5F1 -61BSF%
MF,&1E&*N+;'):IFE@ZJH:^A;JH:">A(LE^"7PYB:!_#56K=5>;143\]$V\C(
M4>VZ[.F>"06-"&W_Y NI,Y:MC8:;^[!FR15%BWDOP4K&)*N)#AM:8)!9RO\:
M#E'+;+"Q7W^#C^0>#R1( >VI!4#M8B00SB#%\W<$RI.KRK)>X.YUV;"1R3R3
M5UT^_@5@UL4LNW+VCKS=]PSW8F=)#--X-JII$CBE5R_*M0>)G+CU#W!W!G2X
MHH,^TWX%M*-WVM"I+ -F*H1WVH<^*0/2[(& 1-8OO"V&+?\1O9MWTH0BB8MT
M[%VJMR\.(BCU.WF9_N;_LK.%P&VFW'C2Z7R16UP'"6D;[E%!\C^.#)X4@$$,
MVLJ?\0DA1VQRH082E6SI'9_%X@-'JJDDOJ'WY\M91F+%/I'&P=C0D&FY<*G'
M*CH#N=L$IC A=&Y )/"W!'DZ3@G93@9U38M*0)V6._+Q51U06<(DN4J Y?"C
MQ##ZNNOHA:I>N!5]/( A/I#!@.X>'_<H\*@EK7A&/C-PK4AC?%L;"8Z8MN:'
M-<KBX>S80NY18I,]W@<0IDWLMX,.4_@B_1BZQ' Z?]>Q(GXG6A(YE8M67%D_
M_+&V N\T($B5*N!63^Q6D,@HBL<+^0'<T]G$%"6=^\:>-8D7J-\IA<'/@J8]
M*2"+'<SI [NX2IW<6_,;$&GJ5>A=.6HMMA49\QVO]AVABD,SPY/Y*KQ]ZRE\
M89RI8Q[HR6#5?CQJ@DTB[S#I&G5KS:J;20Z#)9'%X,H,\=L]WU [9^LR6E/N
MG7\GS"$Q8/(XMV:1_,\,BE2@MS)*$G??#B"3OKU_,S07X,6VKOEMDP_>LO8<
MIH<X>_6K*<:2"X;BEWZU'#:6^_7VD]L+"@/=C-R-.(#'#0BXW&%\$.C&#9RM
M6XW&FW"O\;N5O%.YUCQ[L(EI%X\P!O=_\X0-Z]!KXPCJ0R"VR2W;O^Q]F5<'
M$R9\D8?NJ4+&?09RZ7 C1O+MGR,+CI7U .HN6HXZ57A'?I'-]2%\5ZIM)XZ:
MM2&K<.NIFSJ1B5W<@#!2[Z&KQRL$D%==VXZ%SI'%^;)=P,_5=C757H04:- R
MN25,_.;:+QIJ_2F3;-D(;$]8&'0KGK:+V"F\VFY%%"6J( .Z1GOI+Y]PKX%"
M]!E6A" ^#@CH(I#H(?"; ,(WP?]A$00M_.G^%^ 3KA_O#'K7&#X _+R[%$M?
MJ2-/U=)@XO-S :]QSB?K$^F+(T^EO'"-3->^T(Z(=&Y&3^FUJZ$-IE\X:UY.
MO[\U?QM8<GJFD1)E_7-BXDA18_:1#-\4S_>.OS1/9_BY/7BC>PX"H5K)G-OR
MOUW","91>):XAZ?(Z-J"RS[V%W^4B19?(,@,YO>LA*!.]/WHYIUX.3;GD899
M^QD?[E,2N%H:$'Z@NM^X>,'"NOEFEJO;N8NM*L5_C:G 21BH\V;4J(B#8L%#
M'KIL,^+>Y _OL"C^+K,!B:%7_?GCIS#^[3"ZO.J<,'-S![0DL<E"3'U,@()5
M]-J+LM'\,7+-B;A+F0JI?/G8[E@MDHK4Z9]/='A[LO@B$]_8M@7\WAUVSTLU
ML8)VAPIG)*-Z/A&.7'M@DR*R;?^.@PGK#R@SEIPW8!2V9//8N[14@6I2A=MP
M;<&V#HY@#&/5!,HB=1O>40ZAR+Z2#M!0Y5G>WQN-9CEL4.CCA!*0E>ID[\:
MW_E9731\$>,ZTN+12"YNO5-CMA?J7,O;D\\766ZRQ!"KN-LN7Q;GWB(,&TKF
M?VN[R+M^Q/_SB(V&SHYL,G 2#>K47WJ#05;]UGM8J$^MA;$>"&</BVL+MXMA
MKSZMG3CZ8_!K=A=+DDL8PGN ?TM&.]F)S?RM8!BPQ QH$7> QJOMZ%GD*>7J
MK.<BM'G( =ZQJ26)8'%@E)8K\ST4FDS=%8(G^M,'>^%1[!U_O+I-O& MYFV5
M>6!"/RN$Z(00PRUQG@U2KR!C-R"RI3S9%^ ,@]2Z?@T6'YZ[%20Q)4#7<_C#
MH!<;=J&1;4/"ZZP7YN,,6BLF@C<@XGCA5^"MD^][RI9;WPV8+'@Y4DP^W-[W
M2?BS8+R:-M?.Y6[1JDRT6W]Y\N:5:M1H#J>M305R]BVE72WEX+..6(5OF!G^
M3DN!O%@^^BV9:__L>^(M\F@JIUWS(W(Z'@E\V(#T$\M7HXHU^(+&@-46M 0U
M2")QZ04.R1A?)>']\GAGV;"VKCAHE7"SN %]I@6VF^?;1SB,*L%Y?N0KL2?B
MB!5\(YS9!:"FO&Q^P.VV/$&G_'N]11YN_T^8U(6N,A1]%HG1%6)_IDY%HP&4
MC1C4>OWEV,'DQV:L=J[?VRO1(7$/"&9/'[?O1(VK'KS82!'(O&5!WV#X$XB&
M6Q3>87"R; Q7;*FFP#ZU-LB*XKK.5^*R:/N>;4#H*NQM61L0A3*HQW>S#@.B
M7Y#UC+V18?3H%9LN5JG,%K#51]#Q70+'QF)<73VN9=!A(P9VO:$=GL&J9@Z]
MQ!#TR"JJ=WE!^4B:Z#$CQ)=>YGG3&M?;#VQ4Y&IJRJVV5QTL.-?V\,6K/B*X
MSXPGS7!+L36FC-RQB?ZI0QS-XGRZDK26ATW9]GKJYH%@CG8"A'=C T*2$+P[
MO.;%!L27W^OI9'EH"_<&8>BC9LD)C!M4F>\N LE2N/K/K58$"MRGPY,><6+M
M?\AU^-1C\^-3%_<F87BWM]%H?8T1^V.F_:1I[\,/3Z]0?6>?2[1K"WJQ1]"T
MA<J1*&7.4Q]]Z[0=FY.&5V^JJK=G4LC)&Y!#[7??JL2P$FX)'MNYZ1D]!3<^
M%Q!ZNU2TSI[>@&PZ_F=%QQC=(N;=7>>O%T".3UUR6_02F&E:0%2+^"(_>ZRU
M>Y&8EQF%TJ<TU]]3K_IIV"M-V2I@4Y2S3YU(_B*JG_+<.9V_TU9@5$YJY^]E
M\D@$_+='"'FSY<9@TW#CQ^"46?J['S6VGS__&(PGC!%$ &\*UY/?'4Z40NS@
MW0!S&%@I0CM2I$IBV 8-^DQ!$^JF!QZR7[:W(E4UWZ.WXX\#EVWIY-@)P]Z5
M4CLZY_7KX#M\2IY52(#<LU=!9JF%[BA%YB60O'G03#TX,"GNU\^'X<XPSX+!
M;.4FPE$V,:E>XT4'D&7#7OH'&3 NW*:V#20]7V#2&[*B%^%:S,G$;$1U01/#
M<S+>6Z>?9_EROJ[S)>4Y+B2D:M80@G@&!4Y*@#J/<05*9BQ3M>WG8]HWO30V
M7GZ?ZR&$V;3,UNOR0NGSP<H"/GB?2)W*]N"4TEF17H!9.POK!23W]Z]&KW3Z
M<3K62ZLM IIK!VM8 9&1]%(G+M-X=41\>CJGH;!_(OT&YL:-P*40XU2AJH !
M@CS>:9W"1Q!HO_&W0.+S#FA+UXA-JUPC#)"_R[,LG<W=-D 0P0NSK?A9+UJQ
M+^97/:R+7J+!U;. 0\XKL/=DCJ?=!UN>)R-2D!H1&45:Q7>(/*F%S;(@3XN[
MB[<#(+=BM^/:/ZH9 VU9C%(I+HVZ!X^ZQ910UDI.3>$Y9"/R&-@]$^VJG/PW
M0=F.58W9/Y=-.IN_9NUO.?L.\A?90@:P9)XTM.UD$]X/^,.L34P_TU]BPC*"
M.W-]"0.(?:EG!T-K#V'N3#Q3*V>GK1B&)1^R/H09*7S3&N6W[Y!'ES2O?\V%
M>XC_%2I"O8R.M042IQIJDTKA<KE[!_ .ZNS)%G(<5+::61S<>6TML381H06F
MMWIK1UJ;ODT,.5KM['=9*-$.A_]LMBYB!9%Q_/\O65?.-_&37WXU_S@=0BF]
M9OAKF[,=5N_>3YU81Q4 ?JMI7_*0YO=/:6U#N'$O2]'S@BR73_Q/:)1]Z\SG
M]T9_5C_S@S]&K#DZKHD_U<Z'$2_$RAWNEX&\VWI7X.2;NV,BA=YAH%6S6).B
M3^OOD5>OXSE.I?N)]/ -2(F_EMTZ0T2QB5*V 1%DLT2D/,^,*4%"B_&W#XW-
MYQYDJ]UG4A2#@;E&M>]XNU?N@0B5ZM[ESBT_J]C0>#CL)6;-E<(4#W#HK3;R
MMOM[S7"161=IH-P1O6?P(72TM@48]\;MG_S(WS'("RF@W T5I>YQQ]LD2&SK
M8*K>:LO&"D;1AJ@>6-F1/S2">[(R'-H1VMBGD]U^O \Q:O)T3LPYBN])+Y()
M4+SB]63Z04?Y]:\8NSUO$P\WT]GO#'4X,6?+4@Y#[13A%G $5#8QW\6GH/C\
MLS/GISV'V])^(O=]XUV?<E#NNO649%'\='KE9A#0!&_Z\7CQBON3G\BAY<-C
MUIZ/W#HP3 ,&^[$859:4:7Z(YEAXLB'0IZ&J&&'%7! 8<-_F=/[^SCI!+#6>
M>V"3NIEXU"[D( )18,,&!/8DG:HPGO[!F"YX5'/3UCNCA4ZO%^$?E-R#@==0
MHQH=.WD5T?]2%0/B'B'AACME#S?W3-IY+@Q58[?,9]>DRA;%X=W"2U\6%LP=
MPC0JOK_?YD&]CRRO*HHO9.]/WI](/Q;>#[?DY!S+B:CF;O<R9;&6MGF&(VMU
MDO(:$AW>@28O9M<RG]Q@BM2C"N8G94./E/70FA';@:+$@%YCY<_+'>+[5UM6
ME5*3EE&B=GZWPK>7YKX+J)*7MPJG>*%V@K^?!9R,<% [Q#$Y*)EQ=E+G>9'U
M(QVG6TDW%.9=T(:7GKZ8>VWEVOSE1M(-',;ES^RZ.EZ+$INB3Y;TG1'Q#9R:
MW@4_UH)[[=S"T'<JM,ZPG?I=8K5MWJ$DW^%,59[3A:NA>E_"#B@,G0,&_@?]
ME0DL94X.UM0D]BQ_#%US=%+*[S+V7_#?OZ/_J)"04 *4O]-J,]VGR=2FVZP7
MJ>UD3S<+P!_*2NE^N44H")H\[09Y<.#(MKMWT:Z>A$'SMO=<).C'X-R?(N_V
M $FM5.EE2LQ:.,ED27D]R[JZ'U;O,*%:_Z%Q4/E4];N8JGQLE 7GR:V7PQ>;
MKUZ[UZ%O(WJ1?8 P,1C_!M0>/ \B+5*>,(-/PUV*YFV9R:;NRO3JU<1K>(V7
M8,W 0)1ZC_)H1V;%!_:ID5UH&ZVLF+WRE9-1=8R)IK^ZH$_;4&J9_E$KO?,?
MKR@L4N1M?[X_I=_3-OW]$?M\AOECT/R-_C.778^B"O4K\UUE9O2LN[I;0!:=
M(,$]RL E-)B[UZ R H8)^R[#K9PET ;?WIS,%=HSW_/EC8V$?DJ-FHNN;U3R
M'1FVL;Y+T4Z'A>;G_^6[(;519(&=]DXF\U&;6-_^0;'M-@^KV.8@,I>KF_@?
M:Z[\\^E2MR#*/YVM/^VWB0/1L,&E#'!*- R>&X&HGA<,P':)=^^Y+M^> %W6
M'WI"0\+=TR]0R\$83(G)TGUC* 39XKFP)-84_&(DV;,%]<(BVJ!(<W+X^_A\
MIF:0FRGKADFU/9&_2U:0]%2M81(\HXI>."$TRN/7%W&_]CK#;)D72V[?ZW7H
MQ\@B%W-V!K Y%+,$N&WP[E*ZIUV(?J3"<I2]%E5[QCZ8?%)M-RY&_UV0TV?=
MWDSM0@6KOL[?_DIG/J05.7U(07A_R_D1?OO:_O,,9I='DCZN'Y&6*]Z<<J@>
M5R3I<43_0D):LIHJP]WA0W/;TV*GYM;I@RYO*,&R"A,'LY,Q;0Z94$FGK.Q4
M<)\$3_J[[HE\0J_/-GN((_<&?XA[:G\X_#BQ>:D]L[-#9UPG3>^MP&&%J5.Y
MIDL_3[P@])[[?,^L=9,,?1JRL'9CXHY8M%M.-%: &5Q[7#J]ML4>^=$T6[8V
MQ:188A=XLO=BN9?=6>!EEB!/28_@<M"-?3,#%'5JE,998#*Z7KP43'2J\8R,
M5KI=&/3%(Y#N_AZ=C*Q&)2TOQ9"WX-VF0B0\ 4XU.]BJC[ /3#_;6W^L ,=M
M59,!@^FIVSH95.EY\]LQ;X()<CTKF!#_^N]YGO%++'R'75':R(AG;<+0W\?(
MW4?(RFXZR>9'S$-OM7;=:W5I<TI&^@(*]3U'$H9P>C]E@#\=P(4D%_.%[>9A
MYU65;N;N.Y,4];6CK7%[A^X-S07?6_I#9;)IA=F7#OSUCQA8Z^(T>CWH$(YM
M.Q]:<6?HBWM;\/V/@\WUWYY=A;\QM IT;CJ3JTVTD #WR?.D^\Y>LT[E.B3>
M?]HE$ &?N9<CBC0P7\E O9D*Y<L)>(JYDQEO#XDO,OOSY)H9ZTB;FZV6T>8H
M+%Y.0[[[A6K[[94.VEVF7'4K!",YZVP=DG'JXE+<I#BQ=H4J"BH-7F"3XNIU
M&.)J(VU++4KD6.,E^5GDI>X?9@>LZ*4VMH/U%OZOP>Q)MP^]RPW7^-.^-62[
M*GELW60M-!YK\CAT 4:Z'7"AQZ0!19//5>Z!8_*#ZZ")*Z,4&9S=QUQ5+YUV
MD9<GQ#.?F,554_>,%<[/551EYDH.R/W4'5%/G.T#2"ES_=<CKDB=1Q_.3XK%
M9M3OU\XA6>RJ*F 'E6!\_?2E"IT:] \6B;G*E>G17_6[R"?;S"G33?#PH':+
MK_OB'21;IJN/A"-3?.X5?WO->.6K5_*^.U=#Z(AOGG>*5*-V8=![ B+6N_Q=
MTK%"&(0MP=LCS!=YS6#).P.3B7A)[G%<,2U[)&Z%(H'+XGQ=+UU9%[Z09'Y:
MO3\TQ)-I,9'SJD4SY2B\N .3/Q''#5=_6 KE[;G/%YD6NUUN^8+?>Z[53^7Z
ML)4\B\;ULY%]>E"]5<:TO*AMY;1ZBN;I_!2M4Z?[_5QV/I?PVESQ$SOI/G=@
MS(LGEVF$<JL"Q@=C&:F,'3F(F BU]\+)V/K.8&]^<[RQS(>>>LF(8C!$L[*>
M[-F[8J]MZ]?KX9E1PTF-15<_&VRAQJ]![[((\O,>B+L,(<:")U)J LPY^ZZO
M= 4F!&*;L[OB7U"!SF<E%9YS:][EC,=X#=-7=05O.RBGU&M3+KC_2"6ITHG*
MT^_P#C#E])X\4K-/^>.Z?F3U;X_$>5#,O-4WP-;I:X"A9<SN.P^+2"Y!+AR%
MQ]TQMC[EN\C%CT V_4I$TL?IOV@IUU:_PRK7O++H@<3B,90U2C['=T)8R.$#
M)=TI=K?)#>]O&6>&WI_+(^%*9,IE,3:JT6&-"(& @@D$E'V;O0$G]T%5B*C\
M^GOBU5@CZ0-7DM+9'].2/DH536MNM5+_+SWK;BO7%LBB COJU6"!*AJBRW_=
MCMZ%,)O"BC6]/2IV8CYXF+^;WT>60F@2>@[BSLTKP<EB<$L&-3G;C&1(+3>^
MVDF?C&D>M.NM3H:A>^KM7^/N>5WAMD@&Z3A7LY&QH4827"V7JBCKM97G\>,A
MW!L+'J:%[#VXQ.9&U8;O:!>VUVJS:A!*X0+NYJC7=V,TU!+H.MN[4I7=[ICV
M)<KO0B\<51HX\DB<B*CU*41;!A>V[*U-([SAR["C#-%]&!_@2+U'QV\>_M6Y
M=N<B76(@\^ [A4M/RQ-%A%-IOH?&FGP!X&F^M0+<ZG3?ZUW.P231Y;L H]&[
MT@/\V@7K*,J94;2"NQH8EGK((LLKQHI-BK.M%:^6K[@Z)S7-/+'L8(?I->,2
MWF?NCG[E5!Q7I(A[_C_\  ()G*R:VBI]%?*O.,2+WKSI(\27)TI*?S[Q.Y?Q
MZ+_V;3:.WF2U":9N*?]E6M:N8R6O-R"BM$#]R4,/CL"3E#BC*%#7FWR#WC$>
MTBBU\'/5%I!+9J-=NUDFH\=J*T%,">XZVA/W='(#$D"[:K644%0)E&7XJ[>;
M3#Z[46S/\8Q4CK,I^LSULO$'Y/GR.]Y/K1O0UK[R#_3A)0MQ?J[L ?+NY-+Y
M[+#QL9O><PC#1+O'$YBN(LQ:[*N'[2^(F*H[4=/4H5-O,^&/*6)'F-L-C6\<
MU2@R]/8C?7D+N,>Z.87=&'ISK5KIC'%Y91JIW'ODY;Y"4MZ9<Z\]2H\X2&7E
M98$+=&^,RE4 [JP$=/R^>H68E//YS_R!O(Q+P>WB<2UGPG[7G0M#5,**NYNM
MZJ]HUP<YTKX7.V6<;O^A\5_N&O%TQGJ]:/=<#"V PUPO__M.50?)COS[Z/8#
M'FV >AH90![^0Z]=;  HEJ )D V3HTVE2G@MN(T$X9@,B12"+BZ5I<0O#B\-
MTO[3AI;$GV 09></YBP,=Y;(C[2VF,I-N&2DG<"(G2NZCS^P7GF-H /VTI=(
M50+*ZU:C))'RLKQGM,4)]\'NP_L>W@E8\R@Q0:DMMTZV@42.\J-WB+)T'/I7
MT#4>)6X>;>2:H4^]GJVK)G@.D1;1)>;[ZM*?KYK7+SQUD#ORQ3C30#@!*Z'?
M_W;>.5-",BY&[\W0G;YIZY(\#ZG[,R_3$XE^S? 0&CSL;NO/BT:/NPXU72K_
MTW%#=N:?KQ4K*I</#%WU+')0S)40=FHPBVWS*;:4/"E[8&6?Z_YG[AZVLG]F
M6 >Y!_&ZZZ6-2JD"OJYXB5W8?K\]+I0LHP^*,@):8-'\O?;H4W:?%C71<OA#
M;%@,_&S-75B9ZXR]$H43]>N'V>U>!1^]9559.M258-8N,+^*P/PX*_4..1+W
M;+M^6H<Z80Q9<Z@N_<%I'W;]'@<'A\AL/!(X"05U"LMOU_[+S423CB8*AJE"
M8__A!\K8]BT?MJ4=?JIF16CK/@Y-2?P?/6=H=*W.A@5_BV !%%8']_+.T7"C
M]\+MX@4'I^\J^ T:"_(OE"<M\#MQ#<ZS/?G"ITDL0?K=V9]16ZQ/; 9&=M5^
M+=BM_/!^)Z%ULUTC0;M[-UWEW75!(C9MML7_%2)L,G.) Y^D:@AFO!Z(@\*?
MSS]S-R# 212H4Y5F8YR-8L%_MZ;J6_\+@CC@INE!D/X^8F9:(S>8LS\!PKN>
MP]]I(6B8_8YX*$J:DYU]$C()8[5R_3X-J>[X"4XX"/L\W=VO\;_J/(:GUVQ8
MYG,BKC&>G!_K%8J^_@JN5DB5G:[G($Z0O6)"">N)+_Y!JB#IM$D !3W&@@Z1
MJP;)U*]_J/1WU*M8LZ_?6-P-"#W\UWAN>,#1&1-C,G 2"^JT%!W"H*MXI,L/
M_3<@U]"C^U*S]F][^(-W':G!4L[Z]50LQ>#?LA>6".Y=XDDW\1K6H*Q#?*=M
MJ>&;J=$L,\%VYQ-PXO8KS0?"D/1-QI(H8"P_LC9'J\U(_:L=85-Z:Y\_%[]/
MATF<M-KB4A<#$?K'@'-(T&@H]%][O97:4D#H?6ZGFWT.*0"JO1%I]Q1.@R#]
MSQ%_X1N?/PG#=VV6NT2H4V2I*JQV!A?UH:65$?ZO80.'_A&U;F?>U3T-D2JX
M#J$,9>L*L?N(32+$J5R&VV,,L@K(=AG6I )CU!KK58<=[5C06]%_"E\@D$=3
MYS>K7&J;3MCR0:,;B2GPFM/N6W]'O.J//G3X\:00$Z?\X'=I?Z3;8I3,%O G
M<BJ:"*#.G4^&<IYNU\+T_2MUOWSEP07(W+S$L%8YO,X<^X[\MP1ZHE8)R3IB
MJOGP)?(:<E0E),7I["LJ.Q)T%]'JN][R]"?53_>Y1/OF23V2FY">[Q^XG#H2
MIJC^6S)K<W1E2HYV/2K 8[?9Y-Y..?Q-C_(_0ONTID0^OS=%2S)>:-.PQR+N
MP59._&%3?PJ:V7&K]E7K?R*A6/#\YHZER **^695W'ZOJ&;QYL2 J$9,V_=O
MB",[+GUP"]1D!K8=T-\N>&XWL>G8P G]6735ER_*N >;<7C@^M]O )-)8 W/
MW+Z5>PM=87Q.F+$!B2-._3,)V)/E,>%KT$2X,O<DF&_9;S@C8#/R+<0:$BNL
M;'8MEWQSU]A0D+GW:_:+^>:U+].VGHEVQ1$A,TZN%\:D]+]E;2[W$7SMS=G;
MF;>5=&*1@>M*-%1E;6\55UR',[1.61Y5%D?T:-[K:6[[TL&\*#=PV_2!E8Q<
M36:W%18K=J-5#*.DGSI\1S#677R5?\6;^J50XLCUQ)1K6S:EVSUM^)_]A"/X
MF?2.@-<R3,$#F[55_,&D&H'W'(P[U.+)F5ZO$$DZM'@IFG?]V$VRWF@2I:,W
M83U!$$,:>)C@ R?7[]9#&2AQD&+9@\0H5*?N"E:Z\C[?9(95Q+TXGWD0C9$'
M@EPQX87S:,5?5>/6+>.CIZXMCW(]$T5G:T?'1SNW55A/EIUW_/=XR?]UR?[1
M248&+]WU%@;3"WDJ]6RY6@K/=<"7K=J9NOG[)R"LE0]C:PSCS@S:U;-5>34C
M:HGAV^0\SBI-/+BV7^N]54"?$9/4>7->8$+Z2[C>!N34'^8,7X$2C^8]?RZ1
MKTMY^G^Y4>9+XW2"]F]P'UH(6WKK+=@O5]L:)7KP1RFX(MH!_![P\4C9_7Q<
MTTH<#_8Z: ]Y=W3"H%<Z;8V!64P[=GK$:RHLM4/Y'T3EBT9!(,8^!HK6I;M2
MR:!OHQ;Q][U4$).ZB]@-!_\*[ADPW#8@NKI"(W#TU*0(_CCPJY NH0(&6[))
M,6$Q-?9H&D&K9W&E5.*\W;&.*.L!"TN[OGWO*NH31!?L/%\QW\6>;@&LM,>>
ME\5+:KB<<CEE=?Z4U:Y7"1 7%\AVP=\Y" 2RPV &_7_YRO_SQ?Y!)/V_O_#L
M%X,9Y/]YPP#ILE[,5YLU#YNHI( VS"LQ+^;8)6NYE6]X4F ZYB7F=NP%1MKJ
MN3JL1$9-9>TA@[&Q(\-B)Z;QZ@<A4 ?'TR5E;^8M#73]?3[IT_;>GSVQS<7"
MQJFW*E*Y%.5*K>A9'M7-CNRT=*R[]Z6M9WO;7%G9K\L)$Q-:G\8U*]3%DAYF
M0_Z@4C8@DF6$/3Q%D,Q&=-B9]R_=Q4LS)*2&,3CB_M]_SO;^S.TQN*\H9?3X
MG63#<IQE^Y7TN@=?Q/%V]-21!88KB4D9<3[+-L"A!=%+XN_A*2&EJAXC% /-
M4])?#8-%M+7<UR]P6?2?]8-N(Z4#.:_M.19(K[?O^ZM SXN]L"43RJ[1>:4=
M3S2H/>8DEB?7$)?6V]*HFL/(NE_O56@37@8:M,JMP<U)B:$Z#=5NO7@;^H>%
M=0F'?N/$G$2TN9VX=].UPLCP"*.RAYIC_PA"B3R<>J*\IC>4J(S)E+N=Z:H4
M*GF"WB5WV1V3^? "!K [/&MDT3SB?D*VRNB&9MG;MM?O[AZ'D@F;.)T/]BW<
M)BB\!X.GR'%U_-=,5/R(11W>A'W[/2)]/9E^#*L<K"27E[=0.R'#_\)6R[A1
M@!/RJ'TWL+<NUK/4^V?/EJ(+ZD6C@K0[M<J3D6PTY-EDT21Y^\FG@,P/ -H9
M' <F6Z2#>R86$/I MD<[!7<G"GNRNCN'OR>"9T6W8^E<J"EG&_4_G6%]5GNZ
M5FES2Y52@TOGW%U/PUO22X-IC?O8UZ+YRGW+XIZG!BXI"2>&OB*1PD3=\P="
MQ-=3$OUO%5WH#.S->1]25HI_Q_M\]G75.R\)#GG]0354=.XA&-S>*-4'A[X"
M76FGNZ^%B@M[?>@VD=AA<8]6.((Q3\G)^QP<05_MO>Q8E&/PQ#![N)_U.'_'
M7J@\SH:_ZUD9+A'5O02=ZB+M;^S-!_U:8+?H7?$]\R,Z271V-GC""*X*D"]F
M-7$R)PZ I"D1N-_VP=8&*5S5*%)XSAR1_RIGCG%;[MS<9,U,*C40&DVM>OT!
MM 1>1,DW3U90$O%^P5,2"A<7&F&]>$<FR^PBNRRF!'<+?;Y[ZGN]#S"\S#([
M;K= %D-0MB^.)&6R@Z2MHI0\H]KI&Y 1#8XS\#+Q.2Z<EJOW/31$HGG@ *91
MI?<J7H\1&%(5;!#LZ"^F="=50JYV:^^!8_D1%?G(I[\NWQQYP.\C5MI7862I
MR<MQZBEZ1LP4J"@N6[='I.#/RQA)N/F;<CO8TN7DXS;I,_Y&G1#\%GHJJ&O3
MLK2%AP#^LLV:)G<%*;G%X)VGEF(F]@XL1_D2A:TXHS_8AK5F!"DP'$-GG?R)
ME@C,MK[K5X3)=B--]U=GFFUEA9YZ6_G$IIC&#<3[D^B4Q5Z&#2!\'V_)G$S.
M0L"_AV$EYCQR:PMP9M:#5:GQ2K![5>ZPL(5.F,N@\6/C#T9G/!L(7T+4(VO[
MC"B&+_;L3#NQ<IY<#5L</' "EA+Z^M2MUC"%]&:^]@W5/C%OT4?B]!XYW,7,
M!/^6A^6&2479#XE!E.&FXZ),ELG)SYI?Y&G>NEO\LRT-*_Z!6[2D?3F;=N1O
M[DFO>+]L"(\+H'@R'>UZ$<QU-P:21MT]A*G[]F%J%'4/(54UL!0:Y<$QLD9&
M9WM3Z>-NGOVAL34#^!.85SRKOGK;\%<83LV:=P:]057MMRC.JG\Q1$!>7B.T
M^PE-4;> K+/E"0O'LS<@YRKZ\*B(HEG7.H%G\="FU?_^1E0#_&@DA@E5P[71
M;'N6ETA*INEB=="XL.@&3^2>L>>!S/6M2$&7A[K$DIFE>KGC(W;A"'GV49QF
MJ.2QYG;:</R$R87A!\6'(-$9$&=I3M[Z$V:L:"B[)B63T]-J4B5"1TN5F/XY
M8= E]O84W%Q*SR?75COA=+_'4:\?)U4?/Y!X1E#DCZHAV*L)?-7A8*)H"5RR
M .QHSY7][MN+]O@P4%U,%<5; TNM=I/B0=**H:6RH41IT,\5=+_.AW7[D=S*
M4VT'+QT(TK/(AY,+,GX_VX"P9+D&0=E4TLJZ96N=R40YW;9:F;P;W4DGRU:M
M67PK]=-^\FIL: /2$JWI)N^![QV&<\6*0RQ:3L^F?X7VP4793+I.2\--)@TA
MPBXCEX+W1L_D>&6=]O1R1E'-+1K&2V/:"L642F,2QT8\O2?=/<8ZKVIY1I2Q
MTGQC<;60.]/_PQ$.V4KI3KA[^:488S3#][E(RE1^D/[H<LY6YY\MQFN= Z'%
M7N&G^T/MF$?*!T)'6?K R)@=YJ:1 &5"]HLW](FECSKL>\++B?/2BK6OL/XR
MO[,N:'>!K.T9XS'&FS.2SD\OC<P\\IV6U=,=;]OOZ(31T8HLF:][DV%CO>>9
MO\.U1_KVO47F;XQZH^>M9;5VGKGME!T]YCOV2+.?W%Z'9F4!2HR?'1?[2TU$
MD5+CN#OS@6'V.DUKJW$:Z-T7+^!(;7=V/]R B%Q%0*M2CG5)@@'-JP3]&N!K
MA:5Z?43@M-[VL;]ZW./\3Q_/\M4!$W(,A>="#X;&U65DQ?-WV_I'E$FO/RF=
MX[@YB6_%A6U %.+#.K7Y'6=C0T[^I50K(#HT)A4E+3SYB@93J9QCLY:TM1=S
ME-VEPFF-F@/=&29$DBMQ5\'EAS#9 4_HMF&;PKE#]ZEGTX(_C%JG_/H5@29C
MA\A3QK4C X7A+\$/Y_I,&@YSS>W&+=MS]>O?]UZ6]U9I5*HA&8_DV.8O^'*;
M[\@R@FX;R;#MKYSRW)=]@;PR<I04_>"UF4-1W 6E6T4.[&8&L/O&,[CE,_/S
M_OKQAB:RL)"=@RYOVD*?Y[L[.+^&S9SYB^Q1+U0Z5VK35#_28%X=XGS@XQ5V
MH:YKL_6S.V"<<YZ>G7+\(S6ETK,&S?29,PWN*+&YMHR=7@"U!78WUX)=77M_
MD2\WT52,(8L6#E!,).3P&NFTV[FR@!MG?")5/GKE:+UE@;O7W,F%<[UA[C[
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MAF[7P>MK]:\<FQBNMPNY#OS/ P<HM(5D#19"#5AGO:[N81$D@]T:=_667:7
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MCEQUWND]<Q[7BF[X%6N7-4KV^*!4</>;U0SJ4=MP2H/TQM=THD3^_)W;U:_
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M$-NI-.//H%!EK<#(M Y^R&]R=7A<</D;$1)>GA=BM<W8.,K1Z>AOC?'GR0D
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MM8EJHB*794.T!>JZ4*KXX+ ;QCEL _EV*!ITY'E"+T#DRQL7&\Y9=")-B2Z
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M$*H^^IX6L_;'QVU9&^OMVV$*++@P$RRSE5M!#6/86U@=I:-\%X#K0J6_,2;
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M,._XH@L-Q"B_LVOK[2<EXA+#OE2S2=)HBN%!S'O#X_H[?A>=C-V\1B?K>$;
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M7A;U2O7E)("=?B?#$ET4##M<2KALJWP_5%,')4CW02$R)TAVJI?H*<9127;
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M+>]"3S<";W<1#=KZ9AC_$.VC@BO:'V5:HX)\[3,M_\#H0?ME6U42.BY#:4)
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MB &IC_>8J7&P*KI\%<E,DX-=[X<EC7]?FE7"N\%&K.XQ$<VP4Z09O4H N7A
MMV)*)DUW)L+"\N.X9XE:I1&CUN14A[P_(2#L1FS_H%3]WZ.CO%3L6!7RF4]F
M+#NYR(B/V1[1.+H9&JD;A7"<&]L:@%FQ:7H5P:?S>I'-<R@Q6D3-W-M<D1I5
M"KG419*PS()VC#&?M(6J_8F0R6VW>[?Y\K^YV\B4^5EHLY0BV1Z+6CNE4@O7
MEF":Q!T@G).UY\U9R!.H$>E34^RTS"31J4NP4)43#25WD'6)^E63HWM 4_IC
M"'4(BH[7D@O7VN^PKXJE&0I>T2=)=OG6![^]:L:M);=OM(]$9@1I0R_$0D&F
M!XA-)[J H1R\$3LB,@%WNWE;2CDQ"JSCT*BZI ^J:S\&#NV&RA=QR<WP5.)%
MJ[G"2%P&SNB=F+IV*#/>9J[M8#SJIH9*C*P,W"2__JM \5ARDW)-S=C-W\PV
MT8;(TD>3MD6C?\=-6DK/LW-IPUCE:IK,4OF:#9Q"0=L<9CP!Z@FH, HD2YKD
M^AA-,G*44">QX$9O))P.0\<";M(L<#S-\Q#@D\&<^57 ZCIH</?WQ0O-U@]R
MPATC<*6^\3>N*0^23_?]KY&,96#33"0PVQ&TAPTMBQ5K.I\4AV,<(11G3V.A
MF*I/B+]L9W)Q,.A%W]R;CZW[Z>&[\8+ =^?"MSX5FG?H+8<M_]=T7,+F1J>S
MU]"5&UV P7;,:M"+FD$,%;$I5ZD&T!L_X&VS^T+:-PF?X5\0_900S*5X,&X%
M/YR53T1]NW(WK?5+7$BR]/Z#35C8-W/S\TV*$I)IM^7*BY;KC7PRS1](*T.C
MGI7L[?.^WJ7CFZ;QBK69> -R!6N1J:>(UB"=<L<<J)BQ!R[RN9'G0FO\LTS!
M5I>XU<]:H]QP]8=8V6<+;:P>Y'_[>//RYG1?-U@B/V+0.O+2X#..OL2_8S#&
M_Y\?_IU_!'NBK[AOO?+*:L>.V S7#(MK:]X9[=YI\;A533+8234E6M0#(0O)
M)",5(NIL 7VRB/O'(LOZE)MX8]X]\TB#B('\O=2$AT1+\:$^J]-?/G_NNV[/
M[&3H1*=:WN,>638[YX,089&0:]=.52K2A[!^ T^F9\8'YFAKH9ICX-;\0]\,
MG-+*$S'1V&E@)*\Q>S+!#8]^M,VPL+5LYA>X_!R4_@DE@_ZBNE3T_CHYJE>Y
M,:(7#W5W!.D.;((HE5"->RH2<B=Z/";XN+7QS0'6@^I7.YXV]Q?)3B5]VWY[
MH''4G5&#OOE!H^>,SRL:;!Z>[2/44>Y1/<YZY79"0N=B],U8FC;A.L<%6()Q
M"G!KAH>%A.271>M YCOQ%'EXL:BX<CA\P7%>20TQ>?>@X-/9 Y%QUS$?0S2F
M'&$_6Z2-2[![6F*JS/#7<I/)CX!SHAG^+AOPB1XN:2?7HSJB*4IU%A0OH64B
M=95H0KT!@+@IAV,I<U7C/:QUD:.ZH"IQ,6=\N)B=?78C\..,WKG*.9FE96AN
MPHR_SX!5E'54[K+X^/ %X31/=ECNH*"SEA&M%"4LG9%)!!Y.LH9.O^DDF0:>
M[[FFB.AP2LT5R(X,6NDF_#7-I.MY-K;UVD>>K;U\+D/Y6O3[B^?);_)/.L:G
M+J]UTLL]W26*N+@/C4$@,E^ZZ!PGO+5!F*#=T09F.JEW1B+L=E]M%XM2:T[K
MI(2?JZG^(Z<,$[3&M]P?O[OKPMS5M?H!PZB.L6?/Y?5%.V^#D)5IB.<&-U3G
M^:=W"[CG &CR(<FQ2)?I=Z4BK0BN;W2ZH-C#=>3KXXQII_<(WJ\Q&1/YCM[-
MH :WS@@*?9EOTBDXZU(#5?@T]%R;0%UPO><4TL+*-22.'SJ?%F#0I7X,-A>$
M!-73Q6T(=Q"9.N]O<O7@@/7I!;=^QG#:MR>HF:W=>3&1,3IA7]+_V>1X;_6*
MZW6K%?3BI.BA'^)U^8:AJ^&4ARMZ7/?4D#O\'VF]KK?<_OOJ=C6S9W6/)=G[
M[@:GZ^[[<,XLRTO']7'US6KGF\MO(O]7@21)WLPY%6 Y0 ]EUDH^WE")@)*E
MA":R2E>NP?Y.I=(:M5/ ;3^Z]M83J.+9-*4F#O@R^J-=N0$8N-\4+<)I#@5!
M4A.]LZ!&AEG4<=GI[$@ZPLTQJ-"\JQA<R,:.U;.9/AP9.8,-MX].0L+L4=FT
MAB,IH$2"X!UCJ'R4Z,J$?,786\+EK/5$&-1)KB!:OFCFEX%:%9THG:\TA@%5
M-!P"NGV"KA[M;T553B[$!(8WOTNA5WRKX&*'*&.NJB"VX/Z:=*S-B$9 SXDF
M4":PW'_DHILLTZE;Q98,+L\Y"=-(ZNR>3L$$0N"3_@WM4&+_(W#([7K5A6?^
M >T;&ZQHN]V68"OR59!-#H#4.FA:*'+HB(,'4'<;K=(PH]R((%LHJS)RL:M!
M7*"E=Q0\7)>%#HP33[1Z281KH1P7@)>*QM9"3EWY[UM$[IX<5?=(T^-+WI2'
M-<<RGZN/<W'0CHKI%(#BWPB,=V(W0%/MCB4?"::+B]]E8W$\:[=VP4'Y@8:>
M.K23:1EHY@)=K9*CFWQ/MI4+@C[1]!1Y[FT/Z?:KZ;5;<NWF:=FTQKKI&MEN
M*"$(C)M9#;+;\1IH2Q%M(R%4Q&**\6D.#JR-'Z*(T1(3&*&"D[_B1IOBOC=B
MT)%"69BDQU1TQP:'1*T<E*;TE^;F'8.K3-WN:Y:M(EE"V6&72^G1:QU1-S>E
M;M<_G[T=(:Z[^?AL</:NZKM6^):S?2MTY#>CQ&QG\IB$;NP*(MI1D 69(G<I
M#;^AO*7B).U^*G;7A@SXP&S#\+U[F'2ST_UR?'A5N",KCZS5F5U6'F%P[TUX
MXKGX%0--UWM?K>2>/FRV&09UBV;E)J#,F,"6ROI4U :_CH@M:,?6SQ59#Q#5
M1'7#%MZ@].$2;-6[@;I27)6_/T'(-37(<6W,/*1R'_\:2\*UZ'6N8J>1@[W=
MIYX-,*,<!5UNE=/8<F&JD!D]/0]FOE2N@O* !G%J.J@F6H)QJ:M4JJY(':2D
M6,?2@SE*<X#&>7<B;'1W/V/D>/>)>R.#1_I7/XO<'V1]<%&\/\>=T?I]VVXE
M6MF[! ,.8:%MHZID+!J<T1O[5?=[K#9=@C<F=$RU!VWJU::8-W6HZ(HN(?D0
MNPU(F6-K/PYOU1059.$#>X*!^_E?DD4MEIF:*ICX& $></Y<K,=7>9ZZ_'0_
M2T5PVRW((2C(W<[) L*%D?:&>ROM@%+Z$QS0\>V--!UZMK([E64YX4VZU-B8
M?VWX V'<I<G(G*$%EV]U=$B-6G'CP4>-F;9!'CO%P"]P@'E5'%_"O\0R^BI$
M?+NLD2KW,7,%?G#U OPGC("F3)>$A^;-^;W7HK2WX[E[6]2"PO=.@@UAD]@-
MI(WA#JQ-_#KY 2M$$6*0J"&B_[&YF)!]+H1./'&O [5BZ,G3<%T.H9F;7YCQ
M*B[8_%UNSK@>/2#\S=HOV,/UK/J^Z9E8D[W?!T_Q9^FBUF>L^N<9W]Y_[Q7;
MYXY.#DQJW-/,C!=?R]T@BLLX.Q2XX<&MO95JWQ.D/W\M,E)V8 %<]#*BVP#)
M6N[_81Z;&;2R-]:-"E>^7XSM6PSMI*8M?GXPUDN_1ELSX=AV9WG@SBF?X,BK
MDDT-T/F.T>'3+;+85_PO3=A"+."&@AP1TKV*-CZ7M0Z:*S)2W&'MF6!M[;6C
MKH107:-8*M</U9F)U0W$^X=-C#DG,K34_=GK_;JCHRHF1PT*<+(+>3=2:7NI
M-B4FG_X<DG5W1@]QQA S6!5H=D,5P*S*) [ L,0GZ5=)]$-$;(:UFAAWVPYG
MX!=>5Z/L)^O9M1U<<,GQ;GC1#$AK8BH^N5^R+]1.=/).,31.^%BHDP=)?LV>
M"F4O([?O((^5XAD^G"B] ]#5,>J0K9NB@7P>FQ&DAS,D[,4;$83MF+6]Q) Q
M9,:"!]$8RHP-KH%^'!Z\IH4X"VX:(.[-9PP4[8<22@BI^R6M_:UF$=/+E'FG
M5:3*4[O I@Z57N&.0:;N +-]ASE!5I]HVA<>SO#QD>1I+.-G5]B(=O*_2[".
MHRUN>_]$K(V.P!J1C"90XJ/S\'7OU C'\<M<Q# [N.Y;JPM089P6-4G?3\O4
MJTTYU%RTO30*/6)SMX74>.UC?V$"=@U4PR'M![HIK>%C(W''0>SM5M_'$T5F
M0'?:G--'>VOCH ^Q-?MBM2Q\>IF:/O=&%W!]ERYO:F:\2'+-"#,_II/QE+X(
M^^$ <8 9E#\NZH8'@:;[.W2HAWR.D'8+7#-^!+?N0'%\R;'=AK2CL<V.8W]"
M\8:*A_,A+>K+Y%]4$72*/#8!_]@DW? 4R$V6H=U$^&&\N(LI%JXGD+M,=0 D
M=SL:6T+<R0 P]/!2Z"8TY:]L'[P\8Z\XHO0?AJ\-N[[HK_FC;-*Q\-U,8^'*
MAWWLBDFEMRK,51KX. VRF)V94*6+7J"!Q"<WP#G8C82B66F6XBES/\9L8G$7
M0.[<$&N,$N1(3'-"G%58@UMUK!AJ\4L:/)$ZVF%M&]#/M-[NYR?X[5*CWW#\
M;\@JY--QN4&"5%/12C(B1';2-)6VD+\[E',5"#X##8*:8UI?:DR;P&"1*X5H
M<RZYZP.AY" PA^ 'O!*U3 2G&Y],]:=?[!K']3$4SL7L#'N%6A]FGXI+/@)7
MOEM(WY:*U PW51]D#N#AA,=70\J(QUB)3NUY.W,7K>J#3(*^.V2X1>J_:.Z]
M^2/V+[NO1_]<@FUF R>[DYKQTV4J-Y="AV48AQ2E/H3"0;&_'AQZ ; [_/*2
MB$XBH<84;1VB@XR,$C.QZ^B,2#<$Z,JU-C[ +TD2=AGE!T22=@&''+6;R#'.
MPN$@-J,9]L.2>@>O38\U;MN92#K#?@JE/";N;+X91MKRYV%)M\[$]1L#U,>K
M2WJ#5INU\&,UW5('MCR8LW39D;3@V?0B(RSX>@&8+!JMJ_SJ=Y)6]T;5O^EH
M+PEN9=C3O12QX<KQ=))I[>-1&_Z=0:,3I_S*[S=[_723O8J:&\']HW:TE6W[
MF_E<\__U)='R_8^S"65)%XYMR7?(./OOJ8FM?^QP=3VRTM?DF+?WBEU;UQVH
MNT_4EYE#MAVC6P EO9IU5USHP#'2S@E]'"Z@I%K]WO)L<"[\VF<^LR#QN--#
M(TV3G8-'ZZ/T#J>.;.EE[F=:'Q^=>MM&R)O:N5T-T&B_"KWO5FJZ +*.&[Q.
M5)JI T!.91DK^T#(M4-IV_]Y8%J^6?K.:8SY;E;JI?C\=]P/YIL3H,$+%NL[
M_9#WUW_N6I.68#Z2]VWJJ33 FWU3-WR0A*!YY8AX,[\+.AOO)H!;)'@F\J-P
MI8$%N+(IO<X&#0^K'?86*M>U1+J&;HY6*S^F2/W_'"63*Z$KBW>034NPF1>8
MO'"M;Q7(Z1G9%O>RH<!/S"SZ_%R<D/&0T5@T=^!*5-0WFP>;\E6:3ZO9]I_-
M]RMR7R(?V1>43SD>J<^[%[986U#-JYA$Y!^6330--+T*KI[HC7=,?4@8J'_=
M*$BY(VQNK?^K[!V#MK7'+";H?]#U[M%0K?'_^)1*$>,20DPER7626[G,U'$B
MQ!0BQ%2.&)/F=)"1,5.Y$RKAQ&&26ZZ3NUQF,(-3DCM%S*T4DKTK8Q]FQF_Z
MK-_ZK<]:W^_OCSUK[;W7?O:>Y_U^7N_7Z[F\'RP/DYI%.@H=B $)?/D4>%(D
M7!8RF&$5'@<8"9$Q!"7=G%8CCA5='>BKJRQ/-.XX==.2=NS+NDKO!]\C$]_*
M&G<8.K8JTCXZ+O_:V4X1\MNP)&V!UB515)J%?$_HH2B05=\3^WL"C"!"$#>:
M$=*)Y'WN70YD!6A/(GB(+L+NV/:^.3BXO;FJI#RE"9UL.0+E])\'ODP@L=C1
M#DQ08/!QZ>5+ =; N-BF$PK3FN6"Y *N/[HO]Y:CPZ1[#QH>FE<C3@OZ*V]C
M88G[W[>/X^8#_U*=XCRSO%I2S=M;ZU)'B7J/5M?2;)&E4-(I(*>49ZS*[$49
MM$R:",VX,X-N;]E^X'9:TK,F:L#+D<97UUP&G>4T-)?T(YW"#F0;!;:WQ.2D
M7[O?\CT3^"&620*"N;E]Z(3 'D93E/!0@(Q$YWV]P$VWQT!5H!K/NP^I23*%
M^D%[GMY]H7&%'A,I1Y3FP5.%6C3B &L]E+W8C)!>[2Z;)58._<8(T^E'&5P
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M4S=KKH/X87BYVZAXP=IPOIA'F"YG/:5<)2$A/V#T79PX"Y3MGRZ_OYI>BW)
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MIF'-CUP;,W;SK0:.[:9I%00??WV"?"'GRN>T?G[=OM<9:G*N :6A_SS\Y[_
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MYY\4G%J_IW^U\,CG>V?F$T-&+UY+F3Q3FGH:ON_AO_$EDN.8]:/JDF./=EI
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M3X1QS!AP:@:D[T>ZF@PQQ1I6>=]#O1$LKY<2J+TO>4DA\:^U/FLR;4-:/*Z
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MQG'VH@8A[3KY$#K)I#RE(]B(O'_DIYT4LZ59(1,.4<\^.@EGPU,UKJ57"ZW
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M=VPNA?6O;YYJ%ZKJ'U"1A<\WU)?T<$\\^MYC>Z@VZ4Q/=WC1Y;Z@RB"=$?_
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MV1D135DSJ<NZFB1:AFD/?U8WZ-2"8EQ 0\6C(MRB0V9.*899_-J]"/BT.>
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M[4>/)3L3<TO>:MAC-QCL_]_+?24[MI\3XF1QMH_N: ?@N-G45LXF_Y/A-M^
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M!SU1J$E!/;%J"R5M&:9MA]8FJ',SE]I:-8);%)N!VGS1#);'4M)X#<QG@L-
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M?4_''A'/2L2C:7=6#!".2NKEN8[18E0R<@O ;\&J8X:)>Y*:^486?<5]YVL
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M"V>@(A!$=!9#\+H)HWL6MW4T2#A1\YCZ6F)28TUOYVC=5Q6SD/9RN,)*.A.
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MHN6T_I_6*EM6/'L)\&XGY^R48@6SO$.=CP\?0\D1&^7'QFM0C^[!'Q&H$B8
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M"243_R*L4<@05NHT"068%O<17LA6'K"(<"W@ ,A(JO<F/8'U)1?Q>MBX"U"
M>!W&\#OI>^R0IS]#7,,K:6>9P3$*TX!.\[@=EQU=^SY^+[>\\3OF+R)XF"7@
MRH_FR!,14-@_>E#=@ZD8C^#H Z)BJV6]]-6CZ8@[;^NE6X[.>DW(%'O#S1&Z
MR'R>G/*^X_K9RH;8 SV5'KO'>8:C8"#9/3'I[GDH=*AQ(9-*\U,]Q(ON(9UT
MY>B0!3^42[5$23>C00W*CT'L=*PW4H31W!!+K5T^+R:[:]P\,2E+^I=L1O]5
MJ:M#^QS;Z?;%E76WC#!KO:K'.2!!@^K?VNP^^5K",*+SA"_=4I2^DOS=B@#(
M+:5*./!:-,PJ@]./]$X&_?#[Z#I$/ ">;GE0,N:>*&T8FIE\$!5U(>:\S(/W
M<F]S1Q.FVE1IV"/?#Y=*, ,Z/*2G"-'VYXC#DMASU1_5AK 0ZG;XCQ)5R4DR
M^@JE*<B_BK,)IZ\ C;LZZPTMD\HC8\O@+&[0A("0;D8]WIK<-PNFM^MK'T#7
M]:CUM!3S5ZT%N.?4;]]7'8[!RQQ 4G[UU8U_TTC9)V]46'FWN4S!5,P$XK>\
M:A6K (FWTAS)Y>YR1%#%4X!&=]N=V<[]#G+[["T'3V7NT:!.<ZZ=NV5]]>W7
M<9%?6>;CC2]OF2W>OJ*'(QXD@OLYL^N!_@H-RC!,1-&@UE?.0<026DL5C^#$
M#_PI@M(;GT!4"@[^NS\>P2NWDM6Z? UJ-UIA DC6*1<A[3!AP)?X2B.6^@9&
MODZ#X@7"%DCF.:*HK):I-"01O0F"O5)N#7,9@$C/ >N6"GC#D]?@/PGRUV#2
M59>MQ=XZAZH(>K0C7=;I_E??CH<]WU/Z=%1"\FN9_$18 =PNI?\ZK8Y3':AP
M;B$,A"X2J#AI;VM4G*J\ S1_\L9/P=2[[';%CL8OU+3ABX&E,VUN8W_N<>->
MO/%W,$?U@B/*%+XD-@,F]&;!2)-P(%UN"P<^H)FH7M ,(8IT-3,*U!<#2?X2
M5M/[K0A6\H1ZH32GHQ>=Y]D6I1;VU0=*A+KCF]7FT$KW19_[KLW_)VTV(^E>
MD>Q_T>?@'H""[]?:TU.I6LV5#ZANK2KOGBB].+[FL^J)VC"DW;+PMN%@L$U.
M3,&6@LFQG4DV :_J"LAW_UIFE^T=F,\FJ0KK$74RKU15&DFS)4'!\GY5?B%A
MSA@3O$F-KK=5$&E.8,_1\<W?!$/]XZ;Z1=3.ULM1CX<#!X?ZX\IMJY-.X\YN
M;)%9Q"&A8B! HB,:@<,$=3,33L=K 3\366E ) !;MTYD0#'[57<G<4O5[<)R
MG:9@X#J I&@C)@-C[,Q"$ AA<K9I-533Y*SM*[&@F-(VWY)N _<=1!J2<XP<
MA-6]/SZE02V8+':M/!BQ=MKVY9^(9'WIU8P9\)>?Z5.O(<(5:GU]4%\JSX#<
M@M.;+\! "Q-!O5-XW=7)DMXNY5;QW2J%1_ ;-X%5<:PM/PEK?W_4J)_X?G7^
MER"?XM:S.3]BEG 0*P2"^'YG->."?"<RREFPJP;UOA )>VXU1Y0/?$<HK3Q,
MO:KCC5!]/%R#2HY$D@$)603Y3W0H=S&O<91-G=JM2BQ:CC3OT2?533QDHUX$
M?",15ZGY0@O$8@F IE C,/D:1U1"K,"\^0OK(<6@J<(C=9VX=?0.W&]YO)B"
M19!VJJ1CT?8HJP;I.&%B/,XNN/-^_4U9"+OO%C9 __/]CEXB*&/!=D25&7XB
M4(-*J0 1[?-7$ S($<<6OX/>*C1C&RE=P-8FYX$*^7)XI23$6LY4Y=)B2Z@Y
M!V%CL*C17D+44N+A&G&'"?Q-7,4N%$_-]XPM#J'M!)_<>0:'XA=](/I 2V.F
M1X.>;69>B+JZ #@UE<&9BPCC@S!7VI$.@/Z<?K[D+,;D%#A9_%25)V?"OV>Y
MI=1O$F/T8"O^D9P]M7W/*\<WQ3ZBGK OV&K!M2H(\]V\IDQ28SH=I_I?Y3M%
MK=M_1?WFOS'0.G>5D:HB_.^LS +CA,8<#'B0<94^OR>IJ&B,WZW$J1![$582
MXG,HSN+ R[Z+_4Z3KC(OWG;'LU4>F[L5D?<VO]Q[(KS,]M;0\*8Q=V?9J$*7
M%+0_[\F0>AC_LN#UA>.G*21<Q;-?199V%SWSF>=C(21F;&W>;#)W\O/M=GS_
M1*FCLH6R=MBF"9VB05$Z?D5YEF*;$D6\SIP#G,'T9XF$S1Y$2<T;ENEHP1K*
M54"_WNYRC!B#<)@Y30M"2\*2ST[5VXD2^9/^S7BTTD."UA>2Y&.SEQZ%E;8]
M&4]TB1UL856<10*/"/K*_ 1;95OE2U4I519;;L0[M#L/I(L\ABJ?V(?J[HQ9
M3%VUY_$&W^5_ME5]:#M)'31XCM+9]?\0S%[VDLU7!",.S8QM.4S[#28JKM"Y
M=:MK);$JIS[).$^X'&<./["MKNXM=5U0>K'!>0=\Y]&03_&QX8'!1JN?GSV7
MWIJ7^&3#S5E+\0/)_,Z+#R0EI28_>,23-\9^T"VKZRLZ)YT-?-H*!XE#PE!N
M^+N =SYY[:D;;ITZFZ:DJSAXT9_,EX16QH"_A-$(#'R3GU*ELG64YZ$A5A*#
MRTCA@/?5IO#6 Z ,P93Z*#'%9-QT]DPM(H;F>TI>V_.W=U7I>]5V=N0O&4ZL
M#9?9WBV9&6S"K0*%J2[AYV@;)!Y://F1^1=+\CVYN0U)5<=-'IQ>Z!!]YD=0
M=#-OPR=NK7GP9<NPU%.>-N17I[2*?I6)GHY1ZSM* K'.BE6!H4"3E\*#NG?X
MFT087SFJW*78/99+2<9N*23@F)+ REB.-MP:9$A"W-\U[09*H4\1]<F(7Q?+
M18ANE9SNK/(!%G<4KKOGI33*D5 F@D4$LS% 6[V8+B!6,%L[T@"SB_G.K>Y%
M\6KS" !-"X,,G(V_FML._>#Y>@;"A:*4^Q">QUS O7PAVCEQAI)N<@%NW5ON
MO9(#[:Z-*7Y;3N>.FV]F2"PW3^WF?\]W.];M+ EW_EYZHH7OWT/YG=*P:"AC
MPE_PB2=L7M[E;C5&9H!N3?A$S,+Y(I@,MHJGN(U/+?G2-\/ZH/!ZXK=SCG5@
MN/DYICSK5?;?@Q\D!/]M:+A$C%]"_2%F,NJ-D#''C./U:/X2X8)Q]?).W&KJ
M>:[O1ZRGR#$@L.><BP)O\G6S.>_\:(#[AX1UXT]'4Y_N<KS?4'/M2]I.OXR?
MQH^!QN68_:H_S^)/+N-$<(R\0<%/]4H2QBBZG7(-F)_7HD&9TC#0.;XOQN@T
ME)..]7P(Y_&(8 WV=(D@ K?B(]V--%M5D^[DZG%NM"S2Z>2+KBQ?5>7#JWA=
MO.@Y$21,]5=C!F*E1)FM\P0?1/!"G@ 69(%1E9@,]YRD2 K;9B"$BF_%&V"=
MQ:4[J<\B!;=SL[,>] N.!@^W._Q]_)K)D3]-%G&!?[>EI@_ADL"I=.9"]G)U
M$W,)S5[*60['--&MX=IBJE$C<6%E9(3*T;D^2M(+WQ%E^*@-A>AMC;F*P^0U
MMOF163KM?G^_NW]SVNO_BPMW)Q!I  #_--7C$0A/5Q@!XWMI.!9B]^_>X4Q@
MA;-1KB(A2!3^7,]";-F 1,T3SG8ST27#P)?3% 7:37W/%T7S^/]WB+S*WRKF
M7'/)N-+#FR4F?L];1&\E]%:6^.X7:"T%CY+-;^>V%,Z=?]S0+?=V3XC/IMUA
M0RYO7S[W:[.X]''_MP,O>J2!K*GG$R<NRV2W@MO_BGP4FU?;W=<W%!JVBS1Y
M[E3F\/"*?5G[1Q=&=&\L1BFMNY2Z86(A[,B\ICQ,60J]EW"2\56Z]SC)ZUQ>
M7U(X,4 "96"FA/R;T\R?FY5-DY)_=ES>\3A@:A?]**S8QO\NA->:3A0^CW#W
MD&7>?*YT4Y5QRF?LU?941G.UH.CF0]K2319$5$3VD5GGJR8KZ"<?'AO2G]9K
MK[F%]W^*^G<+58H^MA[LK4'9+U%5<";BZ:WXV8NJ1T^UIH+6/+SZVU>:*0G-
M8+%7+KK0S(@#Q![X)F=Q&\WK:9LH/39DZQ'.QY[ EV#>GHLE1*-/[71YC$!Y
M4%_1L%'PKBE@?1#O4?G#_UF@Q6&$(^"J?6ND!%6*^X@ZQ?B[+>V'XBC05JU$
M\J=<YQ@BB.=>]9AL5V-E^'$!6K7T3GR!'GC]ROODE)-@2Z+5ZT)VA5-^26OA
MP)-'IYU3\D_Q3]6\/GJ]R[OD[8,9G8!%%YMS_9J%EV9RE)<% +\2,VOOX' (
M(B15^H35?YQ187RK/%>0IEPMCBXV*Q.5WYX['=_B,)@7Z[TC_F1MP9ICZVZM
M_1/-Z[@QC*KMP8O*\2\Q/+>>>I_EB*%+8Z\;U2T>_MJNDU3FRYHHE]@<=1FB
MJ!?G>TPY/3*Y41I!NU"ZCG[L7=TIJT 389WKS\.*W=2MAWHT*-$#X(7SC;!N
M[!:#G%(E >XX&58B@!^UU!38U&4+Y:'0;-M\A'VGWH+[[Y+RSLS]X7VD]Y_@
MV!T3N"YJU6S)MOET.F(6WAV*[E!X324",X^PIXGW#_^[-1[ZM?]:OBW@KC)"
M@[JU!0I3MS$9^!F3C^0>A[_5KD#;<AAQF*<Z6IFSZ1&5<_!(IOVTX>AS)O*I
M=AK4P=*-#2;_F_607Q=]+=!(Y)Q!PVL 6;1B"XT"&RFVP@DB%^8B;,R#YG/L
MA:_YN!7*37"M9- !K3\6X$_%?9/X5GTH%UO$;0V!$S#)DV6._+W@)U.UV8LZ
M\$MY:6M8282;EKPL#?5-@[H^&Y;J0DAD+KI(618X6@>D5S)0,'X?Y)N4<7GU
M@\='X30N5Q#]I(I4*'R_=,GP:)_@=L#Z@9"V><X7SMW\N\MZR\&O_]'4@+<:
M5 T@<RM6(^#VDMA"$?CO FV(1E7,Q-G5Z7&/8&U@<5'B"FAWB01M2HUM,C^7
MAT_YIV?F5)>8+%R\W:6FM"CD>13O3?.W<P?0"(#'7U.W%SBI'LP0^SG-=*T>
MUT4G><2*'[)2T%HB+SE+BXH5E^KLAZ/O4Z]]AE-91&I<E8^C?O-L=?[#W3?#
M^ZYD9!85"U3/?BBT?W,Z=\X2D9 .D!X&7M=W%W3F<BS7 :('F I..OX,)1U?
M(2\&)103V$T,I'Y'\',K-W<$881T*PL(2,/:0M9<NG.GRY2>EU5Z6)@(;4YB
MV_9$O\?O^SA1Q4 W/+D3^?S],]*?OM_W%R-B+DJ5_CU.[P?/C6T/M?:[#$ZE
ME #S:[@=AD-C<OHR^#1HP156%G"@)7':?;K13]48(<T.2KX>S4)3K_<#O+$?
M/,'NFY1PY\\%#G^@>_8J?ZUMO*._TZ"JBV1A(%\TA>#^Z1PX^AG5OQ$P86,0
MUY,J(IA0OX7 ,<]A?BB(T!@*3FX\XW&.NY?=->.\@.K70X (*<KMXI 3DUQ%
MS*$:<*8Y+V0X7%X7-U7Z:^=W? &LSQ6"OAK4#2)XD)#(0=..2QCZM U@]0.)
M/F:NTKOJ%1SP=/Q6_[C[YMO[9GE][%4]8E#Y8OQ Q)_PHUVXE=VK*S)/)UUV
M*IV4R=C>JFPD%QOP>NSU-%L(G:FV1]10:)[$PUD2EDK3$?LZRXG,8ZH2FCU$
MV09Z<4LQ$@8/2 7TE0?%4PNHN)%C(+$)8T ^T@<81^M^][D(3J70.QZ,3I.#
MV(4GB_;,48SJ_L4U?'6T[X+YLFR3L-0S FQSZM!!P7I%_*95FYSTU][:=HNS
M@G8!F8XBU>WO4P;T;D%-DZ6.9*05$2<#%2)'#:HU_Q"L_\;\UV%A]"ST-:P'
M9$'H=,&;C4&#VT\CP$LP_AK$ES\I?Q+XU;>H[9E3SM.(V;+4XM'-B$-L 6#[
MF@2<%N)KC\+7( MQT0VL&S@B'7E#R-2@*G4RS\W\=B:]%;- N0ET$^LDJ==%
M7#G<<4TF<SI7[UTVMIXL>X1POT#8WQ[I491O5O?M^IHYLP Q&0"#F?U%\GA5
MA5)'X1'.G(-%/X0EW]Z$;H6^E+ &(^CV8$?RE^XS$/YJ&6)GXXCOH,?E7]L>
M",BFNY0^DHZ%AE#ZFVQ]J]=@VE':SK K(VK$(#7&J(T0L8@TQD%$&?@AO\K_
M/D1N)AKGR>,_8F/ *9X&M:B*>16CSS90+NG6H,+1AO 7#:K)//MFW'-J]C<>
M9B'64RPTA3V]4T8O\4,QO;Z3I<6C,1OR#&?0S4S803@!@!>"K,P@&Z&)*[#T
MO8219+7D!:+$Z:;C]!4?JR)]))S&04JF&A/IN/*6A4]E.4R)MBI^)G 4C$U'
M.*R^=G\T]TOEP[:K^'TNP;$EOACO*O9B1UGUW>,4:G7%4$BP8^_F<J\_'"<I
MJ0VOKNXK6U4 YA6?'+1MW%C1ET\_2.: 1S2HJ_0Y?/5&.+9UUBUSJHJ2*#2M
MCQ,=56X!F6_HO\%94C.UI7(=3 ([) $\YHUA%_ S*[ERD*E'Q8C5.="FW023
M,?O5Q8L>=9!.%FTN+O6)*@R:->6BX;64B2((D$[>4>"H5B.22P]*J>FMN+7P
M:3$AY9MR(V19TT@PI>T &4VE^E+Z P3+%RD/A ]NZYUI9R7B5E1 3_+.WDB]
M\&37!:/V^7!\MT@K3U6$/Z&B2$UEGQ4V-'I/*9;@=DWI"#+D)3 >>GVT1[V6
MFL[="%.:A$;8^8]&0Q<0Y\%76HGE<1A>4%_#YEJ38BE^OB"0^JQ/WW>=D&PH
MZ"?%"[L 40X3A044CO1&8<7(&W2:N2LGN9X"]NR"Z(QG7_L$,YRTE2^JZN&;
M4D?R]A1JO&!,[G%D-R@O+O1Q[0GYM/_,K9UU=\ING23&_4_JP2#:NAJ8B($V
M26IDEQ58=2='[^+@^#A'1]V!J<YIHIB.U27S!J?0H^;SIYK1U_O,G9OV7"0:
MA/H\&\T]_(4E#71NJ9%:ZC0%%;".4\C'<2]J^DQ,-GMYJG4-%5N4YU0Y^#,A
M%'% "W$^B6DP\7TJY4<6S0&DU7#THC6H%',"]S4P'[;;?00ND1+CATW!Y*O*
M&,E@ARD)M_9U#^V@-D/%B185TQPHDO3:Z-?!KTHUJ$/_56DZ0*_5>DQ%M#):
ME16-UPLG:@'B0%+ %<+$9\4!==_PQEZU_5=W=D,1M:<)X:Q_B L?,T6L1/Y>
M"),TZ G9\<[ J:MIAZ:>=X@5(9:KJSJG<B4'[EM]1E#E7$U-GEIW2K'3QV6Q
MKVUUGFB+XS_99O_$7K:0U%Q;W*;E7IZVXT8 [?0QK:MD$>O?5"BH06Y"4-5_
M!Q:K.SC+.*>%!FH$XFOL,MBKJ25->+WH$'P 3%&L4^Z A%R+NZZ^Q#=$PZ*7
M/>I5I,7 R8B-HT%[C_5'.,Z]1GDN^$3Z&POWHQ%>$)41:_8!U91K^),,-,U8
ME8X7/3;-S6G$P&O<)MH4N^&OU&3Y&IAUOU&'BTX,8J4X8X]??N)SX:Q0$-2[
M?LR$.5#G$G%KS&!Z3;;ALA-S5'3^O_-LKJV!0",-?[K!IP512]R0K?)PA$(R
MB$I/L"SC(<S@J74J5:DX^PX)PFFQO%O#V\5#,4>[#'W5S$)R!4EP/>BPC&>_
M:"+;C:2_*?B=J9@%V^HHEU)VJ1B<WPE7.15%+<3^"K4>X31D)QY7'L99UW3B
M3^#3S2<9BR&@A9.BWMJ54582>>[%$*432RALB_I\?]HI-_9,>Q/O*@EH- <^
M+Q?.QT]058\UJ)E"N@._D_G22UGD)D>&J#)4J8-HN!0XD7B;^<)+QGFH1E(K
MN8F5B*E$3SQ ID4;I*1]IZ3@ESQWLB'V#TH.3R9&/5.&PC^D'A3QE_0B\C[Y
MB]!Q*^OT9H%V?EC1+K,"WW,_+S[-#K[Z6M4C(LAZ=+@,V'ZJF26H"%&E<T2/
MO<3H&_@3F$3FG._!_?@3Q+27Y&D$,7*:ITS@]J JYHY,^["$O0S/OK.G:SZ&
M$E=_$3^I/A20[#1GMDV,Z,6C:$F8ZN%6,45=Q><%):OU\S2HU0] O+I;7S%/
M@QK? Z_E8"N9\)J6U%_[Y(E0CBS!;B(8^74-HG7=RM1O<#JJ_+-EK1.[H)/J
M)=KPW?OJSM#U<.K3P.KK*]SL'[&27!MPU)GDZ'B?OH*V -I*9BXRGXAU;CR(
MLU1_TJ JB$T9IO(HU6U$-+'=?(WDM:J[ZG7'R ?4+8"1%)SIN*[6IE&[JCBI
M^('9NE;'PN'2AY[B4@HA9*.;44?I4>_"+UL2*G_'/,+\[\TQ'8<\\PA']* N
M0 8HUI& !6H#>C,'] OFF 72NS 5!-[=AWS."4*ZN>4UD-,T=4.]!.*DG_$9
MS[M@$;I=K#*?#=;'ZCJ7]>GO7--S.57(4AHS1%SEKKPF>\5ZH-'+HAD\RI76
M*FWPQS6HU!'>"WCS-V)MMXSFNYHA9U:OSHAZ-C T^H=PZ;1-KV-85<#&G6]0
ML:9*"PLD _B0J:J *(M%O'#8 =;]7V=J<J8S.A _,?"&/@#,]G&6E4S[JQ>4
M*,XC2:%';Q&P&M$,H#Q,N?1\:VN L)(HTX*<S&C."F/E46CU7UA'"--:$[H*
M_+L[8G/US9::6Z2:!93G32[9,?HVMH_U;GD/ 8TN@.@I'AFNX\[].0A&Z>/#
MIP;<U'HK15.&_;0(6/KLTQ!KXB2$&^?^A,6*O? XC[G(I3^:Y>1 JJ(8!E.E
M7/-(=L%]@@:EJ_TX=^.ZG)4+KV*"_IMOT8R@#=6?1HN!QK-J2_JP">=75ZXJ
MM<!6I9&PF5E!+XVSFS@(!6(/,)>Z,C+PX+W P$&8,B&+QJ71L.Q3=6]O'L_\
MF=WQCI)[6DS'J?MKF$9XT0NA-CZ2@%8W,\&#Y>"F1LR+ !Y^0!C"KE6EJ=<V
M2R["61)*FCLC_6(>F;"H;=Z%3U\['A_C\=U?U>XIG33;_GF/YTO4E8#_QO+$
M0B+H3QC4[I!_4\4K22!+?A()8,J4)36+QS1F&T8(=BDYY2.\$K3>IUT@( V]
M&P=IOZ_?A1F,]/?O+ 0_U#[V.7&@3?7Z."['8;O+^8W 'HP^1U3&T<6M@J5(
M8G(=W>2_:HO<H,;Z0:Q4K)NH'6-(E<K7PH5B@G9X3>[GF;(L[5))QY(QPSRT
M 7RE*;!O/+"/8B8@91MV7-YZ>7W% 9WQP_]I]/[+-6?9O"L0T2P<>'EV,]L!
MG)'7E@Q$%)AVK9M9DOU'6VGC\\8_V,X?L;[WP^6F?L,=\^C+*U[U.L[$-JYT
MSX.3]U45#(L==3/H'0^OXG64;A+T#3^@\;AZ"6S:6K .RDFKUQ()DS%5O\.Q
M%R0E^(6[S,@R-U$]?SIP.-Q\=Y;'X+KSZ0=JRE]E"A9L&UI;SU(T$C.O"*\'
M[$;Z6J/4@LSJP._O)?AD8A4UW$5H# ,!?:7JCH<T8PJ<3XW=#Y;=? X#EW1N
M"5HXDOG,2=[O9T_*-U[5@QW$=LK'/O)?1T3J*I9K4*,]\DQ6 T*/UYG3-YT'
MMZK?VDT@BKV(('"_BIMYF+8&]9\7JT"#(J-_;A9FX.4KQIFS*P(Z[WP3RI <
M7CT(%:EYELB_[=1#_7CM#'^K1.8_'/_=+Z M6>X#REK3)Z+S=__P[<7^YBJT
M(%\IB)]UR>;O*UC#CQZB"_=V1V^-W&Z0]Z3CLL0B"3JT:MA3LKK')>Q,%?D8
MX_G$?WEWYDBX%N@CV4KSZP9$+. EYGH5Q9BVG4]?TD\52D.+Q5LQ2^&DGH"N
M=:X-!/DIR%?VR=WW)16_CUV5V<BBE+K D]B DL+2U/ CO:9.S(8J^#,TQ<UU
M+5(:H^4K(5MVE2@O(^P@XB4RN[_MZJG_W5E)"8O$3-1*,4YQE$:N5XT[CJE(
M#*_2>AX:]\#IK ;U!YNZ6-W2.8?(K.9,W[&\H.Y2B(FJ\(YE 5^-_W458QOF
M_J& 6[28"LCI <AH-:&CJR'52&I8]T/?58-BQ)1M0H1KBM&QC!WO[](V2(C+
M/*/$&:L4;8'[<MSK-P97W:]-U&&NVWF%M_UZ5-+0JU7:P^\Z7JWY("?<R<-?
MSOEL9Q.5AHK[SPC^UU=%&C;6=T@#E#<[TO'R?<K+&M33ZI)M1DK$YM_R 5^K
MV_CQP(QYCT,7^0,; ;LV6SA$@SHUWHB?S2#=^5KY?U3)/Q:0J5Y%W20NN*G=
M(,T_;ZGE7<M)WI<DCR4K'L>.IWS)M@"<"56O[_JT4C;IA/>M7YSTQ]Z$G[:@
MG5J?"'I),<T="^&MP7  9"2F-.'3(:5_EOPLK)"0IPS&K9;#O1QMRJEJJ"9?
MQ%DX%!'J!I\_4U%=S\>NQ08^L>>[D+<4?%,8^<?&.46.'H]R'96L[7P05(6U
MM24:^^5OV6]V96/)_K22H(.^_D_&/A;Y[O6UV]+B]GI#2<J#W1?M/Y;NO;//
MU\L+K9=UXW3HLR+W#_EKVHJV/#OT[%!4AM#&UB%PDSPM[1MK.2QS05]G;X#O
MBGNK^XP\X1B)\_*O49_24];-;"^$SWT+[3GYRBQIS($L7&6<\SE-O.KF*V]M
M'8E7(PMVZ.#E$1,+UL$U4-&; E/XD:B$HD4SZ<,Z2(CQ1 .UHQ)=_@HNAB*^
M'4A5Z_S$5WYNN4F11E[P[I)90WOA'+&ZM 31#:<O9_\(,C_6<>*;Z"Q='1"O
M[L54,+@LP8C(F<<8:)>TP]G.R9REE;&^%KPLZM;05R GS5'THN_B>_J[<4]H
M_O/SGT;=$\N*'Q_]M/WRPDB;,ZN6SCV/=X[DB%ZRS;)V 1GN4TV "=5:'IK'
M!72Q,>)?:E^6G_CC!HT@[DAA5FA0S?@;[NP$Y_@)K)?E5"(M1*PZ^<9DV.)J
MQ/CFNU?..2V\M2.+&TON^JI!@4'.UX>MP4L,R=1"Y7QX0/+JN0AFEM("J\#W
MK=S(_8-B=#P=/899>!QJS71UO$2P$(33-W=%5G:DTY?T5K["88;A9/_>27Q5
MY>&7"8>ZRWX_H&^>K%S,E=OQL9@+OXKDCG,J.1FTX\_@]H,0(Y7M!@OE25!'
MNGH+M2J:D)3;T:A@Z%+3)3HIIWOM:L%#&(,950!7<"2!=/R$B^%E7-&#(9*
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MQ([+3&;JJ5<J5]7W/2*GCW,20W\#@::.^0B=79D,G%G]\6(+OU(60^ASLFW
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MQ\_O<]Z@+J(NS4VS-Y/Y]=NA[JVQS=3^ _5/5K^!M^0JWDJM3]L&._XZ%"J
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M+.;E/WCO-*28\]%$]E?[DE=8^97LS:V_3KSW^3WSF1W,&.J0V"[G"*!E\7)
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MH^I6_);2%9C?Z KL1?5\;?)?94I_MMW!GJZ^*0BZ\Q!:]0[5_\NP:]I5<&E
M:]&>*B648B>4-SM<1J)M'MT;KDLR,5/,W15N76W/\/'Q#/$S\-U;L#YT?0L^
M_]KVPAUH9^X'OZ-O(#R ;:=MF4\QI5;YXOUVUO>3K+)KLXJ7'T?H&;ES]P?V
M,XUZ":;(W"N24$+K*\V$'IZO_U43YF'"-;U4M:%3JW[S04;'P6!X'7]J&HP2
MR.+\E\XI&;WEU\RS4Y ;ERS':!O$T!/!D,V-7J'^_:))OR/@GC>@ 8?3NGB^
M_E/.M<(=C=F?9MH73WUP#W_Y[SL^N9L/N-*VDOZ"?(J)G#9^)7RZ21"S1XG
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M'^\7MY)P@@P5*.\7Q]OE#5Y 2V+M!OWH0*F0FD;:47 <M+S+VDND-%OYOFD
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M+9K5((J/4]^28;V-UN":UCRD[TZDJXBP%9<=E%!^<: 1\Y]L_:<1Y=?GC=X
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MGI]@ADE"E$FO0(7P)$;$K,*D3C\MG:1:/$2\/GNF,>&G$L+\44[Q*/J%W2N
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M=?K080%ZRP1E/=)@Z6^B4ZM$AH*.HO(%IJNPP?4W<L!#0QS9QOXIC^/@0FH
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M/Z$JI!@#VN=4N5&SZC5X*'<A:9"SC8QKQVQNA.1:9? 6/1N^A<D &XNBLTE
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MGN>FB;7LT%[R$)MV_.O*G*QR8JA;-TO/RQNZ)!&+>+*X#!IAU-F[B2X(5QS
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M^R@CGO]]\G94RN_$KG"0UN9;\J^Z&U^%R"2QB8I?R*426@M)^_RPQO\QIN/
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MRDUG$TA <?N-*1EW/;$!FT2A54#WA#C&2=87M:NZDVO,/JWX2=V-V5T-F6L
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M-\B^$CS@#K4 BF"PGD>CCVW^L81P_4C&2DJ )A;,+U!.]3G0UI%EN^:#R[X
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MC%8LO5+:B>4O85/8?HD;.8Y/X!/AP6!7$MOY%=F5%[0,2XN)LN0C#5A1.'<
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MHU=V2CVJQZ()VD#:4LP6;1"A_E-,L*;,I.8Y4URX:M$B.;23_0'D;Y;'6L?
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MX-J>>EQ\GUTX98CN(2C]^R:/\,!&N:(Y(::=ZX$TJG0"&0&E%1#@7U,+'\2
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M:\ZRWO/F!.K?*O-"26I:3O1JD&C +P8*>(]$8:7);6K,/C\1Q9B@+?;/Q_;
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M^:VY7OKD#ZOU%^Y<6;TZ@EK;^.'D'=-?$7W5#&1=.]?SJ=G-\0:"BG9U'D?
MMINM*$"G3*<K78S"I% K+\L#B#:/<RRE>LQE\0THZB@M?_8?YFQ!>$1V11CO
M2.]'-^]UN->]\SC&/,XVCE@OX\]N)3V7$P9 P+1>+C1M9.@(L3V<H,7787$X
M-*?.6-V$>"B$BU]'#['YX;^T=;<W,&J8$9C9XM?T4OZZ%[=U[&]M8W'Z/*[?
M:NHWE# >>(<3VR>E(?P(X%'-^7+N#L9#CI 6LT7*"'RN]+#?+?V<9UOQHR*8
M9D_-?B]'I@0/08Y:V4%_ V(.:,DA>/X-N/N\[]@L./\/]X]'V"KDG1RM@=ZK
M UN"(P0JHK44CQ*>1WC?8@45#_L7ARM;0EI=2NN3JP?_BMDPT93]N\FBZWKH
M+X.'ZAOS/<7?G!I\ZW/3R'H. J>X<G#T(2@Z#$X:2N;\NF'A^%:8.& )3Q;E
M3<QY1)H&GJ"TC.^1=K&>9Q5J<SO6@S\QV3M!LF0V!&3]$A7_F'=V].)/H_Y.
M WD9N*^%A<1&#P6^WPB_5PC-TF2'N:&!-"$L+" O0,;,9F,'=Y-=$_2N&E?L
M0%],!SD0FMOFQE('^"M)SD&5XK2R 5![[',7:Y<X=TN6?1P+GHO<$RJX68=*
MOC"CP3'N%^PQ19-?XVE$,Y5E%G.W8>HRSGXDII6[&B%EUQD)6'*7;#N[2AEM
M@WPWC[/^8$ G^VZ<6]^'>8H;'IN/GRS"[;P[?+P:?C%2CE0H77I*Z"L_BY[<
MBK+-U.$OJG,2HP28QI]L.=K.6V!:,SJPF,] ^D;[/JEXM97-=\;D^#OU:'@>
M>8&$L[-#BC?;R+D-9L,1V8#: X@P-_EX,[IBAA,P.3Y4%K31;+*G,?>&+I/M
MGC).,)#< 25Z0AOQ\[>*[-A=?>8SFD[59'V4+6&_.(2*KG X4ZG"+.\Z+Z:R
MFU83;R*B&V_7,%(H=MK/W7]2]ZCYWS.OI:RTK. LF).00U#UU 54HQ90+_-L
M]:AE#L6+DP!B[G'L'I?L)#KX,DR.V/<HL4WL[768'/+ ;/8F-VWRX;L[Q>Q?
M!CXI?QIV7YD3MK,,M:F-B7&<>]\>(,167(_J(UO.$K'OYW'91+U\<3R1,(^+
MG:,;-$JA"]M@#ILNIC4@>(J+C([);)&7:CZ)NY'C#D@&5S>;I:Y*T[IG?9PS
M!E>-!=C[X@#R\M_)#_+^QO^+.FFZ:7I)KS45S?IB_LUF0V*_5Q/MS_OR<JD.
M,@\@,(/.>1\KH>.8R1O4&EK28&+^(R,MQX>X?/C'B$=_P*ZODYJ]J'OK<A3?
MYG>]W%T:\IONZVA>:R#F+;>DN&*+$(W:..#0*E].=D-NLC+<MR-]?)BW/+2*
M$P6.I=]7I3^(,WEU3]*7Z$:X1)12EC!7?D>NI/&/N]N@2O=56M^"M;J(0N<M
M1!INU@+6J.9Q%APG<!+67.7Z]7B'MU+P'>TMZ8EEKS62>)=?_>TC!QG'W8G=
M2?\6I\<>UTY:#5J3=CVM>Y/L%G*H]LH.Q[.?")]"3>[3R(O/KP<V0[JKNB6F
MM=@ZE'19YA'%=E"8%VRDF+.I@[L19.Y"IEN-.,YQ5%)0?QH6Y7'=023SWO U
M,(\+Z:YKIB_#CJ"%5?#UZK@^$_&I'%W47G%GA)[,KIE*SX0;6^EY\[B%7-*8
MI 9L5Q,&WI5 Y?I!-K:F!EBVVNI.1G,"S0QQ\)6?%TS'G6(4GZ^N8.? ?<<3
M#K;_,]1Z?T_"NBBL6(Y\2\++!<E"01-_?!U:&S57YJMS9E(V]5!\ 5\A7Y#\
M<C?#?2WBG\%9(&8O5D,?RY%4 Q0FS*SJIC@#UY-/<HB+W%@'T.@,]S]BQ"%3
M<T=>@85OY9ACI#XVEQQ2.<RSECF:.N4$'[D]6[,+L/3T51PJX$&W. ZH!>R1
M9UK,X-5=S#:SM-6HS!.=SF8M>FMLBSHZFYJ>IG0YFZE_Z7'XB0QYU0BG;U=>
MZ3[0/#Q! IMU'\;@'Y"+M7>&Y4[U5#YE<QV@F1=P*FG1205B@+0"V==QS$><
M[2#%,#LHMQT$@H-HCJRQV.E&4A+5FLUO&W+3<HY!Z23ED$?G^[Z$/R?P>)."
MN!P+@B7+@8RTDK.OUY>WG-LQI:M[Z, ,>)1Q<::J4&Q>$FFL_B<?ZB^M1M[6
MO(E+X=HVN$SV^+WKFL/"MQ0='K5C1"9EH\*EO-8M%#S8O@^INI(DS*<Z1T)^
M!82VJ%"5:)EW,MU2GL/= #[ISY<PJS@^(!M^N8MHN1-FAL7L3U_7-E IN<N.
MC$3F<5GD,//<*@C%.O['[$=E-I4+2LQ O^BGN=O$MM3P?%\>#DM$S@UYFV6&
M+80D?#+/[-Q\RN)>[@9VB.&&KO"AC CDNWNQPVAH*.*?->$Z)LHQ>5V9-&UA
M*Z!7Y6<N,"K[&VYO,.9*=R0\>)%B'GM']P1)P-T"$F%:?]%49D-=6/!4!*)1
MK*N*DUFQG,&@FE>GR>8DPLTTRS&NC5::#/U/:I6F'Z0N'-LLH8-"DW9_@\O!
M/RY<2%\DEMV@/-&.RI$P'?__1B*LBW*X6[!#2,N[C-D='*^YHF)F@2?D43A!
M7,'Y"D0]!-WAC8]18P9WG=G&8Z](?^ <GL<M[1,GP*%A1X--_VS4A,@Z'R;=
MWO7\C>8H]!YS<-!KVS[O)MK0*_4TZ/*?,*A+1/JS9?= Q.P1I&*JZ"'@ZRWY
MLLT@O+5IJ.82*:N]GNG6EXVF*:<"JOAU;J$AR#^'!^.JRT9<?%S85P[96$Z9
M@^F51^Q@?:^N$'.XA^% IP2+06272TG(>X7X)WJVS+D%E6?Y& 6?ZQJ4*YWZ
M>$AM,M&1[=W51LLK=F^!.M'@-MDBUJH1A\'1:%N7]E\_C3K->IB6"1&>(J"O
M&AI/@WBJV1KQNJ,@[R&8C4)"KB1%BI9B)(1V1<[0K#"]*.8+N.M'BS6""<;0
MIX/F%/N(&/T8.28J\&6VK+72V0(6K6\BU+5&<#X"#]9I6CV9&MLW@U@$D#/=
MRRJQ[[LQ?\>*HC9/IL1:@Y;#(6;Q%@3,XW*3$RZ2L@U*D0,650&Z(?Z5_W9)
M:2C])%I:1>)/9"%]DHU55:&;>(=EYJOP \>M9X(G&#A>9C!'REH-*FGE[D!8
M@LG=<B2[Y<U6;.=<.<::I8W-M!=\X8X/M7+;9\[-ZH%7MT^ONED4D"#).?WX
M\>SRHI]?W/]GP0C=2G[>F"UR,FUC\_33?+(=>D7)-H2!OQYBVT&9A!VR_RDX
MC 8> %;P6\OG9DJ12(F2 5 ZCSMEQRC=@#IF5]XL78]H^+&H8_Z+1\.'Z2!]
MW#=4<IOB;GHK6LG=RNTPQS^N)7OAX!2]VY?$ISN:O+&ONCB;#?B5&)-H5W\!
M^=OSM9@34NTM1(IY%HRIXG^0P?BCK_M!^>%2]9Y?#J_21MRU^O+ON=_D,?1"
MTX*YFCIZ[I#/,_,J#-;'FG^2-;>[U D$?NXC'<U'"3M_-G52G<B>AIAT_>LM
MW!4<"LK+\0DBA2))VHB;)6BPRGQ0\<9995-*)N96_1G(7J8_X HYZT @9,R\
M*+=-( =6,XM_I=O)O#B[@*K&[2?X%?20'(RN.Q$P5%LY0H]Y^N2$3V#H4T58
MX[/(DC\-%V?#QGNN_G '_[*9-5@R]:131L!. [Z!>D6WN-Y*M)##>S;W&WD#
M]'FK>=7X(C3T1)]IPVOL8 ?9*@T.8BI,!.!Y'SPB6:@K=*,#[S0V<0%3M2NF
M+OJE['*-+!'OU=S5SN-8]*NIU#8=7^X\P<LQ@R$6BPR%L=I,RX&PYN3G&:;8
MHWM;T$BE.1%XR^R&,'OS-6ELI^)]S!5F@-67BSLETM,03^!B>=D8&76)['7Z
M_%/&P*N:RO1PTH?;]T9,2\TB+[5"8V"=(CVQ74<DA\R&1()/K3-3UQDPW@9\
M4LK6")3^,]]&I+?G78"$*]@+H;X$C\-(2*$/U7YX8$B0<H'Y,.32CPV--W5!
M(R(D+"I0P;.C.&/?(HWCGFBQ(AHD>A1,SN.>C@TY X(AG4@'Y6B,.D(KE&WE
MQ*4'JD1+)W>;.1>?%U[\KR9GTCJM57)G)R1:J,!G8G:G(;%[^@&W;RRZ3"M-
MW53G2>' )>X"3CC8HY>;55IDOBIV%$_V0>(2+(3E"F:?N]LB_DHWR^>F52*#
M3, LBV3'*DCH+]WT(CJX0,TVP]>F"-92H%6D7FF9RDA._=VIUJRTM+G?R1O2
M47M:KKL;4"'O6^EX[!BJ>^ZD<^0P];=)WX)$U!*V_#!2$W:/LP<)5[P]HE41
M9EY5/?3I:^P&QS]%=G""()UCY:V'$7$#_[;7W!V=21;>-[TB/GD[_6$<)<(2
MY289%0L%9:1VF@.S="O:*U)2EV&NZ;$1YN3RG!,P(!1B7HA.P0WJ\:'Q(W#T
MQ9Q I.5][@;$F$/V6.&24/E[]Y;&1$XY) $;;@N5:21!$V\\%"6JW;]"JG)-
M%%.?R,%DCWEU^&IL%'I=-A&1F4/==64T$61#+X\0%XV8/$O4,W1^LFO"7L5^
M]& M+%S&#E9%R/-BNWT&)UKV_VS1A5'-5R-Z[K;T6/5PM!NBS9)YL46JHJ9I
M9=3G6_](5%6;,?<(9]MC$*G_W*XP&(W-ER; 0K[<47H,,8TI\O1TMSC*NB[1
M<^Y7:$.]V*D%Z;M]5V.(W"S=MFD>I^@U6;Y C,]U+C\@.J$T$+FN"D7]CPN5
M+D/7(*,M-5=*1 SZD%S3CK>@_'FQ1$%R9G]J':AXTH4%I93'SW"KX+# *//Y
M;IDDXMG=>Q&9.+Y3R$#"/X15LA.5I7A4G6ORXQQ#)85DQ[L<>D<2S];-'Z)>
M%G](H&R-*UW6D7RI3FC#V0H2]$:;N)2F#?(,G]M']S9WU[U^=UWI7]P@KO&K
MF"I)BZ01$!YF+X<:LZ1[[@,3L8!J#N$0,[YT@Q8[F8)Z*&;"6X4+XK>S,T^
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MY8R; =_NOW??\L[8YUL*8=MIX+!A'N?.H-=.M]?,A4"BUD')*O;LX:+=G1Z
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M_XO6$<7U^J^]]^X[:5DUAKYD4NS#89*AYZ<+9[[^.#P6\PTYO=0$$/\6X]T
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M[AQTL;D[Y867V_49KT[7'$G('>W&+?U; KM?? 2E]VB.E/7NUF>A;#7:#(K
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MM];3+R!TP+W6*]<OHCTHX5/FPL?.&9\QIE%UR!VO*"$BVFXHM@Q:1+3CD$9
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MR.TG"DB@+6R +(QC6HYQK(B@A$J5=PD.< @P%*BOGL&@.=OXYCU[:%LHL3\
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M.KWC]'@8WSDW.H=L,Z&U\WG'KO0K[_HM-,P^YK3 5^=H&.JE]80I4%RF_9_
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M:N>_Y-V\;WC]M(04:(&^F.N/'41B!53_B=*/O/XT+_0B'**A>X%[HF(0B34
MD5VF*.*KL1V_/L:#E-VKZ<]MXP5D UXT,OKVT[T*'"NS(K8WFL>/@O1<Z+S7
M$J7ZFLDXOI*-5_ +6-0V*G[]P5QY%_'>C9SXY>@];$4C;/TQK"@#+B->S8V0
MRHJ.HI$\I(?.CQ (UV+S^GG%,IH3@)UK0<D9$/LI9U7GWA[0M::/0_MH]<4U
M>IIRJ0.'C$;!Q3]Q9SG@,#@V=&-'3<)2E5<CFS ,>*]3'6_),TDNTWPX$FMY
M%RTD2^17*8+?ZH?F(+EC+19IY%>]WV-[)<P9PI/:WJA(3N52\EPL$>X$X(J"
M@LK:Z96VXX[G]$!EB*,SC8SH+V!K:"VF4'J[JO[\G=X$J,)U=X.\!W1'<BV)
MA=@WR#M<&&:=M$KIZLK/X6[UD/:[E#U7WD>&Q-75//E5+K>?PNFPO(1BW6)_
MW #, \-0FM$E*H^JPD+I?6^AGF8+SF[IZ'DSB]0^M A-M7TN:6<4<><_[27I
M\K7GPC71P?KD;V/O_&Z>(<QC<I=4+F PD)SKS;GKQ+D22K"9WA=D&91?4H0<
MHX_=%YV+5;.+E)N:4>9)2$JV@K!(?^]$U$G;9]@>E$$L!?/2X0_0"0F\S_&I
MDZ;G!'=)/X EP\X<DO[3'NAZ0*]<C>;FR8;=I2- 9X6/$_8<2[5?Y&5F@A1;
M&!B)'K6MSXSX EN%QMI(?V0-;8)#<9^G\HU%R*T\;W ---&_7*\#%G&#L+AB
M#=FC<B#A%37/V !ZP)N&0E"DCOE?XE+L6U:@WN'Y^H=;GUK!8><Z3B@"S")<
M)*1\:MX'1M=@.W 6.PU<\';\LRFM"K9 @[WCL0@)<@9/O\K!T_LG9BYO_IAC
M.49#@M7^S[TMI/8^NIG]SE<U_ST8"@&SOG[J(-=WT>_A,@I66=/MU[@4CK_U
M.4I!O'7&^J=2"4=O?E-B.W88!.VR$XHLD_MXN&7*H)U8BB8>03?G9M4,.]8I
M4 'D-HZ%W"V/JT82\Z.H3+AQ;!5,YW_[*_RL[P^R&,RQ+>1T6#3&!H_'$#V_
MD_N\YQ2696^A;003[+)&'&KG-+RD?8:M1B_2"Q4)MJBL]7\,!VY4(*PJ^*/F
M&:/ Z*TR^R*5%\V&^>"7Y6:I3BX984%T[S^R>L4=OQQL>?RD2QK\J.O[<?;8
MB>KU@TE# ]J<K%/>Y]])Y!4K^)D#SFN6?W'S;[A4_- >Z(E.06)TE:$DBD%O
MGYC'T5MOVN\H2 _!;,30GI!WI#L=+IDA%#L^7U=^+Q7[,F&G7DN;I>B:E,T%
MHX4[89+@X2I$?"DT:C^1?[IE8QH."5+J>49R(P-=J6]E% ,$!=T6/ZSRBEH@
M!6GPA) ;.?SI\PL2)^]@I](#W3T7W'@>SC,+!5/##3,$/C"+*F6;5>U]=> I
ML]'[R.\FN^_(^\,:Y%//-R@U?4\7M5G5]9+P_WZMA!\(SA<([]9D$FY?6?V_
M2Q:(_@*GJ $?,!VFZYK>5TM?C]"=')^- EY1&[+N/C^VB"][@*O2J/-PS7_5
MF@V#AP<-)^^NNXAX'U9<":59=C?Y2>LJ0@9;[N2&B5;Z."''\W%$4J,Y9O%<
MM2G:W>*J30AII\WK441"O O)!_E"F-OQUL0H4I LD?0 #CFY(P>E+984.E;&
MFY[')SQ^.>E/N1HA+VTPHMM<\!$VID3OBT[9HR@O[.:9?@ITZME$]LV2 PVB
M<9^RCUI_1FD372?S&S# 911/<"_<.^Z,?*Z'>HMQF"1BGUM?@I^QJCBZ-N\V
MD=+U5<,"1@S<K37PWU.H_I3ZEL<QA'.?-CG/AE_F4%Q1BYDOPOG6DLNG+>04
MIW1AZ;A6+V@*QT(V1X7# _HRN68PR+)2?^5T\?,4\_N[$-E;>PP)VLGB?0WK
M2W.$GAQ@A^!@=T/A)DGGL2>7U($S!(?;-;CC3>J92&*Q>,FFT"#H0-E=B?ZY
M>YP*/N(++,4H/*1:9PP(501!9XUM'=DTWX[)&8(/MAUY>DEN])B("JX#4'_-
M.0%_*G3?F'O\P+XK!"N]0/R8KJ9?QCEPJX7H@>;K<A.-+I.J_HP=<,OUNSE5
M3\MS,VS[L*1.&@7MIN[X?C(D3NSP',_;^;1#L>QIHF]<1A5)WIV8J'@-*A,A
M(KHJHXWGB2?:TM,#!C^0P2<*N42TW*1:1'TJ,1=<B^]4KL&RNI1?CLHCG$3M
M'7=(/;15W<$=DR)5PE=S&U9<<;^W;B(?^"V&D"?1BE^?&X""-3QW\ @LU H+
M9P@NW.69W#E=-._1RF TEWR)0HE*A:L3>QL,WMF!'JI\/7<A<IXO/.OQV]VM
M]S+3UL-_UOP"R8C/<N^O$M?.S7%+!WPZ>*8RWNP&F3MV&+[-:89^>2[2RMR#
M!53WOQK'?:/3U:*GY :*EM?/5 ^MA?^T2P2LJ]Q5L%%C+(XHZ:DX>3^F=KBS
MCY.GMO;7E',MA\H/K+[ED0>),>]O#988954.0K36V*L:V;X<E5E\5>D.[D'.
MWZ2[-CPP!&(KD5)5%?H/='F K\'\+<ILM3;YRLRVI,D2H,UO>[$L8L1O)+O_
M>DU.:L\?L1H9NL(5-Y1%Q+J'^$1R0S,/.=9U*'A5G(=) ^#:GASW$K+>Z-/(
M*.Y]FN;= R;!1J";YO\+LEL:75I_UA1?XC%#T*4M;NQHH)-2LT?O9,G#[OHX
M#7=\ZC3I6#2(_D1<.$+VHJT96B>RD+W09G59HMA4SHR>C=9;;Z" [?!HQ-I<
M7^4"P=ZNR6':&FQ]8WS6%'/@^;X!=>!G/:</J$(]2L[6@)MMZ=PV6L@C)+%(
MX0Y[Z_KE^<)QZ7T0Z'2L1#L/HB7'),]/Y2'[(5T1XIX"7Z\W%3IFH[]FI\V&
M%><J&^F7J8QYG]X:?-0LF%;6FU/3->'GMM<UZ:[OW4)^J%H\0SC^JW(5)]^L
MTA#G@GN1MVTXN+EODBU$F9^:>SNQ3.,[W^-#4J[/CQ-JT]P0@!]UUBST16,U
M0TNZV5%TLYT[U#-#B"65A1>!].K1B!C[G:<?/0?1*/*CP'JS/7<;POYT*.8,
MP7H-%I1TFJ]7P\_T:9N[5J#[$9)6Y<FBB@.81L\<P"O;3Z(1\H=6 VZC4@CP
M&I'>2>+,&U#3/&'=#7MY-<INGSY>?O?PP-=[MP1:JKB_D^=A:R3<9TV4 D"3
M["NPK8ROC8>-NXH/E&(CT@=@).*J+GX-'KLW<EW45//;^1P)>FU?+R6'VE+?
ME4/V^F=.I*W\1^J_O<^*"GC?4/B'AI:C8LAP92@4X>E5"\&=Z,D'H#^+ 85=
MPZ6O6&UTSY$FLT[M>Q5:C9XWL><DCPY]WDW=)DEEBKVP@RPIY\/A:VKETCQI
M)NT?::;;%Z+](=*8 );K5$]J'ML^>\=^ %)1-L]4XMHZ??RNZ?*K;Y%5%UGF
M_-M*P</^>&F6G_):+?-,YSN_8]K!H>8[(UGW?U\JV7O%].(_<C-O3,XTX[C)
M0 Q:<M'0%_9;M&5XA<4*:+X<H98;^4KA9+[(@A^T7^/@FF$[[/$++H_X@5[P
M[HL>94V]&LI29N)TQ6#)^Y9[J>A%4_E^/VY%35+_SWM<+Z3QVL)/X^+/'756
MRS\MI.L&DWD7Y4U^CA<1UUON8*1>$THQM[BKFR8N):K7<TX=0A-SS++"5Z,T
M9V31QWQ%C S<TX$E0=&QNQM>4=W/[U9K_'8E*YK?.MQZ36%(M+C4:"'I?L5X
M&>S;#=RP1UU13C7,DZ-EY'9>H=AM+1:7Q4J''63B\/2E8<"KL>1XI'NT!X78
M=O]PEN^C=\-56W/N#/GL<67"L58_-!UFFC/T0('A07;E^B?V.U3QHE&5+[L&
MGL!S;%96?]U="]FMG[,QY;>7"C>XN9TV'SUK3IH*7?6O2'OVQ-=P8^-$4=3^
MG/L<F28\XKJ\=O"(',]:7'?M=AAX'HI0,G]2N!@\TI5!=_W?XO;E\*'EO6#,
MK6R_-U)R*[W(+UPSA5@EZV%%F)R^4/DY<X@$E\BTT=_W2^OD-6CB=N'.SM/Q
MOTJ:;]Z^0*U3F?Y!GSM%=@&38=]:) AJL18A*6:CD.O=?%[2=JBWTA,FEBJ_
MY)1;!K(B9O<,+2@Y,;&)Z,N1)W6>EF9H]HXFE^CR5RK\-$W7JURMQ3:&WMCW
M5@WX.U9P4B!'.>*J(\]3!J&\MB:1.F&;1NGU4KD$K<!BX+<'>\;!G=,NNG)D
M?VLEK:,A-3T6<9%89058EKDY-%CK-[]W6N$)_-$W<JK_TA7"7\QD/ ;1#H-R
M-=);J$B"A&3L4,\FWD)49&$4OX]:)S"_N)837JB,0E/VPL:K4^=SH<!KL*,3
MXA6S&Y:P65,,_CZT7.?W,^"Q?]<CV)I/@!L\W_W^WD\VYB_AF,'4>^!1/&FI
M8#+"+N'A@2VEUW.E4,D9.C\PP)?FA([C<GXJ9QB,-*MF8Y'P!/]T0GH,(/#;
MU7]0$_%=C_P<OUH*C)XINR/R+?IN[Y8 5]T,H4^DYI$PNLE_@2NDUU+RN2&P
M:SO%'W1N0(O@-\"<WR$I8';55+BJD\DEV,K[. >[<:K52N[=\/RH-5! B,;W
MW,JZ1K/8\]V9?KX@A[G@157&V3\#E^"Q. JNAZ_2%N,C0?(M9T3P0%N_7J#\
M#,TU=_-K34P6?2<Z8>9=M@*NFWBEOI6X\;_LR_"E%#[$-DL&.*5$UV</G\,O
MZ(6%4?A@YS)3G3+GK7:^_E)ENH:7&K;Q;*Z%Y0S)2TX+2YH$&HH7^%47-V38
MZ,'+:(Z,'#4L01E;8>'5AM?<^5OA MIL-:FX&M;E0P:OT3">!PO<*P6W=AY%
M^%5UC#,?!IY/TTWT.4,H.:[X*Y&.MAPY4WY4\B[B>.G0*L$GZ T+FPXKSKA[
M)/XDKRJSZ;,N&;6Y.:FQ96?>K_-B>'G1RALN_!L!C5==?)S^>!7C0]C[_^]R
MFGG]?U!+ P04    " !S@&5: :24@**L 0#XO0$ $@   &EM9S$T,S@Q,#DT
M-%\W+FIP9Z2[=U@3Z?LO'$1%08Q(4Q!B1Z5D5YI2$A4!$3$B2A6R5DJ$K H2
M84B47H2L#79Q)0("(L2(E B&1$B =5FE)Q*$M*\B3696"+.FG>SO/==Y_SCG
MO<ZYWI-<SU\SF>>YG_N^/V5FHOF@$2/6'?7Q\T'H+--!_*+](C1C""^$SO_E
MY]^+_-]>0T?S!F&T2D=7-U179RMBF9&.KI&.AH= (1 Z*_Z?$Q#__:.S3'?Y
MBI5ZJU;K&VA/:%Z'6*;]U;+ENBM6+%^N/9JF/8Y8;K1B_98?#ZXT#CRKM_6*
MR=Y;=\I7;3O4T&%Z<@#<[GCN:OIJ?3/S#1LM=NRTV;5[CY.SB^N^_6Y>A[U]
M?(_X'0TZ=3HX)#0L_/R%BY>B8V+CKB4F74\FW4C)R,S*SLG-R[][[_Z#XI)?
M?RNMJ'Q255WSM/;9R\:FYA;FJ]:V3BZOJ[OGC[=_#@X-C_ %'T:%$JGL/Y\^
M3WZ9FH;^_K:P*%^"__G^;UPZ"-W_$?K_,BXC;5S+EB_77:[W;UPZRY+_/<%H
M^8HM/ZY<?S!0[^P5XZU[;ZTR.72GO*%C]3;'DZ#IN:L#^F;;G20[H']#^Z_(
M_L\"2___%=G_".S_C4N(6*.KHTV>KA$"BU"K=U7D(_Z7@_&YD:=!@'AJ43B-
MAQ8R_%0/-0CQ/6P39<X?3);[P2(H1!Q-57L ^^ J\1AVS4>X1#Q:A+=\&UN!
MAT^F>5\86OCG\7 V+3[YZ1]R9O##Z-AH(\;TY"Q'@UAAH[I'B=4@1IGBR3G[
M&B ()'8RD,!Y.+ >.#<$6$$YW1/ZH&^A$BONTR<PV2;0>R9]RJTDU\@WQ\-*
M2G?1( Z/*"-C[=06?MO2KSWML?JXYP!FJ8*%BE+5<BYA#>+4"%"#R-,@8D0W
MU9L$;-LI850#R#PL8*,!S, B)2_<AVD2]*6MYJ;3N!?/9:GLQZ%FDDUVO(."
M^V+:19@9Y+WCR<LGN<<UB"X&E;),K1,;GM .C<E\.XGI;=:-*8GOMH7!S9!E
MAP:QUHD><O)T2#PV8!@X7_^%GRQX5E04;W^I^.?Z^O/<90<\+^7#[O(&#2+]
M-S4/U1!]R\- ID%044TH+AUY'*ZIA9/]X; G4]:[0353BLP5@?>FK\2&DYF2
M>(S@E-%'TI[WL0$]N9@M4>.A,)+K\F/[!$<:X.:2\?Z[;A>V:7)V3$PT@AT[
MV*ZJQ^I5),=NE!'=;EZ-@G%=%#,/78D&L1[^W'MBU64'I57Y-'MSTS KD)"R
M@SI;XF;5K#1W[^_8?FOX%^25"K8%_$B;FBVJVVIC\K!H%?8<QU1Y%3RBJB8[
M$UQ3T-ELLZGOZH)K]!C',5*2$G=YPO-NY-&)H8X0Z\U#A4^BU@PXMXHAUR+T
MHJ?+4&?XSI<)Q^ZH#!^K^VD(5A#D& 7;2ZA%J%4>OA"ULP&'S5,;QV#7*\WK
ME,? _[AT>?\E7+JYH(J3=;EY!'_JQ^TLKXIXXCU\).3G/_08 ]XFB,#_W0@\
M<^8@8;D@),@[/C[>I,3<W'S]]A\.+M\U&. T=*1W4Z"W1>/;;2\KMC8ZKE@N
M^!8K0\'[7@Z%O()K(3WY,6UZKJH_X%NPLP6@:Z3 "9LG:A9P;:V,O>'D/;#W
M1[@O'#Y;23!;<JOAT76YQ?WCD6>F?QF/66=)6O&IY\-"Z]SB;@2V2M_V$W%4
M)!>H?N7$H1' &O@6>$\ZGY&T@1(CRK&1TCHI*PENZH)RX!ADDVEO(1W#LYAP
M6MI31MXERJKIXO#B/"G_90.KL7^Q$'VBL8VE0?CL11V[)[\%&Y@R>6-OR:[
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M.ZJN4UZ#?"4E7!W))?@!9/R&@_0M\HBHA'4[?'NL[?L]=GK@98QUK#M?K W
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M4LY_^5D4A[I4.*G WJ_*,4A6'">_XZ-,)+!EFN* TK@1'KGB9 8"6]NT;H9
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M[CN(<9=/7UCI'1>Y/3'Q@4_;^;6_O]@0W=>]$_=F5DA.Y1,A/< .6?H5Q)^
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MU3CP=!=$!Y[U5;06)*K.]CM3@MVD>T&'Z9X0J/!GUB')Y\&*ON!T_0G5_US
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M.V- )0C3_J;]I(FZ\?\4V=0O%-E4_XA(\O]99$/M$H[AY#;RKX\,.;6BR<<
M5YVF3:+OQQ.@"VKW3OH%.6$I9:[JKDJ[3]^)L81.Z'D$5K)2Z=Y/Q^QVONB9
MHI^2DXR@+S]TK@%$=P2'%*/G!J(;VH..]SKGQD],.'X7]@]'I^]]5;.%-J%^
M!+6 7NHKG0@[26K7>X590M.3B)800K%I)O0SPK[SST"^5I<+$MM&[+OI^LBZ
MM(@_>7YX"R#S[KD+45SHX?F!&)+97[RYK;GD<W.^2N9@,RE=]CQ/]DH?7J/
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MA"D;9_XDZ$UE^[.4Y[W)MCFC#W[BE\'NKMG91_NS*++P@]^M9O89P$6(2?Q
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MQ$X%:0+&Z[TR"52JM"@Z[X**FLHKM9IMGD<MPYD74U\"EI-UP#5*XF?R/,I
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M9CIR5[Q^&GB(4MY:/6;)X6%X;I--8)NZ"71K11O 5$"AY3/E+V3\@>9IX]%
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MTR5X5^!6EZX)@T+088M@KV)ZT%=-!8MX;M<8+J*7O <3AWKG461,IM1T;&Y
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M8A*61SH@K/3R ;VRXQ>;JB*!RJ])95:'T=2QI6UUH,?5,1?0H-[#_BE4__U
MOQW3TK;%-B06<_Q*^LB_; U0O846%K&9VAW(8=<3$%SA2QY@ZY'7DLY =TM)
M2)"NH83" D1-WFW+4U2A@'K167]I1Y*?2@-LHGI3+3K"-E&LAD]YQ^J7M2_
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M(1R0<5MDZ;K1Y?A<[/D"<=N^0TE[6I.WS%&@C;09"5"A7AFK<%1:0\44@'!
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M)%5*%246#FTM>X48SCL!Y&7DZKO+\9JYO!Z--F1MCT+4(+A1S% G <D'-.M
MZT&U!\S8YIEWMU#+5+1VLLFJ:/[V'*[%A6:_1PD.SY9(Z0".3A,  8(D/F)F
MJQ"7BJX;GUD4ROT$4-))06,K@+R9:86=\@S41!&SM: -_(%]'[H[Z5FL'4#9
M;0_;TBGKE1"A]'/(!/XOHNOAI#T#XX/(1WN9H$?1MSK&:&\*!0CJA3:8*8WS
MY#$ @L.X0U\S.QHNDMV6SH[^(I;)R1 :#.GFNV:P-DR=!%S853$HEVJ@[7V&
MF+(6X@4;3\U7E;T@L@- K8KXN/$8L]HU/64_%H\I8"!/H*=3+JC)K=4\[HS&
M!#O5 ^@Z-+6*A?R$@WKDY:HJU!KU8.$&,$]J+MZ\G9&B-$ZX+&8@L"3_C^0U
M4%N8(A@T2R7%EQ&]./>61$2+ULSV['NNX=?#B)D"S6>V >,I\8)?U/V(^H3T
M*G0,C5_KU5?70M>AF4 W#@+CK]##A/<#XO. V4R+ C5QGD 5Z,_*]!Z&'$KJ
MXJTB)HE=7M;O$)R"JA">TN-+?X3(J:I&M+":TE#22U5::KY@ ::Z18FB#??*
M3X G2IBR='04(P-E WD#EO(L#26]\>G<W<4%\GQD1YM/QTGZ<COGC,B,-^![
MA@AM 77:G0\9U3W0%X_<"I>@E8:.ZA4;%:<UF*R>(HT(5^"5ZS3!@23W\"P.
MEOU%I.T'(CO8-7#^AC%)MRD_)0^XBLAT<RBVH;7B !__ >DFGGI#C+7%(,EI
MS"//[X-3Y56Y+GY$:H2>=7QR<Q<M90&FC[)66@/H%):Y<BL0N'AZVQ.XF$=X
M @6VD_7[+GAXBMJ6^C!#7PY/YOL]7-Y64'<Z]][>NSHV!?\T%OQ3&+SIXMC_
M/B[TWR24=#O4OP*"VR3W2HC=Y::FB0@:O_)M&2+M$V-6Q;CD'Z0639JN8G;*
MRRIB\KZW1Y1]"GY%<WXW.MBW9]GAWHW/;T<M_7=R8):0QM)2%;$OR,%3.. $
MG5I?Z* J)V'$@N58\M^(Y1Y;%F"U[%2E">4OR+_7!R10'QT'D%GQ>,$:?(-I
M8#_)']S\Y6N!6;J'KWY74UE0AGOJ.&7BD>^FR:%E3(EQ1(Q/S*_54WI'#._Q
MP.<'RXG71S=TI=?*CJ9K]4%H19CZ#7HUV0F/LSP+[5%8D\[4@-TT9_PTC8JK
M*V H5P=VAOT"46(98QG>3O"T!KJ>AS/H-GZL&O!-_D -&$)93Z+TC?#S!RK'
MJ/KWBSXF2]G?AM+PU\*+HTVQ=X;FS.37(Y(K9^7E3E=KQT+XG29OA_H^]WAR
M0E[O=.?D]#KU6&[KL<LV__2?76;9&]#"2A5%^'"4\L6>4DWWZY:2W=M1K[Z/
MHDY]=^/]EV[2>[C2V%W=SU.8JW>W@)_:Y9Z6C&7 ]57P O0%3*;; 7:JVA3:
M*$\"$V:*)(*EH60.KI[=;8]Z/\TE+QTD:T-4";L=;:U<SX)\Q(BEG>#*:5QS
M; CWV)3K4!X?52#6R0MJBSWOK@B6GK"7JM!R(ZA/2%M+'J!K7T&FN"[ ?DFY
M+R% 6VRX]"RZZ17V;?4:*/@I%7K'(.T!"@I+RO$\U+(!R> L3^&L+HO%BRI&
M/LV.G.K99'']\]Y^Q@0OB;R,Y F6<>%+HG$6BZO_PV^GK<VIH2%(;>(-3I@E
MV,OMU;;R"6EK+$0O.P51V^<#L =>_):+S67*8^$^/YC7+N:>:/KN_Q7WT"-<
M$;&HA+8 .[, RVIFMV/,2&&JNVS-FUD\U"\Y7:P-0%\=$,BU.@=MZ!I+/&_N
MX549S??+*_UMSK3^1TR^#=4Y$>N)#THF#VL0TO/)C3!R?J 8KC0S4Z_\ 8RK
M=6XI;$A[!I7K082HCEV/2Z_[]0([DGW'X@<[+;Y@W_'6CW4CGB%=?%G2;%I7
M4:0(IPV1QT^"OTQA?T3G:U541->[F;<6^O!NLU/HD!U/:6(C(4B9FERX5Y-$
M=>6G(9[B@+J'7DN34Y+)EN1>@6DKY@4T+C*['1^JH_1Y-HDPI$3#]89?J1'G
M 2L-B'W,<YU_6A,6$P?=X%[N?H:BHYQ"T1,46MA20(]2(^A$?^I6ZS !?#>B
M;DZJK3@,D3GC8J3T/MC-*=P!RJ1L1>3$=;/4*YXA'1:\F7^!ZB>#R@C 6!ZD
M<$B[=HFLH7^#I/5/E'O[_B02./,$FG-E-,EKG782R04:UCSV#@W+OOUSAS Q
MT ] 2)> O.#^GX04_D6F&+_Q#("7'X1"KITY$R%!9&U7N@)?'Q*$\!1K%)CS
MV;?D 'BC<R?4(K[:?*S5'HAL=SL[+)B^BAB&*U?AU#H,L0S:P)C!@\7[5"_0
M4<@[9O<T#%D\*NBTPF,_* -<\@"JZ!NUE$CP 0HJV)FM<;&BH))!9NJ5\&?3
M#7&3_-""IY>C^;^W#=8[CGK_NU&3JT]I"DP(I3W4#BW,9:%5]'"H /BAUFD7
MH;/G%V"=L5XAC4-J;:BX U?OFKX>1%-G9;K1#?S2EG@)6ON3<B,P$!+DF7+[
M9=1\=_;,[&MGJP2?1]PYM\K'->H_-$ZW3<-L/PNHE!H9YX$&44*_1J;5H4<J
MQ%<S).]\.N@&'I[BT1MB=*;&P]EWW)R>#!T*!V@<-F+*6Z0?T)D_5&XUUL:
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MUJEV=GU=@)W\R/3UX_H."%=Y;>:&A7W"AL+(23R);%$ :R4]5F/D7%5V";0
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MVXA6=@/;N[X$=$HN!R/77+H:_L<_T#Q<7^^D=\=CS)W>BDL"'7"+4=66U=N
M>DK^F;@7!R[&YWWH#"C9RIZ-6FS,^47]*DMQB>2IND-RE*A\Q/ .9&I#,XXZ
MVYN&@#_YT!H"1&) %JNH%2V\(;.(QBH'3N&O%]>Y5%XNGL069I5.F5VMMR@M
MB_[]HC]/;LI^K:60V_7GR7, 0I+:_)2ZW^)\[AS9LKJ_+M2+DVNO.(A,MQBU
MZ&S=+!I=,7ERKSCT"#\TRO3RJ!?%Y.42PM?')?WJFBD$$$" D&4SL6"9/ [:
M+%GL=+RW!C@G;R CH 302_BQ,$]"H:EU!IE>]1F_06D5/253:N1@_.;:NJ:^
M*[X)AWB;/[ZXZ'+J76(E;J0989G::C._"FI*%QTIGK@[VRS$#H\%OWJ8$MG]
M &G%'I+I71K.C<[Y\!;\E,G=)@[;*)QI2=[YMM=,S^D2LW&?>?Z9Z=/;\?J/
M-4;>ON,M&$2V=IBW4=E[;.<<[29F",F4E+)'@5R?+9Q+K&C.XXC'XDO$!FH9
MQLR+2@Q(C:M:UQEQ92HPV6WXHUY]5:B7R2XAN";=>>IH68#*-(HAZ1$OP)16
MVJ!$%,E%KQZ%6M0ZD6"2*+##,M9<ZH0T),YU8CO'N?KNG3FK&QKH'7\IW8#Z
MIT[$R+AMGT:F5^%PS=UG&W*S=C1GT%6/%F#";X(D?Z6I,?DC':9>QU=>[:^,
MKUX'.99%.Y*V@_'OZ@A(:BY?UJ&V<Y,E7W3>>[;F8ZYXY!1SH"P8*0W[JF/:
MA;CW-^L6V_N]G?#?R]U:ET[NZ[X&ETL-$$6XFR0O8#Q;W93.2 EBO#AC"]!6
MC^].O&"UPN_.#L?Y6;QH/*UXVX-X+_[),NCDM=0*KOGCFHM;>AS?6[Y;GTSD
M/[#6Y*5,FAE&[[E;3.41A^C;G+/A?@&9Q1;9>;4Y=YZ4O7U!B:@+_'X"T%4;
M_*/*4F* >5^,/!MR!PDBKXYGSB,*-'2 934<O0 S5CHG_I7L/=L6,]*1,,?2
M:ZIOO'L.;ZG:-NV#-/E8W=S0E#_TQ5_PGAV#@]P90H,<8.R *EN]DK@ ZQ28
M?OOI?NATCB0WJPPBO+) 95?)GN%"O40X<]ST?-<3\/F>LDGY]^BAGDWOXA,2
MZS]C3\T=4Q6BC[QI]5:_H'1HB_E!S(?[[ HCL=>.[+IH8N,,UP#L%Q4[<KT#
M[&^3^XGS:_B-\<NDKNY[_MTN+K1Z;.+U2+1>6_O8C^;'8.;9?_Y]UO6XXL=P
M<$#6UN./*U?L];^'45@\8=]U1T#N.?+C&BP9A3.-06BI-Z*EQV)%L4@I;H6P
M+ITG*BR61)>E#YRPP'4D77L6QH=.]AWA=R"?3?A4M#WPM=]8..?J9=N!!JY2
M7MD3Y/A$?#ME)0DCPO )1X$VOH^(8>SRZ 5I-T!)W_AX)+')V3W1"\,CA98^
M.AWON9,C.#3PS6'+/0&&?<\D)*UWO#5RUG/^.& :FO:.F#0Q)^YI%_U8@/T\
MB]PLG!E(N[SK[=?CX_[)'NPEW,$XCZON#IT*5XQ.QZX+SGYK.\YNUG/V&!;;
M6&!FK5>(/H%J0O+K&H<MP@LN-H8.UQNSUTLNFHLRV4MN9I3\S.1M[XX<SL51
MN:<O77I><?;)N,>5K7LK4E8^+7]C.\\'&[(\;(%QCO46<"[;N0>A3W1O;[8N
M$V.,H:2 NT]>]M5Y6O>'2'V.-5\)S'G-9*9X!Y_-]L9%'2J^=_ XP5CUD(UG
M#,_)64#L>#8+IMP[H(Q],IG?.994L4>.ER)"^N-]#HD*_AJLLSH[UG."F7TC
MY-&-%O<\IL)^M.X-<&3FWE/*F_%V1#8:")!!#I$S$H:7"(%0K@)H[;Y;!!UJ
M;7#T?E53'# >!FIJU(4+L3]W/0&O)CVA&Q%3)X"1J7R/2T$2[ICV1X?JRZ3X
M-:+&VR,ID*T&J]BI6N/IR2YC6X"&3O3-!1B<.0@>+(\+C_R+R!?_Z'1].?ST
MY))2J!+@8H8J<;Z*(ZY:([^%7OSJZ3:YN:G0\D;3TV1T>N/ ;C#DSBZN%?=!
MKS9QP#X//M@5\=CG3_"@3Y9(@TZ1O=L_'K=)8OBL*='3*__]Q/$)<91?_9G7
MV%)X?O)F+&X"OBS1D)P9K]SU;AHJF/T 9*0HCW1$#KO.-Z%TQ!YFJ6NM4D2/
M+UH:!_"_!ETP-4.^<SQ"1AU-CFG,;-G!.4W$PSWT''/!QF'AQ +L'-N4M4-I
M#\&%!5YB=!?:"B*(>F_5E4OM"20?<=9>>W>_;-G1!R&?AO?W-H>T3#=E]^!M
M#Y4U/[J0M=;N[M\]'XD!G87FH""E#FU.= SK)QT388RC<_-[J<H#1;B0*>S!
MZA+<_EHL+GINB+')S.5'5_M]R>]+WM1;!7L!WHH;Y'8*X$^_3=?1%#$^YB2H
M34,90LBC [&RGX\06:P-4+%(I86OW9R5V_9\@KQQ$"5X$N(Q4$F5CT3?'0GY
MC.-&VKU,K$([SDLUA1%#C.P(@VO^B5>_N0Y/KXOUX<Y_1AB<8]$/?YPI&?BY
MPNXGPVAZ?BS'29ZSQ,DG\6F,BZO\ZPFO>_PI<_-537MZ.*?BZ*"9<?CWS)X[
M.Y2[;W&^V%H>K _'&%4,=78;4TO\[Y5[>.HY3;[)W>)X)[K,'_4FX,\2BW0G
MM?ND_JPOP&ZG+R$Z=OKIS?]VB9<Y/&Y$S,D4*F,-X.5_^E"!X% 4HNO\A_*5
M1%*OX[NM7QLMH&W;W[*8)U=[YL;=?/JR$?OGB5.4B?C5QW#/$.U%_[_>;XH&
M7%V*[&#K*4U5=Y3Z8%X7(QZ1Q#(B\P75FK=-G._X7'Z&@$,VBYT^]CWO+AMI
MZ:H5^$:?V73RC]KGK=]N#0?$P3^G*S$:P_R$;#@4HP58..Z.P,#C1A&?2'\U
MAE*ULL]0M* >;H+4[=.TV@RTD1H*I3:G^KZ-\8,<_ 5'!ZJJ[$MN7!,5F.[M
M.YQMDE*W^;!)N5^;*S8S9N ^=MO%1Q5^._VN?#RD^#">?OEK5HGEF+U3OLL$
M/:>-GE-?3\;2W^(Z*9"'P@NT+_EV=W%78 Z*!VW]:C33*S,E;N!ULHUM6@=F
M:0;$P.#0\'T?XV^$]"Z9VH'LU+<]6C/ #%T:TI>K[[AO4&QVJ=VN_J6'H H;
MJ;1>/"#XD-YN<9#]/%C=?Q*UHP5X7_!\2A.7LPNP._+YDO<Y8MN,-66#)%OM
MM"W@EKRB&$*IP&EH:^6F^N;8V<OVXFNVR'N%T6"#6E]K<;V6]0>2C."K/P9B
M2QD@@=/O54HT%@=R5&X8'9(;+W[$%]UQ]0CIFNC!!28!#OD<:6[B52$C6P=)
M<?$1I:JD0V[91=NS*1-E0K;2N%B^%M(&!.T(7;*5N@>W-+9UMQ"Y<F+,L)_
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M ;Y[+:=M6#6#=O'ZUD$'_ISS3EP698GXL P'Q".4JY-$.*X]IET#-]7+22M
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M:.XOHPD:N#,[(^:5C2=M7W"C?40(3_0_&OL904,<9X-T#FTW4W"32'>TXP2
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MLCCN&6[1OL&D4ZEY5.@9%QI?[8F[.74LK'HV>Z# ;>G[7):YXB]]V+"?:'<
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MGX,DG>^A0\\D(/MTZ3O6=;&[<5S-P1[4Y+I(!LLF)K'V";$<,<S.=:-2M P
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M6!HN9*P:/B\ZX^9R+U9&,Z?X'^Z=29]6;QC*,W3K\FW[AV"P,ZAUH9&5S?W
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MFY0'X")AH368D#X=G+5=+B"<P5K!P3)>9D+HFK[X3>@_\!,&S&7P?I@@_F#
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MN63G+PV*1)?AOA&B1[>7:08O6USC.K%->2%8T\&U@(T>4-_.%MK!15+<@&Y
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M?A>&^! .^#[K![5F.(8ZXD^\OUZ5?)1;?>[Z/*+RZ<9%/Y]!'1-$F5@;KF8
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MPE]_3JV1OR)1T)9Y*K.5QD-?H:FN*D5CQUW\0'BN E@$D8H\7:407+0<(G)
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M-<3O"@'"_T%F"BN9G7"%YPAXK/#M@ XUK_19Z3*5/0J!8'P?PP' <3";"''
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MH[7SGDUEA</&F'$+;TMY\AVRL@Z2#I36UZ/.S&)&+:A)8]K  "Y&.RPV7&M
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ML>F/NO+J;[I*<>_#*2T;HY;"%]\^Y8$!;$*X[6ZVT"ZTVZSWTW@3\3>Q817
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MP(X0#?&'O*!J404BZE_2.,H8E'VD.!;9A]GU#Z=LE/?>GQD=?6*[H/5B(N4
MD825W6!&PW2DR"&Y)KYNZ0*D)L;F+&/RSTM#:@E[QA1UPWF4:!Q;:<D<3C$Z
MO<(1D+(Z$1KOH//]',>>KI;&N-+TD:[;QK5)#V;2*7-CMDD925:UVFN^I(Z.
MCOJ/+J6F L%!@L,ZG4U-'5Z]"0D)Z^.U=9> /^JU]QS=NBOQF/[#Q+Z&_(8&
MI<I"<Z7F$Y#*,XHD&2J;5 7^@OY"Y$WUMDH/HPP'^)0AUM:X38VN(E\PJ%T^
MB55_WM!75O[9G6C?-:R)"QY^]^"ZMO]PXH%BQ\YEQHY.&.[X?7UF:Z-W:1=[
MQ-6//?+O]<Q:_7H3[^L+GK$V9Y]L/]#G_]%UO-ZR9MZD/6"\F1)'QF<_(VX
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ML/C/:&8EH@G=39KN9?ZB(17QFL VC/9K''48'PID=V5&L3'=X^!AAAA*XJM
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M%Y^4F#9O9EL2+/G&0J!4\_<"OU;+7@@^,I11>B;9:-8Q:!"492$>Z'4HXW>
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MF]!82ZSQ11-XL)FP$88L"#A7JIPJG KO5;4'BIXUI UEFE5%GFKU,]*SU#R
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M7BZK'1G7:W<WR=!CCU*(N[XVM>46OO**_J^:(7UX+U5$T(M1(H;<_>]="#X
MB@XKA>#,7W3$3"/_NE"+B"/W\J. ];4='!4T#'\\*];N?3-*>[P= 1ZWP&*
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M8 T=,//9RL-R0H3:GV7#8W@O,M)Z$JO2C%,!OBS%<:XP(=-CP3H)-/27[-L
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MC7)V#F,G]X#K0TG?^9KV:GKEV'I*^K+3ZZ[3QQXVNJ3\[%L@VY7'O ,,<G2
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M$&NV5V5\'H/O,M;>*X>) )#M)'9_M 9%8GAQ0QBT8?8L") YH4K=4.C'9;P
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M/G-%W^E2,X7/=T\//1PT0,W0*"$![BMY<RH-R$LNK>+FD]%E1!7;6"5[,<V
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ME6 ?IN8@UZ\"OUB0Q%=L:&)@)T.?K9B_B.;%_#2-EX%8U;.=XQML3F.RKT_
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M9P\"(#>VUSS?I)X]"^EB)&K?ZTR#LC25IR3;3S^LDPU)#9G;=[EO3+KGE^P
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M8:4.UO8.]C"74*F1&;W.R/TFU04G],;,YMQ!S9]_4LYUTZ\PT";QIJA9D+C
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M^W/37;&=;0<ZG)!PV'VF@O>;T#)D.^HAWQH:PL-VB8(DS5=VEPN(#&Y!J_/
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M49U!F0AO486?7U)MNMBSF@O,H1PCOPL400&W0Q_X;?_9DE_4>-">%-HV*)/
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M2D29[S'VY^2'(E 3$69HL\&E"&:M_3[%D2_P)$?)\.#&YR=",A3# ^$^Q=$
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MBRVF@LD3XTYBFHBY2"+;9])38@P>UR]+M]W#-U629#';%#?K[3SW>V7+P-#
MB!]<%P6X&LJ;F,LR& ]L:+6Q-1(*_P_2B5&$T_6??RGNP'U"M=B)ZR>NE]5_
MM#@AR!.FRU*@)T.JS<0@*%:+;4;*FWP?JH1_58=O[#/9Y1+J$24B2E<A7;_.
MMV)DCA;A-W?5;YX'KCK%]F,_6859V0E3JWHKWY$(\GB.Y#(#/_3A,(U,=JY=
M;-#?;SGV*:H-+=JR,\QW.20+C 72'FJ,!3 /;%JW>"77I7T-^/Z^#&'+FH09
M1X3-JKEP5!KYY3 F"WKHB,/UU9$D5I43IDDM($3VQ'D.IOYCVY&3] K&MP"&
M<<T . G4\X:3)&V"EW82!D@+I5LOYC#$:N/]T!/Q/9J3FZF'_:L,T( K\:8P
M&S5$UY,XSS1 <\F^OKH0N 9',R0[TI*O$T^'7FEQ$@L)\+Y>%O(](H/V3$WS
MTZ9+4%_O+>\@31#.MQN.<WJQPHF_3/LO;07C-GN(7]W.@@OHUNC(BU9)GR G
MLJGR?W&Q3DDL;^!^Q3%D44)=/Y"39$1(&1I<)8K*8GH925[XTZ2N:^"+.\33
M_K\4C<7]=()H("]9G#RS2J\L>_?[52-"]L$?("U -A ^?$#=/?JWY7@<]O@D
M6SBE)UO"\)SR:F6^O9I1;E"+JV<Z>9Z_WCU2"<Y$LB*:X]FFUQCVN]=Z4_FY
MM%@=?[6HJ//T:'W38BFF@&H2[L_X&NZOQL#N0Z+06V0F0XFA9]U)CM^Z@!7$
M5^?K1JVS>?LJ@-(C]5,R]=C%3?!JXVD<T).[-V5*%^\XU'OW."VFEQKZF!]=
MEW!JLSHXP>F1:YD3\@I^$TH)7OM!BB $&N7Y:#SWT7#$L\<&+].8--=W]#;,
MN-?'+Q5_['6?6+ ]\;]LA3%Y.F@16=>[*7'S:)]'?RDPC@PD<\H3& JQPR73
MBQRZ+,;U7H,<]O6(30?!62 &F(X@2^=%&_Q0HI*]K'EK[(Y*WO3>J=R(Z.%^
M*4GSJ@O>6%V)BS[97J^)^-5/XYVXU00@WE#HOY#NKKVI5UWLUU]=',O'HP7
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M\ G":2"4Z%8N[6QR)7UFM5>(;,7N.:(VX2-X+L\MP15>8;>\D]=\C(CY9!!
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MH"X!ZZ";BX7ZB\;RW<?)@4+L5 '45;K!WE,L,3\^FJ5">"='=3*?C//.NA"
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M?@\+/++2O&I@ B9'I@HH;53X@;0;2C%=$HS06O:#XG)4>I^SDX4R4NS7,MI
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MV^DMU3/]:Y6/.EGI#!ER8#12#&W,JF3(/-6#":!-6;%5]1X@5C9V#3=E/1J
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M%Y/,VR;I&3DM&9_H_1RK,_]*YLK/-N_^S0^;?Q\K/^U-_@=02P$"% ,4
M" !S@&5:)8@9D9;.! "P4S8 $0              @ $     9F%T92TR,#(T
M,3(S,2YH=&U02P$"% ,4    " !S@&5:+ I- @S1 0"ZB1L $0
M    @ '%S@0 9F%T92TR,#(T,3(S,2YX<V102P$"% ,4    " !S@&5:'CY4
M #8R   =Z@$ $               @ $ H 8 9F%T92UE>#$P7S0Q+FAT;5!+
M 0(4 Q0    ( '. 95I,H+W/+@L  &51   /              "  632!@!F
M871E+65X,3!?-2YH=&U02P$"% ,4    " !S@&5:(^;4C1(Z  ")% ( #P
M            @ &_W08 9F%T92UE>#$Y7S$N:'1M4$L! A0#%     @ <X!E
M6LH>-B!;!   )A<   \              ( !_A<' &9A=&4M97@R,U\Q+FAT
M;5!+ 0(4 Q0    ( '. 95I+W $%LP@  *DP   /              "  88<
M!P!F871E+65X,S%?,2YH=&U02P$"% ,4    " !S@&5::W&E4ZD%  !,'P
M#P              @ %F)0< 9F%T92UE>#,R7S$N:'1M4$L! A0#%     @
M<X!E6LI>+B@,:@( -(H" !(              ( !/"L' &EM9S$T,S@Q,#DT
M-%\P+FIP9U!+ 0(4 Q0    ( '. 95K-?.\  \8$ ,?]!  2
M  "  7B5"0!I;6<Q-#,X,3 Y-#1?,2YJ<&=02P$"% ,4    " !S@&5:MV_O
MT3SS 0 A' ( $@              @ &K6PX :6UG,30S.#$P.30T7S(N:G!G
M4$L! A0#%     @ <X!E6BU-W/D]WP  VN\  !(              ( !%T\0
M &EM9S$T,S@Q,#DT-%\S+FIP9U!+ 0(4 Q0    ( '. 95H[!)[1KUD! #9I
M 0 2              "  80N$0!I;6<Q-#,X,3 Y-#1?-"YJ<&=02P$"% ,4
M    " !S@&5:EI2Z"7;6 @!)"0, $@              @ %CB!( :6UG,30S
M.#$P.30T7S4N:G!G4$L! A0#%     @ <X!E6L<V;4OVJ ( H\0" !(
M         ( !"5\5 &EM9S$T,S@Q,#DT-%\V+FIP9U!+ 0(4 Q0    ( '.
M95H!I)2 HJP! /B] 0 2              "  2\(& !I;6<Q-#,X,3 Y-#1?
M-RYJ<&=02P$"% ,4    " !S@&5:?#EXZ/D9 0#@'P$ $@
M@ $!M1D :6UG,30S.#$P.30T7S@N:G!G4$L%!@     1 !$ +00  "K/&@
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>fate-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:fate="http://www.fatetherapeutics.com/20241231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="fate-20241231.xsd" xlink:type="simple"/>
    <context id="C_805cb483-0110-4ded-9a01-7cfc77c9ed1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_805f2b9e-0637-4e41-afb0-b23379a1c6bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8073b9ee-958a-4e70-8014-118578a7c26b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EmployeeRetentionCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_821efd00-9226-4b6b-acf3-b68a5fe00775">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">fate:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="C_82ed1266-1238-4e4a-9fcf-ef99a6cc8c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_83226ba1-7f86-458e-b153-94d4da5af37e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8515b700-bba4-47e5-8cd3-b446bc59b1e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_85e19190-1f38-4b84-928d-1b10e8632e63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8647c356-eb54-4cef-883d-ccfb6f2c7d27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_87a8873b-2dbd-48eb-a3c4-71b7b6ecb603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8a02d4d5-85f9-464c-8c77-3930bc912652">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8a618607-b312-44dc-9409-e35bb5b9ee3c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8ab196d3-69ab-4d26-b22d-9350aa81b0a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8b609e2a-1e60-4b1e-b0db-d6a181ac993b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8b7007bc-3d95-44d8-90bb-9b611207cb91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fate:November2016PlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-11-30</instant>
        </period>
    </context>
    <context id="C_8bb72297-578c-44bb-bcc6-356a01b01bc6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8cb1a266-41ae-44a5-9398-af9a30767436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">fate:RedmileGroupLimitedLiabilityCompanyAndAffiliatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-11-30</instant>
        </period>
    </context>
    <context id="C_8d696b36-8d44-4c55-9a08-7819757a59b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fate:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8e179833-9ef6-4071-837e-b071b6572377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fate:StockPriceAppreciationMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8f2c86db-20b2-4603-88f9-51afe5ae61e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:AmendedMSKLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8f7a9881-7e2f-4fbb-add2-b72bdff2cc59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_914c3fc5-d128-4c00-a001-75c4add6174a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EmployeeRetentionCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_926e58f0-2ed3-4a7a-845d-34981bf5a884">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_92ae6775-3137-46d3-9d0f-95226e202633">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_94e46ef6-c33c-4951-8ea1-9765cebbe9a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_977cdbf8-9aef-4f82-a0e6-e955360ee9d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_979e1e1b-585d-4deb-90b9-0ebe66970591">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_97e27d0f-6140-4723-b214-d402e6450492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_98c3e645-6b5a-4fbd-a7b5-c0bf4a509495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_99d86bdb-f819-4ada-9573-3db9972228f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9a61a4db-53f2-4f25-957f-9ca42291c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9ba83a55-9961-4e4b-8d65-f9275f3c0342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9c256c41-e766-4081-83ce-a706df7de970">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9ddb50f7-7408-40d0-a949-d5236775a322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:StockOptionAndIncentivePlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-09</startDate>
            <endDate>2022-06-09</endDate>
        </period>
    </context>
    <context id="C_9f433503-cde7-4c8a-84a1-6742576e7a9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fate:ScientificEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a289a3e2-7277-4925-8f75-b1b8d86807d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_a31bca4a-3e98-45a1-a466-8da5458c6984">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a3ff6b11-0c22-4b27-8dc1-b44fdb3a724c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a53d5f30-4ead-4f12-abb3-1d519e3a22c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fate:JohnsonJohnsonInnovationJJDCIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="fate:StockPurchaseAgreementAxis">fate:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_a5e8db20-c26c-4eec-81dc-6ac0d0db25ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a641074c-59aa-4f3c-8a89-4a805c5db02a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a6afb152-c99a-4b4f-8ec2-a459b2a92d61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:JanssenBiotechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a95850c5-78b7-4a48-b9d3-80bfd15bcd46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fate:ScientificEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ac2d1d69-5e84-41e7-b540-c202f61299ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_acf53715-2f34-438d-9496-5f75227814aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="C_ad67a626-7c86-4e93-88d6-33d3a62a1c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ae9121c7-17e3-4b53-8ea5-3c6e73560888">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_afe59ea1-745d-4337-875d-4dbe66b0f606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="C_b1694544-d57a-4079-9403-45d7021d8147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fate:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:StockOptionAndIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b18b95bd-40a9-49db-97ef-2faba14a93a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_b1dc2798-8465-41bc-83d9-cb6a02fcf5c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fate:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:StockOptionAndIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b28e1793-9bb2-4e61-9e28-a2fa970d72c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b3047a8d-c14c-4b39-8c15-7c44dd30c23c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b416aca9-c7b0-442c-b1c2-2934711580f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b434e138-ff00-4c3d-bbe3-be9b301a7015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fate:CandidateTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-14</instant>
        </period>
    </context>
    <context id="C_b44c450a-2dc3-4462-8d2c-f77c56795b1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fate:JohnsonJohnsonInnovationJJDCIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="fate:StockPurchaseAgreementAxis">fate:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-02</startDate>
            <endDate>2020-04-02</endDate>
        </period>
    </context>
    <context id="C_b524e977-baf9-4884-add0-8ccda59b00ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fate:CandidateOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_b5de5eaf-450a-48f0-8a17-e88454281754">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:JanssenBiotechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b7a41695-3727-4f36-8184-049efe051469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b831d8dc-5480-4f60-b15f-b532465e4ca2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b8f2b2d3-e3a5-40c0-8565-7b6bedfecd7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b943fa46-6631-448b-b8ef-ffce3d36d5be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_bbc6feb5-7fbe-40df-a81f-6062a8a5fbb8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_bc041da4-e745-4f8b-9d20-f7e54aa2e7d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fate:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bc446b6b-8934-40b7-bcdd-742d1f50b677">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bc45b335-2d95-4276-ad2c-dab6f6cd2b27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bceaaf53-4594-42b0-af63-0c188d7eaf41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="C_be1fc325-ff5d-4b35-952c-3aa39e4cfadc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fate:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bf1abdb0-874a-4c56-9fa4-d32731526c6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fate:OnoLetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_bfbd6f4d-b000-45b5-9a79-42c6794f12c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bff210f5-02f8-4782-9744-563ff4baaf6c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c138b804-b864-4563-8180-753f77d0e77a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_c1b46ce1-8237-43cf-86cd-6a985c5ce0ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fate:CandidateTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="C_c2029f3a-6dfd-4668-a724-7134c2e52a11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c243b78d-2e22-425b-8d5a-ec8cc2edf72d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c3192fe5-8746-48bc-b8dc-2864fac0be36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="C_c351f635-f8e4-4ef1-98df-8b05b6facf67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c3abcd74-97fc-43ce-9d4c-92aeb8a7a7d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c4256f0f-bf1b-4d25-ba9b-95785d196f09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fate:CandidateOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-13</startDate>
            <endDate>2018-09-14</endDate>
        </period>
    </context>
    <context id="C_c52c4c88-5230-4895-b325-46e4cd2518ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c5d2707d-a24c-478b-b6da-97a0477550df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fate:StockPriceAppreciationMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c61bcb64-4368-4879-8eae-3bea4e1f47f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EmployeeRetentionCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c8f88322-9cd7-4ec4-92f5-a0a2e5bc4363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fate:PerformanceBasedRestrictedStockUnitsPrsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ca3bbae4-b7ef-4100-8179-d51130791abc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fate:CandidateTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_cacd56f9-2988-4b00-88a4-4b37683a2fc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_caf5635b-36dc-4bb5-83b2-d3bfaff93dac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:AmendedMSKLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_cbf96da0-08c5-44ae-8e97-d5dc42fe1fcc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cc863354-869b-4206-b33e-59e639b10e95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_cc8f53ba-0de4-45e3-a08a-c8528a309add">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cd31cee6-b14e-476a-ac84-63e70036233f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ce45b517-0884-46c2-a4a4-3f9f7359e4f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cebe70a2-446f-4a43-a422-52cd427ada3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_cec4892c-e35c-4232-846a-7628de00f77e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MunicipalNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ced1b62f-5a61-4b35-bc5e-24a1d2c9771c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fate:CandidateTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-14</startDate>
            <endDate>2018-09-14</endDate>
        </period>
    </context>
    <context id="C_d0dc00f7-c9cf-41d7-89f0-cc4fe78c6101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:StockOptionAndIncentivePlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d0df7940-8ed7-4acc-bf9b-0fb78b52dd30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d21f4f6f-8713-4aa6-8283-c3de33b87b2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d2920029-80c7-4108-9176-bd4bda38a66b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">fate:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d2feccdf-3708-47ad-92f7-48fa021ea96b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fate:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d7619f35-5038-4477-8ad7-9f872ef12d50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fate:FtEightOneNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="C_d7661ece-b1bb-47ae-89fd-c9e5fb4fce03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d8f9c7ba-407a-4a32-8e3a-a7d43910792c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_da752dee-4bbf-4d64-b7ab-bbf88b372ec6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MunicipalNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_dad32687-8050-4e65-8354-068f686b84df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">fate:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_db4ca2c8-7dec-42f6-9326-27fb5b437f80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fate:ScientificEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_dc572fae-d1e3-4dc6-9902-fa5e71563255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:AmendedMSKLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fate:MilestoneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_df4185ff-6291-44b2-b42f-fe0d6dd2b4c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
        </entity>
        <period>
            <startDate>2008-12-25</startDate>
            <endDate>2009-01-01</endDate>
        </period>
    </context>
    <context id="C_e07453e5-70e2-4589-84ee-63184d1649d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e07a21dc-a40b-48ca-81a4-731bcea56eb4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e122feae-e127-43e8-a5fa-96cea5382fa8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e243220b-bcd5-4012-8eef-5b2d39ca5281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e2c30eb4-cb8a-4c56-94e1-15d379546979">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fate:CandidateOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_e3dc601c-f824-4b78-bf0e-07dae896ef9c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:AmendedMSKLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fate:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e5f0eeec-87ae-44d4-9289-b8c650cd8dd3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e5ff0703-7a69-43d6-9e8c-8654aebbd5ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e741f2c7-90d6-40a1-ab1f-b596c102b3bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e9fc8192-6581-4017-a8d5-9e3b97aa8020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fate:StockPriceAppreciationMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ea581251-e0f9-4e1a-ba72-0e031fd4585d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">fate:RedmileGroupLimitedLiabilityCompanyAndAffiliatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_eb400e71-8a95-42b3-aaea-dc66ceacad22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_eb50e59a-b806-4c03-9930-ed4b25c0c2ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ebe17901-fd0e-4988-91ae-8f5cdea8a285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_edad96f6-a6a9-4612-9c79-acc88724dfb5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f1dea256-3b9e-495e-a654-b31799d22af3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-30</startDate>
            <endDate>2025-01-30</endDate>
        </period>
    </context>
    <context id="C_f1f2b64c-9a2c-4bc4-9f3e-aaf2c1023a51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f255de04-23de-47b2-bf4a-1d7b7bf4d379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f28a10a2-8fc0-44c9-a166-60bb7e722119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:AmendedMSKLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fate:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f2e41800-cc41-4b94-a30a-fb6e56d72a7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f482e228-69f4-4567-8679-ff6ec159f4e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f5465cc9-eacc-41b4-9cfc-f0dad102ddfb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-13</startDate>
            <endDate>2018-09-14</endDate>
        </period>
    </context>
    <context id="C_f6acdf54-a780-4f0d-a5a2-e9a7888f459a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fate:CandidateThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="C_f776f2a9-7c7a-491a-991b-ad0fcec60954">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f98f7f9d-7ad9-48be-9ec2-e497587e292e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-14</instant>
        </period>
    </context>
    <context id="C_f9d2101e-3c01-4cba-a24b-48c0f0b161d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fate:ResearchServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_faac2f19-7ee6-46a4-9641-0352d10ce9d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fb2cf769-bd37-47d3-ab4b-f93d4365d73d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fba769b4-c31e-4914-8c9d-294bd6abcddd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fbf420d5-255c-421e-9863-8fd4aeac0e96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fc28b484-986a-4aa3-ac45-ec88d93742f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:AmendedMSKLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fcdf4845-34e5-4331-ba78-17eade1d2dde">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fd5563c2-aea8-4a6a-8a5b-e1869c4151d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fd6d1a6c-963f-4a77-8037-388fc2ef3404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fate:StockPriceAppreciationMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_fe5fbe72-2c15-4c48-9e0f-6faab2b2ebf8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_fe855db0-cbd1-4634-932c-99540e86df56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fe916e0a-bfad-43cf-8d7e-6d37daaba7da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_febf2ab8-3d7f-42f3-8e8f-9f2795618370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:StockOptionAndIncentivePlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-09</startDate>
            <endDate>2022-06-09</endDate>
        </period>
    </context>
    <context id="C_fece1b4a-7679-43ae-91f1-803e3e834572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ff4ddbec-d136-4b09-a4a0-5e321b435ca7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:AmendedMskccLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_00cbef97-1aad-4784-a3ca-62ddc68740ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0284ad68-4270-4896-8d67-06f5f506fa6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:AmendedMSKLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fate:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_02925833-8677-4697-ab8d-c844642a03e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fate:November2016PlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-11-30</instant>
        </period>
    </context>
    <context id="C_0519f681-f046-4690-9e46-0dd9cba066f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0792edb8-8c75-4ac5-9ff2-3638bf624ca6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fate:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:StockOptionAndIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_07bf6ed7-be95-444c-ba21-1cca631dcf34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0929cf2c-6047-4152-8767-1d831d5874a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MunicipalNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_094d60cc-9d76-4080-b9c2-2f03fda72660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0ad23255-7a2a-4f76-96d1-4206f5e0c875">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fate:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:StockOptionAndIncentivePlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-09</startDate>
            <endDate>2022-06-09</endDate>
        </period>
    </context>
    <context id="C_0c2bd9af-d58c-4b2f-a7bf-36d6102fcb98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fate:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:StockOptionAndIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0d302d4d-cf60-4de8-bf11-2d38492826e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0d4321be-2b98-4d77-827f-dd1e376a2681">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EmployeeRetentionCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0d79e020-c388-40bd-a1ab-ccdba8d6c0f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:AmendedMskccLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_10f659e3-4c5b-460d-bada-3a35f1b947ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_126fd19f-3eec-4444-a458-398859e1ae58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">fate:RedmileGroupLimitedLiabilityCompanyAndAffiliatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-11-30</instant>
        </period>
    </context>
    <context id="C_13e7d164-655d-47b3-8816-15b789699d5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_14a6993c-8757-45a1-9ffd-ead3d146845f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fate:CandidateOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="C_1cb3ab28-0ea4-4691-8f06-03acbacd707e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1cf4be6b-4800-4f2a-bcb7-d38f5709c7aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1de58b0e-3458-4fdb-9110-32fd64de36b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1e42a653-35ec-4959-8224-d96563396f11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fate:JohnsonJohnsonInnovationJJDCIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="fate:StockPurchaseAgreementAxis">fate:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_1eb4c942-f4c7-47f9-994f-95d18338c9fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1f598670-03c3-4c12-a086-312e2fe99e74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fate:November2016PlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="C_1fd96e00-b6bb-46df-a4e7-fd1bd210a4a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_208fb1ba-72a9-4ce5-8560-933151337e0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_228a9429-468e-442d-a38d-9b5441b82b3c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fate:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_22baae92-8d72-48bd-bc26-99cb822ac436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_232568ed-817b-44c3-b6de-570d4f2c0eb0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_2341069e-9c1e-4801-a758-1b22a7e72c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
        </entity>
        <period>
            <instant>2025-02-25</instant>
        </period>
    </context>
    <context id="C_235e1198-6534-41bd-9a50-81f2b487638e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_253be32e-0a0d-4574-b01a-92170bea60d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-10</instant>
        </period>
    </context>
    <context id="C_2575346e-5767-4842-b149-16db06beaf77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_26715720-1a7f-4abb-8779-318e83f66b8b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fate:FtEightOneNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_28eaa775-35eb-4f9b-a403-7245d490401e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fate:CandidateOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="C_2a171456-ff92-4460-82a4-d71189a47904">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_2c762660-e17f-4068-960c-6e97d50571ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2e15e9a9-cf48-44bc-a273-b652fd1f9dd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2e7da839-7541-4872-8420-d82b12974e64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fate:PrepaidExpensesAndOtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2e9f4ffe-10e2-4108-a3d9-3d3ffddd7ad0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:AmendedMSKLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fate:MilestoneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_306e095e-df5e-46ff-bb9b-07308bdff1ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_309808ad-31af-4b1f-8e61-083557c2542c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_31099ea4-f12e-4b2c-9160-b411e31dd257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3121bc29-a859-42c3-8c2f-1cc407771269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_35de3dab-1655-4fae-8a01-0f3d2ee62306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_36c7dc1f-1f68-4486-a90a-7021092d1f27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-02</instant>
        </period>
    </context>
    <context id="C_3993554b-9513-4d91-b34e-db9cda665ac3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fate:CommercialOptionExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3aa72a78-bcb4-4041-8da5-aa19c436d13a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:JanssenBiotechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3afaeabf-cfe2-4152-bbed-2e1495b5dbec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fate:ScientificEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3b620cbc-79bd-4c67-b41b-219dae13d7b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3baffb0b-73df-44c6-85eb-9c15e2247168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3c6a67d5-eeb4-4acd-987b-91a972c863ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3ef185b6-d2e3-41eb-af64-8722d09aa801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_41031951-bbc6-4651-8f90-88528e8885ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_41a96d2d-db51-45dc-a3d4-a00f6dd5f281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:AmendedMSKLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_439addc5-9548-4d3a-bc32-ad8b68c23597">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fate:CandidateTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_453cb5ab-24d8-4b66-961f-9f4dd63a05ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_473eb942-1f90-41e1-b4de-c3380615c958">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fate:JanssenAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_47a8c41d-7932-412e-a1cf-a28cc3a2ebb4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-14</startDate>
            <endDate>2018-09-14</endDate>
        </period>
    </context>
    <context id="C_47e3c4a5-6a9e-488c-9ae1-4d92329efada">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4a27cfd3-c4bb-4733-abe8-a5141e381e3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fate:JohnsonJohnsonInnovationJJDCIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="fate:StockPurchaseAgreementAxis">fate:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-02</instant>
        </period>
    </context>
    <context id="C_4a42522d-d9fd-49e6-a443-91460120f25e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4bd1be9a-9ef2-4939-bc4f-c8ced0fd9412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fate:CandidateTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-07</startDate>
            <endDate>2022-11-07</endDate>
        </period>
    </context>
    <context id="C_4c6c4dd6-4ab5-46a0-bc89-10dab775b034">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4cba0539-2744-4997-a638-c19edef83006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4cd86a5a-2ced-41c7-9f0e-9f68de9fef11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fate:OnoLetterAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fate:SublicenseConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4d2a294e-b4ae-4f93-abc5-44f79d16ce96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4dd02f91-14ae-4ec9-ba06-e9a1c6c69591">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fate:FTFiveOneSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="C_4e4a3db2-068c-46c3-9e45-17fdfb12f653">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fate:CandidateTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-13</startDate>
            <endDate>2018-09-14</endDate>
        </period>
    </context>
    <context id="C_4e67b46a-884c-4f90-a95b-2ef3d7aea6aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:StockOptionAndIncentivePlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_4f0fc4a6-d283-49a9-971d-0333511e8d5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4fb1c409-95ec-4aa9-9296-606146c23c7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_50b6586c-23fc-4c7e-870d-e60fbf83a55e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5445f2d2-5e33-4281-9239-4322ce42c9cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fate:PrepaidExpensesAndOtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_54bb083b-1c65-43f0-903c-ff27e3c8a59d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fate:PerformanceBasedRestrictedStockUnitsPrsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5617f7c9-ae5a-4956-8221-b18d672649e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fate:UpfrontFeeAndEquityPremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5773cffb-0793-4d07-bf3f-34a1272bc4c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5928b276-cfe4-4ddc-bcb9-ba1063ef39c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:AmendedMskccLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_59f16426-b465-46ba-aa94-5befab44d9d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MunicipalNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5c738271-04b6-46a1-bc09-e0d54f7b433b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fate:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5cc2f3d5-6422-4ca7-ba47-f826548fe079">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5e663327-b86d-4b6c-a039-7b7d8ac711f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_60fe76db-e159-48de-b30e-daed5bf713f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fate:ResearchServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fate:OnoLetterAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6199ef4e-6533-4919-aa08-7b8879357aa9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_62a2a941-1986-48b3-9796-58a5b98fe1ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_643af01a-b028-4eee-8c3b-c5192d3e319a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">fate:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="C_6558896f-2704-4857-9934-3ac8fb755e52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:AmendedMskccLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_681d2241-9055-4fd4-b908-7ff2e5469107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fate:FtEightOneNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_687fd488-edfe-4a2c-989f-8d86d4b11852">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_68edd7f5-9eba-4cf2-9c06-c892f1e0d26b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_69c1fc96-8425-49fc-a5df-640ad6ae407c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fate:CandidateOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_6ada6b38-7f9b-45ef-acbb-49e492518216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6bd370ac-1bca-4909-9d77-e3887063a36a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6c678e63-62cc-45c4-9884-6caff102c094">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:OnoPharmaceuticalCompanyLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fate:CandidateThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="C_6c749fc7-3fa7-4811-a7f5-999fcbd298ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6e421e14-6d5d-4504-b9b2-ead06e38f45f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:StockOptionAndIncentivePlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6f3f91dc-9183-4b96-83ab-8d0a1cf21e83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6fcf025e-eabb-4c7b-9b3c-cc45fd082e86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_705e67ff-045b-436e-92bc-cce8ba8f5edd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:AmendedMskccLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7261e0f3-a26f-46dd-86c9-8888bb0227e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="C_7272a2e8-f365-434c-8a2e-ca7e7c674867">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">fate:RedmileGroupLimitedLiabilityCompanyAndAffiliatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-11-30</instant>
        </period>
    </context>
    <context id="C_7388956d-1347-4f5e-b3bd-7ff47628173c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_77ef949f-bbd0-4757-abd9-d2cf6948dfea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_780d7cf9-0c20-4ef0-a014-ce112efe3de2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">fate:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_79fca80f-8b40-4c0b-9152-12e26417ea73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="C_7b598b8d-7ac7-457d-9009-819763ca7cc2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7bc2c0be-3669-4b09-a396-9031cd164016">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fate:AmendedMSKLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fate:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7d04432b-9ec3-45bd-848d-144b3dd8b270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7d5efccd-12ae-4328-a434-fc9ca1b3827d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7df46466-a06c-4ab1-909b-db1961aa969c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7fc491c3-db47-4e1f-9c36-5199ecfed9ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Segment">
        <measure>fate:Segment</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_aab7885e-9564-4d4e-8a32-4335881564a1">0001434316</dei:EntityCentralIndexKey>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="C_232568ed-817b-44c3-b6de-570d4f2c0eb0"
      decimals="INF"
      id="F_c9ca9aea-e8bc-4cae-92f6-da083b3a525f"
      unitRef="U_USD">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_c3192fe5-8746-48bc-b8dc-2864fac0be36"
      id="F_3b4d5183-26bd-4ae8-90cd-1552e3260e2f">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="C_a289a3e2-7277-4925-8f75-b1b8d86807d3"
      decimals="INF"
      id="F_f6ca1fb2-0d37-4e86-ad77-62d2e37595bb"
      unitRef="U_USD">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <dei:AmendmentFlag
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_0c353b9f-246c-41c7-8d40-c96c7ea72723">false</dei:AmendmentFlag>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="C_8f7a9881-7e2f-4fbb-add2-b72bdff2cc59"
      decimals="INF"
      id="F_9b4227fd-6f0b-4b1c-ad07-559350ccc031"
      unitRef="U_USD">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_afe3f5ce-a539-4e46-b9af-82534af2ee03">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      id="F_89c55976-9468-4820-a52b-dae8d981199b"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      id="F_4871b3f6-bcbf-43c8-836c-b69e9e915c2f"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_21f3a184-e10d-4206-ab0b-30c744f8de9d">http://fasb.org/us-gaap/2024#LicenseMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      id="F_55fe3d11-ab15-4251-b6ea-70a768289f34">http://fasb.org/us-gaap/2024#LicenseMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_3afaeabf-cfe2-4152-bbed-2e1495b5dbec"
      id="F_36b18d82-10b0-4496-9bd3-0d13c236998e">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <fate:ShortTermInvestmentMaturityPeriodRangeStart
      contextRef="C_2575346e-5767-4842-b149-16db06beaf77"
      id="F_ac600eed-1df0-477d-b544-b5ccb3c5dacc">P3M</fate:ShortTermInvestmentMaturityPeriodRangeStart>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_2f454c57-baac-4705-a580-50decd7c868a">http://fasb.org/us-gaap/2024#LicenseMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      id="F_ec6c8190-36ba-401a-8dbc-a9e6f704f525">http://fasb.org/us-gaap/2024#LicenseMember</us-gaap:TypeOfRevenueExtensibleList>
    <dei:DocumentType
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_4fe890a3-f2b3-461a-b39b-a4d47c09defb">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_974870f4-ff2a-4e0e-9843-cfd39db6fa23">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_189bf727-0f06-4244-9cbb-9384578a7093">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_9db64099-e67e-47b4-b886-59fe13cf978c">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_7221bdd9-72bb-4b46-b6e4-7a99e64310d2">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_4ebac6df-19f9-4817-9d01-7d149775c427">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_54ff033e-e124-4ea4-984e-a9151190e55a">001-36076</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_a8aef33a-9d65-4593-9790-96c33e7dbef7">FATE THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_ce7e5b7e-e858-45f8-9309-633c0abfe8f3">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_b5d9504d-f2c6-46c9-8369-e843a0151007">65-1311552</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_00b8925c-077a-437b-ab18-2096d3f15fc5">12278 Scripps Summit Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_4a638a18-81e6-49cc-a05e-d60599eb73f1">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_62c994ba-39cb-4a66-bee3-7b7610ebb50f">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_d4207395-b717-4d96-afbc-6cf7d8cb5449">92131</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_da5500a6-45f6-4cf2-9c70-03d52bc73b36">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_06c7a3fa-fe0c-443d-aed1-41a88873c524">875-1800</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_62e3728e-1970-447f-9dce-614b2e94ecba">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_0c0a5860-908d-47b0-b80c-51b137bf13c7">FATE</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_5f3d2d59-3fff-4c0f-8aa0-4dd1b85e2207">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_9328bc3e-b4e6-428e-b31d-8576204be76a">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_de5a4362-f1c8-41b9-a00d-098d15d4bd8d">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_8a86c880-460f-418f-a0b3-4660deeaebd6">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_09ccca1f-244b-471d-914a-e9d820d277b4">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_be77403d-cb4b-4b56-b5b1-a9cde15f6004">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_f65035d0-b284-483a-960a-f654fa9cdeb4">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_c3bc6b1d-fa09-4355-be96-ff4401193b61">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_20bad9c7-6c6c-4956-ac6f-85af7a108856">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_faa54fec-31d3-4cb2-a917-d5df221ea549">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_1c98e526-d6ba-4762-a0ef-30bab2ea1317">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_c138b804-b864-4563-8180-753f77d0e77a"
      decimals="0"
      id="F_687b6aea-9470-4ae2-af99-0c733010c49f"
      unitRef="U_USD">369000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_2341069e-9c1e-4801-a758-1b22a7e72c60"
      decimals="INF"
      id="F_8bbd4716-51ec-435c-b567-f913ed332db3"
      unitRef="U_shares">114597425</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_c89ad169-5c16-4825-913d-69f301930ea8">&lt;span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Portions of the registrant&#x2019;s definitive proxy statement to be filed with the Securities and Exchange Commission, or SEC, on or before the date 120 days after the conclusion of the registrant&#x2019;s fiscal year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; pursuant to Regulation 14A, in connection with the registrant&#x2019;s 2025 Annual Meeting of Stockholders are incorporated by reference into Part III of this annual report on Form 10-K.&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_02dbb3b3-1e31-4b08-9303-32d3d0e71595">&lt;p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ITEM 1C. Cybersecurity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;implemented&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and maintain a cybersecurity risk management program that includes processes for the identification, assessment, and mitigation of cybersecurity risks.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We conduct annual cybersecurity training for all of our employees and periodically &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;engage &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;third-party consultants to conduct penetrating testing and vulnerability assessments. Additionally, we use automated tools designed to monitor, identify, and address cybersecurity risks. Further, we have a process to evaluate and review the cybersecurity practices of our key vendors prior to onboarding, including through a general security assessment and contractual requirements, as appropriate.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We face a number of cybersecurity risks in connection with our business. Although such risks have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;not materially&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; affected us, including our business strategy, results of operations or financial condition, to date, we have, from time to time, experienced threats to and breaches of our data and systems, including malware and computer virus attacks. For more information about the cybersecurity risks we face, see the risk factors entitled &#x201c;Our business could be negatively affected by cyberattacks or a deficiency in our cybersecurity system and infrastructure&#x201d; and &#x201c;Our internal computer systems, or those used by our third-party research institution collaborators, CROs or other contractors or consultants, may fail or suffer security breaches&#x201d; in Item 1A- Risk Factors.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Governance Related To Cybersecurity Risks&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity process is overseen by our Information Technology department, which is managed by our Head of IT. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Head of IT role is currently held by an individual who has approximately two decades of professional IT management experience.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; In addition, our Security Leadership Team (SLT), which is comprised of the Head of IT as well as leaders from our operations, finance, and legal departments, is responsible for documenting, reviewing, and assessing our cybersecurity processes, monitoring for cybersecurity incidents, and periodically reporting on cybersecurity risks and risk management to a committee of our executive team (Executive Committee). &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Executive Committee, which is led by our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, undertakes reviews of our cybersecurity program and assesses any security incident updates from the SLT on a quarterly basis.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Executive Committee meets with the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Audit Committee&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of our Board of Directors on a quarterly basis to report on and discuss material updates to our cybersecurity program.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee provides oversight of our cybersecurity program as part of its periodic review of enterprise risk management and provides regular reports to our Board of Directors regarding our cybersecurity processes, including updates on the status of ongoing cybersecurity projects, the results of cybersecurity risk assessments, and the emerging cybersecurity threat landscape.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Additionally, the Board of Directors reviews the enterprise risk management program on at least an annual basis.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_b81ddda9-7bc4-4dce-8b4b-1c285b50bc9a">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;implemented&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and maintain a cybersecurity risk management program that includes processes for the identification, assessment, and mitigation of cybersecurity risks.&lt;/span&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_6e8f4496-6196-4b51-b30f-04ccb6a49c69">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_ef8f26d4-d948-4ebf-b2ca-b61519a10371">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We conduct annual cybersecurity training for all of our employees and periodically &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;engage &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;third-party consultants to conduct penetrating testing and vulnerability assessments. Additionally, we use automated tools designed to monitor, identify, and address cybersecurity risks. Further, we have a process to evaluate and review the cybersecurity practices of our key vendors prior to onboarding, including through a general security assessment and contractual requirements, as appropriate.&lt;/span&gt;</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_57cc5f09-5801-4ff8-8864-4b6a2d6e940c">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_6c903752-7656-4550-b27d-f544d745ab4b">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_48506c07-4c4e-4e1c-84c1-c1330fdab3da">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Governance Related To Cybersecurity Risks&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity process is overseen by our Information Technology department, which is managed by our Head of IT. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Head of IT role is currently held by an individual who has approximately two decades of professional IT management experience.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; In addition, our Security Leadership Team (SLT), which is comprised of the Head of IT as well as leaders from our operations, finance, and legal departments, is responsible for documenting, reviewing, and assessing our cybersecurity processes, monitoring for cybersecurity incidents, and periodically reporting on cybersecurity risks and risk management to a committee of our executive team (Executive Committee). &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Executive Committee, which is led by our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, undertakes reviews of our cybersecurity program and assesses any security incident updates from the SLT on a quarterly basis.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Executive Committee meets with the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Audit Committee&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of our Board of Directors on a quarterly basis to report on and discuss material updates to our cybersecurity program.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee provides oversight of our cybersecurity program as part of its periodic review of enterprise risk management and provides regular reports to our Board of Directors regarding our cybersecurity processes, including updates on the status of ongoing cybersecurity projects, the results of cybersecurity risk assessments, and the emerging cybersecurity threat landscape.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Additionally, the Board of Directors reviews the enterprise risk management program on at least an annual basis.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_c4c87428-256a-4adf-a2e6-b23eccb62a56">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity process is overseen by our Information Technology department, which is managed by our Head of IT. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Head of IT role is currently held by an individual who has approximately two decades of professional IT management experience.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; In addition, our Security Leadership Team (SLT), which is comprised of the Head of IT as well as leaders from our operations, finance, and legal departments, is responsible for documenting, reviewing, and assessing our cybersecurity processes, monitoring for cybersecurity incidents, and periodically reporting on cybersecurity risks and risk management to a committee of our executive team (Executive Committee). &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Executive Committee, which is led by our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, undertakes reviews of our cybersecurity program and assesses any security incident updates from the SLT on a quarterly basis.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Executive Committee meets with the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Audit Committee&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of our Board of Directors on a quarterly basis to report on and discuss material updates to our cybersecurity program.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee provides oversight of our cybersecurity program as part of its periodic review of enterprise risk management and provides regular reports to our Board of Directors regarding our cybersecurity processes, including updates on the status of ongoing cybersecurity projects, the results of cybersecurity risk assessments, and the emerging cybersecurity threat landscape.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Additionally, the Board of Directors reviews the enterprise risk management program on at least an annual basis.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_0f071a69-7750-413c-a208-a8a73e64531b">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity process is overseen by our Information Technology department, which is managed by our Head of IT. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Head of IT role is currently held by an individual who has approximately two decades of professional IT management experience.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; In addition, our Security Leadership Team (SLT), which is comprised of the Head of IT as well as leaders from our operations, finance, and legal departments, is responsible for documenting, reviewing, and assessing our cybersecurity processes, monitoring for cybersecurity incidents, and periodically reporting on cybersecurity risks and risk management to a committee of our executive team (Executive Committee). &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Executive Committee, which is led by our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, undertakes reviews of our cybersecurity program and assesses any security incident updates from the SLT on a quarterly basis.&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_e59d3a6e-6022-4f66-b650-983ebd418718">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Head of IT role is currently held by an individual who has approximately two decades of professional IT management experience.&lt;/span&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_58c6a48a-bcf2-4a5f-9bc6-b39b0788a060">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Executive Committee, which is led by our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, undertakes reviews of our cybersecurity program and assesses any security incident updates from the SLT on a quarterly basis.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_37cdeb37-814c-4d66-89f0-8b760b5ececa">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_bb869a86-cf20-487f-ab00-4117118c898c">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Executive Committee meets with the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Audit Committee&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of our Board of Directors on a quarterly basis to report on and discuss material updates to our cybersecurity program.&lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_d633354a-5aae-43a6-955c-7a662389e2c6">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_fcc9aaf2-1e38-4927-bdeb-0350138f3380">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee provides oversight of our cybersecurity program as part of its periodic review of enterprise risk management and provides regular reports to our Board of Directors regarding our cybersecurity processes, including updates on the status of ongoing cybersecurity projects, the results of cybersecurity risk assessments, and the emerging cybersecurity threat landscape.&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <dei:AuditorOpinionTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_a523066f-ac40-48ab-91c9-51264d21dbd2">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have audited the accompanying consolidated balance sheets of Fate Therapeutics, Inc. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(the Company) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#x2019; equity and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.&lt;/span&gt;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_cea0dfbd-d8ad-435b-88ad-1251f2c68d37"
      unitRef="U_USD">36056000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_056b18f9-b07c-4257-9588-975e1e2a08c3"
      unitRef="U_USD">41870000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_33fb6c09-ac47-4233-affc-fd045da1360f"
      unitRef="U_USD">3539000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_85cb2596-050d-486e-9e56-effaa21ec5e1"
      unitRef="U_USD">1826000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ShortTermInvestments
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_872100f8-28fd-4334-b712-9b5f9dfca6c4"
      unitRef="U_USD">243012000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_381c4661-c9e5-46bc-9928-0e31db7d3a4d"
      unitRef="U_USD">273305000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_8388298d-5e84-4796-b67f-7f4f63e911c9"
      unitRef="U_USD">9302000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_8ff8d068-07f6-4809-bcf2-2930ad588a7d"
      unitRef="U_USD">14539000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_ebeae2b0-b39b-4111-a79b-a0938d363341"
      unitRef="U_USD">291909000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_f2a09f13-2bad-4b16-b7b6-8ee26b2ccd72"
      unitRef="U_USD">331540000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_c1ac3824-2930-4fef-bdca-2b608b244b47"
      unitRef="U_USD">27657000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_fe3e951c-614f-4c46-976f-b449ae4ed35f"
      unitRef="U_USD">980000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_6d65782a-849e-4076-b01d-4e3193fcd7d1"
      unitRef="U_USD">64384000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_bd0949e7-bec2-44bd-bf62-9bec906cb6c7"
      unitRef="U_USD">96836000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_c113b737-8c1e-4684-abfe-d8926ee296c2"
      unitRef="U_USD">46508000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_25bba73a-b1fe-4fa1-a6e5-6b15d1b17064"
      unitRef="U_USD">61675000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_8b3fbecb-6741-414d-abd3-4ee721edd5ca"
      unitRef="U_USD">10227000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_ce8f7bed-076b-42bc-acbc-e6b392ee0067"
      unitRef="U_USD">15177000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_3470a525-12ac-4c6f-9a2b-2ec68454d253"
      unitRef="U_USD">9000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_acaeaeb0-b151-4643-b0d9-979ef0b8d5f1"
      unitRef="U_USD">9000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_12858f5d-75ae-4106-ae49-7cdc1d6c65a9"
      unitRef="U_USD">440694000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_77ff0b83-bd7b-4249-a10f-c41acbb02aa6"
      unitRef="U_USD">506217000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_7589c90e-776a-42b1-a399-5cdbd22bcb34"
      unitRef="U_USD">9365000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_512cae74-8513-4fb1-b8c0-b40be4b9c265"
      unitRef="U_USD">4719000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_9d7d4e66-46fb-4634-bff7-923cfd681f07"
      unitRef="U_USD">21348000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_76debe4a-e949-42c9-8099-685a1bd908e2"
      unitRef="U_USD">27514000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_f419dce4-76a5-400d-a032-e177ca1e07e3"
      unitRef="U_USD">393000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_377b3efe-fd27-4db1-8b49-942dfe6b8e1c"
      unitRef="U_USD">685000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_5a2ea7bc-1e39-4116-801c-7205e89a25c1"
      unitRef="U_USD">7416000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_5a7fbc11-7f21-4286-af8f-06d78442c509"
      unitRef="U_USD">6176000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_376023cd-65ef-4b3a-9a8d-79f84fb16fb9"
      unitRef="U_USD">38522000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_5d77429c-33ea-498c-8f26-8840cdb58b41"
      unitRef="U_USD">39094000</us-gaap:LiabilitiesCurrent>
    <fate:CIRMAwardLiabilityNoncurrent
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_3827df8e-b569-48a7-bce2-74bfe8d0fb27"
      unitRef="U_USD">5070000</fate:CIRMAwardLiabilityNoncurrent>
    <fate:CIRMAwardLiabilityNoncurrent
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_432338c9-d764-4919-b058-50d06c2c149b"
      unitRef="U_USD">0</fate:CIRMAwardLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_32ca65c6-183f-4355-83db-8c984a9744ba"
      unitRef="U_USD">77849000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_a00da818-0159-4b62-a448-be60488b6697"
      unitRef="U_USD">97360000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <fate:StockPriceAppreciationMilestonesLiabilitiesNonCurrent
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_e9d73ab6-511f-4935-b7c2-4682c4b7173f"
      unitRef="U_USD">527000</fate:StockPriceAppreciationMilestonesLiabilitiesNonCurrent>
    <fate:StockPriceAppreciationMilestonesLiabilitiesNonCurrent
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_093d4de8-08d1-4a2c-9585-716ee5edb19a"
      unitRef="U_USD">1346000</fate:StockPriceAppreciationMilestonesLiabilitiesNonCurrent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="3"
      id="F_54b7c8fe-9ef2-429f-8090-368205d895d4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="3"
      id="F_fb70378f-3646-4cab-b9dc-790da42fed5a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="0"
      id="F_a241fbd4-f186-4cbf-8af4-e5536074f26b"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="0"
      id="F_7f36e0df-e6f3-421e-a809-20da3b45a3fe"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_306e095e-df5e-46ff-bb9b-07308bdff1ed"
      decimals="0"
      id="F_293fe793-df4a-4ea7-9612-14706cc23731"
      unitRef="U_shares">2755086</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_306e095e-df5e-46ff-bb9b-07308bdff1ed"
      decimals="0"
      id="F_3e7d91b4-78c2-4557-aac1-80d3b8e07388"
      unitRef="U_shares">2755086</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_41031951-bbc6-4651-8f90-88528e8885ab"
      decimals="0"
      id="F_e886c381-1fd0-4d8b-96bd-fcfc5acd4d9c"
      unitRef="U_shares">2761108</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_41031951-bbc6-4651-8f90-88528e8885ab"
      decimals="0"
      id="F_0d45029b-d84e-4e73-950a-99a6b38c688d"
      unitRef="U_shares">2761108</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_f418a529-c45b-4b05-bcc7-0c19f128df98"
      unitRef="U_USD">3000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_27e1cb11-2254-42db-a386-8a1fd9d99829"
      unitRef="U_USD">3000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="3"
      id="F_406d9539-2ef6-4f6a-81b6-b2582e7b0862"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="3"
      id="F_e77a7d12-07f3-487e-92a3-b276c63ba7d0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="0"
      id="F_33f5dd60-b53b-4565-ab58-c54793ef0523"
      unitRef="U_shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="0"
      id="F_f8ab9687-01d2-4fe1-aea8-bd93ffac3f09"
      unitRef="U_shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="0"
      id="F_725baf35-efe3-4699-a93a-5f7af8f90e29"
      unitRef="U_shares">113928279</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="0"
      id="F_c602af93-1e34-4a66-a132-2e9edb2d48ba"
      unitRef="U_shares">113928279</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="0"
      id="F_c0e29ade-c042-4c7d-a953-ff063a82eea0"
      unitRef="U_shares">98627076</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="0"
      id="F_27027961-ba98-4fc5-be29-521de07ee590"
      unitRef="U_shares">98627076</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_808714d2-7d00-495a-ba04-892c36071660"
      unitRef="U_USD">114000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_4402f7dd-268c-4684-9491-ec9e669c7aaf"
      unitRef="U_USD">99000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_28163d61-184b-4609-b1a9-70cd246f0050"
      unitRef="U_USD">1716335000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_c6ff9b91-c986-42cc-bffd-0909d9e1bdfd"
      unitRef="U_USD">1580032000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_0fc51f31-25a1-4ad6-93dd-0a5521cf3d19"
      unitRef="U_USD">268000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_036517a7-3710-490f-8ef9-7d2c9c05d500"
      unitRef="U_USD">15000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_c2e06fd9-274d-4266-a536-607f93012e82"
      unitRef="U_USD">-1397994000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_7342c10d-f8f3-4e25-880c-68b8baeefbc8"
      unitRef="U_USD">-1211732000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_c576ac11-6935-4ddf-a489-d509f5b00dcd"
      unitRef="U_USD">318726000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_38d344fb-e78c-4fef-a258-9e7696b92438"
      unitRef="U_USD">368417000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_21401e2e-da78-4758-bcf0-99ace55c62fa"
      unitRef="U_USD">440694000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_90390461-c29d-4b00-8de1-edada2a9b87b"
      unitRef="U_USD">506217000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_199a54a1-62ea-4e7c-b5c9-0710ef1747b5"
      unitRef="U_USD">13631000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_20718c9b-d4cf-4be7-aa09-d1952b842d99"
      unitRef="U_USD">63533000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_2f3d3647-1468-4e0d-b7d4-dcc74fc1f815"
      unitRef="U_USD">135001000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_ee6bdc3d-3567-492b-a59d-24df9dd6691c"
      unitRef="U_USD">172596000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_2efa5ef9-b4aa-4649-b0ff-36726a08b517"
      unitRef="U_USD">74169000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_1d8fd1c5-4c9b-4f69-bcab-5824a1012cfe"
      unitRef="U_USD">81448000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_ec923fc4-7bb8-4ef6-8563-d30a4e04ea99"
      unitRef="U_USD">14737000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_b3fd522e-0cc0-4dbf-aba7-9e3adb9850d8"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:OperatingExpenses
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_434dd900-b4c8-4594-868e-6044a589b9f2"
      unitRef="U_USD">223907000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_789e6066-dd77-49d0-87e1-6ec68f370c71"
      unitRef="U_USD">254044000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_f4f838e5-76ae-465f-8fa1-8ef67dac7276"
      unitRef="U_USD">-210276000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_73b9a446-2575-475c-bd04-da487da27d1c"
      unitRef="U_USD">-190511000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_13c4649e-4c08-4cbb-8656-c19d73e60805"
      unitRef="U_USD">17288000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_e3d11b7c-a1ab-49f6-a7b8-cf70ab2518ca"
      unitRef="U_USD">17186000</us-gaap:InvestmentIncomeInterest>
    <fate:IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_f49d3691-1a47-48f8-93e4-53bd767903fa"
      unitRef="U_USD">-819000</fate:IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones>
    <fate:IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_59a539c3-80fe-423d-be5d-b522ba9a415f"
      unitRef="U_USD">-2515000</fate:IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_0005e251-34b0-4dde-b3a7-aab50a64b64b"
      unitRef="U_USD">5907000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_74f4f7dc-9fdc-4d21-8031-752f20b16fb5"
      unitRef="U_USD">9882000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_91a8b4b4-df01-409c-ab18-c1fee9bd727b"
      unitRef="U_USD">24014000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_cc354f15-0ca0-4d18-ad6c-2ef7fc0c3ab3"
      unitRef="U_USD">29583000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_ac477b3f-2ea6-4929-b6b2-f2b031ab70f8"
      unitRef="U_USD">-186262000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_ab4ec2a6-7468-4c43-ba79-37781547940e"
      unitRef="U_USD">-160928000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_963dc447-1d07-4cfd-8b89-526465f46e7b"
      unitRef="U_USD">253000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_08a723e8-542a-4edb-aa61-405b4fbe2b5e"
      unitRef="U_USD">1869000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_c17c90e2-8b6b-4ee0-a588-c0d210c9628b"
      unitRef="U_USD">-186009000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_a573a730-f032-414a-843c-f4de9868e447"
      unitRef="U_USD">-159059000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="2"
      id="F_325b8c4d-d4e3-4918-8cba-14e7500f86c9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="2"
      id="F_d8c39ceb-73cd-4c00-a83a-77343ec87450"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="2"
      id="F_ee7def0f-b0c5-4364-bd08-6c478ea18497"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="2"
      id="F_dfe7ff9b-1d85-4bd3-aa01-32dd5722e8d4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="0"
      id="F_134c460e-4229-410e-931a-8e024d954ab3"
      unitRef="U_shares">113685177</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="0"
      id="F_f8088458-a8ed-418f-863c-a7ee4586bc0a"
      unitRef="U_shares">113685177</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="0"
      id="F_30b9d36d-e6be-4717-99a2-f2fd0449f938"
      unitRef="U_shares">98411162</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="0"
      id="F_257c9a8d-ae14-4d4f-93e9-bdf1713b6b36"
      unitRef="U_shares">98411162</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_cc8f53ba-0de4-45e3-a08a-c8528a309add"
      decimals="INF"
      id="F_10521dd2-da3b-4cd2-b4c0-2221ea17300d"
      unitRef="U_shares">2794549</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_cc8f53ba-0de4-45e3-a08a-c8528a309add"
      decimals="-3"
      id="F_2e2db3a3-7bfc-4465-bb2c-11742bcc1b2d"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_35de3dab-1655-4fae-8a01-0f3d2ee62306"
      decimals="0"
      id="F_3aaefc2d-5ebc-4b47-98ff-fe1703d1e60c"
      unitRef="U_shares">97294917</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_35de3dab-1655-4fae-8a01-0f3d2ee62306"
      decimals="-3"
      id="F_7df74479-1fd3-447c-bb83-36b0e524c817"
      unitRef="U_USD">97000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_fcdf4845-34e5-4331-ba78-17eade1d2dde"
      decimals="-3"
      id="F_c1b73ec5-090a-46f4-902d-2f3cbaa68fcb"
      unitRef="U_USD">1536497000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9ba83a55-9961-4e4b-8d65-f9275f3c0342"
      decimals="-3"
      id="F_8c4b6462-d6c5-4954-a948-9d588b7de3f1"
      unitRef="U_USD">-1854000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e741f2c7-90d6-40a1-ab1f-b596c102b3bf"
      decimals="-3"
      id="F_461b0e95-f71a-44ba-8f85-a5e85a591f31"
      unitRef="U_USD">-1050804000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6199ef4e-6533-4919-aa08-7b8879357aa9"
      decimals="-3"
      id="F_e84dab35-aeed-4233-a586-b1588a281972"
      unitRef="U_USD">483939000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_e243220b-bcd5-4012-8eef-5b2d39ca5281"
      decimals="0"
      id="F_9f1b2086-e300-442f-b13e-5718f279d290"
      unitRef="U_shares">93787</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_4fb1c409-95ec-4aa9-9296-606146c23c7b"
      decimals="-3"
      id="F_d38b4b41-240a-4b34-a940-59ff4221dc32"
      unitRef="U_USD">76000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_a1272b21-8f53-4455-8dbb-b4bc49aa9763"
      unitRef="U_USD">76000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_e243220b-bcd5-4012-8eef-5b2d39ca5281"
      decimals="0"
      id="F_817e15f8-22bb-4cb6-aecb-31c0cbd62d67"
      unitRef="U_shares">1071167</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_e243220b-bcd5-4012-8eef-5b2d39ca5281"
      decimals="-3"
      id="F_af862436-bb5d-442f-9db5-a58032031231"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_1ab94845-b6e7-4617-9267-5929afbcdbd3"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <fate:ConversionOfPreferredSharesToCommonStocksShares
      contextRef="C_453cb5ab-24d8-4b66-961f-9f4dd63a05ad"
      decimals="0"
      id="F_347bfe30-2a0c-4afe-b8f7-e90eef8c5664"
      unitRef="U_shares">-33441</fate:ConversionOfPreferredSharesToCommonStocksShares>
    <fate:ConversionOfPreferredSharesToCommonStocksShares
      contextRef="C_e243220b-bcd5-4012-8eef-5b2d39ca5281"
      decimals="0"
      id="F_9bd8e56f-1222-47b2-bfa3-55cd075e0f51"
      unitRef="U_shares">167205</fate:ConversionOfPreferredSharesToCommonStocksShares>
    <fate:ConversionOfPreferenceShareToCommonStock
      contextRef="C_e243220b-bcd5-4012-8eef-5b2d39ca5281"
      decimals="-3"
      id="F_4dd000d8-d127-43cb-a77e-948a5c8a2bf5"
      unitRef="U_USD">1000</fate:ConversionOfPreferenceShareToCommonStock>
    <fate:ConversionOfPreferenceShareToCommonStock
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_426edce6-8294-44ea-bf7b-1c3d5a05d9bb"
      unitRef="U_USD">1000</fate:ConversionOfPreferenceShareToCommonStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_4fb1c409-95ec-4aa9-9296-606146c23c7b"
      decimals="-3"
      id="F_13df00ef-553f-46e4-986e-d8f737ac3e83"
      unitRef="U_USD">43459000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_b5c310de-71e4-4d6a-acff-8297f03db824"
      unitRef="U_USD">43459000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_bbc6feb5-7fbe-40df-a81f-6062a8a5fbb8"
      decimals="-3"
      id="F_4766bcd4-63de-4a82-8bed-312d71b2aa2a"
      unitRef="U_USD">1869000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_29f852ec-984a-4a81-8adb-d7f5ba589794"
      unitRef="U_USD">1869000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_eb400e71-8a95-42b3-aaea-dc66ceacad22"
      decimals="-3"
      id="F_1021e347-7b14-441b-a8e3-4914dad290ae"
      unitRef="U_USD">-160928000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_3cb70446-ac78-4d75-b561-b1cdb0fbb96f"
      unitRef="U_USD">-160928000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_7df46466-a06c-4ab1-909b-db1961aa969c"
      decimals="0"
      id="F_2c916f00-2071-42fc-aa51-51125650ddb8"
      unitRef="U_shares">2761108</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_7df46466-a06c-4ab1-909b-db1961aa969c"
      decimals="-3"
      id="F_ea6bca76-a063-4d2e-a929-1a9d2c9e10b8"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_fe855db0-cbd1-4634-932c-99540e86df56"
      decimals="0"
      id="F_8d70cf89-fa79-40d3-990b-de57d9779b51"
      unitRef="U_shares">98627076</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_fe855db0-cbd1-4634-932c-99540e86df56"
      decimals="-3"
      id="F_83212770-06b0-4ecb-87d1-23e13fc07d9f"
      unitRef="U_USD">99000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f255de04-23de-47b2-bf4a-1d7b7bf4d379"
      decimals="-3"
      id="F_b9a541f8-79dd-40bb-a132-2997e8cc328a"
      unitRef="U_USD">1580032000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_77ef949f-bbd0-4757-abd9-d2cf6948dfea"
      decimals="-3"
      id="F_ce04e3b3-c77f-4a5b-88d3-e51ba25e1d81"
      unitRef="U_USD">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_22baae92-8d72-48bd-bc26-99cb822ac436"
      decimals="-3"
      id="F_e3c738c0-4fc2-43e3-ab87-be99e44ab314"
      unitRef="U_USD">-1211732000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_4123f55c-b1a6-4dfe-aacf-f2c20e8f8e49"
      unitRef="U_USD">368417000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_31099ea4-f12e-4b2c-9160-b411e31dd257"
      decimals="0"
      id="F_4b4cbf11-0006-4886-a3d2-719283c04f94"
      unitRef="U_shares">45438</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_00cbef97-1aad-4784-a3ca-62ddc68740ab"
      decimals="-3"
      id="F_92f20ef2-c307-456d-a5a5-529bf65fb99a"
      unitRef="U_USD">295000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_ebf04b13-1e69-4c30-a99d-ab11f7bbf88a"
      unitRef="U_USD">295000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_31099ea4-f12e-4b2c-9160-b411e31dd257"
      decimals="0"
      id="F_92834f17-4cc0-4392-aa75-356ce690c831"
      unitRef="U_shares">680201</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <fate:ConversionOfPreferredSharesToCommonStocksShares
      contextRef="C_805cb483-0110-4ded-9a01-7cfc77c9ed1a"
      decimals="0"
      id="F_be6c86cc-1a35-44c2-b923-c2e209fc83ef"
      unitRef="U_shares">-6022</fate:ConversionOfPreferredSharesToCommonStocksShares>
    <fate:ConversionOfPreferredSharesToCommonStocksShares
      contextRef="C_31099ea4-f12e-4b2c-9160-b411e31dd257"
      decimals="0"
      id="F_d767f1bb-db4c-469d-9c2f-21fd08da784f"
      unitRef="U_shares">30110</fate:ConversionOfPreferredSharesToCommonStocksShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_00cbef97-1aad-4784-a3ca-62ddc68740ab"
      decimals="-3"
      id="F_d2a26260-4b64-4786-a127-228061bee08a"
      unitRef="U_USD">41496000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_1c39cb23-907a-49a8-a959-4404bf40659b"
      unitRef="U_USD">41496000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <fate:CommonStockOfPublicOfferingAndIssuanceOfPreFundedWarrants
      contextRef="C_31099ea4-f12e-4b2c-9160-b411e31dd257"
      decimals="0"
      id="F_5064c4fc-b538-4a3c-85d2-25ca890e13ef"
      unitRef="U_shares">14545454</fate:CommonStockOfPublicOfferingAndIssuanceOfPreFundedWarrants>
    <fate:PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants
      contextRef="C_31099ea4-f12e-4b2c-9160-b411e31dd257"
      decimals="-3"
      id="F_6af51857-7475-4467-a25f-e730ed6d1747"
      unitRef="U_USD">15000</fate:PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants>
    <fate:PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants
      contextRef="C_00cbef97-1aad-4784-a3ca-62ddc68740ab"
      decimals="-3"
      id="F_bec71fd3-095d-42e7-a1ee-63f130bbf533"
      unitRef="U_USD">74516000</fate:PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants>
    <fate:PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_714289b1-686a-4bcc-b87a-8d5340e8cba9"
      unitRef="U_USD">74531000</fate:PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants>
    <fate:PrivatePlacementOfPreFundedWarrants
      contextRef="C_00cbef97-1aad-4784-a3ca-62ddc68740ab"
      decimals="-3"
      id="F_edb686fe-0e71-4f85-90dc-e8ad50de4d57"
      unitRef="U_USD">19996000</fate:PrivatePlacementOfPreFundedWarrants>
    <fate:PrivatePlacementOfPreFundedWarrants
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_b50f455c-89a3-4603-a806-17fa222ff12d"
      unitRef="U_USD">19996000</fate:PrivatePlacementOfPreFundedWarrants>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_7d04432b-9ec3-45bd-848d-144b3dd8b270"
      decimals="-3"
      id="F_5d34647c-3597-4710-93c6-c5de6a205215"
      unitRef="U_USD">253000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_5c72ab05-0b26-4670-a3d2-909bdc0e6a72"
      unitRef="U_USD">253000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_d7661ece-b1bb-47ae-89fd-c9e5fb4fce03"
      decimals="-3"
      id="F_97df79b2-9394-48ca-ac4c-bdc5f0b26def"
      unitRef="U_USD">-186262000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_b6dda60d-32f6-4742-91ea-580c368ecd8d"
      unitRef="U_USD">-186262000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_ad67a626-7c86-4e93-88d6-33d3a62a1c24"
      decimals="INF"
      id="F_99ea3921-aa21-405e-8308-e35a4f6f3287"
      unitRef="U_shares">2755086</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_ad67a626-7c86-4e93-88d6-33d3a62a1c24"
      decimals="-3"
      id="F_57d519e7-60b9-4b06-9157-faf616a00759"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_d8f9c7ba-407a-4a32-8e3a-a7d43910792c"
      decimals="0"
      id="F_0a51925a-b51d-4b0c-ac20-b52c85ba2b74"
      unitRef="U_shares">113928279</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_d8f9c7ba-407a-4a32-8e3a-a7d43910792c"
      decimals="-3"
      id="F_8e4e427d-a4fe-4611-bbb7-938e5ac3f6d9"
      unitRef="U_USD">114000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6f3f91dc-9183-4b96-83ab-8d0a1cf21e83"
      decimals="-3"
      id="F_5b33a3f5-82d3-419a-a8dc-8fc23d1eb3fd"
      unitRef="U_USD">1716335000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a641074c-59aa-4f3c-8a89-4a805c5db02a"
      decimals="-3"
      id="F_6a388aca-3536-4e13-8991-c25dcd8224a4"
      unitRef="U_USD">268000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8b609e2a-1e60-4b1e-b0db-d6a181ac993b"
      decimals="-3"
      id="F_3ad9cea7-09ba-48be-a93b-18f338918761"
      unitRef="U_USD">-1397994000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_f84b9420-d1c6-48a2-b76d-e25bc1796711"
      unitRef="U_USD">318726000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_c0b6a5c1-f07e-474f-add9-68295e9adad3"
      unitRef="U_USD">-186262000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_0490291f-0a14-4f6a-a3b6-ba4a0efc2b63"
      unitRef="U_USD">-160928000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_62a8a08c-32d0-49e7-aaaa-599bebaa6bd7"
      unitRef="U_USD">18962000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_95d4f0c2-9113-4fc3-9bb5-078a3e2ebcda"
      unitRef="U_USD">18282000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_cbd81015-75eb-4cde-aa07-3fd0241a2944"
      unitRef="U_USD">41496000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_8d3c6aa6-c4ea-4b1d-a3fb-c7695a2eb3ad"
      unitRef="U_USD">43459000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_58f9f36d-5a2d-4368-aebe-6c8ed45628d9"
      unitRef="U_USD">9080000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_1dc8d521-75fb-4f9a-918a-687193974842"
      unitRef="U_USD">11398000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_ddf01c27-dd56-42a5-914c-5c998da935fc"
      unitRef="U_USD">0</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_91400ca7-1bc9-46a4-be7c-bd459d37f3e9"
      unitRef="U_USD">7196000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_48e65167-b277-40e7-a9e1-008d701cf801"
      unitRef="U_USD">-892000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_ec2d8f4a-bf97-4267-a839-49d767da958c"
      unitRef="U_USD">-41541000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <fate:IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_13067de5-661f-4386-8eea-dd3e75d187b0"
      unitRef="U_USD">-819000</fate:IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones>
    <fate:IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_d83effff-bbd2-409f-b37a-6ab614f0b770"
      unitRef="U_USD">-2515000</fate:IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_3b2fbdff-7243-4a60-bc06-21315bb4149c"
      unitRef="U_USD">14737000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_0c6269c9-cc6f-4b1c-bfa0-76aea91c6271"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_7f23f616-8410-497c-bf7c-9f1b3cabbd5f"
      unitRef="U_USD">-942000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_e9be0bf8-40a4-4e6e-a321-fd8503f7dee4"
      unitRef="U_USD">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <fate:GrantIncomeFromCirmAward
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_82bdde7f-88ef-49bd-866f-0708f9c3330a"
      unitRef="U_USD">0</fate:GrantIncomeFromCirmAward>
    <fate:GrantIncomeFromCirmAward
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_2910321b-864e-4801-9fab-7e91319e3dc4"
      unitRef="U_USD">4000000</fate:GrantIncomeFromCirmAward>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_f3599681-9daf-473a-8c1c-6400bda1c547"
      unitRef="U_USD">1113000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_c208dad8-c243-44cf-8213-005bb6ec4574"
      unitRef="U_USD">-36654000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_ee6f411e-78d2-4dd3-acfb-51abaa29dabd"
      unitRef="U_USD">-5237000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_7f99a417-ef6b-406e-82f2-29eae0558218"
      unitRef="U_USD">-12876000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_043d9ef6-550c-4e8f-8949-9373a95f25f3"
      unitRef="U_USD">-1661000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_9ae9c872-9a54-42f5-88d9-c25f468ce345"
      unitRef="U_USD">-28940000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <fate:IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_509e3cb6-b593-4a69-9559-aebf34788eba"
      unitRef="U_USD">-4421000</fate:IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet>
    <fate:IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_02226264-6009-4f8c-89a9-56166ee994d6"
      unitRef="U_USD">-1408000</fate:IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_daf8e7bb-89f3-4875-9d35-26296f600552"
      unitRef="U_USD">-122874000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_9cdc9c0d-2cd3-4718-9ed2-e1e8a3106ba5"
      unitRef="U_USD">-132263000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_afa36d65-67f5-4e92-a65a-2324e66cf257"
      unitRef="U_USD">730000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_6b780e27-86fb-48c3-bed0-23fb601b231d"
      unitRef="U_USD">6153000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_8933da28-7a58-4e93-90db-d946cb17837b"
      unitRef="U_USD">317750000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_f1cf6050-4021-4a44-bbf3-47527ea805c2"
      unitRef="U_USD">358810000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_7dfa016a-15a9-4816-bf2e-697d7f2ba305"
      unitRef="U_USD">330698000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_42b26c60-c7a6-4cb1-863d-39da7d146cfc"
      unitRef="U_USD">477628000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_98870a26-f2be-4dd8-a469-de5cdaad1ff1"
      unitRef="U_USD">12218000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_b1e1a0a8-45ef-48ed-a3a7-0767b1559d45"
      unitRef="U_USD">112665000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_66341f13-d10e-43e1-9215-fb14fc36646e"
      unitRef="U_USD">295000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_2925d5fb-349d-42ce-8d66-781d5e8b52e2"
      unitRef="U_USD">85000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_5082482c-f315-4c6a-84cd-fe6372a4f8ee"
      unitRef="U_USD">74531000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_555c5c32-bfb5-4f22-b001-20ead03e7fe7"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_d51dbbea-ce38-4554-a68e-453ed930840d"
      unitRef="U_USD">19996000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_b6c5e64b-284c-4137-80c3-b72c694c5ae8"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <fate:ProceedsFromCIRMAward
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_25352d53-0db8-43dd-8646-9ce1be570d57"
      unitRef="U_USD">5070000</fate:ProceedsFromCIRMAward>
    <fate:ProceedsFromCIRMAward
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_631dea7d-028f-4ef7-a5cc-bcc1cc53e70a"
      unitRef="U_USD">0</fate:ProceedsFromCIRMAward>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_4785044c-1259-4831-ac13-365e932d75c3"
      unitRef="U_USD">99892000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_dd5b18cb-8f8a-4731-a47f-87f2e2ad785b"
      unitRef="U_USD">85000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_c737042c-fe67-4b6f-a58e-96657f2ed7de"
      unitRef="U_USD">-10764000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_2f408aa6-f12e-4022-914d-3d95082478cf"
      unitRef="U_USD">-19513000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_4fc7262d-f129-4853-894b-63fa7795722c"
      unitRef="U_USD">57047000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_6199ef4e-6533-4919-aa08-7b8879357aa9"
      decimals="-3"
      id="F_ecf9fb49-0b46-4555-a35b-a86b1e578d10"
      unitRef="U_USD">76560000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_ec572674-1a7b-49cc-839b-7c93a301f9a1"
      unitRef="U_USD">46283000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_826b4ad1-342a-4d47-9307-05e8c3019190"
      unitRef="U_USD">57047000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_4150fe7c-bb27-4e73-93a4-8e1e16c656a8"
      unitRef="U_USD">140000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_98396104-6b1e-49fb-a07b-03bd0ea5f193"
      unitRef="U_USD">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_cdf8302a-0044-42f7-981b-5200b227c465">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1. Organization and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Organization&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fate Therapeutics, Inc. (the Company) was incorporated in the state of Delaware on April 27, 2007 and has its principal operations in San Diego, California. The Company is a clinical-stage biopharmaceutical company dedicated to bringing off-the-shelf, multiplexed-engineered, iPSC-derived cellular immunotherapies to patients.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the Company has devoted substantially all of its efforts to product development, raising capital and building infrastructure and has not generated any revenues from any sales of its therapeutic products. To date, the Company&#x2019;s revenues have been derived from collaboration agreements and government grants.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The preparation of the Company&#x2019;s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to its stock appreciation milestone obligations, contracts containing leases, and accrued expenses. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated financial statements include the accounts of the Company and its subsidiaries. To date, the aggregate operations of these subsidiaries have not been significant and all intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s financial instruments consist primarily of cash and cash equivalents, marketable securities, accounts receivable, stock price appreciation milestones, accounts payable, and accrued liabilities. The carrying amounts of accounts receivable, accounts payable and accrued liabilities are considered to be representative of their respective fair values because of the relatively short-term nature of those instruments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three- tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1: Observable inputs such as quoted prices in active markets;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents include cash in readily available checking and savings accounts, money market accounts and money market funds. The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,047&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the years ended December 31, 2024 and 2023, the restricted cash balance includes cash-collateralized irrevocable standby letters of credit for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; mill&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;io&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;n and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, associate&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;d with the Company&#x2019;s facilities leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investments are accounted for as available-for-sale securities and are carried at fair value on the consolidated balance sheets. Upon initial recognition of the investment and at each reporting period, the Company evaluates whether any unrealized losses on investments are attributable to a credit loss or other factors. Any unrealized losses attributable to credit loss are recorded through an allowance for credit losses, limited to the amount by which the fair value is below amortized cost, with the offsetting amount recorded in other income or expense in the consolidated statement of operations and comprehensive loss. Unrealized losses not attributable to an expected credit loss and unrealized gains on investments are recorded in other comprehensive income (loss) on the consolidated statements of operations and comprehensive loss. Realized gains and losses, if any, on investments classified as available-for-sale securities are included in other income or expense.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The amortized cost of investments classified as available-for-sale debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest income. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments, which potentially subject the Company to a significant concentration of credit risk, consist primarily of cash, cash equivalents, and investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits and investments are held.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_36b18d82-10b0-4496-9bd3-0d13c236998e;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) and generally consist of furniture and fixtures, computers, scientific and office equipment, and in-process costs related to facilities construction. Repairs and maintenance costs are charged to expense as incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The long-lived asset evaluation is performed at the asset group level (i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities). Recoverability of these assets is measured by a comparison of the carrying amounts to the future undiscounted cash flows the assets are expected to generate from their use and eventual disposition. If the carrying amount is not recoverable, the carrying amount of such assets is reduced to fair value. During 2024, the Company identified an indicator of impairment of its long-lived assets due to a sustained decline in the trading price of the Company&#x2019;s common stock over the preceding year, resulting in the Company&#x2019;s market capitalization being below its net asset value. The Company utilized observed market lease rates for comparable properties to estimate the fair value of the right-of-use asset and leasehold improvements. The Company utilized trend factors applied to historical costs, estimates of economic depreciation, normal useful lives, and benchmark values for orderly liquidations of the assets in secondary markets to estimate the fair value of the property and equipment. As a result of its fair value analysis, the Company recorde&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;d a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million impairment charge on its property&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and equipment a&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;nd a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; m&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;illion impairment charge on its right-of-use asset in the statement of operations during the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; impairment was recorded during the year ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determines if a contract contains a lease at the inception of the contract. The Company currently has leases related to its facilities leased for office and laboratory space, which are classified as operating leases. These leases result in operating right-of-use (ROU) assets, current operating lease liabilities, and non-current operating lease liabilities in the Company&#x2019;s consolidated balance sheets. The Company does not have any financing leases. Leases with a term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12 months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; or less are considered short-term and ROU assets and lease obligations are not recognized. Payments associated with short-term leases are expensed on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities represent an obligation to make lease payments arising from the lease and ROU assets represent the right to use the underlying asset identified in the lease for the lease term. Lease liabilities are measured at the present value of the lease payments not yet paid discounted using the discount rate for the lease established at the lease commencement date. To determine the present value, the implicit rate is used when readily determinable. For those leases where the implicit rate is not provided, the Company determines an incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. ROU assets are measured as the present value of the lease payments and also include any prepaid lease payments made and any other indirect costs incurred, and exclude any lease incentives received. Lease terms may include the impact of options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term. The Company aggregates all lease and non-lease components for each class of underlying assets into a single lease component.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC Topic 808, Collaborative Arrangements (ASC 808), to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, the Company assesses whether aspects of the arrangement between the Company and its collaboration partner are within the scope of other accounting literature, including ASC Topic 606, Revenue from Contracts with Customers (ASC 606). If it is concluded that some or all aspects of the arrangement represent a transaction with a customer, the Company will account for those aspects of the arrangement within the scope of ASC 606.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASC 808 provides guidance for the presentation and disclosure of transactions in collaborative arrangements, but it does not provide recognition or measurement guidance. Therefore, if the Company concludes a counterparty to a transaction is not a customer or otherwise not within the scope of ASC 606, the Company considers the guidance in other accounting literature as applicable or by analogy to account for such transaction. The classification of transactions under the Company&#x2019;s arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. If the Company concludes that some or all aspects of the arrangement represent a transaction with a customer, the Company accounts for those aspects of the arrangement within the scope of ASC 606.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For arrangements attributable to ASC 606, the Company recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration the Company is entitled to receive in exchange for such product or service. In doing so, the Company follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock Price Appreciation Milestones&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company estimates the fair value of the stock price appreciation milestones associated with the Amended and Restated Exclusive License Agreement with Memorial Sloan Kettering Cancer Center (MSKCC) using a Monte Carlo simulation model, which relies on the Company&#x2019;s current stock price as well as significant estimates and assumptions to determine the estimated liability associated with the contingent milestone payments. The Company accounts for the fair value of the stock price appreciation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;milestones &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in accordance with ASC 815, Derivatives and Hedging, with fair value marked to market at each reporting date. The assumptions used to calculate the fair value of the stock price appreciation milestones are subject to a significant amount of judgment including the probability of achieving a specified clinical milestone, the expected volatility of the Company&#x2019;s common stock, the risk-free interest rate, and the estimated term, which is based in part on the last valid patent claim date. The Company remeasures the fair value of the stock price appreciation milestones at each balance sheet date, with changes in fair value recorded in earnings as non-operating income or expense on the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense represents the cost of the grant date fair value of employee stock option and restricted stock unit grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. Performance-based stock units/awards represent a right to receive a certain number of shares of the Company&#x2019;s common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, and to the extent achievement of one or any of the performance conditions is probable, the Company reassesses the probability of the achievement of such corporate performance goals and any increase or decrease in share-based compensation expense resulting from an adjustment in the estimated shares to be released is treated as a cumulative catch-up in the period of adjustment. For stock awards for which vesting is subject to both performance-based milestones and market conditions, expense is recorded over the derived service period after the point when the achievement of the performance-based milestone is probable or the performance condition has been achieved.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, with the exception of option grants for which vesting is subject to both performance-based milestones and market conditions, which are valued using a lattice-based model. The fair value of restricted stock units, including performance-based restricted stock units, is based on the closing price of the Company&#x2019;s common stock as reported on The Nasdaq Global Market on the date of grant. The Company recognizes forfeitures for all awards as such forfeitures occur.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more- likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;more than 50 percent&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Employee Retention Credit&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CARES Act provides an employee retention credit (ERC), which is a refundable tax credit against certain employment taxes of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per employee for eligible employers. The tax credit is equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of qualified wages paid to employees during a quarter, capped at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of qualified wages per employee through December 31, 2020. Additional relief provisions were passed by the United States government, which extend and slightly expand the qualified wage caps on these credits through December 31, 2021. Based on these additional provisions, the tax credit is now equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of qualified wages paid to employees during a quarter, and the limit on qualified wages per employee has been increased to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of qualified wages per quarter. The Company qualifies for the tax credit under the CARES Act and expects to continue to receive additional tax credits under the additional relief provisions for qualified wages through December 31, 2021. In connection with the CARES Act, the Company adopted a policy to recognize the employee retention credit when received and include in other income in the statement of operations. T&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;he &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company received a cash&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;payment &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of other income during the year ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. No such amount was received or recorded during the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non&#x2011;owner sources. Other comprehensive loss includes unrealized gains and losses on available-for-sale securities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Common Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. The Pre-Funded Warrants associated with the January 2021 public equity offering and the private placement concurrent with the March 2024 public equity offering (see Note 9) are considered outstanding shares in the basic earnings per share calculation given their nominal exercise price. Dilutive common stock equivalents comprise convertible preferred stock, warrants for the purchase of common stock, and common stock options and restricted stock units outstanding under the Company&#x2019;s stock option plans. For all periods presented, there is no difference in the number of common shares used to calculate basic and diluted common shares outstanding due to the Company&#x2019;s net loss position.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted net loss per share attributable to stockholders for the years ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024 and 2023 are calculated as follows (in thousands, except share and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;186,262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;160,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares used to compute net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;110,596,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,153,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average pre-funded warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,088,905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;257,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average common shares outstanding used to&lt;br/&gt;&#160;&#160;&#160;&#160;compute basic and diluted net loss per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113,685,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,411,162&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Potentially dilutive securities that are not included in the calculation of diluted net loss per common share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,722,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,850,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,214,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,065,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series A convertible preferred stock (if converted)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,775,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,805,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,712,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,721,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Going Concern Assessment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Substantial doubt about an entity&#x2019;s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year from the financial statement issuance date. The Company determined that there are no conditions or events that raise substantial doubt about its ability to continue as a going concern for a period of at least twelve months from the date of issuance of these financial statements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU No. 2023-07, which requires public entities to disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about a reportable segment&#x2019;s profit or loss and assets that are currently required annually. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The ASU does not change how a public&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;entity identifies its operating segments, aggregates them or applies the quantitative thresholds to determine its reportable segments. The ASU is effective for fiscal years beginning after December 15, 2023, and for interim periods beginning after December 15, 2024, with early adoption permitted. The guidance should be applied retrospectively to all periods presented in the financial statements, unless it is impracticable. The segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The Company adopted ASU No. 2023-07 during the year ended December 31, 2024 and have included required disclosures in Note 11.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This new standard will be effective for the annual periods beginning the year ended December 31, 2025. The new standard permits early adoption and can be applied prospectively or retrospectively. The Company does not expect the adoption of this guidance to have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement: Reporting Comprehensive Income- Expense Disaggregation Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which requires detailed information about specified categories of expenses included in certain expense captions presented on the face of the income statement, as well as disclosures about selling expenses. This ASU is effective for fiscal years beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_41d7cda7-22d3-4586-bf7b-4986ab6652ec">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The preparation of the Company&#x2019;s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to its stock appreciation milestone obligations, contracts containing leases, and accrued expenses. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_f9918a61-6c69-425f-b5e1-9daa5b54294a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated financial statements include the accounts of the Company and its subsidiaries. To date, the aggregate operations of these subsidiaries have not been significant and all intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_cb716ee8-0f8b-45f5-8e83-8e62a8997c97">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s financial instruments consist primarily of cash and cash equivalents, marketable securities, accounts receivable, stock price appreciation milestones, accounts payable, and accrued liabilities. The carrying amounts of accounts receivable, accounts payable and accrued liabilities are considered to be representative of their respective fair values because of the relatively short-term nature of those instruments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three- tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1: Observable inputs such as quoted prices in active markets;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis.&lt;/span&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_24671eec-5380-469a-9cba-6a0538dd91a3">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents include cash in readily available checking and savings accounts, money market accounts and money market funds. The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,047&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the years ended December 31, 2024 and 2023, the restricted cash balance includes cash-collateralized irrevocable standby letters of credit for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; mill&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;io&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;n and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, associate&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;d with the Company&#x2019;s facilities leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_acdcee18-1ac5-4ca1-8b57-2700a8ae939d">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,047&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_375352cd-4883-4edd-9775-a9bf38d00407"
      unitRef="U_USD">36056000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_32c035f6-c346-408c-a0a8-ecf0456e310d"
      unitRef="U_USD">41870000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_92901940-0d2e-4b87-b409-e89f1b9e440e"
      unitRef="U_USD">10227000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_cd5406cc-71e8-4972-ad3f-198edcd77a7e"
      unitRef="U_USD">15177000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_a7ea7f85-8095-4070-81b5-109716566eed"
      unitRef="U_USD">46283000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_889bc29f-0d58-4169-82d3-e0a7fc935f51"
      unitRef="U_USD">57047000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-5"
      id="F_04e8e001-752b-4191-b503-2cf6ff125264"
      unitRef="U_USD">10200000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-5"
      id="F_ab176181-d768-47b8-93c1-a49935289816"
      unitRef="U_USD">15200000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_ebfaadfc-badf-4637-a994-46e11b0cca35">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investments are accounted for as available-for-sale securities and are carried at fair value on the consolidated balance sheets. Upon initial recognition of the investment and at each reporting period, the Company evaluates whether any unrealized losses on investments are attributable to a credit loss or other factors. Any unrealized losses attributable to credit loss are recorded through an allowance for credit losses, limited to the amount by which the fair value is below amortized cost, with the offsetting amount recorded in other income or expense in the consolidated statement of operations and comprehensive loss. Unrealized losses not attributable to an expected credit loss and unrealized gains on investments are recorded in other comprehensive income (loss) on the consolidated statements of operations and comprehensive loss. Realized gains and losses, if any, on investments classified as available-for-sale securities are included in other income or expense.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The amortized cost of investments classified as available-for-sale debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest income. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_10588eff-1fa1-4fac-bf67-b74a20036ace">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments, which potentially subject the Company to a significant concentration of credit risk, consist primarily of cash, cash equivalents, and investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits and investments are held.&lt;/span&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_8a4a252a-9619-4bcb-b11c-c2df45751edc">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_36b18d82-10b0-4496-9bd3-0d13c236998e;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) and generally consist of furniture and fixtures, computers, scientific and office equipment, and in-process costs related to facilities construction. Repairs and maintenance costs are charged to expense as incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_db4ca2c8-7dec-42f6-9326-27fb5b437f80"
      id="F_1b72d334-a768-4b11-9610-7e30695e21c7">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_18dd735e-d7a3-4e23-b624-de13bca2ea27">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The long-lived asset evaluation is performed at the asset group level (i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities). Recoverability of these assets is measured by a comparison of the carrying amounts to the future undiscounted cash flows the assets are expected to generate from their use and eventual disposition. If the carrying amount is not recoverable, the carrying amount of such assets is reduced to fair value. During 2024, the Company identified an indicator of impairment of its long-lived assets due to a sustained decline in the trading price of the Company&#x2019;s common stock over the preceding year, resulting in the Company&#x2019;s market capitalization being below its net asset value. The Company utilized observed market lease rates for comparable properties to estimate the fair value of the right-of-use asset and leasehold improvements. The Company utilized trend factors applied to historical costs, estimates of economic depreciation, normal useful lives, and benchmark values for orderly liquidations of the assets in secondary markets to estimate the fair value of the property and equipment. As a result of its fair value analysis, the Company recorde&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;d a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million impairment charge on its property&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and equipment a&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;nd a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; m&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;illion impairment charge on its right-of-use asset in the statement of operations during the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; impairment was recorded during the year ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-5"
      id="F_889596c7-cd51-459d-8a79-40d82095205b"
      unitRef="U_USD">13400000</us-gaap:AssetImpairmentCharges>
    <fate:ImpairmentOfRightOfUseAsset
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-5"
      id="F_8bb4780c-6fee-4f0a-8e6d-c4d27407d67a"
      unitRef="U_USD">1300000</fate:ImpairmentOfRightOfUseAsset>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-6"
      id="F_d4c1174b-65d0-4c01-bf95-bd74f92bae2d"
      unitRef="U_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_862c0bea-c483-48a9-bfb8-c903019e5766">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determines if a contract contains a lease at the inception of the contract. The Company currently has leases related to its facilities leased for office and laboratory space, which are classified as operating leases. These leases result in operating right-of-use (ROU) assets, current operating lease liabilities, and non-current operating lease liabilities in the Company&#x2019;s consolidated balance sheets. The Company does not have any financing leases. Leases with a term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12 months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; or less are considered short-term and ROU assets and lease obligations are not recognized. Payments associated with short-term leases are expensed on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities represent an obligation to make lease payments arising from the lease and ROU assets represent the right to use the underlying asset identified in the lease for the lease term. Lease liabilities are measured at the present value of the lease payments not yet paid discounted using the discount rate for the lease established at the lease commencement date. To determine the present value, the implicit rate is used when readily determinable. For those leases where the implicit rate is not provided, the Company determines an incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. ROU assets are measured as the present value of the lease payments and also include any prepaid lease payments made and any other indirect costs incurred, and exclude any lease incentives received. Lease terms may include the impact of options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term. The Company aggregates all lease and non-lease components for each class of underlying assets into a single lease component.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <fate:ShortTermLeasesTermExcludedFromCalculationOfRightOfUseOfAssetsAndLeaseLiabilities
      contextRef="C_3c6a67d5-eeb4-4acd-987b-91a972c863ed"
      id="F_f65fabd7-3665-498b-9e74-044fc728bb1d">P12M</fate:ShortTermLeasesTermExcludedFromCalculationOfRightOfUseOfAssetsAndLeaseLiabilities>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_4c134d80-4d89-48e7-81f4-773209937b6a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC Topic 808, Collaborative Arrangements (ASC 808), to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, the Company assesses whether aspects of the arrangement between the Company and its collaboration partner are within the scope of other accounting literature, including ASC Topic 606, Revenue from Contracts with Customers (ASC 606). If it is concluded that some or all aspects of the arrangement represent a transaction with a customer, the Company will account for those aspects of the arrangement within the scope of ASC 606.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASC 808 provides guidance for the presentation and disclosure of transactions in collaborative arrangements, but it does not provide recognition or measurement guidance. Therefore, if the Company concludes a counterparty to a transaction is not a customer or otherwise not within the scope of ASC 606, the Company considers the guidance in other accounting literature as applicable or by analogy to account for such transaction. The classification of transactions under the Company&#x2019;s arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_3e034a2d-2d1b-49be-b950-7742c66765f5">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. If the Company concludes that some or all aspects of the arrangement represent a transaction with a customer, the Company accounts for those aspects of the arrangement within the scope of ASC 606.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For arrangements attributable to ASC 606, the Company recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration the Company is entitled to receive in exchange for such product or service. In doing so, the Company follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <fate:StockPriceAppreciationMilestonesPolicyTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_3a3dc854-00bd-4d02-989d-897972f4462e">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock Price Appreciation Milestones&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company estimates the fair value of the stock price appreciation milestones associated with the Amended and Restated Exclusive License Agreement with Memorial Sloan Kettering Cancer Center (MSKCC) using a Monte Carlo simulation model, which relies on the Company&#x2019;s current stock price as well as significant estimates and assumptions to determine the estimated liability associated with the contingent milestone payments. The Company accounts for the fair value of the stock price appreciation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;milestones &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in accordance with ASC 815, Derivatives and Hedging, with fair value marked to market at each reporting date. The assumptions used to calculate the fair value of the stock price appreciation milestones are subject to a significant amount of judgment including the probability of achieving a specified clinical milestone, the expected volatility of the Company&#x2019;s common stock, the risk-free interest rate, and the estimated term, which is based in part on the last valid patent claim date. The Company remeasures the fair value of the stock price appreciation milestones at each balance sheet date, with changes in fair value recorded in earnings as non-operating income or expense on the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;</fate:StockPriceAppreciationMilestonesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_c8b032ec-614d-4acf-936d-bbd2f3343f12">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense represents the cost of the grant date fair value of employee stock option and restricted stock unit grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. Performance-based stock units/awards represent a right to receive a certain number of shares of the Company&#x2019;s common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, and to the extent achievement of one or any of the performance conditions is probable, the Company reassesses the probability of the achievement of such corporate performance goals and any increase or decrease in share-based compensation expense resulting from an adjustment in the estimated shares to be released is treated as a cumulative catch-up in the period of adjustment. For stock awards for which vesting is subject to both performance-based milestones and market conditions, expense is recorded over the derived service period after the point when the achievement of the performance-based milestone is probable or the performance condition has been achieved.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, with the exception of option grants for which vesting is subject to both performance-based milestones and market conditions, which are valued using a lattice-based model. The fair value of restricted stock units, including performance-based restricted stock units, is based on the closing price of the Company&#x2019;s common stock as reported on The Nasdaq Global Market on the date of grant. The Company recognizes forfeitures for all awards as such forfeitures occur.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_7b460596-6f8a-47a5-913a-fc4634446b13">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more- likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;more than 50 percent&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_6ac1eeb4-43fe-4fbc-88d7-da80faccb06e">more than 50 percent</us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement>
    <fate:EmployeeRetentionCreditPolicy
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_d8381bb6-9a7f-4eb9-92ce-9eabb3de3570">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Employee Retention Credit&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CARES Act provides an employee retention credit (ERC), which is a refundable tax credit against certain employment taxes of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per employee for eligible employers. The tax credit is equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of qualified wages paid to employees during a quarter, capped at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of qualified wages per employee through December 31, 2020. Additional relief provisions were passed by the United States government, which extend and slightly expand the qualified wage caps on these credits through December 31, 2021. Based on these additional provisions, the tax credit is now equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of qualified wages paid to employees during a quarter, and the limit on qualified wages per employee has been increased to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of qualified wages per quarter. The Company qualifies for the tax credit under the CARES Act and expects to continue to receive additional tax credits under the additional relief provisions for qualified wages through December 31, 2021. In connection with the CARES Act, the Company adopted a policy to recognize the employee retention credit when received and include in other income in the statement of operations. T&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;he &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company received a cash&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;payment &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of other income during the year ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. No such amount was received or recorded during the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;</fate:EmployeeRetentionCreditPolicy>
    <fate:RefundableTaxCredit
      contextRef="C_8073b9ee-958a-4e70-8014-118578a7c26b"
      decimals="-3"
      id="F_b04a5055-b9f1-4a0a-8060-c20d20602af3"
      unitRef="U_USD">5000000</fate:RefundableTaxCredit>
    <fate:PercentageOfTaxCredit
      contextRef="C_914c3fc5-d128-4c00-a001-75c4add6174a"
      decimals="2"
      id="F_88b3eec9-048b-49f1-a107-80c9feee1698"
      unitRef="U_pure">0.50</fate:PercentageOfTaxCredit>
    <us-gaap:PaymentsToEmployees
      contextRef="C_914c3fc5-d128-4c00-a001-75c4add6174a"
      decimals="-3"
      id="F_e0fd6de8-e705-42ae-b0f3-5fa4cc9c595f"
      unitRef="U_USD">10000000</us-gaap:PaymentsToEmployees>
    <fate:PercentageOfTaxCredit
      contextRef="C_c61bcb64-4368-4879-8eae-3bea4e1f47f9"
      decimals="2"
      id="F_bfb2633b-0dd0-453c-8743-5ba17e0b31c4"
      unitRef="U_pure">0.70</fate:PercentageOfTaxCredit>
    <us-gaap:PaymentsToEmployees
      contextRef="C_c61bcb64-4368-4879-8eae-3bea4e1f47f9"
      decimals="-3"
      id="F_a92ab14f-784c-4622-ad1a-b1435bc51bab"
      unitRef="U_USD">10000000</us-gaap:PaymentsToEmployees>
    <us-gaap:OtherIncome
      contextRef="C_0d4321be-2b98-4d77-827f-dd1e376a2681"
      decimals="-5"
      id="F_215e2fe0-57ce-409f-a70b-fef16849b4a2"
      unitRef="U_USD">5100000</us-gaap:OtherIncome>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_a515dfdb-367b-4b5f-a3bc-89ea7335cf0d">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non&#x2011;owner sources. Other comprehensive loss includes unrealized gains and losses on available-for-sale securities.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_7ff33053-5f45-49d4-8145-43fcbb78f780">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Common Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. The Pre-Funded Warrants associated with the January 2021 public equity offering and the private placement concurrent with the March 2024 public equity offering (see Note 9) are considered outstanding shares in the basic earnings per share calculation given their nominal exercise price. Dilutive common stock equivalents comprise convertible preferred stock, warrants for the purchase of common stock, and common stock options and restricted stock units outstanding under the Company&#x2019;s stock option plans. For all periods presented, there is no difference in the number of common shares used to calculate basic and diluted common shares outstanding due to the Company&#x2019;s net loss position.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted net loss per share attributable to stockholders for the years ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024 and 2023 are calculated as follows (in thousands, except share and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;186,262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;160,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares used to compute net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;110,596,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,153,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average pre-funded warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,088,905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;257,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average common shares outstanding used to&lt;br/&gt;&#160;&#160;&#160;&#160;compute basic and diluted net loss per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113,685,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,411,162&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Potentially dilutive securities that are not included in the calculation of diluted net loss per common share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,722,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,850,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,214,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,065,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series A convertible preferred stock (if converted)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,775,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,805,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,712,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,721,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_be17614c-2814-4ecf-b9aa-00cd7d4cbfc9">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted net loss per share attributable to stockholders for the years ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024 and 2023 are calculated as follows (in thousands, except share and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;186,262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;160,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares used to compute net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;110,596,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,153,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average pre-funded warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,088,905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;257,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average common shares outstanding used to&lt;br/&gt;&#160;&#160;&#160;&#160;compute basic and diluted net loss per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113,685,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98,411,162&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_d73149c7-0d75-4648-a978-1d3ae57fa137"
      unitRef="U_USD">-186262000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_9d2eadf8-e4e0-4a4c-a3cd-56c15b155337"
      unitRef="U_USD">-160928000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="0"
      id="F_0b241fb8-52fd-4e31-a247-779aeafb9031"
      unitRef="U_shares">110596272</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="0"
      id="F_ac8575f0-90ec-444a-a425-cfa858c191dd"
      unitRef="U_shares">98153852</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <fate:WeightedAveragePreFundedWarrants
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="0"
      id="F_3535c001-3212-4aee-823a-1116361e7eee"
      unitRef="U_shares">3088905</fate:WeightedAveragePreFundedWarrants>
    <fate:WeightedAveragePreFundedWarrants
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="0"
      id="F_c1e9ce1c-6340-46cb-b4ab-5361893ea98e"
      unitRef="U_shares">257310</fate:WeightedAveragePreFundedWarrants>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="0"
      id="F_2ead170d-2d9e-45d9-9f0e-616db3ffe017"
      unitRef="U_shares">113685177</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="0"
      id="F_5cccd998-c21f-48b6-85c1-5cdc29e3f591"
      unitRef="U_shares">113685177</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="0"
      id="F_3d3cc42d-2666-4743-a887-1597651727d1"
      unitRef="U_shares">98411162</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="0"
      id="F_33a99673-a391-4995-a63c-bf87b52797fe"
      unitRef="U_shares">98411162</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="2"
      id="F_c65af818-2483-48c0-840a-a1f28e023089"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="2"
      id="F_8bce824a-bb16-4ec7-9e1b-e54cdae9ba79"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="2"
      id="F_19483d53-9809-4832-a1e1-7dfb47a8efd2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="2"
      id="F_cc2bb94d-2f80-4c50-9de4-c9cce261aacf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_1b228c9b-8377-41b6-860a-98c23a56519d">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Potentially dilutive securities that are not included in the calculation of diluted net loss per common share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,722,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,850,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,214,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,065,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series A convertible preferred stock (if converted)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,775,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,805,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,712,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,721,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_83226ba1-7f86-458e-b153-94d4da5af37e"
      decimals="INF"
      id="F_0499f8ae-1100-4ff1-a0fd-ecb6c62cfc60"
      unitRef="U_shares">10722674</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ce45b517-0884-46c2-a4a4-3f9f7359e4f1"
      decimals="INF"
      id="F_e9333e94-6a86-4338-9c7f-4eebdd8ac065"
      unitRef="U_shares">9850841</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_2c762660-e17f-4068-960c-6e97d50571ec"
      decimals="INF"
      id="F_05e8f48e-7f28-4aff-a0fb-eee268a9791c"
      unitRef="U_shares">6214064</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_1cf4be6b-4800-4f2a-bcb7-d38f5709c7aa"
      decimals="INF"
      id="F_7518b583-05ae-4053-85f0-751a4555aa9c"
      unitRef="U_shares">3065087</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0519f681-f046-4690-9e46-0dd9cba066f1"
      decimals="INF"
      id="F_6dd6fd1c-f30a-4834-82bc-a236b43ae477"
      unitRef="U_shares">13775430</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b8f2b2d3-e3a5-40c0-8565-7b6bedfecd7a"
      decimals="INF"
      id="F_a62b2379-e923-4193-9327-eeeeaa34fd67"
      unitRef="U_shares">13805540</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="INF"
      id="F_ebb6617f-0dfd-4b55-ab79-3bac25913dd1"
      unitRef="U_shares">30712168</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="INF"
      id="F_67c0f04a-5239-4db7-b48b-fa0c9a490422"
      unitRef="U_shares">26721468</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <fate:LiquidityPolicyTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_e6b999c0-fcc7-41a7-98ea-9d33e3d52095">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Going Concern Assessment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Substantial doubt about an entity&#x2019;s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year from the financial statement issuance date. The Company determined that there are no conditions or events that raise substantial doubt about its ability to continue as a going concern for a period of at least twelve months from the date of issuance of these financial statements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</fate:LiquidityPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_b10b001f-f29c-4adb-82d3-caa309a39f90">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU No. 2023-07, which requires public entities to disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about a reportable segment&#x2019;s profit or loss and assets that are currently required annually. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The ASU does not change how a public&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;entity identifies its operating segments, aggregates them or applies the quantitative thresholds to determine its reportable segments. The ASU is effective for fiscal years beginning after December 15, 2023, and for interim periods beginning after December 15, 2024, with early adoption permitted. The guidance should be applied retrospectively to all periods presented in the financial statements, unless it is impracticable. The segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The Company adopted ASU No. 2023-07 during the year ended December 31, 2024 and have included required disclosures in Note 11.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This new standard will be effective for the annual periods beginning the year ended December 31, 2025. The new standard permits early adoption and can be applied prospectively or retrospectively. The Company does not expect the adoption of this guidance to have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement: Reporting Comprehensive Income- Expense Disaggregation Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which requires detailed information about specified categories of expenses included in certain expense captions presented on the face of the income statement, as well as disclosures about selling expenses. This ASU is effective for fiscal years beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_a1a92a81-7872-40f3-970f-b8a915ba36bb">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2. Collaboration and License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Ono Collaboration and Option Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On September 14, 2018, the Company entered into a Collaboration and Option Agreement (the Ono Agreement) with Ono Phar&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;maceutical Co., Ltd. (Ono) for the joint development and commercialization of two off-the-shelf, iPSC-derived CAR T-cell product candidates (Candidate 1 and Candidate 2). Pursuant to the terms of the Ono Agreement, the Company received an upfront, non-refundable and non-creditable payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. Additionally, the Company was entitled to receive funding for the conduct of research and preclinical development under a joint research plan, which fees were estimated to be $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in aggregate.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2020, the Company entered into a letter agreement with Ono (the Ono Letter Agreement) pursuant to which Ono delivered proprietary antigen binding domains targeting an antigen expressed on certain solid tumors for incorporation into Candidate 2 and paid the Company a milestone fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for further research and preclinical development of Candidate 2. In addition, Ono terminated all further research and preclinical development with respect to Candidate 1, and the Company retained all rights to research, develop and commercialize Candidate 1 throughout the world without any obligation to Ono.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In June 2022, the Company entered into an amendment with Ono to the Ono Agreement (the 2022 Ono Amendment). Pursuant to the 2022 Ono Amendment, the companies agreed to designate an additional antigen expressed on certain solid tumors for research and preclinical development, and Ono agreed to contribute proprietary antigen binding domains targeting such additional solid tumor antigen (Candidate 3). In addition, for both Candidate 2 and Candidate 3, Ono and the Company expanded the scope of the collaboration to include the research and preclinical development of iPSC-derived CAR NK cell product candidates (in addition to iPSC-derived CAR T-cell product candidates) targeting the designated solid tumor antigens. Similar to Candidate 2, the Company granted to Ono, during a specified period of time, a preclinical option (Candidate 3 Development Option) to obtain an exclusive license under certain intellectual property rights, subject to payment of an option exercise fee to the Company by Ono, to further develop and commercialize Candidate 3 in all territories of the world, where the Company retains rights to co-develop and co-commercialize Candidate 3 in the United States and Europe under a joint arrangement with Ono pursuant to which the Company is eligible to share at least &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the profits and losses. The Candidate 3 Development Option represents an option with no material right. Under the 2022 Ono Amendment, aggregate estimated research and preclinical development fees have been increased by approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, for a total estimated $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in aggregate research and preclinical development fees over the course of the joint research plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;November 2022, Ono exercised its option to obtain a license to develop and commercialize Candidate 2 (the Candidate 2 Development Option). The Company exercised its option (the CDCC Option) to co-develop and co-commercialize Candidate 2 in the United States and Europe. As a result, the Company received an Option Exercise Payment (as defined under the Ono Agreement) of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The Company and Ono are proceeding under a joint development plan for the ongoing development of Candidate 2. At the inception of the Ono Agreement, the Company determined the Candidate 2 Development Option represented an option with no material right that is distinct and separable from the ongoing development of Candidate 2 being performed by the parties. As such, the option exercise was treated as a separate contract with a single performance obligation of granting and delivering Ono a license to further develop and commercialize Candidate 2. The Company has completed its performance obligation with respect to the Candidate 2 Development Option and accordingly, recognized the Option Exercise Payment as revenue for the year ended December 31, 2022. The costs of this joint development plan are accounted for in accordance with ASC 808, and cost sharing payments to the Company from Ono are recorded net into research and development expenses. In addition, in connection with the ongoing joint development of Candidate 2, the Company is eligible to receive additional payments upon the achievement of certain clinical, regulatory, and commercial milestones&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (as further described below).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the Company entered into an amendment with Ono to the Ono Agreement (the 2023 Ono Amendment). Under the 2023 Ono Amendment, aggregate estimated research and preclinical development fees payable by Ono to the Company for Candidate 3 have been increased by approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, for a total estimated $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in aggregate research and preclinical development fees over the course of the joint research plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In May 2024, following Ono&#x2019;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s exercise of the Candidate 2 Development Option and grant of the development and commercialization license, the Company achieved a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million clinical development milestone for Candidate 2 and the Company recognized such amount as revenue during the period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In August 2024, the Company entered into an amendment with Ono to the Ono Agreement (the 2024 Ono Amendment and collectively with the 2023 Ono Amendment and 2022 Ono Amendment, the Ono Amendments). Under the 2024 Ono Amendment, aggregate estimated research and preclinical development fees payable by Ono to the Company for Candidate 3 have been increased by approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, for a total estimated $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in aggregate research and preclinical development fees over the course of the joint research plan. The Company will continue to receive committed funding under the joint research plan from Ono through June 2025. The Candidate 3 Development Option expires upon the earlier of: (a) June 30, 2025 or (b) the achievement of the pre-defined preclinical milestone under the joint research plan for Candidate 3. Subject to payment of an extension fee by Ono, Ono may choose to defer its decision to exercise the Candidate 3 Development Option until no later than June 2026.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the terms of the Ono Agreement (as amended by the Ono Amendments), for Candidate 2 and for Candidate 3 (subject to exercise by Ono of its Candidate 3 Development Option), the Company is eligible to receive additional payments upon the achievement of certain clinical, regulatory and commercial milestones (the Ono Milestones) with respect to each Candidate in an amount up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;843.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in aggregate, with the applicable milestone payments for the United States and Europe subject to reduction by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% if the Company elects to co-develop and co-commercialize the Candidate in the United States and Europe as described above. In addition, in those territories where Ono has exclusive rights of commercialization, the Company is eligible to receive tiered royalties (Royalties) ranging from the mid-single digits to the low-double digits based on annual net sales by Ono for each Candidate in such territories, with the Royalties subject to certain reductions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Ono Agreement will terminate with respect to a Candidate if Ono does not exercise its development option for a candidate within the option period, or in its entirety if Ono does not exercise any of its development options for the candidates within their respective option periods. In addition, either party may terminate the Ono Agreement in the event of breach, insolvency or patent challenges by the other party; provided, that Ono may terminate the Ono Agreement in its sole discretion (x) on a Candidate-by-Candidate basis at any time after the second anniversary of the effective date of the Ono Agreement or (y) on a Candidate-by-Candidate or country-by-country basis at any time after the expiration of the development option period, subject to certain limitations. The Ono Agreement will expire on a Candidate-by-Candidate and country-by-country basis upon the expiration of the applicable royalty term, or in its entirety upon the expiration of all applicable payment obligations under the agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determined that the Ono Agreement, Ono Letter Agreement, and Ono Amendments (collectively, the Ono Arrangement) were within the scope of ASC 808 and applicable to such guidance. The Company concluded that certain units of account, specifically the grant of a research license to certain intellectual property and the performance of research and preclinical development, within the Ono Arrangement represented a customer relationship and applied relevant guidance from ASC 606 to evaluate the appropriate accounting for those units of account. In accordance with this guidance, the Company identified its promised goods and services, including its grant of a research license to Ono to certain of its intellectual property subject to certain conditions, its conduct of research and preclinical development services, and its participation in a joint steering committee. The Company determined that its grant of a research license to Ono to certain of its intellectual property was not distinct from its conduct of research and preclinical development services and participation in a joint steering committee. Accordingly, the Company determined that the research license, the research and preclinical development services, and the participation in a joint steering committee during the development option period, should be accounted for as one combined performance obligation, and that the combined performance obligation is transferred over the expected term of the conduct of the research and preclinical development services. The Company also determined that, subject to the guidance of ASC 606, the license to develop and commercialize Candidate 2 upon exercise of the Candidate 2 Development Option was distinct and separable from the development and commercialization activities, which are accounted for under ASC 808.  The termination of the Ono Agreement with respect to Candidate 1 did not impact this assessment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In accordance with ASC 606, the Company determined that the initial transaction price for research and preclinical development under the Ono Arrangement equaled $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, consisting of the upfront, non-refundable and non-creditable payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and the aggregate estimated research and preclinical development fees of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The Company also concluded that the milestone fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million paid by Ono to the Company for further research and preclinical development of Candidate 2 represented a variable consideration that was previously constrained. Both the upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and the Candidate 2 milestone fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million were recorded as deferred revenue and were recognized as revenue over time in conjunction with the Company&#x2019;s conduct of research and preclinical development services based on actual costs incurred as a percentage of the estimated total costs expected to be incurred over the expected term of conduct of the research and preclinical development services. The Company recorded the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million prepayment of the first-year research and preclinical development fees as deferred revenue, and such fees were recognized as revenue as the research and preclinical development services were delivered.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognized revenue of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million under the Ono Arrangement during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2023, respectively. Such revenue consisted of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million associated with research and preclinical development services, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million associated with the achievement of a clinical development milestone for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024. During the year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, such revenue comprised $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million associated with research and preclinical development services.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognized contra-research and development expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million associated with the joint development of Candidate 2 under the Ono Arrangement for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024. During the year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company recognized contra-research and development expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As a direct result of the Company&#x2019;s entry into the Ono Arrangement, the Company incurred an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in sublicense consideration to existing licensors. The Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of such expense during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company recognized &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; such expense during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Janssen Collaboration and Option Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 2, 2020 (the Janssen Agreement Effective Date), the Company entered into a Collaboration and Option Agreement (the Janssen Agreement) with Janssen Biotech, Inc. (Janssen), part of the Janssen Pharmaceutical Companies of Johnson &amp;amp; Johnson. Additionally, on the Janssen Agreement Effective Date, the Company entered into a Stock Purchase Agreement (the Stock Purchase Agreement) with Johnson &amp;amp; Johnson Innovation - JJDC, Inc. (JJDC). On January 3, 2023, the Company received notice of termination from Janssen of the Janssen Agreement. The termination took effect on April 3, 2023, and during the three months ended March 31, 2023, the Company performed wind-down activities including discontinuing development of all collaboration product candidates under the Janssen Agreement. The Company was reimbursed for all wind-down activities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the terms of the Janssen Agreement and the Stock Purchase Agreement taken together, the Company received $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was an upfront cash payment and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was in the form of an equity investment by JJDC. The Company determined the common stock purchase by JJDC represented a premium of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.93&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, or $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in aggregate (the Equity Premium), and the remaining $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was recorded as issuance of common stock in shareholders&#x2019; equity. In addition, under the Stock Purchase Agreement, the Company exercised the right to require JJDC to purchase an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in shares in a private placement at the same price per share as paid by investors in a public offering. In June 2020, JJDC purchased &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of the Company&#x2019;s common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28.31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. Additionally, the Company received full funding for the conduct of all research, preclinical development and Investigational New Drug Application (IND)-enabling activities performed by the Company under the Janssen Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognized revenue of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million under the Janssen Agreement for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was deferred as of December 31, 2022. Such revenue consisted of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million associated with research and development services, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million associated with the upfront fee and Equity Premium, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million associated with a commercial option exercise.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In connection with the Janssen Agreement, the Company incurred $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in sublicense fees to certain of its existing licensors. The $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in sublicense consideration represents an asset under ASC 340, and was amortized to research and development expense ratably with the Company&#x2019;s revenue recognition under the Janssen Agreement. During the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of such expense. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, there was no remaining balance on the Janssen Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Memorial Sloan Kettering Cancer Center License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On May 15, 2018, the Company entered into an Amended and Restated Exclusive License Agreement (the Amended MSKCC License) with MSKCC. The Amended MSKCC License amends and restates the Exclusive License Agreement entered into between the Company and MSKCC on August 19, 2016 (the Original MSKCC License), pursuant to which the Company entered into an exclusive license agreement with MSKCC for rights relating to compositions and methods covering iPSC-derived cellular immunotherapy, including T-cells and NK-cells derived from iPSCs engineered with CARs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the Amended MSKCC License, MSKCC granted to the Company additional licenses to certain patents and patent applications relating to new CAR constructs and off-the-shelf CAR T-cells, including the use of clustered regularly interspaced short palindromic repeat (CRISPR) and other innovative technologies for their production, in each case to research, develop, and commercialize licensed products in the field of all human therapeutic uses worldwide. The Company has the right to grant sublicenses to certain licensed rights in accordance with the terms of the Amended MSKCC License, in which case it is obligated to pay MSKCC a percentage of certain sublicense income received by the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is obligated to pay to MSKCC an annual license maintenance fee during the term of the agreement, and milestone payments upon the achievement of specified clinical, regulatory and commercial milestones for licensed products as well as royalty payments on net sales of licensed products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the event a licensed product achieves a specified clinical milestone, MSKCC is then eligible to receive certain milestone payments totaling up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million based on the price of the Company&#x2019;s common stock, where the amount of such payments owed to MSKCC is contingent upon certain increases in the price of the Company&#x2019;s common stock following the date of achievement of such clinical milestone. These payments are based on common stock price multiples, with the numerator being the fair value of the ten-trading day trailing average closing price of the Company&#x2019;s common stock and the denominator being the ten-trading day trailing average closing price of the Company&#x2019;s common stock as of the effective date of the Amended MSKCC License, adjusted for any stock splits, cash dividends, stock dividends, other distributions, combinations, recapitalizations, or similar events. Under the terms of the Amended MSKCC License, upon a change of control of the Company, in certain circumstances, the Company may be required to pay a portion of these payments to MSKCC based on the price of the Company&#x2019;s common stock in connection with such change of control.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; following table summarizes the common stock multiples and the stock price appreciation milestone payments under the terms of the agreement:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock multiple&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0x&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0x&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.0x&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ten-trading day trailing average common stock price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150.54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock price appreciation milestone payment (in millions)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:5.147%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In July 2021, the Company achieved the specified clinical milestone for a licensed product under the Amended MSKCC License and the Company&#x2019;s ten-trading day trailing average common stock price exceeded the first, pre-specified threshold. As a result, the Company remitted the first milestone payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to MSKCC during the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To determine the estimated fair value of the remaining stock price appreciation milestones, the Company uses a Monte Carlo simulation methodology which models future Company common stock prices based on the current stock price and several key variables. The following variables were incorporated in the calculation of the estimated fair value of the stock price appreciation milestones as of December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.147%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Estimated term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Closing stock price as of measurement date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The key inputs to the Monte Carlo simulation to determine the fair value of the stock price appreciation milestones include the Company&#x2019;s stock price as of the measurement date; the estimated term which is based in part on the last valid patent claim date; the expected volatility of the Company&#x2019;s common stock, estimated using the Company&#x2019;s historical common stock volatility as of the remeasurement date; and the risk-free rate based on the U.S. Treasury yield for the estimated term determined. Fair value measurements are highly sensitive to changes in these inputs and significant changes could result in a significantly higher or lower fair value and resulting expense or gain.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At each balance sheet date, the Company remeasures the fair value of the stock price appreciation milestones, with changes in fair value recognized as a component of other income (expense) in the consolidated statements of operations and comprehensive loss. Amounts are included in current or non-current liabilities based on the estimated timeline associated with the individual potential payments. During the years ended December 31, 2024 and 2023, the Company recorded &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of income, respectively, associated with the change in fair value of the stock price appreciation milestones. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023, the Company recorded a liability of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, associated with the stock price appreciation milestones for the Amended MSKCC License.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <fate:CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue
      contextRef="C_f5465cc9-eacc-41b4-9cfc-f0dad102ddfb"
      decimals="-5"
      id="F_3d870057-ac41-4be5-95f3-677f20af50b0"
      unitRef="U_USD">10000000</fate:CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue>
    <fate:CollaborativeArrangementAggregatePaymentsReceivable
      contextRef="C_f98f7f9d-7ad9-48be-9ec2-e497587e292e"
      decimals="-5"
      id="F_a9be82fb-639b-4c17-9947-425484ebe6bb"
      unitRef="U_USD">20000000</fate:CollaborativeArrangementAggregatePaymentsReceivable>
    <fate:MilestonePayments
      contextRef="C_bf1abdb0-874a-4c56-9fa4-d32731526c6f"
      decimals="-5"
      id="F_6b669c8f-b2c1-4988-9f4b-89fb1b942010"
      unitRef="U_USD">10000000</fate:MilestonePayments>
    <fate:ProfitLossSharingPercentage
      contextRef="C_b524e977-baf9-4884-add0-8ccda59b00ff"
      decimals="2"
      id="F_fdac4b2a-7b1b-432d-b8e9-fb6977b781ee"
      unitRef="U_pure">0.50</fate:ProfitLossSharingPercentage>
    <fate:CollaborativeArrangementPotentialAdditionalMilestones
      contextRef="C_e2c30eb4-cb8a-4c56-94e1-15d379546979"
      decimals="-5"
      id="F_dfb38631-838d-4798-9ed7-3af0ec5c29c4"
      unitRef="U_USD">9300000</fate:CollaborativeArrangementPotentialAdditionalMilestones>
    <fate:CollaborativeArrangementPotentialAdditionalMilestones
      contextRef="C_69c1fc96-8425-49fc-a5df-640ad6ae407c"
      decimals="-5"
      id="F_7dd2e5d9-aca5-435f-9c82-aeee244fe2fc"
      unitRef="U_USD">29300000</fate:CollaborativeArrangementPotentialAdditionalMilestones>
    <fate:OptionExercisePayment
      contextRef="C_4bd1be9a-9ef2-4939-bc4f-c8ced0fd9412"
      decimals="-5"
      id="F_d028a311-6ca0-413f-ac67-ff81b17ba7e2"
      unitRef="U_USD">12500000</fate:OptionExercisePayment>
    <fate:CollaborativeArrangementPotentialAdditionalMilestones
      contextRef="C_14a6993c-8757-45a1-9ffd-ead3d146845f"
      decimals="-5"
      id="F_68e16fa5-905a-4387-a19c-b8351511b534"
      unitRef="U_USD">1400000</fate:CollaborativeArrangementPotentialAdditionalMilestones>
    <fate:CollaborativeArrangementPotentialAdditionalMilestones
      contextRef="C_28eaa775-35eb-4f9b-a403-7245d490401e"
      decimals="-5"
      id="F_52b04bf4-2a14-4eaa-8736-ce796843f3ed"
      unitRef="U_USD">30700000</fate:CollaborativeArrangementPotentialAdditionalMilestones>
    <fate:ClinicalDevelopmentMilestoneFees
      contextRef="C_c1b46ce1-8237-43cf-86cd-6a985c5ce0ca"
      decimals="-5"
      id="F_fcddaf3e-f5d4-4c4a-bee8-8abbe269fbaa"
      unitRef="U_USD">5000000</fate:ClinicalDevelopmentMilestoneFees>
    <fate:CollaborativeArrangementPotentialAdditionalMilestones
      contextRef="C_6c678e63-62cc-45c4-9884-6caff102c094"
      decimals="-5"
      id="F_ea0605d5-fba3-4288-8fb8-fab516a9ff1e"
      unitRef="U_USD">7300000</fate:CollaborativeArrangementPotentialAdditionalMilestones>
    <fate:CollaborativeArrangementPotentialAdditionalMilestones
      contextRef="C_f6acdf54-a780-4f0d-a5a2-e9a7888f459a"
      decimals="-5"
      id="F_b22e83f5-229d-4cb9-8054-0f8d2440867b"
      unitRef="U_USD">38000000</fate:CollaborativeArrangementPotentialAdditionalMilestones>
    <fate:CollaborativeArrangementAggregateMilestonePaymentsReceivable
      contextRef="C_4e4a3db2-068c-46c3-9e45-17fdfb12f653"
      decimals="-5"
      id="F_16277907-e8d3-439f-b76d-c2e5d657b30f"
      unitRef="U_USD">843000000</fate:CollaborativeArrangementAggregateMilestonePaymentsReceivable>
    <fate:CollaborativeArrangementPercentageOfReductionOnMilestonePayments
      contextRef="C_c4256f0f-bf1b-4d25-ba9b-95785d196f09"
      decimals="2"
      id="F_a5a4c971-57f9-44bf-b716-acf52889f64a"
      unitRef="U_pure">0.50</fate:CollaborativeArrangementPercentageOfReductionOnMilestonePayments>
    <fate:TransactionPriceOfAgreement
      contextRef="C_47a8c41d-7932-412e-a1cf-a28cc3a2ebb4"
      decimals="-5"
      id="F_4a8a5f32-7989-4ced-a412-67441e5d27d7"
      unitRef="U_USD">48000000</fate:TransactionPriceOfAgreement>
    <fate:UpfrontNonRefundableNonCreditablePaymentReceivable
      contextRef="C_f98f7f9d-7ad9-48be-9ec2-e497587e292e"
      decimals="-5"
      id="F_fb31dfcc-2625-4122-94ae-fe11bd65d9b9"
      unitRef="U_USD">10000000</fate:UpfrontNonRefundableNonCreditablePaymentReceivable>
    <fate:CollaborativeArrangementPotentialAdditionalMilestones
      contextRef="C_f98f7f9d-7ad9-48be-9ec2-e497587e292e"
      decimals="-5"
      id="F_773967ba-53c0-47c4-8420-6aca600cdc27"
      unitRef="U_USD">38000000</fate:CollaborativeArrangementPotentialAdditionalMilestones>
    <fate:MilestonePayments
      contextRef="C_b434e138-ff00-4c3d-bbe3-be9b301a7015"
      decimals="-5"
      id="F_50c4ad60-c217-4c29-892b-bd3096aa524f"
      unitRef="U_USD">10000000</fate:MilestonePayments>
    <fate:CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue
      contextRef="C_f5465cc9-eacc-41b4-9cfc-f0dad102ddfb"
      decimals="-5"
      id="F_a45a094a-d1df-4749-9c59-8770e7f5bf3e"
      unitRef="U_USD">10000000</fate:CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue>
    <fate:MilestonePaymentUnderDeferredRevenue
      contextRef="C_ced1b62f-5a61-4b35-bc5e-24a1d2c9771c"
      decimals="-5"
      id="F_7dde2251-c7ac-4199-ad1c-9ed375e02c06"
      unitRef="U_USD">10000000</fate:MilestonePaymentUnderDeferredRevenue>
    <fate:CollaborativeArrangementAnnualPaymentsReceivableRecordedUnderDeferredRevenue
      contextRef="C_ced1b62f-5a61-4b35-bc5e-24a1d2c9771c"
      decimals="-5"
      id="F_9d1637da-b6a7-4acf-b8b9-325582e27a8a"
      unitRef="U_USD">5000000</fate:CollaborativeArrangementAnnualPaymentsReceivableRecordedUnderDeferredRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_c2029f3a-6dfd-4668-a724-7134c2e52a11"
      decimals="-5"
      id="F_9336a7a5-5669-49f5-92a8-8c086a72731a"
      unitRef="U_USD">13600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_5773cffb-0793-4d07-bf3f-34a1272bc4c5"
      decimals="-5"
      id="F_b4baf354-e79a-4368-95a8-3cf7340a89e4"
      unitRef="U_USD">11200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_f9d2101e-3c01-4cba-a24b-48c0f0b161d9"
      decimals="-5"
      id="F_232f5dc3-7945-4e38-b00d-d94a1dd0e80e"
      unitRef="U_USD">8600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_60fe76db-e159-48de-b30e-daed5bf713f6"
      decimals="-5"
      id="F_8f4fbf40-acff-4c7a-9fb3-852f9000c09e"
      unitRef="U_USD">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_5773cffb-0793-4d07-bf3f-34a1272bc4c5"
      decimals="-5"
      id="F_157f3d0e-b4ca-4162-abb3-880c1e4944c4"
      unitRef="U_USD">11200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <fate:ContraResearchAndDevelopmentExpenses
      contextRef="C_ca3bbae4-b7ef-4100-8179-d51130791abc"
      decimals="-5"
      id="F_90dec9db-a2b2-41d8-ad89-7138b0907354"
      unitRef="U_USD">5100000</fate:ContraResearchAndDevelopmentExpenses>
    <fate:ContraResearchAndDevelopmentExpenses
      contextRef="C_439addc5-9548-4d3a-bc32-ad8b68c23597"
      decimals="-5"
      id="F_b746ee4a-a011-4397-be8f-545bf8088a28"
      unitRef="U_USD">8000000</fate:ContraResearchAndDevelopmentExpenses>
    <fate:CorrespondingAssetForSublicenseConsiderationPaid
      contextRef="C_4cd86a5a-2ced-41c7-9f0e-9f68de9fef11"
      decimals="-5"
      id="F_52370a52-e833-4dfc-9648-f8b2706570f6"
      unitRef="U_USD">9000000</fate:CorrespondingAssetForSublicenseConsiderationPaid>
    <fate:AmortizationOfSubLicenseConsideration
      contextRef="C_c2029f3a-6dfd-4668-a724-7134c2e52a11"
      decimals="-5"
      id="F_7c0c9236-12df-4364-8380-613bbdeb91aa"
      unitRef="U_USD">1200000</fate:AmortizationOfSubLicenseConsideration>
    <fate:AmortizationOfSubLicenseConsideration
      contextRef="C_5773cffb-0793-4d07-bf3f-34a1272bc4c5"
      decimals="-6"
      id="F_d5e4f7ba-b74e-4bf2-9837-44de2112e050"
      unitRef="U_USD">0</fate:AmortizationOfSubLicenseConsideration>
    <fate:CompanyReceivedPayment
      contextRef="C_b44c450a-2dc3-4462-8d2c-f77c56795b1f"
      decimals="-5"
      id="F_cb2a41aa-3182-4282-acd2-e0cddc87efcf"
      unitRef="U_USD">100000000</fate:CompanyReceivedPayment>
    <fate:UpfrontCashPayment
      contextRef="C_b44c450a-2dc3-4462-8d2c-f77c56795b1f"
      decimals="-5"
      id="F_ec77b66d-3595-4f3e-982d-64d0fba1be3f"
      unitRef="U_USD">50000000</fate:UpfrontCashPayment>
    <us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets
      contextRef="C_4a27cfd3-c4bb-4733-abe8-a5141e381e3f"
      decimals="-5"
      id="F_69bcb902-b5a4-4d41-a97b-7b5d23b92fa3"
      unitRef="U_USD">50000000</us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets>
    <fate:EquityPremiumOnSharePricePerShareUnderAgreement
      contextRef="C_b44c450a-2dc3-4462-8d2c-f77c56795b1f"
      decimals="2"
      id="F_7b5085b3-6383-446f-a535-e5774d162598"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.93</fate:EquityPremiumOnSharePricePerShareUnderAgreement>
    <fate:AggregateEquityPremiumOnSharesIssuedUnderAgreement
      contextRef="C_b44c450a-2dc3-4462-8d2c-f77c56795b1f"
      decimals="-5"
      id="F_99c86f51-8c0d-45b3-911b-0f5f558b7dbe"
      unitRef="U_USD">16000000</fate:AggregateEquityPremiumOnSharesIssuedUnderAgreement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_b44c450a-2dc3-4462-8d2c-f77c56795b1f"
      decimals="-5"
      id="F_180cfd8b-a46f-44b2-b52f-f738e69b3a3b"
      unitRef="U_USD">34000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_b44c450a-2dc3-4462-8d2c-f77c56795b1f"
      decimals="-5"
      id="F_5334dd00-fdaf-45a9-84c0-152595daba8b"
      unitRef="U_USD">50000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <fate:StockIssuedDuringPeriodSharesForPrivatePlacement
      contextRef="C_1e42a653-35ec-4959-8224-d96563396f11"
      decimals="-5"
      id="F_8e54204b-cbc3-44ef-b443-a0de644bb7ee"
      unitRef="U_shares">1800000</fate:StockIssuedDuringPeriodSharesForPrivatePlacement>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_a53d5f30-4ead-4f12-abb3-1d519e3a22c5"
      decimals="2"
      id="F_2ee76e3f-c5b8-49f7-9c13-79cc9281da70"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">28.31</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a6afb152-c99a-4b4f-8ec2-a459b2a92d61"
      decimals="-5"
      id="F_c564d8dc-dd6d-48db-a943-f18beb7e9c11"
      unitRef="U_USD">52300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DeferredRevenue
      contextRef="C_3aa72a78-bcb4-4041-8da5-aa19c436d13a"
      decimals="-5"
      id="F_f3d2fe73-3b9f-42bd-9df6-7f4b458742ab"
      unitRef="U_USD">41200000</us-gaap:DeferredRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_c3abcd74-97fc-43ce-9d4c-92aeb8a7a7d9"
      decimals="-5"
      id="F_b1484ee6-084d-48cb-8a59-1718133f4d3f"
      unitRef="U_USD">11100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_5617f7c9-ae5a-4956-8221-b18d672649e5"
      decimals="-5"
      id="F_ace6f79c-9b05-4e13-a6d6-687361bc431e"
      unitRef="U_USD">31200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_3993554b-9513-4d91-b34e-db9cda665ac3"
      decimals="-5"
      id="F_fa241997-8fe3-4cfa-89ef-6c10b69ffea8"
      unitRef="U_USD">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent
      contextRef="C_b5de5eaf-450a-48f0-8a17-e88454281754"
      decimals="-5"
      id="F_5905b783-906e-4a41-aebe-da411c7f38ea"
      unitRef="U_USD">17100000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <fate:SublicenseConsiderationRepresentsAnAssetUnderAscOtherAssetsAndDeferredCosts
      contextRef="C_473eb942-1f90-41e1-b4de-c3380615c958"
      decimals="-5"
      id="F_db51980b-cb75-4ed0-ba1d-3075490be49c"
      unitRef="U_USD">17100000</fate:SublicenseConsiderationRepresentsAnAssetUnderAscOtherAssetsAndDeferredCosts>
    <fate:AmortizationOfSubLicenseConsideration
      contextRef="C_a6afb152-c99a-4b4f-8ec2-a459b2a92d61"
      decimals="-5"
      id="F_a1b96d29-8591-4f02-847a-d439629d5f2c"
      unitRef="U_USD">7200000</fate:AmortizationOfSubLicenseConsideration>
    <fate:EnterpriseValueMilestonePayment
      contextRef="C_0d79e020-c388-40bd-a1ab-ccdba8d6c0f6"
      decimals="-5"
      id="F_e8cb1db9-afbc-40e7-bb20-aed8b46d5125"
      unitRef="U_USD">75000000</fate:EnterpriseValueMilestonePayment>
    <fate:CommonStockMultiplesAndTheEnterpriseValueMilestonePaymentsTableTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_bc5adeaf-b1e1-4d3d-9d5a-f41dbcd7342e">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; following table summarizes the common stock multiples and the stock price appreciation milestone payments under the terms of the agreement:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock multiple&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0x&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0x&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.0x&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ten-trading day trailing average common stock price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150.54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock price appreciation milestone payment (in millions)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</fate:CommonStockMultiplesAndTheEnterpriseValueMilestonePaymentsTableTextBlock>
    <fate:CommonStockMultiple1
      contextRef="C_e3dc601c-f824-4b78-bf0e-07dae896ef9c"
      id="F_a0a78c0c-4ba7-461f-925b-48d836450f14">5.0x</fate:CommonStockMultiple1>
    <fate:CommonStockMultiple1
      contextRef="C_f28a10a2-8fc0-44c9-a166-60bb7e722119"
      id="F_dee9e57f-ee00-4238-8f93-596059ba6646">10.0x</fate:CommonStockMultiple1>
    <fate:CommonStockMultiple1
      contextRef="C_2e9f4ffe-10e2-4108-a3d9-3d3ffddd7ad0"
      id="F_415a8cb6-86fb-40fb-9102-4ab55db52e29">15.0x</fate:CommonStockMultiple1>
    <fate:TrailingStockPricePerShare
      contextRef="C_0284ad68-4270-4896-8d67-06f5f506fa6e"
      decimals="2"
      id="F_b0f62a0c-0bdd-416c-bb92-3fae6ef162ce"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">50.18</fate:TrailingStockPricePerShare>
    <fate:TrailingStockPricePerShare
      contextRef="C_7bc2c0be-3669-4b09-a396-9031cd164016"
      decimals="2"
      id="F_5993db9e-69bd-4a37-8ddc-fac762abad6e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">100.36</fate:TrailingStockPricePerShare>
    <fate:TrailingStockPricePerShare
      contextRef="C_dc572fae-d1e3-4dc6-9902-fa5e71563255"
      decimals="2"
      id="F_9a829a54-51a8-411b-b075-064e051b1e53"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">150.54</fate:TrailingStockPricePerShare>
    <fate:MilestonePayments
      contextRef="C_0284ad68-4270-4896-8d67-06f5f506fa6e"
      decimals="-5"
      id="F_739b8fab-67a3-416f-8a2c-d50d97e3e154"
      unitRef="U_USD">20000000</fate:MilestonePayments>
    <fate:MilestonePayments
      contextRef="C_7bc2c0be-3669-4b09-a396-9031cd164016"
      decimals="-5"
      id="F_31a75d61-a314-4c6d-b901-6ea726c236be"
      unitRef="U_USD">30000000</fate:MilestonePayments>
    <fate:MilestonePayments
      contextRef="C_dc572fae-d1e3-4dc6-9902-fa5e71563255"
      decimals="-5"
      id="F_82cb6d6c-6498-4032-8a6a-39da66d1e428"
      unitRef="U_USD">25000000</fate:MilestonePayments>
    <fate:StockPriceAppreciationMilestonePayable
      contextRef="C_6558896f-2704-4857-9934-3ac8fb755e52"
      decimals="-5"
      id="F_ec64161f-ca4d-49ef-a7ba-9c4b38c0697e"
      unitRef="U_USD">20000000</fate:StockPriceAppreciationMilestonePayable>
    <fate:ScheduleOfMilestonePaymentsValuationAssumptionsTableTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_f63510bb-f3b7-492f-9662-e9994705aae5">&lt;p style="text-indent:5.147%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Estimated term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Closing stock price as of measurement date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</fate:ScheduleOfMilestonePaymentsValuationAssumptionsTableTextBlock>
    <fate:FairValueAssumptionsRiskFreeInterestRate1
      contextRef="C_8f2c86db-20b2-4603-88f9-51afe5ae61e0"
      decimals="3"
      id="F_35ecd59e-48b3-4bb8-ae45-510cd0f383fe"
      unitRef="U_pure">0.048</fate:FairValueAssumptionsRiskFreeInterestRate1>
    <fate:FairValueAssumptionsRiskFreeInterestRate1
      contextRef="C_41a96d2d-db51-45dc-a3d4-a00f6dd5f281"
      decimals="3"
      id="F_54a24f73-d122-4a80-b769-a6b7bced505b"
      unitRef="U_pure">0.04</fate:FairValueAssumptionsRiskFreeInterestRate1>
    <fate:FairValueAssumptionsExpectedVolatilityRate1
      contextRef="C_8f2c86db-20b2-4603-88f9-51afe5ae61e0"
      decimals="3"
      id="F_c03dbc89-e89e-4f9b-bfea-18eee66174a4"
      unitRef="U_pure">0.853</fate:FairValueAssumptionsExpectedVolatilityRate1>
    <fate:FairValueAssumptionsExpectedVolatilityRate1
      contextRef="C_41a96d2d-db51-45dc-a3d4-a00f6dd5f281"
      decimals="3"
      id="F_615da8fe-532b-490a-8e3f-ba80e6d4510a"
      unitRef="U_pure">0.84</fate:FairValueAssumptionsExpectedVolatilityRate1>
    <fate:FairValueAssumptionsExpectedTerm1
      contextRef="C_8f2c86db-20b2-4603-88f9-51afe5ae61e0"
      id="F_6a48b2da-31ae-439f-988d-9f52b3d86c9f">P14Y</fate:FairValueAssumptionsExpectedTerm1>
    <fate:FairValueAssumptionsExpectedTerm1
      contextRef="C_41a96d2d-db51-45dc-a3d4-a00f6dd5f281"
      id="F_9d29a709-924d-42df-9a57-83bad6ee4360">P15Y</fate:FairValueAssumptionsExpectedTerm1>
    <us-gaap:SharePrice
      contextRef="C_caf5635b-36dc-4bb5-83b2-d3bfaff93dac"
      decimals="2"
      id="F_1dfdf8b2-1f6a-4e9c-bdba-603cea67f7a1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.65</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="C_fc28b484-986a-4aa3-ac45-ec88d93742f0"
      decimals="2"
      id="F_23c0919c-d7b0-4553-a1ce-1fd81023fda1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.74</us-gaap:SharePrice>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_705e67ff-045b-436e-92bc-cce8ba8f5edd"
      decimals="-5"
      id="F_7b5d55bb-d762-4de4-a3c4-5657938c6d12"
      unitRef="U_USD">800000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_ff4ddbec-d136-4b09-a4a0-5e321b435ca7"
      decimals="-5"
      id="F_3e8c8c3d-fe8c-4131-a3cd-9df2861612ab"
      unitRef="U_USD">2500000</us-gaap:OtherNonoperatingIncomeExpense>
    <fate:EnterpriseValueMilestonesLiabilityAtFairValue
      contextRef="C_0d79e020-c388-40bd-a1ab-ccdba8d6c0f6"
      decimals="-5"
      id="F_78822599-0d23-431c-bacd-95540f362c7f"
      unitRef="U_USD">500000</fate:EnterpriseValueMilestonesLiabilityAtFairValue>
    <fate:EnterpriseValueMilestonesLiabilityAtFairValue
      contextRef="C_5928b276-cfe4-4ddc-bcb9-ba1063ef39c7"
      decimals="-5"
      id="F_859e8989-88c7-4bd3-8172-7e21bec61f33"
      unitRef="U_USD">1300000</fate:EnterpriseValueMilestonesLiabilityAtFairValue>
    <fate:AwardAgreementForResearchAndDevelopmentDisclosureTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_db8ac0e7-60e4-4dd9-8954-5c98a9eaa407">&lt;p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3.	California Institute for Regenerative Medicine Award&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;FT819 CIRM Award&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In February 2024, the Company was awarded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million from the California Institute for Regenerative Medicine (CIRM) to support the conduct of the Company&#x2019;s Phase 1 study of FT819 in patients with systemic lupus erythematosus and, in April 2024, the Company executed an award agreement with CIRM (the FT819 CIRM Award). Pursuant to the terms of the FT819 CIRM Award, the Company is eligible to receive five disbursements in varying amounts from CIRM, with one disbursement receivable upon the execution of the award and four disbursements receivable based upon the completion of certain development milestones throughout the period of the award, which is estimated to be from April 1, 2024 to March 31, 2028 (the Award Period). Under the FT819 CIRM Award, the Company has certain obligations of co-funding and is required to provide CIRM progress and financial update reports throughout the Award Period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Following the conclusion of the Award Period, the Company, in its sole discretion, has the option to treat the FT819 CIRM Award either as a loan or as a grant. If the Company does not elect to treat the FT819 CIRM Award as a loan within 10 years of the award date, the award will be considered a grant and the Company will be obligated to pay CIRM, on a quarterly basis, a low single-digit royalty on commercial sales of FT819 until such aggregate royalty payments equal nine times the total amount awarded to the Company under the FT819 CIRM Award.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Since the Company may, at its election, repay some or all of the FT819 CIRM Award, the Company accounts for the award as a liability until the time of election. During the year ended December 31, 2024, the Company received two disbursements under the FT819 CIRM Award in the aggregate amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which amount is recorded as a liability on the accompanying consolidated balance sheets. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the entire balance is classified as non-current as the Company does &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t expect any amount to be payable within the next 12 months.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;FT516 CIRM Award&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In April 2018, the Company executed an award agreement with CIRM pursuant to which CIRM awarded the Company $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to advance the Company&#x2019;s FT516 product candidate into a first-in-human clinical trial for the treatment of subjects with advanced solid tumors (the FT516 CIRM Award). Under the FT516 CIRM Award, the Company has certain obligations of co-funding and is required to provide CIRM progress and financial update reports.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the terms of the FT516 CIRM Award, the Company, in its sole discretion, has the option to treat the FT516 CIRM Award either as a loan or as a grant. During the first quarter of 2023, the Company elected to treat the FT516 CIRM Award as a grant. As such, the liability associated with the FT516 CIRM Award was derecognized and such amount was recorded as other income during the year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</fate:AwardAgreementForResearchAndDevelopmentDisclosureTextBlock>
    <fate:GrantAward
      contextRef="C_d7619f35-5038-4477-8ad7-9f872ef12d50"
      decimals="-5"
      id="F_98bf3f2c-d83e-4f0c-95a9-ba7163b104f5"
      unitRef="U_USD">7900000</fate:GrantAward>
    <fate:FirstDisbursementAmountUnderTheAward
      contextRef="C_681d2241-9055-4fd4-b908-7ff2e5469107"
      decimals="-5"
      id="F_c3751e96-e6a2-4f32-94e0-708a9e73f96e"
      unitRef="U_USD">5100000</fate:FirstDisbursementAmountUnderTheAward>
    <fate:FirstDisbursementAmountUnderTheAwardPayableForNextTwelveMonths
      contextRef="C_26715720-1a7f-4abb-8779-318e83f66b8b"
      decimals="-3"
      id="F_dc1842ca-6574-404d-a909-ac2d77bd8711"
      unitRef="U_USD">0</fate:FirstDisbursementAmountUnderTheAwardPayableForNextTwelveMonths>
    <fate:AwardForFirstInHumanClinicalTrial
      contextRef="C_4dd02f91-14ae-4ec9-ba06-e9a1c6c69591"
      decimals="-5"
      id="F_d360d8ff-8129-4b8a-9846-b5bc6710bb78"
      unitRef="U_USD">4000000</fate:AwardForFirstInHumanClinicalTrial>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_06ae2ecd-43a0-4357-b849-82d98578d04b">&lt;p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4. Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company invests portions of excess cash in United States treasuries, commercial paper, non-U.S. government securities, municipal securities, and corporate debt securities with maturities ranging from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_ac600eed-1df0-477d-b544-b5ccb3c5dacc;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; thirty-six months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the purchase date. These investments are accounted for as available-for-sale securities and are classified as short-term and long-term investments in the accompanying consolidated balance sheets based on each security&#x2019;s contractual maturity date.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s investments accounted for as available-for-sale securities as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.960000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.960000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.960000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.960000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Maturity&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Classified as current assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market fund&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-US government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Municipal securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;170,169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;170,327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,907&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272,253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272,503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Classified as non-current assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Greater than&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Greater than 1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,912&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total long-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Classified as current assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market fund&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-US government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Municipal securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;137,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;137,398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;308,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;308,578&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Classified as non-current assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Greater than 1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total long-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, of accrued interest on investments recorded in prepaid expenses and other assets on the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reviews its investment holdings at the end of each reporting period and evaluates any unrealized losses using the expected credit loss model to determine if the unrealized loss is a result of a credit loss or other factors. The Company also evaluates its investment holdings for impairment using a variety of factors including the Company&#x2019;s intent to sell the underlying securities prior to maturity and whether it is more likely than not that the Company would be required to sell the securities before the recovery of their amortized basis. During the years ended December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recognize any impairment or realized gains or losses on sales of investments, and the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t record an allowance for, or recognize, any expected credit losses.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <fate:ShortTermInvestmentMaturityPeriodRangeEnd
      contextRef="C_2575346e-5767-4842-b149-16db06beaf77"
      id="F_dabad995-b5e1-41b2-963a-a3e31361c21c">P36M</fate:ShortTermInvestmentMaturityPeriodRangeEnd>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_0cb24d95-8288-4513-88c2-29fa34ec7b95">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s investments accounted for as available-for-sale securities as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.960000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.960000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.960000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.960000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Maturity&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Classified as current assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market fund&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-US government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Municipal securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;170,169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;170,327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,907&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272,253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272,503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Classified as non-current assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Greater than&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Greater than 1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,912&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total long-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Classified as current assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market fund&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-US government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Municipal securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1 or less&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;137,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;137,398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;308,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;308,578&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Classified as non-current assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Greater than 1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total long-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <fate:InvestmentMaturityDateRange
      contextRef="C_cc863354-869b-4206-b33e-59e639b10e95"
      id="F_b0ca5ac8-e518-486a-ba34-06f388e572d7">1 or less</fate:InvestmentMaturityDateRange>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f482e228-69f4-4567-8679-ff6ec159f4e8"
      decimals="-3"
      id="F_89796295-0975-489d-b874-358b612eb15d"
      unitRef="U_USD">29491000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_f482e228-69f4-4567-8679-ff6ec159f4e8"
      decimals="-3"
      id="F_016496e7-1505-409c-a841-e6a506ab83c6"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_f482e228-69f4-4567-8679-ff6ec159f4e8"
      decimals="-3"
      id="F_07d70390-405a-4122-9c6c-a1cccb050b38"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f482e228-69f4-4567-8679-ff6ec159f4e8"
      decimals="-3"
      id="F_fbaf9b18-d6ce-4500-81a7-9de96e8c14b3"
      unitRef="U_USD">29491000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fate:InvestmentMaturityDateRange
      contextRef="C_97e27d0f-6140-4723-b214-d402e6450492"
      id="F_0661649c-60b6-4bb4-86cd-3b22ed1fcb74">1 or less</fate:InvestmentMaturityDateRange>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_d0df7940-8ed7-4acc-bf9b-0fb78b52dd30"
      decimals="-3"
      id="F_2cce6430-e152-4588-aa48-8b907d0c48d5"
      unitRef="U_USD">40206000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_d0df7940-8ed7-4acc-bf9b-0fb78b52dd30"
      decimals="-3"
      id="F_081a7d31-0d96-4dc7-b2a1-a7b71c99ddc1"
      unitRef="U_USD">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_d0df7940-8ed7-4acc-bf9b-0fb78b52dd30"
      decimals="-3"
      id="F_4d21abf1-761f-4359-be0b-5949bc996e04"
      unitRef="U_USD">91000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d0df7940-8ed7-4acc-bf9b-0fb78b52dd30"
      decimals="-3"
      id="F_ee495096-a4a0-4536-badb-60fb25abfc33"
      unitRef="U_USD">40291000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fate:InvestmentMaturityDateRange
      contextRef="C_8a02d4d5-85f9-464c-8c77-3930bc912652"
      id="F_273b6298-a2cf-49d3-b0d4-06280540f07f">1 or less</fate:InvestmentMaturityDateRange>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_926e58f0-2ed3-4a7a-845d-34981bf5a884"
      decimals="-3"
      id="F_17e5e32e-1ae8-45a2-804b-ec055aaab8d4"
      unitRef="U_USD">2994000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_926e58f0-2ed3-4a7a-845d-34981bf5a884"
      decimals="-3"
      id="F_ccfa1f6e-e522-4cdb-9833-ac6017e9c354"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_926e58f0-2ed3-4a7a-845d-34981bf5a884"
      decimals="-3"
      id="F_930da7bf-33fd-484c-be75-82b1dedfa378"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_926e58f0-2ed3-4a7a-845d-34981bf5a884"
      decimals="-3"
      id="F_81ad61e8-1df1-46b8-8175-845b96a827a3"
      unitRef="U_USD">2995000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fate:InvestmentMaturityDateRange
      contextRef="C_687fd488-edfe-4a2c-989f-8d86d4b11852"
      id="F_4d43c462-38cd-43ec-904d-1ddf78a0bbe2">1 or less</fate:InvestmentMaturityDateRange>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_fe916e0a-bfad-43cf-8d7e-6d37daaba7da"
      decimals="-3"
      id="F_cfa00851-7a9e-452f-badc-0e6c4610370d"
      unitRef="U_USD">2490000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_fe916e0a-bfad-43cf-8d7e-6d37daaba7da"
      decimals="-3"
      id="F_6e5489bc-8c9a-4c24-b1af-75dd0f220a78"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_fe916e0a-bfad-43cf-8d7e-6d37daaba7da"
      decimals="-3"
      id="F_7c11a9a9-e74a-44e5-925b-60b061ad7fca"
      unitRef="U_USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_fe916e0a-bfad-43cf-8d7e-6d37daaba7da"
      decimals="-3"
      id="F_3a829d01-71ed-43a6-bb54-22cbc61b6798"
      unitRef="U_USD">2492000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fate:InvestmentMaturityDateRange
      contextRef="C_fe5fbe72-2c15-4c48-9e0f-6faab2b2ebf8"
      id="F_507f8709-2357-4733-8479-7b8eb35b820c">1 or less</fate:InvestmentMaturityDateRange>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_bff210f5-02f8-4782-9744-563ff4baaf6c"
      decimals="-3"
      id="F_be71c3b1-a716-4fd5-b9b8-8c9746cd082e"
      unitRef="U_USD">170169000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_bff210f5-02f8-4782-9744-563ff4baaf6c"
      decimals="-3"
      id="F_3b8244ed-c206-4b14-ae52-7971d698153e"
      unitRef="U_USD">70000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_bff210f5-02f8-4782-9744-563ff4baaf6c"
      decimals="-3"
      id="F_cf2fba95-33a5-4ab6-bd93-4be0585b765c"
      unitRef="U_USD">228000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_bff210f5-02f8-4782-9744-563ff4baaf6c"
      decimals="-3"
      id="F_71b29265-f5c5-4e32-89c9-b3bacea4e93a"
      unitRef="U_USD">170327000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fate:InvestmentMaturityDateRange
      contextRef="C_edad96f6-a6a9-4612-9c79-acc88724dfb5"
      id="F_5e065386-3e42-49ae-ba9e-41ac78401eb6">1 or less</fate:InvestmentMaturityDateRange>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_ebe17901-fd0e-4988-91ae-8f5cdea8a285"
      decimals="-3"
      id="F_978d61f7-9576-4232-aaeb-2d705fd6f235"
      unitRef="U_USD">26903000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_ebe17901-fd0e-4988-91ae-8f5cdea8a285"
      decimals="-3"
      id="F_3d871b29-784c-4834-b1e8-e56b1ceb0430"
      unitRef="U_USD">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_ebe17901-fd0e-4988-91ae-8f5cdea8a285"
      decimals="-3"
      id="F_3bec3210-2f9f-47d8-a18c-cf483258d025"
      unitRef="U_USD">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ebe17901-fd0e-4988-91ae-8f5cdea8a285"
      decimals="-3"
      id="F_f336b700-095f-46b8-8478-6ecbf1cf1ecc"
      unitRef="U_USD">26907000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_208fb1ba-72a9-4ce5-8560-933151337e0d"
      decimals="-3"
      id="F_7f1244e3-dfa5-45ee-a5c9-7847c990e2f2"
      unitRef="U_USD">272253000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_208fb1ba-72a9-4ce5-8560-933151337e0d"
      decimals="-3"
      id="F_dfdfa803-ce18-47ad-83ae-63dd7d079a3d"
      unitRef="U_USD">86000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_208fb1ba-72a9-4ce5-8560-933151337e0d"
      decimals="-3"
      id="F_1fe67304-f0f6-4ef3-9e4a-cc007866dcf3"
      unitRef="U_USD">336000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_208fb1ba-72a9-4ce5-8560-933151337e0d"
      decimals="-3"
      id="F_a598a460-3bf0-486c-8cb5-12327348d706"
      unitRef="U_USD">272503000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fate:InvestmentMaturityDateRange
      contextRef="C_8515b700-bba4-47e5-8cd3-b446bc59b1e5"
      id="F_61ee2389-dc7c-453f-8eea-d8a5f914ae39">Greater than</fate:InvestmentMaturityDateRange>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_6bd370ac-1bca-4909-9d77-e3887063a36a"
      decimals="-3"
      id="F_37611322-3085-4a8d-a11e-28d9241953da"
      unitRef="U_USD">9752000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_6bd370ac-1bca-4909-9d77-e3887063a36a"
      decimals="-3"
      id="F_5d62e9c1-c64a-4dca-8162-54462b817b10"
      unitRef="U_USD">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_6bd370ac-1bca-4909-9d77-e3887063a36a"
      decimals="-3"
      id="F_3c6c8301-3ca6-4b47-ad18-10a2307e26e8"
      unitRef="U_USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_6bd370ac-1bca-4909-9d77-e3887063a36a"
      decimals="-3"
      id="F_72ca06af-8f9b-4279-9f42-2520752090f3"
      unitRef="U_USD">9745000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fate:InvestmentMaturityDateRange
      contextRef="C_3b620cbc-79bd-4c67-b41b-219dae13d7b0"
      id="F_0ac94c7b-6815-45e4-8e66-d9d90868e18b">Greater than 1</fate:InvestmentMaturityDateRange>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_c351f635-f8e4-4ef1-98df-8b05b6facf67"
      decimals="-3"
      id="F_4db99b2e-c4fa-40e8-9738-6d99b50c0d31"
      unitRef="U_USD">17887000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_c351f635-f8e4-4ef1-98df-8b05b6facf67"
      decimals="-3"
      id="F_f42f582c-c785-4604-b44e-fe8befaafcc8"
      unitRef="U_USD">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_c351f635-f8e4-4ef1-98df-8b05b6facf67"
      decimals="-3"
      id="F_2a8b8315-43e6-4dff-85fd-d25004c22d0c"
      unitRef="U_USD">32000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c351f635-f8e4-4ef1-98df-8b05b6facf67"
      decimals="-3"
      id="F_81cd0a16-bb28-4aa3-b06a-a18d2269446d"
      unitRef="U_USD">17912000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_1fd96e00-b6bb-46df-a4e7-fd1bd210a4a8"
      decimals="-3"
      id="F_f5fdc936-1c02-4bbd-935f-75f23872978a"
      unitRef="U_USD">27639000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_1fd96e00-b6bb-46df-a4e7-fd1bd210a4a8"
      decimals="-3"
      id="F_be9ee334-f80a-4cf8-8b44-5dec410c5b7c"
      unitRef="U_USD">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_1fd96e00-b6bb-46df-a4e7-fd1bd210a4a8"
      decimals="-3"
      id="F_cd336a49-18a6-49e0-aad1-ea7ecad6ac80"
      unitRef="U_USD">34000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_1fd96e00-b6bb-46df-a4e7-fd1bd210a4a8"
      decimals="-3"
      id="F_883aebfe-4611-4994-b72c-bb5647474a81"
      unitRef="U_USD">27657000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fate:InvestmentMaturityDateRange
      contextRef="C_99d86bdb-f819-4ada-9573-3db9972228f5"
      id="F_8704a9a6-3523-4018-9d32-e9eea6057c04">1 or less</fate:InvestmentMaturityDateRange>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_6c749fc7-3fa7-4811-a7f5-999fcbd298ba"
      decimals="-3"
      id="F_6e2ea447-4266-40f3-b7b7-c9877fa339a6"
      unitRef="U_USD">35273000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_6c749fc7-3fa7-4811-a7f5-999fcbd298ba"
      decimals="-3"
      id="F_0dfbde2a-ffde-434e-ba9e-335599e1c4ba"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_6c749fc7-3fa7-4811-a7f5-999fcbd298ba"
      decimals="-3"
      id="F_7c69d064-1af0-43b2-88e5-5d973d12e95f"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_6c749fc7-3fa7-4811-a7f5-999fcbd298ba"
      decimals="-3"
      id="F_00e1295b-0ae6-4a25-8ced-fd51e0ca75d2"
      unitRef="U_USD">35273000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fate:InvestmentMaturityDateRange
      contextRef="C_1cb3ab28-0ea4-4691-8f06-03acbacd707e"
      id="F_78b1cc24-5639-4907-b98c-e97af3598bbf">1 or less</fate:InvestmentMaturityDateRange>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_3121bc29-a859-42c3-8c2f-1cc407771269"
      decimals="-3"
      id="F_d816e9b7-bf95-49c2-a730-5690f8e48dae"
      unitRef="U_USD">82811000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_3121bc29-a859-42c3-8c2f-1cc407771269"
      decimals="-3"
      id="F_f910f4a9-272c-4e37-8008-d8822d7cc264"
      unitRef="U_USD">34000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_3121bc29-a859-42c3-8c2f-1cc407771269"
      decimals="-3"
      id="F_eb803049-872b-411c-8077-c8fcdcc32cc7"
      unitRef="U_USD">27000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3121bc29-a859-42c3-8c2f-1cc407771269"
      decimals="-3"
      id="F_836e6707-ca4e-4293-b808-db71560880f5"
      unitRef="U_USD">82804000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fate:InvestmentMaturityDateRange
      contextRef="C_50b6586c-23fc-4c7e-870d-e60fbf83a55e"
      id="F_1ae4ddbe-7757-416d-a626-d2acda4bd608">1 or less</fate:InvestmentMaturityDateRange>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_07bf6ed7-be95-444c-ba21-1cca631dcf34"
      decimals="-3"
      id="F_167a5d3b-59b3-4ce5-9c3a-ca436576240e"
      unitRef="U_USD">999000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_07bf6ed7-be95-444c-ba21-1cca631dcf34"
      decimals="-3"
      id="F_99c660a6-c555-4901-bbef-75f065b368a6"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_07bf6ed7-be95-444c-ba21-1cca631dcf34"
      decimals="-3"
      id="F_bb1beb61-1d02-47cd-9e5d-8c1e00251090"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_07bf6ed7-be95-444c-ba21-1cca631dcf34"
      decimals="-3"
      id="F_1ddcc6a8-bec2-488b-b07c-0fc33bcdba0d"
      unitRef="U_USD">999000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fate:InvestmentMaturityDateRange
      contextRef="C_b3047a8d-c14c-4b39-8c15-7c44dd30c23c"
      id="F_e1dcd3dd-a36a-4467-9666-d67dafc9aa4a">1 or less</fate:InvestmentMaturityDateRange>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_62a2a941-1986-48b3-9796-58a5b98fe1ff"
      decimals="-3"
      id="F_67862f30-a3f7-4a72-8618-8a6d41e60ec6"
      unitRef="U_USD">5000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_62a2a941-1986-48b3-9796-58a5b98fe1ff"
      decimals="-3"
      id="F_d8ffb9ff-e35a-4a98-9936-0b1886258668"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_62a2a941-1986-48b3-9796-58a5b98fe1ff"
      decimals="-3"
      id="F_6da69c14-f355-448f-81f7-8d2327700253"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_62a2a941-1986-48b3-9796-58a5b98fe1ff"
      decimals="-3"
      id="F_675b32fd-7880-4918-8b6a-64c0d454398f"
      unitRef="U_USD">4997000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fate:InvestmentMaturityDateRange
      contextRef="C_2e15e9a9-cf48-44bc-a273-b652fd1f9dd4"
      id="F_9d11d8d5-306f-4af8-a7e1-204019c52b43">1 or less</fate:InvestmentMaturityDateRange>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_8a618607-b312-44dc-9409-e35bb5b9ee3c"
      decimals="-3"
      id="F_27861f09-526b-4bd5-b376-3d0350b3522e"
      unitRef="U_USD">47144000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_8a618607-b312-44dc-9409-e35bb5b9ee3c"
      decimals="-3"
      id="F_d0fc0e52-aaa4-447d-b360-2149e58bef0b"
      unitRef="U_USD">51000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_8a618607-b312-44dc-9409-e35bb5b9ee3c"
      decimals="-3"
      id="F_bee0701b-2f00-42d2-a459-3653ab1ebea3"
      unitRef="U_USD">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_8a618607-b312-44dc-9409-e35bb5b9ee3c"
      decimals="-3"
      id="F_c35fc4d0-cc12-430a-b47a-08705fa427e7"
      unitRef="U_USD">47107000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fate:InvestmentMaturityDateRange
      contextRef="C_8bb72297-578c-44bb-bcc6-356a01b01bc6"
      id="F_4551165d-f5eb-4ebf-bdd5-677ada5e6133">1 or less</fate:InvestmentMaturityDateRange>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_cd31cee6-b14e-476a-ac84-63e70036233f"
      decimals="-3"
      id="F_d80f2e84-62cd-4d78-ab0f-e788900869ff"
      unitRef="U_USD">137339000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_cd31cee6-b14e-476a-ac84-63e70036233f"
      decimals="-3"
      id="F_d43de351-207a-4752-b118-233ed2280e62"
      unitRef="U_USD">62000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_cd31cee6-b14e-476a-ac84-63e70036233f"
      decimals="-3"
      id="F_ac7673bc-c1f3-4278-ac9a-ac61b7c60082"
      unitRef="U_USD">121000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_cd31cee6-b14e-476a-ac84-63e70036233f"
      decimals="-3"
      id="F_9a338e49-e701-4482-aa70-8602c55da285"
      unitRef="U_USD">137398000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_10f659e3-4c5b-460d-bada-3a35f1b947ba"
      decimals="-3"
      id="F_b539fa49-8798-4998-874e-8c742d0a0776"
      unitRef="U_USD">308566000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_10f659e3-4c5b-460d-bada-3a35f1b947ba"
      decimals="-3"
      id="F_ec9c4774-017c-418d-a411-5b6a5a2fb8cd"
      unitRef="U_USD">150000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_10f659e3-4c5b-460d-bada-3a35f1b947ba"
      decimals="-3"
      id="F_a95846af-f71a-4302-a741-d19b0ece2cbe"
      unitRef="U_USD">162000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_10f659e3-4c5b-460d-bada-3a35f1b947ba"
      decimals="-3"
      id="F_a680ef09-ed05-4378-9896-cac9d54bbacf"
      unitRef="U_USD">308578000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fate:InvestmentMaturityDateRange
      contextRef="C_e5ff0703-7a69-43d6-9e8c-8654aebbd5ed"
      id="F_a123f651-07d0-49f1-885f-e064a41a4207">Greater than 1</fate:InvestmentMaturityDateRange>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0d302d4d-cf60-4de8-bf11-2d38492826e0"
      decimals="-3"
      id="F_fc2c6e2a-cd30-4bab-add0-fa195c0e911b"
      unitRef="U_USD">977000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0d302d4d-cf60-4de8-bf11-2d38492826e0"
      decimals="-3"
      id="F_a10e00e4-e35d-4e88-a6f4-3baceb28e3d9"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0d302d4d-cf60-4de8-bf11-2d38492826e0"
      decimals="-3"
      id="F_40dfb46b-e842-4792-a56b-43403fa9e35a"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0d302d4d-cf60-4de8-bf11-2d38492826e0"
      decimals="-3"
      id="F_b299878e-2ecc-4a99-86db-0747ba85400a"
      unitRef="U_USD">980000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_bfbd6f4d-b000-45b5-9a79-42c6794f12c6"
      decimals="-3"
      id="F_4df20994-7d5e-4a27-8bf6-eefe1ea7d254"
      unitRef="U_USD">977000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_bfbd6f4d-b000-45b5-9a79-42c6794f12c6"
      decimals="-3"
      id="F_ffed2d8e-fbbf-439e-82ae-151191aec0f4"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_bfbd6f4d-b000-45b5-9a79-42c6794f12c6"
      decimals="-3"
      id="F_cb537324-320d-4548-8b15-aedada2cb767"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_bfbd6f4d-b000-45b5-9a79-42c6794f12c6"
      decimals="-3"
      id="F_4ddfe12b-5876-4a2c-b012-616c37e4dc00"
      unitRef="U_USD">980000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InterestReceivable
      contextRef="C_5445f2d2-5e33-4281-9239-4322ce42c9cf"
      decimals="-5"
      id="F_f1aa452c-9234-4b9f-aeee-2d1a90ee76d7"
      unitRef="U_USD">2100000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="C_2e7da839-7541-4872-8420-d82b12974e64"
      decimals="-5"
      id="F_310c76d0-76c6-49bc-bff2-a83d149bba4b"
      unitRef="U_USD">900000</us-gaap:InterestReceivable>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_ddba17f3-40df-4972-a809-ee986cca9a44"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_e91f9730-9da0-41b2-adac-9e131e83e8c5"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:FinancingReceivableNonaccrualNoAllowance
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_ac2d7467-d3f5-4dc5-8213-7504c09cacb1"
      unitRef="U_USD">0</us-gaap:FinancingReceivableNonaccrualNoAllowance>
    <us-gaap:FinancingReceivableNonaccrualNoAllowance
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_63ea366e-6573-4342-b7f4-1368b0aa5521"
      unitRef="U_USD">0</us-gaap:FinancingReceivableNonaccrualNoAllowance>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_0d8abd03-757d-4617-84cf-be64112d69de">&lt;p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5. Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables presents the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements at&lt;br/&gt;Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted Prices&lt;br/&gt;in Active&lt;br/&gt;Markets for&lt;br/&gt;Identical&lt;br/&gt;Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market fund&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-US government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Municipal securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;188,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;188,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,907&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,907&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets measured at fair value on a recurring basis&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;300,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;79,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;220,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock price appreciation milestones&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total financial liabilities measured at fair value on a recurring basis&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market fund&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-US government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Municipal securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;137,398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;137,398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets measured at fair value on a recurring basis&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;309,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;191,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock price appreciation milestones&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total financial liabilities measured at fair value on a recurring basis&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1 assets consisted of money market funds and U.S. Treasury securities measured at fair value based on quoted prices in active markets as provided by the Company&#x2019;s investment managers.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2 assets consisted of corporate debt securities, commercial paper, municipal securities, and non-U.S. government securities measured at fair value using standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers. The Company validates the quoted market prices provided by its investment managers by comparing the investment managers&#x2019; assessment of the fair values of the Company&#x2019;s investment portfolio balance against the fair values of the Company&#x2019;s investment portfolio balance obtained from an independent source.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There were no Level 3 assets held by the Company as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3 liabilities consisted of stock price appreciation milestones associated with the Amended MSKCC License as described in detail in Note 2.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the changes in fair value of the Company&#x2019;s Level 3 stock price appreciation milestones liability (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Changes in fair value of stock price appreciation milestones liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Changes in fair value of stock price appreciation milestones liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;819&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:5.2%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;None&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of the Company&#x2019;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; transfers between levels have occurred during the periods presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_deb613be-49d0-4eb1-95e6-44963390af2b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables presents the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements at&lt;br/&gt;Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted Prices&lt;br/&gt;in Active&lt;br/&gt;Markets for&lt;br/&gt;Identical&lt;br/&gt;Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market fund&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-US government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Municipal securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;188,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;188,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,907&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,907&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets measured at fair value on a recurring basis&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;300,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;79,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;220,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock price appreciation milestones&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total financial liabilities measured at fair value on a recurring basis&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market fund&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-US government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Municipal securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;137,398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;137,398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets measured at fair value on a recurring basis&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;309,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;191,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock price appreciation milestones&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total financial liabilities measured at fair value on a recurring basis&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_3ef185b6-d2e3-41eb-af64-8722d09aa801"
      decimals="-3"
      id="F_8f268726-3ca2-42ad-bf4f-450c5a9d19df"
      unitRef="U_USD">29491000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_a5e8db20-c26c-4eec-81dc-6ac0d0db25ea"
      decimals="-3"
      id="F_3e39601a-c858-4a86-915b-bd222a943025"
      unitRef="U_USD">29491000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_cebe70a2-446f-4a43-a422-52cd427ada3b"
      decimals="-3"
      id="F_b8af5a82-6ba6-4a17-8267-90178e3282ce"
      unitRef="U_USD">50036000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_805f2b9e-0637-4e41-afb0-b23379a1c6bf"
      decimals="-3"
      id="F_6ff37acc-3cb2-4d51-9b8d-afe7cefd6645"
      unitRef="U_USD">50036000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_94e46ef6-c33c-4951-8ea1-9765cebbe9a1"
      decimals="-3"
      id="F_86e46869-3132-412a-bf9c-150294f2a5f8"
      unitRef="U_USD">2995000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_094d60cc-9d76-4080-b9c2-2f03fda72660"
      decimals="-3"
      id="F_3107f192-8680-470d-925a-4d98ce2fce58"
      unitRef="U_USD">2995000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_cec4892c-e35c-4232-846a-7628de00f77e"
      decimals="-3"
      id="F_7b4c1453-1a69-4a84-b529-3099ec2e4593"
      unitRef="U_USD">2492000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_59f16426-b465-46ba-aa94-5befab44d9d3"
      decimals="-3"
      id="F_d1bfc072-c57f-48c7-ba59-080260f00e48"
      unitRef="U_USD">2492000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f2e41800-cc41-4b94-a30a-fb6e56d72a7f"
      decimals="-3"
      id="F_f1e99741-104c-47ca-9d7b-ae2c252146e7"
      unitRef="U_USD">188239000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_1de58b0e-3458-4fdb-9110-32fd64de36b8"
      decimals="-3"
      id="F_6b2c9c54-347c-4da8-b2af-e516cb69ac7c"
      unitRef="U_USD">188239000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_6fcf025e-eabb-4c7b-9b3c-cc45fd082e86"
      decimals="-3"
      id="F_c754115b-2203-46f3-b165-886d755564b5"
      unitRef="U_USD">26907000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3baffb0b-73df-44c6-85eb-9c15e2247168"
      decimals="-3"
      id="F_397eb1fc-29db-4761-ac48-6c49114800f7"
      unitRef="U_USD">26907000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b416aca9-c7b0-442c-b1c2-2934711580f1"
      decimals="-3"
      id="F_d7cebe46-c013-459e-8de9-37ec1c5b5b8b"
      unitRef="U_USD">300160000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7d5efccd-12ae-4328-a434-fc9ca1b3827d"
      decimals="-3"
      id="F_416bc7c1-f637-425b-b631-c0df501823b2"
      unitRef="U_USD">79527000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_cacd56f9-2988-4b00-88a4-4b37683a2fc4"
      decimals="-3"
      id="F_ade6c14d-a2c8-49ab-8cad-b80fb997667c"
      unitRef="U_USD">220633000</us-gaap:AssetsFairValueDisclosure>
    <fate:StockPriceAppreciationMilestones
      contextRef="C_fd6d1a6c-963f-4a77-8037-388fc2ef3404"
      decimals="-3"
      id="F_b4f93854-e896-45f1-8717-931ae82ed90e"
      unitRef="U_USD">527000</fate:StockPriceAppreciationMilestones>
    <fate:StockPriceAppreciationMilestones
      contextRef="C_e9fc8192-6581-4017-a8d5-9e3b97aa8020"
      decimals="-3"
      id="F_8aeadbcc-0bf1-48c7-b110-38a345e50420"
      unitRef="U_USD">527000</fate:StockPriceAppreciationMilestones>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_b416aca9-c7b0-442c-b1c2-2934711580f1"
      decimals="-3"
      id="F_85a11d8b-0707-4d54-814c-a57948414aa3"
      unitRef="U_USD">527000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_ac2d1d69-5e84-41e7-b540-c202f61299ca"
      decimals="-3"
      id="F_808fa75e-e3c8-4324-92c5-f55db177cd30"
      unitRef="U_USD">527000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_a3ff6b11-0c22-4b27-8dc1-b44fdb3a724c"
      decimals="-3"
      id="F_01adf47f-f527-4046-aa6b-e03b5f5085d7"
      unitRef="U_USD">35273000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_d21f4f6f-8713-4aa6-8283-c3de33b87b2f"
      decimals="-3"
      id="F_3a9402d0-8a7c-4ee9-9f1f-b72f8a64d7a0"
      unitRef="U_USD">35273000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_fd5563c2-aea8-4a6a-8a5b-e1869c4151d7"
      decimals="-3"
      id="F_4e334d99-b811-401c-b280-6680a274c7f1"
      unitRef="U_USD">82804000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_977cdbf8-9aef-4f82-a0e6-e955360ee9d1"
      decimals="-3"
      id="F_9e0eb268-d7c8-499b-8c03-ad6d0765e897"
      unitRef="U_USD">82804000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_7388956d-1347-4f5e-b3bd-7ff47628173c"
      decimals="-3"
      id="F_c037bd77-4e10-4d48-8d74-fe2e2d84288b"
      unitRef="U_USD">999000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9c256c41-e766-4081-83ce-a706df7de970"
      decimals="-3"
      id="F_000152d6-a5d2-46e5-b1ee-052828a1f2fa"
      unitRef="U_USD">999000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_da752dee-4bbf-4d64-b7ab-bbf88b372ec6"
      decimals="-3"
      id="F_22d07414-ae63-4882-ad0a-61d1a04120a2"
      unitRef="U_USD">4997000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0929cf2c-6047-4152-8767-1d831d5874a9"
      decimals="-3"
      id="F_034f3a38-05d9-4b73-be6c-151c528918b3"
      unitRef="U_USD">4997000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_82ed1266-1238-4e4a-9fcf-ef99a6cc8c97"
      decimals="-3"
      id="F_928db028-707a-4e86-833b-56cbcd2a663e"
      unitRef="U_USD">48087000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_1eb4c942-f4c7-47f9-994f-95d18338c9fc"
      decimals="-3"
      id="F_3daf85c2-1557-4aa0-899c-3b7077038fe0"
      unitRef="U_USD">48087000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_fba769b4-c31e-4914-8c9d-294bd6abcddd"
      decimals="-3"
      id="F_59a822f6-5987-41f5-87af-fd44c9c9d72a"
      unitRef="U_USD">137398000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_8647c356-eb54-4cef-883d-ccfb6f2c7d27"
      decimals="-3"
      id="F_c124ed4b-f8e3-4a13-80f5-69009b3d003b"
      unitRef="U_USD">137398000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b28e1793-9bb2-4e61-9e28-a2fa970d72c7"
      decimals="-3"
      id="F_bb39c15f-dfe9-4991-9507-bb99b94eb196"
      unitRef="U_USD">309558000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_87a8873b-2dbd-48eb-a3c4-71b7b6ecb603"
      decimals="-3"
      id="F_cf84b0ca-6e76-4e14-9f63-e29bc7c5586f"
      unitRef="U_USD">118077000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_fb2cf769-bd37-47d3-ab4b-f93d4365d73d"
      decimals="-3"
      id="F_ee4aa8aa-ad5f-4af3-953e-99edbf8bc23d"
      unitRef="U_USD">191481000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c52c4c88-5230-4895-b325-46e4cd2518ab"
      decimals="-3"
      id="F_6894410e-911b-43e9-800d-37318a750ecc"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <fate:StockPriceAppreciationMilestones
      contextRef="C_8e179833-9ef6-4071-837e-b071b6572377"
      decimals="-3"
      id="F_77e81504-5457-43c3-8598-c68ad47cffc3"
      unitRef="U_USD">1346000</fate:StockPriceAppreciationMilestones>
    <fate:StockPriceAppreciationMilestones
      contextRef="C_c5d2707d-a24c-478b-b6da-97a0477550df"
      decimals="-3"
      id="F_de8bad5d-aa1f-46ca-8b7b-d3d1d7ffd64c"
      unitRef="U_USD">1346000</fate:StockPriceAppreciationMilestones>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_b28e1793-9bb2-4e61-9e28-a2fa970d72c7"
      decimals="-3"
      id="F_0d981912-82a2-4a67-8011-fc0ed380b463"
      unitRef="U_USD">1346000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_c52c4c88-5230-4895-b325-46e4cd2518ab"
      decimals="-3"
      id="F_1af442db-5556-4ff8-90a4-b12606ad29f4"
      unitRef="U_USD">1346000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_b39cbc43-c6a6-4493-954c-1bef40115d07">&lt;p style="text-indent:5.2%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the changes in fair value of the Company&#x2019;s Level 3 stock price appreciation milestones liability (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Changes in fair value of stock price appreciation milestones liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Changes in fair value of stock price appreciation milestones liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;819&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_fbf420d5-255c-421e-9863-8fd4aeac0e96"
      decimals="-3"
      id="F_b464f4bc-1079-497b-b242-e91966f79a43"
      unitRef="U_USD">3861000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <fate:IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
      contextRef="C_c243b78d-2e22-425b-8d5a-ec8cc2edf72d"
      decimals="-3"
      id="F_86987487-c83d-4b0d-8ffb-ab52960c7221"
      unitRef="U_USD">-2515000</fate:IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_cbf96da0-08c5-44ae-8e97-d5dc42fe1fcc"
      decimals="-3"
      id="F_dc24223b-6245-4db4-99b5-53c92b55f080"
      unitRef="U_USD">1346000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <fate:IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
      contextRef="C_68edd7f5-9eba-4cf2-9c06-c892f1e0d26b"
      decimals="-3"
      id="F_1bfbea23-46d9-4b5f-9c85-f66997c71142"
      unitRef="U_USD">-819000</fate:IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_4d2a294e-b4ae-4f93-abc5-44f79d16ce96"
      decimals="-3"
      id="F_26f2817b-a0e5-472b-8a16-384e4c8f0ef4"
      unitRef="U_USD">527000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_85e19190-1f38-4b84-928d-1b10e8632e63"
      decimals="-3"
      id="F_790b7152-7ca8-4269-891b-9a62fc876e84"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_85e19190-1f38-4b84-928d-1b10e8632e63"
      decimals="-3"
      id="F_06b823ca-284a-4e5a-9c87-eb69c4e5db66"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <fate:Fairvalueassetslevel1Tolevel2Transfersamounts
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_4d2e3acb-f043-4316-ba5f-6285c38a68c2"
      unitRef="U_USD">0</fate:Fairvalueassetslevel1Tolevel2Transfersamounts>
    <fate:Fairvalueassetslevel2Tolevel1Transfersamounts
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_cb2f47cb-e456-4840-a3b7-d54eb3d232f4"
      unitRef="U_USD">0</fate:Fairvalueassetslevel2Tolevel1Transfersamounts>
    <fate:Fairvalueliabilitieslevel1Tolevel2Transfersamounts
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_e0528753-2430-48b4-88c7-a30bca84d4b1"
      unitRef="U_USD">0</fate:Fairvalueliabilitieslevel1Tolevel2Transfersamounts>
    <fate:Fairvalueliabilitieslevel2Tolevel1Transfersamounts
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_3c5d001f-72e9-4e2f-a133-6b03b680ba43"
      unitRef="U_USD">0</fate:Fairvalueliabilitieslevel2Tolevel1Transfersamounts>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_484e35db-1dfd-4e16-9c99-a68062fe24c4">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6. Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&#x2014;building&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,485&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Scientific equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78,853&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99,520&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;144,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64,384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96,836&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:5.2%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognized an impairment charge of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of long-lived asset impairment described in Note 1 above for the year ended December 31, 2024, which was calculated as the difference between the fair value of the assets and its carrying value. The cost basis for these assets was updated to fair value. The fair value was based on a cost approach which utilized Level 3 non-recurring fair value inputs and assumptions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.2%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation expense related to property and equipment was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_157e9ec7-f0dc-4972-aaa6-5e672641216e">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&#x2014;building&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,485&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Scientific equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78,853&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99,520&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;144,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64,384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96,836&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a31bca4a-3e98-45a1-a466-8da5458c6984"
      decimals="-3"
      id="F_aafcaf3a-a7a4-4e97-b711-6b2791fde491"
      unitRef="U_USD">508000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_309808ad-31af-4b1f-8e61-083557c2542c"
      decimals="-3"
      id="F_75698cea-6952-4e86-99dd-02dccfa3d4b2"
      unitRef="U_USD">1309000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_be1fc325-ff5d-4b35-952c-3aa39e4cfadc"
      decimals="-3"
      id="F_33c76b76-7d74-4b6c-be48-c1154fb08cd6"
      unitRef="U_USD">2444000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_bc041da4-e745-4f8b-9d20-f7e54aa2e7d6"
      decimals="-3"
      id="F_be647e7f-2609-474c-a1b3-ebb9da0ab287"
      unitRef="U_USD">3132000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_98c3e645-6b5a-4fbd-a7b5-c0bf4a509495"
      decimals="-3"
      id="F_041599c2-3c0c-4864-b7a6-eca68970f6a5"
      unitRef="U_USD">1188000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_faac2f19-7ee6-46a4-9641-0352d10ce9d7"
      decimals="-3"
      id="F_b8ef2624-a92b-4809-96bf-1cafe125ea2a"
      unitRef="U_USD">2130000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4a42522d-d9fd-49e6-a443-91460120f25e"
      decimals="-3"
      id="F_cc2b9fdb-32cf-493d-a96a-1b57975ec970"
      unitRef="U_USD">59485000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f1f2b64c-9a2c-4bc4-9f3e-aaf2c1023a51"
      decimals="-3"
      id="F_defbf3d8-8b5c-4c8d-a743-adc0c2fe550c"
      unitRef="U_USD">59038000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a95850c5-78b7-4a48-b9d3-80bfd15bcd46"
      decimals="-3"
      id="F_6b1e6df3-8e68-4414-b1c5-edc172dd3aa2"
      unitRef="U_USD">35895000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_9f433503-cde7-4c8a-84a1-6742576e7a9b"
      decimals="-3"
      id="F_92412d6e-14c3-4693-8cd7-1af19a652e9d"
      unitRef="U_USD">78853000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_537712b4-31e6-4804-947e-f500413a346d"
      unitRef="U_USD">99520000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_d0a7a54a-2702-4311-ba70-772d3c9e7cc1"
      unitRef="U_USD">144462000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_1df8a995-9e47-4c16-ba6c-a2abebce4f72"
      unitRef="U_USD">35136000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_479eadef-d77f-4fd1-bcc0-feaf5e074af1"
      unitRef="U_USD">47626000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_69640f5d-5597-415c-839d-a28b13220986"
      unitRef="U_USD">64384000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_b47d0a77-78a3-4590-8b64-f2a1ba9e63bf"
      unitRef="U_USD">96836000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-5"
      id="F_4dd3c870-12c4-42b7-985f-609d39524307"
      unitRef="U_USD">13400000</us-gaap:AssetImpairmentCharges>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-5"
      id="F_3104209e-e998-43b4-891d-b85f4ae15cf2"
      unitRef="U_USD">19000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-5"
      id="F_bc5a6543-02fe-411e-9c07-3166d0566bd9"
      unitRef="U_USD">18300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_86b0edb8-7e74-413f-a416-c3b719441e3c">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7. Accrued Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued Expenses&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Current accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued payroll and other employee benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,710&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued clinical trial related costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,833&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total current accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_bb04031e-fb31-4ed5-ac86-461c097ab9b2">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Current accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued payroll and other employee benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,710&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued clinical trial related costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,833&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total current accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_d491b735-a7a5-4f58-87c6-c5c8df7c931d"
      unitRef="U_USD">9710000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_577816d5-a47d-4333-a4d4-5cb6fb36f339"
      unitRef="U_USD">10563000</us-gaap:AccruedSalariesCurrent>
    <fate:AccruedClinicalTrialRelatedCostsCurrent
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_a720d835-4a23-4cdd-ac02-001a1bcfa48e"
      unitRef="U_USD">5279000</fate:AccruedClinicalTrialRelatedCostsCurrent>
    <fate:AccruedClinicalTrialRelatedCostsCurrent
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_48123a4d-a9b4-4422-ac56-fa311e0a6d9f"
      unitRef="U_USD">8833000</fate:AccruedClinicalTrialRelatedCostsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_11eaa7e8-51d4-4435-b5fe-3f369e43bf36"
      unitRef="U_USD">6359000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_7647c9a5-b299-4455-86a9-384d156f0652"
      unitRef="U_USD">8118000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_07e117bc-7d9a-4529-8d10-518b69b0b488"
      unitRef="U_USD">21348000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_f6a34d55-35a7-4da5-8c6d-a66d559f07f5"
      unitRef="U_USD">27514000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_948e0487-94d3-4c75-995a-0ffb0d584845">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;8. Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has lease agreements for office, laboratory and manufacturing spaces that are classified as operating leases on the consolidated balance sheets.&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; These leases have terms varying from one to approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;sixteen years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, with renewal options of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;as well as early termination options. Extension and termination options are included in the total lease term when the Company is reasonably certain to exercise them. The leases are subject to additional variable charges, including common area&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;maintenance, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;property taxes, property insurance and other variable costs. Given the variable nature of such costs, they are recognized as expense as incurred. Additionally, some of the Company&#x2019;s leases are subject to certain fixed fees which the Company has determined to be non-lease components. The Company has elected to combine and account for lease and non-lease components as a single-lease component for purposes of determining the total future lease payments.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2024, the Company exercised its right of early termination for its Torrey Pines operating lease, which consists of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet of office, laboratory, and Good Manufacturing Practice (GMP) space. In connection with such exercise, the Company paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to its landlord. Termination of the lease, which previously extended through December 31, 2028, will now take effect on October 31, 2025. The Company accounted for this transaction as a modification to the lease agreement, which reduced the ROU asset and corresponding lease liability balances as of December 31, 2024 in connection with such transaction.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, future undiscounted minimum contractual payments under the Company&#x2019;s operating leases were &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;133.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million, which will be paid over a remaining weighted-average lease term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10.6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years. The weighted-average discount rate for the operating lease liabilities was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, which was the Company&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;s incremental borrowing rate at lease commencement, as the discount rates implicit in the leases could not be readily determined.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of lease expense for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.474%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.102%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.102%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Straight-line lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future undiscounted minimum payments under the Company&#x2019;s operating leases as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Operating&lt;br/&gt;Lease Payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Years Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,602&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;133,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; As described in Note 1 above, the Company incurre&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;d a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; mill&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ion impairment charge against its right-of-use asset during the year ended Decem&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ber 31, 2024. The Company applied a discounted cash flow method to estimate the fair value of the right-of-use asset, which represents Level 3 non-recurring fair value measurements. The estimated fair value of the was determined by discounting the estimated rental rates using market participant assumptions. The Company&#x2019;s estimates and assumptions used to determine the estimated fair value of the asset group is subject to risks, uncertainties, and changes in circumstances that may result in adjustments and material changes to the estimated fair values in future periods.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_7fa3ffd2-d2ee-4b6f-9999-1dfff3fe5653"> These leases have terms varying from one to approximately sixteen years, with renewal options of up to ten years</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_92ae6775-3137-46d3-9d0f-95226e202633"
      id="F_5b8141b5-1ea2-4a89-8986-92e919ec3625">P16Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_979e1e1b-585d-4deb-90b9-0ebe66970591"
      id="F_dc0e11bd-08cc-4401-a1a8-707a0be0c927">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:NetRentableArea
      contextRef="C_2a171456-ff92-4460-82a4-d71189a47904"
      decimals="0"
      id="F_588e423c-eb0d-4021-9c0e-82bbf1f52f4c"
      unitRef="U_sqft">72000</us-gaap:NetRentableArea>
    <us-gaap:TenantImprovements
      contextRef="C_2a171456-ff92-4460-82a4-d71189a47904"
      decimals="-5"
      id="F_ebd6514c-3c3d-4b86-89a6-6ecfd7b43e5b"
      unitRef="U_USD">2500000</us-gaap:TenantImprovements>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_47e3c4a5-6a9e-488c-9ae1-4d92329efada"
      decimals="-5"
      id="F_07a9279e-e7c9-4332-bd56-2b462a7e86ab"
      unitRef="U_USD">133700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      id="F_f98ffc9a-ba55-46b4-9a56-cd532a5d2254">P10Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="3"
      id="F_0bc1c92d-bfab-4f85-9b83-5cbbc0064d1e"
      unitRef="U_pure">0.084</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_cd9b30b9-335e-49ba-a2a5-b2ef68f52ad5">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of lease expense for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.474%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.102%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.102%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Straight-line lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:StraightLineRentAdjustments
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_7dfc6e08-688f-437f-8143-a8d537e477bd"
      unitRef="U_USD">12737000</us-gaap:StraightLineRentAdjustments>
    <us-gaap:StraightLineRentAdjustments
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_09461f77-30cc-4d63-9ca7-b32b510410c0"
      unitRef="U_USD">13159000</us-gaap:StraightLineRentAdjustments>
    <us-gaap:VariableLeaseCost
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_fc1524a2-24e9-46e9-8d86-4fb397ddf913"
      unitRef="U_USD">3733000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_f408f5d2-0e54-4108-bf54-f3023d008cb9"
      unitRef="U_USD">2250000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_112e5060-647d-47ef-bc8c-750d14661c36"
      unitRef="U_USD">16470000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_6e7fb761-b376-4607-811b-e66cfde60053"
      unitRef="U_USD">15409000</us-gaap:OperatingLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_ec891862-61df-4484-b630-1873ef3bdf47">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future undiscounted minimum payments under the Company&#x2019;s operating leases as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Operating&lt;br/&gt;Lease Payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Years Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,602&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;133,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_2ac3e488-ea5c-4611-a051-6d704b4add66"
      unitRef="U_USD">14361000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_11de6103-a64f-4f0c-b1f4-042ccfce67c2"
      unitRef="U_USD">11050000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_5c06c9f4-08dd-4017-bcde-c6eeb7d3c293"
      unitRef="U_USD">11382000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_55e06a78-5a07-4938-9e98-9c8305e0dc5b"
      unitRef="U_USD">10293000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_1c4c0b66-3b3d-4bfe-88c8-c1d794af6f67"
      unitRef="U_USD">10602000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_5a87a414-434b-4b2c-b32a-837c34bd003f"
      unitRef="U_USD">75976000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_24b6d42f-01cb-4e4a-a292-9b2112459e56"
      unitRef="U_USD">133664000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_d5840108-a094-42cf-8275-c090a4e4ccc5"
      unitRef="U_USD">48399000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_86351c64-a57c-49da-bcf5-993f8b280126"
      unitRef="U_USD">85265000</us-gaap:OperatingLeaseLiability>
    <fate:ImpairmentOfRightOfUseAsset
      contextRef="C_4cba0539-2744-4997-a638-c19edef83006"
      decimals="-5"
      id="F_6306e5f3-dda7-44d0-a396-dc130905544b"
      unitRef="U_USD">1300000</fate:ImpairmentOfRightOfUseAsset>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_90a8e417-e64b-4c75-a879-d49ea4d6a6c1">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;9. Convertible Preferred Stock and Stockholders&#x2019; Equity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2016, the Company completed a private placement of stock in which investors, including investors affiliated with the directors and officers of the Company, purchased convertible preferred stock and common stock of the Company (the November 2016 Placement). The Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,819,549&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A Convertible Preferred Stock, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; par value per share (the Class A Preferred), at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;share, each of which is convertible into five shares of common stock upon certain conditions defined in the Certificate of Designation of Preferences, Rights and Limitations of the Class A Preferred filed with the Delaware Secretary of State&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;on &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;November 22, 2016 (the CoD). &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Class A Preferred were purchased exclusively by entities affiliated with Redmile Group, LLC (collectively, Redmile). The terms of the CoD prohibited Redmile from converting the Class A Preferred into shares of the Company&#x2019;s common stock if, as a result of conversion, Redmile, together with its affiliates, would own more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the Company&#x2019;s common stock then issued and outstanding (the Redmile Percentage Limitation), which percentage could change at Redmile&#x2019;s election upon 61 days&#x2019; notice to the Company to (i) any other number less than or equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% or (ii) subject to approval of the Company&#x2019;s stockholders to the extent required in accordance with the NASDAQ Global Market rules, any number in excess of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%. On May 2, 2017, the Company&#x2019;s stockholders approved the issuance of up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,097,745&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock upon the conversion of the outstanding shares of Class A Preferred. As a result, Redmile has the right to increase the Redmile Percentage Limitation to any percentage in excess of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% at its election.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company also issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,236,837&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.66&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share as part of the November 2016 Placement. In &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;April 2023, the Company filed with the office of the Secretary of State of the State of Delaware a Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitations of Class A Convertible Preferred Stock which amends the definition of Beneficial Ownership Limitation to be &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the number of shares of the Company&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;s common stock outstanding immediately after giving effect to the issuance of shares of common stock pursuant to a Notice of Conversion. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In April 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,441&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A Preferred were converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;167,205&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock. In December 202&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Class A Preferred were converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,110&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Class A Preferred are non-voting shares and are convertible into five shares of the Company&#x2019;s common stock at a conversion price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.66&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, which was the fair value of the Company&#x2019;s common stock on the date of issuance. Holders of the Class A Preferred have the same dividend rights as holders of the Company&#x2019;s common stock. Additionally, the liquidation preferences of the Class A Preferred are &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;pari passu&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; among holders of the Company&#x2019;s common stock and holders of the Class A Preferred, pro rata based on the number of shares held by each such holder (treated for this purpose as if the Class A Preferred had been converted to common stock).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock Option and Incentive Plans and Inducement Equity Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2022 Stock Option and Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On June 9, 2022, the Company adopted the 2022 Stock Option and Incentive Plan (the 2022 Plan). The 2022 Plan initially authorized &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares, and in June 2024, stockholders approved an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, of common stock for issuance and allows for the grant of stock options, stock appreciation rights, restricted stock awards, performance-based awards, and other awards to individuals who are then employees, officers, directors or consultants of the Company. The shares of common stock underlying any awards from the 2022 Plan and a previously existing equity plan from 2013 or 2007 that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without any issuance of common stock, expire or are otherwise terminated (other than by exercise) are added back to the shares of common stock available for issuance under the 2022 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recipients of stock options under the 2022 Plan shall be eligible to purchase shares of the Company&#x2019;s common stock at an exercise price equal to no less than the estimated fair value of such stock on the date of grant. Under the 2022 Plan, stock options generally vest &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% on the first anniversary of the original vesting date, with the balance vesting monthly over the remaining &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, or vest monthly over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, unless they contain specific performance and/or market-based vesting provisions. The maximum term of stock options granted under the 2022 Plan is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Under the 2022 Plan, restricted stock units generally vest annually over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Performance-based stock units/awards vest upon the achievement of certain pre-defined company-specific performance-based clinical achievement criteria.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Inducement Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On May 10, 2016, the Company&#x2019;s board of directors approved the Fate Therapeutics, Inc. Inducement Equity Plan (the Inducement Plan), the purpose of which is to enable the Company to grant equity awards to induce highly-qualified prospective officers and employees who are not employed by the Company to accept employment with the Company. Under the Inducement Plan, the Company may grant non-qualified stock options and restricted stock units. A total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock were initially reserved for issuance under the Inducement Plan. In January 2021, March 2020, and January 2019, an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;300,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;470,822&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, respectively, of common stock were reserved for issuance under the Inducement Plan. The shares of common stock underlying any awards from the Inducement Plan that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without any issuance of common stock, expire or are otherwise terminated (other than by exercise) under the Inducement Plan will be added back to the shares of common stock available for issuance under the Inducement Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pre-Funded Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In January 2021, in conjunction with a public offering, the Company issued Pre-Funded Warrants, in lieu of common stock to certain investors, to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;257,310&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock (the 2021 Pre-Funded Warrants). The purchase price for the 2021 Pre-Funded Warrants was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85.499&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per pre-funded warrant, which equals the per share public offering price for the shares of common stock less the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; exercise price for each such pre-funded warrant. Given that the 2021 Pre-Funded Warrants are indexed to the Company&#x2019;s own shares of common stock (and otherwise meet the requirements to be classified in equity), the Company recorded the consideration received from the issuance of the warrants as additional paid-in capital on the Company&#x2019;s consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In March 2024, in conjunction with a public offering, the Company issued in a private placement, in lieu of common stock to certain investors, pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,636,364&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock (2024 Pre-Funded Warrants, and collectively with the 2021 Pre-Funded Warrants, the Pre-Funded Warrants). The purchase price for the 2024 Pre-Funded Warrants was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.499&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per pre-funded warrant, which equals the per share public offering price for the shares of common stock issued in the March 2024 public offering, less the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; exercise price for each such pre-funded warrant. Given that the 2024 Pre-Funded Warrants are indexed to the Company&#x2019;s own shares of common stock (and otherwise meet the requirements to be classified in equity), the Company recorded the consideration received from the issuance of the warrants as additional paid-in capital on the Company&#x2019;s unaudited condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Pre-Funded Warrants are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the number of shares of the Company&#x2019;s common stock outstanding immediately after giving effect to such exercise. A holder of Pre-Funded Warrants may increase or decrease this percentage not in excess of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% by providing at least 61 days&#x2019; prior notice to the Company.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, there w&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ere &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,893,674&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Pre-Fu&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;nded Warrants outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock Options and Restricted Stock Unit Awards&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock Options.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes stock option activity and related information under all equity plans for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:8pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.41%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.902%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.142%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.902%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.482%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;br/&gt;(in 000s)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,850,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,210,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,293,354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,722,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.83&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options vested and expected to vest at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,722,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.83&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercisable at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,328,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.91&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the years ended December 31, 2024 and 2023, the weighted average grant date fair value of stock options granted per share was equal to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.89&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.83&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024 and 2023, the unrecognized compensation cost related to outstanding options was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, which was expected to be recognized as expense over approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total intrinsic value, which is the amount by which the exercise price was exceeded by the price of the Company&#x2019;s common stock on the date of exercise, of stock options exercised during the year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. As of December 31, 2024, all outstanding options had an exercise price above the Company's common stock price and therefore &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; intrinsic value. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Total cash received upon the exercise of stock options was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted Stock Units.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes restricted stock unit activity and related information under all equity plans for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.41%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.902%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.142%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.902%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.482%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Vesting&lt;br/&gt;Period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;br/&gt;(in 000s)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,065,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,451,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;680,201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;622,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,214,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.01&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units expected to vest at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,151,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.92&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024 and 2023, the unrecognized compensation cost related to outstanding restricted stock units (excluding those with unachieved performance-based conditions) was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, which was expected to be recognized as expense over approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;years and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2021, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,997,377&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; performance-based restricted stock units (PRSUs) were granted, none of which have vested. During the year ended December 31, 2024, the Company granted &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;300,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; performance-based restricted stock units with a total grant date fair value of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, none of which have vested. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,062,607&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,020,617&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; PRSUs outstanding at December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The allocation of stock-based compensation for all stock awards is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,520&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,849&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock Option Grants Valuation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee and nonemployee stock option grants were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.343%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.343%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk&#x2013;free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;87.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company bases the risk-free interest rate assumption on observed interest rates appropriate for the expected term of the stock option grants.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected volatility.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company based the expected volatility on the historical volatility of its common stock over the most recent period commensurate with the estimated expected term of the Company&#x2019;s stock options, as the Company determined there was sufficient operating history and company-specific historical volatility to estimate the expected volatility.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected term.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The expected term represents the period of time that options are expected to be outstanding. The Company estimated the expected term using historical experience and anticipated future exercise behavior.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Common Stock Reserved for Future Issuance&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Common stock reserved for future issuance is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible preferred stock (if converted)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ccecff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ccecff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,775,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ccecff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ccecff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ccecff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,805,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ccecff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,722,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,850,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,214,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,065,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Awards available under the 2022 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,656,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,633,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Awards available under the Inducement Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;920,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;689,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,288,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,044,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_02925833-8677-4697-ab8d-c844642a03e7"
      decimals="0"
      id="F_022b79eb-9a2a-4a07-9dbd-e34c6178b1c3"
      unitRef="U_shares">2819549</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_02925833-8677-4697-ab8d-c844642a03e7"
      decimals="3"
      id="F_ada62dfe-c302-4d35-a0bc-5296827255f3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_02925833-8677-4697-ab8d-c844642a03e7"
      decimals="2"
      id="F_b9479f34-beff-45e9-99f0-cda7d14f9897"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.3</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ConvertiblePreferredStockTermsOfConversion
      contextRef="C_ea581251-e0f9-4e1a-ba72-0e031fd4585d"
      id="F_279ec3e9-6372-4e01-a687-2ddd365e5c3b">The Class A Preferred were purchased exclusively by entities affiliated with Redmile Group, LLC (collectively, Redmile). The terms of the CoD prohibited Redmile from converting the Class A Preferred into shares of the Company&#x2019;s common stock if, as a result of conversion, Redmile, together with its affiliates, would own more than 9.99% of the Company&#x2019;s common stock then issued and outstanding (the Redmile Percentage Limitation), which percentage could change at Redmile&#x2019;s election upon 61 days&#x2019; notice to the Company to (i) any other number less than or equal to 19.99% or (ii) subject to approval of the Company&#x2019;s stockholders to the extent required in accordance with the NASDAQ Global Market rules, any number in excess of 19.99%. On May 2, 2017, the Company&#x2019;s stockholders approved the issuance of up to an aggregate of 14,097,745 shares of common stock upon the conversion of the outstanding shares of Class A Preferred. As a result, Redmile has the right to increase the Redmile Percentage Limitation to any percentage in excess of 19.99% at its election.</us-gaap:ConvertiblePreferredStockTermsOfConversion>
    <fate:PercentageOfCommonStockOwnershipUponPreferredStockConversion
      contextRef="C_126fd19f-3eec-4444-a458-398859e1ae58"
      decimals="4"
      id="F_e059d750-e932-491c-b806-6777025adbac"
      unitRef="U_pure">0.0999</fate:PercentageOfCommonStockOwnershipUponPreferredStockConversion>
    <fate:PercentageOfCommonStockOwnershipForPreferredStockConversionChangeUponNotice
      contextRef="C_126fd19f-3eec-4444-a458-398859e1ae58"
      decimals="4"
      id="F_cc3d19e3-8787-4da2-a290-ff643da434a6"
      unitRef="U_pure">0.1999</fate:PercentageOfCommonStockOwnershipForPreferredStockConversionChangeUponNotice>
    <fate:PercentageOfCommonStockOwnershipUponPreferredStockConversion
      contextRef="C_7272a2e8-f365-434c-8a2e-ca7e7c674867"
      decimals="4"
      id="F_e6daa836-89c7-44f6-aaaa-0f03135c6f0c"
      unitRef="U_pure">0.1999</fate:PercentageOfCommonStockOwnershipUponPreferredStockConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_36c7dc1f-1f68-4486-a90a-7021092d1f27"
      decimals="0"
      id="F_a73bfb22-e609-4417-8450-58a356f5de05"
      unitRef="U_shares">14097745</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <fate:PercentageOfCommonStockOwnershipUponPreferredStockConversion
      contextRef="C_8cb1a266-41ae-44a5-9398-af9a30767436"
      decimals="4"
      id="F_d92592d3-5789-430e-afd4-b1034826fd5e"
      unitRef="U_pure">0.1999</fate:PercentageOfCommonStockOwnershipUponPreferredStockConversion>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_1f598670-03c3-4c12-a086-312e2fe99e74"
      decimals="0"
      id="F_8093ced1-43f6-45e2-9e2d-c881094fe059"
      unitRef="U_shares">7236837</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_8b7007bc-3d95-44d8-90bb-9b611207cb91"
      decimals="2"
      id="F_3cae5c03-4440-41e7-95d1-c12bcb30445a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.66</us-gaap:SharesIssuedPricePerShare>
    <fate:PercentageOfCommonStockOwnershipUponPreferredStockConversion
      contextRef="C_bceaaf53-4594-42b0-af63-0c188d7eaf41"
      decimals="4"
      id="F_04be4f4f-8f83-4ff1-a002-48b62a6cefb1"
      unitRef="U_pure">0.1499</fate:PercentageOfCommonStockOwnershipUponPreferredStockConversion>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_79fca80f-8b40-4c0b-9152-12e26417ea73"
      decimals="0"
      id="F_a6f59369-5637-4df8-a3f9-47d3617f90e4"
      unitRef="U_shares">33441</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_7261e0f3-a26f-46dd-86c9-8888bb0227e9"
      decimals="0"
      id="F_aaa0dd29-e5ac-4591-86df-73e3ef8e13b9"
      unitRef="U_shares">167205</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_b943fa46-6631-448b-b8ef-ffce3d36d5be"
      decimals="0"
      id="F_8cc100bd-d613-4409-b92b-3eaf64fca108"
      unitRef="U_shares">6022</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_31099ea4-f12e-4b2c-9160-b411e31dd257"
      decimals="0"
      id="F_d1ff4737-b0be-4ef8-81e0-38e2c3ede53e"
      unitRef="U_shares">30110</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <fate:PreferredStockConversionPrice
      contextRef="C_02925833-8677-4697-ab8d-c844642a03e7"
      decimals="2"
      id="F_cf70b179-0c8f-4f3e-a1f2-6b229ca11eda"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.66</fate:PreferredStockConversionPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_9ddb50f7-7408-40d0-a949-d5236775a322"
      decimals="-5"
      id="F_377848fb-03e0-4d38-ad91-951eaf81e02f"
      unitRef="U_shares">9500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_4e67b46a-884c-4f90-a95b-2ef3d7aea6aa"
      decimals="-6"
      id="F_8fccb4fb-5257-4b88-815c-b99931e87fe9"
      unitRef="U_shares">8000000000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_0ad23255-7a2a-4f76-96d1-4206f5e0c875"
      decimals="2"
      id="F_f5f75518-adaf-4171-9472-fd22e5840dbd"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0ad23255-7a2a-4f76-96d1-4206f5e0c875"
      id="F_e78daa6f-0e2e-4c03-8261-95d588ca14bf">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <fate:ShareBasedCompensationArrangementByShareBasedPaymentAwardMonthlyAwardVestingPeriod
      contextRef="C_0ad23255-7a2a-4f76-96d1-4206f5e0c875"
      id="F_4969a46d-eb63-400d-adac-16bab069eba8">P4Y</fate:ShareBasedCompensationArrangementByShareBasedPaymentAwardMonthlyAwardVestingPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0ad23255-7a2a-4f76-96d1-4206f5e0c875"
      id="F_02a50ca1-b165-4302-b833-cc3847488623">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <fate:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnuallyAwardVestingPeriod
      contextRef="C_febf2ab8-3d7f-42f3-8e8f-9f2795618370"
      id="F_3da56a36-1492-4d73-bc54-87bad9e6b1c6">P4Y</fate:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnuallyAwardVestingPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_253be32e-0a0d-4574-b01a-92170bea60d8"
      decimals="INF"
      id="F_55908229-e514-4d60-a393-ab1544a58597"
      unitRef="U_shares">500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <fate:CommonStockCapitalAdditionalSharesReservedForFutureIssuance
      contextRef="C_acf53715-2f34-438d-9496-5f75227814aa"
      decimals="INF"
      id="F_b81e4232-cfdf-4345-bddd-fbe0fedc772e"
      unitRef="U_shares">300000</fate:CommonStockCapitalAdditionalSharesReservedForFutureIssuance>
    <fate:CommonStockCapitalAdditionalSharesReservedForFutureIssuance
      contextRef="C_b18b95bd-40a9-49db-97ef-2faba14a93a6"
      decimals="INF"
      id="F_ec1cf42a-214e-4484-97d3-8c2fae30cb72"
      unitRef="U_shares">470822</fate:CommonStockCapitalAdditionalSharesReservedForFutureIssuance>
    <fate:CommonStockCapitalAdditionalSharesReservedForFutureIssuance
      contextRef="C_afe59ea1-745d-4337-875d-4dbe66b0f606"
      decimals="INF"
      id="F_d4b52162-cfa3-4a3a-b300-4a3cdc9e8dbf"
      unitRef="U_shares">200000</fate:CommonStockCapitalAdditionalSharesReservedForFutureIssuance>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_821efd00-9226-4b6b-acf3-b68a5fe00775"
      decimals="INF"
      id="F_a6384487-f947-454d-a529-18e8e7748c79"
      unitRef="U_shares">257310</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <fate:PurchasePriceOfPrefundedWarrants
      contextRef="C_643af01a-b028-4eee-8c3b-c5192d3e319a"
      decimals="3"
      id="F_0eaf41de-e300-4f5e-abb9-c3ffb7badb0b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">85.499</fate:PurchasePriceOfPrefundedWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_821efd00-9226-4b6b-acf3-b68a5fe00775"
      decimals="3"
      id="F_50a97554-40a2-47a2-b221-62eb28e11a8e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_780d7cf9-0c20-4ef0-a014-ce112efe3de2"
      decimals="0"
      id="F_1c111aa5-10cb-4868-b864-a69223a7b562"
      unitRef="U_shares">3636364</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <fate:PurchasePriceOfPrefundedWarrants
      contextRef="C_dad32687-8050-4e65-8354-068f686b84df"
      decimals="3"
      id="F_7d388a94-0aee-427d-bc7a-a22799a90657"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.499</fate:PurchasePriceOfPrefundedWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_780d7cf9-0c20-4ef0-a014-ce112efe3de2"
      decimals="3"
      id="F_c5bd514a-a811-4d66-9e40-08e766e13b0b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <fate:WarrantsExerciseTermsDescription
      contextRef="C_643af01a-b028-4eee-8c3b-c5192d3e319a"
      id="F_e3b31658-d751-4b7c-b9ac-3c274816bf73">The Pre-Funded Warrants are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of the Company&#x2019;s common stock outstanding immediately after giving effect to such exercise. A holder of Pre-Funded Warrants may increase or decrease this percentage not in excess of 19.99% by providing at least 61 days&#x2019; prior notice to the Company.</fate:WarrantsExerciseTermsDescription>
    <fate:MaximumPercentageOfCommonStockOwnershipTogetherWithAffiliatesAllowableAfterExerciseOfPrefundedWarrants
      contextRef="C_821efd00-9226-4b6b-acf3-b68a5fe00775"
      decimals="4"
      id="F_d0a0391a-4fa3-4a82-8f9c-6e4ab9fe7619"
      unitRef="U_pure">0.0999</fate:MaximumPercentageOfCommonStockOwnershipTogetherWithAffiliatesAllowableAfterExerciseOfPrefundedWarrants>
    <fate:MaximumPercentageOfCommonStockOwnershipAfterChangeUponNotice
      contextRef="C_821efd00-9226-4b6b-acf3-b68a5fe00775"
      decimals="4"
      id="F_7b6333f4-69cc-49aa-ae7b-a231e44215a1"
      unitRef="U_pure">0.1999</fate:MaximumPercentageOfCommonStockOwnershipAfterChangeUponNotice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_d2920029-80c7-4108-9176-bd4bda38a66b"
      decimals="0"
      id="F_72b7eb1f-19c0-458a-98d6-a92e3cca6d50"
      unitRef="U_shares">3893674</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_42c862d9-3a55-43d8-9d4c-1b77fb049ef9">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes stock option activity and related information under all equity plans for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.41%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.902%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.142%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.902%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.482%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;br/&gt;(in 000s)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,850,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,210,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,293,354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,722,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.83&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options vested and expected to vest at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,722,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.83&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercisable at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,328,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.91&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_d2feccdf-3708-47ad-92f7-48fa021ea96b"
      decimals="INF"
      id="F_c20c1ca5-1cbc-4f3c-b246-f4ab2bfda977"
      unitRef="U_shares">9850841</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_d2feccdf-3708-47ad-92f7-48fa021ea96b"
      decimals="2"
      id="F_accff89f-45f8-4b96-86c1-a37e8e64d023"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c"
      decimals="0"
      id="F_b338d061-ba5b-41d6-8ab4-f8e3ec978b66"
      unitRef="U_shares">4210625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c"
      decimals="2"
      id="F_e15a2241-3143-41ac-9600-ad5c81609e57"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c"
      decimals="0"
      id="F_707f4793-f90a-4dac-baa0-3722fd1327cf"
      unitRef="U_shares">45438</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c"
      decimals="2"
      id="F_7abd2d18-19d3-48ee-99f0-d6b1e3d87805"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c"
      decimals="0"
      id="F_e113eadb-25f8-4dca-a85b-51cc9e780c1f"
      unitRef="U_shares">3293354</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c"
      decimals="2"
      id="F_fe4b0148-8a85-48bd-936f-1cd973335221"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.4</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_5c738271-04b6-46a1-bc09-e0d54f7b433b"
      decimals="INF"
      id="F_fc795042-02f2-4c69-a87d-3ad6a3fabd93"
      unitRef="U_shares">10722674</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_5c738271-04b6-46a1-bc09-e0d54f7b433b"
      decimals="2"
      id="F_839fb2f3-d250-4b74-baa9-fbe76731a304"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c"
      id="F_dbf2d1dc-cfde-472c-bf02-3893829cfa90">P5Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_5c738271-04b6-46a1-bc09-e0d54f7b433b"
      decimals="-3"
      id="F_2a7a13a5-c52d-423f-9daa-fb05f6e6158c"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="C_5c738271-04b6-46a1-bc09-e0d54f7b433b"
      decimals="0"
      id="F_a0c46494-915c-4c99-a71f-b2bbdd6469af"
      unitRef="U_shares">10722674</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="C_5c738271-04b6-46a1-bc09-e0d54f7b433b"
      decimals="2"
      id="F_7a70dbb5-be8e-4255-b789-ee8856c85249"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c"
      id="F_809ab1a8-28bf-498c-a7d1-8ab776d224a0">P5Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_5c738271-04b6-46a1-bc09-e0d54f7b433b"
      decimals="-3"
      id="F_c2698d3f-061e-48fd-9cb5-6553999ba34c"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_5c738271-04b6-46a1-bc09-e0d54f7b433b"
      decimals="0"
      id="F_a22c4041-181f-4f73-b4c1-ca6adfa3693e"
      unitRef="U_shares">7328404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_5c738271-04b6-46a1-bc09-e0d54f7b433b"
      decimals="2"
      id="F_58ac7038-fd3c-4173-8542-dcd4b6481347"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c"
      id="F_3a810de8-0cb0-4fdb-812b-d0e98797e234">P4Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_5c738271-04b6-46a1-bc09-e0d54f7b433b"
      decimals="-3"
      id="F_fd2c6621-17f2-4853-97d0-371bfc91776e"
      unitRef="U_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c"
      decimals="2"
      id="F_34007827-b267-427a-98be-104160ba31c4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_8d696b36-8d44-4c55-9a08-7819757a59b4"
      decimals="2"
      id="F_60b747c9-6fbe-4e88-b24b-f0d493ce06dc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_b1694544-d57a-4079-9403-45d7021d8147"
      decimals="-5"
      id="F_508cbcbe-c72d-4532-9555-75bda3f5ef1f"
      unitRef="U_USD">15400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_0792edb8-8c75-4ac5-9ff2-3638bf624ca6"
      decimals="-5"
      id="F_27445156-32ca-4f99-9df2-5838e4ef54d0"
      unitRef="U_USD">23000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_b1dc2798-8465-41bc-83d9-cb6a02fcf5c5"
      id="F_37376a3a-afbb-4bf3-a5cd-d74de5284ff9">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0c2bd9af-d58c-4b2f-a7bf-36d6102fcb98"
      id="F_79ca7e18-e21e-4d3c-8a6c-89bf00fe6a8c">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_8d696b36-8d44-4c55-9a08-7819757a59b4"
      decimals="-5"
      id="F_32278971-a1ba-4344-98a6-e0ddfa541c48"
      unitRef="U_USD">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c"
      decimals="-6"
      id="F_1a921306-0f34-49ef-a2d9-7565434de695"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c"
      decimals="-5"
      id="F_e7aabf5a-0163-4b38-85d8-740bd44fb244"
      unitRef="U_USD">100000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_a5724135-beef-4e00-8ec2-c43f43b10fc3">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes restricted stock unit activity and related information under all equity plans for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.41%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.902%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.142%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.902%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.482%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Vesting&lt;br/&gt;Period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;br/&gt;(in 000s)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,065,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,451,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;680,201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;622,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,214,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.01&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units expected to vest at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,151,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.92&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_e07453e5-70e2-4589-84ee-63184d1649d3"
      decimals="INF"
      id="F_aa9cfa40-d200-4cb4-9b74-c377ecd9ef80"
      unitRef="U_shares">3065087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_e07453e5-70e2-4589-84ee-63184d1649d3"
      decimals="2"
      id="F_a13c06de-5ace-4b3c-bc8e-933e11b6c569"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">37.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_13e7d164-655d-47b3-8816-15b789699d5d"
      decimals="0"
      id="F_d95db063-5596-4633-b970-b0b2cb0922a2"
      unitRef="U_shares">4451874</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_13e7d164-655d-47b3-8816-15b789699d5d"
      decimals="2"
      id="F_f1676fb0-b54c-46ba-bc0f-010f4c81614b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_13e7d164-655d-47b3-8816-15b789699d5d"
      decimals="0"
      id="F_6b8ed1c8-5e36-4dfd-94eb-a356daa3e5cb"
      unitRef="U_shares">680201</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_13e7d164-655d-47b3-8816-15b789699d5d"
      decimals="2"
      id="F_dec01be6-ef46-49b3-a212-f33846027f42"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">33.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_13e7d164-655d-47b3-8816-15b789699d5d"
      decimals="0"
      id="F_7680c28f-050d-419e-be1b-0baf1b8d4960"
      unitRef="U_shares">622696</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_13e7d164-655d-47b3-8816-15b789699d5d"
      decimals="2"
      id="F_db73423e-50f0-4fe4-8a66-e467a11a5352"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">35.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_5e663327-b86d-4b6c-a039-7b7d8ac711f3"
      decimals="INF"
      id="F_8d0b1cb0-6458-4feb-bc51-bc42e320fb5f"
      unitRef="U_shares">6214064</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_5e663327-b86d-4b6c-a039-7b7d8ac711f3"
      decimals="2"
      id="F_22ee9ad8-c241-424a-8348-a7f9823fc6bc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="C_13e7d164-655d-47b3-8816-15b789699d5d"
      id="F_6baf3ea6-a30b-42e7-bbe1-0e27572420ca">P2Y3D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="C_5e663327-b86d-4b6c-a039-7b7d8ac711f3"
      decimals="-3"
      id="F_a522b4ad-47e5-45b1-8368-da873e9c6548"
      unitRef="U_USD">10253000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <fate:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber
      contextRef="C_5e663327-b86d-4b6c-a039-7b7d8ac711f3"
      decimals="0"
      id="F_72f440d4-44c8-4137-aea4-127ca73262d8"
      unitRef="U_shares">5151457</fate:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumber>
    <fate:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue
      contextRef="C_5e663327-b86d-4b6c-a039-7b7d8ac711f3"
      decimals="2"
      id="F_23633ff6-64da-4c48-8aa6-d0ebea9cadc0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.78</fate:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue>
    <fate:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageRemainingContractualTerm
      contextRef="C_13e7d164-655d-47b3-8816-15b789699d5d"
      id="F_79f591e3-0107-4ea3-ba46-5719d53979f7">P1Y11M1D</fate:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageRemainingContractualTerm>
    <fate:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestAggregateIntrinsicValue
      contextRef="C_5e663327-b86d-4b6c-a039-7b7d8ac711f3"
      decimals="-3"
      id="F_2cd90981-ec37-48d1-ad81-f4710cc6bae1"
      unitRef="U_USD">8500000</fate:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestAggregateIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_5e663327-b86d-4b6c-a039-7b7d8ac711f3"
      decimals="-5"
      id="F_2d95d24f-ade5-4978-8244-4ecaf0e3b6e6"
      unitRef="U_USD">31400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_e07453e5-70e2-4589-84ee-63184d1649d3"
      decimals="-5"
      id="F_3bf5771e-6eed-42e7-86c0-4efb2d24d778"
      unitRef="U_USD">38300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_13e7d164-655d-47b3-8816-15b789699d5d"
      id="F_0b5b820e-dd90-497e-ac14-b8749e9c3db7">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_ae9121c7-17e3-4b53-8ea5-3c6e73560888"
      id="F_ed274875-4530-4115-b344-fcaad915f4e7">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_54bb083b-1c65-43f0-903c-ff27e3c8a59d"
      decimals="0"
      id="F_b45feac9-c907-4627-ad17-d73564527d80"
      unitRef="U_shares">1997377</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_c8f88322-9cd7-4ec4-92f5-a0a2e5bc4363"
      decimals="0"
      id="F_12c47d59-65aa-4a06-95b7-90247fe9ce49"
      unitRef="U_shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_c8f88322-9cd7-4ec4-92f5-a0a2e5bc4363"
      decimals="-5"
      id="F_57af6182-a375-44eb-bf13-0bfd1a87457a"
      unitRef="U_USD">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_5e663327-b86d-4b6c-a039-7b7d8ac711f3"
      decimals="0"
      id="F_5bafa1d3-c47b-46f1-9194-466473c36337"
      unitRef="U_shares">1062607</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_e07453e5-70e2-4589-84ee-63184d1649d3"
      decimals="0"
      id="F_a842c688-7cf2-424e-9791-85753c0eee23"
      unitRef="U_shares">1020617</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_419ff781-41d9-43fd-bf6c-81fc46b93796">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The allocation of stock-based compensation for all stock awards is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,520&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,849&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e07a21dc-a40b-48ca-81a4-731bcea56eb4"
      decimals="-3"
      id="F_2fb0ab7e-1ab2-4c26-8112-6410c5b7c2ba"
      unitRef="U_USD">22520000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_8ab196d3-69ab-4d26-b22d-9350aa81b0a8"
      decimals="-3"
      id="F_5611911f-39e1-4616-9614-b1217af6c542"
      unitRef="U_USD">20849000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e5f0eeec-87ae-44d4-9289-b8c650cd8dd3"
      decimals="-3"
      id="F_b4e29880-8b79-4889-8bd7-584aa887a1ad"
      unitRef="U_USD">18976000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b7a41695-3727-4f36-8184-049efe051469"
      decimals="-3"
      id="F_529a70c0-880a-4496-bef3-7cdb7a18db53"
      unitRef="U_USD">22610000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_baaaedc5-b8e0-488d-97eb-d4ff92f3a11f"
      unitRef="U_USD">41496000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_635114e8-1d8d-42f6-8c70-5c702b8fd180"
      unitRef="U_USD">43459000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_1a65d281-abd0-40cf-9643-ff875e96f6de">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee and nonemployee stock option grants were as follows:&lt;/span&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.343%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.343%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk&#x2013;free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;87.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c"
      decimals="3"
      id="F_168fe627-6dfa-4245-8c1f-f52b85825267"
      unitRef="U_pure">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_8d696b36-8d44-4c55-9a08-7819757a59b4"
      decimals="3"
      id="F_e98032e4-8291-4669-84c3-646e6fa4f2ca"
      unitRef="U_pure">0.038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c"
      decimals="3"
      id="F_f0ccdd4e-b96c-4a41-9001-bef72dbc787b"
      unitRef="U_pure">0.871</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_8d696b36-8d44-4c55-9a08-7819757a59b4"
      decimals="3"
      id="F_25c76ec4-7c30-4280-9184-cb2c567f6380"
      unitRef="U_pure">0.893</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c"
      id="F_175c91eb-692f-4369-b418-683d97239acb">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_8d696b36-8d44-4c55-9a08-7819757a59b4"
      id="F_91275898-7127-43be-b327-feee5f485c96">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_228a9429-468e-442d-a38d-9b5441b82b3c"
      decimals="3"
      id="F_19c97ba6-90fb-4d96-9a5a-6c41ad94808d"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_8d696b36-8d44-4c55-9a08-7819757a59b4"
      decimals="3"
      id="F_2185b019-316f-497e-b491-d1f52b841ae3"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <fate:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_62c42cce-3697-45fc-a436-e46f30fee853">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Common stock reserved for future issuance is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible preferred stock (if converted)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ccecff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ccecff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,775,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ccecff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ccecff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ccecff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,805,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ccecff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,722,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,850,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,214,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,065,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Awards available under the 2022 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,656,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,633,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Awards available under the Inducement Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;920,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;689,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,288,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,044,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</fate:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_f776f2a9-7c7a-491a-991b-ad0fcec60954"
      decimals="0"
      id="F_b1335002-ef90-4fd0-949a-29c9d6d85d54"
      unitRef="U_shares">13775430</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_4f0fc4a6-d283-49a9-971d-0333511e8d5e"
      decimals="INF"
      id="F_e5b2ca37-815c-40ae-b98b-075dca4cd963"
      unitRef="U_shares">13805540</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_4c6c4dd6-4ab5-46a0-bc89-10dab775b034"
      decimals="0"
      id="F_6d1a87b5-ff3d-4698-aeeb-bd102bc35d84"
      unitRef="U_shares">10722674</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_bc45b335-2d95-4276-ad2c-dab6f6cd2b27"
      decimals="INF"
      id="F_576a1349-34ba-45d6-84e3-782db27d42cd"
      unitRef="U_shares">9850841</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_5e663327-b86d-4b6c-a039-7b7d8ac711f3"
      decimals="0"
      id="F_bf67eb77-c86f-430c-b555-db3af7b2022d"
      unitRef="U_shares">6214064</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_e07453e5-70e2-4589-84ee-63184d1649d3"
      decimals="INF"
      id="F_418cb805-1cba-418c-baed-358ccf84524d"
      unitRef="U_shares">3065087</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_d0dc00f7-c9cf-41d7-89f0-cc4fe78c6101"
      decimals="0"
      id="F_54d2e9ed-dcc3-4474-8762-9d2b9fd76154"
      unitRef="U_shares">11656109</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_6e421e14-6d5d-4504-b9b2-ead06e38f45f"
      decimals="INF"
      id="F_70820944-a5b8-404e-a399-f9b344afd650"
      unitRef="U_shares">8633496</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_bc446b6b-8934-40b7-bcdd-742d1f50b677"
      decimals="0"
      id="F_60cc8c1d-43b2-4406-9108-d9d4c588eb67"
      unitRef="U_shares">920688</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_9a61a4db-53f2-4f25-957f-9ca42291c122"
      decimals="INF"
      id="F_3122030c-fba4-47bc-9d56-24a0ad4e9dbd"
      unitRef="U_shares">689750</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="INF"
      id="F_317641ef-84d2-4b86-8dd0-49ff846378e8"
      unitRef="U_shares">43288965</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="INF"
      id="F_eb213d98-ff36-43f2-ae47-5b200200b9e0"
      unitRef="U_shares">36044714</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_1b193051-df74-4650-80c7-338244a1f411">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10. Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following is a reconciliation of the Company&#x2019;s expected federal income tax provision (benefit) to the actual income tax provision (in thousands):&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax computed at federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State tax, net of federal tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,429&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-deductible compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,560&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;R&amp;amp;D tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Reserve for uncertain tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Significant components of the Company&#x2019;s deferred tax assets are summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized R&amp;amp;D expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;127,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;134,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147,019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;112,810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;R&amp;amp;D tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,126&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Intangible asset amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,836&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,322&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;374,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;342,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,008&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net of deferred tax assets and liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;362,084&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;323,962&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;362,084&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;323,962&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:86.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A valuation allowance of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;362.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;324.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023, respectively, has been established to offset the deferred tax assets, as realization of such assets is uncertain.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2024, the Company had federal and state net operating loss (NOL) carryforwards of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;689.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;644.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, which may be available to offset future taxable income. The federal and California NOL carryforwards begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, unless previously utilized. At &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had federal and California research and development (R&amp;amp;D) credit carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. The federal R&amp;amp;D tax credit carryforwards will begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2035&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; unless previously utilized. The California R&amp;amp;D credit carryforwards will carry forward indefinitely.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, (the Code), substantial changes in the Company&#x2019;s ownership may limit the amount of net operating loss and research and development credit carryforwards that could be used annually in the future to offset taxable income. The tax benefits related to future utilization of federal and state net operating loss carryforwards, credit carryforwards, and other deferred tax assets may be limited or lost if cumulative changes in ownership exceeds &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% within any &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; period. The Company completed a study to assess whether an ownership change, as defined by Section 382 of the Code, had occurred from the Company&#x2019;s formation through December 31, 2015. Based upon this study, the Company determined that several ownership changes had occurred. Accordingly, the Company reduced its deferred tax assets related to the federal NOL carryforwards and the federal R&amp;amp;D credit carryforwards that are anticipated to expire unused as a result of these ownership changes. These tax attributes were excluded from deferred tax assets with a corresponding reduction of the valuation allowance with no net effect on income tax expense or the effective tax rate. The Company updated the study December 31, 2024 and concluded there were no ownership changes during 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Future ownership changes may further limit the Company&#x2019;s ability to utilize its remaining tax attributes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company files income tax returns in the United States, various state jurisdictions, and the Netherlands with varying statutes of limitations. The Company currently has no years under examination by any jurisdiction; however, the Company is subject to income tax examination by federal and state tax authorities for years beginning in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively. However, to the extent allowed by law, the taxing authorities may have the right to examine prior periods where NOLs and tax credits were generated and carried forward, and make adjustments up to the amount of the carryforwards.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The change in the Company&#x2019;s unrecognized tax benefits is summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Beginning unrecognized tax benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52,767&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Increase related to current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,345&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Increase related to prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Decrease related to prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ending unrecognized tax benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70,505&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company does &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t anticipate that the amount of unrecognized tax benefits as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; will significantly change within the next twelve months. Due to the valuation allowance recorded against the Company&#x2019;s deferred tax assets, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ne of the total unrecognized tax benefits as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; would reduce the effective tax rate if recognized. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. The Company has not recognized interest or penalties related to income tax matters in its consolidated statements of operations and comprehensive loss since inception.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_0980a0ab-94f7-4c95-b2bd-abe3ac758828">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following is a reconciliation of the Company&#x2019;s expected federal income tax provision (benefit) to the actual income tax provision (in thousands):&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax computed at federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State tax, net of federal tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,429&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-deductible compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,560&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;R&amp;amp;D tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Reserve for uncertain tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_f45c0713-f974-47b2-8900-b05c97bbfb29"
      unitRef="U_USD">-39115000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_12da07ec-e313-47da-a3d8-2d75218c9415"
      unitRef="U_USD">-33794000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_ac19dbe2-eed8-4e63-9308-d5f5b4087a69"
      unitRef="U_USD">-8429000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_096cba59-4dd5-4ccb-afaa-bd064b1bb226"
      unitRef="U_USD">-4851000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <fate:IncomeTaxReconciliationNondeductibleCompensation
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_325c844b-d1ed-49e3-8254-cc6fff11eb49"
      unitRef="U_USD">35000</fate:IncomeTaxReconciliationNondeductibleCompensation>
    <fate:IncomeTaxReconciliationNondeductibleCompensation
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_de699c77-ffbf-4d7e-8d6e-38d2a14264fa"
      unitRef="U_USD">25000</fate:IncomeTaxReconciliationNondeductibleCompensation>
    <fate:IncomeTaxReconciliationPermanentTaxDifferences
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_788e1282-2258-45ca-95e1-4796f10388a8"
      unitRef="U_USD">22000</fate:IncomeTaxReconciliationPermanentTaxDifferences>
    <fate:IncomeTaxReconciliationPermanentTaxDifferences
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_778c29ff-40bd-4dd9-bf61-31d14401008f"
      unitRef="U_USD">-2305000</fate:IncomeTaxReconciliationPermanentTaxDifferences>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_832b388b-6341-4f14-86fd-30fb7c77e3c5"
      unitRef="U_USD">8560000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_a440c28d-249c-4b76-8bfb-8331ef38fcaf"
      unitRef="U_USD">12801000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_3e378b58-d19e-4d60-b171-768452d886ea"
      unitRef="U_USD">7672000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_da5073be-c51b-49cb-803d-5512100a18a0"
      unitRef="U_USD">5773000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <fate:IncomeTaxReconciliationReserveForUncertainTaxPositions
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_f3422ea9-ab6c-4f2e-be1b-8f002488b730"
      unitRef="U_USD">8612000</fate:IncomeTaxReconciliationReserveForUncertainTaxPositions>
    <fate:IncomeTaxReconciliationReserveForUncertainTaxPositions
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_2114a3aa-0ebb-492f-b656-cec36151af09"
      unitRef="U_USD">4254000</fate:IncomeTaxReconciliationReserveForUncertainTaxPositions>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_791b98c1-8e9e-4fe3-b4f6-9f72127c1cae"
      unitRef="U_USD">-135000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_139636b5-a8dd-4872-8154-cd822c8d4350"
      unitRef="U_USD">1928000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_e8fb9e9b-06fb-4827-8fcf-37ef752885ad"
      unitRef="U_USD">38122000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_675f8deb-10e6-4b40-b136-10edcad9d10a"
      unitRef="U_USD">27715000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_64e11b3e-360e-4145-9fbf-ed496c14159b"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_4a7d28bf-6d51-489f-a292-b3b31bbf73f8"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_242ac8b3-921f-4942-8ca7-fb3ab1b8a7b6">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Significant components of the Company&#x2019;s deferred tax assets are summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized R&amp;amp;D expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;127,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;134,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147,019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;112,810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;R&amp;amp;D tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,126&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Intangible asset amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,836&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,322&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;374,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;342,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,008&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net of deferred tax assets and liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;362,084&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;323,962&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;362,084&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;323,962&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <fate:DeferredTaxAssetsCapitalizedRdExpense
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_e5e702db-819c-4b57-93af-bcd925d36db3"
      unitRef="U_USD">127559000</fate:DeferredTaxAssetsCapitalizedRdExpense>
    <fate:DeferredTaxAssetsCapitalizedRdExpense
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_a706b936-7452-4e9d-9c60-e0361dd3ee8b"
      unitRef="U_USD">134209000</fate:DeferredTaxAssetsCapitalizedRdExpense>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_18b8ffe1-7d71-40b0-abf2-f36b32811611"
      unitRef="U_USD">147019000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_02d21aab-075b-418a-9e25-00bfe78b48f2"
      unitRef="U_USD">112810000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_03cf3248-8fec-4cb7-9399-4002bdaa1f32"
      unitRef="U_USD">63126000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_f3faeed9-09f5-4dfd-b0b3-e55c923c7d79"
      unitRef="U_USD">55492000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_2af5cd52-b048-4787-ad08-c6f7805ba1a2"
      unitRef="U_USD">8692000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_0d0407a9-21bb-4d28-b9bd-ce96fdf26eb9"
      unitRef="U_USD">9220000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_591efa6e-6496-412d-ac87-9fdb98da2313"
      unitRef="U_USD">1147000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_ce02fbb3-2eca-464d-9c80-0c43ee1b395c"
      unitRef="U_USD">144000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_33921a84-dee2-48e2-bbb5-d7295b9c5c47"
      unitRef="U_USD">7836000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_511739b4-480a-489b-95d1-453949442520"
      unitRef="U_USD">8322000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <fate:DeferredTaxAssetsLeaseLiabilities
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_f4f9c411-4b66-4fd2-9974-8d7eb7d4fdef"
      unitRef="U_USD">17925000</fate:DeferredTaxAssetsLeaseLiabilities>
    <fate:DeferredTaxAssetsLeaseLiabilities
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_53c152e1-4aae-4dbc-9f91-314976bbf3d6"
      unitRef="U_USD">21761000</fate:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_1cc8ff8f-51b3-43ff-bef5-423e2efe1801"
      unitRef="U_USD">788000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_e632b85c-f83c-4d0c-a306-a6ef1a926149"
      unitRef="U_USD">672000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_e0b52635-c6d7-4842-8c88-83183d9a4ed5"
      unitRef="U_USD">374092000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_7572555f-1aa1-403a-9c72-f3c48e309656"
      unitRef="U_USD">342630000</us-gaap:DeferredTaxAssetsGross>
    <fate:DeferredTaxLiabilitiesDepreciation
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_d56017e2-00e9-40a3-8d01-0d62aa011764"
      unitRef="U_USD">2212000</fate:DeferredTaxLiabilitiesDepreciation>
    <fate:DeferredTaxLiabilitiesDepreciation
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_b1f33e8f-fda3-4680-ba27-106ad3fe4d82"
      unitRef="U_USD">5639000</fate:DeferredTaxLiabilitiesDepreciation>
    <fate:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_14caade0-9237-4127-839a-6444f8227655"
      unitRef="U_USD">9796000</fate:DeferredTaxLiabilitiesRightOfUseAssets>
    <fate:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_887f04bb-f920-4ca4-935e-e903f1301f71"
      unitRef="U_USD">13029000</fate:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_24576641-3cbf-4b76-8bc0-10092a82c523"
      unitRef="U_USD">12008000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_9237b7de-2370-454b-aa7b-c7a12d4adf96"
      unitRef="U_USD">18668000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_97afa3c4-8bb8-4605-995d-43b369bbb338"
      unitRef="U_USD">362084000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_8f519f8a-6c66-4187-8667-8fb1909cdbae"
      unitRef="U_USD">323962000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_271a23c3-0b46-435c-96d6-6b840f0cbf6b"
      unitRef="U_USD">362084000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_6cdc8604-dce1-4b35-a29a-cd334fae35f9"
      unitRef="U_USD">323962000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_fc6d04c4-c3cc-4d5a-9686-4288f6897498"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_862c9642-cfa5-47fe-8138-1cf5d9a1f2e9"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-5"
      id="F_9db93f24-ec42-4c96-9871-19c55a1cb055"
      unitRef="U_USD">362100000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-5"
      id="F_322bc58d-5269-4c24-a890-7f68eea16960"
      unitRef="U_USD">324000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_fece1b4a-7679-43ae-91f1-803e3e834572"
      decimals="-5"
      id="F_15eb3006-6182-41e4-bf20-31c2c42e8858"
      unitRef="U_USD">689200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_6ada6b38-7f9b-45ef-acbb-49e492518216"
      decimals="-5"
      id="F_f12a53d9-484f-44ad-be5c-73bef8bd81de"
      unitRef="U_USD">644200000</us-gaap:OperatingLossCarryforwards>
    <fate:OperatingLossCarryforwardsExpirationYear
      contextRef="C_b831d8dc-5480-4f60-b15f-b532465e4ca2"
      id="F_dee7ce50-ba53-4445-9f28-ecb4c10c4593">2027</fate:OperatingLossCarryforwardsExpirationYear>
    <fate:OperatingLossCarryforwardsExpirationYear
      contextRef="C_5cc2f3d5-6422-4ca7-ba47-f826548fe079"
      id="F_de3e78fa-f539-4698-b4c5-20ecac366651">2028</fate:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_e122feae-e127-43e8-a5fa-96cea5382fa8"
      decimals="-5"
      id="F_c1da7584-942e-421d-ace2-3d1b0bac0dd7"
      unitRef="U_USD">45600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_6ada6b38-7f9b-45ef-acbb-49e492518216"
      decimals="-5"
      id="F_0bca3f51-acca-435f-87fa-81af3a0a5bbf"
      unitRef="U_USD">37800000</us-gaap:TaxCreditCarryforwardAmount>
    <fate:TaxCreditCarryforwardBeginningExpirationYear
      contextRef="C_eb50e59a-b806-4c03-9930-ed4b25c0c2ce"
      id="F_c54b7f59-bf9b-4959-a580-cf9b8d37c275">2035</fate:TaxCreditCarryforwardBeginningExpirationYear>
    <fate:CumulativeChangeInOwnershipPercentage
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="2"
      id="F_e48c2d49-5d5f-4b52-9eec-488ef611859b"
      unitRef="U_pure">0.50</fate:CumulativeChangeInOwnershipPercentage>
    <fate:PeriodForCumulativeChangeInOwnership
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_1719cfca-cfed-4b80-89ee-ca4dd860af6c">P3Y</fate:PeriodForCumulativeChangeInOwnership>
    <us-gaap:IncomeTaxExaminationYearUnderExamination
      contextRef="C_b831d8dc-5480-4f60-b15f-b532465e4ca2"
      id="F_90f2d18a-da8a-47e8-ae74-919153df00ba">2021</us-gaap:IncomeTaxExaminationYearUnderExamination>
    <us-gaap:IncomeTaxExaminationYearUnderExamination
      contextRef="C_235e1198-6534-41bd-9a50-81f2b487638e"
      id="F_7ea583c4-873b-4a3a-9a0e-b0257da81476">2020</us-gaap:IncomeTaxExaminationYearUnderExamination>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_aee5e994-a7e9-4706-8ee5-6399b8a78c0b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The change in the Company&#x2019;s unrecognized tax benefits is summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Beginning unrecognized tax benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52,767&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Increase related to current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,345&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Increase related to prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Decrease related to prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ending unrecognized tax benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70,505&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_d7956458-7d9c-4f03-b666-fde558481164"
      unitRef="U_USD">59680000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_6199ef4e-6533-4919-aa08-7b8879357aa9"
      decimals="-3"
      id="F_d14d1c2f-0af4-4824-8fb4-6e85a646a7aa"
      unitRef="U_USD">52767000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_306f22e8-2291-403d-b522-d4e7d70b5157"
      unitRef="U_USD">10345000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_5b66a408-4f60-4fbb-a302-5f814b608386"
      unitRef="U_USD">9724000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_3cad7831-fdb5-469e-88dd-5bd3b8f98da2"
      unitRef="U_USD">687000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_c4c09a29-d6d8-4c66-8843-c542d703b245"
      unitRef="U_USD">90000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_0fd1ca62-52d5-4205-a2d3-324c5d8e17ee"
      unitRef="U_USD">207000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_527a2ed9-6a7e-4453-8604-8f33ec16db32"
      unitRef="U_USD">2901000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="-3"
      id="F_83b67c3e-fc0e-4924-acdf-021dae715ae1"
      unitRef="U_USD">70505000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_22adcf4d-c4ad-4e0e-b075-26a24b5bd4f6"
      decimals="-3"
      id="F_d11fe421-76bc-48cd-8817-f086dd5762ca"
      unitRef="U_USD">59680000</us-gaap:UnrecognizedTaxBenefits>
    <fate:UnrecognizedTaxBenefitsResultingInNetOperatingLossAndTaxCreditCarryforward
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="INF"
      id="F_fa317ecb-f4f6-4444-b46b-f3a8acc9156f"
      unitRef="U_USD">0</fate:UnrecognizedTaxBenefitsResultingInNetOperatingLossAndTaxCreditCarryforward>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="C_4b833be3-96ed-48b8-9d9e-6292de58d8fd"
      decimals="INF"
      id="F_0308d48d-8cd3-46c6-a981-1e474aaff428"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_fe1cff8f-5d21-4000-8479-2012323eaaba">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;11. Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable segment relating to its operations. The segment derives its current revenues from research and development collaborations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s Chief Operating Decision Maker (the CODM), its Chief Executive Officer, manages the Company&#x2019;s operations on an integrated basis for the purposes of allocating resources. When evaluating the Company&#x2019;s financial performance, the CODM reviews total revenues, total expenses and expenses by certain categories and makes decisions using this information.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_2f454c57-baac-4705-a580-50decd7c868a;"&gt;&lt;span style="-sec-ix-hidden:F_ec6c8190-36ba-401a-8dbc-a9e6f704f525;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Collaboration revenue&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical programs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research activities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Facilities costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment expenses (1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113,065&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105,528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;223,907&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;254,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;210,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;190,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other income (expense):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of stock price appreciation milestones&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;819&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,907&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,882&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total other income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;186,262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;160,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other segment expenses include stock compensation expense, depreciation, legal fees, general &amp;amp; administrative expenses, and corporate expenses.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="0"
      id="F_1633fcd5-5ad6-4a1e-8675-fc764ea085ac"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_0c8d46ba-7b96-4017-8e46-a6b4b89866b5">The Company&#x2019;s Chief Operating Decision Maker (the CODM), its Chief Executive Officer, manages the Company&#x2019;s operations on an integrated basis for the purposes of allocating resources. When evaluating the Company&#x2019;s financial performance, the CODM reviews total revenues, total expenses and expenses by certain categories and makes decisions using this information.</us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_2588e50f-0337-462b-a6c2-90bcbde4bb60">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_2f454c57-baac-4705-a580-50decd7c868a;"&gt;&lt;span style="-sec-ix-hidden:F_ec6c8190-36ba-401a-8dbc-a9e6f704f525;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Collaboration revenue&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical programs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research activities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Facilities costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment expenses (1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113,065&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105,528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;223,907&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;254,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;210,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;190,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other income (expense):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of stock price appreciation milestones&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;819&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,907&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,882&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total other income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;186,262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;160,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other segment expenses include stock compensation expense, depreciation, legal fees, general &amp;amp; administrative expenses, and corporate expenses.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_a1e1870d-0307-414c-a652-ad26c70a4a16"
      unitRef="U_USD">13631000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_2430e201-4380-41d9-b89c-8180170bc4eb"
      unitRef="U_USD">63533000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <fate:PersonnelCosts
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_f5616850-5fa9-4429-9dd1-fe82a561caf5"
      unitRef="U_USD">43684000</fate:PersonnelCosts>
    <fate:PersonnelCosts
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_2638df7d-c1e5-40c1-96be-aac1fe512479"
      unitRef="U_USD">63454000</fate:PersonnelCosts>
    <fate:ClinicalProgramsExpense
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_3c810798-7e58-46f2-858d-b90168bf40d1"
      unitRef="U_USD">25818000</fate:ClinicalProgramsExpense>
    <fate:ClinicalProgramsExpense
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_6cbe910d-4901-4749-830f-d46ad97eee56"
      unitRef="U_USD">40289000</fate:ClinicalProgramsExpense>
    <fate:ResearchActivitiesExpense
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_c50688dd-ed68-410a-834a-94a632dd7097"
      unitRef="U_USD">14692000</fate:ResearchActivitiesExpense>
    <fate:ResearchActivitiesExpense
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_55bf494a-2363-4aef-bca4-189800929d0d"
      unitRef="U_USD">18768000</fate:ResearchActivitiesExpense>
    <fate:FacilitiesCosts
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_f51b31bf-b7ed-4525-9575-a63993b9c14b"
      unitRef="U_USD">26648000</fate:FacilitiesCosts>
    <fate:FacilitiesCosts
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_cd397846-2598-423a-a638-0ecaab6a7d9e"
      unitRef="U_USD">26005000</fate:FacilitiesCosts>
    <fate:OtherSegmentExpenses
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_9b365eab-0f43-4cb0-abaf-bc342af9c6ec"
      unitRef="U_USD">113065000</fate:OtherSegmentExpenses>
    <fate:OtherSegmentExpenses
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_09e675d8-070d-4377-b897-566ff7993c23"
      unitRef="U_USD">105528000</fate:OtherSegmentExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_686dae30-7163-4f6c-a400-ac2f4e8ae811"
      unitRef="U_USD">223907000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_bb693143-269d-49e6-bdc0-f32a8eaee239"
      unitRef="U_USD">254044000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_0ed95370-21e2-4047-87fa-c6b9d67c3ba6"
      unitRef="U_USD">-210276000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_ae565115-5a61-4011-8ad9-2ed29c3f6fc5"
      unitRef="U_USD">-190511000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_4d576340-6a07-4aa5-9fb8-fe4b87d6f19d"
      unitRef="U_USD">17288000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_8596f12f-b52a-472a-aaeb-9102c3a7a55e"
      unitRef="U_USD">17186000</us-gaap:InvestmentIncomeInterest>
    <fate:IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_8056bc2d-c0d8-418c-9624-85ef8a154a7b"
      unitRef="U_USD">-819000</fate:IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones>
    <fate:IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_ca891d05-8f63-4a0e-9bc0-828abc11c7db"
      unitRef="U_USD">-2515000</fate:IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_53405b32-abe8-4bf0-ac5d-945152b89b92"
      unitRef="U_USD">5907000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_7a7da979-efb9-4b57-9942-1b6090c76e83"
      unitRef="U_USD">9882000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_dce53816-8b8a-4dba-abf1-275e5b4c64bc"
      unitRef="U_USD">24014000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_a34b3ff0-55af-4ff2-99da-219965ed8928"
      unitRef="U_USD">29583000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-3"
      id="F_5af7607b-06b7-4389-8c37-c59a7986fe69"
      unitRef="U_USD">-186262000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-3"
      id="F_af8dd702-2e0e-4048-a564-6cf5839481b9"
      unitRef="U_USD">-160928000</us-gaap:NetIncomeLoss>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_72d49ecf-d3fb-4f5d-a1a4-51e6ac961c1a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12. Employee Benefits&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Effective January 1, 2009, the Company adopted a defined contribution 401(k) plan for employees who are at least &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years of age. Employees are eligible to participate in the plan beginning on the first day of the calendar quarter following date of hire. Under the terms of the plan, employees may make voluntary contributions as a percent of compensation. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company makes discretionary contributions to the 401(k) Plan equal to 100 percent of each employee&#x2019;s pretax contributions up to 20 percent of the IRS Standard Limit.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;s total contributions to the 401(k) Plan &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; mill&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ion and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <fate:DefinedContributionPlanMinimumAgeOfEmployee
      contextRef="C_df4185ff-6291-44b2-b42f-fe0d6dd2b4c5"
      id="F_23dbb662-f198-4a6b-992b-575a576aa447">P21Y</fate:DefinedContributionPlanMinimumAgeOfEmployee>
    <fate:PercentageOfDiscretionaryContributionsDescription
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_b22853d6-70b0-4612-9bd9-1d8b3ad2c1f6">The Company makes discretionary contributions to the 401(k) Plan equal to 100 percent of each employee&#x2019;s pretax contributions up to 20 percent of the IRS Standard Limit.</fate:PercentageOfDiscretionaryContributionsDescription>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-5"
      id="F_f7ba7e16-79e4-48cb-9729-51a74a19a2c4"
      unitRef="U_USD">700000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="C_a962e13e-8de2-41eb-a9e2-eacfc65d86e1"
      decimals="-5"
      id="F_b44b77c0-f5fc-4349-b602-e3f559d0e804"
      unitRef="U_USD">1900000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_82e35e26-ef9e-46bb-a1a5-07cd83d40f9f">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;13. Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has entered into exclusive license agreements with certain academic institutions and universities pursuant to which the Company acquired certain intellectual property. Pursuant to each agreement, as consideration for an exclusive license to the intellectual property, the Company paid a license fee, reimbursed the institution for historical patent costs and, in certain instances, issued the institution shares of restricted common stock. Additionally, under each agreement, the institution is generally eligible to receive future consideration including, but not limited to, annual maintenance fees, royalties, milestone payments and sublicensing fees. Each of the license agreements is generally cancelable by the Company, given appropriate prior written notice. Minimum annual payments to maintain these cancelable licenses total an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million. See Note 2 for additional information on certain licenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Litigation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the reporting period, the Company pursued claims in two lawsuits that were filed in 2022 against Shoreline Biosciences, Inc. (Shoreline) and certain of its founders and officers (collectively, the Shoreline litigations). The first suit, filed on May 13, 2022, was pending in San Diego Superior Court against Shoreline and four of its founders, Drs. Dan S. Kaufman (Kaufman), Kleanthis G. Xanthopoulos, and Messrs. William Sandborn and Steven Holtzman. The Company's claims included actions for breach of contract, breach of implied covenant of good faith and fair dealing, fraud and deceit, tortious interference, restitution and unfair competition. On August 9, 2024, the court denied the defendants&#x2019; motions for summary judgment preserving for trial all of the Company&#x2019;s claims against the defendants, with the exception of defendants&#x2019; motions with respect to certain theories under the Company&#x2019;s tortious interference claim (which claim by Fate was otherwise preserved for trial). On September 19, 2024, the court denied defendants&#x2019; motion for reconsideration of its summary judgment ruling. Trial began on October 21, 2024, with a jury selected on October 24, 2024. On October 28, 2024, the parties entered a settlement agreement resolving the litigation on terms agreeable to all parties, pursuant to which the Company filed a request for dismissal with prejudice of all claims on October 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the second of the Shoreline litigations, also filed on May 13, 2022, the Company and Whitehead Institute for Biomedical Research (Whitehead) filed a lawsuit in the U.S. District Court for the Southern District of California against Shoreline and Kaufman seeking monetary damages for the defendants&#x2019; infringement of U.S. Patent Nos. 8,071,369, 8,932,856, 8,951,797, 8,940,536, 9,169,490, 10,457,917, and 10,017,744. On June 7, 2023, the Company and Whitehead filed a motion to dismiss our patent infringement claims against Kaufman in his personal capacity; that motion was granted on June 9, 2023. On August 30, 2023, the court granted Shoreline&#x2019;s motion for summary judgment and denied the Company&#x2019;s motion for partial summary judgment as moot. Judgment in favor of Shoreline was entered on August 31, 2023. On September 27, 2023, the Company and Whitehead filed a Notice of Appeal with the Court of Appeals for the Federal Circuit challenging the trial court&#x2019;s claim construction and grant of summary judgment in favor of the defendants; the defendants cross-appealed challenging the district court&#x2019;s earlier denial of a motion to dismiss and partial motion for summary judgment on other grounds. The Federal Circuit docketed the case on October 5, 2023, and briefing was completed on June 26, 2024. On October 28, 2024, the parties entered a settlement agreement resolving the litigation on terms agreeable to all parties, pursuant to which the parties filed a joint notice of dismissal of the appeal and cross-appeal on October 31, 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On January 20, 2023, a purported stockholder of the Company filed a securities class action lawsuit against the Company and certain of its officers captioned Hadian v. Fate Therapeutics, Inc. et al. in the U.S. District Court for the Southern District of California (the Securities Action). On May 4, 2023, the court appointed a different purported stockholder of the Company to serve as lead plaintiff in the Securities Action. On July 24, 2023, the lead plaintiff filed an amended complaint. The amended complaint alleged that the Company violated the federal securities laws by making allegedly false and/or misleading statements and/or omissions in its public disclosures dating back to August 2020 relating to the Company&#x2019;s collaboration agreement with Janssen Biotech, Inc. (the Janssen Agreement), potential product candidates subject to the Janssen Agreement, and the termination of the Janssen Agreement. On September 22, 2023, the Company filed a motion to dismiss the amended complaint. On September 19, 2024, the court granted the Company&#x2019;s motion to dismiss the amended complaint, with leave for plaintiff to file a second amended complaint. On October 18, 2024, the lead plaintiff filed a second amended complaint alleging substantially similar facts and claims as in the prior amended complaint. The Company filed a motion to dismiss the second amended complaint on November 18, 2024, and briefing on the motion was completed on January 21, 2025. The Company intends to continue to vigorously defend against this action.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On June 2, 2023, a derivative complaint, captioned Guarino v. Wolchko, et al., was filed by a purported stockholder of the Company in the U.S. District Court for the Southern District of California (the Guarino Action). On June 12, 2024, an additional derivative complaint, captioned Horrobin v. Wolchko, et al., was filed by a purported stockholder of the Company in the same district (the Horrobin Action). On December 3, 2024, the court entered an order consolidating the Guarino Action and the Horrobin Action under the caption In re Fate Therapeutics, Inc. Derivative Litigation (the Derivative Action) and staying the Derivative Action pending the court&#x2019;s decision on our motion to dismiss the second amended complaint in the Securities Action. The court&#x2019;s ruling on the motion is pending. The Derivative Action names members of the Company&#x2019;s board of directors and certain officers as defendants. The Company is also named as a nominal defendant. The plaintiffs in the Derivative Actions assert derivative claims arising out of substantially the same alleged facts and circumstances as the Securities Action. The Guarino complaint asserts claims for breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and violation of federal securities laws. The Horrobin complaint asserts substantially similar claims in addition to a claim of breach of fiduciary duty for insider trading. The Company intends to vigorously defend against the Derivative Action.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, the Company may be subject to various other legal proceedings and claims that arise in the ordinary course of business activities.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <fate:MinimumAnnualPaymentsToMaintainLicenses
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      decimals="-5"
      id="F_e6b031ed-24da-46fa-b3c5-d9bf74143112"
      unitRef="U_USD">400000</fate:MinimumAnnualPaymentsToMaintainLicenses>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_8ccde67a-0914-44ba-a594-e890c7084e96">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;14. Subsequent Events&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;California Institute for Regenerative Medicine Award&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On January 30, 2025, the Company received approval from CIRM for funding of a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million grant to support the conduct of pre-clinical and IND-enabling activities for FT836.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Employment Agreement with Chief Executive Officer&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On March 3, 2025, the Company entered into an Employment Agreement (the &#x201c;Employment Agreement&#x201d;) with Bahram Valamehr (&#x201c;Valamehr&#x201d;). Pursuant to the Employment Agreement, Dr. Valamehr will have the customary powers and responsibilities of a chief executive officer of a corporation of the size and type of the Company.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <fate:GrantAward
      contextRef="C_f1dea256-3b9e-495e-a654-b31799d22af3"
      decimals="-5"
      id="F_17d8684f-47fb-4ef5-a013-33b360073bb0"
      unitRef="U_USD">4000000</fate:GrantAward>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_7fc491c3-db47-4e1f-9c36-5199ecfed9ff"
      id="F_42226c14-472f-4797-9822-5e01534c2c82">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_7fc491c3-db47-4e1f-9c36-5199ecfed9ff"
      id="F_44afc77e-a5fb-4727-865c-4460ed9753ea">false</ecd:NonRule10b51ArrAdoptedFlag>
    <fate:Rule10B51ArrModifiedFlag
      contextRef="C_7fc491c3-db47-4e1f-9c36-5199ecfed9ff"
      id="F_c2c5cb77-e66a-4444-b149-e096c883ccf0">false</fate:Rule10B51ArrModifiedFlag>
    <fate:NonRule10B51ArrModifiedFlag
      contextRef="C_7fc491c3-db47-4e1f-9c36-5199ecfed9ff"
      id="F_1c9083bb-727a-4458-a9c5-b4340c6e1743">false</fate:NonRule10B51ArrModifiedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_7fc491c3-db47-4e1f-9c36-5199ecfed9ff"
      id="F_8af7c83b-27bf-42a1-8012-a2bb482e2493">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_7fc491c3-db47-4e1f-9c36-5199ecfed9ff"
      id="F_2e01c90e-99e9-44be-9090-12b88993971d">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:AuditorName
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_ae4592fb-2220-4424-aede-170cde3b0d74">Ernst &amp; Young, LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_71de0d36-8423-4bb8-be7a-9da603de4b32">San Diego, CA</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="C_7b598b8d-7ac7-457d-9009-819763ca7cc2"
      id="F_421b4107-5499-4dce-ac93-e43cd12cd69f">42</dei:AuditorFirmId>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_9b365eab-0f43-4cb0-abaf-bc342af9c6ec"
          xlink:label="F_9b365eab-0f43-4cb0-abaf-bc342af9c6ec"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_09e675d8-070d-4377-b897-566ff7993c23"
          xlink:label="F_09e675d8-070d-4377-b897-566ff7993c23"
          xlink:type="locator"/>
        <link:footnote id="FNT_6ec5b87e-3b57-47e9-bcc1-09fda434533f" xlink:label="FNT_6ec5b87e-3b57-47e9-bcc1-09fda434533f" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other segment expenses include stock compensation expense, depreciation, legal fees, general &amp; administrative expenses, and corporate expenses.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9b365eab-0f43-4cb0-abaf-bc342af9c6ec"
          xlink:to="FNT_6ec5b87e-3b57-47e9-bcc1-09fda434533f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_09e675d8-070d-4377-b897-566ff7993c23"
          xlink:to="FNT_6ec5b87e-3b57-47e9-bcc1-09fda434533f"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
